<SEC-DOCUMENT>0000950170-22-004850.txt : 20220329
<SEC-HEADER>0000950170-22-004850.hdr.sgml : 20220329
<ACCEPTANCE-DATETIME>20220329073632
ACCESSION NUMBER:		0000950170-22-004850
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		111
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220329
DATE AS OF CHANGE:		20220329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pyxis Oncology, Inc.
		CENTRAL INDEX KEY:			0001782223
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				831160910
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40881
		FILM NUMBER:		22777379

	BUSINESS ADDRESS:	
		STREET 1:		35 CAMBRIDGE PARK DRIVE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
		BUSINESS PHONE:		(617) 221-9059

	MAIL ADDRESS:	
		STREET 1:		35 CAMBRIDGE PARK DRIVE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pyxs-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-03-29T06:58:50.2387+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:pyxs="http://pyxisoncology.com/20211231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonFraction id="F_01b30c23-8e47-433b-a192-0adf8d0251a5" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_72b2f27a-fcc2-48bb-89ca-eed397dc0270" unitRef="U_pure" decimals="8" scale="0" format="ixt:numdotdecimal">0.15725743</ix:nonFraction><ix:nonFraction id="F_b487119d-da19-4ae4-9043-40f7baa15197" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_6e2e4e5a-08b0-4845-8a93-3b94cd5895c2" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">0</ix:nonFraction><ix:nonFraction id="F_0a1acadd-79fb-4921-bd24-0d8d565584f5" name="us-gaap:PreferredStockValue" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_2fdfa06b-df8a-4632-9899-328796781364" name="dei:DocumentFiscalPeriodFocus" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89">FY</ix:nonNumeric><ix:nonFraction id="F_7234ad04-fa57-47a9-883c-6986dae56233" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_04691b98-e0da-490b-a8f4-4b50017b84c0" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">0</ix:nonFraction><ix:nonFraction id="F_6e0eb586-b179-4054-af6f-b94a1fcee934" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_eb20c638-f7e6-42c8-bbb7-04213dfaf5a7" unitRef="U_pure" decimals="8" scale="0" format="ixt:numdotdecimal">0.15725743</ix:nonFraction><ix:nonNumeric id="F_53b8bf9c-826e-4b8e-93dd-782095518f7b" name="dei:EntityCentralIndexKey" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89">0001782223</ix:nonNumeric><ix:nonNumeric id="F_d7ecb9f2-df8f-460f-9821-26cf851cc9f5" name="dei:AmendmentFlag" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonFraction id="F_d7c513c0-dafa-48ea-8420-1d541d060cf1" name="us-gaap:PreferredStockValue" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_bc1feaae-b4f0-4232-bfcb-7aa66a503921" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_add39c44-72f5-4ca5-ab44-474e2dd8f88c" unitRef="U_pure" decimals="8" scale="0" format="ixt:numdotdecimal">0.15725743</ix:nonFraction><ix:nonFraction id="F_50960eda-5271-4ab9-851d-c8014b79d8e6" name="us-gaap:CommitmentsAndContingencies" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e37b2c3d-2209-4ae4-a26d-141353a73f83" name="us-gaap:CommitmentsAndContingencies" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="pyxs-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_a9c9231a-7100-4362-8c03-86895d680666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3bfacc42-7016-4be9-8736-1d6d637d68e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cab37125-1fa0-46b6-b525-727f58de2829"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_52f84543-c5cd-4e24-8f62-15582b3c85f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6eaa700b-aefd-44cf-9c29-31f008101fed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0419a777-abc4-43c5-941f-c166c8f4b73a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_404bc14b-3eaf-4e94-a492-dc8d161a716a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3e89383-fd3d-4b7e-82f6-24ca7bf96cec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0325835-c766-40ad-a049-921b9832afb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34a68bd8-42d2-4884-8c43-a95f93b476df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ede49b60-05ec-496a-8366-21adc55138b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ca021f9-876b-4a5b-8dc2-fcb1ec552bde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9b6d952-91a3-4a16-ba7e-88b297d8e0b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1004cb6e-29cf-4ad9-a179-5780de31070c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pyxs:VoxallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35ae1bff-4ac3-4b11-b994-17b32b210d6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c5d682d-d0a1-45b0-b0e4-16275df3e997"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pyxs:StockOptionsAvailableForIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43a98943-5b0e-4436-8f96-5a50552b1f8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c05c67d1-e528-474e-8817-657f048332c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83f1f8d4-1a3f-42eb-89a4-fe5b4d42496e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ae77749-d3df-49f5-b129-e03c49c1d9ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b24eb84-4a1e-48e9-939f-d50285a9ebf8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb6bd2f8-ad47-4a35-989a-57aedc56c9c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72eb1cad-9bfc-44a0-9b07-b1629f06a05d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2479e14f-6aa9-4a28-be71-a2c03d3cde43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pyxs:VoxallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a74247c-2b25-4a52-afe0-244e457c4f7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_128e59fb-2071-4047-8fbe-17d937e7523a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_805ffd5b-0773-4785-8a81-7d324e3eaafa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:AgreementsWithPfizerIncAndLegochemBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53514985-e3a7-4155-9770-bf7e144b7596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d95ea6c8-6b64-4ea3-9e32-ba4722916902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pyxs:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1083a66d-cffd-416e-a565-3d03312b0250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75951ce6-a95a-42de-8088-a5a897b8380d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pyxs:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60a4f247-f1f7-4230-bdbf-18fce866817f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_673e5066-a0a1-4324-b5c4-c5590d5143fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4093bae-844d-47d4-af50-d208ea9824d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be0b2666-2fd2-42a7-9eb9-036c72e9e2e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f0edcc6-6967-4a4a-b278-e69a383ba6db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pyxs:ScientificAdvisoryBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bb52469-04b7-49d0-857a-43447b7272be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37f4df29-d5b8-4d2c-bf7f-5a96e5b924a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71c85092-8520-4659-ae48-430a857097a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a87e6b1-9e03-4ac3-8a39-debc18e92132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60a0d615-609c-4658-97f4-896f92d22495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d16739b1-097f-4ebc-b79f-81d904a831e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-08</xbrli:startDate><xbrli:endDate>2021-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9848985a-6cbf-4efd-a97b-7350766a6a66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a579548-3c9a-4e1b-bf3e-98869a574f78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86a53aad-9b46-45bf-8f94-a9e963b999b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0492f1f1-cdba-47c2-b6ed-3d308a2cdd45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a491c51-e3ff-4f01-b86c-22bb7f1219c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b54da75b-957d-4884-98f7-3495f571051f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a39c61fa-aca6-4bf1-8634-94e72b3a3719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_add39c44-72f5-4ca5-ab44-474e2dd8f88c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c75ce941-68a1-475c-964a-d8c55a132c9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_073f9fdb-14b4-4632-8088-b25125b7ae60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86efd6c0-cd6e-4044-a8a6-91df62d66a91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5fb2e8bf-e772-43b7-b907-59150f324329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pyxs:VoxallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc3376eb-8285-406a-bbf7-1c82c1b22a7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13a4aa5e-911a-4c5d-9086-7de944870e14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7063a67b-e132-4dc0-b804-27e9078dfd3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54d4e58d-90af-4c17-b083-9fcffe474079"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8091fae-ef00-4700-b4a2-77ed5956ff06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e0e6445-8830-4b8b-9312-a6c3f7385eae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202001Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_762248a9-dd67-46d8-b8ac-e8d11ca59329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-08</xbrli:startDate><xbrli:endDate>2021-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a48bbe71-5e71-4138-9877-1babd6034c0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfa6104f-d54e-432d-8bca-e8247807eec0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e920cab-08bd-4853-a2c7-07b631b559f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3a5fd86-4b2f-48b5-906e-e21ff053ea3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_152d9614-3fcc-42d6-ad59-684db0e1410f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_40efd25b-f2c1-4224-9850-278e0702aecc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ff4a3a9-acf7-49fe-b336-139827d87918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pyxs:ScientificAdvisoryBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8cf8329-d1fb-4956-86aa-e52d9990243c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0961fd9e-e455-4080-b194-733e8f9aaef7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc36a634-547c-4f28-b1db-420db4a8e3cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pyxs:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a39c163-dd87-4565-b3a7-3a9cd35c9839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_928733d3-c3c5-45d1-9947-05d14b5ad5c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99104f1c-d368-4dd0-8b3e-c298819aba0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pyxs:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb20c638-f7e6-42c8-bbb7-04213dfaf5a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea790169-f5cb-46d5-bb2a-a27a9d87e6bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_931efd56-1c76-41f4-bf5d-55380b0d9598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e0fe443-9856-4876-8a03-0c6ae852fad0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_503f6a97-2a52-4ea2-92dd-c00d66d8adf2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1a3afb5-1db0-4c36-83ed-2876af7a7097"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_529d4c7c-54dc-4be7-b79b-cb508fa84d76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c40a4a9-f63b-4608-bd08-8d0a1321ed5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4f7a85e-0b7b-4341-87a1-c762f3633c3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d235112b-d87b-410d-8d79-ca05e714f0dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc7688b9-57dd-43d0-a91e-30eeb4979d67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pyxs:ScientificAdvisoryBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c358130b-d442-4714-9617-ad3cca7aaa47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5d21c61-6321-4216-b894-327d183af8bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98160ecc-3034-40bb-a317-ac57984c3f17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0fbda7d4-a5aa-4836-8bfe-59b19b15fc3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pyxs:ScientificAdvisoryBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5fb5e1b-3838-47c6-bb70-01be05e587a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_249a52df-36e5-49ab-92ea-306c0765acf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5221cef4-195a-4dfd-95bb-66e798f30b97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebe69ee7-b47e-44a7-9ec7-718a9ea1d455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8718a804-c532-497e-b1b1-1415b90f394e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_856072e1-a9f5-4feb-888d-6f52cd2b0837"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_14084414-5d74-4992-ae92-da97bbd2c4d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bacaab47-1993-4379-b4c5-c1e4533f5d05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pyxs:StockOptionsAvailableForIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4173faad-0fa2-4056-a8cc-cccd57e2e301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:AgreementsWithPfizerIncAndLegochemBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b011e3d-095a-448f-a28b-10116452cf0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-08</xbrli:startDate><xbrli:endDate>2021-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4512320-e5eb-43ea-b73f-15322d518ab6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77b69288-abc5-4593-aa39-850f6b1b0b7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b8a4a3d-2a4c-49f1-81b4-0e6c37ae21f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5062dfa7-6cc0-4b79-8af4-5b4183bdb254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1af731d8-74d4-4ca7-b3c7-e479981d947b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3014eecd-3b62-49b1-859b-5132c70a7d8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5dd6ea79-1ed6-4fd4-bfde-295b989544d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cde6dc02-fc80-4fef-a5f9-c1c479dca2db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f4cbd78-d94e-48b1-892b-e716976eb7fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e0bc3e3-4b08-4944-8059-6999b756147c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e2e4e5a-08b0-4845-8a93-3b94cd5895c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_430de8ee-a6be-4373-9634-ddf883b01c5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed7e79ef-96fa-4eef-919a-c352a3235260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6ec6f8a-bc22-4323-8647-1e511c65aa13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93d8ea59-4f70-435a-800d-684dd2b13280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ab4cd50-7dbc-450e-8807-5e18ae9fabd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffc2f537-c19b-4a4e-86aa-33adffaef56a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37efc727-3d91-4336-9a3f-f491d3514c2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_668767af-d588-4269-bdd5-6d6317ca1174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa4c513f-59f0-4418-b2c2-d90b9bbe35b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e96f6dc-3ab3-4489-961b-e2b6b8303a96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea67ab21-1afc-421d-9c63-09eb80e2cfd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b95ae457-b724-40e9-a605-8b606684a52e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pyxs:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_002caa9d-21b8-41d6-b0f1-07bf5d365ac2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97f1d379-1c6e-4fb0-8b48-b544858a4c77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dca5bfc8-d2fa-4c60-8e05-95c561295a9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-28</xbrli:startDate><xbrli:endDate>2022-03-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a2e39db-f489-43c1-abbc-dbbecbeb09c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c093cb7e-c886-49da-91b1-6affab2f3890"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c28b8bc5-5c32-45fe-b131-2c2fbbfa9d56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0326a5ad-45a2-4a64-829d-d01a89aa86a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1662ef99-8778-4709-9b9e-c988faaab66e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32d8b9f9-d8e4-44c1-b86e-a4702ec224b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b924cc1-929b-4476-912e-1c2d54d69e3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19b30afc-5afa-40c6-8463-3498cd194d89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1f92bd2-7f9c-4761-a7cd-fb5f0d37b59d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f604ee67-0407-458c-8c83-3dcf27014aee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22452cd4-facf-4cb0-b0d8-aef2986fea43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pyxs:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_52a59c4e-168a-478f-9c0c-bb44fa171b44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72b2f27a-fcc2-48bb-89ca-eed397dc0270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a0f2d3a-54c0-420e-9bb9-0592cc6ffcc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04691b98-e0da-490b-a8f4-4b50017b84c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b95c8e6-2fe9-4e6e-b9b7-23db66016497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f621107-7e12-4f37-bdcf-0e86434b9852"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-29</xbrli:startDate><xbrli:endDate>2021-09-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_766b7d60-5964-4d51-abab-3b2019b307a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a174817-ec5a-4adc-91c7-b3f0391f3a67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eefec595-540f-41d0-a397-d2a35572ebb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cffd11cd-91be-467f-9b81-32cb6d435261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de03779b-38b4-48de-abf6-4dfbb5df89c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_113a708f-879e-4c63-8e7a-917c6c0f4303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pyxs:AlloyTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pyxs:VoxallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_822a9797-c061-4b8c-ab9b-33b711164570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b5b3558-a3b0-4002-902a-e67ae5cdd4b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3f40a67-c272-4dd9-b239-cdb25247520e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84680f37-2d8e-4647-bf6e-6e10f83c3b7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>pyxs:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Lease"><xbrli:measure>pyxs:Lease</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_1d02fe45-14e7-49c1-acb0-ad6b9e3a7f80" fromRefs="F_1705cc8f-18fe-443e-b8d6-3e583f9850d8 F_17b2d502-1157-47ab-87f7-2134a0019cc3"></ix:relationship></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="border-top:2.250pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c8d13d3-b0ca-4be4-84c7-a6e6a68b50ee" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.998%;"></td>
    <td style="width:96.002%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_adad96df-1da0-4e0a-8978-a64a9257f83b" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">For the fiscal year ended </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7913ce1b-ceab-40f6-a242-f237a0102cd4" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d51a5ba2-0b0e-4962-8e7d-a4e3e95156f3" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:CurrentFiscalYearEndDate" format="ixt:datemonthdayen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">, </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e35fd5c8-6287-445c-88fb-a91123c1ade4" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.998%;"></td>
    <td style="width:96.002%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bda25842-fa93-40c5-b8a7-ba9ab8c03528" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commission File Number </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e759407-d189-4b48-9021-cb141cbb2c4d" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">001-40881</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:20.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c382e615-b0f9-45b7-b606-76db1dc7ce64" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:20.0pt;font-family:Times New Roman;">Pyxis Oncology, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(Exact name of Registrant as specified in its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d36d799f-bd76-4989-8a09-8f5ff7334457" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55d4286b-e416-404e-b912-ab76efb8c31d" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">83-1160910</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a76c60f9-4029-4e95-829f-f9d66195b956" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">35 Cambridgepark Drive</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><br /></span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc555a07-5cd5-4cc7-b7b2-3fe9ac12facd" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cambridge</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_64c05801-d0f8-48a8-9be5-d5ace39cc6af" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a6d93fd-ea83-4e0e-8e00-a73741c3bdc4" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">02140</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a1aad2c-8ab2-4ca0-9442-56bf970148a8" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">617</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">) </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_906f1026-2d3c-43d0-a668-ea1b0e6957f0" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">221-9059</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d32de20-d9c8-443e-a5d2-f3d5f8730774" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a2c3897-7fad-491a-a047-e45143c1a958" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">PYXS</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f29b98cb-e0cc-49a1-86aa-d72f025d6d1e" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9744;     </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1bf39aa3-3b0c-4fad-ae42-cd64f93cdd4d" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9744;     </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38cd4a01-4e74-42af-a777-88b956c88230" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_13d24af2-face-403e-9a5a-74945d03538b" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;     </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e6688f2-d6ee-47fc-a565-4e8cdee1b6ce" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;     </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.111%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:55.648%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:20.311%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.924%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1738b628-01f1-48ba-844a-2764ee003577" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d4616b0-287f-4467-b4c5-889460d21d76" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7954223a-efee-44b2-8921-cd51a1a2f1ae" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_855efb69-8c0e-4159-b792-949bbb01ef8e" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit re</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">port.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78596760-1baf-4a82-a6aa-d5b232181a93" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9744;     </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66d16560-0a5f-43b7-91ef-534df1f2f95e" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">The Registrant did not have a public float on the last business day of its most recently completed second fiscal quarter because there was </span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81ed7600-3b22-40f8-9e88-f6ab8d702eba" contextRef="C_002caa9d-21b8-41d6-b0f1-07bf5d365ac2" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> public market for the Registrant&#x2019;s common equity as of such date. The number of shares of Registrant&#x2019;s Common Stock outstanding as of March 29, 2022 was </span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55c4d2cb-f52a-4908-b149-7a73a869c458" contextRef="C_eefec595-540f-41d0-a397-d2a35572ebb1" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,841,747</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">.</span></p>
  <div style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12f96385-f3df-4631-9689-34ca3658999a" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Portions of the Registrant&#x2019;s Proxy Statement for its 2021 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2021.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.001%;"></td>
    <td style="width:81.996%;"></td>
    <td style="width:7.003%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART I</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART II</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disclosure regarding foreign jurisdictions that prevent inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART III</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensati"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_of_certa"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationship"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">127</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 16.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Signatures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">129</span></p></td>
   </tr>
  </table>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. These statements involve known and unknown risks, uncertainties related to the global COVID 19 pandemic and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unless the context requires otherwise, references in this Annual Report on Form 10-K to &#x201c;Pyxis Oncology,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; refer to Pyxis Oncology, Inc. and its subsidiary. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In some cases, you can identify forward-looking statements by terms such as &#x201c;may,&#x201d; &#x201c;would,&#x201d; &#x201c;should,&#x201d; &#x201c;expects,&#x201d; &#x201c;plans,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;could,&#x201d; &#x201c;intends,&#x201d; &#x201c;target,&#x201d; &#x201c;projects,&#x201d; &#x201c;contemplates,&#x201d; &#x201c;believes,&#x201d; &#x201c;estimates,&#x201d; &#x201c;predicts,&#x201d; &#x201c;outlook,&#x201d; &#x201c;potential&#x201d; or &#x201c;continue&#x201d; or the negative of these terms or other similar expressions. The forward-looking statements in this Annual Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of risks, uncertainties and assumptions described in the section titled &#x201c;Risk Factors&#x201d; and elsewhere in this Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Some of the key factors that could cause actual results to differ from our expectations include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to develop and advance our current or future product candidates and programs, and to successfully initiate and complete clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability of our clinical trials to demonstrate the safety, purity and potency of our product candidates and other positive results;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size of the market opportunity for our product candidates, including our estimates of the number of patients who suffer from the cancers we are targeting;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our manufacturing, commercialization and marketing capabilities and strategy;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our plans to further develop the FACT platform and expand our pipeline of product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact of the COVID-19 pandemic on our business, financial condition, results of operations, and prospects;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing or likelihood of regulatory filings and approvals for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory developments in the United States and Europe and other foreign countries:</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our expectations and plans to obtain funding for our operations, including from our existing and potential future collaboration and licensing agreements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates:</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our continued reliance on third parties to manufacture our product candidates for preclinical studies, and, in the future, to conduct clinical trials and manufacture product candidates for such clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, statements such as &#x201c;we believe&#x201d; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and, although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events or otherwise.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SUMMARY RISK FACTORS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">You should consider carefully the risks described under &#x201c;Risk Factors&#x201d; in Part II, Item 1A of this Annual Report on Form 10-K. References to </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201c;Pyxis Oncology,&#x201d; the &#x201c;Company,&#x201d; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; in this section titled &#x201c;Summary Risk Factors&#x201d; refer to Pyxis Oncology, Inc. and its wholly owned subsidiary. A summary of the risks that could materially and adversely affect our business, financial condition, operating results and prospects include the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a preclinical stage biopharmaceutical company with a limited operating history and have incurred significant losses since our inception. We expect to incur losses over at least the next several years and may never achieve or maintain profitability.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will require substantial additional capital to finance our operations, obtain regulatory approval for our product candidates, and commercialize our product candidates. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and product development programs or future commercialization efforts.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are heavily dependent on the success of PYX-201, PYX-202, PYX-203, PYX-106 and PYX-102 all of which are in the early stages of development, and if PYX-201, PYX-202, PYX-203, PYX-106 and/or PYX-102 are not successful in clinical trials or do not receive regulatory approval or licensure or are not successfully commercialized, our business will be materially and adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All of our product candidates are currently in preclinical development. Our product candidates may fail in development or suffer delays that materially and adversely affect their commercial viability. If we or our existing or future collaborators are unable to initiate and complete clinical development of, obtain regulatory licensure for or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our preclinical studies and clinical trials may fail to demonstrate adequately the safety, purity and potency of any of our product candidates, which would prevent or delay development, regulatory licensure and commercialization.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory licensure or commercialize these programs on a timely basis or at all.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical testing and product development is a lengthy and expensive process with an uncertain outcome. We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the clinical testing and the development and commercialization of our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The regulatory licensure and approval processes of the FDA and other comparable regulatory authorities are lengthy, time-consuming and inherently unpredictable and, if we are ultimately unable to obtain marketing licensure or approval for our product candidates, our business will be substantially harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we fail to attract and retain qualified senior management and key scientific personnel, our business may be materially and adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face risks related to health epidemics and outbreaks, including the COVID-19 pandemic, which could significantly disrupt our preclinical studies and clinical trials, and therefore our receipt of necessary regulatory licensure or approvals could be delayed or prevented.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on third parties to manufacture our product candidates. Any failure by a third-party manufacturer to produce acceptable raw materials or product candidates for us or to obtain authorization from the FDA or comparable foreign regulatory authorities may delay or impair our ability to initiate or complete our clinical trials, obtain regulatory licensure or approvals or commercialize approved products.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, or if our patents are insufficient to protect our product candidates for an adequate amount of time, or if we are unable to obtain adequate protection for our proprietary know-how, we may not be able to compete effectively in our markets.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates or we could lose certain rights to grant sublicenses.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. If we breach our University of Chicago, Pfizer, LegoChem, or Biosion license agreements or any of the other agreements under which we acquired, or will acquire, intellectual property rights covering our product candidates, we could lose the ability to continue the development and commercialization of the related product.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the market opportunities for any product that we develop are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">T I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1. B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">usiness.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. We develop our product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. We are developing multi-asset, multi-modality portfolio aimed at defeating difficult-to-treat cancers. We consider multi-modality as variety of technologies, either stand-alone or in combination with others, to build the effective cancer therapeutics for patients. Since our launch in 2019, we have developed a broad portfolio of novel antibody drug conjugate, or (&#34;ADC&#34;), immuno-oncology, or (&#x201c;IO&#x201d;), product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that we are developing as monotherapies and in combination with other therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We take a holistic view of attacking the key drivers of tumor growth and progression within the tumor microenvironment, or TME, including targeting of tumor antigens and modulating the innate and adaptive immune response. The TME is an immunosuppressive environment consisting of cancer cells and stroma, which includes the blood vessels, immune cells, fibroblasts, signaling molecules, and the extracellular matrix that surrounds the tumor. The TME plays multiple roles in tumor formation, progression and metastasis as well as anti-tumor immune activity. We are developing our ADC and IO product candidates to precisely target key modulators of the adaptive and innate immune system within the TME for difficult-to-treat solid and hematologic tumors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that the diversification of a multi-modality approach optimizes our ability to effectively progress multiple assets for the benefit of patients. By leveraging our expert knowledge of the TME and established business development record, we are developing cancer therapies and technologies through multiple avenues (see Figure 1) including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Platform Development: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are capitalizing on years of industry innovation and advancement in ADC platforms to develop and design our product candidates. For example, our product candidates PYX-201 and PYX-203 are built utilizing the Flexible Antibody Conjugation Technology, or FACT, platform technology in-licensed from Pfizer Inc. FACT technology leverages over a decade of investment refining the technical components of ADCs to improve the clinical properties of ADCs. Using our expertise in site-specific antibody conjugation, we are developing next-generation ADCs with customized linker-payload combinations aimed at increasing stability and, consequently, a reduced off target side-effect profile potentially enhancing the therapeutic index, or TI. We are leveraging our FACT ADC Platform to further build our pipeline while we consider expansion opportunities into adjacent modalities.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Target Catalog</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: We have a large proprietary target catalog that is based on our own discovery activities and the in-licensed intellectual property, or IP, which formed the founding of the company from the University of Chicago out of the work of Dr. Thomas Gajewski&#x2019;s laboratory. We believe that our target catalog will enable us to identify new ways to exploit multiple components of the TME for tumor targeting, either as new IO, or ADC targets. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Forging Creative Business Models and Alliances: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are continuously evaluating business development and alliance opportunities with a variety of third parties. We aim to be unconstrained by conventional ideas and practices to overcome the many and complex challenges of cancer treatment. We are creating development optionality by engaging in creative business models to further expand the pipeline such as our joint venture with Alloy Therapeutics, known as Voxall Therapeutics, LLC, or Voxall. See &#x201c;Licensing and Collaboration Agreements&#x201d; in Item 1. Business in this Annual Report on Form 10-K. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Product In-Licensing and Acquisitions: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We selectively seek to in-license product candidates to expand our product pipeline. For example, our PYX-202 (DLK1 ADC) product candidate was in-licensed from LegoChem Biosciences Inc. and our PYX-106 (Siglec-15) product candidate was in-licensed from Biosion Inc. (&#x201c;Biosion&#x201d;). Additionally, we also in-licensed PYX-201 (EDB ADC) and PYX-203 (CD123 ADC) from Pfizer Inc. We are actively evaluating opportunities to acquire product candidates which we believe could enable us to quickly reach and deliver value inflection points as we build a durable, multi-asset, multi-modality diversified oncology company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 1</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_0.jpg" alt="img29677477_0.jpg" style="width:672px;height:378px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Developments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PYX-106</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 28, 2022, we entered into a license agreement, or the &#x201c;Biosion License Agreement,&#x201d; with Biosion USA, Inc., or Biosion, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pursuant to which we obtained exclusive, worldwide (other than Greater China (mainland China, Hong Kong, Macau and Taiwan)), licenses for development, manufacture and commercialization rights for BSI-060T, a potentially best-in-class Siglec-15 targeting antibody, an IO product candidate (now referred to as PYX-106), and products containing the licensed compound. PYX-106</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is a fully human monoclonal antibody and is engineered with high affinity to block Siglec-15 induced immune suppression and therefore restore T cell proliferation, function and anti-tumor immunity in the TME. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PYX-106 is a novel immune checkpoint inhibitor targeting Siglec-15, whose expression profile is generally non-overlapping with PD-L1. Siglec-15 is expressed on M2 macrophages but can also be expressed by tumor cells. Binding of Siglec-15 to an as of yet unknown receptor on T cells leads to suppression of T cell proliferation and function. This inhibition also reduces IFN&#x3b3; secretion which may further promote Siglec-15 expression.  PYX-106 may synergize with and rescue PD(L)-1 targeted therapy activity, with the potential for sequential drug administration to synergize for enhanced anti-tumor activity.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are initially evaluating our Siglec-15 targeting antibody for the treatment of advanced or metastatic solid tumors, which could include thyroid cancer, Head &amp; Neck Squamous Cell Carcinoma, or HNSCC, non-small cell lung cancer, or NSCLC and other solid tumors where high unmet need exists. We plan to submit an IND for PYX-106 in the second half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PYX-102</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The anti-KLRG1 mAb, which we referred to as PYX-102, is our first organically built IO development candidate from our internal discovery engine. PYX-102 was identified as a promising IO target through our proprietary target catalog licensed from Tom Gajewski&#x2019;s lab at the University of Chicago. PYX-102 is an inhibitory immunoreceptor trysine-based inhibitory motif-containing receptor expressed on T cells and NK cells in the tumor microenvironment and acts as an inhibitory immune checkpoint receptor via its interactions with E- and N-Cadherin ligands. We believe that targeting KLRG1 to reprogram these suppressed T and NK cells represents an exciting strategy to promote the full anti-tumor activity of cytotoxic T cells and NK cells in the tumor microenvironment. We are working through our development plans and we anticipate IND submission in the second half of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PYX-202</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, we entered into a license agreement, or the &#x201c;LegoChem License Agreement,&#x201d; with LegoChem Biosciences, Inc., or LegoChem, pursuant to which we licensed worldwide (other than Korea) development and commercialization rights for LCB67, an ADC product candidate targeting DLK1 (now referred to as PYX-202), and products containing the licensed compound. In studies conducted by LegoChem of preclinical small cell lung cancer, or SCLC, PDX models, as well as in a human cell line-based, or CDX, mouse model of cancer, we have observed significant anti-tumor activity as measured by durable tumor regression. In preparation for our IND filing and based on observation of our GLP studies to date, we have determined that we will need to conduct additional GLP and non-GLP toxicity studies to determine whether PYX-202 is a viable clinical candidate. We will continue to monitor the progress of our PYX-202 program and expect to provide an update about PYX-202 in mid-2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Portfolio</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our portfolio consists of both ADC and IO product candidates. Our pipeline is balanced across programs with an emphasis on solid tumors. We have multiple assets trending towards the clinic in the next 12-24 months. Our ADCs utilize next-generation technologies that, based on observations from preclinical studies, may allow for increased stability and a reduced off target side-effect profile. We in-licensed two ADC programs in March 2021 from Pfizer, one ADC program from LegoChem in December 2020 and one IO program from Biosion in March 2022. See &#x201c;Licensing and Collaboration Agreements&#x201d; in Item 1. Business in this Annual Report on Form 10-K. Two of our product candidates, PYX-201, and PYX-106 are scheduled for IND submission in the second half of 2022 whereas PYX-203 and PYX-102 are scheduled for IND submission in the second half of 2023. We have additional preclinical mAb discovery programs derived from work at the laboratory of Dr. Thomas Gajewski. We retain full worldwide development and commercialization rights to all our product candidates, with the exception of PYX-202 in South Korea and PYX-106 in Greater China (mainland China, Hong Kong, Macau and Taiwan). We intend to develop each of our programs as a monotherapy and potentially also in combination with other therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are focusing our efforts on eliminating tumor cells through the selective antibody mediated delivery of cytotoxic payloads and by modulating key immune-associated pathways in the TME. We believe our pipeline has the potential to profoundly benefit cancer patients and provide effective treatment options for those who do not respond to currently available therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ADCs are an established therapeutic modality, with twelve currently approved by the FDA, including seven since 2019. Additionally, ADCs have received significant strategic interest from several pharmaceutical companies developing oncology therapeutics. ADCs are a combination of three key components&#x2014;antibody, linker and cytotoxic payload. Many ADCs utilizing conjugation to existing lysine or cystine residues in the antibody, or conventional ADCs, struggled with one or more of these three key components, leading to heightened toxicity and limited efficacy. Despite the improvements that have been seen with currently marketed ADCs, these ADCs still have limitations that impact dosing, and are associated with significant adverse events. We have designed our product candidates to overcome the limitations of ADCs that use conventional conjugation with the aim of providing patients with safer and more efficacious treatment options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The advent of immuno-oncology therapeutics, particularly immune checkpoint inhibitors, has shifted the treatment paradigm for oncology. We have initiated two monoclonal antibody programs that address critical immunomodulatory pathways within the TME and are exploring additional potential targets. Our programs aim to address critically important tumor infiltrating immune cell populations, such as macrophages, T cells, and natural killer (NK) cells, which may play crucial roles in limiting tumor growth and metastasis. In addition to singling out specific cell types, we believe our IO programs also address mechanisms responsible for T cell exhaustion and the immunosuppressive effects of the TME on T and NK cells. We believe that our two new IO programs, our internally developed anti-KLRG1 mAb PYX-102 and our in-licensed anti-Siglec-15 mAb PYX-106, have the potential to provide additional benefit to cancer patients either alone or in combination with other therapies, including other immuno-therapies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current pipeline is summarized below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 2</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span><img src="img29677477_1.jpg" alt="img29677477_1.jpg" style="width:672px;height:279px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PYX-106</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is an investigational fully human IgG1 isotype Siglec-15 targeting antibody that is designed to block Siglec-15 mediated suppression of T-cell proliferation and function. We plan to initially develop this asset for the treatment of thyroid cancer, Head &amp; Neck Squamous Cell Carcinoma, or HNSCC, non-small cell lung cancer, or NSCLC, and other solid tumors. We licensed worldwide rights, other than in Greater China (mainland China, Hong Kong, Macau and Taiwan), to our Siglec-15 targeting antibody from Biosion Inc. We expect to submit an IND in the second half of 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PYX-102</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is an investigational immune-therapeutic consisting of a ligand-blocking antibody which rescues KLRG1-mediated suppression of human CD8+ T cells. KLRG1 ligands E-and N-cadherin are expressed in numerous solid cancers. KLRG1 is an inhibitory ITIM-containing receptor expressed on T cells and NK cells. Blocking ligand/receptor interaction will relieve immune inhibition in these tumors. We anticipate submitting an IND in 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PYX-201</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is an investigational, novel ADC consisting of an Immunoglobulin G1, or IgG1, anti-fibronectin Extradomain-B, or EDB, mAb site-specifically conjugated to auristatin via a cathepsin B-cleavable linker. Fibronectin is a glycoprotein found in the extracellular matrix. Fibronectin EDB regulates blood vessel morphogenesis, which provides the tumor access to nutrition and oxygen, a means to remove waste, and a pathway for metastasizing cells. EDB is overexpressed in many malignancies and is minimally expressed in most normal adult tissues, making it a potentially attractive means to target tumors while sparing healthy cells. In preclinical models of patient derived xenograft, or PDX models, we observed tumor regression with single agent PYX-201. In addition, we observed that the treatment of preclinical syngeneic tumor models with PYX-201 resulted in enhanced T cell infiltration into the TME, which is a hallmark of immunogenic cell death, or ICD, enabling synergistic activity in combination with a checkpoint inhibitor. We anticipate submitting an IND in the second half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PYX-202</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is an investigational, novel ADC consisting of an IgG1 anti-Delta-like 1 homolog, or DLK1, mAb conjugated to MMAE via a site-specific plasma-stable &#xdf;-glucuronide linker. DLK1 is a transmembrane protein normally expressed in embryonic tissues but highly restricted in healthy adult tissues. DLK1 becomes re-expressed in certain solid tumor malignancies. PYX-202 is designed to use the microtubule-disrupting MMAE payload, which is utilized in three currently marketed ADCs providing clinical support that the payload has anti-tumor effect potential. As discussed in Recent Development section above, we are currently in process of doing further testing and analysis and expect to provide an update about PYX-202 in mid-2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PYX-203</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is an investigational ADC consisting of an IgG1 anti-CD123 mAb antibody conjugated to a novel cyclopropylpyrroloindoline, or CPI dimer payload via a site-specific plasma-stable, cleavable linker. CD123, or IL-3R</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, is a cell surface antigen highly expressed on leukemic stem cells and leukemic blasts in acute myeloid leukemia, or AML. PYX-203, utilizes a novel DNA-damaging toxin, CPI, and we have observed significant anti-tumor activity as measured by the reduction in the frequency of the leukemic cells in the blood and bone marrow in nine disseminated preclinical AML models. We anticipate submitting an IND in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the programs identified above, we are conducting research and development activities on various targets, leveraging our expertise in monoclonal antibodies and understanding of immuno-oncology. Our preclinical discovery programs are novel antibody programs intended to enhance the anti-tumor activity of natural killer, or NK cells, and T cells and to overcome immunosuppressive activity of tumor resident myeloid cells such as tumor associated macrophages, or TAMs, and myeloid derived suppressor cells, or MDSCs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our goal is to improve the lives of patients with difficult-to-treat cancers by building a superior portfolio of biological products, including ADCs and monoclonal antibody immunotherapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Elements of our strategy to achieve our short and long-term goals include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Develop multi-asset, multi-modality, durable portfolio aimed at defeating difficult-to-treat cancers. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that the diversification of a multi-modality approach optimizes our ability to effectively progress multiple assets for the benefit of patients.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Progress our most advanced product candidates, PYX-106 and PYX-201, into and through clinical development.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We believe that our preclinical data to date support the clinical potential of PYX-106 and PYX-201 as monotherapies and in combination with other cancer therapies, including immunotherapies and product candidates within our own portfolio. We expect to submit INDs for PYX-106 and PYX-201 in the second half of 2022 and INDs for PYX-203 and PYX-102 in the second half of 2023.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Pursue a multi-modality approach to cancer therapy addressing various key components of the TME.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Our approach is to leverage our capabilities to develop investigational products that directly target tumor cells and stromal components of the TME with ADCs as well as enhance effector cell function and overcome key mechanisms of immune-suppression with immunotherapeutic mAbs to improve response rates and/or deliver durable responses for more patients.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Efficiently progress our preclinical IO programs.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We plan to continue the preclinical development of our pipeline of immunotherapies. If approved, we believe these monoclonal antibody programs have the potential to overcome several of the mechanisms responsible for suppressing immune function and effector cell activity, thus enhancing the anti-tumor immune response in the TME. We also plan to leverage the potential ability of certain ADCs to induce immunogenic cell death to support synergistic combinations with IO agents, including those derived through our own programs. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Continue to leverage the FACT platform and our Target Catalog to expand our pipeline of product candidates.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We plan to continue to mine our target catalog to identify new ways to exploit multiple components of the TME for tumor targeting. Our target catalog may help identify critical immunomodulatory pathways within the TME that can be addressed with monoclonal antibodies. We plan to use our target catalog and the FACT platform to develop differentiated ADCs with potentially superior clinical activity relative to the current standards of care including monoclonal antibodies. Additionally, we intend to use the FACT platform to develop ADCs for attractive targets beyond our target catalog. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Selectively forge alliances to enhance and expand our product pipeline to further leverage our intellectual property</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We believe that the potential for single agent anti-tumor activity of our current and future products could be enhanced by incorporating potential collaborator technologies. We intend to selectively form alliances with partners to gain access to complementary technologies and expertise to develop and commercialize product candidates with increased potential for anti-tumor activity and the potential for a strong safety profile. We seek to further leverage our intellectual property portfolio through the formation of these alliances. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Leverage our team&#x2019;s deep experience and proficiency in oncology research and development to discover and advance novel ADC and immuno-oncology treatments for patients suffering from difficult-to-treat cancers.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We believe our team, which brings deep scientific TME knowledge, functional biology expertise, ADC and IO modality experience, and biologics development capabilities position us to build a leading oncology company focused on developing product candidates for cancers with high unmet need. We intend to continue to augment the team&#x2019;s experience and proficiency through the addition of new members. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unmet Need in Oncology</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Despite the significant advances in oncology with the approval of several new classes of drugs, there remains significant unmet medical need for novel treatments. According to the World Health Organization, cancer is the second leading cause of death globally, accounting for nearly 10 million deaths in 2020. The key limitations of existing oncology treatments include high toxicity, low or limited response rates, and relapse or recurrence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chemotherapy remains one of the most common treatments for cancer, often combined with surgery and radiotherapy depending on the stage and type of tumor. A major challenge in the development of cancer treatments has been the overall complexity and heterogeneity not only of tumors, but of their dynamic surrounding microenvironments. While recent advances in treatment approaches, such as targeting specific tumor mutations that contribute to carcinogenesis or redirecting a patient&#x2019;s immune system to eliminate tumors, have begun to address these challenges, their focus has largely been on tumor cells. We believe that targeting the TME, which has been shown to play a key role in driving tumor progression, growth and multidrug resistance, represents a novel approach for addressing unmet needs in oncology. For example, while the development of immune checkpoint inhibitors has transformed the treatment paradigm for numerous cancers, many patients who respond to these therapies ultimately develop resistance and experience disease progression. Many features of the TME have been shown to influence response and resistance to immune checkpoint inhibitors and targeting the TME has potential to overcome these limitations. Our development efforts aim to leverage our deep understanding of the TME biology with the goal of designing and developing next-generation ADCs, with site-specific conjugation and customized linker-payload combinations, and immunotherapies that target key modulators of the adaptive and innate immune system found within the TME.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview of Antibody Drug Conjugates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ADCs are a therapeutic class in which cytotoxic chemotherapy molecules are linked to a targeting mAb to effectively deliver the tumor killing effect into tumor lesions while limiting systemic toxicity. Systemic toxicity limits the efficacy of chemotherapy, a highly cytotoxic class of anti-tumor medicines. ADCs can significantly improve the therapeutic window of toxic payloads even more cytotoxic than traditional chemotherapies by targeting their delivery to tumorous cells and their local environment and sparing healthy tissue. ADCs achieve this level of precision by pairing payloads with monoclonal antibodies, proteins that can recognize their target antigens with great specificity. ADCs are an established and fast-growing class of biological products. To date, twelve ADCs have been FDA approved, of which seven have entered the market since 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 3</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_2.jpg" alt="img29677477_2.jpg" style="width:279px;height:275px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Schematic representation of an ADC, highlighting the three key components; targeted antibody, linker, and payload or cytotoxic agent (dark blue: mAb heavy chain; pink: mAb light chain).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The clinical properties of ADCs are a function of three components (Figure 3):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.796%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.9288834417523018%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A monoclonal antibody that selectively targets a distinct antigen preferentially expressed on tumor cells or other cells in the tumor microenvironment; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.796%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.9288834417523018%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A linker that joins together the antibody and the payload; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.796%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.9288834417523018%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A payload that can effectively kill the targeted cell. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ideal ADC targets typically have highly tumor restricted expression to spare healthy tissues, are accessible to circulating antibodies, and have well-defined internalization kinetics or can be effectively bound within the TME. Once administered, an ADC will travel in the bloodstream until it encounters its target antigen followed by release of the toxic payload.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A measure of drug tolerability for ADCs is the preclinical therapeutic index, which is calculated from data to estimate the safety profile (Figure 4). This measure is the preclinical ratio of the highest non-severely toxic dose, or HNSTD in monkeys versus the minimally effective dose, or MED in mouse tumor models. The therapeutic index is defined formulaically as HNSTD (mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.36pt;font-family:Times New Roman;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) in monkeys / mouse minimal tumor regression dose (mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.36pt;font-family:Times New Roman;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">). As further illustrated in the figure below, a wider therapeutic index is a key attribute of an ADC&#x2019;s potential clinical success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 4</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_3.jpg" alt="img29677477_3.jpg" style="width:589px;height:324px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The therapeutic index is a measure to estimate the clinical tolerability profile of ADCs based upon the ratio of maximum tolerated dose, or MTD, in monkeys versus the minimally effective dose in rodents from preclinical studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Key Areas of Innovation for Engineering the Next-Generation ADCs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Optimizing the Linker</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The linker that joins the payload to the antibody should prevent the payload&#x2019;s premature release while in circulation and ensure efficient release of the payload into the target cell(s) and/or the TME. There are two general classes of linkers:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.796%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.9288834417523018%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cleavable linkers are designed to conditionally unload cytotoxic agents within the tumor cell or TME in response to the presence of tumor-associated factors such as proteases or highly acidic conditions. Typically, cleavable linkers carry uncharged payloads, allowing the drug to diffuse out of the target cell to kill surrounding &#x201c;bystander cells.&#x201d; Bystander killing can also occur when the uncharged payload is unleashed within the TME. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.796%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.9288834417523018%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In contrast, non-cleavable linkers remain intact upon internalization and rely on lysosomal degradation of the entire construct to achieve sufficient payload release. Non-cleavable ADCs typically release their payloads as charged catabolites, which traps the toxin within the cell where it was internalized. As a result, non-cleavable ADCs are naturally well suited to address cancers with a high and uniform expression of the target antigen since cells lacking the target antigen will not be directly affected. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe our toolbox of cleavable and non-cleavable linkers allows us to select the optimal linker tailored to each program. We select our linkers based on several factors, including but not limited to the level and distribution of the target antigen and rates of antigen turnover, internalization, lysosomal processing, and degradation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Site-Specific Conjugation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Site-specific conjugation chemistry enables the engineering of next-generation ADCs with predictable drug-to-antibody ratio, or DAR, with improved ADC pharmacokinetics observed preclinically. This improved PK results in minimizing premature payload release and less off-target toxicity and as a result improves the overall TI of the ADC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DAR is defined as the number of payload moieties attached to each antibody, which typically range from zero to    eight. Ideally, there is limited variability in DAR to allow for ADCs with predictable PK and more predictable efficacy. Variability in DAR and stability are primarily a consequence of the technology used to conjugate the linker to the antibody. The two conventional conjugation approaches employed in conventional ADC conjugation technology utilize either lysine residues or the interchain disulfides located on an antibody. These approaches result in a stochastic mixture of conjugates consisting of a heterogeneous pool of synthesized ADCs, as shown in Figure 5 below. Each bar in the graph consists of an ADC with the number of payloads indicated on the X-axis. Each one of these parts of the mixture of conjugates contributes to the efficacy and toxicity making it difficult to optimize for either property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to DAR, research has shown conjugate stability and the resulting rate of payload release can vary significantly between specific conjugation sites. Hence, conventional conjugation suffers from unpredictable and premature payload release outside of the tumor resulting in off target toxicities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Together with our extensive toolbox of linkers, we believe our site-specific conjugation chemistry offers us the advantage of fine-tuning and optimizing the cleavage of the drug in the TME while limiting off-tumor release and allowing for predictable DAR distribution. Site-specific conjugation technologies have led to improved ADC predictability with narrow distribution of DAR to facilitate CMC manufacture and consistent potency (Figure 5).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 5</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_4.jpg" alt="img29677477_4.jpg" style="width:672px;height:265px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Depicted above is an illustrative example of DAR distribution for a DAR 4 ADC using different conjugation chemistries which highlights how our site-specific conjugation technology allows for linker/payload to be precisely conjugated, leading to more predictable DAR ADCs. This also improves CMC characteristics and enhances stability of ADCs to maximize tumor delivery of the payload.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The Selection of Cytotoxic Payload</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The chemotherapeutic payload is a highly potent toxin that would otherwise carry devastating side effects as a systemically delivered monotherapy. There are several potential payloads, including antineoplastic auristatins, which act on microtubules to inhibit cell division, and alkylating or intercalating agents, which damage DNA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While an ADC&#x2019;s primary mode of action is to induce direct cell death through the payload, ADCs can exploit multiple avenues of anti-tumor action beyond direct cytotoxicity. For example, a growing area of interest is applying ADCs to induce ICD allowing for synergy with immunotherapy modalities including checkpoint inhibitors. Rapid cancer cell death caused by ADCs results in the release of damage-associated molecular patterns and tumor antigens, stimulating a tumor-specific immune response and recruitment of T cells into the TME (Figure 6). An emerging area of interest is utilizing ADCs to disrupt various aspects of the TME, such as angiogenesis or tumor-associated fibroblasts. Furthermore, certain payloads, such as auristatins, have been shown to engender the maturation and activation of dendritic cells, a critical compartment of the immune system responsible for initiating and regulating the innate and adaptive immune response.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 6</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_5.jpg" alt="img29677477_5.jpg" style="width:617px;height:457px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Overview of the process by which ADCs, particularly those with certain payloads, can potentially trigger hallmarks of immunogenic cell death to enhance tumor cell killing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ADCs have and may continue to revolutionize the treatment paradigm for several cancers. Despite the improvements that have been seen with currently marketed ADCs, these ADCs still have limitations that impact dosing, and are associated with significant adverse events. We have designed our product candidates to overcome the limitations of ADCs that use conventional conjugation with the aim of providing patients with safer and more efficacious treatment options. We believe that our combined expertise in ADC design and insights into TME biology have the potential to yield a holistic treatment spanning multiple mechanisms for patients with difficult-to-treat cancers that will overcome the current limitation of ADCs and result in better outcomes for patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FACT Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing next-generation ADCs using customized linker-payload combinations that are novel and supported by the preclinical data and site-specific conjugation techniques derived from the FACT platform. We believe that these payloads and linkers could be readily applied to any IgG1 antibodies using our site-specific conjugation techniques to efficiently develop novel product candidates. We licensed the FACT platform from Pfizer in December 2020 and benefit from over a decade of research and investment by Pfizer. See &#x201c;Licensing and Collaboration Agreements&#x201d; in Item 1. Business in this Annual Report on Form 10-K. We believe that the site-specific conjugation techniques and ADC technology which underpin the FACT platform enable us to develop next-generation ADCs with more favorable drug properties than traditional technologies based on preclinical studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Despite the clinical successes of ADCs as a therapeutic class, many ADCs still utilize conventional non-site-specific conjugation techniques that result in a heterogeneous mixture of ADCs with varying DAR. Recently, preclinical research carried out by Pfizer to empirically assess the impact of conjugation sites on ADC stability and activity in rodent models has indicated that site-specific conjugation techniques may enable enhanced pharmacologic properties and predictable DAR to potentially improve the therapeutic index.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Though multiple reports have shown that site-specific conjugation techniques often result in ADCs with a wider therapeutic index, greater stability, and better efficacy in preclinical </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">models than traditional non-specific, conventional ADC conjugates, less is understood about how to optimize these sites, as optimization relies upon empirical data generation for each specific linker-payload combination. We believe that the FACT platform has demonstrated that there are multiple biochemical parameters of ADCs impacting performance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and established a framework for optimized conjugation sites for a variety of linker-payload combinations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 7</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_6.jpg" alt="img29677477_6.jpg" style="width:512px;height:269px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The FACT platform technology is designed to empirically define optimal conjugation sites for linker-payloads to generate highly stable and predictable ADCs with potential for improved therapeutic indices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Pfizer optimized sites for linker-payload conjugation through empirical research</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that the FACT platform provides a toolkit of novel and validated payloads, cleavable and non-cleavable linkers, and a strong understanding of optimized conjugation sites. The FACT platform provides the basis for our PYX-201 and PYX-203 preclinical programs and will underpin our development of future ADCs that we believe are optimized for, and guided by the following design elements:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADC cytotoxicity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Target tumor cells require delivery of a certain threshold of payload molecules based on the payload&#x2019;s biochemical properties to induce cell killing at specific dose levels. Our ADC programs are designed to provide anti-tumor cytotoxicity and, as applicable, immunogenic cell death based on data from preclinical models. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Plasma stability and maintenance of the linker-payload</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. ADCs must be optimized for systemic circulation to prevent premature linker cleavage or release of the linker-payload construct in the blood plasma that can result in off-target toxicity. We are designing our ADC candidates to optimize for stability when in circulation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to avoid premature cleavage and support maximal payload delivery to the target site. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Efficient proteolytic cleavage of the linker for payload release</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The timing and rate of linker cleavage is important for achieving optimal delivery and release of a specific payload at the target site. We believe that we have the capability to utilize both cleavable and non-cleavable linkers to achieve potential therapeutic effects that are optimized for individual payloads and targets.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">High target specificity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ADC programs are founded on the identification of promising tumor targets and developing highly specific antibodies against these tumor targets. We draw upon our empirical understanding of site-specific conjugation sites and linker-payload toolkit to select combinations that we believe are well-suited for individual targets. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Defined and target specific DAR. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intrinsic to the FACT platform and conjugation techniques is the development of products with a consistent DAR, which we believe may enable us to develop a product with optimized stability, tolerability, and cytotoxicity. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that the FACT platform conveys several distinct advantages and flexibility in the development of our ADC candidates, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Improved anti-tumor activity in preclinical models with optimized conjugation sites for linker-payload combinations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The FACT platform is designed to select for optimal conjugation sites that are specific to each linker-payload combination. We employ site-specific conjugation techniques to conserved regions found within the antibody backbones that do not affect antigen binding or other normal antibody functional properties, such as Fc binding when appropriate, which we believe makes our conjugation technology broadly applicable to a wide variety of IgG monoclonal antibodies. Leveraging our diverse toolkit of improved and novel payloads, cleavable and non-cleavable linkers, and deep understanding of optimized site-specific conjugation sites, we have developed payload and linker combinations that can readily be applied to other antibodies in the same class. For example, our auristatin analogues, a potent microtubule inhibitor, and CPI, a highly potent DNA-cross-linking agent, have site-specific conjugation engineering with several linkers alongside IgG1 antibodies. These payloads and linkers could be readily applied to other IgG1 antibodies to efficiently develop novel product candidates. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Potential for improved therapeutic index and ADC stability</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that our site-specific conjugation technology has potential to mitigate off-target liabilities of ADCs contributing to an enhanced plasma stability and enhanced therapeutic index. As shown in Figure 8 and 9, applying the FACT platform to a well-established antibody, NG-HER2-ADC, to generate a model ADC was observed to mitigate toxicity and increase the TI and PK exposure and half-life of the ADC </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The rate of linker cleavage and release of the linker/payload construct has been observed to be heavily dependent on the conjugation location and we optimize our linkers for both specific targets and payloads. As a result, we believe the FACT platform and our empirical understanding of optimal site-specific conjugation may allow us to generate candidates against a broad set of targets that result in superior cell killing. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 8</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_7.jpg" alt="img29677477_7.jpg" style="width:620px;height:396px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Schematic illustration of how the therapeutic index of a model ADC generated using the FACT platform can potentially mitigate toxicity while maximizing PK exposure in vivo (NHP: non-human primates)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 9</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_8.jpg" alt="img29677477_8.jpg" style="width:618px;height:306px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of stability and exposure in cynomolgus monkeys of Pfizer&#x2019;s NG-HER2-ADC using the same linker-payload and conjugation site chemistry as our PYX-201 ADC was observed to improve the stability and tolerability over conventional ADCs conjugated with the same linker-payload in preclinical studies (NG: next generation).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Enhanced anti-tumor activity through bystander activity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As depicted in Figure 10 below, bystander activity occurs when payloads that are delivered to target cells diffuse into and kill neighboring cells in the tumor microenvironment and is of particular importance if the target is not uniformly expressed on all tumor cells. Bystander activity also has the potential to overcome resistance that may occur over time to treatment with ADCs, carrying non-bystander active payloads, as anti-tumor activity is not directly tied to antigen expression at the target site and destruction of a single target cell. We believe our toolkit of novel and validated payloads, linkers and site-specific conjugation techniques will allow us to further develop ADC candidates with bystander activity that may result in greater clinical activity, especially in cases with heterogeneous target expression. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 10</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_9.jpg" alt="img29677477_9.jpg" style="width:618px;height:304px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the potential advantages of our next-generation ADC platform that utilizes preclinically optimized payloads and site-specific conjugation compared to the currently approved ADCs using conventional conjugation:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:23.036%;"></td>
    <td style="width:38.601%;"></td>
    <td style="width:38.363%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Pyxis Oncology's Next-Generation ADCs</span></p><p style="border-top:1.000pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:4.0pt;margin-top:1.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Conventional ADCs</span></p><p style="border-top:1.000pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:4.0pt;margin-top:1.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Potential Therapeutic Index</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;padding-left:0.100in;vertical-align:top;"><div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8 &#x2013; 16</span></div></div></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;padding-left:0.100in;vertical-align:top;"><div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1 &#x2013; 5</span></div></div></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Linker</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Site-specific conjugated linkers designed to target a specific DAR and high therapeutic index</span></div></div><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.1701388888888889in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Highly stable linkers designed to prevent premature release of payload</span></div></div></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-site-specific conjugation results in heterogenous DAR</span></div></div><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.1701388888888889in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many linkers are labile, resulting in premature release of payload and systemic toxicity</span></div></div></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Payload</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Extensive array of payloads available to match tumor biology for optimal tumor killing</span></div></div><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.1701388888888889in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payloads include microtubule inhibitors and DNA damaging agents whose potential mechanism of action has been shown to induce immunogenic cell death in preclinical models for combination with immunotherapy</span></div></div></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;padding-left:0.100in;vertical-align:top;"><div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Due to the labile nature of linkers, some conventional ADCs are built with less potent payloads</span></div></div></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our ADC Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PYX-201: Site-Specific Investigational ADC Targeting Onco-Fetal Fibronectin EDB</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ADC PYX-201 is an investigational human IgG1 isotype site-specifically conjugated with an auristatin toxin targeting EDB that we plan to initially develop for the treatment of non-small cell lung cancer, or NSCLC, breast cancer and other solid tumors. We licensed worldwide rights to PYX-201, built on the FACT platform, from Pfizer. We expect to submit an IND in the second half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Non-Small Cell Lung Cancer Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">NSCLC is a highly prevalent cancer with over 200,000 newly diagnosed patients per year in the United States representing 80-85% of lung cancers and remains the most common cause of cancer related deaths worldwide. The rate of new cases of lung cancer was 53.1 per 100,000 men and women per year. The death rate was 36.7 per 100,000 men and women per year. Per National Cancer Institute, SEER Cancer Statistics Review, in 2018, there were an estimated 582,631 people living with lung cancer in the United States. NSCLC encompasses subtypes of large cell, squamous cell, and adenocarcinoma, with adenocarcinoma accounting for over half of all cases. NSCLC is classified into four stages (I through IV) of disease, depending on how much the cancer has spread. For localized NSCLC (stages I and II), surgery, radiation, and chemotherapy are the first line of therapy. Although surgery is potentially curative in stage one NSCLC, 35-55% of those patients will have a recurrence of their cancer. In addition, roughly 50% of lung cancers are metastatic at diagnosis, and 20-24% are locally advanced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For later stages III and IV, chemotherapy, radiation, and immunotherapies are used. For patients with non&#x2013;small-cell adenocarcinomas, biomarker testing can identify genomic biomarkers, which may be druggable and eligible for treatment with targeted therapies. The treatment paradigm for metastatic NSCLC has shifted dramatically with the introduction of targeted therapies addressing druggable driver mutations, such as tyrosine kinase inhibitors, and immunotherapies such as PD-(L)1 checkpoint therapies. However, despite the initial success, resistance to targeted and immunotherapies almost invariably develops and ultimately, chemotherapy becomes the best available option. The five-year survival rate of metastatic NSCLC patients remains only at 7% and effective treatment options beyond frontline therapy are needed for this patient population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Breast Cancer Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Breast Cancer is the second most frequently diagnosed malignancy globally. Breast cancer has an incidence of over 250,000 annually in the United States. The rate of new cases of female breast cancer was 129.1 per 100,000 women per year. The death rate was 19.9 per 100,000 women per year. Per National Cancer Institute, SEER Cancer Statistics Review, in 2018, there were an estimated </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,676,262</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> women living with </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">female breast </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cancer in the United States. Most breast cancer patients have disease confined to the breast (stage I to II), however, approximately 20-30% of all breast cancer patients will develop metastatic disease, and the five-year survival is less than 30%. The spectrum of breast cancers includes various clinical subtypes based on expression of certain hormone receptors, or HR, such as estrogen receptors, or ER, and progesterone receptors, or PR, or human epidermal growth factor receptor 2, or HER2. Triple negative breast cancer is a clinical subtype where there is no expression of the identified proteins. The current treatment paradigm still exhibits high unmet need for more effective treatment options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rationale for Targeting EDB and Mechanism of Action for PYX-201</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fibronectin is a component of the extracellular matrix and its downstream signaling pathways regulate cell adhesion, migration, differentiation, and wound healing. EDB is an alternatively spliced form of fibronectin, which occurs when RNA is re-arranged to produce multiple variants of the same protein. EDB is typically only spliced during embryogenesis and is rarely found in healthy adult tissues. However, cancer cells take advantage of EBD&#x2019;s ability to promote neo-vasculature structures, which are critical to feeding and supporting the uncontrolled growth of a tumor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EDB is overexpressed in a variety of cancers, including, but not limited to, cancers of the lung, breast, ovary, pancreas, head and neck, thyroid, and brain (Figure 11). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">In vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> studies have shown that down regulation of EDB resulted in a significant reduction in cancer motility. Furthermore, EDB expression is maintained in distal metastasis in human cancer. EDB meets our criteria of a highly desirable ADC target due to its strict preferential expression in tumor tissue and its role as a driver of the poor prognosis in many cancers. Our primary lead indications, NSCLC and breast cancer, were chosen on the basis of unmet need, preclinical data generated, and the well-characterized role EDB plays in these tumors&#x2019; pathology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 11</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_10.jpg" alt="img29677477_10.jpg" style="width:618px;height:489px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">EDB is highly expressed in a variety of solid tumors with restricted normal tissue expression (IHC: Immunohistochemistry; mRNA: Messenger RNA; TCGA: The Cancer Genome Atlas portal; GTEX: Genotype-Tissue Expression portal).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PYX-201 was developed using the FACT platform to produce an ADC designed to be highly stable and target a DAR of four. The complementarity-determining regions, or CDRs, of the EBD antibody used in PYX-201, which is the part of the antibody responsible for binding to EDB, is well characterized and has been tested clinically in the form of a radio-conjugated antibody for tumor imaging&#x2014;demonstrating a high degree of tumor-directed specificity. Furthermore, PYX-201 is designed to optimize linker stability to enable delivery of the auristatin payload without required internalization of the ADC into the cancer cell. Unlike currently approved ADCs which bind to the tumor cell surface, PYX-201 is designed to deliver the auristatin payload to the TME consisting of tumor cells, stromal cells and the surrounding blood vessels. PYX-201 is designed to exhibit anti-tumor activity through three distinct modes of action, as illustrated in Figure 12 below. PYX-201 may be internalized prior to extracellular cleavage of the linker due to fibronectin turnover, resulting in the release of the payload in the tumor cell.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Direct killing activity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: After binding to EDB locally expressed in the TME, cathepsin B, a protease which is aberrantly overexpressed in and secreted by invasive and metastatic cancers, cleaves the linker enabling the cell-permeable auristatin toxin to kill both the tumor and stromal cells, which play a key role in maintaining the TME. PYX-201 is designed to attack the tumor and the stromal cells, and thus may remodel the TME and may enhance T cell activity. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Bystander effect</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Releasing the payload extracellularly within the TME may also confer added cytotoxicity via bystander activity, which may enable killing of cancer cells that do not express EDB. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Immunogenic cell death</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Lastly, auristatin has been shown in preclinical models to drive immunogenic cell death by causing the release of tumor antigens and damage-associated molecular patterns, or DAMPs, and promoting dendritic cell maturation and activation, which together initiates an adaptive immune response. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Taken together, we believe that PYX-201 may potentially generate a multi- pronged attack on difficult-to-treat cancers by directly killing cancer cells, modulating the TME, and mobilizing an anti-tumor immune response.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 12</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_11.jpg" alt="img29677477_11.jpg" style="width:544px;height:391px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PYX-201 is designed to bind Fibronectin EDB in the surrounding stroma to kill tumor cells and the supporting infrastructure through direct payload-induced cell death, bystander effect and triggering immunogenic cell death based on data from preclinical models</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical Data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PYX-201 has shown promising preclinical results. In preclinical studies, we have observed strong </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in-vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> activity in NSCLC PDX and in the EMT-6 syngeneic mouse breast cancer models. While PDX mouse models are generated by grafting patient derived cells to immune deficient mice, syngeneic mouse models are grafted with tumors derived from mice which allow the immune system to remain intact. As a result, while PDX models provide the most clinically translatable signals of efficacy in a preclinical setting, syngeneic models allow us to assess the ability of PYX- 201 to generate an immune response. In these syngeneic models, we have been able to show that PYX-201 effectively localizes to cancers and can generate not only significant reductions in tumor burden but can also mobilize an anti-tumor immune response.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In a PDX model of NSCLC, PYX-201 was intravenously administered four days apart for twelve days and a dose-dependent regression in tumor burden and a durable response at 3 mg/kg was observed (Figure 13).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 13</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_12.jpg" alt="img29677477_12.jpg" style="width:609px;height:325px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PYX-201 has been shown to be highly active in a PDX model of NSCLC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The anti-EDB human mAb used in PYX-201 is cross-reactive with mouse EDB-fibronectin. As a result, in syngeneic tumor models conducted in immune competent mice, PYX-201 achieved a durable response with a single dose of 9 mg/kg (Figure 14). In preclinical studies, we observed increased infiltration in CD3 T cells and upregulation of PD-L1 which suggests that PYX-201 may be capable of inducing immunogenic cell death. Combining sub-optimal doses of PYX-201 with checkpoint therapy resulted in synergistic inhibition of tumor growth in the EMT-6 model. Consequently, we believe PYX-201 may synergize with checkpoint inhibitors, as shown in Figure 15. PYX-201 was also well-tolerated in our mouse models and toxicology studies conducted in rat and cynomolgus monkeys. In an exploratory toxicology study in cynomolgus monkeys the HNSTD was found to be greater than 12 mg/kg with three doses of PYX-201 administered every three weeks. There was no differential in body weight or food consumption detected and based on the types of toxicities observed (i.e., no fibrosis, neuropathology etc.), all toxicities are reversible, or are expected to be reversible. PYX-201 was observed to have a preclinical relevant therapeutic index of 16 (the HNSTD in monkeys was 144 mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and was 16 times greater than the dose required for a complete response in mice of 9 mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">), which we believe is promising based on our experience investigating the relative therapeutic index among different ADC constructs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 14</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_13.jpg" alt="img29677477_13.jpg" style="width:618px;height:187px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_14.jpg" alt="img29677477_14.jpg" style="width:431px;height:221px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PYX-201 treatment in vivo of syngeneic cell-derived tumor models has been associated with enhanced T cell infiltration based on increased CD3 positivity. (CR: complete response; rcEDB: Reverse Chimeric EDB)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 15</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_15.jpg" alt="img29677477_15.jpg" style="width:617px;height:511px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">EDB vc0101 ADC combines with anti-PD-L1 and anti-41-BB to synergistically reduce tumor growth in EMT6 mouse syngeneic model</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Development Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to submit an IND by in the second half of 2022. Subject to the FDA&#x2019;s acceptance, we plan to conduct a Phase 1/2 dose escalation/expansion trial consistent with other Phase 1/2 clinical trial models for solid tumors. Initially, we plan to enroll NSCLC and breast cancer patients and patients with other tumor types with a high frequency of EDB expression to identify a recommended dose for separate expansion cohorts in tumor types that demonstrated activity in dose escalation. We may pursue the development of PYX-201 as a combination therapy with the standard of care as appropriate in future studies. For example, in NSCLC and breast cancer, where immunotherapy is widely used in both first and second-line settings, PYX-201 may provide a synergistic treatment benefit since the auristatin payload has been observed in preclinical studies to trigger hallmarks of immunogenic cell death.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PYX-202: Rationally Designed, Site-Specific, Investigational ADC Targeting Delta Like Non-Canonical Notch Ligand 1</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ADC PYX-202 is an investigational novel ADC consisting of an IgG1 anti-Delta-like 1 homolog, or DLK1, mAb site-specifically conjugated to MMAE via a plasma- stable &#xdf;-glucuronide linker. Our development plan is initially targeted at the treatment of SCLC, soft tissue sarcoma, or STS, and other solid tumors. We licensed worldwide rights to PYX-202, excluding South Korea, from LegoChem. See &#x201c;Licensing and Collaboration Agreements&#x201d; in Item 1. Business in this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Small Cell Lung Cancer Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Approximately 30,000 SCLC patients are diagnosed per year in the United States, representing approximately 15% of all lung cancers. The majority of patients present with symptoms including worsening fatigue, cough, shortness of breath, chest pain, or weight loss, and are diagnosed using imaging (e.g., CT scan, MRI scan) and a biopsy. At the time of diagnosis, more than 90% of patients having locally advanced or metastatic disease at diagnosis. Complete remissions are rare as 75-80% of patients relapse within two years, and response rates in the second-line setting have typically been between 14-30%. Over half of diagnosed patients are expected to require two or more lines of therapy. The five-year survival rates are dismal at only 6%. The disease is typically classified into two main stages: limited disease (LD-SCLC) and extensive disease (ED-SCLC), depending on how localized the tumors are to the ipsilateral hemithorax. For patients with LDSCLC, a combination of radiotherapy along with chemotherapy is the first line of treatment, while the first-line treatment of ED-SCLC is combination chemotherapy alone or in combination with immune checkpoint inhibitors. The median overall survival for patients with extensive-stage SCLC is reported to be 8-13 months from the time of diagnosis. Beyond progression, lurbinectedin and topotecan are standard treatment options used in the second/third line setting and only offer a median survival of four to five months. Effective therapy in this patient population represents high unmet need.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Soft Tissue Sarcoma Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2020, approximately 13,000 patients were diagnosed with soft tissue sarcoma in the United States, of which about 10% and 40% of patients will either initially present or develop metastatic disease, respectively. Patients with metastatic disease have a poor overall survival ranging from 12-18 months&#x2014;less than 20% of patients are alive after two years. The current standard of care treatment for metastatic patients is typically a combination of doxorubicin as a monotherapy or in combination with ifosfamide and the median overall survival is approximately 12-14 months. There are limited treatment options beyond chemotherapy medicines, therefore there is significant unmet need for alternative therapeutic options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rationale for Targeting DLK1 and Mechanism of Action for PYX-202</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DLK1 is a transmembrane protein and non-canonical ligand for Notch, which is implicated in the proliferation, differentiation, and survival of tumor cells. DLK1 plays a key role during fetal development and is involved in the terminal differentiation of the fat, muscle, liver, and pituitary gland, and furthers epithelial branching in the lung and pancreas. DLK1 is absent in most tissues at birth, and in adults, its expression is limited in low amounts to the adrenal and pituitary glands, pancreas, ovary, endometrium, and testis. In certain tumor types, DLK1 is significantly upregulated and has been shown to promote invasion and support the maintenance of cancer stem cells, a subset of cells that has been linked to drug resistance and relapse (Figure 16). In addition to SCLC and STS, DLK1 is also known to be overexpressed in AML and tumors of neuroendocrine origin such as neuroblastoma and rhabdomyosarcoma.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 16</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">DLK1 Expression in Various Tumors by IHC</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.839%;"></td>
    <td style="width:26.925%;"></td>
    <td style="width:14.821%;"></td>
    <td style="width:15.06%;"></td>
    <td style="width:9.355%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.750pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;border-left:0.750pt solid rgba(0,0,0,1);padding-left:0.083in;vertical-align:bottom;border-bottom:1.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Tumor</span></p></td>
    <td style="border-top:0.750pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:1.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="border-top:0.750pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:1.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">DLK1 (-)ve</span></p></td>
    <td style="border-top:0.750pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:1.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">DLK1 (+)ve</span></p></td>
    <td style="border-top:0.750pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.750pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:1.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;border-left:0.750pt solid rgba(0,0,0,1);padding-left:0.083in;vertical-align:top;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Colon Andenocarcinoma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24 (41.4%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34 (58.6%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.750pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;border-left:0.750pt solid rgba(0,0,0,1);padding-left:0.083in;vertical-align:top;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ovarian Carcinoma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59 (86.8%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9 (13.2%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.750pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td rowspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;border-left:0.750pt solid rgba(0,0,0,1);padding-left:0.083in;vertical-align:middle;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pancreatic Carcinoma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Duct Andenocarcinoma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33 (71.7%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13 (28.3%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.750pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.750pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Islet Cell Carcinoma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3 (50%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3 (50%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.750pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;border-left:0.750pt solid rgba(0,0,0,1);padding-left:0.083in;vertical-align:top;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Breast Carcinoma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36 (61.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23 (39.0%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.750pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td rowspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;border-left:0.750pt solid rgba(0,0,0,1);padding-left:0.083in;vertical-align:middle;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lung Carcinoma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">NSCLC</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51 (91.1%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 (8.9%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.750pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.750pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SCLC</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19 (47.5%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21 (52.5%)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.750pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">DLK1 expression was determined by IHC, with DLK1 positive tumors containing more than 10% immunopositive stained cells (either cell membrane or cytoplasmic staining). Source: Yanai H, et al., J Biochem. 2010; 148(1):85.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Due to preferential expression and as a driver of a poor prognosis in many cancers, DLK1 meets the requirements of an ADC target. Our primary lead indications, SCLC and STS, were chosen on the basis of multiple factors including unmet need, preclinical data generated, and the well-characterized role DLK1 plays in its disease pathology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 17</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_16.jpg" alt="img29677477_16.jpg" style="width:548px;height:452px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PYX-202 is designed to be rapidly internalized and the MMAE payload cleaved by glucuronidase within the lysosome to target tubulin and induce tumor cell death. Additionally, bystander effect may augment tumor cell killing by targeting neighboring tumor cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PYX-202 is designed to rely upon a tumor-selected beta-glucuronide linker with great plasma stability to deliver a MMAE payload and to limit off-target toxicities. MMAE auristatin is a well-characterized tubulin inhibitor which is currently used in FDA-licensed ADCs such as brentuximab vedotin, polatuzumab vedotin-piiq, and enfortumab vedotin-ejfv. PYX-202 exhibits anti-tumor activity through five distinct modes of action, as illustrated in Figure 17 above:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Targeting</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: PYX-202 consists of an IgG1 anti-DLK1 mAb designed to enable efficient binding to DLK1 molecules expressed on the tumor cell surface. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Internalization</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Once bound to its target, the anti-DLK1 mAb is rapidly internalized into the DLK1-expressing cancer cell. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Drug release</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: The payload, attached to the anti-DLK1 mAb via a stable </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">b</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-glucuronide linker, is released when PYX-202 interacts with &#xdf;-glucuronidase, an enzyme readily present in lysosomes, after internalization into the cancer cell. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">4.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Bystander effect</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Payload released from DLK1-positive target cells may confer added cytotoxicity via bystander activity, which may enable killing of cancer cells that do not express DLK1. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">5.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Apoptosis and Immunogenic cell death</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: MMAE, like other derivatives of auristatins, potentially induces immunogenic cell death and the maturation and activation of dendritic cells based on preclinical studies. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our novel approach employs a site-specific conjugation of a well-studied tubulin inhibitor for enhanced ADC stability targeting a DAR of four and improved construct stability. Taken together, we believe that PYX-202 has the potential to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells or via the bystander effect and mobilizing an anti-tumor immune response.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical Data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PYX-202 has shown promising </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">activity in immune-deficient mice engrafted with patient-derived SCLC tumors. In these PDX models, PYX-202 was intravenously administered every four days for 12 days and caused significant decrease in tumor volume at doses as low as 2 mg/kg and durable regression at 6 and when dosed once a week for four weeks at 9 mg/kg in some mice. In addition, treatment with PYX-202 resulted in durable regressions in the NCI-H69 CDX model</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.36pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Figure 18).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 18</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_17.jpg" alt="img29677477_17.jpg" style="width:617px;height:236px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_18.jpg" alt="img29677477_18.jpg" style="width:438px;height:264px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Activity of PYX-202 was highly active in PDX and cell-derived xenograft models of SCLC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The anti-DLK1 human mAb used in PYX-202 is cross-reactive with mouse and cynomolgus DLK1. In an exploratory toxicology study in cynomolgus monkeys the HNSTD was found to be equal to or greater than 12 mg/kg with a single dose of PYX-202 administered. No findings for body weight, body temperature, food consumption, serum chemistry, or histology were found after a single 12 mg/kg dose. PYX-202 has a preclinical relative therapeutic index of eight (the HNSTD in monkeys is 144 mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is eight times greater than the dose required in mice of 18 mg/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the equivalent of 6mpk)), which, based on our experience investigating the relative therapeutic index among different ADC constructs, we believe is promising.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Development Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In preclinical small cell lung cancer, or SCLC, PDX models, as well as in a human cell line-based, or CDX, mouse model of cancer, which were conducted by LegoChem, we have observed significant anti-tumor activity as measured by durable tumor regression. In preparation for our IND filing and based on observation of our GLP studies to date, we have determined that we will need to conduct additional GLP and non-GLP toxicity studies to determine whether PYX-202 is a viable clinical candidate. We will continue to monitor the progress of our PYX-202 program and expect to provide an update about PYX-202 in mid-2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PYX-203: Rationally Designed, Investigational, Site-Specific ADC Targeting CD123</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ADC, PYX-203, is an investigational human IgG1 isotype mAb targeting CD123 that is site-specifically conjugated to the DNA cross linking toxin CPI dimer that we plan to develop for the treatment of AML and other blood cancers. CD123 is a cell surface antigen widely expressed in AML, including on leukemic stem cells. We licensed worldwide rights to PYX-203 built on the FACT platform. We expect to submit an IND in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acute Myeloid Leukemia Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acute Myeloid Leukemia (AML) is a hematopoietic stem/progenitor cell malignancy, characterized by an aberrant proliferation of abnormal myeloid progenitor cells unable to differentiate into mature blood cells. In 2021, the American Cancer Society estimates there will be approximately 20,000 new cases of AML diagnosed, with incidence increasing with age (median age at diagnosis is 68 years). This accounts for approximately 1% of all new cancer cases in the United States. The rate of new cases of AML was 4.3 per 100,000 men and women per year. AML is a highly heterogeneous disease, although it can be broken down into favorable, intermediate, and adverse-risk groups based on their cytogenetic profile. The majority of patients present with a combination of leukocytosis and signs of bone marrow failure (i.e., thrombocytopenia) and are diagnosed by the presence of 20% or more blasts in the bone marrow or peripheral blood. Standard of care consists of an initial round of induction therapy, if eligible, consisting of what is known as a &#x201c;7+3&#x201d; regimen&#x2014;7 days of continuous infusion with cytarabine with 3 days of anthracycline. Overall, roughly 60%-80% of patients will achieve a complete remission with induction therapy and may be eligible for an allogeneic hematopoietic stem cell transplant (allo-HSCT). Despite a high remission rate after initial treatment, approximately 50-70% patients experience a relapse. The five-year overall survival remains low at approximately 29%, and there is a significant unmet need for patients who relapse after successful first-line treatment or become refractory and resistant to current treatments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Myeloid Dysplastic Syndrome, or MDS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">MDS is a group of disorders characterized by peripheral cytopenia, dysplastic hematopoietic progenitors, a hypercellular or hypocellular bone marrow and a high risk of conversion to AML. Distinct mutations of stem cells are found most frequently in genes involving RNA splicing. It most commonly affects the elderly and up to 20,000 new cases are diagnosed each year in the United States. Symptoms tend to reflect the most affected cell line and may include pallor, weakness and fatigue, fever and infection, bruising and bleeding. Prognosis depends greatly on the exact classification and on any associated disorders. The Revised International Prognostic Scoring System predicts the outcome using cytogenetics, percentage of marrow blasts and degree of cytopenia as risk factors. Patients in the lowest risk category have a median survival of about 8 years whereas those in the highest risk category have a median survival of less than 1 year. Treatment includes symptomatic management, chemotherapy with azacitidine, decitabine or lenalidomide. The one curative therapy is allogeneic stem cell transplant which can only be used in younger medically fit patients. Given the poor outcomes with current treatment there is a large unmet need for novel well tolerated therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rationale for Targeting CD123 and Mechanism of Action for PYX-203</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CD123, also known as interleukin-3 receptor alpha, or IL-3R</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf061;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, is a cell surface antigen that is widely overexpressed on leukemic stem cells, or LSCs, and leukemic blasts in various hematological malignancies, including AML, hairy cell leukemia, Hodgkin lymphoma, and blastic plasmacytoid dendritic neoplasm, or BPDCN. Multiple studies have demonstrated that CD123 expression is significantly lower in normal myeloid progenitors and that high levels of CD123 expression may be associated with worse clinical outcomes and overall survival. Taken together, CD123 is an attractive oncology target that has been exploited by multiple therapeutic modalities, including bispecific antibodies, CAR-T therapies, and other ADCs. In 2018, the FDA approved tagraxofusp-erzs for BPDCN, making it the first ever CD123 targeted agent approved for any indication. Our primary lead indication in AML was chosen based on unmet need, preclinical data generated, and the well-characterized role CD123 overexpression plays in the disease pathology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 19</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_19.jpg" alt="img29677477_19.jpg" style="width:620px;height:217px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">CD123 is highly expressed on AML cells, including leukemic stem cells, or LSC, with limited expression on hematopoietic stem cells, or HSC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PYX-203 leverages site-specific conjugation through the FACT platform with the goal of targeting a DAR of 2 and high construct stability. PYX-203 uses a plasma-stable, cleavable linker with a novel CPI dimer payload designed to alkylate and crosslink DNA to activate multiple DNA damage pathways. In our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cell line models, we have observed that our CPI dimer payload overcame multi-drug resistance, or MDR, and effectively killed cell lines resistant to either cytarabine or calicheamicin which is the payload used in gemtuzumab ozogamicin (Pfizer, Inc.), an FDA approved ADC for AML. The mutations introduced for site-specific conjugation also eliminate the N297 glycation site. Absence of antibody glycation eliminates binding to FC gamma receptors, or Fc</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rs, and consequently may reduce non-specific uptake of the ADC into Fc</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">R expressing immune cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 20</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_20.jpg" alt="img29677477_20.jpg" style="width:618px;height:604px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PYX-203 is designed to delivers a highly potent DNA-crosslinking payload (CPI) to kill CD123 expressing cells. The ADC 1) is designed to targets CD123 expressing cells and upon binding to the target 2) is designed to be internalized by AML cells, where 3) the CPI payload is to be cleaved by cathepsin B proteases within the lysosome and cross-link DNA interstrands to 4) induce tumor cell death.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical Data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have extensively tested PYX-203 in a variety of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preclinical studies. Dose-dependent cytotoxicity of PYX-203 was observed in CD123+ MOLM13 and MV4-11 AML cell lines and PYX-203 did not exhibit cytotoxicity against CD123-negative cell lines (Figure 21). In addition, data from those studies did not show that the cytotoxicity of PYX-203 was not affected by the presence of recombinant human IL-3, which binds CD123 endogenously to transmit IL-3 signals, thereby suggesting that IL-3 may not compete with PYX-203 at the CD123 target site.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 21</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_21.jpg" alt="img29677477_21.jpg" style="width:618px;height:216px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">In vitro cytotoxicity assay of PYX-203 in MV4-11 and MOLM-13 cells in the absence or presence of recombinant human IL-3 (rIL-3), which showed IL-3 did not affect PYX-203 specificity or cytotoxicity. Viability was measured by Cell titre Glo (CTG) luminescent cell viability assay kit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cytotoxicity, significant anti-tumor activity of PYX-203 has been observed preclinically as measured by the reduction in the frequency of the leukemic cells in the blood and bone marrow in nine disseminated AML PDX mouse models which were selected to represent the broad heterogeneity of AML cytogenetic profiles, molecular abnormalities, and disease stages observed clinically. PYX-203 doses of 0.1 and 0.03 mg/kg were associated with significant anti-tumor activity across this range of samples from subsets of AML patients, suggesting PYX-203 may have the potential to treat a broad spectrum of the AML population (Figure 22).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 22</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_22.jpg" alt="img29677477_22.jpg" style="width:517px;height:360px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_23.jpg" alt="img29677477_23.jpg" style="width:516px;height:382px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PYX-203 has demonstrated anti-tumor activity in a range of AML models in vivo</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The anti-CD123 human mAb used in PYX-203 is cross-reactive with cynomolgous CD123. PYX-203 has exhibited favorable tolerability data in toxicology studies conducted in non-human primates. Moderate decreases of white blood cell counts were observed in PYX-203 at doses up to 1 mg/kg in non-human primates. Single dose studies in rat demonstrated improved tolerability for PYX-203 compared to a similarly prepared ADC using anti-CD33 as a model antibody conjugated to the pyrolobenzodiazepine, or PBD, or calicheamicin payloads (internal data). PYX-203 had a preclinical relative therapeutic index of 8 (the HNSTD in monkeys was 12 mg/m2 which is eight times greater than the dose required for a complete response in mice of 1.5 mg/m2). In addition, these data, which are supported by the literature, shows that CD123 expression was restricted to specific cell types of peripheral blood and bone marrow cells in human and cynomolgus monkeys which we believe may translate to lower off-target toxicity in the clinic as compared to CD33, the target of gemtuzumab ozogamicin. PYX-203 was tested preclinically with three doses of 1 mg/kg and 3 mg/kg, with doses </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#163;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1 mg/kg associated with minimal and non-adverse toxicity events. This corresponded to a TI of 8, with the bone marrow and esophagus identified as the organs of primary dose-limiting toxicity in cynomolgus monkeys.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Development Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to submit an IND in the second half of 2023. Subject to the FDA&#x2019;s acceptance, we plan to conduct a Phase 1/2 dose escalation/expansion trial consistent with other Phase 1/2 clinical trial models for hematologic malignancies. Initially, we plan to enroll AML and with other hematologic malignancies with a high frequency of CD123 expression to identify a recommended dose for separate expansion cohorts in tumor types that demonstrated activity in dose escalation. To examine the potential benefit of PYX-203 in a broader range of patients in earlier stages of the disease, we may pursue combination therapy with the standard of care as appropriate in future studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Immuno-Oncology Programs and Target Catalog Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Background on Current Immuno-Oncology Therapeutics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The advent of immuno-oncology therapeutics, particularly immune checkpoint inhibitors, has shifted the treatment paradigm for oncology. The immune system has the capability to recognize and eliminate cancer, but tumor cells take advantage of immune checkpoint pathways, which normally prevent autoimmunity, to suppress and evade immune effector cell activity. The first generation of drugs that interrupt these pathways, including PD-L(1) and cytotoxic T-lymphocyte associated protein 4, or CTLA-4, inhibitors, has generated significant enthusiasm due to their ability to achieve durable responses in some patients. While these drugs provide significant therapeutic benefit for durable responders, response rates remain low for most patients, particularly for tumors with low levels of T cells infiltrating the tumor. These non-inflamed (i.e., &#x201c;cold&#x201d;) tumors can suppress the adaptive immune response through a variety of mechanisms within the TME.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Target Catalog Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have a large proprietary target catalog that we have assembled through both our own discovery activities and through an exclusive license from the University of Chicago for the work on immunotherapy targets out of Dr. Thomas Gajewski&#x2019;s laboratory. We are also building a large &#x201c;cold&#x201d; tumor target discovery database leveraging several human tumor databases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The target catalog is based upon findings from an in vivo mouse model system which examined tumor tissue for functional and dysfunctional T cells based on the ability of the T cells to produce the cytokine IL-2. Furthermore, since 4-1BB and LAG3 positive T cells do not secrete IL-2, the CD8+ T cells were sorted based on cell surface marker expression i.e., 4-1BB and LAG3, which further defined functional or dysfunctional T cells. Gene expression analysis identified upregulated cell surface molecules in dysfunctional cells which included well established markers such as PD1, CTLA4, and TIM3, while many other novel targets were identified of which we have prioritized a select subset for discovery research based on bioinformatics and deep biological rationale.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our cold tumor target discovery database used RNA-seq transcriptome analysis of human tumor databases to identify potential novel targets involved in regulation of T cell function and/or infiltration leading to cold tumors. We have supplemented this database with additional resources which we continue to mine to identify additional novel targets for immunomodulation. These cold tumor targets are potentially dominant immune suppressors that are expressed across a variety of tumor associated cells, including immune cells, tumors cells, and stroma, offering the potential to uncover not only novel IO mechanisms, but additional novel targets for our ADC platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Immuno-Oncology Programs Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have initiated multiple monoclonal antibody programs that address critical immunomodulatory pathways within the TME and are exploring additional potential targets. Our programs address critically important tumor infiltrating immune cell populations, such as macrophages, T cells, and natural killer (NK) cells, which may play crucial roles in limiting tumor growth and metastasis. In addition to singling out specific cell types, we believe our IO programs also address mechanisms responsible for T cell exhaustion and the immunosuppressive effects of the TME on T and NK cells. These effects can occur due to chronic exposure to tumor antigens within the TME and direct exposure to immunosuppressive cytokines and other signaling molecules. Though PD-(L)1 therapies can help reinvigorate T cells, they are often not sufficient to overcome T cell exhaustion and many patients do not respond to standard checkpoint therapy. Several immunosuppressive pathways can also directly limit T cell activity and other critical components of the anti-tumor immune response, such as direct tumor killing by NK cells. Therapies that target both T cell and NK cells to counteract these pathways have the promise to restore immune effector function, either alone or in combination with checkpoint inhibitors. Furthermore, MDSCs/TAMs are another major component of the TME with significant immunosuppressive activity. These cells represent a mixed population of immature myeloid cells and are actively recruited to the TME where they broadly suppress immune activity. MDSCs and tumor-associated macrophages, or TAMs, support tumor growth by depriving other immune cells of key amino acids essential for immune function, producing signaling molecules that block immune effector function, and enhancing activation of regulatory T cells. Furthermore, MDSCs and TAMS promote tumor angiogenesis and growth and are a marker associated with poor outcomes and linked to poor response to PD-(L)1 therapy. We believe our IO programs represent potential novel therapies that have the potential to overcome multiple protumor mechanisms by enhancing T and NK cell activity, or by inhibiting immune suppressive functions of MDSCs and TAMs within the TME.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PYX-106: Investigational IgG1 isotype anti-Siglec-15 Targeting Antibody</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PYX-106 is an investigational fully human IgG1 isotype antibody that is designed to block Siglec-15 mediated suppression of T-cell proliferation and function. We plan to initially develop this asset for the treatment of thyroid cancer, Head &amp; Neck Squamous Cell Carcinoma, or HNSCC, non-small cell lung cancer, or NSCLC, and other solid tumors. We licensed worldwide rights to our Siglec-15 targeting antibody from Biosion USA, Inc. We expect to submit an IND in the second half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rationale for Targeting Siglec-15 and Mechanism of Action for our Siglec-15 targeting antibody</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Siglec-15 is a member of the Siglec family (Sialic acid-binding ImmunoGlobulin Lectins), a distinct subgroup of immunoglobulin (Ig) superfamily proteins involved in immune regulation. Siglecs recognize and bind to sialic acid on the surface of cells and this binding can affect cell signaling on immune cells. Siglec-15 is a single-pass type I membrane protein that has been shown to associate with the activating adaptor proteins DNAX activation protein (DAP)12 and DAP10 via its lysine residue in the transmembrane domain, implying that it functions as an activating signaling molecule. While Siglec-15 is minimally expressed on normal tissues, it is highly expressed on both tumor cells and M2 macrophages in the tumor microenvironment (TME) across multiple tumor types, including thyroid cancer, HNSCC, lung cancer, breast cancer, cholangiocarcinoma. The increased presence of highly immunosuppressive M2 macrophages within tumors leads to impaired T cell proliferation and function, causing a decreased anti-tumor immune response. Additionally, Siglec-15 may exacerbate this immunosuppressive effect by interacting with tumor associated myeloid cells to promote their survival and differentiation to drive a tumor-promoting environment. Interestingly, Siglec-15 appears to function independently from the PD-L1 pathway with largely non-overlapping expression in select tumor samples. Therefore, targeting Siglec-15 in the TME may be a promising therapeutic option for patients less likely to respond to a PD-1/PD-L1 targeted therapy.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An overview of the role of Siglec-15 in regulating the immune system and driving anti-tumor immune dysfunction.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Figure 23</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img29677477_24.jpg" alt="img29677477_24.jpg" style="width:616px;height:493px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Source: American Association for Cancer Research Journal - Cancer Clinical Research Review - Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy by Jingwei Sun, Qiao Lu, Miguel F. Sanmamed and Jun Wang)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Siglec-15 targeting antibody is a fully human monoclonal antibody and is engineered with high affinity to block Siglec-15 induced immune suppression and therefore restore T cell proliferation, function and anti-tumor immunity in the TME. Overall, by binding and blocking Siglec-15 activity on myeloid cells and tumors, our Siglec-15 targeting antibody is designed to enhance immune cell mediated tumor cell kill. Given the broad tumor expression profile of Siglec-15, our Siglec-15 targeting antibody has the potential to treat multiple oncology indications including those where PD-1/PD-L1 directed cancer therapies are ineffective. We are initially evaluating our Siglec-15 targeting antibody for the treatment of advanced or metastatic solid tumors, which could include thyroid cancer, HNSCC, NSCLC, breast cancer, and cholangiocarcinoma where high unmet need exists. We plan to submit an IND in the second half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Forging Creative Business Models and Alliances</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We continuously evaluate a robust set of business development opportunities to build alliances with partners. The set of opportunities include, but are not limited to, joint ventures, spin-offs, discovery partnerships and licenses. Furthermore, we intend to retain the optionality to explore the potential for creative business models.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The Voxall Joint Venture</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One such endeavor is Voxall Therapeutics, LLC, or Voxall, which is a 50:50 co-owned joint venture formed by us and Alloy Therapeutics, Inc., or Alloy, to accelerate the discovery and development of drugs to address cancer and autoimmune diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We bring to Voxall targets from our target catalog and expertise in stromal and immune biology while Alloy contributes its ATX-Gx transgenic mouse and other discovery services which accelerate antibody drug discovery. Both provide FTEs and project execution and project oversight. Under the collaboration agreement, the parties will conduct research under a mutually agreed research plan for up to six research programs focused on mutually selected targets. With this initial wave of targets, we retain an exclusive option to obtain an exclusive license to further develop and commercialize development candidates at our discretion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Additional Discovery Efforts</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe our broad expertise enables us to pioneer scientific scholarship in immune biology of the TME and beyond. We have a flexible pathway to do so via platform development, forging creative business models and alliance building, in-licensing and leveraging target catalogs to expand our portfolio of differentiated therapeutics for difficult-to-treat cancers. The realization of this vision will necessitate rapid innovation and operational excellence from a scientific and business perspective. As such, our mission is to take the next step towards creating an oncology company of the future &#x2014; an oncology company unconstrained by conventional ideas and conventional practices, an oncology company that will rise to meet the many and complex challenges of difficult-to-treat cancers, and an oncology company that will have a significant impact on the lives of patients with limited effective treatment options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biotechnology and pharmaceutical industries, including the oncology subsector, are characterized by rapidly evolving technologies, intense competition, and a strong defense of intellectual property and proprietary technologies. Any product candidates that we successfully commercialize may be competitive with currently marketed therapies and any new therapies commercialized in the future. While we believe our technology, drug development expertise, leadership team and strong scientific understanding of cancer targets and biology provides us with certain competitive advantages, we face potential competition from many sources, including major pharmaceutical, biotechnology, academic institutions, and other public and private research institutions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many companies are active across various stages of development in the oncology subsector and are marketing and developing products that employ similar ADC and immunotherapy approaches. As of April 2021, there were approximately 275 ADCs in clinical or preclinical development worldwide, of which the vast majority are being developed for the treatment of various cancer indications. Additionally, there are several large and small companies working on various immunotherapy approaches for treatement of cancer. Multiple companies are also involved in the marketing of ADC therapeutics and Immunotherapy which include, but are not limited to, ADC Therapeutics SA, Astellas Pharma, Inc., AstraZeneca plc, Daiichi Sankyo Company, Ltd., Genentech, Inc., Gilead Sciences, Inc, GlaxoSmithKline, plc, Pfizer, Inc., Rakuten Medical, Inc., Seagen, Inc., Nextcure, Inc. and Abcure, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our preclinical ADC and immunotherapy candidates may face substantial competition from alternative therapeutic modalities, such as CAR-T therapies, bispecific antibodies, and small molecules that are being developed for the same cancer types that we are targeting with our pipeline candidates. These approaches could prove to be more effective, safer, or convey other advantages over any products resulting from our technology. In addition, we also face competition on specific targets, including the target of our PYX-201 candidate, EDB, from Philogen S.p.A., the target of our PYX-202 candidate, DLK-1, from Chiome Bioscience, Inc., the target of our PYX-203, product candidate, CD123, from ImmunoGen, Inc., Vincerx Pharma, Inc., Macrogenics and Byondis B.V., the target of our PYX-106 product candidate, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BSI-060T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, from Nextcure, Inc. lead program - NC318 and the target of our PYX-102 product candidate, Anti-KLRG1, from Abcuro, Inc. Additionally, there is a wide array of activity in the development of immunotherapies for oncology which may be competitive with our preclinical discovery programs. Furthermore, if any of our product candidates are approved in oncology indications such as lung, hematological and other cancers, they may compete with existing approaches to treating cancer including surgery, radiation, and drug therapy, including conventional chemotherapy, biological products, and targeted drug small molecule therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our competitors may possess greater scientific, research and development capabilities, as well as greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. These competitors compete with us on the basis of establishing clinical trial sites and patient registration, recruiting and retaining qualified scientific and management personnel, and acquiring new technologies that may complementary, or necessary for, our programs. Our commercial opportunity for our product candidates may be dependent on the ability of our competitors to develop new products that may be more effective, safer, or less expensive than any products that we may develop. Our competitors may succeed in developing competing products before we do, obtaining marketing approval for products and gaining acceptance for such products in the same markets that we are targeting. Smaller or earlier-stage companies that seek collaborative arrangements with large and established companies, may prove to be significant competitors. In addition, our ability to compete may be affected by the availability of reimbursement from government and other third-party payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competitive factors affecting the success of our programs, if approved, will likely be based on their safety and effectiveness, the timing and scope of marketing approvals, the availability and cost of supply, the depth of marketing and sales capabilities, and reimbursement coverage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chemistry, Manufacturing and Controls</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe the manufacturing of our ADCs and monoclonal antibodies requires considerable expertise, know-how, and resources. We do not own or operate and currently have no plans to establish any cGMP compliant manufacturing facilities. We currently rely, and expect to continue to rely, on external Contract Manufacturing Organizations, or CMOs, for the manufacture of product to support non-clinical and clinical testing, as well as for commercial manufacture if our product candidates receive marketing approval. Furthermore, the raw materials and intermediates for our product candidates may be sourced, in some cases, from a single-source supplier. As part of the manufacture and design process for our product candidates, we rely on internal scientific and manufacturing know-how and trade secrets and the know-how and trade secrets of third-party manufacturers. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our current product candidates. We maintain agreements with our manufacturers that include confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates. We have personnel with significant technical, manufacturing, analytical, quality, including cGMP, and project management experience to oversee our third-party manufacturers and to manage manufacturing and quality data and information for regulatory compliance purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commercialization Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We retain full commercialization rights for all our product candidates, including those obtained through exclusive collaboration agreements, with the exception of PYX-202 in South Korea and PYX-106 in Greater China (mainland China, Hong Kong, Macau and Taiwan). We have not yet established our own commercial organization or distribution capabilities because our product candidates are still in preclinical development. Should any of our candidates receive marketing approval or licensure in the United States or elsewhere, we will need to develop a plan to realize the commercial value of the approved product candidate. At the appropriate time, we plan to build our own specialized sales and marketing organization to support the sales commercialization of approved candidates in the United States. We may also pursue collaboration, co-promotion, distribution and/or other marketing arrangements with one or more third parties to commercialize our product candidates in markets outside the United States. We may also pursue these arrangements for situations in which a larger sales and marketing organization is necessary to realize the full commercial value of any approved wholly owned or collaboration product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Licensing and Collaboration Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with Pfizer, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, we entered into a license agreement, as amended, the &#x201c;Pfizer License Agreement,&#x201d; with Pfizer, Inc., or Pfizer, for worldwide development and commercialization rights to two of Pfizer&#x2019;s proprietary ADC product candidates (now referred to as PYX-201 and PYX-203), as well as other ADC product candidates directed to the licensed targets. The Pfizer License Agreement became effective for the Company in March 2021. The initial exclusively licensed targets are extra domain B (EBD of fibronectin) and CD123 and we have the option to expand the scope of our license to add other licensed targets. Pfizer has also granted us a non-exclusive license to use Pfizer&#x2019;s FACT platform technology to develop and commercialize the licensed ADCs. In March 2021, we entered into an amendment to the Pfizer License Agreement to include additional know-how within the scope of our license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Pfizer License Agreement, we incurred a combined $25.0 million for license fee, consisting of an upfront fee of $5.0 million and issued 12,152,145 shares of Series B convertible preferred stock in 2021 to Pfizer, and are obligated to pay future contingent payments and royalties, including up to an aggregate of $660 million in milestones for the first four licensed ADCs. Additional ADC targets may be licensed for an additional upfront fee, and such targets would be subject to additional regulatory and commercial sales milestones. Additionally, if products are launched, we will pay Pfizer tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to mid-teens. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) 12 years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. We are also obligated to pay Pfizer a percentage of certain sublicensing revenue ranging from low-double digits to thirty percent based on the stage of development of the licensed product at the time of entering into the applicable sublicense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Pfizer License Agreement, we are obligated to use commercially reasonable efforts to nominate a clinical candidate within four years of a target becoming a licensed target. We are also required to use commercially reasonable efforts to develop and seek regulatory approval for at least one licensed product directed to each licensed target in the United States and at least one other major market country (France, Germany, Italy, Japan, Spain and the United Kingdom), and to commercialize any licensed product in each such country after receiving regulatory approval. We control prosecution and enforcement with respect to any exclusively licensed patents, and Pfizer has prosecution and enforcement rights if we elect not to exercise such rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Pfizer License Agreement will remain in effect until the expiration of the last to expire royalty term, unless terminated in accordance with the following: (1) by either party for the other party&#x2019;s material breach if such party fails to cure such breach within the specified cure period; (2) by either party upon certain insolvency events of the other party; or (3) prior to receipt of the first regulatory approval for a licensed product, by us for any reason upon 90 days&#x2019; prior written notice, or after receipt of the first regulatory approval for a licensed product, by us for any reason upon one years&#x2019; prior written notice.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with the University of Chicago</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2020, we entered into a license agreement, or the &#x201c;University License Agreement,&#x201d; with the University of Chicago, or the University, to obtain an exclusive license under certain patents resulting from research performed, in-part, by our scientific founder, Dr. Thomas Gajewski, as well as a non-exclusive license to certain know-how and materials. Under the terms of the license, we have the exclusive global right to develop and commercialize products that are covered by a valid claim of a licensed patent, incorporate or use the licensed know-how and materials or are known to assess, modulate or utilize the activity of certain specified biological targets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In partial consideration for the license from the University, we issued to the University 48,919 shares of our Common Stock in 2020. Pursuant to the University License Agreement, we are obligated to pay to the University an annual maintenance fee of $10,000 commencing on the third anniversary of the effective date, potential development and commercial milestones of up to an aggregate of $7.7 million as well as running royalties on net sales of licensed products at varying rates ranging from less than one percent to the low single digits, subject to a minimum annual royalty ranging from $1.0 million to $3.0 million during certain years following the first commercial sale of a licensed product. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until: (1) for licensed products covered by a valid claim of a licensed patent in a given country, the expiration of such valid claims; and (2) for all other licensed products, 10 years from the first commercial sale of a licensed product in a given country. We are also obligated to pay the University a percentage of certain sublicensing revenue ranging from low- to mid-teens based on the date of entering into the applicable sublicense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the University License Agreement, we are obligated to use commercially reasonable efforts to develop and bring licensed products to market, meet certain preclinical and clinical development milestones by specific dates, and promote and sell licensed products after receipt of regulatory approval, subject to certain free and payment-based extensions. The University controls prosecution of the licensed patents at our cost and we have the first right to enforce the licensed patents subject to the University&#x2019;s backup enforcement rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The University License Agreement will remain in effect on a licensed product-by-licensed product basis until the expiration of all royalty obligations with respect to a licensed product, unless terminated in accordance with the following: (1) by the University upon 30 days&#x2019; prior written notice for any uncured payment breaches or 90 days prior written notice for all other uncured breaches; (2) by the University upon certain insolvency events or dissolution by us or any affiliate; or (3) by us in full or with respect to a particular licensed product at the end of the calendar quarter following the calendar quarter when we provide written notice of termination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The Voxall Joint Venture with Alloy Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, we entered into definitive transaction agreements with Alloy to finance and operate Voxall, a joint venture company formed in collaboration with Alloy to leverage Pyxis Oncology&#x2019;s site-specific target catalog and Alloy&#x2019;s ATX-Gx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.36pt;font-family:Times New Roman;">&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> platform and antibody discovery services.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Voxall granted to both Pyxis Oncology and Alloy 50% of the voting membership units of Voxall in exchange for certain initial contributions. Our initial contribution included $50,000 and a non-exclusive fully paid-up license to certain intellectual property owned or controlled by us to enable the collaboration with Voxall as further described below. Alloy&#x2019;s initial contribution included $50,000 and the execution of a license agreement and a services agreement to enable the collaboration with Voxall as further described below. Voxall is governed by a board of directors consisting of an equal number of our representatives and Alloy&#x2019;s representatives. We have designated our CEO, Lara Sullivan M.D., as our board representative. The protective provisions under Voxall&#x2019;s operating agreement require the approval of both Pyxis Oncology and Alloy before Voxall may take certain actions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the formation of Voxall, we entered into a three-year research collaboration with Alloy and Voxall to identify and select certain biological targets and create development candidate antibodies directed to those targets for further preclinical development, clinical development and commercialization. Under the collaboration agreement, the parties will conduct research under a mutually agreed research plan and budget for up to six research programs focused on mutually selected targets. Each of us and Alloy will provide research support for the collaboration through separate services agreements with Voxall, which services will be paid in the form of promissory notes issued by Voxall. Voxall will own all intellectual property arising from the collaboration, subject to certain exceptions for intellectual property relating to Alloy&#x2019;s ATX-Gx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> platform.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a development candidate antibody under a research program meets certain mutually agreed selection criteria, we will have the exclusive option to obtain an exclusive license from Voxall to further develop and commercialize all the development candidate antibodies discovered under that research program. We may in-license one research program on certain pre-agreed financial terms. For all other in-licensed research programs, we will be obligated to pay fair market value as determined by a third-party valuation. Any research program that we do not in-license may be licensed by Voxall to a third party.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Agreements with LegoChem Biosciences, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, we entered into a license agreement, or the &#x201c;LegoChem License Agreement,&#x201d; with LegoChem Biosciences, Inc., or LegoChem, pursuant to which we licensed worldwide (other than Korea) development and commercialization rights for LCB67, an ADC product candidate targeting DLK1 (now referred to as PYX-202), and products containing the licensed compound. We have the right to ask LegoChem to use commercially reasonable efforts at our cost to modify the licensed compound if there are certain technical failures of the licensed compound that we believe are attributable to the linker or the payload used in the licensed compound, and the modified compound will replace the unmodified version as the licensed compound. In February 2021, we entered into an amendment to the LegoChem License Agreement to include additional patents within the scope of our license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the LegoChem License Agreement, we paid an upfront fee of $0.5 million in 2020 and $9.0 million in 2021 and are required to purchase certain initial quantities of licensed product from LegoChem for an estimated cost of $7.0 million. We are also obligated to pay up to an aggregate of $284.5 million to LegoChem if certain development, regulatory and sales milestones are achieved, as well as tiered royalties on net sales of licensed products ranging from mid-single digit to high single digit royalty rates. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until the latest to occur of: (1) the date of expiration of the last valid claim of a licensed patent covering the licensed product; (2) 10 years from first commercial sale; and (3) the expiration of regulatory or data exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the LegoChem License Agreement, we are obligated to use commercially reasonable efforts to develop at least one licensed product for at least one indication and, upon receipt of regulatory approval in the United States, China, Japan or any three or more of the major European countries (United Kingdom, Spain, France or Germany), to commercialize at least one licensed product for at least one indication in such countries. We have agreed to purchase certain initial quantities of licensed product from LegoChem and have the right to manufacture the licensed products, provided that LegoChem has the right to control the manufacture and use of the conjugation methods and materials, linker and payload elements included in the licensed intellectual property. We control prosecution, enforcement and defense of the licensed patents that are specific to the licensed products, and LegoChem has backup rights if we elect not to exercise our rights.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the term of the LegoChem License Agreement, neither party may, either directly or through an affiliate or sublicensee, research, in-license, develop or commercialize in the licensed territory any other ADC directed to DLK-1, including any ADC directed to more than one epitope of DLK1 (a multi-epitope DLK1) or a modification or derivative of the licensed compound. This restriction does not apply to any ADC being developed by LegoChem that is subject to our right of first negotiation. We have the right of first negotiation to obtain a license to any ADC directed to DLK1 other than a multi-epitope DLK1 controlled by LegoChem that LegoChem proposes to include in a GLP toxicology study or to license to a third party.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The LegoChem License Agreement will remain in effect on a country-by-country basis until the expiration of the obligation to pay royalties, unless terminated as follows: (1) by either party for the other party&#x2019;s material breach if such party fails to cure such breach within the specified cure period; (2) by either party upon cessation of business activities or certain insolvency events of the other party; (3) by us if there are certain technical failures of the licensed compound; or (4) by us for any reason upon 90 days&#x2019; prior written notice. If we challenge the scope, ownership, validity or enforceability of a licensed patent, LegoChem may convert our exclusive license to a non-exclusive license or terminate the LegoChem License Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, we also entered into an opt-in, investment and additional consideration agreement with LegoChem, or the &#x201c;Opt-In Agreement.&#x201d; Under the Opt-In Agreement, we issued to LegoChem shares of Series B convertible preferred stock as part of our Series B financing in March 2021. We are also obligated to pay LegoChem a percentage of sublicensing revenue ranging from low-double digits to thirty percent based on the stage of development of the licensed product at the time of entering into the applicable sublicense, which percentage may be increased to up to fifty percent for any upfront payment from a sublicensee under certain circumstances. LegoChem has exercised its option under the Opt-In Agreement to make a $8.0 million payment to us, which payment was made in April 2021, in exchange for the right to receive an extra milestone payment of $9.6 million upon the earliest to occur of certain events, including the date of pricing or offer of the first public offering of our common stock or if we are the subject of a change of control transaction. LegoChem may elect to receive payment for up to 50% of this extra milestone payment as well as certain development milestone payments under the LegoChem License Agreement in shares of our preferred stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with Biosion USA Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 28, 2022, we entered into a license agreement, or the &#x201c;Biosion License Agreement&#x201d;, with Biosion USA, Inc., or Biosion, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pursuant to which we obtained exclusive, worldwide (other than Greater China </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(mainland China, Hong Kong, Macau and Taiwan)</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">), licenses for development, manufacture and commercialization rights for BSI-060T, a Siglec-15 targeting antibody, an IO product candidate (now referred to as PYX-106), and products containing the licensed compound.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Biosion License Agreement, we agreed to pay an upfront fee of $10 million and are obligated to pay future contingent payments including development, regulatory and commercial milestone up to an aggregate of $217.5 million in case of normal approval and $222.5 million in case of accelerated approval. Additionally, if products are launched, we will pay Biosion tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to low teens. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) 12 years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our intellectual property is critical to our business, and we strive to protect it, including by obtaining and maintaining patent protection in the United States and internationally for our product candidates, new therapeutic approaches and potential indications, and other inventions that are important to our business. We also rely on trade secrets and proprietary know-how to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our patent portfolio includes patents and patent applications that are exclusively licensed from the University of Chicago, Pfizer, and LegoChem and patent applications that are owned by us. Our patent portfolio includes patents and patent applications that cover our product candidates PYX-201, PYX-202, PYX-203, PYX-106 and PYX-102 and the use of these candidates for therapeutic purposes in certain territories. Our proprietary technology has been developed primarily through relationships with academic institutions, Pfizer, LegoChem, Biosion and contract research organizations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For our product candidates, we will, in general, initially pursue patent protection covering compositions of matter and methods of use. Throughout the development of our product candidates, we seek to identify additional means of obtaining patent protection that would potentially enhance commercial success, including through additional methods of use, process of making, formulation and dosing regimen-related claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For all patent applications, we determine claiming strategy on a case-by-case basis. Advice of counsel and our business model and needs are always considered. We file patent applications containing claims for protection of useful applications of our proprietary technologies and any products, as well as new applications and/or uses we discover for existing technologies and products, assuming these are strategically valuable. We continuously reassess the number and type of patent applications, as well as the existing patent claims to ensure that maximum coverage and value are obtained for our processes and compositions, given existing patent office rules and regulations. Further, claims may be modified during patent prosecution to meet our intellectual property and business needs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recognize that the ability to obtain patent protection and the degree of such protection depends on a number of factors, including the extent of the prior art, the novelty and non-obviousness of the invention and the ability to satisfy the enablement requirement of the patent laws. The patent positions of immuno-oncology companies like ours are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted or further altered even after patent issuance. Consequently, we may not obtain or maintain adequate patent protection for any of our future product candidates or for our platform technology. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regardless of the coverage we seek under our existing patent applications, there is always a risk that an alteration to the product or process may provide sufficient basis for a competitor to avoid infringement claims. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and courts can reinterpret patent scope after issuance. Moreover, many jurisdictions, including the United States, permit third parties to challenge allowed or issued patents in administrative proceedings, which may result in further narrowing or even cancellation of patent claims. Moreover, we cannot provide any assurance that any patents will be issued from our pending or any future applications or that any current or future issued patents will adequately protect our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In total, our patent portfolio, including patents licensed from the University of Chicago, Pfizer, LegoChem and Biosion and patents owned by us, comprises eight different patent families, filed in various jurisdictions worldwide, including families directed to composition of matter for antibody drug conjugates, and families directed to methods of treating cancer and identifying potential targets. Our patent portfolio includes issued patents in the United States, Taiwan, and Australia. Our patent portfolio as of December 31, 2021, is outlined below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Composition of Matter Patents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PYX-201.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    We have exclusively licensed from Pfizer a patent family that includes two issued patents, one each in Australia and Korea, and pending applications in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Mexico, Russia, Singapore, South Africa, and the United States that claim the composition of matter and certain methods of use with respect to PYX-201. The 20-year term of the patents in this family runs through October 2037, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PYX-202.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    We have exclusively licensed from LegoChem a patent family that includes pending patent applications in Australia, Brazil, Canada, China, Europe, India, Israel, Japan, South Korea, Mexico, New Zealand, Russia, Singapore, Ukraine, Taiwan, Hong Kong, and the United States, that claims the composition of matter of and certain methods of use with respect to PYX-202. The 20-year term of the patents in this family runs through March 2040, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PYX-203.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    We have exclusively licensed from Pfizer a patent family that includes one issued patent in Taiwan, 23 pending applications in Australia, Brazil, Canada, China, Colombia, Europe, Hong Kong, India, Indonesia, Israel, Japan, South Korea, Malaysia, Mexico, New Zealand, Peru, Philippines, Russia, Saudi Arabia, Singapore, South Africa, Taiwan, and the United States that claim the composition of matter and certain methods of use with respect to PYX-203. The 20-year term of the patents in this family runs through October 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PYX-106.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    We have exclusively licensed from Biosion USA, Inc. a patent family that includes one pending international patent application filed under the Patent Cooperation Treaty, or PCT, that claims the composition of matter of and certain methods of use with respect to PYX-106. We intend to file national phase applications based on this PCT application before applicable deadlines. Written Opinion of Search Authority found that all claims were deemed novel, inventive, and useful. The Search Authority cited no anticipatory or obvious-rendering prior art.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Projected Expiration of granted patents from this PCT Application is March 2041, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Methods related to T Cell Activity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have exclusively licensed from the University of Chicago a patent family that includes two issued patents in the United States and pending applications in Europe and the United States that claim methods for treating patients with immunotherapy based on the identification of the patient as having non-anergic T cells after measuring expression levels of various genes. The 20-year term for patents in this family runs through March 2034, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Methods of treating solid tumor cancers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have exclusively licensed from the University of Chicago a patent family that includes one issued patent and one pending application in the United States that claim methods for treating solid tumor cancers. The 20-year term for patents in this family runs through March 2036, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Methods of treating cancer by targeting dysfunctional tumor antigen-specific CD8+ T cells</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have exclusively licensed from the University of Chicago a patent family that includes six pending applications in Canada, China, Europe, Japan, Hong Kong, and the United States that claim methods of treating cancer comprising administering an agent that specifically targets dysfunctional tumor antigen-specific CD8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> T cells. The 20-year term for patents in this family runs through January 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Methods of generating target lists</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We own a pending PCT application directed to methods of identifying potential targets. The 20-year term for patents in this family runs through to 2041, excluding any extension of patent term that may be available.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to file future patent applications on innovations that are developed in the course of advancing our pipeline through preclinical and clinical development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent Term and Term Extensions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Individual patents have terms for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, utility patents issued for applications filed in the United States are granted a term of 20 years from the earliest effective filing date of a non-provisional patent application. In addition, in certain instances, the term of a U.S. patent can be extended to recapture a portion of the United States Patent and Trademark Office, or the USPTO, delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the restoration period cannot extend the patent term beyond 14 years from FDA approval. In addition, only one patent applicable to an approved drug is eligible for the extension, and only those claims covering the approved drug, a method for using it, or a method of manufacturing may be extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. We will, in general, pursue available patent term extensions in the U.S. and in foreign jurisdictions that provide for patent term extensions, however, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions. All taxes, annuities or maintenance fees for a patent, as required by the USPTO and various foreign jurisdictions, must be timely paid in order for the patent to remain in force during this period of time.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The actual protection afforded by a patent may vary on a product-by-product basis, from country to country, and can depend upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions and the availability of legal remedies in a particular country and the validity and enforceability of the patent.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our patents and patent applications may be subject to procedural or legal challenges by others. We may be unable to obtain, maintain and protect the intellectual property rights necessary to conduct our business, and we may be subject to claims that we infringe or otherwise violate the intellectual property rights of others, which could materially harm our business. For more information, see the section titled &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Trademarks and Know-How</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the ongoing development and advancement of our product candidates in the United States and various international jurisdictions, we seek to create protection for our marks and enhance their value by pursuing trademarks where available and when appropriate. In addition to patent and trademark protection, we rely upon trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees and consultants and invention assignment agreements with our employees and selected consultants. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and our trade secrets and other proprietary information may be disclosed. We may not have adequate remedies for any breach and could lose our trade secrets and other proprietary information through such a breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting trade secrets, know-how and inventions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success will also depend in part on not infringing the proprietary rights of third parties. In addition, we have licensed rights under proprietary technologies of third parties to develop, manufacture and commercialize specific aspects of our future products and services. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, alter our processes, obtain licenses or cease certain activities. The expiration of patents or patent applications licensed from third parties or our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future technology may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO to determine priority of invention.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For more information regarding the risks related to our intellectual property, please see &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, recordkeeping, serialization and tracking, promotion, advertising, distribution and marketing, post-approval or licensure monitoring and reporting, and export and import, among other things, of our product candidates are extensively regulated by governmental authorities in the United States and other countries. In the United States, the FDA regulates biological products under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations, and the Public Health Service Act, or the PHSA, and its implementing regulations. Failure to comply with the applicable U.S. requirements may subject us to administrative or judicial sanctions, such as the FDA&#x2019;s refusal to approve a Biologics License Application (BLA), warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Approval and Licensure Process for Biological Products</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Biological products such as ours may not be commercially marketed without prior licensure from the FDA and approval or licensure from comparable regulatory agencies in other countries. In the United States, the process for receiving such licensure is long, expensive and risky, and includes the following steps:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preclinical laboratory tests, animal studies, and formulation studies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of an Investigational New Drug (IND) application for human clinical testing, which must become effective before human clinical trials may begin; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval by an IRB at each clinical site before each trial may be initiated; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adequate and well-controlled human clinical trials to establish the safety, purity, and potency of the drug for each indication; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of a BLA; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of an FDA advisory committee review, if applicable; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the biological product is produced to assess compliance with cGMP; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a potential FDA audit of the preclinical and clinical trial sites that generated the data in support of the BLA; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability to obtain clearance or approval of companion diagnostic tests, if required, on a timely basis, or at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA review and approval of the BLA prior to any commercial marketing or sale of the drug in the United States; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with any post-approval requirements and/or commitments, including the potential requirement to implement a REMS, and the potential requirement to conduct post-approval studies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In guidance, FDA has stated that it considers antibody-drug conjugates to be combination biological product-drug products for which a BLA should be submitted. FDA has also stated in guidance that it regulates monoclonal antibodies as biological products which require a BLA. FDA has issued guidance on product development considerations for antibody-drug conjugates, including dosing and clinical pharmacology testing recommendations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regulation by U.S. and foreign governmental authorities is a significant factor affecting our ability to commercialize any of our products, as well as the timing of such commercialization and our ongoing research and development activities. The commercialization of drug products requires regulatory approval by governmental agencies prior to commercialization. Various laws and regulations govern or influence the research and development, non-clinical and clinical testing, manufacturing, processing, packaging, validation, safety, labeling, storage, record keeping, registration, listing, distribution, advertising, sale, marketing and postmarketing requirements and/or commitments of our products. The lengthy process of seeking these approvals, and the subsequent compliance with applicable laws and regulations, require expending substantial resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The results of preclinical testing, which include laboratory evaluation of product chemistry, formulation, toxicity and carcinogenicity, animal studies to assess the potential safety, purity and potency of the product and its formulations, details concerning the drug manufacturing process and its controls, and a proposed clinical trial protocol and other information must be submitted to the FDA as part of an IND that must be reviewed and become effective before clinical testing can begin. The study protocol and informed consent information for patients in clinical trials must also be submitted to an independent Institutional Review Board, or IRB, for approval covering each institution at which the clinical trial will be conducted. Once a sponsor submits an IND, the sponsor must wait 30 calendar days before initiating any clinical trials. If the FDA has comments or questions within this 30-day period, the issue(s) must be resolved to the satisfaction of the FDA before a clinical trial can begin. In addition, the FDA or an IRB may impose a clinical hold on ongoing clinical trials if, among other things, it believes that a clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable and significant risk to clinical trial patients. If the FDA imposes a clinical hold, clinical trials can only proceed under terms authorized by the FDA. If applicable, our preclinical and clinical studies must conform to the FDA&#x2019;s Good Laboratory Practice, or GLP, and Good Clinical Practice, or GCP, requirements, respectively, which are designed to ensure the quality and integrity of submitted data and protect the rights and well-being of study patients. Information for certain clinical trials also must be publicly disclosed within certain time limits on the clinical trial registry and results databank maintained by the NIH.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Typically, clinical testing involves a three-phase process; however, the phases may overlap or be combined:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 1 clinical trials typically are conducted in a small number of volunteers or patients to assess the early tolerability and safety profile, the pattern of drug absorption, distribution and metabolism, the mechanism of action in humans, and may include studies where investigational drugs are used as research to explore biological phenomena or disease processes; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 2 clinical trials typically are conducted in a limited patient population with a specific disease in order to assess appropriate dosages and dose regimens, expand evidence of the safety profile and evaluate preliminary efficacy; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 3 clinical trials typically are larger scale, multicenter, well-controlled trials conducted on patients with a specific disease to generate enough data to statistically evaluate the efficacy and safety of the product, to establish the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A therapeutic product candidate being studied in clinical trials may be made available for treatment of individual patients, intermediate-size patient populations, or for widespread treatment use under an expanded access protocol, under certain circumstances. Pursuant to the 21st Century Cures Act, or Cures Act, which was signed into law in December 2016, the manufacturer of one or more investigational products for the diagnosis, monitoring, or treatment of one or more serious diseases or conditions is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for individual patient access to such investigational product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA authorization under an FDA expanded access program; however, manufacturers are not obligated to provide investigational new drug products under the current federal right to try law.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disclosure of Clinical Trial Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sponsors of certain clinical trials of FDA-regulated products are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial are then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Orphan Drugs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to therapeutic candidates (drugs or biological products) intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the U.S. or more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making available in the U.S. a therapeutic candidate for this type of disease or condition will be recovered from sales in the U.S. for that therapeutic candidate. Orphan drug designation must be requested before submitting a marketing application for the therapeutic candidate for that particular disease or condition. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. Among the other benefits of orphan drug designation are tax credits for certain research and an exemption from the BLA application fee. The FDA may revoke orphan drug designation, and if it does, it will publicly disclose that the product is no longer designated as an orphan drug.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biological product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the biological product was designated. Orphan drug exclusivity does not prevent the FDA from approving a different biological product for the same disease or condition, or the same biological product for a different disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A designated orphan drug may not receive orphan drug exclusivity if it is licensed for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expedited Development and Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA has a number of programs intended to expedite the development and review of product candidates. These programs include fast track designation, breakthrough therapy designation, priority review designation, accelerated approval, and regenerative medicine advanced therapy (&#x201c;RMAT&#x201d;) designation. Fast Track designation is intended to expedite or facilitate the process for reviewing new biological products that meet certain criteria. Specifically, new biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new biological product may request the FDA to designate the biological product as a Fast Track product at any time during the clinical development of the product. Unique to a Fast Track product, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. FDA may revoke the Fast Track designation if it believes that the designation is no longer supported by data emerging in the clinical trial process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Breakthrough Therapy program, products intended to treat a serious or life-threatening disease or condition may be eligible for Breakthrough Therapy designation, which includes eligibility for the benefits of the Fast Track program, when preliminary clinical evidence demonstrates that such product may have substantial improvement on one or more clinically significant endpoints over existing therapies. Additionally, FDA will seek to ensure the sponsor of a breakthrough therapy product receives timely advice and interactive communications to help the sponsor design and conduct a development program as efficiently as possible.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A product is eligible for priority review if it is intended to treat a serious condition and, if approved or licensed, it would provide a significant improvement in safety or effectiveness. FDA intends to take action on a priority review marketing application within six months of receipt, compared to 10 months of receipt for regular review submissions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, a product may be eligible for accelerated approval if it is intended to treat a serious or life-threatening disease or condition and would provide meaningful therapeutic benefit over existing treatments. Accelerated approval may be granted on the basis of adequate and well-controlled clinical studies establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality and is reasonably likely to predict an effect on irreversible morbidity, mortality, or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a biological product receiving accelerated approval diligently perform adequate and well-controlled postmarketing clinical studies demonstrating clinical benefit. In addition, the FDA requires as a condition for accelerated approval the submission of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast Track designation, Breakthrough Therapy designation, priority review and accelerated approval do not change the standards for licensure but may expedite the review process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A product may receive RMAT designation, which provides for an expedited program for the advancement and approval of regenerative medicine therapies that are intended to treat, modify, reverse or cure a serious condition and where preliminary clinical evidence indicates the potential to address unmet medical needs for life-threatening diseases or conditions. Similar to Breakthrough Therapy designation, the RMAT designation allows companies developing regenerative medicine therapies to work earlier, more closely, and frequently with the FDA, and RMAT-designated products may be eligible for priority review and accelerated approval. Regenerative medicine therapies include cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products, except for those regulated solely under section 361 of the Public Health Services Act (PHS Act) and Title 21 of the Code of Federal Regulations Part 1271 (21 CFR Part 1271). For product candidates that have received a RMAT designation, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. The timing of a sponsor&#x2019;s request for designation and FDA response are the same as for the Breakthrough Therapy designation program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pediatric studies and exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Pediatric Research Equity Act of 2003, a BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With enactment of the Food and Drug Administration Safety and Innovation Act of 2012, or FDASIA, sponsors must also submit pediatric study plans prior to the assessment data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Those pediatric study plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA and the FDA&#x2019;s internal review committee must then review the information submitted, consult with each other and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after licensure of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required by law or regulation, the pediatric data requirements do not apply to products with orphan designation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pediatric exclusivity is a type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#x2019;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">FDA Review of BLAs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After completion of the required clinical testing, a BLA is prepared and submitted to the FDA. FDA approval of the BLA is required before marketing of the product may begin in the United States. The BLA must include the results of all preclinical, clinical and other testing and a compilation of data relating to the product&#x2019;s pharmacology, chemistry, manufacture and controls. The cost of preparing and submitting a BLA is substantial. The submission of most BLAs is additionally subject to a substantial application user fee, currently $3,117,218 for BLAs requiring clinical data for fiscal year 2022, and the manufacturer and sponsor under an approved BLA are also subject to annual program fees, currently $369,413 for each prescription product. These fees are typically increased annually. Sponsors of applications for drugs granted Orphan Drug Designation are exempt from these user fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#x2019;s threshold determination that it is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept a BLA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of BLAs to encourage timeliness. Applications for standard review biological products are meant to be reviewed within ten months; applications for priority review drugs are meant to be reviewed in six. Priority review can be applied to biological products that the FDA determines offer major advances in treatment or provide a treatment where no adequate therapy exists. The review process for both standard and priority review may be extended by the FDA for three additional months (&#x201c;major amendment&#x201d;) to consider certain late-submitted information, or information intended to clarify information already provided in the submission.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA is required to refer an application for a novel biological product to an advisory committee or explain why such referral was not made. An advisory committee is typically a panel that includes clinicians and other experts&#x2014;for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not license the product unless compliance with cGMPs is satisfactory, and the application meets the appropriate standard. A BLA must include data that demonstrate that the biological product is safe, pure, and potent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After the FDA evaluates the BLA and accompanying information and the manufacturing facilities, it issues either an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#x2019;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An approval or licensure letter authorizes commercial marketing of the biological products with specific prescribing information for specific indications. As a condition of BLA licensure, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the biological product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product licensure may require substantial post-approval testing and surveillance to monitor the drug&#x2019;s safety or efficacy. Once granted, product licenses may be withdrawn if compliance with regulatory standards is not maintained, or problems are identified following initial marketing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the FDA approves a product, it may limit the approved indications for use for the product; require that contraindications, warnings or precautions be included in the product labeling; require that postmarketing studies, including Phase 4 clinical trials, be conducted to further assess the drug&#x2019;s safety after licensure; require testing and surveillance programs to monitor the product after commercialization; or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval, as applicable, of a new BLA or supplement before the change can be implemented. A BLA supplement for a new indication typically requires similar non-clinical and CMC data to that in the original application, and the FDA uses the same procedures and actions in reviewing supplements as it does in reviewing BLAs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Biosimilars and Reference Product Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological product candidates shown to be highly similar, or &#x201c;biosimilar,&#x201d; to or interchangeable with an FDA licensed reference biological product. Biosimilarity, which requires that a product is highly similar to the reference product notwithstanding minor differences in clinically inactive components, and that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can generally be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the interchangeable biosimilar and the reference biological product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product. A product shown to be biosimilar or interchangeable with an FDA-approved reference biological product may rely in part on the FDA&#x2019;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles and have slowed implementation of the BPCIA by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of reference product exclusivity, another company may obtain FDA licensure and market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#x201c;interchangeable&#x201d; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A biological product can also obtain pediatric market exclusivity in the United States. As stated above, pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#x201c;Written Request&#x201d; for such a study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, there has been discussion of whether Congress should reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate implementation of the BPCIA is subject to significant uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Post-Licensure FDA Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Biological products manufactured or distributed pursuant to FDA licenses are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion with the product. After licensure, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and licensure. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Often times, even after a biological product has been licensed by the FDA for sale, the FDA may require that certain post-licensure requirements be satisfied, including the conduct of additional clinical studies. If such post-approval requirements are not satisfied, the FDA may withdraw its licensure of the biological product. In addition, holders of a biological product license are required to report certain adverse reactions to the FDA, comply with certain requirements concerning advertising and promotional labeling for their products, and continue to have quality control and manufacturing procedures conform to cGMP after approval. In addition, biological product manufacturers and their subcontractors are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements and other aspects of regulatory compliance. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Among the conditions for BLA licensure is the requirement that the manufacturing operations conform on an ongoing basis with cGMP. In complying with cGMP, we must expend time, money and effort in the areas of training, production and quality control within our own organization and at our contract manufacturing facilities. A successful inspection of the manufacturing facility by the FDA is usually a prerequisite for final licensure of a biological product. Following licensure of the BLA, we and our manufacturers will remain subject to periodic inspections by the FDA to assess continued compliance with cGMP requirements and the conditions of licensure. We will also face similar inspections coordinated by foreign regulatory authorities. The FDA periodically inspects the sponsor&#x2019;s records related to safety reporting and/or manufacturing facilities; this latter effort includes assessment of compliance with cGMP. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once licensure is granted, the FDA may withdraw licensure if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restrictions on the marketing or manufacturing of the product, including total or partial suspension of production, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fines, warning letters or holds on post-licensure clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Refusal of the FDA to license pending BLAs or supplements, or suspension or revocation of product licensure; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Product seizure or detention, or refusal to permit the import or export of products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mandated modification of promotional materials and labeling and the issuance of corrective information; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA closely regulates marketing, labeling, advertising and promotion of products that are placed on the market. Biological products may be promoted only for the licensed indications and in accordance with the provisions of the approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off label uses may be subject to significant liability. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#x2019;s communications on the subject of off-label use of their products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the distribution of prescription drug products, including most biological products that require a prescription, are subject to the Prescription Drug Marketing Act, or the PDMA, which regulates the distribution of drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription drug product samples and impose requirements to ensure accountability in distribution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent term extension</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After BLA licensure, owners of relevant drug patents may apply for up to a five-year patent extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory process. The allowable patent term extension is typically calculated as one-half the time between the effective date of an IND and the submission date of a BLA, plus the time between BLA submission date and the BLA approval date up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue licensure with due diligence. The total patent term after the extension may not exceed 14 years from the date of product licensure. Only one patent applicable to a licensed biological product is eligible for extension and only those claims covering the product, a method for using it, or a method for manufacturing it may be extended and the application for the extension must be submitted prior to the expiration of the patent in question. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">FDA approval and regulation of companion diagnostics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A therapeutic product may rely upon an</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> companion diagnostic for use in selecting the patients that will be more likely to respond to that therapy. If safe and effective use of a therapeutic depends on an</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> diagnostic, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> companion diagnostics. According to the guidance, for novel drugs, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#x2019;s labeling. In July 2016, the FDA issued a draft guidance intended to assist sponsors of the drug therapeutic and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> companion diagnostic device on issues related to co-development of the products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic device is not approved or cleared for that indication contemporaneously, except for the high unmet medical need. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. The review of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> companion diagnostics in conjunction with the review of our therapeutic product candidates will, therefore, likely involve coordination of review by the FDA&#x2019;s Center for Biologics Evaluation and Research and the FDA&#x2019;s Center for Devices and Radiological Health.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the FDCA,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The three primary types of FDA marketing authorization applicable to a medical device include premarket notification, also called 510(k) clearance, premarket approval, or PMA, and De Novo classification requests. The FDA has generally required</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> companion diagnostics intended to select the patients who will respond to cancer treatment to obtain a PMA for that diagnostic simultaneously with approval of the drug.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#x2019;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee of $374,858 for most PMAs for fiscal year 2022. Medical device establishments are also subject to annual registration fees, currently $5,672, and class III devices are subject to annual fees for periodic reporting, currently $13,120. FDA requires lower fee amounts for businesses certified by the Center for Devices and Radiological Health as a small business. In addition, PMAs for certain devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, a PMA application typically requires data regarding analytical and clinical validation studies. As part of the PMA review, the FDA will typically inspect the manufacturer&#x2019;s facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. If the FDA&#x2019;s evaluation of the PMA application is favorable, the FDA typically issues an approvable letter requiring the applicant&#x2019;s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA&#x2019;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution, and the requirement for post approval studies as well as postmarketing surveillance. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards are not maintained, or problems are identified following initial marketing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#x2019;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Manufacturers are also subject to medical device reporting requirements as well as reporting certain requirements related to device corrections and removals. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the U.S.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foreign Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our product candidates to the extent we choose to sell any products outside of the United States. Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities and, if required, from independent ethics committees in foreign countries before we can commence clinical trials as well as regulatory approvals prior to marketing the product candidates in those countries. The approval processes vary from country to country and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. As in the United States, post-approval regulatory requirements, such as those regarding product manufacture, marketing, or distribution would apply to any product that is approved outside the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Healthcare Laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Among others, the FDA, U.S. Department of Health and Human Services, or HHS, Office of Inspector General, the Centers for Medicare and Medicaid Services, or CMS, and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the preclinical and clinical development, manufacture, marketing, and distribution of drugs such as those we are developing. These agencies and other federal, state, and local entities regulate, among other activities, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, sales, commercialization, marketing, advertising and promotion, distribution, post-approval monitoring and reporting, sampling, and export and import of our product candidates. Any drug candidates that we develop must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in those foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in the European Union, or EU, are addressed in a centralized way, but country-specific regulation remains essential in many respects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we do not currently have any products on the market, in addition to FDA restrictions on marketing of pharmaceutical products, we are also subject to healthcare statutory and regulatory requirements and enforcement by the U.S. federal and state governments. Pharmaceutical companies like us are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such regulation may constrain the financial arrangements and relationships through which we research, develop, and, ultimately, sell, market, and distribute any products for which we obtain marketing approval. Such laws include, without limitation:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Anti-Kickback Statute, an intent-based criminal statute that prohibits, among other activities, persons and entities from knowingly and willfully soliciting, offering, paying, receiving, or providing any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. A conviction for violation of the federal Anti-Kickback Statute can result in criminal fines and/or imprisonment and requires mandatory exclusion from participation in federal health care programs. Exclusion may also be imposed if the government determines that an entity has committed acts that are prohibited by the federal Anti-Kickback Statute.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal civil and criminal false claims laws, including the civil False Claims Act, or FCA, which prohibit individuals or entities from, among other activities, knowingly presenting, or causing to be presented, to the federal government claims for payment or approval that are false, fictitious, or fraudulent; knowingly making, using, or causing to be made or used, a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. In addition, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. Moreover, pharmaceutical manufacturers can be<br />held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to<br />&#x201c;cause&#x201d; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#x201c;whistleblower&#x201d; to bring </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">qui tam </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery or settlement. FCA liability is potentially significant in the healthcare industry<br />because the statute provides for treble damages and significant mandatory penalties per false or fraudulent claim or<br />statement for violations. Criminal penalties, including imprisonment and criminal fines, are also possible for making<br />or presenting a false, fictitious or fraudulent claim to the federal government.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal civil monetary penalties laws, which prohibit, among other activities (1) arranging for or contracting with an individual or entity that is excluded from participation in federal healthcare programs to provide items or services reimbursable by a federal healthcare program, (2) failing to report and return a known overpayment, or (3) offering or transferring any remuneration to a Medicare or Medicaid beneficiary if the person knows or should know it is likely to influence the beneficiary&#x2019;s selection of a particular provider, practitioner, or supplier of items or services reimbursable by Medicare or Medicaid, unless an exception applies. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal criminal statutes enacted under the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which impose criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program; knowingly and willfully embezzling or stealing from a healthcare benefit program; willfully preventing, obstructing, misleading, or delaying a criminal investigation of a healthcare offense; and knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items, or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Physician Payment Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, which imposes annual reporting requirements for certain manufacturers of drugs, devices, biological products, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program, for certain payments and &#x201c;transfers of value&#x201d; provided to &#x201c;covered recipients,&#x201d; which include U.S.-licensed physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants and certified nurse midwives, as well as ownership and investment interests held by such<br />physicians and their immediate family members.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDCA and PHSA, which regulate licensure of biological products and prohibit the misbranding and adulteration of biological products. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply with respect to healthcare items or services reimbursed by non-governmental third-party-payors and may be broader than their federal equivalents; state and foreign laws requiring pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and/or the relevant compliance guidance promulgated by the federal government or otherwise restricting payments that may be made to healthcare providers; state laws and regulations requiring drug manufacturer disclosures to state agencies and/or commercial purchasers with respect to certain price increases; state and foreign laws requiring drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers and restricting marketing practices or requiring disclosure of marketing expenditures and pricing information; and state and local laws that requiring registration of pharmaceutical sales representatives. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Violations of any of these laws or any other applicable laws or regulations may result in significant penalties, including, without limitation, administrative, civil, and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations to resolve allegations of noncompliance, exclusion from participation in federal and state healthcare programs, such as Medicare and Medicaid, and imprisonment. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#x2019;s attention from its business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance, and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a payor-by-payor basis. These third-party payors are increasingly reducing coverage and reimbursement for healthcare items (including drugs) and services. Moreover, for products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the U.S. government, states, and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement, and requirements for substitution of lower-cost or generic products. Adoption of price controls and cost-containment measures and adoption of more restrictive policies in jurisdictions with existing controls and measures could further limit sales of any drug product. Decreases in third-party reimbursement for any drug product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product and also have a material adverse effect on sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Moreover, as a condition of participating in, and having products covered under, certain federal healthcare programs, such as Medicare and Medicaid, we may become subject to federal laws and regulations that require pharmaceutical manufacturers to calculate and report certain pricing metrics to the government, including the Average Manufacturer Price, or AMP, and Best Price under the Medicaid Drug Rebate Program, the Medicare Average Sales Price, the 340B Ceiling Price, and Non-Federal AMP reported to the Department of Veteran Affairs, and with respect to Medicaid, pay statutory rebates on utilization of manufacturers&#x2019; products by Medicaid beneficiaries. Compliance with these laws and regulations will require significant resources and may have a material adverse effect on our revenues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healthcare Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively known as the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private payors, and significantly affected the pharmaceutical industry. The ACA contained a number of provisions, including those governing the federal healthcare programs, provider reimbursement, and healthcare fraud and abuse laws. For example, the ACA:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the AMP; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">required collection of rebates for drugs paid by Medicaid managed care organizations; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded beneficiary eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 138% of the federal poverty level, thereby potentially increasing manufacturers&#x2019; Medicaid rebate liability; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">extended manufacturers&#x2019; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded the types of entities eligible for the 340B Drug Pricing Program; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">established a new methodology by which rebates owed by manufacturers under the Medicaid Drug and Rebate Program, or MDRP, are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">required manufacturers to participate in a coverage gap discount program, under which they must agree to offer upto 70 percent point-of-sale discounts off negotiated prices of applicable branded drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#x201c;branded prescription drugs&#x201d; and biologic agents apportioned among these entities according to their market share in certain federal government programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">created the Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">required reporting of certain financial arrangements between manufacturers of drugs, biologics, devices, and medical supplies and physicians and teaching hospitals under the federal Physician Payments Sunshine Act; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3766130383777444%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">required annual reporting of certain information regarding drug samples that manufacturers and distributors provide to licensed practitioners. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since its enactment, there have been executive, judicial, and legislative branch challenges to certain aspects of the ACA, and, on June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#x2019;s decision, President Biden had issued an executive order to initiate a special enrollment period from February 15, 2021, through August 15, 2021, for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, policies that create barriers to obtaining access to health insurance coverage through the ACA marketplaces. It is unclear how healthcare reform measures enacted by Congress or implemented by the Biden administration or other efforts to challenge, repeal or replace the ACA, if any, will impact the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. These changes include the Budget Control Act of 2011, which, among other changes, led to aggregate reductions in Medicare payments to providers of up to 2% per fiscal year that started in April 2013 and, due to subsequent legislation, will continue into 2031, with the exception of a temporary suspension of the payment reduction from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. Unless additional Congressional action is taken, sequestration will start again on April 1, 2022. From April 1 to June 30, 2022, payment for Medicare fee-for-service claims will be adjusted downwards by 1%; beginning July 1, 2022, the payment will be adjusted downwards by 2%. Most recently, the American Rescue Plan Act of 2021 eliminates the statutory cap on drug manufacturers&#x2019; MDRP rebate liability effective January 1, 2024. Under current law enacted as part of the ACA, drug manufacturers&#x2019; MDRP rebate liability is capped at 100% of AMP for a covered outpatient drug.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cost of prescription drugs has been the subject of considerable policy discussion and debate in the United States. Congress has considered and passed legislation, and the former Trump administration pursued several regulatory reforms to further increase transparency around prices and price increases, lower out-of-pocket costs for consumers, and decrease spending on prescription drugs by government programs. Congress has also continued to conduct inquiries into the prescription drug industry&#x2019;s pricing practices. While several proposed reform measures will require Congress to pass legislation to become effective, Congress and the Biden administration have expressed support for legislative and/or administrative measures to address prescription drug costs. Since the Presidential inauguration, the Biden administration has also taken several executive actions that signal changes in policy from the prior administration, including with respect to executive actions by the Trump administration related to prescription drug costs. At the state level, legislatures are increasingly passing legislation and states are implementing regulations designed to control spending on, and patient out-of-pocket costs for, drug products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that additional state and federal healthcare reform and/or drug pricing measures will be adopted in the future, any of which could affect the pricing and/or availability of drug products, the amounts that federal and state governments and other third-party payors will pay for healthcare products and services, and/or our ability to generate revenue, attain or maintain profitability, or commercialize products for which we may receive regulatory approval in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Data Privacy &amp; Security</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerous state, federal and foreign laws and regulations govern the collection, dissemination, use, access to, privacy and security of personal information (including health-related information). Such laws and regulations that could apply to our operations or the operations of our partners include health information privacy and security laws (e.g., HIPAA), federal and state consumer protection laws and regulations (e.g., Section 5 of the Federal Trade Commission Act), state privacy laws (e.g., the California Consumer Privacy Act, or CCPA, California Consumer Privacy Rights Act, or CPRA, which goes into effect in 2023, the Virginia Consumer Data Protection Act which goes into effect in 2023), data breach notification laws, and the EU General Data Protection Regulation, or GDPR. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Employees and Human Capital Management</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We view our values of &#x201c;Be Clever,&#x201d; &#x201c;Be of Service,&#x201d; &#x201c;Be Gutsy,&#x201d; &#x201c;Be Tenacious,&#x201d; and &#x201c;Be You,&#x201d; as a mandate for excellence and the foundation for our success. These values create a culture that focuses on science and patients and promotes trust, teamwork, and celebration. As of March 25, 2022, we employed 56 full-time permanent employees. Of these employees, approximately 50% have advanced degrees including but not limited to Ph.D., M.D., M.B.A., J.D. and approximately 61% were engaged in research and development activities and 10% in business development activities. More than half of our workforce and our executive leadership is comprised of women. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our employees. We believe that our continued success is directly due to the commitment, engagement and performance of our employees. We strive to attract and retain experienced operators, oncology experts, clinicians, and biopharma veterans with deep market knowledge and insights with an uncompromising vision of delivering solutions for patients. In order to achieve this, we provide an inclusive and empowering work environment, foster a culture built on diversity, equity and inclusion, reward performance and leadership skills, and offering competitive compensation and benefits programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Culture and Employee Engagement</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also place a high value on the diversity of our team &#x2013;including gender, background and expertise &#x2013; to foster our culture of innovation. Our employees are guided by Pyxis Oncology&#x2019;s Code of Conduct which sets basic requirements for business conduct and serves as a foundation for our policies, procedures and guidelines, all of which provide additional guidance on expected employee behaviors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Compensation and Benefits</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of our total rewards philosophy, we offer competitive compensation and benefits to attract and retain top talent. We are committed to fair and equitable treatment in our compensation and benefits for employees at all levels. Our total rewards offerings include an array of programs to support our employees' financial well-being, including annual performance incentive opportunities, retirement savings programs, health and welfare benefits, paid time off, and flexible work schedules. We also allow our employees to participate in equity incentive plans. The principal purposes of our equity incentive plans are to align the interests of our stockholders and those eligible for awards, to retain and incentivize officers, directors, employees, and other service providers, and to encourage them to act in our long-term best interests.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Safety and COVID-19 Pandemic Response</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Protecting and supporting our employees during the COVID-19 pandemic continues to be a top priority and our approach includes: keeping employees informed of local COVID-19 transmission rates and corresponding risk levels; promoting the health and safety of our employees in the workplace through robust layers of protection; enhanced cleaning and access to cleaning supplies and personal protective equipment; benefits and well-being tools. In 2021, we initiated a hybrid work model that empowers our office-based employees to find the right productivity and balance of in-person and remote work. This model allows for work to happen seamlessly across a variety of workplaces and is enabled by an array of enhanced collaboration tools and technology to optimize productivity and connection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Corporate Information</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We were incorporated in the state of Delaware on June 11, 2018 and launched with our first employee and Series A funding in July 2019. Our principal executive offices are located at 35 Cambridgepark Drive, Cambridge, Massachusetts 02140, and our telephone number is (617) 221-9059. Our website address is www.pyxisoncology.com.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information in, or that can be accessed through, our website is not a part of this Annual Report on Form 10-K. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 12(a) or 15(d) of the Exchange Act are available, free of charge, on or through our website as soon as reasonably practicable after such reports and amendments are electronically filed with or furnished to the SEC. The SEC maintains an Internet site that contains, reports, proxy and information statements and other information regarding our filings at sec.gov. The contents of these websites are not incorporated into this filing. Further, references to the URLs for these websites are intended to be inactive textual references only.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1A. Ris</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">k Factors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business involves a high degree of risk. You should consider and read carefully all of the risks and uncertainties described below, as well as other information included in this Form 10-K, including our financial statements and related notes appearing at the end of this Form 10-K. The risks described below are not the only ones facing us. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition or results of operations. In such case, the trading price of our common stock could decline, and you may lose all or part of your investment. This Form 10-K also contains forward-looking statements and estimates that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks and uncertainties described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to our Financial Position and Need for Additional Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We are a preclinical stage biopharmaceutical company with a limited operating history and have incurred significant losses since our inception. We expect to incur losses over at least the next several years and may never achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a preclinical stage biopharmaceutical company with a limited operating history. Since our inception, we have incurred significant operating losses. We reported net losses of $76.0 million and $12.8 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $91.7 million. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of our equity interests. As such, we expect that it will be several years, if ever, before we have a product candidate ready for regulatory licensure and commercialization. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. To become and remain profitable, we must succeed in developing, obtaining marketing licensure for and commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including, without limitation, procuring clinical- and commercial-scale manufacturing, successfully completing preclinical studies and clinical trials of our product candidates, establishing arrangements with third parties for the conduct of our clinical trials, obtaining marketing licensure for our product candidates, manufacturing, marketing and selling any products for which we may obtain marketing licensure, discovering or obtaining rights to additional product candidates, identifying collaborators to develop product candidates we identify or additional uses of existing product candidates and successfully completing development of product candidates for our collaboration partners.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We anticipate that our expenses will increase substantially if and as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacture product candidates, conduct IND enabling studies and submit INDs and initiate Phase 1 clinical trials for our ADC product candidates, PYX-201, PYX-202 and PYX-203 and our IO product candidates, PYX-106 and PYX-102; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">select antibody programs to take into development including manufacture product candidates, conduct IND enabling studies and submit INDs and initiate Phase 1 clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">initiate, conduct and successfully complete later-stage clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">scale up external manufacturing capabilities for later stage trials and to commercialize our products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seek marketing licenses for any product candidates that successfully complete clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ultimately establish a sales, marketing and distribution infrastructure for which we may obtain marketing licensure; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">leverage the FACT platform to identify and then advance additional product candidates into preclinical and clinical development; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expand, maintain and protect our intellectual property portfolio;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">hire additional clinical, regulatory, scientific, operational, financial and management information personnel; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">continue to operate as a public company. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, since our IPO, we have incurred and expect to continue to incur additional costs associated with operating as a public company, including significant legal, accounting, insurance, investor relations and other expenses that we did not incur as a private company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our expenses could increase beyond our expectations if we are required by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, or other comparable regulatory authorities to perform trials in addition to those that we currently expect to perform, or if we experience any delays in establishing appropriate manufacturing arrangements for completing our planned clinical trials or the clinical development of any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts or continue operations. A decline in the value of our company, or in the value of our common stock, could also cause investors to lose all or part of their investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing those approved product candidates. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and product development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The development of biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we work to prepare for IND submissions and initiate Phase 1 clinical trials of our product candidates PYX-201, PYX-202, PYX-203, PYX-106, and PYX-102 and advance our other preclinical research and development programs. Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with sales, marketing, manufacturing and distribution activities. Our expenses could increase beyond expectations if we are required by the FDA, the EMA or other comparable regulatory authorities to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amount of resources and funding that will be necessary to successfully complete the development and commercialization of any product candidate we develop. Accordingly, we will need to obtain substantial additional funding in order to continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had approximately $274.7 million in cash and cash equivalents. Based on our current operating plan, our current cash and cash equivalents, we estimate that such funds will enable us to fund our operating expenses and capital expenditure requirements into the third quarter of 2024. Our estimate as to how long we expect to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to use our cash and cash equivalents for development and regulatory activities relating to our product candidates, discovery programs, business development activities and other general corporate purposes. Advancing the development of our product candidates will require a significant amount of capital. Our cash and cash equivalents will not be sufficient to fund any of our product candidates through regulatory licensure. Because the length of time and activities associated with successful research and development of any individual product candidate are highly uncertain, we are unable to estimate the actual funds we will require for development, marketing licensure and commercialization activities. The timing and amount of our operating expenditures will depend largely on:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the manufacture of product candidates, completion of our IND enabling studies and initiation of Phase 1 clinical trials for PYX-201, PYX-202, PYX-203, PYX-106, and PYX-102; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and progress of our other preclinical and clinical development activities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number and scope of other preclinical and clinical programs we decide to pursue; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the progress of the development efforts of parties with whom we have entered or may in the future enter into in-licensing, collaborations and research and development agreements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing licensure; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to maintain our current licenses and research and development programs and to establish new collaboration arrangements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs involved in prosecuting, maintaining and enforcing patent and other intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any delays or interruptions, including due to the COVID-19 pandemic, that we experience in our preclinical studies, future clinical trials and/or supply chain; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost and timing of regulatory licenses; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our efforts to hire additional clinical, regulatory, scientific, operational, financial and management personnel. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and preclinical studies or clinical trials, if any, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technologies or product candidates that we would otherwise pursue on our own. We do not expect to realize revenue from sales of products or royalties from licensed products in the foreseeable future, if at all, and not until our product candidates are clinically tested, licensed for commercialization and successfully marketed. To date, we have primarily financed our operations through the sale of equity securities. We will be required to seek additional funding in the future and our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. For example, market volatility resulting from the COVID-19 pandemic could adversely impact our ability to access capital as and when needed. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We incorporated in 2018 and staffing and meaningful operations commenced in mid-2019 and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, engaging third parties for initiating manufacturing of drug product and preparing for preclinical toxicology studies, filing patent applications, identifying and obtaining rights to potential product candidates and advancing the FACT platform. All our product candidates are still in preclinical development. We have not yet demonstrated our ability to successfully submit INDs, initiate or complete any clinical trials, obtain marketing licenses, manufacture a commercial scale product directly or through a third party or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or if we had already successfully completed some or all of these types of activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, as a preclinical stage biopharmaceutical company, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities and we may not be successful in making that transition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to the Discovery and Development of our Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We are heavily dependent on the success of PYX-201, PYX-202, PYX-203, PYX-106 and PYX-102 all of which are in the early stages of development, and if PYX-201, PYX-202, PYX-203, PYX-106 and/or PYX-102 are not successful in clinical trials or do not receive regulatory approval or licensure or are not successfully commercialized, our business will be materially and adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, we have invested a significant portion of our efforts and financial resources in the development of PYX-201, PYX-202, PYX-203, PYX-106 and PYX-102. Our future success is substantially dependent on our ability to successfully initiate and complete clinical development for, obtain regulatory licensure for, and successfully commercialize PYX-201, PYX-202, PYX-203, PYX-106 and PYX-102 which may never occur. We currently have no products that are approved or licensed for commercial sale and may never be able to develop a marketable product. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to PYX-201, PYX-202, PYX-203, PYX-106 and PYX-102 all of which will require clinical development, management of clinical and manufacturing activities, regulatory licensure, establishing commercial scale manufacturing, and significant sales, marketing, and distribution efforts before we can generate any revenues from any commercial sales. We cannot be certain that we will be able to successfully complete any of these activities or that, even if PYX-201, PYX-202, PYX-203, PYX-106 and PYX-102 receive regulatory licensure, such products will be able to successfully compete against therapies and technologies offered by other companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The research, testing, manufacturing, labeling, licensure, sale, packaging, marketing, and distribution of biological products are subject to extensive regulation by the FDA and comparable regulatory authorities in other countries. We are not permitted to market PYX-201, PYX-202, PYX-203, PYX-106 and PYX-102 in the United States until we receive licensure of a Biologics License Application, or BLA, from the FDA for such product candidates, as appropriate. Further, we are not permitted to market PYX-201, PYX-202, PYX-203, PYX-106 and PYX-102 in any foreign countries until we receive the requisite licensure or approvals from such countries. We have not submitted a BLA to the FDA or comparable applications to any other comparable regulatory authorities for PYX-201, PYX-202, PYX-203, PYX-106 and PYX-102. We will not be in a position to do so for several years, if ever. If we are unable to obtain the necessary regulatory licensure or approvals for PYX-201, PYX-202, PYX-203, PYX-106 and PYX-102 in a country, we will not be able to commercialize such product candidate in that country. As a result, our financial position will be materially adversely affected, and we may not be able to generate sufficient revenue to continue our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">All of our product candidates are currently in preclinical development. Our product candidates may fail in development or suffer delays that materially and adversely affect their commercial viability. If we or our existing or future collaborators are unable to initiate and complete clinical development of, obtain regulatory licensure for or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have no products on the market and our product candidates are currently in preclinical development. In particular, none of our product candidates have ever been tested in a human subject. As a result, their risk of failure is high. Our ability to achieve and sustain profitability depends on obtaining regulatory licensure for and successfully commercializing our product candidates, either alone or with third parties. Before obtaining regulatory licensure for the commercial distribution of our product candidates, we or an existing or future collaborator must conduct extensive preclinical studies and clinical trials to demonstrate the safety, purity and potency in humans of our product candidates. In addition, the development of novel antibodies is complex and difficult. Although our discovery and preclinical programs may initially show promise in identifying potential product candidates, they may not translate into product candidates for clinical development for a number of reasons, including that the target selection methodology we use may not be successful due to our inability to generate an applicable antibody candidate. In addition, four of our five product candidates are in-licensed and we continue to look for additional product candidates to in-license or acquire. Our preclinical studies or clinical trials may not replicate or advance the results of the research programs and pre-clinical studies that were completed prior to our in-licensing or acquisition of product candidates, which may materially and adversely affect our business, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory licensure of, or our ability to commercialize, product candidates, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">negative or inconclusive results from preclinical studies or clinical trials leading to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon a program; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product-related side effects experienced by participants in our clinical trials or by individuals using therapeutic biological products similar to our product candidates; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in submitting INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">conditions imposed by the FDA, EMA or other comparable authorities regarding the scope or design of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in enrolling patients in clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">high drop-out rates of patients; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">greater than anticipated clinical trial costs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">poor effectiveness of our product candidates during clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unfavorable FDA or other comparable regulatory agency inspection and review of a clinical trial site; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">varying interpretations of data by the FDA, the EMA and other comparable foreign regulatory authorities. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of the foregoing circumstances occur, we could experience significant delays or an inability to successfully commercialize our product candidates, which could materially harm our business. Moreover, if we do not receive regulatory approvals, we may not be able to continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We have no experience as a company in completing IND-enabling preclinical studies or commencing and conducting clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have no experience as a company in completing IND-enabling preclinical studies or commencing and conducting clinical trials. In part because of this lack of experience, we cannot be certain that our preclinical studies will be completed on time or if our planned clinical trials will begin or be completed on time, if at all. Large-scale clinical trials would require significant additional financial and management resources and reliance on third-party clinical investigators and consultants. Relying on third-party clinical investigators, contract research organizations, or CROs, and consultants may cause us to encounter delays that are outside of our control. In addition, relying on third parties in the conduct of our preclinical studies or clinical trials exposes us to a risk that they may not adequately comply with good laboratory practice, or GLP, or good clinical practice, or GCP, as required for any studies or trials we plan to submit to a regulatory authority. We may be unable to identify and contract with sufficient investigators, CROs and consultants on terms that are acceptable to us on a timely basis or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We may not be able to submit INDs to commence additional clinical trials on the timelines we expect and, even if we are able to, the FDA may not permit us to proceed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to submit INDs for our product candidates, PYX-201 and PYX-106 in the second half of 2022, and PYX-203 and PYX-102 in the second half of 2023, but we may not be able to submit these planned INDs on the timelines we expect. For example, in case of PYX-202, in preparation for our IND filing and based on observation of our GLP studies to date, we have determined that we will need to conduct additional GLP and non-GLP toxicity studies to determine whether PYX-202 is a viable clinical candidate. We will continue to monitor the progress of our PYX-202 program and expect to provide an update about PYX-202 in mid-2022. Further, we may experience manufacturing delays or other delays with IND-enabling studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing us to commence clinical trials or that, once begun, issues will not arise that lead to the suspension or termination of our clinical trials. Additionally, even if the applicable regulatory authorities agree with the design and implementation of the clinical trials set forth in our INDs, we cannot guarantee that those regulatory authorities will not change their requirements in the future, or that circumstances will not arise under which FDA or other regulatory authorities may place our clinical trials on partial or full clinical hold. These considerations apply to the INDs described above and also to new clinical trials we may submit as amendments to existing INDs or as part of new INDs in the future. Any failure to submit INDs on the timelines we expect or to obtain authorization to proceed with our trials may prevent us from completing our clinical trials or commercializing our products on a timely basis, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our preclinical studies and clinical trials may fail to demonstrate adequately the safety, purity and potency of any of our product candidates, which would prevent or delay development, regulatory licensure and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before obtaining regulatory licensure for the commercial sale of any of our product candidates, including PYX-201, PYX-202, PYX-203, PYX-106 and PYX-102 we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are safe, pure, and potent, as required under a BLA. Preclinical and clinical testing is expensive and can take many years to complete and the outcome of these activities is inherently uncertain. Failure can occur at any time during the preclinical study and clinical trial processes and, because our product candidates are in an early stage of development and have never been tested in humans, there is a high risk of failure. For example, in case of PYX-202, in preparation for our IND filing and based on observation of our GLP studies to date, we have determined that we will need to conduct additional GLP and non-GLP toxicity studies to determine whether PYX-202 is a viable clinical candidate. We will continue to monitor the progress of our PYX-202 program and expect to provide an update about PYX-202 in mid-2022.  In addition, any failures or adverse outcomes in preclinical or clinical testing seen by other developers of similar product candidates could materially impact the success of our programs. We may never succeed in developing marketable products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">It is also possible that the results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Although product candidates may demonstrate promising results in preclinical studies and early clinical trials, they may not prove to be effective in subsequent clinical trials. For example, testing on animals occurs under different conditions than testing in humans and, therefore, the results of animal studies may not accurately predict human experience. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through preclinical studies and clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety, purity, and potency profile despite having progressed successfully through preclinical studies and/or initial clinical trials. Likewise, early, smaller-scale clinical trials may not be predictive of eventual safety, purity and potency in large-scale pivotal clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of potency, insufficient durability of potency or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence preclinical studies and clinical trials are never approved or licensed for commercialization. In addition, our preclinical studies or clinical trials may not replicate or advance the results of the research programs and pre-clinical studies that were completed prior to our in-licensing or acquisition of product candidates, which may materially and adversely affect our business, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we expect that the first clinical trials for our product candidates may be open-label studies, where both the patient and investigator know whether the patient is receiving the investigational product candidate or an existing licensed biological product. Most typically, open-label clinical trials test only the investigational product candidate and sometimes do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. In addition, open-label clinical trials may be subject to an &#x201c;investigator bias&#x201d; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. FDA may also not consider open-label clinical trials to be adequate and well controlled trials sufficient to support BLA licensure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any preclinical studies or clinical trials that we may conduct may not demonstrate the safety, purity, and potency necessary to obtain regulatory licensure to market our product candidates. If the results of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to the safety, purity, and potency of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance or if there are safety concerns associated with our product candidates, we may be prevented or delayed in obtaining marketing licensure for those product candidates. In some instances, there can be significant variability in safety, purity, and potency results between different preclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. While we have not yet initiated clinical trials for any of our product candidates, it is likely that there may be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. If that were to occur, or if other developers of similar products were to find an unacceptable severity or prevalence of side effects with their candidates, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny licensure of our product candidates for any or all targeted indications. Product-related side effects could also affect patient recruitment or the ability of enrolled patients to complete an ongoing trial or result in potential product liability claims. Any of these occurrences may significantly harm our business, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, our product candidates could cause undesirable side effects in clinical trials related to on-target toxicity. If on-target toxicity is observed or if our product candidates have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in early-stage testing for treating cancer have later been found to cause side effects that prevented further development of the compound.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory licensure or commercialize these programs on a timely basis or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to obtain FDA, European Commission (based on the opinion of the EMA&#x2019;s Committee for Human Medicinal Products, or CHMP) or other comparable licensure to market a new biological product we must demonstrate proof of safety, purity and potency or efficacy in humans. To meet these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical studies that support our planned INDs or similar applications in foreign countries. Currently, all of our programs are in preclinical development. We cannot be certain of the timely completion or outcome of our preclinical studies and cannot predict if the FDA or other comparable foreign authorities and independent ethics committees will accept our proposed clinical programs or if the outcome of our preclinical studies will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities or independent ethics committees allowing clinical trials to begin.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conducting preclinical studies is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. Any delays in preclinical studies conducted by us or potential future partners may cause us to incur additional operating expenses. The commencement and rate of completion of preclinical studies for a product candidate may be delayed by many factors, including, for example:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inability to generate sufficient preclinical or other in vivo or in vitro data to support the initiation of clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the COVID-19 pandemic, which may result in delays; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in reaching a consensus with regulatory agencies on study design. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, because standards for preclinical assessment are evolving and may change rapidly, even if we reach an agreement with the FDA on a pre-IND proposal, the FDA may not accept the IND submission as presented. Even if clinical trials do begin for our preclinical programs, our clinical trials or development efforts may not be successful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Clinical testing and product development is a lengthy and expensive process with an uncertain outcome. We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the clinical testing and the development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the timing and outcome. A failure of one or more clinical trials can occur at any stage of the process. We may experience numerous unforeseen events during or as a result of clinical trials, which could delay or prevent our ability to receive marketing licensure or commercialize our product candidates, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in reaching, or the failure to reach, a consensus with regulators on clinical trial design or the inability to produce acceptable preclinical results to enable entry into human clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate, including as a result of delays in the testing, validation, manufacturing and delivery of product candidates to the clinical sites by us or by third parties with whom we have contracted to perform certain of those functions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in reaching, or the failure to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the failure of regulators or institutional review boards to authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">difficulty in designing clinical trials and in selecting endpoints for diseases that have not been well studied and for which the natural history and course of the disease is poorly understood; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the selection of certain clinical endpoints that may require prolonged periods of clinical observation or analysis of the resulting data; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or fail to return for post-treatment follow-up or the failure to recruit suitable patients to participate in our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the third parties with whom we contract may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the requirement from regulators or institutional review boards that we or our investigators suspend or terminate clinical trials for various reasons, including noncompliance with regulatory requirements or unacceptable safety risks; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical trials of our product candidates may produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product candidate development and discovery programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of clinical trials of our product candidates may be greater than we anticipate; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, concerns with a class of product candidates or after an inspection of our clinical trial operations, trial sites or manufacturing facilities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in developing and validating any companion diagnostic to be used in the trial, to the extent we are required to do so; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disruptions caused by the evolving effects of the COVID-19 pandemic may increase the likelihood that we encounter these types of difficulties or delays in initiating, enrolling, conducting or completing our planned clinical trials. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be delayed in obtaining marketing licenses for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not obtain marketing licensure at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain licensure for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain licensure with labeling that includes significant use or distribution restrictions or safety warnings; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be required to perform additional clinical trials to support marketing licensure; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">have regulatory authorities withdraw or suspend their license, or impose restrictions on distribution of a product candidate in the form of a modified risk evaluation and mitigation strategy, or REMS; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be subject to additional postmarketing testing requirements or changes in the way the product is administered; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may fail to approve any companion diagnostics that may be required in connection with approval of our therapeutic product candidates; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">have our product removed from the market after obtaining marketing licensure. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product development costs also will increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing licenses. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates, or could allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates, which may harm our business, results of operations, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, cancer therapies sometimes are characterized as first-line, second-line or third-line. The FDA often approves or licenses new oncology therapies initially only for third-line or later use, meaning for use after two or more other treatments have failed. When cancer is detected early enough, first-line therapy, usually hormone therapy, surgery, radiation therapy, immunotherapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second-line and third-line therapies are administered to patients when prior therapy is not effective. Our clinical trials will be with patients who have received one or more prior treatments and we expect that we would initially seek regulatory licensure for use of these product candidates as second-line or third-line therapy. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek licensure potentially as a first-line therapy, but any product candidates we develop, even if approved for second-line or third-line therapy, may not be approved for first-line therapy and, prior to seeking and/or receiving any licensures for first-line therapy, we may have to conduct additional clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Any failures or setbacks involving the FACT platform, including adverse events, could have a detrimental impact on our research pipeline and future success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We use the FACT platform in two of our three ADC product candidates for cancer therapies. Any failures or setbacks involving the FACT platform, including adverse events, could have a detrimental impact on our research pipeline and future success. For example, we may uncover a previously unknown risk associated with the FACT platform or other issues that may be more problematic than we currently believe, which may prolong the period of observation required for obtaining, necessitate additional clinical testing or result in the failure to obtain, regulatory licensure. If the FACT platform is not safe in certain product candidates, we would be required to abandon or redesign certain product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We may not be successful in our efforts to use and expand the FACT platform to continue to build a pipeline of product candidates and develop marketable products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are using the FACT platform to develop three of our product candidates PYX-201, PYX-202 and PYX-203, as well as continuing to build our pipeline of product candidates. Our business depends not only on our ability to successfully develop, obtain regulatory licensure for, and commercialize the product candidates we currently have in preclinical development, but to continue to generate new product candidates through our platform. Even if we are successful in continuing to build our pipeline and further progress the development of our current product candidates, any additional product candidates may not be suitable for clinical development, including as a result of harmful side effects, manufacturing issues, limited potency or other characteristics that indicate that they are unlikely to be products that will succeed in clinical development, receive marketing licensure or achieve market acceptance. If we cannot validate our technology platform by successfully commercializing product candidates, we may not be able to obtain product, licensing or collaboration revenue in future periods, which would adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We may expend our resources to pursue particular product candidates and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result of our limited financial and managerial resources, we must make strategic decisions as to which targets and product candidates to pursue and may forego or delay pursuit of opportunities with other targets or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to properly assess potential product candidates could result in our focus on product candidates with low market potential, which would harm our business, financial condition, results of operations and prospects. Our spending on current and future research, product candidates and discovery programs for specific targets or indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">If the market opportunities for any product candidate that we develop are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The potentially addressable patient population for our current programs or future product candidates may be limited and the number of patients who have the cancers we are targeting may turn out to be lower than expected. Potentially addressable patient populations for our product candidates are only estimates. These estimates could prove to be incorrect, and the estimated number of potential patients in the United States and elsewhere could be lower than expected. It may also be that such patients may not be otherwise amenable to treatment with our product candidates, or patients could become increasingly difficult to identify and access, any of which could materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our estimated addressable markets and market opportunities for our product candidates are based on a variety of inputs, including data published by third parties, our own market insights and internal market intelligence, and internally generated data and assumptions. We have not independently verified any third-party information and cannot be assured of its accuracy or completeness. Market opportunity estimates, whether obtained or derived from third-party sources or developed internally, are subject to significant uncertainty and are based on assumptions and estimates that may prove not to be accurate. Although we believe our market opportunity estimates are reasonable, such information is inherently imprecise. In addition, our assumptions and estimates of market opportunities are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including but not limited to those described in this Form 10-K. If this third-party or internally generated data prove to be inaccurate or if we make errors in our assumptions based on that data, our actual market may be more limited than we estimate it to be. In addition, these inaccuracies or errors may cause us to misallocate capital and other critical business resources, which could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">The market may not be receptive to our product candidates because they are based on our novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if regulatory licensure is obtained for a product candidate, we may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether the product is otherwise accepted in the market. Some product candidates that we are developing are based on the FACT platform, which is a new technology and therapeutic approach. Our future success depends on the successful development of this novel therapeutic approach. Additionally, the regulatory licensure process for novel product candidates such as ours can be more expensive and take longer than for other, better-known or extensively-studied product candidates. No regulatory authority has granted licensure for any therapeutic using the FACT platform. As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the FACT platform will result in the development and marketing licensure of any products. Any development problems we experience in the future related to any of our programs may cause significant delays or unanticipated costs or may prevent the development of a commercially viable product. Advancing our products creates significant challenges for us, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">educating medical personnel regarding the potential potency and safety benefits, as well as the challenges, of incorporating our product candidates, if approved, into treatment regimens; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishing the sales and marketing capabilities to gain market acceptance, if approved. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any of these factors may prevent us from commercializing any of our product candidates we may develop on a timely or profitable basis, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Market participants with significant influence over acceptance of new treatments, such as physicians and third-party payors, may not adopt a product or treatment based on the FACT platform and technologies, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any product candidates developed by us or our existing or future collaborators. Market acceptance of our product candidates will depend on, among other factors:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing of our receipt of any marketing and commercialization licensures; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the terms of any licensures and the countries in which licensures are obtained; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the safety, purity, and potency of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the prevalence and severity of any adverse side effects associated with our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations or warnings contained in any labeling approved by the FDA, or other comparable foreign regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">relative convenience and ease of administration of our product candidates; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of patients to accept any new methods of administration; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the success of our physician education programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of adequate government and third-party payor reimbursement </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the pricing of our products, particularly as compared to alternative treatments; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">availability of alternative effective treatments for the disease indications our product candidates are intended to treat and the relative risks, benefits and costs of those treatments. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any product candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We have not tested any of our product candidates in clinical trials. The results of preclinical studies and early-stage clinical trials may not be predictive of future results in later studies or trials. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later-stage clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The results of preclinical studies may not be predictive of the results of clinical trials, and the results of any early-stage clinical trials we commence in the future may not be predictive of the results of the later-stage clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed on in later stage clinical trials. In particular, the small number of patients in our planned early clinical trials may make the results of these trials less predictive of the outcome of later clinical trials. For example, even if successful, the results of our Phase 1 clinical trials of our product candidates PYX-201, PYX-202, PYX-203, PYX-106 and PYX-102 and other product candidates may not be predictive of the results of further clinical trials of these product candidates or any of our other product candidates. Moreover, preclinical and clinical data often are susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless have failed to obtain marketing licensure of their products. For example, in case of PYX-202, in preparation for our IND filing and based on observation of our GLP studies to date, we have determined that we will need to conduct additional GLP and non-GLP toxicity studies to determine whether PYX-202 is a viable clinical candidate. We will continue to monitor the progress of our PYX-202 program and expect to provide an update about PYX-202 in mid-2022. Our future clinical trials may not ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for product candidates proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving encouraging results in earlier studies. Any such setbacks in our clinical development could materially harm our business, results of operations, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, from time to time, we may publish interim, top-line or preliminary data from our planned clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously announced or published. As a result, interim, top-line and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary, top-line or interim data and final data could significantly harm our reputation and business prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">If we experience delays or difficulties in the enrollment of patients in our clinical trials, our timelines for submitting applications for and receiving necessary marketing authorizations, if any, could be delayed or prevented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to initiate clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials, as required by the FDA or similar regulatory authorities outside of the United States. While we believe that we will be able to enroll a sufficient number of patients into each of these clinical trials, we cannot predict with certainty how difficult it will be to enroll patients for trials in these rare indications generally and during the COVID-19 pandemic, specifically. Our ability to identify and enroll eligible patients for clinical trials may turn out to be limited or we may be slower in enrolling these trials than we anticipate. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates and, as a result, patients who would otherwise be eligible for our clinical trials may instead elect to enroll in clinical trials of our competitors&#x2019; product candidates. Patient enrollment in clinical trials is also affected by other factors including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the severity of the disease under investigation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size and nature of the patient population; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the eligibility criteria for the trial in question; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">competing clinical trials or approved therapies which present an attractive alternative to patients and their physicians; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">perceived risks and benefits of the product candidate under study, including as a result of adverse effects observed in similar or competing therapies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the efforts to facilitate timely enrollment in clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patient referral practices of physicians; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the burden on patients due to the scope and invasiveness of required procedures under clinical trial protocols, some of which may be inconvenient and/or uncomfortable; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability to monitor patients adequately during and after treatment; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the proximity and availability of clinical trial sites for prospective patients; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact of the current COVID-19 pandemic, which may affect the conduct of a clinical trial, including by slowing potential enrollment or reducing the number of eligible patients for clinical trials. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the risk that enrolled subjects will drop out or die before completion of the trial; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patients failing to complete a clinical trial or returning for post-treatment follow-up; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to manufacture the requisite materials for a patient and clinical trial. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our inability to enroll a sufficient number of patients for our planned clinical trials, or our inability to do so on a timely basis, would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our planned clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our product candidates may cause undesirable and unforeseen side effects or have other properties impacting safety that could halt their clinical development, delay or prevent their regulatory licensure, limit their commercial potential or result in significant negative consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Undesirable side effects caused by our product candidates could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory licensure or approval by the FDA or other regulatory authorities. While we have not yet initiated clinical trials for any of our product candidates, it is likely that there may be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny licensure or approval of our product candidates for any or all targeted indications. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event that any of our product candidates receive regulatory licensure or approval and we or others identify undesirable side effects caused by one of our products, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities may withdraw their licensure or approval of the product or seize the product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to recall the product or change the way the product is administered to patients; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities may require the addition of labeling statements, such as a &#x201c;black box&#x201d; warning or a contraindication; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we could be sued and held liable for harm caused to patients; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the product may become less competitive; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our reputation may suffer. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our products may be delayed and, as a result, our stock price may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of preclinical studies and clinical trials and the submission of regulatory filings and may be associated with payments from collaborators. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones may vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, our revenue may be lower than expected, the commercialization of our products may be delayed or never achieved and, as a result, our stock price may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We face competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The development and commercialization of therapeutic biological products is highly competitive. We compete with a variety of multinational biopharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors have developed, are developing or will develop product candidates and processes competitive with our product candidates. Competitive therapeutic treatments include those that have already been approved or licensed and accepted by the medical community and any new treatments that enter the market. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may try to develop product candidates. The biotechnology and pharmaceutical industries, including the oncology subsector, are characterized by rapidly evolving technologies, intense competition, and a strong defense of intellectual property and proprietary technologies. Any product candidates that we successfully commercialize may not be competitive with currently marketed therapies and any new therapies commercialized in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are aware of several companies that are developing cancer immunotherapies and ADCs. Many of these companies are well-capitalized and, in contrast to us, have significant clinical experience, and may include our existing or future collaborators. In addition, these companies compete with us in recruiting scientific and managerial talent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our success will partially depend on our ability to develop and protect therapeutics that are more safe, pure, and potent than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products that are safer, more effective, or less expensive than the therapeutics we develop are commercialized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our product candidates are licensed, they will compete with a range of therapeutic treatments that are either in development or currently marketed. Indeed, many companies are active across various stages of development in the oncology subsector and are marketing and developing products that employ similar ADC and immunotherapy approaches. As of April 2021, there were approximately 275 ADCs in clinical or preclinical development worldwide, of which the vast majority are being developed for the treatment of various cancer indications. Additionally, there are several large and small companies working on various immunotherapy approaches for treatement of cancer. Multiple companies are also involved in the marketing of ADC therapeutics and Immunotherapy which include, but are not limited to, ADC Therapeutics SA, Astellas Pharma, Inc., AstraZeneca plc, Daiichi Sankyo Company, Ltd., Genentech, Inc., Gilead Sciences, Inc, GlaxoSmithKline, plc, Pfizer, Inc., Rakuten Medical, Inc., Seagen, Inc., Nextcure, Inc. and  Abcure, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our preclinical ADC and immunotherapy candidates may face substantial competition from alternative therapeutic modalities, such as CAR-T therapies, bispecific antibodies, and small molecules that are being developed for the same cancer types that we are targeting with our pipeline candidates. These approaches could prove to be more effective, safer, or convey other advantages over any products resulting from our technology. In addition, we also face competition on specific targets, including the target of our PYX-201 candidate, EDB, from Philogen S.p.A., the target of our PYX-202 candidate, DLK-1, from Chiome Bioscience, Inc., the target of our PYX-203 product candidate, CD123, from ImmunoGen, Inc., Vincerx Pharma, Inc., Macrogenics and Byondis B.V., the target of our PYX-106 product candidate, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BSI-060T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, from Nextcure, Inc. lead program - NC318 and the target of our PYX-102 product candidate, Anti-KLRG1, from Abcuro, Inc. Additionally, there is a wide array of activity in the development of immunotherapies for oncology which may be competitive with our preclinical discovery programs. Furthermore, if any of our product candidates are approved in oncology indications such as lung, hematological and other cancers, they may compete with existing approaches to treating cancer including surgery, radiation, and drug therapy, including conventional chemotherapy, biological products, and targeted drug small molecule therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of our competitors have significantly greater scientific, research and development capabilities, as well as greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain licensure for any product candidate, we will face competition based on many different factors, including the safety, purity and potency of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory licenses for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our biological product candidates for which we intend to seek licensure may face competition sooner than anticipated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated licensure pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the licensure of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have an adverse effect on the future commercial prospects for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is a risk that any product candidates we may develop that are licensed as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider any product candidates we may develop to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation, including litigation challenging the constitutionality of the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, in December 2018, a federal district court ruled that the ACA, without the &#x201c;individual mandate&#x201d; penalty (which was repealed by Congress as part of the Tax Cuts and Jobs Act), is unconstitutional in its entirety. In December 2019, the U.S. Court of Appeals for the 5th Circuit upheld the district court ruling that the individual mandate provisions are unconstitutional and remanded the case back to the district court for further analysis of whether such provisions could be severed from the remainder of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the case without specifically ruling on the constitutionality of the ACA. There may, however, be other efforts to challenge, repeal, or replace the ACA in the future. We continue to evaluate the effect that the ACA and its possible repeal and replacement has (or may have) on our business and exclusivity under the BPCIA. It is uncertain the extent to which any such changes may impact our business or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our business entails a significant risk of product liability, and if we are unable to obtain sufficient insurance coverage, such failure could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to be exposed to significant product liability risks inherent in the development, testing and manufacturing of our product candidates and products, if approved. Product liability claims could delay or prevent completion of product candidate development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our third-party manufacturer&#x2019;s manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, including limitations on the approved indications for which our product candidates may be used or suspension or withdrawal of licenses. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#x2019;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. In addition, we may be subject to liability based on the actions of our existing or future collaborators in connection with their development of products using the FACT platform. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to maintain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Regulatory Licensure or Approval and Other Legal Compliance Matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">The regulatory licensure and approval processes of the FDA and other comparable regulatory authorities are lengthy, time-consuming and inherently unpredictable and, if we are ultimately unable to obtain marketing licensure or approval for our product candidates, our business will be substantially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The time required to obtain approval or licensure by the FDA and other comparable regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval and licensure policies, regulations or the type and amount of clinical data necessary to gain approval or licensure may change during the course of a product candidate&#x2019;s clinical development and may vary among jurisdictions. We have not obtained marketing approval or licensure for any product candidate, and it is possible that none of our existing product candidates, or any product candidates we may seek to develop in the future, will ever obtain marketing approval or licensure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates could fail to receive marketing licensure in the United States for many reasons, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the FDA may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> we may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe, pure, and potent; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">results of clinical trials may not meet the level of statistical significance required by the FDA for licensure; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be unable to demonstrate that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA to the FDA or other submission or to obtain marketing licensure in the United States; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the licensure policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for licensure. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This lengthy licensure process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory licensure to market any of our product candidates, which would significantly harm our business, results of operations, financial condition and prospects. The FDA has substantial discretion in the licensure process and determining when or whether regulatory licensure will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support licensure by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, even if we were to obtain licensure, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant a license contingent on the performance of costly postmarketing clinical trials, or may approve or license a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Even if we obtain FDA licensure for any of our product candidates in the United States, we may never obtain approval or licensure for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety, purity, potency and efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Licensure by the FDA in the United States does not ensure approval or licensure by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval or licensure in one jurisdiction may negatively impact our ability to obtain approval or licensure elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval or licensure in one country does not guarantee regulatory approval or licensure in any other country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Approval or licensure processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval or licensure could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved or licensed for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval or licensure in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals or licensures, or if regulatory approvals or licensures in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Even if we receive regulatory licensure of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our product candidates are licensed or approved by regulatory authorities, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of postmarketing studies, track and trace, serialization, postmarket adverse event reporting, and submission of safety, purity, potency, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMP and GCP requirements for any clinical trials that we conduct post-licensure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Manufacturers and manufacturers&#x2019; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA or other marketing application and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any regulatory licenses that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of licensure, or contain requirements for potentially costly postmarketing testing, including Phase 4 clinical trials and surveillance to monitor the safety, purity, and potency of the product candidate. The FDA may also require a REMS program as a condition of licensure of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Comparable foreign regulatory authorities may also have programs similar to REMS. In addition, if the FDA or a comparable foreign regulatory authority licenses or approves our product candidates, we will have to comply with requirements including submissions of safety and other postmarketing information and reports and registration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials of our product candidates must be conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of our product candidates receives marketing licensure and we, or others, discover that the biological product is less effective than previously believed or causes undesirable side effects that were not previously identified, a number of potentially significant negative consequences could result, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities may withdraw their licensure of the biological product or seize the biological product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we, or any future collaborators, may be required to recall the biological product, change the way the biological product is administered or conduct additional clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular biological product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities may require the addition of labeling statements, such as a &#x201c;black box&#x201d; warning or a contraindication; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we, or any future collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we, or any future collaborators, could be sued and held liable for harm caused to patients; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the biological product may become less competitive in the marketplace; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our reputation may suffer. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any of these events could have a material and adverse effect on our operations and business and could adversely impact our stock price. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA also may impose requirements for costly postmarketing studies or clinical trials and surveillance to monitor the safety, purity, or potency of the product, including the adoption and implementation of REMS. The FDA and other agencies, including the DOJ, closely regulate and monitor the post-licensure marketing and promotion of biological products to ensure they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and DOJ impose stringent restrictions on manufacturers&#x2019; communications regarding off-label use, and if we do not market our products only for the approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug and Cosmetic Act, or FDCA, and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We, and any collaborators, must comply with requirements concerning advertising and promotion for any of our product candidates for which we or they obtain marketing licensure. Promotional communications with respect to prescription biological products are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#x2019;s approved labeling. Thus, we, and any collaborators, will not be able to promote any products we develop for indications or uses for which the biological product is not licensed. The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments, but the FDA does restrict manufacturer&#x2019;s communications on the subject of off-label use of their products. The policies of the FDA and of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory licensure of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing licensure that we may have obtained and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, later discovery of previously unknown side effects or other problems with our products or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on such products, manufacturers or manufacturing processes; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions and warnings on the labeling or marketing of a product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on product distribution or use; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requirements to conduct postmarketing studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">warning letters or untitled letters; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">withdrawal of the products from the market; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recall of products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, restitution or disgorgement of profits or revenues; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">suspension or withdrawal of marketing licenses; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">suspension of any ongoing clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">damage to relationships with any potential collaborators; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unfavorable press coverage and damage to our reputation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal to permit the import or export of our products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">litigation involving patients using our products. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA and similar foreign authorities may impose consent decrees or withdraw licensure if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, warning letters or holds on clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal by the FDA and similar foreign authorities to approve pending applications or supplements to approved applications filed by us or suspension or revocation of licenses; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure or detention or refusal to permit the import or export of our product candidates; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-compliance with European Union requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population (as explained further below), also can result in significant financial penalties, and non-compliance with pediatric requirements may prevent regulatory approvals from being granted. Similarly, failure to comply with the European Union and UK&#x2019;s requirements regarding the protection of personal information can lead to significant penalties and sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or licensure process and it does not increase the likelihood that our product candidates will receive marketing licensure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek Breakthrough Therapy designation for our product candidates and some or all of our future product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs or biological products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biological products may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for other expedited approval programs, if meeting regulatory requirements, including accelerated approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or licensure compared to candidate products considered for licensure under non-expedited FDA review procedures and does not assure ultimate licensure by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification. Thus, even though we intend to seek Breakthrough Therapy designation for some or all of our future product candidates for the treatment of various cancers, there can be no assurance that we will receive Breakthrough Therapy designation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">A Fast Track designation by the FDA, even if granted for other current or future product candidates, may not lead to a faster development or regulatory review, licensure process and does not increase the likelihood that our product candidates will receive marketing licensure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek Fast Track designation for one or more of our future product candidates. If a drug or biological product is intended for the treatment of a serious or life-threatening disease or condition and it demonstrates the potential to address unmet medical needs for such a disease or condition, the drug sponsor may apply for FDA Fast Track designation for a particular indication. We may seek Fast Track designation for our product candidates, but there is no assurance that the FDA will grant this designation to any of our proposed product candidates. Marketing applications submitted by sponsors of products in Fast Track development may qualify for priority review under the policies and procedures offered by the FDA, but the Fast Track designation does not assure any such qualification or ultimate marketing licensure by the FDA. The FDA has broad discretion whether or not to grant Fast Track designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive Fast Track designation, we may not experience a faster development process, review or licensure compared to conventional FDA procedures or pathways and receiving a Fast Track designation does not provide assurance of ultimate FDA licensure. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. In addition, the FDA may withdraw any Fast Track designation at any time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">If we decide to seek Orphan Drug Designation for any of our current or future product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for supplemental market exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek Orphan Drug Designation for one or more of our current or future product candidates. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs or biological products for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug in the United States will be recovered from sales in the United States for that drug or biological product. In the United States, Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. After the FDA grants Orphan Drug Designation, the identity of the drug or biological product and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory review and licensure process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a product that has Orphan Drug Designation subsequently receives the first FDA approval or licensure for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including an NDA or BLA, to market the same drug or biological product for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the biological product was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve or license other drugs or biological products that have a different active ingredient for use in treating the same indication or disease. Further, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek Orphan Drug Designation for our product candidates in additional orphan indications in which there is a medically plausible basis for the use of these product candidates. Even when we obtain Orphan Drug Designation, exclusive marketing rights in the United States may be limited if we seek licensure for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we, through our manufacturer, are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In addition, although we intend to seek Orphan Drug Designation for other product candidates, we may never receive these designations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Accelerated approval by the FDA, even if granted, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing licensure. If we are unable to obtain licensure of our products through the Accelerated Approval Program in the United States, we may be required to conduct additional nonclinical and clinical studies and trials beyond those that we currently contemplate, which could increase the expense of obtaining, reduce the likelihood of obtaining and/or delay the timing of obtaining, necessary marketing licensure. Even if we receive accelerated approval from the FDA through the Accelerated Approval Program, if our confirmatory postmarketing trial does not verify clinical benefit, or if we do not comply with rigorous postmarketing requirements, the FDA may seek to withdraw accelerated approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to seek accelerated approval of PYX-201, PYX-202, PYX-203, PYX-106 and PYX-102 and may seek approval of future product candidates using the FDA&#x2019;s accelerated approval pathway. For any licensure to market a biological product, we must provide the FDA and foreign regulatory agencies with clinical data that adequately demonstrate the safety, purity, and potency of the product for the indication applied for in the BLA or other respective regulatory filings. The Accelerated Approval Program is one of several approaches used by the FDA to make prescription drugs or biological products more rapidly available for the treatment of serious or life-threatening diseases. Section 506(c) of the FDCA provides that the FDA may grant accelerated approval to &#x201c;a product for a serious or life-threatening condition upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.&#x201d; Licensure through the Accelerated Approval Program is subject, however, to the requirement that a sponsor perform adequate and well controlled postmarketing clinical trials to verify and describe the drug&#x2019;s clinical benefit, where there is uncertainty as to the relationship of the surrogate endpoint to the clinical benefit, or of the observed clinical endpoint to ultimate outcome. Typically, clinical benefit is verified when postmarketing clinical trials show that the biological products provide a clinically meaningful positive therapeutic effect, that is, an effect on how a patient feels, functions, or survives. These confirmatory trials must be completed with due diligence. If such confirmatory postmarketing trial fails to confirm the product&#x2019;s clinical profile or risks and benefits, the FDA may withdraw accelerated approval of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA has broad discretion with regard to licensure through the Accelerated Approval Program, and even if we believe that the Accelerated Approval Program is appropriate for one of our products, we cannot assure you that the FDA will ultimately agree. Furthermore, even if we do obtain licensure through the Accelerated Approval Program, we may not experience a faster development process, review, or licensure compared to conventional FDA procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if the FDA reviews a BLA seeking accelerated approval, there can be no assurance that licensure will be granted on a timely basis, or at all. The FDA may disagree that the design of, or results from, our studies support accelerated approval. Additionally, the FDA could require us to conduct further studies or trials prior to granting licensure of any type, including by determining that licensure through the Accelerated Approval Program is not appropriate and that our clinical trials may not be used to support licensure through the conventional pathway. We might not be able to fulfill the FDA&#x2019;s requirements in a timely manner, which would cause delays, or licensure might not be granted because our submission is deemed incomplete by the FDA. There also can be no assurance that after subsequent FDA feedback we will continue to pursue licensure through the Accelerated Approval Program. A failure to obtain licensure through the Accelerated Approval Program could result in a longer time period to obtain licensure of our products, could increase the cost of its development, could delay our ability to commercialize our products and could significantly harm our financial position and competitive position in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we receive licensure for one of our products through the Accelerated Approval Program, we will be subject to rigorous postmarketing requirements, including the completion of one or more confirmatory postmarketing trials as the FDA may require, to verify the clinical benefit of the product, and submission to the FDA of all promotional materials prior to their dissemination. These requirements could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development or regulatory review or licensure process. Further, receiving accelerated approval does not provide assurance of ultimate full FDA licensure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA could seek to withdraw accelerated approval for multiple reasons, including if we fail to conduct any required confirmatory postmarketing trial with due diligence, our confirmatory postmarketing trial does not confirm the predicted clinical benefit, other evidence shows that the product is not safe, pure, or potent under the conditions of use, or we disseminate promotional materials that are found by the FDA to be false and misleading.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any delay in obtaining, or inability to obtain, licensure through the Accelerated Approval Program would delay or prevent commercialization of our products, and would materially adversely affect our business, financial condition, results of operations, cash flows and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">If foreign regulatory authorities approve biosimilar versions of any of our product candidates that receive marketing approval, or such authorities do not grant our product candidates appropriate periods of data or market exclusivity before approving generic versions of our product candidates, the sales of our product candidates could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the European Union and the UK, innovative medicinal products are authorized based on a full marketing authorization application and conditional authorization (as opposed to an application for marketing authorization that relies on data in the marketing authorization dossier for another, previously approved medicinal product). Applications for marketing authorization for innovative medicinal products must contain, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter alia</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the results of pharmaceutical tests, preclinical tests and clinical trials conducted with the medicinal product for which marketing authorization is sought (and where applicable the results of the pediatric studies unless a waiver or a deferral has been obtained&#x2014; as described further below).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A marketing authorization can be obtained via the centralized procedure or the national procedure. The centralized procedure results in a single marketing authorization, issued by the European Commission (based on the opinion of the EMA), which is valid across the entire European Economic Area, which comprises the EU, Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for human drugs that are: (i) derived from biotechnology processes, such as genetic engineering, (ii) contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases, (iii) designated orphan medicines and (iv) advanced-therapy medicines, such as gene therapy, somatic cell therapy or tissue-engineered medicines. The centralized procedure may at the request of the applicant also be used in certain other cases. Therefore, the centralized procedure would be mandatory for the product candidates we are developing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Where an applicant for a marketing authorization submits a full dossier containing its own pharmaceutical, preclinical tests and clinical trials data, and where the application does not fall within the &#x2018;global marketing authorization&#x2019; of an existing medicinal product, reference product candidates may receive eight years of data exclusivity and an additional two years of market exclusivity, upon grant of the marketing authorization. If granted, during the data exclusivity period, applicants for approval of biosimilars cannot rely on data contained in the marketing authorization dossier submitted for the already authorized, or reference product candidate, to support their application. The market exclusivity period prevents a successful biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial marketing authorization of the reference product in the EU, but a biosimilar marketing authorization application can be submitted during this time. The overall 10-year market exclusivity period can further be extended by one more year if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, even if a compound is considered to be a new active substance and the innovator is able to gain the period of data and market exclusivity, provided that no other IP or regulatory exclusivities apply, another unrelated company could also apply for a marketing authorization and market another competing medicinal product for the same therapeutic indication if such company obtained its own marketing authorization based on a separate marketing authorization application based on a full self-standing scientific data package supporting the application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the EU, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product, for example, because of differences in raw materials or manufacturing processes. For such products, the results of appropriate preclinical test or clinical trials must be provided, and guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological products. There are currently no such guidelines for complex biological products such as gene or cell therapy medicinal products, and so in the short term it is unlikely that biosimilars of those products will be approved in the EU. However, guidance from the EMA states that they will be considered in the future in light of the scientific knowledge and regulatory experience gained at the time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the EU, marking authorization applications for new medicinal products must include the results of clinical trials conducted in pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#x2019;s Pediatric Committee, or PDCO. The PDCO can grant waivers or deferrals to these requirements in certain circumstances (for example, a waiver may be obtained if the condition only occurs in adult populations). Where required, pediatric studies must cover all sub-sets of the pediatric population for both existing and new indications, pharmacological forms and route of administrations. Limited further exclusions apply, including in relation to biosimilar applications. Certain incentives may be available for completion of pediatric studies. For example, once the marketing authorization is obtained in all Member States and study results are included in the product information, even when negative, the product is eligible for a six-months supplementary protection certificate extension (if any is in effect at the time of approval) or, in the case of orphan pharmaceutical products, a two year extension of the orphan market exclusivity is granted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the EU, the criteria for designating an &#x201c;orphan medicinal product&#x201d; are similar in principle to those in the United States. A medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. The application for orphan drug designation must be submitted before the marketing authorization application. Orphan drug designations entitle a party to financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to 10 years of market exclusivity. During the 10-year market exclusivity period, the EMA cannot accept another marketing authorization application, or grant a marketing authorization or accept an application to extend an existing marketing authorization, for the same therapeutic indication, in respect of a similar medicinal product. An orphan medicinal product can also obtain an additional two years of market exclusivity in the European Union for pediatric studies. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ten-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. At any time, a marketing authorization may be granted to a similar product for the same indication if:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the holder of the marketing authorization for the original orphan medicinal product has given his consent to the second applicant; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the holder of the marketing authorization for the original orphan medicinal product is unable to supply sufficient quantities of the medicinal product. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although the United Kingdom has left the EU, its regulatory legal framework provides for similar periods of protection (namely regulatory data exclusivity, marketing protection and market exclusivity).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competition that our product candidates may face from biosimilar versions of our product candidates could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates. Our future revenues, profitability and cash flows could also be materially and adversely affected and our ability to obtain a return on the investments we have made in those product candidates may be substantially limited if our product candidates, if and when approved, are not afforded the appropriate periods of non-patent exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">The failure to obtain required regulatory clearances or approvals for any companion diagnostic tests that we may pursue may prevent or delay approval of any of our product candidates. Moreover, the commercial success of any of our product candidates that require a companion diagnostic will be tied to the receipt of any required regulatory clearances or approvals and the continued availability of such tests.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the clinical development of our product candidates for certain indications, we may work with collaborators to develop or obtain access to companion diagnostic tests to identify appropriate patients for our product candidates. We may rely on third parties for the development, testing and manufacturing of these companion diagnostics, the application for and receipt of any required regulatory clearances or approvals, and the commercial supply of these companion diagnostics. The FDA and foreign regulatory authorities regulate companion diagnostics as medical devices that will likely be subject to clinical trials in conjunction with the clinical trials for product candidates, and which will require separate regulatory clearance or approval prior to commercialization. This process could include additional meetings with health authorities, such as a pre-submission meeting and the requirement to submit an investigational device exemption (IDE). In the case of a companion diagnostic that is designated as &#x201c;significant risk device,&#x201d; approval of an IDE by the FDA and IRB is required before such diagnostic is used in conjunction with the clinical trials for a corresponding product candidate. We or our third-party collaborators may fail to obtain the required regulatory clearances or approvals, which could prevent or delay approval of our product candidates. In addition, the commercial success of any of our product candidates that require a companion diagnostic will be tied to and dependent upon the receipt of required regulatory clearances or approvals and the continued ability of such third parties to make the companion diagnostic commercially available to us on reasonable terms in the relevant geographies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">If we are required to in the future and if we are unable to successfully develop companion diagnostic tests for our product candidates that require such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be required by the FDA to develop, either by ourselves or with collaborators, companion diagnostic tests for our product candidates for certain indications. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. We have no prior experience with medical device or diagnostic test development. If we choose to develop and seek FDA clearance or approval for companion diagnostic tests on our own, we will require additional personnel with medical device knowledge and expertise. We may rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that require such tests. If these parties are unable to successfully develop companion diagnostics for these therapeutic product candidates, or experience delays in doing so, we may be unable to enroll enough patients for our current and planned clinical trials, the development of these therapeutic product candidates may be adversely affected, these therapeutic product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of these therapeutics that obtain marketing approval. Any failure to successfully develop this companion diagnostic may cause or contribute to delayed enrollment of this trial and may prevent us from initiating or completing further clinical trials to support marketing approval for our product candidates. As a result, our business, results of operations and financial condition could be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our relationships with customers, physicians and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws and regulations. If we are unable to comply or have not fully complied with these laws, we could face substantial penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing licensure. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject us to various federal and state fraud and abuse laws and other healthcare laws that may constrain the business or financial arrangements and relationships through which we research, develop, sell, market and distribute our product candidates, if we obtain marketing licensure. In particular, the research of our product candidates, as well as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business or financial arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusion from government funded healthcare programs. Even if resolved in our favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have an adverse effect on our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">The successful commercialization of our product candidates in the United States and elsewhere will depend in part on the extent to which third-party payors, including governmental authorities and private health insurers, provide coverage and adequate reimbursement levels, as well as implement pricing policies favorable for our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory licensure. In the United States and in other countries, patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. The availability of coverage and adequacy of reimbursement for our products by third-party payors, including government health care programs (e.g., Medicare, Medicaid or TRICARE), managed care providers, private health insurers, health maintenance organizations and other organizations is essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates. Third-party payors decide which medications they will pay for and establish reimbursement levels.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to successfully commercialize our product candidates will depend, in part, on the extent to which coverage and adequate reimbursement for any products for which we obtain marketing authorization will be available from third-party payors. In the United States, no uniform policy for coverage and reimbursement for pharmaceutical products exists among third-party payors. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting reimbursement policies, but also have their own methods and approval processes apart from Medicare coverage and reimbursement determinations. Therefore, coverage and reimbursement for products for which we may obtain marketing authorization could differ significantly from payor to payor. One payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product. Payors consider a number of factors when determining whether to cover a new product, including, for example, whether the product is a covered benefit under its health plan; safe, effective and medically necessary; appropriate for the specific patient; cost-effective; and neither experimental nor investigational. Third-party payors may also limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, a payor&#x2019;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. A decision by a third-party payor not to cover or not to separately reimburse for any products for which we may obtain marketing authorization could reduce physician utilization of such products. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our product candidates. We cannot be sure that coverage and reimbursement in the United States will be available for our current or future product candidates or for any procedures using our current or future product candidates, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future. Moreover, for products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, increasing efforts by third-party payors in the United States and abroad to cap or reduce healthcare costs may cause payor organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or comparable marketing authorizations or approvals. Additionally, we may also need to provide discounts to purchasers, private health plans or government healthcare programs. Our product candidates may nonetheless not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after marketing authorization or approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. We expect to experience pricing pressures from third-party payors in connection with the potential sale of any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lastly, in some foreign countries, the proposed pricing for a drug must be approved before the drug may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, countries in the European Union Member States can restrict the range of medicinal products for which their national health insurance systems provide reimbursement and they can control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these Member States may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A European Union Member State may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Approaches between European Union Member States are diverging. For example, in France, effective market access will be supported by agreements with hospitals and products may be reimbursed by the Social Security Fund. The price of medicines is negotiated with the Economic Committee for Health Products, or CEPs. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the United States and generally prices in the European Union tend to be significantly lower than prices in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Enacted and future healthcare legislation may increase the difficulty and cost for us to progress our clinical programs and obtain marketing licensure or approval of and commercialize our product candidates and may affect the prices we may set.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect results of our future operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private payors. The ACA contained a number of provisions, including those governing the federal healthcare programs, provider reimbursement, and healthcare fraud and abuse laws. For example, the ACA:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the average manufacturer price, or AMP; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">required collection of rebates for drugs paid by Medicaid managed care organizations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded beneficiary eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 138% of the federal poverty level, thereby potentially increasing manufacturers&#x2019; Medicaid rebate liability; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">extended manufacturers&#x2019; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded the types of entities eligible for the 340B Drug Pricing Program; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">established a new methodology by which rebates owed by manufacturers under the Medicaid Drug and Rebate Program, or MDRP, are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">required manufacturers to participate in a coverage gap discount program, under which they must agree to offer 70 percent point-of-sale discounts off negotiated prices of applicable branded drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#x201c;branded prescription drugs&#x201d; and biologic agents apportioned among these entities according to their market share in certain federal government programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">created the Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">required reporting of certain financial arrangements between manufacturers of drugs, biological products, devices, and medical supplies and physicians and teaching hospitals under the federal Physician Payments Sunshine Act; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">required annual reporting of certain information regarding drug samples that manufacturers and distributors provide to licensed practitioners. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since its enactment, there have been judicial, legislative, and executive branch challenges to certain aspects of the ACA, and on June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#x2019;s decision, President Biden had issued an executive order to initiate a special enrollment period from February 15, 2021, through August 15, 2021, for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, policies that create barriers to obtaining access to health insurance coverage through the ACA marketplaces. It is unclear how healthcare reform measures enacted by Congress or implemented by the Biden administration or other efforts to challenge, repeal or replace the ACA, if any, will impact the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. These changes include the Budget Control Act of 2011, which, among other changes, led to aggregate reductions of Medicare payments to providers of up to 2% per fiscal year that started in April 2013 and, due to subsequent legislation, will continue into 2031, with the exception of a temporary suspension of the payment reduction from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. Unless additional Congressional action is taken, sequestration will start again on April 1, 2022. From April 1 to June 30, 2022, payment for Medicare fee-for-service claims will be adjusted downwards by 1%; beginning July 1, 2022, the payment will be adjusted downwards by 2%.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cost of prescription drugs has been the subject of considerable policy discussion and debate in the United States. This has resulted in several U.S. Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. While several proposed reform measures will require Congress to pass legislation to become effective, Congress and the Biden administration have expressed support for legislative and/or administrative measures to address prescription drug costs. Since the Presidential inauguration, the Biden administration has taken several executive actions that signal changes in policy from the prior administration, including with respect to executive actions by the Trump administration related to prescription drug costs. Additionally, the American Rescue Plan Act of 2021 was recently signed into law, which, among other things, eliminated the statutory cap on drug manufacturers&#x2019; MDRP rebate liability, effective January 1, 2024. Under current law enacted as part of the ACA, drug manufacturers&#x2019; MDRP rebate liability is capped at 100% of AMP for a covered outpatient drug.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Individual states in the U.S. have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures; and, in some cases, encourage importation from other countries and employ bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could adversely affect our business prospects, financial condition, and results of operations. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the extent to which state and federal governments cover particular healthcare products and services and could limit the amounts that federal and state governments will pay for healthcare items and services. This could result in reduced demand for any product candidate we develop or could result in additional pricing pressures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country and many countries have instituted price ceilings on specific products and therapies. The price control regulations outside of the United States can have a significant impact on the profitability of a given market, and further uncertainty is introduced if and when these laws change. For example, in Canada, price control legislation for patented medicines is currently undergoing significant change that may have significant effects on profitability for companies selling products in Canada.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. It is possible that additional governmental action will be taken to address the COVID-19 pandemic. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or these third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory licensure or approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, operations, and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The global data protection landscape is rapidly evolving, and we may be or become subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, transfer, security and processing of personal information, such as information that we collect about participants and healthcare providers in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, which may create uncertainty in our business, affect our or our service providers&#x2019; ability to operate in certain jurisdictions or to collect, store, transfer use and share personal data, result in liability or impose additional compliance or other costs on us. Any failure or perceived failure by us to comply with federal, state or foreign laws or self-regulatory standards could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the United States, most healthcare providers, including certain research institutions from which we may obtain patient health information, are subject to privacy and security regulations promulgated under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, which we collectively refer to as HIPAA. We are not currently acting as a covered entity or business associate under HIPAA and therefore are not directly regulated under HIPAA. However, any person may be prosecuted under HIPAA&#x2019;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has disclosed individually identifiable health information in a manner that is not authorized or permitted under HIPAA. In addition, in the future, we may maintain sensitive personal information, including health-related information, that we receive throughout the clinical trial process, in the course of our research collaborations and/or directly from individuals (or their healthcare providers) who may enroll in patient assistance programs if we choose to implement these types of programs. As a result, we may be subject to data privacy and security laws protection such information, including state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, the California Consumer Privacy Act of 2018, or the CCPA, went into effect in January 2020, which creates individual data privacy rights for consumers and operational requirements for companies, including placing increased privacy and security obligations on entities handling certain personal information of consumers or households. These requirements could increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. While there is currently an exception for protected health information maintained by a business associate or covered entity as well as an exception for clinical trial data, as currently written, the CCPA may impact certain of our business activities. Further, the California Privacy Rights Act, or CPRA, recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the European Union General Data Protection Regulation, or GDPR, went into effect on May 2018 and imposes strict requirements for processing the personal data of individuals within the European Economic Area, or the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#x20ac;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the European Union and the United States remains uncertain. For example, in 2016, the European Union and United States agreed to a transfer framework for data transferred from the European Union to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union. Further, from January 1, 2021, companies have to comply with the GDPR and also the United Kingdom GDPR, or the UK GDPR, which, together with the amended United Kingdom Data Protection Act 2018, retains the GDPR in United Kingdom national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#x20ac;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term. The European Commission has adopted an adequacy decision in favor of the UK, enabling data transfers from EU member states to the UK without additional safeguards. However, the UK adequacy decision will automatically expire in June 2025 unless the European Commission re-assesses and renews/extends that decision, and remains under review by the Commission during this period. These changes may lead to additional costs and increase our overall risk exposure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">If we or our third-party manufacturers and suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have an adverse effect on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. Upon an event of this nature, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Further, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of any changes of this nature and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological waste or hazardous waste insurance coverage, workers compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#x2019;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act of 2001 and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We may also have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of these activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to our Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">If we fail to attract and retain qualified senior management and key scientific personnel, our business may be materially and adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management and clinical and scientific personnel. We are highly dependent upon members of our senior management, including Lara Sullivan, M.D., our Chief Executive Officer, Pamela Connealy, our Chief Financial Officer, Ronald Herbst, Ph.D., our Chief Scientific Officer, Jay Feingold M.D., Ph.D., our Chief Medical Officer, Martina Molsbergen, our interim Chief Business Officer and Ritu Shah, our Chief Operating Officer, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, the initiation and completion of our planned clinical trials or the commercialization of product candidates or any future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competition for qualified personnel in the pharmaceutical, biopharmaceutical and biotechnology field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">If our product candidates advance into clinical trials, we may experience difficulties in managing our growth and expanding our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 25, 2022, we had 56 full-time employees. As our development and commercialization plans and strategies develop, and as we continue to operate as a public company, we expect to expand our employee base for managerial, operational, financial and other resources. In addition, we have limited experience in product development. As our product candidates enter and advance through preclinical studies and clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. Our inability to successfully manage our growth and expand our operations could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We currently have no marketing, sales, or distribution infrastructure and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently have no marketing, sales, and distribution capabilities because all our product candidates are still in preclinical development. If any of our product candidates complete clinical development and are approved, we intend to either establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates in a legally compliant manner, or to outsource this function to a third party. There are risks involved if we decide to establish our own sales and marketing capabilities or enter into arrangements with third parties to perform these services. To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our product revenue may be lower than if we directly marketed or sold any approved products. Such collaborative arrangements with partners may place the commercialization of our products outside of our control and would make us subject to a number of risks, including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our products or that our collaborator&#x2019;s willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations or significant changes in our collaborator&#x2019;s business strategy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses, which would have a material adverse effect on our business, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our internal computer systems, or those of any of our existing or future CROs, manufacturers, other contractors, consultants, or collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of or destruction of our proprietary and confidential data, employee data or personal data, which could result in additional costs, significant liabilities, harm to our reputation and material disruption of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the ordinary course of our business, we collect, process, and store proprietary, confidential, and sensitive information, including personal information (including health information), intellectual property, trade secrets, and proprietary business information owned or controlled by ourselves or other parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs, manufacturers, other contractors, consultants, existing or future collaborators and other third-party service providers are vulnerable to damage from various methods, including cybersecurity attacks, breaches, intentional or accidental mistakes or errors, or other technological failures, which can include, among other things, computer viruses, unauthorized access attempts, including third parties gaining access to systems using stolen or inferred credentials, ransomware attacks, denial-of-service attacks, phishing attempts, service disruptions, natural disasters, fire, terrorism, war and telecommunication and electrical failures. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to detect. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If such an event were to occur and cause interruptions in our operations or result in the unauthorized acquisition of or access to personally identifiable information or individually identifiable health information, it could result in a material disruption of our product candidate development programs and our business operations including without limitation, disruptions of our drug development programs, delays in our regulatory approval efforts, regulatory investigations or enforcement actions, litigation, indemnity obligations, negative publicity, and financial loss and significant liabilities. In addition, system failures could cause the loss, theft, exposure, or unauthorized access or use of valuable clinical trial data as a result of accidents, errors or malfeasance by our employees, independent contractors or others working with us or on our behalf or otherwise disrupt our clinical activities and be expensive and time-consuming to remedy. Some of the federal, state and foreign government legal requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors or organizations with which we have formed strategic relationships. Notifications and follow-up actions related to a security breach could impact our reputation and cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed, ongoing or future clinical trials involving our product candidates could result in delays in our regulatory licensure efforts and significantly increase our costs to recover or reproduce the lost data. Any breach of our computer systems may result in a loss of data or compromised data integrity across many of our programs in various stages of development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be required to expend resources, modify our business activities and practices, or modify our operations (including our development program activities) or information technology in an effort to comply with applicable data protection laws, privacy policies and data protection obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we have implemented security measures designed to protect against security breaches, there can be no assurance that our security measures or those of our service providers, partners and other third parties, will be effective in protecting against all security breaches and material adverse effects on our business that may arise from such breaches. The recovery systems, security protocols, network protection mechanisms and other security measures that we (and our third parties) have integrated into our platform, systems, networks and physical facilities, which are designed to protect against, detect and minimize security breaches, may not be adequate to prevent or detect service interruption, system failure, or data loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed and we could be subject to significant fines or penalties for any noncompliance with certain state, federal or international privacy and security laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption, failure or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We or the third parties upon whom we depend may be adversely affected by earthquakes, wildfires or other natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics or pandemics, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations. Earthquakes, wildfires or other natural disasters could further disrupt our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event prevented us from using all or a significant portion of our headquarters, damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development and discovery programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our business is subject to economic, political, regulatory and other risks associated with conducting business internationally.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek regulatory approval or licensure of our product candidates outside of the United States. Accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals or licenses, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">differing regulatory requirements and reimbursement regimes in foreign countries; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign taxes, including withholding of payroll taxes; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">difficulties staffing and managing foreign operations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential liability under the FCPA or comparable foreign regulations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">business interruptions resulting from geo-political actions, including war and terrorism. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We face risks related to health epidemics and outbreaks, including the COVID-19 pandemic, which could significantly disrupt our preclinical studies and clinical trials, and therefore our receipt of necessary regulatory licensure or approvals could be delayed or prevented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, the coronavirus disease, COVID-19, was identified in Wuhan, China. Since then, COVID-19 has spread globally. In March 2020, the World Health Organization declared COVID-19 a global pandemic and the United States declared a national emergency with respect to COVID-19. In response to the COVID-19 pandemic, &#x201c;shelter in place&#x201d; orders and other public health guidance measures have been implemented across much of the United States, including in the locations of our offices and those of key vendors and partners. As a result of the COVID-19 pandemic, or similar pandemics, and related &#x201c;shelter in place&#x201d; orders and other public health guidance measures, we have and may in the future experience disruptions that could materially and adversely impact our preclinical studies and development, any clinical trials we subsequently commence, and our business, financial condition, and results of operations. Potential disruptions to our preclinical development efforts include, but are not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff, limited or no access to animal facilities, and unforeseen circumstances at CROs and vendors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations on employee or other resources that would otherwise be focused on the conduct of our preclinical work and any clinical trials we subsequently commence, including because of sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home, school closures, or mass transit disruptions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in necessary interactions with regulators, ethics committees, and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations in maintaining our corporate culture that facilitates the transfer of institutional knowledge within our organization and fosters innovation, teamwork, and a focus on execution. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have not yet commenced clinical trial activities for any of our product candidates. If we commence clinical trials for one or more of our product candidates, potential disruptions of those clinical activities as a result of COVID-19 or similar pandemics include, but are not limited to: </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state, or local governments, employers and others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and preclinical study endpoints; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays or difficulties in enrolling and retaining patients in our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns, or stoppages and disruptions in materials and reagents; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal of the FDA or comparable regulatory authorities to accept data from clinical trials in affected geographies; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">additional delays, difficulties or interruptions as a result of current or future shutdowns due to the COVID-19 pandemic in countries where we or our third-party service providers operate. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 global pandemic continues to rapidly evolve. Although many countries, including certain countries in Europe and the United States, have re-opened, rises in new cases have caused certain countries to re-initiate restrictions. The extent to which the outbreak may affect our preclinical studies, clinical trials, business, financial condition, and results of operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions, and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures, or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. Additionally, we are unable to predict if a different pandemic could have similar or different impacts on our business, financial condition, or share price. Future developments in these and other areas present material uncertainty and risk with respect to our clinical trials, business, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the Securities and Exchange Commission, or the SEC, and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Separately, in response to the COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. On July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites. According to the guidance, the FDA intends to request such remote interactive evaluations in situations where an in-person inspection would not be prioritized, deemed mission-critical, or where direct inspection is otherwise limited by travel restrictions, but where the FDA determines that remote evaluation would still be appropriate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA has since adjusted its inspection activities in response to the ongoing COVID-19 pandemic. On December 29, 2021, the agency implemented temporary changes to its inspectional activities to ensure the safety of its employees and regulated firms. On February 2, 2022, FDA announced that it would resume domestic surveillance inspections across all product areas on February 7, 2022. We cannot predict whether, and when, FDA will decide to pause or resume inspections due to the COVID-19 pandemic.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Dependence on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates or we could lose certain rights to grant sublicenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a party to license agreements with Pfizer, Inc., or Pfizer, LegoChem Biosciences, Inc., or LegoChem, Biosion  USA, Inc., or Biosion, and the University of Chicago, pursuant to which we in-license patents and technology for certain of our product candidates, and we are also party to a collaboration agreement with Alloy Therapeutics, Inc., or Alloy, pursuant to which we may license patents and technology for future product candidates. Our current license agreements and our collaboration agreement impose, and any future license agreements or collaboration agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement and/or other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#x2019;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We have already entered into collaborations with third parties for the research, development and commercialization of certain of the product candidates we may develop. We may form or seek additional collaborations or strategic alliances or enter into additional licensing arrangements in the future. If any of these collaborations, strategic alliances or additional licensing arrangements are not successful, we may not be able to capitalize on the market potential of those product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We entered into a three-year collaboration with Alloy to finance and operate Voxall Therapeutics, LLC, or Voxall, a joint venture company formed in collaboration with Alloy to leverage our site-specific target catalog and Alloy&#x2019;s ATX-Gx platform and antibody discovery services. We additionally may seek other third-party collaborators for the research development and commercialization of our current or future product candidates. The collaboration with Alloy and any other collaboration agreements we enter into will likely limit our control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we may seek to develop with them. Our ability to generate revenues from these arrangements will depend on our collaborators&#x2019; abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration in which we have entered or may enter.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may in the future form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process for these sorts of transactions is time-consuming, complex and expensive. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety, potency, purity and efficacy and obtain marketing approval. Additionally, our existing partners may decide to acquire or partner with other companies developing oncology therapeutics, which may have an adverse impact on our business prospects, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result, if we enter into additional collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of those transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business prospects, financial condition and results of operations. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies the entry into the transaction in the first place. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We rely on third parties to manufacture our product candidates. Any failure by a third-party manufacturer to produce acceptable raw materials or product candidates for us or to obtain authorization from the FDA or comparable foreign regulatory authorities may delay or impair our ability to initiate or complete our clinical trials, obtain regulatory licensure or approvals or commercialize approved products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on third-party contract manufacturers to manufacture our preclinical trial product supplies and we expect to continue to do so in the future in relation to our clinical product supplies, and if we receive authorization to market our product candidates, for commercial supplies. We do not own or operate manufacturing facilities for producing such supplies. There can be no assurance that our preclinical and clinical development product supplies will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturer could require significant effort and expertise because there may be a limited number of qualified replacements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMPs. In the event that any of our manufacturers fail to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to continue to rely on third-party manufacturers if we receive regulatory licensure for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#x2019;s failure to execute on our manufacturing requirements and comply with cGMP or similar foreign requirements could adversely affect our business in a number of ways, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an inability to initiate or continue clinical trials of product candidates under development; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delay in submitting regulatory applications, or receiving regulatory licenses, for product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">loss of the cooperation of an existing or future collaborators; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requirements to cease distribution or to recall batches of our product candidates; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the inability to commercialize a product candidate, and an inability to meet commercial demands for such products. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be unable to establish agreements with CMOs or to do so on acceptable terms. Even if we are able to establish agreements with CMOs, reliance on them entails additional risks, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reliance on the CMO for regulatory, compliance and quality assurance; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the possible breach of the manufacturing agreement by the CMO; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the possible termination or nonrenewal of the agreement by the CMO at a time that is costly or inconvenient for us. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have only limited technology transfer agreements in place with respect to our product candidates, and these arrangements do not extend to commercial supply and, in some instances, to clinical supply. We acquire many key materials on a purchase order basis. As a result, we do not have long-term committed arrangements with respect to our product candidates and other materials. If we receive marketing licensure for any of our product candidates, we will need to establish an agreement for commercial manufacture with a third party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The CMOs we retain may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. Our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of license, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA or the European Union Member States in coordination with the EMA pursuant to inspections that will be conducted after we submit our BLA to the FDA or our marketing authorization application to the EMA. We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory bodies, they will not be able to secure and/or maintain marketing licensure for their manufacturing facilities. In addition, we do not have complete control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, European Union Member States and the EMA or other comparable regulatory authorities does not approve these facilities for the manufacture of our product candidates or if it withdraws any such licensure in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing licensure for or market our product candidates, if approved or licensed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of licensure, license revocation, seizures or recalls of products or product candidate, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates and harm our business and results of operations. Our product candidates and any products that we may develop may compete with other product candidates and products for access to suitable manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing licensure. We do not currently have arrangements in place for redundant supply or a second source for bulk drug substance. If our current CMOs cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement manufacturer or be able to reach agreement with any alternative manufacturer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing licensure on a timely and competitive basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our CMOs may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing approved products, if any.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to conduct clinical trials of our product candidates, we will need to manufacture them in large quantities. Quality issues may arise during scale-up activities. Our reliance on a limited number of CMOs, the complexity of drug manufacturing and the difficulty of scaling up a manufacturing process could cause the delay of clinical trials, regulatory submissions, required licensure, or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our product candidates successfully. Furthermore, if our CMOs fail to deliver the required commercial quality and quantities of materials on a timely basis and at commercially reasonable prices, and we are unable to secure one or more replacement CMOs capable of production in a timely manner at a substantially equivalent cost, then testing and clinical trials of that product candidate may be delayed or infeasible, and regulatory licensure or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Some of our suppliers may experience disruption to their respective supply chain due to the effects of the COVID-19 pandemic, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We obtain certain chemical or biological intermediates in the synthesis of our product candidates in countries affected by the COVID-19 pandemic. If we are unable to obtain these chemical or biological intermediates in sufficient quantity and in a timely manner, the development, testing and clinical trials of that product candidate may be delayed or infeasible, and regulatory licensure or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">If we are unable to obtain sufficient raw and intermediate materials on a timely basis or if we experience other manufacturing or supply difficulties, our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The manufacture of certain of our product candidates requires the timely delivery of sufficient amounts of raw and intermediate materials. We work closely with our suppliers to ensure the continuity of supply but cannot guarantee these efforts will always be successful. Further, while efforts are made to diversify our sources of raw and intermediate materials, in certain instances we acquire raw and intermediate materials from a sole supplier. While we believe that alternative sources of supply exist where we rely on sole supplier relationships, there can be no assurance that we will be able to quickly establish additional or replacement sources for some materials. A reduction or interruption in supply, and an inability to develop alternative sources for such supply, could adversely affect our ability to manufacture our product candidates in a timely or cost-effective manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We expect to rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for completing such trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will rely on third-party clinical research organizations, or CROs, to conduct clinical trials for our biological product candidates. We currently do not plan to conduct any clinical trials independently. Agreements with these CROs might terminate for a variety of reasons, including for their failure to perform. Entry into alternative arrangements, if necessary, could significantly delay our product development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our reliance on these CROs for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols in the applicable IND. Moreover, the FDA requires compliance with standards, commonly referred to as GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If these CROs do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing licenses for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, or if our patents are insufficient to protect our product candidates for an adequate amount of time, or if we are unable to obtain adequate protection for our proprietary know-how, we may not be able to compete effectively in our markets.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates and discovery programs. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our current and any future product candidates. We seek to protect our proprietary position by, among other methods, licensing and filing patent applications in the United States and abroad related to our current and future product candidates and discovery programs. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We in-license and file patent applications directed to our product candidates in an effort to establish intellectual property positions directed to their compositions of matter as well as uses of these product candidates in the treatment of diseases. Our intellectual property includes patents and patent applications that we own, as well as patents and patent applications that we in-license. For example, our license agreements with Pfizer, LegoChem and Biosion grant us exclusive rights to certain patents and patent applications relating to our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We or our licensors have not pursued or maintained, and may not pursue or maintain in the future, patent protection for our product candidates in every country or territory in which we may sell our products, if approved. In addition, we cannot be sure that any of our pending patent applications will issue or that, if issued, they have or will issue in a form that will be advantageous to us. The United States Patent and Trademark Office, or the USPTO, international patent offices or judicial bodies may deny, or significantly narrow claims made under our patent applications and our issued patents may be successfully challenged, may be designed around, or may otherwise be of insufficient scope to provide us with protection for our commercial products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">It is possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the USPTO may be significantly narrowed by the time they issue, or claims may not issue at all. The claims of our issued patents or patent applications when issued may not cover our current or future product candidates, or even if such patents provide coverage, the coverage obtained may not provide any competitive advantage. The patent applications that we own, or in-license may fail to result in issued patents with claims that cover our current or any future product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our current or any future product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory licensure or approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the patent applications we own or have in-licensed with respect to our product candidates and discovery programs fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our current or any future product candidates, it could dissuade companies from collaborating with us to develop and commercialize product candidates and future drugs and threaten our ability to commercialize future drugs. Any such outcome could have a negative effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our intellectual property rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Furthermore, other parties may have developed or may develop technologies that may be related to, or competitive with, our technologies, and such parties may have filed, or may file, patent applications, or may have received, or may receive, patents, claiming inventions that may overlap or conflict with those claimed in our patent applications or issued patents, and that we may rely upon to establish exclusivity for our products in the market. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or drugs, in whole or in part, or which effectively prevent others from commercializing competitive technologies and drugs. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be subject to a third-party submission of prior art to the USPTO, or other patent offices, in our pending patent applications. Such a submission may preclude the granting of any of our pending patent applications, or may result in patents granting with narrow claims, which could limit our ability to stop others from using or commercializing similar or identical technology and products. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patent rights may be challenged in the courts or patent offices in the United States and abroad. For example, we may become involved in opposition, derivation, reexamination, inter partes review, post-grant review, or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such proceeding, or in litigation, could reduce the scope of our patent claims, result in our patent rights being held invalid, in whole or in part, or unenforceable, or limit the duration of the patent protection of our technology and products, and allow third parties to commercialize our technology or products and compete directly with us without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize our current or any future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, patents have a limited lifespan. In the United States, a patent generally expires 20 years after the earliest filing date of a non-provisional patent application. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our current or any future product candidates, we may be open to competition from generic and/or biosimilar versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent rights may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if our patent rights are unchallenged, our issued patents and our pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our owned patent rights by developing similar or alternative technologies or products in a non-infringing manner. For example, a third-party may develop a competitive product that provides benefits similar to one or more of our product candidates, but that has a different composition that falls outside the scope of our patent protection. If the protection provided by our patent rights with respect to our product candidates is not sufficiently broad to impede such competition, or if the breadth, strength or term (including any extensions or adjustments) of protection provided by our patent rights with respect to our product candidates or any future product candidates is successfully challenged, our ability to successfully commercialize our product candidates could be negatively affected, which would harm our business. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates or any future product candidates under patent protection would be reduced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Obtaining and maintaining our patent rights depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or patent applications will have to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on our service providers or our licensors to pay these fees. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our products or technologies, we may not be able to stop a competitor from marketing products that are the same as, or similar to, our product candidates, which would have a material adverse effect on our business. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, if we fail to apply for applicable patent term extensions or adjustments, we will have a more limited time during which we can enforce our granted patent rights. In addition, if we are responsible for patent prosecution and maintenance of patent rights in-licensed to us, any of the foregoing could expose us to liability to the applicable patent owner.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Given the amount of time required for the development, testing and regulatory review of new product candidates such as PYX-201, PYX-202, PYX-203, PYX-106, and PYX-102, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we have or will obtain patent rights. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, provided that the patent is not enforceable for more than 14 years from the date of licensure, which is limited to the approved indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their drug earlier than might otherwise be the case.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Intellectual property rights do not necessarily address all potential threats to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business. The following examples are illustrative:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may be able to make compounds or formulations that are similar to our product candidates but that are not covered by the claims of any patents, should they issue, that we own or license; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our licensors might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or license; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our licensors might not have been the first to file patent applications covering certain of our inventions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">it is possible that our pending patent applications will not lead to issued patents; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">issued patents that we own or license may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive drugs for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not develop additional proprietary technologies that are patentable; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patents of others may have an adverse effect on our business.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends, in part, upon our ability and the ability of others with whom we may collaborate to develop, manufacture, market and sell our current and any future product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any future product candidates and technology, including interference proceedings, post grant review and inter partes review before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a negative impact on our ability to commercialize our current and any future product candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Moreover, given the vast number of patents in our field of technology, we cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. Other companies and research institutions have filed, and may file in the future, patent applications related to antibody-drug conjugates and their therapeutic use. Some of these patent applications have already been allowed or issued, and others may issue in the future. While we may decide to initiate proceedings to challenge the validity of these or other patents in the future, we may be unsuccessful, and courts or patent offices in the United States and abroad could uphold the validity of any such patent. Furthermore, because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of our product candidates. Regardless of when filed, we may fail to identify relevant third-party patents or patent applications, or we may incorrectly conclude that a third-party patent is invalid or not infringed by our product candidates or activities. If a patent holder believes our product candidate infringes its patent, the patent holder may sue us even if we have received patent protection for our technology. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant drug revenue and against whom our own patent portfolio may thus have no deterrent effect. If a patent infringement suit were threatened or brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the therapeutic or product candidate that is the subject of the actual or threatened suit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are found to infringe a third party&#x2019;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidate(s) and technology. Under any such license, we would most likely be required to pay various types of fees, milestones, royalties or other amounts. Moreover, we may not be able to obtain any required license on commercially reasonable terms or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The licensing or acquisition of third-party intellectual property rights is a competitive area, and more established companies may also pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate(s), which could have a material adverse effect on our business, financial condition, results of operations and prospects. Furthermore, even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidate. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees, if we are found to have willfully infringed a patent or other intellectual property right. We may be required to indemnify collaborators or contractors against such claims. A finding of infringement could prevent us from manufacturing and commercializing our current or any future product candidates or force us to cease some or all of our business operations, which could materially harm our business. Even if we are successful in defending against such claims, litigation can be expensive and time consuming and would divert management&#x2019;s attention from our core business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. If we breach our University of Chicago, Pfizer, LegoChem or Biosion license agreements or any of the other agreements under which we acquired, or will acquire, intellectual property rights covering our product candidates, we could lose the ability to continue the development and commercialization of the related product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The licensing of intellectual property is of critical importance to our business and to our current and future product candidates, and we expect to enter into additional such agreements in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In particular, the rights to the intellectual property covering our product candidates PYX-201 and PYX-203 are in-licensed from Pfizer, the rights to the intellectual property covering our product candidate PYX-202 is in-licensed from LegoChem, and the rights to the intellectual property covering our product candidate PYX-106 is in-licensed from Biosion. We may acquire the rights to the intellectual property covering future product candidates from other third-party licensors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we fail to meet our obligations under any of our in-license agreements, including the Pfizer License Agreement, the LegoChem License Agreement, or the Biosion License Agreement, then the licensor may terminate the license agreement. If one of our material in-license agreements is terminated, we will lose the right to continue to develop and commercialize the product candidate(s) covered by such in-license agreement. While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under our in-license agreements, we may not be able to do so in a timely manner, at an acceptable cost or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time consuming and is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our owned or licensed patents at risk of being invalidated or interpreted narrowly and could put our owned or licensed patent applications at risk of not issuing. The initiation of a claim against a third party might also cause the third party to bring counter claims against us, such as claims asserting that our patent rights are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is or will be no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license, and such a license may not be on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current and any future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The United States has recently enacted and implemented wide ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce patents that we own, have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or have licensed or that we may obtain in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Filing, prosecuting and defending patents covering our current and any future product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents and any future patent claims, or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since we rely on third parties to help us discover, develop, manufacture or commercialize our current and any future product candidates, or if we collaborate with third parties for the development, manufacturing or commercialization of our current or any future product candidates, we must, at times, share trade secrets with them. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets. Despite our efforts to protect our trade secrets, we may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that is licensed or disclosed to us by our partners, collaborators, or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third-party illegally or unlawfully obtained and is using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products of our competitors. We have not yet selected trademarks for our product candidates and have not yet begun the process of applying to register trademarks for our current or any future product candidate. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks, and we may not have adequate resources to enforce our trademarks.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, any proprietary name we propose to use with our current or any other product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to seeking patent and trademark protection for our product candidates, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees, advisors and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. In addition, our confidential information may otherwise become known or be independently discovered by competitors, in which case we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our operating results to be subject to annual and quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">results of preclinical studies, IND submissions, clinical trials, or the addition or termination of clinical trials or funding support by us, or existing or future collaborators or licensing partners; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">variations in the level of expense related to the ongoing development of the FACT platform, our product candidates or future development programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our execution of any additional collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under existing or future arrangements or the termination or modification of any such existing or future arrangements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">additions and departures of key personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">if any of our product candidates receives regulatory licensure, the terms of such licensure and market acceptance and demand for such product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory developments affecting our product candidates or those of our competitors; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in general market and economic conditions. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our stock price is volatile, and you could lose all or part of your investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our stock price is highly volatile. As a result of this volatility, investors may not be able to sell their common stock at or above the price they purchased their common stock. The market price for our common stock may be influenced by many factors, including the other risks described in this section of the Form 10-K titled &#x201c;Risk Factors&#x201d; and the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">results of our preclinical studies, IND submissions and clinical trials, if any, of our product candidates, or those of our competitors or our existing or future collaborators; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory or legal developments in the U.S. and other countries, especially changes in laws or regulations applicable to our products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the success of competitive products or technologies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">introductions and announcements of new products by us, our future commercialization partners, or our competitors, and the timing of these introductions or announcements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">actions taken by regulatory agencies with respect to our products, preclinical studies, clinical trials, manufacturing process or sales and marketing terms; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the success of our efforts to acquire or in-license additional technologies, products or product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developments concerning any future collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization partners; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability or inability to raise additional capital and the terms on which we raise it; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our failure or the failure of our competitors to meet analysts&#x2019; projections or guidance that we or our competitors may give to the market; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">announcement and expectation of additional financing efforts; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">speculation in the press or investment community; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">trading volume of our common stock; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sales of our common stock by us, our insiders or our other stockholders; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expiration of market stand-off or lock-up agreements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the concentrated ownership of our common stock; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in accounting principles; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">terrorist acts, acts of war or periods of widespread civil unrest; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact of any natural disasters or public health emergencies, such as the COVID-19 pandemic, and other calamities; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">general economic, industry and market conditions. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">The future issuance of equity or of debt securities that are convertible into equity will dilute our share capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will need to raise additional capital in the future. To the extent we raise additional capital through the issuance of equity or convertible debt securities in the future, there will be dilution to our existing investors and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#x2019; rights. Future issuances of our common stock or other equity securities, or the perception that such sales may occur, could adversely affect the trading price of our common stock and impair our ability to raise capital through future offerings of shares or equity securities. We may choose to raise additional capital through the issuance of equity or convertible debt securities due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. No prediction can be made as to the effect, if any, that future sales of common stock or the availability of common stock for future sales will have on the trading price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">If securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading research or reports regarding us, our business or our market, our stock price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us, our business or our market. If no or few securities or industry analysts commence or maintain coverage of us, the trading price for our stock would be negatively impacted. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval and their interests may conflict with your interests as an owner of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 25, 2022, our executive officers and directors, together with holders of five percent or more of our outstanding common stock and their respective affiliates, beneficially own approximately 54.5% of our outstanding common stock. As a result, these stockholders, if acting together, have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with interests of our other stockholders. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#x2019; perception that conflicts of interest may exist or arise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock price could decline as a result of sales of a large number of shares of common stock or the perception that these sales could occur. These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Approximately 22,341,747 shares are currently prohibited or otherwise restricted from resale as a result of securities law provisions, market standoff agreements entered into by certain of our stockholders with us or lock-up agreements entered into by our stockholders with the underwriters in connection with our IPO. However, subject to applicable securities law restrictions, these shares will be able to be sold in the public market beginning 181 days after the date of our IPO. In addition, BofA Securities, Inc. and Jefferies LLC, on behalf of the underwriters, may release some or all of the shares of common stock subject to lock-up agreements at any time in their sole discretion and without notice, which would allow for earlier sales of shares in the public market. Shares issued upon the exercise of stock options and warrants outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, market stand-off agreements and/or lock-up agreements, as well as Rules 144 and 701 under the Securities Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain holders of our outstanding shares have rights, subject to certain conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or our other stockholders. We also registered the offer and sale of all shares of common stock that we may issue under our equity compensation plans, which shares will be able to be sold in the public market upon issuance, subject to applicable securities laws and the lock-up agreements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We are an &#x201c;emerging growth company&#x201d; and a &#x201c;smaller reporting company,&#x201d; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an &#x201c;emerging growth company,&#x201d; as defined in the JOBS Act. We will remain an emerging growth company until the earlier of (i) the last day of the fiscal year (a) following the fifth anniversary of the completion of our IPO, (b) in which we have total annual gross revenue of at least $1.07 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeded $700.0 million as of the prior June 30th and (ii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An emerging growth company may take advantage of specified reduced reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">being permitted to present only two years of audited financial statements and only two years of related management&#x2019;s discussion and analysis of financial condition and results of operations in this Form 10-K; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">exemptions from the requirement to hold a nonbinding advisory vote on executive compensation and to obtain stockholder approval of any golden parachute payments not previously approved. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have elected to take advantage of certain of the reduced disclosure obligations and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our investors may be different from the information you might receive from other public reporting companies that are not emerging growth companies in which you hold equity interests. The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected not to avail itself of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also a &#x201c;smaller reporting company,&#x201d; and will continue to be a smaller reporting company as long as (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time, we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and have reduced disclosure obligations regarding executive compensation, and, similar to emerging growth companies, if we are a smaller reporting company with less than $100 million in annual revenue, we would not be required to obtain an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Anti-takeover provisions in our charter documents and under Delaware law would make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provisions in the amended and restated certificate of incorporation and our amended and restated bylaws may delay or prevent an acquisition of us or a change in our management. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a prohibition on actions by our stockholders by written consent; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a requirement that special meetings of stockholders be called only by the chairman of our board of directors, our chief executive officer, or our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advance notice requirements for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a requirement that directors may only be removed &#x201c;for cause&#x201d; and only with 66 2/3% voting stock of our stockholders; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a requirement that only the board of directors may change the number of directors and fill vacancies on the board; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">division of our board of directors into three classes, serving staggered terms of three years each; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the authority of the board of directors to issue preferred stock with such terms as the board of directors may determine. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, as amended, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions would apply even if the proposed merger or acquisition could be considered beneficial by some stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. Additionally, if we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a new public company, and particularly after we are no longer an emerging growth company or a smaller reporting company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Also, the Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, [and we may be required to accept reduced policy limits and coverage or to incur substantial costs to maintain the same or similar coverage.] These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors or our board committees or as executive officers. However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, as a public company, we will incur additional costs and obligations in order to comply with SEC rules that implement Section 404 of the Sarbanes-Oxley Act. Under these rules, beginning with our second annual report on Form 10-K, we will be required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company or a smaller reporting company, we will be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaging in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively, and implement a continuous reporting and improvement process for internal control over financial reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. Our internal control over financial reporting will not prevent or detect all errors and all fraud.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on Nasdaq.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These inherent limitations include the facts that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, your ability to achieve a return on your investment will depend on appreciation of the value of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of our common stock, which is not certain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">We may be subject to securities litigation, which is expensive and could divert our management&#x2019;s attention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the past, companies that have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Regardless of the merits or the ultimate results of such litigation, securities litigation brought against us could result in substantial costs and divert our management&#x2019;s attention from other business concerns.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our certificate of incorporation and bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, another state court located within the State of Delaware, or the federal district court for the District of Delaware) shall be the sole and exclusive forum for the following types of proceedings: (1) any derivative action or proceeding brought on our behalf under Delaware law, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or bylaws, (4) any other action asserting a claim that is governed by the internal affairs doctrine or (5) any other action asserting an &#x201c;internal corporate claim,&#x201d; as defined in Section 115 of the Delaware General Corporation Law. This provision would not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. Our amended and restated bylaws further provide that the federal district courts of the United States of America will be the exclusive forum to the fullest extent permitted by law, for resolving any complaint asserting a cause of action arising under the Securities Act or the Exchange Act. This choice of forum provision may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation and amended and restated bylaws inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation and amended and restated bylaws described above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our ability to use net operating loss carryforwards and other tax attributes may be limited in connection with our recent IPO or other ownership changes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred substantial losses during our history, do not expect to become profitable in the near future and may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, subject to certain limitations (including the limitations described below) until such unused losses expire (if at all). As of December 31, 2021, our federal and state net operating losses in the United States were $10.1 million ($48.0 million before tax) and $2.8 million ($45.9 million before tax) respectively. The federal net operating loss carryforwards in the United States can be carried forward indefinitely but may be subject to annual usage limitations to the extent certain substantial changes our ownership occur. The state net operating loss carryforwards begin expiring in 2039. In addition, as of December 31, 2021, we had $1.0 million and $0.6 million of federal and state credit carryovers which begin to expire in 2039. These loss and credit carryforwards are subject to review and possible adjustment by the appropriate taxing authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our NOL and credit carryforwards are subject to review and possible adjustment by the IRS, and state tax authorities. Under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, our federal NOL and credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership of our company. An &#x201c;ownership change&#x201d; pursuant to Section 382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#x2019;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including potential changes in connection with our IPO. Similar rules may apply under state tax laws. We have not yet determined the amount of the cumulative change in our ownership resulting from our IPO or other transactions, or any resulting limitations on our ability to utilize our NOL carryforwards and other tax attributes. In addition, we may experience ownership changes in the future due to subsequent shifts in our stock, some of which are outside of our control. If we earn taxable income, such limitations could result in increased future income tax liability to us, and our future cash flows could be adversely affected. We have recorded a full valuation allowance related to our NOL carryforwards and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1B. Unresolved S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">taff Comments.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 2. Properties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our headquarters are located at 35 Cambridgepark Drive, Cambridge, MA 02140, where we lease approximately 8,955 rentable square feet of office and laboratory space under a lease that terminates on March 31, 2022. On September 29, 2021, we entered into a new lease agreement for approximately 31,659 square feet of an office and laboratory space in 321 Harrison Avenue, Boston, MA 02118. The 10-year lease term begins on April 1, 2022, and ends on December 31, 2032, with an additional five-year option to extend the lease beyond December 31, 2032. We believe that our existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">tem 3. Legal P</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">roceedings.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. As of the date of this Annual Report on Form 10-K, we were not a party to any material legal matters or claims </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results or financial condition</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">. Mine Safety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not Applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RT II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 5. Market for Registrant&#x2019;s C</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ommon Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Market Information</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 8, 2021, our common stock began trading on The Nasdaq Global Select Market under the symbol &#x201c;PYXS&#x201d;. Prior to that time, there was no public market for our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Holders of Our Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Broadridge Corporate Issuer Solutions, Inc is our transfer agent and registrar for our common stock. As of the close of business on </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 25, 2022, there were approximately 67 holders of record of shares of our common stock. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These numbers were derived from our stockholder records and do not include beneficial owners of our common stock whose shares are held in &#x201c;street&#x201d; name with various dealers, clearing agencies, banks, brokers and other fiduciaries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dividends</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if any, for use in the operation of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, our financial condition, our capital requirements, general business conditions, our future prospects and other factors that our board of directors may deem relevant. Our ability to pay cash dividends on our capital stock in the future may also be limited by the terms of any preferred securities we may issue or agreements governing any additional indebtedness we may incur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Sales of Unregistered Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, we sold and issued the following unregistered securities:</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of Preferred Stock</span></div></div>
  <div style="margin-left:13.593%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">a.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, we issued a total of 92,356,299 shares of our Series B convertible preferred stock to 36 accredited investors at a purchase price of $1.6458 per share, for aggregate proceeds of approximately $151.6 million in cash, net of issuance costs.</span></div></div>
  <div style="margin-left:13.593%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">b.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, we issued a total of 12,455,949 shares of our Series B convertible preferred stock to LegoChem and Pfizer at a purchase price of $1.6458 per share. LegoChem was issued 303,804 shares as part of the $0.5 million research and development expenses under the Opt-In Agreement and Pfizer was issued 12,152,145 as part of the remaining $20.0 million license expenses under the Pfizer License Agreement.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company effected a 1-for-6.359 reverse stock split in October 2021. Upon the initial public offering, 22,724,925 shares of Series A and 104,812,248 shares of Series B converted to 20,056,145 shares of common stock.</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted Common Stock and Stock Option Grants and Exercises</span></div></div>
  <div style="margin-left:13.593%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">a.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Between January 1, 2021 and December 31, 2021, we granted stock options (net of forfeiture) to purchase an aggregate of 3,326,693 shares of common stock, with exercise prices ranging from $5.34 to $8.71 per share, to our employees, directors, advisors and consultants. Between January 1, 2021 and December 31, 2021, we issued 350,258 shares of our common stock upon the exercise of the restricted common stock and stock options for an aggregate consideration of less than $0.1 million in cash.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The issuances described under (i) above were exempt from registration under the Securities Act (or Regulation D promulgated thereunder) by virtue of Section 4(a)(2) of the Securities Act as transactions by an issuer not involving a public offering. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The restricted common stock and options described under (ii) above were exempt from registration under the Securities Act under either (1) Rule 701 in that the transactions were under compensatory benefit plans and contracts relating to compensation as provided under Rule 701 or (2) Section 4(a)(2) of the Securities Act as transactions by an issuer not involving any public offering. The recipients of such securities were the registrant&#x2019;s employees, consultants or directors and received the securities under the registrant&#x2019;s equity compensation plans. The recipients of securities in each of these transactions represented their intention to acquire the securities for investment only and not with view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Proceeds from Initial Public Offering</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our initial public offering of common stock, or the IPO, was affected through a Registration Statement on Form S-1 (File No. 333-259627) that was declared effective by the SEC on October 7, 2021. We issued and sold in aggregate 10,500,000 shares of common stock, at a public offering price of $16.00 per share, for net proceeds of $152.3 million after deducting underwriting discounts, commissions and other offering costs of $15.7 million. BofA Securities, Inc., Jefferies LLC, Credit Suisse Securities (USA) LLC and William Blair &amp; Company, L.L.C. and LifeSci Capital LLC acted as underwriters for the offering. None of the underwriting discounts and commissions or offering expenses were incurred or paid to directors or officers of ours or their associates or to persons owning 10% or more of our common stock or to any of our affiliates. We have invested the net proceeds from the IPO in a money market fund. There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on October 8, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Securities authorized for issuance under equity incentive plans</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes information about our equity incentive plans as of December 31, 2021. All outstanding awards relate to our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.327%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:14.83%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.72%;"></td>
    <td style="width:11.45%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:18.646%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number of Securities</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">to be Issued Upon</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exercise of</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Outstanding</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options, Warrants</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">and Rights</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(a)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Average Exercise</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Price of</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Outstanding</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options,</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Warrants and</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(b)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number of Securities</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Remaining Available</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">for Future Issuance</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Under Equity</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Compensation Plans</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(Excluding Securities</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Reflected in Column (a))</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(c)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity compensation plans approved by security holders:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2019 Equity Incentive Plan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(2)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,411,929</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 Equity Incentive Plan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(2)(3)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,563,548</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.19</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,289,259</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 Employee Stock Purchase Plan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(4)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">424,595</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted Common Stock pursuant to Separate Agreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(5)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">569,986</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.01</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity compensation plans not approved by security holders</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6,545,463</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9.15</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,713,854</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">(1) </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted Stock Units issued under 2021 Equity Incentive Plan, which do not have an exercise price, are excluded in the calculation of weighted-average exercise price.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">(2) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 27, 2021, our board of directors and stockholders approved the 2021 Equity Incentive Plan, which became effective on the date immediately preceding the date on which our registration statement declared effective by the SEC. The 2021 Plan replaced the 2019 Plan and our board of directors has determined not to make additional awards under the 2019 Plan following the closing of our initial public offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">(3) </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The number of shares of common stock reserved for issuance under the 2021 Plan will automatically increase annually on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022, and continuing until (and including) the fiscal year ending December 31, 2031 by lesser of 5% of the total number of shares of common stock outstanding on December 31st of the immediately preceding fiscal year or number of shares as may be determined by our board of directors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">(4) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 27, 2021, our board of directors and stockholders approved the 2021 Employee Stock Purchase Plan (the &#x201c;2021 ESPP&#x201d;), which became effective on the date immediately preceding the date on which our registration statement declared effective by the SEC. The 2021 ESPP initially reserves and authorizes the issuance of up to a total of 424,595 shares of common stock to participating employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">(5) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2019, we issued certain shares of restricted common stock to the employee co-founders and certain non-employee consultants. The shares of restricted common stock were issued pursuant to standalone restricted stock purchase agreements that are independent of the 2019 Plan. The shares of restricted common stock carried a purchase price equivalent of $0.01 per share.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 6. [Reserved].</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7. Management&#x2019;s Discussion and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Analysis of Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> audited consolidated financial statements and related notes thereto included elsewhere in this Annual Report on Form 10-K. Unless the context requires otherwise, references in this Annual Report on Form 10-K to &#x201c;Pyxis Oncology,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; refer to Pyxis Oncology, Inc. and its subsidiary.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. We develop our product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. We are developing multi-asset, multi-modality portfolio aimed at defeating difficult-to-treat cancers. Since our launch in 2019, we have developed a broad portfolio of novel antibody drug conjugates, or ADCs, immuno-oncology, or (&#x201c;IO&#x201d;), product candidates and monoclonal antibody, or mAb, preclinical discovery programs that we are developing as monotherapies and in combination with other therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We take a holistic view of attacking the key drivers of tumor growth and progression within the tumor microenvironment, or TME, including targeting of tumor antigens and modulating the innate and adaptive immune response. The TME is an immunosuppressive environment consisting of cancer cells and stroma, which includes the blood vessels, immune cells, fibroblasts, signaling molecules, and the extracellular matrix that surrounds the tumor. The TME plays multiple roles in tumor formation, progression and metastasis as well as anti-tumor immune activity. We are developing our ADC and IO product candidates and mAb preclinical discovery programs to precisely target key modulators of the adaptive and innate immune system within the TME for difficult-to-treat solid and hematologic tumors. We believe that the diversification of a multi-modality approach optimizes our ability to effectively progress multiple assets for the benefit of patients.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ADCs utilize next-generation technologies that, based on observations from preclinical studies, may allow for increased stability and a reduced off target side-effect profile. We in-licensed two ADC programs in March 2021 from Pfizer, one ADC program from LegoChem in December 2020 and one IO program from Biosion in March 2022. Two of our product candidates, PYX-201, and PYX-106 are scheduled for IND submission in the second half of 2022 whereas PYX-203 and PYX-102 are scheduled for IND submission in the second half of 2023.We have additional preclinical mAb discovery programs derived from work at the laboratory of Dr. Thomas Gajewski. We retain full worldwide development and commercialization rights to all our product candidates, with the exception of PYX-202 in South Korea and PYX-106 in Greater China (mainland China, Hong Kong, Macau and Taiwan). We are focusing our efforts on eliminating tumor cells through the selective antibody mediated delivery of cytotoxic payloads and by modulating key immune-associated pathways in the TME. We intend to develop each of our programs as a monotherapy and potentially also in combination with other therapies. We have designed our product candidates to overcome the limitations of ADCs that use conventional conjugation with the aim of providing patients with safer and more efficacious treatment options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Developments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PYX-106</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 28, 2022, we entered into a license agreement, or the &#x201c;Biosion License Agreement,&#x201d; with Biosion USA, Inc., or Biosion, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pursuant to which we licensed worldwide (other than Greater China </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(mainland China, Hong Kong, Macau and Taiwan)</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) development and commercialization rights for BSI-060T, a Siglec-15 targeting antibody, an IO product candidate (now referred to as PYX-106), and products containing the licensed compound. PYX-106</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is a fully human monoclonal antibody and is engineered with high affinity to block Siglec-15 induced immune suppression and therefore restore T cell proliferation, function and anti-tumor immunity in the TME. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PYX-106 is a novel immune checkpoint inhibitor targeting Siglec-15, whose expression profile is generally non-overlapping with PD-L1. Siglec-15 is expressed on M2 macrophages but can also be expressed by tumor cells. Binding of Siglec-15 to an as of yet unknown receptor on T cells leads to suppression of T cell proliferation and function. This inhibition also reduces IFN&#x3b3; secretion which may further promote Siglec-15 expression.  PYX-106 may synergize with and rescue PD(L)-1 targeted therapy activity, with the potential for sequential drug administration to synergize for enhanced anti-tumor activity.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are initially evaluating our Siglec-15 targeting antibody for the treatment of advanced or metastatic solid tumors, which could include thyroid cancer, HNSCC, NSCLC and other solid tumors where high unmet need exists. We plan to submit an IND for PYX-106 in the second half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PYX-102</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The anti-KLRG1 mAb, which we referred to as PYX-102, is our first organically built IO development candidate from our internal discovery engine. PYX-102 was identified as a promising IO target through our proprietary target catalog licensed from Tom Gajewski&#x2019;s lab at the University of Chicago. PYX-102 is an inhibitory immunoreceptor trysine-based inhibitory motif-containing receptor expressed on T cells and NK cells in the tumor microenvironment and acts as an inhibitory immune checkpoint receptor via its interactions with E- and N-Cadherin ligands. We believe that targeting KLRG1 to reprogram these suppressed T and NK cells represents an exciting strategy to promote the full anti-tumor activity of cytotoxic T cells and NK cells in the tumor microenvironment. We are working through our development plans and we anticipate IND submission in the second half of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PYX-202</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, we entered into a license agreement, or the &#x201c;LegoChem License Agreement,&#x201d; with LegoChem Biosciences, Inc., or LegoChem, pursuant to which we licensed worldwide (other than Korea) development and commercialization rights for LCB67, an ADC product candidate targeting DLK1 (now referred to as PYX-202), and products containing the licensed compound. In studies conducted by LegoChem of preclinical small cell lung cancer, or SCLC, PDX models, as well as in a human cell line-based, or CDX, mouse model of cancer, we have observed significant anti-tumor activity as measured by durable tumor regression. In preparation for our IND filing and based on observation of our GLP studies to date, we have determined that we will need to conduct additional GLP and non-GLP toxicity studies to determine whether PYX-202 is a viable clinical candidate. We will continue to monitor the progress of our PYX-202 program and expect to provide an update about PYX-202 in mid-2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current pipeline is summarized below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><img src="img29677477_25.jpg" alt="img29677477_25.jpg" style="width:672px;height:279px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PYX-106</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is an investigational fully human IgG1 isotype Siglec-15 targeting antibody that is designed to block Siglec-15 mediated suppression of T-cell proliferation and function. We plan to initially develop this asset for the treatment of thyroid cancer, Head &amp; Neck Squamous Cell Carcinoma, or HNSCC, non-small cell lung cancer, or NSCLC, and other solid tumors. We licensed worldwide rights, other than in Greater China (mainland China, Hong Kong, Macau and Taiwan), to our Siglec-15 targeting antibody from Biosion USA, Inc. We expect to submit an IND in the second half of 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PYX-102</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is an investigational immune-therapeutic consisting of a ligand-blocking antibody which rescues KLRG1-mediated suppression of human CD8+ T cells. KLRG1 ligands E-and N-cadherin are expressed in numerous solid cancers. KLRG1 is an inhibitory ITIM-containing receptor expressed on T cells and NK cells. Blocking ligand/receptor interaction will relieve immune inhibition in these tumors. We anticipate submitting an IND in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PYX-201</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is an investigational, novel ADC consisting of an Immunoglobulin G1, or IgG1, anti-fibronectin Extradomain-B, or EDB, mAb site-specifically conjugated to auristatin via a cathepsin B-cleavable linker. Fibronectin is a glycoprotein found in the extracellular matrix. Fibronectin EDB regulates blood vessel morphogenesis, which provides the tumor access to nutrition and oxygen, a means to remove waste, and a pathway for metastasizing cells. EDB is overexpressed in many malignancies and is minimally expressed in most normal adult tissues, making it a potentially attractive means to target tumors while sparing healthy cells. In preclinical models of patient derived xenograft, or PDX models, we observed tumor regression with single agent PYX-201. In addition, we observed that the treatment of preclinical syngeneic tumor models with PYX-201 resulted in enhanced T cell infiltration into the TME, which is a hallmark of immunogenic cell death, or ICD, enabling synergistic activity in combination with a checkpoint inhibitor. We anticipate submitting an IND in the second half of 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PYX-202</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is an investigational, novel ADC consisting of an IgG1 anti-Delta-like 1 homolog, or DLK1, mAb conjugated to MMAE via a site-specific plasma-stable &#xdf;-glucuronide linker. DLK1 is a transmembrane protein normally expressed in embryonic tissues but highly restricted in healthy adult tissues. DLK1 becomes re-expressed in certain solid tumor malignancies. PYX-202 is designed to use the microtubule-disrupting MMAE payload, which is utilized in three currently marketed ADCs providing clinical support that the payload has anti-tumor effect potential. As discussed in Recent Development section above, we are currently in process of doing further testing and analysis and expect to provide an update about PYX-202 in mid-2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PYX-203</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is an investigational ADC consisting of an IgG1 anti-CD123 mAb antibody conjugated to a novel cyclopropylpyrroloindoline, or CPI dimer payload via a site-specific plasma-stable, cleavable linker. CD123, or IL-3R</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, is a cell surface antigen highly expressed on leukemic stem cells and leukemic blasts in acute myeloid leukemia, or AML. PYX-203, utilizes a novel DNA-damaging toxin, CPI, and we have observed significant anti-tumor activity as measured by the reduction in the frequency of the leukemic cells in the blood and bone marrow in nine disseminated preclinical AML models. We anticipate submitting an IND in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the programs identified above, we are conducting research and development activities on various targets, leveraging our expertise in monoclonal antibodies and understanding of immuno-oncology. Our preclinical discovery programs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">are novel antibody programs intended to enhance the anti-tumor activity of natural killer, or NK cells, and T cells and to overcome immunosuppressive activity of tumor resident myeloid cells such as tumor associated macrophages, or TAMs, and myeloid derived suppressor cells, or MDSCs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our inception, we have focused substantially all our resources on organizing and staffing our company, business planning, raising capital, conducting research and development activities, filing and prosecuting patent applications, identifying potential product candidates and undertaking preclinical studies and a clinical trial. We do not have any products approved for sale and have not generated any revenue from product sales or from any other sources. To date, we have funded our operations with proceeds from sales of convertible preferred stock and our recent IPO. Our ability to generate any product revenue, and in particular to generate product revenue sufficient to achieve profitability, will depend on the successful development and eventual commercialization of one or more of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred significant operating losses since our inception. We reported net losses of $76.0 million and $12.8 million for the years ended December 31, 2021 and 2020. As of December 31, 2021, we had an accumulated deficit of $91.7 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We expect that our expenses and capital expenditures will increase substantially in connection with our ongoing activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COVID-19 Business Update</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are monitoring the potential impact of the COVID-19 pandemic on our business and consolidated financial statements. To date, we have not experienced material business disruptions. We are following, and will continue to follow, recommendations from the U.S. Centers for Disease Control and Prevention as well as federal, state and local governments regarding working-from-home practices for non-essential employees. For example, the COVID-19 pandemic in Massachusetts resulted in a temporary reduction in workforce presence at our Cambridge research facility. While we have increased workforce presence at our facility, not all employees have returned to our facility, and we cannot be certain that we will not be required to close our facility in the future as a result of the COVID-19 pandemic. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business, and it has the potential to adversely affect our business. For additional information about risks and uncertainties related to the COVID-19 pandemic that may impact our business, financial condition and results of operations, see the section titled &#x201c;Risk Factors&#x201d; under Part I, Item 1A in this Annual Report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Licensing and Collaboration Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with Pfizer, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, we entered into a license agreement, as amended, the &#x201c;Pfizer License Agreement,&#x201d; with Pfizer, Inc., or Pfizer, for worldwide development and commercialization rights to two of Pfizer&#x2019;s proprietary ADC product candidates (now referred to as PYX-201 and PYX-203), as well as other ADC product candidates directed to the licensed targets. The Pfizer License Agreement became effective in March 2021. The initial exclusively licensed targets are extra domain B (EBD of fibronectin) and CD123 and we have the option to expand the scope of our license to add other licensed targets. Pfizer has also granted us a non-exclusive license to use Pfizer&#x2019;s FACT platform technology to develop and commercialize the licensed ADCs. In March 2021, we entered into an amendment to the Pfizer License Agreement to include additional know-how within the scope of our license.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Pursuant to the Pfizer License Agreement, we incurred a combined $25.0 million for license fee, consisting of an upfront fee of $5.0 million and issued 12,152,145 shares of Series B convertible preferred stock in 2021 to Pfizer, and are obligated to pay future contingent payments and royalties, including up to an aggregate of $660 million in milestones for the first four licensed ADCs. Additional ADC targets may be licensed for an additional upfront fee, and such targets would be subject to additional regulatory and commercial sales milestones.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, if products are launched, we will pay Pfizer tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to mid-teens. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) 12 years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. We are also obligated to pay Pfizer a percentage of certain sublicensing revenue ranging from low-double digits to thirty percent based on the stage of development of the licensed product at the time of entering into the applicable sublicense.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with the University of Chicago</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2020, we entered into a license agreement, or the &#x201c;University License Agreement,&#x201d; with the University of Chicago, or the University, to obtain an exclusive license under certain patents resulting from research performed, in-part, by our scientific founder, Dr. Thomas Gajewski, as well as a non-exclusive license to certain know-how and materials. Under the terms of the license, we have the exclusive global right to develop and commercialize products that are covered by a valid claim of a licensed patent, incorporate or use the licensed know-how and materials or are known to assess, modulate or utilize the activity of certain specified biological targets.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In partial consideration for the license from the University, we issued to the University 48,919 shares of our Common Stock in 2020. Pursuant to the University License Agreement, we are obligated to pay to the University an annual maintenance fee of $10 thousand commencing on the third anniversary of the effective date, potential development and commercial milestones of up to an aggregate of $7.7 million as well as running royalties on net sales of licensed products at varying rates ranging from less than one percent to the low single digits, subject to a minimum annual royalty ranging from $1.0 million to $3.0 million during certain years following the first commercial sale of a licensed product. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until: (1) for licensed products covered by a valid claim of a licensed patent in a given country, the expiration of such valid claims; and (2) for all other licensed products, 10 years from the first commercial sale of a licensed product in a given country. We are also obligated to pay the University a percentage of certain sublicensing revenue ranging from low- to mid-teens based on the date of entering into the applicable sublicense.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Agreements with LegoChem Biosciences, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, we entered into a license agreement, or the &#x201c;LegoChem License Agreement,&#x201d; with LegoChem Biosciences, Inc., or LegoChem, pursuant to which we licensed worldwide (other than Korea) development and commercialization rights for LCB67, an ADC product candidate targeting DLK1 (now referred to as PYX-202), and products containing the licensed compound. We have the right to ask LegoChem to use commercially reasonable efforts at our cost to modify the licensed compound if there are certain technical failures of the licensed compound that we believe are attributable to the linker or the payload used in the licensed compound, and the modified compound will replace the unmodified version as the licensed compound. In February 2021, we entered into an amendment to the LegoChem License Agreement to include additional patents within the scope of our license.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the LegoChem License Agreement, we paid an upfront fee of $0.5 million in 2020 and $9.0 million in 2021 and are required to purchase certain initial quantities of licensed product from LegoChem for an estimated cost of $7.0 million. We are also obligated to pay up to an aggregate of $284.5 million to LegoChem if certain development, regulatory and sales milestones are achieved, as well as tiered royalties on net sales of licensed products ranging from mid-single digit to high single digit royalty rates. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until the latest to occur of: (1) the date of expiration of the last valid claim of a licensed patent covering the licensed product; (2) 10 years from first commercial sale; and (3) the expiration of regulatory or data exclusivity.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, we also entered into an opt-in, investment and additional consideration agreement with LegoChem, or the &#x201c;Opt-In Agreement.&#x201d; Under the Opt-In Agreement, we issued to LegoChem shares of Series B convertible preferred stock as part of our Series B financing in March 2021. We are also obligated to pay LegoChem a percentage of sublicensing revenue ranging from low-double digits to thirty percent based on the stage of development of the licensed product at the time of entering into the applicable sublicense, which percentage may be increased to up to fifty percent for any upfront payment from a sublicensee under certain circumstances. LegoChem has exercised its option under the Opt-In Agreement to make a $8.0 million payment to us, which payment was made in April 2021, in exchange for the right to receive an extra milestone payment of $9.6 million upon the earliest to occur of certain events, including the date of pricing or offer of the first public offering of our common stock or if we are the subject of a change of control transaction. Upon our IPO in October 2021, the extra milestone payment event triggered and we paid $9.6 million in January 2022 to LegoChem.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The Voxall Joint Venture with Alloy Therapeutics, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, we entered into definitive transaction agreements with Alloy to finance and operate Voxall, a joint venture company formed in collaboration with Alloy to leverage Pyxis Oncology&#x2019;s site-specific target catalog and Alloy&#x2019;s ATX-Gx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> platform and antibody discovery services.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Voxall granted to both Pyxis Oncology and Alloy 50% of the voting membership units of Voxall in exchange for certain initial contributions. Our initial contribution included $50 thousand and a non-exclusive fully paid-up license to certain intellectual property owned or controlled by us to enable the collaboration with Voxall. Alloy&#x2019;s initial contribution included $50 thousand and the execution of a license agreement and a services agreement to enable the collaboration with Voxall. Voxall is governed by a board of directors consisting of an equal number of our representatives and Alloy&#x2019;s representatives. The protective provisions under Voxall&#x2019;s operating agreement require the approval of both Pyxis Oncology and Alloy before Voxall may take certain actions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the formation of Voxall, we entered into a three-year research collaboration with Alloy and Voxall to identify and select certain biological targets and create development candidate antibodies directed to those targets for further preclinical development, clinical development and commercialization. Under the collaboration agreement, the parties will conduct research under a mutually agreed research plan and budget for up to six research programs focused on mutually selected targets. Each of us and Alloy will provide research support for the collaboration through separate services agreements with Voxall, which services will be paid in the form of promissory notes issued by Voxall. Voxall will own all intellectual property arising from the collaboration, subject to certain exceptions for intellectual property relating to Alloy&#x2019;s ATX-Gx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> platform.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a development candidate antibody under a research program meets certain mutually agreed selection criteria, we will have the exclusive option to obtain an exclusive license from Voxall to further develop and commercialize all the development candidate antibodies discovered under that research program. We may in-license one research program on certain pre-agreed financial terms. For all other in-licensed research programs, we will be obligated to pay fair market value as determined by a third-party valuation. Any research program that we do not in-license may be licensed by Voxall to a third party.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with Biosion USA, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 28, 2022, we entered into a license agreement, or the &#x201c;Biosion License Agreement,&#x201d; with Biosion USA, Inc., or Biosion, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pursuant to which we obtained exclusive, worldwide (other than Greater China </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(mainland China, Hong Kong, Macau and Taiwan)</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">), licenses for development, manufacture and commercialization rights for BSI-060T, a potentially best-in-class Siglec-15 targeting antibody, an IO product candidate (now referred to as PYX-106), and products containing the licensed compound.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Biosion License Agreement, we agreed to pay an upfront fee of $10 million and are obligated to pay future contingent payments including development, regulatory and commercial milestone up to an aggregate of $217.5 million in case of normal approval and $222.5 million in case of accelerated approval. Additionally, if products are launched, we will pay Biosion tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to low teens. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) 12 years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Components of Our Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses consist of costs incurred for our research activities, including our discovery efforts, and the development of our programs. These expenses include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:5.602%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">employee-related expenses, including salaries, payroll taxes, related benefits and stock-based compensation expense for employees engaged in research and development activities; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenses incurred in connection with our product candidates and the development of research programs, including under agreements with third parties, such as consultants, contractors, contract manufacturing organizations, or CMOs, and contract research organizations, or CROs; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">laboratory supplies and research materials; and </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expense research and development costs as incurred. Non-refundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our direct external research and development expenses consist of costs that include fees, reimbursed materials and other costs paid to consultants, contractors, CMOs and CROs in connection with our preclinical and clinical activities. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities expenses, including depreciation or other indirect costs, to specific product development programs because these costs are deployed across multiple programs and our platform and, as such, are not separately classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will increase substantially in connection with our ongoing and planned preclinical and clinical development activities in the near term and in the future. The successful development of our product candidates is highly uncertain. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates and we may never succeed in obtaining regulatory approval for any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses consist primarily of salaries and personnel-related costs, including stock-based compensation, for our personnel in executive, legal, finance and accounting, human resources and other administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees paid for accounting, auditing, consulting and tax services; insurance costs; travel expenses; and facility costs not otherwise included in research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our programs and platform. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance, and investor and public relations expenses associated with operating as a public company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other (Expense) Income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income primarily consists of interest earned on our invested cash and cash equivalent balances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The change in fair value of derivative liability represents the increase in the fair value of the derivative liability recorded as a result of an opt-in, investment and additional consideration agreement with LegoChem.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Loss from Equity Method Investment in Joint Venture</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, we entered into definitive transaction agreements with Alloy Therapeutics, Inc. (&#x201c;Alloy&#x201d;) and Voxall Therapeutics, LLC to finance and operate Voxall, a joint venture company formed in collaboration with Alloy to leverage our technology and Alloy&#x2019;s ATX-Gx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> platform and antibody discovery services. We account for our investment in the Voxall joint venture under the equity method of accounting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our inception, we have not recognized any income tax benefits for the net losses we have incurred or for the research and development tax credits earned in each year and interim period, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss, or NOL, carryforwards and tax credit carryforwards will not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, our federal and state net operating losses in the United States were $10.1 million ($48.0 million before tax) and $2.8 million ($45.9 million before tax) respectively. The federal net operating loss carryforwards in the United States can be carried forward indefinitely but may be subject to annual usage limitations to the extent certain substantial changes our ownership occur. The state net operating loss carryforwards begin expiring in 2039. In addition, as of December 31, 2021, we had $1.0 million and $0.6 million of federal and state credit carryovers which begin to expire in 2039. These loss and credit carryforwards are subject to review and possible adjustment by the appropriate taxing authorities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of the Years Ended December 31, 2021 and 2020</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our results of operations for the years ended December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.692%;"></td>
    <td style="width:1.302%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:11.271%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.302%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:11.271%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.302%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:8.448%;"></td>
    <td style="width:0.865%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,054</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,048</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,006</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,663</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,846</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,817</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,717</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,894</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56,823</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(69,717</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(12,894</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(56,823</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other (expense) income:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(43</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Service fee income from related party</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">181</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">181</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of derivative liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(6,231</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(6,231</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other (expense) income:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(6,027</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(6,093</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from equity method investment in joint venture</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(231</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(231</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(75,975</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(12,828</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(63,147</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our research and development expenses for the years ended December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.32%;"></td>
    <td style="width:1.302%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:11.342%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:1.302%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:11.322%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:1.302%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:9.354%;"></td>
    <td style="width:0.636%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development program expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,363</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,927</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,436</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Personnel-related expenses including stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,836</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,645</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,191</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,855</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,476</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,379</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">51,054</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9,048</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">42,006</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses increased by $42.0 million, from $9.1 million for the year ended December 31, 2020, to $51.1 million for the year ended December 31, 2021. The program expenses increased by $35.4 million, which was primarily due to license fee of $25.0 million related to Pfizer License Agreement, license fee of $4.4 million related to LegoChem License Agreement, increased cell line development fees of $4.5 million and laboratory supplies of $1.0 million. Personnel-related expenses including stock-based compensation increased by $5.2 million, which was primarily due to higher personnel-related expenses of $2.7 million and higher stock-based compensation of $2.5 million, both of which were due to an increase in headcount to support our research and development activities. Other research and development expenses increased by $1.4 million, which primarily related to the increase in facility maintenance costs and higher depreciation on laboratory equipment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our general and administrative expenses for the years ended December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.324%;"></td>
    <td style="width:1.302%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:11.341%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:1.302%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:11.321%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:1.302%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:9.353%;"></td>
    <td style="width:0.636%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Personnel-related expenses including stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,622</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,387</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,235</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional and consultant fees</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,606</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,610</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,996</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Facilities, insurance and other costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,435</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">849</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,586</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total general and administrative expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18,663</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3,846</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14,817</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses increased by $14.8 million, from $3.8 million for the year ended December 31, 2020, to $18.6 million for the year ended December 31, 2021. Personnel-related expenses including stock-based compensation increased by $7.2 million primarily due to higher personnel-related expenses of $3.3 million and higher stock-based compensation of $3.9 million, both of which were due to an increase in headcount. Professional and consultant fees increased by $6.0 million related to recruiting fees, intellectual property counsel fees, accounting fees, audit fees and corporate counsel fees, to support our growth and operations as a public company. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Facilities, insurance and other costs </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increased by $1.6 million to support our internal growth and operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other (Expense) Income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income for the years ended December 31, 2021 and 2020 was less than $0.1 million consisting of interest earned on invested cash and cash equivalent balances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other expense consists of change in fair value of the derivative liability o</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">f $6.2 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million for the year ended December 31, 2021, as a result of the Opt-In Agreement. Service fee income from related party consists of income from services provided to the Voxall joint venture of $0.2 million for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We had cash and cash equivalents of $274.7 million as of December 31, 2021. For the years ended December 31, 2021 and 2020, we had net losses of $76.0 million and $12.8 million, respectively. As of December 31, 2021, we had an accumulated deficit of $91.7 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 2021, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we completed our IPO in which we sold </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,500,000 shares of our common stock at $16.00 per share and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">received net proceeds of approximately $152.3 million, after deducting underwriters&#x2019; discounts and commissions and other issuance costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials for our product candidates in development. The timing and amount of our funding requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the manufacture of product candidates, completion of our IND enabling studies and initiation of Phase 1 clinical trials for PYX-201, PYX-202, PYX-203, PYX-106, and PYX-102; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and progress of our other preclinical and clinical development activities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number and scope of other preclinical and clinical programs we decide to pursue; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the progress of the development efforts of parties with whom we have entered or may in the future enter into in-licensing, collaborations and research and development agreements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing licensure; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to maintain our current licenses and research and development programs and to establish new collaboration arrangements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs involved in prosecuting, maintaining and enforcing patent and other intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any delays or interruptions, including due to the COVID-19 pandemic, that we experience in our preclinical studies, future clinical trials and/or supply chain; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost and timing of regulatory licenses; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our efforts to hire additional clinical, regulatory, scientific, operational, financial and management personnel; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">incur insurance, legal and other regulatory compliance expenses to operate as a public company.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time, if ever, we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions, engaging in acquisition, merger or collaboration transactions, selling or licensing our assets, making capital expenditures, redeeming our stock, making certain investments or declaring dividends.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides information regarding our cash flows for the periods presented (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.713%;"></td>
    <td style="width:1.481%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:13.021%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.481%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:13.011%;"></td>
    <td style="width:0.865%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(35,326</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(10,084</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(590</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1,483</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">304,044</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">268,128</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(11,532</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, operating activities used $35.3 million of cash, primarily resulting from our net loss of $76.0 million, partially offset by non-cash charges of $34.0 million and net change in our operating assets and liabilities of $6.7 million. The non-cash charges of $34.0 million was primarily due to the $20.0 million of research and development license fees for Pfizer settled in Series B convertible preferred stock, the $6.2 million change in the fair value of derivative liability and $6.4 million in stock-based compensation. The change in our operating assets and liabilities was primarily due to an increase of $9.7 million in accounts payable and accrued expenses and other current liabilities, partially offset by changes in prepaid and other current assets and lease payments of $3.0 million, all of which were due to growth in our business, the advancement of our research programs, and the timing of vendor invoicing and payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, operating activities used $10.1 million of cash, primarily resulting from our net loss of $12.8 million, partially offset by non-cash charges of $0.9 million and net cash used in changes in our operating assets and liabilities of $1.8 million. Net cash used in changes in our operating assets and liabilities for the year ended December 31, 2020, consisted primarily of increase of $2.3 million in accounts payable and accrued liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended December 31, 2021 and 2020, net cash used in investing activities was $0.6 million and $1.5 million, respectively, due to purchases of property and equipment. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The purchases of property and equipment consists of laboratory equipment, leasehold improvements, and furniture and fixtures. During the year ended December 31, 2021, we also made an investment in our joint venture, Voxall Therapeutics, LLC, for $0.1 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, net cash provided by financing activities was $304.0 million, consisting primarily of net proceeds of $152.3 million from the issuance of our common stock in the initial public offering and net proceeds of $151.6 million from the sale of our Series B convertible preferred stock.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No significant financing activities other than exercise of stock options during the year ended December 31, 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Outlook</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on our cash balance as of December 31, 2021 of $274.7 million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and our research &amp; development and business development plans, we expect to be able to fund our operating expenses and capital expenditure requirements into the third quarter of 2024. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. In addition, we could utilize our available capital resources sooner than we expect.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contractual Obligations and Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following summarizes our contractual obligations as of December 31, 2021, and the effects that such obligations are expected to have on our liquidity and cash flows in future periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We lease our operating facility in Cambridge, Massachusetts under a non-cancellable operating lease agreement for our corporate headquarters and laboratory space which expires in March 2022, with a remaining lease obligation of $0.5 million. On September 29, 2021, we entered into a lease agreement for an office and laboratory space in Boston, Massachusetts. The lease will expire on December 31, 2032, with future undiscounted operating lease payments (base rent) under the lease agreement of $33.8 million over an initial lease period of approximately ten years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During 2020 and 2021, we entered into a few licensing and related agreements in the normal course of business. In accordance with the agreements, we are obligated to pay, among other items, future contingent payments, royalties, and sublicensing revenue in the future, as applicable. We have not included potential future payments due under these licensing and collaboration agreements in a table of contractual obligations because the payment obligations under this agreement are contingent upon future events.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Pfizer License Agreement, we are obligated to pay future contingent payments and royalties, including up to an aggregate of $660 million in milestones for the first four licensed ADCs. Additional ADC targets may be licensed for an additional upfront fee, and such targets would be subject to additional regulatory and commercial sales milestones. Additionally, if products are launched, we will pay Pfizer tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to mid-teens. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) 12 years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. We are also obligated to pay Pfizer a percentage of certain sublicensing revenue ranging from low-double digits to thirty percent based on the stage of development of the licensed product at the time of entering into the applicable sublicense.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the LegoChem License Agreement, we are obligated to pay up to an aggregate of $284.5 million to LegoChem if certain development, regulatory and sales milestones are achieved, as well as tiered royalties on net sales of licensed products ranging from mid-single digit to high single digit royalty rates. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until the latest to occur of: (1) the date of expiration of the last valid claim of a licensed patent covering the licensed product; (2) 10 years from first commercial sale; and (3) the expiration of regulatory or data exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the University License Agreement with the University of Chicago  (the &#x201c;University&#x201d;), we are obligated to pay to the University an annual maintenance fee of $10 thousand commencing on the third anniversary of the effective date, potential development and commercial milestones of up to an aggregate of $7.7 million as well as running royalties on net sales of licensed products at varying rates ranging from less than one percent to the low single digits, subject to a minimum annual royalty ranging from $1.0 million to $3.0 million during certain years following the first commercial sale of a licensed product. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until: (1) for licensed products covered by a valid claim of a licensed patent in a given country, the expiration of such valid claims; and (2) for all other licensed products, 10 years from the first commercial sale of a licensed product in a given country. We are also obligated to pay the University a percentage of certain sublicensing revenue ranging from low- to mid-teens based on the date of entering into the applicable sublicense.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Biosion License Agreement, we are obligated to pay future contingent payments including development, regulatory and commercial milestone up to an aggregate of $217.5 million in case of normal approval and $222.5 million in case of accelerated approval. Additionally, if products are launched, we will pay Biosion tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to low teens. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) 12 years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also enter into contracts in the normal course of business with CMOs, and other third parties for preclinical studies. These contracts do not contain minimum purchase commitments and are cancelable by us upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation. These payments are not included in contractual obligations above as the amount and timing of such payments are not known.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Off-Balance Sheet Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While our significant accounting policies are described in more detail in Note 2 to our audited consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">critical accounting policies used in the preparation of our consolidated financial statements that require significant estimates and judgments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. At each period end, we corroborate the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include those related to fees paid to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">vendors in connection with discovery and preclinical development activities; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CROs in connection with preclinical studies and clinical trials. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We record the expense and accrual related to contract research and manufacturing based on our estimates of the services received and efforts expended considering a number of factors, including our knowledge of the progress towards completion of the research, development and manufacturing activities; invoicing to date under contracts; communication from the CROs, CMOs and other companies of any actual costs incurred during the period that have not yet been invoiced; and the costs included in the contracts and purchase orders. In accruing service fees, we estimate the period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expense accordingly. There have not been any material adjustments to our prior estimates of accrued research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principle or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The three levels of the fair value hierarchy are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We maintain an equity incentive plan as a long-term incentive for employees, consultants, and directors. We account for all stock-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The grant date fair value of the stock-based awards with graded vesting is recognized on a straight-line basis over the requisite service period. We recognize forfeitures related to stock-based compensation awards as they occur and reverse any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We value stock options with service conditions using the Black-Scholes option pricing model. The Black-Scholes option-pricing model uses various inputs and we make certain assumptions regarding the fair value of our common stock, the expected volatility of our common stock, the expected term of stock options, the risk-free interest rate for a period that approximates the expected term of our common stock options and our expected dividend yield. The following summarizes the inputs used and assumptions made:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected Volatility&#x2014;We lack company-specific historical and implied volatility information. Therefore, we estimate the expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until we have adequate historical data regarding the volatility of our traded stock price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected Term&#x2014;We use the simplified method described in the SEC&#x2019;s Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-Based Payment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(&#x201c;SAB 107&#x201d;), to determine the expected life of the option grants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-Free Interest Rate&#x2014;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividends&#x2014;Expected dividend yield is zero because we have not paid cash dividends on shares of common stock and do not expect to pay any cash dividends in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Determination of Fair Value of Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the our IPO on October 8, 2021, the estimated fair value of our common stock has been determined by our board of directors as of the date of grant of each option award, with input from management, considering our most recently available third-party valuations of common stock and our board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Our common stock valuations were prepared using either an option pricing method, or OPM, or a hybrid method, both of which used market approaches to estimate our enterprise value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The assumptions underlying these valuations represented management&#x2019;s best estimate, which involved inherent uncertainties and the application of management&#x2019;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could have been materially different.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since the completion of our IPO on October 8, 2021, it is no longer necessary for our board of directors to estimate the fair value of our common stock in connection with our accounting for stock option grants and other such awards that we may grant, as the fair value of our common stock is based on the publicly quoted market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Leases</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use (&#x201c;ROU&#x201d;) assets represent our right to use an underlying asset during the lease term, and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are initially recognized and measured based on the present value of the future fixed lease payments over the expected lease term at commencement date calculated using our incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. We determine the lease term as the non-cancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease ROU assets also include any initial direct costs incurred and any lease payments made on or before the lease commencement date, less lease incentives received. Operating lease ROU assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. We account for lease and non-lease components as a single lease component for all its facilities leases. We had no finance leases as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We account for income taxes in accordance with FASB ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (&#x201c;ASC 740&#x201d;), which requires the use of the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between amounts in the consolidated financial statements and the tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income tax (benefit) expense in the consolidated statements of operations and comprehensive loss in the period that includes the enactment date.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recognize deferred tax assets to the extent that we believe these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of our net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For information with respect to recently issued accounting standards and the impact of these standards on our consolidated financial statements, refer to &#x201c;Note 2 &#x2014; Summary of Significant Accounting Policies&#x201d; in our consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Jumpstart Our Business Startups Act</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;) permits an &#x201c;emerging growth company&#x201d; to take advantage of an extended transition period to comply with new or revised accounting standards. We are an &#x201c;emerging growth company,&#x201d; as defined in the JOBS Act. Section 107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also a &#x201c;smaller reporting company,&#x201d; meaning that the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and have reduced disclosure obligations regarding executive compensation, and, similar to emerging growth companies, if we are a smaller reporting company with less than $100 million in annual revenue, we would not be required to obtain an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7A. Quantita</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">tive and Qualitative Disclosures About Market Risk.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under SEC rules and regulations, because we are considered to be a &#x201c;smaller reporting company&#x201d;, we are not required to provide the information required by this item in this report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 8. Financial</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Statements and Supplementary Data.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The financial information required by Item 8 is located beginning on page F-1 of this report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9. Changes in and Dis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">agreements With Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9A. Co</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ntrols and Procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Evaluation of Disclosure Controls and Procedures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We maintain &#x201c;disclosure controls and procedures&#x201d; (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act), that are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021, the end of the period covered by this Annual Report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2021, at the reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Report on Internal Controls over Financial Reporting.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report does not include a report of management&#x2019;s assessment regarding internal control over financial reporting or an attestation report of our registered public accounting firm due to a transition period established by the rules of the SEC for newly public companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Changes in Internal Control Over Financial Reporting.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal quarter ended December 31, 2021, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Inherent Limitation on the Effectiveness of Internal Control.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures, or our internal controls, will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Attestation Report of the Registered Public Accounting Firm.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting due to an exemption established by the JOBS Act for &#x201c;emerging growth companies.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9B. O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ther Information.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 28, 2022, we entered into a license agreement, or the &#x201c;Biosion License Agreement,&#x201d; with Biosion USA, Inc., or Biosion, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pursuant to which we obtained exclusive, worldwide (other than Greater China </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(mainland China, Hong Kong, Macau and Taiwan)</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">), licenses for development, manufacture and commercialization rights for BSI-060T, a Siglec-15 targeting antibody, an IO product candidate (now referred to as PYX-106), and products containing the licensed compound.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Biosion License Agreement, we agreed to pay an upfront fee of $10 million and are obligated to pay future contingent payments including development, regulatory and commercial milestone up to an aggregate of $217.5 million in case of normal approval and $222.5 million in case of accelerated approval. Additionally, if products are launched, we will pay Biosion tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to low teens. Our royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) 12 years from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9C. Disclosure regarding foreign jurisdictions that prevent inspections</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">T III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 10. Directors, Executive </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Officers and Corporate Governance.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this Item will be included in our definitive proxy statement to be filed with the SEC, with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensati"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 11. E</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">xecutive Compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this Item will be included in our definitive proxy statement to be filed with the SEC, with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_of_certa"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 12. Security Ownership of Certai</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">n Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this Item will be included in our definitive proxy statement to be filed with the SEC, with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationship"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 13. Certain Relationshi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ps and Related Transactions, and Director Independence.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this Item will be included in our definitive proxy statement to be filed with the SEC, with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 14. Principal Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">nting Fees and Services.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this Item will be included in our definitive proxy statement to be filed with the SEC, with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RT IV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 15. Exhibits, Fi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">nancial Statement Schedules.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.796%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.9288834417523018%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For a list of the financial statements included herein, see </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Index to the Consolidated Financial Statements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on page F-1 of this Annual Report on Form 10-K, incorporated into this Item by reference.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.796%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.9288834417523018%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:4.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.796%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.9288834417523018%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibits:</span></div></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:6.964%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:55.411%;"></td>
    <td style="width:6.001%;"></td>
    <td style="width:9.999%;"></td>
    <td style="width:6.001%;"></td>
    <td style="width:9.999%;"></td>
    <td style="width:4.623%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">File No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Filing Date</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Filed Herewith</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000095017021004476/pyxs-ex3_1.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Amended and Restated Certificate of Incorporation of Pyxis Oncology, Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">001-40881</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">November 15, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000095017021004476/pyxs-ex3_2.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Amended and Restated Bylaws of Pyxis Oncology, Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;&#160;10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">001-40881</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;November 15, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex4_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Description of registrant&#x2019;s securities</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521288350/d156228dex101.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Amended and Restated Investor Rights Agreement, dated March 5, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">October 1, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521290298/d156228dex102.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Form of Indemnification Agreement</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">October 4, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521290298/d156228dex103.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Employment Agreement between Pyxis Oncology, Inc. and Lara Sullivan, M.D.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">October 4, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521305462/d248391dex43.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Pyxis Oncology, Inc. 2019 Equity Incentive Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-260441</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">October 22, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521305462/d248391dex44.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Pyxis Oncology, Inc. 2021 Equity Incentive Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-260441</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">October 22, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521305462/d248391dex45.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Pyxis Oncology, Inc. Employee Stock Purchase Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-260441</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">October 22, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521276227/d156228dex107.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">License Agreement by and between Pyxis Oncology, Inc. and Pfizer Inc., dated December 8, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">September 17, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521276227/d156228dex108.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Amendment No. 1 to License Agreement by and between Pyxis Oncology, Inc. and Pfizer Inc., dated March 22, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">September 17, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521276227/d156228dex109.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Exclusive License Agreement between the University of Chicago and Pyxis Oncology for Cancer Immunotherapy Technology, dated April 16, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.9</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">September 17, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521276227/d156228dex1010.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">License Agreement between Pyxis Oncology, Inc. and LegoChem Biosciences Inc., dated December 1, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.10</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">September 17, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:3.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521276227/d156228dex1011.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">First Amendment to License Agreement between Pyxis Oncology, Inc. and LegoChem Biosciences Inc., dated February 25, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">September 17, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.12</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521276227/d156228dex1012.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Opt-In, Investment and Additional Consideration Agreement between Pyxis Oncology, Inc. and LegoChem Biosciences, Inc., dated December 1, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.12</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">September 17, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521288350/d156228dex1013.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Amendment to Opt-In, Investment and Additional Consideration Agreement between Pyxis Oncology, Inc. and LegoChem Biosciences, Inc., dated August 2, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">October 1, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.14</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521288350/d156228dex1014.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Collaboration Agreement by and among Pyxis Oncology, Inc., Alloy Therapeutics, Inc. and Voxall Therapeutics, LLC., dated March 30, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.14</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">October 1, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.15</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521288350/d156228dex1015.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Lease by and between B9 LS Harrison &amp; Washington LLC and Pyxis Oncology, Inc., dated September 29, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.15</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">October 1, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.16</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521290298/d156228dex1016.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Employment Agreement between Pyxis Oncology, Inc. and Pamela Connealy.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">October 4, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.17</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521290298/d156228dex1017.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Employment Agreement between Pyxis Oncology, Inc. and Jay Feingold, M.D.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.17</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">October 4, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.18</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1782223/000119312521290298/d156228dex1018.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Employment Agreement between Pyxis Oncology, Inc. and Ronald Herbst, Ph.D.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-259627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">October 4, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">21.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex21_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">List of Subsidiaries</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">23.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">24.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Power of Attorney (included on signature page to this Annual Report on Form 10-K)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">31.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">127</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:6.964%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:55.411%;"></td>
    <td style="width:6.001%;"></td>
    <td style="width:9.999%;"></td>
    <td style="width:6.001%;"></td>
    <td style="width:9.999%;"></td>
    <td style="width:4.623%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">31.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">32.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">32.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pyxs-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.INS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.SCH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.CAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.DEF</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.LAB</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:3.25pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.PRE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*  The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Annual Report on Form 10-K and are not deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">+  Indicates management contract or compensatory plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#134;  Certain confidential information contained in this exhibit, marked by [***], has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 16. For</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">m 10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.243%;"></td>
    <td style="width:2.823%;"></td>
    <td style="width:5.667%;"></td>
    <td style="width:46.267%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Pyxis Oncology, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 29, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Lara Sullivan</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lara Sullivan, M.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lara Sullivan, M.D. and Pamela Connealy and each of them, as such person&#x2019;s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for such person and in such person&#x2019;s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Annual Report on Form 10-K </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or such person&#x2019;s substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.976%;"></td>
    <td style="width:1.042%;"></td>
    <td style="width:43.304%;"></td>
    <td style="width:1.042%;"></td>
    <td style="width:21.637%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Lara Sullivan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer; Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 29, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lara Sullivan, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive Officer)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Pamela Connealy</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Chief Financial Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 29, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Pamela Connealy</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Financial and Accounting Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ John Flavin</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chairman of the Board of Directors</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 29, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">John Flavin</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Mark Chin</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 29, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Mark Chin</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Freda Lewis-Hall</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 29, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Freda Lewis-Hall, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Thomas Civik</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 29, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Thomas Civik</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Darren Cline</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 29, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Darren Cline</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">129</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PYXIS ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Page</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm (PCAOB ID: </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16c5b53b-094a-4903-b18f-3b08a07be810" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Balance Sheets as of December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_convertible"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit) for the Years Ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_of_independent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Reg</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">istered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the Stockholders and the Board of Directors of Pyxis Oncology, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Opinion on the Consolidated financial statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have audited the accompanying consolidated balance sheets of Pyxis Oncology, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#x2019; equity (deficit) and cash flows for the years then ended, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis for Opinion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b820805-0e30-4644-9525-4fdf9c795de0" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ernst &amp; Young LLP</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have served as the Company&#x2019;s auditor since 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a065e93-6eff-4f13-b6ea-23fc541ebeff" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boston, Massachusetts</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 29, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PYXIS ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(In thousands, except share and per share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.933%;"></td>
    <td style="width:1.493%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.041%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.493%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.032%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current assets:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b216c834-a954-46de-957d-29b837624214" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">274,735</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_849d248a-cc94-4645-8eb6-be471e35ed4f" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,080</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e70cf33-6753-44ce-8382-4f5b015ba8fd" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,472</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca748584-5125-444e-9b5e-3ce6b96dedeb" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,466</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0c7fe07-8ace-4c6c-95a3-2426fcad3428" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15284b59-3f57-48da-ac6b-fc84494a6cc4" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">278,673</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6c6e41d6-2544-4351-90c0-e8830f2e0fca" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,103</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a220c01-5233-49e0-999a-44a0777fcb66" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,007</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9be5bac6-8ed1-4cb8-b992-443d67885d96" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,103</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96e5e1bb-2e40-4bbc-9660-2829c1c7d951" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b7e6d80-c7e5-4b53-9fa2-1e048f09b58a" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">836</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other assets, noncurrent</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e59304a-a2cf-4eb2-ae9b-a5633fb5fb45" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c6277e78-eed4-44f1-84d6-58ba92faacc3" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b95e06a-7912-4614-83b1-3e90fd85795f" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">280,021</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a39a782a-d527-4c6f-b979-cc48a44a091a" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,151</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liabilities, Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e3d2ca42-50cc-4821-860b-def8324ebd19" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,951</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6fd98350-a859-4d1b-9933-73839c738057" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97911dda-9040-4138-8620-6e9d6b0d0a92" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,592</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91fe08b2-4543-42f9-8620-fdb2ebfeca33" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,997</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_846937fa-8781-4f1d-85f0-2c45912bea75" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_21b2d2a9-7bbb-42f8-a4ca-c11990e65ede" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">615</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88561de3-b415-4704-8488-6d6fe8eb2daa" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,708</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_94fb4a91-9619-4ef1-89f4-9fdac515e4df" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,689</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e20a49d6-48f7-4a44-af55-2bba6bccb232" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6e17582-0dff-4af8-bd4c-4981ec7bd39f" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,708</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa66a669-fe37-46ee-a0c9-f236651c0590" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,854</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_50960eda-5271-4ab9-851d-c8014b79d8e6;"><span style="-sec-ix-hidden:F_e37b2c3d-2209-4ae4-a26d-141353a73f83;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commitments and contingencies (Note 16)</span></span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A convertible preferred stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5580615-b442-4c65-8e92-6b30ab07e684" contextRef="C_de03779b-38b4-48de-abf6-4dfbb5df89c9" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_65401b66-38ab-4880-bfea-6ed03553dbb5" contextRef="C_8e0bc3e3-4b08-4944-8059-6999b756147c" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value per share; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e738fd0-de97-45fc-9b35-005fd128e97a" contextRef="C_de03779b-38b4-48de-abf6-4dfbb5df89c9" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73635248-2c43-4489-9c5f-f4c317518864" contextRef="C_8e0bc3e3-4b08-4944-8059-6999b756147c" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,724,926</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares authorized as of December 31, 2021 and 2020, respectively, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef673e1d-735d-4356-a908-656dc855cee4" contextRef="C_de03779b-38b4-48de-abf6-4dfbb5df89c9" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_504ad540-8915-4e3b-9731-fba0c79767a9" contextRef="C_de03779b-38b4-48de-abf6-4dfbb5df89c9" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_27ef5f75-5ea4-4625-9c55-7545d148d497" contextRef="C_8e0bc3e3-4b08-4944-8059-6999b756147c" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_61578d20-a23d-4d1f-b62f-516c10b3cfa0" contextRef="C_8e0bc3e3-4b08-4944-8059-6999b756147c" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,724,925</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;issued and outstanding as of December 31, 2021 and 2020, respectively, liquidation value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_730ad7ba-eec8-4230-bf9a-56dae659696a" contextRef="C_8e0bc3e3-4b08-4944-8059-6999b756147c" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;as of December 31, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c20eaa5e-a4f4-400e-9d5e-b73d4f4010ae" contextRef="C_8e0bc3e3-4b08-4944-8059-6999b756147c" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,942</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series B convertible preferred stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2c6af2f4-7acb-4dbc-b263-303c91022a7d" contextRef="C_04691b98-e0da-490b-a8f4-4b50017b84c0" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_962c6c2c-948e-4ca6-ad27-36ab63248ec3" contextRef="C_6e2e4e5a-08b0-4845-8a93-3b94cd5895c2" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value per share; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eaebc958-6edc-4ab5-a4f1-81edc618d9f0" contextRef="C_04691b98-e0da-490b-a8f4-4b50017b84c0" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e357f22a-c7f0-459d-aa75-4e4361a78ea2" contextRef="C_6e2e4e5a-08b0-4845-8a93-3b94cd5895c2" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_dc50d673-d83b-4d24-ba46-1b6cfca8a25e" contextRef="C_04691b98-e0da-490b-a8f4-4b50017b84c0" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_95e37cb5-d7e5-46cd-9f30-59b6b86af103" contextRef="C_6e2e4e5a-08b0-4845-8a93-3b94cd5895c2" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares authorized, issued and outstanding as of December 31, 2021 and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7234ad04-fa57-47a9-883c-6986dae56233;"><span style="-sec-ix-hidden:F_b487119d-da19-4ae4-9043-40f7baa15197;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2020</span></span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stockholders&#x2019; equity (deficit):</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preferred stock, par value $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_983767e4-0975-4c5a-a102-e915fdf196e5" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_d2488bef-1317-4048-aed4-8d670147ee0d" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;per share, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_283d0ffd-6d59-4914-89b5-c466c270631d" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c838cd1-4a80-46e2-8e4a-06e3bc41125a" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares authorized as of December 31, 2021 and 2020, respectively, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc9e622c-692e-487f-9845-313f2cac1689" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9a3d4c5f-d903-4700-b920-0c0301f7c75b" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1bf4ab27-2fdb-474d-94c7-eb341be473a8" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e6235a5a-519b-4665-861b-4a4604fd4061" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares issued and outstanding at December 31, 2021 and 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0a1acadd-79fb-4921-bd24-0d8d565584f5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d7c513c0-dafa-48ea-8420-1d541d060cf1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3372c316-790c-412e-b62d-741d85ab75f7" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_ca763d8a-dafb-4ea2-9dc3-f988b65d4209" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value per share; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cdc44667-76af-4499-81ee-d57814e3c081" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">190,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2dff5d80-f392-4a07-a1cd-509a2f1a59ce" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">40,300,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares authorized as of December 31, 2021 and 2020, respectively; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_068580a7-0d3b-4bb2-8271-093adfaa19eb" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,792,867</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eed9987e-4d5e-4fc7-8760-72f74d307f49" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,177,956</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares issued as of December 31, 2021 and 2020, respectively and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a3f76fac-61fa-485b-9fb8-e4578c666cab" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,222,881</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f7cf3a0-d088-480c-a18e-a57495662d4f" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,289,342</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares outstanding at December 31, 2021 and 2020, respectively</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_542af9fc-3ab7-4832-a24c-d15ef01937ec" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef5a056e-fc9c-4e31-98e3-547ca62b0eb6" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_702376a8-0b80-4577-bbe2-d0b3c5dc2ff0" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">352,999</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c35bbe1-34f9-4639-86c8-0357e6e04cc5" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a11eb69-e81d-4c7e-b25f-6478f8fe915c" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">91,718</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28682d48-a9ef-455c-9816-525c80f41f16" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,743</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stockholders&#x2019; equity (deficit)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05fcaa4e-8652-422a-b610-37aea175a378" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">261,313</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_92c84fb8-f59b-4897-9319-9368090b9254" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,645</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total liabilities, convertible preferred stock and stockholders&#x2019; equity (deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32f1ba3d-a265-4704-b509-1f882ab2c155" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">280,021</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8761100b-4571-4d34-be21-5e60fc20b94e" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,151</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PYXIS ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Op</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">erations and Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(In thousands, except share and per share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.908%;"></td>
    <td style="width:1.493%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.05%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.493%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.05%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e401272-2eeb-42cc-9e8b-8a4fc2fbc5f3" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,054</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ebb1532-5db7-43ef-afdf-42effcabda34" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,048</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_47ada345-f81d-48b1-a412-36ab9ec6697a" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,663</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a6cfd03-7f03-4140-b9d8-4d88baff6bf3" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,846</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28cba468-6582-4cd1-b75f-febf07fe4703" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,717</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ecea12e5-b008-42af-8634-372e39c4258c" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,894</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36fa9b6b-55d1-4256-bef5-718826deb2e2" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">69,717</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28084cf4-56fd-49ba-8550-4ddbd39ad5e7" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,894</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other (expense) income:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ec70c38-1ce9-43c6-ae9e-cc4e63cd0745" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_92fdc938-0bd5-430c-ad66-bf4c91c60d17" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Service fee income from related party</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd504bba-09aa-44a4-9621-021eea9fe898" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="pyxs:ServiceFeeIncomeFromRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">181</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of derivative liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_24fed7bd-45ed-47dc-81f0-04f10c134dc4" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,231</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other (expense) income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd481415-1141-459a-867a-a712953aedae" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,027</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1125698-3d7b-426a-af81-59b19e89cb20" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from equity method investment in joint venture</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b6c6336-e542-4a84-866d-f7376e8c6b2d" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">231</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net loss and comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f7c6d43-3cac-46b3-b70c-08e7fd9eb3b8" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,975</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6003a08-2414-44a1-972c-3930848e0726" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,828</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per common share - basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_781125fc-974a-450a-b4fd-0b91e76b04ab" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">8.95</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_adeeb1cc-53f1-4753-b569-dc15c4f625e3" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">12.45</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average shares of common stock outstanding - basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f818b5a2-28b1-4a21-8602-60a51b3ae04f" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,493,273</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_78912931-2377-47f9-8998-fe81d9b9ee93" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,030,556</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PYXIS ONCOL OGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_convertible"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Convertible Pre</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ferred Stock and Stockholders&#x2019; Equity (Deficit)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(In thousands, except share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.874%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:0.408%;"></td>
    <td style="width:9.184%;"></td>
    <td style="width:0.557%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:0.835%;"></td>
    <td style="width:8.757%;"></td>
    <td style="width:0.557%;"></td>
    <td style="width:1.095%;"></td>
    <td style="width:0.408%;"></td>
    <td style="width:9.276%;"></td>
    <td style="width:0.408%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:0.835%;"></td>
    <td style="width:8.85%;"></td>
    <td style="width:0.408%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:0.835%;"></td>
    <td style="width:8.887%;"></td>
    <td style="width:0.408%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:0.835%;"></td>
    <td style="width:8.803%;"></td>
    <td style="width:0.557%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:0.844%;"></td>
    <td style="width:8.813%;"></td>
    <td style="width:0.557%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Convertible Preferred Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Common Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Additional<br />Paid-in</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Total<br />Stockholders&#x2019;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Equity (Deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Balance at December 31, 2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7208de5-81eb-4fbc-95e5-620891b34754" contextRef="C_5221cef4-195a-4dfd-95bb-66e798f30b97" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,724,925</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a51bdf40-3ab0-4c0e-8aa1-33f300bea1b4" contextRef="C_5221cef4-195a-4dfd-95bb-66e798f30b97" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,942</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a162c3e1-3467-4f76-bd0d-2a774b6dda99" contextRef="C_b6ec6f8a-bc22-4323-8647-1e511c65aa13" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">828,356</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aeada01d-666e-4d3c-aca4-057495456b89" contextRef="C_b6ec6f8a-bc22-4323-8647-1e511c65aa13" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c68e98f-b564-4836-b269-0d49f9763c8a" contextRef="C_7e96f6dc-3ab3-4489-961b-e2b6b8303a96" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b9e51892-442b-47c6-811f-cda3f5e2ac45" contextRef="C_6a491c51-e3ff-4f01-b86c-22bb7f1219c0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,915</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_19ff0f75-5411-477d-a088-9b83b05b7f72" contextRef="C_37f4df29-d5b8-4d2c-bf7f-5a96e5b924a3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,874</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52d9cd53-fcbe-4147-9ae6-6f79b75b4e35" contextRef="C_c75ce941-68a1-475c-964a-d8c55a132c9f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">49,061</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a915a22a-78f2-4b82-a614-730f03f31f71" contextRef="C_cb6bd2f8-ad47-4a35-989a-57aedc56c9c0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_040a64ee-3626-4215-adbe-68f06d989a8c" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_962f3d75-f158-44ae-8511-fa3346f668f6" contextRef="C_c75ce941-68a1-475c-964a-d8c55a132c9f" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">411,925</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1d1d574-9918-4db3-826a-d6bfce5bc2d4" contextRef="C_cb6bd2f8-ad47-4a35-989a-57aedc56c9c0" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_104e451f-2bf5-4d94-b541-156b2311439e" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_492a3c1e-6565-4404-8271-7fc9bab921da" contextRef="C_cb6bd2f8-ad47-4a35-989a-57aedc56c9c0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e4679cae-f0c5-464f-bcba-9ee03803af7e" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1d10b89f-723a-4f8b-8a0f-71c1edcdbcaf" contextRef="C_a9c9231a-7100-4362-8c03-86895d680666" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,828</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1921b5d-39bb-4335-b137-b6f27267039f" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,828</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_67552021-f07c-4c1f-b946-17bcbc298c68" contextRef="C_856072e1-a9f5-4feb-888d-6f52cd2b0837" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,724,925</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee595d94-e02f-4e8b-b29f-1c1f6a6890f3" contextRef="C_856072e1-a9f5-4feb-888d-6f52cd2b0837" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,942</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f3ad696b-8759-449a-a01f-9928e07859d0" contextRef="C_766b7d60-5964-4d51-abab-3b2019b307a8" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,289,342</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1dc89f10-384d-447e-8c99-2e284cd3eb88" contextRef="C_766b7d60-5964-4d51-abab-3b2019b307a8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb85e2eb-4c3e-4b3f-bfdf-599084370ae3" contextRef="C_0492f1f1-cdba-47c2-b6ed-3d308a2cdd45" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_80cd654f-98bd-46ae-b2cd-7fa3112b5924" contextRef="C_d3f40a67-c272-4dd9-b239-cdb25247520e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,743</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fbdada60-45f8-4ca6-ac79-859b70b67289" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,645</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of Series B convertible preferred stock to Pfizer, Inc. (Refer to Note 3)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81431cbd-f407-457e-835a-dd36e7baa22d" contextRef="C_b5d21c61-6321-4216-b894-327d183af8bc" name="pyxs:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">12,152,145</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de28cc03-c55a-4570-af94-ee7bceaa52b8" contextRef="C_b5d21c61-6321-4216-b894-327d183af8bc" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of Series B convertible preferred stock, net of issuance costs of $</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_637fb36a-a282-458c-a533-274d6f6335fe" contextRef="C_8e920cab-08bd-4853-a2c7-07b631b559f3" name="pyxs:TemporaryEquityIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">419</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f71a00f-7364-4172-ab1c-917f5c0bca90" contextRef="C_f604ee67-0407-458c-8c83-3dcf27014aee" name="pyxs:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">92,660,103</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1c222ff-e95d-421b-901a-02dae88f3511" contextRef="C_f604ee67-0407-458c-8c83-3dcf27014aee" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">152,081</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of shares of common stock through initial public offering, net of underwriting commission and issuance costs of $</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52d5e0ba-02c4-445a-ab9b-0003bebdcd79" contextRef="C_822a9797-c061-4b8c-ab9b-33b711164570" name="us-gaap:DeferredFinanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68edf472-a22f-4a66-a330-91b06c24ef00" contextRef="C_8b24eb84-4a1e-48e9-939f-d50285a9ebf8" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,500,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15ce4fdd-942b-4c26-afb7-768e2afae3e3" contextRef="C_8b24eb84-4a1e-48e9-939f-d50285a9ebf8" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_14c3561c-7850-40f9-a346-eafc9c168c76" contextRef="C_cab37125-1fa0-46b6-b525-727f58de2829" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">152,285</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3cc5c48c-34d5-47c0-9c03-36468c2856a7" contextRef="C_60a0d615-609c-4658-97f4-896f92d22495" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">152,296</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Conversion of Series A and Series B convertible preferred stock into shares of common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e797421a-9e2a-435a-b382-644fa5b65da7" contextRef="C_f604ee67-0407-458c-8c83-3dcf27014aee" name="pyxs:TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">127,537,173</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36331d4b-17c0-4f4e-806e-0dc58d7b5ca7" contextRef="C_f604ee67-0407-458c-8c83-3dcf27014aee" name="pyxs:TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">194,023</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_517512d5-59a9-461b-a892-b6b2e8dce59f" contextRef="C_d8091fae-ef00-4700-b4a2-77ed5956ff06" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">20,056,145</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e3106c54-a977-4f20-a065-c184034836ff" contextRef="C_d8091fae-ef00-4700-b4a2-77ed5956ff06" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4d634b35-6626-4c21-a0fc-9868d908b548" contextRef="C_5c40a4a9-f63b-4608-bd08-8d0a1321ed5b" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194,003</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_50ee77cb-40d2-48eb-a3d2-ca90740e31e8" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194,023</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Stock options exercised</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f5b8c54-a14a-48a5-a457-e0de372f4dd7" contextRef="C_d8091fae-ef00-4700-b4a2-77ed5956ff06" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">70,396</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2156b94-c23d-4344-ba52-3caa78e45170" contextRef="C_5c40a4a9-f63b-4608-bd08-8d0a1321ed5b" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_16f3b4bb-24c9-4222-82d6-a7744ede1d76" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f27f295-a75f-412d-a0d9-b12d7f8ccdfc" contextRef="C_d8091fae-ef00-4700-b4a2-77ed5956ff06" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">306,998</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f97770d5-5716-4e90-aa5a-955ba8b49676" contextRef="C_5c40a4a9-f63b-4608-bd08-8d0a1321ed5b" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df15c236-db6c-486a-bef8-9f32a460dcb5" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_800ca1e2-618f-4f78-8439-26a0594b7da0" contextRef="C_5c40a4a9-f63b-4608-bd08-8d0a1321ed5b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,441</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_78243338-4e37-4160-a0dd-ecc351ebb565" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,441</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89701edd-8e62-4576-bba9-7cc9c1ce6719" contextRef="C_5dd6ea79-1ed6-4fd4-bfde-295b989544d7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,975</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf2631d6-e024-4e30-a6dd-92a2d7294976" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,975</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90b9c22e-4676-45be-8655-7c3468da98a2" contextRef="C_84680f37-2d8e-4647-bf6e-6e10f83c3b7f" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,222,881</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_556bca05-21c4-4856-87d9-58e7b1fece34" contextRef="C_84680f37-2d8e-4647-bf6e-6e10f83c3b7f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_662b1f47-7baa-4414-9a1b-c6ef536a09a3" contextRef="C_aa4c513f-59f0-4418-b2c2-d90b9bbe35b3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">352,999</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6c00a64-549e-4301-afda-50b84b0b45b7" contextRef="C_98160ecc-3034-40bb-a317-ac57984c3f17" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">91,718</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_670080b5-16fc-4ca9-bb48-1f1f75cfe9ec" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">261,313</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PYXIS ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statem</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ents of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(In thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:68.568%;"></td>
    <td style="width:1.41%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:12.308%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.41%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:12.298%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3a5d796-3fc6-4477-8a64-36282aae222f" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,975</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_895f1389-37c2-486d-83a9-c326ef4c7bc1" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,828</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08e220a2-f979-4778-b9e8-f88f0bdccdd0" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">647</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4d0f5f7-fa70-4b09-9d05-2441867fc5d1" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">469</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_acf685b4-0908-4f2b-9bd1-bd367ad58ef6" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,441</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_622fa3e9-2070-4a66-aaa9-baf62ba734a9" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-cash research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ffca598-ac0e-4efd-b67d-a2b51239e1fc" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ResearchAndDevelopmentInProcess" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-cash lease expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17cd7340-6c74-464b-9d2a-06832e2035cd" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">604</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07b36869-1aaa-40be-ad42-33472cfd1ccb" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">365</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-cash loss from equity method investment in joint venture</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bef55334-2e1b-477a-a707-b6b8e1393344" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="pyxs:NonCashGainLossFromEquityMethodInvestmentInJointVenture" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value of derivative liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e6ec0ec-ee27-45e3-90c3-e9f22d7089e6" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:UnrealizedGainLossOnDerivatives" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,231</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0511b958-6d44-41b9-96f7-7de0e13ef4e6" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,444</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf4c7109-e5b4-4cea-87a1-f74e9837950d" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7755b041-4c98-4a08-8387-cd0e3441fc3e" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,643</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33d8fe3a-a2c8-4e1b-a264-3dcea8037777" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">558</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9439ce4-5449-4ef2-aa84-a9cbd1595ba7" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,092</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c196b9a4-79d8-4522-9326-b68e93694797" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,742</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_801b56e3-3c15-40d3-87fe-63d2787c88ca" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">615</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a97dd8e5-4259-4f29-93f8-1a11b2922546" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">421</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4f643c3-488d-463f-be00-713741edfe58" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,326</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6c522bf5-2818-4d9a-91c4-dd2637f37ad7" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">10,084</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81f14186-0342-4c1a-bfdd-0042d1d55367" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">540</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_62f013e2-09e8-481d-81ad-2bb722907da5" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,483</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investment in joint venture</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7df1474b-262e-40b4-ac8d-50a804ae4771" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:PaymentsToAcquireInterestInJointVenture" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_609d8991-4b1e-40a3-8037-7640b6857365" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">590</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e7d21dd0-ddc2-48d3-9165-e8ae2f094768" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,483</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of Series B convertible preferred stock, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ba69741-3c92-44cd-a933-884f7e10d57a" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">151,581</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock in initial public offering, net of issuance costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb6b79bb-dfc9-432a-803b-a09aa47d2cf8" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">152,296</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_abb1e9b5-9272-4b13-b224-9d852fad8d02" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from the exercise of stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4569a5ae-b35c-4be9-a45d-666ace4c46c9" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">167</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_50ae19ea-ffc6-4683-a5fc-b87127679554" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d438ef1f-eb55-4889-bf6b-44b64902ba0a" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">304,044</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b9c008b7-959e-4dfe-9f38-fdf05263e9d6" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8586458f-b294-4173-9c06-9627bf5601d5" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">268,128</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36b5cded-4685-4591-b15c-a46f8badf2d2" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">11,532</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash at beginning of year</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef4bf6a6-aca1-4667-b1d5-3605ff27f260" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,188</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9d3a33f-4370-4b85-b29d-7e1d335bece0" contextRef="C_37f4df29-d5b8-4d2c-bf7f-5a96e5b924a3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,720</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash at end of year</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7324655c-670f-4091-a2c4-0711c7bbcdde" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">276,316</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_45fdc56f-daad-4670-9415-68c57442fbf0" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,188</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Supplemental schedule of noncash investing and financing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchases of property and equipment in accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49fa73ee-cbdb-4db9-a0de-0687e2ff9dc0" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_16bfb2d4-7e2e-4c6b-a100-8b3f0a19eb29" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use asset obtained in exchange for new operating lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9d1787f-d493-40e1-a2e0-1eecd842975d" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,186</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Reconciliation of cash, cash equivalents and restricted cash:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ebfb343f-650c-4d3d-aed4-67f6955826ce" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">274,735</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d8c6365-6539-48d9-a424-f87634df8fd7" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,080</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3fba815-9ccd-4300-925d-14775336e6d0" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,581</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04cc726b-bd7d-4613-ae48-a6bd1219d692" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total cash, cash equivalents and restricted cash shown in the statement of<br />&#160;&#160;&#160;cash flows</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_481610ae-1531-4faa-b633-80dc6ce84d88" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">276,316</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_360767c6-8f72-4320-b046-21dd8c565980" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,188</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PYXIS ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">d Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50c32070-110c-4c2e-9afb-ef595a192aa1" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Organization and Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa8e54d9-852a-4f6c-b57c-cc37bc961d79" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="pyxs:NatureOfBusinessPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pyxis Oncology, Inc. (the &#x201c;Company&#x201d;), a Delaware corporation, was founded in June 2018 and launched its operations in July 2019. The Company is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The Company develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since the Company&#x2019;s launch in 2019, the Company has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates and monoclonal antibody, or mAb, preclinical discovery programs that the Company is developing as monotherapies and in combination with other therapies.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has determined that it has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ccada53d-8214-4fcc-8fff-440570b7107f" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_89197659-e9ce-4858-9c92-e0630d3d84ed" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating and reporting segment.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99e345a9-8152-48ee-9e1a-6700f098c49c" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:StockholdersEquityPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reverse Stock Split</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 1, 2021, the Company effected a 1-for-</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6e0eb586-b179-4054-af6f-b94a1fcee934;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.359</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split of its issued and outstanding common stock and stock option awards. The par value of the common stock and preferred stock was not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the convertible preferred stock conversion price to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The shares of common stock underlying outstanding stock options and restricted stock units were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All issued and outstanding shares of common stock, restricted stock units, stock option awards and per share data have been adjusted on a retrospective basis in these consolidated financial statements, to reflect the reverse stock split for all periods presented.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_badcd654-1e35-44dc-9bf2-3395fefefb7c" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="pyxs:InitialPublicOfferingPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 8, 2021, the Company completed an initial public offering (&#x201c;IPO&#x201d;) in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6120adf3-28bc-45fa-afb2-4c551959185a" contextRef="C_2b011e3d-095a-448f-a28b-10116452cf0e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,500,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91a5bd24-78e4-4863-99c1-6d5bf9697fea" contextRef="C_f9b6d952-91a3-4a16-ba7e-88b297d8e0b1" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">16.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_211bd13e-82bd-46c7-917e-f68c85bc23fd" contextRef="C_762248a9-dd67-46d8-b8ac-e8d11ca59329" name="pyxs:GrossProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">168.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company raised approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_01984122-8302-403a-84f0-f7e6c58ebbc3" contextRef="C_762248a9-dd67-46d8-b8ac-e8d11ca59329" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">152.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in net proceeds after deducting underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7624d22-9682-477d-b812-83542b73a4be" contextRef="C_2b011e3d-095a-448f-a28b-10116452cf0e" name="pyxs:UnderwritingDiscountsAndCommissions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and offering expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2354df97-9b26-4651-a27c-1bdee6a06601" contextRef="C_2b011e3d-095a-448f-a28b-10116452cf0e" name="pyxs:StockIssuanceExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon closing of the IPO, all of the outstanding shares of Series A Convertible Preferred stock (&#x201c;Series A Preferred Stock&#x201d;), and Series B Convertible Preferred Stock (&#x201c;Series B Preferred Stock&#x201d;) automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3b4cf24-795b-4074-b7b6-eecd4ade0e76" contextRef="C_d16739b1-097f-4ebc-b79f-81d904a831e7" name="pyxs:NumberOfCommonSharesIssuedUponConversionOfPreferredStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">20,056,145</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock of the Company. Subsequent to the closing of the IPO, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a793bbe5-b79e-44b7-be33-ba92345f72c5" contextRef="C_13a4aa5e-911a-4c5d-9086-7de944870e14" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of convertible preferred stock outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the closing of the IPO, the Company filed an amended and restated certificate of incorporation (&#x201c;Amended Certificate of Incorporation&#x201d;) to change the authorized capital stock to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_939c204c-6d65-4065-a2e1-987cd3fc4f12" contextRef="C_2bb52469-04b7-49d0-857a-43447b7272be" name="us-gaap:CapitalUnitsAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96eea108-c658-4d6e-a50f-db52829b39b1" contextRef="C_2bb52469-04b7-49d0-857a-43447b7272be" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">190,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> are designated as voting common stock and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86e09246-6d9e-4bae-b115-5a1a9c384251" contextRef="C_2bb52469-04b7-49d0-857a-43447b7272be" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> are designated as undesignated preferred stock, all with a par value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a441a29e-e02d-43b9-8e8e-7d17abf99261" contextRef="C_2bb52469-04b7-49d0-857a-43447b7272be" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_6508b6ae-df7f-42b1-aa09-5695482fab4b" contextRef="C_2bb52469-04b7-49d0-857a-43447b7272be" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23050be1-32a6-4ed3-b02c-9875798b10d6" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="pyxs:LiquidityPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6c3723ae-898c-4671-9a2d-11b258bdda46" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">91.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f5e1cbe-1cc5-4bad-9004-1eb452affac4" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">76.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1aacec5-563b-4887-bc8d-8379a49feabe" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">12.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, the Company has primarily financed its operations through the sale of convertible preferred stocks and the proceeds from IPO. The Company has not generated any revenues to date and does not anticipate generating any revenues unless and until it successfully completes development and obtains regulatory approval for its current or any future product candidates. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to expand its research and development programs, business development activities and develop its product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company currently expects that its existing cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bc216805-209e-41c5-b9dd-96c12161da83" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">274.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021 will be sufficient to fund its operating expenses and capital requirements at least twelve months from the date these consolidated financial statements are issued. Additional funding may be necessary to fund future clinical and preclinical activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company plans to continue to fund its losses from operations and capital funding needs through issuance of equity securities, convertible or debt financings or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ce32211-f35c-4ce7-8228-0fcca59aed0e" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db3f7fbf-fa77-42a4-87ed-877642f0bafc" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s fiscal year ends on December 31 and its first three quarters end on March 31, June 30 and September 30. The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Section 107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ad66a1c-ee51-44d3-8016-0208e8199d14" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expense, and related disclosures. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, derivative liability, research and development accruals, operating leases, assessment of the useful lives of property and equipment, valuation of deferred tax assets and liabilities, impairment of investment in joint venture, and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, the management considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the year ended December 31, 2021. However, the extent to which the COVID-19 pandemic may directly or indirectly impact the Company&#x2019;s financial statements is highly uncertain and subject to change.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Actual results could differ from those estimates and there may be changes to management&#x2019;s estimates in future periods.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11fc562b-0650-4be6-869f-d4de0cb9c6de" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="pyxs:RisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to risks common to early-stage companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key suppliers for active ingredients and third-party service providers such as contract research organizations, protection of intellectual property rights and the ability to make milestone, royalty or other payments due under any license, collaboration or supply agreements.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ba62724-1cb8-4e49-8695-ad5f722c6f15" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risks</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company&#x2019;s cash and cash equivalents are held at an accredited financial institution and the Company has not experienced any losses in such accounts. The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company&#x2019;s cash equivalents consist primarily of short-term money market funds held in accredited financial institutions. The Company believes it is not exposed to any significant risk in cash and cash equivalents.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3e2d0ab-d6c3-49dc-a187-ac52997f2377" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all short term, highly liquid investments with original maturities of 90 days or less to be cash equivalents. Cash equivalents consist primarily of money market funds as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3b5b8a7-690f-493a-824e-3b9abf682def" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principle or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, the first two are considered observable and the last is considered unobservable:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></ix:exclude><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9e3561b-756b-4b18-8503-3b249382c134" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d3b7541-fac9-4e45-b26f-5a7c6c144c4a" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="pyxs:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the related assets as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:73.139%;"></td>
          <td style="width:1.898%;"></td>
          <td style="width:24.963%;"></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Estimated Useful<br />Life (Years)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a03809f-8887-4e34-9bf5-71692969b4fd" contextRef="C_152d9614-3fcc-42d6-ad59-684db0e1410f" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and office equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78d0f3b4-c251-493c-a041-d1e3865bcdd5" contextRef="C_ea67ab21-1afc-421d-9c63-09eb80e2cfd0" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f22eac62-a7d5-422d-9535-3e3eea40fe36" contextRef="C_c8cf8329-d1fb-4956-86aa-e52d9990243c" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of remaining life<br />of lease or useful life</span></ix:nonNumeric></span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and amortization expense is included in research and development and general and administrative expenses. Major additions and upgrades are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are expensed as incurred. Upon retirement or sale, the cost of assets disposed of, and the related accumulated depreciation and amortization are removed from the respective accounts and any resulting gain or loss is included in income (loss) from operations.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5495aa31-2ac5-4bff-81d8-a914175ca7a8" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates the long-lived assets, which consist of property and equipment and operating lease right-of-use assets, for impairment at least annually and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. Management then determines whether the remaining useful life continues to be appropriate, or whether there has been an impairment of long-lived assets based primarily upon whether expected future undiscounted cash flows are sufficient to support the assets&#x2019; recovery. Recoverability of these assets is measured by comparison of the carrying amount of the asset to the future undiscounted cash flows the asset is expected to generate. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. The Company recognized </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d7b200d-023d-4f57-9bfc-82af6dd7a1c8" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5e48f387-cf6e-4851-bcf5-129b9c074a6b" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment losses for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_455378d3-045e-4aa8-868a-002dd1f0a38c" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lease right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are initially recognized and measured based on the present value of the future fixed lease payments over the expected lease term at the commencement date calculated using the Company&#x2019;s incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. The Company determines the lease term as the non-cancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease ROU assets also include any initial direct costs incurred and any lease payments made on or before the lease commencement date, less lease incentives received. Operating lease ROU assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. The Company accounts for lease and non-lease components as a single lease component for all its facilities leases. The Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a014d39d-b70f-4056-9f43-7d3dd9955e94" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="pyxs:NumberOfFinanceLease" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_181929bf-a4b1-4cef-965a-311e1c28c454" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="pyxs:NumberOfFinanceLease" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> finance leases as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8bd7d98a-0c4c-4272-9302-d6cecab2159b" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investment in Joint Venture</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investment in the Company&#x2019;s joint venture is accounted for using the equity method of accounting. The Company </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">apply the equity method of accounting to investments when the Company has significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">equity</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">method</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">investment</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the equity method, investments are initially recorded at cost and are adjusted for dividends, distributed and undistributed earnings and losses, and additional investments. In the event the Company&#x2019;s share of a joint venture&#x2019;s cumulative losses exceeds the Company&#x2019;s investment balance, the balance is reported at zero value until proportionate income exceeds the losses. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_63503608-3851-4e63-9463-b90ff689ce84" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingencies</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company, from time to time, may be a party to various disputes and claims arising from normal business activities. The Company continually assesses disputes and claims including resulting litigation to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the contingencies, including an estimable range, if possible.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed83cf87-3d5d-420c-8598-acd76c5706d0" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company expenses research and development costs as incurred. The Company&#x2019;s research and development expenses consist primarily of license fees to acquire intellectual property which does not meet the definition of intangible assets and costs incurred in performing research and development activities, including personnel-related expenses such as salaries, stock-based compensation and benefits, facilities costs, depreciation as well as external costs for outside vendors engaged to conduct preclinical development activities and license fees. The Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and efforts expended pursuant to the terms of the contractual arrangements. Payments under some of these contracts depend on preclinical trial milestones. There may be instances in which payments made to the Company&#x2019;s vendors will exceed the level of services provided and result in a prepayment of expenses. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or prepaid expense accordingly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8c8af615-9852-4135-a198-ba96eebb15f6" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company maintains an equity incentive plan as a long-term incentive for employees, consultants, and directors. The Company accounts for all stock-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The grant date fair value of the stock-based awards with graded vesting is recognized on a straight-line basis over the requisite service period. The Company recognizes forfeitures related to stock-based compensation awards as they occur and reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs. The Company classifies stock-based compensation expense in the statement of operations in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company values its stock options with service conditions using the Black-Scholes option pricing model. The Company use certain assumptions to determine fair value of the stock options pursuant to the Black-Scholes option pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate, expected dividend yield and the fair value of the Company&#x2019;s common stock. Since the Company has no option exercise history, the Company uses the simplified method described in the SEC&#x2019;s Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-Based Payment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(&#x201c;SAB 107&#x201d;), to determine the expected life of the option grants. The Company lacks sufficient company-specific historical and implied volatility information. Therefore, the Company estimates the expected stock volatility based on the historical volatility of a publicly traded set of peer companies. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. As the Company has never paid and does not anticipate paying cash dividends on its common stock, the expected dividend yield is considered as zero.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Prior to the completion of the Company&#x2019;s IPO, the fair value of the Company's common stock which is one of the key input in Black-Scholes option pricing model, was determined by the board of directors with input from management and based on certain assumptions including probability weighting of events, business and market conditions, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. The Company used 409A valuations to determine the fair value of the shares of common stock. The 409A valuations were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;font-style:italic;">Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">. After completion of the IPO, on October 8, 2021, the Company uses the fair value of its publicly traded common stock to determine grant date fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For restricted stock awards issued pursuant to standalone restricted stock purchase agreements, the fair value of each award was estimated based on the estimated fair value of the Company&#x2019;s common stock, less the amount paid by the grantee. The Company recognized deposit liability for restricted stock awards issued pursuant to standalone restricted stock purchase agreements. As the awards of restricted stock vest, the Company reclassifies the deposit liability to additional paid-in capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d7a57aa9-8590-4331-902e-94ba50851b61" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes in accordance with FASB ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (&#x201c;ASC 740&#x201d;), which requires the use of the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between amounts in the consolidated financial statements and the tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income tax (benefit) expense in the consolidated statements of operations and comprehensive loss in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e710380-89af-40b8-b43c-b7bd3d6643ea" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="pyxs:ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Classification and Accretion of Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Classification of the Company&#x2019;s convertible preferred stock was treated as mezzanine financing and not as part of stockholders&#x2019; equity (deficit) because the holders of such shares had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock was not redeemable, except in the event of certain deemed liquidation events enumerated in the Company&#x2019;s certificate of incorporation. Because the occurrence of a deemed liquidation event was not probable, the carrying values of the convertible preferred stock were not accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares of preferred stock were automatically convertible into shares of common stock at the earlier of (i) the closing of a firm-commitment underwritten public offering resulting in at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_999368f6-aa31-4d56-9a89-9e759120a7e6" contextRef="C_4a74247c-2b25-4a52-afe0-244e457c4f7f" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of gross proceeds in the aggregate to the Company, prior to deductions for underwriting discounts, commission and expenses or (ii) the date and time, or occurrence of an event, specified by a vote of the Series A and Series B Stockholders. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon closing of the IPO, all of the outstanding </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A and Series B </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">convertible preferred stock automatically converted in</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to common stock, resulting in </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32d3e388-2945-4dee-b2e2-de8d2bcfcaa2" contextRef="C_13a4aa5e-911a-4c5d-9086-7de944870e14" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> outstanding convertible preferred stock as of December 31, 2021.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f0241cf-b40f-4f06-8c23-f16e99782dc6" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company follows the two-class method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the diluted weighted average number of common shares outstanding for the period, including potential dilutive common shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s participating securities contractually entitle the holders of such shares to participate in dividends but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12197a84-7146-43ff-ad5c-74e0d807f918" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2020, the FASB issued ASU 2020-01, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments &#x2014; Equity Securities (Topic 321), Investments &#x2014; Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The new guidance addresses accounting for the transition into and out of the equity method and measuring certain purchased options and forward contracts to acquire investments. This ASU is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c4953ef-48e0-43d6-b354-1259e09c3a58" contextRef="C_3e0e6445-8830-4b8b-9312-a6c3f7385eae" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopted</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> this ASU from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da9bc9ae-3089-4f21-a3a7-51d656467cd8" contextRef="C_3e0e6445-8830-4b8b-9312-a6c3f7385eae" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and the adoption did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91418e0a-6701-4a77-a105-ce450b3d65b6" contextRef="C_3e0e6445-8830-4b8b-9312-a6c3f7385eae" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have any impact on the Company&#x2019;s consolidated financial position, results of operations, or cash flows.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df007390-d93e-4cee-b774-bbe099e2aeb0" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="pyxs:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(&#x201c;ASU 2016-13&#x201d;), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses on available-for-sale debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. As an emerging growth company, ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2022, and early adoption is permitted. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is currently evaluating the new standard and expects it to have no material impact on the Company&#x2019;s consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC did not, or are not expected to, have a material impact on the Company&#x2019;s unaudited consolidated financial statements and related disclosures. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31d821dd-e6f8-445e-ae53-edca3ac7dbe9" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="pyxs:LicensingAgreementsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Licensing Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The University of Chicago Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2020, the Company entered into a license agreement (the &#x201c;University License Agreement&#x201d;), as well as a sponsored research agreement, with the University of Chicago (the &#x201c;University&#x201d;) to obtain an exclusive license under certain patents resulting from research performed, in-part, by the Company&#x2019;s scientific founder, as well as a non-exclusive license to certain know-how and materials relating thereto. Under the terms of the license, the Company has the global right to develop and commercialize products that are covered by a valid claim of a licensed patent, incorporate or use the licensed know-how and materials or are known to assess, modulate or utilize the activity of certain specified biological targets.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In partial consideration for the license from the University, the Company issued to the University </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8620594-7dfe-40fb-89bb-bc3a2cb3778d" contextRef="C_1ca021f9-876b-4a5b-8dc2-fcb1ec552bde" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,919</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock in 2020. The Company recorded the value of the shares issued of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89169314-4259-4bcf-add5-0688b1469d3b" contextRef="C_d235112b-d87b-410d-8d79-ca05e714f0dd" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">as research and development expenses during the year ended December 31, 2020. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5390a0bc-7a88-47bc-8732-80234bd5ae84" contextRef="C_1662ef99-8778-4709-9b9e-c988faaab66e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t incurred any expenses relating to the University License Agreement during the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Pursua</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">nt to the University License Agreement, the Company is obligated to pay to the University an annual maintenance fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1243f0c-9309-45ee-85bd-9af1a93e7dc1" contextRef="C_1ca021f9-876b-4a5b-8dc2-fcb1ec552bde" name="pyxs:AnnualLicenseMaintenanceFees" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">10,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> commencing on the third anniversary of the effective date, potential development and commercial milestones of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9c6e7cda-2c8b-4ad8-bfbc-bc3210fc4fd0" contextRef="C_ede49b60-05ec-496a-8366-21adc55138b6" name="pyxs:PotentialDevelopmentAndCommercialMilestonePayment" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">7.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as well as running royalties on net sales of licensed products at varying rates ranging from less than a percent to the low single digits, subject to a minimum annual royalty of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7be22d89-bcc7-4f9f-980d-ee1aba721001" contextRef="C_72eb1cad-9bfc-44a0-9b07-b1629f06a05d" name="pyxs:MinimumAnnualRoyaltyFees" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during certain years following the effective date. The Company&#x2019;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until: (1) for licensed products covered by a valid claim of a licensed patent in a given country, the expiration of such valid claims; and (2) for all other licensed products, ten (</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7055879b-7000-42b7-98b8-a05432f0f9ff" contextRef="C_1ca021f9-876b-4a5b-8dc2-fcb1ec552bde" name="pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) years from the first commercial sale of a licensed product in a given country. The Company is also obligated to pay the University a percentage of certain sublicensing revenue ranging from low- to mid-teens based on the date of entering into the applicable sublicense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assessed the milestone and royalty events under University License Agreement as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020, and determined that </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9767cc2b-75f7-4c6d-bab0-1177f47c0d10" contextRef="C_9848985a-6cbf-4efd-a97b-7350766a6a66" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_225eb254-4ff8-4e19-a62f-79adacbfda59" contextRef="C_35ae1bff-4ac3-4b11-b994-17b32b210d6c" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such amounts were required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pfizer, Inc. Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company entered into a license agreement, as amended (the &#x201c;Pfizer License Agreement&#x201d;) with Pfizer, Inc. (&#x201c;Pfizer&#x201d;) for worldwide development and commercialization rights to antibody drug conjugate (&#34;ADC&#34;) product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates. The Pfizer License Agreement became effective for the Company in March 2021. The Company&#x2019;s rights are exclusive with respect to certain patents owned or controlled by Pfizer covering the licensed ADCs. Pfizer has also granted the Company a non-exclusive license to use Pfizer&#x2019;s ADC technology platform to develop and commercialize the licensed ADCs and licensed products. The initial licensed targets include CD123 and extra domain B (EBD of fibronectin) and the Company has the option to expand the scope of its license to add additional licensed targets that have not been licensed to a third party or are not the subject of a Pfizer ADC development program. In March 2021, the Company entered into an amendment to the Pfizer License Agreement to include additional know-how within the scope of its license. The Company determined that substantially all of the fair value of the Pfizer License Agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development associated with the agreements. Thus, the Company recorded payments made under the License Agreement as research and development expenses in the consolidated statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Pfizer License Agreement, the Company paid a combined $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c67ab746-9845-4ca8-9a12-02da2895777b" contextRef="C_9b924cc1-929b-4476-912e-1c2d54d69e3d" name="pyxs:PaymentForLicenseFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for license fee, which was recorded in research and development expense in the consolidated statement of operations and consists of an upfront fee equal to a cash payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03dfd7a8-bd09-408d-82ec-da33061b2cb2" contextRef="C_93d8ea59-4f70-435a-800d-684dd2b13280" name="pyxs:UpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab16d50c-f84f-4d56-be1c-d3d197284be4" contextRef="C_34a68bd8-42d2-4884-8c43-a95f93b476df" name="pyxs:IssuanceOfConvertiblePreferredStockShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">12,152,145</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B convertible preferred stock with a value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf93045c-9bb4-4e12-bf4e-ae75f95275b1" contextRef="C_404bc14b-3eaf-4e94-a492-dc8d161a716a" name="pyxs:ConvertiblePreferredStockSharesIssuedValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in 2021 to Pfizer, and is obligated to pay future contingent payments and royalties, including up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_209f5733-e5d1-4a1d-ba5d-2f67ada13756" contextRef="C_71c85092-8520-4659-ae48-430a857097a7" name="pyxs:AggregateMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">660</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in milestones for the first four licensed ADCs. Additional ADC targets may be licensed for a nominal upfront and milestones. Additionally, if products are launched, the Company will pay Pfizer tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to mid-teens. The Company&#x2019;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0969149c-7ce0-4dbb-bc60-603718a98f0a" contextRef="C_a1a3afb5-1db0-4c36-83ed-2876af7a7097" name="pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. The Company is also obligated to pay Pfizer a percentage of certain sublicensing revenue ranging from </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ed24da66-598f-4196-b4de-f075ef13fa96" contextRef="C_5062dfa7-6cc0-4b79-8af4-5b4183bdb254" name="pyxs:SublicensingRevenuePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">thirty</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> percent to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the Company effected a change of control transaction or sold all or substantially all of its assets relating to the Pfizer License Agreement within 12 months from the effective date or closing of the IPO, the Company would have been required to make a one-time payment to Pfizer of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c66969c-64e4-4dbf-8ce9-2b486bf2264d" contextRef="C_073f9fdb-14b4-4632-8088-b25125b7ae60" name="pyxs:OneTimeMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_715327c6-91ef-4736-a997-8ccb1f147509" contextRef="C_8e0fe443-9856-4876-8a03-0c6ae852fad0" name="pyxs:OneTimeMilestonePayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such event took place during the year and the one-time payment was not required.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assessed the milestone, royalty and other events under Pfizer License Agreement as of December 31, 2021, and determined that </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b306df5-41ee-4362-9df2-1d72fb9c93bd" contextRef="C_8e0fe443-9856-4876-8a03-0c6ae852fad0" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such amounts were required.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">LegoChem Biosciences, Inc. Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company entered into a license agreement (the &#x201c;LegoChem License Agreement&#x201d;) with LegoChem Biosciences, Inc. (&#x201c;LegoChem&#x201d;) pursuant to which the Company licensed worldwide (other than Korea) development and commercialization rights for LCB67, an ADC product candidate targeting DLK-1, and products containing the licensed compound. The Company has the right to request that LegoChem use commercially reasonable efforts at the Company&#x2019;s cost to modify the licensed compound if there are certain technical failures of the licensed compound that the Company believes are attributable to the linker or the payload used in the licensed compound, and the modified compound will replace the unmodified version as the licensed compound. In February 2021, the Company entered into an amendment to the LegoChem License Agreement to include additional patents within the scope of its license. The Company determined that substantially all of the fair value of the LegoChem License Agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development associated with the agreements. Thus, the Company recorded payments made under the LegoChem License Agreement as research and development expenses in the consolidated statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the LegoChem License Agreement, the Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_756a5c83-7e62-4aa7-b6ee-6178a969e780" contextRef="C_3bfacc42-7016-4be9-8736-1d6d637d68e5" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in 2020 and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f7a8dfc-781d-4efb-8143-1ef5737b2686" contextRef="C_7063a67b-e132-4dc0-b804-27e9078dfd3e" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in 2021 and is required to purchase certain initial quantities of licensed product from LegoChem for an estimated cost of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8c226b7-ceb0-46b5-83f7-8f62920aae8c" contextRef="C_8718a804-c532-497e-b1b1-1415b90f394e" name="pyxs:ResearchAndDevelopmentLicensedProductEstimatedCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recorded upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7933c980-8675-43c3-b9aa-86c8a1db3639" contextRef="C_60a4f247-f1f7-4230-bdbf-18fce866817f" name="pyxs:UpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in 2020 and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d6d29de-569b-4a63-bec1-7f62e1295613" contextRef="C_8b95c8e6-2fe9-4e6e-b9b7-23db66016497" name="pyxs:UpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in 2021 as research and development expenses. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_725b09c0-f28c-4e77-b6eb-738e4b465666" contextRef="C_7063a67b-e132-4dc0-b804-27e9078dfd3e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="1" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> expenses incurred related to the manufacturing of the initial quantities of licensed product for the year ended December 31, 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company is also obligated to pay up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5c41f55-8e38-45b5-af54-cfff21eaeab5" contextRef="C_86a53aad-9b46-45bf-8f94-a9e963b999b2" name="pyxs:MilestonePaymentsPayableUponCertainAchievements" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">284.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to LegoChem if certain development, regulatory and sales milestones are achieved, as well as tiered royalties on net sales of licensed products ranging from mid-single digit to high-single digit royalty rates. The Company&#x2019;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until the latest to occur of: (1) the date of expiration of the last valid claim of a licensed patent covering the licensed product; (2) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_caedbcdb-d1dc-46e6-bc00-74836e15e523" contextRef="C_3bfacc42-7016-4be9-8736-1d6d637d68e5" name="pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from first commercial sale; and (3) the expiration of regulatory or data exclusivity. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assessed the milestones and royalties under the LegoChem License Agreement as of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and determined that </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58f72048-fef6-40b2-b609-93efb2e4f6a8" contextRef="C_5a579548-3c9a-4e1b-bf3e-98869a574f78" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e0099029-7a65-413d-889a-57c94af1d2fd" contextRef="C_8718a804-c532-497e-b1b1-1415b90f394e" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such amounts were required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company also entered into an opt-in, investment and additional consideration agreement with LegoChem (the &#x201c;Opt-In Agreement&#x201d;). Pursuant to the Opt-in Agreement, the Company settled $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7efcf7fa-9517-43e0-b7a4-83296125168e" contextRef="C_ed7e79ef-96fa-4eef-919a-c352a3235260" name="pyxs:UpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of upfront payment for license fee through the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cfd48cea-75ac-4ecc-83bf-aa388f3e5945" contextRef="C_97f1d379-1c6e-4fb0-8b48-b544858a4c77" name="pyxs:IssuanceOfConvertiblePreferredStockShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">303,804</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B convertible preferred stock in March 2021. The Company is also obligated to pay LegoChem a percentage of certain sublicensing revenue ranging from thirty percent to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense, which percentage may be increased to up to fifty percent for any upfront payment from a sublicensee under certain circumstances. LegoChem exercised its option in December 2020 under the Opt-In Agreement and paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef64171c-77d4-443c-9947-54982459ea84" contextRef="C_52f84543-c5cd-4e24-8f62-15582b3c85f2" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to the Company in April 2021, in exchange for the right to receive a milestone payment (the &#x201c;Extra Milestone Payment&#x201d;) of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_301f0f08-0a44-4ac1-8462-329b3ece893c" contextRef="C_32d8b9f9-d8e4-44c1-b86e-a4702ec224b4" name="pyxs:ExtraMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the earliest to occur of certain events, including the date of pricing or offer of the first public offering of the Company's common stock or if the Company is the subject of a change in control transaction. The Company determined that the Extra Milestone Payment meets the definition and recognition condition of derivative under ASC 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Derivatives and Hedging&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for which there was a binding contract and firm commitment as of January 2021. An initial derivative liability was recognized for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7d11e74-2f7b-4ba4-a451-a7cc0d964427" contextRef="C_673e5066-a0a1-4324-b5c4-c5590d5143fa" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million with an offset to research and development expenses in January 2021. The derivative liability was re-measured at each reporting date, with changes recorded in &#x201c;Other (expense) income&#x201d; in the consolidated statements of operations and comprehensive loss. Upon the Company&#x2019;s IPO in October 2021, the Extra Milestone Payment event triggered resulting in realization of derivative liability, for which the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d9fe76a-c7cb-4ed2-a97b-a2bef08cf19b" contextRef="C_5a579548-3c9a-4e1b-bf3e-98869a574f78" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million within accounts payable as of December 31, 2021 and subsequently paid in January 2022. The Company assessed the remaining milestones and royalties under the Opt-In Agreement as of December 31, 2021 and determined that </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1826480-56aa-4cb7-9c5d-6a018196f41c" contextRef="C_5a579548-3c9a-4e1b-bf3e-98869a574f78" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such amounts were required.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4fb90442-1db4-4472-a4d1-7b61ba65a009" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Joint Venture</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Company entered into definitive transaction agreements with Alloy Therapeutics, Inc. (&#x201c;Alloy&#x201d;) and Voxall Therapeutics, LLC (&#x201c;Voxall&#x201d;), to finance and operate Voxall, a joint venture company formed in collaboration with Alloy to leverage the Company&#x2019;s technology and Alloy&#x2019;s ATX-Gx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.025pt;font-family:Times New Roman;">&#153; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">platform and antibody discovery services. Voxall granted to the Company and Alloy, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_13a357ea-f1a5-4277-8ad5-5ab8d09c57f5" contextRef="C_113a708f-879e-4c63-8e7a-917c6c0f4303" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the voting membership units of Voxall in exchange for certain initial contributions. The Company&#x2019;s initial contribution included $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5fda7134-89f3-417e-b115-928fa945a350" contextRef="C_2479e14f-6aa9-4a28-be71-a2c03d3cde43" name="us-gaap:EquityMethodInvestmentAggregateCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand and a non-exclusive fully paid-up license to certain intellectual property owned or controlled by the Company and the execution of the services agreement to enable the collaboration with Voxall. Alloy&#x2019;s initial contribution included $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d00af995-d067-4ea5-8ad8-fba6e86193b1" contextRef="C_113a708f-879e-4c63-8e7a-917c6c0f4303" name="us-gaap:EquityMethodInvestmentAggregateCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand and the execution of the Alloy license agreement and the Alloy services agreement to enable the collaboration with Voxall. Voxall is governed by a board of directors consisting of an equal number of the Company&#x2019;s representatives and Alloy&#x2019;s representatives. The protective provisions under Voxall&#x2019;s operating agreement require the approval of both the Company and Alloy before Voxall may take certain actions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounted for investment in Voxall under the equity method of accounting. The initial contribution was recorded as &#x201c;Investment in equity method investment in joint venture&#x201d;. Additionally, the Company has recognized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ddd8b262-9b83-4432-b188-dee8568f5d7a" contextRef="C_1004cb6e-29cf-4ad9-a179-5780de31070c" name="pyxs:ServiceFeeIncomeFromRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million in service fee income from a related party within other income for services provided to Voxall during the year ended December 31, 2021, for which Voxall issued a promissory note to the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Voxall has incurred losses since inception and the Company&#x2019;s share in the losses of Voxall aggregated to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_412e1a13-8d0c-4c06-beee-e6b142d0014b" contextRef="C_1004cb6e-29cf-4ad9-a179-5780de31070c" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million for the year ended December 31, 2021. The Company recognized its share of losses of Voxall only to the extent of the carrying value of its investment in Voxall and the promissory note issued by Voxall, which aggregated to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d00ddd47-e3e1-4788-be88-88d259e3ae91" contextRef="C_1004cb6e-29cf-4ad9-a179-5780de31070c" name="pyxs:ProceedsFromPromissoryNoteIssued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million for the year ended December 31, 2021. The remaining unabsorbed loss will be offset against future income, if any. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d3838cd-c35c-4934-b011-41ae10a050c4" contextRef="C_1004cb6e-29cf-4ad9-a179-5780de31070c" name="us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As the Company has no commitment to fund the losses of the equity method investment, the carrying value of the equity method investment has not been reduced below zero</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b091083-448a-45a4-8348-0ba68fc9ffd2" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f51f6ff1-212d-4fba-9c92-dc81bbc0d277" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables present the financial instruments carried at fair value on a recurring basis as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively, in accordance with the FASB ASC 820 hierarchy (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.787%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.566%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.529%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.529%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.566%;"></td>
        <td style="width:0.594%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Measurements at<br />December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10d37615-4b54-432c-86fe-ce999e4865a9" contextRef="C_2ae77749-d3df-49f5-b129-e03c49c1d9ad" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">272,210</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b962b705-920a-40fd-9ec9-764164d78396" contextRef="C_a4512320-e5eb-43ea-b73f-15322d518ab6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">272,210</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Measurements at<br />December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d99f600-7ca3-4592-88e7-ffabaac17dd3" contextRef="C_c093cb7e-c886-49da-91b1-6affab2f3890" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,996</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a120273-278e-4f2f-9362-e8405af6d935" contextRef="C_928733d3-c3c5-45d1-9947-05d14b5ad5c6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,996</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s cash equivalents represent deposits in a short-term United States Treasury money market fund quoted in an active market and classified as a Level 1 asset. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_736d4d81-691c-4069-9e7b-3b06884b5fbf" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_72370c76-a218-429c-b614-84ace48b9da8" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_61ecf1ae-b425-48ad-947e-323185041875" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_67f2377f-701a-4d8e-806f-4052785058a0" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> assets or liabilities measured at fair value on a nonrecurring basis at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the years ended December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of the derivative liability was initially determined using a probability-weighted income approach and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of the derivative liability are recorded as expense within other (expense) income in the consolidated statements of operations and comprehensive loss. The significant unobservable inputs used in the fair value measurement of the derivative liability include probability of payment factors and the discount rate. Refer to Note 3, Licensing Agreements, for additional information on the derivative liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_8a0fbb6f-4c26-4838-a31e-ceeb26c651a0" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables provide a summary of changes in Level 3 fair value measurements for the year ended December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.246%;"></td>
        <td style="width:2.671%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:24.079%;"></td>
        <td style="width:0.798%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Derivative liability balance as of January 1, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Initial recognition of derivative liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f34cb26-7a69-47b0-86dd-34883e531dfc" contextRef="C_430de8ee-a6be-4373-9634-ddf883b01c5d" name="pyxs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,369</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value recorded in earnings</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8576f082-796c-4973-8265-22bf097a16db" contextRef="C_430de8ee-a6be-4373-9634-ddf883b01c5d" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,231</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transfer to accounts payable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d59b8f7f-4a0f-4838-9c70-94468b03e78e" contextRef="C_430de8ee-a6be-4373-9634-ddf883b01c5d" name="pyxs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,600</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company paid the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9a49af9-0ff9-43b9-bad8-c67264e4390f" contextRef="C_ebe69ee7-b47e-44a7-9ec7-718a9ea1d455" name="pyxs:ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of Extra Milestone Payment, for which it previously recognized a derivative liability, in January 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58965979-5214-40a6-a5d2-583ad065fca8" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:OtherCurrentAssetsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Prepaid Expenses and Other Current Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da3b3f68-f8b5-49fc-bf09-2a985773d4c2" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.657%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.254%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.244%;"></td>
        <td style="width:0.603%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Insurance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a3aa34f0-a5fc-4af9-8e5b-3e3dcd3755a8" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,763</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f8781bca-07c2-4db1-b190-d389b0ce6403" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_01276319-8c6c-44db-b7a7-10c38d873e1d" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="pyxs:ResearchAndDevelopmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">619</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ae5a769-0a60-4000-8d23-9ca6caea620f" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1d78ed3b-b87d-45f8-9ead-466aa38e9f11" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5df506a-3ca1-49e9-8088-41189c66ebf9" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,466</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69cdc881-b22f-42cb-92c0-0fdee04ef1ea" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14048b97-f474-4912-8f56-cfbf0f621024" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c2c8558-ca3b-40fc-b4bf-eaf39a27451f" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net, consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.503%;"></td>
        <td style="width:1.605%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.228%;"></td>
        <td style="width:0.798%;"></td>
        <td style="width:1.605%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.052%;"></td>
        <td style="width:0.798%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54853b22-7863-4342-90d4-9dbdcf67e6a9" contextRef="C_d95ea6c8-6b64-4ea3-9e32-ba4722916902" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,804</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f00669d8-de94-460c-bf48-53bcedc4f50f" contextRef="C_b95ae457-b724-40e9-a605-8b606684a52e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,264</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54af8afb-1683-4ea0-8489-5b94ff1adf22" contextRef="C_0961fd9e-e455-4080-b194-733e8f9aaef7" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">225</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb22ff9c-31fa-4962-b471-5196fa0a7516" contextRef="C_c3a5fd86-4b2f-48b5-906e-e21ff053ea3f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">213</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and office equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ef8762e-de0d-4c05-baea-762b06bb7be1" contextRef="C_bc36a634-547c-4f28-b1db-420db4a8e3cb" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a7ee766-8ac5-457c-93ea-653b6d8fb0fb" contextRef="C_75951ce6-a95a-42de-8088-a5a897b8380d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2daa52a9-da18-4e89-b1c8-c9f201ac10dd" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,123</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58f90ad6-0017-44bb-bbd9-4093d0aa9f19" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,572</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0863952a-2e2e-40a2-908d-5e68a854ed38" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,116</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98dd5569-b892-468e-af66-95dfb000dafa" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">469</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2c607ec5-89de-4ef2-a656-a4b4739df546" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_276547dd-aad9-4354-bdbc-3eadd3ca2f44" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,103</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense for the years ended December 31, 2021 and 2020 was</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7392682-2ac0-4f60-8209-2615dfa24cfd" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b5cbf4c-7445-4613-a7eb-1309bd5b44e2" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7bdecb96-695c-4068-95ce-c8857a150661" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Accrued Expenses and Other Current Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12436fe0-b9ad-44c3-9418-5cd919327abf" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="pyxs:SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.648%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.254%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.254%;"></td>
        <td style="width:0.603%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee compensation and benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0f6c015-1a54-4ba2-bbf9-8a46708ba5e2" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,963</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac366af7-2327-49aa-9059-0fa8bd8a39e6" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,002</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">External research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8cf6e534-80e5-4a23-8134-48ce895f5345" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="pyxs:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,381</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52b1f0e7-45b8-4138-977c-39cb2b9c4be6" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="pyxs:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">712</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3de9c81-b65c-42c3-836d-7c54f9380079" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">982</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d43ebc3d-f7f9-46ca-bc02-f94464112de9" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">167</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0a5bafb-e030-43d8-b216-eabd01ace1d7" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">266</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d49b3f0-5bcd-4e20-982a-b0a60a05f80c" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">116</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_754fc51e-c652-4454-b033-6ebfe0893084" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,592</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0844b55-0684-4f2e-8402-61ff08cd438e" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,997</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ec2c4a0-90c5-4f37-913b-cbf4932c663d" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. Operating Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9397d920-ef60-4e07-9282-2ef80973541d" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="pyxs:NumberOfOperatingLease" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b5447c7-c235-41fb-966e-3705e33bd98a" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="pyxs:NumberOfOperatingLease" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating leases, respectively, where the Company is the lessee or sublessee, for office and laboratory space. Lease terms are through </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d8ac6f90-b787-4c13-9354-d45ae1d62fbc" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="pyxs:LeaseExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_590868f1-2322-4f64-8960-20225ce0db46" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="pyxs:NumberOfFinanceLease" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ec999906-9f69-4bcd-ba7a-e12e92627dde" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="pyxs:NumberOfFinanceLease" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> finance leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b4ce9c8e-517e-4ca2-ab7f-87e5eee8fb32" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of lease expense were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.422%;"></td>
        <td style="width:1.605%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:11.984%;"></td>
        <td style="width:1.994%;"></td>
        <td style="width:1.605%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:11.984%;"></td>
        <td style="width:1.994%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_92f6f19c-863f-4485-8b7a-1c72a065b0d4" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">650</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a197c38c-62fd-4c26-baab-cd4100670cda" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">497</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6272b7a0-b41a-4f82-9c8e-1a6d41c2e56c" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dda1cd69-2811-44c2-ad08-b437a9aca4d3" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">146</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease cost (1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1705cc8f-18fe-443e-b8d6-3e583f9850d8" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17b2d502-1157-47ab-87f7-2134a0019cc3" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_19039eed-3064-43fb-984b-eff365018cc9" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">730</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8aa65485-1154-4b2d-86c3-1bcdd79ed339" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">713</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other information</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use asset obtained in exchange for new operating<br />&#160;&#160;&#160;lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58420ef6-273a-48a0-bccb-a3d8f8182616" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,186</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of lease liabilities, included<br />&#160;&#160;&#160;in operating cash flows</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ebbc539c-f417-40f9-b2f8-5c101fe70230" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">663</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c21f6e60-f5e2-4e34-b122-d27d90243763" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">484</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef90a04e-7dfa-4463-b4ad-af6b7ae2cb67" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.25</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d06d2084-af84-44a4-8581-9bca0a7e342d" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.25</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99edc8e3-2fcb-4bd9-a57b-b15089737a32" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">10.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e3879ff2-9af0-4584-9724-fcf07d315bd0" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">9.98</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:3.0pt;border-bottom:0.750pt solid;margin-right:83.704%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_1d02fe45-14e7-49c1-acb0-ad6b9e3a7f80" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Variable lease cost includes common area maintenance charges</span></ix:footnote><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></div></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e13c7abc-c69f-468b-885d-e110abda8d05" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Maturities of lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.019%;"></td>
        <td style="width:1.939%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:16.039%;"></td>
        <td style="width:0.798%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ending December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating lease</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85fd8b00-53a9-4bac-ab44-2176d7185dda" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">168</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de80709a-33da-435d-93da-d61baa122261" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">168</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: amount representing imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ecb18948-f04f-4007-b2e1-d4b5dd3d64e6" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total future minimum lease obligations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a5d05fc-9c85-4d00-9da9-ac1e3afc4d07" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to above, on September 29, 2021, the Company entered into a lease agreement for an office and laboratory space in Boston, Massachusetts. The lease will expire on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_271dcf5a-3573-4ef5-96ec-54423ddaa5df" contextRef="C_7f621107-7e12-4f37-bdcf-0e86434b9852" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2032</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and has scheduled rent increases each year of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c5c519e-4287-4e8f-b386-83c0ef108104" contextRef="C_7f621107-7e12-4f37-bdcf-0e86434b9852" name="pyxs:RentIncreasePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ea7eca8-f1f7-43f5-bcc0-3001ec7874e3" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c46cffe-f79c-4776-9815-f2dd3c6d72a0" contextRef="C_c05c67d1-e528-474e-8817-657f048332c3" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> option to extend the lease beyond December 31, 2032.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The future undiscounted operating lease payments (base rent) under the lease agreement is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3f3fea5-6f85-460e-9ff5-39da0bab8f94" contextRef="C_c05c67d1-e528-474e-8817-657f048332c3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">33.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million over an initial lease period of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74b10833-d3b9-4b7a-a1dd-1009887f4c13" contextRef="C_c05c67d1-e528-474e-8817-657f048332c3" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company will record the right-of-use asset and operating lease liability upon obtaining the possession of the property, which it expects to occur in the second quarter of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_52e3ac2c-9d3a-4664-9916-455111558b45" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:PreferredStockTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Series A Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2019, the Company entered into a securities purchase agreement (as amended, &#x201c;Series A Agreement&#x201d;) with certain investors to sell shares of Series A convertible preferred stock (&#x201c;Series A&#x201d;) at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5359e4c-3e1d-433a-88a8-b310ad448b35" contextRef="C_931efd56-1c76-41f4-bf5d-55380b0d9598" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">0.9681</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. In June and July 2019, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b41dc18-5211-427f-a6de-961508ae030a" contextRef="C_c28b8bc5-5c32-45fe-b131-2c2fbbfa9d56" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_c92a6d74-246c-4003-a0f5-382c506b3b73" contextRef="C_931efd56-1c76-41f4-bf5d-55380b0d9598" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,724,925</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series A to institutional investors at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69a4ab3b-a3cc-4df4-a3c3-34c97ba00d6b" contextRef="C_c28b8bc5-5c32-45fe-b131-2c2fbbfa9d56" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_811e19fd-2000-43dc-be95-31121db57bb8" contextRef="C_931efd56-1c76-41f4-bf5d-55380b0d9598" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.9681</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for gross cash proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c34c7866-a475-4fec-809e-209015080ce5" contextRef="C_b4f7a85e-0b7b-4341-87a1-c762f3633c3c" name="pyxs:GrossProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">22.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, less issuance costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5034021-d8bd-4389-9eb8-905e7ce7a357" contextRef="C_b4f7a85e-0b7b-4341-87a1-c762f3633c3c" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, resulting in net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04a9c40f-4adf-45e6-b1f0-0047daad39f2" contextRef="C_b4f7a85e-0b7b-4341-87a1-c762f3633c3c" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. On October 1, 2021, the Company effected a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3257e42c-1a0b-4622-a8a1-8438e616c2db" contextRef="C_add39c44-72f5-4ca5-ab44-474e2dd8f88c" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bc1feaae-b4f0-4232-bfcb-7aa66a503921;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1-for-6.359</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Upon completion of the initial public offering, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f112e245-66f2-4aa0-82ac-2f30e604d148" contextRef="C_249a52df-36e5-49ab-92ea-306c0765acf5" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,724,925</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series A were converted to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6593539a-1bb6-4a91-821f-654d8382b131" contextRef="C_5a87e6b1-9e03-4ac3-8a39-debc18e92132" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,573,659</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Series B Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 5, 2021, the Company entered into a securities purchase agreement (as amended, &#x201c;Series B Agreement&#x201d;) with certain investors to sell shares of Series B convertible preferred stock (&#x201c;Series B&#x201d;) at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_950d99cc-4f0a-43c5-a83b-c00ada1dda72" contextRef="C_cffd11cd-91be-467f-9b81-32cb6d435261" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">1.6458</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. In March 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2d6a6e8-9507-48f2-adc4-1652f290a55e" contextRef="C_a39c61fa-aca6-4bf1-8634-94e72b3a3719" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">92,356,299</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B to institutional investors at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6fe1dac-c636-4dc2-b1ab-5cb406279cd0" contextRef="C_a39c61fa-aca6-4bf1-8634-94e72b3a3719" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">1.6458</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for gross cash proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d202c9e5-993a-4b15-bdf6-e609fa041573" contextRef="C_52a59c4e-168a-478f-9c0c-bb44fa171b44" name="pyxs:GrossProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">152.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, less issuance costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2423d8e0-a419-48ec-8b17-b1a1c7118d76" contextRef="C_52a59c4e-168a-478f-9c0c-bb44fa171b44" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, resulting in net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b00eb146-799c-4cf0-9730-3d3a7b57d115" contextRef="C_52a59c4e-168a-478f-9c0c-bb44fa171b44" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">151.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In addition, the Company granted </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa5ca3bd-c224-4fc3-be23-1a9d4c3cb821" contextRef="C_4173faad-0fa2-4056-a8cc-cccd57e2e301" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">12,455,949</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, or $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_edfcb1e0-c983-4af7-91a9-e3a33f0403da" contextRef="C_805ffd5b-0773-4785-8a81-7d324e3eaafa" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, of Series B convertible preferred stock through separate agreements with Pfizer, Inc. and LegoChem Biosciences Inc. On October 1, 2021, the Company effected a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b10691b2-ba4d-4b77-ae42-d312326a9a5a" contextRef="C_72b2f27a-fcc2-48bb-89ca-eed397dc0270" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_01b30c23-8e47-433b-a192-0adf8d0251a5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1-for-6.359</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Upon completion of the initial public offering, the entire outstanding shares of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da79018d-32f7-4ac1-aa25-8b9383f44b40" contextRef="C_128e59fb-2071-4047-8fbe-17d937e7523a" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">104,812,248</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of Series B were converted to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_afe94c45-0b72-442b-89a1-7a1901353e27" contextRef="C_fc3376eb-8285-406a-bbf7-1c82c1b22a7a" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,482,486</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_fa47b434-7845-4029-b10d-1eea566d471d" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stockholders&#x2019; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the closing of the IPO, the Company filed an Amended Certificate of Incorporation and authorized </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b46ec05e-448b-40a9-9113-131e877d0b71" contextRef="C_2bb52469-04b7-49d0-857a-43447b7272be" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock, with a par value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_65e6ae05-f86c-4f73-9427-8f554d330dcd" contextRef="C_2bb52469-04b7-49d0-857a-43447b7272be" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The board of directors has the authority, without further action by the stockholders to issue such shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the dividend, dividend rights, conversion rights, voting, redemption terms, liquidation preference and other rights, preferences and privileges of the shares. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a2acca6-a511-461d-b3bb-d17797a94f49" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_04deceb8-bfb0-4542-8913-24659043f9b0" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> issued and outstanding shares of preferred stock as of December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company was authorized to issue up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99a61f40-bb8d-4ec8-ba68-7c878cecbaaf" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">190,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ada70c6e-aca4-41aa-97d8-d06e3947a273" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">40,300,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock as of December 31, 2021 and 2020, respectively, of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7f9b731-bf69-4b3d-9501-cd3f348a1c9b" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,792,867</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d721dda3-6f5a-4a55-9e13-d32f825b02cc" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,177,956</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were issued as of December 31, 2021 and 2020, respectively, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1caefe84-694d-4b74-8df1-03b0fdd83fa2" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,222,881</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e7cc0989-3a00-49b3-8eda-686989dc6f85" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,289,342</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were outstanding at December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Voting, dividend and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Voting</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;Each holder of outstanding shares of common stock shall be entitled to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d787032e-b062-4b0b-9e12-586772169244" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> vote in respect of each share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reserved Shares</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f69fed3e-4011-4f8c-968a-4d7a600a5416" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="pyxs:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" escape="true" continuedAt="F_f69fed3e-4011-4f8c-968a-4d7a600a5416_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reserved the following shares of common stock for issuance:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Calibri;"><ix:continuation id="F_f69fed3e-4011-4f8c-968a-4d7a600a5416_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.41%;"></td>
        <td style="width:1.796%;"></td>
        <td style="width:0.641%;"></td>
        <td style="width:17.811%;"></td>
        <td style="width:0.641%;"></td>
        <td style="width:1.954%;"></td>
        <td style="width:0.641%;"></td>
        <td style="width:15.463%;"></td>
        <td style="width:0.641%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A convertible preferred stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c476fabc-8b9a-45e7-8262-687203d8a044" contextRef="C_ffc2f537-c19b-4a4e-86aa-33adffaef56a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,573,659</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted stock options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a5f58e2-9ecf-484a-9cd4-d2e268bea3aa" contextRef="C_b54da75b-957d-4884-98f7-3495f571051f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">618,494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b1c2786-5114-464a-a125-659d0d0b7768" contextRef="C_53514985-e3a7-4155-9770-bf7e144b7596" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">888,612</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options available for issuance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f29b131f-9d46-443d-8927-3802e28d0435" contextRef="C_bacaab47-1993-4379-b4c5-c1e4533f5d05" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,289,259</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85382ba3-2c7d-473a-a702-50e6ddd03e68" contextRef="C_3c5d682d-d0a1-45b0-b0e4-16275df3e997" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">35,585</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_732801e4-c411-48c9-a8aa-2ffcac7a6159" contextRef="C_3f4cbd78-d94e-48b1-892b-e716976eb7fc" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,926,969</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_507c0746-dce3-43c1-8ad1-87021d7fccee" contextRef="C_7ab4cd50-7dbc-450e-8807-5e18ae9fabd1" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">220,383</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15f3144d-eb47-48e9-9efd-2fe327bb34bf" contextRef="C_0419a777-abc4-43c5-941f-c166c8f4b73a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">424,595</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b29d293-12f7-476a-be5f-06154558d7cd" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,259,317</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c264e250-0828-45ff-befd-98ebc91dc2f7" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,718,239</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af664d18-ec5a-47f8-a85e-ba1c99bb15ce" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 27, 2021, the Company&#x2019;s board of directors and stockholders approved the 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;), which became effective on October 7, 2021, when the Company&#x2019;s registration statement was declared effective by the SEC. The 2021 Plan replaced the 2019 Plan as the Company&#x2019;s board of directors has determined not to make additional awards under the 2019 Plan following the closing of the Company&#x2019;s initial public offering. However, the 2019 Plan will continue to govern outstanding equity awards granted under the plan. The 2021 Plan allows the Company to make equity-based and cash-based incentive awards to its officers, employees, directors and consultants. The Company has initially reserved </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_823cedeb-8682-4358-8991-8385e4e85cdb" contextRef="C_37efc727-3d91-4336-9a3f-f491d3514c2b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,852,807</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock for the issuance of awards under the 2021 Plan. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The number of shares of common stock reserved for issuance under the 2021 Plan will automatically increase annually on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022, and continuing until (and including) the fiscal year ending December 31, 2031 by lesser of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_475bc1aa-cf3e-4231-8c36-a372a51b73ea" contextRef="C_f0325835-c766-40ad-a049-921b9832afb8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the total number of shares of common stock outstanding on December 31st of the immediately preceding fiscal year or number of shares as may be determined by the board of directors. The maximum number of shares of common stock that may be issued pursuant to the exercise of incentive options under the 2021 Plan is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9614102d-1962-4690-a86d-c942e4009c16" contextRef="C_43a98943-5b0e-4436-8f96-5a50552b1f8d" name="pyxs:MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,705,614</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, options to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ffdb890e-f18a-4ae5-8e28-dc1a1e5cfd55" contextRef="C_43a98943-5b0e-4436-8f96-5a50552b1f8d" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,515,040</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89b2b060-e4b4-4067-8d4a-8435bdb036cf" contextRef="C_b54da75b-957d-4884-98f7-3495f571051f" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">48,508</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> restricted stock units were outstanding under the 2021 plan and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_38f3f7ab-e6e4-4dfb-bee0-91356bcd9643" contextRef="C_43a98943-5b0e-4436-8f96-5a50552b1f8d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,289,259</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares remained available for future issuance under the 2021 plan.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2019 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2019, the Company established the 2019 Plan, under which the Company grant options and restricted stock to its employees and certain non-employees. The maximum number of shares of common stock reserved for issuance under the 2019 Plan was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_66c8d305-2291-485f-b302-29ad3bcfd099" contextRef="C_be0b2666-2fd2-42a7-9eb9-036c72e9e2e4" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,042,408</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options granted under the 2019 Plan include incentive stock options that can be granted only to the Company&#x2019;s employees and non-statutory stock options that can be granted to the Company&#x2019;s employees, consultants, advisors and directors. The 2019 Plan also permits the Company to issue restricted stock awards.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The exercise prices, vesting and other restrictions of the awards to be granted under the 2019 Plan are determined by the board of directors, except that no stock option may be issued with an exercise price less than the fair market value of the common stock at the date of the grant or have a term in excess of ten years. Options granted under the 2019 Plan are exercisable in whole or in part at any time subsequent to vesting. All the shares of common stock were issued under the 2019 Plan. As of December 31, 2021, options to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f8c70d32-a93c-42aa-8707-8b07a81f7a79" contextRef="C_503f6a97-2a52-4ea2-92dd-c00d66d8adf2" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,411,929</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were outstanding under the 2019 plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b4b4de3-fb20-4698-b541-6918521a7830" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes stock option activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 (in thousands, except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.848%;"></td>
        <td style="width:1.456%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:7.894%;"></td>
        <td style="width:0.798%;"></td>
        <td style="width:1.456%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:7.272%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:1.456%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:8.979%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:1.456%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:7.958%;"></td>
        <td style="width:0.603%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number of<br />Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Remaining<br />Contractual<br />Term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a2183e7-2c7f-44c5-af07-1acd79c9e8a4" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">220,383</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c6c4275-5f30-45f0-8eb0-3c1e44420fa8" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.64</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8641f5bd-f09a-46fb-bf92-b97eff841804" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.4</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1484c89-1529-41a4-9f7f-09350723584e" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">348</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca4c13db-e4bb-4d01-b290-8bd8d49cf66c" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,351,820</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_087a716d-598e-4df5-8e79-7b2421c37350" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">10.12</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d53bade1-0ea0-4c18-84db-95902169a3ae" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a176a23-7bd8-4966-acce-12f87c15194c" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">70,396</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a308223-134c-4d59-85ed-ae05c249f63a" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3e1fed3-d662-4765-be14-640cd588adee" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">574,838</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7fbb5340-deae-49c2-8cd0-a5f5edecd165" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">8.41</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_93448da5-25a8-435d-a5d7-d54f3c4b2c44" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,926,969</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_82f48f31-edd1-4c4e-8144-cbd5d9729583" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">10.03</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fec7cb4c-f0b7-497a-8219-12f00d7edb39" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_78fbbd79-1867-4c36-b9ec-51ded077b259" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,414</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1510c9b-3363-43c6-962b-874bea3dd875" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,033,510</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_407e6f7f-ecd1-488c-ab65-ddee90864310" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.04</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9fcffd35-5e31-444f-b5fe-2f771147b0f7" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1c8b66c6-2e11-4ee2-bda2-dfd490ad10fb" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,125</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average grant-date fair value of options granted during the years ended December 31, 2021 and 2020, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c86ce4ec-74b0-41a8-a7ec-b7f708c35b5e" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.57</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_380412e9-9fec-40a6-a246-54fd3bf00060" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.62</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">per share, respectively. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding and exercisable stock options and the fair value of the Company&#x2019;s common stock as of December 31, 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The intrinsic value of stock options exercised for the year ended December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1977fc7-657d-44ba-a7eb-db3da8fb1922" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_ef7d2d59-0e56-4080-832a-49dcede3a447" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company estimated the fair value of each option on the date of grant using the Black-Scholes option pricing model applying the range of assumptions in the following table:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.968%;"></td>
        <td style="width:2.05%;"></td>
        <td style="width:20.466%;"></td>
        <td style="width:2.05%;"></td>
        <td style="width:20.466%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15da046f-918d-449a-9adc-1ae031ff36e4" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">72.88</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99118d62-4313-4807-9f95-7d066ab059ad" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">103.41</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_232da12f-6f43-44d1-b6c6-b9fce78b38b9" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">79.40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#x2013; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bce1a0db-34db-42bc-bddd-52df4640e5f6" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">87.40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5d3039c-81ce-457a-9e8d-370661298596" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.81</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f4a75cf-8aab-490d-bfa5-72020f633f97" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.36</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_76d606c2-dbae-4925-b2d1-6ca34a7db03e" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.38</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#x2013; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4999216b-ebf3-4046-bd79-1f1eb1a06a30" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.56</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20c76b8a-c162-42b7-be85-ba3234d5a699" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7dcaafc7-9d5d-469f-bc4e-55c6aa3369bf" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00c2f259-ceb5-40c1-af54-44b15cd36c00" contextRef="C_77b69288-abc5-4593-aa39-850f6b1b0b7e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.25</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e65a3a9-15e1-410e-a171-a69f04a88b54" contextRef="C_d1f92bd2-7f9c-4761-a7cd-fb5f0d37b59d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.00</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9ed3331-90ee-4e7c-ad26-dfecf18807e4" contextRef="C_8a2e39db-f489-43c1-abbc-dbbecbeb09c3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.02</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1617b2f-5604-44a1-9b14-abc9507dc881" contextRef="C_e5fb5e1b-3838-47c6-bb70-01be05e587a5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.08</span></ix:nonNumeric></span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b58c966-8e1b-4b22-ac0d-1756393d7ba6" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense related to stock options recorded in the statements of operations is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.973%;"></td>
        <td style="width:1.493%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.216%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:1.493%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.207%;"></td>
        <td style="width:0.603%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_42f2ac11-cc9e-41ee-a424-bc9ee7de1d63" contextRef="C_83f1f8d4-1a3f-42eb-89a4-fe5b4d42496e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,396</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2714f49-a838-49e4-924a-579715566c9c" contextRef="C_86efd6c0-cd6e-4044-a8a6-91df62d66a91" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_113883bb-88d7-47db-8115-c9116f664ad2" contextRef="C_0326a5ad-45a2-4a64-829d-d01a89aa86a2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,976</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39899845-6702-4071-98e2-b1be003fd94f" contextRef="C_1083a66d-cffd-416e-a565-3d03312b0250" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd092daf-f7e1-4f21-9d01-7f94859cbecf" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,372</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df2d4cbc-e749-461c-955d-f9b5453f53ba" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has an aggregate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c654034-4656-4159-b464-269c8944ab5b" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">38.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million of gross unrecognized stock-based compensation expense as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, remaining to be amortized over a weighted average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b7561e2-8f4a-4fa5-b48b-42e5db0c3114" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.9</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years. The Company has not recognized and does not expect to recognize in the near future, any tax benefit related to employee stock-based compensation expense as a result of the full valuation allowance related to its net deferred tax assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Awards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2019, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b47d778e-e5dd-410c-a736-fae5ea54c0c1" contextRef="C_c358130b-d442-4714-9617-ad3cca7aaa47" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">994,650</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of restricted common stock to the employee co-founders and certain non-employee consultants. The shares of restricted common stock were issued pursuant to standalone restricted stock purchase agreements that are independent of the 2019 Plan. The shares of restricted common stock carried a purchase price equivalent of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_400af050-f2dd-4173-af2b-133615444780" contextRef="C_6b8a4a3d-2a4c-49f1-81b4-0e6c37ae21f3" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.01</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The compensation cost was measured based on the fair value of the underlying common stock less the purchase price of the restricted common stock and the Company recognizes compensation costs over the requisite service period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of the restricted stock purchase agreements, the Company has a repurchase option whereby it has the right to repurchase any unvested shares upon termination at a price per share equal to the lesser of: (i) the fair market value of the Company&#x2019;s common stock on the date of repurchase and (ii) the original purchase price. The shares of restricted common stock issued to the Company&#x2019;s co-founders and non-employee consultants vest based on a predefined number of shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognized an associated deposit liability for restricted stock awards issued pursuant to standalone restricted stock purchase agreements upon issuance based on the purchase price of the awards as the unvested shares are subject to repurchase upon termination. As the awards of restricted stock vest, the Company reclassifies the deposit liability to additional paid-in capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_46e25817-eb12-41ef-833b-bb2e26436075" contextRef="C_cde6dc02-fc80-4fef-a5f9-c1c479dca2db" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">48,508</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of restricted common stock to employees and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> certain non-employee consultants under 2021 Plan. Compensation cost related to these awards were recorded based on the Company's stock price on the date of issuance.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca663547-9ffe-4645-be5d-04bdd521c5e6" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes restricted stock activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.494%;"></td>
        <td style="width:1.484%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:13.525%;"></td>
        <td style="width:0.798%;"></td>
        <td style="width:1.623%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.683%;"></td>
        <td style="width:0.594%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Restricted Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-vested at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ff95b7e-ecea-4847-a6b8-72f853d1097b" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">888,612</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_431b50fd-6493-42a7-9d6c-ac7b7bea3601" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.01</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issued</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d99ae751-9c92-4f58-abed-3d484ccebaa7" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,508</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8a67940-dc97-4bea-b505-81fa51397cb2" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">15.58</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43fa601c-289b-4219-b091-7776e168fbbc" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">306,998</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4867b80-9223-4bda-a015-fd6f1e17341b" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.01</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c47d098e-1cd9-4946-8b27-a348f7592fd2" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">11,628</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Non-vested at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60d485a7-1245-4f03-aa1d-82c3b37d2164" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">618,494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d7e8d29-a703-40a1-a676-2f8671faca5b" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.04</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate fair value of restricted stock vested during the years ended December 31, 2021 and 2020, was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_166b4d7a-f692-4d9d-9756-2087d4b2d406" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac70f771-060e-466b-891b-ea89dd07d2f0" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has recorded stock-based compensation expense related to the restricted stock of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5fef466f-1a02-4128-86a3-bb7bd3e66d4a" contextRef="C_668767af-d588-4269-bdd5-6d6317ca1174" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_38084a94-d7de-4fe4-80c0-39deec653a30" contextRef="C_c3e89383-fd3d-4b7e-82f6-24ca7bf96cec" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively. The Company has an aggregate </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_079d664d-e252-43f0-87e5-9a6bddce7563" contextRef="C_b54da75b-957d-4884-98f7-3495f571051f" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of gross unrecognized restricted stock-based compensation expense as of December 31, 2021, remaining to be amortized over a weighted average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e308d357-30a2-4a47-9032-102627bd26f2" contextRef="C_668767af-d588-4269-bdd5-6d6317ca1174" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Employee Stock Purchase Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 27, 2021, the Company&#x2019;s board of directors and stockholders approved the 2021 Employee Stock Purchase Plan (the &#x201c;2021 ESPP&#x201d;), which became effective on October 7, 2021, when the Company&#x2019;s registration statement was declared effective by the SEC. The 2021 ESPP reserved and authorized the issuance of up to a total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc282523-38e6-4971-850b-94b916577447" contextRef="C_4a0f2d3a-54c0-420e-9bb9-0592cc6ffcc8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">424,595</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock to participating employees. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3953ffb8-87d6-415b-86cf-36602ad0bef1" contextRef="C_cde6dc02-fc80-4fef-a5f9-c1c479dca2db" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares are issued under 2021 ESPP plan as of the date of issuance of these consolidated financial statements.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_e5f3d89a-2c2f-4cfb-b91d-255be911645d" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company recorded </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d07762c2-4f22-4753-a9cc-ba7bd2ee29d7" contextRef="C_1af731d8-74d4-4ca7-b3c7-e479981d947b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d8fce774-2c6f-4769-88db-c7d4282f45ae" contextRef="C_2a39c163-dd87-4565-b3a7-3a9cd35c9839" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d0cef481-9a51-4210-af55-441e9d68c3f7" contextRef="C_1af731d8-74d4-4ca7-b3c7-e479981d947b" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_00c3ba6b-5a01-41c5-ae1c-a7b7499d0afb" contextRef="C_2a39c163-dd87-4565-b3a7-3a9cd35c9839" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> current or deferred income tax expenses or benefits as the Company has incurred losses since inception and has provided a full valuation allowance against its deferred tax assets.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb0747ce-4cb3-4310-b647-5ed2832f6110" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the expected income tax benefit computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.543%;"></td>
        <td style="width:1.605%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:12.526%;"></td>
        <td style="width:2.004%;"></td>
        <td style="width:1.605%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:12.526%;"></td>
        <td style="width:2.004%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax computed at federal statutory rate %</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_35db2a8b-48f9-42d7-83ba-b85fa4e3f7d2" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">21.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_974cfdac-ea1b-49ce-9fe2-98f0c951f20d" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">21.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b21740f8-f965-4b1e-9e33-e72d8641ee25" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3726ff14-fc64-4ae9-8042-00582aa48345" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.60</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a1070d6-0a08-4e76-a4f3-375bce685c50" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:numdotdecimal">27.70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6210427-9d53-4116-8460-66ef6f6c41e4" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:numdotdecimal">27.90</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credit carryovers</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77b0e56f-3746-4ff5-80a1-6015d2f31b34" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.90</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd36ce12-19ed-4a51-9b86-8be72874cee0" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.50</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9e6d7cc-1f46-4578-9ffa-7db9cd55fa83" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="pyxs:EffectiveIncomeTaxRateReconciliationPermanentDifferences" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:numdotdecimal">0.90</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aaec76b1-35c2-485d-8b70-a175e5f03b7a" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="pyxs:EffectiveIncomeTaxRateReconciliationPermanentDifferences" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:numdotdecimal">0.20</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Effective income tax rate %</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74c898ca-ac3d-4932-b3b9-5abd09cde422" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75d2af73-3158-46f6-b90c-f5b741d842e9" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company's effective tax rate was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6c25c259-63a2-447f-b283-efdf556b3efa" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal"><ix:nonFraction id="F_ef6ebc64-2b44-4f8c-b1d3-ddda2c2f0767" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% for the years ended December 31, 2021 and 2020, as a result of the valuation allowance that eliminates the company's net deferred tax assets.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f32ef832-0ca8-4c4e-8f52-bced104976f4" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_f32ef832-0ca8-4c4e-8f52-bced104976f4_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Significant components of the Company&#x2019;s net deferred tax assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 are as follows (in thousands): </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_f32ef832-0ca8-4c4e-8f52-bced104976f4_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.169%;"></td>
        <td style="width:1.512%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.3%;"></td>
        <td style="width:0.798%;"></td>
        <td style="width:1.512%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:11.501%;"></td>
        <td style="width:0.798%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1ed4bbd-c551-4787-ab5f-7fd4e7a85439" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,918</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8556998e-3acc-4c82-afc4-10798c99dbe2" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,515</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangibles</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_71867427-0601-4aa8-940f-55a0a7671a47" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af1cce98-e7cf-475e-b239-0dabb992cbea" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_280ac9d7-ff04-437b-80ac-b144d33c2f26" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,648</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f2fd2fe-3d47-429b-995c-ddd346fe0e0b" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">187</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Derivative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_25b1d606-2993-4aa2-9796-f9364dcacf6f" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,577</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock based compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ca2aa4d-7136-4864-aeb7-364d4ecfb5bc" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,003</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reserves and accruals</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1bd1532-a8d2-48cd-a885-f15cd913d308" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">804</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34a18394-8bfa-491e-bc45-c5de67e12d4a" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">257</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">License fees</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f0a8bb8-45d6-4ddf-8dfb-821b036db0e3" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="pyxs:DeferredTaxAssetsLicenseFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,716</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89888dd5-b85c-4893-a38b-86cad0ddf39b" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="pyxs:DeferredTaxAssetsLicenseFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">252</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c6254a91-82c6-44b1-ba2a-02e68608c122" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2cdce77-df7f-4f1c-a101-6c51ed653529" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">299</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets before valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2b2123eb-e41a-4127-80e1-fa9431b80fdc" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,811</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f3dbe049-aa02-48ff-ac0c-32ad9dbfbdc0" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a5b41ed3-77d7-4822-9555-0442b30824f4" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,748</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8fe0abfd-cccb-4b6c-a5cc-511970936f86" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,343</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8173056a-6300-42e8-b2d8-6c4af712ab8f" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e309d32-2973-43b0-b719-803e4f4c1cf0" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">214</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_162cc6df-7d6b-4aac-809f-ded13ed5c8a1" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="pyxs:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e08990a-706a-48d6-a35e-092efa2138dc" contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c" name="pyxs:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">214</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company's federal and state net operating losses in the United States were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e3ae27f2-ed6b-4280-b1bb-30ba5bcec374" contextRef="C_529d4c7c-54dc-4be7-b79b-cb508fa84d76" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million ($</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11ee892d-bb7e-45bc-adac-ddfa685366ad" contextRef="C_529d4c7c-54dc-4be7-b79b-cb508fa84d76" name="pyxs:OperatingLossCarryforwardsBeforeTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">48.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million before tax) and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_35c00873-a11c-448b-9996-6b072de062ac" contextRef="C_14084414-5d74-4992-ae92-da97bbd2c4d3" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million ($</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4af52255-e94f-4ed5-bd0c-487456ca3ee6" contextRef="C_14084414-5d74-4992-ae92-da97bbd2c4d3" name="pyxs:OperatingLossCarryforwardsBeforeTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">45.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million before tax) respectively. The federal net operating loss carryforwards in the United States can be carried forward indefinitely but may be subject to annual usage limitations to the extent certain substantial changes in the entity's ownership occur. The state net operating loss carryforwards begin expiring in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54c3a4e6-a555-42dc-94aa-a3a9a2746fb4" contextRef="C_f4093bae-844d-47d4-af50-d208ea9824d5" name="pyxs:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2039</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In addition, as of December 31, 2021, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d034628d-707d-4c87-b5a5-8cf2054bb42d" contextRef="C_529d4c7c-54dc-4be7-b79b-cb508fa84d76" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e3225db-b5cf-4e89-883c-2426ec42f8e2" contextRef="C_14084414-5d74-4992-ae92-da97bbd2c4d3" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of federal and state credit carryovers which begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91d6d207-f2f5-4d1a-a359-867b280cf9b6" contextRef="C_1af731d8-74d4-4ca7-b3c7-e479981d947b" name="pyxs:TaxCreditCarryforwardExpirationYear"><ix:nonNumeric id="F_96e7a75c-a1b4-40c7-9eae-5d682a8c9366" contextRef="C_f4093bae-844d-47d4-af50-d208ea9824d5" name="pyxs:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2039</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. These loss and credit </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">carryforwards are subject to review and possible adjustment by the appropriate taxing authorities.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assesses the realizability of the deferred tax assets at each balance sheet based on the available positive and negative evidence in order to determine the amount which is more likely than not to be realized and records a valuation allowance as necessary. Due to the Company's cumulative loss position which provides significant negative evidence, which is difficult to overcome, the Company has recorded a valuation allowance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8658173f-308c-4fca-b1ee-e7120495f533" contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021, representing the portion of the deferred tax asset that is not more likely than not to be realized. For the years ended December 31, 2021 and 2020, the valuation allowance for deferred tax assets increased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_082c17a9-213b-4944-802e-068106fe0dcb" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5be6ab0a-7062-48ef-ad43-956c8ad0877e" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. The amount of the deferred tax asset considered realizable, could be adjusted for future factors that would impact the assessment of the objective and subjective evidence. The Company will continue to assess the realizability of deferred tax assets at each balance sheet date in order to determine the proper amount, if any, required for a valuation allowance.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The U.S. tax attributes may be subject to an annual limitation under Section 382 of the Internal Revenue Code of 1986 (the &#x201c;Code&#x201d;), and similar state provisions if the Company experiences one or more ownership changes, which would limit the amount of the tax attributes that can be utilized to offset future taxable income. In general, an ownership change as defined by Section 382, results from the transactions increasing ownership of certain stockholders or public groups in the stock of the corporation of more than fifty percentage points over a three-year period. If a change in ownership occurs in the future, the research and development credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#x2019;s effective tax rate.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to tax and will continue to file federal income tax returns in the United States as well as in certain state and local jurisdictions. The Company is subject to tax examinations for tax years ended December 31, 2019 and forward in all applicable income tax jurisdictions. Tax audits and examinations can involve complex issues, interpretations and judgements. The resolution of matters may span multiple years particularly if subject to litigation or negotiation. The Company believes that it has appropriately recorded its tax position using reasonable estimates and assumptions, however the potential tax benefits may impact the results of operations or cashflows in the period of resolution, settlement, or when the statutes of limitations expire. The Company does not currently have any reserves related to unrecognized tax benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0e7c447-a9e1-436f-a34f-1142083cf159" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_024246b6-c4b0-4235-8a55-fadcb7eb83b8" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.906%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.196%;"></td>
        <td style="width:13.198%;"></td>
        <td style="width:0.798%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.196%;"></td>
        <td style="width:13.717%;"></td>
        <td style="width:0.798%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f23eceb6-b445-4cd2-a3fa-485cd2569335" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,975</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cc3d2626-8576-41fd-a8a7-cd8e1545a3b0" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,828</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08e3ade2-fdd7-4e75-b20e-8cbd01ee0934" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,493,273</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a610686c-1ce7-4b92-a754-5daf63eff550" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,030,556</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d2cd6497-c092-4aaa-ab03-a17734095d12" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">8.95</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_effef5bc-d973-47fa-b0dc-4519e6d95172" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">12.45</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s potentially dilutive securities, which include convertible preferred stock, restricted stock, and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4135e090-e607-48af-8e3c-17d3b1548abb" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.64%;"></td>
        <td style="width:1.938%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:10.536%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:1.938%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:10.536%;"></td>
        <td style="width:0.603%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Convertible Preferred Stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7646b5d-9c2b-4208-bb76-14f16a9eea57" contextRef="C_5a174817-ec5a-4adc-91c7-b3f0391f3a67" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,573,659</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested Restricted Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f47d57f8-300e-4562-bdf9-a7a6688a4c7e" contextRef="C_99104f1c-d368-4dd0-8b3e-c298819aba0b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">618,494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_495fe011-73e7-43ef-9fb7-67a2291993d0" contextRef="C_22452cd4-facf-4cb0-b0d8-aef2986fea43" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">888,612</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d7b0cf8-6c45-4e21-8771-003c50f6970c" contextRef="C_6b5b3558-a3b0-4002-902a-e67ae5cdd4b2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,926,969</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58869ef0-fe09-431c-b3ba-cc8acb181d30" contextRef="C_a48bbe71-5e71-4138-9877-1babd6034c0e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">220,383</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58643769-a064-4224-92ab-90ca60e6a09e" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,545,463</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_27d27e26-b3a6-4f92-9b1c-1e8b83fdb900" contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,682,654</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_736597c8-071d-4bda-b715-dc90208ef3c6" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. Related Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2020, the Company entered into agreements with several Scientific Advisory Board (&#x201c;SAB&#x201d;) members whose members are comprised of the Company's board members. The Company paid monthly amounts, ranging from $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f8805f91-837c-4aba-9365-6eefeab7e37d" contextRef="C_6ff4a3a9-acf7-49fe-b336-139827d87918" name="pyxs:PaymentsToRelatedPartiesPerMonth" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_47b8746c-389b-4ce6-b21e-19acb5239254" contextRef="C_dc7688b9-57dd-43d0-a91e-30eeb4979d67" name="pyxs:PaymentsToRelatedPartiesPerMonth" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand per month. No board member was paid more than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e7544bee-4793-46fd-b080-9524e4628a26" contextRef="C_8f0edcc6-6967-4a4a-b278-e69a383ba6db" name="pyxs:MaximumAmountPaidToRelatedParties" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_1d1ba1bf-7b5e-4911-afd0-e19c479ac2f9" contextRef="C_0fbda7d4-a5aa-4836-8bfe-59b19b15fc3f" name="pyxs:MaximumAmountPaidToRelatedParties" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million individually for the years ended December 31, 2021 and 2020, in the aggregate, all board members were paid less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e3ce6af7-cac8-4d07-80d8-ef77532da01b" contextRef="C_8f0edcc6-6967-4a4a-b278-e69a383ba6db" name="pyxs:AggregateMaximumAmountPaidToRelatedParties" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_d1ad85ab-ab40-4898-9c77-da4c1e00e907" contextRef="C_0fbda7d4-a5aa-4836-8bfe-59b19b15fc3f" name="pyxs:AggregateMaximumAmountPaidToRelatedParties" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for both periods combined.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company was founded out of Dr. Thomas Gajewski&#x2019;s laboratory at the University of Chicago. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2020, the Company entered into the License Agreement with the University of Chicago, as well as a sponsored research agreement, which had previously purchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6231df14-93b7-4890-8d47-104274aa9c04" contextRef="C_40efd25b-f2c1-4224-9850-278e0702aecc" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">309,885</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s Series A preferred stock as part of the Company&#x2019;s 2019 Series A financing. In partial consideration for</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the license from the University, the Company issued to the University </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8fff1535-1472-4ec7-8939-d65acccf706e" contextRef="C_3014eecd-3b62-49b1-859b-5132c70a7d8a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,919</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock in 2020. The Company recorded the value of the shares issued of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_31417b2c-6407-4958-a6dc-5eda4725c179" contextRef="C_d235112b-d87b-410d-8d79-ca05e714f0dd" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand as research and development expenses in the year ended December 31, 2020. There have been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2153b565-bf6b-4221-8650-3f33af8d4c75" contextRef="C_1662ef99-8778-4709-9b9e-c988faaab66e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> further expenses incurred for the year ended December 31, 2021 with regards to the University License Agreement. Refer</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to Note 3 for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to IPO, Pfizer along-with its affiliated entity and Bayer HealthCare LLC (&#34;Bayer&#34;), were principal owners of the Company. Subsequent to IPO, Pfizer and Bayer are no longer principal owners and, as a result, neither Pfizer nor Bayer are related parties of the Company. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2020, the Company entered into the Pfizer License Agreement. The Pfizer License Agreement became effective in March 2021. During the year ended December 31, 2021, the Company incurred a combined </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae4acb28-4dd5-4136-99e0-997a95e6d901" contextRef="C_93d8ea59-4f70-435a-800d-684dd2b13280" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (which was recorded as research and development expenses), consisting of an upfront fee equal to a cash payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4b4166e-cb8b-4944-bdc6-10d24b3705e4" contextRef="C_6eaa700b-aefd-44cf-9c29-31f008101fed" name="pyxs:UpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">illion and the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c42a8b5-7923-4b64-83fa-552b6c1e5705" contextRef="C_34a68bd8-42d2-4884-8c43-a95f93b476df" name="pyxs:IssuanceOfConvertiblePreferredStockShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">12,152,145</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B convertible preferred stock with a value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d32e8870-e901-453d-93f8-cc6d3d08c8de" contextRef="C_404bc14b-3eaf-4e94-a492-dc8d161a716a" name="pyxs:ConvertiblePreferredStockSharesIssuedValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in 2021 to Pfizer. Refer to Note 3 for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company and Alloy formed a joint venture company, Voxall Therapeutics, LLC (&#x201c;Voxall&#x201d;) to leverage the Company&#x2019;s technology and Alloy&#x2019;s ATX-Gx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#153; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">platform and antibody discovery services. The Company and Alloy contributed $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1394f864-8a3d-48e1-b5c2-39064d4b54ff" contextRef="C_5fb2e8bf-e772-43b7-b907-59150f324329" name="pyxs:ContributedAmountToJointVentureByEachEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand each to Voxall along with certain license. During the year, the Company provided services to Voxall for which it recognized service fee other income of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cc544be4-823a-4af0-86dd-dd9e75d310f1" contextRef="C_5fb2e8bf-e772-43b7-b907-59150f324329" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">181</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand. Refer to Note 4 for additional discussion.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c426c0c-76af-4458-ad18-023ebbc06198" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">16. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Legal Proceedings</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of business. The Company is not currently a party to any material legal proceedings, and is not aware of any pending or threatened legal proceeding against it that the Company believes could have an adverse effect on its business, operating results or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the normal course of business, the Company enters into agreements for research programs with vendors for nonclinical studies, manufacturing and other services and products agreements, which are generally cancellable by the Company at any time, subject to payment of remaining obligations under binding purchase orders and, in certain cases, nominal early-termination fees. These commitments are not deemed significant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, COVID-19 disease was declared a pandemic by the World Health Organization. The COVID-19 pandemic is disrupting supply chains and affecting production and sales across a range of industries. Currently, the Company has not suffered significant adverse consequences as a result of the COVID-19 pandemic. The extent of the impact of COVID-19 on the Company&#x2019;s future operational and financial performance will depend on certain developments, including the duration and spread of the pandemic, including its variants, impact on employees and vendors all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Company&#x2019;s future financial condition or results of operations is uncertain.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f04958c-9e9f-4f5f-8821-5dc097e49fee" contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">17. Subsequent Event</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with Biosion USA, Inc.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 28, 2022, the Company entered into a license agreement, or the &#x201c;Biosion License Agreement,&#x201d; with Biosion USA, Inc., or Biosion, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pursuant to which the Company obtained exclusive, worldwide (other than Greater China </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(mainland China, Hong Kong, Macau and Taiwan)</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">), licenses for development, manufacture and commercialization rights for BSI-060T, a potentially best-in-class Siglec-15 targeting antibody, an IO product candidate (now referred to as PYX-106), and products containing the licensed compound.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Biosion License Agreement, the Company agreed to pay an upfront fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2cf68fb7-c0a1-426b-bce2-d8b01d3c558d" contextRef="C_dca5bfc8-d2fa-4c60-8e05-95c561295a9b" name="pyxs:UpfrontFee" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and are obligated to pay future contingent payments including development, regulatory and commercial milestone up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cc054cd6-fb94-47cf-978d-a2d43c717c54" contextRef="C_ea790169-f5cb-46d5-bb2a-a27a9d87e6bf" name="pyxs:AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">217.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in case of normal approval and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d552c3ed-7cbc-41d1-a7c7-96967fb64264" contextRef="C_ea790169-f5cb-46d5-bb2a-a27a9d87e6bf" name="pyxs:AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">222.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in case of accelerated approval. Additionally, if products are launched, the Company will pay Biosion tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to low teens. The Company&#x2019;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67b2ed84-abf2-4561-90e6-ceeef55a2f41" contextRef="C_dca5bfc8-d2fa-4c60-8e05-95c561295a9b" name="pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>pyxs-ex4_1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html>
 <head>
  <title>EX-4.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 4.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">DESCRIPTION OF REGISTRANT&#x2019;S SECURITIES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">REGISTERED PURSUANT TO SECTION 12 OF THE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECURITIES EXCHANGE ACT OF 1934</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pyxis Oncology, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;): its common stock, par value $0.001 per share (the &#x201c;common stock&#x201d;). For purposes of this exhibit, unless the context otherwise requires, the words &#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us&#x201d; and &#x201c;our company&#x201d; refer to Pyxis Oncology, Inc., a Delaware corporation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Description of Common Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">General</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following summary sets forth some of the general terms of our common stock. Because this is a summary, it does not contain all of the information that may be important to you. For a more detailed description of our common stock, you should read our amended and restated certificate of incorporation and the amended and restated bylaws, each of which is an exhibit to our Annual Report on Form 10-K to which this summary is also an exhibit, and the applicable provisions of the Delaware General Corporation Law (the &#x201c;DGCL&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation authorizes 190,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of undesignated preferred stock, $0.001 par value per share, the rights, preferences and privileges of which may be designated from time to time by our board of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dividend Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and only then at the times and in the amounts that our board of directors may determine.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Voting Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The holders of our common stock are entitled to one vote per share. Stockholders do not have the ability to cumulate votes for the election of directors. We have a classified board of directors consisting of three classes of approximately equal size, each serving staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">No Preemptive or Similar Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock is not entitled to preemptive rights and is not subject to redemption or sinking fund provisions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Right to Receive Liquidation Distributions</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Preferred Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions, in each case without further vote or action by our stockholders. Our board of directors can also increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control and might adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Anti-Takeover Provisions</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The provisions of the Delaware General Corporation Law, or the DGCL, our amended and restated certificate of incorporation and our bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and encourage persons seeking to acquire control of our company to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Section 203 of the DGCL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#x201c;business combination&#x201d; with an &#x201c;interested stockholder&#x201d; for a three-year period following the date that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">before the stockholder became interested, our board of directors approved either the business combination or the transaction, which resulted in the stockholder becoming an interested stockholder;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">upon consummation of the transaction, which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans in some instances, but not the outstanding voting stock owned by the interested stockholder; or</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">at or after the time the stockholder became interested, the business combination was approved by our board and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock, which is not owned by the interested stockholder.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 203 defines a business combination to include:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any merger or consolidation involving the corporation and the interested stockholder;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subject to exceptions, any transaction that results in the issuance of transfer by the corporation of any stock of the corporation to the interested stockholder;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Amended and Restated Certificate of Incorporation and Bylaw Provisions</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation and our bylaws include a number of provisions that may have the effect of deterring hostile takeovers, or delaying or preventing changes in control of our management team or changes in our board of directors or our governance or policy, including the following:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Board Vacancies</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation and bylaws authorize generally only our board of directors to fill vacant directorships resulting from any cause or created by the expansion of our board of directors. In addition, the number of directors constituting our board of directors may be set only by resolution adopted by a majority vote of our entire board of directors. These provisions prevent a stockholder from increasing the size of our board of directors and gaining control of our board of directors by filling the resulting vacancies with its own nominees.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Classified Board</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation and bylaws provide that our board of directors is classified into three classes of directors. The existence of a classified board of directors could delay a successful tender offeror from obtaining majority control of our board of directors, and the prospect of that delay might deter a potential offeror..</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Directors Removed Only for Cause</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation provides that stockholders may remove directors only for cause.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Supermajority Requirements for Amendments of Our Amended and Restated Certificate of Incorporation and Bylaws</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation further provides that the affirmative vote of holders of at least two-thirds of the voting power of our outstanding common stock is required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to the classified board, the size of the board of directors, removal of directors, special meetings, actions by written consent and designation of our preferred stock. The affirmative vote of holders of at least two-thirds of the voting power of our outstanding common stock is required to amend or repeal certain provisions of our bylaws, although our bylaws may be amended by a simple majority vote of our board of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stockholder Action; Special Meetings of Stockholders</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation provides that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, holders of our capital stock are not able to amend our bylaws or remove directors without holding a meeting of our stockholders called in accordance with our bylaws. Our amended and restated certificate of incorporation and our bylaws provide that special meetings of our stockholders may be called only by a majority of our board of directors, the chairperson of our board of directors or our chief executive officer, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders to take any action, including the removal of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Advance Notice Requirements for Stockholder Proposals and Director Nominations</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:4.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. To be timely, a stockholder&#x2019;s notice generally must be delivered to us not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year&#x2019;s annual meeting of stockholders. Our bylaws also specify certain requirements regarding the form and content of a stockholder&#x2019;s notice. With respect to nominations of persons for election to our board of directors, the notice shall provide information about the nominee, including, among other things, name, age, address, principal occupation, ownership of our capital stock and whether they meet applicable independence requirements. With respect to the proposal of other business to be considered by our stockholders at an annual meeting, the notice shall provide a brief description of the business desired to be brought before the meeting, the text of the proposal or business, the reasons for conducting such business at the meeting and any material interest in such business by such stockholder and any beneficial owners and associated persons on whose behalf the notice is made, or the proposing persons. In addition, a stockholder&#x2019;s notice must set forth certain information related to the proposing persons, including, among other things:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the name and address of the proposing persons;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">information as to the ownership by the proposing persons of our capital stock and any derivative interest or short interest in any of our securities held by the proposing persons;	</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">information as to any material relationships and interest between the proposing persons and us, any of our affiliates and any of our principal competitors;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a representation that the stockholder is a holder of record of our stock entitled to vote at that meeting and that the stockholder intends to appear in person or by proxy at the meeting to propose such nomination or business; and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:4.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a representation whether the proposing persons intend or are part of a group which intends to deliver a proxy statement or form of proxy to holders of at least the percentage of our outstanding capital stock required to elect the nominee or carry the proposal.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#x2019;s own slate of directors or otherwise attempting to obtain control of our company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">No Cumulative Voting</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#x2019;s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation and bylaws do not provide for cumulative voting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Issuance of Undesignated Preferred Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock enables our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Exclusive Forum</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf under Delaware law, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or bylaws, (4) any other action asserting a claim that is governed by the internal affairs doctrine or (5)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any other action asserting an &#x201c;internal corporate claim,&#x201d; as defined in Section 115 of the Delaware General Corporation Law, shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court located within the State of Delaware, or the federal district court for the District of Delaware) in all cases subject to the court having jurisdiction over indispensable parties named as defendants. These exclusive-forum provisions do not apply to claims under the Securities Act or the Exchange Act. Our amended and restated certificate of incorporation also provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act or the Exchange Act. Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed to have notice of and consented to this provision. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Transfer Agent and Registrar</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transfer agent and registrar for our common stock is Broadridge Corporate Issuer Solutions, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exchange Listing</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#x201c;PYXS.&#x201d;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>pyxs-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 21.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">List of Subsidiaries</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subsidiary</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Jurisdiction</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pyxis Securities Corporation</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Massachusetts</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>pyxs-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 23.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We consent to the incorporation by reference in the Registration Statements (Form S-8 No. 333-260441) pertaining to the Pyxis Oncology, Inc. 2019 Stock Plan, Pyxis Oncology, Inc. 2021 Equity and Incentive Plan, and Pyxis Oncology, Inc. 2021 Employee Stock Purchase Plan of our report dated March 29, 2022, with respect to the consolidated financial statements of Pyxis Oncology, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2021.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Ernst &amp; Young LLP</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">                                                       </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boston, Massachusetts</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 29, 2022</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>pyxs-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lara Sullivan, M.D.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, certify that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Pyxis Oncology, Inc.;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">[Reserved]</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any fraud, whether or not material, which involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:45.455%;"></td>
    <td style="width:5.055%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:46.454%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 29, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Lara Sullivan</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lara Sullivan, M.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>pyxs-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pamela Connealy</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, certify that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Pyxis Oncology, Inc.;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">[Reserved]</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any fraud, whether or not material, which involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:25.014%;"></td>
    <td style="width:25.014%;"></td>
    <td style="width:25.014%;"></td>
    <td style="width:24.958%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 29, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Pamela Connealy</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pamela Connealy</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>pyxs-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Annual Report of Pyxis Oncology, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:45.455%;"></td>
    <td style="width:5.055%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:46.454%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 29, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Lara Sullivan</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lara Sullivan, M.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>pyxs-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Annual Report of Pyxis Oncology, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:25.014%;"></td>
    <td style="width:25.014%;"></td>
    <td style="width:25.014%;"></td>
    <td style="width:24.958%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 29, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Pamela Connealy</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pamela Connealy</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img29677477_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" :2"ZX# 2(  A$! Q$!_\0
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M%'ZT (:#TH[TX#-( "$C(I!SP:D:0>5M'6HQ@BF F>:*,4N*0"4$4N106!-
M"LH4"FGIQ0QW48QWH <$;9NQQ30<=JFEF#1*JC&*ASG% ">YH))ZTIZTG6@
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M1?9I?*5\K3;6!'NHP[83/-)*Q1#O0,V!D&D5]I^5>:U=7@L8Y(Q;/DXYXK+
M ER#18:#>S9 XI5+I\J_>ZYIAC._:3@MTI?,*G!ZCC-(&/DEEG(9FZ=*8LC
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M)I3P.*2@ 7KFE8]#28H//%( /2DQQ2C&*3I0 4HYXI.E&:  ]<4HQ2#KF@T
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M_0%_\FIO_BZ!\*/!(Z:+_P"34W_Q=/ZW#LQ'S/#)Y"'C+&FORN_G=Z5],_\
M"IO!&<_V)S_U]3?_ !=+_P *H\$Y_P"0+_Y-3?\ Q='UN'9B/F)D8IN!^8TH
M$I;:_P!T]Z^G/^%3^"<Y_L7_ ,FIO_BZ4_"KP41C^Q>/^OJ;_P"+H^MP[,1\
MR"-45L$^U-:3@+BOIO\ X5-X(./^))T_Z>IO_BZ#\)O!!ZZ)_P"34W_Q='UN
M'9A8^9B6)$:_G3<1PG$F2QKZ<7X4>"5.1HO/_7U-_P#%TU_A+X'D;<VB9/\
MU]S?_%T?6X=F*Q\VI$HA9VQBH41F!*E<5]-GX5>"RFPZ+\OI]JF_^+IJ_";P
M0HP-$Q_V]S?_ !=/ZW3[,7*SYE1@LO!P:CE.XMG)/M7TZ?A)X';KHG_DW/\
M_%T#X2^" ,#1/_)N;_XNCZW#LQ<C/F!I0JA<&D!PX)'RU]0'X2>!SUT3_P F
MYO\ XNE/PF\$,,'1/_)J;_XNE];AV8N1GS!)TR.O:FEF?ANO>OJ#_A4G@?\
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MA(^7VVJ%X/%&5D.!Q7U%_P *E\#XQ_8G'_7U-_\ %TP?"#P(#D:'_P"3<_\
M\72^MP[,/82/F!UV<@C%'#)@<5]0?\*A\"_] /\ \FY__BZ7_A47@7_H!_\
MDW/_ /%T_K<.S#V$CY<C&,C^=#;<@D?E7U)_PJ3P/_T _P#R;G_^+I!\(_ P
MZ:'_ .3<_P#\71];AV8_82/F2UMTO;D(#M&/I3[J'[%,8HSDCN*^FD^$W@B-
M]R:)@^OVN;_XNE;X3^"6;<=%R?\ KZF_^+JOKM/LR?J\CY8+>8#YC'=FIB-B
M[2< C@U].'X/^!&.3H7/_7W/_P#%T]_A)X'D4*VB9 Z?Z7/_ /%TOKD.S*]A
M(^69<[0H))]33TC"K\YYKZB/PB\#'&=#Z=/]+G_^+H/PC\#$Y_L/_P FY_\
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M4CYM$^8MNXTR0Y(QFOI,?"?P0IR-$_\ )J;_ .+I_P#PJSP7_P! ;_R:F_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /APY!YI>W-(3SS2]L&N\XA*,X&!3N#3>] R96 A([FHB"*%P#S0[
M9/% @!I",&@<<T,<F@:%0<\TC?>P*.] ZYH 3'O13RC;=VT[?6FKWH 2G$8I
M/XJ5B.U "=Z"2:!R.*,=LT@ #!HSUH!P>:"!0 >U!HH- "8S1UZ]J.^:.IH
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M/4T 1 E:3J232G/0TG?% PZ4@Z\TII :0"TG>ES2=>E "YSTI1TI!\HI,XH
M7%?2/[/'_(D:E_V$F_\ 1<=?-IXKZ2_9W_Y$C4O^PDW_ *+CJ9;#6YZ]1116
M984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!\.\YP*3G-*>#1BN\X@Z8Q2[2%S012E\KMH $(523UIHR
M30 ,<TO?K0 F,TE*P I,9-  1WH!QQVIRCYL&D8!3Q0,:*4 '&: .]+P30 K
MD' %*LQ1"@[TT@9XI._- "&II+F69%5CD#H*B(Q2]3\M "9YI=I-&,<]Z<#C
M!/% #.G6E%/8J:CZ4 )["EW$\4#J:3&: %.,\=:0^M&#UI<T@$[T$"@]:.*
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M^M+GTH 0T#BE !HQZT (.:4MR".M(!SS0>O% $DDTDV YR!3,4G>@\&@ ^M
MX.*#THQQ0,0\'BESD\4<&DZ=*0"]Z,\T#UI1C.30 AH'O1Q^-&": $S7TE^S
MOSX(U+_L)-_Z+CKYN/%?27[/'_(D:C_V$6_]%QU,MBEN>NT445F4%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%&:,T %%)FC- "T4E% "T4E% "T4E% "T4E
M% "T4E% "T4E% "T4E&: %HI,TN: "BC-% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P[G-*,YH
M8<\4F:[SB#O2'FE'K2@9- "8Z4>M [TH/'O0 F,=:4<4W)-'- "DG-!XSZT8
M-*<#CO0,;VHP,<4NW')--SCI0 H''O1GC%*O7FE8"@!O2E4XHP2<4Z1-A&.M
M #<G<,TZ1@V,4SG/-&<>] !@4#I[T8STI<#IG!I (?UI,9^M.-- +<BF N,B
M@4G0XIW3ITH :>#Q2A<BDSSQ0&P:0$ML%^U1[_NYYJWJLZ33((_NJ,52CPTP
M!/%.N"N_Y>@H B[TI)Q[4E!ZT *!D<"D&,\U8MF6/<S\Y%5V.7)[4 /DQ@4R
M@Y/?-!P!UH&!R!3XIF@8E.I%,SQ29X]Z !F+,2><T'BG#;M]Z:: #O0W6C&1
M4ML%+Y?\J (J#BG2']X:8: %S1[9XI,8I<#%(8@'-/D*\ 4S%*!S0(0'TH)]
M!00?2EZ=#0   CWI.AI<$4G0\TAAW-)TIW%(10,,T=312<BF(7BBEQ2$T +M
MR,TG0>]&>,4 9I &<T=#2'K2@$T )WS0?:E(P*,\4 (.E*IV_2C/'%)R:!BA
MF5MRY%.W[@<]:-V%VX_&F#K0 O:D ]Z3- Z\T"%VXI.E..",TT#- "CD4Y'V
M @#FFDX%/AP22:0R/.<DT8QTZ4K=32=L4 *2,<4@% HYH #STI"*4'%(: '9
MXQ3H@"V33.XI<X/% "E2\FU1U-+-"86VMUIUO,(IMY&:;-+YTY<]Z &-@#CD
MU*D:^26)YJ(C%*"QX)H&-7WI4 ).:1AZ4@SF@!QX)Q33UI3D&ANV*!"#FE'-
M ZT9VDXI#$XI!2@TM R>UA\TDL?E%0N!O..E*LA12 >#3.M A30>E)BE[4 )
M1CC)I3QQ2 Y- RQ:6IN"QZ*!4,B[)64=!4L5V\$3(O\ %Q4'J>] D)[4IP![
MT8&,T8R*0QO(I<=Z,]J2F OOFD/KF@"CO0 O44@I32KQUI#$((HP>W4TK'><
MU+:A3."YX% F0D$'IBDZ]:GN7$DY(Z"H#U]* 0=Z, T48H&!SVI1S24G6D X
MC) J2955 !U(J(=:,GJ>:8 !1P*.] &3BD F**"/>DQCK0 M H/%+[T )C -
M%!/Y44 A!UI:2B@8H /)I#UXH[4M !TI*#C% H */:CO0:0!CFEQQ2#(HSGJ
M: $[TI.<44#W% !QFDZ4<&EQQ0 8[TO &32 >]+UH 0=.>E)UI>G%-!YS0,=
MT7/>DR,>]!()HQCFD  <9-!YH)S010 '%*<TF,>]!R* $[U])_L\?\B1J/\
MV$6_]%QU\V5])_L\_P#(D:C_ -A%O_1<=3+8I;GKM%%%9E!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11FDS0 M%)10
MM&:2B@ S1110 4444 %%%%,04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1112&%&:** #-+FDHH 6BDHH 6BDHS0 M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P][TGWCG%+D8H((
M]Q7><0'MBD-*!BE=" ": &4=Z<<9P*0@4 *#QQ2 ^M*, 4WN<T +R#UI6 !R
M*3!H/% Q.@P:.V<4O XZTI! ]J!B<EA00>:0#CWH).*! .#FG$E^3UI![TF
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M!>:9TH&>YI@*>N:3^*EV]^M(,@YI *PQS24NTM1WQ0 'IUIRX7)/6F[3FE4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !111F@ HI** %S29HHH ****
M "BBBF(**** "BBB@ HHHH **,T9H **3-% "T4E% "T4E% "T4E% "T4E%
M"YHS244 +FC-)10 N:*2B@!:*2B@!:*2B@!:*2B@!:*2C- "T4F:7- !1110
M 4444 %%%% !1110 4444#"C-%%(!:*2B@!:*3-+0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?-IZU])?L\?\B1J7_82;_P!%QU,MBEN>O4445F4%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4449H **2B@!<TE%% !1113$%%%% !1110 4449H **2B@!:,TE% !FBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** #-+FDHH 6BDHH 6BDS2YH **** "
MBBB@ HHHH *,T44ABT4E% "T4F:6@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%%% !1110 49HHH ,TN:2B@!<T4E% "T4E% "T4F:7- !1110 4444 %%%%
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MTI.,>])F@!V[/6F]^M'44O;WH 04O'3-)G%3+$!"78\]J!D. 32Y]*0T8XH
M7K]:0]:,X'O0#^=(!#BE49.*.IH/7BF!*\011SS48Z\4%CCDTZ/ R30 Z*+S
M21TQ4;+AB!VIP<IG'>DW#:?6@!N<#%(,TN.*3O[T#%Y I!UH.32FD HP#2'D
M^U(<BC'% @Q12Y["D(-  .!GO0S$\GK2X7BD;VH  WH*": *4#J30,:.M'7-
M&,'-'?- !VI1R<4WG-*#BD K<&FXR:7'&2:!Q0 N.,YI,X[4$9-"C+<]*
MCDTO-7;2V%W.%_A'6HKZ-8;DQIR!0!5QBG =\TG.:,Y&* $ZFC)SBCG- Z&D
M,!UI2>>E(.M/3D$FF S.:3FEQDFDS2 4G%*>G2F]:,G/% "CIS0"*#@]:.*
M >])C%*.E(>* %/-)D#BG(N2*E$&Y6?L* (><4AHSVH(H&)GN*4MD4AXH[T
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M*** "BBB@ HHHH **** #-&:** %S1244ABT4E% "T4E&: %HHS10 49HHH
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M:: 1SVIQ.X<GI0!8LKYK3=@<FJ\CF20N>2330./4T=Z  T_Y=N.]-.,4F>*
M$J2) P)/:F4N_ V^M #3UI1DTG0\=*,_E0,!Q2G %-S2T '':@#G-!H#8%(
M(H.*&H&* %QSQ2'FCOQ2?7K0 HR!4@F;RS'V-,49X-(W!IC  9YI#FE_AI">
M*3 0G)I<=Z0<4$<4 +U&* <"D!%+CF@!,T8[T$>E%( SCZFE;IBCC-(3FF
M9/-'? I!G- SGWI +G;Q1G'2AE(&32<XS3&+[]Z.<\TF,T9]:0#CZ4T^U+GU
MH[T &>.E- IV:2D E* ":0T"@!3BCC%)CFC&*8 !UH!..:7^&F]J0"YXHQFD
M'2CO0,>F *0G)-(:!SWH$&<<T<49YQBCK0 F!^-*/>DI3TQWI#$]J#Z4=Z*
M%[=*2EZ"D I@%&?2CH:<K 9S2 ;S1G%+D'FD)!ZT )@]:,T#G@4=.*!C@13>
M_M2=Z4#- #F8=!3: .*!Q0 "EZ4=303S0 G%?2/[/'_(D:E_V$F_]%QU\WDX
MYKZ1_9Y_Y$C4?^PBW_HN.IGL.)Z[1116184444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1124 +2444 %%%%,04444 %%%)0 M)110 4
M444 %%%% !1124 +1FDHH **** "BC-)F@!:*2B@ S1113$%%%% !11FDS0
MM%)10 M%)10 N:3-%% !FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ S2YI** %S7AU[^T%#IWC2^LGT];K1(I?*CGA;]YQPS#/#
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M%,8#(I*4'!YI":0 !GK1CTHZ^U!/I0 'BC'>C%!'- "4IXP:3'-&.>:0#T(
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MHSS2G!P!0>!0 F2>HHZ4;ORI#0,7&>O6DQ2_PYI <?6D 9% '/M2XS28YP*
M#]:7.!Q2?=Z49[T )3LDC%)U- R#0,=GY<4T8I.]+T- A<X.:3)8T9[4F.:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1124 %%%%
M!1113$%%%)F@!:2BB@ HHHH **** "BDHH **** "BDS10 N:2BBF(***,T
M%%)10 9HHHH **** "BBB@ HHHH ***,T %%)FB@!:*2B@!<TF:** "BBBF
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?)GQE\
M7GQ3XUDM[:4O8:?FW@ .0S9^=A]3QGT KZS(!!!&0:\\N?@UX5D\46>N6ULU
MJT$WG26T9_=2$<CY?X<'!XXXZ4F,O?"OPD/"'@FUMI4"WMS_ *1='OO8?=_
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M8  ;\3G\,4 >N4444Q!1110 4444 +FBDHH 6BDI: "BBB@!:*2BD,6BC-%
M!FEI** %HI,TM !1110 4N:2B@!:*2EH **** "BBB@8N:*2BD M%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M *"+?^BXZ4MBH[GKM%%%9%A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E%% !11
M13$%%%% !1244 %%%% !1110 44E% !1110 44E% !1113$%%&:2@!:3-%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#X?Q@X]:.-W'6ACDTAP/K7H'$+SGGI2X)Z&FYS2]%XH 0@#K0!GD]*"
M.*,\4 &3F@^U*I I,Y- "A!MR>M-:E/6@>_2@8HZ9I#@T'I@4 $<4"$QQQ2@
M[>G-"YS@T,N#0 GO0>.0*4CC-&<C%(8H?MWIH7<<=Z7/8=:$;;]: !CQ@#I3
MUYCIA/YF@$@8H 1J0=*<..M!(/2@!N!2=.U+S2=Z #N*<3@8I!CO1UH ".*#
MD"E)].E!Z8H 3-'M2$=J .: '#BE;&0:830#0(.N13@QV[13?2ES@\TABCA2
M*9[TO(.:..O:@8=N>E/*C:#3,4N[*X- A,^E*>E(#BESNH&)LP,TG3FGOR,9
MI%&3S0 WIS0",XI6'-& 1[T@#'Y4-UI0V!BE(  S0 @7 R::13V;(XZ4W%,
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M*00/:D]J0!P*4'C-)CCGK2\$4 )QUI.II2.*5D90&(P*!C0<<4'K2<<4N#0
MO3F@L3Q2=^:7I0 =*4G/2FYQ1CO0 8^;F@]?:DI0,T  YHSGZ"COBE.,8I )
M[T_RV*&3' IG4XJQ+<*T"Q*,>M %<<]:.#UH. ,4F.* #.*,G%!'-!- "9XY
MI>E)VI<@GF@89!XHZ=:3'S4N,T !/Y4*N]L=*4 $>](<@YZ&@0YP%8 <TP\T
MHZY-&!NI#$YQS1TI3R<"DZ4P"C'% /- ZF@8A%'?% HQFD O(^E!.>U*BY-'
MJ*!#1][BK=O H#22\8Z"JJ':X)'&:?+*SL0#\M,!CX+DCIGBDQ0><4$#'%(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%)0 4444 %%%%,0444E "TE%% !1110 444E "YI*** "BC-)0 9H
MHHIB"BBDH 7-)110 4444 %%%% !1129H 6BDHH ,T444P"BBB@ HHHH ***
M*!!11FDH 6BDHH 7-)FBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!:*2EH **** "BBB@ HHHH 6BDHS0 M%%% "YHI**0Q:*** %HI** %HHHH
M**** %HI*7- !1110 4444ABT4E+0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+1249I +1110 4444 %&:** %HI*6@ HHHH 6BDI:0PI:2B@!:*2EH ****
M"EI** %HHHH **** "EI**0Q:*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#X?<#.>U+M!%#XW9[4A.X#M7H'$.VA3[TW
M&3DT=.3001S0 +R3B@@YQ2ID'=VIR$;R33 81Q2<_A3FQNI&.:0 !D\#FD(*
M\'@U);.JR OT%)<2"68N!@=J8#.IYHSC(J5%#;5[YHND6)]J]: (NW-& *0Y
M(S1GG-( (SS2Y^6GQ*KY)[4TGJ!0 +D\&D8\XI5^4[C2'#-D4#$Z=:<H]:0C
M)S1(<XQQ2 :?O4O2D.:<#QS0 T<GI0.N*=GTIO([<T"%*YH[<4@/7-&2#Q0
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M9X_Y$C4O^PDW_HN.OFW%?27[//\ R)&I?]A)O_1<=3+8J.YZ[1116184444
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M>*93E9$# ^Q&:$Q-$M)FBBF(**** "BBB@ HHHH ***3- "T4E% "YI,T44
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ME"KUYJ,Y- "YHQ2#FE[8%  12=J7Z4<8]Z $[4 \48H(H /K2_6DQS01^5
M>30>*7-)[T@#&#2YP,4 ]J#SQ0 F*!P:0G]*,YH&+FCK24N.] "9P:L16CO"
MTQX457(R:N2WF;40*,#N: *G:ESQ2# R*3C'O2  <C!HX&:!0!0 F.]*.O-*
MH).!0^ <4 )P.M ]:#G%!Z"@!!2\BD/ Q1T% "\#FOI']GGGP1J/_81;_P!%
MQU\W'I7TC^SQ_P B1J/_ &$6_P#1<=3/8J.YZ[1116184444 %%%% !1110
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M^&_B!I>NA(9F%I>'CRY#PQ_V3_2NMKY<!(.0<$=Q7:^&/B-J&C;+:^W7EF.
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ I*** "BBBF(***2@ HHHH **** "DHHH
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M6D;OCIO*C</SR*^1K<CPI\4$X(33=6V\#^%)<<9]A7T7\$+B\D^&UM;WMO/
M]K/)$GG(5+H<,",]OF(_"N+\8_!/7/$?C[4M5L[FSM["YD616=B7SM7=\H']
M[/>@#WK-<A\4-/&I_#37H",[+5IP/>/#C_T&NGLHI8+"WBG=7F2)5D=1@,P
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MFF O04AS1GM2]Z0"9SQ1T-&.:.G- !SF@J<TM)@@T# 'FC'-(1S0* #!_.E
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MYDYZ$^Y(_"OH3XK63:K\,-86 AML G7'.X*0W&/I7AOP%URWTGQXUM<.$%_
M8$8_W\@@?CC% 'T_:Z?96-LMO:VL,,*C"QQH  /I3K>SMK3S/L\$<7F-O?8H
M&YNF34U0W=S%96DUU.X2*%"[LQP  ,FF(P/'OAE?%O@W4-) 'G/'O@)[2+RO
MZBODK0+J'PKXPA?7=(2ZBM92ES9W" ^QX/<=1]*]U\-_'&?Q5XMT[1K'0EA2
MYEVR/),7*H 2Q& .F*ZSQQ\*] \;$W,Z-:ZB%PMU#P3_ +PZ-2&:.A>./".I
MZ9'-IVK6,,.T?NI)%B9..A4XZ5PGQ5^+FE66B76BZ%=)>7]U&8GFB;*0J1@G
M/<XZ8KEY?V<-46?$.OVQB)^\T)! ^F:[#PG\!M"T.YBO-5G?5+A,$1NH6(-Z
M[>_XF@#*^ '@JYTZVN/$]]&T;7<?DVJ,,$QY!+_B0,>V:]4\6>%[+QAH$VCW
M[2)#(RMOCP&4J0>,_2MI55%"JH50,  8 %+3$<WX4\"Z%X-B==(M3')(H665
MF+,^/6NDHHI@%%%)0(**** "BBB@ HHI,T +24CNL:EG8*HZDG %8][XKT+3
M_P#CXU.W!Z81MY_3--1;V-(4IU':";]#9HKAKSXJ:' "+>.YN&![*%!_'_ZU
M8%W\7KEC_H>F1(/^FKEOY8K149OH>A2R;&U-H6]=#UBBO#+KXE^)+C<$N8X5
M/:.,<?CUK%N/%&N7>1-JMTP/4>8<5HL-+JSNI\-XA_')+[V?1$MQ#"NZ65(Q
MZNP%49O$&CP ^9JEH,>DH/\ *OG1[F>0DO-(Q/JQ-19S5K#+JSKAPS'[=3[E
M_P $^@)?'7AJ(D-JL1(XPJL?Z52E^)?AN(\7$TG^Y'_C7AE%4L-$Z8\-X5;R
M;^[_ "/:F^*OA\=([P_]LQ_C4#_%G1Q]RTNF^H KQRBG]7@:KA_!+H_O/7S\
M6]-SQI]P?^!"FCXN:=WTZX_[['^%>144_J\"O[ P/\K^]GL*_%K2B?FL;D#V
M(-3+\5]#/WH+L?1 ?ZUXQ12^KP$^'\$^C^\]M3XH^'7.";M/=HA_C5V'X@^&
MI@,ZB(R>SHW^%>"T4GAH&4N',(]FU\_^ ?1UMXBT:[4&'4[5L] 9 #^1K11U
MD4,C!E/0@Y!KY@!(Z'%6K?4;VT</;W<T3#H5<BI>&[,Y*G#*_P"7=3[T?2]%
M> VGCOQ):'*ZE))[38?^=;MI\6-6B"K=6EM..[ %2?RXK-X>:V."KP[BX_#9
M_/\ S/8,T5Y]9_%G2Y?^/NRN(/\ <(?_  KH;+QMX>ORJQZE$CG^&7*?J>*S
M=.:W1YU7+<72^.F_S_(Z"BHX;B"Y3?!-'*G]Y&##]*DJ#B::T84444 %%%%
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MG=A29&,4F<=* %8<>] /&*#TI"*0"=*=CTZ4F#WH]N@H&)U-&"*!U]J<!Z4
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MN+CNCPZV&K4':K%H?1114F(4444 %%%% !1110 4444 %%%% !1110 4444
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M %HI*6@ I:2B@!:***0Q:*2EH **** %HI*6@ HHHH *6DHI#%HHHH ****
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M,]BHGKM%%%9%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBE74X*D8(-?3]<KXI\#V'B&)IHU6WOAR)5'#>S5O"K;21]#@,Z<+4\1JN_\
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M "BBB@!:*2EH *6DHH 6BBBD,6BDI: "BBB@!:*2EH **** "EI*6D,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /B''.:3<-V11GDT#J>*]$X1>#QTH7!;':DXHZ]*
M'*A9\ T'Y&P:$8H0YI'?+[O6@ )YQUII7N.*D0 J2>U618,;)K@M@=J+ 5%!
M;GTH3_6;CT%+'( IS30.<T#'D[G)6F-R>>M )!)I,$\F@!0-W%.=0JCN:9GC
MBG*V>M #01F@X%&!GF@X-(!,4=#3LD'I2 YS0 [..M-89YI1TSWII)S0 ;,G
MBE(SP>HIT9PYH^^YQ3L P]:3.32GY3BE8#&12 :HR?:E(STH! %+R>>@H ,
M"G^4VS?CY:B.3Q5I[E6MO) Q[T 5L#\:0''6G)\O6FGJ?2D N:.">:.XH"C=
M0 TC!SVI3BGO@# IJX(P: $'#9[TK$DY-)C-'U- P )YI>0:3)%*<B@!N><D
M4H- P>M'&>M "<^O%& >:7J:3.#Q0,7O0,]:3/IUHY/% #E&]L4CD XH'R]*
M"._K2$)DYHQSFE  ZTF0#[4 .CQOR>@I'(+DCI29I#S0 H)[T#)YI.*7IP*!
M@0*7/K1@]Q2?6@!#GMTI0">W-(>E2Q%0=Q[4 ,;(X84WOTI\K>:^<<4BC\:
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MHR'(KEG"4=SY+&8"OA)6JK3OT)Z***@X@HHHH **** "BBB@ HHHH *,T44
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MD!P&/5<GK7M%(!:***8@HHHH 6BDI: "BBB@84M)12 6BBB@ HHHH 6BDI:
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M :3\U./)I"..*3/&.] QPR:0C!I.30>!0(7ITH[T X'-!Z4@'%N,"FCH3WI
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M0 4444 %%%)F@!:3-%% !1110 4444""BBDI@+1FDHH **** "BBB@ HHHH
M**** "BBC- !129HH 6BDHH 6BDHH 7-&:2B@!LL4<\9CEC5T/56&0:XG7OA
MIINH[I=./V*<_P (&4/X=J[BBJC)QV.C#XNMAI<U*5CYYUKPUJF@RE;VV81Y
M^65>5/XTW1/$6I:!<>;8SE5)^:-N5;ZBOH2:"*YB:*:-9(V&"K#(->?^(_AC
M;W.^YT9A!*>?(;[A^A[5TQKJ6DSZC"Y]1Q$?98R*5^O3_@&WX9\<Z=KZK"Y%
MM>XYB<\-_NGO759KYMO=/OM'O/)NH9+>9#D9X_$&NX\*_$B:U*6>LDRP=%G
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M<D\GBD'&1VI .#!NU')SZ4F>-O:I20(< <^M,+D.><8IX;:IXIHZ<BC)'O0
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MV()'I36()&*3J?:FD<T@ CO1C/':@<'FEW<4#&]/<T#K0?UH4$G% "XYJ2W
M>X16^[FHSG.#0#MZ?G0!M:S-&MND"8./2L, ?C3F=F.7)-("0>E#&& #0!S2
MY%)SG(H .32<YIR\DCO2$8-(0NT8YI"* "V<T['K0,:!QUI._O2GO2$\T (V
M0?>G8Z4?6D[8H ,4#'>C=QBGH@VDFD PTIXP:,]:;F@!V#UHZT8XYHSV% !T
MH.<BCZFD5L'VH&'W6YI2.])P<GUHR.!3 "!0%P<TGO2\M2 1CFCWI,9HSVH
M.E'N:.@YH]C0 'IF@YZT=#@T9YQVH 3/;M1QG%*2 <4AZT . S\J\XIIR#BI
M(F" GJ337^]F@!.<<TE+VI,<9I#%I#CM2@#%.90H H 8.*%&:"":#]: %XZ=
MZ"<F@<'-(0,YH 0G!I0<T,0!2#UH ,X-'N*,<T#I0 '&:2E. ,4"@!!S2]J,
M49[8H&)@"G*N3UI.* ,<]* #@'%'(HQGFDZ\T@%/'(/-)UHR,<BA>>*0!GC%
M'M01C(H')%,8$8-!!XH/6C)H$%(.M+COF@Y)I )SG%+MYH/:@]* #H:3-&:!
MUS0,#FC:Q.*>A')-/B=5RQZ]J+ 1,I'!IO04XL2V32JNXY/2BP#1U&.]/D4)
MBF' 8XI3\P^:@!#BOI#]GC_D2-1_["+?^BXZ^;^E?2'[//\ R)&H_P#81;_T
M7'43V*CN>NT445D6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%)0 4444""BBBF E%%% !1
M110 E%%% !2444Q!2444 %%%% !117#^+?B'::(6M+$+<WO0\_+']?4^U5&#
MD[(WP^&JXB?)25V=+K6O:?H-H;B_G"#^%!RS'T KQSQ5X_O]?9H+?=:V7]Q3
M\S_4USFJ:M>ZS>-=7T[2R'UZ#V [52KNIT%'5[GVF79+2PUIU/>G^"] HHHK
M<]L**** "BBB@ HI0"Q  ))X %=[X8^&MYJ7EW6J%K:U."(_XW']*F4U%79S
M8G%4<-#GJNR.0TG1;_6[M;>QMVD8GDX^5?<FO6_#/PWL=)9+G4"MW=#D*1\B
MGZ=ZZ[3],L]*M5M[*W2&-1C"CD_4]ZMUQU*[EHM$?'8_/*V(O"E[L?Q8@ 10
MJ@ #@ =J***P/""BBB@ HHI*!!1110 444E !1110 444E !1110 4444 %%
M%)FF(6DHHH **** "BBB@ HHI* %I,T44 %%%% !1110 4444 %%&:3-,!:*
M2B@!:,TE% !FBBB@ HHHH **** "BBB@ HHHH **** "LG7O#NG^(;0PWD?S
M@?)*OWD/M_A6M10FT[HNG4G3DIP=FCP3Q!X8U+PK>K(2S0ALQ7,? _\ K&NY
M\&_$%+[R]/U=PES]V.<\"3V/H:[RZM(+VV>WN8EEA<89&&0:\B\7^ 9M'+7V
MFAI;/.60<M%_B*Z5.-1<LMSZ:CC</F<%A\7I/I+^ORV9['FES7EO@CQ]L\O2
M]8D^7A8;ACT]F_QKU $, 0<@]"*PG!Q=F>#C<%5P=3V=1>C[CJ*2BI.06BDI
M<T %%%%( HHHH **** "ES244 +1249H 6BBB@ HHHH *7-)10 M%)2T %<'
MX\\$KJT3ZGI\8%Z@S(@_Y:C_ !KO**<9.+NCHPV)GAZBJ4WJ?,#HR.4<$,#@
M@]J2O5?B%X*\T/K.FQ?..9XE'7_:']:\JZ5UQDI*Z/NL'BX8JFIP^:[!3D=H
MW5T8JRG(([&FT51U'NG@7Q4GB#2Q#.P%]  )!_>']ZNMKYOT/5Y]#U:&^@)R
MA^9?[R]Q7T)I>I6^KZ=#>VKAHY%S]#W%<M2'*[H^+S? ?5ZG/#X9?@^Q<I:2
MBLCR!:^7_B);/X7^-4>J7" V\UQ'=*3T*Y /Y5]05Q'Q*\ 0>.=$"(5BU&W!
M:WE/_H)]C2:&CKXY+75=.5U*3VMS'GU#*17S=>I=?!SXK_:848Z3<MD#LT3'
MD?5:SM-\:^.OAB[:3=0M]GC8A8;E"5'^ZWI7KWBC1X_BI\+;:^MT07_E"X@(
M[./O+^-+<>QY]\<?'ECKRV.BZ5.L\,>)YI%/&XCA?PKUCX3:1+HWPYTR"92L
MLJF=E(Y&[FO)OAS\%M1N]2BU+Q+;FVLX6#+;-]^4CU]!7N6H^+_#6A2):WVL
M6=L^-JQEQD8[8'2A=P?8W:*K6.H6>IVRW%C<Q7$+='C8,*LU0A:*2EH *6DH
MI +1110 4444 +124M !1110,*6DI:0!1110 4M)10 M%%% "T4E+2&+124M
M !1110 M%)2T %%%% "T4E+2&%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'Q%CM30<'%.SVI!CI7HG".V[3D
M]*1C\W'2D'S<4H'6F G !Q2"G9"]><T$@KQUH 0=J.N11VYI!P>G6@!V_"[:
M9G!IP0DD4AX;%(!1PO-)U%.Q\O-(""<'I0 @R#@TA'-.8YIN>.>M Q>@HQCF
ME]*5F!X XH$-(R,]*E:0>5LQS46<\=J.IH&'1<4?=H/-.09'- D,^M)CG)I6
M'.:#B@8AQVI<9'-"C'6E<8QB@ W_ "X%(6I#QP.M ]Z0 %SFCJ/I1WXH/O0
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M M%%% !1112&+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\1'FD;I2@<]:0\5Z1PBCTH/R*:3//%&,]:   [
M:",8-&<$^E'+"@ ST)HY+9[4=.#2D#;P: 'QN%0@]:C((YI,'-.;)7'2@!O)
MXS0!R:=M*H".](PP,"D F :0J12]*.0:  9VGBI(T!C+,?PIG)% )48H :/?
MI2GBEP6]J;G:<'I0 #)'%2'A0*92\XQ0, 1FF<E_:G =300".#S0 C<D8H9C
MFE'"Y-(1QD4 (!SFG8!R.].C --. QQ2 0=.:;UIQ/K29XXH 4<\4GW>G6E
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MAI#STZTT K;3(3VI,GOTIQ0I@D=:DDVB,>M," ?>Q2Y&2*!BDVU(!P:4#%(
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MO6OA?XA^TVCZ/</^\A&Z'/=>X_"L:L;JY\_GF#YX>WBM5OZ?\ ]'HHHKF/E
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MX_W$I_?*!]UO7Z&O.J^F+VTAO[*:TG4-%*I5A7S[XCT*?P_J\MG*"5'S1O\
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M<4N#MP:<_P P!%(3M QUI -Z<D_A2GY_:DQGFG ^U( '<4G%&3]*0\4 &W%
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M %(':D)SQ2@9''6@@CM0 F.,@4\'Y#2*<<'I2CH<4 ,&.M /:E&!Q1WQU-
M ,4AZ4<@X(H//M0,0$"@C-!],T8Z4 &,D9I#UIQZTAYH !@4=328XI=V.!2
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M** "DI:2@ I*6DH ***2F(**** "L'QGIS:IX3O[:-2TGE[T ZDKR/Y5O4C
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M1244 +1244 <QXK\,OJ1CU33&\C5[;YHW7CS /X3_GVJWX8\0KKEDRRKY-_
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MC^1Z)1117,?)"T444 %+244 +1110 M%)2T %%%% PI:2B@!:***0"T4E+0
M4444 +124M !1110,*6DI:0!1110 4M)2T %+244 +2BDHI#%HHHH *6DHH
M6BBB@ I:2BD,6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK3,CFG8W=.E(1G\* $YSQ2]..]!X J78 @/>@9&3D4@.!2'&<4!2>M(8!NU
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MB\B!/N@^Y[UZ*JA5"J  !@ =J6BL)SE-W9XF*QE;%3YZKN%)2TE2<H444E,
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M!TA+/O)Y-)C)I.E'TH 7(!I>".E(#@'(YI!D'- $A0J,TP9S3P^X<TP\MQ0
M;2#2<GBE)IP4[<T@(]II01TIQ/'O30.,]Z!B #/O0O)]Z/?% /(.* '$XX-(
MP..*'Y;/:E))7CI0 F?E %)SC- '-*3QB@!O0\T[<Q'/2@?=QBG #;D]*!C
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M &*N1[TTY(-+]TY%(?7UH&&,#-&3GZT^, @YIIP#Q0 G XI1Z4<'K2 XZ=*
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MPBW_ *+CJ9[%1W/7:***Q+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!'6@9S0>1GO0 F[GIBG,<GFF]N:#R<F@ ')I2,4#@9I"<TABCBD)YHH)YQ0
MF>U+2C[O-)F@ YH-&<4#DY- !C!HI3UXIN"12 OV-H;D-QA0.M4I%"RLB] :
MOQ7ZP61B0?.>]9_.23WJF) V M)VS2CWI0,M4E"'@9HZG-!(!HQS0 =CBDSQ
M2Y/.!S28XH #Q1R/>E[<TG'6@8&@<FE&!]*0'GCI2 3'-.]@*3[IHW=Z %P<
M4@'S4 G/UH&: %8@\5]'_L\_\B1J/_81;_T7'7S<>37TC^SS_P B3J/_ &$6
M_P#1<=3/8<=SURBBBL30**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 0T444 %%%%,0AHHHH ***0T %%%!H 2BBBF(
M2BBB@ HHHH #2444P"BBB@ -)110(**** "DHHH *2EI*8!1110 444E @HH
MHH 2BBB@ HHI* "BBB@ HHI*8@HHHH **** "DHHH **** "BBDI@%%%)0 M
M)110(**** "BBDH 6DHHH **2BF 4444 %%%% @HHS24 +FDHHH **** "BB
MB@ HHHH ***,T %%)FB@!:*2B@!:,TE%,!<T9I** %S1FDHH 7-%)10!<M7!
M4IGD<BK%98)!R.#4OVB7&-U9N%V6IV1/=. FSN:J4$DG).32525D2W=BT4F:
M6F(**** "BBB@ HHHH **** %HI** %HHHH ****!A2TE% "T444@%HI*6@
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M<<4K#(!S^% "J !\U)C#<4A-*6!% %F*Y2*)DV\M59ASFD/ YI1R.:0#2<4
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M?BE/(H 3L<]:!DT*,F@ C- (.AI,D&E'-!Z4AB#K1DFES[4#IF@!,#;6A_:
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MAQW/7****Q- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*** "EI*44 %%%% !2TE+2&%%%% !1110 4444 %%%% !1110 4444 %%%%
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MDY)Q3VAVKF@8C9XQTI4'4T@R?I2K3 0$DX-)_%Q3LC--YSP: #OQ2 \TN*3
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M8@/))I6. *">:0F@ ZT#CH** :  YS0<BEP3TH;I[T (#GJ*./?-*.E X'-
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MF@!RTTDGM0.>M)@]: #!/:@''UIZ XI,DDB@ /R_UH!X.*%/SX/W:1MN<**
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M"@YQBC.!3 09/2@8!YIVW"YS2+W-( )H/)I.HI3TH ,C%&/ESVH & *#QQ0
M@P:3DGBCOQ2CY10 9(% !(S33DTX$XXH #T]:0<<XIP&WFDSDYH&'?-''4=:
M  *:%.<B@!W4>]*>%]Z;@DYHSFD N[''>F]\4HI.IH 7!'/:D..M'(H)SQ0
M9XI .:&XP.U*05YH&*>#2<TF"3FE%( '-!:EYQD4FWY=QI@  S1CGVI!ZTM(
M .!UI#TXHZGFEIC #CFC''-)DYXH8\8I 2P@-(I?[HJU?WJSHL,?"CTJB#A"
M!WH48X(H 3;C/-.&=N.](1D\]J.II (0>E?2'[/0QX)U'_L(M_Z+CKYQ)ST[
M5]'?L]?\B3J.?^@BW_HN.IG\(X[GKE%%%8F@4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %(:6DH ****8@I*6DH ****  TE%%
M:2BBF(*2E-)0 4444 %)0:* "BBBF &DHHH$%%%% "&BBB@ I*4TE, HHHH
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MD2V6K&+?+O/1?YUI5#;Q^5"%[GDU-292"BBBD,**** %HI*6D 4444 %%%%
M"T4E+0 4444#'I(R?=.*D^TR8[?E4%/1&D.%I-(:; NS'+'-)5D6HQRQ_"FM
M;$#*G/M2YD'*R"B@C!P:*8@I:2B@!:***!BUXY\4['[/XAAN@!BXBSP.XXKV
M*N$^*ED9O#\%T!_J)>?H>*NF[2/3R>K[/%Q\]#QVO?/ MU]J\(6#9R47RR<Y
MY%>!U['\*[GS?#DT'_/&8_KS6M5>Z>]GT.;"J79G>4445S'QP4444 +124M
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M(S@'--[<]:,Y'/6C'3)XH!#._'6G$#L*5P%Z4W=D&@8'Z4'&!0,;@:0C)S0
M%2:#U&.:<"7X% 0J>O(H 3[IR1UI#CO1NW'FC;GO2 &[8I6Z# H"X-/3:<T
M1=33@,]>E(>O%+]WO0 JX!Z4/CK3<TE !TYHSDX-'WN:#UH 0@@X%.SWI0,\
MTUCGC% !D \TC<GBC/8TN!2&!&!FA2<\TH'XT>HI@*Y .!2 _)CO0  .>M)[
MT@%!^7!I<@#'7WI,4G3K0 ;><T<*.>M'UI"!F@ (YZ\4X<<@T] "IS4:CK0
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MLMG'2C@"D[9I (?F- %.1#(P0#FG2QF)MK4QC&.:,C/M0!@T$"D 4'VH&<4
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M&#X:\':3X7MPMG"'N"/GN9 "[?0]A["N@-%)7*VV[LZDDE9!1112&%)2TE,
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MH ;M'0F@#G':D) [<UH66F-=PM+NQMZ4#**G:W/2D<@GBE<%79>N.*11D9-
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MH "N ,TO\..U)SFCDT )C(]J4$XQ2-VJP]G-';B=QA30!!BCJ>:3)ZT9YS0
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M**** "DI:2@ HHHI@%)2FDH$%%%% !24&B@ I*6DI@%%%% !24M)0(*#124
M%%%%  :CFFBMX7FFD6.-!EF8X %4=;URP\/Z>][J$ZQQKT'=CZ =S7@'C'QY
MJ/BJX:/<UOIZGY+=3][W;U-:TZ3GZ&52JH>IU_C7XKE]^G^'7('*R7F.OLG^
M/Y>M>322R32M+*[/(QRS,<DGU)IM=MX'^'UWXGF6ZNM]OIBGYI,<R>R_XUVI
M1I1.)N561B>&_"NI^*+WR+&+Y%_UDS\)&/<_TKW[PIX-TWPI9[+91+=./WMR
MX^9O8>@]JU]-TRSTBQCLK"!(((QPJC]3ZGWJW7)4K.>G0[*=%0UZA1116)J(
M:*** "BB@T )1113 #2444"  DX%/\I\9VFK$,85 >YJ6H<BU$S^E)5NXC!3
M<.HJI5)W):L20OLD!/3H:NUG4Y9748#$"E*-QQE8NNX12QK/)R<TK.S'YB32
M4XQL*4KA24451(4444 %%%% "55O(=Z;U^\O\JM44P,2BI[J'R9,C[K=*KU1
M 4444Q!2444 %%%% !1244 %%%%,!T<ACD#KU%;MM=$1[DP0W//:L"K=E/L?
MRVZ-T]C4M7&G8T2<G)HI**0PS1110 444F: %HI** %HI** %S1FDHH 7-&:
M2B@!<T4E% "T4E% "T4E+F@ HHHH 7-%)44TZPID\GL/6@!9YU@3)Y)Z"LJ2
M1I'+,<DT22-*Y9CDTVJ2%<4,1T)%)110(FMH_-F"]AR:UJJV,6R+>1RW\JM5
M+*2%HI**0Q:*** "EI** %HHHH ****!BT4E+2 **** "EI** %J6&8Q\'E:
MBHH:N-.Q?$L9&=P_&FO.B]#D^U4J*CD17.Q[N78L:;115$BT444 %%%% "T4
ME+0,^?\ QE;_ &;Q;J,8&%,I8?C6G\-)-GC"($X#1./TI_Q.A\OQ:S]I(5-4
M? ,AC\96/^TQ7]*Z=X'W#E[7+;]X_H>\T445RGPXM%)2T %%%% "T4E+0 44
M44ABT4"B@ I:2@4 +2TE H 6CK110,^;?%UE_9_BS4[?C G+#'HWS?UK%KO/
MBQ9_9_%:3@86>!3G/4@D'^E<'7?!WBF?1T)<U.+\@HHHJC4**** />_A=<_:
M/!$"9_U,KQ_KN_\ 9J[,5YS\';C?X>O;?O'<;O\ OI1_A7HU<%16FSY_$JU:
M2\Q:***@P"HKJVBO;.:UG7=%,AC<>H(P:EH%(#Y/UO0O&/PA\17$VDSW,=G+
M\L5W&@=)$SP&!!&X>_X51\-Z'XB^)_C:*>^:XN TBF[NW7"QQCMZ#CH!7UU<
MW$%K;23W4L<4$:EG>0@*H'<DUYAJ_P >/!VD3M;V:7-^4.TM:Q@)QZ%B,CZ4
MAGITQ:WLW-O"9'C0[(E(&X@< 9XKYS^&?AW6]7^,UUJVN64UM-:-)=SI,A&'
M;(11GW.1[+7NGA#Q5:^,/#D6M6L$L$,C,NR;&X%3@]":T]-U.PU>U%WIUW#=
M0$E?,A<,,CJ,B@"Y2BDHIB%I:2@4ABT444  I:2EH **** %%%(*6D,****
M"BBB@ HHHH **** "BBB@ HHHH **** /B/&/K0!UYI<?Q#K2?Q<5Z9P"Y&W
M&:3J*#@&C.V@0'G&/QJQ:-&)#Y@XQ59<YSVI_ ''2BX#IBC2DKP*8,#@=:3
MS2# X% "L* A)XI.OTI=V*0["NFP#%210-(<"HW)(&33X[AHL[>33 C=6C8H
M>QH&0:5RS-OSDFC-(! &R2M!=C3Q-M7;BH\<T#%Y;GTHSG@T G) HY- " 'D
M4NS*Y[TH_NBE7Y!0(BR<'-.497)Z48SDTJY/7I0 F/RIRCG'>EE(V@#BF="#
MGF@8-@-[TIP*1B2V<8I.",T"%/UI#UZT$]/2@=3F@8NT$9[TH(*X--Z"CO0
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M"@8/M248)%*.#04(: <<TIZTT=?:D 9YS2C[W%*U(#Z"@!,DDT[&!ZTA'&:
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M@ HHHH #24&B@ HHHIB$HHHH **** $HHHH #2444P"BBB@!#1110(*2BB@
MKF?%_C73_"=F6F(FO''[JV4\M[GT'O6=XZ^(%MX7MVM+4K/JCK\J=1'_ +3?
MX5X%?W]UJ=[)>7LSS3R'+.QKHHT>;66QSU:W+I'<N^(/$6H^)-0-WJ$Q8]$C
M'"1CT K)HZG KUGX=_#7SQ%K.N1?NN&@M6'WO1F'IZ#O_/KE*-.)R1C*I(H>
M OAI)JYCU/64:*P^]'">&F^OHO\ .O;H88K>%(88UCB0!511@*/0"G@!0
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M)??FI*S<G<U458J26Y09!R*AK1JC*NV0@=*<97)DK#*6DI:HD**** "EI**
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MV$#,3W)C7-:U,0M%%%(8M%%% !2TE** "BBB@ I:2EI#"BBB@ HHHH ****
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M2HP&<]: &[<G)I001DBD!P>.:5CR !0 F[M3U(SAABF[0.G6@9/+=: %;!;
MXH( (%(P)P>U*QZ8I ,8;3UHP-O'6@@G)/%(,YZT#%'3!%)QU%.Y_"DS\W2@
M!R0LRE\<4!>"2:D6?:A4=*AR2QIB#H>.:.2<T\(5R3Q[4UL9QVI#0TDYI1R:
M?&HY-1G )% "[21D]!0<XXIRR87;C--YZ]J %) ''6@-D8IN.^:4# XH&(0/
M6E6FX(.32YSTXI .'J336(_AI<#..M!!SSQ0 @&>O6@@],T -U IRX'-, .0
MM1X]:>^3]*0G=C%(9)L.P$]*8!P>>E.,C;-O:F[: #KVYHXQ[T Y&,4$#;[T
M"&@E34JCN14?\.#4RL/)QBA 1-R<BD ZT8I2=HQ0,:PQTZ5-#;F4%@>!47.,
MFGQRNB':>#0@=R2"V,S,,_=JNV4<IUP:D2=T!VGD]:C(RW7)H8(3::7MFC.T
M8I.@I +@D9(I2IVY[4A<E<4_=E,4 ,(XXZ4F?EXH.1P:#CJ#0 <@4E+D$8[T
MG3WH&+S]ZCG&1THXSUI0"1@<B@!-I/%(>N*4-CD=:0D]:0"Y.,4@&#0/>@GL
M!0 NWWI".QI.?QH )X/:@ P15]+1'LS,3R*HG)%/\UQ%L#?+0!&!G- ]*3..
ME.SQTH 3&>:0G)X%+1G!XH  VW@B@#!SVI203323G H&!Z]*4?I29(/(I>U(
M!,@=*7MDBFXYI^?4<4 -Z\TO3FDR,XQ05((R>*  ,<\T$CM2'KGM2@#&:!B"
MD8GO3LC/M2'.<F@ Z]:,\8"G'K2]0!W/%;:VD5OI#/( 7(I 8?04W!Q2]3\O
M2C!SP>*8"8W&G9XQVI,XI,T@%XZ4#- RIZ4N: $R"OO1UX H]R*,X'% "@\X
MH; Z4G09H/(R*!@",]:0DD^U+C(XI..F*  <'FEQS0>*/QI  '>AL$49(I .
M,T  P*.!0<8S2X'3- #3@?2C''%#9/TI1QVH 3/R^]*",4F 3GH*7&>*  ].
M:#C'6D(].:4 8H ;W]J6@_2@9'6@8<T9YQ1UI N:!"X.<FCCJ.E*#\N#1T4C
MUH&-[Y[4 9.: /EQ1TI *>, 4$<4''%!S3 3 QTHSF@ G.:!QS2&!'/%*IV\
M]Z;UYI2"* !B6/-)C)R:7K2=\&@!<[3P*3'?O0<YZ<4'AJ0 #GZT$<YH^G6@
M<\=Z %R0.:. ,TAR3]*=VSVH&-Z<TN[F@$XQ0>!0(3&>]?1_[/7_ ").HY_Z
M"+?^BXZ^<,&OH_\ 9ZS_ ,(3J.?^@BW_ *+CJ)[%1W/7****Q- HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6DH ****8@I*4TE !11
M10 E%%% "4444Q"4444 %%%% "4444P"@T4E @HHHH *0TM)0 444&F E%%%
M !112&@0444&@!*\_P#B!\1(?#T3Z=IS++J;C!/40CU/O[4SXB?$*/0(7TO3
M)%?4W&'<<B '_P!F]J\(EEDGE>65V>1R69F.22>YKIHT;^](YJU:WNQ%N+B:
M[N)+BXD:6:1MSNQR2:CZT5ZO\-?A[]I,6N:Q#^Y^];0./O\ ^TP]/0=ZZIS4
M%=G+"#F[(F^&_P .=WE:WK4/R\-;VSCKZ,P]/05Z_1THKSYS<W=GH0@H*R"D
MHHJ2@HHHH #2444 %%%!H 2G1C=(H]Z;2JVU@?2A@B]12 @C(Z4M9&HR0;HV
M'M5*KDSA8SZG@53K2&QG/<#24451(4E%%, HHHH$)1110 4444 %)2FDH **
M**8!1124""D(!!!&0:6B@#(N(3#*5['D&HJU;F'SHB!]X<BLH\<52)84E%%,
M04444P"BBB@ HHI*!!1110 5>L9LCRF//\-4:%8JP8<$4AFW14<,HFC#C\13
MZDH****8!112C&><X]J $HHHH$%%%% #ED=!A6('UI\*^=.H<DYZU%3HW,;A
MQU%)KL-/N:H10NT*,>F*S[J(1R_+T(SBK0O(BN3D'TQ5.:4SR;L>P%9P33-)
MM6T(J*4J5Z@CZTE:F8445'-,L*;F_ >M !-,L*9;KV'K69)*TKEF-)+*TKEF
M/_UJ93L2V+124M,04444 .13(X4=2:V44(H4= *HV$7+2'Z"KU2RD6C>.8]N
M!GUJOFDHJ4DMBFV]Q:*2EIB"BBB@ I:2BD,6BBB@ I:2B@!:***!A2TE% "T
M444@"BBB@"_ X>(>HX-25G([1ME35@7?'*<_6LW%]#1274L]*H2MND)'2G23
MLXQT%1548V%*5Q:*!13)%HH%% !1110!Y[\65SI%@WI,?Y5P?@OGQCIG_78?
MR->@?%8 Z#:GN)OZ5PG@2/?XQT_C.U]WZ5T0^ ^OR]_\)<O21[W124M<Y\B%
M%%%(!:*!10 4444 +1110 4444ABT444 %+24M  *6DI: ,;Q9;?:_"FIPA=
MS-;OM&.^.*^;*^I[E/-M9HR,[D(_2OERXB:"YEA;[T;E3QCD'%=.'>C1Z^6R
M]V2(Z***Z#T@HHHH [OX33>7XQ*?\]+=U_D?Z5[G7@/PQ;;X\LAZK(/_ !QJ
M]^KCK_&>+F"_>_(*6DI:Q.$****!GRQ\0-/U/X:_%4Z[IP989YC=VSGE6+?Z
MQ#^)/'H178>*OB_X;\7_  SU*QWRV>JS0@?99$8@L"#PX&"/KCZ5[%X@\.:5
MXHTM].U>T6XMVY&>&1O[RGL:\0US]G"\%PSZ#K5NT!/$=ZK*RCTW*#G\A4C*
M7PP^*>A^!_ 5S97BSSZ@;MY8X(TX8%5 RQX'(/\ A7+V[:W\8OB3$\Z$+(PW
M!/N6T"GU_/ZD_A76:9^SAK,ERO\ :FM6,,'\1ME>1C[ ,%'XYKVWPCX+T;P7
MIGV/2H""W,L[\R2GW/\ 3I0!OPQ)!"D,:A8XU"J!V X%/I!2TQ *6DI:0Q11
M24M !1110 M%%% !2BDH%(8M%%% !1110 4444 %%%% !1110 4444 %%%%
M'Q(<#@T=5XX-)CG%#'H*],\\7 (Y-*0,=::!B@#O0 #D'/2@@ 9'-/?:% %1
MCCK2 7JO-)T&0: 31C)IC!23UZ4I&!TH.!\M. H ;R1R* #N -*Q)Z4I'RT
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M' 4 9)-?'7CKQ1+XO\6WFJ,6\@MY=LA_AB7[OY]3[DU,G8<5<^E_^%J>"/\
MH8+;\F_PK=T/Q'I'B2WDN-(OH[N*)MCL@/!QG'-?$]?1/[/'_(L:M_U^#_T
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M <BD"[^E+C!H!"9P..*4 =<\TAZ9I0._2@!& SSUJ0J%3/>HSQR!S2?,>2:
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M%LG<>E,)!-  !QS030.:"0: #OFCGMTI!^E!//%(!<'K2&C)[4N.,TQB=NE
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M24&BF 4444 (:YSQEXMM?">CM<28>ZDRMO#GEF]?H.]7?$?B"S\-:1+J%X^
MHPB _-(W917S7X@U^]\2:M+J%Z^6;A$!XC7LHK:C2YW=[&%:KR*RW*NHZC=:
MKJ$U]>2F6>9MS,?Y?2JM%3V=I/?WD-I;1F2:5@B*.I)KOV.#<TO#'AV[\3ZU
M%86H(!^:63'$:=R:^E-&T>ST'2H=/L8]D,8Z]V/<GW-97@KPE;^$]'6$8>\E
M :XE]3Z#V%=)7#6J\[LMCNHTN17>X4445@;A24M)3$%%%% !24II5C9N@XH
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M*3\EP*3FAJ#9]A[U_O#\Z4$'H0:^'GO+J1MSW,S-ZLY)J]8>)M=TMP]CK%]
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MT;L<#I2 "*0C\!3NIIO\6#0 I8CBFXP>:<1S31RW- "[3G(HQQ3CP.*/X,T
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MY/4T2T"HY8PZG^\.E244D,H44K_?;ZTAK8R$HHHH$%%%(: /FG]H+_D?+/\
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M-$?S#<;,Y&>FTUD']H2X*$?\(Y'G'7[8?_B*N4[.R(C"ZNSV"BO%O^%\S?\
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M3*/*[#MA"\TTGM3Y9 V .E,_AS5$C1UH;@\4HYI<9Z4#&C!'(HQCDTOL:4@
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M8H&-)P>G-+P>>]'0YQQ2GGF@0W/7- I>#10 T]:D0#!+4SO2Y)XH&'!/M00
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M8>+/^1NU?_K[D_\ 0C7V?7QAXL_Y&[5_^ON3_P!"-:5#.GN6/ G_ "/>B?\
M7VG\Z^R*^,O!EQ':^--&FE8*BW<>2>@R<5]F@@@$'(-%/8*FX5\9>,O^1TUG
M_K\D_P#0C7V;7QEXR_Y'36?^OR3_ -"-%0*>X_P1_P CQHO_ %^1_P Z^RZ^
M,_!'_(\:+_U^1_SK[,HAL.H>3?M ?\B79?\ 7X/_ $$U\W5](_M ?\B79?\
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MC;AU%7]"S_PD.F_]?47_ *&*]4^/L$4.I:0(HD0&%L[5 [UY;H) U_31C/\
MI47_ *&*49<T;@U9V/L+4/\ D#77_7N__H)KXZNGCPZ*,ON/\Z^Q=0_Y UU_
MU[O_ .@FOE+P7/9V?C_3;B^EBCM4N"9'E("@8/7-94'9-FE97:/2/V?01+KF
M0?NQ=?\ @56OV@P3IVA8S_K9OY)7J6CZQH6JF4:->V5P8\>9]F=3MSTSBG:S
MJNBZ4D3:S=V=LCDB,W+*H)'7&?PK/G?/S6+Y?<M<^,\=R/SJS#J%]:Q[+>[N
M8D)SMCD91G\*]0^->KZ'JK:3_8UY97/E^9YGV9E.,XQG%=K\$;6WE\"EI;>)
MV^TORR FNAU+1YFC%0]ZUSYWN)[B[<-<S2ROC :1BQQ^-0E><5ZA\=(TA\9V
MRQ1JB_9%.%4#N:Y+P"JR>.]&61 RFY&0PR#UJE*\;B<;2L<YANF#BG1QO,X2
M*-G<] HR37U_XG\-PZYX;OM,@C@ADN8]@D\L?+R.>*HZ5H/A?X=:*),VUJJ#
M]Y>3D;W/UZ_@*Q]NK;%^R=]SY<?0M7BA\V33+Q(O[S0,!^>*S\%6*\@U]86/
MQ1\&:C>"UM];B$K' \V-XU)_WF %/\5_#_0?%UK(T]K'%>,O[N\B&'![$X^\
M/K1[:S]Y#]G=:,^2\X;@UT?@(D^/-%R/^7E:I^)/#M[X6UV?2[]1YD9RKKT=
M3T85<\!?\CYHW_7RM:MW1DM&?4/C+_D3=7_Z]G_E7QU@CZ5]B^,O^1-U?_KV
M?^5?'9.!ZUE0V9M5W$R-WM2\L< 9K;\)^%+_ ,7ZW'IUD ,_-+*P^6->Y-?3
M/A?X>^'O"5JGV>TCFNE&7NYU#.3ZC/W1]*N=11(C!R/EN'0=9GCWQ:7>R)C.
MY8&(_E52>UGM'V7,$D3_ -UT*G]:^L;WXD>#]/N3;W&O6OF@X(C)< ^Y4$5H
M1R^'?&6FL$:QU6T/!'RR!?Z@_K6?M6MT7[-=&?&X[YH'H:]9^)_PI'AZ!]9T
M,,VG _OH"26A]P>Z_P J\FP1U-;1DI*Z,G%IV8$@< 4 DFEP,'!YI%7CK3 E
MAVK,&;I3KMTDFRHXJOGG%2*I=E11EF.!3$>S_ /P[YE[?:_*GRPKY$!/]X_>
M(_#C\:Z_XK>+CX:ET%(GQ(UXL\B@_>C3J/S(KI? >@+X:\&Z?I^W$HC\R;U+
MMR<_3@?A7SU\6=>_M[QW=^6VZWL_]&CQTROWC^>1^%<T??G<W?NP/IF_M+7Q
M!H,UL^)+6]@(!]58<']:^/-5TZ71]4N]-N1B:VE:,Y[X/7\>M?2?P>\0?VWX
M%@@D?-Q8-Y#Y/.WJI_+C\*\Z^._AS[%KUKKD*8BO5\N4CH)%Z?F/Y44GRR<6
M*HKQN>1$ #%*%;&0"12'@^M>Y? ;5;:X@U#0[F&%I%/VB(L@)(Z,/Y?K6TY<
MJN9Q5W8\,(/TH%>__';PU%)H=GK5K B-:R>7+L4#Y&Z$X]\?G7@'!XHC+F5P
MDN5V <9S1@MT!I.^/2OI3X+>&8;'P9_:%U;QM-?R;QO0'"+P.OOFE.7*KCC'
MF=CYMY Y!'UII'/6O6OCKK%O+K]IHUK'&JVB>9+L4#+MT'X#^=>?^%O#-_XM
MUN+3+!1O;EY&^[&O=C0I75V#5G8QL'.,9K0AT#6+F/?!I=[(F,Y2!B,?@*^H
M_"GPX\/>$[9#%:1W-X!\]W.H9L_[.>%'TJS??$3PEIUPUO<:Y:B13AA&3)M/
MH=H.*S=6^R+]GW9\D7%G=6C[+FWEA;TD0J?UJ$DU]E6][X<\8Z>ZPRV.J6O1
MT^63;GU!Z&O%_B=\)(]%M9=<\/(WV)/FN+4DL8A_>4]2OJ#T_DXU$W9B<+*Z
M/','/6G;2>@)H*XYS7T!\ [:WG\-:FTL$;G[4!ED!/W:N4N57)BKNQ\^LI!J
MS:V%W>G;;6DT[#M%&6_E7TYK/PPT_P 1>.QK.I(IT^&UCCCMH_E\QPS$[L=L
M$?6NAN-=\*^%8Q937^F::$&1;ATC('^X.?TK/VO9%^S[GR-=:/J=BI:[T^ZM
MU]9867^8JGDA,5]IZ=K&DZ_:L^GWMK?0]'\IPX'L1_C7F'Q2^%FG7&D7.N:'
M:I;7MNIEF@B7"3*.N%[,.O'6B-76S!T]+H^>>E* 3T!I>M>T_L^V\,USKGFP
MQR82+&]0<<M6DG97(BKNQXL01C((I-W.*]Y_:!@A@TC1S##&A,[YV*!_#7@V
M0!2B^97&U9V =:7:P_A)_"E\LX#5]?>"K*T;P/HC-:PDFRB))C'/RBB<^4<8
MW/C[!Z=*< ,8[UTGQ 54\?ZVJ*%473  # %8VF:7=ZSJ5OIUA$9;J=PB(.Y/
M]/>FMKD^142,R2+&.I-;$WAK4G1&M+"ZN-W_ #RA9OY"OHKP3\)=$\,6\5Q?
M0Q:AJN,O+*NY$/HBGC\3S]*W]6\=>%O#\WV;4-9M895X,2G<R_55R16;JZV2
M+5/N?(MUIU]8_+=VD\!/3S8RO\ZJCI7V7IOB'PWXL@>&ROK+4$Q\\!PQQ[H>
M<?A7F/Q'^#5I)9S:OX8@\B>,%Y;)<[9!U)0=C[=#VQW%5ULP<.J/ ^.E(!05
MQUZUU'@7P=<>-?$4>G1.8H%7S+B;&=B#T]SD ?6M&[:D;G,HC,VU%+,>  ,Y
MK2'AW7&C\Q='O]G]X6[X_E7UEH_AKPWX+TW=9VMK9QQ+^\NI2-Y]V<__ *JH
MO\4?!4<WE'Q!;%LXRH9E_,#%9>T;V1IR6W9\F3V\]O)Y<\,D3CJKJ0?UJ(X4
M^M?9^WP_XOTL/ML=4LG& V%D _'L?UKP+XL?#*+PFT>K:/N_LR=]CQ,2Q@?M
MSW4\]>GXU4:B;L)PMJ>7$@\4F=O%'(&#S2?459(M ZTN >:3\*!"8HP<TN:"
M,B@!0!^--'O3N@SWI.^30 TBCFG+U.:;_%0 "E(.0M*>M(3SGO0,5EQ2 <9H
M&>II<9/'2@!,8[]:3M2D8:@\T (.E+]XX-#48STI *3VIF>:7/:ER,4 -/J*
M.U* 30RXH 0'CD4 '.<TN<BDSVQ0,7CFA6*\@X-)[4=..M( 8ESN)R:!P,>M
M+G Q4R6Y\DR-P*+ 0@C'2DSCK1S0:0!G%!R>E'0T9YIC G ]Z/0T'K2J1WH
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MBIA0CC.6('5A2EL$=SY6KZ)_9Y_Y%C5O^OP?^@"O,O\ A3/CW_H"+_X%P_\
MQ=>S?!OPIK/A/0M0MM:M!;337(=%$J/E=H&<J3413N7)JQZ/(BRQ/&P!5@00
M>X-?%7B/1IO#WB*_TF<$-;3,@)'WES\K?B,'\:^UZ\Z^)7POM_&R+?6<J6NK
MQ+M$CCY)5[*V.GL?\BY*Z)B[,^6@2I!!((Y!%>A:7\:?&.F6*6GVFVNE1=JR
M7,6YP/J",_CFLK4/AAXSTV8QR:!=S8Z-;+YRG\5S3;3X9^,[Q@L?AV]3)Q^^
M3RQ_X]BLE=&CLREXD\:^(/%<@.KZA)+&IRL"_+&I]E'&?<\U1_L+4!X>.NM
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MUAR#@L177T4R658DW,?_ *])*VPVV]PEE6)-S'_Z]?$+_?;ZFOLJ69IGW-^
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M5.5)!]17U?\ &#2;;5/AY?R3LJ/: 3Q.WJ.WXU\GU$E9FD7<5$:1U1 2S'
M[FOLCP%H2^'?!>FZ?M D$0>7W=N37S/\+] _X2'QYI]NZ;H(6\^7_=7G^=?7
M@Z54%U(F^@44459(M<YXZNQ:>$+XGK(HC'U)KHQ7GWQ6O/+TBTM PS++N8>P
M%.*O)'9EU/VF*A'S_+4SOA-9;KF^OB.%41CV)YKU.N1^&]A]C\*12,H#W#F0
MGU':NNIS=Y&F:5?:XN;[:?<%%%%0>>+1110,6BBBD 4M)2B@ HHHH *6DI:
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M.F:)2@>[=#@L#T3/IW/X5X@DA1"N.M?5.M_"OPQX@U>XU2_BNFN9R"Y6<@<
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M7?\ <B_FU>1:_C_A)=4_Z_)?_0S7KO[/./M.NX_N1?S:KJ? 1#XB_P#M"_\
M('T;_KN__H-> E>>:]^_:%_Y!&C?]=W_ /0:\"/I12^$<_B'&3Y<5]B>"/\
MD1="_P"O&+_T$5\<U]C>"/\ D1="_P"O&+_T$5-;9%4]SY?^(2_\7!US_K[:
MO4/@%X<C$-_XBF0&3=]E@R/NC +G\<J/SKR_X@Y_X6#KG_7VU?0GP?@$/PRT
MM@ #*9';W/F,/Y 43=H"BO>,GXS>.;CPSI%OI>FRF*_OPVZ53\T40ZD>A).
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MDYSVH 3D&E[<<TH/."*55!).?PH :P90#6T^I0'1A;J!O(Z5CN13  7R>*8
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MC/#?EP?PKYO'ZU]M7UG#J%A<6<ZAX9XS&X/0@C%?&^O:--H/B"^TN?.^VE*
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MC"_U(-F%G\N >D:\+^?7\:]B^ ("^&]4 _Y^A_Z#3J? $/B.=_:$Q_;.C?\
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M* "BBB@ HHHH **** "BBB@ HHHH *2EI* "BBBF(0T444 %!HI#0 4&B@T
M)0:*#3$)1110 56OX);JPN+>"?[/+)&468+NV$C&<9%6:\TO?C;X9TSQ9>:'
M?I<0QV[^7]L5=\9;OD#D#Z9H \4\7?";Q=X5GEOEC?4+;)<WEGEF&>I=?O+[
MGD>]4_A[\3-1\ W$R16Z7=C<,#- Y*D$=U/8_4&OK/2M9TS7+076EW]O>0'^
M."0,![''0^QKE/%WPF\+^+M\TMI]BOFR?M5H C,?5AT;\>?>E8=R7PG\4?"_
MB]4CM+Y;:];C[)=$)(3_ +/.&_ FNSKY/\6_!?Q1X89KBTB.J62\B:T4[U'^
MTG4?49'O7:_ KQ'XNU?5)["ZOFN=(M(OG^U*7=&Z!5?K^!)^E.XK'O=%%%,0
MAHH-% &7XBUF'P_H-WJ4Y&(4)4?WFZ ?B:^6KV\FU"^GO+ABTTSEW/N37H_Q
MA\2&]U>/1;>3]S:C,N#P7/8_2O,:[\/#EC=]3@Q$^:5ET"BBI;:WDNKF*WB4
MM)(P50.Y-=!SGJOP9\/"2>YUZ9.(\PP$_P!X_>/Y<?C7LE9?AS1X]!\/V>FQ
M@9AC&\CNYY8_G6I7F5)\\KGITX<D4@-)0:*@L*0TM)0 4444 %)2TE,04444
M (:*** "BB@T )1113 2BBB@04&B@T )0:*0TP"BBB@ I*4TE @HHHH *2E-
M)3 ****  TE%% @I*6DH ****8!24M"J78*HR30(2DIS J2",$4V@ HHI#0
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M" <?6@9<HHHH$%+24M !2TE+2&%+24M !1110 M%%% !1112&+1110 4444
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M655^R3<DKC'W*^8YF$DKMV+$BDW;A2["1TI0IJ.PY3YMSIO 7C&3P5XA6_\
M*,UM(OEW$0."R^H]Q7T)8_%;P7?P+(-:C@8CF.=&1E]N1C\C7RF3GBE! ;)'
M2E.DI,<:CBCV;XQ^*O#7B71[&+3-3CN;NWG)VI&^-I')R1CL.]6?A9X]\,>&
M?"1L=6U/[/<&=GV>1(_!]U4BO$"=QW9XI5/S#/(H]DN7E#G?-<]/^*FJ:/XF
MU:/5-,NA<1);A VQDYR>S &N2^'QSX^T;U^TC^1K!DED8; YV^E;WP^_Y'W1
M?^OD?R-.UHV%>\KGU7KEW+8:%?7<! EAA9TR,C(%<'X5^-/A_5[:.+6)1IE\
M!AO,!,3'U#=OQQ7:^*?^14U7_KV?^5?&PXZUSTX*2=S:<G%Z'U[/X_\ "%O$
M)'\2:80>R7"N?R7)KSKQC\<K5+>6R\,1R23,-OVV5=JK[JIY)^N*\'('6AB2
M*T5&*(=5LEN+B:[N9+BXE>661BSNYR6/J36KX2U"VTOQ;I=[>2>7;03J\C[2
MV!ZX'-8N"5Q0!CK6MNAG<^D_$OQ4\%ZAX:U&TM=9\R>:!D1/LLPR3[E,5\UX
M.>*7IR*3D'DU,(*.Q4I.6Y<TO5;W1-2AO]/N&@N8CE77^1]17O?A?XZ:/>P)
M#X@C>PN@ #,BEXG/KQROY'ZU\[XQ[TO'7/-$H*6X1DX['U_#X\\)3KN3Q)I8
M&,_/=(A_)B*HZG\4?!NEQ,[ZW!<,!PEKF4M[?+Q^9%?)WWCTI6P#6?L%W+]J
MST'XA_%2[\8C[!9Q/9Z4K9V%OGE/8MCC\*\]W<>U)C!R:!U]JU225D92;;NP
MR#1P:.AHR!Q5"/>OAIXW\$>$_!\-G=:P([V5VEN!]EF;#'@#(0@\ ?G7*_&#
MQYI_BJZL+/1;HW%C ID=_+9 9#P.& / S^=>7^U':LU32ES%\[M8-N>M)T[4
MXYP*.V!6A(G).,TH)1P1]X<@TAZ<4JC=UI ?2/A;XP>%QX9T]-8U4V^H1Q".
M9#;ROR.,Y52#D &O,/BWK/AOQ#KUKJF@7XN9)(O+N5\F2/!'W3\RC/4_D*\[
M(.>O2E4]\5G&FD[HMS;5F&,5[G\+OBCH6C>%!I?B#4#;2VTA$!,,C[D/./E4
M]#GKZUX8#D\T8&>M5**DK,49.+NCV'XO?$72/$FDV>EZ%?&XA,GF7#>4Z=/N
MK\P&>>?PKR,H=@)/%1#DT[<Q&#T[41BHJR!RN[B2* 1BK&G:C>Z3J$-]83O!
M<PMN21#R#54G/7K0"#TJGJ(^A?"OQUTN[@2#Q'$]E<J #<1(7B?WP.5_(BN[
M@\?>$;E R>)-+ (S^\N50_DQ%?'_ %HQGI6+HHT55GUKJ/Q/\&:9$7DUZUF(
M'"6I\XGV^7(_.O%?B)\6+GQ="VF:;%)9Z5G+[S^\G]-V. /;FO,^AH.>M.--
M+43J-BJ2N>*]D^#WCGPYX6T._MM9U'[-++<!T7R)'R-N/X5->- FCH*N45)6
M9*=G<],^,?BO1/%>J:9+HM[]JC@B=9#Y3I@DC'W@/2O,NA!%.%(Q[4)65@;N
M[BI@2*W3G)KZAL?BYX'ATRVADUO;(D*JR_9)S@A0#_!7R[GBCG=S4R@I;CC)
MQ+NKSQ76MW]Q"VZ*6YD=&QC*EB0:9I>H7>D:I;ZA82F*Z@</&X[$?S%53C'O
M2HX60'TJTA7/I/PS\;-!U&WCBUPG2[W #%E+1.?4,.GT/3U-=>?'GA$1>8?$
MNE;?07:9_+.:^0KF3SR"O:H>V#63HQ+51GT7XM^.&CZ?;26_AW_B8WQX$I4K
M"GOS@M^''O1X(^+'ANT\(646OZXXU7,C7&ZWE<[FD9ARJD=".G2OG0<=.M&<
MC'>CV4;6#G=[FYXQU"VU;QCJM]92^;;3W#/&^TKN'K@@$5BQR20RI+$[1RQL
M&5U."I'0@TG;WI#RI]:T2)9[EX,^.T26\5CXIBD+H-HOX5W;O]]1W]Q^5>F6
MGQ$\'7L:O%XCTY0W033"(_D^"*^1?(_<>83BH3S6;I)ZE*HSZ]OOB1X-T^,O
M-XBL7 [02><?R3->4>/_ (R-K6FS:9X>CFMK64;9;J3Y9'7N% ^Z#Z]?I7C7
M7CTI2688S1&DEJ#FV-)P/>M+0==O_#NKP:IILWE7$)R.,AAW4CN"*S1COUI2
M<< 5HR3Z6\-_'#PWJENB:L7TN[QA@ZEXF/LP&1^('XUUZ>._"4B;QXETD#&?
MFO$4_D37QUCD4ASGFLG21:J,^L=5^+'@O2HBS:S%=/VCM 92?Q' _$BO#?B%
M\4;_ ,;'[%!$;+28VW"'=EI3V+GI] .![\5P13Y<TSFG&FEJ)S;# _&E![&D
M')QWI<<_2K) ]*3/M3N#2'(H ._7F@CH#2#KFEY[T +G'>D-.V'8*;D= >:
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M\B5J/_81;_T7'45/A*CN>M4445@:!1110 4444 %%%% !1110 4444 %%%%
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M-_!71O,N[[6)$XB40Q$CN>20?IQ^->S5P8B5Y6['?AXVC?N)1116!N)1110
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M(1@9%-SWQS3B, ^OI2=,9I@ Z<=:3(Q@]:7OGM2=^:0#NW%-*XYHY)]J"U
M"<T9&[FIE""+/\50D'J:8"'@^U.)';K29&/>@#CCK2 .1S03SQ2@GH:3@=*
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M_P"0A;?]=5_F*^VHO]2G^Z*5-M[CFDMA]+24HJS,MV 4NQ/W@.*M7 4P/NZ
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M/L7@\W3* ]Y,7!]5' _7=6->5H,VH1O-'H%%%%>>>@)1110 E%%% !24M)0
M4444"$HHHI@%%%% "4444 %)2TE, I*6DH$%0W<_V:TDE"EV5?E0'ECV ]R>
M*FK+OW%QJMC8#!&3<R@_W4QM_P#'RA_ TT"-"",Q01QEMQ50"?4^M/I:2D 4
ME+24P"BBB@0E%%% !1110 E%%%, HR0<@D'VHI#0(4DDY))/O2444 )7QIXW
M_P"1\\0?]A&?_P!#-?9=?&GC?_D?/$'_ &$9_P#T,U$]BZ>Y1T'_ )&'3?\
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MLOQ>K_R^04"BBD8"T"B@4@%HHHH *44E** "EI*6@84444@ 4M(*6@ HHHH
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M15"%HHHI %**2E% !2BDI10 4HI*44AA1110 HHH%% !1112&+1110 4444
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M110 4444 %%%% !1110 4444 %%%% !1110 AHH-% !1113$)1110 4E+24
M%)2TE !24M<A\3/$EQX5\#7VI6;^7=C;'"^T-M<G@X((_.F(\*U>SAL?VB@N
MJ!!;2:BLN9.A4CY2<>]?4=?%?B;QOJ7BRXM;S4H;4:C;  7D"&-W Y&X9P<=
ML 5[1X-^/VCR:9;VGB9+BVO(U"M<QQ[XWQW('S _@:0SVB>WANH6AN(8YHF&
M&210RGZ@UPVN?!SP3KF]CI(L9F_Y:V+>5C_@/W/_ !VNET;Q5H'B&,-I&KV=
MV2,[(Y1O'U4_,/Q%:],1B^%/#-GX1\/P:/8O(\,1)WR8W,2>2<<5M444P$HH
M-% C-U_41I.@7U^Q(\F%F!'8XX_6OE.65YYGED.7=BS'U)KWCXR:I]D\*Q62
MMA[N8 X/.T<G\*\$KNPT;1N<.)E>5@HHHKI.8<BEW5!U8@"OJKP]IXTOP[I]
MD%"F*!0P'9L9/ZDU\V^$=/&J>+--M&0LCSKO'^R#DU]2UQXI[([,*MV%%%%<
MIUB4444"$HHHH *2EI* "BBB@0E%!HI@%%%% "4444 %)2TE, I*6DH$%8FB
M.;[4=3U(@[#+]EAR/X(\@D?5RP_X"*G\1ZG_ &1H%W>+S(J;8AC.7;A1^9%3
M:+IXTK1;2Q&"88@'(_B;JQ_$DG\:KH/H7J2EI*D04E+24P"BBB@0E%%% !11
M10 JHSG"J32,C(<,"#5RU(\K ZYYIMV1L4?Q9J>;6Q7+I<J4&B@U9 E%%% "
M5\:>-_\ D?/$'_81G_\ 0S7V77QIXW_Y'SQ!_P!A&?\ ]#-1/8NGN4=!_P"1
MATW_ *^H_P#T(5]LU\3:#_R,.F_]?4?_ *$*^V:*85#P#]HC_D*Z'_UQE_FM
M>*U[5^T1_P A70_^N,O\UKQ6HG\1<-BU965[J^HQVEI#+<W=P^$1>6=C_GK7
MKVB_L^7UQ:I-K.L1V<K#)MX(O-*_5L@9^@/UKI_@=X1M]-\-#Q!/$C7U^3Y3
MGDQQ XP/0D@D^V*]8JXP5KLB4W>R/E/Q]\+]2\#I'=_:%OM-D8)]H5-A1CT#
M+DXZ<'./I7"5]@?$6P34?AWK\+J"$LI)QGUC&\?JM?']1-6>A<'=:GN_[-^L
M-!<:[ICDF)DCN$ _A8$J?SROY5[7K$OG6-TP& (7 _(U\Z_L_.P\<:A'GY6T
MUV/U$D?^)KZ%U#_D&W7_ %Q?^1K2"5KF<V[V/B*E#,$*!CM)!(SP2.G\S25T
M'@GPZ?%7B_3])+;8I7W3-G!$:C<V/? P/<UB;,T_!?PTUSQIBXMU6UTX,5:[
MF^Z2.H4=6/Z>]=W??L]2QV#-8Z^)KM5)"2VVQ'/ID,=OZU[C:6EO86<5I:0I
M#;PJ$CC08"@= *E-;JFNI@ZC/B._L;G3+^>QO(6AN8',<D;=58=:C@GDMKB*
M>%BLL3AT8=B#D&O1_CI91VOQ$,J* ;JSBF?'<Y9/Y(*\TK%JSL;)W5S[<L;D
M7NG6UT  )XEDP/\ : /]:\D^.7C273K*+PU83;)KM/,NV4\B+H$_X%@Y]A[U
MZ3X.=I?!&@2,?F;3;=C]3&M?+?Q#U-]6^(&MW+G(6Z:%/]V/Y!^BYK:;M$Q@
MKLYFNH\(>!=5\83L;4+!9QG$MU(#M!] /XC[?F17.6MO)=W<-M",RS.L:#U)
M.!7UGH>CVV@Z+:Z9:*!%;QA<XQN/=C[DY/XU%.',]2ZD^5:'G*_ S21;[7U>
M],V/OA$"Y_W>OZUY]XR^'.J>$1]I9UO-/)P+B-<;3V#KV_,BOI?M534M/M]5
MTVXL+M-\%PA1Q['T]^]:NG%K0R522>I\A5['\&O%LC2/X;O)=RA3)9ECR,<L
MG]1^->5:SIKZ/K5[ITARUM,T6[&-V#@'\>M3>&]0?2O$VFWR'!AN$)]US@C\
MB:PB^61O)<T3W;XMZ'_:W@R2ZC7,]@_GKCKLZ,/RP?\ @-?.M?84\$=W:R03
M*&BE0HZGNI&"*^3M=TJ31-=O=-ESNMY60$_Q#/!_$8-:5EK<SHO2QZY\$-8\
MW3=0T>1OF@D$\8/]UN"!]"/_ !ZO6:^9OAIK']C>.;!V;;%<G[-)]'Z?^/;:
M^F:TI.\3.JK2.-^*&L?V1X&O-K8FN\6R?\"^]_XZ&KYKKU3XVZQ]HUJRTB-O
MDM8C+(!_??H#] !^=>:Z982ZKJEK80#,MQ*L2^V3C-8U7>5C:FK1N?0OP.T#
M^S?"$FJ2IB?4I-P)Z^6N0OZ[C^(I/C+X*N?$6F6FIZ7:O/J%JPB:.-<M)&Q_
MH>?H2:[_ $.WAL-+M].A&V*VC6.,?[(&*T))(X8FEE=4C0;F=C@*/4FMN5<O
M*8\WO<QX+X9^"H*)<^(KI@QY^R6YZ>S/_0?G7H-E\/O"MLJPPZ#9OVS-'YI_
M-LFL?Q!\7?"VEW4D5G)-J+@];9?D!]-S8S]1FN<3X^)#-N3PV7'^U>X/_H!I
M7IQ':I([?Q!\'O"VL6+):68TV[ ^2:WX&?\ :7H1^1]Z^:]5TRZT;5;G3;V/
M9<6TAC<>X[CVKW.R_:!TJ211>Z)>0(>K12K+C\#MKROXC:SIGB#QK=ZKI,C/
M;7"1G+(5(8( 1@_2LI\K5T:PYD[,K>!M>E\-^,=.OT?;'YHCG]#&QPV?Y_4"
MOKWAT]F%?$%?;&GR&;3;61NK1*3^552>Z)JK9GD7BCX,>&M)\-ZGJ=O=:FT]
MO \J!YD*D@9Y 3I7@E?8'CO_ )$/7/\ KSD_E7Q_4U$D]"J;;6IW/PO\':=X
MTUVZLM2EN8XHK?S5-NZJ<[@.<@^M>LQ_ ;PI'(KB[U8E2" 9X_\ XBN'^ /_
M "-VH?\ 7G_[,*^B:J$4UJ3.33$50JA1T Q7RC\6/^2EZQ_OK_Z *^KZ^4/B
MQ_R4O6/]]?\ T 4ZFPJ6YR5C_P A"V_ZZK_,5]NVK*ODEON@#-?$5C_R$+;_
M *ZK_,5]M1?ZE/\ =%33ZE5.A\X?'CP\ND^/&U& #[-J<8FRO02#AQ]>A_X%
M7F$4KPS)+&Q61&#*PZ@CD&OISXT>'_[9\"R7<:;KC3G\]<#G8>''Y8/_  &O
MF"HE'E9<971]G^&-737O#.G:HF/](@5V [-CD?@<BM:O(O@'KGVOPU>:/(^7
ML9MZ#_8?G_T(-^=>LW$\=K;2W$S!8HD+NQ[*!DFMXNZN825G8^=?CSKGV[Q;
M;Z5&^8["'YA_TT?D_IMKS32=-FUC5[/3K<9EN9EB7VR<9_#K4WB#59-;\07^
MIRYW7,[28] 3P/P%>B_ CP__ &AXKGU>5,PZ?'A"1_RT?('Y+N_,5A\4C?X8
MGT)I>GP:3I=K86R[8;>-8T'H *^=?C/XUEUOQ"^B6LW_ !+K!MK!3Q)+W)]<
M=!_]>OH;6[XZ9H5_?#[UO;R2CZA217Q9/*T]Q),Y)9V+$GU-:5'96(IJ^HQ5
M9V"J"S$X  R2:]Z\#? ^S^QPZAXHWS2RJ&6R1BBIG^^1R3[# ^M>5> +W1M-
M\965_KLA2RMR9/\ 5E\N!\O !/7G\*^@?^%T^!O^@K+_ . DO_Q-1!+=E3;Z
M%ZY^%'@FZMS"=!ACXP'B=T8?B#_.O$?B3\+)_!F-0L)9+K29&V[G'SPGL&QU
M'O7L/_"Z? O_ $%9?_ 27_XFLSQ%\5/ 6N>'=0TV349'%Q R*#:2?>Q\I^[Z
MXJY*+)7,F?-0)!!!P1T-?4/P=\:2>*/#36E]+OU"PPCL>KI_"Q_E^%?+[8#'
M!R,\&O1O@CJ;V/Q#AMP?DO(7B8>X&X']#^=9P=F7-71]14445N8"Y.****0P
MI:2EH ****!@*6D%+2 *KWUQ]EL9I@<,J_+]>@_6K%5;I#--!#SMW;WQZ#L?
M8TT5"W,KBZ;:_8]/A@QAE7+?[QY/ZU:H%%(4I.3;84"B@4 +110*0"T444 %
M**2E% !2TE+0,****0 *6D%+0 4444 +1110 4444ABTUV"(SGHHR:=6)XOU
M'^R_"NH70;:XB*H?]H\#]332N[%0CS-174^?];O3J.N7UYNW"69F4^V>/TQ5
M"BBO06A],E960445;TNQ?4M5M+*/[\\JQC\3B@;=E=GNOPYTPZ;X,M-ZE9+D
MF=@?]KI_XZ!765'!#';6\<$2[8XT"*/0 8%25Y\G=W/FJD^>3EW%JCK4MY!H
ME]+I\'GWB0.8(LXWO@X'YU>HI$'PB9;VQU!Y#)/;WL4AW-N*R(^><GJ#FNUT
M+XR>-=#VI_:GV^!?^65\OFY_X%P__CU>O?%KX3Q^)89-<T2)4UB-<RQ+P+H#
M_P!G]#WZ'MCQ+P;JVAZ=J3:7XNT:*[TR5]LK,A2>V?.,AEPV/5<__7@H]:T+
M]HW3IML>NZ-/;-P#-:.)%)]2IP0/Q:O2M#^('A3Q'M73-<M))6Z0R-Y<A^BM
M@G\*\RU+]GW0]5M$OO#6NS0QS+YD0F FC<$9&&&"!TYYKSK7/@OXVT0,ZZ:N
MH0K_ ,M+!_,/_?'#_I1J&A]<45\8Z5XW\9^$+C[+:ZI?VIC.#:7(+*OMY;@@
M?D*^N?#%Q?WGA?3+K5#&;Z>V26;RTVC+#.,9]Z:8K&K110*8"T444@"E%)2B
M@ I124HH *44E+2&%%%% "BB@44 %%%%(8M%%% !1110 4444 %%%% !1110
M 4444 ?% P3UYI=N!S0H ;FG$Y.*]4\X9@@>U(?E&,<T]3U![4W.>>] &@=(
M T[[67&2,XK,)R,U8-U,8?*9CY?I42H#Q0!)$N^/G@T/&$7KDTTL1QTIN6/)
M- " 'J?RIVX X X-)N&3ZTW^E QQ)*X XI"> >M("U'((SC- "DCK2#"\^M#
M8)HZ\=A2$/$A5<#FF$D<D9IZGCITH?Y<$]#0,9M.,@=:!D=J7>5QCH:1CCF@
M!<Y.,8IH3=)BDZ\FGJ"G- ",-AP::?UIS'.<TTCC(H 11EN:=(JK@#K35^]F
M@\DGO0 FWGKUI5^5L&D()Y[TY<$9:D -CM6AI.D7VMWBV.F6S7-TP)6-2 <#
MKUK.QDDYXKI_ /B6T\)^*X=5NX9I84C="L(!;)'N0*4KI:#5KZGJWP:\(Z[X
M;U#59=7TY[198XUC+LIW$%L]":U_C%X?UCQ#HFGV^D63W;QSEY$5@,#;@'DB
MMGP;\0]-\;7-U!86EW ULJLQG"@$$GI@GTJUXQ\:V'@JRM[F_M[F99Y"BB *
M2"!GG)%<3<O:7MJ=24>2U]#YKU?P7XCT"Q^VZII,MM;[PF]G4C)Z#@GTKG6)
M# X_"O6?B+\4](\7>&?[+LK*]BF\]9-TP0+@ ^C'UJC\*OAZGBJY;5-40G2[
M9]HCY'GOZ?[H[_EZUU*;4;S,'%.5HG'Z+X2U[Q*V=(TR>Y4'!D "H#_O-@?K
M76+\$_&+Q9,=BA_NM<<_H,5[]J>JZ/X2T83WDL-E90@(B*N![*JCJ?85YM<_
M'_28[DK;Z+>RPY_UCR*A/X<_SK+VM27PHT]G"/Q,\OUGX9^+=#A::ZTF22!1
MEI;=A* /4A>1^(KD><XKZU\)>/\ 0_&,9&GS/'=*,O;3@+(!ZC!((^AKC_BG
M\,K;4[&?7=&MUBU&$&2>*,86=1U./[PZ^_UIQK.]I(4J2M>)\^@[CC&*VM#\
M(Z[XCBEETG3I+J.)MKLC*,'KCDBL,[@Q_6O??@",:#JO_7R/_016M23C&Z(A
M'FE8\?OO#.MZ=J\&D7>G3)?3@-% ,,S YY&,^A_*NHC^"WC%K42BWME8C/E/
M. _^'ZU]!G1+%/$,FORJIN_LX@5WZ1H"2<>F<\_2L67XH>#(;XV;Z[!YH.TD
M(Y3/^\!M_6L'7D_A1K[**W9\T:YX:UGPW/Y&KZ?-:D_=9AE&^C#@_@:H0VOV
MA"=V *].^-WBBWUC5+'3+"ZCGM;>/S6>)PRL[>XX/&*\K25HT*@\5O"3DKLR
MDDG9".FP^N*6.:2WECFB8K(C!E8=01R#33N;DTG!IDGV%X1UQ/$?A73]30C,
MT0W@=G'##\Z^>/B[H(T/QW<RHFV"]'VB/ [G[WZYKM/@+X@RM_H$K]/](@!/
M;HP_D?QK;^.6@_;_  I#JL:9EL)/F./^6;<'\CC\ZY8^Y4L=$O>A<^<R23GM
M3PC/RHIN<\5/9W(@+ C.:ZCG.H^&OAXZ_P".;&W==T$#?:)O]U>1^N*^E_%&
MM1^'?#%_J;$#R(CY8]7/"C\R*\Z^!6A>1H][KLJ8DO)/+BR/X%_^OG\JI?'K
MQ#M@L/#\+\N?M$X![#A1_,_E7-/WZECHC[L+GA\\[7,\LLK%I)&+,3W)K5T/
MPMKVO$_V1IES=*#@NBX0'W8X _.NH^%?@6/Q=K<D]^A.F6>#( <>8YZ+]/6O
MH;5=6T;P?HGVB[>*SLH0$1$7OV55'>M)U>5V6Y$875V?/T?P4\9W #2P6<)]
M)+D'_P!!S4%W\&?&MK&SI8P7 ':&X7/Y'%=_<_M :2DY6WT6\ECS]]Y%0D>N
M.:Z3PM\6O#OB>\6R!FL;QSB..Y Q(?16!(_/%0YU5JT4HTWI<^9=1TN_TB[:
MVU"TFM9UZQS(5/ZU6[<=:^P?%WA>Q\5Z%/8W<*M)M)@DQ\T;]B#7R'=6TEE>
M36\@P\3E&^H.*TA4YT1.'*>J_ +_ )&C4<]?LP_]"KLOCN ?!MMG_GY'\JXW
MX!X/BG4<?\^P_G78_'@9\&VW_7R/Y5E+^*BU_#/G=$:61(HQN9F"J!W)KJC\
M,/&@C\TZ#/L"[L[TZ?\ ?58.EJO]HV?KYZ?^A"OL:;_D$R?]<#_Z#6E2;C:Q
M,(*6Y\5L&61D889201[TW/YU/?8_M"X_ZZM_,U7(YR*T1F:NB^'=6\1W#P:1
M9/=RQKN=4(&!Z\D58UOP9XB\.VRW.K:7+:P.VU79E()].":] ^ !_P"*FU,?
M].P_]"KK_CR,^$+3_KY'\JR=1J?*:*"<>8^<R#VI3@#%'0X[5[3\(_AG;WT$
M?B'6X/-A)S:6[CY6_P!MAW'H*N4E%79,8N3L>=:#\/\ Q/XCC673])F>W;I/
M*1&A^A;&?PS72#X'>,53?LL2?[GVCG^6/UKW?Q-XQT3P=9I)J4^UF'[JWB&7
M?'H.P]S@5YY_PT)I@N=K:%=^1G[XF4MC_=QC]:Q4ZDM4C3D@MV>1>(/!'B/P
MWF35=*FAASCSEP\?_?2Y _&L#! Z5]A>'O%&A^--+>;3Y5GB(VS02J-RY[,O
M^17B/Q;^',?AR4:UI$973IGQ+$.D+GT_V350JW=I;BE3LKH\JX/M1TZ]*7EN
MU)C/>MC(0G&<T '&:4]?FH W#/:@9[;\!O"\<CW7B2XC!,9\BV)[''S'\B!^
M->A?$OQB?!_A=[BW9?M]P?*M@><'NV/85-\--/73?A[I$2KAGB\UO<L2<_EB
MO'?CQJGVKQA;6 )V6EN#_P "8\_R%<J]^H;_  P/,;N[N+ZZEN;J5Y9Y6+O(
MYR6)[FH!R*#R>:<2!TKJ,! ,\9KV3X'>,)K;4V\,W<I:VG!>VW'[CCD@>Q'Z
MUXT!\U2Q3S6\JS02O'(ARKHQ!!]B*F4>96*B[.Y]3_%.UTK4?!5[:WUY:03J
MGFVWGRJAWKR ,GOT_&OE0YSG%.DE>9S)*[.[')9CDFD+9XJ81Y58<I<SN=/:
M?#?Q=J%C%>6NBSR6\RAT<.@W#UY-0:'X4UW7[V;3=-T^26>!BDV2 L1!P=S'
M@=*^H?! SX&T8?\ 3HG\J+>#0O NC3RS7$-I;O,\TTTIP9'8D_B>P ]*S]L]
MB_9H^?KWX*^-+2$RI9V]Q@9*03@M^1QG\*X.ZM+G3[I[:[MY8)T.'CE0JR_4
M&OK'3_B7X/U21HK77+?S%!.V4-%G'H7 !KYI\1:E<>,?&UW<6Z-++>7'EVZ+
MR2,[4 _#%5"4G\1,XQ6Q@10RW$R10QO)*YPJ(N2Q] !7<Z=\(/&FI0K*-,%J
MIZ?:I50_]\]1^(KW+X?_  [T_P &:<DKQI-JTB SW+#.T]U3T'\_T%3Q7\8/
M#OAB[>RC$NHWD9P\=N1M0^C,>_TS2=5MVBAJFDKR/(;KX)>-+>,NEK:7) SM
MAN!D_P#?6*XC4](U'1;PVNIV4]I..=DR%21ZCU'N*][TGX^Z%>72PZCIUU8(
MQP)0PE5?=L8./H#7H&L:+HGC701#=)%=VDZ;X9HR"5ST9&['_)I>TE%^\A\D
M7\+/CC&6R:<Q'&.E;?C'PO=^$/$<^EW)W*OSPRXP)(ST/]#[@UC002WES%;P
M(7ED8(BCJ23@"MDTU<SL$,,US.EO;PO+*YPL<:EF8^@ KL].^$/C74$$HTG[
M,AZ?:95C/_?.<_I7OG@+P'I_@S2(U6))-2D0&YN6&6+=U4]E'ZUD>)OC-X=\
M/7\EC%'<:A<Q,5D\C 1".HW'J?H#6+J-NT4:<B2O(\M/P.\8HFX+8.3_  BX
MY_45S.N> O%'AN)IM2TB9+=>LT>)$'N2I./QQ7L%E^T!HLLZI>:1>VZ$XWHZ
MR8'J1Q7J&EZMIVOZ8E]IUQ'=6DH(#+T]P0>A]C2=2<=T/DB]F?%BH7?TK=T7
MP7XA\0PO<Z3IDMW!&^QG5E #8SCDBNJ^,7A*V\+^)H;K3XA#9:@K.(E&%1P1
MN ]!R#CZU=^&GQ/TGP7H=S87UG>S237!E#0*A &T#NP]*T<FXWB0E9V9[[H-
MO+:>'=,MIT*316D4<B'^%@@!'YU\X^)OAKXPO?%.KW=OH4\D$U[-)&X=,,I<
MD'[WI7TM87B:AIUK>QJRQW$22JK=0& (!]^:\XU3XX:!I>IWFGRZ=J32VTSP
MLR+'@E202/FZ<5A!R3=D:R2:U/G,V=U]O-@8B;D2>5Y???G&/SKIG^%WC6*-
MI'T&=54$D^8G _[ZK/LKI;_QS#>1J56?41*%;J TF>?SKZ\U'_D&77_7%_Y&
MM9S<;&<8IGQ)SNP:-O:GLV\YQ7<_#'P$WC767>Z+)I=H0UPPX,A/1 ??')[#
M\*T;25V2E=G,:+X:UOQ#.8M(TVXNV'WF1?E7ZL>!^)KLX?@?XSFCW20V4)Q]
MU[D$_3Y017T0[Z-X2T+<WV?3M,M5[#:JC^I/YDUYG?\ [06BP71CLM(O;J('
M'FNZQY]P.>/KBL?:2E\*-.6*W/+]5^$OC+2(FFDTEKB(#):U<2D?\!'S?I7&
M-N0E&!# X((P0:^K_"'Q.T#QA*+6W>2UOL9%M<  MZ[2#@_S]JS?B7\,[/Q5
M83:CI\*0ZW$NY67@7&/X6]_0_P!*:J-.T@<%:Z/F#GK6YH7@_7_$MO+-H^F2
MW<43;7964!3UQR16*R-%(RR*5=2596&"".U?0?[/O_(MZKC_ )^E_P#0:N<N
M57(BKNQX9J_A[5O#]^EAJ=G);73H'6(D,2I) /!/<&NFTGX1>,]5@$Z:7]FC
M;H;N01G_ +Y/S?I7TA/X:TD^)V\3WB(]U%;+#&\N-L"J68L,]#\W7L!]:Y'6
M_CAX6TF[>VMUNM1=#@R6RKY>?]XD9_ $5G[23V17(EN>47OP4\:VD32):6UU
MM&=L%PN?R;%<)?6%WI=V]I?6TMM<H<-'*A5A^!KZG\(_%+P]XON19V[RVEZ1
ME;>Y !?_ '2"0?IU]JE^(_@RU\7^&IU\E?[1MT,EI,!\P8<[<^AZ8_'M0JC3
MM(;@FKH^2^#R.#28R.*=Z\8IM;&0?A4L#I&V6&346<TN!0 YB'8GH*:/2D Y
MY-*<@T,!!R:,8XHZ9'>E7IS0 @&/>D/7BESCOQ1D=<4##[O7O1WI&Z4=5S2
M,9-.0A&W9IO..*, #WH 5F+G=CBD'KVH />C/&*  4AR>:520<"C&*!B@X^E
M!(&: ,F@<<XH 0=* O%&<GBEH&-XI>.W6@-@\BE/M0 A&1R:,^U##O29_.D
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MKM*N6F@Y=@I*6DJ!!24M)3 ****!"4444 %%%%  &*G()!]J"23DDD^])13
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MNO\ KB_\C5P^$SG\1\15Z%\%/^2FV/\ UQF_] ->>UZ%\%/^2FV/_7&;_P!
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MKXP^+X_$<VB06KY@2S6Y< ]'D .#] %_,U$96BT7*-Y)GF%?5GPC\/\ ]@^
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MM0<'I0,=D8I .*"* /RH 4*,4=1@4@/!]*7MF@!1A1UYHXZGK2  ]#2]>M(
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MG^M:E>7-WDV>K!6BD%%%%24)1110(2B@T4 %)2TE !1110 &DI324Q!1110
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MVDT2D!GC903[C%7!61$W=GP]7H7P4_Y*;8_]<9O_ $ UI?\ "@?%G_/[H_\
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M]C+J=H.?<****W/1+VC:;)J^L6MA%]Z:0+G'0=S7TS;01VMK%;Q+MCB0(H]
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M*DG%.7YN10 T@J1W%/R<=*.,8/6DQQUH !@Y%(<;?>@YR,4Z10-II@,QQP*
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M:>$_"DTZJ$MK"W_=J?884?B<"N/F?+R'5RKFYCP?XV^(/[4\6KIL3Y@T]-A
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MPMP?F;?YCD>P''YFK52-KW(<)7-W]GZP<3ZOJ)!\LJD()]<YK=^/)QX0L_\
MKY'\J[OP_H^D^$].M-$LF5"P8J'/SRD<LU<)\>O^1/L_^OD?RK%2YJES9JT+
M'A_@^_73?&&E7C<+'<H3^)Q_6OKK4[1=2TBZM,@B>%D!^HXKXJP00P."/2OJ
M+X5^-X/%'AV*TFE U.S01RH3RZCHPJZT>J(I/H?,U_:S:;J-Q9SAEE@D*,#Z
M@U6R3R6-?2?Q%^$T/BN=M4TN6.UU,CYU<?)-]<=#[UY2?@WXV\\Q?V4FT''F
M_:8]O_H6?TJXU(M$2A),XW3+"YU;4K>PM$+SSN$0>YKOKSX)>+[-&D4V$Z*,
MGR[@CC_@0%>E_#?X4IX3F_M/5)8[G4L8C6/.R'UP3U/O5KXL^-+?P[X<FTZ&
M;_B97J%$13RBGJQ]*AU6Y6B6J:4;R/FH-Y!DCDQN5BIP<\BJ[<\YI.&-+@9Q
M708"#WHSD8J>&V:Z8B(<#K4+*8FV'K2&>[? /Q"KV=]X?F?#QM]H@!/4'AA_
M+]:Z;XO>$'\2^&/M5I&7O[#,D:J,EU_B7^OX5\ZZ%K5WX=UJVU6Q?;- ^['9
MAW!]B*^L/"?BW3?%^CQWUA(-^ )H"?FB;T(_D>]<U1.,N9'1!J2Y6?'3*5)S
MD$'!![49KZ<\9?!W1O$]S)?VDK:=?ORS1J#&Y]67U]P17F]Q\!_%$;;8;C39
MDS]X2LI_(K6L:L69N$D>59KU+X+>$9=7\2KK4\9^Q6!W*Q'#2_P@?3K73Z%\
M"%"1_P!N7L> <M':Y);VW$#'Y5Z[86&GZ!I26MI%%:65NG ' 4=R3_4U%2JK
M61<*;O=E+Q=K</AWPM?ZE*P'E1'8#_$YX4?G7QW),\LSR.=SN2S,>Y/6O2?B
MS\0E\57ZZ9IDA.E6K9+C_EL_K]!VKS,$<8-52ARK4FI*[T/L/P1_R)&B_P#7
MHG\J^8OB$<?$#6_^OD_R%?3O@C_D2-&_Z]$_E7S%\1!GX@:UC_GY/\A44OB9
M53X4<R<$5[1^S[J,::EJVG$X:6)95]]IQ_[-7B^ *V?"OB"?PKXFLM6@!;R7
M^=,XWH>&'X@FM9QNK&<79W/?/CCH\NH^"%O(5+-83B5\?W""I_+(/X5\U[^P
M)K[/T[4--\3Z&EU;-'<V-W'@@X(((Y5AZ]B*\1\7? O48+R2Y\,O'<6KDD6L
MK[7C]@3P1]2/QK*E-)<K-)Q;U1X\">3DUTG@[P1K'C>XN8M,:%!;H&>2=BJY
M)X&0#R>?R-;VF?!7QE>W*QW=I#81$_-++.C8'T0G->_>#O"-AX,T--/L_G<_
M//.PP97]?8>@[54ZB2T%&#>Y\X>(_AUXD\(Z<U]J4=L;7<$WQS@Y)Z8!P3^5
M:?P5T6#5_'RS7"!TL86N0I&06!"K^1;/X5H?&GQG!K^JP:1ITWFVEBS&5U^Z
M\O3CU &1GW-9_P %=;@TCQVL=PX1+Z%K8,>@8D%?S*X_&FW)PNQ62EH>^^-?
M$H\)^%;S5O+$LD8"Q(>A=C@9]LFOF#6/'OBC6Y7>]UF[VL?]5%(8T'MM7 KZ
MF\5^'8/%7AN\T>=S&LZC;(/X&!RI_,"OG'4?@_XSL;MHH]+%W&#\LT$J%6_
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MF6NV_9]_Y%O5O^OI?_0:\(UC5;G7-:N]3NR&GNI3(^.@SV'L!Q^%>[_L^_\
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M.@ZO()-1T;3[MQT:>V1S^9%2Z;H.D:.&&F:79V>[[WV>!4S]<"BP7/-/@_\
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MCM-;L_[1C0;5G1]DN/\ :[-^A]Z[)?CYX9,>?[/U4/\ W?+CQ^>^OG'Z4_\
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ML\%ZB/\ J(M_Z+CKYRW%?N]:^C?V?B3X+U G_H(M_P"BXZSJ?"5#<]9HHHK
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MD(Q0,0Y[4IZ"EVX%,R>E  3DX%.QCK30O&,THX&#S0 ?3I3N!R*:>*.B\<T
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M9P2:,Y/-+VYI##MQ7T9^S[_R)6H_]A%O_1<=?.0Z<"OHW]GW_D2M1_["+?\
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M"Y:V)V<$]Z!B3((I&B)Y%,'RFAW+N7;EC31GKF@0I.XY-)NP, 48W4 C;2
MV: W-' 7WH^O6@!>2:0_=XHI0.:!@%PM'2DXW4I(P<T '&,T 9'-(JDBE]J
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MGM2L!C /- Q.,>]&1CFD521STH! ;%( QCFG9&WY:;SGV-.^Z<#I0 WH..:
M"1Q2Y/3%+T6@!G/3O2X*_6EZ8/>D+-F@!..PYI<L1S2 \].32XZT#  ],TN3
MC!YI%!'6AC@\4 (<'K4L$37!\M!S477KTJQ9W/V.3S57- T1S1-;ML;@U'G-
M274YNYO,(Q[5&OI0  9-.&%--Z<4F":0"EB3[4*0#1VQ31P:8A^XEN30 ,Y)
MH50S<\4.NTY[4#$)&>!06*].: 10!@4@&@'/R_C2[>?>E#87 '-36UN]U((T
M')I@0=3GO2'(-3W-K)9S>6XZU$<YZ4AB#CMG-%'OVI.>H- @SSR.:<PP>>M
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M$6_]%QUG4^$N&YZU1117.:A1110 4444 %%%% !1110 4444 %%%% !1110
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MX5R#WJW6<MS2.Q%/&'0GN.E4JO3.$C/J>!5&JAL3/<*2EI*L@**** "DI:*
M$HHHI@%)2T4"$HHHH 2BEI* "BBBF(?'$TK;5QG&>:C(P<4H..E)0 4E+10
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M    . !7R8OQS\>KUU6%OK:1?_$U]%?#G6]0\1>![#5-3=7NIP2S*@4'GT%
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MA 3]: #'%'-.==@P>]- W<4 "KO//6D(*M@TY6V/QTI'8,<]J $(&:4\# I
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M%%( I:2EH **** "L[7M:MM TB:_N6^5!\J]W;L!5Z6:.WA>:5PD:*69F.
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MXU_-;[N9[PLD,?J0#_05].Z1KVB^(FN_[,NH+O[)+Y,I3! ;&>/4>_3@UKJ
M.  ![4K#N<YX)\&Z?X(T!--LOGD8[[B<C#2OZGV]!VKI***8@HHI10 4444#
M"E%)2T@"BBB@ I:2EH *6DI:0PI:2EH **** %%%%% !1112&+1110 4444
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M;&,@]*8$U%%%,04444 ?-/Q+&/'NI?[X_E7)5V/Q07;X]O\ WVG]*XZO5I_
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M4AB@YI<8YI <GCBE)XP.M #3E3]:<&*G(IGUIV1B@0N2Y.:0Y'2EYQ[4@ %
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MYX Z4XL0,4@;:Q]Z0Y/)H ,;CGM2%<4 Y;BG'@<T@&D\5]%?L_Y_X0O4,_\
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M\F#^X*.0/]6<+_/+\#R9M+ONUK)^5']EWW_/M+^5>L^3!_<%'DP?W!1R,/\
M5G"_SR_ \F.EWQ'_ !ZR_E1_9=\!Q:RY^E>L^1!_SS%'D0?\\Q1R,/\ 5G"_
MSR_ \F_LN_)R;63\J0Z7?=K67\J]:\B#_GF*/(@_YYBCD8?ZLX7^>7X'DITN
M^/\ RZR_E0-+OL8^RR_E7K7D0?\ /,4>1!_SS%'LV'^K.%_GE^!Y+_95_G_C
MUE_*C^R[[_GUE_*O6O(@_P">8H\F#_GF*/9A_JSA?YY?@>2G2[_'%K)^5']E
MW^,?99/RKUKR8/[@H\F#_GF*7LP_U9PO\\OP_P CR3^R]0Q_QZR_E3O[+O\
M_GUD_*O6?)@_YYBCR8/^>8H]F/\ U9PO\\OP_P CR7^RKX_\NLOY4?V5?\?Z
M++^5>M>3!_SS%'DP?\\Q3Y _U9PO\\OP_P CR7^RKX,#]EE_*K$ME?/$%%I)
M^5>I>3!_SS%'DP?\\Q1R,7^K&%_GE^'^1Y*-*OP?^/63'TH_LJ^_Y]9?RKUK
MR8/^>8H\F#_GF*7LQ_ZLX7^>7X?Y'DQTJ^(_X]9/RI/[*O\ '_'K)^5>M>3!
M_P \Q1Y,'_/,4>S#_5K"_P \OP/)O[+ONUI)^5!TN](_X])/RKUGR8/^>8H\
MF#_GF*/9A_JUA?YY?@>2'2K_ /Y]9/RI1I5_C_CUDS]*]:\F#_GF*3R8/^>8
MHY _U:PO\\OP/)TTN^\Q2UM)COQ5N\T^=XU$5I)D=>*]-\F#_GF*/)@_YYBC
MV8?ZM87^>7X'DO\ 9=^?^763\J7^RKX?\NLGY5ZSY,'_ #S%+Y,']P4>S#_5
MG"_SR_ \D.E7W_/K)^5.&EWPZVDGY5ZSY,']P4>3!_<%'('^K6%_GE^!Y(=+
MOR?^/63\J=_9E^!_QZR?E7K'DP?W!1Y$']P4>S#_ %:PO\\OP/)?[+O_ /GU
MD_*C^R[_ /Y]9/RKUKR(/[@H\B#^X*.0/]6L+_/+\#R4Z7?'_EUE'X4#2[[_
M )]9/RKUKR8/[@H\F#^X*7('^K.%_GE^!Y(=+O\ _GUD_*C^RKX'(M9?RKUO
MR8/[@H\F#^X*.0/]6L+_ #R_ \D.E7Q_Y=9?RH&E7W>VD_*O6_)@_N"E\F#^
MX*.0/]6L-_/+\#R5=*O<\VTGY4W^RKX-_P >TF/I7K?DP?W!1Y,']P4<@?ZM
M8;^>7X'DITJ]'2VD_*E.F7W:UD_*O6?)@_N"CR8/[@HY _U:PW\\OP/)O[+O
M?^?63\J7^S+T'_CUD_*O6/)@_N"CR8/[@HY _P!6L-_/+\#R<Z9>@\6TGY4W
M^R[W/_'K)^5>M>3!_<%'DP?W!1R!_JUAOYY?@>2'3+XG_CUD_*C^R[X'(MI/
MRKUOR8/[@H\F#^X*.0/]6L-_/+\#R,Z7?=1:R9^E!TN^(_X]9/RKUSR8/[@H
M\F#^X*.0/]6L-_/+\#R/^R[[_GUD_*C^R[[/_'M)^5>M^3!_<%'DP?W!2Y _
MU9PW\\OP/)1I=[_S[2?E1_9=[WMI/RKUKR8/[@H\F#^X*?('^K.&_GE^!Y-_
M9-YCBWD_*F?V7?9_X]I/RKUSR8/[@H\F#^X*7('^K6&_GE^!Y(=,OL?\>TGY
M4?V9??\ /M)^5>M^3!_<%'DP?W!1R#_U:PW\\OP/)!IE\/\ EVD_*A=*O.]M
M)^5>M^3!_<%'DP?W!1R"_P!6L-_/+\#R)M+OB>+:3\J7^R[[_GUD_*O7/)@_
MN"CR8/[@HY!_ZM8;^>7X'D7]E7W_ #ZR?E2C2[[&/LLGY5ZYY,']P4>3!_<%
M'(+_ %:PW\\OP/(QI=\/^763\J&TR^)!%K)^5>N>3!_SS%'DP?\ /,4<@?ZM
M8;^>7X'DG]EWW_/M)^5!TN](_P"/:3\J];\F#_GF*/)@_P">8I<@?ZM8;^>7
MX'D?]F7W_/K)^5']F7P/_'K)^5>N>3!_SS%'DP?\\Q1R!_JUAOYY?@>1'2KT
MG/V:3\J#I=]_SZR?E7KODP?\\Q1Y-O\ \\Q1R#_U:PW\\OP/(?[+OO\ GUD_
M*G_V9>X_X]9/RKUOR;?_ )YBCR+?_GF*.07^K6&_GE^!Y#_9=]G_ (]I/RI1
MIE]_SZR?E7KOD0?\\Q1Y$'_/,4<@?ZM8;^>7X'D)TR^W<6LF/I0VG7J\FVDQ
M]*]>\B#_ )YBF/;VY'^K%'('^K.'_GE^!X\\$L9^>)U^JFF _-7JUQI]O(/N
M@5S]_P"'K:7)5 #ZKP:FQS5^%YI7HSOZJQPYS^-!!K3O=(GM6++\Z#\ZSR!T
M[TCYO$8:KAY<E6-F1X/7'-.ZT#(/-*!DXH,1#D\"G ;>HYHQL84A.XT +\Q'
M-(#BE)!&*3D 4#$)H"Y' HZGGI29/:D #DX%*5(I<=Z&(QQUH ;@D^].X(YZ
MTC9;IQ2'[OO0 N,_A2$C-(,GY:D:';'D]30 P]:7@=*1>5QWH.10 K#Y>:;D
M$=*?RXI=N< #)H 0'C X-("2?>ED ( 7C'6D4<T#!LCGO0,D>]*PY'?VH)P.
ME !3@=QYIF><FC[WW: %8#<".@J0X(W5"0>]/09[\4P%P>3BOHGX C'@O4/^
MP@W_ *+CKYVS@_+7T3\ ?^1,U'_L(M_Z+CK.K\)<-SU>BBBN4U"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!**** "@T44Q"5\U?
M'[Q5<:CXEA\-VLC?9K50TB(<B25NG3T]*^E:^2?B-_Q+_C9=3W8_="\BFY/\
M&1_A0!Z3X ^!.DQ:7!J'B>-KN\E42"VWE8X@>0#CJ?KQ79ZC\(/!&HVA@.AP
MVYQA9+;,;#WR.OXYKM;:>*ZMHIX6#Q2(&1@>""*DH ^0/''@^_\ A=XMM9+2
MZD>$D36EQT;@]#CO_.OJ/PAKH\2^%-.U? 5KF$,Z@YPW0BO(?VD=0M3;:+IX
M=3=+(\S*.H3&.?QKN?@M!+!\,--\W/[PNZ9_ND\4(#T"DI:#3$)1110!X-\:
M8MGBJVD_YZ6X_0UYK7J_QQB(U72Y<<&%AG\:\HKTZ/\ #1YE;^(PHHHK4R"B
MBB@#ZF\(7?V[PCI=P3RUNN?PX_I6W7$?">[-SX%MU)YAD>/IV!XKMZ\J:M)H
M]6#O%,#24M)4E!24M(:8!1110 4E+24""DI:#0 E%%% "44M)0 5S/Q _P"1
M&U3_ *Y?U%=-7.>/%+>"-6 _YX$U4/B0+<^< <$&OJ+0Y/-\/Z;)_>M8C_XZ
M*^7*^EO!T_VGP=I,F<_Z,J_]\_+_ $KJQ&R-*FQN4445R&0E%*:2@ HHHH 2
MBBBF!<B&V-?IFGU'"^Z,#N*DK)[FBV"J4HVR,!5PD 9/2J3MN<MZU4"9C**6
MDJR I*6DI@%%%% @I*6DH **** "BBB@!**6DI@%%%% ",0JECT R:HH5EW.
M0"2>:DOI=L8C'5NOTK.!(Z&BUT*]F.E"B5@O2F4M)5$A2HC.P51DFE1&=@JC
M)-:EO;K OJQZFAL+7$M[=8%]6/4U-112&%%%% PHHHH$)BBEHH 2G)(T9RIQ
M28I* )'FDEP&;/M5V.VC11E0Q[DUG@X(/I6G'*LJ@@\]QZ5G/1:&D-7J5[FW
M4(708QU%4JT+J51&4!RQJA3A>VHIVOH)12T59 E%+1B@!**6GR0F-58D'<,T
M 1T4M% "44M% %>[@\V/('S+TK,Q6W6;>0^7)O ^5OYTTQ,K44450@HHHH *
M*** "BBB@ HI:*0!5NRFVOY;'@]/K52@<'-(#<HJ&VF\Z($_>'!J:I+"BBEH
M **** "BBB@84M%%( HHHH *>L3N,A3BGV\8=R3T%7:F4K%QC<SV1D^\"*;6
MBRAA@C(J@Z['*^E$97$XV'0R>6^>QZU<5U<94@UGTM$HW!2L7V=4&2:IR2&1
M\]NU,I:%&P.5PHHHIB"BBB@!11110,*6BB@ HHHI ****PO%'BFR\,V!FG8/
M<.#Y,(/+'U^E-)MV148.;Y8[B^)_$]GX9TXSSD/.PQ#"#RY_PKP/6=9O==U!
M[R]E+R-]T=E'H/:C6-9O-<U&2]O92\C'@=E'H!Z5GUUTZ:BO,]["X545=[A7
M5>#?!=SXGNQ)(&BT^,_O)<?>_P!E??\ E5GP5X%N/$4RW=V&ATU3RW0R^R_X
MU[A:6EO8VL=M:Q+%#&-JHHP *FI5MHMS+%XQ4_<AO^0VQL;;3;**TLX5B@C&
M%5:L445RGBMMZL44450UK6+30-'N=4OF9;>W0NY52Q_(4@+5T9Q:2FU5&N A
M\L.<*6QQD^E?+5IJ/Q"T[XKOA9_[>N)=LD+ F*2//3TV8[]L>M>@^#OCM!JW
MB:>QUJ&.SL[B3%G-G_5]@KGW]>U>R&VMWN4N_)C:=4*++M&X*>2 ?3@4MQ[#
MH6D\F+S]BSE!O5#QNQSC/;-<-\6/!^K^-/#=OI^D2VZ/'<"603.5#  X' /<
MBO&_B5XC\:Z+\1Q?WDDEFUNQ^P"(DQ&/V]<]\U[)\.?B?IWC>T6VE*6NL1K^
M\MR>),=63U'MU%%[A8U?"&F_\(;\/;*TO@D365NSSD,, Y+'FO'_  ;8R?%_
MXC7VOZR"VEV)!CMS]W&?D0_D2?7FO:_&MI/?^"-:M+4$SRV<BH!W)4U\Z?"+
MXC67@:[O;75()6L[PJ3+$,M&RYQQW'/-)C1].:A:VKZ/<VTL,9MO)93&5&W;
MCICI7R[X#^&$7C[3]2DM-1:TFL[A4!D3>CHV<<#!!XKM/B+\;=/U+0I]'\-"
M=Y+H&.6YD3:%0]=HZY/KQBNV^"_A>;PWX&22[C,=U?OY[(>JKC"@^^,G\:-P
MV-[P+X(L/ NA_P!GVCF::1M\]PPP9&_H!V%=1113$+1110 444"@!:***!A0
M**6D 4444 %**2EH *!12T % HI:0PHHHH *6D%+0 4444  I:**0PHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ^*,# '8T.-C86@*3P#THQDDYKU3S2
MS$B>46;K5;";B,TN6(]%IS(H7/>F P@ C'-29)CVXQ3%RV!C%2&%PV <T 1\
MC&:, G!ZTAW X/:D 'WB:  D#CK0.#[4  T,,D$=*0Q>G'8TI!^[CB@$#K1\
MQ^8=!3 :2/RH'(I&'(]33PI(V]*!#,\XH(VG'8T$;3CK2\%>:0P#$<#I2'U[
MTW(/%36UL]U<)%'R6-)ETX2J24(*[98TO3)M2N0B A?XF]*]*T?1;;38% 09
MZ^Y^M5=&T^+3[5%4#('YFM1IO>K@NK/T7+,IA@:?>;W?Z+R_,N-.%&!P*KO<
M>]56F]ZA:2J<CUHT2P\U1^;5<R4W?4<QNJ9:\VCS:J;Z7?1S#]F6O-H\VJN^
MDWT<P>S+?FT>;53?1OHY@]F6_-H\VJF^C?1S![,M^;1YM5-]&^CF#V9;\WWH
M\WWJIOHWTKA[,M^;[T>;[U4WT;Z=P]F6_-]Z/-]ZJ;Z-]%P]F6_-]Z/-]ZJ;
MZ-]+F#V9;\WWH\WWJIOHWT7#V9;\WWH\WWJIOHWT7#V9;\WWH\WWJIOHWT7#
MV9;\VCS:J;Z-]','LRWYM'FU4WT;Z+A[,M^;1YM5-]&^BX>S+?FT>;53?1OH
MN'LRWYM'FU4WT;Z+A[,M^;1YM5-]&^BX>S+?FT>;53?1OI7#V9;\WWH\VJF^
MC?3N'LRWYM'FU4WT;Z+A[,M^;1YU5-]'F4N8/9EOSJ/.JIYE'F4<P>S+?G4>
M=53S*/,HY@]F6_.H\ZJGF4>91S![,M^=1YM5/,H\RBX>S1:\VCS:J^91YE%P
M]FBUYM'FU5\RCS*+A[-%KSJ/.]ZJ^92>92N'(BWYWO1YWO53S*/,HN'(BWYW
MO1YWO53S*/,HN'(BWYOO1YM5/,H\RBX<B+?FT>;53S:/-HN'(BWYM'FU4\VD
M\VBX<B+?FT>;53S*/,HN'(BWYM'FU4\RD\RBX<B+GFT>;53S*3S:+ARHN>;1
MYM4_-H\VE<.5%SS:/-JGYM'FT7#E1<\VCS:I^;1YM%PY47/-H\VJ7FT>;1<7
M*B[YM'FU2\VCS:+ARHN^;1YWO5+S:/,HN'*B[YWO1YWO5+S*3S:+A9%[SO>C
MSO>J/FT>;2N%D7?.H\ZJ7FT>;1<5D7?.]Z/.]ZH^;1YM 61>\ZD,W%4O-I#)
MQ0%D6'FJM(X-,:2H6;-(1%.BN""*YS4]+#9DA&&]/6NC=JJR@$4FCCQ>$I8F
MFX5%<XHCDJ1@CK29P:U=5L]I,Z#_ 'O\:R0>:1^=8W!SPE9TY?)]T!YY-+C'
M-(3^M.&0,=J#D&D_-QTH.0,T #/M3A\S8[4#&8X!HZU(%.3QQ3&& 32 7&1U
MINW+9IVT[=P/-"J6.%'-,!!DT$'&<5(Z%.#UI-V1B@!(\9QT-*26;Y^<4TG'
MUI3R,YH '.!D'\*9R>:4#)XZ4$>G2@!?GV\#@5+#((P3C)-(TP$010#ZU$&/
MI@4@%#88^]&0#D4A'Y4O [9H&:.F6T<I::4CCM56Y9#>-LX2F(9%X5L TJPE
MVP>IHL,B/WR!TIP(5:=- 8B 3S4+# YH$+G<2*,$4 ;<4^3D B@"-3BOHS]G
M\Y\%ZC_V$6_]%QU\YMV]:^B_V?QCP7J'_81;_P!%QUG5^$N&YZS1117,:A11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AHI:2@ HH
MHIB$KQ;XZ?#RZUR"/Q%I41EN;:/9<0J,LZ#HP]2*]J-)UH ^2O!'QDU[P;:K
MITL2:AI\9PL,Q(:/V5NWT.:Z[4OVDKJ6T=--\/QV]P1A9)KCS OX!1FO4/$7
MPE\'^)9WN+K3!!=/RTUJQC)/J0."?<BL*Q_9_P#!=K.))Q?WBC_EG-/@?^.@
M&D!X9HFD>(OBOXS,EQ)).\C W-RPPD2>GH/85]=:9IUOI&E6NGVB!(+:,1H
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MG<35BQ:, 67UJU6<"0<@X-3K=$#YER?:HE%WNBXR[EJJ$K!I6(Z4^2X9Q@#
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M ,\T#'*VUL#FIDF(;.,D5 !W4TJ/LZBF!+,SS?,:KG!X-3R3 @!!QWJ'CO0
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MG:P;T.:O"YC*YW8]JSDWT-8I=2BRE6*GJ*2G2/OD+>M-JB6)12T8H$)1110
M4444 )12T4 )12XI* "BBBF 4444 %%%% !1110 4444 %%%% !4ZW 6W,>W
MG&,U!12:3!.P4444P"D*JWWE!^HI:DBC\R0+G%*X;D'DQ?\ /-?RH\F+_GFO
MY5<GMQ&@92??-5Z2=P:MN1^1%_SS7\J7R8O^>:_E3Z*8#/)B_P">:_E1Y,7_
M #S7\J> 2< 9I2"#@@B@"/R8O^>:_E1Y,7_/-?RI]+0!'Y$7_/-?RIRHB_=4
M#Z"G4JHS'Y030%A**5E93A@1]:2@8444^) \BJ>AH; 18W;D*2*""IP00?>M
M(  8'2HKA T9/<5FIW9;AH4:***L@NVQ!A ]*FK/CD:,Y'Y5/]KX^YS]:S<7
M<T4E8==$>6!W)JI3G=I&RU-JXJR(;NPHHHI@%+110 4M%%( HHHH ***6@ H
MHHH&+1112 *:[K&A=V"JHR23@ 51UC6[#0K)KJ_G$:#[HZLQ] .]>,>*_']_
MXA+6UOFUL/\ GFI^9_\ >/\ 2M(4W(Z*&%G6>FW<Z;QA\3 OF6&A/D\J]UZ?
M[O\ C7E<DCRR-)(S.[')9CDDTT DX')KO?"7PWN]7*7>J![6SZA",/(/Z"NE
M*--'LQC2PL.WZG+Z#X>U#Q%>BVL8B0/OR-]U![FO;O"_@K3O#4(=%\^\(^>=
MQS]%]!6UINEV6DVBVMC;I#$O91U]SZFK=<\ZKEHMCR\1C)5=%HA111161Q!1
M17$>/OB;I7@6-(98VN]1E&Y+5&VX7^\Q[#^=(9W HKD/!_Q)\/>,XPEE<^1>
MX^:TG(5_^ ]F'T_2NOH *^=_VA?$4\NLV7A^-RMO#$+B10>&9B0,_0 _G7T1
M7S3^T'I4]OXRM-2(S;W5J$5L_P 2$Y'_ (\/UI/8<=ST3X,>!].TGPK:ZW-;
MI)J5ZID\UUR8TS@*N>GK^->GS6\-S"T,T221N"K*PR"*\\^"WB:WUOP+;67F
M+]LT_,,D??;G*MCTYQ^%>D4(&?+GQ;^&/_"(77]L:5_R"9Y,>7GF!SV^GIZ5
MI^!/CI+H6D)IFO6TU\L1"PSHXWJGHV>N.WY5W'Q_U:WM/ J:<Y!N+R=-BYY
M4[B?IQC\:Y+PW\$]/\6>$]$UD7\MA--%FYC$88/AR,KD_*2 /7Z4NN@^FI[C
M;7.D>+- 6:(PWVFWD>"&&58'J"/7VKY,\<Z/;^$_B->6.E.RQ6\R/"-V3'D!
ML9]LU]&>)-.NO!/PPN+?P>I@FLT#)B,2,PS\QP0<L1FO)/A[\*];\3Z^FO>)
MHIH;(2^<_P!HR);ELYQ@\@>I/X4,$?1FES2W.DV4\PQ+) CN/]HJ":MT  #
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MFNE^)@ \(.0 /WR?UKF?A"<ZAJ?_ %S3^9KIOB?QX.?_ *[I_6JE_%.G&?\
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M@CH165?Z_H]J9K>XO[>.95(*,W(.*M:/_P @6R_ZX)_(5X;X\)_X3/4?]_\
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M/-<\0@UOQ%:V*65O<WD5NF=J(",5F7<MY*X>[:9F/0RY_K7TDBP2#*+&P]0
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M9W >QJ&>92FU3G/6JM%2H),IS8444M42%%%% !1110,*6BB@ I:2EI %%%%
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M,YPJCHJ]@*]@^%G_ ")J_P#7P_\ (54X\M-(Z<QPSPV5PI/=-7]=3F_C"?\
M3=*'_3.3^:UYG7I7QB_X_P#2_P#KG)_-:\SS6E+X$>ODW^XT_G^;'44W-&:T
M/4N>D_"?6DM]0N=+FD"K< /%GNP[?E_*O2?$>BQ^(-$N+"0[2XRC?W6'0U\X
MV]Q+:W$<\+E)8V#*PZ@BO:/"OQ(L-4@6#5)$M+P<;FX23WSVKGJP=^9'RF<X
M"M"NL707K;HUU/)-6T:_T2[:WOK=XV!P&Q\K>X/>H+:.]NY5AM5GE<\!(\D_
MI7TLT=M>P@LL4\3#@X# T06=K:C]Q;Q1_P"XH%+V^FQ*XE?):5/WO70YOX?:
M1?Z/X<\G45V322F0*6R0"!U_*L+XO_\ ((T__KN?_0378:MXIT;1HV:[OH@P
M_P"6:-N<_@*\=\:^-6\4RQPQ0"&SA8LF[[S'ID_X4J:E*?,<^64<1B,:L5*-
ME>[[?(['X/\ _(-U+_KJG\C4GQ?/_$AL!_T\_P#LIJ+X/'_B6:G_ -=4_D:?
M\8#_ ,2.P_Z^?_931_R]+?\ R._G^AY!FO;_ (5WB7'A+R WSV\S*P] >1_6
MO#LUTG@SQ7)X7U4R,&>TFPL\8ZD=B/<5M4CS1LCWLVPLL5AG"&ZU1W?Q:T:X
MNK*SU.!"ZVVY)0HR0IQ@_08_6O(XT>618XT+.QP%49)-?2FFZQIFN6HDL[F*
M='7E,C</8BDM] TBTN?M-OIMK%-UWK& :QA5Y59H^?P6<RP='V%2#NMNGWE/
MP9I4NC>%;*TG&)MI>0>A8YQ^ P*\Z^+M\DVN6=HI!:WA+-CL6/3\A^M=]XG\
M::;X=M7S*D]YC"0(V3GW]!7@FHZA<:IJ$][=/OFF;<Q_I3I1;ES,VR7#5:N)
M>,J*RU^;?Z':?"K5?L?B9[)VQ'>1E0/]I>1_4?C7L=Q8P75Q:SRKE[9S)&?0
ME2O]:^:=+OI--U2UO8S\\$JN/P-?3=O.ES;17$1S'*@=3Z@C(I5U9W,N(:+I
MUXUH_:5ON_X!P_Q6U+[)X9BM5;#W4P!'^ROS']0*Z7PW?C5_#%A=$[C+  _N
MPX;]0:\L^+6H_:?$D%DK96UAY'HS<G] M=/\(]2^T:!<V+-EK:;</]UA_B#^
M=)P_=IF=?!\N50J=4[_?I_D=U9VD&FZ?%:P+MA@3:H]A7SKXEU0ZQXCOK[.5
MDE(3_=' _0"O<?'&J_V1X1OIU;$KIY4?KN;C].OX5\[YJZ"WD=O#M%OGQ$MW
MI^K_ $/8O@\?^)1J/_79?Y4?&$'^Q=//;[0?_0365\(]8MK:XOM-GE6-Y]KQ
M;CC<1D$?7D5ZK>V%IJ,'DWEM%<19SLD4,,^M1)\M2YPXRJ\+FCK26E[_ ('S
MGX8_Y&G2?^ON+_T(5])M]T_2O'_%-G;V7Q5T=+:...-F@.U   =Y']!7L#?=
M/THJN]F&=UU7]E52M='RW<?\?,O^^?YUZI\&O]1K'^]#_)Z\IN/^/F7_ 'S_
M #KU7X,_ZC6/]Z'_ -GK:K\#/>SK_<)_+\T:/Q?_ .16M/\ K]7_ - >O%LU
M[1\8/^15L_\ K]7_ - >O%J*/PD9#_N:]6+FBDS29K0]FXZBFYHH%<=1FFT9
MH 7-%)FC- 7%HIN:*!7'44VB@+BYHI,T9H%<,TAI,TA- K@:::4TTFD0V,<\
M5C:H^<*/6M:1L*2:P;E_,G)["I9X>=XA4\,UU>A6 !%/ ^4\_A36&3QQ2X)%
M4?#"#D8I=M.&,8(YH(P* &XSWIK?2I54X)IN>.E " YP12DAN*, #-(>> .M
M Q#4@  &:UEM8H-.WN!DBLE<G/UH :V,\<TT\=*<>N105RM #?FSTI'#%A5B
M!5W#<:;,09N.G2@"-$W<GM3=I.:=EER.U,!(/7BD FWN>U(<N<]J?(X)&*:H
MYH '   '6FJW&* ,N0:<RE32 ;3ADXQ2D?)FDSQD4 /#%>",TB\&F[OE]Z<6
M(P0*8QS XS7T/\ ?^1+U#_L(-_Z+CKYUW8X/0U]%? $ >"[_ !_T$&_]%I6=
M7X2H;GJ]%%%<IL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 &DI:2@ HHHIB$-%+24 %%%% "4444 )1113$)7SG\6++[)X
M[N6 PLZ+)G'4D<U]&&O&?C?I;"XT[5% V,IA?'7/45OAG:9AB5>!Y%1117HG
MG!1110 5W7PCE9/'MLBGB2*0,/7Y2?Z5PM>F_!;3&N/$ESJ!0^7;0E0W^TW&
M/RS6=5V@S2DKS1[I12FDKS#TPHHHH 2BE-)0 4E+24P"BBB@ I*6DH$%)2T4
M )1110!Y9\:++=8Z9?#_ )9R-$>/[PR/_0:\>KZ%^)MA]N\#WA"Y> K,O'3!
MY_3-?/5=U!W@;0>A['\&M2$FGZAIC,-T4@F09Y((P?RP/SKU"OGOX::K_9GC
M6T5F(CNLV[ #.=WW?_'@M?0E<]>-IF<UJ!I*6DK(@**** "DI:* $HHHH 4*
M6. ,U(+8XY8"I8DVH/4U)4N78M1[E9K=@.#FH2,=>M7ZAN$RN\=1UH4A.)5H
MI:2K("BBB@ I*6B@!**** $HI:2F 50O7,DBPH,X_G5YCA2<9J*"#82[\R-R
M3Z4Q,;;6PA7)Y<]3Z5/2T4@$HHHH **** "I8[=I!GH/>HJT8R#&N.F*F3L5
M%7*,D+1=>GK4=7[G'DG/X51Q3B[H)*S$HHHJB0HHHH ****!!28I:* $HI:*
M $HI:,4 )12XI,4 %%&*,4 %%&** "BC%&* "BEQ10 E%+10 E+BBB@ HHHH
M ****!A1110 444M "4M%%( HHHH **** "BBEH **** "BBB@84M%% !112
MT@"BBB@ HHHH *6CH*YO6O'.AZ*'62Z6:=?^6,/S'\^@H2;V+A"4W:*N=)63
MK/B72=!CS?W:H^,K$.7/X5Y3KGQ0U;4=\5@HL8",?*<N?Q[?A7+66FZKKUR1
M;03W4I/S-U ^I-;1H]9'H4LO=N:J[(Z_Q#\4M0U!7@TM/L<)X\S.9"/KVKB8
MH;[5KS;&DUU<R'MEF->CZ'\)7;$NM7.T=?)@/\S7HVEZ)INC0"*PM(X0!@D#
MD_4]ZIU(0TB:O%4*"Y:2N>8>'_A3=7(2?6)OL\><F!.7(]SVKT[2=!TW1(?*
MT^TCA'=@/F;ZGO6C2UC*<I;GGUL34J_$] HHHJ# ***6@ HHHI %%%% Q:1E
M#J589!&"*6B@#Y+O9&^'7QDEF"D06MYYFU.,Q-S@?@<5TOCOXLZIXOO3X>\)
MQSI:RMY>^,'S;CZ>B_Y-3_M#Z&8=8TW6XT.R>,P2$#@,O(_,$_E72?L_Z?HD
MGAJ?4(;6/^UDF,4TK<L%ZKCT'7\JGK8KS)?AQ\&+31H5U+Q)%'=ZA(O%NWS)
M#GU]6JGXT^ =I>^9>^&)1:S'+&TD/[MCZ*?X?Y5[92T["N>#?"3X;^+-&UIM
M0U&ZGTNUB?#6RN#]HQV(Y&VO>:**$@W"BBE%, HHHI %+110 4444  I:**
M"BBB@8HHHHI %%%%  *6BB@ I:**0PI:** "BBB@!:*** "BB@4ABT444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!\6 8'/(I&&" .AI6;C%
M(2._:O7/,+,D<2P Y^:JG1<8I221@]*!@9S^% "JPW#CBED/F8 X%(H &3WI
M,9.3TH 7  VXIG0[:E+ C@=*C+9YQ0-"#)?CD4]SNX'2F\_2EP <T  ([#)I
MI^E.P1TH)/04 )@'ZT9[=Q1M[YYI%.#GO0,4@'D]:3IP*,'=FG.,  =34@1C
M@U:L+GR)^3A6X/L:JLI7%*5XR*31OAL1/#U8U8;HZR*4,M2YK!L+W&(W/S=B
M>];$<H8<&HV/U' 9A3Q=)5(/_@$^:,TW-+0=_,+1110%PHHHH"X4444!<**2
MB@+BYHS244!<7-%)10%Q:*2B@+BTJLR,&4D$="*;10%R;[5<?\]Y?^^S1]JN
M/^>\O_?9J&B@FT>Q-]JN/^>\O_?9H^U7'_/>7_OLU#10'N]A223DDDFI/M5P
M!@32?]]FHJ*!Z,<S,S%F))/4FA)'C.49E/J#BFT4!=$C7$SJ5::1@>H+$UN^
M";.PU#Q1;VFI1AX)0RA2<?-CBN>IT4LD$J2Q.4D0AE8<$$4FKJQE6ASTY0B[
M-K<]RG^&/AV3)ACG@;U29N/SKSZ\^'?BA+MX4A,\(;"R>:,$?B:W-%^+;PP)
M#JUF9648\Z(X)^HK='Q9\/;<F.]!]/*'_P 57.G5CYGR].>;X633CS^NOW:F
MIX&\-S>&M#:WN75KB60R2;3D X Q^E<7\7[])+VPL%8%H5:1@.V['^%6]5^+
MT(A9-*L7,AZ23G@?@/\ &O,+^_N=3O9;R[E,DTIRS&G3A+FYI&V6X#$RQ;Q>
M)5GK][(4EDCR4=ESUVG%*\\LB[7E=AZ%B:CHKH/IM!ZNR-N1F4^H.*<UQ,P(
M::0@]06-144!H+3UGEC7:DKJ/0,14=% -ICWE>0@N[,1_>.:;FDHH"Y9M]1O
M+3_CWNIHO]QR*DN-7U&Z&)[ZXD'HTA-4J*6A/+!N]E<7-)124RN86BDHH#F)
MA<S@8$\@'^\:C9F=BS,23W)IM% M!:?'-)"X>*1D8=U.*CHH"]S1_M[5O+\O
M^TKK9Z>::HO*\K%I'9F/=CFF44M"8QC'X587-/2>6-=J2NH] Q%1T4RFTQ[R
MR2$%W9L=-QS3,T4G-(5Q<T9I.:.:!W%S1FDHIBN6H-2O;7'D74T>/[KD5--K
MFJSKMEU"Y<>AD-9]%*R(<(-W:0K,S'+,2?4FDHHH+N/2:6,$)(ZYZ[6(H>:6
M08>1V _O,33*2@6E[BT9I** N2PW$UN^^&5XV]5;%7'U[5GC\MM1NBG]TRG%
M9U%&A$HPD[M#F=G.68D^I.:;1107<,U(+F<  32 #H YJ*B@3L]Q6=G8LS%B
M>Y.:<DLD>=DC+GKM.*910%T/>>608>5V'H6)IF:*2@+I#@Q4@J2".A%7DUW5
M8XO*34;E8_[HE.*SZ*"9*,OB5R1YI9)/,>1F?.=Q/-.^UW'_ #WE_P"^S4-%
M ] S3TFDCSY<C)GKM.*910%Q[SRR##RNPZX9B:9FDHH"Z0N:,TE% 7%S29HH
MH%<,T9HI* N+FC-)10%PS1FBB@5PS1FDHI!<7-&:2BF%PI*6C%(ER&TTU)MS
M56[N%A0\C-)LYZM:,(MME2_N B%0>:QB26R*EFF,TFX].U(L1QD\"A(^$S/'
M?6JNGPK8CSDTH7UH'W\#I4A4$8SS3/-&A@!ZT8R,TG(.VE49.1VH$+\S<CM2
M _*>]2*3L.>M0YVG YIC$Z'K3XCAQD4%-V#GFEYZ4@+E[=>=$L2G@=:HCC@=
M*< "*#P3GB@8PCTZ4#FD+ 4!P/<T /!VCWIN_C!HSGGO36 ^\: %/3VIH SF
MG @].E*P&.:0#,#.<4VG9P>!3EBX+4 1\"C)Z4,1B@9 S2 3!S@]*.WRC-*2
M6(-*Q /'2@!H&1TXIP)Z'I0<9QVIV!M(H&'RE<&OHCX _P#(F:A_V$&_]%QU
M\[+@@U]$? #_ )$O4/\ L(-_Z+CK.K\)4-SUBBBBN8V"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH 2BBBF(*2EHH
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MU8T04R7_ %3?2GU7GD!&T?C0EJ#=D04445J9B44M)0(**** "DI:* $HHHH
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M:36H[Z&\****8@HHHH&%+110 4"BEI %%%% !0**6@ HHHH&% HI:0!1110
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M8S_?_+_Z]&H?VUA/YT;&RC961_;B?[?Y4?VXG^W^5%V+^VL)_.C7VT;36/\
MVXGJ_P"5']N)ZO\ E2U#^VL)_.C8VFC::R/[;3U?\J#K:#KO_*GJ']M87^=&
MOM-)L-9/]MIZO^5 UM&8*-Y)_P!G_P"O1J']LX7^=&ML-&TUFR:J(B-Y=<_[
M-,_MI/5_^^?_ *]+4/[9PO\ .C5VT;:RAK*$9!?\O_KT'64'=_\ OG_Z]&H?
MVSA?YT:NTT;365_;*8SN?_OG_P"O1_;*?WG_ .^?_KT]0_MG"_SHU-AHV&LH
MZR@[O_WS1_;"^K_]\TM0_MG"_P Z-7;1MK*_MA/5_P#OFC^V4]7_ .^:>HO[
M9PO\Z-7::3::R_[93U;_ +YI/[:3/5_^^?\ Z]+4/[9PO\Z-7::-IK*_MI/5
M_P#OFC^VH_5_^^:-0_MG"_SHU=IHV&LK^VH_5_\ OFD_MJ/U?_OFC4/[9PO\
MZ-;::-M91UE .2_Y4G]MQ^K_ /?-&H?VQA?YT:VPT;#61_;<>>K_ /?-*=:0
M=W_[YHU%_;&%_G1J[#1L-9/]MH1_'_WS1_;<?^W^5%V']L87^=&ML-&PUD_V
MW&.[_E1_;:>K_E1=A_;&%_G1K;#1L-9/]MI_M_E1_;:?[?Y478?VQA?YT:NP
MT;#65_;:>K_E0NM(W3?^5%V+^V,+_.C5V&C8:R3K: X._P#*C^VX\9^?\J+L
M/[8PO\Z-;8:-AK)_MN/_ &_RH_MM/5ORI7#^V,+_ #HUMAHV&LG^VX_5_P J
M3^W$S_'^5%V+^V,+_.C8$=!V(,DUBOK+,#LC./4FL^;4KF8$!MH_V:-3EKY]
M0BO==S;O-1CA!4'GT'6L*>X>=\MP.PJ#.YLG.:<&&.E-(^<QF95<5H]%V$P=
MW'2GLQ/RYH/*9IJ G)[51YXHXZ<FA@RGKS2HP7L/K2!LL:0"[@5I1@KGI2#)
M'3BDS\P'84 *V[-!&!G%.=]V !1GY=N.:8#%X/J34IAD10S@C-,5@L@/\0[5
M<=WOF2)!@CK2 ID$&DD.0,U8O+=K5E7J:A5-Y^8XIC(2N:5,*":& W[5/'K3
M>"<'@4@#KSVIP(-.51T)X[4TKM.<4 (#CVH.5ZTY1\W--?.[VI *,>E#,R\#
MI2 =Z=R1ST%,!FT;<T ;CCM3V(V],4T(3SVI ,8'<!FI"F%R!3>"_-2K+MRI
MH AP3VHP0,TI.6X/6I00$*D4 1=J^B/@!_R)>H?]A!O_ $7'7SS@XYZ5]#_
M$;?!>H8/_,0;_P!%QUE5^$TAN>KT445S&H4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 E%*:2@ HHHIB$HI324 %(:
M6B@!*#110 E%%%,0E%%% !1110 E%+24P"BBB@!**6DH$%%%% "44M)0 4E+
M0:8"456O-0LM.A\Z]NX+:/\ O32!!^M<-K'QH\&:2K"._:^E'\%LA//U.!2
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M%% !BDQ2T4 )12T4 )12T4 )12T4P$HI:* $HI:*0"44M% "48I:* #%%%%
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ML(J8#<4@X^6A<EL4XK@TK#&D8( I2H'-'/XTC'! HL WJ:=T^M!I -I]<T6
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MR8'O0 >80FT5&&PW%. ^:@CYLB@ &<YIP.!ZTT\C/>D&<C%,!X)Y!Z4[(\O
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M"DYW CG-6/LC+%YS=/2H5;!R.M,+@^[.#TIG(XY-.=]Y%*..G6D =1@#FD/
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M=?/#!1T.:^B/@",>"]0_["#?^BXZSJ_"7#<]7HHHKF-0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BBB@ H
MHHIB$HI324 %%%% "4444 )1113$)10:* "BBB@!**6DH ****8"44M)0(**
M** "DI:2@ KP[XM?#+6_$OC.TU'0K96\V';-([A51E/!/?O^E=SXF^+/A3PM
M=M9W5W)<72'#PVR;RGU.0/UJ?PK\3O#'B^<6VGW;1W9Y%O<+L=OIU!_.C09T
M6C17<&B6,-^5-Y' B3,K;@7  )S[]:R?'7A8>,?"ESHXD2*20JR2.N0A!SG%
M87Q<F\76WAH3^&&*)&V^Z:+/G!1S\OMZ]ZK?"GXF+XTLFL-0*IK%NN7QP)E_
MO >OJ*/(#1^'/PXC\ 07:KJ<UV]UM\P%0J KG! ZYY/>NYHHH$)12TE,1POQ
M7TC^T/"+72*#+92"7IR5Z,/ISG\*\$KZNO+6.]LI[64!HYHRC ]P1BOES5+"
M32]4NK&4'?!*T9R,9P>#^/6NS#RNK&L'T*E>]_"W7O[6\,+:2N#<6)\LCN4_
MA/\ ,?A7@E=;\.]>.A>*X-[ 6]U^XEST )&#^!Q5U8\T1R5T?0U%+25P&(44
M44 %)2T4Q"4444 %%%% "44M)0 4444 %)2T4 )12TE, I*6B@0E9%_'-IUP
MVI6B-)&?^/JW7JX_OK_M#]1QZ5KT4TQIV(K:YAN[:.XMY%DAD7<KKT(J6N=N
M]_AF[>^B4G29FS<QJ,_9V/\ RT4?W?[P_'UKH(Y$EC62-@Z, 593D$'N*&@:
MMJMAU&***0A**6C% "48HHH 2BEHI@)11BB@ JQ:8RWK5>G(Y1MPI-70+1FA
M39,>6V?2HA<H1R"#44T^\;5&!_.LU%W-')6(:***U,@Q28IXC=AD*:0J5.""
M* &T4M% "44M% "44M% "44M% "44M% "44M% "48I:* #%%%% !1110 444
M4#"BBB@ HI<44 )BEHHH ***6D E+110 4444 %%%% !11BEH ****!A2T44
M""BBBD,***6@!*6BB@ HHHH *6BB@ HHHI %%%+0,**** "BBEH **** %HH
MHH ****!A2T44 %%%+2 **** "BBB@!:*** "BBB@8M%%%( HHHH !2T44 %
M+112&%+0** "BBB@ I:** "BBB@ %+112&%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% 'Q;T^7/%*QP!CFEP "2>M("$7FO7/-&C&
M.O-*HW*23S1C(R:.% (H ,#;SUI&)91[4[(!Y'6E5,DGM0 T*,>HH) Z4GW&
M(I-_)Q0,>!SDTA/.12#ID4@)YXH$*?F&#2I@,?6FD@C&.:4<&@!#\Q(JVMHP
MMO.)X%5#RP-6'NV,7E?PT 0*V?FI-_S8/6@#& >E. &[)Z4 .7:A#'DT^>9I
M%"]JC*@G(-!4\=J8PZ8I#WQTI2V6]J:P[BI$2/=.4\OM3" L>0.:8>/FI5)8
M9'2F+9"@#;D_>]*>B((SN/S>E-#8.:5<;]QZ4 ,VCG=0-N,+2G[Y]*-N#GUI
M#"(98[N@Z4LC ME>E&<<=J:P/;I0 OS-P3\M)U^7'%+D!,4T$@]*!@%PN<U-
M%'N7#=*9G%'*T *RCIGI2=!CO3E(9O:B1E' ZT#&8/4FDXW"G*-W%!(&3WI
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M2C:",#M2J<=*!@3W7\10#M.<4Z, 9)[T< XI"&$D].E._A% !#=.*D4#^*F
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M&<T'&0#U%+C<>:&,%Z\BDW$G%*..>U!Y.12 7R\]^E(V67F@L0 .]#$8P#0
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M&_9A7.^&/$ES:Z@?#/B [-1A^6"8]+A>QSZ_SKMJYOQAX6B\2:>#&1%J%O\
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MB@!*7%%% !1110,*,4M% @HHHI#"BBB@ HI:* "BBB@ HHHH *6BB@ HHHI
M%%%% PI:** "BBEH **** "EHHH *P/%/BNQ\+V!FN&#W##]U #\S'_"L[QG
MX[M/#5NT$!6;46'RQ@\)[M7A.HZE=ZM>/=WL[33.<DL>GL*VI47+5['31H.>
MLMBSKVOW_B+46O+Z4L3PB#[J#T K+HHKM2MHCT$DE9!1110 4444 >M?!O5W
M;[=I#G*@>?'[=C_3\J]9KPKX1;_^$P;;]W[.VZO=:X:ZM,\[$*U0***6L3 *
M***!A112T@"BBB@ HHHH 6BBB@ I:**0PI:** "BBB@ %+110 4444  I:**
M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEI#"BBEH **** "EI*6@ HHHH *44E+2&%%%% !1110 4444 %%%% !1110
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M5P#CFO8/,&DXP%YI=I R:$8'( IK$DT /)W+UQCK4;CCBEP&Z'ZT$9&!0 U
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M\5/8^6MXK3?<]Z 1&T;Q(-ZD9J/!ZUIZO>1SRJD(&T#M6<3QD=*0,80>O:G
MC;28+<BE''N*8( :!U(I< ')Z4J\CWH&-)V@YZ]J0[@F3S3@O/S<T(,MC&1F
M@ C.%^M7?[+F%L;ACA3VJLRX*E1P#FK]UJ?G62P1\''-)W&9@4%CS0V>U)C:
M!C\:F\L>7N[FFA$())]J<3SBD4[5Z<4?>7=TH 3G.>]6(RODG=]ZH1CKFAB%
MY'- Q.6Y]*4_=Y%(&R,XXI-V[/I2 09QQ2X) (.*0-Z"I!@+3 0\+QS32=X
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M@=*C [F@!X(ZFG;\K@5&QXZ<49!&* #G/6OHCX _\B9J'_80;_T7'7SU#MW
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;F ]<5Y)J?[1>D0EUTW2;FX(SM>5@@/IQUI#/:J*^9-2_:$\37/%C:6=F/\
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M?[0]ZPK4N;5;DRC<^BZ2H+&^MM2LHKNTE66"5=RLIZU8KB,1**7%)0 4444
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MN(;TB1P016T*0P1K'&@PJJ, "I***YSE"EHHH ****!A112T@"BBB@ HHI:
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MY??^=.!#$DTWC'M30O/&<"@!>Y]*%XR:"-QVK32Q!QCI20R0 MR3^%-(V]J
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MH?\ 80;_ -%QUG5^$N&YZM1117*;!1110 4444 %%%% !1110 4444 %%%%
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M7,%[;1W-M*LL,B[D=3D$5+7&9"44M% "4444 %%%% "44M&* $HHHH ****
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MM)2TAA112T %%%% !112T %%%% !1112&+1110 4444 %%%% !1110 4444
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M@# .: X(R>*3(P2!0 U\,1Z4A; ('2E/)P*"N.@X- #5POS#I3L94D"E(5<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKI:*)_L=J>/+B8Y(]S7($DG)))/<TE%="BHJR.N,5%604444QA1110 4444
M%%=)H'@?6_$#(UO;-%;'K/*-J_AZ_A7K/ASX9Z/HN);I1?W0YW2K\J_1?\:S
MG5C$RG6C \L\.> =9\0NCB!K:T/6>48&/8=Z]B\,^!M*\-1[HT^T7)ZSRJ,_
M@.U=,JA%"J  . !VI:Y)UI2.*I7E/3H%%%%9&(4444 %+110 4444#*VH7]O
MI>G7%]=R".WMXS)(Q[ #-?,>L>(?%GQC\32:=HR2Q:>N2L"OM14SC=(?7_\
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MW*M#Y(7\:KAA@<<5[)Y@BL-IS^5!^=1V-*X#."HI=I;@#IWI 1@MRIY IX(
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MCWI54'KVI%#<;QGTI5 7#4K8XQ2 D9]*!"$LW&,"FLI&!VJ0L>/2D*G=QR*
M&CY!@G*FE##DXXI&X]Q2'(&[MZ4AB\EL=C0Y"_6A3N'O0%'(;K0 F_)ZT]0!
MTQS40([#BGA3C@4P!A\O'6A!M&6ZT^./GK0^W< .M QAX.1WIP7!R>E(RG.,
M<4#+';VH M64P1F+8]A4$C SDKP*C .XTXX48SR:0"%@Q)/2D#KW'THSA<8X
MINW'6D N"6ST%*PV*2.:1@2!VIP4J,4P&1_,/FI[)@=<T8#>QJ41&.,L>:+
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M+10 E)2T4Q"4444 %%%% !24M% "5FZ^NJ/H5X-%DBCU'RCY#2KE=WO6E13
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MSP7\0;+Q-&MK<[;;4@.8R?ED]U_PKM*X91<79F35A**6DI""DI:* $HI:3%
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M]:^B:RO#GAZP\+Z);Z5IL6R"$=3U=N['W-:M !112TQ!1112&%+110 4444
M%+110 4444 %+24M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK$!^PJFJYP30!)NVKS7T)\ CGP9J!_ZB#?\ HN.OGACW(KZ&^ /_ ")FH?\
M80;_ -%QUE6^$N&YZO1117*;!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSA<_,/?(_6M/P=X-TSP5H_\ 9^F^80QW2R2,27;'7'0?A0!T-+113$%%%+0
M4444AA2T44 %%%% !2T44 %%%% !112TAA1110 4444 %%%% !1110 4444
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M782'('RT ,V@=3D4X9(SCCM1D#KTI4^9>.E # 2,_+UIV?EX'-+RO!IN<&I
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /C88=,D_+2 9&!P.U(S''R\
M"G#A,^M>R>6&SC!;YJ/* X!I1\R<=12*!C!XH <3E=GZTTHR\X_&G;5SNSP*
MD>3>@"]!3 @SA2H'6DW?PM^=&225'.>]&#]PC)]:0$BOY6<#)J+))SC)-.VX
MZU/I_EJ[&8\#I3&5V^3 '4TFTHW(ZU-,09R5'%1L<MUS2 ;M(88I7<Y_2K;0
MHL&[/S55 RO-  %V+DCDTC9P,?C2C)/6E" 9&>30(1FR,"F+D'FGA !P?FIJ
M@YP<\4# MN^8\4HSMR>]  /T-2)M'!- $2YP1^M*%]>*>, '@59M+5;@%F.
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M!D4G5N.:<!@>U-8D_=%(!#DMP>E.SE.>HHQM4'OWH('4&@!#NQ[4H''-#,
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M<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR-;OQ5\++XI\#WD,<8:[MAY\![@CJ/Q% 'B/AFUE^+_Q-2YU0.+."%6F7/\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XT?Y>!G-.5@ORD<GO2
M%FRW I^X;\5[1Y8S&&QCBG':3SQBGXP<@Y]JB./XNO:@ R-^5H/)P>]*^ @
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MP<@Y[4@&M@+@4Y58+\W>FD8^E*7^7GFF $\8 _&D5R,BEW @J.M- !'7IWH
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ML?B/<5]$>(3'XY^#]S<Q+M^UZ>+E 1N*L!OQQWXQ^- 'SMI-YK'C/2-#\"6
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M0-LA]* V3R*W>%@9*O(^S$=70,C!E(R"#D&EKP;X3>-[FRU6'P_>SF2RG.V
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M,?+ZT#[QR*0@AN* '9XX&#WIH'S<4O);-(P*\@=: %90.:"> >]"Y8@=J=(
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M%+10 E%%%,0E%+10 E%%% !7RY\</&UYK7BJ?0(9"FFZ<X4HI_ULN,EC],X
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M8I:0PHHHH *6BB@ HHHH ***6@!*6BB@ HHHH ***6D,**** "BBB@ HHHH
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MYO"?B)!/(?[.NL1W SPOHWX5C7I\\=-S6E/E9],7%Q#:6\EQ<2+'#&I9W8X
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MEHH 2BBB@ HHHIB"DI:* $HHHH **** $HI:,4 )28I:* $HI:2F(*3%+10
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MDTT\=.:4-NZ_G2JI5O8T "J"-V>G:FOG;D#@TI'S9Z8I?X<YXI# #:H"=Z3
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M_H:[*-?F]V1SU*5M4>8MP05H(. <\TY^<$#FE8KQS\U=)@1MG.1VH!.?K2R
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%?1-$LD?EVRL,%@>K?3C ^IKNM-^&_A32IUG@TF-Y5Y#3,9,?@3C]*ZH
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MQ&)<16Q9W6+V&!@=R<=_K70?"[X1ZGX.\6W.LZY- (K2$K;/!*=LA8?,QZ$
M#/!'4Y[5[;7F?QO\5_\ "/>!I+&"3;>ZJ3;)@C(CQ^\/Y?+_ ,"H @\)_&O3
M_$WBU] &F7"F6=TM+B+YUD09.YQP5X&>_P"%>IU\:?#\>*/[4N!X2L&FU*6+
MROM(0'[.I/)!/RJ3@#)[9]:WO$6G_%?PK$-7U6_U:.'<"TL=[YB(3_>"L0!G
M Y&*+A8^K:*\4^$'Q<OO$>IKX=\0,DEVR%K:Z5=IE*C)5@.,XR01CI^?M=,0
M4444 &*3%+10 E%+10 E%+1B@!**,48H ****8!1110 4444 %%%% !1110
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M "BBB@ HHHH **** "C%%% !BC%%% !BC%%% !BC%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%&*7% "44M% "8I:** "BBB@ HI<44AB
M4M%% !111B@ HI:* "BBB@ HHHH ***7% "4N*** "BBB@ HHHH ***6D,3%
M+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?'#@J=M+AE7%.=S@<9SWIIRAY/
M6O;/*# QFF%0^ O&#3SU&.E-9>1M- #WD"Q[,TW<0HR*%4%LMUH*DY)_"@
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MG=QVIP*[<4=>U-"\YH$.! ^]THV$G<O2G87C/>GR-A0JT 5U+,^T#BI"2@(
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M 23Q@4 E?1";\+M(P/6CC@9S4C6UR%R87"CKE:C4JGR]Z"YTITW:::]1^<#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!&:  .P'!X-.7*KST-,P<Y XIY*#@<FD,1"JY'6E#[R..!UI,=.,4Y2.2!3
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MEK@&6-<_W@*ROX_O=>U=)QTK,O;(+F6)1[BHC+HSW.(,DWQ6'7^)?JOU^\H
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MSC(IS$''M350XP/QI0.<'I2  0>7X]J:R88,.!3B-S>U(Y).%Y% P.<\'BG
M@ ;NM, )/)X%*2 /Y4 .(YR>]-(&: QQ\W7M1DYQ1?4!X3C).!3&251DJ0IZ
M&G0E3=(')V]ZW+V6W2RP-I..*F3UL.QSV#7T-\ _^1,U#_L(-_Z+CKYYSP37
MT+\ CGP9J'_80;_T7'6=;X"Z?Q'J]%%%<AN%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP^T#ZTN%ST KVSRB(@-GC&*<K<C'6E/!.1D4B  DCK0 YU/WE/'<4TEAPO%
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M(Z-LSFD[8SBG-]XX;C%")\GS'KT- #1GHHX'4TT L3CO3D)0E1R* VUCQQ2
M5?F&T]J 06QG%/V;QQQ30H9J8Q"1N 4X/K1P.6IC%=Q&.11C=][@4"'OCA@*
MC^7E]V#3OF)]J"552I H&(A51N/-.RK?,!P*9M.W*]/2ER20H&!0 N_G*]*0
MN <^M+*"A&!BD"ASN[4@#!8$GI1E=N!2?,&XY%*1D@D8H <F0 &IVW )S2!2
MW/I4?+/R<"@1=T]E>[X[*:N:B2+7 [L!69:3"*\3LN<$ULSQ">!D]>E92TE<
M^XR1.OE-:A3^+7\5H8<GKWI%0%2QI64K(4(.1US0.25Z5J?$RBXNSW$!!&!P
M*V[,G[*F?2L1$9I B+EB<5OQH(HE7LHZUG4>A];PE1G[:=;[-K?,Q[T#[:_%
M3Z6Q::3C Q5:Z?S)69.03UJSI0_>2'/:F_A.'+IQJ9TIQV<I?J3:C(\8B9#@
M@U/;7"W$?;=W%5M4)"1X'>J$,QAD!3[W>I4;Q/6Q>;3P&:S4M8.UU\EJOZU+
M5]9[&\U!E3U'I6A:_P#'M']*(9DN(LCZ$4]$"*%48 Z5+>EF>U@,OHTL1+%X
M9^Y-;>=^G]:&'>'_ $N4 9):M#2QBW8GJ3S5&[R+N7CJW6K6F.!NC)Y/-7+X
M3Y;*9QAG4N;JY+\PU4_ZL=JSN0O'-;&H6YG@ROWEYK'(QT)IP>AAQ+1G#'RG
M+:5K?=8:QZ#H:4J1U% &1R.:7G'-,\ %P64=LUT/2+CL*YY>H/0BM^%Q)"K#
MN*B9]CPG.-ZM/JTOU, DJS>I/6F)PV6.35F\@,$YR/D/*FH0-PX7I5H^5Q-&
M=&K*G46J8AR3E3BM'2F^:0=L9K.4-WK9L(/)B+$8+?RJ9O0];ARC.ICXRCM&
M[?W6(M64M"A!P0U9]J&-U"3U#C-7-5DRRQ@].35&SS]JAYS\XH7PFV;3C/./
M=Z.*_(WI_P#42?[IKGB,D'O70S\P/_NFN?*;!C.2:4#LXN_BTO1_F)MW' ;F
MKVED&Y88Y"]:IB+DD<58L)1'=+Z-P352V/!RBI&GCJ4I;7+^I$BV '0MS6*S
M!0<#!/2N@NH?/MV3OU'UKGV5E8AQ@@_E4PV/7XIHSCBE5?PM:?+H*%VIENIH
MQC':E7)&<9J2)?/F"(,Y_2K/FH0E4DH15VS:M26MHR?2L:[4&_D7L&%;J@11
M =E%84K&68OV+9K..Y]IQ(U3PE&E/XDU^"LS> PH'I7/W)!O)">N:WH7$D*L
M#GBLC4;4QW!E'W6HCHS;B6$J^"IU:>L4[_)K1E,CYMW2K?\ 9UPP!V#GW%5"
M,G(/'I6Q!J,<C)'L<,<#FFV^A\WD^&P6(G*.*DT]+6ZW^3*,EA<1*SE00!D\
MU5XZ=/6NAN?^/67_ '#7/'.<8_&B+N:Y[EM' U80I7LUU'+NB8/&<$<UOV\P
MN(%D QD<CWKGB2O!Z&MS3ABS3ZFB>QW<*5IK$3I7]UJ_S31!J<[;?)0X/4UF
M9VCYN6JUJG_'T><':*I*01SUIQV/+SNM.KCJG.]G9>B$;EL&G95?E'-"@+DD
M\T ?-D#\:9Y(N!OR332 V1FE8#L*:,G(P :  YZ4IR<9/%(O7'>E8;>#SFD
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MBB@ HHHH **** "BBB@ HQ110 F**6B@!**6B@!**6C% "44N*3% !11BB@
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M6&EKG)E8_A52*_FB0#<'_P!ZK U-L#,8!/O46DMCZ>>8Y'BW[6O"TO1_IO\
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M(_[ZK-*2V/ML7F&28QJ5=W:VTDOR)&TUBN!-C_@/_P!>LY@8V*9P5.*NMJS
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M;%5*D'HV[", IR>:4.2.,"D)))/IVIBJ6R2.*9QDF2Q]*86"L>.*4J3R3@T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1BBB@!,
M44M% "44M&* $HHHH ****8@HHHH **** "BBB@ HHHH ,4F*6B@!,44M% "
M44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "8I<444
M &**** "BBB@ HHHH **** "BBB@ HHHI#"BC%+B@!**6B@ Q1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M W+M/2F8.X#/6I&7:N!0 W)SA1TI"R X[TJ9$?S=:4@!-W&:!B!<KSUIQ&,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,444 )BBEHH
M2BEHH 2BEQ28H **** "BBB@ HHHIB"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBBD,**** "BC%&* "BEQ10 E%+10 F*7%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\=&/:O)Y]*?C:,
M <4AVY[YZ4NQD/!^6O:/*&@@G&*&4$#:<BFD'.X#BG!E5/3-,$-#%3@=Z<_
MY]*<<;<TUL, O\5 Q4X3--7YV)QE:<V%"]3F@';E?6D Q7*'"=:>HWDG/--
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MR32&-&=N3TH'S$;NE!.._%!!"$CI0 C[<X_6@#@8%-49&#R:>0RC!I@-+8;
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M;\?]/[?^BTK*M\)I3^(]4HHHKD-PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHQ110 8HQ110 F*,4M% "8HI:* $HI:* $HI:* $HI:* $Q1BEHH 3%+BBB@
M Q1BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+/\ H\/_ 'P*1K2VVC_1X?\ O@444P 6EMM_X]XO^^!0UI;;1_H\/_? HHH
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M444( %I;>8/]'BZ_W!4MS9VI S;0_P#? HHI 5FM+;C_ $>+_O@4]K.VR/\
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M*** %^QVWE_\>\/_ 'P*0V=KM'^C0_\ ? HHH&"V=KC_ (]H?^^!0+.UR?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img29677477_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1Y"LH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV/0O[',>^X:#SOM&<8)&<;?;UKTFB4)0^((SC/X0HHHJ2@HK \8>)?\ A%-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M29<O?CI)]H(L=&3R0>#-(=Q'X=/UKI_"/Q6TSQ'>)874!L+R0[8@7W)(?0'
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M\R7'E X)'3GK7(_!JRM;[Q5>1W=M%.@LV8+*@8 [UYYK5^.2+'>:*B*%189
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M9!VSD'I_6B2HP?(U\PBZTUSI_(H?%J>*Y^'+3P2+)%)+$Z.IX8$Y!K*^!O\
MR ]5_P"NZ?\ H)JW\2=*@T3X5+IML\C0P2QJAD;<V-V>OXU3^!W_ " ]6_Z[
MK_Z":2M[!V[C_P"7ZOV,_0O$N@7'Q!BLX/"EO!=&\9!="4E@VX_-C%=WX[\:
M'P996MP+(71GD*8,FS&!GT->,>%O^2MV_P#V$7_]"-=Y\=/^0-I7_7PW_H-5
M.$?:11,*DE3DR.Z^.%NFFP/;:67O9 3(C2?)%R0!G&6..>W6K7A;XQP:OJD.
MGZG8BU:=@B31OE=QZ @]![YI?@YH&GGPQ)J<MM'+=3S,F]U!VJ .!Z=37F?C
MBRATKXC:A;VB"*))T=%7@*656./Q)IJG2E)P2V$ZE6,5-O<]Q^(NH66F^$Y;
MB_TU-0@$J P.VT$D\'-9WPNU;3=6TR_?3=&BTQ$E4,D;[MYP>>E)\8?^1!F_
MZ[Q_^A5S_P &9_LOA;7;C&?*</CZ(362BG1;\S5R:K)>1N^+_BMIWAJ^?3[6
MV-]>1G$H#[4C/IG!R?;]:YJQ^.DAN%%_HZ>23RT,AW ?0]?TKCOAWI\/B'Q_
M;+J8^T(QDGD63GS& )Y]>:]L\4^ -'\4V]O'*GV5X7R);=5#%<?=Z=.GY5I*
M-*FU&2,XRJU$Y19L1>(-,F\/_P!N)<K_ &?Y1E,OH!U&/7MCUKRW4/CFPN&7
M3M(4P@_*\\ARWO@=/SKN8_"/A_0_!MUI%Y+*^D9,LQGF(QT/5<8Y X'>O-K+
MQMX,\*37 \/:%<7<DIQYMPX'X+G)Q^512A!WLKEU9S5KNQT/AKXRV^J:G#8Z
MGIXM3,X1)HWW*&/ R#T'OFMCXP?\D_N/^NT7_H5>%:QJ#ZCXFEOS9)8O+*K^
M0BE0G ['UZ_C7NOQ@_Y)_<?]=HO_ $*KG3C"I%KJ1&I*=.2?0P_@7_R!]6_Z
M[I_Z":]8KR?X%_\ ('U;_KNG_H)KUBL:_P#$9M0_AH****Q-@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** .>\=_\B)K?_7H_P#*O&/A%I&GZSXH
MN[?4K.&ZA6R9U25=P#;T&?R)KV?QW_R(FM_]>C_RKYQ\-6NOW>H21^'3<B[$
M19_L\OEMLR,Y.1QG%=E!7IR5[''7=JD7:YZ]\1_!'ABQ\(W>HP6D-C<P &)H
MOE#L2!M(Z'-<S\#KB5?$^H6P)\E[,NP[;E=0/T9JR9O OQ UF1%OK:ZE /#7
M-TK!??[Q->L_#WP(G@ZPE>>19M1N<>:Z?=51T5?\>].4E"DXN5VQ1BYU5)1L
MD>-^.9%A^*.H2N<(EVC,?0 +7;:C\<A'=E-.TD26ZM@232$,X]<#I^M<-X^B
M^T?$O5(<X\RY5,_4**]L\1>&=(M?AYJ5E#8PK%;V4CQ_*,AD0D-GKG(ZU4W!
M*',KDP4VY\KL2^"O'%EXSM)6AB:WNH,>; S;L ]"#W'%5?&WQ%L?![I:B!KN
M_==XB5MH0=BQ_I7F_P $'(\8WB9^4V+$CZ.G^-=5\1(? =EJOVO6H;B?5)=K
M-';R$D@  ;@3@# K)TXQJ\MM#55)2I<U]3$3XZ7PER^C6YCST$C _G7IOA'Q
M;9>+]*-[:(\3QMLEA<Y*-C/7N/>O&_%?Q MO$6@2:;8>'(K:U0J1.?F,6".F
M  N>GXUT/P(8[-=7L# ?_0ZJI2C[-RM9DTZLO:*-[HV_%OQ<LM U.73;"S-[
M<0MME<OM16[@=R1^%<_:_'*X2<+?:)'Y>?F\J0A@/QS7'^)].U;P=XXGO3$>
M+EI[>9TWHX))&<\9YY%:EQ\1=-\1"WB\4^'8;E86R);21HF'KWY^F15JC"RL
MKD.M/F=W8]UT;6+/7=)@U*QDWV\RY!/!!Z$'W!KSOQ'\9[+3KZ2TTBR%[Y9V
MM.[[4)]AC)'OQ5^[U/1+3X1ZG>^%AY-H8RH5<AD=B%.>X/->0^"=?TOPYK#W
M^I::;Y@F(1D81L\MSWQ6=*BG>35[=#2K6:LD]^IZ?X=^-%CJ%[':ZO9?80_
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M<9.3"BBBN<Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOMLBXFOG\SG^Z.!7D,\MY\0/'.^. A[N4#8O.Q!ZGV%?3-E:QV-C!:Q ".%
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M6'<$@@UU5YX7T'4'C>\TBSG:-!&ADA!VJ.@'MS5FXTC3KO3DTZXLH);) JK
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M .N\G]:^A[+3K/3K06EG;106XSB*-0%YZ\52M?"^@V-Z+RUTBSAN021*D0#
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M+147VF'_ )ZK^='VF'_GJOYT 2T5%]IA_P">J_G1]IA_YZK^= $M%1?:8?\
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M_P">J_G1]IA_YZK^=.[M85E>Y+147VF'_GJOYT?:8?\ GJOYTADM%1?:8?\
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MHHH **** "BBB@ HHHH *P?&$CP^';R6-RCI#(RL#@@[3S6]7/>-?^18OO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&EM>18\R'3%=,^NP8KDOA9K.H7^KZC%=W4LZM&)/WC9P<_\ UZZ.3_DDB?\
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M/0?_ %J\K\=^*%\2ZP#;Y%G;@I%G^+U;\::?/--;(TI5'F&8QK4D^2"W^_\
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M%% !1110 4444 %%%% !1110 4444 %?0/@3_D5K/_KBE?/U?0/@3_D5K/\
MZXI7/B-D?-\3?P(>OZ'34445RGQ@4444 %%%% !1110 4444 %<]XU_Y%B^_
MZ]Y/_0370USWC7_D6+[_ *]Y/_033CNC;#_QH>J_,^>:***]$_4159D8,I((
MZ$'%.>623&^1VQTW'-,HH"Q(T\KKM:5V7T+$BD262/.R1ESUVG%,HH%9"EV+
M[RQ+9SG/-.>:608>1V'HS$TRB@=D2>?+LV>:^W&-NXXIJ2/&<H[*?53BFT4"
MLAS.SMN=BQ]2<TYIY77:TKLOH6)%1T4!9#XY9(7#Q.R,.A4X-237EU<,&FN)
M9".A9B<5!10'*KWL/>620 /([8Z;FS2B>4)L$K[<8V[CBHZ* LA5=D;<C%3Z
M@XI7D>0@N[,1_>.:;10.P^.62)MT;LC>JG%237MU<?ZZXED[?,Y-044"Y4W>
MP4444#"IX;VZMO\ 4W$L?^ZQ%044":3T9--=W%R<SSR2?[S$U#110"26B)!/
M*$V"5PO3&XXIBLR-N5BI'<'%)10%D.>220@N[-C^\<TL<LD+;HY&0^JG%,HH
M"RM8GGO+FY_U]Q+)_O,34%%% )):(L1W]Y#&4CNID0]5#D"H&=G;<S%CZDYI
M** 44M4AZ2R1YV2,N>NTXIK,68LQ))ZDFDHH'8EANKBV.8)I(S_L,1237$UP
MVZ:5Y#ZLQ-1T4"Y5>]C=\(7FG67B&%]5ACELW!1Q(NX+GH<5ZGJ/@SPWKD,3
M6%W':*.<VCKAA[BO#Z>LLBC"R,![&LY0;=T['FXS 3K5%5I5'!KYK[CW*_U'
M1O!/A1[&WN4DD$;+''O!=V/<XZ5YYX)\+Z=XG>Z:_O)(7C8$*C*-P/7K7',S
M,<LQ)]S2J[I]UF7Z'%)4[)V>I%#+)4:4XPJ/GD[N7_ /</%FOZ=X:\+-I]C-
M&9S'Y,,:,"5'0DXKPWJ<TK,S'+$D^I-)50ARHWR_ 1P<'%.[;NV%;_@[7/[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\
MII_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_
M  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\
MII_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@
MT4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^
MT\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?W
MGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK
M2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W
M\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK
M2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W
M\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>T
MEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_
MS\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_
M  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\
MII_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_
M  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\
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M^%5:5_TT_P"_AKT&BCVDNX?VGC/^?C^\\^_X55I7_33_ +^&C_A56E?]-/\
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M:?\ ?PTR'X7Z1-'O7S<9QS(:]$/W3]*K6'_'M_P(T>TEW#^T\9_S\?WG$?\
M"JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"F
MG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\
M"JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\ "JM*_P"F
MG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#1
M1[27</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3
MQG_/Q_>>??\ "JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>
M??\ "JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*
M_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"FG_?P
MT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\ "JM*
M_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\ "JM*_P"FG_?P
MUZ#11[27</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27
M</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/
MQ_>>??\ "JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\
M"JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"F
MG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\
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M  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\
MII_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_
M  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\
MII_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@
MT4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^
MT\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?W
MGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK
M2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W
M\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK
M2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W
M\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>T
MEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_
MS\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_
M  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\
MII_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_
M  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\
MII_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@
MT4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^
MT\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?W
MGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK
M2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W
M\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK
M2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W
M\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-=9H-BFF6ALHL[( $7)SP*U
M:J6G_'Q<_P"_2<F]V8UL77KI*K-M>9;HHHJ3G"BBB@ HHHH **** "BBB@ J
MI>?ZVV_ZZ"K=5+S_ %MM_P!=!0!;HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* *LW_'];_1JM55F_P"/ZW^C5:H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DW^ID_P!T
M_P JBLO^/./Z5+-_J9/]T_RJ*R_X\X_I0!8HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** $/W3]*K6'_'M_P(U9/W3]*K6'_'M_P(T 6J***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JII_\ Q['_ 'S5NJFG
M_P#'L?\ ?- %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MJV'^I?\ WS5JJMA_J7_WS0!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *J6G_'Q<_[]6ZJ6G_'Q<_[] %NBBB@ HHHH
M **** "BBB@ HHHH *J7G^MMO^N@JW52\_UMM_UT% %NBBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH JS?\?UO]&JU56;_C^M_HU6J "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 9-_J9/]T_RKS:'XMV$$0B.EW)*\9#K7I,W^ID_W3_*OEV3_ %C_ %-;
M48*5[GOY'@*&+]I[97M:VO>YZY_PN'3_ /H%7/\ W\6C_A<.G_\ 0*N?^_BU
MY#16_L8'T']@X'^7\6>O?\+AT_\ Z!5S_P!_%H_X7#I__0*N?^_BUY#11[&
M?V#@?Y?Q9Z]_PN'3_P#H%7/_ '\6C_A<.G_] JY_[^+7D-%'L8!_8.!_E_%G
MKW_"X=/_ .@5<_\ ?Q:/^%PZ?_T"KG_OXM>0T4>Q@']@X'^7\6>O?\+AT_\
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M5S_W\6C_ (7#I_\ T"KG_OXM>0T4>Q@']@X'^7\6>O?\+AT__H%7/_?Q:/\
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M3_\ CV/^^: +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6\51^)['5731[+3?)D0%;48#Y!Y-9?Q"^.:^'=7ET?0[2.ZN8&V332'Y5;T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]\U;JII__'L?]\T 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JK8?ZE_]\U:JK8?ZE_\ ?- %JBBB@ HHHH **** "BBB@ HHHH ****
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M)&"3C@<T >1_##XNZ]XQ\8II.H0VJP- \A,:X.1C_&O6/%2A?!FMA0 !I\_
M_P"N;5+8^'=&TVX^T66F6MO-@KOCC .*C\5_\B=KG_8/G_\ 1;4 ?.'[//\
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M/H **Y:]\?Z)8>,[?PK.TXU*XV[ (\I\V<<_A74T %%%% !17)ZW\1-"\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW17/^$?&6D^-=-EO](:8PQ2^4WFIM.[ /]:A\3^/_#GA#"ZMJ"I,>D,8W/\
MD* .FHKSK2OC;X*U6\2V6^EMW=MJM<1%%_.O0T=)8U=&#(PR&!R"* '45Q_B
M;XG>%O"=S]FU*_S<CK#"N]E^H'2J>@?&#P=XAO$L[>_>"=SA5N4V!CZ T =Y
M11UHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J
M6G_'Q<_[]6ZJ6G_'Q<_[] %NBBB@ HHHH **** "BBB@ HHHH *J7G^MMO\
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ME 'T1X<^*&A>*]<?2]'BO)VCSOF$)$:@=R?0]J[:N>\'>$=*\':'%8:7&""
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MZWTG3+;3[5=L%O&(T'L*MT %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA:VL8BC#MD[1ZGO0!X=X]_Y.4\,?]NO_ *,>H/BJL_@[XSZ-XP:%GLI?*9V
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M5FE6!B&:/!#=/3(/X&M;Q+\+?"_BO65U;4K:;[6%52\,I3=CH2.YKLBJE-A
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M1Y7.2[!ADD_6JOPC\<>&-'^&FEV.HZU:6UU&9=\4C8*YE8C]"*],\1^'=/\
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MP#"!VW'\ZTJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M* "BBB@ HHHH X_QU\.=)\?+9?VE-<1/:;O+:$@<-C(.1_LBM/PGX1TGP9I
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M3_\ CV/^^: +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=I^@1:)#;)]@2'R/*(X9<8.?7-?.NJ_!+QCI'BV2[\,0I):PSB6TG-PB,O<
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M>'[)[F:\<),58#;&.3^9Q3_A5X)_X0KPC'!<(!J-R?-NCUPW9?P% '=4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 59O^/ZW^C5:JK-_Q_6_T:K5 !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ,F_U,G^Z?Y5\E2G]Z_P#O&OK6;_4R?[I_E7B"?!K6;A?-74K !B2
M=_\ \36M*25[GMY/B:5#G]I*U[?J>;9HS7I?_"E-;_Z">G_^/_\ Q-'_  I3
M6_\ H)Z?_P"/_P#Q-;>TCW/;_M+"_P Z/-,T9KTO_A2FM_\ 03T__P ?_P#B
M:/\ A2FM_P#03T__ ,?_ /B:/:1[A_:6%_G1YIFC->E_\*4UO_H)Z?\ ^/\
M_P 31_PI36_^@GI__C__ ,31[2/</[2PO\Z/-,T9KTO_ (4IK?\ T$]/_P#'
M_P#XFC_A2FM_]!/3_P#Q_P#^)H]I'N']I87^='FF:,UZ7_PI36_^@GI__C__
M ,31_P *4UO_ *">G_\ C_\ \31[2/</[2PO\Z/-,T9KTO\ X4IK?_03T_\
M\?\ _B:/^%*:W_T$]/\ _'__ (FCVD>X?VEA?YT>:9HS7I?_  I36_\ H)Z?
M_P"/_P#Q-'_"E-;_ .@GI_\ X_\ _$T>TCW#^TL+_.CS3-&:]+_X4IK?_03T
M_P#\?_\ B:/^%*:W_P!!/3__ !__ .)H]I'N']I87^='FF:,UZ7_ ,*4UO\
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M-'M(]P_M+"_SH\XS1FO2_P#A2FM_]!/3_P#Q_P#^)H_X4IK?_03T_P#\?_\
MB:/:1[A_:6%_G1YIFC->E_\ "E-;_P"@GI__ (__ /$T?\*4UO\ Z">G_P#C
M_P#\31[2/</[2PO\Z/-,T9KTO_A2FM_]!/3_ /Q__P")H_X4IK?_ $$]/_\
M'_\ XFCVD>X?VEA?YT>:9HS7I?\ PI36_P#H)Z?_ ./_ /Q-'_"E-;_Z">G_
M /C_ /\ $T>TCW#^TL+_ #H\TS1FO2_^%*:W_P!!/3__ !__ .)H_P"%*:W_
M -!/3_\ Q_\ ^)H]I'N']I87^='FF:,UZ7_PI36_^@GI_P#X_P#_ !-'_"E-
M;_Z">G_^/_\ Q-'M(]P_M+"_SH\TS1FO2_\ A2FM_P#03T__ ,?_ /B:/^%*
M:W_T$]/_ /'_ /XFCVD>X?VEA?YT>:9HS7I?_"E-;_Z">G_^/_\ Q-'_  I3
M6_\ H)Z?_P"/_P#Q-'M(]P_M+"_SH\TS1FO2_P#A2FM_]!/3_P#Q_P#^)H_X
M4IK?_03T_P#\?_\ B:/:1[A_:6%_G1YIFC->E_\ "E-;_P"@GI__ (__ /$T
M?\*4UO\ Z">G_P#C_P#\31[2/</[2PO\Z/-,T9KTO_A2FM_]!/3_ /Q__P")
MH_X4IK?_ $$]/_\ '_\ XFCVD>X?VEA?YT>:9HS7I?\ PI36_P#H)Z?_ ./_
M /Q-'_"E-;_Z">G_ /C_ /\ $T>TCW#^TL+_ #H\TS1FO2_^%*:W_P!!/3__
M !__ .)H_P"%*:W_ -!/3_\ Q_\ ^)H]I'N']I87^='FF:,UZ7_PI36_^@GI
M_P#X_P#_ !-'_"E-;_Z">G_^/_\ Q-'M(]P_M+"_SH\TS1FO2_\ A2FM_P#0
M3T__ ,?_ /B:OZ-\&+B+4XI-7OK>6S0Y:.#=N?VY P*7M(]R99IA4K\YA?#_
M , 2^(YUO[]6CTN-OH9CZ#V]37O4$$5M D$$:QQ1J%1%& !Z40016L$<$$:Q
MQ1J%1%& !Z5)7/.;DSY?&XV>*GS2VZ(****DXPHHHH **** "BBB@ JII_\
MQ['_ 'S5NJFG_P#'L?\ ?- %NBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *JV'^I?\ WS5JJMA_J7_WS0!:HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *J6G_'Q<_[]6ZJ6G_'Q<_[]
M %NBBB@ HHHH **** "BBB@ HHHH *J7G^MMO^N@JW52\_UMM_UT% %NBBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH JS?\?UO]&JU56;_C^M_HU6J "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH 9-_J9/]T_RJ*R_X\X_I4LW^ID_W3_*HK+_CSC^E %BB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0_=/TJM8?\ 'M_P
M(U9/W3]*K6'_ ![?\"- %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *J:?_P >Q_WS5NJFG_\ 'L?]\T 6Z*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ JK8?ZE_\ ?-6JJV'^I?\ WS0!:HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J6G_'Q<_[
M]6ZJ6G_'Q<_[] %NBBB@ HHHH **** "BBB@ HHHH *J7G^MMO\ KH*MU4O/
M];;?]=!0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *LW_ !_6_P!&JU56
M;_C^M_HU6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 9-_J9/]T_RJ*R_X\X_I4LW^ID_
MW3_*HK+_ (\X_I0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** $/W3]*K6'_'M_P(U9/W3]*K6'_'M_P(T 6J*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ JII__'L?]\U;JII__'L?]\T 6Z*** "BBB@
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MT>3=?\_ _P"^:M44 5?)NO\ GX'_ 'S1Y-U_S\#_ +YJU10!5\FZ_P"?@?\
M?-'DW7_/P/\ OFK5% %7R;K_ )^!_P!\T>3=?\_ _P"^:M44 5?)NO\ GX'_
M 'S1Y-U_S\#_ +YJU10!5\FZ_P"?@?\ ?-'DW7_/P/\ OFK5% %7R;K_ )^!
M_P!\T>3=?\_ _P"^:M44 5?)NO\ GX'_ 'S1Y-U_S\#_ +YJU10!5\FZ_P"?
M@?\ ?-'DW7_/P/\ OFK5% %7R;K_ )^!_P!\T>3=?\_ _P"^:M44 5?)NO\
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M HHHH **** "BBB@ HHHH *J7G^MMO\ KH*MU4O/];;?]=!0!;HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** *LW_ !_6_P!&JU56;_C^M_HU6J "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH 9-_J9/]T_RJ*R_X\X_I4LW^ID_W3_*HK+_ (\X_I0!8HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/W3]*K6'_'M_P(U9
M/W3]*K6'_'M_P(T 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JII__'L?]\U;JII__'L?]\T 6Z*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JK8?ZE_]\U:JK8?ZE_\ ?- %JBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI:?\ 'Q<_[]6ZJ6G_
M !\7/^_0!;HHHH **** "BBB@ HHHH **** "JEY_K;;_KH*MU4O/];;?]=!
M0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** *LW_'];_1JM55F_X_K?Z-5J
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAC_GYF_[\-_A7A5%'L(A_JY@^\OO7^1[K_PL_P ,?\_,W_?AO\*/^%G^&/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %5+3_CXN?]^K=5+3_CXN?]^@"W11
M10 4444 %%%% !1110 4444 %5+S_6VW_705;JI>?ZVV_P"N@H MT444 %8/
MC+Q/!X/\*WNM31B7R% CBW;?,<G 7/\ GI6]7SU^T;XFWW&G>&H'^6,?:K@
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M^^:MU4T__CV/^^: +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 55L/]2_^^:M55L/]2_\ OF@"U1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML?TK@U^/&JZO96D/AWPO+?:HZ%[F--\BP_,0 ,#+< '/'6KMW_R:\G_7@/\
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M 4444 %%%% !1110 4444 %%%% !1110 54T_P#X]C_OFK=5-/\ ^/8_[YH
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M_9VT6\TZVN7UJ]5I8U<@1K@9&:J>)/@%H^B>&M1U.+6+R22U@:549%P2!T-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_A\6*6/]AZ:;1'WK";5"@;&-V,8SCOUK41$CC6.-51% "JHP !V H =3)O\
M42?[I_E3Z" 1@\B@#Y[_ &<?^0UXC_W$_P#0C7T&XW(R^HQ5*PT32M*>1].T
MRRLVD^^UO;K&6^NT#-7J /F#P9XH3X4?$;7K'7K>9;6>1D:1$R5PQ*,!W!!_
M6K?Q=^)UGXTT0:7X?@N)K&WD6>ZNWC*J!G:HP>0,L.3CG%?0.J^'=%UP#^U-
M*L[PJ,*TT*LP'L2,BF6_A;0+33I-/@T73TLY"#)!]G4HY!R"P(YP?6@#R^[_
M .37E_Z\!_Z,K>^!?_)++'_KM+_Z%7>G2]/;3O[.-A:FQV[?LQA7RL>FW&,?
MA3[*QL]-MEMK&T@M8%)(B@C"*,]>!Q0!X1XR_P"3F/#_ /V[_P#H35Z]X]_Y
M)YXE_P"P7<_^BVK3ET;2I]1CU&;3;.2^CQLN7@4R+CIAB,BK4\$5S!)!/$DL
M,BE'CD4,K*>""#P0: /'_@!:I??"S5+27_5SW\T;?0Q1@UQO@GQ'<?!CQ7JF
M@>)+:<:=<."EPD9/3(611W4CKCD8KZ,L-,L-*MS;Z=8VUG"6WF.WB6-2W3.%
M &>!^5,U+1],UF$1:GI]K>1K]U;B)7V_3(XH \.^)GQ>TWQ-H#^&_"BW%[/?
ME8Y)1"RX7(^501DD].E=KX4\+3^$?@K=Z?=KMO)+.XN+A?[KLAX_ !0?<&NQ
MTOPGX?T2;SM,T:RM9>GF1PJ&_/K6M)''-$\4J*\;@JR,,A@>H([T >,?LW?\
MBCJW_7\/_0!5[XQ>(_%_A*^TG5M'G?\ L8,%NX5C4@N&SAF() 8<<>E>H:?I
M6G:3$T6FV%K9QNVYDMH5C!/J0H'-6)H8KF%X9XDEB<89'4,K#T(/6@#R34OC
M+\.-9T%CJ4+74AC/^A369=@?0,1M!]\UA_L[:->)=:WK9MWM].N (8%;.&.X
MGCUVCC/O7JP^'W@\7'G_ /"-Z9OSG_CW7'Y=*Z&**.")8H8UCC085$& H] !
M0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ*** .&^,-TUI\*==D5B&:-(^/\ :D53^A-><_LTVR[?$%T1\Y,,8/H/F/\
M6O3?BMI[ZE\+]?MXURRVXFQ[1L'/Z*:\K_9IO%6\\063,-S)#*B^N"P/\UH
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MRX8_=!&:^5_A_&=>^.<-R@R@NYKAO91G^I% 'UG1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!5F_X_K?Z-5JJLW_'];_1JM4 %%%% !1110 4444 %%%% !1110 4444
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MI)SF[MA1112("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J:?_ ,>Q_P!\U;JI
MI_\ Q['_ 'S0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"JMA_J7_ -\U:JK8?ZE_]\T 6J*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_BZ[RB@#C_'VK6W@_P"'&H2PXB"6_P!FMD!_B8;0!GT&3^%>:_L[>%Y$BO\
MQ/=1D&;]Q;,1U&<N1^.!^%>N>*?!^D>,;*&TUB.62")]ZJDA3GIDXZUI:7I=
MGHNF6^G6$(AM;= D:#L!0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JS?\?UO]&JU5
M6;_C^M_HU6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -\U:JK8?ZE_]\T 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "JEI_Q\7/^_5NJEI_Q\7/^_0!;HHHH **** "BBB@
MHHHH **** "JEY_K;;_KH*MU4O/];;?]=!0!;HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** *LW_'];_1JM55F_X_K?Z-5J@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &3
M?ZF3_=/\JBLO^/./Z5+-_J9/]T_RJ*R_X\X_I0!8HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** $/W3]*K6'_ ![?\"-63]T_2JUA_P >W_ C
M0!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JFG_\ 'L?]
M\U;JII__ !['_?- %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *JV'^I?_ 'S5JJMA_J7_ -\T 6J*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "JEI_Q\7/^_5NJEI_Q\7/^_0!;HHH
MH **** "BBB@ HHHH **** "JEY_K;;_ *Z"K=5+S_6VW_704 6Z*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"K-_P ?UO\ 1JM55F_X_K?Z-5J@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** &3?ZF3_=/\JBLO^/./Z5+-_J9/]T_RJ*R_P"/./Z4 6**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#]T_2JUA_Q[?\"-
M63]T_2JUA_Q[?\"- %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *J:?_Q['_?-6ZJ:?_Q['_?- %NBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *JV'^I?_?-6JJV'^I?_ 'S0!:HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\^D'_?;_ .-'_"Y=;_Y](/\ OM_\:\WHH]A3[![>IW/2/^%RZW_SZ0?]]O\
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M76_^?2#_ +[?_&O-Z*/84^P>WJ=STC_A<NM_\^D'_?;_ .-'_"Y=;_Y](/\
MOM_\:\WHH]A3[![>IW/2/^%RZW_SZ0?]]O\ XT?\+EUO_GT@_P"^W_QKS>BC
MV%/L'MZG<]'/QCUDL&-E;DCH=[\?K2_\+EUO_GT@_P"^W_QKS>BCV%/L'MZG
M<](_X7+K?_/I!_WV_P#C1_PN76_^?2#_ +[?_&O-Z*/84^P>WJ=STC_A<NM_
M\^D'_?;_ .-'_"Y=;_Y](/\ OM_\:\WHH]A3[![>IW/2/^%RZW_SZ0?]]O\
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M76_^?2#_ +[?_&O-Z*/84^P>WJ=STC_A<NM_\^D'_?;_ .-'_"Y=;_Y](/\
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MO_C1_P +EUO_ )](/^^W_P :\WHH]A3[![>IW/2/^%RZW_SZ0?\ ?;_XT?\
M"Y=;_P"?2#_OM_\ &O-Z*/84^P>WJ=STC_A<NM_\^D'_ 'V_^-'_  N76_\
MGT@_[[?_ !KS>BCV%/L'MZG<](_X7+K?_/I!_P!]O_C1_P +EUO_ )](/^^W
M_P :\WHH]A3[![>IW/2/^%RZW_SZ0?\ ?;_XT?\ "Y=;_P"?2#_OM_\ &O-Z
M*/84^P>WJ=STC_A<NM_\^D'_ 'V_^-'_  N76_\ GT@_[[?_ !KS>BCV%/L'
MMZG<](_X7+K?_/I!_P!]O_C1_P +EUO_ )](/^^W_P :\WHH]A3[![>IW/2/
M^%RZW_SZ0?\ ?;_XT?\ "Y=;_P"?2#_OM_\ &O-Z*/84^P>WJ=STC_A<NM_\
M^D'_ 'V_^-'_  N76_\ GT@_[[?_ !KS>BCV%/L'MZG<](_X7+K?_/I!_P!]
MO_C1_P +EUO_ )](/^^W_P :\WHH]A3[![>IW/2/^%RZW_SZ0?\ ?;_XT?\
M"Y=;_P"?2#_OM_\ &O-Z*/84^P>WJ=STC_A<NM_\^D'_ 'V_^-'_  N76_\
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M\:/^%RZW_P ^D'_?;_XUYO11["GV#V]3N>D?\+EUO_GT@_[[?_&C_A<NM_\
M/I!_WV_^->;T4>PI]@]O4[GI'_"Y=;_Y](/^^W_QH_X7+K?_ #Z0?]]O_C7F
M]%'L*?8/;U.YZ1_PN76_^?2#_OM_\:/^%RZW_P ^D'_?;_XUYO11["GV#V]3
MN>D?\+EUO_GT@_[[?_&D7XQZR@PME;J/0.P_K7G%%'L*?8/;U.YZ1_PN76_^
M?2#_ +[?_&C_ (7+K?\ SZ0?]]O_ (UYO11["GV#V]3N>D?\+EUO_GT@_P"^
MW_QH_P"%RZW_ ,^D'_?;_P"->;T4>PI]@]O4[GI'_"Y=;_Y](/\ OM_\:/\
MA<NM_P#/I!_WV_\ C7F]%'L*?8/;U.YZ1_PN76_^?2#_ +[?_&C_ (7+K?\
MSZ0?]]O_ (UYO11["GV#V]3N>D?\+EUO_GT@_P"^W_QH_P"%RZW_ ,^D'_?;
M_P"->;T4>PI]@]O4[GI'_"Y=;_Y](/\ OM_\:/\ A<NM_P#/I!_WV_\ C7F]
M%'L*?8/;U.YZ1_PN76_^?2#_ +[?_&C_ (7+K?\ SZ0?]]O_ (UYO11["GV#
MV]3N>D?\+EUO_GT@_P"^W_QH_P"%RZW_ ,^D'_?;_P"->;T4>PI]@]O4[GI'
M_"Y=;_Y](/\ OM_\:/\ A<NM_P#/I!_WV_\ C7F]%'L*?8/;U.YZ1_PN76_^
M?2#_ +[?_&C_ (7+K?\ SZ0?]]O_ (UYO11["GV#V]3N>D?\+EUO_GT@_P"^
MW_QH_P"%RZW_ ,^D'_?;_P"->;T4>PI]@]O4[GI'_"Y=;_Y](/\ OM_\:/\
MA<NM_P#/I!_WV_\ C7F]%'L*?8/;U.YZ1_PN76_^?2#_ +[?_&C_ (7+K?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO/L:N/-1M#N<C\%&<>-)E&=ALWW?7<N/ZUM_%15'Q&\-D?>/E9_[^FNK\">
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MX@>!'?RQ''?0LC1YW&)QQU]C@_E4/GIRC)JUM"UR5(RBG>^IYY\"O^/W6/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$*Z^]Z3JBD$3^6G9=OW<8Z<=*R**.6/8.:7<ZAOB)XK?4H[]M7D-Q&FP$1H
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MM:HZ"S\;>(M/U*\U&UU'R[N\(,\@AC._'3@K@?@*T/\ A:?C3_H-'_P&B_\
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MQJO2IPY(J(ZD^>3D%%%%:&84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P# ;_[*O<**/K%3N'U>GV/#_P#A2-U_T%C_ . W_P!E1_PI&Z_Z"Q_\!O\
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M_@-_]E1_PI&Z_P"@L?\ P&_^RKW"BCZQ4[A]7I]CP_\ X4C=?]!8_P#@-_\
M94?\*1NO^@L?_ ;_ .RKW"BCZQ4[A]7I]CP__A2-U_T%C_X#?_94?\*1NO\
MH+'_ ,!O_LJ]PHH^L5.X?5Z?8\/_ .%(W7_06/\ X#?_ &5'_"D;K_H+'_P&
M_P#LJ]PHH^L5.X?5Z?8\/_X4C=?]!8_^ W_V5'_"D;K_ *"Q_P# ;_[*O<**
M/K%3N'U>GV/#_P#A2-U_T%C_ . W_P!E1_PI&Z_Z"Q_\!O\ [*O<**/K%3N'
MU>GV/#_^%(W7_06/_@-_]E1_PI&Z_P"@L?\ P&_^RKW"BCZQ4[A]7I]CP_\
MX4C=?]!8_P#@-_\ 94?\*1NO^@L?_ ;_ .RKW"BCZQ4[A]7I]CP__A2-U_T%
MC_X#?_94?\*1NO\ H+'_ ,!O_LJ]PHH^L5.X?5Z?8\/_ .%(W7_06/\ X#?_
M &5'_"D;K_H+'_P&_P#LJ]PHH^L5.X?5Z?8\/_X4C=?]!8_^ W_V5'_"D;K_
M *"Q_P# ;_[*O<**/K%3N'U>GV/#_P#A2-U_T%C_ . W_P!E1_PI&Z_Z"Q_\
M!O\ [*O<**/K%3N'U>GV/#_^%(W7_06/_@-_]E1_PI&Z_P"@L?\ P&_^RKW"
MBCZQ4[A]7I]CP_\ X4C=?]!8_P#@-_\ 94?\*1NO^@L?_ ;_ .RKW"BCZQ4[
MA]7I]CPT_!2X5U0ZOAFZ#[-U_P#'J=_PI&Z_Z"Q_\!O_ +*O9IO^/ZW^C5:H
M^L5.X?5Z?8\/_P"%(W7_ $%C_P" W_V5'_"D;K_H+'_P&_\ LJ]PHH^L5.X?
M5Z?8\/\ ^%(W7_06/_@-_P#94?\ "D;K_H+'_P !O_LJ]PHH^L5.X?5Z?8\/
M_P"%(W7_ $%C_P" W_V5'_"D;K_H+'_P&_\ LJ]PHH^L5.X?5Z?8\/\ ^%(W
M7_06/_@-_P#94?\ "D;K_H+'_P !O_LJ]PHH^L5.X?5Z?8\/_P"%(W7_ $%C
M_P" W_V5'_"D;K_H+'_P&_\ LJ]PHH^L5.X?5Z?8\/\ ^%(W7_06/_@-_P#9
M4?\ "D;K_H+'_P !O_LJ]PHH^L5.X?5Z?8\/_P"%(W7_ $%C_P" W_V5'_"D
M;K_H+'_P&_\ LJ]PHH^L5.X?5Z?8\/\ ^%(W7_06/_@-_P#94?\ "D;K_H+'
M_P !O_LJ]PHH^L5.X?5Z?8\/_P"%(W7_ $%C_P" W_V5'_"D;K_H+'_P&_\
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M_P !O_LJ]PHH^L5.X?5Z?8\/_P"%(W7_ $%C_P" W_V5'_"D;K_H+'_P&_\
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M_P !O_LJ]PHH^L5.X?5Z?8\/_P"%(W7_ $%C_P" W_V5'_"D;K_H+'_P&_\
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M_P !O_LJ]PHH^L5.X?5Z?8\./P2N0"3JQP/^G;_[*D7X*7#J&75\@]#]F_\
MLJ]OF_U,G^Z?Y5%9?\><?TH^L5.X?5Z?8\7_ .%(W7_06/\ X#?_ &5'_"D;
MK_H+'_P&_P#LJ]PHH^L5.X?5Z?8\/_X4C=?]!8_^ W_V5'_"D;K_ *"Q_P#
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M&Z_Z"Q_\!O\ [*O<**/K%3N'U>GV/#_^%(W7_06/_@-_]E1_PI&Z_P"@L?\
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MK_H+'_P&_P#LJ]PHH^L5.X?5Z?8\/_X4C=?]!8_^ W_V5'_"D;K_ *"Q_P#
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MK_H+'_P&_P#LJ]PHH^L5.X?5Z?8\/_X4C=?]!8_^ W_V5'_"D;K_ *"Q_P#
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M/_@-_P#94?\ "D;K_H+'_P !O_LJ]PHH^L5.X?5Z?8\/_P"%(W7_ $%C_P"
MW_V5'_"D;K_H+'_P&_\ LJ]PHH^L5.X?5Z?8\/\ ^%(W7_06/_@-_P#94?\
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M/_@-_P#94?\ "D;K_H+'_P !O_LJ]PHH^L5.X?5Z?8\/_P"%(W7_ $%C_P"
MW_V5'_"D;K_H+'_P&_\ LJ]PHH^L5.X?5Z?8\/\ ^%(W7_06/_@-_P#94?\
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M/_@-_P#94?\ "D;K_H+'_P !O_LJ]PHH^L5.X?5Z?8\/_P"%(W7_ $%C_P"
MW_V5'_"D;K_H+'_P&_\ LJ]PHH^L5.X?5Z?8\/\ ^%(W7_06/_@-_P#94?\
M"D;K_H+'_P !O_LJ]PHH^L5.X?5Z?8\/_P"%(W7_ $%C_P" W_V5'_"D;K_H
M+'_P&_\ LJ]PHH^L5.X?5Z?8\/\ ^%(W7_06/_@-_P#94?\ "D;K_H+'_P !
MO_LJ]PHH^L5.X?5Z?8\/_P"%(W7_ $%C_P" W_V5'_"D;K_H+'_P&_\ LJ]P
MHH^L5.X?5Z?8\/\ ^%(W7_06/_@-_P#94?\ "D;K_H+'_P !O_LJ]PHH^L5.
MX?5Z?8\/_P"%(W7_ $%C_P" W_V5>I^%--.CZ-%IS2>8ULBQEMN,X]JW:J6G
M_'Q<_P"_43JSFK29<*4(.\46Z***S- HHHH **** "BBB@ HHHH *J7G^MMO
M^N@JW52\_P!;;?\ 704 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K-_Q
M_6_T:K559O\ C^M_HU6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9-_J9/\ =/\ *HK+
M_CSC^E2S?ZF3_=/\JBLO^/./Z4 6**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!#]T_2JUA_Q[?\"-63]T_2JUA_Q[?\"- %JBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *J:?_ ,>Q_P!\U;JII_\ Q['_
M 'S0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMA_J7_
M -\U:JK8?ZE_]\T 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "JEI_Q\7/^_5NJEI_Q\7/^_0!;HHHH **** "BBB@
MHHHH **** "JEY_K;;_KH*MU4O/];;?]=!0!;HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** *LW_'];_1JM55F_X_K?Z-5J@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_9=#N_P_R#^UJ_9?C_F>_?\ "RO"G_01;_P'D_\ B:/^%E>%/^@BW_@/)_\
M$UX#NHW4?V70[O\ #_(/[6K]E^/^9[]_PLKPI_T$6_\  >3_ .)H_P"%E>%/
M^@BW_@/)_P#$UX#NHW4?V70[O\/\@_M:OV7X_P"9[]_PLKPI_P!!%O\ P'D_
M^)H_X65X4_Z"+?\ @/)_\37@.ZC=1_9=#N_P_P @_M:OV7X_YGOW_"RO"G_0
M1;_P'D_^)H_X65X4_P"@BW_@/)_\37@.ZC=1_9=#N_P_R#^UJ_9?C_F>_?\
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M#R?_ !-> [J-U']ET.[_  _R#^UJ_9?C_F>_?\+*\*?]!%O_  'D_P#B:/\
MA97A3_H(M_X#R?\ Q-> [J-U']ET.[_#_(/[6K]E^/\ F>_?\+*\*?\ 01;_
M ,!Y/_B:W-(UO3M>M#<Z;<K/&K;6X(*GW!Y%?,NZM;P]XBO?#>IK>6;\=)(B
M?ED7T/\ C6=7*X<K]FW?S-*6;5.9>T2MY'TI165X?\06/B/3$O;)_:2,GYHV
M]#_GFM6O$E%Q?++<]R,E)<T=@HHHI%!1110 4444 %%%% !533_^/8_[YJW5
M33_^/8_[YH MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5
M6P_U+_[YJU56P_U+_P"^: +5%%% !1110 4444 %%%% !1110 4444 %%%%
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MVTV41G\^2 2;]@W;LG.<YSF@#F?^&F9/^A33_P &!_\ C=>K>+/&A\,>!?\
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M0SG[/J$;(8\\>8HR#^0-3?M$_P#(^VO_ %Y+_,T ;_\ PTS)_P!"FG_@P_\
MM=:NB?M'Z3>WJ0:OHD^GQ.0OGQSB95]V&U2!],UJ>"]+^&\O@C19-1MO#)O&
MLXS.T_D^87VC.[/.?K7D'QBM_!MOXBMQX1:UP8S]J6S;=$'SQ@CC..PXH ^M
M()XKJWCN()%DAD4,CH<A@>A!J2N-^%5K>6?PTT6&^#++Y&0K]54G*C\L5V5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 55L/]2_^^:M55L/]2_\ OF@"U111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM76WG24J+=LD*P..OM7=?'(8^%5^/^FD7_H0KSW_ (:7OO\ H6;?_P "V_\
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MH **** "BD5E<95@PR1D'/(X-+0 4444 %%%% !1110 4444 %%%% !1110
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MX3ZAHK(\.>([#Q-I27UB_M)$3\T;>A_Q[UKUXDHN+LSW(R4E=!1112&%%%%
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MT'3)A-8:)IMI*.CP6B1L/Q K4HH **** "BBB@ HHHH **** "BBB@ HHHH
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MB6,]F*MMW#TR"/R%<S:S^'+_ .,6O-\1Y)O+%Q*D(=G\M6#X56*\A0O3MZT
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MLUQ+;C>Q'WB.,UT]4M'TNWT71[33+48@MHA&F?0=ZNT %%%% !1110 4444
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M4-8MXI7&UIKW[1&6ZX9=S#/L10!]:T5Q7PO\<-X[\)K?W$:QWT$A@N5084N
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** *LW_'];_1JM55F_X_K?Z-5J@#Q+]I'_ )%K1O\
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MX=_[!EM_Z*6L7XD_#W_A86F6=G_:G]G_ &:8R[_L_F[OE(QC<N.M>=#]FV<
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M\U;3K?4+'[;-:W$8DCD6Z."#^%<_HFC_  QTOXJ6FAZ3:ZU/K%I< QS1RJ\
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M 4444 %%%% !1110 4444 %5;#_4O_OFK55;#_4O_OF@"U7SOI'_ "=-=?\
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MX)[ >U7?V:/^/_Q%_P!<H/YO7J'Q@_Y)1K__ %Q3_P!&)7E_[-'_ !_^(O\
MKE!_-Z /H"]M8[ZQN+289BGC:)QZAA@_SKY9^#]])X>^+XTYB52X:6T=>V1D
MC_T']:^K:^2=!!D^/T7D<9U60CZ?-_2@#ZVHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MJS?\?UO]&JU56;_C^M_HU6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *JZCIUGJUA-8ZA;1W-K,-LD4@R&%6J* (X+>&UMX[>WB2*&-0J1QJ
M%50.@ '05)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,F_U,G^Z?Y5\>R_ZY
M_P#>-?84W^ID_P!T_P J^/9?]<_^\:[<'U.+&=!E%%%=IQ!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JS?\
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M +Y-'E2?\\W_ .^37V&47:?E'3TJM8*OV;[H^\>U'USR#ZGYGR+Y,G_/-_\
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M:MU4T_\ X]C_ +YH MT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !56P_P!2_P#OFK55;#_4O_OF@"U1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 54M/^/BY_P!^K=5+3_CXN?\ ?H M
MT444 %%%% !1110 4444 %%%% !52\_UMM_UT%6ZJ7G^MMO^N@H MT444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% %6;_C^M_HU6JJS?\ '];_ $:K5 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ,F_U,G^Z?Y5%9?\><?TJ6;_ %,G^Z?Y5%9?\><?TH L
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'[I^E5K#_ (]O
M^!&K)^Z?I5:P_P"/;_@1H M4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !533_\ CV/^^:MU4T__ (]C_OF@"W1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %5;#_4O_ +YJU56P_P!2_P#OF@"U1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54M/^/B
MY_WZMU4M/^/BY_WZ +=%%% !1110 4444 %%%% !1110 54O/];;?]=!5NJE
MY_K;;_KH* +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5F_P"/ZW^C5:JK
M-_Q_6_T:K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ,F_P!3)_NG^5167_'G']*EF_U,
MG^Z?Y5%9?\><?TH L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% "'[I^E5K#_CV_X$:LG[I^E5K#_CV_X$: +5%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 54T__CV/^^:MU4T__CV/^^: +=%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% #)O]3)_NG^5167_'G']*EF_P!3)_NG^5167_'G']* +%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 A^Z?I5:P_P"/;_@1JR?NGZ56L/\
MCV_X$: +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54T__
M (]C_OFK=5-/_P"/8_[YH MT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !56P_U+_P"^:M55L/\ 4O\ [YH M4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %5+3_CXN?]^K=5+3_CXN?]
M^@"W1110 4444 %%%% !1110 4444 %5+S_6VW_705;JI>?ZVV_ZZ"@"W111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY&_Z @_\"?\ [&C_ (7(W_0$'_@3_P#8UY3FC-'U##?R_B_\P_M#%?S?@O\
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M-&:/J&&_E_%_YA_:&*_F_!?Y'JW_  N1O^@(/_ G_P"QH_X7(W_0$'_@3_\
M8UY3FC-'U##?R_B_\P_M#%?S?@O\CU4_&1B,?V(/_ G_ .QJ.W^+S01;/[&!
MYSG[3_\ 8UY=FC-'U##?R_B_\P_M#%?S?@O\CU;_ (7(W_0$'_@3_P#8T?\
M"Y&_Z @_\"?_ +&O*<T9H^H8;^7\7_F']H8K^;\%_D>K?\+D;_H"#_P)_P#L
M:/\ A<C?] 0?^!/_ -C7E.:,T?4,-_+^+_S#^T,5_-^"_P CU;_A<C?] 0?^
M!/\ ]C1_PN1O^@(/_ G_ .QKRG-&:/J&&_E_%_YA_:&*_F_!?Y'JW_"Y&_Z
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MK$O[GA8+AC]ST5CZ>A[?3IZYG(R*\*O0E0GRR/H,/B(5X<T0HHHK W"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *J:?_Q['_?-6ZJ:?_Q['_?-
M %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JV'^I?_?-6
MJJV'^I?_ 'S0!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 4444 %%%% !56P_U+_[YJU56P_U+_[YH M4444 %%%% !1110 4444
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M&@>-- \3WEW::1?BYGM/]>OENNWDCN!GD=JWZ "BBB@ HHHH **** "BBB@
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M76IOW7"V]RY^YZ*Q]/0]OY>Q@Y&1TKPJM*5*7*SWJ-:-6/-$****R-0HHHH
M**** "BBB@ HHHH **** "BBB@ JII__ !['_?-6ZJ:?_P >Q_WS0!;HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMA_J7_P!\U:JK8?ZE
M_P#?- %JBBO+-5^/7A?2-7O--N++5&FM9GA<I$A4LIP<?/TXH ]3HKR%?VB_
M"!/-EJX'KY,?_P 77<>%/'_AWQFCC1[W?.B[I+>12DB#UQW_  )H Z:BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0G )]* %HKC?"?Q)T?QA
MK5_I6GP7D<]EGS#,BA3AMO&&/<5V5 !17&^)_B5HWA3Q#9:+?P7CW-YM\MH4
M4J,G SE@:[*@ HHHH **** "BN0T3XBZ1KOBZ]\-VL%VMY9[O,>1%"''7!!S
M^E=?0 4444 %%9/_  DVC_\ "0IH"WT3ZFR-)]G0[BJCKNQT_&M:@ HHHH *
M*** "BBO/O%WQ@\/^#-=;2-1M=0DN%C60M!&I7!SZL/2@#T&BJ.CZK;:YH]I
MJEFQ-O=1B1-W4 ]C[CI5QW6-&=CA5!)/M0 ZBO.=#^-'AO7_ !-%H5E;W_VB
M64QI*T:^62.^=V<<>E:_B+XBZ1X9\2Z?H5[!=O=7VWRVB12@R<<DD']* .OH
MHHH **Y#3/B+I&J^-KOPI!!=K?6V[>[HHC.!DX.<_I77T %%(2%4LQ  Y)->
M::W\=O!NCWDEK'+=7[H<,]I&"F?]XD9_#- 'IE%<7X2^*?A?QE<_9-/NI(;P
MC*V]T@1W_P!W!(/YYKLG=(HVDD8*BC+,3@ 4 .HKRW5?C[X-TV^>VB^W7VQL
M-+;1+L_ LP)_*NP\)^-]"\:V;W&CW1=H\>;#(NV2//J/ZC(H Z*BLO7_ !%I
M7AC3&U#6+Q+:W!P"W)8^@ Y)KSG_ (:'\'?:?+^SZKY?_/3R$Q^6_- 'K5%9
M>@^(M*\3:8FH:1>)<V[<$KU4^C#J#57Q3XRT/P=9+=:S>"'?GRXE&Z20C^ZO
M]>E &]17D]O^T+X-FN?*>'4X4)P)7@7'U.&)KTW3-3L=8T^*_P!.N8[FUE&4
MEC.0?\^E %NBBB@ HHHH **** "JEI_Q\7/^_5NJEI_Q\7/^_0!;HHHH ***
M* "BBB@ HHHH **** "JEY_K;;_KH*MU4O/];;?]=!0!;HHHH :T:/C>BMCU
M&:555!A5"CT Q2T4 %,:*-CEHT)]2M/HH 88HV #(I Z9'2G !1A0 !V%+10
M SRH]V[RTW9SG:,T\@$8(R*** *L6F6,,YGBL[=)3U=8P#^=3F*-FW&-"?4B
MGT4 %%%% #&BC<Y9%8^I&:3R(?\ GDG_ 'R*DHH 1551A5 'L*6BB@"/R(?^
M>2?]\BCR(?\ GDG_ 'R*DHH :L:(<JBK]!BD\F/=N\M,]<[13Z* "FM'&YRR
M*Q]QFG44 -5%0850H]ABE95<890P]",TM% #514&%4*/88IU%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% %6;_C^M_HU6JJS?\ '];_ $:K5 'C_P"T-J]Y8>#+2SMG:..]
MN=DS*<94*3M_,5:\ _"GP6WA'3KV:Q@U.>Z@662>4[QN(R0!T&.GX5V_C#PE
MI_C30)=)U$,JL=T<J?>C<=&%>'M\+_B;X)E=O"^KM<VP.0EO/Y9;ZQM\OZF@
M#5^*'P@AT^WMM9\%V$\=Y'*!);6Q+?1E';!]*]9\/ZI>1>!;34M>B:WNXK7?
M=++P05SDGZXS^->+67QH\;>%+^*U\9:,TD1.&=X/)D(]5(^5OR_&O4?&&M6V
MN_![6-5TJ3S+>XTZ1T;H0,'(/N.: /'O#>D7WQN\=7NJ:S<31Z/:'(B1ONJ3
M\L:^F0,D_6O9A\)O PL_LO\ PCMILQC>0=__ 'UG/ZUR'[.:1#P3?NH'FM>$
M/] HQ_6O8Z /G4>#_$?PR^*EK+X8L[^^T>XPSK&A8>43AHW/3(Z@GV]*W?VD
MO^19T;_K\/\ Z :]MKQ+]I+_ )%G1O\ K\/_ * : /4O!W_(CZ!_V#;?_P!%
MK6W6)X._Y$?0/^P;;_\ HM:VZ /'_COXWN]"TJUT'2Y6BO-1!,DB'#)$"!@>
MFXG'T!J7P+\$=!TW1X+GQ#:#4-4F0/(LQ)2(GG:%Z$CN37'?%L"7X[^'H[D#
MR"EJ,'H5,K9KZ,H \B^(7P7T*_T"YO/#M@MCJENADC2W!"S8YV[>F3V([UK_
M  :O/$<W@\V?B.QNX);1PEO)=(5:2(C@8//&._8BO1J* "BBB@#!\;:E<:/X
M(UK4;3_CXM[21XS_ '6"G!_#K7B7P3\!>'?%FFW^M:Z!J%ZMR8_(DD)"C .]
MAGDDD]?2OH:ZMH;VTFM;B,20S(4D1NC*1@BO M8^!WB/0-4DU'P/K+1H22L3
M3-%*@_NAAPWXXH ['QG\%_#&IZ!='2-,2QU*.,M ]OD!F X4KT(/2G?!"/Q'
M9>%KG3/$%E=6XM91]E-P,$HP.5'L"/\ QZO/6\??%KP-@Z_I\EU:(<,]S '7
M'_71/ZFO8O 7Q!T[QYHLMY:HT%S;X%S;,<E"1P0>X.#^5 &EXD\9:!X2@676
MM1BMB_W(^6=OHHYQ[]*YO3/C5X'U.[6V75'MW=MJFXB**3_O=!^.*\L\%Z3%
M\6/BKK&K:XS7.GVC%HX22 5W8C3Z8Y/K^->F>._A3X:U?PK=C3])M+&_MX6D
MMY;:(1G<HR%;'4'ISZT =OK&NZ=H.BS:OJ%P([&(*SRJ"PP2 ,8SGDBOE_3=
M<\(:G\8=7UKQ-(+C1I'E> RQ,X<Y 3*XSC;GKZ5Z7\"M37Q5X"O] UF**^M[
M&54$<Z!P8VRR@@]<,IQ_]:N5\">'M&O?COXDTRZTJRGL(1<>5;20*T:8D4#"
MD8& : ,GXP>(/"]Y::!I?A1TCL[7S9I8(HFC1?,$;*<$#.1FOHGPQXPT3QA;
M3W&B79N(X&"2$QLF"1GN!7AW[0FA:3I$WAQM-TVTLS,)ED,$*IO"B(*#@<X'
M ]*]^TK0])T.*2/2=-M+%)"&=;:%8PQ]3@<T 7I(TFB>*0;D<%6'J#7"_P#"
MFO 7_0!C_P"_TG_Q5=Y10!\M^"_"&A:I\;-:T&\L5ETRWDN1% 78!0KX7D'/
M KW&P^%/@K2[^WO[/14BN;>02Q.)7.U@<@\FO*OAW_R<;XC_ .NMY_Z,KZ';
M[I^E 'G'PWM_ L.NZT?"=S/+>,?],$F_ ^8]-P]<UN>)_B3X6\(W(M=5U$+=
MX#?9XD+N ?7' _$UY;\ O^1Q\6_4?^C&KE;74='\-?&+7IO'NE/>))/*8FDB
MWJF7RK[&ZKMZ>E 'N.A?%SP9X@O(K.UU7RKF4X2*XC,98^F>F?QKKK^_M-+L
M9KZ^N([>UA7=)+(<!17B^L^$_AY\3)+*3PMK6G:5?H_SK##L>5?3RR5R0<<C
M-7_CQ8:HOPSTZ.*26YCM9X_MLBJ<N A&]L=!NY/N10!M-\=/ BW7D_VA.RY_
MUHMVV?X_I7:Z'X@TGQ+IXOM'OHKNW)P63JI]"#R#]:\7\&^)_A'>^&[72M1T
MNSL;KR5CF-U;;M[XP6$@!/7G)QBNQ^%WP_M?"-UJ.HZ7XACU+3;[B.*( HN&
MRIW!CD@$CMUH ZF;QOH%OXLC\,27I&KR8VP>6W.5W#YL8Z>];TLJ00O+(=J(
MI9CZ <FO =8_Y.KT_P"L?_H@U[KJW_(&OO\ KWD_]!- &;X8\9:'XP@N)M$N
MS<);L$D)C9,$C(Z@>E1>)O'?AOPAL76=2C@ED&4A4%W(]=HZ#W.!7E'[.URE
MEX7\3W4GW()$D;Z*C$_RKC/ FI>%?$'C#5?$GQ"U"$R,X>&VF1V1V8G.0 ?E
M4   \<^U 'NF@_%WP9XAO8[*VU3R;F0[8X[F,Q[CZ ]/UKN:^<OB=+\+=7\-
M2W/AZ[L;;6;?:T*VEN\?G#(!4@*!TY!/3%>I_"#Q!<>(_AQI]S>2>9<P%K:1
M^[;#A2??;MS0!W5?.WQRNI=7^)F@>&KN[-II96$NY.%4R2%6D/;@ =>F#7T3
M7!_$GX8V/Q M89//-IJ=LI6&X"[@5/.UAW&?RH DL_A%X&M;);<:#;S +@R2
MDN[>^XFO+O$/P\UCP%\1],U?P18WL]BQ$CQ1Y81X.'C)SRI'KZGTJNOA?XR>
M!EVZ5>37MI']U8)A,@'M')_05L>%_COJ-KK$>D>-],^R,6"-<K$T31D]W0]O
M<8^AH ]VFFBMX7FGD2*)%+.[L%50.I)/05Y_J'QN\"V$S1#4Y+IE.T_9X&89
M^IP#^%:GQ'\,:CXR\(OI&FZC'9^;*KRNX)$D8R=O!]=I_"N.T33_ (5>"] @
MT_5KO0KR^1!]KF=5N&>3^+H"0,\ 4 =SX7^(/AKQ@[1:/J*R7"+N:"12D@'K
M@]?PS4^M^-= \.ZQ8Z5JE\+>[OB! I1B#EMHRV, 9]:^>-+O= A^/VDW'@UV
M33)KA$VJI106!5P >=IS^M;/[1$#W7C;0+>+_62VNQ?J9"!0!ZG8?&#P9J>O
MQ:/:ZC(]Q-((HG\AMDCDX !QZ^V*W_$GC#0?"-LL^M:A';;\^7'RSO\ 11S^
M/2L/0/A+X1\/7&G7EKIY:_L?F6Y>1B7?;@L1G'?/3CM7D?AS2X_BK\;-8NM:
M+3:=8L[+ 2<%%?9&G';N?7!]: /4M-^-G@?4[Q;8:D]L[G:K7,112?\ >Z#\
M<5Z 98Q$92ZB,+N+D\8]<^E>=^./A'H/B'PX]MI&F6.G:C'@VTT40C YY#;1
MR,9KAOB/<:YX%^#ND^%[O45FO+F5H7FBS\UNO.S)Y_B0?08H [[4_C3X'TN\
M:U;5&N'1MK-;1%U!_P![H?PS72>&_&.@>+;=Y=%U&.Y\O[Z8*NGU4X./?I7)
M> /A5X;TKPG9G4=)M+Z_N85DN);F(28+#.U<] .G'I7FOC;2(_A-\5-&UC0C
M]GL+L[V@R=JC=MD3_=P01Z9]A0![OXF\8:)X/MX)];NS;QSL4C(C9\D#)Z U
M@:[\8?!N@:B]A<Z@\UQ&=L@MXRX0^A/3/TKBOVDSG0-"/K<2?^@BNE\%?"?P
MM;>#K-=2TFVOKRZMUDN)YT#/N89(4_PXS@8]* .CA^(WA.;PVVOKK, T]&V,
MS9#!_P"[MQG/MCWK(TGXS^"M8U&.QBU&2&61MD9N(BBL>W/0?CBO$_AIX&L-
M<^*.I:/J :;3=,:61H2>)2CA%#?GG\*ZWX\^"= T3PSI^KZ3IMO83B[6W<6R
M!%=61FY XR"G7WH ]^) &21CUKA-8^,7@C1KF2VEU;[1-&<,MK&9 #_O?=/X
M&IUL]2\5_""RMK2^%K?:CI<&;AP6QN12_?/(R/QKC/"_ACX>> -*>V\3ZAH=
M[JY=C.\NV4H,\*%Y*\8SQUH [?PU\4?"7BJ\6RT[4MMX_P!R"="C-],\'Z9S
M78U\F^.=1\(K\0-'U'P,ZQ!)4:;R(FCC$@<8*@@8XZX&.*^L5Y4'VH 6BBB@
M HHHH **** "BBB@ HHHH **** &3?ZF3_=/\J^1Y3^]?_>-?7$W^ID_W3_*
MOD.4_O7_ -XUZ& =N;Y'GX]7Y?F+FC-,S1FO1YCSN4?FC-,S1FCF#E'YHS3,
MT9HY@Y1^:,TS-&:.8.4?FC-,S1FCF#E'YHS3,T9HY@Y1^:,TS-&:.8.4?FC-
M,S1FCF#E'YHS3,T9HY@Y1^:,TS-&:.8.4?FC-,S1FCF#E'YHS3,T9HY@Y1^:
M,TS-&:.8.4?FC-,S1FCF#E'YHS3,T9HY@Y1^:,TS-&:.8.4?FC-,S1FCF#E'
MYHS3,T9HY@Y1^:,TS-&:.8.4?FC-,S1FCF#E'YHS3,T9HY@Y1^:,TS-&:.8.
M4?FC-,S1FCF#E'YHS3,T9HY@Y1^:,TS-&:.8.4?FC-,S1FCF#E'YHS3,T9HY
M@Y1^:,TS-&:.8.4?FC-,S1FCF#E'YHS3,T9HY@Y1^:,TS-&:.8.4?FC-,S1F
MCF#E'YHS3,T9HY@Y23=7M/PD\5:IJ2OI%U!+<6]NF4NO^>8[(Q[^W?\ #IYE
MX1\)7_BW5!;6P*6Z8,]P1\L:_P!2>PKZ0T/0['P]I<6GZ?$(X4ZD_>=N[,>Y
M-<.,JPY>3=_D=N#I3YN?9?F:-%%%>8>H%%%% !1110 4444 %%%% !1110 4
M444 %5-/_P"/8_[YJW533_\ CV/^^: +=%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 55L/]2_\ OFK55;#_ %+_ .^: +5?-W@#3;'5/C[X
MEM[^T@NH0UVPCFC#KGSEYP?J:^D:^3;*_P#$VF_&/Q'/X4M!=:B;BY4QE W[
MOS>3@D=P* /I5_!/A:12K^'=+93U!M$_PKY]\1Z9#X"^.^FQ>'288IIH6,"$
MX02':R?3&3^-=$_B;XXSKY<>AK$QZ,((^/\ OHXJWX ^%/B"7Q?_ ,)9XWE#
MW2-YB0M('=I.@+$< #L![=,4 >@^+_B1H_@K4]/L=4BN,WN")(P"D8W8RV3V
MKFM.^//A_5/$T&D6NG7[K/,(8YP%Y).,[<]/?-<?^T1;F[\3>'K=?O2Q^6/J
M7Q7L6A^"/#FCV>GBUT:S6:T0&.<PJ9 V,$[L9R?6@"KXS^(_A_P.B+J<SR74
M@W):P+N<CU/8#ZFN,L/VB?#<]TL5[IM_:1.<+,0K@#U(&#CZ9KD/ >GP?$'X
MS:UJNKI]I@M':2.&7E?O808/8 =*]M\8>$],\3>&;O3[JTB)\IC X09C<#@@
M]J -JPU"TU2QBO;&XCN+:9=T<D9R&%>=>*?CCX;\.:D^G017&I7,9VR?9\!%
M/IN/4_05YU\-/%5[I'PQ\9VJSL3IJ;H,G_5^8=G'XY-=1^S]X9L?^$=G\17$
M*37]S,R+(Z@E%'! ^IS0!IQ?M ^$WTF2[D@OH[B-U0VI1=YSGD'."!CV/M7=
M3>*[*#P7_P )0T4QL_LRW/E@#?M...N,\^M>2_M#^%=/BTFS\16]ND-UYX@F
M9% \P$$@GW&#75:C_P F[_\ <(C_ )+0!0O/VA?#$&GVUQ;V5[/--DM!\JF,
M D?,<GDXSCTKL['X@:)<^"HO%=U))8Z<X./M"X;.2, #.<XXQ7F7P$\&Z-?^
M%[S5]2TZWNYIYS$AGC#A4 Z 'ISFNT^(W@71-9\,6=K=ZJNA:5IQ)41A5BZ8
M P?3' 'K0!SMU^T7H*.QL]&U*XB4X,C;4']:[+P1\3M!\=M+#IYF@O(EW/;S
MJ VWU!!((KE8/BS\-?#&DQ:7I[27,$"; MM:\-QU.[&<UYY\.]5L-2^/*WVC
M6KV=C=&4K <# *Y(P..O:@#VK7_BCH/AKQ9'H&IB>*1H_-:X('E(-I;GG/;'
M3J:X^7]H[PZE\8TTJ_>V#8\[*@D>NW/]:Y3XIZ3%KGQVTS3)\^3<"!),'DKU
M(_(5ZUX[\-:0OPRU6QCL+>."WM6>)5C V,HR"/?B@#-UWXW^$='TVUN;>:34
M);E/,2" #<@_VR?NGVZTWP?\:_#_ (LU6/2_(N+&[EXB$V"KGT!'?\*Y3]G;
MPYI\FC7^N3VT<MX;CR8W=0=B  \>F2369\8=-M-&^*?AJ]L($@FNG1Y2@QN8
M2!<_E0!]$TC_ '&^E+2-RI^E 'SU\"?^2C^)_H__ *,-?0U?//P*./B3XG4\
M'#\?]M#7T-0!\[_&G_DK'AO_ +9?^C!7L7C7QOI_@72XM0U&"XFCED\M5@ )
MS^)%>._&CYOBUX; Y/[K_P!#%=+^T7_R)=C_ -??]* +6J_'_P -V4PAL+*]
MU%@H9VB "KD9QGG./IBNI\%?$G0?'2.NG220W<8R]M. ' ]1CJ*B^&7A33_#
MO@BP2*WC,]S"LMQ*5&YV89Y]J\G\7V4/@7XZZ1?:4@MX;UU=XDX7YCM88'8Y
MH ]V\1^)M*\*:2^I:M<B&!> !RSGT4=S7F<'[1?AR2\V3:7J,5J6VB?"M^:Y
M_K7/?&9Y/$'Q1T#PR\C+:C9N4'@ESR?K@8KVW_A%]%_L#^Q/[.M_[/\ +\OR
MO+&,8Z_7WH \0^%5[;ZC\;M=O;2026\Z2/&X[@XKV+Q=XZT+P39I/J]RRO)_
MJH(EW22?0?U)%>+_  @TI=#^,VM:8A)2V21%SZ9XKM_B)X3\+/XIL_%'BGQ!
M]GMX=H6RE 99 O8 ?,>>O6@#,?\ :-T1901H6H_9R?\ 6DJ#^73]:[_2OB!H
M>M^$[KQ%I[RRVUJA::+;B1"!G!&<9_&N$\0?&?X>RZ1<::EI/?Q/&8UC2U"I
MTP/O$8_*L/\ 9QE#W?B"- 1 =K*A.<<\?I0!Q^C_ !(TO3_C'?\ C"6VNFL;
M@2!(E"^8-P &1G';UKZ2C\8:1_PB,/B6[G^QZ?+$)09^" >@P.I]A7COAB-#
M^T]K*E%VXGXQQ]T5#^T1K#?VOHVB-*R6*J9YHT'7)P#^6Z@#HI_VB_#J7)6#
M2=2FMU.&FPJ_IG^HKT/PEXUT3QIIYN](N2Y3B6&0;9(S[C^HXKS72OC!\--&
MT:+2;/3;Y;1$V%#:)\_');YN2>]<3X"\0:7:_'%'\-":WT?47,7D2*%^\.F
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MDN]5EV_9K@(I$?S8')/K[5P5[%';_M-V,,2A8X_*55'8!, 5/\7?^2R>%?\
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MP@UZTEDO/*DD7S$,,I>*0=U8$#/TQ7T1<?$*!/A2?&,<:EC;!EB)X\T_+M_
M_P J .W9E12S$ #N32@Y&1TKX_T?2?&GQ>UJZD6_,K1#=)+<RLL<>>B@ '\@
M*=9:UXL^$?C'[#=7#[8F4SVPD+Q31GN,^W0]10!];W-[:62JUU=0P*QP#+(%
M!_.ID=9$#HP92,@@Y!%><_%K1$\6_#*6\MAF:U07D)']W'S#\N?PK&^ ?C*3
M6O#LNA7DNZZTW'E$GEHCT_(Y'Y4 >P4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 59O\
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M8\1DV]M-(%\X@[4<?=;_ '2#_*OH,^(=%%G]K.KV/V;;N\W[0FW'US6/XO\
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MH \!^ 7'C'Q<??\ ]J-6[IGBWPG\3_$-]H'B7P];6EY:DQP?:909'(8AU5L
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MV'^I?_?- %JOG?X8_P#)POB;_M\_]'+7T17-Z5X#\.Z+XCNO$%A8M%J=UO\
M.F,SL&WL&;Y2<#D#H* .DHHHH \#^.W_ "/?A+_>3_T:*]YB_P!2G^Z*P=?\
M$>'_ !/J%G?:O9-/<69!@83.FW!ST4@'GUKH  H '0<4 ?-VAZFOPJ^,^J0:
MRIBTZ^+!9@"0%8Y1OIU!KU+QC\5/#&C^&;J>TU>TO;N6)EMX;>4.Q8C )QT
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MKCSCIDLV#D)+<.5'X9Y_&MZ3X<^%9-<M-8&E+%>V@40/#(\:H%&!\JD#I[4
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M)'J#MHEJVS,L$Z1HZ-CD8(R?PKG/!WCA/%/Q+?3]!\-Z4NC0$O\ ;?LQ655
M^]D' R>G%=)<_ SP)<7'G#39HLG)2.Y<*?PSQ^%=AX?\,:-X6L?L>C6$5K$>
M6VC+.?5F/)_&@"EXK\<Z'X,6V;69I8Q<DB/9&6SCKTK>M+F*]LX+J DQ3QK(
MA(QE6&1^AK%\3^"= \8K;KKEDUR+<DQ8F=-I/7[I&:V[6VBL[2&U@7;##&L<
M:YSA0, 9/L* ):^?/%W_ "<SH?\ OV__ *$:^@ZYR\\"^'K_ ,4V_B2YL6?5
M;<J8YO.< ;>GR@X/7TH \T_:!TF2WBT;Q5: K-8SB.1EZ@$Y4_F,?C5?X-+<
M>+_'>N^.+^/#8$4([*S#''T48_&O9M;T/3O$>DS:7JMOY]G-C?'N*YP<CD$$
M5!X<\,Z1X4TS^SM&M?LUJ7,A3>SDL<9.6)/:@#Q/4_\ DZ*T_P!^/_T"I/B[
M_P ED\*_]L__ $97KDO@7P]-XK3Q-)8L=70@K/YSX&!@?+G;^E.UGP/X?U_6
MK36-2LFFOK3'DR"9UVX.1P" >?6@#R;X]:9>:9XAT/Q=;1%XK=A'*0.%96W+
MGZ\UZ+9_%?P?<^'EU9]9M8?W>Y[=W E5L<KLZG\!76WUC:ZE9RV=[;QW%O*N
MUXY%RK#W%<"OP.\""]^T_P!ER$9SY1N'V9^F?TH \S^%.M?\)%\<M1U?:56Z
M29U4]0N,#] *^DJYO3/ 7AK1O$#ZYI^G"WOW38721]H7 & F=HX Z"NDH YS
MQSXMM_!?A6ZU>91)(@VP19_UDAX ^G<^U?.?A*[\.^*O$UQXD^(GB!-RR9CL
MV1SO[C. 0$'H.O\ /Z5\3>$]&\7V$=EK=JUQ;QR>8J"5TPV",Y4CUKE?^%'?
M#[_H"/\ ^!DW_P 70!;A^+/P^AC2&'7[9$4!418)  .P VUD_''09?$7PZ^U
MV2&62QE6[4*.63!#?HV?PJX/@?\ #]2"-%?(Y_X_)O\ XNO0(X8XH%A5?W:J
M$"GG@#&* /,/AK\4/#M[X)L;?4M5MK&]L(%@FCN9 FX*,!ES][( Z<YKAHKQ
M?BE\>[*^T]'?2=+V-YK+@%(R6R?]YC@>U>E:M\%O!&KWSWDFF-!+(VY_L\S(
MK'_=!P/PQ74>'/"NB^$[$V>BV,=K&QRY&2SGU9CR?QH \H^.7Q)N=)8>%M(F
M,-Q-&&O)U."B'H@/8GJ?;ZU5^&M[\,O!%FMW<>(;:ZUJ5?WMP89"(\]53Y>!
M[]3^E>CZY\*O!_B35Y]5U72WGO)\>9(+F5<X  X# #@"L[_A1WP^_P"@(_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z+PAX0O_%^JBVM@8[=,&>X(
M^6-?ZD]A1X0\(7_B_51;6P,=NF#/<$?+&O\ 4GL*^E-"T*P\.Z5%IVG0B.%.
MI/WG;NS'N37/7KJ"LMSHH4'-W>P:%H5AX=TJ+3M.A$<*=2?O.W=F/<FM*BBO
M.;;=V>BDDK(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *J:?\
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MV>M6AN8(WWJHD9,'ZJ16S10!!96<&GV4-G;)L@A0)&N2< =.34]%% !1110
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M$)_$&L2ZWX=G@AN9SNGMYB55F[LI ."?2O;:* /FK0OV??$5_J<4OB.^@@M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?_"C_A$?$?\ T M1_P# 9_\ "OJ^BCZW+L'U2/<^4/\ A$?$?_0"U'_P&?\
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M - +4?\ P&?_  KZOHH^MR[!]4CW/E#_ (1'Q'_T M1_\!G_ ,*/^$1\1_\
M0"U'_P !G_PKZOHH^MR[!]4CW/E#_A$?$?\ T M1_P# 9_\ "C_A$?$?_0"U
M'_P&?_"OJ^BCZW+L'U2/<^4/^$1\1_\ 0"U'_P !G_PH_P"$1\1_] +4?_ 9
M_P#"OJ^BCZW+L'U2/<^4/^$1\1_] +4?_ 9_\*/^$1\1_P#0"U'_ ,!G_P *
M^KZ*/K<NP?5(]SY0_P"$1\1_] +4?_ 9_P#"C_A$?$?_ $ M1_\  9_\*^KZ
M*/K<NP?5(]SY0_X1'Q'_ - +4?\ P&?_  H_X1'Q'_T M1_\!G_PKZOHH^MR
M[!]4CW/E#_A$?$?_ $ M1_\  9_\*/\ A$?$?_0"U'_P&?\ PKZOHH^MR[!]
M4CW/E#_A$?$?_0"U'_P&?_"C_A$?$?\ T M1_P# 9_\ "OJ^BCZW+L'U2/<^
M4/\ A$?$?_0"U'_P&?\ PK4\/_#K7]:U:.TFL+FQ@^]+/<1%0J]\9ZGT%?3=
M%#Q<K:(%A(WU9FZ%H5AX=TJ+3M.A$<*=2?O.W=F/<FM*BBN5MMW9U))*R"BB
MBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JII_\ Q['_ 'S5
MNJFG_P#'L?\ ?- %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *JV'^I?\ WS5JJMA_J7_WS0!:HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *J6G_'Q<_[]6ZJ6G_'Q<_[] %NBBB@
MHHHH **** "BBB@ HHHH *J7G^MMO^N@JW52\_UMM_UT% %NBBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH JS?\?UO]&JU56;_C^M_HU6J "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 9-_J9/]T_RJ*R_X\X_I4LW^ID_W3_*HK+_CSC^E %BBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 0_=/TJM8?\ 'M_P(U9/W3]*
MK6'_ ![?\"- %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*J:?_P >Q_WS5NJFG_\ 'L?]\T 6Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JK8?ZE_\ ?-6JJV'^I?\ WS0!:HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J6G_'Q<_[]6ZJ6G_'
MQ<_[] %NBBB@ HHHH **** "BBB@ HHHH *J7G^MMO\ KH*MU4O/];;?]=!0
M!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** *LW_ !_6_P!&JU56;_C^M_HU
M6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH 9-_J9/]T_RJ*R_X\X_I4LW^ID_W3_*HK+_
M (\X_I0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/W3]
M*K6'_'M_P(U9/W3]*K6'_'M_P(T 6J*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JII__'L?]\U;JII__'L?]\T 6Z*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ JK8?ZE_]\U:JK8?ZE_\ ?- %JBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI:?\
M'Q<_[]6ZJ6G_ !\7/^_0!;HHHH **** "BBB@ HHHH **** "J=^&+0!3AB_
M!]*N54O/];;?]=!0 >3=_P#/P/\ OFCR;O\ Y^!_WS5NB@"IY-W_ ,_ _P"^
M:/)N_P#GX'_?-6Z* *GDW?\ S\#_ +YH\F[_ .?@?]\U;HH J>3=_P#/P/\
MOFCR;O\ Y^!_WS5NB@"IY-W_ ,_ _P"^:/)N_P#GX'_?-6Z* *GDW?\ S\#_
M +YH\F[_ .?@?]\U;HH J>3=_P#/P/\ OFCR;O\ Y^!_WS5NB@"IY-W_ ,_
M_P"^:/)N_P#GX'_?-6Z* *GDW?\ S\#_ +YH\F[_ .?@?]\U;HH J>3=_P#/
MP/\ OFCR;O\ Y^!_WS5NB@"IY-W_ ,_ _P"^:/)N_P#GX'_?-6Z* *GDW?\
MS\#_ +YH\F[_ .?@?]\U;HH J>3=_P#/P/\ OFCR;O\ Y^!_WS5NB@"IY-W_
M ,_ _P"^:/)N_P#GX'_?-6Z* *GDW?\ S\#_ +YH\F[_ .?@?]\U;HH J>3=
M_P#/P/\ OFCR;O\ Y^!_WS5NB@"IY-W_ ,_ _P"^:/)N_P#GX'_?-6Z* *GD
MW?\ S\#_ +YH\F[_ .?@?]\U;HH J>3=_P#/P/\ OFCR;O\ Y^!_WS5NB@"I
MY-W_ ,_ _P"^:/)N_P#GX'_?-6Z* *GDW?\ S\#_ +YH\F[_ .?@?]\U;HH
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M=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\
M/P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^
M^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT
M4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/
M)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^
M?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]
M\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3
M=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\
M/P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^
M^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT
M4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/
M)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^
M?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]
M\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3
M=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\
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M]\U;HH J>3=_\_ _[YH\F[_Y^!_WS5NB@"IY-W_S\#_OFCR;O_GX'_?-6Z*
M*GDW?_/P/^^:/)N_^?@?]\U;HH J>3=_\_ _[YH\F[_Y^!_WS5NB@"IY-W_S
M\#_OFCR;O_GX'_?-6Z* *GDW?_/P/^^:/)N_^?@?]\U;HH J>3=_\_ _[YH\
MF[_Y^!_WS5NB@"IY-W_S\#_OFCR;O_GX'_?-6Z* *GDW?_/P/^^:/)N_^?@?
M]\U;HH J>3=_\_ _[YH\F[_Y^!_WS5NB@"IY-W_S\#_OFCR;O_GX'_?-6Z*
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M=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\
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M% !1110 4444 %5-/_X]C_OFK=5-/_X]C_OF@"W1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %5;#_4O_OFK55;#_4O_ +YH M4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5+3_ (^+
MG_?JW52T_P"/BY_WZ +=%%% !1110 4444 %%%% !1110 54O/\ 6VW_ %T%
M6ZJ7G^MMO^N@H MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %6;_C^M_HU6
MJJS?\?UO]&JU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)O\ &C_A;VL_\^=E^3?XUYUFC-'U/#_R(/KF)_G9Z+_PM[6?^?.R_)O\:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%5-/_P"/8_[YJW533_\ CV/^^: +=%%% !1110 4444 %%%% !1110 4444
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M7Q7X3LOB9=65[X-BO+Y;F-6NVGP68[<'&.U 'T&IW*#ZC-+34(**0,#'2G4
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M&(]J /9Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#E'YHS3,T9HY@Y1^:,TS-&:.8.4?FG)(T;JZ,593D$=146:,TN8.4]I^'_Q
M745CTG5I0MV!MBF8_P"L]C[UZ37R<LC(X96*L#D$=J]G^'WQ"74ECTG5I0MV
M!MAF8_ZSV/O_ #KQ\9@[?O*>W5'LX+&7_=U-^C/2J***\L]4**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JF
MG_\ 'L?]\U;JII__ !['_?- %NBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *JV'^I?_ 'S5JJMA_J7_ -\T 6J*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "JEI_Q\7/^_5NJEI_Q\7/
M^_0!;HHHH **** "BBB@ HHHH **** "JEY_K;;_ *Z"K=5+S_6VW_704 6Z
M*** &331V\$D\SA(HU+NQZ  9)KXI\2^((?%?Q N-6U!Y%LKB[&[:,LD (
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MZ?E0![U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,F_U,G^Z?Y5\G2']Z
M_P#O&OK&;_4R?[I_E7R7*?WK_P"\:]/+G;F^7ZGF9DK\OS_07-&:CS1FO3YC
MR^4DS1FH\T9HY@Y23-&:CS1FCF#E),T9J/-&:.8.4DS1FH\T9HY@Y23-&:CS
M1FCF#E),T9J/-&:.8.4DS1FH\T9HY@Y23-&:CS1FCF#E),T9J/-&:.8.4DS1
MFH\T9HY@Y23-&:CS1FCF#E),T9J/-&:.8.4DS1FH\T9HY@Y23-&:CS1FCF#E
M),T9J/-&:.8.4DS1FH\T9HY@Y23-&:CS1FCF#E),T9J/-&:.8.4DS1FH\T9H
MY@Y23-&:CS1FCF#E),T9J/-&:.8.4DS1FH\T9HY@Y23-&:CS1FCF#E),T9J/
M-&:.8.4DS1FH\T9HY@Y23-*DC(X=&*L#D$=JBS1FCF#E/;OAY\0UU)8](U>4
M+=@;89F/^L]C[_SKTROD=)&1PZ,58'(([5[7\._B(NI+'I&KRA;L#;#,QXD]
MC[_SKRL7A;>_ ];"8J_N3/3:***\X]$**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *J:?_ ,>Q_P!\U;JII_\ Q['_
M 'S0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMA_J7_
M -\U:JK8?ZE_]\T 6J**\^M/BA'=?%"7P5_9;J\;.OVKSN#M7=]W']: /0:*
MY#XB>.D\ Z'!J3V#7@EG$.Q9-F,J3G.#Z5/X$\;V/CO0!J5HGDRJQ2>W9MS1
MM]>X(YS0!U%%,FD\J&23&=BEL>N!7#?#SXDQ^/KC4X4TUK,V)4$M+OWY)'H,
M=* .\HKR;QG\;8_"/BNYT+^P9+MX0I\Q9]N[*@]-I]:PS^T<J<R>$[E5[G[1
MC_V2@#W6BO._!GQD\.^+[Q+ "6POW^Y%.00Y]%;N?RKT2@ HHHH **KWU];:
M;8SWMY,L-M A>21CPH%>0W?[0-I)>2PZ)X;O]2BC/,JG&1ZX"G% 'LU%>?>"
M/B[H?C.].G"*6PU+DK;S'._'7!]?:I_B1\1X_AY!I\KZ:U[]L9U 679MV@>Q
MSUH [JBH+*Y%Y8P7(7:)8U?;G.,C-5=>U4:'H-]JAB,HM86E,8.-V.V: -&B
MN/\ AWX[3Q_HMQJ*6#68AG,)1I-^> <YP/6LOQI\8-"\(7QTU8I=1U%3AX(#
M@(?0MSS[4 >B45XU9_M V:7L4.M^'+[3(I#Q*QW8'K@J,UZ[97MMJ-E#>6DR
MS6\RAXY%/# T 6**\P\6?&O2/#^KMI.G6%QJ]\AVND#856],X.3]!4/AKXXZ
M3J^KQZ5J^FW.C7<A"IYYRI)Z \ B@#U6BCJ,BB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 <7;_"?P3:W8N8]!M]X.5#9(4^PKLD1(T5$4*JC  & *=10 4444 %%%%
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M]0?<5E>/="7Q+X$U/3W3,K0&2(=Q(HR,?EC\:\@_9W\2R0:AJ'ABX<[6!N(
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MM;"!8+2WB@B7HD:A1^E3T >#_#GXV:5IN@6NA^)5GMKBR00I/L+!E7@!AU!
MXK4\9_''PP?#U[9:09+^[N86A13'A!N&,DGKUZ5WNL_#SPIKT[3ZAHMM).W6
M15VL?RJOI7PP\':/<+<6NB6_G*<J\@WD?G0!RGP"\,7NA>$;J^OHFADU&57C
MC<8(C4$ D>^37K5(    , = *6@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_$DUL@ # &!10!XK\?O!$>H:*/%5JJK=60"7/_32,G /U!/Y'VKR7X4>#/\
MA-?&,4-R<V-FHFN 3]Y0<!?Q/Z9KZ.^+O_)*M>_ZXI_Z,6O)/V;/^1BUK_KV
M3_T(T ?1\<:11K'&H5% "J!P!6)XRO\ 2M-\(ZG<:TJO8>0RR1G_ ):9& H]
MR:W:^6_C?X^/B37AH6G2[M-L'(8J>)9>A/N!T'XT >32%3(Q0;4).T>@K['^
M$]YHUW\.],&C*$BBCV31_P 2RC[V[W)Y_&O,='^!PNOA7++<1[?$5P!<PY_@
M '$9^HZ^Y'I7%?"GQO-X$\6FTORR:==/Y-U&W_+)@<!\>QZ^U 'T5X[^(>F^
M 8[%]1@GE^V%PGE8XV[<Y_[Z%<I8?M >'-0U&VLH["]$EQ*D2D@8!8@#^==9
MXS\!:/\ $""P.HRS;+7>T30OC.\+G_T$5S-C\!/"MAJ%M>137IDMY5E4&3C*
MD$?RH ](U35;+1M,FU'4)T@M85W.['_/-?*GC[QQJOQ1\26^FZ9;RFR23;:6
MRC)<GC>WO_(5-\8_B!<>*/$4VE6DI72;"0QHJGB5QP7/K[5>^&GCOP7X&L1/
M/87=SK$H_>S[1A!_=7T% 'M7@SP?_P (1\-Y=-+!KQX9)KAAT,A7M], ?A7S
M]\','XN:?NZ[I<?7::^C?!7CO3/B!8WLMC!-'' PBD$HZY%?,UK+-\-OBVLU
M[$^VQNVW #[T;9&1Z\'- 'JW[2>/["T//7[1)C_OE:V_V?MW_"MQGI]JDQ^=
M>5_&?XAZ9XWN-,MM&,KV]J&9F=-N7;' 'X"O3M'TWQ!X/^ T1TA=FKQQ_:F0
MIN.&;<PQZ@']* -[XK>&_$/BGP_;:?X?F$4GG[YF,QC^4#IGOUKY\\.SM\+_
M (B*/$NDK/- P!+-GR\_\M%['BNZ^'?QS>&>\@\97<CJY#0S+'G9ZJ0*X+XB
M>(E^(GQ \W1[:1TD"6]NI7YI.V2/K0!]?6]Q%>6L5Q"P>*5 ZGU!%?)W@QCH
MOQV@AB)5%OY82/4'<,?RKZDT&Q;2O#VGV,C9:WMTC8GU KY=\#H=<^.T-Q&,
MH;Z6=CZ ;OZXH ^M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *LW_'];_1JM55F_X_K?
MZ-5J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** &3?ZF3_=/\J^/I?]<_\ O&OL&;_4R?[I
M_E7Q]+_KG_WC7;@^IQXOH,HHHKM.,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***]8^&OPU-\T6M:U$1; [H
M+=A_K/<^W\ZB<U!79<(.;LAGPU^&IU%HM:UJ(BS!W00,.93ZG_9_G7N*JJ*%
M4!5 P !@ 4*JHH50%4#  & !2UYE2HZCNST:=-05D%%%%9F@4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5-
M/_X]C_OFK=5-/_X]C_OF@"W1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %5;#_4O_OFK55;#_4O_ +YH M4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;_T!;C]*/^%<^+?^@+<?I7T_11];GV#ZK'N?,'_"N?%O_0%N/TH_X5SXM_Z
MMQ^E?3]%'UN?8/JL>Y\P?\*Y\6_] 6X_2C_A7/BW_H"W'Z5]/T4?6Y]@^JQ[
MGS!_PKGQ;_T!;C]*/^%<^+?^@+<?I7T_11];GV#ZK'N>+> /A7/]L_M'Q%;F
M-(F_=VK=7/J?:O:%4*H50 H& !VI:*PJ5)3=V;PIJ"L@HHHJ"PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "JFG_P#'L?\ ?-6ZJ:?_ ,>Q_P!\T 6Z*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ JK8?ZE_P#?-6JJV'^I?_?- %JBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI:?\?%S_OU;
MJI:?\?%S_OT 6Z*** "BBB@ HHHH **** "BBB@ JI>?ZVV_ZZ"K=5+S_6VW
M_704 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K-_Q_6_T:K559O^/ZW^
MC5:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!DW^ID_W3_*HK+_CSC^E2S?ZF3_=/\JBL
MO^/./Z4 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#]T_
M2JUA_P >W_ C5D_=/TJM8?\ 'M_P(T 6J*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ JII__ !['_?-6ZJ:?_P >Q_WS0!;HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "JMA_J7_P!\U:JK8?ZE_P#?- %J
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M JI:?\?%S_OU;JI:?\?%S_OT 6Z*** "BBB@ HHHH **** "BBB@ JI>?ZVV
M_P"N@JW52\_UMM_UT% %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JS?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img29677477_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_2.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2<64&AO=&]S:&]P(#,N,  X0DE-! 0
M    )OJ^F7@X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   )@   X
M0DE-!"4      !"H<CR.\+B]1))=K(K5'*#I.$))300Z      $9    $
M  $       MP<FEN=$]U='!U=     8     0VQR4V5N=6T     0VQR4P
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _@
M.$))30/R       *  #_______\  #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              -*   #6          !
M      $              U@   -*                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     8X0DE-! P     '$(    !    H
M )T   '@  $F8   '"8 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( )T H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MM>+Q3D_LUHPWMKVY%[[K,9KZ:OYM^1_QGIJ_Z[].(QFX=5]]U]M%=K'4VL]
M6Y/[->W,<:]N/D-NKRF5T6?SUF/_ ,5ZA[?J=T.VV^US+@^\N>(R+@*K++FY
M]M^&/4_5+K,RJF][Z/\ 0L3U?4_H=5M%S67;Z"UQG(NBVRNYV?3?F-]7];NK
MS+;KVOOW_P ]8DIM]+Z[TSJQ=]@M]8,JIN<0T@!N0UUM EP_G-C?TE?TZO\
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M^'J/;_WU5Y[/0?&81."$R/5&8B#_ %91EQ1_YK__T?54DDDE*22224I<9_C
MPB'XG46C2#CV'PG]+1_Z.79JGU;IU?4^G7X5ACU6^UW[KQ[J[/[#PB#1ML<G
MG]C/#(?E!J7]R7ID^:]&]/\ ;/3_ %/H?::Y^,_H_P#P78N<S'Y%F;DV98(R
MGW6G(!T(L+W>JV/Y+UM74VTVV47M-=U3BRQHY:YI_-/_ $ZW*'7\?[94>NTC
M](2UG5:V@ ,M/LISF[?\!F[?TOM_1Y7_ !BLXR!+S;WQ_EYSACSP]4(>F5=I
M?+-PDB 1!U!T(224SS;ZQ]0.O.ZKT?[/D.+\SIY%-KCJ7L(_5KG?UF-]-_\
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MK>(LHOJ=[;J+6_28N_=U/JIR&46Y73NG9>0W?C=,O)NR'-U^F^O(QO?[7;\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" $- 1(# 1$  A$! Q$!_\0 'P !  (" P # 0
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MCE%UB$W]M&!T]L=!.>2V!Q:VNQJJVQJ;+P$Y /ZN_M3&,L<=8:!8HZ>=%G8
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MWCS W!.JO57,%4[$[UU44#*"=!G 4IPM#]VQ?8$R2<JC)S2I0#R]>24 QC"
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M>Q=] ]KE<R9N),K ZE7M[C)QPK9VKJ=.LEOBK:PBF1_P7"S*1L;,#\N%;#@
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MI8;R[(4H@J9!Q&1S6NN1)V*!+$ ', & A\Z\/<8+_/I/(O-%CHS='?;SB1'
M.HUL,S2 'UCZ UA''V2-C@WMT;4N0D%L #IO) YYF'N.4",_^H*\^L1[CW'\
M\V% T-#TJ!J^,YI3%*8I7]VS=5VNDV;I*KN'"A$4$$$S*K++*G*FDDDD0!.H
MHH<P$(0A1,<P@4H"(@&?+-RC>P .I)Z   DDGT KD D@ $DD  #9)/0  =22
M>PK:9TUK)'I2\.'9YI-)GSPYB59,LFW#L2<T)HM[Y"E%J& 3*Q]FL!TO6>
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M8VR&.9SUWYUW"HWKMVQ'L+H:<>=_Q,A:NF_R^K5XEDVZL@32FWWK:/M":!0
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MG<[M_9*S$M&"(&5D%&J1#F*[5R"0002"#L$="".Q!]"*IYYT=/6C[8JI^8_
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ML@5-5VUC'K+X5%62<!QY)B\3!BACQ=743-%:2M,(XB)9&9%F7E))1G(^%E#
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MHD-2-A%05308O&RZ[E18E7;@KCP[#UK19OB',-D^O7ZD]^Y_.MX\IBF*4Q3
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MDGU:./VQ>DKS^UEU.^+$49CJW8UU,O?ZLQ!1K76%[E$W"E\HTP@T("2%3VS
MI/YB/ Q3!'V5.879%:K1\*)'Z]J[%(8<I';L?77]-?\ 2KH'_5PC;5==27O4
MZ*,UH*ST>I6*S1SV*!"TG=6AF21EFJ;E91/X27J23E&/,T2,9@ZDV,@D==9!
M9%PCL9P9X-6O$? DF4O&N;//9(S7&&ED=H[>&WB^"U%Q;\I+Q7CK([2$<XA>
M&2'H-2:>^(OVA\APEXH183'"TO\ A;#"WM.(;>.**6ZN;N;]I>FUN^=?*GQT
M<D<<<(81M<PW,5P26'DV5I\TN+QZL6VCN6G)QXM@<#'G?B%D((D\A;&K!2&G
M1=%'NF9$C WZ0.P&$.QAC!O"_CT7YQW^S.1:8.4\]8A]Q/70<7Y86@C/X@QE
M!Y>I ZBII'C=X6'%#+GC/$+!Y?.;5I6_M0'EYC$<4$-^9!V(6W*[[,5ZUE_5
MVT:9N2F1M^H,DI*UJ55?(-72S-TP7!>.>+,7:*S1XFDND=)P@< \B>)R"10A
MC$.41QO/X#*<,Y2?#YB!;>^@6)WC26.9"D\:RQNDD3,C!D8;T=A@5(!!%9EP
MIQ7A.-,);<0</W+W6-NGGCCDE@EMY1);RM#-')#,JR(RNI[C3*59258&LA99
MJR.F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2L!V#E%Q_JEUE=>6C:=6KMLA"H&E(Z:=J
M1J+0[ALD[204DG:*49\29LNBL+8'@K%(H3R( B 9E]GP#QCD,7;YFPP%_>XZ
MZ+_=YK5%G>0([1LZP1NUQY8D5EYS$%)4Z) W4>Y#Q6\/,3G+OAS*<58S'9>Q
M"?>[>]>6VBA:2)9EC:[EC6S,IB=&,2SF0!@"H)U5<G-GJ"QZ$='T+C?=U%9@
MSY-]9K[ %3,S;,6Y3F0A81^Y1.5RN[<>"S]\T2%!-LB1JBY4%RX*E-?A=X.3
M--/E^-L6@MQ$T-AA[LGS6E<CGN[N&-O@6--I!#*W.9&:5XUY(RVM_C=]H2#R
M+;A_PVSDAN?/%QE>(+  1+#&K&*PL)Y8R96ED*RW-S"GEK'&D$<K^=,$H5ZM
M')+D/U';3PKX+ZPK$]'1=P?U^1V1:7$>JSJEAVRNXD8(SQ[(-!4:MZO1:RWD
M[I()K@W*F,TLK\,(P[50(M\0O#_*<)9V]2WQ]W)@[B=YL5>11R7$(MY6+):R
MS*K<EQ;[,3)*1(ZHLJ\RN&,Y>$?BOA..^&,?+>96QAXGM+9+?-X^>:"UN6NH
M5"27T%NS)YEK=Z$RO IBB>1X&Y&C*C;YXHZ1U?QKX^ZQT)J!Q'.Z7JNLLJNW
M>,'31VI)RJ(&=3TW*K,U%$S3,_-.GTW)^0@/Q;]0"E(D"9"Q[/;7%JP2YMYK
M=V4.J3Q20LR'>G"R*I*G1TP&CHZ-2O;7MG?(TME=VUY&KF-I+6>*X19%US1L
M\3NH=01M2>8 C8ZU(C.FJFF*4Q2F*5TS8_\ -[>N_P!/NA9._P#Y.\S@]C]/
MK2J]>F)_\"[1]NW_ $MA_P"YU/?]_P#;WP.P/3J >GT'UV???6E6>YS2F*56
M1U.1 ->:V[__ %F__H'M"./K^?U[?3]_MG!]._?T[^O\/K_#KJGK_'^E3^UA
M_-KKW_4BJ?W$PSFE=YQ2F*4Q2F*4Q2F*5K1]0BU[UD+KLOC_ +OFV=QU58Y5
ME9(:I2M=KCJM2=7),?-JDX025B1<@K$NH]-JLH*XN"R4:Z*JLN0QCK;G^&_"
M7ASG^&\/FK7A^SN+N"..WOFO#/<NF4MDC^]">&:5[>0.Y6>,-$8S#-'RHJGE
M'G1XO<>>+W#'&7$7#E_Q;DK6QN)I;K&+CQ;V,4F$O9)?N+6L]M!%=1^7"K6D
MSK.)!<P3AY)&4R- =NW1:H(MFR*3=LW3300113*DB@BF4$TTDDB 5---,@ 4
MA"E*4A2@!0  [9-X"HH50%55 1% 4 *  J@#H    .@'36JUO9F=F=V9W8EG
M=R6=V8[9F8[+,Q)+$DDDDGK7W,/8!'L'[?U_J[?7Z?4?I["/ZO8>?7]?]/R[
M]OSKX8Z!/R]MG]=_0]^WH=F+IQVNJ3O%VF0M?<-@E:DZGHNU1Q#D^,:2[N=D
M95-TZ3[^H*<DQ?-G3=8P>!BB9N0W=L<A-&_&S'Y"TX]R=U>)(;?)16=QCYB#
MY<EO%9P6S1QG\(:":&1'3?-O4A&I%)]+OLVY;$WWA;B+"PDC%YA[C)6N6M@P
M\^*ZN,C=7L<TJGXBEU;7$,D4FBATT*GF@=5G?D25/E,4IBE,4IBE,4IBE,4I
MBE,4IBE:UW4P:5AORGFE*^= S]W5*NZMI$%!."5C%LX;@58H=RI.#02$(JJD
M7M_G"JF#U%#B.\'@;)?/P!:"\#^5'D,A'CBXT6L?,5_A)US(+M[M58GL.4?"
MHKS2^TM#BX_%?(MCC&9I<5BILN(V+<N4,#QD./PHYQ\>/=E775^<[9F @!_A
MDP?UJ!* '8WF!A*8.XE,41 Q1$OCW*8.P@(@/B/8?H(]P[9P>O0C8.N^M=_Z
M=^W\Z^>4;)V=GY]NFNGMT[^A]16QSTQM<(5#CFVN O5'3[9\Y)SRZ7J"*#!I
M"O7=;8M")]Q JQCQSMVX4]C'^*23$/% @YI3X[9M\EQH^-\H1Q8&T@M$;7QS
M2W<45]+(6]4 FBB1?3RV;NY ]&OLO<-1X?PZ7-F8RS\4Y"ZO7C#?L[>#'SS8
MN"()V\QGMIYY'T&831Q_AB6K%\A:MD*8I3%*PIR(Y :TXNZ<O&\MN3182D42
M*/(R"I (I(23M0Q4(R"A6AU$OCYN;?J(1T6R*<HK.ER>9TT2JJDK<=C[G*7D
M%C:)SSSMRJ.H55'5Y'(!Y41068ZZ = 3H519"_ML9:37MV_)#"I9O5F;]V-%
MZ<SN?A5?4^PV:T&N977#YK\GK=8$J3L6P: U"NJZ9P&O-9R0PDF,.<%$"*6F
MZL$VUDG)1\V-WD4DG[*$(<YTF44@F43*3[AN!<)C;=!<6T61NR!YL]V@DC)Z
M;$=N_-$B _A/*SD:+.=U!F7XUS61G<V]S+C[4,?*AM7,;A>P,DZA96<CJ=,J
M@DA5%=HZ:?6DW5PYO:-?VT[>;<T1;I5B%W92*:#J]ULI>S4+/59\XH.Y!W'M
MS"9Q 3CERPDFQ%$&RL8]43>DI.(. ,7?P228R&/'WR@F+RMI;2L =1RPC:*&
MT )(E5P=$AP-558+CG)V$\:9&:3(63,%D\TAKF)3T\R.4Z9^3OY<C%6&P"A(
M8;_.O[]3]ITBJ[&U_/Q]HI5U@X^QUFP12Y7#"5AY1N1RS=(*%'V\DS@55(X%
M506*H@L0BJ9R%@:XMYK2>6VN(VBG@=HY8W&F1U.B"/Y@CH1HC8(J<+>>&ZAB
MN+>1989D62.13M61AL$?U'<'8/45VI==!J@LY<K)-VS=)1=PX74(DB@@B05%
M5EE5!*1-)),ICJ*',4A"%$QA  $<Z@"2  220  -DD]  !U))Z #O7:2 "20
M  22>P ZDGY 5HR=8#K13>_KZYTIQ@=MX'4FM9]ZB;:S8A5[)L*<116C9![7
MU7!3MX2GIF,HE%+H(#,2P)%E!>LVCA-@$U<+< VD,$5YFXOO-U*JNEDY(@MU
M/Q 3!2#+*1KF5MQH3R\K$<U0WQ+QU=2W$EGA9?N]O$Q1KQ%4S3D$AC$S ^5$
M3^%E D<:;F4'EJOSCGUB>?W':U0\Q';\N6RZPP6:$D=>;<E7E[JTM$MS$*:(
M1--+.9BO(^@0$&SBLR<0NR(5,B0F0**!LIR/!O#]_ 8SCK>U?E(2>R1;>2-M
M'3:C"I(?<2K(&]='1K&\?Q?G["82_?YKI-@O#>.UQ$Z@[*_&2\>^P,3(1Z=.
ME;YW KG!J_GQH2&W-KOO$2:*_P AV%1'CI-U,4*XMD4UGD.\4(5+XN/=(J)R
M,%+E112E(M=)44F[Q)ZS:P-GL'=8"_>SN/C0CS+:X TEQ"3H.!LZ93M9$V2K
M@]U*DSA@LW:YVQ2\M_@<'DN("=O!,!LH3H<RD?%&X #J>P8,HFKEDJ\TQ2F*
M4Q2@B  (B(  !W$1]@  ^HB/Y &*=N]:R74%W;6]U;[6<5 Y75?HT$C24)8
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M*K#MU]/3K[5-OK!VA:V=2KEM)KG,J#;9"4"W$QC")6M9K4#7VY $Q0'L1*.
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M,E(:8B[#$QD]"/FTG#S+!I*14BS4!5J^CWR!'+1VW4#V.BX04(JF;V[E,'<
M'VS![FVN+*YGM+J%[>YM9I(+B"52LD,T3E)(W4]F1U*D>XJ3;*]M,E9VN0L+
MB*ZLKZWAN[2YA;GBN+:XC66&:-AW22-E93T.CU /2L1[OY*: XUUPULWWN'7
MNIH+P.=NYNUGC(9S(BF!A,C#1:Z_S6<==B'$&<.Q?.C 0WBB;Q'MT55:)[#=
M:\'*'[4+QMI#EY4^)NJ;KR'MPN#Q\?9+ FO0: L[,8R+=:-;*-Y"[V$BBPI@
MFT^0U\SDI_T3PH^/FK["$]^GZ]MUJ<<J3\A[=MRT[VY$Z.E]%V#D1-S6V(6
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MXMX:<6=V.E/G1B%,5%FUF26*-,LJ)2_%SK!$HB=8I<L7ACD@DM_B7;7FA;V
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M= ,HY"#\4<"LRJW9G9B-JJDS?P+PW)C('R5['R7MTG+%&PT\%L2&^,'JLDK
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M.[L=*JJ-LS,3H*H!+$]AU)Z5]*CR,L<:-))(RI&B@LSNY"JJ@=2S,0% ZDD
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M8VO*6C\Y9I_800?M)-GTY@O(/FP%>G:4I2E*4H 4I0 I2@  !2@'8   ]@
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MA"&C?7821.&C?7IS*=>FJMV0Q..RL8BR%I%<JOX"X(=-]^21"LB;]>5AOUK
M7'WI7<"^,-N0OVHN/=:B[LR4%6+M%CD['>)6%4[=@6@E+C,3:$*Y*'?Q>QB#
M5Z &,7XGQ$ "X9#BK/9.$V]WD)&@8:>*)(H%D'M)Y*(7'0?"Q*^NM[JAL.&,
M'C91/:6$:S DK+(\D[H3ZH9G<(?FH#>FZL'S'JO],4IBE,4IBE,4IBE,4IBE
&,4IBE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img29677477_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_3.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1N24&AO=&]S:&]P(#,N,  X0DE-! 0
M    &W:^<# X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   )@   X
M0DE-!"4      !"H<CR.\+B]1))=K(K5'*#I.$))300Z      $9    $
M  $       MP<FEN=$]U='!U=     8     0VQR4V5N=6T     0VQR4P
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _@
M.$))30/R       *  #_______\  #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              /9   &_          !
M      $             !OP   /9                      $
M                $     $       !N=6QL     @    9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   /9     %)G:'1L;VYG   &_     9S;&EC
M97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L
M;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%
M4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%
M4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   #V0    !29VAT;&]N9P  !OP    #=7)L5$585     $       !N
M=6QL5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     8X0DE-! P     $+X    !    H
M %@   '@  "E    $*( &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( %@ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M=:_;E_6:JZBS%@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M13=_*0EIZL>XBVY+.:JGI+:8H.)'T82#(3QO[D[WU#:B]TPZFEHN*TD72C?
MI1ZBF1#)MC<!O[99%P5P#R(J?NGM @7)L]1&G*<#8U0VZ19D%?IAW^Z_,!@K
M^R'2P$S'D3?*K&]B7*>U5<:,R/1:NVX>>Y9DB7ZCS\WT-EV3WE-(4GS6L=4<
MKJWM=.,]22G<7>9!9'=4R2W+$3Z^+D* ]4",LN(CUW!M-$<N+1-Z_>V&G,.O
MN6UNJ^<>0;AUI*2Z$)9MWRE#7>A+CCOIH2I0$DS'-NM8;M[I5HS9WM^^TRBX
M?39-LK##3JE!LK+K[(4MSL44-M][BDIGM@B?L5FWB2G2>;I%I>Q4SJ_6FM%0
M)155":J/4IEQC43FR4_0J2&]=.L[GSM,TERQ); 2\*"Y?(-?IA2K7*8?6-#8
MB6*4ZOV?39:,]=LW%TNYL[*RMGA;KO+MU88<N% J2PP&&GW7W"@>H0VV4I;^
MVI0!$ZKO5FK5UBV1;W=Y>/M&X1:6K:"\AA)"5//%YQEME 60V.]P*4Y]A*20
M8KW;GN/D'<U)3Q-\D(IJE]=*4YO]-ZA2%/K($N3[3>H<K"EB?I,G%F+5N"1*
M[H4[@W+H#6QS=&M:WN*)8A<5)1UX>-J.FW&F/H9?4TXEYENYM[AA?J6]S;NS
MZ;S*R$J*%%*DPI"%I4E04D16_I^H,:BRMUD.MJ:=7;OL/H]-^W?;CO9>1*@%
MI"DF4J4DA0*5$&K_ &N!7.II2N0G[L&^R7M._.*?/W:/VE*Z<=HWV4=L7YO5
M%OW;RUI2LA=*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*
M4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5SG-
MVVZN2;8C4J?Y2II.S9N3VT^(/7;=A0R57"6'IMF2=43)6)Z.=&-K:#VZ%W?F
M&J%,769D#2F:TRE/-"DYF%$"V'U 1?1#J-E^?K:W=NF%:;J>@6.E7SJ7$*:9
M+ED@)6M05V-N6MTAHK4H@M +[BG-=!1I]ZG0WWFK=Y.H:=KE]J=FTIM:7'@B
M\<*FTI*>]:+BV6XE 0"'5%';.*^W-NW6MKAX>[;/,T4WG)TW*[G]ZM!=U%99
M-:9:>W69Y/)?*Y2,M:936,Q"$Y[:FBDE*F:7&9U2N)!<,N&-;T:O%*$*D8=+
M.HV2>H5,-7+*-,TO1;_2K-YQU"&GBBQ?2MU*RKTUKN[M;BTE)/JA2.V?LUJ>
MT^\5H27G+=U>HZEK%EJ=XTAM:W&@N]9*&B@ K2BUM4-H4%#][[5E49B]NY*;
MZUQ[NZM2M5<W?*U4*04[IR?M98MF,JS0+15":W!M<(JG)JCU$DM@6*F"<$,S
M>QMC&W3K-\E20WRL3"^."J %1BPWA::S8_FBS=M/S&J_5<W(U5S67FN^U92I
M/RQMK9]82XRIJ5+6RR^^IX^FD8@<W4'KS\ZW35U^>4V08MSIB-(:=[+EU25?
M,BX?902AU+D!"7G664M +4<R<99*H/6>I/AH[*_#T<:/5#D^;ZMS%,ZZK]0I
MND5_3D[::?TUK5-$_N,VG/JU&0WMU69D-+8V2ER"-;"H=O?BQ^@$&<HM4IR;
M]_96W4VM=0IO+=YFT::3:6[3[9.IW%S8M6Z6?32HJ5:-_;7=*[>U!0EO^'@8
MYJRO+CI[1]"-H^T[=..*NGW6'(TYBWNW7RZ5J2$INW#V(MQ(*N]3@^P)/W9C
MIU7$CPH*E;-'.A$Z)ZJ[8JP[?Z6MHR33N9SI<KA(\M[FJ33DTUKIR*)K/@F1
M._2@6X3'4:-N.7+F&8VZ9W*92VR%1###MMW-C^ZNVUE%\R;74[+4+I7KW+0=
MLGW-,NV%65S*AZ90]VM6P4$I<;4TEONBM3MO>#IBXTA5D\FYTZ[L;9/HV[A;
MO&&]1M747EOVI(<"V0IRX[2I3;B7"YVS6Q62))G%)XI%?*@*I4F-/(KOLXH1
M++3.A[(Y%2JYS$UU/JHO=&!OF Q-"U+'EN1+$2Q>V)U9BU(E5)5"@@LH\J./
MKK[[)Z7L+</-%]&LWSJV M)=2VNUM4H<4W/>E"E)4E*B DD$ DBL^RP\.I;Z
MX+3@87I-DVAXH4&E.(N;E2VTN1V%:0I)4@*[@""0 0:P\E"D-4TOAN^*G(RB
MF<]IIRJ%6+Q%W2091-E!^)F2=6R<W"8QDYPE)CC;X7*8D4U0QE#+:IH2JR'H
M#"_=D:D(H+Y=Z[M5=2=+/BZ84S;VG3B7WO6;+;"V4M>LEY85VMJ:(/J)6049
M[H,UBF;6Z3T_U.RJW?#UQ==0*8:+2_4>2]Z@94TCM[G$NR/3* 0O':2*_=-K
M=/VWFKWAJ;EIAI!5Z<J=25L^?=OM64E,Z=S//L\TMFF8Y3IH[L#A,L@2\WK)
ML%J4NLNN,NN)J-K/-9G$OU3B42<:D3JXTJWU&TZETQN[M&;E_6&]0M#=7#3#
M%TTV]<H<2T^XH-=X0XEQ(*_MIRB0%*37$OV%UT[J*[6Z=MV=)7870M[=UYZW
M<<:MUH4XPA)=[>]M2%0B4*_A & ;<&2U6NK%-O'&GI9MWK/3U5N%I;+0T<D:
M<).7PSM.Z)MVNN<EM<#2TM!;C OF)T/1(35\I-2IS>Y9='8J5WPA-,"56B@Y
M'J65I<]$,)U&R?&GW3GSC[+R2PPI6J)>65K64]K: 3#JTH0ZA!=05-J2JM@-
MW=U;]:/FPN[<W]JCY1EUDAYY*=+6RCM0D*[G%D#N:2I2VUJ]-8#@(K)?</32
MH3U2SPC&YGD&<'5PIKNPVHS%4)"W2R\+5<A2]+E#ZB-<P/<WITR(PZ6FAB=%
M:)N=W%X@1HVY>I3)59I*@XJ"+&Z=<VZ+KJU2[AE*;G2=5;MU*=0D7#CE];*;
M0R2H!Q;B05(2@DJ2"0" :R&HV[Z[;I9*&'E&WU72W'TI;62RVW9OI<6\ );0
MA1"5*6 $J(!@FKM$2/.</BY.M21E*9 IX;X<C!)$$]BQN02@9.A.YF9'XV4H
M9D]F]SQ3*4QGD/!C("P7.!K.*7Q)@2QP&CQ"^S^Y%-MZS7S'[HU/^AWI];T3
MIB&_6].>_P!(N H"X[>\%,SBN4&7OW5*N/2<^7/3[;/K=BO2+PU%Q?I>I'9Z
M@0>_LGN[3W1&:R\W"MCD]T!KBS,S>M=G=WH_4QL:FMM2G+7%R<E\EO21"WH$
M2: U0K6K%1I2=*E3EF'*#S"RBH(S(X81Q&GK2W?V*UJ2A"+RV6I:B$I2E+R"
MI2E& $I )))  !)Q65U!"EV%ZA"2I:[2Y0A*05*4I3*PE*4@$DDD   DDP!-
M:;E5+ZS4XVP>#E7,BC-2)Y4[/)>DDRMM%Y=E=8KJRTL,[4 "G#T^-E/EP(GE
MWF:G+N>2H62PG("8"_7*8BDL$"1:8G[BFYL[G4^L; WMLP-8<>%C>N.A-HXX
MQJ'S+;:KA/<A#5R@$!TGTS E64@]2-M=V^F])7HM+AXZ2TP;RS;:)ND-O6(8
M6M-NKM6IVW602V!W@S]G!*;^R<LF7=[X@U$MQ<HTJJY3BB.V.C%79=43U6"G
M$RTE=:H3]6&-A:B)3E>49V0M$WN,MRBTM"QY<)A6,Z-K@?8P;TD1\8EJ#> \
M&](Z?O=.>NK2YO=3O;1P,6=RU=IM;>S[U^LZZR5LH=>6L(2VE:EEO[1@2!SF
M2YJNNV>H-6MU;V>G6=TV7[NW<M5W#]V4)#3;3R4NJ;:0DK+A2$=Y[1)@G!"#
M;%7 S8=M/?SJ85W][;==^-;ZOU&IA3R&8Y#KTKI=,=8:Z-)\T4U10F,<R*9H
M;VJ;&B9I<2M9Z16_2\L6'M1YY2DGU^<&IV(UW56Q<V'9J.@V-G;W5P&[BP3=
M-V=@L-7)/J-AI2V5M.J7*4.I3W@08PWYNO?S+ICGR][WZ?K=[=W%M;^JQ?*M
MG+N]27+8#L<+B4NH6VE)!6VI78HR)SRVT290*<:Q3)5"GTI[])CJ%+]"IPDU
M!4[=2W5^12J@8YF=V!<XT\ED*Y"U.3C,Z]R1(784\OL3BV$)&]>8<ZD*C4I"
MO!ZD]?L6;5K<.Z"U;N7S+RK72E6"G5+:0XE-R[\CWI2TE"BB7%I4HJ3"% **
M<UIK-B]=N7+#>MNOMV;S*;G4TWP;2AQ;95;M_.]BE.*4E*X;0I "5$K!*0JF
MJ#,^Z.C7@JR(ST6D&8F+=+)^WJ*"5Y%?Y5C1S@U3,9,*LYS]&3IE2IXCYK1L
M:IR=V)D=T,<+H]%MR90B60*Q3G[E^O2[WK5]=[<-N:6]J(]5]MV65M!M(3+S
M1,-*6$H<6A0*$%1"@1(V[%&I6G2#"+-EQ&I-6!]-EQHAU+O>2K]Z<$ET)*EH
M0M/VE]H*3,''FE<LS'/&^GP^ZB2>W>(54649"#<&-7*H[M)4GR7I5E6:)RV]
M3,VMS.T2Y-$NRHEEE<H>4IC:]NTNRRCD,]P5R[+S/,#LYQ>R$9&[=:8T+J"V
M>5T];/7'YN-G:Z2[;N.NM,:@VI2UNM..J= 0H*0AQU3X2EUQ;:$CN/ MFW'M
M:T)]E.O/M,?/_-7.J-/MM-NO6#J4I0VZVT&R5@H6IMI+!5Z;:'%*E-7KV_2_
M.37,/B9;0)IIQ6&4IQW)[AMTM3::U-CII-9M&U%/JP4KEYJEB9AJPE0&RBE6
MD.;>H;CF:)P%X+=Q(0E(S3X%L*/@Z@XRMOIK6&KFS>9TW3M*M;FU^9:%X+BS
MNG%.M?*%7K%)0H*[^WL*)43!3W<RP;>2YU'I3MO=-/:C?ZG<VUS\NZ;0L7=J
MTAISYD M!04D@H*@OO(3VS,8JT+I%2MRH!2/:YN9I)XHZRI$M-U.J;S_ $5;
ME&XE]H6I=I&<F-.CFI@F9M<RZ#$TF2.;,WS2TJ"IO1)&5O2DD(TGM*%*6;EK
MZ\NT:A=ZIIEWTLFV=5<7-O>J3IS5^$OI65-+;4GY\W92M32P6E%Q1)4848QE
ME:6RK*UTW4;;J55PVFWMW[-)OUV)6RI #C;B2+$6H4VEU!#J4H2( D169+5.
M\X;--[^]I_G:@M>JF29NG447J31F=*(TLF*J)+P]R535'3F8:6S2J823$DD/
MB-V;BU\O*9K6M4M&LBU2Y+7AK*A"$S"J89UG1-%;8O["U>TH7MM>L7MTW:E"
M'[E5RU=-!>7T*0HI=#06X' E"4+.V62^[I.LZPMZQO;AG4S:7%F]9VSER%K9
MMPPY;.E AE84D*;+I2V4$J4M(&;S>%5*=2I2VX3P15BF\QTGG)_W0;EYP623
M-">,M>UI9JJJ^/"3V5;ZDE&_-,9:D86N8VGUS*_)"X')I4J$*@DV+A]5.VSN
MI,FTN6[MEO3--92^T92LM6K:#*9*FU8^TTN%MG[*P% BN7TPU<-:<\+JW<M7
M5ZEJ+I9=$*0';IQ8@P$N)S]EQ'V%C[2"4D58J;*A31MN\3C</5B8=O&Z2I%/
MZE;;*#RG*LT4.H%/E5V53,,JOLZJWIJ6.\MMYC2W*TA2])ZPE6N+,*]>48HA
M(),+-CY[5NUJ73.G6C>HZ7;7%KJ5^\ZU?7]O:+#;R&4H4E#J@I0)2<A)]I(,
M<)U]S3^H]0NG+#4KABXT^R::<LK%^Z07&EO%:"MM)0D@*&"K',""?W2/0FN&
MZVK6[W=54.GDP;>$]6-HCILOVWR#4$YO3U+12.ZF3'-+[4:I+0PKGA)*"UUG
MM\2BRR^#BJ>D36WJ8G(@KT&]0X:7[^QTFTT?2K>X;U$VFKHUK4G[<*-J7T!M
MINVMEN)0IX(80?4<[4H4M0[2?M!&IFRO-3NM5U-]A=B+K2E:1I[%QVBX#*N]
MU=Q<(05AHK?7]AON*@A)*@,%6,KK4"J\\^&JT^'.@VC;C6K=(HHQ*>V%U9WN
MD,PME&9=.8$;1*+G5M77$PB.EQ\@EM;:;-+8XM,Q.3JL<C4;>F;3C3/:M9-%
MO:,=2KZB7J^G+TM-Z]JB%HNVUWKH6I;R+1-C/S7S'>L-*2IM*4I"E%0 BL<M
M^Y>Z>3H"=*OTZE\FUIJD+M7$V;9;"&572KR#;ECM274J0XI2C"0F3-73WERD
MP2"["LI)*^^>2=[%,Z&R;3^D]:=O5*9WFV0-P43$PPJ)6DNHBEN:YHI-,LK-
M4U&FES8GJDGE9XETLY2X-SB>V%M\9_%T9YRX04W;NAOZ)=7SUQ=V6HW;#5QI
MX<=(=?MDJ6U=M/+:@M&U]5#IA)2%%4<G5VD,+*K5K66=9M[)IBUO+&U>=8O^
MQ$MLW!2EVV<;0Y/JBY#2VQ*DJ*0F:=K/3"JDK;LZ8;F-Q\N;HDTJU/V6TQI;
M4^9ME;K5!4X4NK]*$QN4SS.P35+U&5*Z=EU,'LV9%@2\ZHT+^W)IA3>J40EP
M&PN&MVRNK1W2;K3=-<TI3MKK5U=6K.MHM0FZT]YM+33C3EX$LBZ;#0]1*E-J
M+9D;=M:+NVNFM3MM1U!&I):N-(MK:Y<TA=P56UZTXIUQMUNT*GE6RBX>Q24N
M)]3>!!K8OL2D.DDL275";:425N/E0JIM55\SS4[[HR)[15(J&_I97E=I@GI.
M@J2L.G,F6U[:E1M3:?,#<QN2Q4T.)D39[%"A5JNN:]<7;KUJU=OZ:\;:T2TT
MC2S;FVMFRZZKY<JMDA@NI42M0;4XE(6D=W=W)&>T5BU;9N7;5G4&Q<W2G75Z
MD'DW%PX&FD>N$W!]4-J2 D%:4**D*^SV]I.<NL%6:II2N0G[L&^R7M._.*?/
MW:/VE*Z<=HWV4=L7YO5%OW;RUI2LA=*4TI32E-*4TI32E-*4TI32E-*4TI32
ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4
MTI32E-*4TI32E1<.X?72I(&Y ^^EP[A]0TI(\C\12X=P^H:4D>1^(I<.X?4-
M*2/(_$4N'</J&E)'D?B*7#N'U#2DCR/Q%+AW#ZAI21Y'XBEP[A]0TI(\C\12
MX=P^H:4D>1^(I<.X?4-*2/(_$4N'</J&E)'D?B*7#N'U#2DCR/Q%+AW#ZAI2
M1Y'XBEP[A]0TI(\C\12X=P^H:4D>1^(I<.X?4-*2/(_$4N'</J&E)'D?B*7#
MN'U#2DCR/Q%+AW#ZAI21Y'XBEP[A]0TI(\C\12X=P^H:4D>1^(I<.X?4-*2/
M(_$4N'</J&E)'D?B*7#N'U#2DCR/Q%+AW#ZAI21Y'XBEP[A]0TI(\C\12X=P
M^H:4D>1^(I<.X?4-*2/(_$4N'</J&E)'D?B*G2K32E<A/W8-]DO:=^<4^?NT
M?M*5TX[1OLH[8OS>J+?NWEK2E9"Z4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*YT_$N<%Z?<^XE)URM.6$DRC%Z!*HXHL!B3J[B$$$<,/I#R(\C
M;OG7[1^![+2^@V%+:;6K\Z:B)4VE2L.((R03''WYQ7G=^4D\\W\3KP(=<2G\
MT:00E"U@3Z"S,)4 )B-M\GD5K_%W=@&WO-QSQ_CRGJ'_ .]'J'?&0N(#KZ^+
M>W(GT6<;_O2.#_\ <C@^,X, BO@8N;@B?F'\;_OCG!^HX/C.# (I[W=1X='#
M@.%JG _,V]O/G(!G@9\NP(EAG<G+;>WW)@&#MM )QN'S-R-WW]SN\O(^Y43[
M;8)QN'OAVM_TFXB-A'_GJ@,_#UF0  OU^'8;9B?[BR!(']R2<?6,$DQQ]?(W
M%S/]\/ 2!_=7#CZ]V"28X^OE[W=O_O-Q_KR@.XX$#,\ATL <AP.K\O;_ .\L
M_P"22? R",;'F2=CN*?,W'_K#W^4</@9!5C8\R3L=Q3WPZ__ 'HXWZ66J1 1
MN(6R://0.EKAS;4^78_WAF.9;0"! ,X2-N3S,'::?,7/_K#T<RZX"! ,X4-N
M3S,'::@'AUY]Z./F'MJD>E[V];:P#?M8 \]4VS&WH,\0?31&^T]LSMYR?:J;
MBYV]=_V/K+',03W3)$>9)]JGWN[#<?>;EQQ[:HZWR'^$ . [<YS:PSY>W$#T
M6-]_23Q&#@G<^=L8F1/F;@0/F'=]_5<XC!^T3N?.V,3(>^'; ^\W ;]!6J ^
M(?\ * %[_.UN;B&GRS&1Z+0CD-I/T.Q,1]TSM -/F+C(^8?$<AUP_0_PB8C[
MIG: :@'=V$<.CA;%KKE-_@/^$M<<\@/':UZ;=@#+#4YF&FX^NTP,;$;^9BFY
MN ,OOSF8=7'U_A3 QL1OYF N[MG_ '4<;_\ YU3D '-O\('7M; #<,9"WM\?
MO#,?_>D8)&)P>/,Y(@YP%S<8_P!4/1_]]<P2,3]L\>9R1!SB?>[J/+FX!CGV
MU5?O_P#:@ ".1#-K8XU/EV!LRT<[>DW'C_<DD# .)G.]3YFY&UP^<[>JN/'D
MD@8!Q,YWI[V=@ !%T<?Z\I"^./\ E<<6'K<1[7%Z%N20&&?\D@QG?^#G>1Q
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MF<GW,^V8J+C>V1$![YR(!81#';K@>O35@1. "/&, F8.?/&1QS5@1. "/&,
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MFE*:4II2FE*:4II2OXJ"H#TYY,9AI4!Q)I49I)T:<XN R"*"(PI05% 80;
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MU)Q$!G\W7&%O<*"E)8>4E"$N+(:60EM0E*U$)A*%#*5&$D9!(KDE]A)2%/-
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M6^0'GGC.M(C$<9VWF9P!Q&"-MM\5I$8CC.V\S. .(P1MMOBG' !>UPR/ ]
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M !NU^/ORZO\ ;7Z>&T=!Z=CQ_K]U%S]W^@K,SQ(__F_=Z?YL-:_W?ONG3?\
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MM#R2#[?^[.8\21OCDQ(F'DD'V_\ =G,>)(WQR8D2"X"'>W A8.;Y&_ <]\"
M@&A@@^)W!D[1@1N=O&9!-#!!\3N#)VC C<[>,R":<B-N;W'.!"X=[AVQG/P
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M-VS:ZFU<H67$OHM[D.APSW+[^SN*E2>XDGN!(5()G)NZGTZ^PJU>U'1G+=:
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MN"<0/KN#4@8C?[SF>"-YVQGG<&HN. Y#K< [VL/Q&_2X!WXTP)V'TB,9D8S
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M3(DG>*$#&)^\QG.\GWF)Q)\4&**W8<CTX[6'/:W40_2$3C8B-O/N!!YGB?U
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M +B.,"%QQTXXM>^,]Q[B(AH8 SD&!GG?>8C./ \  T, 9R# SSOO,1G'@>
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M]:#ZV+HH3FEX&7V5*@?EXF/]AJ>=]<#7O[\0/_X='ZUN?YJ^*?EU#_SK]/\
M\P].'/&O=1>?_'S6J.JX!_*E4J]K??\ 3C?RO,+@'GGL AYW[>@F@3^8=$&9
M_-.FQ[_ZC:/,8V!(/M'G^;7J@G]TW4<3/Y^UB!YC4;H^V/)!]H\T"%KV[V 0
M&W(=,>86OZ/F ]\L9B?$D$3L><^QF.[V(\8$S$^)((G8\Y]C,=WL1X %QP&+
MCT#(#QC%[CD+A8+!;@=4F-SF!R<$;YS$#!@R9,[BA,;G,#DX(WSF(&#!DR9W
M%>>F.@#?@,CVQ?ZY$ 'X:O.>2(W.!YS'X8!(^M:N<\D1N<#SF/PP"1]:FW'
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MQ!X@"8WB8!QY&_(P2*O7MN#_ (PU#>?Z6Z>=;A_UK:1_1<0SG(#UUU?K4_\
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M A?J/.<ZGXGR-YC!\@D&.!MC%/Q/D;S&#Y!(,<#;&*D;7$1'I>U^1^?8!L&
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M IC&\9&<1[P1$#(V@2!4C;T;@%\V"X<XZVMQG/?N.=!/=!,8DP=L\3.^,>/
MQ4$]T$QB3!VSQ,[XQX\#%1?X (6YOTZ9''80'ZC?"-]R#.T<\F!GR"/P$9L;
M[D&=HYY,#/D$?@(R$0'OY"/0>H!;IG \\=@L (/'N!R."9YQD;;^3( @\>X'
M(X)GG&1MOY,@N.>W'-KB(=QQR'%N_30P,>=]I@3X&=C,SXYH8&/.^TP)\#.Q
MF9\<T$.G?H/3%@'D.+" WO:W7J!Y\<CG))&QWD$1$SQP!Y\<CG))&QWD$1$S
MQP''%@ . Q?M>_6_6UPM]=!G>23N<QYB.(XF#/X4&=Y).YS'F(XCB8,_A0+=
MNG6XXZ8Q<.0&P6 +>=Z9\\\0,\YS!V(DR3/M SYYX@9YSF#L1)DF?:($!\AX
M\N>!M?G/%K!\- 1[C?WVW$QMC>9/UJ@CW&_OMN)C;&\R?K0!ZW'-PS<?[.UN
M! 0M\ $1Q Q!Q _K\SN"#/U($<0,0<0/Z_,[@@S]2)#KG@.EN+6'J'/F&+!?
MSAXQN>9WF1P=O8YDQ[0\8W/,[S(X.WL<R8]@!8.@\XYL(XR(#B^.N0OU -"9
M/(VSM(&=B,QGC!C@FA,GD;9VD#.Q&8SQ@QP33_* +6O@ MT +Y'M\@OP'73^
M"3,QDF>28P//WF-SQ3^"3,QDF>28P//WF-SQ4AWOFT0A?] ^7(B/(#81T/B,
M2 8_6/?8 ;$2!4/B,2 8_6/?8 ;$2!48\PXS8?TAYVR ASFXAIGV.^)'ZC[3
M@@[8@&KGV.^)'ZC[3@@[8@&IOGFUN<#?-Q'Y<=\V#(<R,;3.V1&( ^_?QB3@
M[2,;3.V1&( ^_?QB3@[>1OGN&/,+"(XM@/J/EC6H1]QS[&0!F<G\![YK4(^X
MY]C( S.3^ ]\T'S'IR%\CQD1SP.>.F!"UWT'.QC WV&-QC?G(,P^@YV,8&^P
MQN,;\Y!F)&]N_HX_LS?.>@8$.<8U,3X[L^_G$8QR<@[9S4Q/CNS[^<1C')R#
MMG-2'F'(]1O@<#?]7:^!M:VH?8[ [",C(C]OF,B9FH?8[ [",C(C]OF,B9FH
MO:W3GI\KV^,/ @ ]<CD+$SS]_P!\3]%;@D<8&#8F>?O^^)^BMP2.,#!#Y#<0
M$1'%K=[ (\]1\QQ:V@]Q ( &9GQ) VX'L,S-![B 0 ,S/B2!MP/89F:#:V0$
M!&]\A:^>;B(\AP(\AQ<-!,X(($1@S&-H &QW V.\&@F<$$"(P9C&T #8[@;'
M>#5ZMMN=PM#1$/\ SMT\S?\ ]JVF_'QS?J/<!UUCK;'1W50!_P#H[K,X_P#9
M]S&_TQ' \&NZ?#C'Q!Z' /\ ]+NGL1_[6M8W^F(X'@UUIZ\\:]7Z:4II2FE*
M:4II2FE*:4II2N<CQ-,[HG(/_8B4+9Q?V=9R%AZ8\^.XA^U/@;CH*W/_ +4U
M*<9CU&]C(YS[;^ ?.G\I7'Q0NS_['T><9CT5[&1SG&V_@'7SY#8+CS8!^8WN
M VXYN'6^OL/N),#:2/N$01.^T'B*^!>XDP-I(^X1!$[[0>(I;C-PSV&P"%KC
MG. L/0+=N4[X@X\B2#,#&,F1R9\[)WQ!QY$D&8&,9,CDSYV@,\@ WN'(WP%Q
M&XX\\^8<:IQL2(@[",D@"!GVQ]=ZIQL2(@[",D@"!GVQ]=ZD! 0SYX[CC/%P
M\QN(\V[:$$''MGP,XW@^P@#:?-0@@X]L^!G&\'V$ ;3YH A:PCS\[<#P-P /
MD-^<6U"#,@;?=.XW$$G[Q&V9H09D#;[IW&X@D_>(VS-2(C:X]!'@0L(?7I?L
M/2X#J "8'(Y!D'\.8\CF"*@ F!R.09!_#F/(Y@BG<+C<0''.;VL/:P6 !L =
M;V#3P8$ C.V(F1YDR2))XB33P8$ C.V(F1YDR2))XB346 0P ^8!_<>^1'-^
M #-K)!R1[$_Z#Q@#$;DXFR0<D>Q/^@\8 Q&Y.)#;(6L.;A;Y?.U_*UA$0'03
M@S(Q!G[_ +ICWF0 103@S(Q!G[_NF/>9 !%>L!?K:X@(YM;H 7#X<\V[#;3D
M^TP"!B9Y)@_7;:?(G3D^TP"!B9Y)@_7;:?(GR(7''<1&T0=<6ZVO\PSG'&H&
M!GP )2>,SQ,?<<8SOJ!@9\ "4GC,\3'W'&,[Q<,].O%[A<.@CD;WYOU[:L''
M/&\08/(&!$;1QYJP<<\;Q!@\@8$1M''FI$.0QS<0N 6#RZ>7%^,9MJ ['.T
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MR["EOI2Z5)LK5+BY9;%9F>!G]E2H/Y>)C[?_ *#4\[8^FN#KO]^(_P 71_\
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MU]_'ORJ<G4R"3I8,F!$,V&DP??*? )P"VMX&N#?:(OU4 G&%>V'E^T)P*0J
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MXZ9^? ]1'7H'H$C0=%Y'YHTW$QO9-'WQ!C;<3@"OYM.J?XS=1^/S]K B8_\
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M[PZIZFA0RL2>8'3< !HN*5J2$') <'*6XC$J,\"A5)D!0*3224L!PP%)A$D
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M/J*_A**405*B 2HS,&).!!-?D,*[W2L-I;"G5+2AN>QM*G"H(3M]E(/:F3,
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M<K2S"PRG2:3&GU+J>UHTKC.[R]HRSU\S*' B#USBG$(!3!$9%# 6]POP 7#
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MQX,=4_QFZBVC\^ZR3YC\XW.9&?;WV^EO[\V&UQ'FX@.>M_(;\#]1L&8C:1,
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MW<^865I#KJ$W++*WU..-ML%Q4:_%:PQ4O4.!D!,!BI6<L,*)@]61 8>=&='
M26 Q# 5#%&,!<-Q]"$  > '7V%II*&D- J*4-H;2I1E12A*4@J,"28"CY),<
MU\!4XIUQQY24A;CJW2E [6PI:_4*4@]T("C@9A.TY%9L39O:>)JW%4TW!&2
MVHUM.)<@EXJ6"WY4<E=B@*F8LQ48YQ-A9J2./[Y3A*+@1J(8?9B0BCC]9';Y
MAIWPOMM/Z+USHY.KON,ZW>F\5?JM&TN6ZBJQ(;3;A]27 GY%/<HNH)[U0!VB
MOM&K_&B_U;XA=-?$!>@VC#_3E@FP;TU-\\MJ[2$ZBE3B[@VX6RH?G%9[0TL#
MTDRHRJJ6ICNS=*:[A9_K^1);>[+)]BG 5$M&O"E(E;@FMZ2/47J7.!"H-4>P
MG)"R(?22%^O+BCB$"HO1]'G:[\/&-;Z.TCH]6IO6[6DC3>R]3;(<<>.GVSEL
M.]@NH2CU4N%?]T/8<2H5C>FOBM>=-_$'7>OFM&MKM_7/SN7=,<O'6F;8ZO>-
M7J@BY3;K<7Z"F0A)6RGU$DD]A@5^ZAV[B.ETD3E2N=J92]5FF,XO!LPGRN^+
MCFZ) \&1HS(S2%?L+G 8DB-;F]5"0*,L].N2P+$BP@R(Z&/9ZJ^'2=>U33-?
MTK7+SI[7=,MDV2+^U:0]ZULE+B0E:/59(="7GFRL.E"VG"TXTM(01O=$?%A?
M2^B:STOK/36F]6],ZS>'4'=*OKA=OZ%\LLJ4IIX,725-%=M;N!M30<0\TEUI
MUM15WJS[Q'RKE.I1IVGD&6J?MTB3NGFN4C)//.1HF1N;6U<VLK&D;?9H88#$
M/MT:TUU]J]-4L 3(4::","B[TQ\-[3IW6M1UE>KWVL/ZMI2]/U%.II2Z[=OO
M/-/75TX_ZDD.^D&DV_8 VW"2ZLRHZ.L?BY?]7]/:3TZG0M+T"VT+6DZKI/YG
M6XRW8L6]L];V=BS;%H"6%/*><NB[WNO2H-MI(2FNG_>M(-1Q;'^L>UV0JB5(
M;6Q(V#. S*],"5S+1 (IS75A2(E)2P &,R.).>L.)A].(I- F3# G+Q5G\,-
M7T0/VG377FKZ+HC[[C_YL^2M;QRW4['>FWO'7$*;V [T-(48"G"M?<LY[4?C
M)H74?RVH]9?##I_J+J.UMFK7\\?G2_TYJY2Q/IJO+!AEQM\R5%2''U-I[BEL
M-M0VFTS%NA4RE32LTC2;(#!*3U6J8EB]\FIB6GI!8I65JO702/+;,"7T$3*C
M2GN3:DBB<33"4;HJ "P.@3F$]AN^A&]1USIG5M3U>\U&VZ7LVFK2PNVD."[O
MVF^TZK?7/?+MTXXEFX<_>4)4[;MF2E2TKZE8?$I_2>FNL]"T?0=.TF[ZVU!^
MXOM6LGG6_D=*>="QH6FV?I%+%@TRNYM6BNX40Q=.@#N#2D?CKSN66[@)7IFA
MFN3T*:>:?- ,2VH*=U..7S8V 07 );FVBB**).]K*]Y>M@6G0%K%3E$2266M
MC@*W.DNAV>D+_7'=/U)U>DZS<F[:T==NE+.G/E9(+#P=4I2?24& E322IIM@
M*45- JV^NOB/==?:9TRSJNDVK>MZ!9C3W^H&[EQ=QJUJ$( 3=VZK=*4N%U/S
M(6EY24O.W)0A*7^U.,7;CD+\Y&XC:P7S8<]N+CKO7G?8QM@0!,F,2,>=X%?-
MO.^QC; @"9,8D8\[P*@;Y&P#W'(=>/\ -N(8OCMQH(P)(\#!XW_PH!S&?.]4
M1@21X&#QO_A0#F,^=ZO5MMM^$)0WM_*W3P ^(36T^=LW'_:(ZZQUM/[CNJ_/
M[G=9)^AT^Y]IQ _\ *[I\.)_2%T/Y_=;T\3]#JUK[ X@?LV KK3UYXUZOTTI
M32E-*4TI32E-*4TI32E<Y'B:_:B<1Y_WDRACK_S=9D0L.+?3I;7[4^!G\0F!
MM_KGJ6>/[HW@9&9_'WKSI_*4_P!M"\&W^LVCYX_N*\#(S,?6M?/ @(9#/2WQ
ML%^@9\KV'BVOL.X(.#CF?I)CDX]XD;S7P+<$'!QS/TDQR<>\2-YH(AR&.1S>
M]QYL(#<1^(?.PAH =CG8<1 VD$0!]#]T@T .QSL.(@;2"( ^A^Z0:#U&P8&V
M<<W[" 7ZB/<>E@T&(SQ./:/(F. / \DU(D$3NDF)WP/8F#L(X')-90;@MQI=
M<Y4HG+,,HF2R-(9*+E(U;$] Z@_&PMS WBO@(!K;O=A=F,#031'+H@%4,'M
M@2$9G1>D.C#TKJ'5-]^<4WW[I-55J0:%M\O\HDO7CWH=WS#_ *Y_U64^H$-
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MRMKZ0<\8P,P"/)R#[<S/O-?)3GC&!F 1Y.0?;F9]YH/&;9 !P%N!&P_/RZ7
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M6%NPY=K0Y=W#CW4O4]U=75TMMMEM5Q=7=P_<.^FTVTE3A0TVAM*4C235B_\
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MF)Y' IUM>+SZB X^MA#H ?'B\XF$^W (S^$@\D_3>'$PGVX!&?PD'DGZ;QZ
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MZ7L(!>X][WL/?GL(@/EG2.8D$Q \1$CQMY (]\4CF)!,0/$1(\;>0"/?%/1
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M0[V&"3YXYVW@<\XSL#XD8)/GCG;>!SSC.P/B0@(CC/(AU^(#?'4+].PB-[I
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M>UP ,_$1\QP \@ ZI/W1O!)Q] /89(V)%4G[HW@DX^@'L,D;$BI[9S>V!XP
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MM<<?&W C:WQMCN-\:3M,#/TG<"9^DY\",TG:8&?I.X$S])SX$9H%P !Z= #
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M;=1#KB';<G<$C,#/D^^1/ /&8=MR=P2,P,^3[Y$\ \9@.F;7#BXWSS:V.0P
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M?KXB1Q.2(!SD.P@(7'@0_P!HCUO<+W"]&X@XG(.//_@![1N# [8.,R-N#_X
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M=YC_ &&IYK"Z[_?B/\71_P#&[7X\_+I$?%;I[^8>G#\->ZBK5)5C^E*I.?\
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ME*40 E(#$DJ,  9)BN4KX+_"M"2I71NE)2D%2E%=X E($J))NH  $D[8DUC
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M)_0M\+?Y&:5_RKS^U4_ IVK_ (EI4_TG?^)ZGZ3^OOY3ZA_T?_L*?H5^%O\
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M-^V7;+I71+EL&"IEZZ6$F(A0%U*3'"@#%7<_ HVK_B5E/_2=OXGKB?I0Z_\
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M6^-\9#H ?(1'GOS?['XS/TC.#R3]X V\;1\$\9GZ1G!Y)^\ ;>-H".;"'0.
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MY'@;8Y\\W&^IQ$G(]H(C8;B<[>V($5.(DY'M!$;#<3G;VQ BEL" 9'GN-N
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M4/M B5K.HZ4S=Z?=:?I=Q;*L[MFY=2]J7S0?2TXAP-)_U&SZ1)2?WS[>_P#
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MP<;"(_ $@;_X,#G(*XC<1#H/>W&?J 6L&>1N%M( @ \CQ.^/P)F3C809I $
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M..UK7'(XZ\9#SN'P&9P=_,S P,\;X/M!^HF<'?S,P,#/&^#[0?J('Y\?, N
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MN-!Z*ZB;TC2[K4'=5?MEZ+H6HE=\_;VUJZ]Z^IZ;>7"0IBSMT>FAU+0+?<E
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M28SQ0C !((D$?3;&YY&28SQ47O@ N%NPW#FV0_1Q\KCJQ&28,^1!VG!_7O\
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MO;0?YQO(&^(D2,;B9@^)H/\ .-Y WQ$B1C<3,'Q-3;I;/]Q' A80N(YN$(B
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M&^/><^VV8KSH_*4'_G0O,$G\S:1&?_S"A@>#.=O;,5KYM\P$;=LWZXQR/2X
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M\QM 'ZH/D$8J<];Q6"X9$!SCH&<?'K<1OJ8XA,F#@$8SR<9^G$ 14QQ"9,'
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M8^MLA\ '4QG$@P9)\\Y_"<'ZD5,9Q(,&2?/.?PG!^I%3C(B/E8!L @ 7P%N
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M1L B&._&<@(XX'. N&K&?& )(!SXWQ@@9W&,F#5C/C $D Y\;XP0,[C&3!H
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MPI:<W3$I,()*5;=SH]N+!_4=-U%&HL6;S+-XDVSMH\Q\P5I8>"'%+#C#JT%
M6%I6%%(4VF3&[;ZJ^;UFQU#3UV#UTTZ[:*%PU=-/^@$J>:*VTH+;S:%!904E
M!2%%+A@ V?\ %V=)@1[=*4,[#-DX2<7/&[O;3(,QN,C36_R4_K)3FV?"VN8&
M@J8)9<&MY1D.",P8#12+28PC@*-AB PJ"*'F=((;5J-VMQIEXL:1J=PVE]IM
M]M+K+'>VLMNI6A12H2)21N-C7#ZJ4XFPM4-NO,^MJNG,.*8=<9<+3KW8XD.-
M*2M(4#P1Q5D]U%-9I\->690W94#K=7IYII)=2Z;RS7F@M8JOSI6>1)PIE42;
MVF0U[O*<=1G"8YDE"?6%ZF)H=6US:'TE$H**4$+41J0#TBWFZ5=-=2.O:1?V
M.GHN7[:Y=L+^SLV+*X9NK=E;Z4._+)::>8<0TI"DK;*A@I5,%/#U.V=Z>;9U
M2QO;]RW9N;=N^L;N[=O&7;:X>0PI;?S"G'&GVUN(4E2%@$2%")"LOZF;T)[)
MKE/6WO;+MK?MRT^4@E^57ZL[C_*9)M(Y)IZIGI"I=I-E$9DFQ.Y&S!.SVR)O
M?L3,W-4"%N:5:%0N>"CC3TZ7#VNBVYL6-0U/4V],8O''6[)/RKUX_<!A00\]
MZ310&V$+5Z?>I94I:5!*" "K+7.KOB]?L-.TYS47[1MI=VKYAFU98+X*FFO4
M="BX\M [^Q*.U*2DJ6#(%(1>)?(!NV ZOB*F,[A/*.NB3:T[4$>G"7F";9<W
M'J9J1RB;3F9IK6+8Y/9F]&J7I'E1.!JXUKAEQ2F6 G]YG S0[W[F;@:H+!5R
MQZ"K$ZHB_0EQQES30T7A<M-)3ZRU*"2@,A/=ZH*9[1WG:/43!TXWR;=[UA>I
MTU=BLH;=:OU.AKT'7%'TD)!4%EZ2CTR#'<>T76F+=K,U&: U-KENEH8\T;CI
MXZMS4V2?*L]RQ6%54I1,:EC9Y/2R(Y,9,OFFNLR38_)93(:IC9Y>/2.4$:PX
MR)F$'+7%;TAJ]U"UL=+OV[P7"%+4\\P[9BV#06MXW"7"X AMELNE;3CH*<"%
M_9KDN:HY:6-Q>ZE9+M"PM*$LM/-W9N"X4(9#"D!N5..N!H)<2V0K)/9]JJ:D
M'>548NM-+:);D=LKYMW>Z[M4UK*-/I=4)/JNP3$^20RPS-,LBS0HE=$V'29.
M:.6A->$B8PIYE]V@1.*1LF14L2@2;N7&C6WR5U>Z;JC>HHL%M)O6S:O6CC:'
MUEII]D.J6'V5.P@D%#B.Y)6VD*FMMC5K@7EM9ZAIR[!=ZEPVC@N6KIMQQE'J
M.L.EM*2RZEN5 $+;7VJ"7"1!S[U@*SE-*4TI7(3]V#?9+VG?G%/G[M'[2E=.
M.T;[*.V+\WJBW[MY:TI60NE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*P#\3&D=1:W[3WJ0*5RPJF^<%-5=OK\0R(U3<C/,:)2KI3Z9YC6@>
MZK$","VM@:7%R/@B4@:82E,@(+-.& J+/]-7=M9:JE^Z=2TR+34&RM041WO6
M-PTTF$!2OM.+2D0,$\5@^H;6XO-,6Q;-EUTW5@L(24@]C5];NN*E92G[#:%*
M,G88DXK#7>EL?KI4[>&U!2=O*+VP;S6.F4K[ZE2=>C0J&Q)MUFLB<&)U++-7
MI5IBZITF%%TCC,;&]V])"2<4[0I4AY9PYG1=;L+;1E_.*)U31EW+NA)*20HZ
M@UZ*T2$*$6SQ-W"U(R04$D$5B=7T:]N-63\JD#3=61;MZT04@I^0<]5M4%25
M$W+0%J2E*\ A4 @UEDS46J*@\12NU7H)0/2TKF;972VE\KS*4H:BVY;.;!4&
MH+HX2TF0%K0<4YK>U.;:H$TY 0W@2I)@*4Q1@,$.)7>VRNG;&S]8&Z:UJZNG
M6H65)9<M[="72KM[2%+2H0%%1(.*R;=G<)Z@O;OTB+5S2+6V;<!3VJ>;??4I
ML)![@4H4D_P0F" #Q6'M$=JVX"6*#>#9*C]3=T;I@VWU4=WZMK8:Y,!AL@M"
MFFM6F@A:Y&$.YJ=:68Y/S0C"!F-<SH3EY01%PP@;$7F+W5=/=ONLG6[E"F]2
MM4(LE=K@^84+FU64I!1*2$MK/VPD0DYV!Q-GIE\U9=(M+MU)<T^Y4N\3W-DL
M(-M=("E$+(5]IQ A!49.V]9AK*-U+-\2Z>JVP2JKBI:Z^'ZT4B;YN]K; 1J:
MC$5PF6:#I7A1BN!T@5%L*Q*XQ*C$,#=ZHZ$L%@G^D4&&3>6PZ;8LBZ/FDZ^J
M\4S"Y%N;%MKU2>WL@N)*8"N[&T5ES:7'[HGKWTC\LK0T6J793!N!>NNEOM[N
M^0VH*GM[8,3.*P^HEM7W 2Q0GP;)5?:;N;=,&W"J3P^UM;37%@,-D!I4TTJR
MT$+7(PAV-3KH#'-]:$7H,QKF;"<N*](L(0,B@S%YJFGN7W63J+E"F]1M4-V*
M@ER+A8N;59")0"G["%JE81A)SP<19Z9?-672+2[=27-/N5+O$]S9+"3;72 5
M$+(/VG$)A!495M@QFQ*%)*BMWB85IK<MEA412R9MHU'Z>L4WQ*FZ)$X3E+U2
MI_>GEB*1P+(G4M0@:W1 L-./0%(XBU1<)2DPSTH(<,]>6RNF;*Q2Z#=M:O>7
M#C,*E++ELPA#A5':0I25) "BK[)D 5F6;6X3U%>7BFR+9S2[1A#LIA3S=Q<+
M6@">Z4I4DDE(&1!FL!7W9UN16[*MQ\KLE.8CZMMGB4S]NUIA(#H_L#:%2Y.8
M]PS14%D3I'KWB>UM!DW2JD<#V8'92B.A6PI$R\M$)XQ0YUO6=-3K6FNKN/\
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M%$@E'C&7.CW*]/Z9=<L57B])MDM7FGAU+3JT/6;3+I:7ZK:%.V[C25!'J +
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MA0:4M!0I#*47EPM?J!2DE0;0GMDD@P*N1XHU*ZL55H'3E/1NG;M5*:J?[G*
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H4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img29677477_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /8";\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJI_*K/AWQ=H?BR.XDT2^^U+;E5E/E.FTG./O*,]#TKPK]H#_ )'RQ_[!D?\
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M)_ /2=1M)=:N+T74$<6R!;>7<H#GYF)0]P-O.,\U[90 4444 %%%% !1110
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MJ[21 S;EEP,DHW?UP><>N#0!Z!1110 4444 %%%% !1110 445A>,M9G\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4&D:O8Z[I<&I:;<+/:SKN1UX_ CL1W!J'Q!KMGX:T.YU>_$IMK< N(DW,<D
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M!<&2:!9)#[ER,Y_&@#AO"OQXL-2NX[/7[(:>SD*+J-]T6?\ :!Y4>^3[XKV
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MQA\!D@#722?2SG_^(K-^.&N?V7X":RC?$VHS+#QUV#YF/Z ?\"KQCX5>'?\
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MOBCP=J.E8!EDCW0$]I%^9?U&/H37R)8WEQI.JV]Y#F.YM)EE3<,893D9_$4
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M/%7@^^T."=+=[CR]LCJ2J[9%;H/]W%?,'CGP;<>!];ATRXNXKIY;=;@/&I4
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M?YB@#[>KB[KXL^"+.[FM;C6]DT,C1R+]EF.U@<$9"8ZBNTKXU\: #QWXA &
M-3N>!_UU:@#ZPUKQ;H7A[38K_5-1B@@F7=$#DO(,9^51R>H[<9YKBQ\>/!YN
M?**:D$_Y[&W7;_Z%N_2O*O#O@_Q+\5;Y]1N+M8;2W5+<W,H)50J@!$7O@8)Z
M=<YR:E\<?!_4_"&E-JD%]'J-C&0)F6(QO'DX!*Y.1GC.>_2@#Z-T77M+\1:>
MM]I-[%=6Y."R'E3Z,#RI]B*T:^2?AGXIG\+^,[*59"+.ZD6WND[%&.,X]5)S
M^?K7UM0!#=7=O8VLEU=SQP6\2[GEE8*JCU)/2O/=1^./@ZPF,<4E[?8."UK
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MPR!Q^8J>OG[X;_#OQ/X?^(]J^J6D]M:PQ22M+%)F.7 VA2RGU8'!]#Q7T#0
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M*S-?UVQ\-Z)<ZKJ$FRW@7.!U<]E'J2>*^7/&/Q)U[Q?<R":Y>UT\GY+*%R$
M_P!H_P 9]S^ % 'U!<^*/#]G)Y=UKNF0/G&V6[C4_D35VTU"ROU+6=Y;W*CJ
M895<?H:^5-*^%?C/5[9;FWT62.%AE6N)%B)'LK$'],5UGPY^''B71OB-I\^K
MZ;/:VUN'E:56#(Q"X4;E)'4@X/H: /=M<T'3/$FF/I^K6B7-LQW;6)!4CH01
MR#[BLOPQX!\.^$99)M)LBEQ(-K3RN7?;Z GH/I7'_M ?\B'8_P#83C_]%2UY
MA\%?^2G6'_7*;_T6: /J6OB'4+R34-2NKV4DR7$SRMDYY8DG^=>X?&KPEK_B
M'Q)I]QI.ESW<4=IL=XP,!M['')]Z\'H ^Q/ >F6^D>!=%MK9 JFTCE<@?>=U
M#,?Q)-=%7R#;_#GQA=6T5Q!H%V\,J!T< 892,@]?2L[6O"VN>'4A?5]-FLUF
M)$9D ^8C&<8^HH ^SZ*^;_V?_P#D?+[_ +!DG_HV*OHB^O;;3;&>]O)EAMH$
M,DDC=%4=: +%9M[XBT337*7VLZ?:N#@K/=(A!_$U\V^.?BQK/BBZEM[&>73]
M)!*I#$VUY1ZNPY.?[O3Z]:Q]#^''BSQ';+=Z?I$K6S\K-,ZQ*P]1N(W#W&:
M/K"RU?3=2_X\=0M+KO\ N)E?^1JY7S%H'PK\6:?XRT<:CI<T-K]K1I+B*175
M4!R<E2=N0".?6OIV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP,)^?)^C"N7_ &B_^9:_[>O_ &E0!E?L^?\ (V:I_P!>/_M1:^B*^=_V?/\
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MC_\ 1LM '2_L[_\ (/U__KK#_)Z]KKQ3]G?_ )!^O_\ 76'^3U[70!\>_$
M?$+Q!@8_TZ7_ -"-?1'P=_Y)5HO_ &W_ /1\E?._Q!_Y*'X@_P"OZ7_T(U]$
M?!W_ ))5HO\ VW_]'R4 <-^T7_S+7_;U_P"TJH_L\_\ (<UK_KV3_P!"-:7[
M14+M;^'9P/D1[A"?<B,C_P!!-<[\!]9L]-\67EI=S)";RW"PL[ !G5@=OU()
M_*@#Z1KPS]HO_F6O^WK_ -I5[B)$+E ZEP,E<\BO#OVB_P#F6O\ MZ_]I4 9
M7[/G_(V:I_UX_P#M1:9^T%-(?&>FPG_5IIZNOU,C@_\ H(I_[/G_ "-FJ?\
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M@?\ CGY5[3XF\1V/A;0KC4[^9$6-#Y:$\ROCA5'<D_XT ?&-?;.C?\@/3_\
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MEFGBMXFEGE2*-1EG=@H'U)HM[B&[MX[BWE2:&10R21L&5@>A!'!% B2BBB@
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M\,];30/B!I5W+*([=Y#!,QZ;7&WGV!(/X4 =-\=];_M#QK#IB,#%IL 4\_\
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M'X&O$_C'K7]L?$6^16+0V*K:)SW7EO\ QXL/PK7^"?BE-!U#6K:Y?%L]D]T
M3_'$">/JI;\A7 Z;97?BKQ3!:AMUUJ-U\[^A9LLWX9)_"@#Z&^"/A_\ LCP,
MM_*F+C4Y#.?7RQ\J#^;?\"KLO%'ARS\5>'[K2+T?NYERD@',;C[K#W!_,9'>
MM*TM8;&S@M+= D$$:Q1J/X548 _(5#JFIVFC:7<ZE?2B*VMHS)(Q]!V'J3T
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M;I)$X89]#Z'V/-7*^0? 7BR\\)>)[6ZAF86DLBI=P[L+)&3@DCU&20>U?7U
M!1110!P/C7X3:'XOEDO4+:?J;=;B%<K(?]M._P!1@^]>'^*/A1XG\+QRW+VR
MWMC'R;BU.[ ]67[P]^,#UKZNH/(YH ^./"GC#5_!^IK=Z9<,$+#SK=CF.8>C
M#^O45]9^'==M?$OA^SUBSR(;E-VT]48'#*?<$$?A7R[\4M,L=(^(NJVFG(D=
MON23RTZ(S(&8#T&2>.V<5[+\!7E;X?3"3[BW\@C_ -W:A_F6H \C^,7_ "57
M6O\ MA_Z(CKU[X#_ /)/'_Z_I?\ T%*\A^,7_)5=:_[8?^B(Z]>^ _\ R3Q_
M^OZ7_P!!2@#5^,7_ "2K6O\ MA_Z/CKY_P#AE_R4G0?^OD?R-?0/QB_Y)5K7
M_;#_ -'QU\_?#+CXDZ#_ -?(_D: /KJOG[]H/5I)-<TK2%?]U!;FY90>"SL5
M&?<!/_'J^@:^</C]:/%XVLKK_EG/8J ?]I7;(_(C\Z *OPL\?>'? UI?MJ5G
M?S7UU(H$EO$C 1@<#+.#G)/;L*]#_P"&@/"G_0/UK_OS%_\ '*X'X6?#OP]X
MYTJ^DU&\OXKVUG"F.VE11Y;*-I(9"<Y#?E7??\,_^%/^@AK7_?Z+_P"-T >&
M>,]5T_7/%^I:II<,T-I=2"54F4*X8J-Q(!(Y;<>O>OI3X2W[ZA\,M'>0DO$C
MP'/HCLJ_^.@5SW_#/_A3_H(:U_W^B_\ C==_X8\.67A308-'L'F>WA+$/.P+
ML68L<D #OCIVH \QUOX]?V/KVHZ9_P (UYWV.ZEM_,^W;=^QBN<>6<9QTR:H
M_P##1?\ U*O_ )4/_M5>@WOPI\%:C?W%]=:+YES<RM-*_P!JF&YV)). ^!R3
MTJO_ ,*=\!?] '_R<G_^+H O_#_QI_PG6@SZG_9_V'RKIK?R_.\W.%5LYVK_
M 'NF.U?-GQ#T6ZT/QWJ]O<HP$MP]Q$Q_CC=BP/ZX/N#7U1X?\-:1X6L)+'1K
M3[+;22F9D\QWRY !.6)/11^50>)_"&B^+[ 6NKVHD*Y\J9#MDB)_NM_3D'TH
M \H\ ?&K3M/T6RT;Q!!+"+6-8([N%=Z[%&%W*.1@ #(SGTKVC3-6T_6K);S3
M+R&[MVZ21.&&?0^A]CS7SWXS^".H:!8W&IZ1>#4+.%2\D3IMF11U/'#8')Z'
MVKD? 7BR\\)>)[6ZAF86DLBI=P[L+)&3@DCU&20>U 'U]7PS7W-7PS0!]>?#
MG1+?0? >DV\" /- EQ,P'+R.H8D^N,X^@%=%?65MJ5C/97<2RV\Z&.2-AD,#
M6;X0GCNO!FB30L&1K&'!'^X 1^=;)( ))P!U- 'Q5KNF-HVOZCIC$L;2YDAW
M'^(*Q /XXS7TYX5\1NOP9M==D8/):Z;(26/WFB#+SGN2E?-?BS4(]6\7ZQ?P
MD&&XO)7C([J6.#^6*^@O#^CS?\,^#3P#YLVE3RH/4OOD7\]PH ^;[:>&35H9
M]2,LL#3J]R5Y=U+9;&2,DC/<5]!Q_'WPC%&D<>F:PB( JJL$0  Z ?O*^?-,
MBM)]6LXK^1H[-YT6=T(#+&6 8@D$ @9ZBOH4?L_^$R 1J.LD'_IM%_\ &Z!G
M*_$3XK>&?&/A"?2[6PU)+SS(Y8'GBC"*P;DDAR?NEAT[US'P:OWLOB;IR*2$
MNDE@?'<%"P_\>5:]2_X9_P#"G_00UK_O]%_\;K4\._!SP[X9UZUUBSN]3EN+
M8L42>6,H25*\@(#WSUH$<7^T)K$OG:1HB.1%L:ZD7/WCG:OY8?\ .L#X'>&;
M;6_%5QJ-Y$LL.F1JZ(PR/-8G:3] K'ZX]*N_M!VCIXJTJ\(.R6Q\H?5'8G_T
M,5-^SWJD-OK>L:9(P66[ACECSW\LMD#\'S^% 'T%1110!Y3^T!_R(=C_ -A.
M/_T5+7F'P5_Y*=8?]<IO_19KT_\ : _Y$.Q_["<?_HJ6O,/@K_R4ZP_ZY3?^
MBS0!]2U\,U]S5\,T ?:/AC_D4]&_Z\8/_1:UY3^T1_R#] _ZZS?R2O5O#'_(
MIZ-_UXP?^BUKRG]HC_D'Z!_UUF_DE '-?L__ /(^7W_8,D_]&Q5V_P ?-8EL
MO"5EID3E?M]Q^\P?O(@SC_OHJ?PKB/V?_P#D?+[_ +!DG_HV*NE_:(M'?3=!
MO!G9%--$?JX4C_T T ><_"KPU!XH\=6MK=H)+2W1KF:,CAPN  ?8LRY]J^L%
M4*H50 H&  . *^8O@?JD.G?$1(IV"_;;62V0G^]E7 _'9C\:^GJ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "FR1I-$\<J*\;@JRL,A@>H(]*=10!XKX
MR^!$5W<2WWA>XCMF<EC93Y$>?]AAT^A&/<"O+K_X9^,].8K-X>O9,=[=1,#_
M -\9KZ[HH ^.H? ?BV=]B>&M6!_V[1T'YL!7K7P=\"^*?#/B"XU'5+-+6SGM
MFB*/*"Y.Y2"%7/H>N.M>UT4 8/BWPEIOC+17T[4%(P=T,R ;XG]1_4=Z^>->
M^#GB[1;EOLMG_:5N#\DUH<D_5#\P/Y_6OJ6B@#Y(/A3X@:OMM9]*UV9$.%6Z
M20(/H7P*]!\$_ N=;J*_\5O&(T(86$3;MWL[#C'L,Y]17NU% #418T5$4*JC
M 4#  ]*\K^-'@[7O%G]B?V)8?:OLWG^=^^C3;N\O;]]AG.T]/2O5J* /&?@[
MX%\2>%?$-_=:UIOV6&6T\M&\^-\MO4XPK$] :]FHHH \#^*'PY\5^(O'=WJ6
ME:5]HM)(XE63[1$F2$ /#,#U]J[OX/\ AK5_"WA*[L=9M/LMS)?/,J>8CY0Q
MQ@'*DCJI_*O0:* "O#/BO\,-<USQ=_:WA_3Q<QW,*_: )HX]LB\9^9AG*A>G
MH:]SHH \(^%OPMUW1_&":KX@T\6T-I&S0 S1R;I3P.%8] 2>>^*]WHHH CN+
M>&[MI;>XB26&5"DD;C*LI&""/3%?/WC#X%:E:7,EUX887EHWS"UDD"RQ^P)P
M&'X@_7K7T+10!\A+X2\<Z7(T<&B:["3][[/!*0?Q48J[;?#/QYK4X,ND7><\
MR7D@3'_?1S^5?6%% %#0[>[M- TZVORC7D-M'',T;$J7"@$@D#N*\B^,'@+Q
M-XI\6VE]HVF_:K:.Q2%G\^-,.))"1AF!Z,/SKVRB@#R[X,^$=<\)V>KQZW8_
M96N)(FB'FH^X -G[K''4=:]1HHH ^;O&/PL\9ZKXRUB_LM&\VUN+N22)_M4*
M[E)X."X(_&O9OAKHU_X?^'^F:7J<'D7D'F^9'O5MNZ5V'*DCH1WKJZ* .6^(
M'@Z/QMX8DT[S%BNHW$UM*PX5P",'V()!_/M7S7J7PW\8Z9<-#+X>OIL' >UB
M,RGW!3/ZU]>T4 >*_ [PQKNA:EJMQJNF7-G#-"BH9UV[F#'L>:U/C1X.U[Q9
M_8G]B6'VK[-Y_G?OHTV[O+V_?89SM/3TKU:B@#QGX.^!?$GA7Q#?W6M:;]EA
MEM/+1O/C?+;U.,*Q/0&O7KZRMM2L9[*\A2:VG0I)&XR&!JQ10!\Y^+O@;K&G
MW4EQX=QJ%D22L+.%FC'IS@-]1S[5R2^&/'\$1T]-*\0) <@Q)%+Y1_+Y:^N:
M* /FKPQ\#O$.JSI)K.W2K/JVY@\K#T"@X'XG\#7T+HFB6'A[2(-,TV 0VT(P
MHZDGNQ/<GN:T** .4^)6C7_B#X?ZGIFF0>?>3^5Y<>]5W;948\L0.@/>O&?!
MWPL\9Z5XRT>_O=&\JUM[N.25_M4+;5!Y. Y)_"OI&B@ KR[XS>$=<\66>D1Z
M)8_:FMY)6E'FHFT$+C[S#/0]*]1HH \3^#_@+Q-X6\6W5]K.F?9;:2Q>%7\^
M-\N9(R!A6)Z*?RKN_B-X%B\<Z"MNDBPW]LQDM96'R@D<JW?:<#IZ \]*[&B@
M#Y$N_A]XUT:]Q_86I&6-OEELXVE'U#)FNFT'X3^,/%5]%-XADN;.S4_-+>2%
MY2.X5220?<X'UZ5]*T4 ?+NJ?!GQC'JUY'IVCF:R6=Q;R&ZA!>/<=IP7!Y&.
MM?2FBQW$.@Z=%=Q^7<I;1K*F0=KA1D<$CKGI5ZB@#Y]^)7PU\7>(/B!J>J:9
MI/GV<_E>7)]IB7=MB13PS ]0>U>C_"7P[JOACP:]AK%K]FNC=O)L\Q7^4A<'
M*DCL:[NB@ HHHH \3^,'@+Q-XI\6VM]HVF_:K:.Q2%G\^-,.))"1AF!Z,/SK
MS[_A3OCW_H!?^3<'_P 77U;10!\I?\*=\>_] +_R<@_^+K0T+X3>-[+Q#IEU
M<:)LAANXI)&^U0G"AP2<!\]!7T[10 5X/^T+86:W&C:BLBK>R*\+)W:-<$'\
M"Q'X^U>C>,?B7H'@WS(+J5[C40H9;.('<<],MT4?YP:^9_$WB34_&?B!]0O<
MO-*1'##&,A%S\J*/Q^I)H WOA+X9/B/QU:-)'NL[ BZG)'!VGY5_%L<>@-?5
ME</\+?!A\'>%52Y0#4KTB:Z]5X^5/^ @G\2:[B@#S?XP^$]?\6:+86^BI%,M
MO,TLL#2!&<XPI7/'&6ZD=:\17PS\0M&S;V^F>((%S]VT24K^:<5];44 ?*ND
M?"?QGK]X&N-/ELXW;,ES?-M(R>3M/S$_A7T9X/\ "MEX.\/PZ59$O@EYIF&&
MED/5C^@ [ "MZB@#RGXT>#M>\6?V)_8EA]J^S>?YW[Z--N[R]OWV&<[3T]*S
M_@[X%\2>%?$-_=:UIOV6&6T\M&\^-\MO4XPK$] :]FHH Y3XE:-?^(/A_J>F
M:9!Y]Y/Y7EQ[U7=ME1CRQ Z ]Z\9\'?"SQGI7C+1[^]T;RK6WNXY)7^U0MM4
M'DX#DG\*^D:* "O+OC-X1USQ99Z1'HEC]J:WDE:4>:B;00N/O,,]#TKU&B@#
MQ/X/^ O$WA;Q;=7VLZ9]EMI+%X5?SXWRYDC(&%8GHI_*O;#R,444 >&>.O@=
M-/>3:CX5:+;(Q=["1@@4G_GF>F/8XQZ]J\U/@KQQI$Y$6A:S%(>"UK"[9_%,
MU]>T4 ?)D7P^\?:W(HDT?4G)QAKQMF/^_A%?2'@/2=2T+P5INEZKY7VNV1D;
MRGW#;N)49QU ('X5T=% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5A^*_"FF^,-$DTW44.TG=%*F-\3]F7_/(K<HH ^2_%GPQ\
M2>%)I'EM'O+$'Y;NV4LN/5AU3\>/0FL?2/%WB'04\O2]8O+:(<^4DI*?]\GC
M]*^S*S;SP[H>HN7OM&T^Z8G):>U1S^HH ^6)_B?XUN(RC^(KL _\\]J'\U -
M>J? 34M2O(-;6_-W,KO'*ES-N8.<,&&X]^%KT^W\+>'K1MUMH.EPMUS'9QJ?
MT%:H 4 *  . !VH \2^*_P *+J_OI?$/AV RS2G==VB?>9O[Z#N3W'7/(SFO
M+?#GC/Q)X'N9HM/N'@5F_?6MPF4+>I4]#[C!K[ JE?:-I>I_\A#3;.[XQ_I$
M"R<?B#0!\I^)OB)XG\9Q)97]R/LY8$6MM'M5V[9');Z$UVWPR^$5_<:C;ZUX
MCMFMK.%A)#:2C#S,.1N7^%1Z'D_2O=+'0](TMMVGZ796AZ9M[=(_Y 5?H *^
M4OC%_P E5UK_ +8?^B(Z^K:* /,/@/\ \D\?_K^E_P#04KT^BB@#X@OO^0A<
M_P#75OYFOL+P5_R(?AW_ +!EM_Z*6MVB@ ZC!KX_^('A[_A&?&VI:<B;;<2>
M;;\<>6_S*!],X_"OL"B@#YR^ WAW^T/%%QK<R9ATZ/;&2.LK@@?DN[\Q7T;1
M10!SOC;PE:>,_#<VF7!$<O\ K+>;&3%(.A^G8CT-?+FM>&_$7@?5E^V03VDT
M3YANX2=C'L4<?_K]17V+3)8HYHVCEC62-N&5QD'ZB@#Y=M/C5XVM8%B:_@N-
MHP'FMU+?F,9_&F+\4O'.L:G:J-0N90DJO]FLX0ID ()7Y!D@],$U]'-X0\,O
M+YK>'=(:3.=YLHR<_7;6E:V-I8ILL[6"W3^[#&$'Z4 3JP90PS@C/(P?RKXW
M\:_\CYXB_P"PG<_^C6K[)HH XWX4_P#),=#_ .N3_P#HQJW?$_\ R*>L_P#7
MC/\ ^BVK5HH ^&:^YJ** /!/CMX.O3JD?B>S@:6U>$176P9,3+G#'_9(P,]M
MON*\O\/>+]?\*O*VBZE):B7'F*%5U;'0E6!&??%?9?6LB3PIX=EN//DT#2WF
M_P">C6<9;\\9H Y_X4:YJ/B'P-#?ZK<FYNFGE4R%0,@'C@ "O"?C%_R576O^
MV'_HB.OJF"WAMHA%;PQQ1KT2-0H'X"I* /,/@/\ \D\?_K^E_P#04K0^)_P[
M3QMIJ7%H4BU>U4B%V.%D7J4;\>A['ZFN_HH ^-XI/$G@+7Q(JW6EZC%Q\RXW
M#T(/#KT]170:K\9/&.JZ<]D]Y#;)(NUWMHMCL/\ >R<?ABOJ&ZL[6^B\J[MH
M;B/^Y+&''Y&J%OX7\/6<OFVVA:9!)G.^*TC4Y^H% 'S-X)^&.M^+[J*5H)+/
M2L@R7<JXRO\ L _>/Z>IKZDTO3;71]+MM.LH_+MK:,1QK[#U]35NB@#PS]HO
M_F6O^WK_ -I5E?L^?\C9JG_7C_[46OHBB@ KY:^-?_)3K_\ ZY0_^BQ7U+10
M!Y3^S_\ \B'??]A.3_T5%63\</ U[J$\/B73+=Y_+B$5W%&"6"@DJX'<<D'T
MP#ZFO;** /COPKXWUSP;/+)I-RJI-CS895WH^.AQV/N*Z7[7X[^+]W':$EK*
M%MS;$\NWB/J3W;T&2?UKZ*N/#'A^[N/M%SH6F33YSYDEI&S9]<D9K2AABMX5
MA@B2*)1A410H ]@* /B?2Y1;:Q93/]V.X1CVX# U]MT44 ?&WC7_ )'SQ%_V
M$[G_ -&M7TO\*?\ DF.A_P#7)_\ T8U=E10 4444 8?BOPIIOC#1)--U%#M)
MW12IC?$_9E_SR*^9_%GPQ\2>%)I'EM'O+$'Y;NV4LN/5AU3\>/0FOK2B@#XS
MTCQ=XAT%/+TO6+RVB'/E)*2G_?)X_2M.?XG^-;B,H_B*[ /_ #SVH?S4 U]3
MWGAW0]1<O?:-I]TQ.2T]JCG]14=OX6\/6C;K;0=+A;KF.SC4_H* /,/@)J6I
M7D&MK?F[F5WCE2YFW,'.&##<>_"UZ_=VL-[9SVEP@>">-HI$/1E88(_(U* %
M4!0  , #M7&^//B+I?@O3Y%,D=QJKK^YM%;G/9G_ +J_S[4 ?+OB#2)-!\07
M^E3'<]K.T6[^\ >#^(P?QKV;]G_PWL@U#Q).G,G^BVQ([#!<_GM'X&O'K.TU
M3QAXH2",M<:CJ,Y+,>[$Y9CZ <D^@%?7^A:/;>']"LM)M!^YM8A&"1@L>['W
M)R3[F@#1KY_^+GBWQ-H7Q!633+F^L+>*VCCC8 B*<\L3@C:V"V._2OH"F2PQ
M3QF.:-)(SU5U!!_ T ?,I^.?C,VQB\VQ#D8\[[,-P]^N,_A7,:'X<U_QWKCB
MUBEN9IY"]Q=RYV(2<EG;\<XZ^@KZJ_X0_P ,F7S?^$<TCS.N_P"Q1Y_/;6O#
M#%;Q+%#$D<:]$10 /P% %'0-&M_#V@V6DVQ+16L0C#-U8]V/N3D_C7F7QS\'
M7NLV%GK>G0-/+9*T=Q&@RQC/(8#J<'.?][/8UZ]10!\6Z%XCU?PS>F\T>^DM
M)V7:Q4 AAZ%2"#^(KZ&^#/BC6?%.CZI<:S>FZEBN55&**NT%<XPH KM[KPSH
M%]<?:+O0]-N)LY\R6TC=L^N2,U>M;.UL8O*M+:&WC_N11A!^0H \D^+7PMN=
M=N3X@T&(/>[<75L#@S8'#+_M8X([X&.>OC.C^(_$G@J_E2PNKG3YLXF@D3@G
M_:1AC/X9K[(JI?:5IVIKMO["UNUQC$\*R#'XB@#YID^-_C5X]BW=HC?WUMES
M^N1^E=M\&?%?B3Q#XDU$ZS<WEY;R6VY)70^4CJPX&!M4D,?KMKU.#PGX<M6W
M6_A_2H6]8[.-3^@K75510JJ%4<  8 H P_&O_(A^(O\ L&7/_HIJ^/;'_D(6
MW_75?YBOM^B@ KXV\:_\CYXB_P"PG<_^C6K[)HH XWX4_P#),=#_ .N3_P#H
MQJW?$_\ R*>L_P#7C/\ ^BVK5HH ^&:^YJ** / _BK\)[W^T[CQ!X=MC<03D
MR7-I$,NCGJR+W!ZD#D'/;IYSH'C?Q-X09[?3=0EMXPQWVTJ!DSW^5AP?I@U]
MA50OM#TG5#G4-+LKL^MQ;I)_,&@#YLG^-OC::/:E[;0'^]';)G_Q[->F_!/7
M]<URRU=]:EO+@^;')#<3J=K @@JIZ8&T' _O5Z!;>&- LF#6NAZ9 P.08K2-
M3G\!6KTH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /C;QK_ ,CYXB_["=S_ .C6KZ7^%/\ R3'0_P#KD_\
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M<@WP"\)-+O%WJZKG.P3QX^GW,_K0!STW[0DDUY;Q6FAQV\#2J)99YRY"9&[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X]\6_AQK'BSQ'IM_HM
MO&Y: PW+O*J!-K94G/)SN(X!Z5K> /A#8>$YDU+4I4O]57E&"_NH#ZJ#U/\
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MT_>(W)1XW^]&XZJ?T_ B@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=BD,S-CN%4$X]\5=TG6-/UVP2^TN[BNK9R0)(SD9'4'N#[&@"[1110 4444
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M1G!//O0![]117@/QP\0ZWI/C6S@TW6-0LH6TY':.VN7C4MYD@R0I S@#GVH
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M^HXKZKT75K77M%M-4LV+6]U&)$SU'J#[@Y'X4 7Z*** "BBB@ HHHH ****
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MJ,?T!H ^5K2WFU/4X+9&+3W4RQAF.<LQQD_B:^R]!T2R\.Z+;:781"."! O
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M/!GBQ[2VW&PN$\^V+')522"I/?!!_#%?6E>$?M%>7]H\.XQYNRXW>NW,>/\
MV:@#7^ GB674-$O-"N9&=K!A) 6Y_=MG*_@1_P"/5:_: _Y$.Q_["<?_ **E
MKB?V?1)_PFNHD9\H:<P;Z^9'C^M=M^T!_P B'8_]A./_ -%2T >$^$?#TOBK
MQ38:-$YC%P_[R0#.Q "S'ZX!Q[XKZAL_AIX.LM.%DN@64R;<-+/&'E;WWGD'
MZ8KP7X*_\E.L/^N4W_HLU]2T ?)7Q-\)0^#O&,MC:;OL4T:W%N&.2JDD%<]\
M%2/IBO5/V?=4DN/#NJ::[[EM+A9$']T2 \?3*$_B:YC]H/\ Y&S2_P#KQ_\
M:C5J_LZ?\S+_ -NO_M6@#W.BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8%=9\./@Y!K^D1:UX@EGCMI_FMK:%@I=?[S'' /8#ZYKQVOM^RM8[&PM[.$
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M3C_]%2UQ7[/MPZ^,=2MA]R33S(?JLB ?^A&NU_: _P"1#L?^PG'_ .BI: /
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M/_HL5Z?^S_\ \B'??]A.3_T5%6QXH^$>@>+-=FU>_N]2CN)5566"2,)A0 ,
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M7V<K"R2TU"/^%HI@A/U#XP?Q- 'LWCGXB:3X3T6=X[N"?4W4K;VT;AFW'HS
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MUVWBKX)_:= T?3?#<EI%):-*]Q/>.RM,7"<_*I_N].P_&@"O^SO_ ,@_7_\
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MWILEO$DBLL$DA?+*0, H!W]:]GH ^=_V@_\ D;-+_P"O'_VHU:O[.G_,R_\
M;K_[5K>^*7PSUGQOKEE>Z;<V$4<%MY3"YD=23N)XVH>.:N_"CX?ZMX%_M?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A:YXS\.
M^&]ZZKJ]K!,B[C!OW2X[?(/FY^E;M>(_%3X;>(O%'C=+_1[-);9[6-9)GF1
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M%O@$ZW"7/B:^C:)>?LEH2=WLSD#'T _&O;[:VAL[:*VMHDA@B4)'&@PJJ.@
MH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHIDTT<$+RRNJ1H-S,QP * 'T5E_\)'HO_04M
M?^_HH_X2/1?^@I:_]_12YEW-/95/Y7]QJ45E_P#"1Z+_ -!2U_[^BC_A(]%_
MZ"EK_P!_11S+N'LJG\K^XU****9F%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !114<\\5M"\TTBQQH,L['  H#<DHK+_ .$CT7_H*6O_ ']%'_"1Z+_T
M%+7_ +^BES+N:>RJ?RO[C4HK+_X2/1?^@I:_]_12CQ%HS$ :G:DG@#S!1S+N
M'LJG\K^XTZ***9F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 445F-XAT='*-J=J&4X(,@X-)M+<J,92V5S
M3HK+_P"$CT7_ *"EK_W]%'_"1Z+_ -!2U_[^BCF7<KV53^5_<:E%9?\ PD>B
M_P#04M?^_HJ_;W$-U"LT$BR1/]UU.0:$T]B90E'5HEHHHIDA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !67XC_P"1;U'_
M *]W_E6I67XC_P"1;U'_ *]W_E2ELS2E_$CZH\5HHHK@/JPHHHH ]^HHHKT#
MY **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q3_P BOJ'_ %R/\ZV*
MQ_%/_(KZA_UR/\Z4MF:4?XD?5'C-%%%<!]6%20?\?$7^^/YU'4D'_'Q%_OC^
M= GL>]4445Z!\B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5X3?_\ (0N?^NK?S->[5X3?_P#(0N?^NK?S
M-<]?H>ME6\OD5Z***YSV0KV+P?\ \BI8?[C?^A&O':]B\'_\BI8?[C?^A&MJ
M'Q'FYI_"7K^C-RBBBNH\(**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *R_$?\ R+>H_P#7N_\ *M2LOQ'_ ,BWJ/\ U[O_
M "I2V9I2_B1]4>*T445P'U84444 >_4445Z!\@%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !6/XI_P"17U#_ *Y'^=;%8_BG_D5]0_ZY'^=*6S-*/\2/
MJCQFBBBN ^K"I(/^/B+_ 'Q_.HZD@_X^(O\ ?'\Z!/8]ZHHHKT#Y$**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KPF__P"0A<_]=6_F:]VKPF__ .0A<_\ 75OYFN>OT/6RK>7R*]%%%<Y[
M(5[%X/\ ^14L/]QO_0C7CM>Q>#_^14L/]QO_ $(UM0^(\W-/X2]?T9N4445U
M'A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !67XC_ .1;U'_KW?\ E6I67XC_ .1;U'_KW?\ E2ELS2E_$CZH\5HHHK@/
MJPHHHH ]^HHHKT#Y **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q3_
M ,BOJ'_7(_SK8K'\4_\ (KZA_P!<C_.E+9FE'^)'U1XS1117 ?5A4D'_ !\1
M?[X_G4=20?\ 'Q%_OC^= GL>]4445Z!\B%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X3?_P#(0N?^NK?S
M->[5X3?_ /(0N?\ KJW\S7/7Z'K95O+Y%>BBBN<]D*]B\'_\BI8?[C?^A&O'
M:]B\'_\ (J6'^XW_ *$:VH?$>;FG\)>OZ,W****ZCP@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K+\1_\BWJ/_7N_P#*
MM2LOQ'_R+>H_]>[_ ,J4MF:4OXD?5'BM%%%<!]6%%%% 'OU%%%>@?(!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5C^*?^17U#_KD?YUL5C^*?\ D5]0
M_P"N1_G2ELS2C_$CZH\9HHHK@/JPJ2#_ (^(O]\?SJ.I(/\ CXB_WQ_.@3V/
M>J***] ^1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *\)O_P#D(7/_ %U;^9KW:O";_P#Y"%S_ -=6_F:Y
MZ_0];*MY?(KT445SGLA7L7@__D5+#_<;_P!"->.U[%X/_P"14L/]QO\ T(UM
M0^(\W-/X2]?T9N4445U'A!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !67XC_Y%O4?^O=_Y5J5E^(_^1;U'_KW?^5*6S-*
M7\2/JCQ6BBBN ^K"BBB@#WZBBBO0/D HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *Q_%/_(KZA_UR/\ .MBL?Q3_ ,BOJ'_7(_SI2V9I1_B1]4>,T445
MP'U85)!_Q\1?[X_G4=20?\?$7^^/YT">Q[U1117H'R(4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A-_\
M\A"Y_P"NK?S->[5X3?\ _(0N?^NK?S-<]?H>ME6\OD5Z***YSV0KV+P?_P B
MI8?[C?\ H1KQVO8O!_\ R*EA_N-_Z$:VH?$>;FG\)>OZ,W****ZCP@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K+\1_\
MBWJ/_7N_\JU*R_$?_(MZC_U[O_*E+9FE+^)'U1XK1117 ?5A1110![]1117H
M'R 4444 %<KXE\7R:!J,=JMFLP>$2;C)MQDD8Z>U=57F'Q&_Y&&W_P"O1?\
MT-ZSJR:C='7@J<:E7EFKHN?\++F_Z!D?_?X_X4?\++F_Z!D?_?X_X5PE%<_M
M9]SV?J.'_E_,[O\ X67-_P! R/\ [_'_  K?\+^*'\0R7*/:K!Y(4\/NSG/M
M[5Y+7=_#3_CXU'_<3^;5=.I)R2;.?%X2C3HRE&.IZ'11172>&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5C^*?^17U#_KD?YUL5C^*?\ D5]0_P"N1_G2ELS2C_$CZH\9HHHK@/JPJ2#_
M (^(O]\?SJ.I(/\ CXB_WQ_.@3V/>J***] ^1"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\)O_P#D(7/_
M %U;^9KW:O";_P#Y"%S_ -=6_F:YZ_0];*MY?(KT445SGLA7L7@__D5+#_<;
M_P!"->.U[%X/_P"14L/]QO\ T(UM0^(\W-/X2]?T9N4445U'A!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !67XC_Y%O4?
M^O=_Y5J5E^(_^1;U'_KW?^5*6S-*7\2/JCQ6BBBN ^K"BBB@#WZBBBO0/D H
MHHH *\P^(W_(PV__ %Z+_P"AO7I]>8?$;_D8;?\ Z]%_]#>LJWPG?EW\?Y'(
M4445R'T 5W?PT_X^-1_W$_FU<)7=_#3_ (^-1_W$_FU:4OC1R8[_ '>7]=3T
M.BBBNP^;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *Q_%/_(KZA_UR/\ZV*Q_%/_(KZA_UR/\ .E+9FE'^
M)'U1XS1117 ?5A4D'_'Q%_OC^=1U)!_Q\1?[X_G0)['O5%%%>@?(A1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\)O_\ D(7/_75OYFO=J\)O_P#D(7/_ %U;^9KG
MK]#ULJWE\BO1117.>R%>Q>#_ /D5+#_<;_T(UX[7L7@__D5+#_<;_P!"-;4/
MB/-S3^$O7]&;E%%%=1X04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **9++'#$TDKJD:C+,QP /4FJ7]NZ1_T%;'_P(3_&E=%*,GLC0HK/_MW1
M_P#H*V/_ ($)_C1_;NC_ /05L?\ P(3_ !HNA^SGV9H45G_V[H__ $%;'_P(
M3_&KX((R#D'N*+IB<91W0M%%%,D**** "BBB@ HHHH **** "BBB@ K'\4_\
MBOJ'_7(_SK8K'\4_\BOJ'_7(_P Z4MF:4?XD?5'C-%%%<!]6%20?\?$7^^/Y
MU'4D'_'Q%_OC^= GL>]4445Z!\B%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5X3?_P#(0N?^NK?S->[5X3?_ /(0N?\ KJW\S7/7Z'K95O+Y%>BBBN<]
MD*]B\'_\BI8?[C?^A&O':]B\'_\ (J6'^XW_ *$:VH?$>;FG\)>OZ,W****Z
MCP@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#XC?\C#;_P#7HO\ Z&]>GUYA\1O^1AM_^O1?_0WK*M\)WY=_'^1R%%%%<A]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KPF__ .0A<_\ 75OYFO=J\)O_ /D(7/\ UU;^9KGK
M]#ULJWE\BO1117.>R%>Q>#_^14L/]QO_ $(UX[7L7@__ )%2P_W&_P#0C6U#
MXCS<T_A+U_1FY11174>$%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &7XC_Y%O4?^O=_Y5XK7M7B/_D6]1_Z]W_E7BM<U
M?='MY7_#EZA1116!Z@5[U!_Q[Q?[@_E7@M>]0?\ 'O%_N#^5=%#J>1FNT/G^
MA)11170>.%%%% !1110 4444 %%%% !1110 5C^*?^17U#_KD?YUL5C^*?\
MD5]0_P"N1_G2ELS2C_$CZH\9HHHK@/JPJ2#_ (^(O]\?SJ.I(/\ CXB_WQ_.
M@3V/>J***] ^1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\)O_P#D(7/_ %U;^9KW:O";_P#Y"%S_ -=6
M_F:YZ_0];*MY?(KT445SGLA7L7@__D5+#_<;_P!"->.U[%X/_P"14L/]QO\
MT(UM0^(\W-/X2]?T9N4445U'A!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ->\?_H(KPVO<M)_Y UC_P!>\?\ Z"*WH;L\K-?AB7****Z3Q0HHHH ****
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M "BBB@ K'\4_\BOJ'_7(_P ZV*Q_%/\ R*^H?]<C_.E+9FE'^)'U1XS1117
M?5A4D'_'Q%_OC^=1U)!_Q\1?[X_G0)['O5%%%>@?(A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,@:Q_Z]X_\ T$5O0W9Y6:_#$N4445TGBA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% &7XC_Y%O4?^O=_Y5XK7M7B/_D6]1_Z]
MW_E7BM<U?='MY7_#EZA1116!Z@5[U!_Q[Q?[@_E7@M>]0?\ 'O%_N#^5=%#J
M>1FNT/G^A)11170>.%%%% !1110 4444 %%%% !1110 5C^*?^17U#_KD?YU
ML5C^*?\ D5]0_P"N1_G2ELS2C_$CZH\9HHHK@/JPJ2#_ (^(O]\?SJ.I(/\
MCXB_WQ_.@3V/>J***] ^1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\)O_P#D(7/_ %U;^9KW:O";_P#Y
M"%S_ -=6_F:YZ_0];*MY?(KT445SGLA7L7@__D5+#_<;_P!"->.U[%X/_P"1
M4L/]QO\ T(UM0^(\W-/X2]?T9N4445U'A!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &!XV_Y%"^_[9_\
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M_75?YBO=JVI3<KW/.QV'A1<>3J%%%%:G %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A-__ ,A"
MY_ZZM_,U[M7A-_\ \A"Y_P"NK?S-<]?H>ME6\OD5Z***YSV0KV+P?_R*EA_N
M-_Z$:\=KV+P?_P BI8?[C?\ H1K:A\1YN:?PEZ_HS<HHHKJ/""BBB@ HHHH
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MK2E\:.3'?[O+^NIZ'11178?-A1110!3U;_D#7W_7O)_Z":\-KW+5O^0-??\
M7O)_Z":\-KFK[H]K*OAD%%%%8'JA7N6D_P#(&L?^O>/_ -!%>&U[EI/_ "!K
M'_KWC_\ 016]#=GE9K\,2Y11172>*%%%% 'G'Q)_Y"-C_P!<F_G7$5V_Q)_Y
M"-C_ -<F_G7$5QU?C9]+@O\ =XA11169U'7_  Y_Y&&X_P"O1O\ T-*]/KS#
MX<_\C#<?]>C?^AI7I]=='X3Y_,?X_P @HHHK4X HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH R_$?_(MZC_U[O_*O%:]J\1_\BWJ/_7N_\J\5KFK[H]O*_P"'+U"B
MBBL#U KWJ#_CWB_W!_*O!:]Z@_X]XO\ <'\JZ*'4\C-=H?/]"2BBBN@\<***
M* "BBB@ HHHH **** "BBB@ K'\4_P#(KZA_UR/\ZV*Q_%/_ "*^H?\ 7(_S
MI2V9I1_B1]4>,T445P'U85)!_P ?$7^^/YU'4D'_ !\1?[X_G0)['O5%%%>@
M?(A1110 4444 %%%% !1110 4444 %%%% &!XV_Y%"^_[9_^C%KR"O7_ !M_
MR*%]_P!L_P#T8M>05RU_B/=RO^"_7]$%%%%8GI%BP_Y"%M_UU7^8KW:O";#_
M )"%M_UU7^8KW:NBAU/&S7>/S"BBBN@\D**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O";__ )"%
MS_UU;^9KW:O";_\ Y"%S_P!=6_F:YZ_0];*MY?(KT445SGLA7L7@_P#Y%2P_
MW&_]"->.U[%X/_Y%2P_W&_\ 0C6U#XCS<T_A+U_1FY11174>$%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 8'C;_D4+[_MG_Z,6O(*]?\ &W_(H7W_ &S_ /1BUY!7+7^(]W*_X+]?T044
M45B>D6+#_D(6W_75?YBO=J\)L/\ D(6W_75?YBO=JZ*'4\;-=X_,****Z#R0
MHHHH \D\=?\ (UW/^XG_ *"*YRNC\=?\C7<_[B?^@BN<KAG\3/J<-_!AZ(**
M**DV/0_AI_Q[ZC_OQ_R:N[KA/AI_Q[ZC_OQ_R:N[KLI? CYO'?[Q+^N@4445
MH<@5E^(_^1;U'_KW?^5:E9?B/_D6]1_Z]W_E2ELS2E_$CZH\5HHHK@/JPHHH
MH ]^HHHKT#Y **** "O,/B-_R,-O_P!>B_\ H;UZ?7F'Q&_Y&&W_ .O1?_0W
MK*M\)WY=_'^1R%%%%<A] %=W\-/^/C4?]Q/YM7"5W?PT_P"/C4?]Q/YM6E+X
MT<F._P!WE_74]#HHHKL/FPHHHH IZM_R!K[_ *]Y/_037AM>Y:M_R!K[_KWD
M_P#037AM<U?='M95\,@HHHK ]4*]RTG_ ) UC_U[Q_\ H(KPVO<M)_Y UC_U
M[Q_^@BMZ&[/*S7X8ERBBBND\4**** /./B3_ ,A&Q_ZY-_.N(KM_B3_R$;'_
M *Y-_.N(KCJ_&SZ7!?[O$****S.HZ_X<_P#(PW'_ %Z-_P"AI7I]>8?#G_D8
M;C_KT;_T-*]/KKH_"?/YC_'^04445J< 4A( ))P!U)I:CG_X]Y?]P_RH!%/^
MW=(_Z"MC_P"!"?XT?V[H_P#T%;'_ ,"$_P :\1HKF]N^Q[?]E0_F9[=_;NC_
M /05L?\ P(3_ !H_MW2/^@K8_P#@0G^->(T4>W?8/[*A_,SWN*6.:-98G5XV
M&593D$>H-/K+\.?\BWIW_7NG\JU*Z$[JYXTX\LFNP4444R0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,OQ'_R+>H_]
M>[_RKQ6O:O$?_(MZC_U[O_*O%:YJ^Z/;RO\ AR]0HHHK ]0*]Z@_X]XO]P?R
MKP6O>H/^/>+_ '!_*NBAU/(S7:'S_0DHHHKH/'"BBB@ HHHH **** "BBB@
MHHHH *Q_%/\ R*^H?]<C_.MBL?Q3_P BOJ'_ %R/\Z4MF:4?XD?5'C-%%%<!
M]6%20?\ 'Q%_OC^=1U)!_P ?$7^^/YT">Q[U1117H'R(4444 %%%% !1110
M4444 %%%% !1110!@>-O^10OO^V?_HQ:\@KU_P ;?\BA??\ ;/\ ]&+7D%<M
M?XCW<K_@OU_1!1116)Z18L/^0A;?]=5_F*]VKPFP_P"0A;?]=5_F*]VKHH=3
MQLUWC\PHHHKH/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KPF__P"0A<_]=6_F:]VKPF__ .0A
M<_\ 75OYFN>OT/6RK>7R*]%%%<Y[(5[%X/\ ^14L/]QO_0C7CM>Q>#_^14L/
M]QO_ $(UM0^(\W-/X2]?T9N4445U'A!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^8_Q_D%%%%:G %1S_P#'O+_N'^525'/_ ,>\O^X?Y4#6YX+1117GGUP4444
M>U>'/^1;T[_KW3^5:E9?AS_D6]._Z]T_E6I7?'9'RE7^)+U84444S,**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BO+/B%_R,B_]>Z_S-<I6$JUG:QZE++?:04^;?R_X)[]17@-%+V_D:?V5
M_?\ P_X)[]17GGPT_P"/C4?]Q/YM7H=;0ES*YYN(H^QJ.%[V"BBBJ,0HHHH
M**** "BBB@ HHHH **** "BBB@#+\1_\BWJ/_7N_\J\5KVKQ'_R+>H_]>[_R
MKQ6N:ONCV\K_ (<O4****P/4"O>H/^/>+_<'\J\%KWJ#_CWB_P!P?RKHH=3R
M,UVA\_T)****Z#QPHHHH **** "BBB@ HHHH **** "L?Q3_ ,BOJ'_7(_SK
M8K'\4_\ (KZA_P!<C_.E+9FE'^)'U1XS1117 ?5A4D'_ !\1?[X_G4=20?\
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MW/,.EHKFO^$\\/\ _/U)_P!^6_PH_P"$\\/_ //U)_WY;_"@#B?'7_(UW/\
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M3SP__P _4G_?EO\ "N@\DZ6BN:_X3SP__P _4G_?EO\ "C_A//#_ /S]2?\
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M2T5S7_">>'_^?J3_ +\M_A1_PGGA_P#Y^I/^_+?X4 =+17-?\)YX?_Y^I/\
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MYX?_ .?J3_ORW^% '2T5S7_">>'_ /GZD_[\M_A1_P )YX?_ .?J3_ORW^%
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MWY;_  H_X3SP_P#\_4G_ 'Y;_"@#I:*YK_A//#__ #]2?]^6_P */^$\\/\
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M7_&C_A#?$'_0-D_[[7_&O9J* /&?^$.\0?\ 0-D_[[7_ !H_X0WQ!_T#9/\
MOM?\:]FHH \9_P"$-\0?] V3_OM?\:/^$-\0?] V3_OM?\:]FHH \9_X0WQ!
M_P! V3_OM?\ &C_A#?$'_0-D_P"^U_QKV:B@#QG_ (0WQ!_T#9/^^U_QH_X0
MWQ!_T#9/^^U_QKV:B@#QG_A#?$'_ $#9/^^U_P :/^$-\0?] V3_ +[7_&O9
MJ* /&?\ A#?$'_0-D_[[7_&C_A#?$'_0-D_[[7_&O9J* /&?^$-\0?\ 0-D_
M[[7_ !H_X0WQ!_T#9/\ OM?\:]FHH \9_P"$-\0?] V3_OM?\:/^$-\0?] V
M3_OM?\:]FHH \9_X0WQ!_P! V3_OM?\ &C_A#?$'_0-D_P"^U_QKV:B@#QG_
M (0WQ!_T#9/^^U_QH_X0WQ!_T#9/^^U_QKV:B@#QG_A#?$'_ $#9/^^U_P :
M/^$-\0?] V3_ +[7_&O9J* /&?\ A#?$'_0-D_[[7_&C_A#?$'_0-D_[[7_&
MO9J* /&?^$-\0?\ 0-D_[[7_ !H_X0WQ!_T#9/\ OM?\:]FHH \9_P"$-\0?
M] V3_OM?\:/^$-\0?] V3_OM?\:]FHH \9_X0WQ!_P! V3_OM?\ &C_A#?$'
M_0-D_P"^U_QKV:B@#QG_ (0[Q!_T#9/^^U_QH_X0WQ!_T#9/^^U_QKV:B@#Q
MG_A#?$'_ $#9/^^U_P :/^$-\0?] V3_ +[7_&O9J* /&?\ A#?$'_0-D_[[
M7_&C_A#?$'_0-D_[[7_&O9J* /&?^$-\0?\ 0-D_[[7_ !H_X0WQ!_T#9/\
MOM?\:]FHH \9_P"$-\0?] V3_OM?\:/^$-\0?] V3_OM?\:]FHH \9_X0WQ!
M_P! V3_OM?\ &C_A#?$'_0-D_P"^U_QKV:B@#QG_ (0WQ!_T#9/^^U_QH_X0
MWQ!_T#9/^^U_QKV:B@#QG_A#?$'_ $#9/^^U_P :/^$-\0?] V3_ +[7_&O9
MJ* /&?\ A#?$'_0-D_[[7_&C_A#?$'_0-D_[[7_&O9J* /&?^$-\0?\ 0-D_
M[[7_ !H_X0WQ!_T#9/\ OM?\:]FHH \9_P"$-\0?] V3_OM?\:/^$-\0?] V
M3_OM?\:]FHH \9_X0WQ!_P! V3_OM?\ &C_A#O$'_0-D_P"^U_QKV:B@#QG_
M (0WQ!_T#9/^^U_QH_X0WQ!_T#9/^^U_QKV:B@#QG_A#?$'_ $#9/^^U_P :
M/^$-\0?] V3_ +[7_&O9J* /&?\ A#?$'_0-D_[[7_&C_A#?$'_0-D_[[7_&
MO9J* /&?^$-\0?\ 0-D_[[7_ !H_X0WQ!_T#9/\ OM?\:]FHH \9_P"$-\0?
M] V3_OM?\:/^$-\0?] V3_OM?\:]FHH \9_X0WQ!_P! V3_OM?\ &C_A#?$'
M_0-D_P"^U_QKV:B@#QG_ (0WQ!_T#9/^^U_QH_X0WQ!_T#9/^^U_QKV:B@#Q
MG_A#?$'_ $#9/^^U_P :/^$-\0?] V3_ +[7_&O9J* /&?\ A#?$'_0-D_[[
M7_&C_A#?$'_0-D_[[7_&O9J* /&?^$.\0?\ 0-D_[[7_ !H_X0WQ!_T#9/\
MOM?\:]FHH \9_P"$-\0?] V3_OM?\:/^$-\0?] V3_OM?\:]FHH \9_X0[Q!
M_P! V3_OM?\ &M/P[X7UJS\065Q<6#QPQR LQ9>!^=>IT4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% '">.]!U#5;^UEL+,S!8B
MKLI YSQU-<I_PAOB#_H&R?\ ?:_XU[-10!XS_P (;X@_Z!LG_?:_XT?\(;X@
M_P"@;)_WVO\ C7LU% 'C/_"&^(/^@;)_WVO^-'_"&^(/^@;)_P!]K_C7LU%
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M_P"@;)_WVO\ C7LU% 'C/_"&^(/^@;)_WVO^-'_"&^(/^@;)_P!]K_C7LU%
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M_P"@;)_WVO\ C7LU% 'C/_"&^(/^@;)_WVO^-'_"&^(/^@;)_P!]K_C7LU%
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M_&O9J* /&?\ A#?$'_0-D_[[7_&C_A#?$'_0-D_[[7_&O9J* /&?^$-\0?\
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M_&O9J* /&?\ A#?$'_0-D_[[7_&C_A#?$'_0-D_[[7_&O9J* /&?^$-\0?\
M0-D_[[7_ !H_X0WQ!_T#9/\ OM?\:]FHH \9_P"$-\0?] V3_OM?\:/^$-\0
M?] V3_OM?\:]FHH \9_X0WQ!_P! V3_OM?\ &C_A#?$'_0-D_P"^U_QKV:B@
M#QG_ (0WQ!_T#9/^^U_QH_X0WQ!_T#9/^^U_QKV:B@#QG_A#?$'_ $#9/^^U
M_P :/^$-\0?] V3_ +[7_&O9J* /&?\ A#?$'_0-D_[[7_&C_A#?$'_0-D_[
M[7_&O9J* /&?^$-\0?\ 0-D_[[7_ !H_X0WQ!_T#9/\ OM?\:]FHH \9_P"$
M-\0?] V3_OM?\:/^$-\0?] V3_OM?\:]FHH \9_X0WQ!_P! V3_OM?\ &C_A
M#?$'_0-D_P"^U_QKV:B@#QG_ (0WQ!_T#9/^^U_QH_X0WQ!_T#9/^^U_QKV:
MB@#QG_A#?$'_ $#9/^^U_P :/^$-\0?] V3_ +[7_&O9J* /)='\*:Y;:W83
MS:>ZQ1W,;NQ9> &!)ZUZU110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%>3_ !=^)<WAI!H6C2A=4F3=-..3;H>@'^T?T'/<
M&@#OM9\7>'_#S!-5U>UM9",^4[Y?'KM&3C\*R+;XJ^![N7RX_$$"MG&98Y(Q
M^;*!7RU8:=JOB/5?L]E!<7]].2Q RS-ZLQ/ZDULZ]\.?%?ANQ^VZGI3I:@#=
M+'(L@3_>VDX^IXH ^N+>Y@N[=+BVFCFA<922)PRL/4$<&I:^0_!'CO5/!6II
M+;2-+8NP^T6C'Y9!W(]&]#^>17UCI>I6NL:7;:C92"2VN8Q)&WL?7T/8CUH
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M7_Q5?'$<;ROLC1G8] HR:F^PW?\ SZS_ /?LT ?8/_":^%/^AGT7_P #XO\
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M/^$U\*?]#/HO_@?%_P#%5Y;^T-!--_PCGE1/)C[3G8I./]57B'V&[_Y]9_\
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MUCX<LS:!24:ZN5#29''RIR!^.?H*\?U#4;W5;Q[O4+J:ZN'^]),Y9C^)[>U
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M/0*,F@#['_X37PI_T,^B_P#@?%_\51_PFOA3_H9]%_\  ^+_ .*KX^^PW?\
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M10 4444 %>-'X%Q:CXNU/4M3O_+TV:Z>:&VMA\[*QW8+$849)& #QW%>RT4
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M_HU:]S_: _Y$.Q_["<?_ **EKPSP5_R/GAW_ +"=M_Z-6@9]DT444""BBB@
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M:^?OA9\*]0O]6MM<URU>VT^W<2Q0S+M>=QRORGHN>>>O2OHF@ HHHH ****
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MY5OS&W\J]TH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M8GC&-I? ^OQH,LVFW"@>YC:OC2OM^\MEO+&XM7^Y-&T;<9X(Q_6OB2X@DM;F
M6WF7;+$Y1QZ$'!H ^N/AIS\-]!_Z]1_,UU5>?_!>_6]^&=C&#E[626!_KO+#
M]&%>@4 >%_M%D;O#:Y&1]I)'_?JO._A>A?XEZ$%Z_:,_DI-=?^T#J"S^*]-L
M5.3;6F]O8NQX_)0?QK(^".GF]^)%O/MRMG!+,3CCE=@_5Z!GU!1110(****
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MW:RK+;S()(Y%/#*1D$?A4U>:_ S4);[X=B*5F86=W);H2?X<*^/_ !\UZ50
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MR'W)Z#V["OI;X-^%!X=\&QWLZ8O=3Q<29'*QX_=K^1S]6- ST6BBB@04444
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M/YD1AT+G^(CT''N:]DH **** "BBB@ HHHH \,_:+_YEK_MZ_P#:5<+\'?\
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M[D,MQ<2-)(Y_B8G)-?2OP7\)3>'/"CWUY&8[S4V64HPP4C .P'WY)_X$*SO
MWP2L]$N(]1\02Q7]Y&0T=N@S#&?4Y&7/U 'L:];H **** "BBB@#D/B7X6;Q
M;X+NK*!=UY"1<6P]74'Y?Q!(_$5\G12W%A>I+&7AN;>0,IQAD=3D?B"*^X*\
MN^(/P=M/%%S+JFCRQV.IOEI5<'RIV]3C[K>I .>X[T :'@WXL^'_ !#IT*ZA
M?0:=J:J%FBN'$:,WJC$X(/IG/\ZL>+OBGX=\-Z9*]M?VVH:@5Q#;6TH?YNVX
MC(4=^>?2O -1^&'C/3)6230;J8+_ !VP\X'Z;<FHK#X;>,M1D5(?#M]'DXS<
M1^2!_P!]XH YRZN9KV\FNIW+SSR-)(W=F8Y)_,U]4_"GPM+X6\$00W49CO;M
MC<SJ1RA8 *I^B@9'KFN;\ ?!>WT&ZAU77Y8[N_B(>&WCR8HFZ@DG[S#\A[]:
M];H **** "BBB@ KYH^-OBS^V_%0TBVDS9Z7E#@\-,?OG\.%^H/K7T+X@FU.
M#0;V31K7[5J7E$6\6]5!<\ DL0,#.>O:OF:3X0_$":1Y)-$9W<EF9KR DD]2
M?GH N?!GPJ/$'C);VXCW66F 3MD<-)GY%_,%O^ U]/UR'PV\)'P?X/M[*>-5
MOYB9[O!!^<_PY'7:,#TX)[UU] !1110 4444 %<'\8-"FU[X>W2VT9DGLY%N
MT11DMMR&Q_P%F/X5WE% 'PR"58$$@@Y!':OJ?P+\4-%\3:3!'?7T%GJR(%GA
MG<()&'\2$\$'KCJ/UKF/'/P.CU*[EU+PS+#:RR$M)92\1D]RA'W?IC'TKRB^
M^&WC+3W*S>';Y\=[>/S@?^^,T ?3FM^./#?A^R:YOM7M> 2L44@>1_95!R?K
MT]37RAXGUZ;Q-XEO]9G38UU+N"9SM4 !1GOA0!5^T^'GC"]DV1>&]24YQ^^@
M,0_-\"O2?!WP'N/M,5YXJFC6)2&^PP-N+^SN. /9<Y]10!L_ /P]-8:!?:U<
M1E/[0=4@![QIGYOH6)'_  &O7Z9##%;P1P01I'%&H5$0850.  .PI] !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R_\9O"TF@^,YM0B
MB(L=3)G1@.!)_&OUS\W_  *OJ"LCQ+X;T[Q7HLNEZG%OB?YD=>&B<=&4]B,_
MS% 'SS\(O'UOX1U6>QU.1DTN]P3)C(AD'1B!V(X/X>E>[:I\0O"FE:6U_+K=
ME,FW<D=O,LDDGLJ@Y_H.^*\&\1_!?Q3HURYL+?\ M6SS\DMN0'Q_M(3G/TR*
MYV#X?^+[B8Q)X;U,,#C,ENR+^; "@"EXGU^X\3^)+W6+D;7N9,JF?N*!A5_
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M(+!GMH KD="YY;'MDFN6\ _"C3/!KK?W,@OM6Q@3%<)%GKL'KVW'GZ<UZ%0
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MA!$5U DZ ]=K*&'\Z +5%?-'Q6\4>(-.^)6KVECKNIVMM'Y.R&"[D1%S"A.
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M: /=Z*\]^$_CRZ\;:/=KJ*1B_L759'C&%D5L[3CL?E8'Z5Z%0 4444 %%%%
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MEX ^(=OX%\'ZF$A%SJ5S=#R(6.%4!.7;V]N] SZ;HKY'U/XG>,M4F:237KJ
M-T2U;R54>@VX/YG-6=#^+7C#1;A7;5)+^$8W0WI\P,/]X_,/SH$?5]%<YX+\
M8V'C70QJ%F#'(AV3V['+1-Z>X/8]ZN^*+RXT[PEK-]:R>7<VUC/-$^ =KK&Q
M!P>#R!UH UJ*^4O^%Q>/?^@]_P"2<'_Q%?4>F327&E6<TK;I)($=CC&25!-
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MUDN0;B^F!\BT1L%_<G^%??\ +- '6T5\K:U\8?&.KS,8]1_L^#/RQ6:A<?\
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MYW[F-]VWR]OWE.,;CT]:Y_X4_$/Q5XE\;1Z?J^J?:;4V\CF/[/$G(Q@Y50:
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MYBNJKE?B5_R3?7O^O5OYB@#Y#KZ-C_9^\,","34M79_59(@/RV'^=?.5?<U
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M;3)I+C2K.:5MTDD".QQC)*@FOGG]H#_D?+'_ +!D?_HV6@"_^SS_ ,AS6O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY+;S.N);2W@D$B ]G9AP2.P!([YKVNOG/X'>,+C3_$(\.7,S-8WP8P*QXBE
M)X] P!&/7%?1E !1110!\B_$W_DI.O?]?)_D*]D_9_\ ^1#OO^PG)_Z*BKQO
MXF_\E)U[_KY/\A7LG[/_ /R(=]_V$Y/_ $5%0,]6HHHH$?-OQ^C5/'UHRC!?
M38V;W/F2#^0%3?L^LX\::B@'[LZ>Q8^XD3'\S7/_ !@UB+5_B/?F%@T5H%M0
MP[E1\W_CQ8?A7;?L\Z8_FZUJS+B,*ELC8ZGEF'X?)^= '>_&+_DE6M?]L/\
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M@@A<@@]Z^:_@[_R571?^V_\ Z(DKZMH \I_: _Y$.Q_["<?_ **EKQOX9?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"RD>\VL]M;)&6&QC@E0.*\Z^%-E::C\2M(M+ZUANK:3SM\,\8=&Q"Y&0>#R
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M^V__ *(DH ^K:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?X1Q_=K0^!O@_4M-UC4M6U;3+NR>.%8(%NH6C+;CEB P'3:!G_:H ]QHHHH
M^0_B1HG]@>/]6M%3;"\WGP@=-C_, /IDC\*];^ &N_:O#]_HDCY>SE$T0/\
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ME//B.Z*#WW=&;T R/7T/@2P:WK3(%BU"_/\ #A7E_+K75:%\'_&&M2*9-/\
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M3KA(XXU+,[&-@  .22>U 'QE7VSHW_(#T_\ Z]H__017R'_PA7BO_H6-:_\
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M^(-1^)6KW=CH6IW5M)Y.R:"TD=&Q"@.& P>01^% CL_V>O\ D7]9_P"OI/\
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M1D -Q_M4 >&Z/ILNL:U9:;#GS+J=(5QVW$#-?:EM;Q6EK#;0KMBA01HOHH&
M/RKYY^#W@C5XO'4>H:MI%]9P64+RHUU;O&&D/R@#<!DX8G\*^BZ "OF#XVZ)
M_97C^6[1-L.HQ+<#'3>/E;]1G_@5?3]>7_&[PO=:]X:L[O3K.:ZO;*? C@C+
MN8W&&P!R>0I_.@#D?V?==\G4]3T&1_EGC%S"#_>7A@/<@@_\!KU3XE?\DWU[
M_KU;^8KY]\%Z+XK\.>,=+U4^&M:6.&<"4_8)?]6WRO\ P_W2:^A_B#:W%[X
MUJVM8)9YY+8JD42%F8Y'  Y- 'Q]7W-7QM_PA7BO_H6-:_\  "7_ .)K[)H
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MVMM'YV^:>TD1%S"X&21@<D#\: /I>BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img29677477_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_5.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2/"4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M  !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$
M8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,
M   #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M  !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!Y
M    "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G
M4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M            4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN
M=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E
M8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R
M;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (
M 3A"24T$)@      #@             _@   .$))30/R       *  #_____
M__\  #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          (X0DE- _4
M $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $
M6@    8       $ -0    $ +0    8       $X0DE- _@      '   /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z   .$))300(       0     0   D    )
M #A"24T$'@      !      X0DE-!!H      S4    &              =-
M   )V@         !                          $             "=H
M  =-                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  =-     %)G:'1L;VYG   )V@    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M&O\ +_!74*&KH_5ZZ<9^/=DV96=06C+?:-IW1L8]E.^RJJM[:_\  _X3U?\
M"^HM98?U?Z5U''RLSJ?57UG,SM@]*F2QC& [6[C&Y_N6XFR !H&T&KT4DDD@
MA__1]09BXS,BS)92QN1: VVX- >X-^@VRR-[]GYJ*DDDI2SL0/ORL@W8[7X]
MCB1<XAWNI>:&4>BX;O9Z7K[_ -^Q6\JO(MQWUXUOV>YP]EI:'[3X^F[VN0NG
MN?&14^I]?I7V!KG@ /#S]H]2J"[=7^F]/^PB--?Y1_K(.NFH^SU?U6VDDD@E
M2'D7LQZ7W63M8)@:DG\UC!^<][O8QJ(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                      #_X443
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X]
M(N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!8
M35 @0V]R92 U+C8M8S V-R W.2XQ-3<W-#<L(#(P,34O,#,O,S M,C,Z-# Z
M-#(@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W
M=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @
M(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%
M=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C
M945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS
M.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R
M+S$N,"\B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @
M/'AM<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.C$X-&0R
M.35C+6-C8S M,3%E8BTX939A+60Y.64X-#DS,S@S8CPO>&UP34TZ1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#IE,S)D
M-F,Y-2TT-#!E+3AD-#(M.&$U."UA-F5A,C-B8V(U.6(\+WAM<$U-.DEN<W1A
M;F-E240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP
M+F1I9#HR,V1C-3%F,BTT,#%C+30Q,C M.6(X8BTU,S(Y,S@Y-F)E,S@\+WAM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I
M=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @
M(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C$U
M9C$Y.3 R+60U8V0M.3<T-BTY931B+3%A.60V,#4Q.&8W,3PO<W12968Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I
M9#IE.&$S.#!A-BTQ,30T+31D,C M8F5F.2TW8C5F9#@P,C!A8CD\+W-T4F5F
M.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M
M96YT240^>&UP+F1I9#HR,V1C-3%F,BTT,#%C+30Q,C M.6(X8BTU,S(Y,S@Y
M-F)E,S@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @
M/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO
M;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @
M(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z,C-D8S4Q9C(M-# Q8RTT,3(P+3EB.&(M-3,R.3,X.39B93,X/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(Q+3 S+3(V5#$T.C(Y.C$S+3 T.C P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU
M<W1R871O<B R-"XS("A-86-I;G1O<V@I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I"
M04-$1CA#04)#0T-%0C$Q034Y1#E#-#(P14-",48T,SPO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-BTQ
M-%0P.#HS-3HR-BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!I;6%G92]J<&5G('1O(&%P
M<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F
M<F]M(&EM86=E+VIP96<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O
M<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z0D)#1$8X0T%"0T-#14(Q,4$U.40Y0S0R,$5#0C%&
M-#,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C$M,#8M,314,#@Z,S4Z,C8K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HQ
M-68Q.3DP,BUD-6-D+3DW-#8M.64T8BTQ83ED-C U,3AF-S$\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M
M,#8M,314,#@Z-30Z-3<K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M0R R,#$U("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N
M=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T
M;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#IE,S)D-F,Y-2TT-#!E+3AD-#(M.&$U
M."UA-F5A,C-B8V(U.6(\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#8M,314,#@Z-30Z-3<K,#4Z,S \
M+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R
M94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#0R R,#$U("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O
M<FUA=#X*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT
M(CY&:6YA;"!W;W)K:6YG(&9I9W5R92 R0F=V('1W;SPO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I#<F5A=&5$
M871E/C(P,C$M,#8M,#E4,3(Z,S@Z,#0M,#0Z,# \+WAM<#I#<F5A=&5$871E
M/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(Q+3 V+3$T5# X.C4T
M.C4W*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.DUO
M9&EF>41A=&4^,C R,2TP-BTQ-%0P.#HU-#HU-RLP-3HS,#PO>&UP.DUO9&EF
M>41A=&4^"B @(" @(" @(#QI;&QU<W1R871O<CI#<F5A=&]R4W5B5&]O;#Y!
M9&]B92!);&QU<W1R871O<CPO:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^
M"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,34N
M,# \+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO
M9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#
M  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MP  1" '! ET# 1$  A$! Q$!_\0 'P !  (" P$! 0$           <(!@D$
M!0H# 0(+_\0 1!   00" @$# P(#!@,%!P0#!0(#! 8!!P ($0D2$Q05(18Q
M%R)!"B,R0E%A)'&!&%*1H? 9)3,T0W*24V+!X8*RL__$ !X! 0 !!0$! 0$
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MNDAWW;(:'57LTH$.$4.")K0]*3=]T/[;W;LE;>T%.V(3UU+LVD]F-!8<'4L
M0<H,"DV$I</T(_ V_7-Q[/%;$.E:U7H4VUB#%7TQ>:'8<SQUAUO%%%*R1EHF
MQGB(XB.(CB)JX]07<'8BK;LZ"Z"Z_P"VX6DY':3<6U:3=+\[KJJ;+)"PU#TK
M9]ECT"0-P2H3AZ62KR(4EU66W$QY2G$+\M8;<1\C^[^9 _SE?:[ZDFS>J.QN
MS>B>[OT^Y4]<;;U4>;[&:;HXNC0W]1]M#LZF@;KM_7I.XRAM2<UC>(+8NXD:
M@8)-E@!@<:$U5E0\EAY*\<^WX^_U'R'[>?'\/VRY;O40KUP[ :>UOKPGMBE
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MOWU.-7^?[;<+88=>0<O=E3LLDY>+;DBVM\CT7N:LBI5K1%P#TR?[01NSKR?
M:J[AV"Q[RT),D11;=\+O/G=N:M96I#+91)E_+A/8=9B8\K)@SLB998\7R_72
M[GT+5;*; ZI^'.%L:[,S25U8.> 7.,O"8>5[DJ$'W<>T_P!ET J8^'0<FQ?P
MSZ7^(F9@V5X>[LLS<%BJ+E-]_+Q1X 9V [LFH?V@W-RCDH[@"L^Z^C7BH;,I
MU9V#0+&)MU)N06!8JO9@4MN<(-A2D=$J"0@RFLY2XR^RXG/MSA+K2\+9>;;>
M;<;3H.^B[&NMQ\BMZ;Z7:NVJQ2KUNIX964^00?X^X\3>U-U6157?18EM-R+9
M5;6P9+$<!E96'@A@009E7/*>D<1-.?J?>L?HST[ABZ1!B,;=[*%QC<X'J883
M3#@5>'.;RJ!8]G'&6Y*Z^+>1G$H:!BL/V6PM_ IB.+$2_P!0Q9GTKT9G]2OZ
MQ)P]96_;;F.O)L*_K58M9(]5Q[,Y(KK//<68>F8?U1UC@=-U^D1]KV+J&JPD
M;M[5;GMMR+."*J_'@ -8_P#97MY=?/1UU]7#U%=O,]@NS-PW5@0$!2:%J37F
MN:W4JM#UQ7[?L$F8NTHK KQ(08<.+K=(UA8PCLZT$C1EEZ]"W\DG/A;;1+^J
M^FNG]+CZW6X>&6RKVNR;\NVVQ\AJ,9%J[6(9406W7JP6NM$XI;QSYF\_R(NA
MS\>?BQMJ.M@V9T?T]TYG;/-T^-;?KZ<K(NNQ\'!I7+PK:,]&Q\C+KRNY<KOL
M6AJ[":G=&]*/I:=YKGW&H5^%[0@"FMCZK(5UHF;!P\#!UG!6MDPH.1<%I6XS
M!+Q95?*QBB(7PCW6U#Y$6-&4Z^PWK#9X28EB&HL:[0Q ;R59>.X<_,?>!'/G
MWYYFY_RI_@7IO@WO]!D]+Y&6_3?5>/L7Q<'.N.3DZO.U+X8S,=<HJKWX=M6P
MQ+<5KN_(1AD5VV6!:W;:ES&3E6.(CB(XB.(CB(XB.(CB(XB.(CB)$N_=4Q=[
MZ+W/I":9?KD/<6J=A:MEV&+#;(R@4:_U(O5'S$<>\_%:G/C&BRIK4-V5&;DN
M,I96^RE>7$HE&+_Z<9PHWT</:B[+6G2VTNDNH#.APVPH&NJE=VK[K6VT"CT2
MWQB-2M4MT.#L<C- !V&L&TNFH==+_.F>$LD13;"$?U_7\9AFC?29JFCQNJ!0
MW=%C/Q]4=+>P'3* X0J(V-(+@M\;0'[*D7F<XP;<0R7K+@]L.T)9;5$+I<7/
M<F#U>(F$KS[_ (GG_'_6<//H^:I-TS4FNKYLRT6BF:U].ZU^GF3@P@<"OD[1
M5[5.H$]>S8Q1)(HBO6<3)H,.2,$?0&1J9<E+LF1(9BYC2D<^>?GSS_C_ "\_
MR$QNS>D09VS4=LPNPO;2U[>V'=.HTOI7KJ_HU34Z5%UAJ,F;%V(Z9E5,,<E-
M7G9-G+ 03UBM4TT#@R6!J8@NOAV7WL*1S[<#CSS^_P#T_G^,LEV+Z^TS>.D-
MS=4]M.V8S3++6]8-5U^ODE!+<,>HD:N$XMNU[,RB3&#7*N&*HU<:Q'<1,9,&
MZX98<@%!L$VQA* \'G^OZ_QE>K5T*VAV7TB;Z^=K>[5FW?7C#-&LNG#)?K'J
M^FG:GL#65E&7*LW6QEF7[/KS=\E^' ^U6BISQ<:LW2JS+"^L>I3KY6"E>?IX
M]_Y_])FE3]+L<*%Z#;.7W4PP[HKMS4NU+4[1/5+7'74#<U4W7MFH@JBGZK1C
M\N,ZKS;"QE5QFSRA-I;^1<8<R/2RAA*<_P"DART^B_%M'6_5'59_L1#:UEKS
M8NQMDR[#(T!326XH=@V%OTWO-TSIO:DRTJ-:.M0W!I5)59 D6PY)!X^)CPUB
M0\IA"5!X_K^O])O%QCVXQCSG/C&,><YSG.?&/'G.<_G.?]<Y_.<_G/$I/WB)
MY!?[4+Z/^Y>Y W7'<[JW4)^QMK:>I<O7.U-65^,J9<;GK&,7)6>M6*CBV?#]
M@/TPN;LS)2LPFY1T^'.Q' ;#\D!D<11/$!LK=':7=FJNM_0MS4LL*"ZS$K^S
M2-1Z_P!;7.%L&U[$V69CEKA;MCA),HR?MFQ)3D:.*@NH&#6@@1O <.(@PUN-
M+1/>Y_9D_2.VOT&U5L[L7V9KKU*WQV*&UP$"UI/6C)_66J ,F28:C6YIE2FA
MUPO!N5#*EJXXM^56A=?KT0DJ#8)1\*,1/04/ZB=>X76J5U"D:]B&^O<^N':I
M/H%A)F3+,P)8S)"P$F7#4P@NP-RT&B4@F,*QBC!8+/;AS0\V#*@0GF$2&YGI
MSZ/(BZ=&*7SLX7L>N3)TEKS9)GL[N8QM"E"[2%$U^S4P'>BEKEFLTBPB@(5)
MNN$WB,8D3$B['+6[9AL S&1,I=Z#=<?UR;V<-"W2O[%.V79US>NU=V7>A%B'
MVW;VI-=Z1NMC#3HIU.1165K_ %51X U^*A"0Y,2X<'ML%2)&5*1.16NAG6:L
MZQU=J!FE$3%%U-NHIV( "[+:;$?4;W(:+76QEKI>'"!!U-R>F6G8%CM6 IQN
M36X5AR'(C0T)=>!)'HG3C_3PZMA+V$V'7*A8JN=!W7?EW8AUR^7 16Y;W9^%
M3V-YU>?68I= 1^AWTG0:E:9]-;ALA(5M$8L J-!FSR:IJ)&U2])[I]3B6KB8
MX7MN:YJ*%HB!5(IK>NUBHV7%ZO7PYL#KNQ;1TBT?27./IXA9"X.FP[,T2A1Z
MJ]%"$(Q!L4(>@HG;Q?2TZ<II%>U6:IEQNNHJ38K$?UWJ.^[2V%<M;ZV8M6L-
MGZ>,U:B5@]89L6OTIRA;@O0B#56%."P^9@:0'9@.U6L9$(EDI_6C51BG:(HY
MZ'9;$(ZWVZB7O5DRP7.T%[# M6MP)6M5,Q8;)-*.F[E*B!S)"/.<M4TLLT^]
M]<85.GIQ)XB5>_\ 91=+USK]+DTR^38FP@&Z:G.KL[<6TI=3K%4[";2J^[-N
M5O7M6>M2@="%6[:U2'7:2W5X0Y^*3?GQ84B.(?:'1T25[+T$ZKW.<6FVS6V;
M$@]MO;6[CHXK9+-)$&+_ +QT0:ZU[.ED1>2R8DD/9-.V$O5UUY3> L%R7DP.
MA13+;4Y"/Z_K^,QG7GIO]6M<'ZC<!P&^V:[T:]4&^UN\["VQL:_7"%-U3KS8
M6J]85UP]:+&1F2Z30J/M78 RO5&6IX.@A:3%E(1Y]HGRC+R)>[B(XB.(CB(X
MB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(F
M%[)I(_96N[YKHNK+8N^TVSTPBXE.%J;@V<+-"RG4HS^%+;9FK6G&?QE2<<^Z
MW-=B6#W1U<?M5@P_PF:Z;W>1TUU%H>H\0!LK0;G5[K&4D@-?J\VC-J4D>0&>
MA5)'D GB>#L#7=@:BV)NNDQQ'Q;KJ.K^Q]"JH1U*EK7LA>M+O4DQ1:,>QR>>
M6Q**.4.-&0XLU;\UF)%9DYG(:=V'KSBW9FL?(<+AOG8+WOSX%0R*WY8^0$[@
MHM)X[:^]B1Q/UO\ RL-KLNJ_R4NMMYT&&V5.ZZ;TNZJ>@%LANG[<[6[+*R*T
M3N(LQ\11;EUG_=45Y2V<=C<>=G\X_?\ &<9SC/CQCQG]OSC&/SX_/G]\?GQ_
MKSHKWG\UWM[SUD?V:3OZ8KVPS/0C8IQV73KQ%/7?0V2$G+F:Y=A,9XW=:0.R
M\O.6A-K QB-NAPFLHBPCX(T\PRY.M4IS.GOBAT[6^.G4.-6%NI:O'V':./5I
M<A*,EN!QWU6%:&8^62RL$@5 3;_PRZA=;K.G\ERU5BOD:\L>?3L7[U^.O/LE
MB]UZ#V5DM^=GCVK<TA-TS7%ZIW>X5Z??4NW;?CI@$-G6&0B@Z6KT_&'HQ38I
MR%-?ADR,3"DN2 -2&0B-H,M>YEN<T,8!XE199F&[B2=*:"SJ+<4X7WEQJP<C
M-M4>:\:ME#*I]A9<S+57]"Y?@A&$CO5&]KZ>U%^<>ULAOT&%4WM9E6*W9W#W
M*5!6ML XY1"H(+ S_,KOE\N.S[I9]B["L9:WW>YFY]BM-F.2US2IHR3?7)FS
M9DA>/"G'7%YPAMO"&([.&X\9IIAEMI'4N/C48F/5BXU24445K7556 JHB
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MM2V10V.H[;:&=@I'ET=N[E?;N[69@1]"I^9,O;8/45UPQ57)6;./RGZ52O\
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MA>[M^EP=3?75YD0B"<B.RUMPTE'C9:7!9%QWWVXKD,;'(O.-R2<@J:/?1=R
M"S$ < %B0!] "> /P$\Q54K%EKK5B2Q8(H8M]20.2?J3Y_&75AP80]G$>!#B
MP8^%*7AB'':C,X6O/E2L-,H0C"E9_*E>WSG/YSG//F>DY7$1Q$<1'$1Q$<1'
M$1Q$<1'$3&KG3JUL.H6BA7,1&/U&YU\O5K,$F87]*6 GH#XPJ/?RTMMU#<J%
M)>9RXRXV\U[\.,N-NI0M/TCM6ZNC%'1E=&4D,K*0592/(*D @CR".1*@E2&4
MD,I!!!X((/((/R(/D&>/CNAU^W9TL(R:CL:%9KQH7)G$C4'8$0CXY0E4AS+
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MDO,DSIJ21BP[#E.QCC\<BL2HC+!MX<0$%H<--B94T9Q'[9:#55&:$59-<L8
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M5C*/<2K4!+OC#D=3S"D.JOZM+L;1R*57D<@675(Q_ JS\J?EPP7SXETFMRW
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MF9CQV_+LJ4IEA:(L1G"GY4A34=A"W74)S55+,JJ"68A5 ]R2> !^))XE0"2
M 220 ![DGP /Q)FM>OL$=@E,;RW.RN3:RJ7HE1J#;K1"'KT*3SB1&H=.:PXJ
M']<N/'C.7FVM*;DW,Q!62F/1*V+JM;K4LQ\;[&HHJ"_:"O=D7GCA!XY ;@L*
MU/"A1YL;R1R0!FZZ?LX].OCU..;K3Q]T_->1R0BD]O \L>/')'$AFJAL0H-7
M*$!:T'B9;4MF+('2BC^4YQG*4R9F9D1MW\9QC.6(<7/G"O&?]/:K)PJW[;++
M[6Y +!UK4>X^ZO:Q'/G]9F^7OQY^TMQD8!VM8_WE=4'X\*02/8^[$_A-27:"
M-#<G-U78@%BHV.5.CO4VZUR1-'0D6:%(;E!OII.)&2U5L#)!F/)KQ:&4>6@L
MW'^EECB"(7U$\U5*9./9Z1&;B-61DXF2$=Q3X+-X 2U$'!;A%= .]>[M)64X
M%:6U.5/VJ@KQ?1< Q-9/!)\ ,!XY/:&3@,.?<;'_ $M>Y]C[&TN\:BVT1^X[
MOT++&CR]@=0VP_L2A&,S&:M<Y+*&V&<V6&^-F@+JB"AR,J8P%LCF8*K@R('Z
M^ZPZ=&@SJ6Q^YM;L:CDX+-R6K[6"WXK,?+/CNR\,?)JLJ+$N6D3WNJ_->4HJ
MY.+DJ;<=B22H!X>IF/NU9(\^Y1D)^\3-K7(C,''$1Q$<1'$1Q$<1'$1Q$<1'
M$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1-=VLC :]]R^SN]K,7&C
MJ5U^K]3ZRTTP7F1( ,>9E_27O;$QV;.=;B0R;9\M6*VN3\K+SD=E,)WRE3:%
M>^-C9.9>F-B8]^5D6EA5CX]3WW6%59V%=5:L[E45F(520JDGP#+7,S<+78UN
M;L,O&P<.@*;LO,OJQL:D.ZUH;;[G2JL-8Z(I=P"[*H\L ;]"[ !-ND& IL07
M>$R&H95D62ASW1DM^,S-9BD&XCSJX4AZ'(CRVF).&G7(S[+Z$Y:=0M7U?AY>
M*M+96+DXRY"-;CM?1;2M]:NU364FQ5%J+8CULZ%E#HR$]RD#YQ=A@9SY->%G
M8>8^':M.6F+DTY#XMSU)>E62M3N:+7HMKN6NT*S56)8 4=2>WY;2\CB(XB.(
MCB(XB.(CB(XB.(CB(XB.(CB(XB.(E>^S>^8/7O5\VVM"W+1=SA&!2]54*)G*
MB=^V79'%0JM683*%)>4R]+SF:6>:S\D0-#GR&DN2$,,.HG0=4]!3=)TDH5O!
M1NU[SVL6S?-X7K.$K<.7*>WE20HUWVIRS4J;%=_3]6',I8A1X3#TR-"A*(O1
MT(GGP]93N/;\=P=2T;4!=I$OI,6K>V<)5*?:%E>Q!V- L0X$<0U_B& M3R8%
M<(R8RU9F =WWZOR$I=C.HYF-=@#)IR+''NIJI)'M8 &+>X]CV+SY\,P\\$3M
M'\FO\GO'^*'0OQ*W^WH17S-;=TQT5D7@A,;J"C[/MKMLI^ZRUXV15J]>;JR1
M;C96WQ6_MK/3+I?;-2WOJ36^YZ)(=DU#9],KUV YDI0U/C0; -CD,#2L="U_
M1&1+KS@LT/6KYAQ6',@R,)?CN)QB""I*L""I((/N"#P0?Q!\3C;,Q,G R\K!
MS:+,;,PLB_$R\:Y2EN/DXUK4WT6J?*V56H];J?*LI!]IW]:H%&IDVQDJE4*U
M6R=Q-3+';204*/'$K.?(/+?EF+!/BQVI9@BZM>4_5$'I#K;*6X[2D,---HN\
MK89^:F-5F9F5DU85"8V'5??9;5BX]8"I3C5NQ2BL <]E:JI;EB"Q).+Q=?@8
M3Y-N'AXV-;FWODYEM%%==N5D6$E[LBQ5#W6DGCOL9F  4$* !EW+.7D<1'$1
MQ$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1*7>H"34*ZQ6-_*E-Q7=A:
M*BD'TJ5A+4)_>6N\.MO83G'OCSUI:%R&U>6G&9RTO)4SE:<Y71U"[;859'/-
MK,/^9*WL7Z>S*"/Q^OM+[6H+,[&5O(+D@?\ $J,R?_<H\?.5TH=V%D-A4\%)
M?:S$'TV&7BM*7CVJDEBI.'*=]OGQG.&@D5"5>/*<87C'C"L^9;EXMB8>3:H/
M>^0];'@G[J5JRC\/-K?0-S]??.7T,F/<X!Y.0RL?;PJ*0/XV>?/!/'TYFS-B
M<&R'2I+D?X?@_;^7_NY\?G_^//X_T_KF"%+1;[-W=WOYX]_F?G^(^?X\^8R5
M<.?#=W)X/G\?/)\?UP9YY_5H+UMNBE,,NLH(?.UF$MI6$/MR</HRPMI:<X6A
M:',)4E2<I5A6,*3G&<>>;D^'M5QRZ>5)3^T""05X^\&!!\%>1Y]P>#)_TLEG
MJ\\'MX)((]AQP>?V^W^LJ!Z.]R,3O42BS(SSOMM^DK\,LS2?.6GHR6*18GGW
MD)QA*5-6($+0AW*4^Q3ZF<9Q\_M5D?BGB5T]-ZLGCOHV[TTGW(IMHRRR@\^
M?0J8_7M$]^M*T76X9X :O+[$\'GL:JTL.?H2B$\GSP/?W'L YH.:UCB(XB.(
MCB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB?-YUN.
MRZ^\K"&F6UNNK5G&$H;;3E:U*SGQC&$I3G.<Y_&,8XB:$DZ_VYM'TZ!MRUQ^
MMB5HWYNO9FW;W2ZF*BS_ -9"[UL"P$(SQY>(BC## 8;6J\[#4.G,0Y>'L#9T
M&>E\>J!N#X*;;I[3]7_:NH1JZ*:\*ZW#VNQOLI;79B\5+]F'J#&L?)KOL1_6
MJ>RM4%U-M(KM%O//Y2VAZNZA^'OV'I$[S+R;=EC4[#1Z;&IR5V^O8'(<YI]%
MLVNO"NQ*K*OLU]==SV''R:,DVT&C[^D]5MSA;Y9)<V/?:QJ J",S'69%8]M.
MMERKY*+7DPGC),>XX+)!\3R:W$AWX,HA,#N#I\AYD3(@YVS^4-L.E\O4X-=-
MFHS^I,?+QJ@]>>3LM?K,RBS-]5<:BY5OIR?2H .2EJ4UY(NJ5'R$MF@_R1-3
MUO@[_:6Y%74&JZ-R\#-O9+=4!I]ON]=E5:WT7S<K&9\7)PA?E%UP[,>W(OPF
MQ\BQTP[*#OJYR-/T"CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB?RM:&D+<<6
MEMMM*EN.+5A"$(1C*EK6I6<)2E*<94I2LXPG&,YSG&,<1-<FBVE]MM_E^UQA
M"Y.F-1RK#K;JL-?PK,&P$FWG!6R=Z)95G*'\FY<=RJ4V2M./C"P)4A42*0;1
M)=1-CO$3Q3^KYI";H7NML0X.&$B%9[!"X6[*1#A,N2)$^V3LLU38M(#X<RIX
MF<S>( ^TXCI6O#7\6*\(B);:9891)-3E(N+<EAX^S=UGXFM@6/U'(<,/_&HG
MZ??D<_%K6:[X3=::7?9"TU_#1=AU,O 57LZ<SZ\C87I4#P;[Z-K1GJ23SSL,
M&@#RO/JVZ5Z!5U>ZL:4T=*>8E'J93F7KK-B.N.P2&Q[5.G7+99(;EW.5M"B%
M^L-CFBHW^&(-?BQ4?R,IY'K;&MLLM;]:QV=OVL23_C/S=ZFWV9U3U'ONIM@$
M7.Z@W&RW66M0"U)D;/,NS+DK4 <5H]Q5!Q^J!SYEHN?$P<<1'$1Q$<1'$1Q$
M<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$2#^R>GT;[T7LK4R9K0LC;*\K%;+R
M,.*C!+H#FQ+)1CLIMI#CC\4'<0X,M*C(0O,F/#<8PG/R>.7.'DOAY>-EH.6Q
M[J[@I/ ;TW#%"?HX!4_@3/;'N;'OIO0 M38E@!]B48-VG\&XX/X$SRO/=AKU
M62K,&<-E5G=^F"9*GWW71EY$0J^B(\C) 2PXZM,>5-&2F_N=?EQU_;; ()N3
MA<J9&(B7G]^86#@[+$7(K8/K=DBV59 '(Q[QW!Z[U7DHPY]*\>3796A *<\[
M0Q\?&S:!;60^)EJ'4CCFFWV*V*/(X'*6>_!12"!)T3ZN ^( 7 FPS,4NPUEA
M^"_"DMOM2$)]JFG$K3C"%I7CVJPOQXS^_P#KBW_]W=CW!U])JR00ZNA4@\GD
M$'R./PY]CYEM_LNIL[@ZE>?!Y/!'X>../PYY\_/CSJ8[(]FK7V#/_5DE.Q L
M9Y3L2 IS*EN.?G"77_"LI\IQG.$(QG/C_%G.<XQA.Q-'H:--5PO#W,.&8 <*
M/HI(YY\ $^.1XXXDEPL"K"K[4 +<<%N /'T ^0_;R3]9N^]!GJ\='*V%V\M@
MQV .LH*1JK4"Y32VWS011R"7V/;6$+PIMP-(.URLUFOSVE-/NS0%U0MM8]T=
M)E:6^*O4%.PV.-IL2Q;*=4;&RG0]R-G6A4-0(Y!.+4O8Q!\676UMPU9FO^L-
MFF5E58-+!J\/N-K*>5.0_"E!QX/HJ.TGY,[KX[?.V3KAZ@G7KL@:GT@-8,TO
M: LF1$R==W)V,/*DY V5(BNOU,AAS[;:HKOTSC[; ]Y!MB,G+Q$+!;\*5J>0
M[@CY2\7$I'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$
M1Q$<1'$2,]TDW@NG-LF8ZE(D"=9WPFPM.?"D/0*L5E-*3G'YPI*VDYQG^F<8
MXB1)T=@M#^G76)AE.$I<T=K:<K"<8QC+Q2K#24A7C&,?E;\MQ6<_OG.<YSG.
M<YSQ'O+1M,LQT?&PTTRWE;KN4--I;1\C[JWWG/:C"4^]YYQQYU?CW..K6XO.
M5J5G/TS,Y[G9G;A5Y8ECVHH1%Y))X5555'LJ@ <  3Y1$K7MK147N=NU%"KW
M.S.[<* .YW9G<^[,S,2229].?,^HXB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(
ME#.Y]PL=SDT7IUK H^-V'V(^N1=; /SA4O6^@A"DIV/<7,X5XBSCL=6:96,2
M4MLD2)$@S&D,SHC&>(ERZ;4:SKNI5>B5(=&"5BJAAM:K@EC/M;B#!$),:'&;
MRO.7'W418V7'GEJ6_(6EZ2^M;BG',HF3+4E"5+6I*$(3E2UKSA*4I3C.5*4K
M.<82E.,9SG.<XQC&,YSGQP 2> .2?  ]R?I!( ))X \DGV ^IE4]^]4-4=HK
MCUBV5<'5RI77';$7<=.D"EQ9$2SH2$D.P*X0F>7$+K#UU@:YV.[]'E62!?6]
M=C+7F!(EX7Z'U*6LK(>MOO56HP*L.U@6K=2 00Z#N4@$$<$>XF0UVZV.OQMG
M3K,^W'Q=]K5UFR&-8!7L-8V;A;,8UK+R'H?+U^%D?=(#^BJDFMG5K7<\YCYU
MS!@3)*$ <<H.D&A,0=/*"&9L9TF-@F%SVQ,R? 0ZJ5#BE'!11L=(D--M35C9
MZ8RW51)&&T3L>(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(X
MB:Z^ZWIJ:/[FN,6XE*)ZOW0,@-#1FV*=&BNSB(^-G.88:] 7UQHES#0LY5]!
ME<T19!2%.10EF%P94^),DG3W56VZ:M9L&Q+,:U@<C!R5-F+<0 .XH&5J[>T<
M"VME;@!6[T';,KK-QFZIRV,X:IR#9CV@M381X[BH(*OP .]"K<  \@<32-:/
M0@[DY)NQ@FXNOUL#,NY9B&;+8]G50K)C(SG")+]>B:VO4<8XM/A68#-J+H84
MKX\3WTI^7.T<;XNX"U@WZ"ZJ[^T,;)J>LGQRP+U5,H)Y(4ANWQ]YO>2^KK>D
M)^EU]BO\Q5<I0GZCN12O)^7!_:9:KK1Z"U:KAP;:NU.RX>Q&8$AN6G5.N(I4
M-3YTAA:<ML6F\E,PK190SRL9>>$A:_0W7'$M19Y,H+5-@3HYOOBGM]G39BZS
M'7446 J]R7-?FLI'!"7]E*4=WGDUUFU?'9<O!+8K8]89V6C58M:X5;@AG#FS
M(8'WXL*HM?/GGM3O'/AQQR?0B&#!ZX(%5^OBAP("#'0@X4('A1AHD0)&QFX8
MX8,'0VF8D ? B,LQ8<.*RU'C1VFV66T-H2G&KB222222222>22?)))\DD^YD
M0))))/)/DD^Y/U,T'@>@]"Z<=D.O6U=J.B=RUK;>S+'1+$\< 89KNL]IW%_!
MW3ID*.7+D))MJ+P)M9?*63"XL:;+BFHHX?.^A1"I*DD^/8?3Q\A\S\_]?X3T
M!<2D<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$
MZ"PVNKU*/#F6NR :S$(3D"X$JP&!X:--)N1I4QL=$?(R(S4B<Y$A3)2(C*EO
MKCQ)+R6\ML.J3=X>OS]B]E>OPLO.LII.1=7AXUV2]5"O74UUB4H[)4MEM59L
M8! ]E:D]SJ#C]CMM5J*J;MMLM?JZ<C(7%HMV.9CX55^4]=MR8U5F394EE[4T
M76K2A-C5TVN%*UL1&EH/5?<VB]BR: >&VL':*5LBL#RX=_$L?,G,#SM9G-Q9
M"<>R0VR4CR8Z)#.5QY*4)D177XKK+SGIL]7L=-EO@;7#OP,VNO'MLQ<E#7=6
MF517DT%T/E&>FVMRC<.A8I8JNK*/+2[S4=1Z^O:Z+8XNUUMMV7CU9N'8+<>V
MW!RKL+)%5@^[8M>3CVUBQ.ZNT*+:GLJ=':.>B91DQTUZR2X[B7&V=+T(4I2,
M^['S @40))3Y_P"\W('NMKQ_1:58_IRPF5/N9;#B(XB.(CB(XB.(CB(XB.(C
MB(XB.(CB(XB.(G06NT :16+%<K22CAZU5 A2Q'RLI7MCC@X:$\0(S'LXQE64
M1XD=US*4X4M?M]B$J6I*<HE!NK#T6-5]O]_=^S8-%E[@&/6N#*MLMD=!U#UD
MID:1+HXB?,E.9BBT3Q++]]M,F.ZU%(2B<&2^PB9&<QE[^T^E5G9416=W8*B*
MI9V=B JJJ\EF)("@<DD\ <F:8:QZC-P[6>JKU,M\:4>J?7.H[3ME&U;KV2N6
M,>-,;%U7L;7,/9FP!"LM?)<+2>L@)P*&)LJ<U_6,,!([,.Q%KG)*9:W7FC :
M^T'UB]9[?_EUD]O:1_>)92W]W@*/GSV'U-^37?T#^3OLOB!U3397UMD;3IW+
M&O8NHZ=T69F# &!D5@@-L\R[/QLC8>H#]C]*C"K"6IE/=Z*^WMX7KCJUV#ND
M=]N,1"ZAOF0CCKZ8K>;(0KTX766525Y2ECZFP3AL;#JLXPVIW"OZ<]>FTI??
M:ELE+7Q*,['S,U::7R+OL.$XS,XU45@O<ZXE%S+4@+6$!5!)$X;ZJR6P^F]Y
M?6Z5W#69E6,UEBU5C+R*6Q\0/8WW44Y-M2EV\*#R?::A.IQK?M+FU<!TH$G-
MH:HAO#1=JK]UD3!O66-#C?%&*%Z-M(KAZ953_A#LJ1!TV,V76WI[SCQ[7>",
M]9QCE?\ )9Z@_*UZK&XS_P J[IO5Z'H_:6[7;],[OJ:\ZGXY8#9]E^;K]3;T
MC@X>3?O=#2]M6)4/B-_L?NL3#86:[J?.Q,*C369'JW'Z%T[:_$^#&7F;?(Q%
MQ,/;:_'4V_#JQ*%KIRLO%WV18@UNQ95>UQTJF^P+;^1F:6F^^S/3;)V][44K
MIWH6S;IO;"2,V$B.#I5(@SDLDM@[',,2/TW2 LIV,IQ&)LB-)G&#*A[K5<J8
ML];241(P'.PCI*NIKK5JJ!8NW:G([3QS^LP!8* /+<%@HY\GCF3#I'I7>=;]
M1:CI7I[#.9N=UE5XF+0I;TT+ O?D7VA":L/#I2W)R\AD[:<:FVYEX4B:&?17
M[%7S8?=_M'(VM8%638'9?50[;5D)X2\R+C%M*72'6H%?K4)^0^H571%;W;%
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M[L\3U!:XRQ;<^*1K>\7?U*:1\Z);=H'/LI?2,_X'*)8RH=D=EV^U=\>Q-_[
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M[E=4*32*N,U?H.9WL[']9K<N?L-,G;NRBFB^I&\[59A=ZT\]0&HU&I\;9 P
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MZ$SH7NUU>PP\J/5#2Y.&U9C-O2X+3#CO^5+[R,NN,MY_S+;COJQ^V&\^?./
M]4X_:W&+<6 ^Z"]84G\6!/ _$!C]!,BGP=V9L06;C!6HL/59*,A[%3YFNMNQ
M;&^BM;6#_?'L:ZW/=%\NBW6I19P4+<SG"1 53L&+EOSGPF2ZAS,N;YQX]^)4
MA;&5X]S;#7G"<1[,W.?F<AK334?^ZI)1>/HS ]]GXAB1R.0HFS='T)T[H@CU
M8:YF6H!.;GA,BT-\VJ1E%./YY[356M@4]K6/Y)BC^O\ 7\_OG_S\Y_WSG/[_
M -?Z\Q/[_P#4\_U\Y,?;VCB)_2%K;6EQM2D+0K"T+0K*5H6G/E*DJQG&4J3G
M\X5C.,XS^<9Y4$@\@D$>Q!X(_>)1E5E*LH96!#*P!5@?!!!Y!!'@@^#)QH_8
M"\5'+<8@_FU"$XPGZ(O(<^M93C'C&(A?V/RF_P#+CV2T3F4HQ[6F6LY]W,WA
M;_-Q.%L;[52!QV6L>\#Y=EW#,/D.&#J!X"@^9K[?_#?0;D/;BUC3YK<GU\.M
M?L[L3R3=A<UU-SR26I;'L9CR[L!Q,UF]K;2XK.1U8 1$9_PIF/D2"DX_TRME
MX:E7X\?G#:?Z_C_2]?JK))_1XM"CY=[6.>?GY4U\_P !,%1\'M2H'VG;[&YO
MF:*\;'!_8+$RB/WL9PF>U-Z2OR^#J;J/ZI:BEV5?]%J,OXQ_^&>?"]4YO/WJ
M,4CZ*MRG^)N;_">[_"#I\C]'L=PC?5[<*P?^5<&L_P#W3.P7:T<ZXAJR527"
M1GQA4L/.:(8\Y_=684MJ IM&,^/.$S'U^/.<)5G&$YOJ.JJB0,C%=!\WI<6>
M?^1PA ^?Z['\#(]L/@]EHK/J]O1D'W6G-H?&/'T]>ELA68_+FFM>?!('D6,J
ME\J=VCY?K9J*04VA*WX?E3!"+A7C\R8#Z6Y32?=GVX=RUEE:L9PVZOQYY(<7
M.Q<U>[&N6S@<E/*V+_S(P# <^.>.TGV)FLMQT]N-#:*]I@W8P9BM=W LQK2.
M?]UD5EJG/ [NP/ZBC@LBS+N7<PL<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1
MQ$<1'$1Q$<1'$1Q$<1'$1Q$<1.J.A1MD"&*Z98S*$'Q1 *5BI>?CJDC2L1Z#
M.83(C.,R6,O17W6\/1W6GVLJ][3B'$I5BH)4A@>"""#]"#R#_&/:></U%?3M
MT+TMZK2=]]9Z[::I/U6=JR+W%FW:U6^-8JA93$:JNE)$*RS3*H182?,5Z3\M
M?6#%,ALFGIHZ2MN,]$W'T;UEN^H>I,?5[W.KRZMF+::F?%Q,<TY2UO;1V'%I
MQQQ:4] (P8%[$(X/),RTV[S=ALJ\78Y"W5Y0:L-952@KM"L]; U5H/OD=G#>
M.6!\$>=,^H^\'8TZ4GU/KG6[KL6YE1:Y+U5H^OI^S#JH@S"TX*M !P4[.;9'
M*FYR],3%3$1\Z$S<K1EI.-L;3IK1X259&_S<3 Q_4[*K<O-3#6QF^\U:,;$-
MC%5#%*^Y@!W  <F2K-T^IJ5+-A;116&^XUF1Z18GCE5X?EN0.2J@GCDCM/)D
M?=*.WM_T#ZF>M]M]@(-C&3R5QFZ^VU#O0T@$LE>$[(A?IB88*C"<:'-#N5-X
M@)/NCUP6LH#!UBHL:.T\S\7WUCH==O/A[F4Z"_$RJL!$V>'9@VUY%%QP%=[J
M4LI=U=WQGR H)[FR&4OY),\]WBXN;H7HUK5/1B\9-!I971VH#!P"I/WO2:T
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M6<YSG/GSE2E9SY\_G.<YS_7D%\L?FS$_B22?YDDSH?[J+\E51Q\E55 \#Y
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MEQ24I2IQ6$X4O.,>,K5A"4HPI6?SG"$I3C.<^U.,>,<Q'U^7X?Y>3S_C)J/
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ML3YFGO:O6-K/8:U]A-%]G+]T]VEM417:]MAJ5K^F7[7FQD52$@16R\T!<D+
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M.9GPW\K5Y1. (ZH]7J^S!C@NN.B@L<9K YI,:P*U-0Q[,#35G(RS%DU/":B
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ML+;O4*TIKY(U5^J.]J4N543^P3<6R::MX\E2]>UFQ!JN7O-P$_3.%A=8C%K
M*;S/8A3EX9DJ>6PA+$CXL&FKOMY].S'L =:U*7(PLL=6<(AYX+D(?'/R_9->
MW]6ZS$[/M5&SQBU%F58MVOO1Z,6JZNBS)O3@NE*V6H.X*W@\\>#Q*FR.W&D=
M2[5":=O=@FAK78-77'<$"2L8^[7DTNB#+ ;L,F4:;5EB-.8"U6QEF(*T>^3
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MXZZM*$*5A$\)W8O^TE^H;W%[$V_0OHU=>Y=EJ=/9+D8=SBZF)[>V[=*R"*1
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M5>JN'QS64C<82EM.$X2QX2E.$XQA*<>,)2G&/QC&,8Q^,>/QXSB=W;Y@W:K
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MTG/E6<Z9WG0?6]5OJ[K P]42H:G%V6]T6OL6MO;TL?,V=-K<\$LW868@\^W
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M81$V2B4[[$Z%[@7CM+WV"TC7^XDZC[^[6)Z-V=9X@>UPQE.UEU3T!U7NU0M
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MM=>.@/AT;((X-?F\ZIS5P]8,%3^GSBH(!\ICUN'=R?\ C=5J4?-?4//W?/H
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M<Z[[)L6J;YEABR4@ND7,?C84F 5BN1H\\0=%^YQ[/VT\&F#R\)IQY4J&U-Q
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M$$'D'C@\SYVB/D:S848[J+[\'+KH/</]X]%BH??R Q'/R\'DB2!7X=;J58$
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MOZYG]HP[/A+5V:ZX:(%2^NM5+65LLWKKKE'N.L@,>I#8QP\+.W&R235MD/A
M4N)..3(UD&YPF0J2RQ ;6W&81-X_I$>JCU"]8ND[$K/:?KSH*@]G]-U55ZV,
M@A6P*Z3;==15-1"^TJ=8K.F38*N-KD]^-%N0,Y89ZZTV3#$6+(7A$)?VA$VG
M4WIQZ=FRYA9[0YH(R8%ICR#$GKSV-M;<@.W.6^F&Y,&TW8,\4+:E.1Y*8BGA
M;"'E,/I9RKXEX2B<JH=9]07B?9 &G^_/: B2I,MH=; - [9BKU)IQ!YR2VQ
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MV!OY3.5?$CHZT#G;&HG^S;@[ $?M9<5T_@YG!QHS:^<^,4V9Y\^/R0"IQ_\
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M3Z]EU62K-JG":ZY5K/7I=8?0[]53A,]EZ$/@RH?TB$2&ME0^P+W6_2]&Z?\
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MI3C*E*5G"4I2G'G*E9SXQC&,8SG.<YQC&,><\J 20 "23P /))/L /F3*$@
MDD  $DD\  >223X  ]S/E]3'^%N1\[/T[V&<M/\ RH^%W$A2$Q\MN^[V+P^I
MQM+/M5GY5+1A'NRI.,U['[F3M;N7N[E[3W+V E^Y>.1V!26Y'W0"3QP9\^I7
MV+9ZB>F_9V/W+V-ZA45]K<]K>H64)P3W%E"\DB?;GS/N.(CB(XB<2?/@BH,T
MH4F11PT;$DSR)"=(:B08$&&RN1+F3)<A;;$:+%CMN/R)#SB&F64+<<6E"5*P
MCV]YISVGMN?V,O,,OA,R%J^K37'=:UV8V[%?*R5,O0G=F6(>ZEMR,7+PY4B-
M4Q$].9M8J\I3L]@79+'8 HC9O3^B&NQQGY:?]MN4^FC#_P#"U,.?8\<76*"'
M/ZU:GL!'+@\V]?\ 6[=09MFAU5W_ .R,6T+E75D\;+(K8<\,/UL2AA^B ^[=
M:IN/>JTD1=M;8;VN5"P *##=-3Q[927-G-+?8A0G9#\:.W'8PMM#LI]V)(4X
MXZI3;#3:,8:=6_A;&=QZSEE[+&9:U8HJJ>"S=H))/'( ##V\L3YXXX.O-IFC
M4K1C8]5;9%E0N>RQ2RI6S.BA5Y 9V9'))^ZJ@<!B_*?/6NP/XC1R8@S#B1SX
MZ)F>V_";4U&(#TNMQWEJ86MS#$F*Z_'2O"',MOH>PI#;7Q.87]6UMBNC*S&I
MV[>&/WD;WYY^?/!(/ XX\GVGG@Y:[6JZFZM$RJ:_5#U@JME8(5B5);M96900
M#PP8%5':9(.D#E:U]OEN[6"^1-;U>K5]UV[R7"#T16R)AZ&<"T#7.03&%.W6
M8R\BSWB$V-BESU8<J4=B'"C0KC+D*C'5SU9*86+3B_:-C86L[JJV>^O'3E>W
MBOEF6RPDJ&#*HK8@ D&;6^$U>5@-N-IF;,X'3]"KC&G)OKJPKMA9V.;.;CZ=
M;T4JH8UFNQS?4I9E4J=HNN^PFG-J$W@5)N\*?868SDW-:+#C=3L[T!E24/D8
ME:MPP$=G#&%K;1()0A\B"PXXTAV0A;K>%0/(PLS$[?M6+D8_=^KZU-E8;]A=
M0"?P'D3>6!M]5M0YUNRP<_T_]X,3*IR"@)X!=:G8J"? +  GVDS<MID8XB.(
MCB(XB.(CB(XB=6;.!:T)('[&7&  0F*[-*F34^*+%#8;./<]+GD)KK$2)&:3
M^7'Y#S;:,?E2L<1*'7;N#L0W-7&Z_:E8L->:<<;SL38\TK7QI7+2LX^IJE)@
MPDV R&?4E3+1BP%Z6X]E/UXD4;#2()*94#GW('CGY>?/'U_;_1CG_3^OI,3J
M/>/9%7LT(3V*U*(K=.(2(L)6SZ&9(2AU;D2GD,IGW&I'(V9(NJQ\J]Y.R"[.
M;?$H4B5. H#M$C VI7QR#SY(_A_C]?V?OXIS[?+G^7X2YEZW=3JOIT]N:N%
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M"9F%Z?SGZV;6&FSD;8Y36=K=OV'[3Z_VKNXX[&I_58^#817P'Y6=9U&ZF;Y
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MW[S$@D S3/Q:ZOV_3]>JP=/D'#NS_M-^1EHB-:*,=JJZZ:C8KJHM>QWM<#U
M*ZU1@KN#SNL.USF^];7,3?/A)V6C/#&UGL16(JRXHZR15 ^M9BM,Q,D8CPF<
MR\\PTPF3&7#4ZSF2F1)D6_5.IHUF119B@I1DI815W%O3>DIWA2Q+=C"Q64,Q
M[6#@'MX"W_PJZPV/4VOS\?:OZ^;J[<8-F!$K.31F+>:?56M5K]:M\>U7=%0/
M7Z1938+'L[_IK830'96\M'M152J56E ]H Y6',)Q5"&R2UEC&*REC.$)4-L9
MRL';F.4Q\[[)R7<UDG6F)X-G$78<<?(D<\ <<?U_ES\^!MC^OZ_Z38;SYB.(
MCB(XB.(CB(XB?F<X3C*E9QA.,9SG.<XQC&,8\YSG.?QC&,?G.<_C&.(E1.O7
M=O1G:7:^_M7:2-2KHSUV3KV+;M@CV6G*!8#=]E[#AK$44ZEY6+4U5Y.NB,,Z
M?',N5UPE+2/$$R3P\GF-],C*%+*0''<I(X[EY(Y'U'((Y]N09D<[4;364:W)
MV&!E85&XPOSEJK,FEZ5S]?\ :<C#&;B]X!MQFR<7)I2Y1Z=CTV=C,!S+><^9
MCIT=FLU<I==.6^X'@]6JE8$SSUCLMA)0PX("$%1G)I,N8*D'H\$<-'Q&794R
M;+?9CQF&UNO.(0G*L(G8CY\,K A%!TAN6/)1(T^#*:SG+4F',91(C2&LYQC.
M6WF'$.(SG&,Y2K'G&/VXB<OB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(
MXB.(CB(XB.(CB(XB.(CB(XB1X)U7K.L6LOL(%1:L&NIADNDY;!H6%$L!AHQ-
MAE"B2I1AE,PEB3-'0Y&,3'7\LJ82B-\3:EH5F,GJ#>9VNQ]/E[;/R=7BMCMB
MZ^_*MLP\9L6JVB@X^.[&J@I5?:GZ)4[PY+]S $1W"Z2Z8UFXR^H=?H-3A;S.
M3+3.V^+@T4['-3-R*,K*7+RZT6[*%M^-19^G=^PU@5]BDJ?\XOK_ .I-O&)Z
MI57[FG+=99\_8.Z(XBZU]1><] EZ;NEE2%D:S9@+6N*Y7ZO69\=%4%NL+C"S
M ,(7C(03AMR\=";'IC /2%NGKIJ48V#ZM-O8 PS::O4.4S#[W?=8I]4\\LCL
MA^Z0!H_7=2YW^V";9[K6&3G-1;5WL5.%;8:UQ@I('92A5JQP +$#\=W),R^E
MGWN[!G?5VUMM>W7ZQGB?:79SNO\ ;0R63F21)T!>5S8E>#_;W',QHHB@%Y(>
M93XD9IEBO01#8T:W&'/2HK]GU9T]K:>C<C$IQZD&HQER,2P(!8EE/;ZSEP.X
MMD)W^L23ZC,&;EE4B[Z4ZAV-_65.5=D66?G;(?'R:RS&LU6!S0BH3PJX[!/2
M  [%# >&;G_0'(:;U85OL':1&B5R9L08N(L?<I ]M9^']# G#8K<<AG^^:8;
MA$I;68Z<X8<4MIYUM;\6(ZQHNGJ7?X^HMT-&VS:M->+!=K$N88=OJVU7V%Z?
MU6=K:*V[R.]0"JL$=U;<&1T7TIE]08_5>3H-9?U)BFDXV[LQD;8T>ACY&+4M
M>2?OI6M&5<GI@^FQ*6,K64TO7)?,')/'$1Q$<1'$1Q$<1*?]P>K)'M=6*C3\
M;*S0 5<.SK)/C(J3=F<-E_MCHL&]\RK "6/:$L3S.'64_5)GX))RKZ=R&RM6
MR/AOU_3\/<_8[/\ ,@V^7FXE6#2[;%L%<7']=;\I>T8>4+FR'IQNUCZ9I]$\
M=XL8#3?QE^%&1\7-3J-+_M.>GL#6["[9Y%:Z=-HV=F#%?%P7[VV& V,N)7D9
MH9%]49'VD<^F:4)U&:R]*7;-LM^P0E[M,;7M<II90<%:,5U\_B^K<:^JC%0
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MZHEH1RFBH UPN3>98%UZ&E3\^4^]\CSRUJO\+;[#7+8F'D>DEK=]B^E38'8
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M"W-6;BY:SD&OU?=NLJ!+A;3!2-?! FI=@6L+=XEFJ-9&6K:$ I5U'D3[ 'L
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M*[ $8,&0+LU5:LH>W!LH+5^>,+Q?I3P$7,5B).9Q(3'5%D?+%>?9<1*P[_\
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M6RX/:P;=M=+.0^ZK5*;[%,O6FW,8N3NNJ6#H-(FC%1#C"Z61K=>K8+ Z?2U
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?.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img29677477_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_6.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1SZ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '-Z^<Y X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   )@   X
M0DE-!"4      !"H<CR.\+B]1))=K(K5'*#I.$))300Z      $9    $
M  $       MP<FEN=$]U='!U=     8     0VQR4V5N=6T     0VQR4P
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _@
M.$))30/R       *  #_______\  #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              ,X   &(@         !
M      $             !B(   ,X                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     8X0DE-! P     $B4    !    H
M %0   '@  "=@   $@D &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( %0 H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MBRRS[+?2\%C]MP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MTHF1<-"%3,"-PN+,>H&CT%A@H9R4"R[AZZ0<0H;)X5X"GU,17^K![;3VP\4
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M4Q2F*4Q2F*4Q2F*4Q2F*4Q2HA\Z..3?E)QHV%J])!N:T>9%LU!=KE+U976O
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MKU^VJ/;\O;YN_P _S]<^ /5[/D]'K^7T>P/F^TH1W/SYSZ_B[YSU\<'Y9U\
M.#-]YS[G;TF&<>]76%313M&Z]JOBIHP&NJ(S%5>0?.7CHQ&BDS(HMG#2"CS'
MZK.N^[< 2.8OG"%@XAUZWT&Q:XDQ)<RYCLK49+W$Y'1<#J(TR&D?P7H/290<
MHX4X7U+BO5[72M-MYYY9YH8B(8C-*3,XCABAC0,TEQ,["*")06=R,+M#5EWY
MJ<BZ-> H?'?CO'#5N*7':+"IZNA$.^D-JD&I3MY78LT50J:[N2G53.%6J[TG
MGADG3R1<@F^F9!(NI;6*XDEGOKYS+J%Z_-N9"<A 3E8$QD*B#"X'H^BJKZ**
M3^C'ZE'ZGJT\B/!<5SJ5M$O&FO6T!U0C8YT>Q4++;Z'#*I8.\<A\XU.=&(N+
MTA=SQ6\#F _01\>GK]7^X,N&0.F?#Q_2:ZNK/?V*G#I6\WMURDO,6(U'73MQ
M$ZV1=I!Y&<O9D>X^FB)*$$%6=39N.ZW7#Z49UX@=%3RT2N4N,:]?"./S6,XD
MF :7!R5B!Z GOF1A^ #G&X9X%^K<\LJ:%H$7DIT*['NQQ'#%=\3/"V'L- #A
MH+%F4@I-J\\?UU3EO<^"1779>1D[3&8?7RIIBE4A>]@T35U5EKSLNYU;7]+@
M6XNINV72?BZS7(EN'_TLA,S+IG'M"F'Z4GEG!!4.($(!CB!14J%0<P]F[Q K
M+A3H*<V1!O4U"H\BMZ'G-&<=&G43$(^KB,O!.]S[A3 "^<QZU UNC0)]/R:*
M6UHHJPO$%*IS9J<\ESIXEI6IU$/K0GPDY<IV1[7V+R+@7D\3;7!,LPZA(R1D
M9>0CHAQ( X5C6+Z6E'C1F=%NZD7JZ9W*N%<=?O7:_P"_I_T]S5VT?]T2?T)_
MMI4G\U9614Q2F*?EIBE1 YW5HMOXPWZNJ6^_T9)\_I#A>PZZUWL3;,F5"'O5
M<G%X2R:[U*X9;(M>M[6E&'JFSHFGR<1+N:%-6 A)>,0%=XC7Z8_+O87Y<4I
MD 266& 9:)T#)-< PQS1[N9"SJRB54]%NQDSC,3#<R]5ZJK-V8'#*F&*G&&
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M5CMN;?.4AU.RW-)9SE2&!DMI<PSOC2;V]J*_:-O]AUGLRONZW;ZV[,V?,'(
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M)I<8C=72[#.A&&40AGD#@C(VJK9SC'4'N:].0AR*$(HF<JB:A2G(<A@,0Y#
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MH86<1[?6QE#,0?LB5C/=>:,BMV>23ZF[C_RJ:@EIHNA7]_L*&X6 1P06:/\
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M'/;PQ_YK;**D:+'&BQHH"JB *BJ.RJH "@=.@Z=!TK\.HCU'K\_CT_W=<]8
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MM@/IV)NI*#*NRA#2,I%S#ZN/G4,PE'*<MI+<W5VVHRP31MK6G/E989MUE_\
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M'O\ #1KC^TF/,;W^!W7]7E^A3G0_=8_PU_33XV_%+ZYOCW^&C7']I,>8WO\
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MX/K!]1R,]>XK(>&N*.(^$=275N%]:U'0M1$4L!N]-N9+:5[>92DL$NPA9H9
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M3W'AUK%>)_*YY,N#('GXDXXX=TWE@DVYU&"ZO7P<%8M/LC<WTC=1TCMW/7J
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M_'OVUC[2R_$2?X]/<FU]<OX8^C3XL6W_ +(7S@_G3C#^J_CW[:Q]I9?B)/\
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MNCOE,8DQM$&Z)#U19)E0._P>@8K,-P=Z(8F#N"VTM&,+NQW+X8CN54L0._7
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M+:=/4M12T42[7Z8?6>ZQ\7>IC7S_ &'$4FR7&3D;B]@6-A3EFD[(/4H>RQD
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M,!WDG*/EG$A*R+AU(R#AP]=+KJ*57V*4Q2F*4Q2H*=IW)K1/9Z\QGB'>!0=
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M4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE8T@_A(^1_\
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J&?'%6NZG\YF:7;LW!1MSGX( [X'?'JJ;^7.J>F*4Q2F*4Q2F*4Q2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img29677477_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_7.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2#D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (,B^@Y(X0DE-! 0       << @   @   #A"24T$)0      $.CQ7/,O
MP1BAHGMGK<5DU;HX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q =#KQL         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M T$    &              4=   ( @    8 9P X #8 >0 T #<    !
M                      $             " (   4=
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   4=     %)G:'1L;VYG
M   ( @    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   %'0    !29VAT;&]N9P  " (    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     <X0DE-! P
M%J@    !    H    &8   '@  "_0   %HP &  !_]C_[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( &8 H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M^LN\V^ETMSQN=6QU+-C7;0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ML\'A&"4U-U.4E;+Q-D566&)R=':UU0D91E=UA(:7ML/6*$-(8V2'HL7B_]H
M# ,!  (1 Q$ /P#W\<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M7
M79OS$=&NL!\S!B]A%[>M"/NUAYRLJ#!:V-(0))MMG1T)E,AP0#UK"S37?'JN
M 4SGD?-)YSZ?A^<8VSC5:EKFD:.H;4M0MK0D96.1\S./6D"!IG'M6,@>)%=E
MPIY/>-N.)6BX4X:U76@C;9;FVM]EC"^,[)]1N&AL('(.0DURC-_5!JD3'_)'
M/714CHF3ZI=NQ83=;738KHUZ\%'K5';;&,NG80=V 6<;:):Y]HL@,<E'GJXV
MU;-G2OJ)[\\GE#X2>01^Z;+DX#O97JI\I8V_HCUE@ /'I7I\_P"2]Y;(+9KD
M\)12[5+M!!KV@2W& ,X6)=3_ $C'P2)G8]@,UN>ZS=IJ-[?5DUMJ@YLVF444
M(.0A9%5B0!R2)R5BDW7(1:914TV8GHO(F*+MHY4&EF+?=R/>,"P_=Z((CW[K
ML+>X@NX8[BVFCN()5#QS1.LD;J?%64D'KD'KD$$'!!%>&:EIFHZ-?W6EZM8W
M6FZC92F&[L;V"2VNK>50"4EAE570D$,N1AD974E6!-A.9J@TXI3BE.*5C[J6
M1=E)PT)>2((UF,B#'I$!BS@FS1D!H#%G8%A)3(L0HMJ_?C #V4QMJ8?-D%6X
MYP>$I.E$MW[;"BE9!Q2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2O'Y:/DU\A@GSUP^.QWJ]V?>]0
MHQ#S=3.*J95+8.Q.=4TO-@H&P.WHR+[AMW3YL LQ6,K Y$W9817K\,-BZ:@T
MG,BRZRE>P/BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5K+\M@KMU*>H!.
MO^EX:0%;0L^R*YKB2.XH=3BTCC]8RTSN.EQEC)\K).HN-W6V$!9?*Q>JQB)0
M8Q)Y.*U1>B$7C6)?)=R6D\=C*D%U(H2*>1=ZP%V57F$?:1XHRTD<;81Y%5'(
M1F(W7#L^BVNM:?=<165SJ6C6TS7%[IUK,+>74!!%)+#8&XSNMX+RY2&VNKB/
M,T%K+-+ K3(BFLG3OP+=/:-@PK^$-#HUVAM%=BW^+[304HI3$35V3QLO'ZVJ
M1PKM'$Q#57.=?F69LY'-C*VJKU<H+9N4@(_7:9P]INF*SK"+J]E.^ZU&\ N+
MVZE/ZSR32!F4$YVQ1[8T'0+G)/5<7^4_BOB^5(9KTZ/H-FO)TCA;0B^F</Z1
M:+TBM[:PMF2.5U4>G=77.N96+,T@4A%J+YK>@O3+KQULBM[T35%?]?;/&7%7
M,$'!*M$,8/'K6"SHKN+D\9-0L)HSCI<G&XVD4L@<>1%IR(2WA1%'0E@(_,LW
M6FXZTK3;KAW4KBXAA2>SMWN+:Y"(LJ3(1LC$@ 8K.V(2A)5BX.-X4CN_R=>,
MN*M&\J/"FEZ7J&H3Z=KNIQ:9JVDF>::SN+&=7\XNGMF9HUETZ,-?)<HJRQ+!
M(I?DR3(^$_Y'/&2]2[>XIT?J03K9*OJ1 2%7^RZA'UFI&K$*B&R&=L^[*R$)
M"GRBYK"&/>VP>2Q3)#.6[L/C&E\E272Z%=O+O\VDU!S:!LX(6*)9WC!Z[#(-
MN1TYB2#]8-7??EESZ1)Y1=%ALN2=5MN&8%UIH@-X,E[=2Z?%<D?_ +];5C*
MWIBVFMR3L,8'J_YZ?7R%3BE.*4XI7BN[J0#R[EO/YUOMZ!-*G:NA06S"/5:K
MBEF:-(R7ZS58J)#W"'GSQN$=)!99;PZ=.2)!7V15Z+<E1C1@^]6$A=]%*]IC
M?=55!%19'+991)/=5OMOHKL@KOIKLHCLHEG9-3*6V<Z9W3VSIOG7UM,YUSC/
M%*^O%*<4IQ2G%*<4IQ2G%*<4IQ2G%*_GK:_7_*Q]6?5S]>/JV^KZL_[?UX^K
M\OUXXJN#ZCVS\WK^2OSA1//I]"FF?1]>?1OKGT8_V<_7RF0>Q!IM;U'KVZ'K
M7[_+^3E:I3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5H<[7=CH%U
MB\RM(3NQ&$Q(A2WC<N*+-D83&7,J*ZDGO9.K"B*CA@U52518X;!W6JCO.V=-
M%]VZ6<>LMKG&GUK6[30;6.\O4NGBDG6W M(&N) [I)("R*00FV)@6\&*C'I=
M.VX#X!UORBZO<:+H,^E07=MI\NI2/K&HQZ;;&WAN+:V94GE5E>8R7496(#+(
M)&SA#5F/XWGJW^:W8/\ J:-?]]YS'YR- ^#ZS_T7+^*O6_\ <M>4CXQX&_SL
ML_X5/XWGJW^:W8/^IHU_WWC\Y&@?!]9_Z+E_%3_<M>4CXQX&_P [+/\ A4_C
M>>K?YK=@_P"IHU_WWC\Y&@?!]9_Z+E_%3_<M>4CXQX&_SLL_X5/XWGJW^:W8
M/^IHU_WWC\Y&@?!]9_Z+E_%3_<L^4CXQX&_SLM/X-/XWGJW^:W8/^IHU_P!]
MX_.1H'P?6?\ HN7\5/\ <M>4CXQX&_SLL_X5/XWGJW^:W8/^IHU_WWC\Y&@?
M!]9_Z+E_%3_<L^4CXQX&_P [+3^#3^-YZM_FMV#_ *FC7_?>/SD:!\'UG_HN
M7\5/]RUY2/C'@;_.RS_A4_C>>K?YK=@_ZFC7_?>/SD:!\'UG_HN7\5/]RSY2
M/C'@;_.RT_@T_C>>K?YK=@_ZFC7_ 'WC\Y&@?!]9_P"BY?Q4_P!RUY2/C'@;
M_.RS_A5_<>7GJWG.,?*_8/Z\XQ]=-FO1]?\ ^]X_.1H'P?6?^BY?Q4_W+7E(
M'_?'@;_.RT_A5F/;&\[JK"WZ[7JY$@>B[6MY"ZE4&0$MW24@DUBF6=>U ^6>
M>XKD&/PBR'@!,AA!XV:Z 21IR^35PW1W2S\1ZQJFGZG9-IX>:W6QE:YLQ$K"
M6>^E6QTV0OL9UY=\\(< A.2\K,#@$:KR8\&<(\1\*Z\G$;0V6I2<06,>F:RU
MS)&UCIV@VDNN\50+")T@F\ZX?BO6MR\4DIO;>TCA9>8X:,:VDE\%U:2<22^;
M/=/UX)VS?3EJT&UXR!GY5ULM:+P>-KKM-Z^5>L1\G:/2RQ]BU(-E'Z:B&XI<
M5[';;>!87&KR^Y33ZO?L[67$DEV!'9)%-<Z%J-M:0,4-D61+A'E:9%<%P08S
M&%Z]%Q!I_!5JO&*:?P5P['#'K7DP@T:26XUV:\LM-\H/#.IZSJ")(NNK!-/I
MTL-JEC-)!(L#*XN4N=PQ(_3BXYE84@@#1K<!&](I(.M<:GUJEWK6&/6M778^
M5B6J,-'R:#QV/LM'$A:$IFX+08WN7.1;>),U]G U CLU=SN&-4NKV>S1=3?6
M+:70K>\U&5UM76PU60V^+5)[2&%<S(]RTEI+S);?S=6+H'*MH/*QPGI.A6.N
M2R<*P<&:G8^4'4=$X:M(I-7BEXDX/@75"^K3Z=K-_?3&.PEM])CMM9LQ:V6I
M#5)8Q'</;B6+9!SN:\ IQ2J%]Y/(MUZZ&1@>YLTB2E5F2IB]=5U24&T9D;$F
MNK+;""Q39N\=,Q<3AK)WMH@6G$K?"H^T4]9BR7*'=V85Y U+5+#2+9KO4+F.
MV@7H"Y)>1\$B.*-07ED;'1$5F/4XP"1TO"G"'$?&^KPZ'PQI5SJNH2C>R0J%
MAMH P5[J]N9"MO9VL98;[BXDCC!*H"9'1&\VX.IN_OG>MP+>,RP,HCJS%7)(
M57,D7T>F(##@[IUJPE.U( 7Z(LE?-JEM&6PF17+(6<5K89LU5#QG55N/-PLM
MR%QIVH\9&!]12;2>'4=9H]-8[=2U,KUCDO2I*V<&,,D"EY>K,Q5^4\?N&F<4
M\+>0<:A%PM/8\:^5":VDL+GBE%YO"G"0E&VZM= #@2ZYJ ]*.XU%U@LLJD40
MEA\[MI_5GU9ZM4_TZIN/4A2@-R*BH55T4)E2[O!663:6%?9;GYQ-CN44%#DJ
M/KHI;OGOL&S-HU08A@K 4 %BA3'N+>W@M((K:VB2"W@01Q11J%1$7L% _>2<
MEB2S$DDU\\ZIJFHZWJ-YJ^KWEQJ&I:A<275[>W4ADGN)Y#EY)'/S!5 "(@5$
M5455%B>9J@4XI3BE.*5YG_+X^[$C_)EX\W'5U=XUM;/7;M^FT<,7L88+IA-B
MU.9,^A>7?YC^KNCJFGMIO_EC;&WI0^O&>3=/UNVX?N!J-UPD.-(@C0^XAU1=
M'WM+C;<^>,D@!M]I/*VYDW=QBI5GPS9\6SKI%]Y0OS96[!K@\4>]ZZXFV- ,
MK8^YEI+#,?/"V.>'VP\OT@=U8%\U>;?T?Z/R;T^C\YJ$]'IYO?SJZ)_XN:8_
M]?XNW_-?]7S5MQY".&/_ !S"?_[-:_\ 9_3_ !^?]]7K,>03O) HRF7FO2N#
M#!PULT;/SQGL=!V"3EW[/5+VF=?9XTRZ?+:;*)M&V%%-U-\Z(I[>KZ,>)7G$
M_&<)FN'X+M;6W,C,HDU^RVQH[DI%N+ L5!"CIDD=LD ^MW_"?Y,^@:;Y]KOY
M1<UE;6Z1)<7MUP#K5O"\Q 7T0PR7F?)CB3>[9P@;!K[Q?R']V9L*2-Q'I- )
M&)5VSIJ^$=E80]1U4U].-T5O8Z[;MU],X]&[=?5-?3/^?3QC..8H.)N-;J,2
MV_!]I-&<^G'KUBXR.X.'.&'BIPWLJ_2>%_R8==M%OM&_**EU.T<E1/9\":S,
MBN.Z2; 3'(O]:.0(ZY!90",X)=?:/R?V/#=8[7'61A24AU,,2&TT 7/6LF?;
MCVR3O1R&^&G=-66$'RBZ"JCGT^V2RTTU3^I3?G5<*\8Z_I.J&ZXB\ED7$6GF
MUFB&GCB>UL2)W:,QW'/193^C5'7E[1NYF<] #K.+/)7Y&-5TH6O#/Y2UWP_J
M0NH93?S>3'7;Y#;*LHEM^2)(,&1GB<2!R%Y9!4[CBI&)5YM_MZ3?\9J#_P"S
MT_\ 9STC\ZNB>'Y.<?\ G_#[/7;#YOY->9_F)X8'_P#&8?\ [F=?^;M??OQ]
ME?WYJ\VWV_)O^,U"?]G*?G5T3_Q<T_S_ (O]=M5?S$<,_P#CF'YO(UKW]_)J
MV52=L_)?5-?J"[5ZV!;:*LGY(H\L*5WA6,052&+^QR@P<M16-13=J-PFIZKM
M137=3"VV5LX]7'/->*^,M>U+4VO=!\E\'#>F"WA0V,G%%I>!)8PYFG-PXB($
MF5]$J0FWN2<#T?ASR:>0_0=#=>+ORFYM7NX9KB>?5V\FVM:9;1VAV<M)%EED
M2,0X8M*\H5@V< #)[N)>3_MC.R#@3#^H57R$HUQOE0>.[.0=5YMHGZ?:+-V^
MVFBCMOIC&<[.6NJR&N/1G*F,9QG/)6_%W%UV[1VW"EC,ZYRB<06); \5&_+*
M/%E!7VBLFCV'Y)FOW,EGHWY3,>HW46XM;6W!&LM,57.YXXR%>:-<',L(DC'3
MTNHK/W?=SR#KM7*"'0V,-%EFZR2+K3L+#%-VRJB>VB;C1/=/&N^R.^<*:Z;^
MC7;.N-=O1C.>;"/7^.EDC=^!X)$5T9T]W+1=ZA@63.21N&1N .,],GI712^3
MS\GIHY$C\OFH1R-&ZQR?F]UPA'*D(^,8.UB&VY&<8Z9S6O+YI\VWI_T?D_\
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M<L,T;+)')&S(Z,&4D$&O%I8I8)9(9HWBFA=XI8I%9)(Y(V*O'(C ,CHP*LK
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M=GOU&@DDI6UGJ%Y$;'[$]Q+FZTSB!P"O8_6@F1E(5*AY,\<7NIZ%<P5G-HU
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MD977]#TS63Q$UJ=0MEN/-QI8FY6YF79S?="+?C;G=RT[]JQ'^&^K_P"+9/\
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MN%;F(4](R,Q SW*A@&]1Z>%7KYQ]3Z<4K35?'^K#8/\ ^87/_-H\_"/\H_\
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M:,VC9'71%NV;-TTT4$$M-4TDM-=--===<8QT:JJ*J(H544*JJ %55&%50.@
M   '0#H*]N@@AMH8;:WBC@M[>*.""&)%CBAAB01Q11QJ J1QHJHB* JJ
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M8A7FMA-C]P_H-KJ@;XL>CB_3B'=J8==$&JV3E74@:REF7D>KG84ZV8,V%>;
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ME) C+9%25U^SEGMH+:*[NS<P6]SS+>$-'!!<OLBEN"[HZKG_  FQ)#& 3(%
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MV<(:MU76=<9^K97=7*.-ML?DSG31/.-<Y_)A3?T?ESSC.*I6YMI!GT CRE?
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MF241U>M5PN[W/(:0M<1+#'!%<\\B3:T<SHL8";.8)&#$[-N<J1V(:J&/JV6
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MI3BE.*5!5K?Z+C?_ #;G_P!Z6_Q_+_Z/Y^'XI_QNV_\ 1S_I'J!=YWKCH2F
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M,8\Y7BI<4.E1'9CLY.,W;9,)N)0T.+I]),$=R1=1236J12RP*D@(BFV[6#L
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M9[#23J>1$U[:E0@;K=,YCV;Z[0F?-8A)I$69!F%>UR4E#B7VY*58@S#3]Z%
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M*;N5W43C3V.NCSE3^P:+2)DV3]"B:GIUDUJ\$-O+(P#7'-(B((=%B?E[FST
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M%*A0&5F(+-VR <'.,Y.=H[^P5G4#\.<7F<+F&W;.\;BO&66%U$BG4H2C(OD
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M$.N=ZWBP3KUM :\E%@;Q5K#RK9B\FNDOEPU\_E;-$JB#CVSN/-M&[DGHFL:
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MG 4849#,3Z)4 %'0 DDX8Y/4DDD=/9WQT[9Q:GB>"3IY;DQB%]RNN[9FO=&
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M]OJ,MM:W%JJ*1,2RR9P\+,G+D*8[[T 4]1Z^M8TD949!_6.0?%<C!P" !E<
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MB-Y&Q=5NP?C1R>P\HX>.\,D=C:\.03I#)-K%O;Q7U[-8Z4YMKF07[PND9E(
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ME/!<V]S8W,>BC4H+@26\\D\2*J/+M(:..;>0PCE+Y#$MM(P9#F_E1>58$F+
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M+(2")2H9/..>ZDK)7]BM9V/*.R\LD\>A_:&%VU*_(,K9DEEIQ*TX-1<?ZOU
MS#5JHX9K;NAM63_-[P&KQ$68@LM9%/EDI>*-$1X:(1<283HD4KW;LL=W',^I
MF9G831VZVD(6+(/2&3SF.%4"8>7TU9@J(K"DEQ;Q:?'&\NGRVT>B"W2)/-YK
MQ]1NF>X&1AKF'S.:X>0N2D(,3(I:61E,_=U8#:%DV#;9,6*O0A":2Z/V <@D
M4J^0V'#AUP]@;/-G\1N-I.H&0"DI@?@*%11]\B#;OETA#JP@;]ZWS[VCIO)O
MXI99)F5;ADM["1HTA:6,3W,S-L3,95I&B$*G:&PID4GO4+29[>WAM59K19KO
M5X$FEN(X)6M;*W1.9)B=76))C=.-Y4;A Z@]#B#IC3O92G=)^PALG[0S(7FH
M>D<.NBPF4HLJ=S^:OSUV3#?M18]0#%GQ)5">QFG6C$:BTJ,6Q,1X?)V>L6$;
M&8Z!;HQW@NH.:L;7;KR;".>8/+))(6G?SR6!23B1(  !"H90XV+N514R*ZL+
MLPF:/3HF\ZU>6TA,=O##$$M(O<Z"Z8*H,,ET2Q:Z8JYC)E?8[D\)U%;:"KO'
M(**]M8_TJL_L[!VI2$M5;[DU]#ZEAU#31V=.M(RL3-W_ %S ;K[#,*^C<D!X
M^!'&<89FSTE%1@+.#;OE"DRY*)>K82W<8:,><O<+#';R%F"$FYBBN+H1HRC#
M!0SN$$C&JB2V? >33'U:WT^4K,191V37,MY$$0R;4LIYK.Q,SQOZ:&4HD;2/
M"@J#A]4]AP8*)-EXA>M6U9;]K]M;4E\7.0[M+>TU;R1K.(=4/7"(VPKU]L83
M:RK".T7"FLABJDGL+Z+B2WP_0A)M\QV+OL8!#<HL8*7,4,\U[,ZM'>7,FX2)
M#:I.;659L);QADWR<DG&6RB-4PW-B[R$2VEQ<VMMIMM%)'+IUE$4,,MU?2V_
MGL#6P+WLICEY4/G*C<5C DD%64)4A?(V6G8PU=W1,G;'^+=ZD,;N--#S252.
MM:OESV^>RMLOSS93=?9A,Q$A7K^52+8J[;[2EA\!?&7Q9!?*THV]P'9!SY#_
M +UV0N'#AVAA<W%U,3U.)%;ENV<;QMW$@BM>MY9M$DA6TB4^[VI-:(4,<<]S
M$+*PM@A &Z)XQ/'&%!Y1WJBJ1CHD*_[0!4J_OR+C;W?7=+9_WWN\A&9E*[ :
MP*&U_F WD-Z[4(<@A4JT@,>;&91*J3D+1O(0J)UX:BQ)RD^29 FB(:P17@Y5
MPHN3/))J-P4=Y1&D?+N!:V[1EA&@9WMV <;BR'KZ(VWF;3VY]E(UD+2*#1K0
M2110&:6<36;7UZDZ*9W*1QWB$HYC"2*,%G)?+>CK9R8[4X0';=F6:-5=/80]
MN);L!([98O;%O2\YFINM-'57V0:WQ%RP=&FYV,3>#XI%1CQD=PWC+!>$CHD_
M<7Z>-UZ<>=CDV,9G-R\P,MQ</UD,,K>BRB"1<B-5(;T1LV$X]8(73O2\P)N=
M3F%J+*.V(@L[.+I"+BW7]*K&ZA;#2RLK(3(W.:4"]UQQVV(^WGEF:]I3E=5W
M'0Q&3O(^/I>"33:/@P0CWLKAFJN()2<^OOJS=O$6:2#PBY77U8,6ZV_NZ.VR
MG691)+YVT<2J7*""*3:JKD@94LQ."0.I).!GI6GM9+9^3;G3HYYW98Q(UW-#
MO=WPN[#K$@ZA<DJH W,>YJ$O'/2]S55$+4D-D&RXB$6W/-9_4-%FX['(X4IH
M 2:K+'5RH>+:Z@8:;LPRYS,S=5QS*T:KHBJLT;.%I 5D^=8^EP3PI,TK$1S2
M<V"W*(I@1AEBP3T4:5B9&A3T(B2 2Q;$O7+JTN9;=($5IK:'DW5VDDDBW3J<
M*%:7+RI HY27$A$DZC) 18ZZCJJ:D]32GL'7T]IZX7ETV?VOO*?N9JVK:1OZ
MREU>R*3/,4U*-[HW:Z5XSCD5IT?!82I$G\KUG8)Q'W0IE$'F_L5'=MFSPM<Q
M203&XFO+B4R<IC"\;,1 YGQR@B0+&A0N)%*E1&3C-VI)'<Q6,T-U:BUM]-LX
M>49XUGBG2-?.X_-<\]I)+III>8L7)<.&,H&<5.KI'L6/#PNY8W"NV2MX5[UN
MOF=]ND+%2N%F!M"^B];*JPRBJDKF5OMXC-40ULJ.7M<GJ<C;V$1F&Q@:#'2M
MPXF"[1[#B%R%2=8[PW$=K<27O-$X66Y:+]';P0N>7(%F),;P(8T1 N_])@[*
M<V+-+:R3:;YI-?V<.EF#S8O;V2W YUY<SQCG1;K8*LZ7<BRR2R,YC B!7JYE
M4%NT)')!6@V=7NJM/^N'3'J\3L.76-8QS6P^P/8>]7M<SV7Q(D<./!X205'6
MK$@7>K0E,1F.@9*-142UT8L5$:203VR-$)+C,MK8VAEDEE;F7-U<F*1T9F]%
MX8MS$Q[2JNOB!5T5U:WLD=P\-IB&_P!5U!8(H($,%E8V:W$,4JH@+I<SE5 E
MW<QXV.<LU3XY+7S)KA=U6C +^':S'R'"9_.)VN!F >K81U]I"$1XW7K$)-W&
M$ 9J-V\XI2,M2@B'+D0R)J;R0)8>XH\?;BY#(+7+3F$17(YFIK)))MD6&.VM
MXT:(+(2%99_-T!$9*[I'6;:S8:&JV<=J+CG6;&+0V@@A#Q/<S7MY,\<[/",R
M+):B[D*M* Y6&.2#<B%DJ $D78HU,(,1B\;[()=R M"=W^R=C#)Y(;("UK,;
M0CT=?5]2=10VNY#(&U<RN!1>6VU%/H^DT9C.L)?#0;1<3*SLA>SE0=!5KII(
MRB71OEM]0NI!*\JQ/,JF.W@CC9A&T:O,G*=4Y;!.CLQ<C9.EBD4RR26)TM[W
M2+"!HH[=KB*VD=9[NZEGC1IXYI([:7GQ22<X,YWQ)&(@V1R&HK'E59=N'%=P
M7N6]!I=!Q%>QW:X2E])2NX[_ +6/'7%C6A'*XF9[,B;S&!XKV**EA V/1U^=
MU>ZAP<<(0PZ W.WM;RR0WACCOL#35B3GFX#SW,Q8RRI%(V[?&(T!4*A;.U5*
M,I:Q+F".?3!/-I0?W9>=_-5LS%:V5LB"WMY)XDV&*;GR!&9W"8W/(LJ.$EN>
M0BRX7[\&H"(=D(AUFB=>]/:^43C NXD+2TK:>VS.)KV7.5_&"VN]GXF@>OA]
M:Q$HA&AF]EP$>:D#**BQ!\(T9-\TD<T>5MDNH[1([*,[%FYW*EFD>[:-6S-O
M6-84;8O-C5G"!74"HL,T$V'O9;&74)9]4G!D:U-OSX+:*&P2>13YORGG-Q*A
M=N1.RQF5F1V)[".TQ<DR.!H=%TNRM7=9;2[A!)>$%')E; FQX90U6]<RSB5+
M%3<D./+)J,%>E^BA+,3#RQN/2EB*(.Y"S'Q:1'%$&%RP3R$1H+J&TFOE<*TD
MPECMH;4[R6=C)"MQ<JH$997 )8!'8@4DN[6)'ED\PN-0M]+>%V2*V:"6\N;Y
M1'M2-%@N7L[)G+RJDD9<!"TB("9<!!^S%?>.V[L5B/LAI=3^4=C25.1R59D<
MPL.NZ_D5Z31I7: EI-"#Z32 S#ZB7'2R)QTJ\=NW1%,='6*"[?W%EMF1;N/2
M[@1"5;@O=&!7+22Q1O<2<O:)"79DA(=$8DDX0> J,[V%QKEIYPUN;41V"W4D
M>R*">=+.(SES$HCC26Z#122*  I:1B#DU4UW0FDCK2%06=3>V)4([.]N.LD$
M8U],P/:FJ$!3"E<RBZ[9DR CL=8,AN$T;M"NXG*P<VE*^8Q%GZXH"[$QM(X!
MS)B$(V^^*..22=EN[VTC$4B7D.! 6N)GQ=2-.S2Q1NDC>@APA";DW'9"]V7$
MLT,5M$VGZ9J$QFB?3;@N;KEVEM&6L8$M42WGEC>*(&610SAY"D@C&:0>F=B$
MRN^S*:C\\T>6EY#*BH9&1 I789M&,=<^KI>J_I?^+OG)X@BT GIS2MNQ%T<?
M9QNV7FF(PT(I(FE1[O)'!N>>6!9"9M3@MPZO*P2UM&AY^3O8!6D@G0L<=9 H
MZ,0V*:[VQ6EO=/ 1;Z)=7I1XH$,E]J*W(M=H" LZ07=M($!((BYC+E<KSTP]
MJ2ZC[\+%(?VZ:=U):ZM2!ERN^M[@:\AHFVK<7J6%CZP0U),:=DT0KBKY(&GX
M*0P%A($(^WB9:Q92="S)<BZ=5"RR6]PS)?"_<S1L?Z2L:":4PQB(;E@9(HG6
M16C#;0AD=E?.;2]O%=V2++IATF(6TRJ/,WGE>UMA<RM<X5KI)KBXC:!TF*;S
M*MO&K1;0.=!(/V!F7;*9RNU)9=\+VK"^)Q*H9&XY6795Q'S=!5PV(AZV@$?L
M9M-6?5PK'K5C387*)D.TA\PM612HV_ D] A,2() JQ1W+WDCS/<1\FXD>-%B
MNBK6T098HDE#BT*3( \@Y;S,S%<*P5EI--91:;%%;QVDOG%G#'+(]Q8!TO9R
MK3SO 8CJ*O;2,\<1,L-M'&@==ZNZOA0*INX=5U_#IU7OT[23L,IX\^PMB6(I
M+Y9-I+'2_9JQ7M6EJKJD;#Y68VKP:9JLCM9*D=CPX0*)9T'H(E]W"TI-O2&-
M8+Z&-)(O.'N?<RZEE+O(RM=RF(PPK&[<H-$1*40!6Z#><N2<KW6EW,TL,_F<
M=C[MV,, BCAC=+"!;A+FY:6->>RW"BW$CLS+Z1*XY: 9M91AI0L%ZWW/U[C'
M:R4R-OV7CD%)5M=4ENT'.NPA>64+;L*3V7A%ZFV[T?N\G,PC\LF<HVC 46@E
M 2DQW:.@$/&E4,DI%O':W%LEXS^=I&8IVN%DN2]O,G6.X;*@RNCR.44#EE\%
M45JQ0*;R:_M+V338T.GR3+<6L=H\5DD5[:S$"6S3! AB>.*,.Q;G+$&#RE:V
M0UI4EEPOKK%ZR<V\1UMQ 5@A+;<^%M96H\GLAD"\PGQ,4$EV7C;X"1/%3K".
MB7_KZ1^.KCF#/5/X8VUTVL4,L=JD1F(G"@O-M#YD9M\I57R-I8L$4_JK@#M6
MAGN;>6^DN!:KYL6VQ6NXQA84010JSQ8.]45#(RX+N&8GTC6O3MA2O9"T9G5U
M'0?L5*I)= DV!M\/:.U*5[%P?6R.#2[D4O8[V<"!2#YX>E:#200N/50$>*+6
M<T4D(N9)#Z[;20HEK;RWNII(K>.Z=IU99EFY$2+:J"5,ID4 EG 9%A4_IAN#
MXB#D;O3;RPMXKB[EL(H[1T>U>W\[GD>_D90_(6)V*JD9,<KW+K_1SL:(M.T:
MFX?<]E=TUK<!U[I(<]5EMYJD(I-+1?:FP,0KJKA O5]8Y0Q*XZ-(KQN5SP<H
ME7L ;C$-C*!J6.I6)0W9PDJHA-OQ</$EM;@E[@E))CN5(H57,K,Z ['D'Z*/
M:-VYRZC$9QK-*-G%.][>,.59A9(K<;'EGN';; JQ2,HDBA;,\^XA"D0B8YF7
M.N@G +<JV"6K3,YI20LZ\.^1;K/82R77RL+9L^##**&0JH;9D[>(!(K!7\O+
M1IC.J/)0>2?#XPNU$F9JT%.<)-G#==75F.>&.>"2W<1-JEK+_1H9IHQ;B.&9
MPBK&79!);M&X"85I #@$&MZLUM<SVUU#>1F=-#OX ;ZXMK>9KQIKJVC,KRSB
M))&ANUF3,@+K$7 R"*S+LW7=O=AI!+NPS"EK'0IMB3ZFUN6JDI&EAMRW=1=:
M=A7EOWD?WK%XJA(6\?=H/P B.UM*&8Z=RH( L!%>,-DI0%&%\EW%/=.]R()1
M K6<1A*8GN+>*YY]PW*/I;""JK$X$CJLHV#>H;!I\]M9+%8M=P&Y*ZE.MRL@
M:UM+RXL1:VD?G &PN"':2XC9H(W>$B0\MV7:K&KF&RF"2RPQ5=7&S#1;0CLP
M#R.K9/#)W,FXL.U*K;Q&N)<U!SM3VZSA4*-9R"/1U\4,,728YHY8;,B#O<+.
MKQO*L4X5,[5:%XY)  #^CB<+)U/H@.J$D=!C!/.R6K1310-/:EI,9:.XCEAB
M+,4 EGB+PCH [%'=51AN(.Y1IEF]9V(2ZR]I:#K>"]B93TQ>":/#U8"G]56+
M#;GA69O=NR/8.&5]"_@$8NRPZFK*KWK>4 T)1#B9Y\X4)PZ/$9Z$::-F&BDB
ME:UO+>*.Z>P86XA26*6.>/F7&+F../:EQ+#%"0Z!XRQ.Y%,J@ =5#/ NH:=>
MSS6,6JJUVUR\-S!+:2\FS'F4LTO,DM(;FYN 8WY<JQJ LL@A<DMV=^5K8DD-
M6W5<-K_MZ.9N776JM>IA""&+\BT!K*H+)7AREWV_+I<SD8IFO,PT@F\\!3:-
MSIX>GX>)Q("EI&A\&UDAEK6YAE=IH(XKT#-I#9%&N4BAAE,9N)W<,/TBM)(K
MK(6D5(U&U8]Q%MG<0HMM<RSZ8Q"ZA<:DLRV4DUQ=6XD%I:Q1%&(B=(8'ADA"
M0M)(YYAEY:'L856]FR;L3*Y:(AO:6$VW*_(*\M.1R@TTM>$4E&^JU1("JZ1V
M:ZX<#ZQL%U>5;5@#B+:.Z,I)82^98,+OQHF)Q<07TK'%*]R[K'>1S/J9G=V$
MT<"VD $73]6*4W$<*H%(:4\Q68*BJPI+<6\5C'&TNG36T>B"W2-#;37<FHW3
M-<'P-Q +.>X>4OF. <MD4M+*RG']8+VL.UJ7ESJ%7(UM=?I'9J$2>D!,IS)H
MC=7D8[+$31X$-662V?#3?6V'1&&*R)@SW2Q6\8W8Z+:BF"?H2LY5XT3.8YQ.
M=/FV$A]Z7&J73%E'0L&M42,L,_HDQ^J.HNYVFI<+$);4V_NM;\X!HQ'+::%8
M*B.W7#)?RRR\MCD3R ]7:NSMJN$ZP'>3;L%I';;@5GP6R:?G5<R!X^M8:!EU
M0TT%H68AP4-DY$EI!YZ0LB?1.S #B+!'Y8TQS)\0Y\+%(R1(<5NFBY(U:XV3
MQ2QRP21-F8*\$"VSA4<GER&:6.53&I9@&V$*'VFVVN/.&X?L=]K-;RP74,Z!
M;8O%<W3WL3M+&JF:%8(9H7$CJB-LYH9N7O7:!UMB=GYKB<SNQB1R,V??LND=
MH;@"B_QK>F1)L,+C=9U^T%/EW0=N_@<$C\6VF UCK@&3LA69D],.42N[A?;V
MB2\J264LDMR[3;2=W(5E"PQ@'*@QQJG, ]%I=[=FKG[Z6W\XAA@5)+:RBCM]
MZ^AYVR.TEQ,64!]LTTDG*8^FMN(5."@ J#W(K&\"%9I4^3N^57G+;J>[Q: 5
MFVI&L S)P>%X1-8G$AG[(*IM54=K91!G+GECMEDI''B#$5B"MBT\=QH.^A7\
M5P8A 9WN'G.R*(6\*C>N&YK2!?T*PD"0RCTE(7EAI"BG::7<68N#=+9PV<5H
M.9-<&[N78(WH<E(#)_27G!,0@(Y<BLW.*PB1EG6WXA?D'\=LVK/>4G[Z['?P
M>G=5XG(>.*HFIC8TM ZP1.9X!B=%UTFPPD;U/DG>WK+)BQ;LP47T4U>.-9$\
M=S'I<D(=KBZ%J81(J>D\KKR^9M7K@%MQ/? +'QJ%:RV4NN0S\M+.Q\^%SR7<
M%(H(GYW*WO@$LJ;%'8LP51V%5DO;I!-T*>;Q3,TD5G6%8S#K7T^&G(17;&*1
M2ENL8FX(?(K-?CXEH[F>--W<- E59/)9@=,C7SP;$12(X6.178$HEQI\@@"<
MQI991:6*M'%L2WM5F1IB$W28S&IW.[$$B,8 R#L+/5X?.C+RDMX(#?ZFR33M
M+)=Z@]K)' KRXBR!*X$<<2(RAY6+,Q#+9;J%'[%K'JW,H6XK1R-OZMRUG!).
M6--R;9AV-MH6W5?#+W1E1]PH]E(^\,.(_(R)AX5=;1LF_*P19TT^3<M&DNR2
M6&S>,Q8N8C*KLP(%U,N2+C>V2XN,JY)8["QC.-F! U22"XU&*47 :RG6W>-4
M*DV-LV UF8D $;6F'C50HYBJLP!YN3KPJ"M.P!>EK#DTPDW:667A9%--*3*P
MIK .T%-.5[\M<@/+:W#*)K<4G-04&RI R (;,YA2L1C=4P2&O"H,'\\[2"$0
M_&K@BN3!*\C7CW$D MV017<&;F8AN>\D[M&BP,I*O;HD,:$H#)NCCK>75Q9)
M=0)%'IT=I!=&[64SZ== 6=N&3S6.&UC69S=I(NZ*[E>YFE"N_)$<TE<K!*P=
M"W6R)=EM>V)FRC4M[26WVG&4T+MQ=[*"-2_"*#KX'#X[5FK23A^LTS^?1QBO
M5HD@@)+L6K<U81;8@7G9_9F0-:I=^>O*SW<UX(!,2YAVVT2QI%AUM).8&C*
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MJF$,K>U]..6CA'4N6'W1Y.M^XI3#Y#\SE>=DXQYOS,KG];QQBKO?18;RFV3
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M*4XI3BE.*4XI3BE.*5PR'UL'V,?7GW-S_P SOS)#_A8O\HG_ %A6&X_Q>?\
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M1L69OV"GO ]ZZ;;>V:J9TU5VW3SHIKIOK,L(TFNHXY%W(P?*DD9PC$=00>A
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MN<8U323]??V;9JWT2:,FJ:+-F@@U011T^C[>WAM8(K:WC6*"!%CBC085$48
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MD4&$WB#Z-B2C92K;S'IK"IK0O87K^1ETO8QWL3-K(G,B-C?@6# 4A9$E2E)
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M663<!&0=?54^4"02'*$5,=>;(M"Q"63&T>!T2-;&7IQSAWJX&,7J$G? (I"
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M3=#$VJVFN^%*ZR(=<.G&A&R'L"HGK7J6E#(C6]NNXC6E98(R >KEL\+P.Q7
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M[089=CY&F\.27]M:73ZA96<=]=O86JS\]I9;M=@2,)%"X"R%P!(SA$(PY!9
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M\[MUE4]^AX8XEU'A35[;5M.ED!AD4W%J)I(H+Z $[K:Z6,XDB;.0&5MCA9$
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M4IQ2G%*<4IQ2G%*<4K4_;?C$)62?[ 1X+V4DD&ZX]J[) 6I?='LZXC9DN?E
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MW6;@A$_2AV\:(29RW&(N,HJ8>\@W.A26>EP:E<7<*/=()8+3EW)>2,S<D@7
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..*4XI3BE.*4XI3BE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img29677477_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_8.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1J\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &J"^:!8X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   )@   X
M0DE-!"4      !"H<CR.\+B]1))=K(K5'*#I.$))300Z      $9    $
M  $       MP<FEN=$]U='!U=     8     0VQR4V5N=6T     0VQR4P
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _@
M.$))30/R       *  #_______\  #A"24T$#0      !    %HX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              .K   '90         !
M      $             !V4   .K                      $
M                $     $       !N=6QL     @    9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   .K     %)G:'1L;VYG   '90    9S;&EC
M97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L
M;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%
M4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%
M4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   #JP    !29VAT;&]N9P  !V4    #=7)L5$585     $       !N
M=6QL5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     4X0DE-! P     #^@    !    H
M $\   '@  "4(   #\P &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( $\ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MUK:R_;Z?\Y;Z;/4?_P"E+$S?JXX-L8>J9[Z[6.80ZX;FDN98RRH
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M[L2B=F@;$D4,L6)$D%XP8CRZ>GR6'2#9="/'/Y?S\\?SX_SX_I(!7N!*DKW
ME>[@E>?*]W'@D>.[C\^/M,HIOP\4EU[;6H,CI!"R*RE\%O2*#:HD%.==1LS6
M$76D75/1(CV+:5P-N(Z);HFS,>C*4@F>B(X.3;,3KLPQ$,-6Z4R2O%GTBDG4
M7H#$:!M97.+AFK::RR\S#8VA)GR\YG^Z[#*2DCUUW:G'<1A#2)0M$FEJHR=I
MQ=!5OC9KMIZHD?"O"_UT%R_H)/M)E/\ >7="ZY$U4')IZQYLC=$-CP,N)C;&
MSFB8K.,KQQQ(I.^#.@*HY1KI*#[';XJ3ILHR1, @_@NH:%TS;_7O2RS;RJ[)
MJ22U  W94SUSC%KPX*;F4?FX@L5O",U8,LVQRT3)1D6R%(3 ZX"$A>F=)*)-
MD&PLB-1,S<>( 48B5VZ2_MG>LQN.Z[4ZO7>^O4O'ZE;2.+VAU,5;9K(N#B B
M$#H(L#19,1PIU&R0)TWW8#V^5G3E_N[?.D?^O]Y)\G\6M:3>KNV]<2^V+.*$
M.VUMUG>T@L)FE$ TO@MKU/':L&Q26Q#1C'M8_HOK(JH#2IZP>!=QRRI$H&0;
M-AFZ.J2)J9V!\3MME7-4S"N>P%D3GL+,O(/1/9?L1V:.-ZCBTLBT,I>A[4J2
M&/H% $(@A7"S*!-Y!'&;2'.(X>7DGU0VL6W=,E<HL43,GW@UI94)5Q!M;LJ+
M7)!9/?,OF-L6?5=%7,TM\]V0DPV7V03FE6637QVNF)!J="!EH0_C @,[B[1D
MJSW4+)OWNRJ),LZ\3%33J%]HX2[LN:B6':BI^HE3RI8#'*] (1<;U"6<+18K
M$H_'8P%BHI>6[.,_70[$&RCHG7&&\9%"66B#1!$CNWO"I35M')-('EO3X>ZE
MG9WL!V9)"R\,J.Q8DF;[&UW"JXEXIK";*@\JBF2T2%P=B2JV=OQ#^20<P3,N
MF^S[5]E/23QXX''CSYYY/X^PX_E_G*W*-V=BE>$"ORW=W..>7'TKV@C@=GU<
M$<]QYX$\3OQJ0B9=!J?Z%LK9L"+1ZDT*,VAMJC!T3?370M0<DC\IBAAZ*,"'
MT6=*NR<=:;D&:HO=GOIOMI\/=/&VBD2C\/R_V(_ZR/;A\4 'LB_ZVR3L?V2M
MJW9O0$R(%#LJ=1BJX5F\*W>V%7%HH4K:$>@$.C<;>P$?-*IAQ5OHP&-R*BC9
M_LX<JKO?CHHF%H^%:FT^TA+M"K;T^<GW=NWG<+82XAM2[FMC/8&L)36<M 2&
MU<0K%J2V(Q=C)MG=91LU*E0\+;M,BTV1%-?5TV?C_E^7G_/QR/ZRH%0&[E))
M7A"#QVMW*>XC@]P[ R\<CRP;GZ>TX',?!-6TAKT75\<[37[7T.?]2JHZBVL*
MC(RKW.EOQ"CBA<]64@/N3\-+D(\5%&3+E<RTB+X.UD#!% 4ONV:*DOJ*4R4D
M/#94"/;EGVUWM:;NS[#L/OV0;@'L-JIR86E+FNE*Z<Q C;6\-_:P^K$<P^"]
MB-?YE:,9BJ^SWY4>[<K,7HQ^O]OU_I)! /D<CAAQSQY*D*>>#_"W#$?<#CD<
M\CI8EX4J@&5[3E1SN\;>LVLJ*AW<&K*]C9EA7X)T.J3N+ P\%EL)<G(S%1K\
M@YA^H\C(8Q*7WS!E0T==Z$=EQ+,4,9/U^O\ +]>SQP?!YY'!Y\  -R../))*
M^>1QVD<'GD? IX7(7.8+8$:N;M!>-ORN54G2O6R(6$?"U<!+UK15&W)$;PCL
M-#"HG#0PD^6D,RA@?>83"4I%#)5JW2U9_3%-%-UWZ_V_7^D#@'R"1P? /'D@
MA3SP? /!(^X''(YY%B=-=8XS3%S]J+J#R,Z8-=K)W IY*0Y-(?H*C#ROZQCM
M8#V,?W:MTG:S9\.CR1-ZH16<*X>N5$T,IH)ZZ[)$V8XB.(CB(XB<$HY=,AA%
MXQ'JEWK1B[<LQ2#AHT7)ND&ZBK<>BZ?K-V+95ZMIHV3</7"#1'=751PLDCKO
MOJB:[=3NP93LO5+VQ#E:D:C.";-MRL#<$*R@!,7P@O4ECR2NB6ZTAB^RL??;
M/'D<6=YP)=$&#?979NT)E&Z:9!RB;+\1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1
M'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q
M$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'
M$1Q$<1'$1Q$<1(7N+L?U]Z\CFQ:^+OJ>FQSW7?=BZLVP(K"-2&J>WL4R.TD1
M0>H0RGMGT4PST7SI^<[8QC&?1$[&I;WI*^P2DFH^WJSM^/(;))N3-:3B-38>
MT56TRHDB]<QPD139+J:8SOJ@ZRBMG7'N]GIQ$E?B(XB=+)1_U:.GQ7TH0>^I
MA2H_Z'(-]DP)GYUBNV^E&]]6)3;001^)\F2WU&$=M62RVV&+O.,-U$2NCQ.Q
M;>$=6Y3$587!JZ4CG:SN.%4@U:.%W<!BFXSLM9;+,?B#ET B[A>.!_@?3@JJ
M\?#JJ#&K7?<:PVSEF@D#R!_*68\28XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.
M(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB5_=K8
MR,SV?\>$UTW,('TNP4ZB.RC61R)H*<Q]_P!:;X-N61".-2B,<)J;%! ]TD^(
MBG1!M\MA%J[1046242#_ -0/\_\ S_I+ >),<1'$1Q$<1'$1Q$<1'$1Q$<1'
M$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$K"[SGE:3F@"_P7
M0GK]V&>MX:G&I?V#MJ[*!H8K6X=@><JQJ&YF%RQU\Y5!D",C+/VB0XVQ8HDW
MRZ*C51T]TWVG[<\CW]O//\_;CC^O/Y2KM'9W=Z\]W;Z?#]_''/?SV]G;S]/'
M?W\_\O'F8]XN@+:;A+T[-RZL^NT2LVR[MG(>/$:-E5#6HZC=)HBH$_C-6R"X
MZ('-!,NV!R1 X;PR/.G1MA]5;K.L))N6VO'D#[\'R/P/'(Y_/@\CG^8DD.J@
M$,J6 6+R"%<*70.O( 8*WJ)W#D!@Z\\@RU[D2B.(G2R7 O:.']3;=V["[!"N
M"[1@U)/7SH7EBO@@W9L@R:I=V[6:?%3;M122I)PMMHDQ3W=;I:Y1*Y?$PE"$
M>J\F2K4.8 0%/M3W%TAX60!I7'C8N.:]E;*U#,2H2<MVDO%D&H[#9!XQDC=$
MVT<IJMRB>C]-QIJB6:<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$
M<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$PJQ[&A-10256;8\@:16"0@,[D
M,JD;Y-VLS#!F.GO=OG"3%N[>*)HZYQG.C9LNMMZXQHGMG\<1-/ZI\G_0J\+"
MC%4U5V0B$RL&9/%Q\8C(\1,VSPN\:L'91=!!<E&63%/=-@Q=N,Y<.D=<ZH[:
MZ[;*;::;)/''X?W!_P!)OKQ(CB(XB5Y]M8:%=]I?''.EE#>#PKL1/8XT31DT
MC;@-AI+K%?A)SLZB:!1.+OB>'(]OAN:>B%S#1KEPQ;/DF3IPW52#_P!1_J/Z
M^/[?CS+#.),<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$
M<1'$1Q$<1'$1Q$<1'$1Q$J.\R\0DDZZP5^RAD5>3(Q$^T_7R8E4P%$&NS\EA
MP 1(7ZIB8#*(%K)!Y[L.%*ND2H2=*(QEW%7L@^2W^\<13B)-/C12((]=GZ1+
MZW\QI9,F]/KW2]/HBZPGL*C>^OP:327<Z/&OKMMG2=86WR=7RX&[>W8%G7$D
M\\>_@<>3S]R?'X#S[>?/)^_ K=NX5CESV(5^I^Y?-CO^[7M7TT^ODIRW-A>S
MN'?VK81R)1'$3A$G:@\<0?HL'I59DR=.TA8W#7)$DHV04638,,/73)EEZ\VT
MPW:X=O6C7*ZB?S#INE[U=$3RL>$ZVV<<[>]@89,CKJ!N+,9FT@M?2YZS8ER5
M@"IZY>Y#;#V[Q\T6E8<4YDV7K9D\<Y2U^I^Y57X>VVOT[\7=<^?T7TWLL3":
M[Y$T69.12B6_*X=V"J.UMM+/6*GR%QU9@[(; @#3B^G[13L\_'LN'-A/IJQ9
M38ZV,WT+8%<D(2>.T?3RPY7S/5ISYBG:1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$
M1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1,6FDWA==1M_+[
M"ED9@\1&JCFY.33 X,CD='JF";,*+3?F3+EF-:;$2Y%@,9X<N$_F7[QLU2]R
MRZ>FR)YU;(9]W0O;J 7)5U)>46\ZJ@W9"<SL[#9'V+Z6Z]?9M6[^*6< C;JF
M0$6GT%F60S<[)(L8AH.RSKD9]E-W363#W4@29;I(GI*9+JNF;1RNT78+.&R"
MZS%SLANY9*JI:**-'&[59PVV7;;[915V;KKH;*:;91643SKOLB1]<5KQ2CJR
MF-L3?4VI&(2'5+DV\; EI1('N,*)MVH\, "-7I,F2(/5V[)HW;M\Z_&7U4<*
M(-M%ET\?*R$Q:'OL#,J#GM0 LQ^P!8JBC[M98R55J"]KI6K,+M%+7VI4I52Q
M_B8D*H'DD\ L>![*BL[GA*U9V53IU9?DII&K*WZ[6<<B]E$0?8B!,[88- 0<
M&\)UY57RT)6D%@3]%S(F2" 2).+$B+$TUCB\A-JKD]MQ(HDW:.E4LZVDU;0Z
MIW1;E>E'O)(QJWRLW&UV(KOP7!RL[+IHJX0@?O++"E=;-,>I_6U[;&M6-0]4
MK5X%UGR^+EYV1V*2$_<XF%D7,&=2W:M:=UCJLZ'M#<M4O^W_ $%IQE/XNYM0
M3V(DDH)0%$JWWD[&//NJE_X9F'(O&WQT6+G+YGA);?7&N_S*/M]??KRT002#
MX()!'YCWD\@@$>0>T@CVX)'']P?'XCF66\B51Q$<1'$1Q$<1'$1Q$<1'$1Q$
M<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1..L\:-E$$G#IN@JZWRFV267
M224<*8QZYT0TWVUV5WQC\YU3QMMC'Y]/3D%E! + %CPH) +'\ #[G\A+B4W6
M+8]=5EB4J&M=*V9:E)X#6,H(12? +$#GQS.1R9;CB(XB5->2"KNJ</VA_9*P
M8GV/CMY2F6Q&D(G;?2J22Z+=C-OG&4GD0T?N-B9U@RLF- A@61$GD:E49GC)
MN/T=N$HZNW17W11,(\:_;N06[<5LTJX['3CLY64?@,;GE&VW9W7^*U9+; CN
M_P!OXE[UI/X!)Q\8L@;$MIQ!@I5P5HNG9(W.%-U,:2AGLL^;/''Y_P O''\^
M?\N/ZR?I[?<]W/MP.WMX]^[NYYY\<=O''GN^TN<XD1Q$X[MVU8-7+Y\Y;LF3
M)NL[>/':R;9JT:MD]EG#ERX6VT10;H(Z;JK+*[Z)I)Z;;[[:ZZYSA$\4^*VG
MK&^I=WTKZ!R^QZH@'=N>S-S.HR2ABM8&HS#+]?($G+.9MY*X(MM%2K-V,>%U
MH\O&$6+C4\N;P(17W4^N]7U/T_O.F,7I*G=ZQ<G/Z4KU*5=N8^;5L#J31;7\
MN<=*+O28%E6O)%UEB&JJMW=#.!R,'*QM@^Q;&R"E>P.06+4"DT>ORI]3U>]"
M5(![Z@B EG95! ]:]0=L.O=Y?0V5>6I$"<K-C%R6:[<G!K&R ^S#3;)D:?A"
M[K$@$% *R2[8RT<LL99K(*YSONA[%M_F3;=+;_2>N^PU>75BT6+7^T%HM?77
M"PCT;,?-5/E[JKU*M2ZO]:L/ ;E1VE&;BY!5:KZVL*EC5WJ+DX\,KU$]Z,A\
M.K %2"#-B><_,J.(CB(XB:T6AVYHRG9E*X!/90Y$RR'TJ5O\D)3$OW2CRN ;
MTLQ*O0JJ*642I=DJ%?K*@FRFQ++-/YS1'9MHLJETFLZ3W>WPL;88.,MN)E;F
MG0UVFU%";'(2IZ4N!/-5+^M6HO<"OO8(2&*@XEV;C8]IINL[+/EKLO@JQYIH
M#-800#W,%1V"#ER%8@<"<BV>T]74^ZC HVC.)1))=&R<T%1&N()))[*$X4%2
M;*&)@4$1]DZ5$QX;N\:-EGS_ '0^.\7U9LDW3C15-.C5=,;/;KE6TMA8N-AY
M%6'=E['.Q\'%^<O9A3B5W7NHMR+>QV5*PW"*7<HO!,VYE-2TD^H[9 +454U6
M6W6*JJS,*T5F"H'3N9@ "RKR6(!FR'RV/SV*1R;Q,A@K&9:$&2( 2PW=-/GA
M!=HD^8.<M'R#9ZUV5;+I[[MGC=!TWWSLDX125TWTUT^9B9&!EY.#EU^EDXEU
MF/D5]R/V6U.4=0];,C@,#PZ,R,.&5B"#+U5J75I;6>ZNQ0Z$@J2K#D<JP#*?
MQ# $'P0#(8A?::GY\O43:.%RKA:\%[/;5]JY!$6GU!6H'C]C-\/\K)8P+PR7
M&N\,MGF4\$==-=FWNQOKZ[?+Z8VV"NV;(JJ5=+7K+<\K?6_8FW6I\$U\'FTN
MMR=X3GT^3W<<&6AET,:@&)];(R,6OZ6\W8QN%R^W@*:+.&/ ;@<<\B=96W;&
MN;8GI: PN-VR^5"2>90XC,G%6RUG6R$A@;T@-D3#,\68XC_Q$"(QTP;9V=:_
M-O/@MTO55=/7:[L.EMAJ]?3L,S)U5:WXN'FU88V>*VR;'SEK?'L&"']<@I8K
MOPI[$[F/A3(7,J>]\=%O9DMLH=Q1;Z*V5 EU:XH*QQQP#W<,2 O/(G0UQW=H
MVT)Z'KL!O/QY>3FYS&X<7DU<2X!#IJ>K=<HA,Q,5F#T;@ 5?!?HI95=#1\GO
MLFP<X3QLMI\+-_8=%[O6X%NQO&!93C8^%E9=./L<2_,P\?8BHX=V3AI8;ZJ[
MO7J ;L/!=2>%/=+:['%:X4!K [7VXRLU-JU/?07]2I;2GIEAZ;\#N\]IXYF:
M0+M+3EDVM*:8BQDVM-XHE)%UTR41DX8$<1AAYG%IDI$Y*4%-0DGTBLD(,PAO
M<0]<ZMWR^N$LKHZJ+:8>;TQM]?JL7<Y--(P<HXP4UY6-;?0<RE\G#^:QJ[6O
MQOFZ*[+:/51>]$//:2 ;BYE#9+8@9O67O\&NQ48U>F;52TJ*W>KU:^]58D=X
M_!N.[M'L-5%-RZI8/8$C^C22[97M#*_9:LW+K4B:UPUTQAZLW3W3&,MWI$6+
M3?/-DV^Q,J.:8V][CUUL:OI_:[G&VN9K\;UJ--B'-SW[U0UT#N)[%8@VV=E=
MMOIH"WIU6/QPLJR,JC%]'UG[/7N2BOZ6;FQSP.>T$*O)4%FX4%E!/+#G"+L[
M?T_0$M9PR?:3U<JO"']DD5H=7<LG#"-P(45U#%99)5XN-)*B HQ]MKJ_>+(;
M:-DMM%5,8UWT]V;I>DMMOL6S,P3@K4N;5KJQF;#%PGR,^ZHVTXF,,FRL6WVH
M"40,.X@@>QE.1F4XI5;!:S.EMH6FFVYA72:Q8Y%:L0J^HG)/XSM+0[5U%5;.
M$N'[J3S-Y8@ A+X>#J^('[#/&(4''LRIB:IC(VS>*MXJ,8D1RS@NZV104W?M
M&S3#ETMJARWK>E]ML[,Y$7%PDUU]>)FW[/+HU^/1F6VO35AFW(=%;*LLKL5:
ME[B/3=G[44M%F916E%@+VC*'..M-=EUEP"+82B(I8J$96+$ #N4$]S*#-T2E
M0&=1:.S2+/\ 4I&I6%&2$"2U0<M</A!=FD^'NOE7J+=XVV6;+I[[-W;=!RAM
MG*2Z*2NF^FNER\3(P<K(PLJOTLG%NLQ[Z^Y7[+:G*6+WHS(X#*0&1F5AP58@
M@R]5;7?57=4W=78H="05)5AR.58!E/XJP# \@@$<3(>8\N1Q$<1'$1Q$<1'$
M1Q$<1'$1Q$<1'$1Q$<1'$1Q$A#LO)X%!NO%X3NT8(E9]=0.J9Y.II7:L>&RO
M$TCL,C1&3DXZG'#*2XDPY*-Q6[9HS(I99J.MT<N,Z)Z[;ZHGFCI(JT877UY$
MTA'F?CR%=G9CN'KX?T;\A%9]I*Z^Y'$)D=C--K:Z23&KW-5#HJ^"Q0F,D,OI
M] 0M&R+T8B[*:IN=2::)ZRL>N,8QG/KG&,>N?3T]<_QSZ?P]?\W$3IY$#9R>
M/G8T1V7T'R$.3!OMVN^B3G1F69+L'.S911-71-?5%QOE%3=)7313&NVR>^,9
MUSCY6-7F8N3B6EA5E46X]A0@.*[JVK?M)# -VL>"58<^X(\2[1<^/?3D5]IL
MHMKN0,"5[ZG5U[@""5Y4<@$$C[CWFB=G^-JAK5KWKY6AL_9XJ/=>(.UJP*L
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M0CS)ON[>'6,YC#L.U:IZ>]1PX)-RBC-%'33^ELJHMKIKK^<YQCC[@#DEB%4
M$EF8\*J@>69B0%4 DD@ $F7L?&R,NY,?%HNR<BT\5T45O;:Y]R$K0,S<#R>
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M\&R+,8DZ7^'JX=*[:-\*_!7RE"D/ZO;]7H^EZO'GTS?ZAJ#?@;!385'OPI)
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ME*LI4L&Y+8:/(RLO+O6K%;U[*6JNLR+TLJ5*ZE<&E*_3?N['7RX(!Y# \<6
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MPOA_L^3W;^I] =-=,=?X.YQ[-=F:+Y7*UN1>FKV NHO=JL]*A5^T<3,RL>I
MUI>DY=R6.:GY4U*)S^WV.7J&QRK5Y0M6Y0;JRCJ%-1/<:72MR>1P?24KP>.>
MXS#_ /<]Z@#JI(^QX509>-CU_(X]#2I 9&HHZLD3#BK<@4;.) 0BL99?6$/K
M#/5L/6("P1A974:@DZPV12TW4N]>_#36Z#4ZW$TVSK1\C8Y%_9O]A@8SVN,:
MJMJ\/*.)B5#D*C659&0J$JC5_47YC4;NW.MO:_'*BM*QW8R6V =S/QZB=[M]
MCVE$)\MW$ ">FH5:'0:ZGN\><N*$-GEOZ*\0L>'QZ-2W.V?=C*2\1L8$&D/Q
M,9QMC9/89G;'Z^GIG&<^/9O2?4>!7ZU^HRVQ_/\ VK%1<[#('W^;PFR,?C\#
MZLW]>7C6'M6Y Y_Y')KL_K78%?\ NL[LIX_^BLAS\T]ZA];%U%\8W^=94[ 6
M#A7&W]+"F'HP&U7W]?7W:[X6SG^.N?X\YX@@D$$$$@@^X//D'GVX/V^WM,GW
MG0)^.#I>S4PL!I=*&*ZY]VN]=SZT*WVUV_SZ9@<VCOLS^GYU],X],>F?QQ$U
MG[E4_P!>.E_62XNQSN<=Q! JLXHY*L8_">V_:(BN9D;U9$3% 2#-]8TB2:HE
MY(_%CG)%RWRQ&-5U7[Y31JV5VQ<KK-A8 HO:CN2[J@X12Q +$<LW':B#EG8A
M5!)D>W^0\#_;[#W\SPL^+?MH3"^0EL=[1G;FEU:]GIAK&+\W 6/<,=-%I'+'
MJV(5+)0[KN1@I++4H_)'Z*+D87<$6RH(H7W38+NDVWLJ6AV9%/:@L/"/8PKK
M8_D[<+P.0"Q/:O([B >8/X_A_4_K^7G\)_I!UUTOZEU0^U,5]UTI^/'OQG:3
MIP4$0EJVWXSG=S+"[-_)'2FVV/?LHY**J;*9SOMMG?.=LV9,V83332TU32TT
M3TUQZ:Z)ZZZ::XQ^F-==<8QC&/\ -C'$2'.P=&Q3LG3TVI.;FIS'HM/&#4<7
M+UO+RL$F31!H29D]/I$G#;Z/6/QEF*2#Q+VJMGS%1RQ=H+-G"J>R)4]77^Y_
M>E=76$PL^)V5W$:RMK)XY+7SS/964M\R(K%7""XC$F<#& \D9;I:(8:;:N7^
M5]6*BK5!=!+?TPB7C_[?Y_\ MXB.(D#W;V=H3KH(4,W)9\7A26J6RR(]\]^9
M//M=<9SCY"/C]71EYC;/IKA1%ELCKMG'O4TQGUY@Y&QQ,:^C$:Q[L[+<5X>N
MQ*;LW99EA]J\37XE=V9D.?PJI;CW) Y,[+ICX?\ 5_6%>1DZ/377:S"4OL=Y
MFV8^KZ?UM0/#V;'>[.W$U.&B^Y%^6CGCA58^)7R0[2]B>X"&174?J>(0K]]L
MHCKV [7"$@T'V;;^Y/8A%X!A%Q(93KG^BHU<-]7;%3.,:/$4L>_&O0)I,ZH"
MWJ#(IZ9I!Y_9G;3M^JKTXY _9V-D#5Z7O!'%FXV;9M# BW1V> =K;K?A[TX2
MN=N[NO-JJ_5B],-=J^E,:T>?3R>I<_$.RW7:1PU&BTV/@9(_[CJ>@\/,2A/A
M&ZUR.6ZVKVY;@>QUE.,:J.!;*"16K*F';_$^-HV80J##A;HDBWWSG3&YPPY;
MO=?\HZ%X4VSC%=V=BU8[86HP1@T,U;6Y^5:-AO\ +-3^I6UVU>JFO! L"N*-
M!A::GQV6K>"S/JL_JQ+AZ>!H])@5)7=7173KJS1BKD5BF\T8^19EW9+VU@+\
MSU#G=1;''/G"S\5.VM=O!7C5Z?11KNSK> 3"G&^R^SK1M2=VWC40Y!SMG.=U
MT M?V* !:*[9SZ[;9&;>N<8SG'KCFJ/EK'/E[7:VUSY>VUOXK+&/U/8W_,[$
ML?N3.2MOOO\ 2]>^Z[T*EHI]6Q[?1H3D)35ZA;TZDY/96G")_P JB<G?I&]&
M[;[0?N-W:@^/QLDWS<P:RV:6V,XSC_)W;!+.<[Z?CTV3V>8USC/I^,8].):G
M(Q0';H%C?[3[XR UK[/\DA</7NG)CIJIKZ>WXB];LZ6>;I[>GHIZK94],YSK
MOC/M]J/]/U]__*>9GM-W!O"R/.AX]>H-AV96D]8=8[_CQ,Q+*LK"05<S<V%/
M8^CL9CA-M);&LW))8+%]!XQPL+)#&F'<A-#%66[IDFX31/:)Q$<1'$2J;S!@
M14CZU5N-TQ)GED8[/TF^HB.PZK(-<4CE]SC'YHA&8PSAEHS*"5>HQ?"&TC<2
M,K8)]..BXNS-N,-UC'TG=)$SGQ>RV02:@)@-F[HFC9<#NF8P6SH<<HFK.OIV
MMYF+ PXBM#2L3I>4S6N)#OL$+A)4,G4=E!9"0@I0)265;N!RC)LB9RQZE(Q_
MR%+=P8L"@X0/*^M4NJ^RW[/#AO/9C8C^=U41BQ@IKH,V;$0P>#U]L#2<N32:
MX]1-FV9B]DG+MUK30#3\^H %62->]:+X NHLVKY=M@X'UVC,Q@'Y9F6KL;M2
MJL&JYO57$)Y-F.V4KLWWILKQ%HK0^?IK:F]BO"J#:7'<SO-&>MWC1O.!E>Q0
M6Q937HB*2/K1?'5RJ)1"S<@-RB6"+MOVX[QULZP1!",QYM%CD81LP9&M  PW
M+?GB(\^83-MFQ!HVYAV8C7:/*U[6=F3DZK3ZD=O)HK73:W.P$R0WA^<PYHML
MJ"#TA65[["P(S5S%3:X^:*P]%.UV.U(;_OF;99F%E/C<<]O;C#%:M+"_[WOK
M;LK["#)G43I)95645V<&]G4H*(+VZRJA',6I.=VNXCP8'UZZ^5K4@0[]V0\;
M5=DX(S K6RDJ+ 8BFS(-PCMA%="IEQ\WLMMKKEM%S@,'R]GLMK:C$,*'V+TD
M8R/X]5:5H4FWMK]1[&(K4#DZJNLU^C7R"F+K\+75/Y'K+AG(;YAJ_/I&PY!4
M5![.RNM 7/VBKQH]>*PN#HG+-G8@2E+"_8'M&U8VE"HX?%V$BC'^S\V/A<1J
M27VC(+8$>T@+:;,,SXPK+Q>=M5"91I(D%B27-[;I_6[6G)-F-75F75UJ-CC4
MXJ;)/0MKOI]'+MJ=T9;*D*-W UD!D>MU5U].Z&^)_5?1>?J1B[7(S=%@9.78
MW2^XV&YNZ2O&RP\G79K9^EP<RFK(J?&S;S=4*K%R 6KOHRJK+<>W8#J)Y,H3
M=TZC/7V9"3(^VMF!0/O+FZ _>%S:115!\J1<#=&CU=Z'4,BQ;@X@W<(*#TE\
M.QR#]3&C!5]PW2/Q.UV]V5/3F57=7MU2ZDY:K7\CGY.&']5J MC65&ZJI\A4
M=2@X>M;'XK:SWGXU?X4M_P! ].[7XE:/,P<KHL9&'FKIK;,D;[0:O<68ZXM>
M6UV/71FK@YF77K[+:[$R6K]'*LQU+9*8]JW/59\?1Q$K:\D'3:6=M*NA$1K,
M=6J9<+;XBP98UG9&11<5)Q8Z'RJ-[MG9B%"GQ]8EC<RPT;J^]ONFT04QJ\UP
MEHW6]$^'?5^+TIM,S,V-FQ-5NHNU^*V#7CY5N-;9F8N2&6G-MKH%7[FPLO#
MNW\')+#4;?7OGT555"DE,A;G6YK$5U5+$(+5 OW?6.#X\#W^QUMZF>*A[7+>
M4.[Q&4<OH3F<KD4?A];"9>D6B;<D'"(1W6'=@4R4.M^*MQA%BZT=@UE),RW:
M:)/F+IF6?/U]^CZJ^**;%L9-)9NU->'BX^1F;&[$-64U5US9!R]":\S493VU
MNO;>HQG[B4L5Z419BZ_2F@/\RN-]5MEB)0M@:H,$""K+YKR$[2I)7ZAY!4J>
M9,?V%V^HZ!,I,+L*X7DAS*,@759CMP_<^!L07RNSAI,-GT]949?J(;=9'8<[
M#"YS+#HK=9HLDT+MMG"K73C.Z3W6>^-;@:A,?Y7UTV5@MZ.SGO[@KXG9@6;O
M0M<%(L2ZW!Q:;0K@M4W:'RO3S<>L.+;RW>5- (V-2J>2+"UPQ<QAXX*K<[+R
M. PY(S]CVSO&'6$?J.>5375P3B)!T9)(F/7>QD LS:1E9N/<X/[51>.L,^./
M32*,,N58Q9TQT:.'6C%QOHZT4UQ@/TMI,S7T;;!VNQU.%EW'&QWZ@US78;9*
MM8IH_:ND.9VV%JK HR=9A]RJ7'*$&7!F9-=C4VT59%B+WLN'<!;V'CA_0R12
M OD<]F1:>?''/B01*/-+U[B5VC:7/5Q;<=<+2**1R0R:8#0<1'PI>1JC-7[R
M4#C!A,FT'QE EA\4>MDG;1R/;J/A:[UHHW65WN+\'-_EZ2W<X^QU.0JX^5DX
M^-B6W9=F:N.MA1<6VFDU.^2:^RI&*.MC!+51@P&%9U%AU9:XCU9",7K1[+%2
MM*C9V\FP.X8*@8%F"D<>5)'!EN@*11^4#T2T:.!Y"*<8QL@3!DV18>MKG\XR
MD\8+N&ZF,X_3.BF<<\HOQ\C&L-631=CVK_%5?4]5B_S2Q58?U$WZLK ,K!E/
ML5((/\B.09W'+,F.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(C
MB(XB.(CB)A]A&1\=@,W/EHP:FHH'$9(7)PV-@?NF12P>-#/'CV- 8QZX^XS)
MULBJ+& O7'U=ZZ0'^N/F.(E9-1=P/&[;LLZP4#0@M[:4LKTJW+UO!H?5=@J$
MNK'V="9A TC]R_<8D.O2&04=?GH$S#V(NRD[M4^S:B(\0;.47Z*);-Q$<1'$
M2OKMH?B2'9WQSQMT9CR4T>=C9T6&@EWX[23.H^UZPW\S?D60Y17!180W(N6#
M9V[01V9IO%VJ*N^%E$M<I!Y^WXC^W/G_ "E@O$F.(CB(XB.(CB)CLMB,8GD<
M+Q"9 ADFC!YFJP, S#1)Z.?M%<?TDEVZVNVN<ZYQJHDIK[54%=-%D=TU4]-]
M<?*Q<;.Q[<3,HJR<:]&KNHO1;*K$8<%71@01_3D'@@@@&;/3;K;=/;3"W6CV
M.7JMMKKUR<'88-SX^5C7)[/7:A!'()5U/*6(S5V*R,RFLIW%[G\>;IP;KIO)
M;RZ<9<*O#M;*+J%K-HIJLHHN\*0ATYWQO(H6TSMLNX#N%,+-$_<JMLVVP_/.
M?-VQ=S\/V:[7+D[SHX,7OU?<;MIH$)+/;KW<]V7@)R6?&=C;6/*D#U+3]7T[
M?H3_ !+TU8'4]NJ^'WQQ%:4:_JI:EPND_B%;6BUT8?4%52E=9OK@!75G5+V7
M-PB"X?+ZZK<1H'ZN=R8;$[#=1.L+RC"*+W[:)2B+A9,J!5?Y:Y+COE3C%P\
M$=E&;/0J.61:NL*-6_S"6<)H[<]3Z<ZMR&PAL.F-[E4XF<$9[=;F7XPM-?=V
MI>E;UL+:2[@UW*+*RS J.3S\N]9]#[WHO>Y?376.CLUNXU[\68N;378K5O\
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M!!!\$$>XE2.];K96S(Z,KHZ,5='4AE964@JRD JP(((!!Y$H [.RH@W[I2)
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MMC4U)3ZOHMD6TG(JOQQ9394;3'A%[1U7/X3/Q]V44Q>QN5Q64^Y6)DY*^&K
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M%@(&2%-N+V1/2?Q$_G7V^W7VY]=?;CVYQGUQG7T_&?7^/KC^/)//)Y]^?/\
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MKS-?9D"FK(:BG/QFLQ+KJZKJVMKKN9Z^X!P#.[Y>F!-69_TJZQVC:C.YY[5
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M'KG+DG7Y!$/: KTTQG95L!"3I-'/IKJ06QGWX?M;;X)"[?2VW5 ?5L-$QV%
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MHQ!JBB=7E7$OS6KR?6LR9FNS( R^A[L)K,) VDKU^1L%T]8(%R$>?X>.D3U
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M^?36[)P P" ^;;*,VJQ"W<BT-8>PV,CUQMVLFUJMN^_CW@+Z-1C:J"-U3.2
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M%3;T"W3?"3I/9=3J''[K(ZBR:K-?T[@<GP+LC)MR+L?R"+\6L\CW&^X &,C
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M^,.RQL+I'!Q.G>G\1.D=[TWU!19CU955FQS>FM>^MQAL"F0OK+ETMZV;;_\
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MNWI5LRH.?^9V"HH^[,!/ .A>E<SKCK'IGI' Y&3U#N<#5K8 2**LF]5R<E@
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M@7+]--NMOMA/9$\]?0GQH=C:C[60SL=V<ZD]5BEA,B!CY6S:EN(/7T%HH82
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M(-LWSV%J-E0<GYW/I!V=]V#;KKFLJ'JY-6 N/;6MN2&M<BNXU%W<)AZ/XO\
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M-*I:H$6B+Q#9)VV3=IZ)X6RV71WSLDBIC;"B*6VENRJNU62Q0P>MZF]PWIV
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M(J01*/Q$A$61.[V#2SG#H@].#TXRF6'UN^ANPAP*+E AOYDT.;QM$AZ$>+I
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M"Q,3 )RNVW9*KH[.(?)AVRFI((1:-Y(()!]U]_(^QX_KY_#G\?:7'J>M[*W
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MVJ+9;D# U#Z[HC'Z_7X?UE)! 4DCZAR.&!/'++]0!)4\J?I;AB"K =K*37)
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MXB.(CB(XB.(D"WEU\C%[B\,CTHLR-.6H4Z)'JP2T;#@@[;8VWT2V7/!(;)@
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M:_8X_$TU+FB$;<D;%JZ:R,,(4[_=>@'51:)MR"+E7$NEO6Z0VU@Q*I<T+*_
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M87;E( A"^;.92K[ 3KY&K+ /2Q975]DF=+890V/,2TY5$1PK/ZY_OX_KX_\
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('$1Q$<1/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img29677477_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_9.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1^X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'YR^@)(X0DE-! 0      ",< 5H  QLE1QP"   "   < @4 #TUO<F4@
M8V5L;"!D96%T:  X0DE-!"4      !#M61X':)J%])Y\81HO@KXB.$))300Z
M      #E    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O
M;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E
M96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10
M<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M #^    X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             $
MVP  "=L          0                         !              G;
M   $VP                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   $VP    !29VAT;&]N9P  "=L    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P  !-L     4F=H=&QO
M;F<   G;     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    #.$))300,     !4B     0   *    !/   !X   E"   !4& !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !/ * # 2(
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M0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M9E _P6Z!J_3KE'B37PHX!&21$%W9ABS')Q<Y/ND=$J,+@@,=^V/3XX[4+YV
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MAC\S<WP.:JW7_806RO ](ZO1WZV67Z[=9>R]<[%Z"TB<T[2Y4*H215LGVPJ
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MN8_ 9V+N:XS!3NTZY"W1*B2S.O%ZP.UC%*U].JE@,"+L9G$Q'-JL.&GO-/\
MQ33-%-*"]M&4RA09Y3*<%AXN,H5_*I#$-G Y;K_M)AT;7ETN*S6\M+9A'J4Z
M2$3),V"R6JY\-C; XE60@R2<T0,?)SMU7ZH]P]>=H]:FK6S'=UK?];RG*]OS
M4%Q)#V[7I2Y08>9I ;8Y"%M0B%5G0D+/4K8,'":Q=JD[%L(F0A&9L.!K4T,M
MO*\$Z-'+&Q5T88((_0@C=6!(8$$$@@UTFSO+;4+6&\LYDGMKA!)%*ARK*?U5
ME.5=6 9&!5@&! Y?;-['[7[RW0I+TOMO8^CNG%+F2Q%)N^I2_P"QVR^T%O@O
M.126Q1MUS!E%:UH*OR6W!U!C@<0YFVR+4^W%)SE#:K4 ]LVA\/K>QFZO?$2W
M;(AC0E7E.-Y">4XC&1R8W=LG91[W-.-^/Y-$F73-%$,]^A#7<\J^+#;#8BW"
M!EYYV&[Y.(EP,%V/A[]ZA=S[70[S$ZG]R;U#(6\I]J]UN[%V-@15A_8&OL(R
MY*U[=7(3 NKBNQ-):Q_YP<,CC(6U*LEBZ5@3'*0K@%#UFL:3)I=QR^\]M(28
M)2-R.OAR8&!(O0[ ,!S  95=FX1XKMN)['G(2#4;<!;VS#?E/03PAO>:WD['
M<QMF-R2%9^O>%)5_E5C/Z9QG^W*>MNK^\4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2OPEQM2EH2M"EM93AQ"5)RIO*DX4
MG"TXSG*,J3G"DX5C'E.<9QYQGSQ2OTI24)4M:DH0E.5*4K.$I2E./*E*5GQC
M"<8QG.<YSC&,8\Y].*42I*DI4E6%)5C"DJ3G&4J3G'G"DYQYQG&<9QG&<9\9
MQZXXI7]XI3BE.*4XI7YRXA*TMY6C#B\*RA&58PM>$>[[^4ISGWE81[R?>SC&
M<)]Y/GQYQQ2OUQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2N=O=_MY>]-6#6>@^O8RF'
M>QNW8IRTM3]@0RYJ@Z?U%47X4.S[5O5?K9JN'K!F<<)B*5K^I0[%6<VJT$ID
MET]"#U4^M,_3=/EU*Y6WB(08+R2L,K'&" 6(R.8DD*JY',Q R!DBAXCX@M.&
M],DU&Z5I2'6*WMD8+)<SODK&K$$(H4,\DA5@B*3RLW*K1OJ1WDMMSV*KK+VL
M#TRC]A)(XE8-8VRBM%QFH^Q]0$MXD&Y^NX%E*'#-3V'2V%MN7[4IBQV,H/%K
MCW"MGK)5WY\@%]ZGI<^F3".4AXWR8ID!Y) .HP<\KKMS(2<9!!(()P\-<3V'
M$UD;FTS#/$0MU92,K36[G.,E<"2)\'PY0H#8(*JZLHVCW8[A9ZU :O2-;@!F
MR.SNY'B G2FL)\Q^*(;;&)C_ +3;5V7,@>\0 :?UO'F1)UJ*1DI(G"4L)2*W
ME=DLPY3,:SM)[ZX2WMUYI'.Y_P J*/S.Y[*HW)ZG8 %B ;+5M5L]%L)]1OI/
M#@@7H,&260YY(8E)'/+(1A5Z 99B$5F'/BI=Q>UG5*P"+OVJVJ-[&]<#LAB)
MN"V#-55O7EOZV2Y[B41]C5P51&DLVW00B6YB)>0UE:L.RJ*"4W>/VUM@L2>&
MIO\ 5>&WL;=;BWF:Y5%'XA>4!EVWE0*3F('\P.60>\69>8KH7"WM(@UW4)-.
MO[:/3I)G/^'.)2\<P/Y;>5G"\MR1@HPQ'*V8U5'""3NZ**C#HP<;"$8)@,7@
MQ"@DL+EQYXPH-GL-RH) ?.B..Q9L&;%=:DQ)<9UQB0PXV\RXMM:59U>NGU[_
M !2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2H
M[;[=5Z!5;'>+O8!%3IU0"$[):+.?GQQ80  #0WIY4N6(RW&HT(>/A,/294E]
MQ#;3+:EJ5C&.*5PPF]GNX_;*?)V3JG;IKI]H&:^XYIH$$U7KBV;GV354JS@9
MLS:DC=52O 6DB[@TE!BJZT 5$99Q%<DP)-OM'XW.E5X'MNF\,_B;<7%[+)!X
M@YHHHU7Q.3J'D+@@!A^5 O-C<D'*CE7$GM(&FW[Z?I%K!>M;L8[FYG=_ \4$
MAH81$RES&?=>7F*\X90I YCA[U7^ZFY:48T]N'N1!/Z<M\50784&CZ KNLMK
M7>H2O=:.4N9LT->)P8 $M4##P:R3*EKH%8)(6>2AB3 1Z2B7'EIPK;I*&>ZD
MDB4Y,?AJKM@_E+AF 4]"0H;&<8)!%1+[4K^6U>.'2H(+ITY5N/Q#RQQEACG$
M)A4EE.2H>3E! YN89SO416QH06-"AAL(6'$#X8L4,@1VXT :-'QVXD&!"BL(
M0Q&B1(K34>-'92EMEEM#;:4H3C&-J#A0%4 *H 51@*JJ,8 '0#&/(=/*N6M$
M\KM+(Q>61W>21B6=W=BSLS'F)9B22<Y).36G=G]4-#[G.1K-LG6XJQG&A.*]
M,(HG' ;MBJ^):9_[(75%>*B6;Y2_OR<R\TVZ-GZOF2X^]D1EQ]]3D&XM+*Z=
M'N((I9(\!796YL Y )4@.OHW,OIO5SI^LZSI4,MOIU_<6L,V3)&F"O,PP60.
MK^$Y& 9(N1]AOL,;NC X@^)%'P(<:% @QF(<*##CM1HD*'%:0Q&B18T=*&8\
M>,PVAEAAEM#3+2$-MI2E*<<FK(  %Y0%&  "  ,  #L .G8#/EM3R0M(S/(6
M9W8L[N269F)+,S-DEF8Y8G))WSFHC>=:4C9%<GT_8E-K%[JA/",$:U;P(NS
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MM;J ^'#?%/OR_K3*^6QQT[;GKGI@$$XSG'RKLUI,+L.O:CUR'VW9/VNVE$J
M3.Q;$AN&S%(W:3":EV=0UJ!&AQ6@\8P_,AA6VXZ,MB8\)#N7'L..K5\UM#BE
M.*4XI3BE.*4XI3BE<\>XG=DQIBV5OK_H*I5_:79RYA56Q8>SE9XS7.FM;IF.
M#O\ %'<1(*Q),H'%"C$D/0Z.&3'LFQ#,(JU G!00*PV01.T_3[C4IQ!  ,#F
MDD;9(D_U,?7HJC=CZ D4FO:_8</6)O;YF/,WAV]O'@S7,I&1'$I(&P]YW8A4
M7<G)56JD.[->TZ"YSF=*Z+[-;=_>PG%#WUI%R$I6/.6L2&]F[Z02;;5GPAS,
M(6MU"<>\E"LYSS8)>$IEQX5[#)Y\\3Q@=.X:3;<=<?#&]:';>U:QDS^(TB\@
M\O"GAN,C?<\ZV^.G0<W??IF#ZZUY?W[ULO>^]+*#NN^MPR <:R$:L.("J/1J
M%3F9L:@ZBUM ,3)Q>-3*HHJ>-RIY.1DK:[K:K5:B34+\3AB16PZ/IR:5"Z\W
MB3S,#+(!@87\J)N3R+ECG8LQ)( P!S[B[B.;BF\B<1-!86JLMK;NP9N9\>)/
M*1A3+)RJO*I(1% 4DEF:2[0TO2=Q5QBMW4=-=;&&!MGK)X$8+5JY4BW@WLR0
M-THMQK\H?8Z?;0<C*G1A\"2A3F4.2(BW'8,N9%?F7<,%["T%S&LD9W',3E6!
MV96ZJPZ9!!Z@['%4VEWM]HUTE[ITYMYT!4E0"LB,1S1RQD%)(VQDHP.^&&'5
M6&&USH.O:]L%FO$RQ7_:&T;G&&C;3MO;]M(7S8Q<&$R]^!5A!R>VQ%!U,*J1
M)?'U>LC0@!$^7-+OCWS$^:0D1["QM-.#?A5Y6?'/([\TC8Z L0,*/]*A1G<[
MY-3]<U[5>(7C;49D:.'_ )4$*^';QL00SA,L6D/=W9F /*I"Y6MKR1+,AEV/
M(80]'?;<9?8=2AYEYEU.6W&G6G,*0XTXC*DK;4G*5HSG"L93G.,V/B\PP<,I
MV8'# YZC!R,8._7/D*UWP.4\ZY5E(96!PRE<88$;@@@$$8(QGM55H73O6]7:
M<@ZUN?8_3 #+S\ABEZ/[6]D]0Z^&.R7EONI :[H>T0='K<?+RU+Q!KP 5 1G
M/A,9*4XQBJ?0='F9G:UY2=SX4LL: G/1%=5&_90HZ  =*VR'COBZUB6)-3\5
M$'*IN+:UGEPHP.:5XC(Y\S([,<;G))K<'7#9>U>LO:#2FJ;1NK;&W>OW9:3;
M]9CHF\;E-V7:M7[R!5$MLFBRJ_LFQHE7J?5M@U.F;!KIBOV\]8&8MIB4Y^NS
M1>)Q* 0UCB#1K?3TAN+3G$4CF*1&8OR.5+H5)', P# ABV"!@[XKI? /&-_K
M\MYI^JB$W<$2W,$T,?A>+"'$<PD0'DYHW>+E9%7F#MD>Z">[/-7KIM.*4XI3
MBE.*4XI6#-V>M5G(C%DL(.OY/F8=<!8-EH K)JPD4O+'@A&)\B/^)&9R(\A4
M,7#^VG2DL/*887AI>4_:1R2<WAQO)R(9'Y$9N1%QS.W*#RHN1EC@#(R:^6=$
MY>=U3G8(O,P7F<]%7)&6.#A1DG&PK.<^*^J<4IQ2G%*<4IQ2G%*<4IQ2HO=;
MI5]=4ZUW^ZF8E?I]'KQFU6HY-4O[H&  !SY4N0DX:2X[EN' C/2%-M-N/N83
MA#+;CBT(5EAAEN)HH(4,DLTB11(O5W=@JJ.V[$#)V'<UCDECACDFD<)'$C/(
MY.RJ@+,3\ "37./JK[7#J=VB'N36["O4$LQN56F-; =J$P(D_M$Y(@!IPN55
MAH\D0<S]\R=&09<-]?D42)!8$N5]Z."VI&PZIPIJNF,%,?XL)9_C+A[59'CM
M4#.K+*Y50"O(S C\RJ[ <J,13:?Q#IVH(763P UT;6%;@HC7#A58&)>8DAN<
M#!P02 <$@5U$YK-7M.*5P&W;>-M=G>S_ &0K;6]]V:FTKUQOE<TA3:;HS817
M4DRUW:-K.D;)V/?[K;ZAB%=364D=CC:17*^U9(5:%QJ<2(OAY14R[*8VWA[1
M+74+>:YNQ(P$IAB1'*;JBLSDC<D\X &0!RL2#L1R?V@<:ZIP_?V>FZ4($=[7
M\7<331"8D/+)'%$BL>5<>$S.Q4D\Z<I&&S "?6&IGH[#NY-Q]D=STFOS(MF=
MI.^>R6T[_JK,ROO)*P"]HI5BL_[)V>."DQ6RD9%T@FQL&5%:(_=T/QF7VM@3
M0-(MG640EC'EAXLK/&"N3DJQ"L%Z^]D=#@5H<O'G%FHPM:-=HGCCPS^#MDBG
M<.>7D210TBLV< Q<KGHI\[;#FH\V-'EQ7F9,22RU(C2(SJ'X\B.\VEUB0P^T
MI33S+K:DN-N-K4VXA6%)5G&<9S9M*#N#D$ C!R"#WSTP1Y=OB36L);LK%65@
MZL596&&# X((ZA@205_-G8],5D!LL'.R*3"+BYJC@MTV$3$GPY&3 5C [+Y<
M5AEU?X@+9_%Q7VI"'AZ*W@H.^T>QB;&^UC-*#R^\N&!91S?F48)8#_,!D9(V
M&1YU8+9RKS\T4B^$XCD!0@1R$MA'R,(YY7PK>\2K$#W34J:'9SCT1\<?3S_I
MG'Z>/7\O7GP9%'<G<=\ ;'X'?R-9DMCC8?#;(/3X#O\ >:Q8HS5S98V #V.O
MESU9<CM6,*,,#9Q:ONR\.YBM&QL62[+%.2<,O9CHG,QU/X:=RVE7V:\XQ"Y1
MBRJRDICF4-S,,].8=0=N_7SZXEMITZ)'(\$B)*"8W>,JD@'4HQ7E<#(R5)QD
M9JM&R!.W=@[;U02T'OS78VDZ\*$YV\]<-M!K*:M(Q9LM6(<);\1)*4)]\Q4;
M_4/,B17VQ5E FGL/%S-9D#!,NVO+(Q7*2QB6<J!"Z2[0MS,I++D?YT8;@Y*,
MFV&-9OP/@QG\1;2J)1B.5HR <QI(.0D  A9(I21S$QR(1A6!.6ZV6;?U[I1T
MCV+U0*U+<H-Q,#0X8&5:+0"U4;:A20YO#B2A5UB0M4F3 ?;>>:R\N#B;B-"7
M*<&P<UT+:*51:3F9#&K%G4H5<Y#+NH&!@$'!ZXR<<Q@W5I"C#PCS KOOS'()
M&<\J=0 >4;CS.:WG)@>,9S[OG&/GCSYQY^'YX_MZ_3',2R$$9^7G^FQV!/<^
M=5LD'7;;[VW]2>N,^M5VL&KME5[:)+=/7S>5CT%L6TU +0MAO#JA2M@4_8U:
MJQ(P6IJ[-3[J,EQF[+39=CL;5=M(6>))MB[ 3#E<E1N8$>!6ZCHUMJ<B2M(\
M,RJ$YT"L'09*AE;'O DX((.^"" ,;-P[QEJ'#4$MHEO#>6LDAF6*5Y(VAE8<
MKF.10WNN%4M&4.ZY4J6;FQ1-GO?A+YR%[13;J[E"0M\$/GZ5ZM-ZH=F(3[S$
M*T4P5I8?;# .0[C[&>@?L<*>Q%<<_#CH^8AB4W%_\(V9C;%U<^(1A&(B\-6W
MP7CY.8KTZ2+WZ'I:-[6M62X1GTNP-J''BQH;@SM'D<WAS&7PU?&>4M"RYV*^
M?13IIW9A=BEG=3[1K4;47:O6PF(2V-JC)!<\)8ZZ_(P.A[?TP>DML.WC45@(
M8Q';F_8MV&CFG<4^^#11M,)PMI=[97%A.UO<H4<;JPR4D3. Z-C#*?D0<@@$
M$#LNC:SI^O6,=_ITPEA?W70^[+!* "\,\?5)$SN-U8$.C,C*QOIR)5K3BE.*
M4XI3BE.*4XI7,_VN&_-[]9^DUYV_UY(H W>OVJ@12%G4"#V-=9JYBSPAA,DT
M)L \J&>S+F2!8%YV>-EHBQ#,B2QB/+:CS(VQ\*6%CJ6M6]GJ"EX)(YRL?B-'
MXDJ1,R+S(5?8!G 5@25 .02IHN([R[L-)GNK(@31O#[Q0/R(TBJ[<K C&#@D
M@X!)VZCCE[-+OAW"W%[2,4O;I*X.:F[-:,?O3=/G2RCNL*A!I-'3A-^UZ-G.
MR(%7"+O=1LM2G.CW6&IQ$\^Q8'RAB)"EM[?Q%H.DVO#S+9)&;W3K\6WB(%-U
M.T]Q@03\N&ED\&6*11@D!/X85"PK6]%UG4KC6PUTSK97U@+H*^1;PK#"I:6,
MGW402I(CDD9Y@7)(!/T_ZZVC0MLA9-BUY9(=G#0RDL+*FPVI;"6"<+#2WXKK
M4V/%D(7AE^/(;4IK"'HTB/)94MEYM:M#UG0M6X?NDL]8LI+&YD@CN8XI6C8O
M!+S!)%:)W0CF5T8!LJZ.C ,K ;+H'$NA\4V<E_H&H0ZE:0W,MG+-"LJA+F'E
M,D3+-'&X(5TD4\N&CD1U)5U)GW*FKRG%*<4IQ2G%*<4JI6\=][#T992-M/:T
MP1ZV4^BE+AL;9 TJ&P<K$4-"(SRT] <I8!*IL,3&BQWWQT*-/-$V5R$!8DR>
MF-!E[98Z3H%YP]+.-5N/_%3ZC#:V.BI;DP3P320H)7G9 JD!Y6+>,H3D4&-^
M8E-+OM7XIM>++:S71+1N#?\ #)KK4-?DN@MS;7<4<[^"ENLA=@2D*!3 W/XC
M,)4Y<-\*,+K_ *\W#5-?D*;V-JP^\=I.W=OJ[-1V=F14GJ;0:O@AD%LO89)I
MPM7X$D@[=W%38B3$ME^7.C"ZO./385F_">JR:G-827)N;!Q;:3H\4KW$#+(C
MS2\GB00\W(W(O@8#%1@(7D"*8^;2TTZ*]C@%O?*9M5U651%,K1N((3)RRR8Y
M@6)D)P#NSA%)8/R_:5LF^.F.GY:B=+[F2O-[UG,Z_:K&RJ?)*0SB0C6SM=T^
MP3EG(=6MDH6'G:_C6:65O(6MV=@"#:+66%'FJ%>[SC>N:)K6E/;7>K6$EFNL
M1M?V;,T;1SQ3<LI*&)W"E1,G-&_)(H9<H 1GHW#W$O#^O?CK71-3BOWT.?\
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M$MQ*]N3)&THE;/XKEY"L7X=?>=_C0T:2[R;28Z?V('4]@7VI=8=XM=:H(P>
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MN\8V]_IVL/I%]KHX@72X8+>VNX[F2X@BA>&.06\0D>00F+(22-'8!U/,>?F
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M?E0G&21@G &YW \C\\8K#S(7QQE/C/\ 3/C_ %^'CUQX^?Q\YE*W<9VZCO\
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MY:(?PLAYI8U7:V<[[ =(F[=D;*[#E%?H7@#C4:M FD:K,!JL"A;>:4A3?PJ
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M?F;J>H)SDDY-5G[ :Y[/V+:FA[#I+;U7H>L*I9I$S>-+/5=@Q,V!7%RQ.<0
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M.)%BC0)&@Y41 JJBCH% V_J<FM9N&GNII;BYDDGGF8O++*Q=W=CDLQSD^@Z
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MS3$<D4,:*J1**U/[39\O%]G'WVD 5/(+,]..RCD1<;*L26\IT]<,O.QLH_\
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MYE#MB=<JM 4KSE6*Y ZGZAM$)I&<X\XCHL-TMKB,8S]GB0_*SC&'%.^>@<(
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MPRTVEIEAEI.$----MI2VVVVA*4(0A*4H3C"4)QC'+ MC8;8Z 8 P!L/(#K@
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MUJFG88._7)WZ8]?EG'8=]JYU]6ZC5+3?^X6SC=8KI"YG^V%UK,LL0"#)1^$
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ML*SGDQ+B*=/$B<2*3[KKN"< [9 Z @@C;<8.,BJF?3KO3Y? O()+>8+S&.0
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MQ#J/CZ?Z^OSQ_'_GY<SCKZ')!SW[C^?QS\JZ1#G8C&^/+['F.OUK0M.VG-Z
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M"Y!SMR@KAA@>\0R^]MG>S[1'SX]?3./CC.//CX?+SC&/G\O]H)C(]?U_??\
MI^_J7!'?;Z^G;8_,?.O=22QG_P!>?X>OP_G_ %QGGP8QW4;]<Y'Z;_'&W:LJ
MW'?/[?V-?M1+'_SJ_/T^7]/3SC^?//#'4+Y]SOW.^YV\NF/E7T;G/?\ 4?\
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M0A*E+6I24H0E&/.5J4K.$I3C'G*LYSC&,8SZ\D$[@YQE3\!C?)^&]5LBEFP
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M9/F>Y/<_&M9N@TCM(Y+%COGL1M@>0'3]-ZD,]G&/.<8^'Y?G\/'I\?.<>/\
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MH%-N!2P!"VI*QM(X[7ZM6ZC2K5L?=[>D/P.<)QM:U'LDR!N!8" =BG3]E@Q
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M*LT"OD0AU;WUBY4<^^ZE@K"=;6=HES+>I;Q)=RQB&6X1 DDL:E65967'B<I
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M3K33MI;2-PZ!^RUI@#-V7,":,U2<.(&Q[='(ZN-@:I,''G94G*DTZ9/*S'E
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MD%')8%2V0J<^_0D\O4[9RP;=Z(M#:/LI5%U :LTQ>F(^$@JU0RYJAQ-P[UK
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MKB('FYE 5T?D."%96Q@@UYP76W3%98G8_88#8)4W9<G;BB5G#ARTV+>_LQ<
M*8&8R-8AB5U($ K-:J>!L.*L,&K )*'72$19%^9';0IL$5R9&ERZACXG^4C8
M <JJBKC& H\LFEN]4O9#D3O&JVXM.6)V0&'+EU;#%F\5Y'DE+$\S2-T4A1Z,
M;0.C _W%(C3NL1:1=E;N8Y ^C5J$B#;6\1,,62*B..;0R:C8'C_NA%M*943\
M.'YC.-9@1,LRXK6W V@A #\Z@(N VQ#;# .RX.Y&!Y"JF?5-1?//?W;%XO ?
MFGE]Z$YYHCEMT)9N93LW,P(()S@(VA='!83@L/I_60L6Y^*X<'CZ/6H<-23N
M 6#*%1HXUMG*";=5K#4UO*,H?8K@%A:5,B![<?/%:VZ@ 01#<@@1J![P!;H/
M\Q1,Y&_(H_R@"OGU74Y'$CZA>,P*89KF4L/#,ACW+$^YXTQ&^QE<]7;,<+Z#
MT:5(2RI/3VL2)*7%LL"5/FT:M29DF%<G[9(MT1^0\-6ZZQ9W[Y>'C[3BLH+N
M7"SKGX?R=)YDR19VK$EK>!FS("QC3/O\_.,\N2'\64MOOXCYSS&H)U;58T$<
M>HWJ(KQ,$6YF5%:W$"VY"A\ PBVMQ$1^001!2/#3&\?9D,9E[=]HT>:QA41/
M8W4%-;=3ZI7*K/470QF:WCQ^[C,=RY-M+3C.<I5C.%>/3'.?<1D'5[H#_*(%
M/Q$$9/T)(^%=^]GR%.$]-+=9&O9#G?\ -?7 &_?(4'/K77'E'6Z4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7,;VN,%3/46!?4X]YK
M3W9/J5M,BC'^?-?!=C=;BK8M"L^C?W>J'C<IQQ6<)2RPYE6?'IF;IT@AU"RE
M/1+J!F_[?%7F_3-4_$-L;S0M8ME&6FTR]1!@G+FWDY!@$$@O@$ C(K2#.?A_
M'']//]^=A/YEQ_U9_0_WK\?1#<'KG^61],=OI6:C*_=Q\_'CT^'U^7\O7'Y<
MP.,<P^]M_(_OZ=:LXCL/AU_O\MA\3VJ01E?#U]<XQZ?3USC]?AG'C].17&<D
M#MGX8(Q] 35A&<D'ID=/U_E_;KB1QL^J<_+RGX9^OI_W^7([#*GY['TZGYC^
M72K"(]-^WZC'Z_MO4FAJ\I\?P_[_ "Y$;.Q\_P!^_GC<GIT\JM(6P, =#\=L
M]1MGH#\N]2&,OQ]FKQCTSC&<_'UQ\LY^?IGX^?EGD5]GR-\C'PQVWV)/??/P
MP:N83D ]/[_RR0#]1Z2F&OQGQG/Q],>N/GX^.?/\OEZ<QN-L^60<9Z=1^A[=
MS5A"<-CID9'3KW_4;5*(;OCQG_Y?[9\^?I\_./\ CD%U[;[?3X]\_ ;[U;0M
MT[CI\SOT )P1N ?+Y5,8,C'A.?/CTQ\/X_GG\_KG\N1G4GX8P1Z>@[_V%6T3
M[#?![?'N.O?L*T[VIU3=M[=>-GZQUCM*XZ7V8>KK[NN]ET:TG:B9K%U&+;)5
MQ^25KLJ*1779Q&*P*M$!&7?OM?G$6V6\3/NC[,.>(R(0I(;&QZ9(Z'./TQOV
MZ5<6EPJ2(S ,,X=2 <J<@X!VZ'(^%< __L\W7_N()LV^]S]DMG;P#TVI;(V5
M00VF;1?;5^S=KWQ-L$C&\MF6JMK+*$6 F%-)D T&ID8HP:N!*Q%%2OQ>K1)6
M:RWBD)9F!P#L"1NW?T('0^M75[<Q((T4J690W,J@D1[\J@XV!&X'^G'8U]%7
M:+;AO2O7'?FY*Y"&%;%JG36S-C AAIJ8^'GF*333-C'0BK ^8/GO#Y4P:RS-
M:A3X4IR,MU,>7&=RAY$PH41GP-E)WW&>V3WW)VS]1FJZ-Q+*D>X#L 3T."=]
MSTV]#\:HS$[O;7#OHI&T=2SZ]=HECT=,FW!BLPA%;G:UWOVNC==:"5D:N)[<
M(W>GVJV,1C9# F3:K7BFQ&8MI-1R\G+>N)WVDSJ KI@CE/-@#*O($!Y2V022
M?@-^7M6*:WC?)CE!3$P"Y))DB@,S#Q G(0N!O@9)*YZFL9I;OAK;9IW7E#UI
MI:U %;54$O09J&]K8>&'TS9M8+[58OEJ0%LKGX599PV(;GV^EHBSKK"L\N'@
ME%D1S>#:94$ZL418R"Q! ]S'*P+%VWV)&25 + ^=5E[9R1QR2R3J1&"K960L
M71EB$:<R^\N655?/(1G&XQ40<]H"#;*EJO>-3FH;\?:NS-=$FQ=AJ1N(W4JC
MV!K77$78W!TXD.)'2I^T74%,(TD(.)DQX'$^=C[ZLC3H%MD1W8YBKQG\[)E2
M".42+$"02"Q9G&5 ) !/EF!-I3%!)%.N/ 28<R."9&@DN2,@$(JI&V)&(7FP
MO^5BOXL?<&DZ2@;^CW("(#4#KONBIZA'CJ%$A1I=9UX4Z^Z6OP&Q%ZTHBWA
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MV[\\@66=K:1G'2-895 <Y=E$L!D2,RA1GMJ![==NS/0N@Z_L8VGW>7OO:=Y
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MQAZ;J3V0&_#=,EMN,M3-][YZZ=>#Y".ZG*5)DZ]L5FN%AAM/L+Q[S)1B*O\
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MHNP &YWV]<D^6_GY[;U7RGKN.G^V?KL-_P!:V1[)09]YZ[[6V>OW</[J[?\
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M%ST'4$D^C'/4YJMEN9R"OCR\IRO+XCXY>18B,9(P8T2,CIR*J_E4"H="U_0
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M:;9]YQ26UR;*X-I=V]R,GP9DD('5E##G7_U)S+\ZKM7T]-5TO4-.DQRWEI/
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M8+$4M?\ ?5-S>CZH=2'E]5AW;.<#.JEP++A$MZ&C5HU_-[S%),%66)N7"\Y
M]Z51(WNYC',1N#-%OHI2=DN)"5B)C07$#,&26[C\7GD\%7++%;R>"IY^69@B
ML"K)NCMIV&VN(M6K^I'4^&&,=O\ L>DLNH$C\?!&HZ(U8 4TS?>Q>QX.$N8>
M 4],EF!40<MO[.ZW9^&$B,D_ND\3)Q:E="V0(AS+)GE!'Y%'5SY^2]B<YR :
MD</:<^H2M)*"+6 KSD''BN=Q$".F!AG((*J0!CF&+P]-.@>D>F@<H5KK)'96
M^;WC$_='9S9:TV+=6W;"^EE<^6=M,W,F:'K>'V&L!**"D1*P!B,16F(<B:B2
M2EZN26)9B22<DDY)/J:Z.B)&H1%5$4 *J@!0!T  V%7CYY7U3BE<9NW/0:TZ
MHM5C[N>SB#C*!V.'-J.[CZ]"/=!:9[IU8=EV:7J]KJ\%M(:M;M7'5.D:]VT&
M'QS#UAD.";8LD..29X_+#,\#AD/Q7LP\C_(]1VJ+=VD5Y$T4@WP>1Q^9&[,I
M_<'8]Q6Y^N?8V@=I=)T7>6MI$S%9O M<AP468S#L-5L V4^*M%+M(]6<J'6>
MH6"$2KYR%G*FT$![SD5Z3#<CR'MJMV6>-)%W5M\=\Y]X'K@@Y'[;$&N;WR26
MD\EO,!S1L<L3LRG+*R^C @^?4'?.-F&4-DQY <Z\^PU.ARH;KT9S[&0RW*86
MPMUAWPK[-YM*\J:<\9]QS"58QGT\6-NQMYH9@JLT,B2JCKS1DQL'42+D91BN
M&7(+ D9ZU1W8%S!/ 6=$FBDB9T;ED D4HQ1M\.H;*MO@X/E6K]?TUO7E5B55
MH\:L3,.3.D8)GI")$Y6)DE3Z(R%(0C"&&$92AI'E6?>RXYC*$.(9;MM<U9M?
MU*6_-G:6)E2%&@LXVCA'A1!"Y!))D<C+' '0')!+:YH6D)H&EQ:8M[>:@D4D
MKBXOG$D["61G"94+A(P0%4\QSS-E5(1<_(?^.<Y\8QZ8QX\>GGZ?VQZ^O\>0
M%4  #]O+S/7IUZX'SJ1-+DG?I]C^WZYR<1V4]Y\^OQ\^/C\/GGX^GCX8^/S\
M<DQKD^B_OCIW'4GOW(["JN5^ISM]X'V.F^<$U'Y3OC&<>?&<_KZ8_P#;Z>?C
MGDA1D_#.3Y#OC ^6^-P-JKY&\^VY^)^_UJ/R7/3.,9]<Y\^N<^<?+QC'I\/3
M^O\ &0HS@>?7I][#;Y5!D;8^NY_?S_?;UK!25^<^//YY^'R_Y\Y\_3^DI!_F
MV 'I]/38>OPJ!,W;RWQO_/U[8[>F^0]FC<,Z]VUVJZEDUX:AM6MOMKIQ*\^Z
MF30M]$Y[>UPD-M'EGWZ?OL+;3Y!+?V2F!^V*NEQC*G?O,CF7$5F;74I6 Q'=
M 7*8&!F0GQ%\LB0,<=@R^=?I/V>ZNNJ\-6@+ W&G9T^<9R1X"KX#8)) :W:(
M>1=7QTKL-RBK=Z<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2OG6U[55Z&WOV@ZJ2V\Q!U!V:0W5J!IQ.&FYVA^RI8[L4+@=A7A;L&
ME;75M_6+:4^^B'!I@E'O-MR8[2>C\*78GL&M6(+VCD 'J89277Z/SK\ !7YT
M]JND&RUV+5$0^!JT"\[ ;"[M56*1=N[PB!QG!+%SO@U8QA?NYQ^GC/KCT\?#
M/P_+X<V5@"OJHQMUVV_N*YS"P'\Q],9SOCZ8WQMM6<CK\9^.?&?3Q_?Z9^OK
M\,9\?7D9QOGSV/7^?F/EL:LHB!CKC&/GMY$_V^%9Z*[X\>?G\?[^O\/&<?#X
M^O(S+W\OWP=_F/US4Z-NA\MC\/O]14@CN^/'K^?Q^&?X?_-S XS[R[D=?4=\
M]_KW SL*GQ/V)^?IV/\ (^AJ11GO>QC'G/E/C^?\/K\_^?/(Q&#Z'R_VVW'3
MXC/6K**3I@[[9^QDGKV.#GIN#6<8?SYPI.?"\>/>Q\?/I\<8^?G'QQC^'C./
M'(SH5.1DCN//MGUZ? ]/C;139Q@[CMY_#]Q\R.XK0_:[LR(ZKZ*M6VI(.;<K
M*V^&J&L=<B,JR>V?MN[DX]:UQKL$RVAV2]-LMGGPHTER)'E2!P=LH7Q$?:'.
M-YB7<Z6\+S-OR[* 1DL?RK\&ZD]0-]QL+K2K22_O(K:/*\Y)D;&0D2[LQQG?
M& O8EE&Q()V1[/[HA(T&P7[&]C9X_:_?+=PV+/W/MF6TB;%H0V5C$R#H72R'
M_M44[4E#PX@4W%#_ '9ZYDX2[)8')*E"H0C3))'E=I)#S,QR3_(#L!T '05U
MJW@BMH4@A0)&@P .Y[L3W9CN2=R:Z:\^*S4XI6O-KZFUKO37EKU-N"DUW8NN
M+N*?"VFGVD<R3#EH#_C/NNL/8]YB7%>2U,&DHCD<B*(,1B0V7$GQ8\AI2N(^
MA'K]T5[+I]G7M:V'[WIVZU0[L;H%MJWS'R5GFT.HY8S?^L-T.2,9?.W#2L*5
M#,4XL^[(DF-7/Q\RY$1P1&#P[O3+@NWX>1B=B8R=S@#=,^@W'H"/*M0XBL!$
MOXZ!>4%L7"C. 6R%E Z DG#8'7!ZDFNDDB5Y\XQGZ^OGXX_/Y8Q\_I_+..7Z
MICJ/D-B?CG]^^//%:/)+S9P1O_F[?I^W7&"=LU@9$GWLY2G/URI7GT\?[?'Y
M^O\ /.,G4X&<G;;.!Z>G3/3?&<'85$=Q@C/3KV)\\Y\]QY =_/!R'L9\XQG]
MW&?C\\Y]?CGY?#^&/3T\>.9XTY0-MS]3Z^?7X[_# K9Y>J@[?[]=OOIYU'Y;
M^,^?7TQ\/CXSGY8_Y^6/KR0JYV SG<_#<>7ZCL3OT-5<LF3\/WV/?R&.I\O4
M"/R'?=QG.<^<^O\ '/\ Q\,?#\N2@.BC^7WO\//O5=(_EWV'H//[\_2L!)=\
M85G/Y^GUSX_AY\8]/Y_GS,B]^O8?'O\ MCUQGI4"1NI'3H/O(Z_7Z5@9#GC&
M?7USY^N?7/U]?/C]?RY*1=POZ['?&3W^6X&WG4&1AUSY[^?Z?'N1W\\U6W_:
MGM(V31/;@<I33W6?:P@K>LM9Q]H2T%L[+6LM["W,*\M.1Q%7/PMGLL.^ZAP[
MK$"K[:.IM+[='Q/:"YT]Y@!SVC"53W*'W95_]I#GUC'RW3V::P=/XC6S=C^'
MU:-K4C/NBX3,ML_7&2P>$#_ZVV3@5]&V,X5C"DYPI*L8RE6,XSC.,X\XSC./
M3.,X]<9QZ9QSFE?I*O[Q2G%*<4KQNM-OM.,NIPMIYM;3J,^?"VW$Y0M.?'C/
MA2<YQGQG&?&>*5'J=3:IKVK J11JZ(J=0K Z.(K]< P8XT0(&Q4^ZS$A0HR&
MV66T^5+7G"??==6X\\IQYQQ:E*DO%*B]TI-0V-62E+OE;#V^HG$Q6S5:L$%@
MF$,,0YT8BS$*C927(I"#F7#CN2(,MIZ'+0C,>6P_'<=:6I4HQC&,8QC&,8QC
MQC&/3&,8^&,8^6,<4IQ2G%*<4KQO,M2&G6'VFWV'VULO,NH2XT\TZG*'&G6U
MXRAQMQ"E(6A6,I4G.4JQG&<XXI7S6!XT#HM?BO4G<+ZZ'1(]TL&>GVQ;-G,'
M7VQM-6$A*L%0U6,NTC+8*'M#3;4V5K>3K\O)&6,O5:W6+578)D84E/0.@\.:
MQ ]K'87,JQSPY2(R'"RP]457/N\\?Y AP>0*4S[P7\_^T7@Z_BU.XUW3;5[F
MRO LMVENI>2VN@ LLCQ*.;P9@/%,JA@LK2>)RCD+6X8<\9QGSZ?#/C/\L_P_
MA\_7FUD97U78_#^F.A]-JY=$W+L>QP<C^V1@]CU_;.1W?&<9\^F<>,^/^/K\
ML_'QX\?+D=UVSU\_V!]=MC^U6,;[_OWV\^WP]*S$+#+"WEM---JD._;25H;0
MA3[WV3;/V[V4I3EUW[%EEG+CGE?V33:/>PA",8C,HWQL>NW?&!GXC;.>HP?,
M5.21CR@DGE&%R2<+DGE&>@R2<#'4GKDU(F'O'C./&?3Y?E\O/UQ_7F%EYAT.
M0=OCZ??Q[BIL<F.^Q_0]QVV_L1CK6=C2?AC.?.,_]\?[X^7Z><<C,N^PPPZC
M'4>8'\C^NV9\4G0'SV/J.Q[9';MZ8R!FV9'C'C.<Y3Y_CCZ9^GK\_7UQG]<\
MPN@8=,$;CL0?(?/?T/7."3913]CT/Z^1\OU[;],U5_V4%:3MK;G>[O+8V<RS
M=_[ 6/JSJ"4_E3[8/K_U7EXI:6J^MWWLP85\VQ^W5M/QHZ\LS244;(=PER,A
MIG1;^4RW<S=E<QK_ -L?NC;MG!/0;D[5V[0[5;32[., !GA6:0[9+S 2')[\
MH(0>B@5VQY#JVJC?M$>Y8[HIUAM6\7 ;-HLZR@JE:\K4MQY@:9O5C1-=&(,2
M(ZD2&@PL:,+V HW'=8E388AX;#DQ9<UB2U=\/Z.VN:G%8AS%'RO-<2@ LD$>
M.8H#L79F2-,Y 9PQ! (-5K6J)I%A+>,GB,"L<4><!Y7SRAB-PH +-C?"D#<Y
M%%O9R>V'KW:$OI+KWML&0QVDV, O]DL$NAU; W58"" =L]FK(\B^7M$XW$,F
M=<"1YO.!L4T)2]/@LRB,"?,DC!MWQ#PC)IB7NH6CJ=+MI((HQ/+S74C2>'%(
MRA(U1HTN'9-V5]F(5E7F-5HO$B7[6EE<J1J,\4LT@B3$$:KSO&'+.65WA"MR
M@, 2 2I/*.L9<7N]>[*R5#6*L,Z/9KTR/:*Y*B)<LDJP+:(9BS(,G$##B&$O
M?A?NXP3;0RAJ9]I'E8E(1%K[>?A<<,7UO<V5\W%+7D3V%[')RV4=F&B\2.5/
M%P6*^/\ _ 8L6CP\?(2^&[MN,VXRTVZL]0TU.#$L)H]3TZ6(-J,M^RS^%-!*
M(.98U?\ #;?B%"A9N9)1(!%QQU\#8ZS>T^[E=<@R<PM<=C]>T7OUKT#';0R-
MK]UL=A*:@[$,PL8\8RY:+E7Z?=I49E&&XLH[+>\8S-_>CZ)*<S0D[8$B^AR%
M;L<9RN?AGM6'C&W41VEV ,AVMWZ^\&4O'G&/RE7&21^;RJ_+\K*O\V?=3]//
MKG^?KCY>N?'S\?+FPJK-TP!D_'OC.YZ[GOOCSKGSR@$Y/RV^6<''?IT[;UB7
MY&,^GG&$X^&/Z^OY_P /.?'IR0JX   )]/7S/F/B?7N*KYI\YWV[Y^/;KOT/
M3K]*PDJ3Y\^OI\/'U_+_ +\/U\\RJA/Q[X[?W_0;$[XJOEESL.G7X['(W[;[
MGJ3G?J1@9#V/56<_\^/EC'SQCX_GGZ?'DI0% 4??K_3K\\&J^23.3G/EZGS^
M^VVV:P,A_.?>SG/P^/TQYQY\?KGXY_+T\^N.9E7'WOD=OEU/KMV-09&Z[^I]
M3Y???X5@WW?\RLY_3X^GU\>F/'^_Y?"2@]-S^VV!G;<Y!/8CYX@R/U[?/H-]
MM_Y=_+;.%>7Y\YS\_7^&/AC^.?A_+DC& %[=6/WYGH?3TJNE;.<8S]2/H#^V
M=M]MS#NI$27LKVC\JWTU"GZMUJZR[(UEMVS1_4>[L+?UYTG=*)K!+_HB8;KM
M4U(7O5DBM*=<KT&U4G[SAI5G;3S0>+KB&2YMH$(:6W20S$'(4RF/EC/_ % )
MS$=@R]R0.\>R33KRVTW4;^=6CMM0GMQ9HPP9%M1.LMP!_HD>41JW^8Q,1[H4
MUW3YJ%=<IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*YD=^NL6S[M:-7=H>NH 7;=SZ=#6JCVW64XQ"J[N\-(W)\68+4L39B;C(,5
M?:=; (BXZVDV=^'6WY+UKK)0L!C6]XZ.L])U)]+NUN IDC93'-&#@O&Q!]TG
M8,K ,N=C@KL#FM:XKX<AXGTF33WD$$Z.MQ:7!7F$5P@8#G W,4BLT<@&X5N8
M LJBJ+Z^[(:TNUJ=UM/D']9;EA,*?+:.W%7B.L]N#D,X=R_(C5"RMQ7K2(8R
MR[_^:J/*M-0E(0IX?8)<?*7<]*LM5L+_ !^'G4N1AH7PDP]>0D<Q'<ISJ!G!
MQN?S?J_"NNZ ['4+&06RG O8 9[1@>F94SX>3^59A&_3*Y%6.CN^<>//KC_N
M/YX\8^?]>2W3MY]_EU^/3KVVZ&JR)_/L //Y_J?UZFLXP_Z8_+X_#X8^?CS\
M<?EY]/./'PSR,R]0>O0]N_\ L1TW],YGH_U[]-QZ?'T_I6>CO^<8QG/K^OQQ
M\L?[?Z\P$8SY'[S\#W\CG/?$V-^F_P #_+]_VK-QI'C./7U],?K^7Z_E\_/\
M<8'0#<;J<Y]//]>WF,]1O.CD[CTS_3^A\MCMTSK$G&?&<9\*QZ_/S_SC^N/G
MCY\CE<?#.,X^H\OU^ASB?%-OD'IOC?OOGS_OC.,YJD%O"IWG[5+H=ITJRB;3
M-":[WOW7L8B0E#T(K<JU^R^EM.DGF<^/LI-.L>QCUC&2$Y5G\2;BK]W'W?RK
M6-??E:WA'3E:1O4YY%/;<>_]<]]^H<#1!X[V[(RW-';H2-P,&20 ^1)C/0=-
MNM=_N:[6_P!1RQW"JU!J(]:K&$KC1!R:R/<.%((IJ<^.%SCDZ/%=GOQVGWXH
M882*OLH7E;0X?.FK2F-$D.M_2JSLJJ"S,0JJ 222<  #)))Z #)KQF"@LQ "
M@DDD  #<DD[#YU\5P'VV7<2B;EVCV?N VPV/6FU1MIH_7S1UFDD NIPS@JTU
MB>W86(<%EE\Y.I%:1@(?,C7HI2R6.V_8K+M0H4R /[*_!FD3V=KID+QQW-J8
MY]1OHPKW3<\4@\-B20@FD//'&V5CBASREBK-RX<4ZI!=7-_*CO;W#/;Z?9/E
M(25D4^*,*&<QIA7==Y))0 0HP/L_UK8CMOUS0+9:*^NIV:T4FJV*Q55QU;ZZ
MR=- H!(O7UON(:<>6&(29 Y3JVFUN9C96I"%9RG''KF-(;B>**3Q8XII8XY<
M8\1$=E23&^.=0&QDXS7387>2&*21/#=XHW>/.>1V4,R9VSRDE<X&<5RD]M^)
M9J_4FG]K1S*47+I-V,T/V  SFL9;G.UQS8H/6NSJWF0WE#F0]EU[?#K)J IQ
M$>:U"C+=QEZ+%6WY#(8IHI1U1U;Y @D>>XR#7Q=P+<VMQ P!$L,B;]BRD*?B
MK8(]15DGY6<Y5A2L)3CTSC&?/G]/K^2L^,9^7GF]!6;H"!Y]#WP>Y.0,;XWP
M=C7$))0,Y.,$]/CZ=,YZ?3KBL4])\_#/NIQ\O3U^6,YSG^^?[_'.J =.Y\AN
M?CUZ[_3RW@RSYSC]\ =>W^V/3:L-)E?'&,^,8\_R^GY_Z_/T\<SJNX[L=QCH
M/7]\=O+ID5TLO7&=^I[_  Z#]MA\@V"?>\^<YSX_TQ_OG^GKGT^/)*KRCS/<
M^9^_3]L"!))U\OW]!_7OU\R<')?RKSXSCQ\O/R_/\_RQZ><_7X\RJO<YSC[.
M.V?\OPSN!4*1SY[_ +#RS]]SWK!ON^]GX_NIQXSCX^OP_C^N<_'/RY(4#;MY
M>N_4;=O+^6:A2-Y=.G7;.^_7^_E6$?<]Y6<^?A\,?7/GUS]?^/3\^25&!G R
M>@[_ .PZ[=NO;%=*_D<]MCW(R3^W]JJ-V0$D]^_AW1S7B/Q/9?: 02K%F5'1
M]X9U;U\EO,A]R;GM:DX4V,&B*U.G5NCMRG([UKV8;K8 5EQ*"\L90\1:A%9V
M$EOD-<7<;PHF=Q&X*RRL.P )5"=RY'+D*Q&[>SOAZYU?7;;4>1X]/TF>.ZEG
M(P)+J(B2WMHS_F<N$>4#(2)2&P7C#?2;$C-0HL:&QA6&(D=F,SA:LK7AIAM+
M3>%+5^\M6$(Q[RL^JL^<Y]<\YC7Z:KV.*4XI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE1*\T&C;/JIBB[)IM5V!2K#%5"/5&ZU\5:*R9B*SC.8Q0&;B31D]GWL85A
MN3&=2E:4K3C"DXSA2N-W8GHB7ZEU(SO#I&]>9M(HL=5AV+TOGF2E[IMEH0[Q
M(M,GKE^TDR?:=8;)!"4S3=9H 0Z_K*Y/PLU*)30!<O"L$.\TO7+O3Y$5I'FM
M<@20N>8JF=S"6.491N%!",=F&^1I7$W!.DZ]!-+'!%9ZIR,T-Y"@C\24 \JW
M2H LJ,V SE3*@W5B 5;R4:[5G852K-YIAF%8JC<00NRUDZ/<RY"+A#,-F>-G
MQE*2E>&Y,1]IW"'4MO-Y5EIYMMU"D)Z4KQS1I-$0\4J*Z,.A5@#WSU'8X\NU
M?G"6*:SN)K2Y1H;BWE>&:-^J21DJRMOO@@X(R",%<@C,]8>SCQCSGSY],^<>
MO^_T^?G\O3.,;+CX=CY?W_?ZBL\;YQ^A\O3X^7Z=JS4:3X],_EY]?A^?Z?UQ
M].8&7&XZ[YV_;TZ9 .VV^*F))\,]".F?A699D>/7&?Y^G_MG\_X<Q,H8;['S
M&^/O_?;-2XY?I^H_MY8Z=MQMF&)GCQZ^<>GG&?CC\OE_3SC/T\\C,F-CMY'T
M]1V^^@P*FQS';OG?KCOG;OU[=?0G)K5_L.9;$?HW/I#KV';)JSM9W/H-V0KT
MD,6B-V<V;9'6Y>/3.)#@>RAI/KCU9D,YQZ9QSF]P"L\ZM^99I%;XAR#7Z/L7
M66RLY$QRR6MNZXZ<K1(P_0UUG(60&*)@0Q E&BE+.1D"0,)>5Y>)$8@4K8I$
M1G"$J2AUL*#+D?\ QE-)4Q D>XI2TX1G%4SD?EY^5N0G ?E/+GRYL8SZ9S7Q
MB>TD[5;0?[X[1,[&U<<LO4'K?M<,+F:9LS!F-J7;.UX%#(CJF3N$4FW*K1:P
MVY;$LK%=8@J?;U97Y$V!!F2V9LDMV#AO1[)-%A%I<I%K.K6[.UY&X-U:VWBH
M)A"%;FC6) L;8*\]RZAV Y0G,==U2[.JS-=6[OI&F2JHMI% ANKDHQA+EE(<
MNS<P'O!(4+!<Y)ZG>Q5ZKTE *U^T&O5#LE8W7V"DWRV#D&V T/6].H=TOUF*
M^]J:)'($#;$$Q '053"=O^XEXP%4&$%CJKI1XS9-9XOU6Y>X3AR!_$L]-_"P
M*5RT]W/';QH#,1LSQNS)R(J@RAF(+! M[PWI]O'!)KTZ&*ZOUGGD#GEBMH&E
M=\1<V"L;(JOS.20F!D*#GM]JS;VOMT5Z5:=<'L'PL(Q-!2I.8!$:XR1@X9=6
MTY$*1(<M*7HLF)-CN*9QAR-*9SGW'<.M-T&O<.ZQPS>1V&M6GX.ZEMHKI$\6
M&=6AEYE#"2WDEC)61)(G 8D/&W5>5FF\,\5Z#QA82:GP]?"_LX;N:RDE\"XM
MV2X@",R-%<Q0R@-')%*A*8:.5"<-S*O&WL9,:+>VJUG#&YPI^@>S3O4^TO-^
MN&&=B=DZK$JD)]:?3#LE=$LLQEI><*PU'4[A.$KPK/FA*6NY#C98&S_ZGCP/
MT./A5?QO*(]*A&Q9[V/E\_=BF)([]P#Z'U%6[=E8QY]?.?7\_7^WZ^/.?TYN
M 4_ =_\ ;KDY^=<B>?S8'(V&WS].V#Z;D5 [S.M>*T5S26QKUHPRW@4@LI28
M.%YD-8?4[G"D)4XB)E_,9+CB&<R<,Y?RIG"VUVVCQZ:VHVPU<W":;S'\4UL
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M,(>/B<U=VD9G=F=W8LS,269B<DDG<DG<DU^DHHHX(XX88TBBB18XXXU"I&B
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M\JHI8G?LJ@D_(5U'VSS:7;^U#V@RVLT$-BO%6LLTA=(X5G-W(;W#LP0*+PW
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MDH#NL8,,<*LPR S2,%)YBC;J>NO3KK,/ZH:0$:S_ &B>O-U*G+%L7;NQY4%
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M["UP;-ZV=L]CWI7-1W*K@X%;N=>N4JP1'9QF"%)DH8<'@BS&/M?M!6V'U/\
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MZ0R\PXMEQ"L\ENKA[JYGN9/S32O(1_I#'(4'N%&%'H!7ZPTNPBTO3K+3H/\
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MM3K-73MFBPXO5S7\@:5J^T-$6N1#V=+$VZZ9M6O<!:YMB=KXIJ:;4KF\8)A
M5YIPT5#@EVE>;>6/J?/^H^G?.*L7?M;=]V]Z[8L.J;,[4=93]D2;_6AP;&E,
M,[!P/K?0ZKAJ_=E6:N%[0@%.$USMJQ/=A$*[9\9@@$MV&+'738[R@QMD>63\
MSD]?+';Y5%K_ **[6QNU'939.L A\*K95CT!!UKMF G19-JJZ[@,]>J]NJ./
ME7ZV%;6#*IKM:VL\/K+FIC%9)D7F#;4]PS-BL+5[D8&PVS\3GIGIL/CFM7[
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M)+#I&6E*_O$AN(A[,.&AZ=+RQ"8??;SP6MQ<^*;>"680QM+,8T9EBB4$L\C
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M_:<A0=OJM]:CM4PE#ZNU@#G7]?L=/6P,M$X:3D)D%R<I2M8[!T+[4?8U3VK
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1N*4XI3BE.*4XI3BE.*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img29677477_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1_(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'ZR^@0@X0DE-! 0      !\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @   #A"24T$)0      $-/)GTL]C>HHA4@U:H05G"LX0DE-!#H
M 1D    0     0      "W!R:6YT3W5T<'5T    !@    !#;')396YU;0
M  !#;')3     %)'0D,     26YT965N=6T     26YT90    !#;')M
M $UP0FQB;V]L      ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R
M3F%M951%6%0    - %( 90!A &P ( !P '( :0!N '0 90!R       /<')I
M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M     #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         !.$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ,U    !@
M   %V@  !V0          0                         !
M  =D   %V@                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   %V@    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !=H     4F=H
M=&QO;F<   =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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M24D?CXKV;'TU
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 1$  A$! Q$!_\0 'P !  (" @,! 0            8'" D!"@($!0L#_\0
M:!    4# @$$"@L-!0,)! @' @,$!08  0<($2$)$C%!$Q05%A=15F%VEC=7
M<8&1E)6VTM35(C4V4U15H;&UP=/6\ HCM]'Q)3+A&"0F-$)$1E)B&45F<C-'
M9&6"A::R.%AC=YBBP__$ !P! 0 !!0$!               ! P0%!@<""/_$
M $D1  (" @$" P8$!0 &!P4)   ! @,$$1(%(1,Q408B07&1\!1AL=$C,H&A
MP0<(%20S0A8E-%*2X?$7-39UTC=69'2#E+.TPO_:  P# 0 "$0,1 #\ [_%
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MIU<.3/Y2,&:Y!&72;QK&W@EQ\&72.$LZ]<V+9>S,@\GV7+8\4L;5I0G(LJY
M1)S0B%80!6M&WW[??T_3??ML$V=^6S9S,VY>P+C/D_M?6<)O@@<"2Y6!BG&4
M%D2>%.N0HBCEK.S/Y?A&3K&QQ(*.<6I24K3%!&YL3N!*-0G3A/,D&4;ARG>
M(?J=SKI8R^US3"<QP?I]*U/CD^1T\=;X9D7#B-HNZ2Z18_<&V0N:YR4P892U
MND32X-S:X]N-#X)N(7)69>H) O\ T<:GV;67ITQUJ4C&/,A8RB64T"U\B$>R
M@C8FZ6K(N6Y*T+-)CD,??)"A3M4H2)0O3#<;AVRJ9EB)<,@HM43<0&3M * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@.FQRDL\PICGEVY*]9YUQYKT!Q-
M;R>&/V]JRW@T:HJ3RE]'F!W/)@*\:;'N1QB8EZ%(Y/RBW<9(#NA&T&[D4(-D
MRD"T=5VL73!A/E5^2!U6S_/2A?IM,T*Y?,;=0$I9)2YK9JADL:?F.-2EZ;&.
M)A?QO4O7KD"MQ""*M_8G!R&8>@;B+]C* QTRJO7ZKTG+^\HOBZ"3&+Z5,E:(
MF+!^*IG*XF^0DS/4B@T=8QR+)#''Y A;7E2R-2>/6;DCPM;R1#0.J%,9V!S(
M>FUN I/DZYK&G+6MR/K]I9U-YDUZSMCP:5C#4CC/+\&?G^%:%8,Z8HBZ696Q
M3.5,-A[% "F%6!YAK>-$?(%SVU1YNC:N2.:=];TB\#=ARX6-XSF'47R.F+9P
MD<G&#9!UH2*'S5J;'=X83'R)O\#);I''5;HPK&]T):9$R'.#(^)TRU/W18U[
MDW'#NF5'AN!HERQH=TV-N#_[0X8AQN8F1Z.<UL1^E1C+D4MM&L#*92K99%*E
M^-(W=YNRL+A(;L["V/+B0A&M5QIF:6$1X6E*6GN!EA-\3ZJM57*5XR3:?]44
MYTZZ@'CD \+3R^2V1H:'USGLA6S,BZF&R5Q?=E+&AETH>D;@YRQF/)D3,N0$
M+T0S+@/3G 5ABEPPGD3D^N0RQW"\8WA8X5RN4(PQJ4QF_FN+XKOF9,@GY66^
M^J[[<Y<>&<I'M-(#VA?SR6AG?B8O:PTK1M3[^_D#[&G:'Y'T>\MSH@Y/S(87
M<_#FD*4:\<I:9<AOZLQ02?I8U!8!>I1&8\K<#^)M\:2.'S%D=W0TP!(G,Y<C
M*(1HT",!H&.^1(=KFUL:7N4!USXOT>-LIA^H;4HGU=X9U2N><X]&<GXMQGHJ
M=GQBQ<WQ#"KA'%3\_J&*#,L\9BST,B:%+TLDJ@UM;5 F],4Y =VO1?J,:=7&
ME#3[J49BB$Q.8\61.9.+<F'<PEEDJUN*(E\> 8+B.\=E:9Z8ACO_ +XV\0NN
M@.O/I2Q3/,V80_M,>(<;%J19 R7K!UDPZ%I"3.U37>0/T#=4;6QEJ!C* 59_
M/4$LXCAF!* 6X]D-OV*XMP+UY(OE4-$4<T;:,-(,GR(HQ]JHBS=!=+C[IS7P
M.=EY.09<0.9</6'K8\GC1MT;.N77'*GR3+3T[.Q)5#E=_6H'%O7HR7W]_?J#
M4Q@S4&DT):(-3NA'*VL:<<G/K?TXZB-0&:6YXMCI$]F:MV%XCSR=C^\;>Y9%
M7QD>F+(#Z!F(*<FY1=^[39614G[.WGJ@HP+9F^H_5YK9Q[R(F V/'1^K#4$W
M0Q+RDFHR"S.8LF%VR<-.*)0[1##2J;2HR/'L+2SN<F/=7%6A,CAZ=^.1QXLM
M((QU(6E 6KR?^KR>\FDHY87"NJG%3-@5WQ8VRKE&L/89;YVW9$CC6QYD&!I4
MXYB4U:$+2VO#!;(BO&$58Q)&YO[6>9*Z(UB<A4F4#N!ZV8- ^<F_^SC)6=BB
MLBR5J(R--H)K\U#Q%.B4+)CDQ^G4^:<FSUH6M:<HQ6Z/L>A2ME$YM?852Y4?
M"U1*5*H<1)DHP.<O<JL3F;6OR=4IT)\H-.9##]1FI; F.<R:#RL8QQO#B''(
M1L+;D8,E4.D*%*D:Q4K"XHWWFNUT:(1B]RC3H8S(4ZTD#/+,A8[_ -I4T@CL
M =P6Y-W*>X[!O<%MLAY'M?<6VUMKC!:_'A<8;=(K;@:@E&8M-N&>6,Y55VU$
M<HSGS0:6;FS3^ZQJ/X=[H=R,X)V6!FJWE!.B46*\CC4-T> >VHT9?9F,1B26
MNP2AK.?<:0"UN6UQ)+>5EU82/"VC^.L;O).3PTK33*68LH$%N@5^0))E9(TO
MD+TEMZQL4MPU"V2Q1I=7A,C7'C3 6O\ (VHZ[4>F="G(#LH\FYJ@QCK T4:?
MLVXH9&B(1QT@++&'''C(39*W8OE<)1$1>3XW1H^QDB2-T1=6PYL8PB))LICP
M&A>44!.L)M0&7:^;PMJ6'M[G+XNVKTUP!4H5[^THUB<1A8#@!/3*%99Q5QE&
M%F@L8 -Q%C .VX1!O<#U/"/CSR\AGK0Q_7J >$?'GEY#/6AC^O4 \(^//+R&
M>M#']>H!X1\>>7D,]:&/Z]0#PCX\\O(9ZT,?UZ@'A'QYY>0SUH8_KU /"/CS
MR\AGK0Q_7J >$?'GEY#/6AC^O4 \(^//+R&>M#']>H!X1\>>7D,]:&/Z]0#P
MCX\\O(9ZT,?UZ@'A'QYY>0SUH8_KU /"/CSR\AGK0Q_7J >$?'GEY#/6AC^O
M4 \(^//+R&>M#']>H!X1\>>7D,]:&/Z]0#PCX\\O(9ZT,?UZ@'A'QYY>0SUH
M8_KU /"/CSR\AGK0Q_7J >$?'GEY#/6AC^O4!Q?)&.[6WO/87:W1O>4L=K;[
M[;;]O>/A[O"@.?"/CSR\AGK0Q_7J >$?'GEY#/6AC^O4 \(^//+R&>M#']>H
M!X1\>>7D,]:&/Z]0#PCX\\O(9ZT,?UZ@'A'QYY>0SUH8_KU /"/CSR\AGK0Q
M_7J >$?'GEY#/6AC^O4 \(^//+R&>M#']>H!X1\>>7D,]:&/Z]0#PCX\\O(9
MZT,?UZ@'A'QYY>0SUH8_KU /"/CSR\AGK0Q_7J >$?'GEY#/6AC^O4 \(^//
M+R&>M#']>H!X1\>>7D,]:&/Z]0#PCX\\O(9ZT,?UZ@'A'QYY>0SUH8_KU /"
M/CSR\AGK0Q_7J >$?'GEY#/6AC^O4 \(^//+R&>M#']>H!X1\>>7D,]:&/Z]
M0#PCX\\O(9ZT,?UZ@'A'QYY>0SUH8_KU /"/CSR\AGK0Q_7J >$?'GEY#/6A
MC^O4 \(^//+R&>M#']>H!X1\>>7D,]:&/Z]0$F;G-M>$93@TN"%T0'W,L0N;
ME9"U&=<DT9)MBE*8PTDRY1Q9A1E@#OS#0#+%L,(K6 ]V@% * ]<U(E/%89Z9
M.<.UK!L(TDLP5@VO>]@V$,-[VM:][WM;?;>][]=ZAI/S2?S &C2&!+ 8E3F
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ME][VVOO;IWZK<;T \7N\>OC[ENFUNKQ\>FU +V\]M_UVMPZ;WVZM^GAQ\6U
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MI4XRMM,:U*$N/.*=]7-Y:5$2K/*<@GICAF".3@+,*%:]A@ ZS?)Z:D]7[7I
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MR-GG.,W[RD^\D]ONR1U)3% * 4 H!0"@% * 4 H"GLZ^QXH])X'\]X_0%PT
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M$H>7Q6DNM):&XH+<A4)FI(6E %$A36$9SP+]MXM[VZ_'X]^CS=/"_1??:V]
M<6OT\;]6VWFZ-_<ZOW4!SOUWXVZ>C;>^_'JO;JX]/#AX]@./W>>WZ^OS6^"@
M&^W5PO;W_-[G'CM^NVU 5_D_\#SN'_B"$=/IQ'.-OAVM?_+:@+ _1U_Y;>]>
M@&WN?Z;_  ?OX4 VZO%T^:_1Q]_W=M^N]Z YOPMXNJ_GOQWX^;]5]O'>X#JZ
M-^'Z^B_BX7MMM?AU;;[T!QT^+AOT;[<;\-O/YO%;KVH#F_1;;S^+AQOMQMU^
M._#>VWBH#CA^KHOYN/O_ /&U <WX>?CQOQWZN''S[\>G>V_"@.+;6O;KZ>KA
M[OGMUWZ.C:@'C_1[GGOU[;6X?!0'-[<+?OWMOP]S:]K=%NF_BX;6H!QOOT7X
MWWWVM?W^NUO':U^BU_=H#BU[\/-OMU^_XOW<+WZ>- /ZOPMT='[_ (=K]- .
MCKMQM^_;:V]O'^BW30'-_-;:W1>U_?MO?S\-_-?](''^5^KQ\./Z/-;W=Z 7
M\7B\^^W7M^GJ\_30&(>J#07I&UFFQ=;J2PHP9%>866I3Q.5 =I5#II'TBLVQ
MZIO;9I GZ+RHEK./N)0-J$[C;>V3#5 4H3S33!@3O3AI4T\:1H0IQWIPQ/%\
M4Q1>Y">G=&PEKE3E(7HPHM,)XD\D>UCI)9,Z=K@ G+7O[PXJB$X IR32R;!+
MH#(*W^O1OT]%M]M^'#;C;C0$=E\2C4^BLE@TT9&^31"8L+O&)1'78@*EK?(^
M^H#VMX:7!/>^QR-P0*5"507:X;B),%S1!OL*P")15B@L4C,*BR(;9&8='V:+
M1QN&M7N(V]BC[<F:6A")P=52UT7"2-Z1,GNL<5JQ<IN7V96J//&,T8$A\>_]
M;^+WO>^&U /=X^YXN&WZ+>*U_'XJ \#2@GE&$CN/F&EB+'V,PP@SF#!<-^QG
M$C+.*'L*_,,)& T ONP#".P14!!,68NQ_A/'D4Q1BJ+-\*Q["&P+/%XNU75#
M1-2"QYRLP 3ERA6O5J52U2J7N"]>K5.#BO5*EZ]4I6*3CA@7OBO\$A>E4^^?
M4BH"QJ 4 H!0"@% 0N_LA@]#3OVTGH":4!_%2G(5ISTBHDM0F4DFIU!!H;#*
M.(. (LTHP K7",LPL0@##>U["#>]K\+T\_,E-IIIM----/337=--=TT^Z:\B
MBI+,,(Z48"S)E:1OQ[ B7 UM:6R.,"D;<D6+##EQX0(&=*;VO8XXPT\XT1=@
MW,&(8Q?[PK4)3HQ:X[XU51]V*C%J,>SEI**>EI-]EHR5&-U/KN9;X2MS\VQ>
M-;.RU.VS<ZZN<[+IISDYV5P[R<NZ^">KI9G= _M+:]M1UU+:[(DS@@47+,*N
M<D5E!.(,N4:$!I?/+&$7,, $0=]KVM>JR:DE)/::33]4UM/Z&/LA.J<Z[(N,
MZY2A.+\XRBW&2?YIIH^E4G@4 H!0"@% * 4 H!0"@*>SK['BCTG@?SWC] 7#
M0"@,<;?A;DGTR3\>-_\ P-">OA:WBOU6MO;IH#W^/1>]_%T]'N]/BZ* =7#Q
M<=N/#>_3XNKA[] />XVW]W^K;>]0#S7X>[U?O_KS4 MOT6Z_]..W'K]R_GH#
MG:]MM^'5[W7?IWOU^:]^%M^B@..'^?G\W#>_3;AU;]5NL!?IOY[WX\/W<-^C
MHOPH!Q\?3?:WP\-[<;=?1Y_/Q ;WOU^*WO4 M?S</W==M^K??^M[[@<\+==_
M-M;;S?J\W3?S4 MPO;X>-[>[;J]SCX]][;4!Q?A_5O'TVVWVOPX^YTT Z-^-
MN'N<>KHMPOY^KQT O;;IOOU6O;CQM^[]'BWZ* 7Z?<WMYO%OU>];:VUK6Z:
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M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"L,P_@*?Z3X]_Q"BU 6?0"@%
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M!0"@% * 4 H"L,P_@*?Z3X]_Q"BU 6?0"@% * 4 H!0"@% * 4 H!0"@% *
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M-Y0TDS#4V@QKB9F="\?0_&6,3%!.IUM-D2(E2P/4U;PK.Z"MD;6\Y/&QE&V
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MG Q'+'LYE5P=+D7(\M-(@BX<3)/?WZS;*&LD*!Q1,*82SM@NR^Q)-CQE^_\
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M)G0"@% * 4 H"%W]D,'H:=^VD] 32@/EOB<"MF=4IBE8C+4-RPD:MN$("],
MQ.8$1Z(0+"&%44&]QD"!:XK&6#<-M]JAKDFMM;36T]-;^*?J>H2X3A/49<91
MEQFMPEQ:>I+MN+UJ2VMK:,!%.2L"NL$C$ *S8LAV0H>TH'^/3G*C/;O];VXF
M4CCRMP[)*$90#E#RH2*6;LI)AAXTR@HX&X!ECO8.W'\.-/XEU65PC)67+5JC
MSX-\K4DW-IP;7=I^C1M:P>K+,NZE+H]>=B961?3;B=.E)]/LN>,LE51KP;)2
MC#&C97D0BUPC.O4GRC-+8*A'8Q$C,"J"N"-*0.RT%@6 KL(H(K*0V+O<%@GV
MOV6U@7YMK"^YX;5D/[FI/S?P_+T/:H!0"@% * 4 H!0"@% * I[.OL>*/2>!
M_/>/T!<- * @<,^_.3/3TO\ 3!(/0A?Y?]F3RA(H!0%?R'$V*Y=(FR7RO&>/
MY/+&3L5F:3R&&1QZD318@RYI%FQZ<FU2Y(.PFBN85VHI*[&9>XP<T5[WH"P*
M 4 H!0"@% * 4 H!0"@% * 4 H!0%89A_ 4_TGQ[_B%%J L^@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!#()]YW+TSR%\^Y%0$SH!0
M"@% * 4!"[^R&#T-._;2>@)I0'I.79^YZ_M504D4]IJ>UU1P+&DIC^PC[$>:
M7>]K#+)'S3!@O>UA!#>V_&H?D]=GIZ;\E\R8ZY1Y)M;6TGIM;[I/3TVNR>GK
MT9H+Q9CZ=:M\T$1'52BT\YD0199*5C!F7&L^3L4]86-OD(1,\4[R&\"92,TE
MX:;&*#UR,8 E&J?^<&")+,,P5-4\^[6;7AWJI62JR*+'XL8^)Q4/#[2@G*+4
MI;:>M;WW?4.H9E/LS@N?LUD^T/3'FRQ(9G2NIX,)8-D_PLK97/*;E7=-0MKE
M76HUS7B>(XJ+BEOX1)"4"-*A3\_L"-,2E)[(*XQ]B3EA*+YX[\1BY@+<X5^(
MK[WOQO6>\CE[;;;?FWM_-GLT(% * 4 H!0"@% * 4 H"GLZ^QXH])X'\]X_0
M%PT H"!PS[\Y,]/2_F)!_P!="%_E_K_@GE"10"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0%89A_ 4_TGQ[_B%%J L^@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4!#()]YW+TSR%\^Y%0$3S_:86PIE V Y.;,+2U)#'
MM>TY9>(45D9NQ[W.2#7+I6H@QZYN(E%VAM3K%1#2>K 0H4 *[,4I+")*<!U'
MPZD>3.F(2Y5/O[0IRJ\CG*^W;ITCQRDSGBB"A6F7YXCX[C*(Z4U$4:&KLMQ"
M(:@F.*<HN_8>S# &UJ$>OWO^_P"NCLI\G]%LG,N%FZ32O6-)]:6+<E-$0R!@
M#(V0L4M>-,F-V-9)'B7-O0398W)F13,EC@F5-SFF=Y%#HK*4ESE:-\1FG\P"
M429V4 H!0$+O[(8/0T[]M)Z FE >DXKD38WK7%Q4$I4"%*H5K5*@5@$$)2"A
M&GFG"%P"666$0AWO_P!FU^%ZAM)-MZ23;;\DEW;?R)C&4Y1A!.4YM1A&*<I2
ME)ZBHI=VVVDDN[?8ZZNFN)ILNZA6;- L?/5VYGU;9)7MV6&B*2IG;7G&9,0"
MJB8EDC0%-32.,(G=,>8*SR66V"4JQA[*N7*QI"]>QHK(RJLJ5'>.;E^%D1A8
ME91X<HU2<X<$ZUREQ\53J;:=;<GR.L]8NLZ9T3-Z)'J2W+V<Z)^+Z3=DXKEB
M=5>=">=17BW2NFLM^'5*Y8=E67!)QR80K3K.QH686:6 TH8#2C V&686((RQ
M@%;<(P##>X1!%:]KV$&][7M?>U]JV(Y*TTVFM-=FGYI^C/.@% * 4 H!0"@%
M * 4 H"GL[>QXH])X'\]X_\ U^CHH"X: 4!2C/D&!QN2Y,;9%-HDPN'?N0?V
MB]2-G:UG8#(+"0EG=JKEA!W8AB+&$!G,Y@[@'8(KW"+81Y?!^;]7\?R]?,DW
MA@Q+[:&//72.?:5!M?G]'^P\,&)O;0QYQ_\ C2.?:5!M?G]'^P\,&)?;0QYT
M[?AG'/M+H\_10G?[^3^_Z>8\,&)?;0QYZZ1S[2H1OY_1_L/#!B7VT,>>ND<^
MTJ#?S^C_ &'A@Q+[:&//72.?:5!OY_1_L/#!B7VT,>>ND<^TJ#?S^C_8>&#$
MOMH8\]=(Y]I4&_G]'^P\,&)O;0QYZZ1S[2H-K\_H_P!AX8,3>VACSUTC?VE0
M;^?T?R]/OS\AX8,3>VACSUTC?VE0;7Y_1_L/#!B7VT,>>ND<^TJ#?S^C_8>&
M#$OMH8\]=(Y]I4&U^?T?[#POXF]M#'GKI'/M*@VOS^C_ &'A@Q-[:&//72-_
M:5!M?G]'^P\,&)O;0QYZZ1O[2H-K\_H_V'A@Q+[:&//72.?:5!OY_1_M^?WI
MCPP8F]M#'GKI&_M*@VOS^C_8>&#$OMH8\]=(Y]I4&_G]'^P\,&)O;0QYU_\
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M%ROH4 [11?D:7XN5]"@':*+\C2_%ROH4 [11?D:7XN5]"@':*+\C2_%ROH4
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M<V%O;HS(5*MV,='MX"7(P =D2@% * 4 H!0"@*PS#^ I_I/CW_$*+4!9] *
M4 H!0"@% * 4 H!0"@% =>KE4]*F?-3N1YK$,6\E+I0S?();CA+ \=:_,O98
MQ@WNV(PR%G/;GE?*,5O$-59#D"O'RMP=%T&$RN+^E1K!(7A&C+4@5-AH%":W
M.3KU^E:>]"^@#39CV-YUT/X-Q?!RM3K"'.33IZEFHV<Q):H,'"7M^<4<@<V#
M&*UV1))FN;V1O6*7-2\F-QC@C6L#.Z) -]^CQ9F4[!<:;,X:<X#I6DL6--B,
M>PUC+(K3DV&QV!1U(A;XD)H?F./1AL0IQ(2Q)"F!*UV+:DZ(@ 3A!-L64!E#
M0"@% * 4 H!0"@% * 4 H"&03[SN7IGD+Y]R*@)G0'7"U)\H#J^%K9U-:?X-
MK&Y-G1#!-/YN+V^*-^K56J79"RZCGD";Y>NG3<J4SB+L!+,WNRI?&K,[;8QW
M:3FVPGU*39>VJUP&^7 [W()+A+$DBED\Q]E*3OF.(8[2').)[!MC">O+A'T"
MIRE^/>8X.P+PR1*S376-W Y+@B:52405)H;V'<"V* 4 H"%W]D,'H:=^VD]
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M>!_/>/T!<- * @4,^_&3/3TOYB0>@)[0"@% * 4 H!0"@% * 4 H!0"@% *
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M]/@<URK+[<F^S*ME?D2ML=]TIJR5MO)J<W8FU/E)-\DVI>:[,F5>RW% * 4
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MY:1/UC9_KE ._P!@OEI$_6-G^N4 [_8-Y:1/UB9_KE ._P!@WEI$_6-G^N4
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M7U2@/F8[3)D; M2HTY"1,1,,@EDITQ19!!)89W(N: HDH("RP6Z@@#8-NJU
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MEI K4:<I.<6"P$_H!0"@(7?V0P>AIW[:3T!-* _D?<82#A%%6/,L49<L@0K
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M>_XA1:@+/H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M[)R>Y3D_C*3>V_BV22O13% * 4 H!0"@% * 4 H"GL[>QXH])X'\]X_0%PT
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MGFK&.&<E:8<K$8]B,80,QEI-*(TVNF.)FI1FH92N8A/9#0V1H1:5!83NG47
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MTGH":4!&IFB7N,0D[>UDA4.2]@=D2$@1X4P352I">00"Z@99H"=S# _W@RS
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M;L?+N7CW8N3?C9%$L:^BV==N/--2HG&34JI*3<DX/W7MM]N[V3FO9;B@% *
M4 H!0"@% * 4!3V=O8\4>D\#^>\?^#^K== 7#0"@(%#/OQDST]+^8D'H">T
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MXE .Z;;^<4/QM/\ Q* =TVW\XH?C:?\ B4!&(",!C(X&%C"8 <RR"( P"L,
M@WG<BVN$0;WL*U^J]KWM0'P<Z."%HPEF)U=&=+(FULQ9D%P<8^N.4ID3ZA11
M)W4JV=8H1&%+"$KFG*,1*#DAI:DHD\8R# &A *P'3+Q= ?[/U,6K'Z&4::]+
M,7?Y/R=;+J]?W4W6YD5*P1[.J\:!$MTKFLCAE<M:GF",]4>NNB62 N7%(4PD
MIT3L.PUP6UZ_E_7T!VJM$L]BZODY]*F3H_C6\1AIVC?#,X9L0P,#W,1QR-WP
MW'GU#CR'%O*I;(I28V-O8HZP%NBQ6\O0R4@%BD]:I,-$7Y_?_J#K-.+7E_E
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M 4 H"L,P_@*?Z3X]_P 0HM0%GT H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MC@>3':/('#+#,@?\<1^63A!#E$*A$HE[4Z-ZAJC$P?V1][(M3(U2!,M.+3B
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M)-7@\E/9U]CQ1Z3P/Y[Q^@+AH!0$#AGWYR9Z>E_,2#_KH0O\O]?\$\H2* 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * K#,/X"G^D^/?\0HM0%GT H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@(9!/O.Y>F>0OGW(J F=
M * _@I/"E3*%(RSC0IR#3Q%)B3%"@P))8C+EITY01&GG#L&X2B2@B,-,N$
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M!0"@% * 4 H!0"@% * 4 H"L,P_@*?Z3X]_Q"BU 6?0"@% * 4 H!0"@% *
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MU[D^Z\U[K[K\UYESA[_&8NHJ;_$T:@]:F_%AJ+WVU+R>^VGW/R+UBC_GAIX
MJ+6$XE!4".MS0D%F%J3!\RU^>0/8 K]C+)+N;8)>X; YQEJYA"OE7X;E5/\
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M?.Z'<-8J2+DJ)4-J>^Y#KW&>4Y)S2[7;5UF]:HNE/Y@&3] * 4!6&8?P%/\
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MJ'4DYNJEJRQ12I;<N,7K7??D?GK@+LD)V[;[($LBYAP5)P2A]K6/!;L)5R0
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M<3"/8VS=AC3-&<69&?(^YMT(G#LU8=)8'Q-&I$H3 ;GH; Z\]&] ;CU VX\
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MCM.;9 V2^0-H!A67-LWG]KN8T+>!V"Z 4 H"L,P_@*?Z3X]_Q"BU 6?0"@%
M* 4 H!0"@% * 4 H!0&B'E;,/9KUMY_T,Z"F#&V13=*\GR:5J!UD9;1Q]V+Q
MIWA8J$N<(AAUTEQ9%V<;S-GML<QJ& U2%P1KQ01Y G,('V8@"*\KOC32RHRY
MAS(&0M)G*/Y(S7&,6/L<QEEGD]67(#>:;'375Q#;!,ZF^.WY$?&D#FN6JW!.
M!P:4Y"1I?7,U$\<Q2N;Q@9'\AUI R-HMY/N!8WR\Q&1')\WFN0LRS&"FN0GE
M1 5.0GSMACARUX&J6F.3LS1)NCP'X\Y2><6_&N:0U0J&FNJ/ V\T H!0"@%
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M@V"$SN']P(5[[6'_ -F][7ZJQ*Z%B;7_ !'_ /K6_P#U&D_^S7H7QC=KL_\
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M;;>]>226W/1E'>5ZC^J/$LCU XFR;&\+LJ]].GHR<VK<B <4*AA7)6]$;%W
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M* >#>*?BW_USF?\ ,% /!O%/Q;_ZYS/^8* >#>*?BW_USF?\P4 \&\4_%O\
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M&\4_%O\ ZYS/^8* >#>*?BW_ -<YG_,% /!O%/Q;_P"N<S_F"@'@WBGXM_\
M7.9_S!0#P;Q3\6_^NDS_ )@H!X-XI^+?_7.9_P P4 \&\4_%O_KG,_Y@H!X-
MXI^+?_7.9_S!0$G9F9M8&\MK:2!IT11JL\)9BE4L,$>N5G+EAQJE:<H5'FJ%
M:@]0:8<<8,1AHKW%T6L!]2@% * 4 H!0"@% * Z>VH601I%RA.39,]Q_3>#4
MTR:S,=Q;$NB5\Y-"#3:=ZB,5+I7CE&7GX&K!1!E<Y)?U\<<Y1D,G(;?+"H]
MUL-"U/*,P:0X(P.X30"@% * ZU/*\174\#-SU-8KJ?R5C."-,$Q63B[#F*=;
MV*M(CK.@NC1J'8LMN7:L]D\6*>Y3$LBK].DT*?)$J%'W#'S/,8@RGVD)MR*
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M\%2&'XN7MK A2*(/'GT@1A+PVQT95VXEQ+4+ K+D"/[?<+CNM/ O^@% * 4
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@.G[ES >3#<49(Q&ZZ)L(:N8+@N8<H$SX>UK/VIK3DGTN8]1ZC<F.LMR9D[
M4]&YN:MFD.S3IO<$?:<F,:"!.2!TCKP0WN2=0H&H1@=J#3O!"\6Z?\&8R*E!
M,W*QSAW&4$+FB<P)Q$O+B$*9(^"4$&@.4@-)?PM]G8LP*@\(P*PB"<;:]AB
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3YP.:9>XJ M?HZ* 4 H!0"@/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img29677477_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2<\4&AO=&]S:&]P(#,N,  X0DE-! 0
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MYT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M  "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$
M]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M  4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V
M)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M   $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M          1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M   $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M       %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0
M    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M              5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4'
M)C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296
M-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W
M)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$
M))30/M       0 2P    !  (!+     $  CA"24T$)@      #@
M     _@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _
M,       D           $ .$))32<0       *  $          CA"24T#]0
M      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M   0!:    !@       0 U     0 M    !@       3A"24T#^       <
M  _____________________________P/H     /____________________
M________\#Z     #_____________________________ ^@     ______
M_______________________P/H   X0DE-! @      !     !   "0    D
M      .$))300>       $     #A"24T$&@     #-0    8
M  !5    =D          $                          0
M '9   !5                       0                         0
M   0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&
M]N9P  !5      4F=H=&QO;F<   =D    !G-L:6-E<U9L3',    !3V)J8P
M    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W
M5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
MUA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26
MUG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   50     %)G:'
M1L;VYG   '9     -U<FQ415A4     0       &YU;&Q415A4     0
M   $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%
M1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D
M%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97
M)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V
M)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M  "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
MQB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #
MA"24T$*       #     (_\        #A"24T$$0       0$ .$))3004
M     $     SA"24T$#      <HP    $   "@    <P   >   ->@   <AP
M 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0 # @("
MD(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,#
MP,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0
MP,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ <P"@ P
M$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'"
MD*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&"
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MT(;8T[?=N%MS?L^S_PTVBS?_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(T)2L<'1\ HDX1@E,V)CDO$94R9#1'*"-&2BTN+_Q  = 0$  @(# 0$
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ME%8YPY(PGX"215CYF'=&2D(MZDHU>MT%R&("E9%I2L"FLJXPK=@E*I8LBT:
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M2&,CX5.<KK24:P5E6@8M27:+M'UK96>?MN)M7M-&N-"M[@1V-S([R84^>JR
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M1W%2 @@@U01;-D4F[9NDF@W;H)D10001(":2**28%32223*4B:9"E(0A0*4
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MI7\*8I@Y*8#!R(<E$!#D!$!#D.W(" @/T$! >X:4K^Z4K'JM;JI>(@+!2[-
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M;MQ[B/I_OZ=_7OJX,^>_3KZ*-_3KVVZG\:T_#!GH/KU[]OCZ'[N^,C;1W/\
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MJ:EB]T$=&4'&QQD X^1R/3T^%88_;@)3E$/8?8>>._ \!QZ#Z<\?;TUF1/\
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M1LB*GE1!4@*J8\<T87WL^1;J1S<O+;Q*% #!\MK"(,) &&$Y/+#8BY<(N&C
M"G*QQ+G?"Q(HPO,&EHD0BB#.+C6J#9 @(,6+1JBF@V;I% J""#=!(A$D4$2
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ME.E*G\XE;%)D2:1;V4+;V*Y8=BV8QX1Z9WGQ6COE^OSK<?S_ %^56LK?AQ[
M*K&?*H?9'M,;-U4P*].;;UBMVXD3B4 55D'LE6'\C('5'DQU)%Z\7-R/F+*&
M$3"I6"2GAA;4HA9U.;?*Y8MF5\4'S6EXV@V-UA+RG(*%5 TWC>#27PK?&1U"
ME%Q$9$QG;(I8  P-$UR(KI*5T]>W&YMVN72LXIWRKUNRX_N\ZPJ6(]ZU)@QJ
M=(FK-*N$F%<QYN0I)73UEAK)5E=G(TK5UA'BN&[_ ##A"%9&Q]:'\-39-2MD
M>E*:4II2FE*:4II2FE*:4II2FE*:4J(MP+IXQP+FY['B<'[/$6273$4^>L'C
M>FS2K82<=^OSB$Z>._/'&E*C#8BT81^Q_9NQB^@8UIM6V]MV IB D,T2Q+42
M-S%$.P@9("F ??GG2E6LTI4?Y3QYC+*F/[11,QU&I7C&L[%N$;96[S%QTQ6'
MD6@07*JTDTE4E69"LO*!ZB],":T>N@F];+MUT$UB*$ @@C(.Q!Z$>AK07L_D
MOG.!ZK,L7]ADZ;,V#)4QB%Y;9"1E[2K@&4RA<W^WG]H9B857F)F5+@]?'Y',
MG,++S+W@J\RZ>RIGCUQM;1S.=+LFN69Y&AR&8DL8R[F').Y/E%-^N,9WKRMQ
M<+%.*=833D2.WCN50I$ (UN5B1;KD4#"CVD29 ]T-G& <5<>/-P).?7_   1
MY'T_W_AKNE&<]MNGU(V]<9[XZUA0=CG;_7K^O6L^BS!Q^8B/';GCL/Z^GU_E
MSK"FW.?B/Q%6"T(##.Y'ICT!^9S\Q4@1)P Q>1_/^(\_PZO\OIJ.<;'X'_3^
M]6:V."IV.<@GZ#/:LK7AT9EL5(3 DZ1$QFZP@(E Q@X,DJ !R*2G24!Z>3$,
M!3E >#$/@\YC)VR,[CU[9&>X/TP=QWJ8-NEU&%V1U.4<CY'E;ORDX&V2#N,[
MJ<>!FZBE12>-CH*"(F PE 4UN  H'36+R14.DH!U 8PE  *8 $!*' \K@\N,
MD\Q &-\8W!WR0,;^@P<8KJ5)+9N25"I)RI.X?'0AA[K9^>W0XQ@<Q5V*I2IE
M 1,/X2E*41$PCZ  >HCSV  ^OY\]8C())V!Z[C;\_C\-Z[VEYACJ2<  \Q/P
M ZDG';/^,B@Z^JS.,M(IBFL!#?!M3]E$Q.42F76+ZD.)#"1)(W!B@<YE"E.!
M +R:0-A$.1U)['/0#U&0#GOC8X!SWV]HT;&XG7E;'\*,]5SU=@=U8@D*O49R
MV_+B ]Q>/<>W^!KSW)5H/4ZU0;%-6E22/+1$%'J*6#%^1\2/&LM)S*"K=LS^
M19.F7C8Z2C5<DPSBS&64;$<LW63!9RWLB00133RLQ"0P1M+*_,C)A4179MF)
MV4D8%?/:I8'D:) [,JKN">7RY8Y@=CCK& <G&,_"M6T)M"VNVF]H1BV>[E<+
ME.DAI!9&8AJ)!2EM:TW]E)1NI2ID,<0Z[9$A:)"J3:F/I !EJTG,,9DSR/>*
M.6\A)PK?V\)O+B"X]G0JDLJB!Q$S,JHLWE<[VQ9U"?Q1&6;^']H@5UW>M7\$
M19;.&-%YN3WY7"$@@^8GG8< .Q =<!BL@&U9!(^'#C5PQGF\WDS)TY(6*)E(
MF4EUPH[!PJE*XD>8;.LBUBZ>SCVZK2L/ <M0*U$@R;=!9R5RD*Z*_6FDQ-GF
MEE/,&5F_A@[Q>5L.3&P.1TWW)WJMS\77<;*8[.T15='5,SMNLZW."3+S'+@A
MCD;;;9JR5!QC6\30,O6JF4[>$D[C<KDA&E;L&;&'<W6Q/[+(Q4.RC6C%HRB&
MDA(NO@6Y$14*0XF7676.HL>>M(D@4H@PI=Y.7"X'.Y8@<H "[[#'SJ@ZO?37
M\BSSX,BP6\!;+,7$$8B5W9F8M(RJ"S9P3T &U89G&Z&QUB#+&0R+HMST/&MZ
MNB;AP"8H(GJM7DYXBBQ5@\LR9#, $Y5 $A@Y P"41UES/Y-K-+D#RX)9<GH.
M568?E\/RS#65L+W5;&S9>87-]:V[*#NPDGC1E'Q*DC;Y]:VR[,L2LL%[4-O.
M*FC19JZJ6):4A8U79E%9.8N\E"M9J_V:<<K"9=[8[9=I*?LUDD'!C.)"=EI!
MZN855SCK2[,68LQ+,Q+,Q.223DDD[DD[DGJ:]FHB1HD<:JD<:JB(H 5$4!55
M0-@J@  #8 8JS&OE<J:4II2FE*:4K4?XIOA9,/$\D-JL58LQ6/#M-P#DFT9$
ML<G0VQ R--FDX>)8Q$92IQT)XZIR*+^.!ZK97;*74C@11!G#.W"H+LU*VH5.
MO)5*L5ZK(RU@GDJ["QD(G-VN8=6&SS!(QFBS+)V&=?&,\F)I\"/Q,G).1\YZ
M\56<* !E! %*R#2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5KGWU[G\EX
MNGL1X%P"_JL1F3,2=PM4Q<K7!K6QABC#6/T(ME:+RVJ:4I#-YZU2UOM=*IE)
MCIF11A"O9B7L4DSFV%5>P;^3TG37U2[%N&\M%1I)9,<Q2-2!L,@%F9E4 GN3
MN :K7%G$</"^D2:B\0GE:1(+6W+\GG3R9(#-AB$1%>1R 3A<#!(-:\U,:9+L
MRYWV1=W>\B^RRPBHN\9Y]LV&(TBH]S SK&V]+#-7:H (\)(C$+'3)T@=94P"
M<U[BX6TB-</'-.<;M+.X)/P$/E ?7(^N*T/=>*?%MTY-O-9V*9V2"SCD^0+7
M7GL3ZXQZX'2N<C@Q^3@S'</O2CU _=42WJ;H7XA[=T9O*<HV,!0'T40. AZE
M'N.DG#FC$$"V=3W*W$^W7/60C[MOID'E!XC<99RU_"X(V#V-GOZ?8A0COU(K
MMVV(<MM!$T/O9WLQ!1XZ"GS)$6DJ?''8!O\ 1;>=3V[K'6Y_M<\CSBOPWI1Z
M"=?^6;(/?'O*WWC/WU,0^)'%('O_ +OD^+6I7_Y)4'T]:[E&B;GVH?\ (^(C
MO#1[=BO&&TN7*7CT#F5VK/%3?<3JF$>.1$1YYQSPUII/NRW0^'.C?CY/Z^-9
MJ>)7$('O6VF/\?(N%^_%P1M\*YR,?O4C# >/\1'/+PH!V0L^'MF\PW'@0'^L
M-&;;JZ^$!]!$C](P@(_B >!UP/#%@WV;BZ7?N8FZ]A_"3\Z[E\3M;7/F:=IK
M^@4749&>F29W!^@['<5!V8L)9OS':*9?\JV?:7N#NV.$?(I$_N(V:-[%,0"
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MD_9C*F-T!*@5K+5=T,S7V:K%G?*S3)Q0T,EM33=8L]1CC2(B*=$ :V? 90
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MJS2=8J242K9[!!UY.>L$+4H(TU)LXP)FTV1\G&P%=BOBUDOF$W,/U4VL;%M
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MKCZU'\37"7VJW]Q%_N1,8[7 V%K;J+> #&P40Q(3O@'IWS,:Q>E0?OW]./\
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MD>@6*IS[("Q\H9@N\CVI$==WMK#=W'FQ2S1JDO-$K$@>7SY7*AV,;E,9*R.
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M7@E.]E91XHL^E9)R[D7RZ[MTLJ?4))))))).23N23U)/<FO70 4!5 "@
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M?K53;;<K!<I-69LLFO(O5E"D(*AC& #KJ@1)NV1+U")UEE")(I)@=5=4Z:9
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MGTLF9!HD(*)M52\+.CAP) 42'ND@40Y.!P ZH ! 3%,XG#!E8+E4R6)P6 R
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MI=EBZ!)V$K<! D(E-NY"-(N\_P"2)89:OHC_ ,^XC]*5XKMQ.:J/DW8)X?\
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M0%P)55"K!"<$J>8G*]0#G.,'UKLU#PXT=K*X%@;J.]$3&V>2XYT:502JR+R
M<LA'*Q7'+GF4;8,KH33=^U;/F3I!VR>().V;MLLFX;NFSE(JS=PW73,9)9!=
M(Y%4E2"8BB9BG*82B'.P50, 5]X$ @]01C(WZ8QO\OI7GV6=HW>.0A'1F1E8
MGF5E;E;(Z@@@J=]CVS4&9 RO#XEIU]R%,)*N(=E:6C=%!L"BSM^\=H5ZM)L(
MEDW25<2DQ(64%8B)A69/C9J<70BV?4\>H@;!GN%L8+NZ8 QK<@=< >Y#$Y&Q
MSRRJXY0,LPY5RS"IZRT^77+_ $C2XV9;A],+L G.V\UU<P(P9E YX)8#SNW)
M'&RNWN*:G;'NS#$KW%D5N&\2"FP=NO<B=*W1N#<@S25MQ1A)*00;GKV,XVA)
M+)T'(V1FR#=J:TV>=B;:NO<UY5E4)1*JLHY9?7&HZG<:C,TDK$1 D10 GRXU
M/;ER06( YV.2Q]%  ]%</\-Z=P]9I;VL2/.0K7-XZJ9[B4#=B_*"J*21'&N%
M123@LSLUS:'6KMD991*8(RQ[7T$*7*/&%:(FUE$&#>'?+5*D0K(&#9K58J#C
MY-.:6<+%D)]*3=-3-30XD+'P\=5AJ1,I+L3.J7BAL+"'IJQHI6XIG*DWCTZ9
M&I2+MG653J&319PTS&U.PHR"O4 %8Q/RXY0;R2RB3]?KYTJM6['>['8#J\0C
M5XUQ\YM*J-?Q?4XJ$;RV1LE3;EDX6A8?&]$>/8ADU0<-V3MZG,V]U%P<37XJ
M9MEG)6J)&&MJG9%#)/(D,*-))(0J(HR23^  ZDD@ 9)( )K'N[NVL;>6[NYD
M@MX$+RRR'E5%'KW))P%4 LS$*H)(%:[:#C#)=PNP9^W06I3(&;7;9PWJ\ 26
M=3./L#5Z03%-Q5<;-W+.,;/; _;F\J[9,/!P\K9W!G+"#B:E33-JLELG1M%A
MTQ1-+RS7K <T@^Q "#E(2=\[D-)@%AL,+D'SCQGQG>\22-96A>TT>-_=BR1+
M>%3E9;H*<!<@&. GE0^\Y9P"MCR1QA#L01X]NP>OL/(<_P ]3IEQG=?E^CUJ
MABTV_F[8.P';TSCYD8/PKA.*U'N72#]Q&,5GS4!!L\6:MU73<.1'A!P=,RR0
M )C"'EG+P)A$.XCSP)C=U<I$SI]AV0%U_P"5CN/H:R%6YBADMX[BX2&4YDAC
ME81/Z\\:E5;.!]KT^&*P')&&,89;B2064<=4O(42B<JK9A<ZS#V)%DX3,"B;
MN/\ FK1T:/>HJ "K=ZR.W=-U !5%9,X ;2:*WN5Y+B".93VD19!].8'&.Q&_
MI7RTN=2TR3S=/OKFSD'>WFEA/IA@C!'&.S9';'6JY9"VE+3E8;5"J9:OK>F1
M:GQ4-BK+[Y]N$Q+%/2MU&R3BO,LC2RN7,9&2;JF:H&P7FC$JS9D=1@@H5DLN
MV6BOW#;PS+=Z7<W6EW:9Y)K29P%)&^06YP&Z,BR(N-BI!Q5]T;Q9XGTF1#=>
M7J"QX]]LVEX!M]FX@"HV<;^9"_,,@FJGP^TS$=,E0)N=H.Y2L5$ZRQULI[/[
M56LT8\K[$@F,"]FQ!D/%%EW,UEL1(JAA)6)#<D#-%,B\Q:$4Q66+D3<1<>Z;
M&0+N#4HE'^^]C@>= !_,B1Q.Q&"22LQS]I^U;MT'QNLM4"02W_[NNFPHBU.&
M%5+;;)=H! ^#L#.8W8Y 4UOLV,;-_#YK=<J^=]M(P6=7"QW8U[-UBM*.1IAC
M*-#*L)(D4W*BQJ] M,88SF(FF]=J-3L<><SR)F4DE!<MM4#5>(M<UGW-3U"X
MN$5L^SGEA@5UV!-O"D4/.ISAF0L-P".E6ZYU2]U!5-Q=//&0&4 J(B.JL$C"
MQGKD-@GXU<;-FZ/;7ML;1+S<+G[#>$&\\H9*#4RMDFH4(9DY# 10(I.S2\:I
M( B80!<[0BQ$.>53$#OJ$K"J4*9=Z9D:LQ%UQ];:U>J=/M2O8*UT^=C++7)E
MF<1 KJ+FX9T\C7[<3 8OFM7*I.HIBB;J*( I63Z4II2FE*:4II2FE*:4II2F
ME*:4II2FE*TN^(?7W&)-S.&-T4MUIXLOV/0VM9'L)R?]WX^N 7=Q=\%S\^\$
M?+B*K;IFQW_';^8<]#1&ZV#&L:X52)+><C9>%[Z*TOVCF(5+I!$KL<!958-&
M">@#^\F3_,R]LFM;>)^AW.KZ"EQ:(TL^E3F[:% 2TELT92X**,EGC 23 &>1
M7QO@'^QR@ )?IR =_?\ T_Z>VMBR@[XZD?+<?K<5YUM&P=^@/7T! [?/\_I2
M[XYK63ZZO7;*Q!^P7%)11L995N551N(F;'$Z)R\K-E# LW%8JJ15BD4.F)TT
M5$H+4M/M-3MVL[Z(36[-S\O=77)20 @J7C)YXR0P254E4"1%99Y8A*/=(#%2
MI! (92<X(((YA]I&P>5AG(QD9ZU%PW, .4E$CF'OU$$"F$P]7440#I,7GG@Q
M1$H^W;7.10<@;YWZ_/Y?+ZBLZ$NI'.&4G&<C&3Z@C(((VRNU9U$"X<F*FW14
M6.(AV3*8P%'ZG,  !2CQR)S&*4/J >L;*N,@D#L<[#'R/?Y;]1O5ALGED($:
ML[?\(S]"?LKCU) !/SKH\Y9P;;<Z*C*(+-U\@6PRL764#MT9$D6C\3%QSF21
MC%';(\])FEIVO5R%AVJY0D+19H!&16BZDG9[+#YNA:$VO7K(P(LK4"2X(8Q^
M8>61TB,BH_D)Y<,]Q-,P)BMK><QB2Z-O;S7S2T6U!EE8>>PP.7=8PQ (&X!=
MB55CD %@N0A=ZA*APW]'D//V7/\ :)="5RFP6D7^-TYIX\NUE!LBT^-M%N?L
M7,8,&UBV2!6<G+BM!QL' .CLK];H&C#6\28PG+V87\L-OH=M$T6FN(X]0,,:
M6=L7+\EM:QNLGG/(YYHHN6::>=0]A9SWWM&J:C(2W#,"(L\V"6;F)&0N#OG+
M8&!G!V^T1'RI%'N4:YD7-EJ)B%A!Q-:Q/631AF<5#,1_HQ0K*(-W-=E'Y4FT
M4WMQS-T!5BJBFVCHYN[!M'LH D.V8YK-GZ9<:?H]J=5>:6YU2X\P&2:3_P"L
MVNCS"XC0\\S6F&<>9=%I79"TCSF9I-&$///!#&\C$.Y'+RD;C_A"X'*  5((
M'*.@.%>K4QD#$TZNQE9ABKA'Q3<R1%7BYW;]ZX654=R$I)O5 !5_+R[]=S*2
M\BORN_DWCMZX$RRZAAKKS2W<\ES*09)#DA%"(H4!4CC0#E2*)52**-?=CC14
M "J*H&HW!E=W)W))/<+CIC)[;;'?X$YK$958!Z^!]>1$ X_Z_4>WK[\ZRX5Q
MUSMZ_#O\]^O^*JEV^Q]?D=CO_?/]]NL#6^SK0$T91TFN>'3KZ[CEN45E#O\
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MDQY<<;/$[H2LK%.;..85L:VGX_-M\PW:TI.?@;=G_,=OMEWEEH%H9.0GK*\
MT%68UE$/EU92/I5/81+6/BB31FZ4#7VRKFPJI3*LVX<4NYN)+JXFN92#)-(S
MMC(49.RJ"20J+A5!)PH%;DTVPM]+L+33K52(+2!((^;!=@@P9'( !DD;,DA
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M^TV:37.K37TB!&NKV73[A9;A2MQ8W-L%5)&X-E>02Q7K+/!,G*T3.Q1LG)&
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M@'KZ=_N/Z?;4C))U'3U)&_4[=3N<?>,G;8URW@SC QZGO\!V^OW#M6<LHL.
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M$$"F(@BDB0ZBBQRI)D3*=58XJ+*F*0"@9150QCJ'$!,<YA,81,(CI2NM+7H
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M8L69Y)&)DE=F9F9Y&9V9B2Q)-<G*WAGL7\=9LVP,A.XJR"[<FO\ >$:$[J#
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M;L99!E)E:*(G>,6:YCM4^BPO[;4;9+RSD\ZVD:18I@00_ER-$S#!)Y2ZL%)
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MV$ Y[?0?L'W[_KW'-C?N/AG^Q']OT:A+FV&X('0X_6.@[]B-QBH\EF0%Y'@
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MQZC[<_QX[=OOZ^_=*<?$COGMD]"?B2?C6#:@#E^_Z'.!Z;;YS@?&I3BDPY(
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M9 2.4GO@X/<$@&JQKO!^A<1213:C:L;B(<HN+=S!,Z=HY74'S$4[J'!*[\I
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M?E>(R!8TJW18O]F*P[J=>D)Z-N\FQH=O&4AW;P#C$V9V?X2Q-##Y_P#&R_\
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ML)!BCD48]9HBJM"OGUFAIQ2$?N@+Y;EHYMU3@)92O."E.""E5R3CJK6,1/T
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MR3B30>,D-?$EB68DLQ)))R22<DD]R3N36_D18U5$4(B*J(J@!550 JJ!L H
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MNXBL>VKXH2F((1U7OG]%639-4PF(WC,?O51(/'(<;W^'[->#_P"SS>7+C/\
MU>YY8WSCLDGE2G8@!&VKLT$BZ.I:,V"=1L_:+13_ "ZAIH>YAY<_S36XN[9=
M\EIE!S@9OS%' .D.?M^7J'''<>X?]/KK[+U]?CG;&?[=>N^<&N-JPRN>N=\Y
MV[ ?#&?Q]*E&*5#A,>?8.1]>.0[?7N/IWX[ZBIQ@DGM^ Z'/U%6RP?  ^63^
MO7H>F]1'N.N4GC_'-UMD-))Q$LC%QQ(B46:(.V[.0D'["&:J. =]3-JB9PX!
M(\B[0?H1@JD?*1,UY!8A] ZU=&PTRXN%,BLACC5HA&74SSQPAE\T%,KY@(]R
M9RP"PV]S,4MY<BYD6&=G<OR.J$F/DYU)Q#E0ZNI8, 57DD9L@+'(Q6-H"J&!
M,F6:KU6]/=Q%J;Y 1IE5<U%VFL%KKU6ES,$)*2-(J#97\9D0YY%],-4I\YF[
M5_'O2H.&TM H,H=.LIP]?W-M:7$VLW3WD?DW$,A(8H7BB,L,S13>5,C2H928
M5C@\UG$<7L7E6<67%YC*C&XE1UD\WIAP&"%X).1_+?,D8<\JJB2<R(GLP6V'
M/F<4;DLA&<XZR3E1HIBYG"S$<ZM,,UC6-LO+R1$$6+A_"-V"J#-I$QZO+ %Y
MDCAE-)G>/4[(Y81,V;G^Z==O&DM;R^\BUCFD>*YMB(I)XS),8HY$C<2GR$-L
MR,9XU,R3">&XB6-IN<\US*7#2F)5D+QR1MRDJSS85@G)(IBC,!C83 -*)?/B
MD1$,MF8R'BJI7(*J0B2C>$K$)%UV';JN%W2K:+A8]",CFYW+DZCA<R#-LBF*
MRZAU5!+U',)AY&Z6T"PQQ0J25CC2)"<%BB*%!8^Z,D#)P !T"@;"*O)00<DG
M(QON3@;$XQ@[$] /0>F7'ZD6#5(_('3;D X#V$IS% QBF$?<HB)1[=^-9D0R
MV0<C.!]/\ >E)CR6T2,,,(UYO@2,L#D[8)(/7IMM4)62XM(^8-$N8Z8 XI*N
M"ND69'22K<A$3BX:MVJZTB^1(HL=LZ!BQ<.(Y1'SI)NS8N&+UWFK,J2"-DD]
M057F!  RRJIYW',0#RJQ3[3A59"T-+8O/ UQ'-;CWN4HTGELKY?W7=U6&)B
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M!_WS_/\ +V'W#656#N#\1^NWZ[UU$A%I.B&*8A>1 0].P\_[Y$/M]-8\L"R
MX !/PV/^/UT))K+MKMX67WC@';X?']?YS5[*F"XBWMEP,T3*N<!$! H%Y,(C
MP8I@X$H\CU=QY 0#I'MWJ^HZ.LH)488$E<95D;L4;&1Z@?/X5LOA[B^:S90S
MDKTWW&.AY@<[=L8 /?<XKO<7;P=ZVVINWKZ,W'YEHL<1-NRKN44G\E+1K%$
M(1M#W-BZ:6%(I$2D1;)32\^Q9I$(FU8I)ATC/Z+XA<8\/*MM-)%K=E'A$BU
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MF*2<-6#8H>4J8[IVQ:$7>H8]W=6]C;37=W*(;:WC,LTK!BL<:_:=@@9L#J<
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M(*_U&WLX"EMRM-( V00>4E6 9VY=V SRIV."<+@5:Z26  $I0*!0_"4I0
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M<:2HY6L]>;().',A'9.SK=8%TT2\I]$JMP.B?XS*BL[L%5069F(5551DLQ.
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M/SS4VQNWL[R"Z&28Y S#NZ-E9%.>I9&8;]SFMS:UI<6KZ1?:6P"+<VS11$
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MK%<I)C) ST((QZ^I_,_$"JU<V$L!.0=AN"#MT]?T>W2NY I#E'@ $!Y]>_\
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MQY8)&ZP67L0_LY7\M8FRQEZEWV';77$*9K5"SE<Q%95HN164K='<-XVP'>9
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MCBMX)IWR0^H:.0EC<@N2\DEN+*[E;=KPYQ5M:ED;PR=Y[].'RMB*H8FS!+*
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M!(WND$$Y!&#M_?\ #[]LC*)3]P'D!]A^O'J'Z?K]=9E19!!P1@U^#MDC_O%
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M6)"RAF&1F1-<ZQZ:4II2FE*:4JL6ZC=OB/9Y2(6^Y?&V#$V.QI52#;5.L/;
M[?3BL>^E_A%774R@8CIBXN1?)GG9J+!ZFQ<(QOQKPGPPQVJZMI^B6C7^ISFV
MM$=(VF$%S<!7D/*@9+6&:10S>Z'9 G,54L&90;1PAP9Q)Q[K47#O"FGQZIK,
M\%Q<PV3ZCI>FM+#:H)+@Q3:M>V%M(\<>9#"DS3&-9)%C*1R,F=X)SYBK<ICF
M+RIARTHVJGRCATP%Q\(]C)**EV IED8.>AI-NTDX:88^:BHJR?-DC+-'+*29
MF=1C]@]<]UC?V>IVD-]87"75I<*6AFCYN5P&*,"&"NC(ZLCHZJZ.K(ZJRD#
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MO.RI2\A8XD[/3]AN [&ZL&/)Z/DY:#F=[&;&OQK-;)+U^DLA*3VVVBNG;UY
M/I!0B6=\F==M63D,>52 =73.J KD[BMC\-F"3&OM+A*XUN\3+2MRP+D&$(FG
M+UIV?SW\A6ZM+G5.VB@9"\?L)JGS4%8JS:*,NW;+QLK%,IV)B^V&>6WE6:"1
MHY4.5=>H^!'0@]"#L1L:Q;VRM=0MI;.]A2XMIUY9(I!D,.H((P593@JZD,K
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MGKM'XBI[K&6.9B:<XF,ZRWEVRT/&3^3J.-4LJ&B6\9&R"K65EXM5=P\(I7K
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M<50AP[" _;GG\M=H(.X((]0<UCD%3@@CYU2_=+MMD,JJI7&L'1=3D;#%CG<
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M.'\Y<3!]V<.'#?:()WKD\6F:E:FT(M;JUY0GE1O&Z(J@!0HC;^&4 '+R\I7
MQBJ!S=]H/AZTG(F3Z5@\U]K.+J^G9RR%-DACK'D-2F-)G&[)_:I2SO)Q5JG\
MKNC"]3CNO+SZ2-8>DO[.IMF<@_:QW*QMYM=U6"TEN4ADOKA^::1 (T9^>5B(
MTY 2S K'&"H+LJ@J#D6;BCCKB2]X=TBRUC4]0U;2.#=*BTW0-*9T$&GV%O%!
M;1Q6\:(JEE@A@CENIA+=/# @DED6- *7;>_^(YQ+)OY>G9;P?;L5U>39S1ZR
M[K-L:Y!;UR07;.5VL*@J9EC21:PKQX8K.%:D71&ON%RI?M''01&H05PO_#V_
MT]5NK*XCU)8&622V$0@N'1#S.(5D]H@E/*/L2#WOLB.8D1MJRPX[T^_8VMU$
M^GR3!HXIV<RVX=QRKYC1F*6+<_:! !Q_$C^T-E/AS^']DC P9%ONX>XQ-ZL&
M8HNKR[RN-)63L?RFR(OYR;D)^;L\U%LY23MZ*\S_ ,C8XEVQ636D+ JX%XNZ
M:.T)'Q'\0-+XRL- LM.T0:4-)1C(&$7+ 9;:VC-E9&'RU%I"\13+V\;2+!;.
MB0 /&<?@C@S4.&+O6+N^U9M2_>,N8\&0>8J3SNMU<K(9";F5'#^[.XC,DJLT
MI(<;01H#M >B*R'D.):\=)6@2D)/%*7V*5[<*]9)41 .P'/('/Q^\8P\"&IZ
MV-7=P%/AZ\X<R*'QLE-OD4V[^P3;U>5FG;=(QE$VOQ;DPE9QY%3G73BHQ)C$
MHKJ*+(,4E%#F,I64Z4KB/X]A*L7D9*,FDE&R#99D_CW[9%XQ?,W*9D7#1XT<
M$4;N6SA(YTED%DSI*IF,10ABF$!4K7V\\.VET"0<V#9SEK*>R:7<O7$H[I^'
MW<)8=O$Y(NE 4<*3>VK(T7:,61)78]17SW%T;C&R.P,!SV(JR2"J2E?1O.>*
M%C8RB4[0=GFZB%;%%-&9I-YR=M4O[Q,@\)+J4:WUK<-1G;U0@?\ ,E+E2M,C
M+F$[=-NCPB12OY_VK-YB/*#KPN,Z+NP_#\1#[C]EKN#$WIU ]EL\0$UY/OUC
M6@6Z>XMP-^#2E?%S:?$QR\DE'UC$VW79U!N^I&1N64<ARVYK*<>W5$ .K XI
MQQ#4'&#>321Z_A'TUFZR1J#PR2KNMRK1%1JZ4K MCWA*;?-B.=\R[C<<V2[V
M_*6?:?%0>39RY(U!FE)V<URG[O=KA"PU(K-2K=4+>YB2@A?U.N04;68A.IQ@
MQ+)%1R],JI6T_2E:I,^;;<W--_M=W=4O".)=T%%F=M\%MX=4K(UY84FU8-FH
MO*$]>I/)5#4L=)N-<F(6Z14ZTBKI&,CP=J4<U"NG:N)-B!VB"E:YZUX<?B96
M.8AUL^9<=91<U7=CC;*[M6P9@D[+CZQ0M78[E&<QD3'U;L2LC)8TF'T9DNAP
M#K'L'&T^HIQT:T91D$(U8DU,*5-[K8UNDH6)/",B(C!>(=P%AV;;:,J86S;C
M:[9)AJW1'EAR#@O'F,V+@LQ,U&T$L%69S=>EEI?X*LO)!:)(46D>JNY(D"E0
MMACPW/%$VZ6'"%3J^X8EKQOB#;A$5&HQL%F/(=0Q-$7Z,Q9E>.G,977':4E"
MO)W&,WDJVU12MY$A(5WE6 K=<K3F'E:,[IK*.DE*CJI>&%XD$\MC2UYVFY'(
MLS3K5NGCH2!G]WV3YYU0*1N'VE8YH\6#:9EGTF>T5NO9Y@+R\EJ)/2\\HZJ=
MD81J\M98HKX"J5M:\+G:=N+V@U:W8WR]=9VRXZ3Q5M&CL;0,YE:RY33IE_IV
M X:G[B(ZL+6I=V\J=&>Y&B$'52J\.X;51C&DZJW!P+)0S'2E;6-*4TI4 9SV
MNX+W'1A6&6:#$SSYLW40B+4U!2(N< !^HQ30MJC#-IAHFFJ(+BP.Y6BG*I"_
M','2?4F:"USAG0^(X#!J^GP76%(CF*^7=0YZ&&YC*S1D'?E#<A(]Y6&0;UP5
MXE<;>'UT;CA77KO3XI)%DNM.=A<Z3>XP"+S3;@26DI91R><(UN8U),,T; ,-
M/>6?#7W"X65=6';G;S9FJ#?E8*+:7,?!9)8MRB(F3828@PJ=K\DA3*'$PU>0
M4 2MV<9(N1 5-*:YX4:SI9>YX9O?WG;*>8:?>.L-^B]Q#<X2"X( _P"T\ECL
MJJQKV)P=^TYP3Q2L6G^(FDCA;4W'(=;TR*>]T"9]L-/;9GU/3>9B% 4:E H#
M/+<0)TJQ7<^*1$XZIN0X6;HUPBU0;2M=M$8\@YABN \=+F.DDFSA,I@#E,X$
M\M0@^8F)R& PT%=3N;&Y:RU.VN+"\C)5X+F)H9E/0^ZX4.I.<,APV,[[5NBX
MX4L]4L8M7X?OK+6=+N5\RVOM-N8;RUF0]XYX'D0GH".8LIV8 @BK+PMPC95$
MBK=TDL0P (&(8!#N'(<A^\'/KW /]9Z"_BF PP.?3J/F#^8VV[U0[W1KFT8A
MHV7!.Q'7&QQVZ[ 9SZUEB:R2Q>2F 0'[]O?W_36<&5AD$$']=*B&1T/O C'Z
M_O7#=1;9T40.F4>?L'(_K_T_CQWZY((Y,Y !/P&/J/\ TKNANIH3E7/7/7X?
MGZ?'K4.W7#=;M#=9-[&MU#* ("8J1.H>0$.1#CI-[^P#ZB(C[PMYHT,RD%%Q
M@_R@CIZ?R^F1R]L5;](XNO;%EY)F !!*ECV[ YZ8P.^:@I:AYAI%:D<?4ZV)
MS&,I8%RN,;WJ$@\@T9DX6*<"2T)6KC'S#&MS318P/&DM721CPKI-,RRJR0J)
M'Q([CB#3;:33K:Z%UIDRE6T[4;>/4K*,ML)((;I7-O)&?>0Q\N"!G(R*L4C<
M&:[J5OK^HZ:UCQ':LK)Q!HEY=Z#K,R(5+6UYJ&E7%I-J%I(H\N6VOC<1F-F"
M!'Y6$3P&U"_1K8IX._N8IV!NKX>0:%D6!S!R(D*5JJS6:E'D Z@.X @!P5$0
M_"$+%H-S]I9C Q.3R*%0Y[&,%E W[ ; C?K5MO/$#2'?EN-.2XCQCF20QRX
MZEF#K(>N<A2QW+=JR,U!W45'@S2*@[HV( F,I7K$@T<E3+VY4:64($QE.._D
MM%'@\\ 0Q]9'[KUZ'WH_(NE&<<K^4V.O\W*">FPSOTR-ZCQQ%P%?Y\Z6ZTUR
M< 75H\J9WZ261N<#XR+'\0-Q7'#<#<:0[0:9(J5DJ1E#E*FM/Q+QFR<#S_\
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M<LZLNT_)*PH)BLZ#%>3Y!99#@!%0K*LWMLW4<H 4I0;L65I8/144,!W]J13
MQPTWKGA \1>YX4U PX);]UZD[20^O+;WB@RQ],*LRR#IS3*-Z]=<%_M76E\L
M6F^*&@))D+$>)>'8%28 X!EU'1I)%BDR<O--IL\&!D0Z:YP*HG)9.R+A:P)4
MS/M!LN-;$(F*W+/LO+CY0J0]"CB#GF:CF"GVH" @+N'D7S<! 2BJ4P"4-87<
MFL\/W M=>T^YT^3HKS+S02@;9AND+P2KG.X8XZ=:]#Z?I_"_&]@VK<$Z[IVO
M6> 9!92_[3;LPYA'>6$HBO;*0C<I=6\+=#@@@F5(S.-1>HD53EVO!@ 0ZSE
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M E8DO8S:8\THO]*0,R6RO#=6\=J1;7$2! \UD<&147DK$D7E;-,G,U7'^'F
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M%UI96SDSU]Z)5:V??<EX"V>C#)SO7@_]I'Q6X1Y(7UW_ *4:<N =-XL675T
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MK71>"^+]*NWN(XM1DT33KP/)!*T$ZEKBT%Q$Z2(0RN(W(Y9!S)(C--47G#Q
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MX#Q!E4'CLF/M8+7QGX5E*K=6^KV+'JTMHDD8._\ -#.[GZ1=QVR11=1_8_\
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M.U"S8K>6-Y:,.JW-K/ P^8E1"/J*[O7=6'32E-*4TI32E-*5_#&*4!,8P%*
M<B8P@  'U$1X  _/2OH!)P 23T W)^E819<G8VIB8JV_(-(JJ0%ZQ4LEK@8,
MG3W_ !=4F_:AQV'OSWUASZA86HS<WUG;CKF>YAA&,XSF1U'7;YU,:?P[Q!JS
M<NE:%K.IL3@+I^EWMXV3T&+:"0Y^%0#-[\]FE?.HG(;D\2JJ)"(*)P]K8V)0
MH@/ E%.OFE#]0?W0#J^VH.?C;A*W)$O$6D@@D$)=Q2X(SD'RB^#D$;]ZO-EX
M)>+=^JM;^'G%05@"K7.E3V*D'H0;T6XQ\:P%UXG>Q=H;I4SU&+#W[LZ9DE^0
M>.>P*,J:NF//';@P\]N.>0YCG\2N!D)#<0VA(_IAO'_^6V(_&IZ+]F[QLF',
MO EXHZ_QM4T" [[[K-JJ,-O4#'>N&CXH^Q181 N<TD^/=?'F5D"_^Y:C$+_/
M7!?$[@5NG$%N/^:VOE_$VH%=C?LU>-JC)X'G.V<+K?#3GZ!=9)/T'8UD<=XD
M.R"3.":&X:H-Q'C\4JPM,(D'/]Y:9@&")?OU*!Q[\:R8O$/@J8X3B*PR?ZS-
M%U./^UB3TK N/V>_&>V4M)P!K+@?_>TFGWAV.-EM+V=C] :E&"W@;5+*)0A-
MQV$GQS_NI!DRH(+\_P!T6[J606*;_P IDP-]M2L'%/#5S_N=?T>0[;#4;4'?
MID-*"#\",U6;WPJ\3=.!-[X?\8P*.K'AW573'3(>.U=2/B"1\:EV'R%0;"!1
MK]XI\X!PY(,/9863 P>O)19/5P,''?MSJ5BO;.;_ '-W;2_^ZGBD_P#E<U5;
MK0M;L21>Z/JMF1U%UI]W;D8ZY$T*5EQ3%.4#%,!BF#D#%$!*(?4!#D!#[AK)
M!!W!R/45%D$$@@@C8@C!!]"#TK^Z5\II2FE*:4II2FE*:4II2FE*:4II2OPH
MHFD43JG(F0/4ZABD*'YF,( 'ZCKX2 ,D@#U)P/O-?55F.%4L3T"@DGZ#>L4E
M<@4."ZOG=VJ,/T!R?YK9(:/Z ^IOBWJ/2'W'C6/)>V<7^]N[:+_WD\2?_,XJ
M3MM#UJ\Q['H^J7>>GLVGW<^?EY4+Y^E8"\W+;<X]3R7V?,+M%NX"DXRA2$E
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M60SE5U5QS^R%POXR<03\3:WXD:G[)%;VEEH6D\-1:7/9Z=90I')>E[F66_\
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MSI+)'_?1D<M7EP@?GUZFZD\*1N0^J?'';C6))<<57&1/Q#KDH;JKZC<A3O\
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M!V..HR#FI$C=R52>=(A() (_W5BB _?N'/;\Q[AS[=\N/7X&&.="/_> =.N
MWW_(_.H:XX$O$)_AL<>H &<?,?KTWQG+'-M9= 7HDT@Y]>HY![_4.#?Q[ 'L
M/MK-368C@!SM_200.F=P1GY?H1$W!UZA/\ ]^@(_'?KU]<5IQWWNL_9_NLI5
M(O($!"XN@WS)G"4%J[LK%*; Q$3*V6R*M89=&=D165.LW9*B:/BH]%%*&2=R
M2CQW)>Q_!V?A/0>'[+6WTJYO]6U""6>XUAOW?+[(%9U]BM5FNX_9(D">7+(&
M-Q+.7-SY4*I'#YA\:/V:O'_Q(>.YX>UCA5>%#/%'9\-PZW?:?>>43RS:IKKW
M.GV]G/-$_,S6L-U<"VA"I:Q3SF1Y9TVL8XR+M?Q@ZMU6AH^>?-8TS22IZR4D
MVE[RXF9%LXD;-\,S6468*08(L&D2D^C7#E_7XY4AV\8L<L@YA]>XDX/\2..-
M+X;UCB6TT.PN[V0W&OR2VTEEHD=K97(M-/BN97B@=[R<?[1()A!'>7(42N28
MHK1J?!5[^SSX Q\/\%<-6GB'QOI]XNO\6RZ7:W;G6M0N9#:-:Z9-'%[;/::3
M9SQ^Y[,RM;6,DPBBN;FX6+!<P[*MLL')8\S [;96H$Q?+K67LUCZF3C!2&K;
M^0<(2]A",>.ZZXFX96/,*_PC5O*JG3=B1&'1;-&X&;6S@CBWCKBV\XRX0X<U
M+A'7[#A'2=6GMN(M;CDMWUG3+"5K.S=8;>\>WN'O8@LBRSP+;JF'U"96E59/
M*7B+X:^'G!EGP+QWQ+I7&O#.J<:ZUHR7G#&A2I/'HFIZ@BWNH(9[BR2YL_89
M69#!%.]P9!Y=A$RQ.Z9/7?#PSS3<]Q&3:SNF4DH!G:D)QY(7(MAFKG(17S$K
MUU%2\8[4?5ZP.'#?K:KO74A'HKKG&028,E0313I=UXU<'ZEPK<:+>\$+!>26
M+VT<6G&TMM.BG\GRDN+>9!%=6JH^'6)(YF"#RFED7+&[V?[./B!I'&UKQ!8>
M(CW6GQ:C'>2OJJ7MWJDMMY_G2VUQ;RM-973NA:-I6DB4N?-$<384;IBO6YO1
M0.1^_P!?00]A_P!_KYY$T9_F_ G\LUZP-M*IW7Y?''7/I^=?<%DS>ARC^7^_
M3V'_ !#7,.AZ,/OQ^==7EN.J'Z[?KUKZ%,41#OVYY[=_KZ^H^OY>P:Y5\((Z
MCX;_ )CH/S[DU]OP#_=[A]O32N-?SI(//8!^O _IW[Z5]WVZ_#_2@ID'V_W^
MO.E.8],G[S7S,BF/82"//?D"A_IKX54]5!^8%?0[#HQ^\U\Q;(#W$@!^9!Y_
M+MV'_'C[ZX^6G](KF)9!T<[?';TSO\=]^]?,6;4?4I?_ &_]-?##&?Y?Q/\
MFOOM$O\ 5^?^:_(Q[;^Z3\^>/Y=]<?(C_I_+_%<O:IOZJ_@1K?U A?T'^/MI
MY$?I3VJ;^K\!7]^6H?W _P!_IIY$?]-/:IOZOP%?T(UN _N%X^_?_(-/(CQC
ME_+\\9I[5-_7_:OT$>W#^P7[=OK_ +_AK[Y,8[?B1^6/U]<_#<2G^;]??7Z!
MD@'H4O\ [0_7[_Z:^^5'_3^)_P U\\^3^K[J_96J)?[ <_7@ '_?\-?>1!_*
M/NS^=<3+(?YS\LG^^:^H(IAZ%#7+ ]!]U<2S'J37ZZ"?W0_GK[7S)]33H+]/
MYC[_ *Z5\_7W5_/+)_=#2ON3ZG[S7Y%%,?4H?P#_ $U\Y5/50?H*^AF'1C]]
M?@6J(_V"_J'^G&OG(F_NC?K\:Y>;(.CL/K7R,P0-SR0H_3L ?S[^GMKB8HS_
M "_B?R)(_"N0N)1C#;CO7P-%-C>J9!_,.?\ +C^6N'L\?H1\L?W!KL%Y, !S
M';XD?A7Q&%;#SP0 _0/X@/;_ %_R^&VC^/Z^X?A7,7TPQN-N^3FOF:";&_L>
MWU /]?\ '7$VJ'O]XSO_ .:NP:C-W)^F/\5\C5YJ/]@ ^O<._P#E_+7SV1/4
M?^7_ /&K[^\IOZF^\5^?V<:]OP!_+_?^&N/L:^H^[_2OO[SGQC+?>?OQG&?I
M7]"NM0]"!V_+O]A[_P"GKZZ^BT7OC[L_W%?/WE-_4WW]/U]37T+ MB\<$#V^
MG\?S_G]]<O94]0!G.RX_$'_3X5\.HS'?))QW/W;?HU]/DK?^X'\ '\^XC_O[
M>WWV9/4_C_FN!U"8]_S^FV<>G^M?H(9J <B0/UZ0#_#GC^?V]M??9H_0_/)_
M+<>G;'7Z?/;ICMZ^F<_GUK]A$M _L)_R_P!/\>=??9X_C_\ #_\ NUQ]LF_J
M/WFOL6/:A_9+V^G?@?RX[?;]/MK[Y$8_E_R/EMM7 W4QS[VQ_76OV#1N _NE
M[?\ D_S#U_/G^/OR\J/^G\3_ )KB9Y#_ #'Z?K]>H[?0&Z(>B?/W G^OU^W;
M7+D3^D?+J/N.U<?-D/5V^6?\YZ??7Z\E+^X;^&G(G]*_^4?XKYYC_P!1K?1K
MTU7YV4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-
M*4TI32E-*4TI32E-*4TI32E-*5_! # )3  @(<" @ @(#Z@(#V$!^@Z4!(.0
M<$;@CJ#ZU'MGQ%BB[$.E<\8X]MJ9_P!\EFIE<G2F[<<B$I&N@$?H/J'L.L&X
MTS3;L$7>GV-R#U%Q:03 _P#X2-O4U.Z;Q3Q-HS!](XBUW2V7[+:=J]_9$?(V
MUQ$?I5?[!X?NRZS>8,AMPQFS,ISUGK4.I3C\CZB!ZBYA#E-_YBF ?OJ!N>!>
M#[O/G<.Z7OU,5N+8^O6W,1'T_N:O>G^.OB_IO+[-XA<22!>@O[P:JN/3EU..
M\4CX$$5!=C\(W9I,&.>$@,AT,Y^_-4R99W!2F_O$1N+FVH$[]P(5($P] ( =
MM5^Y\(^"+@DQV%S9$Y_ZI?7(P2>H%P]P!Z ?9 Z**O&G?M6^,5D +O4]$UH#
MMJG#VFJ2!V9M+BTQS\^;F_XJAF:\&'&@"92E;@<S02H /DA9$*;;$43#_9 K
M""J2YDP'C\)G/7Q_^8(]]0T_@OH_*R66N:Y:HQYN226"X3F[$H(H P VW][
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MXZD0$>>. ]L)O#_Q$BR?W1;R8&QCU.R.?D&N0V?F!4O'XV?L_7 __C)X&/\
M+/PWQ*F,]BZZ2Z#&2/M'OCUKK5,"^(<S,/G;;K<<   'X:TX_> /''/'PUQ6
M,(#[<!R(>G(^G2>#/$)3_P#F"3;NM[:'UW&)]_H/S%9:>*G@++]GC_35)/\
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M0)R =14EI.R5 3=^0*8Z!?[W0 _AU,0^"VJ/@W?$\,1(W]EL'E .V /,F@)
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M"<;Y8&MR49XC^T1XV(*%NR-'E2$&XLY#;=N2BEVATP H-56SO$: H*D  *"
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M3MF"Q4R3%4F0-\IM-8D_,;N&3SY9)_&-G3=ZKL!-)MM3M%M+W_:;"Z)2&X
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MK[=Y43@9Z?)%DHDHT@*P@0Y0*VC83'60#3TJN4'!IB1ML&@V<1IJK*MIC8W
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M3,NT@8I],/DY)9G'-SNG"41#3%ADSI)\=0,H2 8R<U)+]^2M8Y@[<G#D2(F
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M!\LLWW_=.>TVXQ5CA$IQZX16D9A163>J")!$[Q^H+IR8?<O]:J;@/[( !0X
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MJ2^9DGWQRLS^_P!<. ^3AE#9%;&Z3>J5DJL1-VQW;JW>J?.M_BH6T5&;CK#
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M[CE%_P =6#7.N6.L3;?[1K%[.)M;TUG;?RKI9K"%B>2>./&+]>%M:(F9QON
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M*K33K;7EN94NH-/N%CMYGC+/8ZOI(:YNKNS5K>?R$%Y(\LDD5TLOM%K,IG]
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M+VSDCDC\P /SC.2%(YT51AF9@Q4==OM*V[8/Q]BMCA.M8PIB6+V<7\J7J$E
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MTRYD,+QVUXUOS+R7ME(RRV]Q$R.>0V\WFVLLT#S)4*35:%#(0%1A&<)%MRD
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M.8W+G&<K2T<9Q^:[=M?F]QS?%,PWE[V^L^.4;%'56?;U@UU5^8&9F82 C(P
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M:E6LO'@N;P)!#-CBL7/#B=@S%?-H65LA69/)]HCK%FDV*<!Q>.,[8:R"K<\
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MT%<:YD8[#(.2H6VQ4\WMT3B>KV)T]BF:E6H\/OPV\[[8L]8KRYD.R0BU;J&
M-S^,7U.5RNCE&0JT_FW-F!LE0,3C]W7-MNVVF0^,6#/&%I??LQ&T:$3JLS8D
MHV'1EXQ<[B-4K>7I2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
D:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img29677477_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_12.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2L44&AO=&]S:&]P(#,N,  X0DE-! 0
M    *OB^$0 #A"24T$!       %QP!6@ #&R5'' %:  ,;)4<< @   @   #
MA"24T$)0      $,==%^5TM6[UV[XYE,#I>5PX0DE-!#H      1D    0
M   0      "W!R:6YT3W5T<'5T    !@    !#;')396YU;0    !#;')3
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M]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M  3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T
M]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M!'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D5%
M5N=$8C4FQT                0FQD(%5N=$8C4FQT                4G
M-L=%5N=$8C4'AL0'*FM$         *=F5C=&]R1&%T86)O;VP!     %!G4'
M-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M    !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M       !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;V
MUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%
M)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M   ! !*FM$  $  0$J:T0  0 !.$))300F       .             #^
M X0DE- _(       H  /_______P  .$))300-       $    6CA"24T$&0
M      !    !XX0DE- _,       D           $ .$))32<0       *
M$          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0
M"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M   3A"24T#^       <   _____________________________P/H     /
M____________________________\#Z     #_______________________
M______ ^@     _____________________________P/H   X0DE-! @
M   !     !   "0    D      .$))300>       $     #A"24T$&@
M #-0    8              ^    =           $
M       0             '0    ^                       0
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M0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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M       0$ .$))3004       $    !#A"24T$#      @0     $   "@
M  5@   >   *%    @)  8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6
MYO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R
M!S4D="               !  #VU@ !     -,M2% @(
M                                              $6-P<G0   %0
M  ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H
M(8    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&
M0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&
MUE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\
M (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=V
MQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.3
M8V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                    !865H@
M      \U$  0    $6S%A96B                      6%E:(        &
M^B   X]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X
M0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M     6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                   &1E<V,         +DE%0R V,3
MDV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M      +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("
MT@<U)'0@                            !D97-C         "Q2969E<F
M5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M     L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3
M(N,0                                  =FEE=P      $Z3^ !1?+@
M 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
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M $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2
M99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^
M4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1 ))0DZ"4\)9 EY"8\)I
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M,3%1,3&!$,# P,# P1#
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-G%TM+7!%R0E-#4W0G-V@9&RL]$)=:&Q)D-38F;A=WCQ_]H # ,!  (1 Q$
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MF^\J_P"K)A.U"EOFVD&%3L$]B\7AZF0LCD6S(:1V8K0?^HQ:&S_50X!FHTR
M;OVJC]SJ!UC\^]#4]U/5@2[*%F;6P:MDI.5"H],&# L/'&EX;*C,,.KCDC3
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MFT;H&F $RIZ&;5S4TL#5A"ALEK*O]T'K7:$P XS"HDXA%-FI,FVR  .AXO\
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M TZL%*.M<,0"<UE@X<W.RC0*RUU:"M33][JP;ZZHM<))ZZZX _N64_4T\E\
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MC_9G"J%(D7:;#-K!AR4LK9&N=*N6VQD\U:N('B3;L\1S;5)V+3764PKA)+?
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ME]!W7 49,EF]6SF+Q\3XXY+E['V*]=CYGI'$QTLC&M1TCU1K45>5<O"&TO3
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M1AIJZ:99%@A48;#/" D@T>+ ;[\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
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MX!X!X!X"('R$_P#D"]P_^J!TM_W,37P&J_BW_P!EAPE_ZEE#_P#=+'O>2_\
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M#F@&A+S^0A2L+(N2!UGS5;_10_E^)QN;=1RJN"M?"&]5")7'W,S$@HX$FLH
MF;7L'2!LUYP1AD/0RLQ .@:622QT^+#+@3J@M@PZRJ_B%IPH\Q.0&>1 %/(K
M)4%/QCRL3DH=J?#&DU%\)Y2:NQ+QN\QE?">R2>_T6UTVUVQ@#^-+)KI1<PU3
MGT*4<QX6B;/M])2"V7!A7">JS<N81U?Y4&"UT=M547[W5!HJGMJIHKMKG&<@
M?7M.X/I%<3K>9132$9:8?XF.TA$:Q7+'._X\/<2'+S C+3*G^KPYP\_#G?\
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MP#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P'+A\H'!G;\>K(5?TK[
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MLF.K(2W1'V-UFGH/'IH))-$DV3?=OIJT;8UT;([(ZX3TTSIC($@^P^G*RYQ
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M[^D\U>G-'5P?3(7);]5_5>9 Y40_=/WO#++#&C7]OQOKEUL!:M\474-F=G\
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MCUKV*."J5,JU$IT[JM]?"C'=KY97M>B,:CHU[%]O<NC]-S7\> > > > > >
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M !ZE_.ZW_685^?$/_LZ.9O\ AR6_]X\R]'M/_BWB_P#53?TJ<LSKC_G5V_\
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MP+L=N7Z-VC?.D1V@R&(]R<6BAR@!J9<^W2@!6$5X=JF,.6^6Q5'<UJ+@4E-
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M(;6$KZK0-N+36)BI6^K[#)\:E]U1E!XQUR&&;!\R64B]-102-IOD!3 #M7\
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MO8+3_P"+>+_U4W]*G+"ZX_YU=O\ YW1_JC'ED?I*50/ / / / / / / / /
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MW BU (02YIK'XD>NH]8]LR:[.I;:YOK[JXO*[6GTI 7VSZYJB0%Y(_DD/.2
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MP\QT]%ZJ[KL 1&HT\A]PRB1SVDF4CJJ8VQ&PMF"2=?! 4AE)@!'$TUGT2*Z
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MN7V5R2(GZ+CH1]8YJZ/ / / / / / / / / / / / / / / / / / / / /
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M?46>UJK%"JR5*Z1QO?V^9S9DD2-'-C5'*CV[6]0/CSUN]J&7I=.\'MF,V^Y
MRMC<GGJ&!3'8Q97M;9O(VMFLF^Q:KP+(ZE%-2=6=9\3[+70L?#)<M3O''-M
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M];LOL:W:_L.J(GI(#5G,0#>06-"7X34<$!%G(20AWHG=?=^^$B/Q%A[-AO\
MNVNNKT3LX2)-]7-3L]2,KUGIY"SBWYK=:F9\^3I9B%T-:FRNQ:LTEQ&,;'C:
MN/K/_O*>*/QUWMJNJ0SR.BAEVAVJMTVQ?1NY0KY2+#:5<Q'@QMW#3-GLVWSR
M)9BCJ>1ZRY*W>LQ?W[!-)Y+#?4MN20,;-+%)MM\479RL00^0YU\D]X9^372B
MTW:1+496^.9-8QIOO:"7.2]<Z175XM6&9 JH.7+Z2;1AL454FND4RY_ZAM].
M&\\(JIPJ^ZISSPO[$7A/M_(G_$^9J\<KQ]OU<IPO'[TY7C^3E?Y2(?Q:?)9!
MD>NKM[=^1**Q_E=U\B-.4:XY@NN8ET7]..H]ST/D53W-7 &RG*&K"M=9%8,;
M1L'2$R=Z-7_3:#<'"15WB*&9/R"PCG*SJ^[3^;63]2\?O-95SW2G%A&@;ZOZ
M-CGK:N;CML]93&3P^OHX?W:MA\^>P0"V2-NY..4(-&35JT%Z/?T*H3=\!T.>
M ?Y_Y^ JOM]!#'RT\?:812QIMS3T#G;7">F-<YP]'?3.=?I],YQ_NSG&?I]?
MX]$[B)^6&&]D_P E9'_G9^[]Y=&#<[^X?O*]R\_EAK2<\KRB>)_V7[I]C">T
M@+/N?I:N_C]9+.M:GK=FSOWK$T&WRV>,F>K=9C558L2FB>Z0PW*'1-:0ODOI
MA[H$T9%&6<X9.D]_/G(VY_*5M=3N]'5:W(Y=[/94;PK:=1KT_0?*KED<GZ7C
M[7MX[5Y]_3^S)TXU'*]3I&L7-Y9\FLZ37L(CHY)%>V3-9B2%519J]-D*5HW?
MP:V/+!)_"L<VQKGOGJJ^7ZLCM/T]'4H]$H^EG;;??*:Y@^67U3P1D<E)ZHHJ
M%Y 5W3TW>OE4]-==$T&3-!H.:,V;>2XW&U,54CI4HDBAC3]ROD>J)W2ROX19
M)7JG+G*B>W#6HUK6M2J=HVG-;CF;6=SMI;-ZRJ(B-Y97JP-55BJ4X5<Y(*L*
M.5(XT555SGRR.DFDDD?NSWO(\/ / / / / / / / / / / / / / / / / /
M / / / / / / / / / / / / / / / / / / / / / / / / / ?YJI)+I*(
M+IIK(K)[I+(JZ:J)*I*:YT4343WQG3=/?3.==]-L9UVUSG7;&<9SCP$6Z=X=
MX]Y\FI&QZ0YIIFK)T4:/AR\IA4# @B[884<:NB8H.Y9M-,@!)%SHFL_% L#A
M[Q1)'9PV4_$G]H$J/ :DNFA*6Z,AW]WU[U="+9AFI-F<;QZ=1\?(&# X/U6T
M8'!>'R*BHDVQ3<N4FA<:JT(MDG+E)%SHFX6UW ^NGZ3J+GZ$LZWI"MH954$8
M.WI%O%8+'QT=#Y)DE,+$BKEJ.01P]+$E==52!5YEP0?*:Z[NG*NVNN< ;,62
MU7251WRIC19/=+?*2JB*N-5-<Z;9361VT524QC.<Z*I;Z*)[?3?3;7;&,X Y
M._CU[-Z1@EU51P4C\E/QE7LRAEGD8R8"%%NI)=?,EB?];$C,C@<-NB5L U=V
M/80,0X) (FY<&#A%WD>PT)[%=VZZR@'61X!X!X!X!X!X"COX^/\ :Z?.]_QE
M\>__ "RR'P&UD?F7Y75>2AEL.F3%Q$IY/J[*H%258CG>AVNYH=@QC?\ 1K6'
MEPBT>$P#EZ*RZT0=+BG+%RY:M%EMVR50;)UFPFL9F]A+>L;U=FH21127,7K\
M=O'3NF@BG:M:TZ_"LK429(W+XV\2M>WA4;RMXZIT W+<,%CMAQ>2U>*GDXI9
MH(+V1O0W&,AGFKO\T4.*L1L7O@<J(V9_+%:JJBJJ) 3AG@#BCMRZOD,Z2Z I
M*DK\_O/ZJ4E=;O#3G24R.$PLG!@&N(O),BG>@T26R4:O2*H]D_+-_P ;I)?5
M]ME3*:<MTO=J6[TKEVCB=@Q#*=EM5\6PXUN-L2N=$V7R5XVV+"20HCD:LG<W
MAZ.;V^W)"M]Z>9KIW?HX[-6\3;GOTW7878BS8M1,B;,^!6RNL5*;FR*^-51K
M6/;VJB]R*O"5-_)#4(SA#YON**-^.TE_H-,>H:9I*I)Y(Z3""-WNHZW^I)=%
MY*8U&R=N9&NG^6L4B2^N%4TL+*1L:ALIHEE;"DR(&6<_)!\6=]DN.K;WOOY>
M.C[%KX0V 2%2'V'7]7#XL6D *1BR4<R^<1 (WDF%!Y5N@3;:BE/S859ZJ*?:
MV374TC>V[#7UC 7\O/#ZN2*-(:-!'QLDR61LJD-+'Q>1S6J^S.]K'JJJD4/E
MF<GCC>J2S1]4O[KM.(US'*Z.6]919[2(JMHTH$6:Y>>J<(C:U=CY&HJM\DJ1
MPM7OD8BXQ#1GQ"S6A M97WV%*2K8O!(V#DH8"4MN-'$=F&G_ %AB4G :*YD)
MI5X/3'#Y%ML0PF7>(EU'+A\Q*Y;):U],>FND8/(4MVVG)5+>SV8UR3\(VDV+
M#X#+W+$]F3T<%>%87NHPRPUJT:(ZO3L0S3UG/YJK6VYZEV>L^<H7=*UC4LC5
MUFO+\M9FERE27,9[$4Z\-6/U<]B^DS&WI89[-E_+;%NO-%7LHWMM):PVJJ+O
M*D?D?NR@/@UG5?06KJ\Y@Y_?]6,.F$)//J#4M7]F1"TX*!N(XP6GPZU2M0ZH
M262/VY%JU**-2G]1I;D4DD-=MFN:]K7M7EKVHYJ^Z<M<B*B^_"^Z*B^Z<FCT
MT4D$LL$K59+#(^*5BJBJR2-RL>U5:JHJM<BIRBJB\>RJA'V/_'WVUVE\D7R
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M(,@ES5<U!G<:V.>:Q"V!]VNUC&VV.K/=+75.YD<D+U7B1#;OLN0L> > > >
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M!H]6T"$#ZWC$<_O[O;6)#F]BV;.FC<$R<R8)$5GRPJ,HGOUB>YG;]X0_3/\
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MA4KWJ4S+%2W#'8KS,Y[9(I6HYCDY1')RB^[7(CFKRUR(Y%1-1LWA<KK>8R6
MSE*;'9?$7;&/R-&?M\M:W6D=%-$YS'/C>B.:JLEB>^*5BMEB>^-[7KDGO28L
M> > > > > > > > > > > > > > > > > > > > > > > > > > > > > >
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MSGLC=(][6H]4<DLO2XIH> > > > > > > > > > > > > > > > > > > >
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MBDG8LC)X5>L?>J-E=<%_U!0D.8S^UYJPBL3*$60H65RU)F?W-^1;+O6B(]D
M9%"#W"K-JX=Y6;-5$$FR6RRJNB>==LRW,[!A]?ILR&7O14ZDLC(8IG-DE262
M1KGL;&R!DLC^6-<_EK51&-5RJB>Y3ND=-]VZC9NQKFFX"SF,S4JSW;=-)JE'
MTM:M+'!-)9GR5BG6KJV>:*%(Y9F2/E>D;&.=RB8%&>SN8Y?5\EN8);0)2MH<
M8; )+(W[(Z'_ &DN]RQPQ9KB"PID<4V?;$6NK%1N-61>;9<:MU%,LWF$,?5W
M75KF+M9J#,5G8RE,RO:M/;/"D,TGC2-CHIHF3\R+*Q&*V-4?R[M5>Q_;(LKT
M*ZLX7;<3HU_2\BS:<Y1FR6*Q=>?'7O64JZ6%L3QW:5RQCVI62K,MALMMCX$\
M:RM:D\"R9Q3W0]*W^W..J=L().THTLR;GL"L/D5A:A+1PH/RZ;$F;%SJD\U:
M._TZ^J.R"N[5PGJIE1%377WX;8\)L#9WX;)5\@VLYC;'@5_,2RHY8^]LC&.1
M'HQ_:[CM56N1%Y:J)']WZ9;YTWEQ\.[ZSD-=?E8[$F.6YZ=\=MM5T;;*1359
M[$2O@6:'RQJ])&-EB<YB-D8J_9*[]HZ"N#+*86_6D<)Q]!9P9#%9O'&AUAH@
MT_7;Z+ U"."^7.S7.JR#31ENZ<ZJ)8;HJ[*IXV_=O8,%0=,R[F<96EKM5TT,
MUZLR>-$9W\.@63S=RL5'-8C%>Y%3M:JJG/1A^G/4#88J-C":3M>4JY*1D5&]
M3P&4FQ]ETDWIVNCR#:OHO$DR*R2=T[88E:]99&(QRIK&F>V>8N@98K!JFM)E
M)Y6F*=&L!E0$KC[AP/8J()O%62DE!"&[Y5O^H355:,UEW>K;"SK\'Z9NX52Q
M>%W?5MAMK0P^6BMVTA?/X/!:@<Z*-6H]S%LP0MD5O>BJQBN>C>7]O:URI+-Z
MZ"]6NFV&9L&YZA8Q&&?<AH>O9DL-DHH[5ALKH&3MQ61O2UV2^)[633QQP+*L
M</D\TL3'RE55202577431013W5665WU32223USNHHHIOG&FB>FFN=M]]LXUU
MUQG;;.,8SGTJ541%551$1%555>$1$]U557V1$3W55^Q43&/D>V.-KGO>YK&,
M8U7/>]RHUK6M:BJYSE5$:U$55541$Y4K;B'RM\F32T1-5BR<T;/SDIVB(J5E
M(^-9PET04=JL!SO!?!]5ZB+,.]$$1SUP*2Q_UUJJ]39(Y740K.EU;U"]EH<1
M#-=;)8MK3AMRUHV47RJY61.2;U"R)%.]&LB>Z%.5>Q7HQJJYNTV;^#KK-@=1
MN[A<J8&6MCL0F:N8>IDK4^?AK,A98M0^B^6LKON48%DDM017'K^8F9 Z>1(V
M26!E)I#@FOW&I9&A&N/K]=BAT6/U_C_/^7;I+'\?[_Y_C_?ZQ);E.!.9[5:%
M$^ZRSQ1HG^][T-;*F"S=]>*.&RMU?;VJ8ZW97W^WM#"]??\ 5^TKH[2^2ZO.
M:1D4:5JI#+HFLC(.]GH@/,6;@5'0(]'.J[TN1 X+9;D7C]9JV&#5=4MUT$B3
MI3;35JEJXK;>.IV.U:&HS&^BS5^S(_O@AN,=%6KQM^J2:2OYE;(^1S&Q1*B*
MY$D>JHC$[MGNA'PJ;-U5MYB;:FYW1,#BZT*07;N#GCN9/(V7HL=>E5R/HDEJ
MP5V32V[3%>V.1]6%J.=*]8JRI%\XE_N7B&\2J.G@C#5IIHY:R+6:2AXJ^PNO
MMNX0?#91$$4&FS;9JEHS4'.%M%TEU\OE$W";=K5EGKQL+WM6GA\-!&C.'ML^
MNMO63N<JN;)%:I-:SL5B=BQO<CD<[R*CD:W;#%_^']TWB@D;FMTW>_969712
MXM<#B(&5_'&C8I*]O$9N229)4F>L[;,3'1OCC2NUT3I9K) ?R?\ (]ET^V0G
M$XE<,DTQ@S@9,(]&819CTM&BY44L--MX_)0<5)#L+,W2KE0$71(;[):X9N5_
MP.M54$K0K]4M0RF'C];>N4K-VBZ*W7JT,K+-5FEB='.R"U6IRQ]S'JY8)FR*
MJ?0]>UR*U-6,A\)?6C5-VEDU_7\/G<3@]@CM83)978-4KT\K2IW&6\?+DL5D
M,Q4M>.>%D3<A2DK-1R^>*/R0JR1_-T[Z#EW]XZQ%G85XXK#66Y<(QE>W)3F3
M;0K0IC; Q4]J\PWU/JAL92V):L,M$B._YL,MV^N$,ZROV:[\U=*S)9],2ESN
M2H[-7?5+127^#6QY>$L+#S^<[%8V5>>Q6)VK]2X>FF$_)=E6?6>GZ[:N%\4F
M5CTO#_*4SRU.%MLQRP>1<<R\O>E5;"3/JIXUG;*OD3IC@?7%JN(5$P=,\0=.
MS,((C8,2"/VZ8B=<.SHUB*:-AY<@=/ORNQ14BVT1=KF-4E-7^ZN[O&,Y4SIC
M:*AM^6?2J08;1=INP0UH(H+.8FI8U\\4<361323V9I'2K*U&O=-V_G%<K^/<
M^4>Q=%]/BSN9R&\]?NDV"OW<KD+F0QNE4LSM$./M6+DTMFE6Q^-K4TJ,JRN?
M#%15S5KM8V!51&HXYV^\)9?4DZ;G)2^H\]@,UQN,W$PI,TW-#HE%%&"2T:&A
M#0M=065038+?D>EQFR:1 VL6<*H-'2CEFWUMZ@W-AL[5>EV"O)C[R>%8*+;"
M3Q4ZBQHM:*O/$Y8ID1CE62:+ALEAT[E:QRN8WZ<?#OANG6+Z3Z_4Z=9.#8\"
MJ6TN9Y]"2A:S.9;9<S*V[]"W&RW3D=9C1M>E;1SZU".E$V2:%L4\G29\<5&)
MUIS[$9S,88V%779PY:3S^5E'1$S-C[,J0<OXYB0E#>ZY(>XR"4%KO(^@MHS9
MOLJJKH:DE'>-=G.FV!3%Z[3O7:+8<YE(EM9&W,^2>_8;+(Z2OZF:?NEC=X%C
M<^LUR1QR*Y5:DBO/EC\474%VU]2LUK^#SLMS0M3M,Q6MX>I#5H8#&STZT5?*
M?+*>/;'5LQID6VXX,E+&ZQ-71K(Y%JMAYL']89K4/ / / / / / / / / /
M/ / / / / / / / / / / / / / / / / / / / / / / / / / / / / /
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M3"2"2BN^NN0(J<U=!]N6_$ZTZWY^^"#G'(NR!&EBP"P$.U:DC,@<,9,DZ_\
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MQE\?$Z"AE,C2A<]9'0U+UFM$Y[D:USW1PRL8KU:UK5<J*JHUJ*O"(25QU_\
M-9C'T_Z'2K\8Q_&,8^1*H_IC&/\ +^/Z$_\ Z?3_ '?]O^[W>8X_?]+_ .:W
M_P SI5__ +1*H_\ \_Z$_P#T?_N_G_/P&@>=OE:^4OJB+3"9TK\2U>22/P2T
M9U3<E=O>\Z^CRC.?UN12%2X2DU.ULP<NVX]ZLFDB4:I+#7V,Y49.5T\9V\!O
M[_2_^:W_ ,SI5_\ [1*H_P#Y$\!\K[LOYI1S)X0=?#O6*;5BU</'.^/D/J53
M;1NU2W76WQII \[[YU33VVQIKC.VV?\ #KC.?I]0-.<X_*-\K'5])P+H2D/B
M2KN35998\@4AYU_WO7<<=$60PV3CSQ18*>K@>78;)E0[]#";UFANIHEJMIKL
MBJGOL!/SEGH#Y'K*M#,;ZE^/B%<SU?\ TV7(8LD!UO KJ?YDC55AJ)CW]&1N
M,""/X"J2[Y50OEW^G8Y9::*I;Y<Z?:!9!X!X!X!X!X!X!X!X!X!X!X!X!X!X
M!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X"N6WOBBX@O/HC3IV
MQJO+%;&>'(!*)>*8S^<AJULV455KII6LCM&L!1YK"9X7A:2>C<2N>#NDUF>O
MZ$JB29;;M]@+&O 5Q\M<AV727=/R6=-RLU"'\"['/\LE:P%1\F==RT(WI&GR
MM?RS2=,",;%!Q:S\R^1<Q_4 >DVCL9JHL14%.L:L]P+'/ / 5X_'QR98_**W
M<REBF(48QTS\AW1W6<#Q#"1PCD57%O,H"VC0>6_O<=CV&$U9;Q4ADX-$9.@V
MVBS/+&1$LJ+:MP+#O / 5Y?%OR;8_$O'<1Y]M8S"STT 6#=TK>$J_)'"T94'
M63<,VL$$BV>R*.Q8IN]:A9(Q;%DU0R*"!-)VBT<OFJ:+U<"PWP&I[[@A>T:+
MNBLH^X'-#UBU-8T$".S"SEN(:EY=#S,?&N"CADT(/$!R+T@BH^6:,'KE)MJK
MN@T<JZZ([@:4^/OGV9\I\4\S\XV(2C)B<4U4T9@DH*0QZ4(Q5\7#(;I.G %\
M;#1XLZ';[;8R@L0"#'.^/KE1HEG^/ 3#\!#7Y#.>9KUEQ+TMS=7)*,!YS<E6
MG(3&"DT>E1L48E2>S?*"YU\$"R(LU'Z82V_*JP!DW&OUU^QJI]<_0"0]11(E
M :GK""F5F3DO"Z\A42*N!JBZPY<E'(V,#OEF"SILS<JLE73-7=JHX:-5U$-D
M]E6R"F=DM0-A^ KR^4/DVQ^U^2#E"U49A8&8$[/HV:H$9^2."HWH*K2W(?/3
MR"SR/1V4D]7[H/'WK<2EH(4;N"2C9%XZ8MMU7B(%AO@'@*\N].3+'ZBE?!IR
MOS$+$M.7^Z*FZ:GZ<P)&Q[@M H)'IN)+BHAH&CI],A+7#F2L-QS RJ #K().
M]G)YHHFBFN!8;X!X"O'I#DRQ[@[Y^-CJ6,F84RK[CO?L/:S1!PB;;3 WCH&E
M0]<0S^AA[".D@Q/(TX/7=2;]^D$:PR%;)+B_WEWG9EH!8=X!X"N0QR'91#Y8
M8?W4B:A&M11_A"0\P/8^J3.ZV*I/RUXHV6V+-A&L;WC>\0T I[-5B"LM1,ZE
MLX0T *,_J^P!8WX!X"O*FN3+'KSY&NT^NS9F%N:UZ,JGFF#0@*+)'%YN,+4V
M'E ^4.)2-=1UD"8CGRQIIL"6$R0VY=):.-G[09OHGHJ!8;X!X"O+C/DVQ^>+
M]^0BTYJ9A9./=7]'!;>KII%R1QZ8#QH=78*)+LIHW*QT*R''-B0QPLDV"$)$
MPV9;HJ[DM%]MVR8%AO@'@*X_C*Y#LOC*HKK@-HFH0<,6/UOT)?0-Q R9TH-:
MP^V).U-1P<56D$;C#E"2,VJ&Z9IFT9OAC9QG71B7(IYRK@"QSP'DGV"Q0$:&
M-]D]'!$218(;K;;:HZK/&:S=+97;313?5/7=37.^VB>^V-<9SKIMGZ:Y @]\
M7W+=@\5<&<Z\O6H6AYVP*DC<C#R0M 2!DK$'KHO/99*6VX0A(8_%C+E#0>=9
MHK[/@ U35XFY33241T3<+ 3W\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
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M/4AI"(PRT%,"U6$&?[!W!$7^XJ_L8'^?8?Q%=7G+D^0@3S9">;9U3/R;QBB
MTJL"WI03C\]Y8.50FBPD!<$#:0\^I/A1Y-+,D"(""X9^QDF@S]4BDB 2<F .
ME^N8EM *]@D$W+/#^T*AL7B6QTA]?UYK:-A&(;)9]]5%<_K".667CGZJJY_,
MMO\ 53?_ ,;(&9> > > > > > > > > > > > > > > > > > > > > > >
M> > > > > > > > > > > > > > > > > > > > > > > > > > > > > >
M> > > > > > > > > > > > > > > > > > > > > > > > > > > > > >
M> > > > > > > > > > > > > > > > > > > > > > > > > > > > > >
M> > > > > > > > > > > > > > > > > > > > > > > > > > > > > >
M> > > > > > > > > > > > > > > > > > > > > > > > > > > > > >
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MTE'$WJND;)H$2XA]4$V<#]]_T>IN/&Y<[)/#6--2&L;A:8=)3+1XZ2W Z+?
M/ / / / / / / / / / / / / / / / / / / / / / / / / / / / / /
M/ / / / / / / / / / / / / / / / / / / / / / / / / / / / / <K
M/S<1\\4^7+X&2(P(7(CQ/1*2Q5^P&O'C,8CBZZ%5RJ0=-T5$&26$D55<J.=T
M]?QI*;_7[=-LX D9_:@ Q<]\4,Y'@Q1(R_WN6EU=6(IBZ(O-DTI(OLJIJV9I
M++;:)Z_RIOC3.NF/YVSC'@(37)$S+_YU_@K(JQPJ[#AN' &I(AL)>*CA9)E
M+]7;:/W?X-FS)XV>?I%$TW"B:R:^4,XUQOMI]0-S\;Q<HA_:?_D^D[P 11%N
M.7((U%'G QTD.<**QODC5T@Q)*(:M5U=MF&^JJ:"V^_U:J8VQ]4M\:@54TYR
MI>'1?QP?/]4E50R2$+"*=UZS^*0](4^:DYX(KFU/ZY,A8XT5214,D'H$&_6
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M#.SQ@MEYE3?5-BW2<*J;8USO@#J6\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
M\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
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5@'@'@'@'@'@'@'@'@'@'@'@'@/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img29677477_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1;84&AO=&]S:&]P(#,N,  X0DE-! 0
M    %KR^6" X0DE-!"4      !                      .$))300Z
M  #W    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    * $$ 9 !O &( 90 @ %
M1 !&       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M  !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O
M;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L
M;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14
M;W!L;VYG       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F
M       .             #^    X0DE-! T       0    >.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M       ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!!X       0     .$))300:      ,U
M    !@             "/0  !V0          0
M   !              =D   "/0                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   "/0    !29VAT;&]N9P  !V0    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   CT     4F=H=&QO;F<   =D     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    '.$))300,      Q3     0   *     P
M   !X   6@    PW !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1"  P * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
M/P#L[<;H%3'^@S)L-#G8SQC^L]P>YCV6;O\ 2.V;MWT__!$7#Z7T;-H])C,F
MO:?4=7<;:WP?M-(GU?S?TV1]'_@_^#4\2G.K&9=TQU-YRLHV[[O;7M+=CO3M
MQW7NN<Q];*_?L_T?^#5K!.8<VS[:*FW^A7(I+BS^<R(_G&L=]':DI@SH&$QI
M8+,G86[ #D6G:W<VR*I?NJ_FF?0_,3.^KG3'Y!R+!8]Y))#K7EI):ROWLW>_
MVU?GK46?U3*M:ZK'Q[O0L<^LVVD!P:QSQ4QCFN#O=E7'T*\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?1E\J]Z,2JUY3LB5=?$N/<<NN>$I(DG5JO-8SEK$^0GC2KL)J[M3F)(GK/\
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MNKB@)Z+\Y6?/8=+>-*ZALWI%Q8,JK;:1]5-K)-OCLM"(&2<D491(/"F(\3$
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MA7+:N^E[QD;N=RZW)<+B$2:QIWM=#((^:;+DE#+]_DLFU; 191\FHONW3;K
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M7?\ 3V%_VI!_\=X!^9%=_P!/87_:D'_QW@'YD5W_ $]A?]J0?_'> ?F17?\
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MJ:_:TVVUVQC;/V<_("I:55W#4O8-_7?0%P\K%*TZR)4H6M4=;<C/)S*NB-5
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M350?U4UM_8:,?POP#\FJ@_JIK;^PT7_A?@'Y-5!_556W_;_^AHQ_E_[?^:_
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ML^9CH>) T+!&T_NW6JI?1S4K91_]$]*PM6-],RX>YLXHR@RQ$3-1 ;EV4H/
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M(7J1^S9IUN[ PNLW]2 M--X?<%62QC)$H,L'C9F3-IG]].XU&8]%[,8S8&#
M-0P$S(<A4>[J*G:5F<8VL*&4C7+2MH<SE3]\HAD<A7R59+'GXP<Y8!UY8I$O
MKV#"1ZC]"L<_&C6\8=!]R;O94"7A58PP-,$)^S&NU)DA !%8_I"0-G"I!Q#
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M!4#_ /Y"]R_^,%4?_P"M-0>Z]=_ZUZA_^KP/_P"JQ#)ZE_\ 9?Z//_LFZ_\
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M;@1M7_(=:AJ2AE-V?QE85N9@\Y(S,/,CV.<]99MJWO@]>L-"D)*1Z3-RTN.
M%2C(2;;F)(09S9NV*9D;-RRD),;N_'[OV!F''(]/NC4G,N.3NL%-)0/M4-L!
MQT)"$8E&P5Y'VDHN '!XHWZO2 PH58IUI];)6L;8COJM'+I@CNW&*ZLM ,Q(
M^9:RD41&0!/E7K")P<)9Y"X@D1KOH""5W' T_?RD1.4BH@1#.K@K(:U"38*V
ME\6"M$40L4D;DF5CC 8Y*/\ =<"W[6SIRT;-FB?-=ZJZ-D$F^BKJ3<[.W*FB
M">J>N[ETYZ$4<.5]\:XV5<+J*++*9V45WVWVVVR!Z/S6G?\ FT7;_K[G#_\
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MNTI*X%ZZD@*TD+KZ9;<S=M7;M8MQM3L8LZ_H16Q_,^J!U#V(V+]H%ZP#,H7
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M=07W?EDTO95@MWLKHJ4\W_#Q.WG80*OY@;':1WI'H6'N=X)!WI<:NSP9*4O
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M27M"Z[$Z IDE!UZ\A=6L+I[;KD1'3]A2F.%YJ0YXHRS=&I2[@JP)HQ P E,
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M9.95>46(BK(+U[*)4V5FD2?FA0A_A3ZW1->+EP*X4C2'9%I"N%.D%)A'965
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MOA[TR1(*R.CY,5CTS)Z"QXY[9$ )PZQG(P>'9JRO?2/1W(D/7KU_62>P'/\
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MA4<Z\:VC/:R8C)+K(Y;7;V<RCETFZ)5XX3BA=J '/FB#AA##JK,"R')U3]]
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M+4YH?S&UZNB\8M(JI9]9,XO$Y=-G%=RFF[6@Q'6"BIF8"!]'1Z02:-1&7/\
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M[2SM/$1'+-,S/$1'F7%=:4UI56L)76BHBQSPJ)$*JQS,SQ$1$1S,GN]UG,>
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MV"!3Z:ZI0'12/2'[61>Q"1JV4E&='_TWT[]X%2*J%1@Q\-($&;5F09K+/O\
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MLN1/6TA-Y!/8\A#AZ4E7,-S*0'FZOXNLF[+O@MXU_P! "H^^C$LH;[B'RJ+
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MK.M+A$S"R/A]Z Y8X>E"-WT4SJ'IJ/NYVSKF+M(#)-'D5D0:0K2.6&&,YA"
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M8\\]F(%_?KV/_?6G_F4?_7X!]>Q_[ZT_\RC_ .OP#Z]C_P!]:?\ F4?_ %^
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MG6TQ)\Z2#[J%\_@'#W!)J> ,YFUS-;+DXY<<S*S9$S% ""X$4_'P)MODBB0
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M496""!:R91.:9,P22;Q1*#9 DU0,:B=@C$S[U;0L&TD*H\:FHT.$]DP)Z_\
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MA%)&/E$#;*EABRA ]@"F@5T32"C,J;)]7:^/=@X<?_BT?_H6WL.%_P#)XO\
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M!4$F<8C]?V1>,]GL !#AK<8(9!_P>(2$,.<!!S+4:'<ME1PY9RS;(N% +7>
M> > > > > > > > > > > > > > > > > > > > > > > > > > > > > >
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5 > > > > > > > > > > > > __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img29677477_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_14.jpg
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M! ,! 0     !$0(A,1)!46%Q R*!D;$3,E*AP='P<I*R,T+2\2-BX5."_]H
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MO:(X/,< < < < < < < < < < < < < < < < < < < < < < < < < < <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M< < < J%9NZU455M)0.H\@CMJOK)V*SD:</D8>OR&=5!%HY#)G.E&4HL<JX$
M@>S)$) I'DTC<34E<D89)#GDC$ @Q@64=BI-INUMIOE+'BN1 $A]7J!KZZK
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M)*OVWLAM7T6K*VX$A,:E-W]1TSL!G!T8U>](QRQ&]6F;"AB46F\G/@&S>4D
M2Z "P0L1DSN-R:/2!,3TV?JI-172Z<[.'R>8_P!20E+_ &BURK\I-G4TK.\P
MM8B,MB1-77"F%@96); SC5F5C8);< JX0,L!S-6\@QF1/"/PEY/HS"XW-7#
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MF1;E:EGK.-6$TR&]I+)OE^X[FR2S14[Z=9IX]9]@Z:E=IQQRO!JS\&73X(.
M. 5EW6_(VVU_9EOG[+)7P6G*ZKU/[Z9_D?ZI?LV47]E\6X%67U?J63X(. .
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M1[.L:<@- K4YKSL5)'#^+NB<8)HQ4!90487^FL5'+/#%I6HSK+YNS9*C5$'
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M8_DTZY?\ *3_ +*H)_X'@2^+\V/Y-.N7_ "D_P"RJ"?^!X$OB_-C^33KE_P
MI/\ LJ@G_@>!+XOS8_DTZY?\ *3_ +*H)_X'@2^+\V/Y-.N7_ "D_P"RJ"?^
M!X$OB_-C^33KE_P I/\ LJ@G_@>!+XOS912LH-"8!Z]7"(@D.BT*$NO-[7PD
MZ&1*/"8V.<D5=G=EVJC]=D&:,FRSU1LT:M\W2B62^:#9NEDIVFBGCB#;:4N;
MOZ&J_!!P!P!P!P#&'W&N1:H]8*@8OI;K]7,&MS:FJZELFT=C*BC5_1"LHD:!
M3J2=34-2\L[[#SR1B#L4#9](*-WZ@(!F>D>3=DS%/)""&Z%+Q4X4I4V;\=EQ
M?AN?5\FK!CEEY;%2@;Z 4+OY(G1"J$)/+J9U:@^MI6&8#04H#1UA.G,1*EGE
M@]DPHM(=%%SJ_7T4$Q5R+$_>:/5$4!*E$=UT\FY\I2X_ES8G@R. . 5EW6_(
MVVU_9EOG[+)7P6G*ZKU/[Z9_D?ZI?LV47]E\6X%67U?J63X(. . . . . .
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M!!P!P!P!P!P!P!P!P#-'T$_&_P"5_P#S' W_ &>;A\&J<5_I7\Z32[@R. .
M. 4_OZA9I:&QVBMM1UY'F\9UJMJX9S/VQ5\^;&'P>?:S6Y3P5*+M6PQZU(OT
M93.@SDBB1?!T$ J)!V@Y=.T$&#D:32IJ7Q)1X-.Y<#@R. . . . . . . .
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M3&QRBH $IVP)E7;7X841W\7WV-9]HBIO36I<:5;;WZ=C7_@P. . . . . .
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MIY6<P>,W (0S-D)M'!SG-^51=&":!,*0#2%TW+BUVB(C3ESF6G>7*R7<X(.
M. 5EW6_(VVU_9EOG[+)7P6G*ZKU/[Z9_D?ZI?LV47]E\6X%67U?J63X(. .
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M'&?F#LP-W6OJ#L;;Q,>A>H\*G1YB'@ZVP!ND"D_KD$?%QN.LFT=:2(V-<1M
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M;)C):/L7+6.F4Y4W$,V;PF5$O#35CD_8CB3-H5*(O!4VL/=/Q6/(@H1Y2Z'
MZTD-4#Z5(]1N32RO)R^-O;?N\K9["55"Q6%5,6C-T%;(>V]#LJQ$.GH>!,XG
M-PH^*B"1<8':-&)DL@]%U53,\;0HOFT1?>U]SD-UTA5FNOG3L?3M,Q!G"*ZB
M&L.Q.(./M7A0IFFX,0&<'31,D://RI\\<.G"9$T=/GBA(V:+OWA(H_=O'*RV
M8)MU)N[;7Y_YL2YIG^1_JE^S91?V7Q;@E67U?J63X(. . . . . . . . .
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M@%3-^/R%=T_V3-C?L>F7!:<KJO4\;K@[QP!P!P!P!P#L*?<P'YVZK?U4W=_
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MYO&%P:*M$WTBE!Z)+,Q =FJZ;LDG#YSDMETDEF[=-V^.7?7?WU5D\?\ ^W&
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M$&VZ?8T^PWFH?3_8>Y$*P.22Q0,?@<)Z<C%K*$H6%]#"HTM'WSBNZ[6G;B.
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M+HN&C*-L2JJ91()IT:6G,MY47A<'LC5?@P. . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
0. . . . . . . . . ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img29677477_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_15.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[3*64&AO=&]S:&]P(#,N,  X0DE-! 0
M    ,GJ^$I(CA"24T$!       %QP!6@ #&R5'' %:  ,;)4<< @   @   #
MA"24T$)0      $,==%^5TM6[UV[XYE,#I>5PX0DE-!#H      1D    0
M   0      "W!R:6YT3W5T<'5T    !@    !#;')396YU;0    !#;')3
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M]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M  3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T
M]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M!'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D5%
M5N=$8C4FQT                0FQD(%5N=$8C4FQT                4G
M-L=%5N=$8C4'AL0' M&J         *=F5C=&]R1&%T86)O;VP!     %!G4'
M-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M    !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M       !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;V
MUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%
M)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M   ! ! M&J  $  0$"T:H  0 !.$))300F       .             #^
M X0DE- _(       H  /_______P  .$))300-       $    6CA"24T$&0
M      !    !XX0DE- _,       D           $ .$))32<0       *
M$          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0
M"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M   3A"24T#^       <   _____________________________P/H     /
M____________________________\#Z     #_______________________
M______ ^@     _____________________________P/H   X0DE-! @
M   !     !   "0    D      .$))300>       $     #A"24T$&@
M #-0    8             !4@   9@          $
M       0             &8   !4@                      0
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M0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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M       0$ .$))3004       $    !#A"24T$#      GP@    $   "@
M  A0   >   /E@   GI@ 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6
MYO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R
M!S4D="               !  #VU@ !     -,M2% @(
M                                              $6-P<G0   %0
M  ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H
M(8    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&
M0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&
MUE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\
M (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=V
MQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.3
M8V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                    !865H@
M      \U$  0    $6S%A96B                      6%E:(        &
M^B   X]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X
M0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M     6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                   &1E<V,         +DE%0R V,3
MDV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M      +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("
MT@<U)'0@                            !D97-C         "Q2969E<F
M5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M     L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3
M(N,0                                  =FEE=P      $Z3^ !1?+@
M 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
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M $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2
M99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^
M4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1 ))0DZ"4\)9 EY"8\)I
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ML-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,#
MP,# P,# P,# P,# P,# P,_\  $0@ A0"@ P$B  (1 0,1 ?_=  0 "O_$ 3
M\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M/DOIKSOY'VNVK_  =5*Z9))3QUGU?^N%MV]W4=KG^@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^%'46AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! ?_  !$( ?8"70,!$0 "$0$#$0'_Q  ?  $  @,! 0$! 0$
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M<'3H-*1M'KO=;"MO$.RNM(P 7'N,4$Q)D5HO)04C+=DUL58(!"O&ADX/&PW
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M_EB9'"VOFHZ5=:[]YC?& ]9-?R)?]?"Y56+V>2W;[I$_B!&#$]7:Z&-Q<Q+
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MAM+D=T*,73P)U\!O':VZNF'>7M?T43O:P2K1MK7FE#T-5&.'9TZ<1E3 0_[
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M<F:5,&CQTF2.'39>=.+&C!"<4)S9<Z7(?<*W+@. X#@. X#@. X#@. X#@.
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MS.VJ6 2I8MNQ[#M6CZ?7";=W."TPR3])CLU^'=W:^?FJ+XI]:L*FVC8%E@G
M=-Z^JLU=JB[(_'9J#.S-DA:J1W$>$ODR<TB_-UE7ZX#U1^M">(WYW$[85F$&
MCE3O8QH.7>_@Z35[:5HW]L]$+5)-ZLZ<U%9Q[]]N!($0S+W(8D!RRXU"I"7)
M0I\%5@3\D#;#EQFHD.VN.JO0Z^%(4.QYLALG/YZ?GGSU^7;$\UN>%. X#@.
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MO"765K;5E*L92K&%>N%8SC/IG^0U[?M/TZV(M6Y;6+W*<I+U@KM1&BGZ4W5
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MZ\_IISUZFT:^W[HK<YRX4S6NSJ+L4S3X0I^WAJV9@G<01=D1-:&2WLQU/0R
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M<Q(A$;A)1%A[+N:G,+<C/2P,B._JP*MEMB<#EP=I0GWI,6QH9BC>_P >2>>
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M<R[&7KW6#\Z/.&5],%]#;D&RVK, 7:=BN/-)GK.(%5B2_*%T>OY9*S6T+H8
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M&V>@<7KQ(L%)"[UCZOUX#=,ZSGVW4&IF[W4V 2"*0(VK946$ZWR] FH$T^3
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MK2=-.F'#LG BR]E=QPX\8=:##<MKYF*PNR"\0_Q=\OK&$-1801C"M9:FP]^
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MRVB'"&B=>ZVC/PXD^'2*D!%A*R,E$D+.EA8 ,P2D8&!J^("EW^_7>G-<K@.
MX#@. X#@. X#@. X#@. X#@4>\CE%)['Z>;/JH<?8BL]PYJ \V,J(6UV"S$&
M:=NS75PF0@@^D:UW!:D3Y,(#(99*"-:VUX#[\G'Q[<,=(FQ0>.LP"-=5J@_7
MAUA#PQ]KVA7YH:UO6AVQAC]9V1:*]9 YI%STOU^LT0B*/C"(^8/*ZIKD@?(C
MN0\.%6V4%I@<]>X6[O(O3MM=J!NC0/88C41$76+VOCM&TH,NE=H]>5/TE!.(
MUW7C&E3LO=.P+I-.;,FFYP*[W@7K6HUXXD[0 Y?-?+))^XY\MZZ=R<^F6VO(
MQ;MH=D!N]=>.JAUT#J^32P&Q +NG-:"K<4.WN-8P^L]HUS7%R([%".T(?2K-
M8966+TBOW0B_7,FP&)#PR"7Z=^^]<CI8Z8?TH:>L,$:+.N]D>Z;A<<&+2CHF
M"15W*WUF7%&FIP6N3"L)A[*VXT^4!#ORFDI>=&PUKRP@+8<"/;_L<106!;#L
M$K8[38Y+D"HTBML,S+-:)S66,2,06),B)"@"AF)4=\_93<T96Z[#>;EFRL)I
MUG+I)G3?UG?AJI/V0VB*UVJ+/W86K=PL\M<2?2=&1#TVN:IIL-]A6$VK<QQ[
M,R;L9+!(66=K49RG29I^6.5"UII\Q9JZ:M$4N^7GO7[,WU/J&J;28E[<L.[P
M'9GL*5%Q)A.S2!#52CZVK4QQ,H76-5Z7*RYY[3U%0E<94;\N^4MEE<0R5L]L
M/S'&WFR1I'A_?]?*%]Y4N+!C2)LV3'APX;#TF7+E/-QXT6-';4Z_(D/O*0TP
MPPTE3CSKJTMMMI4M:DIQG."J1W_R']6JI\H^N[<UM=3B\3F8;\;8=5!Z^:FC
MW5QIS1?:A:<BFM*$24*P=#UV7:KQ#::>Q IA:?A@?()V?K[<OMXZ(KU-N*O[
M+'SI@39\=N1L8@HI;MC:^JQZP;=V4,'PI,9D73Z97PMHEZ4I0%M30JI)LTRS
M7Z/7$DI\H35[V<D75PN][^*T%+N#<*%&J&C-+W5P3"E(66LFS1MNU #S)=<1
M@H0)D]D5^7M:\VR>VG,YT\U2;#"/S4N+/7:'+>^=P-IC:OM%DL FR;6O#=C9
MK=@S8JO0JH#16*$+(1<N_I\B>1-FGK-=;#7/G4_"(3S@JK*,-0['#H8DT,$2
MAI-.>NL_'E\-_76;^%0S:]NQ6#CE"UQ!9V%LE$R'"*AQLO.0.OF)B/GP;V?8
M(K4J+4XJ8.'9@D#(]ULMRVE1JT'EQV29,4'WJE4$:M"G+ML&X13=I?@N$]@;
M1LZH8""Q!AI<EK'"F)<QZ#1M=U["W\@ZRV2?CCV52"QXM8;63L-H,AJU<A3]
MUGP^QCS9D3K*O3,S]:48G"DAY-K+177$1=J7<?(6B8N$WZ8D:PIQ.)%0(1EN
M_6*)*M<JIP==#<?E8C@. X#@. X#@.!S(\JD.Y%=&:T"5RL7&WU@UO>LP=JA
M*13#]U*O4!%&V-/9=E1*IU_[.6<.+9OD*D*E'0NG;&_'<S'@2Y <82G%H9.?
M9OYQOYW3Z[LYCZ&TW'S$,#\1M9TJ,B!8&348W!:CU^ RS#*QK)K[4Y^-/BM(
M0Q)CF-8:^(L.MJ:ETVNO(6*BEW^7"+<>_?)^ V3O&!0AG:(C7XM_VS)IA>O]
M=(!RJA3(N'V!3ULTI6@9GKU@C9=:78M6-22]U=@!=_O-9'"K*)'XMNIW)AB>
MHFO?RZI^GWY<]->?)=_I9M'OQ;P6V'MOT::;/#R560Z,WE (]? M4NT[%YSM
M*DZ@-5O1)J;M34=-S"H#%"OI 2719V#)F;_$0^_&7!@%3CXM/^;1\??_ )EW
M67_Y-4[@7QX&@WO9=4UW'@_G9,R48,JDLUJHUX;-L-SM<J(VAV5%K=7$M22Q
M3Z33C<@K-;CH% H*E%3Y 6)9D3F0IELJ^VK<C5GJEVMHGK%U]K#,B'O"_(V*
M+#7W$Z6[$>"ZK';):?C4K7YQT<ZA_;<VMEKB\"'%!E6J%V8LA8B8JQ-]6GUW
M';X6+U"?ZR5"G#*OI:W:>ATZ VK$2/3+C52$62\AE*I1&>1A%9<@R7EI:S*+
M&RDN:6)/_+.)S9,AQU]149[\[\=7>OD9F-:]P:UDVTC%<E"*BUL6E#IKL=+B
M(Z2)><3-1X8,3F4ZVPRX_F09.2,+%4T%:K'F,"E$UWOEJI1![+*[;LD28VZT
MRFU$KEP=K&S[-<)#Z/7RDV9$BPS\K0T4@BS;+)0OD=_$G^QY?1 T78VJ\4J^
MH\/-3"1,;[=?C$^6Y6P?UA1M80PE#L!ZY[RV$:1^7#:?#E9=;K5AF.26F"ER
MOM="S'W"E.D%&V9%OV#V"L&S7'2"6X;16P6B<%KY(=N]/7]=_5RUB:A6GK:1
MCN0;/=44BH*DYD0]7Z(A_P .PT6.\E#[\,UL&&VSL P020^61D]296I6I[64
MLSJ^M"G\/CLW]_OKZO>4E:ST6P- T>F!G[]:FE0*I2:[@5$N=V<B.H7,(%"Q
M!S!%\*(<E9+6^XGI4Y(]IU^;*<(FIL."2+OR^K/5#7,QJQO;&V#/;L6P)#<R
M*(8COR'JKK@%-^%*ZS18DAB)G+DAJ.PJSW2="8LEPGX=<?0%K3 "GUX,G?-J
M5JA.PQ<AHM9KB78=?KVO:=!2<NY]IEYJ,[+BB?L18PP'&ER(T0E;;+/!4T)(
MEQ$'+"-Q*84L-/F46^[/RSG9AE=-ICL-K[&K=?G23,\M(=^Q]EJ\;.@X#&9X
MS+*X:<5>EPJO!1):)Q#EDO0(@U#C$T\9C7RY?7[IO@P80R%$&C8D8>/'QF(4
M"!"8:BPX4.*TEB-$B1F$(9CQH[*$,L,,H0TTTA+;:4I3C&"O5P' <!P' <"J
MO;?3NX-UTO7];TQL^!J<X"W'1[C9[&3@R#D&?0P;9E%DKDBJ)1D7<FS&)T-.
M:O9'X==(_!\A"6TJ-'2L)3TQ1+=KFC1JQ=KP*V$;CD",K-B"Z] :P@*B3'L.
MQX;=4K4J8+87%_M_+,;>R]-6YEUY*58].!*_ <"AW76]%*><[X6_L%+U=JQL
M/VOA.SR4'8D@C1QU6B]0NJ.*^6*6ZZU;76!Y&8!;BSSX]T7D>%).3!\$T<AQ
M6RLH*37#RT[7[ V\CK+Q5]2;CVW=%JEP;/V8V ]*TUU4J$UQG+0^0&M5O8"E
M=NXCS?D>)CZ@L7]H8RU.K)&PQ9R)$<G7WQ\/WOK5U"^(KR+[Q+G=E]L/('4=
M=;3N\5(:U'.MNK<V2^BZ@I?R.T[6N\+\NJV?3->6TK+3E:T_5J;7I4Y4TS9V
M+H7)S"#I=_ATIZF>*'J1U# 2Q54$779A<O*=FV6U[EM\RY$[9)?4AYURT!XS
M :FV%>9:/O-R#-9GSFI64+3,](\5+ ='APT<(A1AHF!"%CH;>&8@\=%8A0HK
M6,YSAJ-%C-M,,-XSG.<(:;2G&<Y],?OP/;P' <!P' <!P' <!P' <!P' <!P
M' IEVVUGN?;Q#3="HPK6%BT\<L-Q1V)K6X:@)O5#-UB'39Q*@L%:T^4"6*<[
M$V3"KQ >JLE(SD6=%CR3") MIYK))WOG]$X:*UG&T_K&OZ]A5K5M1B G"V8]
M?TS2G=?:]A()%YQ12P]5>)F'(,F6[-<FF9"R#ZR1F1.(KRER4M."I=X&)/D9
M@8$:+C@)2T3Q0@D1@U@&Z&CF[%,@PWI,8"'?L18#7F"A=YI \>Z=.!0S<N0R
MLF6'04OS&0I/U,VS6ZSU6L&V=P?%H,(UOGN?8[? V[9:('?UUE_N%OJ7.#7&
MQ +;9* @D&7ER&0D@+B>!.R6'%"S)&-EJ0X'+[;_ )[IUJO!;6_COZ?[,[FD
M(&"8]C8&'Y]&HYDQ CH??D4H*X")WC8-?%M.I?)3P8F)(<4EIF/&;&DA]@=#
M7F<>>W<(],O2.GNO73LW<1H8A?MQ]A[)"O\ M<\2>Q,R1# 6!;6RX5%J-:<>
MPNEU&=IW$.&B9)>D#A9115T\&Z]<_"3L'5^SYVWMV=C:[V;M9%PD<6UN.K[0
ML64W$S+^T0/'R%?W'1A6P'OK/2@B$6BGY%-ALQX0D$!@H='NM_!.?ES^,?9,
MW8[H_,G0R8BN]-M9,@C$N&2(;.ZC]@+UU<V"-FK3(Q8#]EUQ6-<'1MU8'0W'
M%!*XO.V'3LB3*C_IB!*^L])+U;WOK5*"5;I74+Y'G;(TGN*M&*Z5BCW9?<?3
M=1[(ZK".3TP(TJ=7ZY7K2%V=KARRD(36!LJUT^H.G)+;DM-&FM2?@43GIX[[
M]?OIXNJ.M]UZDI\EP?K366A/PHB*F/%$ZXD!-&[.<>;0\AR**U)M^J:N#?B8
M3,''N)QMG*PZPWZM"T)992^)\O'?7/R\EH:9V9TA=R[M7'W\*&NL9#"I=#MT
MA-2N;/SX]$N10)_,&4<@?+A3#9VM_F:],=3G(\M+:4VXLN][^R8RIX&#;:=-
MF10=I[*DLNE2,,>VZI"?>M+2Y;S*7,H1_:5A.<Y2G^UGTQ^_ B,EV#U]F5+#
MTE9G;=FC.9C?@-6"W;6VW/2XAM< O;T+BZ[J,AK*\K>S=;C7&6\-K;^54C+3
M#@WOO]-6FV&$S8DX(]@=F5:IUL=!;FS-55.[2:_7F9;+;CQ-%\NCDZOV'88R
M.RI$9(+(FH4Z=%<GHL]6LR9 [(LFF^O?XZM&=KUX)F80P'HK5;@BGM(90U<+
ML"G:NI T>MMW*OTO1I(R!?;/-8<5$?BQ55FGTXM >D2(6P4OL-1916PUO3L%
M@M%N&QC3^U+]%4AZ <L V##K]2=QE3BF-=4N/\XFH,-O.R$M%W7SE]F05L#[
M%>+!'@P?KC?P^:9> X#@. X#@. X#@<QO(K;H11[5/7\CK0W>8FQ!>PMF_EA
M'5X/V_;K\C4A+7 !J%/TZ>&RQC#1QO;3SS%Z<F17Z\^%2)8C3/U,XY#"YW6V
MLC:7U]TG4 \8Y"%U?5E%K\")9J9$US88\417!T!EHS0($6#"I1%"6,8E56)$
MCQP+ON&--)1&QP)KX&G[ L):ITFSV0%2+-LDP&#3)XZATR5485JM4IEO.6PX
M*7?;32:;'(RLYSAARQVP +3G&?L$F,>F<ASVZ%[AU9HKQ-=%MD;BO]5UO1JY
MT@ZWD2]EMIB&('1XT+2M0?>2RJ2XEV=,4A&4QAP]J5/FO*;CPXTB0ZTVL.4V
MV/Z1]KF][ G:XZI:\NAN@PIR8!OL 6$V2+)=C--OR9TK7^O06L-N7%QUR/&R
MR+G6#6Q;*)JU#[+7*J])$39H0T:[\=W-I&E5SJSI?LII;6]KGH%O[3"=*MOW
M_L#LY2<)9L5J)[:V5_$J*$#C%*D,5%=OUX'L3X]MEL;&J8^(+@1QO?P?YKX/
MW(UXF<'U_P!<>W8ZRJE2L@-\YZT*L>[[*\59E/R8M]O/9VP;4,5D#,+NX*FL
MTJ[5Z"N4_B-"K ^)D@IP)OL07R6F'00S;]+I72Z1:2)J#)L?7+70*T6G: R*
M&'QITN5!?V5LG1(W;9Y[!8SB.7I51L@88X,G:]VH0=KMQ&BB>&]]^B=]"21G
M1ZBE+A5/'I:KM=X[/N/;MM^^NNQ_=%MD-YE9M=DM;#FZ=P7>MB9#K4,LD#KN
M9;9DW,Z6Z2IH<A!<41*MHSY$0]^%S $*#8AQXC %XG0-):GN7;T@&AV6,J1"
MB*GZHB%P(*R$17S.#D[#KPX6)F82\<"EH4>3 ?)IKUZ\^SE\/SS\F UYL.ZZ
M<F*B=4^DG<*PU0R\F7;JGLROZQU\-*E84<;!5:@MXW-O"IW.LD7QD;,!58=J
MUAJA"3&&X! J+$R</3A]^KPW^NYMYCM9V<MR1\(MI\?U7 3&RB;)+V&6VR3V
M@'="2I#4R*./UOJ]L;KL(B2LLQE,VQC8>Q(4X5(EY"PH\UX<9B%WO>JP6G+5
M2X8N-$H%_P"N^3!9N/*/NQ-@%]BW(W+D)4B#.LUKL!<9=K.47E26,2K1'3/P
MVA,)E,=IEIAHDQZ:>7+\<O3OB4Q&*1MJUI:&'=LC*Y6WDR,&&-8TF;6+B0;<
M3EIL?&O%@NEP2#'N,..IG2P-9&6KYL190&T5QZ.M4@K?*=0J?0!RAE1 P@S+
MRDNSY3>'91@U,]/1TK8ST]V4<LIN6K*GIYP^0)&",EQV5/G2)+KCJPV[@. X
M#@. X#@. X#@.!0"S]IMRA.V=RT>&U!FXU6NT*+9Z\'"QECM@7M:J!:K7(.@
MK7:[)7=;0JZJY"0.I&FSC@L=!MYV-(,W,>W(8'I&]_!SB@T#&]>T/9+<6ZO%
MOV*WJ8JN[::Q6M;WK=G4BR:BUE8(75[KIC)Y6H;+VA:U@4VD4&NC2+FP&@UF
MFQ:P_50T(T,*"3 R&33??]W2Z/V;[(Q([,6)XT>RD6+&::CQHT?;71UB/'CL
MH2VTRRRUVE2VTTTVE+;33:4H0A*4)PE.,8P5J=I[Q;OIA6@!+%XZ>SL$EL^X
MNT&EL)VETNE8*VEBF7#8#HYQZ)V>?9'H35*':"7W2+D2$I8Y$),C,Z;"COAN
M7]:3LS_JV.S7^U[I!_Q3\!GM)V8_U;'9K_K_ /O>Z0?R_P#1VFSP- U3WRW)
MNO6= V_KCQV]G3M V=4*_>Z6:=V=TQ$N%:Q:!<8P$(+%E^SL$J/7+'RV'U0R
M,*)-CY7EJ3'9>2M"0W_^M)V9_P!6QV:_VO=(/^*?@:4/[S;L)[#M.K(7CJ[.
MNWBEU"C7NQB,[0Z7MMP*QL@O?P5/(().=GD#):R936%UCKAQ);\V D4V\0CQ
MF2 YR4&Z_P!:3LQ_JV.S7^U[I!_Q3\#0=D=\=RZE #;/>_';V=#A2]ZUIK>!
M+;V?TQ)*>N&WMB5?55 &9CB^SDR2TV:O-QKPAR>ZT@>+;G*(E),,;%ERV0W[
M^M)V8_U;'9K_ &O=(/\ BGX#^M)V8_U;'9K_ &O=(/\ BGX&I4?N[O+8U?3:
M:AXZ.SI,(LS::^F6O:72R K)6EVDS3+'&^O/[01I.,0;$ *P4OY:^"6F-B7$
M<?B/L/N!MO\ 6D[,?ZMCLU_M>Z0?\4_ TMWO)NUG8D'53GCI[.IO!*EE=@PQ
M'\4>EV6W:H%.!JX2(Y)8[/9&-KCESXJ-B"N8F<ZF3E]F.MAE]QL-T_K2=F/]
M6QV:_P!KW2#_ (I^!CBG<3=E7C,&;UX_NQ],J+90)!.VTALWIZ7'UR$9,P N
M3,\95^R1RQSH0]T@W)EQP@8H37';<Q#@R7O8TH+\\!P' <!P' <!P.7NOO)0
M./[F[;ZXMFHKK^G>MIH&/$$=,5G978/8MEC3]D[%U-._4>H=7:[-7&NS<V36
M\VS!_P 3&LL&50C4,Z2EBVATQUXGG^M_7GU.1VO]:=2-\;/M^]^TT'RA[]K8
MOL9VF.ZBZVR.D'=ASK;J19'LMMZ;^6'5VA=>FWBVQ)#\QZ=9IM@L.;#6SLPM
M2+"/CO 5"!Q=[_3LE2^['637 */6-?=:NYU'KD5;KL<#4O&!W>KHAIY]65OO
MH'B>N$2+\\AS.79#^6LO/NY4Z\M;BLJR&8>\F&@HYH?6W]8=XV;"5%ES8L$[
MXZ^]#9@B&K\L) /%H(U?7[$R6-"SK-7(9:<PRY&'RCX:/+=9=)PD/AE/^44T
MW_T-=]?_ ';O?+_AYX&.+^2O0M?%$SI[5O>4*$"P)A4P8+>.GO4.%BA8^.Y+
MGD24^7U]9BPH,**T[)ERY+K3$=AMQYYQ#:%*P'R.=]^OUH$S@-DT#W?L0(HP
MJ,1#&_&;WF+B",9?IE3$T?/ZZ2(<QA?IC.6GV7&U>F,Y3G]N!4>UV?I65+2[
M-K[47DVZ_6^:EIM^S:"Z*>0;7DA4=EO#34' )CKS/J+0["<9]\&/76&'%J6\
MI/V,X>2$4S]R:XOT.Q@F;GVSW*=HY^%7CL+>7A1W_N^$ L;08):(XC8,(5UW
MI=Q_5&:M: !V&P[<J[*CA3-9*QQ_XN6W@H$?@[W6*-:)-H"=&;H<FOAIK$R1
M3NEWEXZ]KG'7D->Z2)# >K^TJU3:P13%CL2*:*'S&!ZLXE,F)R8Z84@G=]=Z
M=?@D09WTTO "AA6S/&-O.I$[#9<5,!6-E]3>WUSG;!M# 4Y95"=7S3O3DYFU
M$Y(BLG30P;8GZ4;DAQ,TN3%B(XPEF (W^]]JW&I>[W6 3!</ ^C'=W1IJ4^[
MB6*5XN.SHTZ[E32$+E/$-6Z5M A]MY&<LX4HTJ2I+></,-HRCW%31_RBFF_^
MAKOK_P"[=[Y?\// P%5\G_72]5H!=*3KWNS;Z?:A ^P5BU5CQY]XSU<L8$M%
M:FBC0,T+T#*&EA)*&\S+@$($E^)+C.MOQWG&EI5D,_\ \HIIO_H:[Z_^[=[Y
M?\// Q#7DUZ^O'YM59UIW?=LXT.+L!&N-^.[O,L[  FYI<:&-3!*>O\ F?&$
MEB%?.P1I%Z.B)-F!2L:,\X\/EH:#+_\ **:;_P"AKOK_ .[=[Y?\// \LKR3
M=?Q>(C]BH'<JG"I14*&<LEYZ#=TZ34ADRP%X((4L];;5HH37*_!D%2,*(LF:
M)P1\=<A"I,EIOU5@+_\  <!P' <#_/3'KZ^F/7TSCU]/W],^F<X]?Y^F<XQZ
MX_ZL<#_> X')'0GE(&;,K-YLFP=-["B0(;]-*T\=UXUSN[M-:8E2V0SL!RNB
MMN534FIC1O6>Q:\WKPBF]"9L677@\XR#%L'GYTC#3H<'.F?3[H=N/KOU'VAW
M:$^4[M_8 G7?2<6G:^+=2^[Q;K7K*NPM?5O,&EZIB:2T+ JUQI$+XFX\>TLV
MRS";] CQ#<N67Q-7.EA^@/479OI=H"NM5/2'4#MAJ6N-,L,J$Z]\5O=2J1I*
M8Z/8T[/_  W6N(Z2E8QZJ<F$'),MYQ2W7GW'%K6H)!:\FW7Q^P3ZFQK7N^]:
M18<38B=;:\=W>9PZ/ 'IIH:#-SA*>O\ F?%$F2-;L, 61?81$GS 1B-%>=>&
MS$,AF/\ E%--_P#0UWU_]V[WR_X>>!I]]\C75UJK$$;.T[W'12ID@0+*(O7C
M>[M?I>5*+FAXH"/GH/\ 7G\4^^3L,P4.$Q9&%N3#$J!%B-N37HZ%"?W\&>$]
M^]!@8:!P/0G>,*/:SG+4$3XS^] Z&WE6?5641H?71EA&<YSG.<I1CUSGUSP-
M,NO;WK!?Y4,F?T#WY9L8UC,45<J[X\O(34+R)B+=^=V ,NU5T0'M$(7)>PEV
M<(9*I$DLI2DE"EM8]F0T.M>0RF+'6E.MB'=?:/X(U*KJXU\\9?=&QNUVT5UY
M#!ZE%K+K/K]3GQ\N.CX84S]0@[%: ,]Y1$K^=]<"EAZ\>598EYN/8^B_D$-X
M>^+&)NINE7;:S0(V5R%M.*(8VEH/2!%I#+*4RE_CAY=S+:\--(=?2I'!YMU-
M>2WJ\?:!T'8&D^Y\<GLD896.U?>_'-W'GEK1! L0Y5FBLUO.BB\&RL 8\^ \
M=_%J+P(#4R([)?2W(96L-+:[/:, 9>1K*N>3[4HY]UMQ5<J7CP[GG:?&0RA2
M6H0&I;-ZHW\!2A*?7&<B:!!J<#.4XSAE*E+4HFD\^?7X<]>_T\O5ZI'D!C5.
MM&)LB+V^+*$#LSTFK]XGN^(N(S$&-*DD9-A)5?5-<&PVGXC+N91:,'CPA']N
M?^(EL,9@.%WO]O90/*I3K2L2HQU;[R8 'PT:P MCZ\Z/]S;]K0H)GQ43!;S!
M*=UWIMQ>=+17&9D%X;1RH!V')COIL2\+5A 2_P#\HIIO_H:[Z_\ NW>^7_#S
MP,='\E>A99 D(B:M[RRBH=,)9<;'\=/>IZ>+02:<?'*(1&^OJI$),]EEUV'F
M0VWB2VTXMGWI0K. R/\ RBFF_P#H:[Z_^[=[Y?\ #SP,F \@NCCMHJ54DT;M
MK2Y5VM0"E 3>T.D';W55*S9K218$5X85OFQ-+5JG 5ERLF,-@NFC<!B1.DQX
MK;N7WFT*"\7 <!P' <!P' YV].^VL/?V[.S]$BZRI]%>IMCD6$@3KUF_,6\]
M-";<W7U=1(W$ S70ZZC=YHKJT*-5Z*Z2/*FZ_)UR$B6VBO\ ODAT2X'.'NKV
MR':!WITNUY/US0[>QM+9LF0Y=+D<EQ"&I93MHUMI 6?IE?#URS6 U:K-CL"4
MJ\&9"BCQ(R')(Q+,<#!C+TQ!/'NW]O+O='N%5@[>[^L'6C3J-HU[7N=C.)V3
MJ&D%1R[#!K4,"%V9LRKZ^G6R?,E-2I<QD(JR,*BB0XX@0(E) ]AU$ 3DH9&!
M"'13LT!V^9WQHRHZEJFIZ5U4L\;65%$TDS'G V::$N^V-6!04P%$!AH5(L G
M^#,HN[3X&2,(35[14<,S7%N.\#H=G^6?[^!QD ^1%Y.Y-$M&-"4/75T["[QW
MKUGV49,W-92ZUX)UC[%2-,ZR"M+IU5.+NTXY9]CVTDQ%:FM4>A%#!A4FSY$F
M'CZR>77W=?X[M(ZG9OA7+[NKVW;U5MFHZ3):IU#MP!/I.-U2H-KV"T,LE L>
MLIMDO>M]E6*I$*D1&PZ* V=KFGN0+..-S+J-GM6&^ :N\(U-9)R2?:?M^_'\
M6[ZI;R?[)]?M<;JE5Z)5Y=U@F53 PTQFQ!FIM>LQNJS)U>/J@C%'*R9D@W35
M8+J'PU$@! ;,5';4]E."OAVPWB]URT3<=O1W*&A^LNUYEE&R+(:J]:E/G;&*
M QQZ9U;K5O/SCQ1\DT-JP /7YTZPV26+#M9C8F*DM#>]ZJB=&.Z3^\ML[,T8
M]J/76F8E%IE=V0-K-0O&;N6DE+Z@+8]BO$I59K$?7T=H;L6W'A[I&':)!*VR
M\XM$$=('D)LJ$'4C@<+[9Y0V*UNR\CW=/Z-.W36FU/X0HN@/<&2)&P:</VV@
MQ/P5.+(H>?O;4,6$LKXM48FM12%GUY8ACT^,\.'$)A.^>KOU\/UV^6O5H[H<
M*YH=_NZ,'JZ0U_6S]$U5LFF7D?99ENKEGV9#K]YB?@PAL_528NCSJX1@E*M+
MLM9B@YMD(%X,(:;)#4/XA18\PI')//E\]_OQCJUFWHSV=)=MM!"]L6 !7*E:
MDV2R52V5.JFC=D$5H_7IC;;XANR&:[6VCTAF))AO2B(.// *??7'@EI;D>2A
M@OIO?]+A<!P' <!P' <#2E Z'057F_Q*U7*[/,QL6+8%D#@!T$U94UH6ZB.0
MLA ?$;(V"4*$LN18#A%V8_&BX^K%RAO.&^!6SHQN;7^\M)/W37%#N.M@Q.\6
M2YS*I>B 0H?:);X;&=G4FWIE>/602AJV!]XB+6D3%+/8K3IIZL*:84&^)(WO
M]KD<"DUVWM1P?>S36ERFN[8Y>#&G+DS6MMOD8XG7T"!L:<3M9?741J8^RW:K
MZ43U>CV%0@8W+,A*X/<,):;$/&'D!=G@5![@;UUOJ>KU"B;5IE^M%,[#GC&F
MCA.HC7E!JJ'/5$]),E+78,2H6!#$D7$E0!,,8[*LI.<_EX0.=B#"T\:-_KO>
M[J%VRK';NAV&Z5VE7#7[M6/5<&4KEU<KL@HF/>M/ZOWQ22K,NK&CXAY@WK#<
M-&*R8R9_VPY>43 SFL2A;CCHC?;OQ6?,$V@HDH8>BD9S(D=-).P@XZ67+RVX
M,9V4N*+%0&GYQ,C(2UEJ$/A,NRYLE;4:.TX\XA.0Y?\ 6?N=JBZ;BJH+7^C]
MMT]WN;&SV!M=WO"HT.NB[[$I=NU:*HKSZIY(0_L)V@=1'B!"CU$G*<$A1_ZI
ME1W6)!8C@.J/ YB]J>TVM:;NNET/86B=H6NTZCN^M=AZ*+ +10H$"Y;;VN9!
M=7J5$;%JO40R$KA,MV8)5%BU;*#@J=,+ ;Z\,60DT=F1(#H!K#8 ;;&MM?[1
MKC,V. V-2ZQ>0L<FTVP2C"[4%A'(,<@RRZ^RS.CQIS;,MII]YI$A#B6WG482
MM01MV<WZUUJU41VK)U_:]C#Q,^+&)B*D1IXF:/@O1ILEPK*FW:QUD4I"W(;0
M40+AS)AVQ6HS7:V%%RYQ=K+00;TDV[K6:Q<.JFKM7WG5U.ZB!ZCJVE1-B2UH
M-6>CUN39M="K '%EWW;7*JT8QKD_78-N+?8AV0B%*8A$)4@?/PT/GX[[U]<Y
M],9S_ACUX'(F7Y#M'4WLS&#6K1^Y:COK8&P:[U9LHX@1H!%%>H]-OFH(]'V&
M58#;!*"/TJ0N?>[7;32@.2%KDQ;$=DNCI@RENN8)SU_K3Z:_3\==N%4=[G[;
MUU4HVN]1[DU=L*UZPWB:*")UXJA %# 5>U:^"S]NU6OG4YLXNXK(VU_7\J'7
M6P(8BR1+LQ KBW'26(_ EKJ[V"B=F=2C]HQZ<8U[*D&[!7B]%LL\;,M54,5T
MDZ.G![1%&K5^$.L+0ER:"GMQR8[Y6T2V$Y6A2PL1P' <!P' <!P(=L_\,NO&
MM]P;-%T4)70@8->=Q;!BT.M PQ6W$@X*8>L9N:W!:%LG+:8B"U-+*%Y.9<Z1
MAA,R?A"?D0$4=&K#K<CUKHM)U52+-K.HZ#>/]8F==6\M$L)ZD3^N)R=IV?7)
M5F@ECL.T1X+U0_\ LZRL%YV3@YR*1D.-RWY##06YX%$*YO6@/]_MC:C3K&Z@
M=@2-35&K/;<L,]L51M@#M=QY&T8E.UX*GO-JM!6G,;](SK64KS$A8U1%,(TI
M#<&'\;>_@+W\"C7=;>FF-:UN+3=Y4S85@HI*I7_=AHY5A\AD*%A=60F>P>8L
MDVF>,^Q8R#NO4O@JW D/.$4CI2368 IY#DP)LZW;[#]D-71MDBJO8Z-*8MFP
M*#:*3;G <BPU*[:PNY[7]P D)M8+'JX1^F?KL[,0D#,D1\Z Y%DMOH6XXPR$
MA;+O4+6.O+OL8B(/'X%&JIVURPE7'++V(M'!#9!%T<%'(4C[1&6F/EB,EUUB
M,AQ>'9<B-&0\^V%"^I_9S4UBVA$U?KO5=ZH\/?VNXO<C]7W0Q$P)LEOW#7J-
ML*SU&KLRYLB0=-UL'=JW/M3%96^&K2I+;2FF&),9]\.E? Y&=D.[&H-:[],&
M+KU\W!:MD=4P=E>HIBIV37CPLL%V92SUGOC,N(K8,*%5SDC7>F+-;:M7]H,U
M\W:0%>R5JC&62;;RR3V>LSWZ>$>>FY=6JX?%VRO ;2#D*EA+*&%GP\I3+T=4
MD69@L$1\A4>2VU(84]$DLN99?:;>:RK*'6T+2I."JU=O]YA-'ZW&/6?6ETV=
M7-F6@;J0N'HI2JP+"TS?TO &D"!]BLE>)VHV2?F('B*I2DEK:2==>DP!^(\"
M7)8&]>YK'2;?U.V]2K'0:CKFV:G@]?IH35HFF7\C%7<WJ,'%?BZ#<I09;[AT
M?7+<%"N2JL5-(S^HHD.5,AS)F6):F@N7.D.1(4R6S#DD7HL61(:'PU143)SC
M+2W&X<5<Z3"A)DRE)PPPJ9,B14NK3F1)89PMU <GM3^1W4]BW@JIR=#;GU[L
M2Z["J>H=SNVF=0Y,35-Y?.7RC:@"V*$)NY.5/;OA"HV! PC3AQ6'''2@MA+.
MIKY8>8=#K7P.<?=WM#3]-G:A2ME=>]T[(#.PI&Y=9V+7.0<^#;-P:)8)[;KN
MK!@D=8\7)=OG+I,:2-B3ZZD,<5-99C**C!UNDUXF_I.O5V>'UZK@:)VS$WEJ
M>H;2A!9-:1:(Y/,JMSY\$D2KI4*<)UTT +2!ZE1VC(8N)G#3 ]6&I8DG%EBR
M$>,0AR8[14N<!P' <!P' PHNM5T).-DPP *()66<V3L9 8*@P)Q\DS&:A-$#
M<N*PT^5FM0V&8C<J<X^^W&9:80YAIM",!FN!@RM8K9V:#)'*\#,D:S/64K<\
MJ)@$)M?)N1W(CA$)*EQWGQ4YR*Z[&7+@.,2%QW'&5.9;6I.0SG QI8,(/P5B
MSHH::&NO0Y+HXM!BD8+D@=-CDA[[D28T]'6]!(Q(L^&ZIO*XTR-'E,J0^RVM
M(?,8 !!'BT@,%$B9!XDX9./C!T2 \9,.L,172I5R*RTLB2<C18L=R=+4]*6Q
M&CLJ=RVRVE(9;@5DW7M'KQUU=UL8V)6G&C=PV!;!FL(5#TO;MHW4AL$K4+AL
M2]3:W7M8TRV6J.4(4ZK7.SVX]&'L_:'CBLHQ.<RXOY!_>^[?BW6I=BM"7IJM
MN5/<FM#3]OK%,N=<&1[F ;/%*OL5J&[1#35>DSF#K4*VX(0F@*Y(]E9*3):B
M1D+E*^'@8B(GJYM?8$N; QH396TQ%1;;G2HG\/;C?Q="L\(D-:;EO,_D;%!J
M%B'%RX]"'E-!2\,H1BXQ(9G26W0G$<.'AX$(4)@0Q8L;%CP1PT=%8A0($&(T
MEB+#A0XR&H\6+&90AF/'8;;99:0EMM"4)QC 8:VTRGWX)(K-ZJE:NM<ENQGY
M5?MH(78PDEZ&\B3$=D"C$69 >=BR&VWX[CC"E,O(0ZWE*TX5@/G7*+2:>Y+>
MJ5/JU7>(1 T">[7:^)"NS8-='MB:_"EN#8D9<F("%--# \=[*V1@]MN'"0S'
M0EO ;3P-*QK;727DR4T&EID)MBKZE_%6!X>3>5-?"JYI=Q!]Z;8IG.6E6+"L
M%U-9RWF9E.<XX&Z\#7R=3JILJ(.&:T +&Z^@BV!,$PPZ>5"-F(N819L00E1G
M98U!2%G,0BB&\RF;&S\$G#K7]C@?>OURO5(1#K]5!!JR!'(<;'A*^,A!A$!M
MUYR0ZB&-',1H<5#C[SKZTL,H2MYUQQ6,K6I60S/ <!P' <!P' ^;K33[3C#S
M:'67FUM.M.)2MMUIQ.4.-N(5C*5H6G.4K2K&4J3G.,XSC/ B[3>D-5=?:6QK
MO3=,'42F1ICLZ."&/D94=E]R-$@M(;?*S)\Q,0>+'# @8?B3] %7Q0BOAHT
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M"UWKAJ%L I$&5  DVY0#NUMF5:RD:F-E*J_7BSW-ED>"-[,LRMN!:)8ZN*C
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M?U^^[RE8CA3@. X#@. X#@. X#@. X#@.!R5[3=[=Q]>-E=CAV:UKAW4NO\
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M7D.&'C<CJ@ R[D'5H.8<=G,6O!LO/9%AF/8/@9=<^K':]ZO4-EX#@. X#@.
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M+FBOS$[A@UB-8T5OKY;X^-!7+;0]0$G: \W8<3">W!2G;-KE;?LUA-5+4U7
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M@(+(P%7A(X&&'1_=AB *$Q&8 ^$S[E*5\46)'98;]RE*]J,>Y6<^N<E9;@.
MX#@. X#@.!2WOC9:;0M%R]A7/K;6^S8^LG0L>14+%395V9 "CDYB&7M21(?7
M&U[0['&(:BJE-5NDE93CF8CI!8T1&G%QP>74FY=):GZCP.PUDU=6NI^N'ADB
MQFJB,J?Z>;@1<&WJS5IJ:Z-J%3/NSKB.C 9U?"%J<&M\6,:%@C0$49BRQL4G
MCO?=W,7L+R2]3M6EMRB;M;[>+QH:VA*/L0M%U=L8T!BV<O49>P9HP&8"5HC"
MM#E/H(TS=K^L X012:N!-EK$J#'&2<H*E?47;_KMO8QM(!KG8@\O,T_9$U:[
M+)P"E>&IF/'+G58Y  4L,(:-ME<F6K7.PZO"LE<DDPDX[1;4/BS7G0\GVAI_
MC_<:=ZEZN=86VZRY-V6XRXTI*VG&E[9O2FUM+1G*%MK1G"D*1G*5)SC*<YQG
M&>!'EW[.;,"#CI, 8UB2.3;CFHUK5;=<+D+^ ^KNFOZL?)&<N7P&..KFPRZ2
M<>%*716&9Y,-&:)S!_VY_-1RN.Y=FW<KM7,&Y>KR_P"-9X?3;KKS+,4\3L\/
MJN7(_EVJ+O2INTW.C5_%Z-=VS3%==,S,^\\"_P ;>S_$,G"Q,_&]H\/"L\'C
MB_$/:NYEV;'L[F3>]CN(>T]O$QJHX'EY&%[N]AUXTW[5/&;E=C&S+M>+:NT4
M6YWX/V1O[6E:AL0CKR/9+(=L)\(2"@VK=#6-8$$C,)B45#U6M;9(5PW\8QEL
M]69TR:BOE7I0MT]+DQ4H>Y='&LBGA5C.KPZK]^Y=NVZ[%BWD351%NY>II]Y:
MQ[.=79N]&BBF]9KJJILWJJK<WJII_P"NAS/\><)J]M^+>S.-Q^CAW#\#A^%F
MV.(<3O\ "J;657DXN#?JHPLSBN?[-8O$<*Y7E7+G#>(6:;-?$,&BSF4X-JW>
MGW?\;O[+6359:B?0'5:?"L-7.E#E=F.$/U0.(II=NL=86VA,J(19'$3%5<!Y
M5FIS6EI_+2BI"K.#8,8RXGQJ[@WL.FW38KIR+5ZJY8KZ<9-%5.'E95FJ(Z5-
M70JKQIM51[BK2.G777;FBBW<Q]B_\?8/M/@<?N9%WBF/>X7G</LXO$;%-BOA
M-^Q<X[PGA6?;JN>[N6*\FUC<4C.IZ/$;<Q31CTV+&=1?O7,7387:G9 ]M!:R
MB:--I#)NV4MR\5U@PN&7.T^XYB%+0'"L&#9+%<;ID4E*;@(63;EVY VNQ[1B
M05C,9^-KCF5T(NW;>/7CTWLO&G(L1=FF[<Q<F:)NV;<5W*YMUXU%=RFF)N4S
M?FBS[Z.E%3M,_P#QOP+WM>'P_+XU9XM/#>#\:CA'$8PZ;N)C<:X-9R<;AF7F
M5V</&C.CB^19L7<F[&)%GAL7\ZOA\Q9JA?(.6'GA(LX*D)F"S(Z"6&RT)<0B
M4/(QFID.0A#J4.H2_'>;=2EQ"'$X5C"TI5C.,;-;N47;=%VW5%5NY13<HJC7
M2JBNF*J:HUTG2:9B><1/>\9RL7(P<K)PLNU-G*P[][%R;-6DU6LC'N56KUJK
M29C6W<HJIG29C6.4S'-'.WK"3'5^#5:P7_"WO913%'I9)$1!!\-/FP)Q$U:F
MH+O^;R,TRK#3EH:9G90/FSQ<$3)=2HFRAS-\-[WZ2WBJU@)2JT"J5<AX@ JX
M+A!Q43Y77UM0X#"&&<OR7UN2)<IS"/EES93CLJ;)6[*E/.R'7'%!G^!A;)8@
ME0KYJTV0C'$ *Z+FF3).4K*8\$:.CN2IDESVX4M6&F&EJPVVE;KBO:VTA;BD
MH4%9I.L+78Z-8-F'/\TW48)UG95;CL-RI.**U0W72U(U2.RA0V>^/=%3+!7+
MU(2N*]9".P-@K;9B!2T$&/)OU^&_@U/=79"R3851J77^4"_-[*U3-VRWL\S%
M=-B-7ZX;?"K_ (@%*@C$9PO&4$EGG12)$WUQ:1X(0JN62,4)-"QN?II$\NU'
M77#6=CU)3$:]$&K\<WYV D.[BW/LW8A218;QK>LFH+ (-+L9(M@X,8N$,<)8
MKM+U] ^*CPKG'O!6J@(- J\T"V7OW\O5TC3CVI3C.<JSC&,95G^:O3'IZY]/
M3'KG^>?3&/WX$ "E.[HML2S9?BKU)K^PD45F$A,,C'V5> JVH'ZQE..,.)CU
MK7YIHS JD9EQQPS;H>;CA<>)7JG+)DZ]?"8^T[\%@.%. X#@. X#@<\?(QL#
M7NI=;:\OFP.J-8[2!Y.U:M1S,0_0"M_>UQ6+-F6LS>XPNMZEW!8GV1F1T9MR
M!% BX4]^1'9E'8<C,./-&]-^<)6';KTQUVZ>!.P>QJF"ZRZN"ZIKFS;C1QE<
M=@LZ\E6,$-,$*A&K0.M!"9*QQ#!']/,C(=3@&S!I+<9(6/.?Q#0$?6_R6=4J
M0:V8!-V'8#L[5%AJ52LR@>H-FV6'-M5RJ+5^@5RJ3 %8(L6TR+I69=HM$ "N
M:]5PXHQ*-IAX&RDH'[^6_P IGU-VTT/NXOLX+0+@[-5J:P.5BV$S8 _5J[)(
MLVF]428NKV"S#10>XC8-ZUCL6ESBE:EDQ\:S4NP"79&'X6<+".?'@ZVYT_U>
MZPMIQIPMMAQEQM25M.-+W-L)3:VU(SE*T*1E*DJ1G*5)SC*?7&<9Y.J/CU^?
MAKZ&^S[S$?&8:;9NTFQ!XV]%1,[7'YN'<3E(JFJ'PAB?L&&[7=N5W6WZC)JS
M;@@\S%L(\PFPCQDI-*C1TF*_'9L9%C,R8O4;O'LN+>7<LSAU7Z,N[B8_#8MW
M*\^(M<3L8$7JZ9OVJ+L7J;U-ZBB?XM.EVS3%ZJ)JJCWKAW^,N 7\G@6)E4\?
MHP<C@N+QSB?M=&5BV?9NY&9['\2]IJN&V)M\,SLC#NX&3@5<-OY%O_;7JYQ>
M(7*^'V+E%FS,@5SL9>W-%AMFDJ)BQV6;<C]5G5P>+M0&;!:#FK"+Q)+UZM#-
MP&*Z58P&9:)!9+Y&/#DR,X=-,K6Q&<Y=GC63_J;7$+N'7=O5Y-['JQ[5K)B[
M1-N]>MTQ<L8UKB%VS=CW<4W;<].BW7K%5Z)Z-,Z_Q#_'O":?;G,]F,;C^/P_
MAUK@_#N*X_%,S-X7?Q+_ /-X?PW+]WA\1XEE>R^'Q''N_P ZJO$RK=&/7?M6
MYZ&+7337>C6MK]K;G0;72QX^H"90XMJ&1L:P!I;9K!UDO+KUS*! $*3*2%GL
M9>(5!T;C_P #2<Q2W7\GXM.]HY13X<2]H,C"R+%NC%BN*^'59MVW5%R+M-RJ
MUDUV;.DQ1<IFY<QJ[7+'NS$Q5[V,?_B;G9^R'^+.&^T?#.)Y-_C%_&O8_M9:
M]G<3+MQC7,&K&MYO",?.S[DVOY.+739Q^+49,Q5Q7%MU41;_ (%SBE4WZ,?
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M [5"C;9VW[<4NINEKS3!)=*TPB1F:7(6RR[]L=?RQ&C2+SLNW$"%IH@J4/\
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MU@H<P7!2G5+?$%,&B^)\!<>7@I/P[]IT)TX&(L$(H2 FQP,TJMFIX@E"#V%
M^(66!*2H;S \R@7/]8))0N6MJ:F!,Q]29EC$>1_D7%\"F/C:BD(/2[3L(L54
M<*PY&S8I,VN'&'+,$(^W[\U-**'P\8B05$)*'9:H<7'UXJGLL,?Y-M/ O+P'
M <!P' <!P,2=/ ZN'(V&RF15> "(KDTJ;-D(@H2,AM8]794\C.=8B0X[?KCW
MO2'FVT^N/56/7' B!.S[U<H<<AI[6[!L+(R\MBV;0L1/5U?*PTM(^"96AL:H
M72\E6I,E?I'DF*A5PI <VLN&-E83XY4\,'>']O#01NRW/:E%U/1 T#\F;F4>
MGS++>(D6)%<5)8"VFZSY=8^Y-G9CL0F7]2G)LU#GXH?#P6F1)L<;_O<^3^-"
MZ3"TLA;-MEA!#&TMK*C.F2=H(3#MLK](@.ONTS7DHN2+'GFL@XDE1&RQ!Y62
M'=N9$U^'6BMPJV/%A93@. X#@. X#@.!5;N^$ V+J=O,19[M3]< 9%)?>)7C
M8,RJP*/6V(,^!/P0M<F\&:]3\ <.Q6V23-E-#PTJ,ZY%G/\ P/*0L(<\8-A#
MV/JL-D ;C1]@BQNPMD XUUUH-H<#7]DP*LTF,LG4)&LKA>Z2:#/.)4EHT&LL
MS,I]$A@C''%(LT?&"+^Z/77NALO=<ZZ]=-I6&I5DAU^G:ZP#SL>54:G L+4'
M<A":>%H#(3:*SM*RF[-K*NA;Z+9*C0=6$'"LMN$? UA$\,7H7K[WPJNZ+7:;
MAM&;#J!E&R2NO$6V_P!CVE7M<TVR_GT:OTY:M:9M@F);K7K:?,KQ@[?1EC9D
M68:)D5YG82DJ^U/"S_40;?A-O[H0MF6VLW:W-]I "IUAJ%((:\!RH[G3KJ4N
M S&JQ.[[#F0W8D134>2^Y:)B9K[:Y3;$)#F(S87->>:CM.OONMLL,-K>>>=6
MEMIIIM.5N.N.+SA"&VT)RM:U9PE*<94K.,8SG@5]5;K9NJ,B/JJ8[5=;RWG6
M"6W9L20V7LPS'L;7_!H1);93)@DFER,P-KFO2O(91 +4@'?1I5@\()Z3U;CK
MZ]ZOAL/:W7KJ!2(Y"\V891QIPWED*)Q^9MFQ]I7DU)BQ\#ZO61S9_9&W=CV"
M;(B-Y@A!UGMA5Q;2W6W6FLN-EWOZN6.[8^W^U&["0[;:QFJ-#B6Z_ JVG#")
M>SMHVJ3*$*>M5)(Z9U\\Z/N-SM8:P>_8RX=^/T'5VJI8P%>A%R1;[]#U\37?
M9UZ1Y^7SYQ*R8AF<,A27IIZX5$%2[ P"9+S! <M9*L=L:9S5EK-&ATK$^M;'
M[27:66D50@5UT#DZ\TE6"BM7ZXC.G:W:TF!SYZ_+EV?+K[9Z^?E;6@ZC?)."
M3M["Q@E=#2FS= TPIR(8@5$R^2787[SL,O\ .21>MS$#TA\Z2-9(DPM8.2)+
MH$E9C^2&Q;$5-UMN%8H8*79;<:@@0D)3+3DR:YG&7I4IU$: -@1FTN2RA<G+
M<9@" PUB65+D7XXX9#ESI#$=P3RWOY\E6;F;O%ZMU*2BF2!!:<,*E=2T^T2_
ML(!%8ST=LINS<8,?#E"P[6OXKP9C7529L!TR:L-Q<CE!]6+PG#%+)S_/XWI]
MEG:/2@M KL2NA?N/H:4Y+)%RTG,\]8S4OVK*6.QE%)0Z5/&)&,RB4]Q*?D=5
MAMEMB*TQ':*V[@. X#@. X#@. X#@. X'/KR95B^6+K-B9K(<2*WFF[6U1>@
M$ 39HU.F27*W;X4B<PFSN;JZ\SPS3XMV<P]+![=J9G"'<MQ5%FG) 0B$C]"]
MA%MJ=3-0WH\S-BG"\*TQC$0B?.6B?"* ;S9ZZ0@S#]DVINTV2D0I8EV*ZY.V
MI<EM+:5':(1X[+(V$-[^GHY5]E*+Y6IFQNW"]+-[HF56PWP85U";#;)IU/=%
MQF]0[4KFNZSK@ :W.;K:]<@-UITEL3=!\E5]2VDU6EWJKR:SLB"G+3C<"U_4
M@!Y)@-C[-R-Q/!".2=]#OZ[_ (L6M!*F27U; W[+N!35$>AOFCM;U8O6$[K6
M&I->LPZOEV# *_2C@9LY(FESA-8WZ_B5DO'I^0SU U+DKB&DI\NQ?R21RGUC
M\$/XJWC[F(*Y*4250\2/DQ&5(0A]3'LRZE+F58P5='@84_9*[5!<@Y:#P:MA
M8GM^V7/E((<7&]V?1/V)Y!^/%9]V?V3\CJ?7/\N!S/V+WKD[%2@)H94BE4":
M28AE>QU]&PJ^/FUA^9^-E6;3P.ZSJ^+="29:)L"O;8VG-K55LC\-TKHJE=ET
MPB(>&3X]N_OR9/7NZ^LFE%NP:5JO9]\-@0!=S&Q*&J'VPLY^!.,/GSTTYL.D
MW?9=SJS%J.SR%GFE=M9UX&LAETK.;?DSXTI+)5KPO:K21B# *O68G7 1/VI'
MVVWU"WU;7L]Q:IJ$,C-HF0<769=UQ8^8AE BWS_G4SZ,Y<^5G+A-8WYZ?5,E
M?N50M@U\S5;56[,'BO/QY)6OG!9D;'?BX]9+#\X=*DQ67H^/W?;<=2MK'[N)
M3CA5/;#WNH1BZE-5=;*/>^V&RQ'S1SG\)1[36FJ.02RXMJ+LCL38%0-1UV3A
M]IR/,K8 _<=BQELRDLT.:]%>82&"UAU;VYL"Y$-S=V;_  KI:7)!N)0.OFL3
MMBC=<=058G!F!4,JC3H8 SMS8Q  4-";/L.X#!L*6+/$@ .G!1"EIDDTZ^OG
MXK[#1@X*.@" X^$*$BX<8<,%C8K$$<.'PF41H<&#"BMM1HD.)':;CQHT=IME
MAEM#32$(0E."HKMVR"*ST[76L!X^T[$CCVY9A^<0:8J6MXY!I2A!._28RWBF
M))1"'Y-=J8B%(-6/$1:GG:^!S*LX\-@H6O(%(9E3'RA6UW TQ$;M5ZL;S<FP
MV)<.23G16%X8;8@!P0Z8:+N@JJ!B#:X 01EMBAL?,F4X^$@\!P/&1(CQ$"84
M+3H8P8.C/32!$C*8A0(,.,VIV1+F3)*VH\6,PTE3KS[[B&FFTJ6M:4XSG W\
M4'8OMUVH/>3IJ*S7:Y)D(:B;CN8O$X*6%Y3(Q(,:TIK1&&6MS+CT=$438K,Y
M5:A-C3H=OK3NPZZEB&7)^?UOYZ<TL5*LHJ81@/@Y9+(\EV1+FG+89D&C1.?,
M>5(F2WW5X9A0&79"UKC!@4 371#.40 0<6-8CPVBZ;_/>V7@. X#@.!S)\HH
M[:7\+-06_4 ,O8[?K_=35A_$AKR_KN3(%$M6;/J,_*[- [*=5C++3?ZD9<Q#
M#[-??G.H;8E5@L/S+?@#?PTW^.2YG6RVN7[KKH2]/)DI=NNE]7VUU,V63(3$
MN6.D S"TRIYJT7<S-DI5,SA^67NEN)R',*>GV<_+6\5EAQK[$4'R5R-Q]ER%
M _K'G=86#9@$C5H^O;Y4J"4%42%JP\&JH#3"S'8N< F"7-K8I-NVD0FT72EK
M;&P;2(=_B"+-8CQR:^?PGZ]2UW5$'WY!G.R[^SV24JP3[[ERER-UW6"7U:3'
MKW/V-(1YVGX&NRE@,U:H1=$$^N ' DV"JLQZRA;!()C)9O!@V3+O>X3CXX\S
M\]-M2Y*XAI*?>VG^22.4^N!B?_&/8'W,05R4-R51,2/DQ&5(;0\IGV9=0E>5
M8P%W^!KMIM]4HP:38KI90%2 0\H3*-V4O !BHZW5>UIMV>2D1HJ''5?V&FU.
MX6ZOT0VE2LXQP(H7V2UG\ ^9#A;<-P2O]H<2K/7?L':A4MKV96F4R5K>L"H[
M,)Q"<Y9G9E8AO_MAE]:E)QD)"I6R*+L6-*D4NT"CK@U:&#0R._E@_6YJE/-K
M$VNMS4QK!5#<9^-)BS@5C&BS$"9%E0YL*/*C/LMC7\^/P8JW[>H=+*,5T@5E
M%K?*2PY%H]0#E[G=7(\E?QL$9%7J\(J6% LNY0T_9S48;6!ZW&LDS,)M>'.!
MKLLEO:WQ8*ZP$J6GHLJ"B9)E[*9SL:X09>7?8H'(I-"M8:HQ5_!G[*K#$VY8
MV&7D8A)KTQ#V9\8>7SY?9\%ZXV\2E.OENQ-D$L+B881!U_KK601AE_'KZS4.
M7RO;1EJ>5Z_VFG)*XWHE'L91G"\K#XD*+0Z&-=O^W+G8+^JJS!QV-:-H2A,V
M."*049&!I=<IU4 5RDC;,[)GKABYE8I<>V&"A-H?&D3Y3P^(@F_[Y^O[?80O
M:>R9L>Q*)F=.4+$3+@*OMB*]*V=9''\K2@M<F[2%L8:DB\L>V2+I\,=*MF</
M1)=I,5L@V3H\4K9UZSP2EB7K9=+;=X 0O!L$(#8XE$9"Y."7?M!"DN/6Z37I
M,Z0#(I8,AVIDQZ'!.01AIJ-^4%#944FGC,_#[1"3N%. X#@. X#@. X%6^TF
MD-E[Q@Z<&ZSW79]#R:-N%%[M=QIL*H%K+/J:-5;5ICM<& MB4O8>NCBI]BNE
M=G2X-WIY<2S %RR@[$.T#J_/BA+&HZ)9M;TF#5+;M>X[H,PY9"0Y>[T U?6;
M#,CS)2Y$> \(T]K_ %E1V8PU"_K17(-2B3'FDX<(RILK*Y"@DS@.!SCU=O 3
MHG'??:7:BPZSU.*!=LAC<@B)MQ0W7G1/]4+JDFJ-19IZM5,M.M9D,S&?FUP<
M%F9C%53((N:8AQ4D70Y:W_S=ZOW??RM5ZV=?]W=^I=198?BZ?Z^!2LG6\&;.
M4D>Z2W1>G($J)?9L1]4R"*JU6KEIU&-=;>L4BT75:ZS:Z@32?QVZ3\O'Z1II
MSVW9(O\ I#'<4-*'5D#U<\?>OG\36LAB^R3%DVO:@Q!>/Q2I-GIU,VDS59@R
M*AJ3,'QX-==ER77!1F+*&IFCI1=[_;0-;^'/M;KBW'MJ[*D]=>V^QIP!J(,*
M7C;&XJ#*K[JQ[K!F!594_5^S+, D&I#<9<HQ0MD:A;F-+7"3!",)D/S1O>Y3
MQ4M!;;TC7)]AG=;+)HQ<9B&%@ZWZE#REZJ&T/FLCEA>SM^JUJ_62YW-ADX2E
MSE'W=JZ?ESQI.Q";#,(B?EBEPM10NP#E1F1[;<.JG:HI9W'7AX*+4NOU@QJG
M6 V2U,?<%Z^JX-HA:HKL^5.FMW*^%J=FT6@X0GX<E0:)&K@(*.[Y[T_"T,OL
M/LLK&BM:_P! 6L^:G-I>:BVR'L[6@V&PN+ES*B!>Z:=&06IC$M33#@[+[>7&
MLNO-2_<U\2A.][\IZF"JVJ=XW4F-O.PCS5'L\N*F6Z2=17+;;J"I;LUARJZK
MJ3T>S:CUNPB')E-%+[.D;@OES&E71!HL.ABP48,3[]>_AOKL]2]>5.@Q76*]
M D?;E)1@F>-%"MEM1M2'7WT.';789I.PF%-O2I*XZ2!)]J)A]QJ&W'8SAK!6
M[<!P' <!P' <!P' <!P' <"B?;SKOO3?MXTZQKN_:FK6JP%8VW$VS4MTZG<W
MS1[H=.$]33M8R7M22;;1P18G5W*Q=) ^TE+#]JK**.L#!,Y1^7*&C[+0Z<I1
MO7.LJA1["1I14M6AF1C\W7.O&=44A;+4J0J Q7-=Q[%:V*J/ACUQ8:1S-@(M
M*=CNRFEL(D)BL!)? Q!^66'@R\X"'183<0=,DB03A)D.@P1986Y$&K+2&9$<
M:F8^E#&9KS#S4;"_F6VM*,IR',3K_P!J=+]7.AFH=@=@+F!UW^8(;#@!:Q*+
MP9ECM%LE;5NRL4^F#_DC/V<JB2[AEV3$:9&P(:739N6(!QIA"*'#_L/YLMX[
MNVK-U]U\A'H@M9P.%KFG=9$".-OOB)GQ,%[K>['3DN30UNK<]4U"-+FK_H(@
M[@?AIE[9@\N++,CQWOS;,BE=L-L5^FVRWZX[6FX2A1@#F%LKKIB)8:JXY'E/
ME38*GIU+J5ZLD3S7RH@[2O78K;!Q#$^/ S$E1IIH=%;A-_/X]OE'@GJC]/[Z
MF9BRT?J=OW9I5VS1"9>R;EWN3B;#'E)\,.S,/,-[^JU(T?&'1H K -42JZMW
M]**C8<)+]G"N3YKA ?+GOX]?U[EO:T$T*]8KUK:XIOO7:_6.!)78Q%JZ]Z)K
M,XM&'SFY)VXC=BZ(U/1K X*C'C"&&MD/6(?4R%GEN*I-D,SVY+S8G?K/CON:
MT7ZJ]QH)0:9Z+]H=Y#Q49DQ!L8_M94:]4];76')/PBD\._9,T@3V<FV)3#4L
M>(VW:J3L&U/C"DA0';\9+32TE]-]Z'2=+H<W; VL=_>N>VX5\N!5R#7::*W"
MT7T)M:*P^YD8'=W+NW:U;#W8W/8CQ9!35<2^4IP_&4IB7IJ<-;,>XGKV_O3X
M.R=+V(NJ"X5-H75X]0:8%@IP!@0;/UKK=3C-R'%2%0Q0:F;;,_13\KSLA_+8
MIB,XMQQUMQ]QS/N+O>J:1I^]$X;,QJIU6/\ *RM2H\B_/OO,2,9S[&'7!-.*
M05)SC&<N.L37O9Z>B6W/WS@-#)1.Q-M<:!R<:XU37Y:<X,VJF7$[L.]-QD.I
MRY"K$"SZOIE:#3I['JUBPE4V1(C'R*CUV?)<8EPAUI8JE0K=(#L@JL)BB!K*
MOE6AA*ER9TQ3;;<@F6GO*<G&#$[XD.D3!23+)D9'ND39;[ZE.9#9.!\GY#$5
MEV3*?9C1V&U.O/ON(999:1CU6XZZXI*&VT8_=2UJPE./WSG&.!"#6Y'[OEUC
M2-;3LB)F/+PUL6278 Z>;GM,)<C18]Q0P6+W!$AQ66%3];U>Y@X$R/+&'#08
MDPN-@;ZM_!]A.GW2Y&-9=PV+.S;!&RAP<#R/6$U76'DKC/)=KNO%3RD8@2:D
MPX\N+9[X3N=I%R_M9K1>NC9SXC 3=P' <!P' <!P.?\ VLZR;PW_ +5H\RJW
MK1XG3X'7EDAV*E[WT6GL=6BFQY5FK\BM645KPE>*"$$&A%:;LPU%R65GE(\,
MM+"QQR(I.5*0%V*0#FUBF5&M$I .61KU8 A)\JL5QNGUJ3-%"XL"5(KU1:(E
MVZL#>?8<<%5QLL40$@*8&)(SDQL270VC@> H_.BC",H6/25)QH,Q\<+7+;'I
M)3FF''(L!4]UMYJ$F9(2W'5+<:=;CX<^9;:THRG(<T.JO83477#QY:^V_P!B
M;Y5-.4T1*VE(-D;2;8^".5?V_L-[].A4QVU3[8>?D8=A!PM<'3S1^4E# @7)
MD/-L9#F1NOSXUS<!:+J[HY+MQ*R&Y$@>L[0M!6'LSL^#$S(1B.=!TRJ&6:$'
M2_!4P0CN.S-T60 F<F%L;4%/(Q'X60JRBE>5^^W@O,AZ&W*:L!$*_+!;SVL.
MD1VGR9D8D-/DQ0.X5V5C6#\X3-D9?%T;0&HB55Q%P"#%'?<HNL)J-6/OKUVB
M46 ;V75*UKR(/%"+:6V%U"I^P!XDV_E4!P7!"6JK]2-M[+<C$?8S L-+)WJ1
M*:2^0FP)PQ,6=,"2(79,U7[:##[([&=6*6[:->BB+<+=.DMNBZ?"?M"438[C
M]MNF\JEVEZH029 :U)A#+QK*H:+KL:8BO5D@:M'T%$2>G+GOU_'CI>ZI=FMO
MZ_4,<L&O>O>H];VV4A\?MG2-;,=C-2WTA*DQ!(F2(M%&N^L[:5L!O#PZ&-#2
M]=S[86>1-7#ARQ(E\LH3.D=^GI\^4+R:\L>S-@Q212N[_P"O]W$Q9:AZU4G3
M]F:E@R;.$KDBCZI'8FQJBE8Z5)3*%31P@C"<]R),="TJ;P5)20^W\9]<[ U^
MK'^'\*CV/_UQMOUX.>X_;RB=8J>M6+S?CN;O98+:(U:C8@/AJ;3HZ<,+=DUR
MHNEC4=%BFR&/GF6TM.+6)MIQ8L1/$A5NC'2=VO/Y)7X4X#@. X#@. X#@. X
M#@. X',VQ]FNR8[O'L?1]7H@>X4ZMZ=7::/KM\41J!:Z2<T]-@C;#=W04>(5
M<<!E[$3C2;E?17'LB",E-FG3GL-_CU$[].?/3R[_ %CK^3GW!T_L3>O9GLQN
M7</B<UQO6]@-U4<9$#[/[>4^T4+7A -UAT$Z-2%US9Z<5UF0M+PPRP??V)%J
M#%D^(R.K;I-Q-1A*9+U^&_O\?*70VM;8[L4L4T"IWC$U]4PC"LK8#UKMMJ<$
M*97E*494T/%ZPBQ&U90A",J0RG.4H2G.?1.,8#4MB=W^Z.KRNJ0UK\> UF=N
M;9L74E(3"[@Z\FMR+C,IEVOK+!%QO7:<#X&:]0+$ZJ<[[FTRFHL7VY7*1G 2
M;_6$\@7^KIKW_;/UQ_W<\!_6$\@7^KIKW_;/UQ_W<\"/=4=TN[&Y]<T_:=(\
M=XN14KR&8.@'B/</78^<Z/DJ<0TN5"<UTIR,[E3:O5I2LYQCTSG/[^G D+^L
M)Y O]737O^V?KC_NYX$9-]W^Z+NY9>B$^/ ;_$"%K(?MM^-GN#KS S%.*6HG
M3HCZ2?\ #KXE3U&Q$UM<'"?D1'2W(RK*7,8P$F_UA/(%_JZ:]_VS]<?]W/ T
MZ_=ON\>MJF4NEG\=H=H&'6.1-<A]Q]=2Y*<E2L$-$^..C725.8S-(1\.9PK'
MQMY6YGUPC..!N/\ 6$\@7^KIKW_;/UQ_W<\!_6$\@7^KIKW_ &S]<?\ =SP-
M*I/</O!?T6ERN^.X0ZFGW6QT U]ON+KN+ENQ5:2W%+M1\+UUG[$1#KJ,,2D^
MB'TYRI*<8QP-U_K">0+_ %=->_[9^N/^[G@:::[@=X@%PI-&(>.T0D_L!NS.
M5UMKN-KIV*ZFI#XI,Q]N3C76$Q<HBS&<Q\+PKYUY4A/IE.>!N7]83R!?ZNFO
M?]L_7'_=SP,+9.T??&J5T_:"_CK!H$UL*5/E%L=RM<OOH'!X+Y&:IEE.N<*>
M=3&C.Y;:3G&7%XPC&<9SP+Q:EO\ 'VOJK6>TH@UX-%V5KZF7^*(DR$2Y J/<
M:X-L3 U^4TVRW)>@M$4QG9#;+2'EM*<0VA*L)P(G7J2#P' <!P' <!P.3VBO
M(SL7:%G[/!L]9+QLE.C]E#Z@(!Z"F4XI;XD6=LSL;K.<!OS6U[]K2LQ+C4L=
M?1EUMK NPLR88K=M!%0JS-AC7[?8 X_]0^EW6BSLQNR^Z_&UY!.V>S;3:MGE
M11+9MOZ]W+4]($D=D6O'Z+UWKDQVMJP*)51C#;8IX79:T93B3'GMQI#HY]*G
MP[<T+?G\*A206K_%-VSUP$0TPP@/0Z'TGJ M+,1*D16L0*_VI'Q,-1T*4AA'
MQ>UE*LI1A.,YQP,@OR"61%X8UNKH%WIQ=9-5E7=D%^)ZI9>75H1>&"E%_M8[
M8_0PTT6GQ(>6%2\3%+>2XB.IE*W$C>_@VO\ KF[,_P!77WM_]AZC_P#%SR:^
M$_+\^O[Y#0-D]K7#-7)S=I>,GN0?JX >3*SEV:I]/#T89!;@/I*38[#_ &MF
MR&',#\R&W7(+6)2V5+;1[O=[<M?"?E^3>]^:NA>#.3'<;UIU#\Q>C).493$<
MUCOC1DL&*5G["O>+UUL_N;LG5$-67I&9#R$4)3,IYMO,MN0C"T+HP+VSO("-
M:D"H^I.X>X*E(B,Q)%7[)]6NAEH?G8:>%YPY-.Z>[JZ3'R,X;AS'\IET^;AR
M?-0_ZMMQ&6>#>_IY(.J=CVH:L%XG5GQG[/&6.K6IVMVM6H*#UIUG7V;4R%"'
M/H'=<;$[+[QU@2DRZR<K>3)T55F3\YEYI<*U#)T=I(TGKO?PY>38IO9?R4U=
MJ,'&>$"L[0K+WVV","+=M$::<S&??6C"\P9%OVP*DKDQ,-9(,?&RRM_Y/9E3
M7L;3/AO<J\9KM=V>I<VHUP?XB.R^IMA;.*&8]%I^L^\%.KP&:8 !%VBPNBZY
M"FIU2B6)KP:43Q&L-._#D&HBAZT.?<<CN4WX;]4K1^Y?ED@#$,P/')M BGX8
M>&G[T5Z_'KG$<Q(1^0_)RJ/OS5U)LSSD9:\PUC05!8CO,)0\S*1)RY'"69/9
M'>KM<DVW<O57R8P1XH2[8+36:2UTJH=1$MB!K\HH] *TWL[G:KD%IM$B4J,Y
ML<A\V&64ICJ4CV./37X?>8-ZLGJOLG3+C0:UL&B>,SNK>JCM*L5R\A+I;QO6
M"[';C6;,%A&*T6)']E=O"]RFL2@DZ*_"BGI6'X+$C+&8L5>7&L!/S?<K9+3;
M;37CH[UM--H2VVVV/ZBH;;;0G"4(0A/;C"4(0G&$I2G&$IQC&,8QC&./3Z?G
MU_?(:S"\@5E(W*QZ^A= .]+]QJ5?J=JL(3 GJBEX;7[S/MPRJ$G)+G;%$!YL
MQ.HELCM,QI3TF.H,\J8Q';D0ER7IZ\OSK\AM/]<W9G^KK[V_^P]1O^+GCT^G
MY&",]_Y=.GT1&S.EG<G5M=ONUM3Z<A7FX".MLFK!;=NG8M;U;1EGTTWLO;+(
MR)DV^V!8L^8+KI9^'&?<E?3=2TI/ Z%<!P' <!P' <!P.6^E._NP=C'.ST9>
MB3NS%:4VJ5H@376A)%4([3$C1&]^RNCE.[%1M38VO*LV3(1.O(W:[7T"85V/
M4]N587 "V",,;N5D&^KGOPT<<^HO4_K_ +!K0K?'8?QR]^>Z-O*7C9IFG,[>
M/]<+]H[5X96T[>XU1]5:CL?:6L5&!6Q\M#ZB[-GIQJ61L#II_P#(S1LF,IP.
MV-'[!OZQ&9":V\5O;G7P97Q>X32*/TJJ@U7PIRAK*H('M7 BY^)"E(;]6LY0
MG*DH],9],O3Z?G>OF/Y>\BI>/LD=J%[H3WG1L8M1S.R!U8R'ZJYD2:37CP*L
M&#J9J>UV1:&81VS AZXSLYN>XX0;=9BN1VI#K,])^7Y&Z.]R-D/M.,O>.?O4
MZRZA3;K3H[J(XVXVM.4K0XA7;A2%H6G.4J2K&4JQG.,XSC.>7T]>7YU^0J%V
M*VMJ%G7%TV3MGQD=VJ!4]<:^MAJTWRFCNK54(5JB QV;%89LMFE]LTNGX >(
M%_+QA)$-86F9,/#L 6N4YE#H4JOG2:DVX:XD+TI\G$(H_*=FQCY0[U]"$8#,
MII#"H,6=H#O?UV,S!C4-MAF*,L98\.9=83+=AOR7)*WPA^)H+R4Z8;*O=>J?
MW+OZ)Y!DTW4>VNKNL]X!""45;CL-&NMAT/O#6-_ZE8B2R!::ET)MJP*D.R%Y
MEQGIA$H1D$T]/+?/U>OKOWD\]JMH72K/],8^S*#JF_1M:[1@)Q22)>G6;-;J
MFPWP8E^Y=J(EOG%9VOM@4D^V8-;-O8H3^:0/;@$Y<:8W''ER^G;OEI/4Z?N>
M0/R/Q)L)EWPP;F*C5.(00)!^T.@F9[;/R)2N1%!&'($9;RFO>]B"Y8\-MK]L
M?\F]CUD\*F:3Y%+Q6TZ]@;#\=?>2F6?9ML<HE3 I;ZG6!LM;VZM:[QD+$*CN
MU#;&%_I*DV<UF418&1,-BGXWS9ENQ&9(2-_7-V9_JZ^]O_L/4?\ XN>37PGY
M?D?Y_7.V;_JZ^]W_ +#U&_;_ /RY_P#AZ\HQ%?[V7:U 0EG >/?O61!6,0-/
M!""!G4QE$\27ALD!LQ#,GMJQ):1*AR&7TMR&67D)7A+K3;F%(P&8_KF[-_U=
M?>[_ -AZC?\ %SR>D_+\C58?D#LA"ZV'7</H#WI?N=4K52N%@!I$]4DO#:W>
MR5R#U,JY)<[8H@/-&"6OKA%99C2GY<=01Y<R/&:D0ER;Z?3X=?Z\1M7]<W9O
M^KK[V_\ L/4;_BYX&$.]^BE+9#E=C=(>Z&N*D3N-!I,N[V@3UFDURO$]D7>O
M:\K,LVW5>SMEL.!CEGM :),>% 2LJ,S(5(3#=0TOT#H1P' <!P' <!P.<G3'
MMQ.[";B[(4N3K^D5#]%F"!B?(J\MYVW,EP>\-]=;XPO<45V*S\-V*TWKC3KU
M7YCN6)+U&M@4&F!^*K @[8"1.ND]\:NC?"N=?=_LT[H39_4*M2=;5&Y ]D;4
M=9E6ZQ(HI<WK0VFP:]UF ,T:IV?8]!M)6QEF]QF!\@UK>!>K-6@"##LBH$1)
M&8G))[^[^^WR=%.%5A[B[NN/7/KW=]QTBH +L6ISU;>EAK*?FUT8@&3LHD.:
M)?;'BB\N9.'P"#KXP2VQ%;)$,1XTHF,B*?FLA#G4KLQG9NX=\:!%Z^H](J.A
M6W8U=A4ASZRJZQ!WYV,TFQ5;37X\5@8#*&A&BA&WP+4%H8A=0VD%BH%2(H^)
M:;,'0'@<8;=W^M=+O[=@L6D-; RD;N%<.GUKNH4C7[C=(NK:V5U1)IDD=#/6
M?5%ZMTH^9V^V0,5378O8DNERTS2$&D6R$Q..9#L]P.67D2[NS.K!&I52!7-)
M[2F6ZC;!O2-+76RRQ5_M8K5U=/6\T=&-2A\JM#P8>4%KPP$S+8/V6]W4[#K-
M5!QIL!XF@>BT?3SL 7[(ZG)7PS$J6)(?96Q]?L'M?E))BB76#1[/,"0KA4IL
MM<AS(PJPREJ3&21+LP34,K!9+3FXR7LA(78C:36E-*;$VM(L>MZA$HP+\[/M
M&W#96O:\ C6)L1HD4L,\$-+&7_J0'I#HH(+A9GV8VD;7(LH>\520BAS2Z<>0
MVR;G[!533YS5NO:"!VEKR?M$ ;U^2IEI>NED?#M6HV;L<&M;0GW#72YP*6*E
M2,WC6\P<[9<EZ2]L>9; Z($XFGIW[T\9G7E+LKPKBCVO\CUCT1V!/:X8JG7>
MQKK+XIJL;+-W)M^)J5H]7[01LL':L@:0EEJ68*8JP(%] LQKV/*?OU)37YFQ
MTMV", #L33#[UJI]4M$@<Z(D62M C[XE]2E/C'C N*1<'O*6VRM3L)<C,9Q2
MF6E96TK*FT9]4X"M_<3><K0NNP%D:9UF4'G;J"JMCK&P3L,:0M%4,O*BV8?1
M0DTB,1<+&/"KF'IU>AN%S<FL"3JJW3[S84BZD7$M!Z)]E2G8 )MX&4HU8URW
MI?9QK6M8JM.?J1(!!H0,@4$4E396CW^\@HY-P(%9P7J$R'0[)2Y:,BB='@#7
M 18T/-?/@. X#@. X#@1UM2]B-/:MVAM@B*E$!>N*'<]CFAH9EC!4O#IE;(6
M*=$AX<4RT\3F1!:XL3,AU*%/K:2XXE&,YP$%](-C0]EZ !%XFLZSJ'(T[91,
MJATNYR-A5,5*>)N6%<@%<9=9ITDRR4:/LDB/S5L6X--RB@=;3JA^9+P6YX%
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MMWLE'.UUR?L#7.IK>HP#+5N8+L,4QK\ H>?BDQ\')8;&A'"06,X#@. X#@.
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MCLD19,(0S *;TV3.B9G!C<,>9$3,QWV\RAA>!!)CW_DB$(<66R\PV/DM[P'
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M*[ $P,NK1$1G@2CP' <!P' <!P' <!P.?GDXH<O8O4VP X(RVF9$'86H+/\
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MI"%K"SS1XS5Q>4 O[TZ)"5(AO5DQ!#V.8/FP9+;4YQ^+6K,_B'&DI:K-B6K
M6<)_'7Y[T\6A]!MM; W/H95LV21+V$_$O5IKL>YS([,>O7H.(R/2/ME"]=,Z
M$)N4Z?\ .]%9_.:X@DHI^#8![)FRAX8H]/"Z_ ^;J%.-.MH=<86XVM"7VL-Y
M=94I.4I=;P\VZSEQO.<+1AUIUO*L8PMM:?5.0IWTH$$0%&V^&+6H]=R([M!V
M#CR[9:(U8B6 Z[B_SU9FE8U+KE1JS,I6%80I(6M!X?L0C*8F',K6L+D<!P'
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M'&SR;>]]EHGS1XB23-21<*5*PZ_%'2#)9Z"PXW&=)SUM*E.E6XX#@. X#@.
MX#@. X#@. X#@. X#@. X$(=B=<7C;.JB-$UUL@UJ.T$[;JTDC8-<_$+.@@%
M6VI2[9<VQ,:Q5RWUDC.-4T&? 1P]IK!VJFEE<";.-D@9I%&0_K1NI[7J&O%
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M5WT.)K$^T3;<4H S6U@-V5@D(CPPH=ZO;?UIM77Q ?&(H41?DD*TT9'O,1G
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MP[IV6/$7SQY[!$[)W0FRV%VS ]E==#1@U-HRAQ,D6GV.^6"Y$!).-BQ-MPY
ME\>\_'F38F%I9]4X'KONWV^')2^)X,MV:R*S+%U2VQWIZL'9[BESVM9[6Z]A
M*J8]TA<K.;%7*1M+7SIUU3^6OD<F&<(4TVM&&DK?==4&V)T?_2 .J%0MMJI7
M8(5V,JE6KYFUD@/:1/U'&8XB%-)F7HMKIW;*Y[ 4I,&.N5"@YL+XY$M#<*(-
M@P_7Y M5UPV7YF1M8$[&5XW_ !_E".R P.V2;=1>Q!G6-BL@@^)@E8CEDE&J
MILHU.)O(?:?==(&9:6,Y3'S'6MC+[@WZ+G .Q7E;<(C6;1XT-&Q!+DZ(V8)
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M[4]4=6OZXK1L)MF><KI'9L\C7Y5JH1BSSA02IA*U5$%FKY(@76=$G1[%9 @
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M^N-F@TC[C5+!:*E:(\NJ;)K\Y)*N&78L?[/X@E"#V 89#P0N_P !P' <!P'
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MNQ]@M$5/9ESK$"EW2<1MX&X5,24''Q-?L=/N!VJDAHVQA#%B 6.*RL0G*38
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M#E#LEM*6DY#*5/LIU^O >KG:SN;6T^#=*U#N%::?MP866)UN=/P)9*?@"\N
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MD6,'C<D9CQ$AD?"C0\SB$C"</SYF8[3?VICV$(P]*?\ >^YA"<+6KVX] R'
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M' <!P' <!P' <!P*Z=C^OR>P K5S#%W*T ]J+<M0W;4SPP0*/(59:<-L8N#
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D8I*2#C!(AF/!B%["/-7:=8K<<&]PN7P' <!P' <!P' <#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img29677477_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_16.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2L44&AO=&]S:&]P(#,N,  X0DE-! 0
M    *OB^$0 #A"24T$!       )AP!6@ #&R5'' %:  ,;)4<< @   N_C'
M(%  I&:6=U<F4@,39!.$))300E       0&W+\#Y7^8$6RWMYI41!Z-SA"24
MT$.@      Y0   !     !       +<')I;G1/=71P=70    %     %!S=%
M-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7
MAT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0      #W!R:6
MYT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M  "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$
M]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M  4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V
M)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M   $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M          1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M   $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M       %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0
M    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M              5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4'
M)C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296
M-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W
M)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$
M))30/M       0 2P    !  (!+     $  CA"24T$)@      #@
M     _@   .$))30/R       *  #_______\  #A"24T$#0      !    !
MXX0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M      "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M$ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M    8       $X0DE- _@      '   /____________________________
M\#Z     #_____________________________ ^@     ______________
M_______________P/H     /____________________________\#Z   .$
M))300(       0     0   D    )      #A"24T$'@      !      X0D
ME-!!H      S4    &              5I   &CP         !
M                $             !H\   5I
M$                         $     $       !N=6QL     @    9B;W
M5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M!,969T;&]N9P          0G1O;6QO;F<   5I     %)G:'1L;VYG   &CP
M    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W
M-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96
MYU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96
MYU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M    !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M   $)T;VUL;VYG   %:0    !29VAT;&]N9P  !H\    #=7)L5$585
M$       !N=6QL5$585     $       !-<V=E5$585     $       9A;'
M1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%
M1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D
M%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697
M)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6
M-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
MIL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M X0DE-!!$       $! #A"24T$%       !     4X0DE-! P     (&4
M !    H    (0   '@  #W@   ($D &  !_]C_[0 ,061O8F5?0TT  O_N
MY!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q
M@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$
MX.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,#
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M\S[,_'S<:ZO_ V?9KOT/
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)=,Q]2*O[61G"IR+7$V!J+&*HTM!T4%@@GLG"-ZVZ<NV G%NL=:^WD!%,.+
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MGSV&>_\ 0U\Q2*/F40^/;^(]P^G?OJ;('^X#Z@Y]=_R(J0Q'!Q@@>1VW[X.
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M/6V?,^*\4R.<LY9ZA,C364ZIA'$U4KCBH-*LG&RSZ3;Q<8WFU\TN9Q%(S'*
M)K6!K6Q7@@EBM'*J J5+_P#LN6P#+CG >]_=E*UYU#Q^>L$W#;5@!"7*:*+>
M#/F[Y_<+,V6>E11_=E&TQU3K,=-@<S)Q*,;4@*A?L=43*5F3"_2)R9A_!65I
M/>53JGL^VX1'3-M&W;<W<+?G8VXJ8R+E" LL?=<;9?HL-'IV]'"]+QI;HJ+M
MS2I52?:-I2;CHM@UHJZSM1XR4JH43IO[L]VW3:JNXFYX>>Y(WK[G\_5?<^HG
M8;)BB!JU<A,;80_P/V_*9JQ9N%I=KI.6,=RM;:OKK)4IW%M+1"-LB"_A%DWK
M5Y#NE*V0R9TK=Z-=R/OCR#C#;%LRN&2]U&R/;%3:WD(K#'*..L>YLQS$U:L;
ME\>5W%>2ZC,)K1&:6#:8F:5+3S!Q2&SZMT$N0$'@-W+6.4JP<.=%7<RE1L;X
MFR=AVHC@UAU;J!NTG\26G).+K/&1^VAUM_DZ/D6&EHW&]0QOCIY+O[*^)%V:
MATFB059E43O$8QE+0/+]^I7SB>C?NYID7MZBK%MWPQN;P9A/<#O[0K^SG)&8
MF%>QO3\=;C9E-S@?+<*\<Q-J@#!CI 9!22JYXE];*V5Z+VH1RT^[</H]2L*6
M/H5[XGN&=E]+O52')U=Q?M%MNW>[8OQSEG;U7K/B;(\EN(O^4!R?1;;GW#^5
MJQ&-K759VJLWMVQ0XJ6981[7F31"45BFYXQ92IXNG?T\I/;CNDWT;DLLU",D
MLA9>R^DAAK*LE96UGNTAA)SCS&K"P(3 1ZJ3"#E+3>J8$Q9TRQ;%[-NXR*=N
MO$U9QJ#52ID-*5'E:>H]B4-X%.V288J=VW'YE-)I*YZ6Q*C%/Z3M6I2C9<2V
MS-UUE'["NP\DJ_!HV:4!B_=75X@JNHE%?:2D##V%2I#=*5PY;<.O!OVQ_P!5
M[<QL=<8CLF^'&;S>!N)J&.*)6B1D=G''55K>2+B)6M/M<BYC*S*TNH0,:N\7
MB\DNV3&&AF )(7JK0; J)%*[A&:ZKIHU<K,W,<LX;(+JQ[PS0[QBJLD511FZ
M.P=/F!W+8YA07,R>O&AE2&%LZ<(B14ZE>G2E-*4TI32E-*4TI7\,8I"F.<Q2
M$*43&,80*4I2AR8QC#P %  $1$1   .1[:4KEPZAO6^R%D/*4IL&Z/T;'9JW
M(./>8S*&Y-NDTE<-[?X\BZD?,.XF<<D<UV?L4*J)"O+,\2DZ;$/56L+"M;M<
M')H.)NK2SN+Z98+:,NYZGHB+_N=CLJCS.Y.R@L0#C=6U?3]$LWO=1N%@@39<
M[R2O@D10QCWI9&QLJC899BJ!F&"=GW2=Q)@NQJYXS],R.ZW=]9I/]ZKEG'+#
MAY:18VQR!5';JEQ=@5>BV7;+\ UM<[]HVPQD2KLGL$T4)#MNB:9P_:6 6255
MN+D8)ED *1G_ /(QD87T=N9\C(Y?X:\\\3<?:OKKR6]H\FG:825$$)*SSH=O
M_-3*<D,.L2%8QT//CF,LQ"<CQV W<W ]SB'D(^'L/ ^HCQP(^NL]D#T]6W/<
M;#KVWST).U:,L.W,V>N^ 3OOL2-L[#;(..]>DC<1 .0Y]>1^/R\@\_QU(S#.
M22>G7M@;^Z,@=L_+-5%C/;8'; Z_#_DFO01 !#D/O!Y<E[AR'80Y#MV[@(>F
MJ9ES^V^,8VZ>G3_FJXAQN1C8 Y&>VWIN!FO05'X '?X^8\_+CS_74I=NY[^G
M_./GO4_(/7[^_P SZ8^@(C\./H''U\_IYZER>Y/ZGX?#TS4XC_[>GG_?K\Z_
M?L!^!O+GS#R^/TTSGK][Y_>HB/\ [1^1_>GL!^!OS#0GX_,Y_88IX9_VCS[5
M^11'\/@/ _S[_EIGN.N_8#[_ &[5#PN_+^?EZ9W_ 'KY"B'?D 'Y>7Z>6HAB
M/7KU^_R[U(4'P^_KV\^M?$R ?,/[^(=@\P\@\]3"0CX^AQMZ_?\ >0Q#.P&/
MA]Y'H3\?.J1,/8R"BY*<FI!C$0T.P>2LM+23I!C'1D9'MU'C^0D'KDZ39HR9
M-45G+MTY430;H)J*JG*F4Q@G\5%!9R%4 DL2%Y0.K$YQTW.3^6:E6WDE=(HT
M>221PB1A2S/(Y"JJ@ EF8X  !)/3SJ%YM&;M.N-,VS%NSRRRNVCI[5J<>U/*
MF\.9C7Z-HW /(]VDTGJ)A2OE6BY5>LJ,W"RDD_6=1+9^@0C.TR<8F\5I4OH6
MM<0R77-:V;-';@E7E'NO/N<\N-TC/D,,XQS8'NUW?@WV?0:5X6IZO''<:B0'
MAMB!)!8G8ACDE9;E?]VZ1'_I\S 25T];&=A6VWIX82C<&[;*86OP95$)*W6J
M542DKWDFTD:)-'%MO=A*W;&E99PFGX6[5JW804(V-]GU^)BHXI6H:K74:S]F
M/#.*MP>-;7A[-E"K>3,8W>/^R[33+7'IR4-+-2K).FYCI'\*K9ZP>H-Y"+DV
M2K:2BI)LUD8UVU?-D'":E<V-P_9%NF=8KJXLD!?]U%"K;IZH[-CZO9#HLE!,
M43JBH$;%2]NQE8[8DQ2*/L4S2D],2'LP 5'ZB@"<5*G7V6["=J_3\QDIBK:U
MBZ,H$)).&K^U3JSAU.7:]S#1 S=&8NENE5'$O-ND2*+^XLS+(0T,5TZ0@HN+
M:KJ("I6XFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4II2FE*:4II2FE*UOW0;0MM6]#'1\4[H,/5#,-(*[&1CX^S-'"<E
M 2HI&;C,56RQ3F.LU3F!;G.U/*UN7BWRK115FLNHU651.I43F./V9SI"8YNZ
M5W#;_9+T9H[![&U/(^4[U::0P6(H"B1%:\:59ISS1/CP"PM;BP,7"8B1XW<@
M.E*E)W59DAMD^SK-F<:ICV'E8#;=A:S76OXQAEFM*@G450J^J[CJG&+1T2^9
MUN-]U9I,&GN4*Y;QS<I"H,3)IE3TI4)V1>N]8*;M#99OO>'MK86K+63<*XGP
MW3Z;NK3W 4I%UE9B[G;'.;@'N.L6K3V,VF.ZZV1D)&I)5Z>M=@=K*QT2P]LP
M=G(I6:]H'7!Q5G)SNIR)F:VX5Q-M_P *9I@]ON+W<,?+]BRUE&\+MY@YI]G3
ME*$BK,0=]+ 3TICVHU"/E\BQL+7)YY=X&*;M4GBRE2!3?4WV&0$=@Z2=[EJ(
M^2W),DY/";.MM[+;YN]11YDU;4EVU<JD%-6"&AV5C2<5Z5EK'&0\=#SK*0AY
M5RSD8Y\V;J5X]DW4?VZ[]IO<+7\(.K.64VYY9G,6VII:(-:)4FV\2L+-A?8
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M:FQY@'I]X.>GQ\_G'.#U.-\]^F.NP([Y Z'X$5K1<]A&SVW^T-9=J.W*:54
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M3HFVPN)<C.G,#CBH1AG=7S7O ?D2%1=O72+@WDL0[;VC0Q9;(&3ITL3/3%4
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M\6,FR5>R<TZC&#!1=-BNX^TUFS!?6;:TFNW*Q*,+_&['"(/^XX/D=@"< G&
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M!QZ8)]*Y3*H&2-OCC^N?@?D=\53E2 ("'H;]!_OO^>JR'?!. V ?SP2._EV
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M35N-I2FE*Y/^KWU*LU[BLZ2?23Z;5C5B\@K(*M]X>Y:'<OFT=A&I%521GZ'
MV"-,FNQL1$5T&-REXM4S]N^DFF/8!=*T.K I7[_3=.N-4NDM;<;GWI)#GDBC
M!'-(Y'89PHZLQ"C<U@N(N(=/X9TR;4]0DPB>Y!"I'C75PP)C@A4D99L$LW\,
M:!G8\JFM0:ET)>GE!U!A VC'5NR!9DVB99?(,[DR_1=@F)(Q"B[DACJS88:M
M,06<>T41:(0QRHIG!-=9XJ4SA3I<7"6C)$L;PR3.  TS3RJ[-C=N6-U1=]P
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ME.J*,)%! Z[))2QLX%)35N,HX9M+C274GTL"X//<P7L6GWXMWAEAG33[F::
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M&H.A!B@@LFDD99&@67_4)K9WZE=@5)4#%E#PL6>2*<.#%?F8H&> 8/0P.!4
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M@*83@45*Y6.BSAFIT+9-2<L-5%I[)>XYY.92RM>I4YWD]8IQ:RST;'L'<FY
MS]=I"-&ZH^S<.%P6GI*QS ']K,KAKKG"MG#;:3!,@_U;P-+,^,$XD=$3<9Y4
M51@;CF+,.NWDOVK:O>:AQ7=V,S%;721';6D /NCGACFEG(R09)FDW;KX:QH?
MX:EOULE<SKTHE\Q^/  '?OQP//YB =NW;C4&V4]LX&_KMGY;[]JNHP-AY#/S
M']_^/*I)%Y, !SP ?[=_U_'5 G +;;>9^F/AL._4;5<(,D>GW^N*J+F/9R;%
MW&R+1N^CY%JX8R#%V@FY:/63I$[=TT=-U2G2<-G*"BB*R*I#)JI*&34*8IA
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MC%UJ-JGMX_60W)R6/(*OS,Y;*MM8Q=7\'2#JNP\<XD9EJB_QLW=SLZ95@W<
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MCGDCTC4K6_T^"-1(ZZ9?VL2R:?Q#!*CO(CW%Q:W,4KKA9DDL6/-XC+)>ZK!
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MTDO8D"@1@D>1Q53K5P?M75SEHOIMX_QA#N#(GSYNYPWC24( B4B\0SA+]?R
MJ(=A32LE+K2WA$#?YA"& H^ 1+%%YW1!U=E4?_Q$#]ZIS2"**64](HWD/?9%
M+'\A69*] Q]5@(*KQ*)&\56X>,@(QNF4"IH1\.R0CF2"92@!2D2;-DDR%*
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MU[U5T"<B B/\NW <!P'IQW#@>WGQJR!W+$G'8';8#.,=#UVWZ[XZUE(UR!Y
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M:3FD>G;Z-,EWJ%Y+<&-=8%LVJ:;;HK:?/=VP1A=Q"X22YMI)+@SSNL,J(SS
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M1ZCH3Y;9STZ=3G<UCY$Y6[X/Z_UR<=-O+>J"X3X$0$.X<AZ\^7(!]/,/Y:K
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M?OSY?SXT.P/I]YZ]/3/PH=R.OO$9[;>78XQW/H=N:LOQ#<  GW?G\?Q[>?D
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MF&/GU'Q-5*QQ+M^?'V_3T]>>_H #Y^7Q]=0&Q]3MT]<]">H .3Z=NRL0V!H
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M>G:MLZQUMCC9$8I%C:+B^E9PR=_D8=!M9TZQ(+M1CJV9R"[D$$&K=DV,_-'
MP:R;[VKLS)$!323DXRXZU3BV6+QVDM+&*& '3(IF>T-W"K^+=!2J%F=I'\,2
MF1XH^5.<]3=:%H%GHT;"(+-.[R9NI$"S&)V7EA9@2.5.49Y @8Y;E!.*W;0+
MQX0'T#\.X_A\?EK11T'PZ^6V-O+?M_Q6TJ >W4]?@,C';MOZ?&JVB' "(?@(
M>8\C]//N'I]-6LK$*?7._0]?+;OW'EZUD(%R1\,[>O?/GC\^G2JNW((" >8!
MVY'Y>0?#N!?PYU;$8&#GKUQG.<  ;XZ#._3&!OO62B&^>WKTVWW^_/:J^U((
MB4/AW'UX\@_O^@:E).!OZ_F?K\:O8QN3@#I^GY8W'_-5]N0!,4/+U'GX!_0.
M^K9SC.,XSL/+/D,;;]L;=]Q60B&=^^,9\ST^>WUSD=:^<O7R33<3I>%-Z@41
M;J&[ <H^:"P@ _<.("8AAY]F<1,7[IE"FII*5;?=3U&>F<[@>GEMD>9%375@
M+N,<N%F0_P"F>@.=RC$#/*<^Z=^4[^8,:>^W$EXO6/JTZI$1=W]HIEO46E65
M#<1)[.:HS5=FHZ6]TK-BE8NM79!C8BTZQ.*W)&=NW;6".[KC9S.MH]LYP'%F
MEOK.G1P0S7T2>*RW3Z9+X-_+8S0L+BWMY1)&P665;8SHC+(\,;B,K)BM8O+&
M:=!;&ZN;!?$Q>FTC0WL]KR.7LX9'VC6>86_XC! EMTDC4JSI(EC[#,_V_($Y
M><+V4*BZ:8HK\$:%<P..YK$L[&M_M24@'<+:Z#-/ 5BI!)Y&*F0!M7:H1,B2
MBBL6=-\S5U:<.:I;32RZ/9S6\]OIMLJH;:SDLQ:>'*8!:S(V(C*"K-_HQH%Y
M'\1064M#3;G2OQ,FD:3=175OIL*1LD%G):I8,I\$64Q*QP-<<\<KF.WB00JH
M65<LC/)TBAQP(A_0OK^(_P!_/6U$YS@@ =3]< >GP_YSZICL,_DH&#]?( XW
M/K7L*ESWX#CXCS\ ].._Y!^>I,C&!DYZYQZ]!VQ\?E5?DZ'?(V[>9R>H'Q'F
M.@VK^F2'X /;CL/?U\@\A_3S]>_ $=QD''3T/8_K^M1,9/GZ;X\NHSVW\\X^
MO[9Q+B4=),V20G76-P \>$J9 [G56$.0*DF7DQS]^ #@H"82E-%I!&O,S K\
M<DGR'KGH/7XD0CMGGD6&-<NQZC8 =V;I@ ').,[=,X4YP80J$-'H,6WW@2+R
MJH( !EESCRHL;_[S=BEY'P$*1/D0*'%B9"[ECW&V^P&^!GN/7YG'?:HK1;:%
M85'\(R[8&6<GWG.YZG;&3@ +G:O.Y1 Q1[#Y<AQ]/(?]N1XXY^513T(]#V^\
M_I5%UZ^8_/\ Y_/Z5;+U+MXO(0'P_#GSXY^G\_EJN#T(VSCT/I\_+>L?*N,^
MG3KT_MW/I5!<E[@(!_J#GS]?^0$?C\?AJXC/3IUQL/09V^!QM\!6.E78^8Z=
MOO?'[&J"Z)WY\N?S^/Z#JY7&PSML/EG'[&L?*#CF(WR=OC@X[^G_ #5ON"]A
M^'/D/GZ_U#O^6JBX.WGC(QUV]!D8/?('PJRE'NY_4[['OVZ']JHZY>P@/H(_
MB \?_P A[AQJK%MD'UP//O\ /J?+X5CIQW_KL/VW\JHBY>_<..>0'T'N'P_,
M?A^NKM=U4C/;OVW\L^>X\AY;UC7&,_U.#C;R\R.OEVJ@K )5 $/,![#Z]N./
MU =5%&Q&-MQOMMG/?KM5H^0QP=]L';KC;/\ Q\JC)Z5296NRNIP[3[T)7,N;
MHJY6#AW3-6XC<WEUK$%1-Y"@@@7W9#@>"I(D('8H:M-'WL4'0+-<JI.WNB>3
M';?&X^0':LUQF =:D?\ G>TTUY1UQ(^GVY;/7<X#$]RQ/4U(&Y+R'KW#]?E^
M6LU&"1C<Y!/7TV[]C_P*TJ7&1MT/EUSD_/.W[9'6DK@/81^@#\N._E\_]M5Q
MUSY@8Z=OAZGR%8Z0=?('\\@#\LU2UPX ?@ B'?\ 0?KZ<^G.I^AS\_WJW;H>
MGS^^O_-414/]0?C_  $=7/0[^7_Z.!5DV<G(QZ53%@$#_(0[?F/\/GZ:K#HI
M\P/F<;_F?O%6LHZ_'/U_YK2KJ ;KX?9IM;R/F1RX:#;$V'[KXOAW!DQ/.Y)L
M:2[2M-DVR@#[VVB1(ZM$R@'!C0$#*^ P*^S*;%ZSJ*Z9837)(\3'AVZG^>=P
M0@ VR$WD8?[%/I6R<%\.R<3<066GA6-JKBYOY -H[.%@TN3V:4\L$?\ ^4D7
M.V2)%>@7L=G=D'3SQ_%Y&9/6N<<_RSW<3FA.7(H$Y&67($?&?8-6ES. ]\))
MUFFQ\ TGF;HQCM+<O9N!$5C&/Q1F+,68DLQ+,3N22<DD^9.YKVFJJBJB*%1%
M"JJC"JJC"J -@    .@J:O4*FII2FE*:4K@@QC9R[C.K7U4]T!7!9"(CLQM]
MNU*DR#[1N\@,6&+3'*K _?\ [FZ8XWJ,DD)/ "I9 BYR^-7M5C[[^AS]<^>V
M/VWSBI6^&?L#N".A/6IBJ@V#A$ #_I >?/T^GQ^7Q[CY3_8Q_P ^7?\ K1OY
M<^>?A@9WZ_E6T%9;APB'' =OY>O;Y]_R =0/\0SV&WQZ=?AV\O+%2KT8]SMC
MU/F.G7T^?7&?(%$ *3@/0/X?A\?/S]/4-2M_#WW.?D22,^F/SQ41_%UZ; =-
MAMMN>XZ'XUEJ(1#@H  #\_/L(>7;CG\/EWU3'\0^/3KD#&WR QM@;[U/6/Y)
MP+Z8D'//B*+@Z20]^!20X12$/AR0@&'S[B8>.>^M@@7DAC78'EYB=OXCN2=L
M$ACYC& -\5S_ %&;\1>3MG8R$*<_RH?#3'Q5<D>9V-:XY:VI4?-]OF;/=)*2
M493F![5@QU!M$FZ9&[6RW*K7EI<8^2/XUVEEK,]4XI[ F!%1!N^00?&Y4;)I
MFCS;]AOG/<]O+U)Z>>!VJBK<HP!W!],8(P<8/Y_M6N$OTO(*4I$/18S/%Z@(
M<<&PV![K[O5*E(*W:NUG)<EE:MR2BDFFX7K[]I:)-0LC]E./%*QB*30KA@8[
MA==S>F^0<Y/8>I^1\_SJ<2#)]WKGOCJ,>7;ML!Z>>8;=L/)9X+<K0V6:K/"8
MJW-6B8R)9Z(:I5B57KN2K%8:C8)ZSP%K4!I-FCWZU3(W3K3\5V+,C]51%QXF
MZ1!<V,'&^,=>HZ=OO88Q4HE&Q*^\!USO@'RP>XZ8V)(P35">=,W%LCD/,=Q=
MV15Q#9G6S-)2<4ZIM;<V^K3><ZK/5>Z/*CD54/M./8 6RR\C&1;J)>"W.Z.Q
M</G,8<[91G8#]2<=1C8G&,#TZ^E3"5L#S&-]NWR_?SVWQ5,-TU$GU0R)7[-G
M20NLUDN&PK 3-BMN*:,_3BHW!E9M=2J"E8B8Y6*&!FT(NP1KEO9F4F2QLYF"
M.[-*.V,W)Q9H X[;;]]]]^O?!'<8].F(^-TPN"/78]NF/CWSZ^<CE J842C4
MRD_;U@M(4ZK0%8_>:UOOM2SV+[!BFD7]N6*2]FC]H3<I[H#Z4>>Q2]Y?+++>
M OC\(0JD3DDX R<X'2H@.HQ=\%7MM6KW7;W(O+CAR??42RI4>.DX"W%KENL%
M1=S4E0,BRL=$U&5G:-*UJ&LHP3^R25+DZ^%E5D6BS]".4+S?B?5.$KV[L[75
M)FN7MYB4@:UOQ:B1)HV%TET+;\#/-:31*R1RW#Q@%Y(T\5$)T77=5X3FF@.L
M7%V8M-NWA;ECU*ULX9Y9/ >\6Y-O'IU[+8O$P9'N)XHHFN6\)YA&*W<V,9 R
MKD3%,_)Y)MD3DF&BKU(PF*\KL&2T=)9*QXWA8%XVFK.U&MT^.<6:"L+^?I$W
M,0=7@82:DZL\?1T>=N<LG);AHMU)=6\S&XCO($N&CM;R,#%Q"$1B25]QS$[-
M TB8#/$P*AE8MLVEW2WD4TL-[;ZE9K<O'9:A;%&BN[<)&P<21/)#,T3L]O)-
M"WAM+#(I5'1U&Z7EY:S%9.MJH)\,G#QKXP@*CAHB=40\O;E+X%^/E[8IPU@Y
M5Y)'7L&./AG(_+%= M)?'MH)2<EXU+'_ +P,/_\ G U5M4ZN*_)@Y#M_8>OG
M]/E]=*@0.I[>G7Z;]_A@G;RLNYVVK42MS]ON,]&5NL5>(>3U@FY9TDT8Q,,P
M147=R#Q50>2((II''D ,=0Y?9I%.H8I!NK*QO-1NK:RL;::ZN[N>.VMH(4+R
M33RL%2) .K,6'D #DD#)JSN[NUT^WN+R]GBM;6UA>YGGF?DBABC',[NQQA0
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MU]/Z_+CXB&K63)!SYYSV\O[#X^0-9&%>@QMG/7; Z[?7X]:N%D7[A?01-_
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M78CN/7SZ?'-:$]#O)8;-^J1N^Z>\RY3B,7;I8HVZ?;C&'-[-@G;HU)PO=:U
MH!P*:CFLI61L<BA3 6+PRU$IR^V3]XHL,'X[]_WS^M3UV2:EI7&]U?<'538[
MU;-@F[_!+=&FK[Z+W9<$;D:-!I@RA+S)J2M&C37QU%H"5!:7E O$3,3ADDTD
MG%GHT'8EDU9B5F7;[-</W4MKJUFT9($TJV\B]GCF8(01WY25<?\ <HK4./-,
MM]4X5U>.=%9K2TEO[:1NL-Q9QM,CHW\I95>)O..1U[U*0GY%^O\ /77U_B'Q
M']?S[5X_7J/B/UJLMP^Z/T+_  'O_?PU0?\ C8_]Q_4U=H-C]_/]?I570\S?
M0/XZD[CX']OO[-7*=/F?VJJ-?(/I_P#RU0?^ >>/_P!+^QK))_&?+W3W\LD^
MGGZ=]JK3?\NP>G]_7G^NK>KV/O\ +]ZH]VQ]1\IU60HN1ZI!W>FS"T.XF*O9
MH]"6@I52"F6%BB2R48[*HT?MVDS$QK\&CM)5JNJT(1RBLB*B1[26-)4Y)%5T
M;ERK#((#@[CON,UDK2XGM)4GMI7AF1'"21DJZ\\;(W*1N"58C(W&<@@@&HU]
MWF/;;LZS"'4AV\5E[,UY&%AZMOJPG5VJ0*92PO!%,A%9DJT0DFD@KE?";-0S
MHRIE$#3=";/8L[MBV9ORRN)O(GM)?\PMU++CP[R%0 )(1L)%4?SQ#;INH^NZ
MZ+=1:O9GA_49>64L\VCWDA):"Z8Y:W=R2?!N#L,]')QEBF)8L<W^F96HU1R5
MCNQ1UMHMY@8RSU2R1*HJQ\S!S#8CR/>MS'*FJ3VJ"A?:MW":+IJN51J[01<H
MJHDK-(DL<<D;!D<!E8=P0<? CN.QK$M;36L\MO<(T<T+LDD;=59=CZ$'.01D
M$8()!%>S)>3:=A?'%WRSD*16AZ-CJLRUNM<HWCG\JNP@8-H=]).DHR+;NY)\
MHBV2.<K5DV<.5A "))'.(!JE+(D,;R/[J(I)(4DX &=AECWQU)SCSK)6-O+=
MSPVT #2S.$120H+,V "3L!GN?EOBLB5ZQPLU$Q<RQ?HF83$(QL3$ZX^ZK'AG
M[5)VV?JMG/LG#9$R"Z8J"NFF*)Q%-4"*%,4(<RX!R!E0PR0#@C(/P_3I5T(I
M%+H5/,DC1MR@L.=3@@$9!.>F.HP15V-)6+757;(R+!5PU;(O'*";QN=9NS<%
M,H@[72*H*B398@"=)=0I4E"@)B&$ $=6;D$XR,C)(!&P.-\>77&.V_2LE$C@
M+E' .5!*MNV>@)&Y].M5UK.P@1S25&8BRQ;I1--M)#(,RL'*BZHI(D0>"M[L
ML=57_*2*FH8RB@> H";MJB64J3S#!S@Y !W)QY'/YC>LC$CYY>1N8+NO*<CI
MU&,BKO1DXT':S#W]D#YJV3?.67O2'OC=D83%*[7;>T]LDV,8IBE<'3*D8P&
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M\?(![_#UU,>V/]_P[DXZ]CT\\5#^4_\ M4[=>F.OWL2*UFN(!XEO_MY\_CR
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M248:",'?=5"$9WV*X[DG?(R2>IJEXKZM>3< 96K>V;J[[?R[,LK6MV>,QWN
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MN,$]\@'T'8_GT\_I7)TZ? D?O^]55J;CC^7J >@_+M^(_CJE+_*?3!/KL?\
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MVBO<_ RQP:K9UZ<^,K[6?;&* 27^'^2("D/D&HFX$ZI"Q4JX.DGXA!-@Y5,
M 3D-=U12MVVV R(P^&"#D=MP?EBM_P"&Y!)IB$'/)-*AZ;$$,!M_VLI^==)F
ML=6>J*7;]N6WIVG?[F_;_F/$L16\(U^(M-FH%A2A1B7Y*S'2U<CJ7,M;"E99
M^'MB=DCI1)>?CH]5V]B;#(NT#J0B4$_@&W6.).'_ &>6G 6@ZOH>OO=<4W/X
M,:EIS7(F):5;H7P:S:UMI[2.UN86BMYW18Y88XR1,UU%</R[A_7>/;KCC6]*
MUG0DMN&;?\4=.U%(/"7EB-M^$_\ ,BXN(KF2Y@F62>%'+Q2M(!X:V\D2<F76
M_P AYSW8]2S+F)7#6?1QYMAA#14%%&:O3P-"Q_$5&(NN2,L3;?QILT232KA>
M55F!%!S-0K*G5QFH]>(Q+=;;>!K>PTCAFUO08S=:FY+ME?%GN'E:&VLXS_$>
M3  09"LTLIP"Q&F<=2:EK7%$^G8E2QTR-3GE806\"PI/<WLA_A)*LP#X!(58
MTR>M9VW9FN/5?W>XPJ6X' ULSQM<VE8;MS^I8,Q:O6("VU/'-:B*C6XI[-W6
M4L^/Y:^3$S*0E*-<8UQ<2.)]4)4*-5T%CI0JE#5K->#]&FETJX$6L:SJ%M!+
M<R,G)+//)*\ACCG=;:WBA#RF-F $:\IED(RU7.D:A_XTUM(]5LQ+HNBV%S/;
MVZ+(72*)85B\9X@\UQ)-X:EHUYN9LB-"=JZYNG;ONQ!N[@KI1<48EG\-1>"V
M]9K\14Y!"MM()"FKMWD76V5?903L@QJL(E JL96!3B4XV!;JPB364?F>F2:Z
M?[1O9OJO ;Z9<ZCJEGJPUI9Y#/;?B/%2ZB\-Y_&,L?(T<GCJT$XF+SE9R88Q
M'E]T]G_M#TOCA=2M[#3;O3&TAXHS!<> (VMY.=(3$(W#JZ&)A-"80D :$>(Y
MDPLE&N8UT>N>#]ILF&[CIUU+$R0^TL.?]W&W'%-6:$[KN)9>T/;>(ID !,8"
MMJFLD80#LHNB7GDX -2%2\T2#J\B*/BS #]:H74HAMKB9B L4$LI)Z 1QLY)
M] !O6P"Q@$Y^/]("( '//GR/?M\!+SW#N'GZ#V=1R@#KR@(/7SSU[XSV\L]*
M\:W#Y)8C',SN1Y DD#Y$MU W]*I:@\_'N//X?#^&JO3[Z?"K$G)^&WQ]?F=Z
MH[HX !S"( 4H&.<P\ !2@'<QC"/!2E#GD>> \Q]1U5CV#'Y?3!._T].N>U6\
MF22H!).P"@DGIMMGX8^.VYJ 3?QD>F[E=_72[VW[<;'&Y,W!T#>!3LAV!"BO
MDIPF-JG!3]4G+&YLDQ&G781J[2,K3NS2\:#E20BH>J.'DPT9INHKW_0^,+RT
MF6UMHI%EN(9)'DY"&6)64+R,P]WG9@"5!)4+[P&17>/9!HNK6)U34+RVEM;*
M[@MXK<3H8WN)(Y'<RI&P#^&B,5$A 5R^$+<K8[QM:-7;Z:4II2FE*:4II2OX
M( (" @ @(" @(<@(#V$! >P@(>8:4KACZD^QG)/1TW!6_>IMOJ4C=>G;G"VH
MR>>\2UIK[61VXW2??> ]CK<>4Z#1E2W\@Z%.L.Q4;PS$SP,=3WV4D%%G G1R
MI]#U'PZ'X@X_O4" 1^GWY>=;L8.R;3LI4RM7^@6&/M%/M,<C*04Y&J*&:O6B
MHF3-R14B3EJZ;+IJM7\>]0;OXUZBX8OVS=XW703JYSOGR^@J Z$>I!Z=]QU\
M\XZ=:W4J+\#$3)R'( 'E\/T]>_GZ?/L/WW^_O&*E.V#OGH1L-P.IQMTZ#?KW
M&U;#5Q[R5/[P=N ^/;MP'I\_/\-0[ GN #Y;^?Z#XT8=<#&-_KG)^1QGI],5
MF6'=\@3O\!^H]OAS_P <^0:IL.W3J?/KU[9./7.1OZ5.#D??Y?>W3J*R3&N.
M?#W#R[]^>W/U[\?/@/R#4.H]5S\Q^X'F-@/.HUD".=<@0!'D0\NX#V]?QY[A
M\?AYZ*<??H?[?#]92,_ C\\C'[Y^\?N5J$3/"9QP+&0,'(NVY0$JIA[ +E#D
MI%^_F<HI*CV 51*' 74=P\:]>91N5/;I_"0"5&-P#D;Y(SO6)N]-M[HEL>#*
M>LB >\>G^HFP?U(*N<#+$#%6*]HEB8B)D6Q9%$ Y]JR4 QA+W[&;J>S<>(0X
M$2I)JE#G@%!'5XES$VQ)0^3;?/(R,9'<C'<"L#-I-Y%G"+,O^Z$Y)].0X?/H
MH8=@QJB*,WC<PE<LW3<X" >%=NJD(?'D%" /Z>0\ZN.96R596^!!_3N._?/G
MN:Q[PRH<21.A!'\:,N>A. P'K\,['K7[22<*& B:*JHB(<%2344-VY\BE*(\
M#W[!]/CID#J0.VYQ^M0"N=@K$^0!8_3&?OY5=4?3;-)&+[&*713,/=9Z'N:9
M2CY&$''@5.'/<0224-P(<%'@=47N(4_B<$XZ*>8^FXR!\R-JO8=-O9B.6W=0
M?YY!X:@>?OX)'_M#5DZ&QO'1I1?3[I-X9 AEE$@,*,:B1,HG,==13P*+)I@4
M3F,I[!$"@/M4S% =6<EV[^Y$I7F. <9<D[  #."=L8R<]#6<M-$BC(>Z82L,
M'PUR(@?^XG#/\PJ]05-:IVGJ!X[>SDO0=K^/;[N_OE>76CIMOAA"%98GICYL
M'!VMZSS;Y&!Q37Q0 BA%V,1.66=:'2,1>#3 !$NVVW >H)!#?\2ZA8<)V-P!
M)"VL-,^J7B-N&LM#M(Y]4GSD8>6"V@;((F/2KMM2AR8;*&2]DC]TK;!%MXR!
MLKW,A2!,="J,[C&"E:&W_J59[82\O$_XN[(*+-QH*+N\;8JINY7?1D"ME3Y%
M2/ND]AQG0Z)7W[4H&"0%R<C%N8@</Q!0I=;S8>SK0I(HI?\ *>-+Z&3"KJ&J
M7?#O!-A<$X_U+.#5WOKZX1B?],*"[9WCV)K&RZM=!F43Z=&P/_1@CO-3E0>4
MAMQ%&C#OG"]LTV3=:JJ9FS0A@;.4C0&+JS+GBL<9FJ%;OV.:18+BDZ!H3'%I
MK&2%YA6L7"6*51U7W$==;!#RRH$AU/LN9<,F3MQE['+K1]&.N:(E_(MNHEU'
M1[NXL=0O;>T*ESJ%M<Z<L(N;2+99UDLX)8AF8&6%7=8:=Q#'<7 M;EH@7RL5
MQ&DT,3R@X,+I/S<DC;E"LKJ^.48; :>XRG'?TY$/KQZ!]?C_  UPNMC9AN/3
MY_,9!_;IDX->%57SY'@?Z]_S'Y?II4O7?&PV&>W_ +CY#K@GT&U4E=7S[_#R
M_E\O]Q#GC551C'0YQ\L]=]SW'D-QYU!COZ@GY],9'3^N,$5HEO=V6T[>O7</
MP]FRCE_#TU@K-E<S[CF]X4EZ?#7"'R!5:]::["N1<W:E7R(.Q;-[8^> B6'3
M<&?-F)P= @FX;N!7IN=NAZY/PVW[Y'J3YT#8SL#GSK6NR],S'5M?*V')V?-R
M&6;P\VB9UV8S%^OEBQLYM4[C'/EM=6VPSTHM!XN@XL]XK(JMX"G2#6+;03.!
MCV2,S79Q^1>07IG[_;\O4[8WJH/D ?UV&WIZ'!S6",@](#;Q8)+"<_!7W)M,
MLN%]O6,]KXS:4#@/(/\ B%BK$[4C6I!<H/,>$\CUAG<6I?>?:7*E0=2DC(/W
M;$I2, :-VK&!D]^GRZ[=?OU%357&/3WQO2[SN(F:GE;-<%B7=&\RE/Y@VULY
MNE&PS*W;,=5-4;[=(,CBB+W^LRTJR$LF#*'O3>%1FTD' 1IHYNWBT8KG(]3C
MXC;/P_I@YWH3C<U=>"<+,-LN#:%@F'OU[R- XT@T*M6+'D=Q775I1JL6 M:U
M7W+FK5VK1*S*LPB3*"BE"Q";P\?'MS/W+QX*SE6IC [[#K\NP.VPZ?''G4@W
MZ@#F/0#RWW_0[;_"O%;'WA3.7Q=Q].?SX[=_7Y\^7.H@;'UW.1Y_I][U#.26
MVP <'UZ#._7SSV\MC6K=SD *17DW?[WKP/  //TY[<<^O/SU&IL8 &-L8\]S
M]-NISMT^%:L6%S[=X(<\^$1$?7OW#Z]^_P!?AJLHP/@!\B<DY_+^V:I$Y)^)
M^_*M <[1:UUWV])/&T8(*2T]O9H5B,F0!,HVB:C<<?.Y-\H!0,)4$&3MVX.(
MA_H:+& !\!N*4YV4>I/W^WGOY5/'W^7[UT>_M(NUEUN(Z9V0L@5-!T7*FTBQ
MP&YC'\C&@))-JUI:JC#(223E,AW";9O0):>M'L4>/;3%5A%#\"V(<ENK,C*R
MDJRD,I'4,#D$>H(R*F=$D1XY%#I(K(Z,,JR,"K*P[A@2".X-8!VBYU8[E]MF
M%LYL10!3(]!A9F9;M3 +=A;&Z1HJYQ*7 C_EP]L83487G@1!D B "(@'<=.N
MA?V%M=+C,T*,^#_#*!RR#(Z<L@(KQ-Q#I3Z'KVIZ4P(6TNY$A+ Y>V<^);O\
M'@>-SZY&=JV93-QX1_OZ_F'.J^V<;8./,C<>0ZD9QO\ .L6IP1]._P"U5I W
M;MZ<#\^_Q^7;R^'UXU;D$$@]1\ZO5.1\ /O^@\OCBJFB?T'R$ 'O\_S_ "^>
MI3ZXW&#VV_MD]/,?&JZ-C&.H/7U'3\A\-O6JF@< $.?D _$/ASQ\A_/Y:HNN
M0?,#';L-NYZC Q\:OXVZ8VR,C'F/UZ=3W![U6$#\"'GY\#^?;^FK?\M\??[_
M +YJ^C;IY']?^=JJJ1_+Y?P_/S#^FJ++C/3!SCT\]OR']2*NT/;RW'W\?UJ)
MCKK6-_$],7.\5&KF;.[M.8>H_O!!, D:3F7Z0:1((E$/\MS'-'+14IA\)DG!
MRFY\7A'!:X2NFSX.Y,:G/4JTBCYXZ;]/3;.\<"*LO$5F6_\ 3CNI .Q=8' Z
M^08L,;]O.NH6MT8*5AR!QI0#MJ\%3QG%T:E*E3(5I!A!59" KB@)%;KIE;QO
MNK,P)E:K$!-'P@W4+_EFTBU>&.YMY+F,RVZ3PO/$-C+"LBM+&#S+NZ!E'O+N
M?XAUKNMRLSV\Z6[B*=X95AD/2.9D81N=FV1RK'W6V'0]*TBZ=V*]].+V66VF
M\[)C'(996S$>8_4^URV&1;I'D[ YFY!&1;*,VL3"3"SQL]C:R:&(K$LU&3-!
MQ'M&1(&.Z9[3-8]GVK2:*_ VE2:9X-IR:D/!-M&S"*V2")HW5WGG@5&CEN_'
M(F<2.RRO(;B3G7LZTKCO2X]73C74X]1,UWSZ>1-^)=$,D[S.LBE$BAE9PT=L
M80T:<B!D5!"F7M]-9Q6]P;)W_+\1-R-)Q(]0NML<5NTP53E6^/B_^&Y*9N5[
M,HW@K!696EO)1M:*:\=LW]AC"&+4';:_LZBY1X;Q!P3P_P =QZ3I?$&AVVOI
MIO$&C\1:1:7"2/\ A^(-$NA=:3?P"-T;QK>;F!5B89H)9[:YCEMIYHGZ<NH/
MIB7%R+G\+'^&GBN92P5?PTB$3*Y.W*5WSU5@K*0RJ1Q$90VJUWJ2;JMU^=-H
MUGEY#9?MMHL%:;;:[U(.VEXA:34<;RL@UI=%ILN*UK?EGE*!:X?&BS^&8,V$
M0U8.KR\)8@DE)CO? ?#O#7L9X4L^%M%T"QT&XU_B#6]:;3]-0+93ZWQ%JIN]
M1U"YF#&./,MW%XD,;%(8HXK6RBCM8HDBX-KT<WM#XAO]:BOFNM)T>PM()99>
M=+A;:RMY'6"V@8<[>,R3F*1E52SLSDN&#9'Z"6'\X;HNHY4=RS]29+CS;A 2
MB]ELACODX&*9.<>3.-<98<JZJAE44&;"+DFQ(VMHJ VC:36'I513.HR*\V/C
MZ[L-)X;DTM!&;G49$\./"F1F6X2XN;V7&#S,ZG,A&6FDP-@W+:^S^WU36N)5
MUF5I5M-/B=2V66%5:)H+>QA&2.2-2#R#8)'EO>8&NO>O[^*W8,US6.6%<JLU
M08R^4S'S;)E-RK%W-RZD\BJ1\72)ES5XBN?9#6NS-M?#45U&M\D[#$2C=5Q)
MUMO&I.G;7P=J'MZX7TGVSZ![%K_3=635>*M.O;OA[B*V?2K[A^]OM+M[JZU3
M1;DVFHRZEIFI64-I*)(KVPB!<PYY8KB":3TNFCW$FE3ZJDD1CMI$2>!O$2=$
MD9%CF4,@1XW9\95ST/4A@L@@@ @(" " AP(#W 0'S 0]0'7<JQ%<O/0R9)X]
MH'4!P+'']G7<!=3W=7CNFMN1 D?4&BM,5BXU$@")2$0>_:K@2DX#VCPX\>8Z
MSVE9:%P =I#\-U4_7Y[[;>>D\3>Y>0$9!>WW.>I5V'4D8VQCY^=3B^\G'C_-
MX_\ W#R'GW[<?H/U\^V4Y&'8_J?RS^=:X92,[Y^G_(^F/+MGX&7+SR8PB/J
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M:,? \L@ \Y#VK@?MEX>/_D^)+=-@%T_4.4=/XVM)V(['+V[L=AB!1N:G#3,
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M&H\OV@D6Q]M&W$9HH*T[_MGXH"WM5.1;N88:EDGWA-R'^@R)FX.2F Y1*(F
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M:J#I].G3Y=<"K*?ON/%][^7EW /D'S#GO\0\ICY _$^>-\#/T[9J-8^EI
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MI^H7(DU*\N,?YUQ3=AN6.XU1HAB.U1@%T[1K95L[.((/#>959,U9:<L CEN
MAEB3EACCWMK) "2D ..9\$^-<OF24Y.54XKW7S?%.9,2L<!LU:5&QPE9!\CD
M7=WE)VI!;5,2H1WC^V%F$\9S'/,SVB-1* IQ%(=$IS)PZ9K6*\,FZ3YF6%CP
M7!IAMIN,'N[>>Z"-IW".EJ)^*=6,G_162W"R+HUM*6PTU\OXQU1Q;V3.8WJ+
MW[3<RV 1UCSXM_-D64'+U(?*FY=?]L1\,''B2J 17EH[6(W3X7B;YB'(KFQY
MQQHT>8PH^]G(>W^"2GK'%R:U?>Y,N^"H:43JE8.TFV82=9JEF1:GK36<C7'M
MD[#!G<R4W/?2S<+ZS-8:OIRV^BZDRZG>\&:?K\S6]O+$+A--L=;FB-U<AX6,
M=S=VK/\ B&@D7E,$_+'"C5;R!98)N>>+,,6H26J<[AN0S2VRGD4JX!2-Q_I\
MZY(=<\^"MOFQ!SD5%E)YRHTKCS!C:SGO37!%UG&-SS5N#O@JIJER]O<R(T6?
M(VF4=.6Z$O$X5@9)6EP2B48WL OBQ2=?;9OB#CL:<7BT._BU#6WMELI-<LH9
M+/1=!L>5A_E/!>G/X;6T2*S13:S/&M[.&D>WY#*9VM+;3!*5>YA$5NCF5+:3
MDDN;B5L<TU_. W,S<H(MT;PEPHD+<H19E <I))D22*1-)(I4TDTR@1--,A0*
M0A"E "D(4H 4I2=BE#P@'  &N.'))+'F)R=R223G);S)).20<YWWR3G]A^G0
M#'R_3IZ=*\*S\._?CY?'G\N.!Y\_H(_&&0!M^_GZ;#?X8\M@*B%8_ID_#MY[
M=,?*J&ZD0 !X-]0 >_;CUY'C_80[\\:D+9^N?(]ML[_H-P#UJ<+CRSN/U[8W
MV]?/R%6R[D!'G[WTX'U ?GY=_41Y$ X\M0&6)QOC\MMMSZ=*FP/Z^OQ_ITSO
M5I/I#@#?>^/(CY>GEZ_'T'MSZZCD#8'<[%O+X?UQ\*>GWC]/E5C2<D'!OO<_
MP#Y?Q_#Z]H 9Z9)_3]/OS)V;#O\ 4_?G6-9J5  -R;L'/K\![^OX?$?IJJ !
ML,'IGI_S\,]//H#)N2">F=@.^?RV'7?';KFL-3\P  <QC=@ >._/8.1_E^OQ
M\W7X#ICOC]A\P=M]B*,2/=SDG.?3/8>6?C^M:_6B; PJ#XP\(<\ /ISS\/3L
M'Q^'/EJ;]_O[^M148V\NOJW8=]A^O:M)\\9PQQB"M/KAD^[P%(K;7Q$&3GI!
M-H#A;CQ TC6H>-]*R"I>Z,;%M7D@N'/L6R@AW9 &YQWWW/K^OUQC WHQ)( \
M_ED?K@X],^?:-'&UNWQ]4&UO,=]-K#<S XW^T586Y;R,OL%ZOCBI-@/[-VXK
M0NVKT'<J5,2J-X]C'VB["@Z(J-)A!0-+M)6E/1=O4]<#H!Y ;[]3Z&@3IGZ?
MU\_TKJ^Z6W1YP!TSZY+V6.D9#-.Z/(;0_P#B[N4O"'M+78%7RS=_*5^I-G#A
M^K4J8O+-R2#AC]H24[/O4V[VT3TP=E$H1='YU/4N^E*:4K"^XS!E,W-8&R_M
M\R&W%Q3,QX]M./I_P%*9PT:62)<QZ<JQ\79.2AG2K>6BUNPMY%DU7*(&3 =*
M5QO=(O(5WQBPS9TW,]B6.S]L>OMCJ:;%43B%BQ2[G55(6?B%E>%)&(CY21,5
M@\ I$0J%BH!D?$5U]SI_!^I"XLVL)&_UK/)CR=VMG;(Q_P#NW9E/8*R>9KS3
M[7N'6L=7BUZWC_\ *ZJ%CN2![L>H0I@\VV +B!5=<DEI(YCY5-8F;D #GD!#
MD!^?\/\ ?6V,,'X=,>0_IZ=L=AD\D4Y .=^_GFJDW5XX#GR'Y_R^/Z^78/.E
M(N1S# \P#OU.^/3],>1JYC?SP/,>GPW]/IU JJIG[ //8>_GY?I^7&J/PJX!
MP0>O[C^XJH)'Y]>! >0]0#M^? ASSWXXY\N.=2$8[GS7/;T^'[9Z8R;F.3E.
M>H[]LC]B/3T['%5)%;T$>WD/_M_OT^7Z4G7.=L8/3RSC.P[>1]!\[R-QD8Z=
MO4>6_KMGTZ9&*J:2O''?Z?/_ ']._G]=4,'\L_?Y_0CKM5XK8^'<??\ P1\C
M41/5>V&*;DZ7";@,5MZP&?<"-QGVM<N9%C4/-E!@W)IZ6Q5> ;.F+IF+H$G@
MUV>8OXITW6?2$,\E(YG*(3E=MW75UDY]!N7MM1G"6X5!#_YE2_N0EIE94;G(
M*ME1G9B!N-QT+7+&*&/2.(E>]X<2YFOX[:26X:#3[Z6***:_CMHI%5FFA@AB
MNL(TCQPQ$<QB"-DW9SNBIBV':G.[!NG=AS:IE&=KK:+S!E7(18"?C:79DT_!
M.5FF/ZW)262<HM .!7\2XL4[68=J)T6\Y'KN"K%'SG_B1_Q)>RS_  Q"WL?;
MKQ)Q+Q'QY>:?%JNC^R3@N%KG5[BTG:1+:^UOB.]2+A30-.>5"LK07.IZLT3%
M[/3YV1U7KOL_T36_:1XY]D6@:-IV@P7+65]QUKZ_AM/CE0 RPZ=H\)&N:G<(
MK97\4EA:!UQ)(5()U(ZADSF:A4F_6JX9OR/F&\YAVWYQQW9)>SO6[&$911K!
MA^;FHNE4B#0:5REP2U>:V11W'Q;<QW")5E'[QT)2B37/\"?^+G5/\6<OMMMM
M3X&X3]G_  _[.]:]E6J\&</\/)=7E_'9Z[+Q[87\_$?$FI2O>\0ZH9[+1H_Q
M2VNFV<:D+:Z? TDK2V'MM]FDOLKON$+G_P 3:YQ3JW%&@\;6&LW^IRQ6]JLU
MC%H5Y#'I.CVB)::;:"%[T^$CS3-REIIY=@L5_3PW*7RLW*MSR3HI[!MM4J5\
MK-B)XD91S0&5M@:A*T2:6*?P3$>D6TQT9!JN$BOV-7=S-:=/GL$TJT;7O9W'
M6BVL<8OHEY&OY7@N8P 4>9HI)4N%'5')B(DY3RLY23E#F1G]<_X!_:CKW'UE
MQA_AAXOG&L<&ZQP5KU]PN+H&6YT'4HI;>5[:UFSE;%FN9-5@B?F6SU.SCFM3
M$;BX$O\ I4E]@];IJ&3(LBND"A2JD*<!371$H@)3 (??15.F</(Q#G(/)3"
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M-J='M+&S:U6:*TU?4@;W4KY5:"&V@MXYYHIX);=YH9O,O[0-N>CS5U65V?\
M3CI+LI6;R6I2,CGO.S-@;@BA8ET]DK1C0ZOL.4RNVKZL238W^:S>I+@11/GD
M/#U[(?\ 6:* =\N)'[?RID'YN,G'8YKR'?>T/18^=[<7-]*Q9LI'X$;,22<O
M+AAD[[1-@'S&*O[:MTRL%[<KZ_SU<IZ^;H-U<\J=W/[E]PLXK><@E=K-_=E_
MW12?G784UK[ RK5LLR]]L:,:NK$K65U&"5J78;'2+2SPV#+,.LDF/=.,>XO\
M*C?J,MN,MC KGNL<7:GK :(LMI:'_P##P$CG&?\ UI"2TOP]U,C^ 9R9*"N
M^/EQQ_8\?S_#64\,=03OZ=/[_3ITS6MB0X&Q^.,].QQG\_KFHI<Z=(+:5N(W
MDQ^[K(]<=/GCG'DG6[M0XB3FZI'W&^-E8=E2LI+V&HS$#9(VRURL)2\(\-'R
M* RBK6G215FCF"D?MW%3:-!/=?B7[H0Z*2O,^W+)S+@A@,@^?N^5;19<7:A8
MZ4=.B(YDE5H)W4/X<!YC) 4D5E9&<J5S_""Z[@KRWF/2QVTG)]GNKUN\>U;_
M $?N.\WI[G%:E[O_ /I!8!DXCT6O@X3%(TB;E,.!,(B(C/\ Y1!C'B7'+G/*
M;JX*_#'..GQS5,<6:B?>$&FB3&/&&FV@DSOE@3$5R>^V,]AO6P&"]E&TC;3(
M+SF$\!X]I-H<E4(ZNY(I2Q9"=IK  +IN\A6MS/7=TDOP KI.)]1-8WWE"F-W
MU7ATZVM_>BB17V]_',YQYNW,W3]!6/O->U2_4I=7<TD>Y$()CA&,=(DY4VZ#
M(SZUM&9P(\\!^??\>_E^6KOE4'!R3U^7[Y^9_6L07WP3ZD9Z;9\L?0_ 5B7,
MF',7Y^I:V/,P55M<Z:M*Q,XI".9"9C"?:T$[*^AWR;R!D8J21<1[PA7"!D7B
M8 H4HG*8  -23P0W,8BF3G3(;E)8'*'*XP5;(V/<?D:N;+4KO3;@7-E,89@C
MQ\X6-O<D'*R\LB.I#C8AE;T.:PJWV4;5F$%(5IMB5@>&E,963#<@U>V:[R2K
MO&5PMG[\6.I+/I"SNY 6,G:O_%SNBN@DFZ@ U:/6[$H-@MUTZT"<G@+RF)H3
MS-(<Q._.R#+YP7]XDD'Y;5<OQ+K!D$OXUO$6XBNU*16Z@7,,1@CEPL07*Q$K
MC!4[E@6WKX/]ENUI_DIGE]SAZ!_Q$CYZG6II8$92SM02M- 09M:C9_L9K.HP
M"EDB63%K'_;RL6>6?QJ0QTH\>L55FZE3_+;-I?&:%3+S(^<MLT>.1N4,$##
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M8@X_<'H:'>MG-EF^+"^]/%C')^'YTQS-Q;L+I2)<R+:X8^L1T?:K0-ECDU%
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M^?\ 7YU0'4L  /WQ\_GY\^G?S\O7T[]O, 3Y]< XW_L<>O3.XIG'Z_2K6?3
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M(+HJ-A?6RD!FQLIEMO#*YW=HI3GK4V"2G(!Z"'8>.../[]..W8?+C6X,,Y8
M==QV/7'KD=O3;TKD*-G [$#']_C]?K7M34XX'T_@/K\_[Y#5(XP0<X./F/AG
M'KZ';X5E;'GC.?U^_E]/\YCJ1[AK)GS?CG*]745K%!TW*4]CRI5>2=OF\<SQ
MWC:S/X"(KB(,G*#F+;RZ+!W*3!HQ=JX4FIV8DDE4WCDRH<:UFZ>[U*[D<DJD
MTD,0).$BB=D4 '&,X+$8'O,QQDU[(X/TR#2>'-*MX456DLX+JX< <TMS=1)-
M*[D?Q$%@BDDX1$4'"BI>-^> -J=KZ05.WB8ZVM[9\:Y8>;@Z=78*<V+94R#F
M"H8QQ39J(TFS4C=](W.;E$:SED9>4:Q/N8HGE26 D,V(\CDWDO&/,76S5B_H
MN;X\JX"V][^:E C&V1EB#!<QN;QI VU.1?5J'MD ^CJS9&2[>.DHI^,3:!F:
MPZ?,&4DQ$'$&LZ:K-W+Y\JXVC0=1GM;;4E0AQ!;FZB20$H'#*C@@$'E<,N0"
M-UR#G.>:<<\/66J:EPY-,&C-YJ"Z7=20E5E>"2*6:+#,KKSQ-'(%9D;"N1V7
M$^==Z@.>,$W7&,#O,@\2V&CYNVUY.W$8_O>WR"N,',0G^#./6F4LA4FWTF]7
M"S$?+ITUT*U>L$18F#=]*$1C7$>0'*SIAL/^97%M)$FH+"\=Q:R7,4MLKJRB
M%/%D1TD=LGE/NE6 ) &,YQSYN&]-U*WO)-!EO(;C3M4MM-NK?4I(9(W_ !<Y
MM8)XIX(HR 91[Z/&Q"EMSMG9>@]2W %_<PJ$97<S0J-HQ#D[.]2>V_'#BK-K
M9BS%,?#R4Y;J^G+2B#][%3;>:;_N@\,Q2:6 S9ZJBX1:)H.7%9-4MG*CEG4/
M#)<1EXN4/#%@M(.9@2#GW,@!AW&,58S<*ZE;J[&:Q=H;RUT^=8;GQ##=W3%4
M@DY$95>/ \9>8E.8 @G:K-M?5YVKU*K1=R+#9OME>4P;3-PMP?TG&"UB;XIQ
MWDA,/\/5,H.49A%G6YJYN3%:1$6U=2H(&.60F7$3"&"5&D^LVBJ'Y9G7P$N7
M*1%O"CDSX9DWPK.>@!. 020N]7L'!VL2R/"SV,4@O9M/A$MT(S=SVXS<?AQR
M%G2)069B%S@JBLP"GY]0K?+=]K[G:DC1K9AC'-<S]9[O'6O)>>*G=;=6Z/#5
MJ@)W&)=C#4.YU*4,XE'QTH5QX7<A[-5ZW.@B/LC^UEU&]>V_">$\,27+/S23
MHSJBI%XBGE1E.6/NG<]<]JK<-Z'#J9U<7,5W<RZ:L CMK&:&)YI))WAD'B31
M2+[@7G7/+D!LYR,690.K_CFM;>\#9"W.U.?J>5\J8MG\S62DXM@7$[%UG#T/
M>)FH1.:UD+1.14PRH=S91S6R5ZOI.+)D!1B[=MVL!+EBG+X]NFK1+;P27<;+
M++&TK)$I8+%SE%EPS!@C@!E YG()P#C:[FX/N9=0OX-+F22TM+B.U2:ZD".]
MVT,<KVA\-"IEA+E))"J1# /,.;%5FF]3^LU6R;MI?,,\WG:!2=R.,\,[;XK'
MD"U7M.04LB8?@<CQ4:Q6DI:*AGSIVV<S4^:?L4O6H*-@F1SR$BV$J +RIJ2H
MUX9FS''<1PVRQKEI/$BYP-S@[ MD\H50<G<"JD_#$LL6CQV<8CN9["YNM3>X
MD81PFWN%@9L*K,OO,(Q'&CLSD8&-QD>W]7C:I2L28[SI*MLH.,77YU8(YY9&
M-6@@''TO4;3^YUL@KQ%25NCIE6>KLV58)"'H;"\R*T8C]O1C>0@W+&2=5'U:
MU2&*;$ACD+ MX8'A\K<C*XYP>8-GF5 PQOTZVT/">JS7-S9AK5;B 1E4,KD7
M"S1B6-XF6(J$=#LTIC'."AP5.,N&ZBNW@N3\TXX!:Y'C=NU/7NF:<KDKS;_"
MN@QR%/;7KW23E#RY+6\?.:X\:.&"\-3I.%D'SA.'93"\P"C$E8ZA;F2:,\Q$
M"EYI0#X2#DYSDYYC[K;84@D\H)-6QX>U+\-9W#"(/?3"&TM3(?Q,K-*83@!3
M& '!Y@TH*H"Y 6J[M7WX81W>/KI#8U2N,%9:+&U*PS%7OT+'PDTO4+XV?N:?
M;XT(B<L,:YAIH(J2;G:+23:R03UF=C:8""=KLT7,UK?0WA=8E8,@1F60<I*/
MDJP YA@D'8D,#_$!M5+5M%O=&6&2Y,,D=PTD:R0,702Q8,D3<Z(0R\P((!1P
M<HQP<;AB\[]N/IQ_/OJ] ;OCUW)[^1Z?7RK!^*>V?KC]SFOD9T8?4>/Y_+R_
MAJ/(<;DY[]!GR]?/H=^U2F0[]!^WW\*\QEA^/E^(]O[]0#Y^NI@OD"<C)QMU
MZ'.W[].N,XI%QW.<?.O@97C^H]Q'^_GR&I^3Y#R&>F_<_'?;!J0N>VWY_8^^
M^*\AU_/CU]?[\_EP'EY:G QT^?Y#/Z=*HE_F?R^\^7UKQ**^O/'G]?H']?UU
M$*3T^_[519^N^3Y>7V?G7A57].> $>WJ(C_/Z^0?KJNL>,>?3_N/3/IZ[XVW
M\R;9Y,_+OV&.I&?EWWVWZ"K-M]VJ-$AG-CO-JK=-KS/_ .;G;7.1E=AFO("(
M>\RDPZ:,4C" ")046+SP/ =AYB[QQ+S2.D:@G=W"*IQG)9C@G&,=LU3BAN;M
MQ#:037$AR?#@C>61NN_*@)QCS]?,YT9M?51Z>%0571F-W>&W"C<3E5+6[ K=
M.#)B)3%*:FLY\JI@$!#PI"H81_T@81[V)UK28\\U_;YZ$AB^<;?^F'^^N]9N
M+@KBRX ,>AWJ@X.952#8]L3O&V//8D_# K5+)'7FV#5M'W'%]CR/N$N;Q3W.
M$IN+L8W%H\E)17DK-H#^^Q5/:BBNL)$SK119IV4IA,WCGB@ B>RGXHTJ)6\.
M22X<#98XG4$]ASRA% [DC.!V)VK,V/LMXINI%%S%;:=$2.:6XN8I6"]RL5JT
MSD^2N8\D89E!S6TW2%Z;N;L^[B)CJS=2C'[^L9.<+$8[.]M]O;*%)@VCMQ6<
M1-WF:\_(FYCK&@G(.4:?&S;".F&4LXL60YB);S\Q6EX7GVH7TVHW+W,QW/NQ
MH/X8HP25C7T&22>K,2QW->@= T.RX>TV#3;)?=C'/-,0!)<W# >+<2X_F<@
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MKR,0P5AE549 8X'!^...H?\ .]*32#%>1:%=&[ED);\/<7G*8_"5T8%XH$+
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MYK]3E)JLQ,7!3[N33"2<R=.30X)54&:52(6@<HD"AU9VDSRB+E1@6QS(%9E
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MP6/AQ GDB0G94!VZ?Q-U8Y)\AZMT+0K#A^PBLK*)%*HOCW'*!-=2@>_+*_\
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M+=1IU])RQ$_^5G<^[&6ZPR$Y"QDY,;8 5B0Q"E>7A_M0]G\VIL_$6B0&2]5
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M*X'L'/X&[?@ ^7Y>FI"@)\NO7; /?UW)['!R:K"3J0<CS4]NFXSD=?SK[%<
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M0>6YG)S!: ]"I(,D_7_27D.#(IJ=+I,=.*F],W:35\+,%V5CRO9UR7W<!D5
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M8GS).23ZFLXB)&BQQHL:( J(BA451T554 *!V   J;X  H 4H !0
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MW+/:X2H5Z=MMFE&D'6ZO#2=@GYI^H"+&)A8=DO(RDD[5X'V;9DR;K.%S 43
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M)P*K!YUM2]URFR%K8[E+LIO]Y[,Y6DO>;$WEG4-XP:0"\4Q(1L52L563I ;
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MP$D:2>&AW'_7D\*+K@^+OUQ7OKVJ\12<5?\ P\;B/AS31JTNCV?#_#G$EO
MTVB+H&OV3W.HR1 %G8Q0Z;>OX88K::G^)<JD<K)HKT3>I9;MDFX^KXWN-D=+
M[8<UV9A6LAUV1<++15)L4ZHVB8/*L&D)Q)$O8AZ$<UN!T"&2F:?[X#MJZDXB
MNN8WI7'7"\&N:;+>6\0&J64;2P2(!SW$2 N]I)C^/F7F,)SE)>4 \KN#\=>
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ME"2LG9$HN(?RJQHJ)1M<ZDVGK$D#5,D@1Q+,VBT6+\8!JD:.B6:JF.]I&O\
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M[B]<W=O;N;>$<\8@BLG20EW,,YGD<!2*YC!JFO<=^S:XU/6K!--OK"_\6/\
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M2"YM;B&19[*^MW,5S'SHRP74%U:V]GK&CW6BW7X6YY6YE\2&:/)CEC)(YER
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MO+/PUHLEQEI38Q9+C+8 9$.^^3%@9ZE3C)!WDF  * %* %*4  I0     .
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ML?N?18,ZD.8]HY<9.=YX[?$>IZIB"^+[57])2VWAFP$$L=M,U@52\.[_ /\
M]'R337+P547'C(1HA,IK.VZE:Z[--^V]G;5LJZ>V)\<UFA757>-1[SCW;E8;
M=4;I-.HC=>UW_OJ]D2+R0NG;XQP./&6W"XV3),"@]+!2;-_CN79.9=TV*+=%
M2M]NICG1>1R]T[83>*TR3LJV[3.YS.M8RK)/=T;;%\1D:F0&W2USE,LTI?=N
M>6HZ5KD2:_MX(\+"3MCB9K[9%LT.P53>F1<*5A+9]O%WXIS.T[;QBS(#.X8A
MW+;J^H1&8"SQNVJ5^ON4[1LNVU-<47C%-F1>FL5'L=DEK='2F4*=7+1?$UGK
M^/7J=E=%790A(J:4JPZQU\=T5FQ(I.U&FX:R-F&C["L\9MS3CJ I-^(ZQIN'
MQSNSI6%V4'9X9K;'DW&5RE8FMQ\H7JB@=2V/XU@A*-)N%C95D)E*EDZ5.]_*
MF[RT;PZGD#*6$,YUS;Q?L1U''>:<$XZM.,JMDJ(O.*8Z]R\ZK7;3?\B+IJ-I
M:0/$(J,9@C!;[.7=MD_=W:":"E3"Z4II2N?[J_9(6KFX_9[1<_Y&MF(]AUPI
M.X)_>K%#Y4R!@?'&0=RL# PR^$,4;A<X8O5;W+'&+91%6:E&:K-\P9S<Z@I[
MZA-EA4V2"E1(US?EDBJQ^/=XVW''+>M2V..CMNZG*)C&R9(RIN7IJ*6+^I#4
M\=+3SR\W"2@\AY#A5ZC"3%IBIB8?M9*.K[E!JF[/%1I044K>>^=;7*L[(Y44
MQ+?MN%8P,;>QA#;I4]Y5PI-PN.'</XHR!MH;9:G\CWYA%W^JH6I]*Y$1?4>F
MRSBQTFDM!<(A.OE032>.%*N.O=9',(9^I^VMS>-OM]ODQU!\#X-:NJS1[-#*
M9 V=9/VML\G#N)JL,.0[ C'1]RR8[9I4VQ_;4Y7F\!*,X0$)QZ 3:JE8@9=7
M7?HVVP[-LUY5O^S[!<5O"C-S%V1S+9\.9)DL7XL;;>*<<:3A:98N<S0@RF3=
MP5UB)QW%RKFQ1+6)@TG%;J-?N-E:)N5E*J5HZQ/4"(U7R>CC[!V-Z;C##73"
MR[EO#%TQMD*1R'8'N^'(/^&MYJ5;N!<DPK>E-ZTNZ+:H%>=IE@F&:",?$RZ*
MRGVB9PI6MV6^H]G"JT#<WMYAIS">VZ@W[)W5_06RGE*O9OR>EF"UXTR M5:S
MM]Q:O+YC*YJ&7LA-K;*6@KB+E7=;BUC1*5 Q<S:-EJ_*J5E;;;U;,Q8NR+TQ
M-H=2=4BPT.4Q!T^\/YBKE_IA:_>4'>>MK\;=FN1:3>S9G>VRX1,"\1ADK#8C
MX,94*+?O'%-<V63M:R;A%2J>IUUMWZ6"GDPJ3!4CD4=V;#"U]RM3ZC0IG:_A
MVIV#%UIR324J5F":W@U[%.5'-S^R86*_>+(V4L+R=&=+S$%:Z(K:'=88/5*Z
M8MF.6LBYWVJ8$S%EN"I-<R3D7&M=M%PB\:VJ%NV/@F)!MXE9&DVBNV&VPTK5
MYM(J4W"'8VBPD;1\@W9*S,DX;*NU5*V;TI7&=UY<U91Q_OZN3"FY]DL7J5#I
MV83R)CFNLMR&:\27)SD5SNRRK#S<AMUQGC>;94[,6>)VHQR< UJF1XQ]6)"$
M;I*3!56\4W(D^_OZTK>*W]3S??6]PV;]LS&H8+@+1A&D;@-TSZZYMA+!CZDH
M;2"X%QS/;5QR#91NJ$)7;[+;@KS-XVR].MG2$,@UQQ;E6,+5TDTY5-2M=Z/U
M0=T&1LF]+7+5HW)U6DXIR%-[X,?9XKC?;^K'U#)&4\%M*FX3I%3<T?<GDBI9
M47M<?*KUC;Q::3>I*)F+7'3%G)#65[)ITZK*5;&&NNGO*ROCO*J]7_[/=CL3
M;,'3U@,3WN1QJ\8Q;:H;T+Y::-98G)>.L?;C<D-8^S41:!820P;#*Z-CK*[J
M2JET1+/L%3ME*\>>.K5O!G<2W/;_ )/NVVK"<F4G4SPA>MP]@Q-DES2\_7;;
M'(L\?TC#V&:>PRJR<XWRIE2%M+B;34DKC=EF[IK'K5>$EG *U^04JK;5NJ/N
M\HMSZ=VSVG4?%2- 0VQ=-"/5;98L&/ZE=\]UC..(*D.3K[CFX9"W"8]L4I+X
M\?.3PE?JN.L,Y@=S5KJ]C8VR0B3S<"W04K86W;M=X.XOH!;N-XF6;=1*;=+Q
MB;(CW$;? $+><=V#'\?0<A2^.'SV4LDA=9V5>6>P358>3K-S7U(1M"Q3YK$%
M"1<).))RI6M6,-P64(&U4V&W)JSDWOGF>L?M I&9:-9<G9:>8UQ_M\R'1KA)
M;=[+MJB*G<*#%KXU6I3-1!ZO;8JPM+AD5K:Y++=7F7Q:LUB5*TPV>[L<U;3,
M65C</CFN/LG7C'W1JL$I%UZR!-3L"U>3O5ZRA2Y2\6.*2GJ^O)1M#JTNZM$P
MF-BKXJP=?.V>6*#BBKR;)2MK,J]7[>'D7 +G'E_O.TK"];RGCK?"PB-Q:D?#
MY:K>?VV.L?X_)CC!U&8[?=S61J+B[<)=4\E6-O)QXY;O+YHO6X.8K]4<'DDZ
M]*J5TC],IPZ=].+8,Z>KKN7CG9IMF7=N'2JBSE=RMAFF*+K.%E3&55755,8Z
MJBIC*'4,8QQ$PB.E*W@TI5-F9B,KT1*S\T]0C8:#C7TQ+2+H_LVS",C&JKU^
M]<'[^!!JU0575/P/A33,/II2N'/&F]#=+&1.]C,&25]S6,Z?U*MA&^/<!MGF
M+U=T3U:"R)A.>RAD+&J&W4:_D2PSN.XV)VNWNIE?FDJ_C67D+-2B2D9'2[<K
M:;44J[6NX+/%8QM?7W2>SGG/< Q9]*%AD#<TBIE3)NY6H8CW3NYO&R/V]BRR
M9*L-X5@,^K5!]EJ9F,9U*=-'-R5]H^&JMI*/:IHJ5,'A"T;&673\WT77I_;F
M;WF:Y,MI%NLV4;Y8=R&9,KY3@[RVPYE&3J%MM++(=QEG6(\ERLFA89&7:5:$
MHSK[5B&Z:\2V)7H9%BI4*M<W"K0. 8:8V@9NRIN3I;GHT99R;U(Z3><]9YS%
MAVCY_;X>I4C0W;>[/,E%M.+<SW3(KZ]0%VHF*,C5"18UEFJX;P=?59B_34K?
MF^=53?ECBC[S+W2JK@V2Q-M$CME&/H**<T>\SMQ:26Z#%&WJWSF4+K8K#F.N
M0CNCX>;6F_+'0F+% 'GG,U7%;I>:Y#U:<GIQ2JKCCJ[[K;G+;4J+EC)&S[:W
M6<OR.>W[C=Q:6->S)BC,J&*LAU6MT'$E#:8AW,6'%V/,RW2OSS][=(J2SG>$
MHB1B5"51D]4<,HUZI6KE#SONLRMN:Q#0,J[F:AD7+&)NMWN@Q57JZ%&L%=>8
MMAX[!>Y-ICY];*\ID::</\-6LT5"S.+J:4L:XB86NS:"MUNDA(EFXY2IC>E/
MOJW2[X++F0,ST2E8[@=M]<I&!\L14/6YZ/EW6]ZOS5R2W"Q4-)2=CDVJ-!I\
M/'T52)ARM'[LJ]R36/9Y$K<Z"2E30:4II2FE*:4KY&;H'.90Z")U#$*D90R9
M#',F4_M"IF,)1,)"G$3E((^$#_>  'OI2OQ[HT\8J^ZM_:B90XJ>Q3\8G5("
M:IQ/X?$)E$RE34-SR<A0(81* !I2OX+-F8Y%3-6QE$_9>S4%!(3D]AXO8^ X
MD\1?8^,_LO"(>S\9O!QXAY4K\+1[!P)Q78LUQ4.5105FR*@G4(04R'.)R&\1
MR)B)"F-R8I!$H"!1XTI7U!JU*5 A6S<I&Q@,V("*8%;F #% R!0+PD8"F, "
MF!1 #&#G@1TI7S58,5UR.EV319RFG[$CA5NBHN1'VI%_9$6.05"I^W236]F!
M@+[5,BG'C(404K 6W_:UAW;3$Y"CL:PTPJ_RWD:PY8RA;+K99R^76_WJQF;I
M+R]GM-I>R4K()1<4QBZ_7XWVR<9!044P81[1$"+*+J5GX&+(KL[\K-J#Y1 K
M51Z#=('9VQ#"<C<[@">V,@4XB<J)CBF4PB8"@(\Z4KX%AXDK4[ L7'%8J)E2
M49E8M@:J)$.*A$SMP2]B9,AS&.4AB"4IS"8  1$=*5[4TDD0,5%)-(ICF4,5
M,A2 90X^(YS 4  3G-W,8>3&'N(B.E*\;B)BG;MM(.XR/<OV8<-'KADV6=M0
M$1,(-G*B9ED \0B/"1RAR(CYB.E*^JK!BNL5PNR:+.">'P+JMD5%B> ?$3PJ
MG()R^ WWB\&#PCW#@=*5^RLVA 1 C5L4&YCG;@5!(H('4Y]H9'@H>R,IXC>,
MQ/")O$/B$>1TI7]]V;>R40]W0]BJ*@JH^R3]DJ*HB945$_#X#BH81%03 (G$
M1$W(B.E*_*K)FN!06:-E@*F*)05024 J0B412+XR#PF(D((D#@HB4H\?=#A2
MOPO'1[DATW+!DX3471<J$7:H*D4<MS$.W<'*HF8IET#IIF15, J)&(0Q#%$I
M1!2M3]T.R#!6\%A"P>:C95<5.-8SD-,T>A9PRYBFCY KME48JSM:R74\;W&L
M0M[A9(8]%-9"?:.W!6RKYDBZ392+]NY4K9Z,JU:A6<(PB8"'CV=;BFL%7V[6
M.:HDA89BV29LXN,\*0"R8-FB*+=)JW$B)$4R)@3PE -*55TFK5$2F1;()&(D
M"!#)(IIB1 #>,$2B4H"5(#_?!,." ;[WAY[Z4K[Z4KY^Q1]J*_LD_;"G[$5O
M 7VHH^+Q^R%3CQ^S\8B;P<^'Q#XN.>^E*LF^VW'F*J-;<BY$F*W2L?T>NR-F
MN-IGSM(Z"@*W -UI20DY1TJ4J2+*/125=#R!A X?Y)#+'*4RE:];:=X>WW=C
M&VNXXC99#0KT E699:Z9.P3E3#$#;8BQ)2I*S9J7/Y7I5/;7B$<MXU\",I K
MR!6#99D=T#1"7C3/%*VG U?C3FX-#L%'Q6:9^!9-3O"*#[HP3-_Y9G!3B(MF
M91\8&'_)1 ?].E*QS2<BT"\3>2*##0<U&JXENC*E3;6RT29JM>DYQ:LP-Y0=
MT1[.1;&(NL.V83[+VT[5E)"/:3+9^R4<$=,C\J58UHVXX)MFX/%FYZVHK3.2
M\34ZTU;#Z<G<)(U&I9;0#XMSN53H?V@G5$;_ #4)(.*W,7HD:O/A5.(0CUNP
M%4BBE9DMT[0(J%GIN[R-7;P=(B7MJL;Z?5CE&E8AXMDM(/9V1][]I]FM6;!N
MNZ4>*%3 J"9S@<2AI2O-1\A8[R73J)D>BV:OV>FY @8NR8]LT<X1.QL<!8(Q
M&4C)""46!)99"0BE471"))E5%L("JD4"B!5*_E\QM6,B4JW4.9":AXB[1$K#
M3,G1K)/X^MR",PD";Q]!W6E2,%:J],\E361F867922*Z2:A'/)>!4K$FV7:/
MA3:3 W*'Q#%6DTCDFVFOF2KQD*_W;*>2,AV_[*CX%";N%]R#.V&R2RK"#B8V
M(BV0OTHN+8M"IL&+<ZSI1=2MF-*4TI7F=LVC]NJT?M6SUHN7PK-7:"3ENL7D
M!\*J*Q3IJ%Y !X.40Y !XY#2E?DC!BF0J:;)HFF1N9H1,C9$I"-3?ZFQ2%(!
M2MS?^I$ !,?4HZ4K1_<EORVH;5;_ %'!V6CWQS?,ATM_>*]0L8;>\QYL>/Z1
M7Y=G6G\T_C<18]NJ4;%1DJZ81QU)8C5) SAF4 *FJB)E*W,;J5D[A-1$(8CT
M6A#E*)&:3]-I&A]TITS 5TBE&BZ$HIG*4&)W!B&*D900%2OT"E9D44F '@G[
M<%2G09 :/=(@NW$7)3I-@%0@*H"45RF(3QIB J@)>/%I2OH9Y7ESE SJ&64>
MF12(!EV*AW9T2JN$$R@)A,N9(J"ZZ) \8D*BJJ0 !,Y@4K\**UM5JS?*J0:C
M)5V59@\4.P.U5?NO:(D59N#"*)W;D3JI%41.*RWC4( F\1@%2O>$;' L5P$>
MR!P1)% BX-4/;$1;&.9NB57V?C*D@910R*8& B1CG$@%$QA%2OC]BPWN2\;]
MDQGV<Y445<L/<&ON3A54X**J+M?9>P5444 %%#J)F,<X 8PB8 '2E5!-)-%,
MB**9$DDB%3323(5--,A0 I2$(4 *0A0  *4H       &E*_>E*IR\1$NGK>2
M<Q<<XD6A? UD%V399ZV)XC&\#=THD9=$OB.<WA34*'B,8>.3#RI6"L:[7</8
MLRGG'-E?AI:4RGN'DX5WDJY7"QS5OE',)662[*K4.O?;SQXWJF.JT#V5=PU+
MKZ#"%;/YF3>J-UEW!3)*5A[.&_':CM]RI7-O]L=W"T9;^Q(JZ)8TPU@W*6;9
M^B5*2D%X:)NEN88HI%L0Q] NGJ;INPD)]2)5=))N%V22[4JBH*5N4A^[*17:
M#;["2+&J)^_HH?9Y CU154<H@[33X!HI[915=,%BIF]J=14OWS&,*E?I4]<.
MU5>K&A#LH]XX77=JF8&:L7Z0G0=+*KG$46SQ,QU$7"ASD6()SIJ" F, J5_!
M"MN'3 PA!KO63+W^,,(,%732..!4Q>L!'Q+-V1@\)/>&_@0$/"7QB' :4K'&
M9,VX6V^8DNF8LQ7:LT3$>/X]-];[/)F]O$Q:#MRS;LVON4:@]>/Y*6?RD<RB
M8:-8O)68D9)@SC63MV];)*J59FWW<QB/<U4)+(E$A\B5V$B;&A616S/AG)&#
M9IZ_-&1LS&.X2'RY5*A,3$.]833)6,F8MJY8*KJKL2+D?M7;9%2L)2'47VOP
MN>7>W!P2X)Y'9[CJ9M*630IJ(P?^*.0<,OL_03,DH5^7Q5A2B,W+A]*BV B$
MT8(\6BICBN"E;X)0L,@W;M$(F,1:LUA<-&R3!JFW:KF*<IEVZ)$@306$JBA1
M42*4XE4. FX,8!4JHD(1(A$TR%333*4A$R% A"$* %*0A2@!2E*  !2@
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M7<+O0P=N6Q32*)DJGXYV\W?$DS3YS=_N%V=64MGLF1J_<8V=:7G;S3[%8IV
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&4II2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img29677477_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_17.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1OZ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &]Z^<30X0DE-! 0       \< 5H  QLE1QP"   "(   .$))300E
M   0MV9>?53;01#W5P=W'7#,93A"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!Y
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  /'   )V@         !                          $
M"=H   /'                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   /'     %)G:'1L;VYG   )V@    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   #QP    !29VAT
M;&]N9P  "=H    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     0X0DE-! P     $:8    !    H    #T   '@  !R8   $8H
M&  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)
M" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( #T H ,!
M(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)
M"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@%
M PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A
M\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!
M  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:B
MLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ .UR/J]U6W,R,H=5
MO8V[)8]N,RQ[:QCM:&VXS8EU5F0[_#T[/2_P7Z;WJH?J]]:OL6/C'JHLMJ]4
MVY.^ZNQY>VS8T['OK]+WU4_0]7&91]IQ;?M-WZ/HNH4YM^/LP<D8=VX'UC6+
M?:/I-]-Y;])4,1W5L3J>/A9N8W-9D4WVEPI%1!J=BMKC8]WM_3VI*:(Z)]:F
M85S*>J!F8;A93<XOL;L;1]FA]5XL:QUN3^LVU-WX_P#H:ZK%+JG3?K6VW)R^
MFYX=O<VRK$,  BNK'>RNRYMK*ZWO;=?MM9D5_P"CK]5=(DDIYK%Z3]:\;*Q7
M/ZG]HJ-C1E!P! J]^1>&;_SW7^GC8[MOJ5XUMG^BH36=)^N=S7-MZM6)>7-]
M)HKAI<_]$[;5ZMGZ.QGO]6K^9]/])ZGVJOI5B5]3ZB,+*MORNGBRO+?30]AL
M=6*Q_-4Y,N#_ +;_ *;9^B8E831()K0;H_V9];7&]MG5JWL=6!1%086V-NWM
MM?Z0:]V[$9LL;ZFSUK+?T?I(>7T#ZPY5-6_J]@R**<ANZLFEMMECP<7[0W':
MQOIU4?HGOJK]?_"T>F]6/VMFGTV,R>GNML!TWO D.>QVT0?W-COW%;QNLX)Q
MV.RLS%%KQN/IVC;M=[J2/4+7^^O8DAS:.B?66D9!;U,-?;76R@DOM%):]C[M
MK<HVLR/5Q]V-ZMU?J?J]>3_/YF8H6](^N=C?3/6:]LLEPJ#'0';C_-,9]'_"
M;7_K?\S^H^EZN5MV=7Z758ZNW+IK>SZ37O:TC29AQ^BK-=C+&-LK<',> 6N&
MH(*2GG\3I?UPJ>YUW5JK/5JL#]U0<&WFNNO&NJ;M9M93;7ZEE3?3JL_T7JV>
MJH.Z']9W8S">J3F?;*\E[RYXK%;*64_9O2I]%EU7JM?995LQ:LNS]/9Z7]'7
M2KG\ZKZQ]/P<O/=U5EPQJ+;FTG&:&ES&&QH+V6-?L]J2FOD=%^N=U7H?MIFP
MR76"L5V3IZ;6OQZZO:W;^;_PO\Y7_-&R.C?60Y=MN+U(5-L-,.>;+(K;6RK(
MQV8SS]EJ_35OROM;&?:[O7^S^KC^GZBTCG9XS<R@XU3<?'I;91D.O$O>X.W,
MNHV;\:MFW^>=_P"<!;U3J'H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                      #_X3_Q:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U
M33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@]
M(F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C8M
M8S V-R W.2XQ-3<W-#<L(#(P,34O,#,O,S M,C,Z-# Z-#(@(" @(" @("(^
M"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY
M.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z9&,]
M(FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @
M("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S
M:&]P+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V
M=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E
M179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @
M(#QX;7 Z0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I#<F5A=&5$871E
M/C(P,C$M,#8M,314,#@Z,3DZ-34K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@
M(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,2TP-BTQ-%0P.#HT.#HP.2LP
M-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$
M871E/C(P,C$M,#8M,314,#@Z-#@Z,#DK,#4Z,S \+WAM<#I-971A9&%T841A
M=&4^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T
M/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z
M0V]L;W)-;V1E/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED
M.C9A-V$Y-V(W+3)A,#$M-3(T92UB,6(V+64P83 V935A9CAD-3PO>&UP34TZ
M26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^861O8F4Z
M9&]C:60Z<&AO=&]S:&]P.C(T.6-D.6-E+6-C8F8M,3%E8BTX939A+60Y.64X
M-#DS,S@S8CPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C="13%!0T5"0D1#0T5",3%!-3E$
M.4,T,C!%0T(Q1C0S/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8W)E871E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C="13%!0T5"0D1#0T5",3%!-3E$.4,T,C!%0T(Q1C0S/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(Q+3 V+3$T5# X.C$Y.C4U*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&EM86=E+W!N9R!T
M;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A
M;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HW
M0T4Q04-%0D)$0T-%0C$Q034Y1#E#-#(P14-",48T,SPO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-BTQ
M-%0P.#HT,CHS-"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C S939F9#,T+3$W,C0M-30T
M92UB93,Q+68Q,V0P83AA.&5E8SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-BTQ-%0P.#HT.#HP.2LP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-#(#(P,34@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H
M;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L
M:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T
M179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.C9A-V$Y-V(W+3)A,#$M-3(T92UB,6(V+64P83 V935A9CAD-3PO
M<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H
M96X^,C R,2TP-BTQ-%0P.#HT.#HP.2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO
M=&]S:&]P($-#(#(P,34@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @
M(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,#-E-F9D
M,S0M,3<R-"TU-#1E+6)E,S$M9C$S9#!A.&$X965C/"]S=%)E9CII;G-T86YC
M94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C="
M13%!0T5"0D1#0T5",3%!-3E$.4,T,C!%0T(Q1C0S/"]S=%)E9CID;V-U;65N
M=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM
M<"YD:60Z-T)%,4%#14)"1$-#14(Q,4$U.40Y0S0R,$5#0C%&-#,\+W-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D
M1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #H ET# 1$  A$! Q$!_\0
M'P !  (" @,! 0            @)!@<%"@$"! ,+_\0 5Q   00" @$# @,%
M @D%# 8+!0,$!@<! @ ("1$2$Q05"A8A%R(Q>+<Y01@9(R0X45F8UB5287%W
M&C(S-3=7=H&2MM'7)B<HL;2U-#9"0T=C<G6#AZ'_Q  = 0$  @(# 0$
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M/MVUV],_KZ9QG^&<<(O/")PB<(G")PB<(G")PB<(G"*CW\/S_H*S;^=+N?\
MUYE7"+8/E0\.-#^3NIPU?OB("@)BRM\+;!VX8+4\-,V!+MA,0FL45C,@+K*
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M$2[ !JO/-9J1921[97; NQ]0]7+):4AM,+.A\+L0O/8VK)V<-K\8'!3 K;<
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M$ A3KJM:G9^73&82"-0UW"ZOMRYX/0&T@AQ2.R/L!/JNK!;#:;R"! C*ZM/
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MMHCOC8BMQ\8W]FQX]_Y'^I_]!H%PBG%PB<(G")PB<(G")PB<(G")PBC?%_\
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M7;FF.SY=TND0;DG;AX@OE;;9%97;*?MU]-<$4<KT\??7:\X."@#H$K7(8 ,
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MD %?:EXC!)!7D/!L=6S2.Q8#,I2*F,X4$,&S9);#^9&HU$%C:SUV\1T3B0C
MIL,47-JER+;'")PB<(G")PB<(G"*BC\1O ;FLOQ<63$Z$!3.1V00M6BD1 B
M;O=).]P]LP&*T:#M1R[=ZX7(/R+$8V8MM]W!!Z^:L6Z*[APDEN15J?A,NN_;
M6CX5W".]E:YMF"QBRD.MA.G']DI%4QDG#"FEU;G'4.R1<KI;LVB9F.Y?99ZI
M:8U>CODQGU3]I%W N$3A$X1.$3A%XVQG.NV,?KG.,XQ^]G7]<X_YVOKMK_\
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MH>K*C[;5K NU\DKB87Y96)Q+(L1C++-@]F[8,7);Y",19E*BRD; E944:LA
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MT'J#HN:#Q'<._IO1O^#X,@V1C1[=%V$JQ*&W],VMV <@!(RB;JMW+\15-,'
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MQ&QI/+MO\A%L(3.8:?D,OB0.4@2\GK]8,VG( :49O2\0<R$5H=!-9&P;JJ.
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M;'Y(+;1[))K'W48V3C Z0/B+43/QK6Q$C,L(N[,AW:.,GK(KFPC-:=A1P6(
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MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%U_NZ/DU[3]>N[1:@H7!HDZ
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M)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBZ;'<CK9UGI'NS*
MU<=7^K\$DE?RGKV6ZV=<5^E$MLR2][G-@OP!"P),$O<*5095TZA<D?G8NQ4"
M-_9!B4/5F]A:$HR:8M$R+N3\(G")PB<(J/?P_/\ H*S;^=+N?_7F5<(KPN$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$6K;>LU>I(@\F>M=3VQAXM-\]-L:^_)&Q0
M*&&"WQ5^=>I3F;09DN.:H,=D=T1;X@64<N&^J Q5+*RR)%K(_<!>5]9K;M!K
M#9_3S@=5DZD$<WG;B#M3GT[: NI (EK!:#3:;C63+3=9/=OL1)L"C9VQ<;.1
MR".J"ZY%_/V\'_:+R4=CO)]3=0]@>QG<EU4=KO[->W2@YE4YC:,C<1GKE,7T
M<0D$C^D0=AW+EO%HD*9E1SX1)&;!,>O&3 <OH+*-B+^C["8-#JWC0Z'0*-!H
MC&!.JN& 0$P0'L45'*RCIXZW30TURX?D'BR[XF1<[+/R;]PX?OW#EXX67W(O
MBL"NXO9P-..RW0_N+2?HD]=8Y,YE!GV73=!TV3PH8@Q^.&%FF4GB^%1ZS_<>
MNIE)9=JHLV;*)$7$U53L I2/8BE<#C(>.Z89)M1129368-QK8<Q0&L& ;,SD
M,A5""V;%L@V;"1*C(:CHGK\;37;UVR1;.X1.$3A%IBZ/_P!&K/\ [9ZX_P#S
M93D7E?X:'^=*'^U5ZX)_7<K_ .8O*?\ <FJ,ODR[%V!U<ZKG[3JXL%$3EO+(
M<%$*&Q[(NW<(ER^B)1!$8^S\;I? [5PKCV:[J()IJ+^F-4]ML0'/<W=X_P =
MFR./EBBMMLU8HC*QDK7"64"1HC?\./0./P"0 7?8%;:_"?Z7\:]7O6+&</Y?
M2OW>/2X;.W[S,?9L4I8WTJ+I*DDENN.\,?NG1,/8M;(][(MDO ,0/"SVRN3L
ME%+BB]I% I$33K*J \(3% 6(=9JQ.H3Q,AH^7:8QL1WWUCHSXU%_WDLZ*YU_
M\-MRL^E?),IG:^4KY"2)\>,9C8J@CA9$6LE;<#P\M^7DB"/1=\C1U]RMW?CS
M]&.#>E>9X-E^(5+]6YSB?F=[D#KF1L7HYK&/EXXZLZO'/L56M.4M]FQ_2\/9
MO^K"O YME?GZG")PB<(G"**?=^/PB5=6K8CMB=?K"[2Q(LPC;1[0U5*:M; G
MI#>:QO:.IQPIM+H'B/N([)-1,M=RG$P ;Q0: >R1-]C<5JDH15P^.;KGY)ZR
MNAY+;1G<BJ'I0O'2C2,]-;OO]+NI>$?/K);: RB5_.X&',0@ )T^FU3@VULW
M.SU33<M,E$?5JY0(KRN$3A$X10'\JW]F)Y$OY'^U/]#YQPBY;QC?V;'CW_D?
MZG_T&@7"*<7")PB<(G"+1'9J31N,T)<"TDD(./I$*OL1@P5.%F E-Z^4AAO9
M-DTW?N&^KEVIKKMMHV1SNMMKKMG73.,9S@BT+4IP+V4F<+=@S N14YUC&Q=#
M=<21:DQ,S[(/H0+=ZZJJL7*C5\'I"&2)NNBDOJ_'.[/FR+M/49+*9;*X(/L/
MR_E^B\W%V!H6)=K*)#RN[JBC)>-1:]&DC%R&R88%(Q]T3'5BY'-3;(D:;.13
M@@WQE=DB^204=HX^5#533'NX13;-'0D;#$Y'(C H#'@H]T6,GC1!H+#"13)#
M=R\)DRCY9!BP'M&R>[AT\=+I-FZ&FZJJFB>N=L$4->HMUTU/3=[QZ"VW64T/
MN+XLR2( XG/8K(S"T=]L8;_?T1@<J\>J!?J%T$/NFB&S'YEDDOG]ZFFN2*;_
M  B<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+K&U
M-UO[[+W/&9-XZJ]O_P <O6AM-M",]B?=:_V-K0&PHC@M]1(V%9],3(N])=3Q
M60*;+K#"C"ZZ508L]O\ ]6M,[HMD"+L<V8VLAY Y.TJ$K#@5E.AN[:(&[ #E
MY##@Y5=5)+!4Z  E@)8VU'M]EW:8AF<#;$G2*#-4J/065=HD75B?^2KN:EUX
MZ/V"Y[":@)N3Z403LN=8*0:I-=>WMP2'M_3E&E:C*CBL.<.6(C\B3$KAL%I3
M>#RUK(9>!-[&5&@=NP<$7SG/)EW):F;/21[%:,]+'E%CQZ4#,PJF5-N@0^&^
M7:K^BH F,W5A2CC=<_U]G$DF#A2_=ITT<3:*:3%@BA%DR@%4BL5I/O=W>QU'
MI.=P7J)//(=*#EF=MZWE-F0FT*%I++J+4#V-F52U18Q@?(LQ>+F7EOPP F<6
M<5^''Q[0D%+$6HT:*-A6VI%QGX=4B3+^/0P6- W$8,%.W';LB6C3MXT(NH\3
M>W7(W+\&Y(,-MV#YP)=*JL%GC+?=HY4;[+MMMD=],Y(KW.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$55WEU\C5)>.'K'M-;OC-G2<5=1"2TC%D*P#1@T_82J05]
M+2S-^=2D\OAZ#8"FV#N='+I@Y)/]%MT-4QJNFVZB9%I'QV]SJM\O5+H3R$!)
MW%NL'7XJ KB:5[8 <2TEMR6W$(?%94HG)QT4D$N'*TQ%V18$28Q5$FZ)V=*5
M=F<M&#(E&58]8)%-_K[;,5/WEV-9,QMCLLS^RHF9B#R14W;\2#&1@+K_ %B)
M*/$S\J@P8&T2;%(Z9&:_7D&FSD@QW9--5W*J"2I%.#A$X1.$6/2>.MY.+V&.
M24@%)X63<X=QH^4CA+WHZ[XU3^XB'+5W]/O[\Y5;_+\2N==,[Z[>S7TZ+$#;
M$?C=)/&.P=VKS202?&_CR1.:_J=_+=Z/QL?"D\3DY<3;%N*KC;C_ !NB\.5Q
MU/*5=/+=N]K=BF@\C>OT2=.[-NZD=BM6=<&;O-,UK)2<@E,C-S2O(%*#K^3R
M(J?4W+EHJ,?D%6.I)PNF,;N7;M9;9FPT;M==MM<:):ZZ:XQ'X-CABZ,\D]B>
M6U2IV)GV)Y)R99*\;WEGD<X1M<YQ/1G5H/V 5O\ 5*>$<[Y7BJF-Q&+H8+DW
M(\1CZV)Q=/&L;2I9BW6K,L&K%&ZW+%##'&)[+I)B 2YY+G$[/E,RB4'':EYC
M)047&*.$F:+T\49BT'+U?.<-V+39XLE]6_<[8]C5BVPJ[<J>B:"*BF<:YD+%
MJM4C\MJ>&O'L-#YI&1M+C_"QI>1V>[[-8W;G'X:"?A5+$8/-<@M&E@\5D<O;
M;&Z9]?'4Y[DL4$>O)8F;!&_PUH@>TUB7I#"W;Y'M:"1U?_+KV\[!1OLE#0U,
M3VVH- F]:PN4,1*D>.Q)%U,&LPG26LH9B)$'8E\*;I-&#5H]<LV^KO##55JD
MLTR@X7T!ZE<FS5?.U8L5<R52FVA5L-B,$U8.M-M7 +#8IXF2;(:QK7N:T.Z!
MS06Z<?UP_!1Z)^FF5]*\[>YWQSA?(>1R<KSV)L76Y/'9J2#!S8/CKSB)[N+O
M6*75KY[,LT$4\KH#9+)G1SB2*.[7J?6,6M_K%2-A7L(;W;.Y_4T&.2<S<(T7
M-5-'+\0.)JCA08R.W!QY@F\3;*N$ XEBY+O634O(W)DZGL4WVOQW'U\E@,3=
MR\;<M<NXVG-8ER<<=LATD,<ACCBE88H&!VBYL4;#(]K99S+-N0^ _67EF8X3
MZM<_XUZ>79. \=XWS/D6.Q%'@]JW@&.BK7K=2.U<O4;3<AD[+H'2LCDO7;$5
M*"Q-2Q<5#'.;3;M7J375?0:DH 0A,%AL/?R>%Q9U)'L6C 2/NY"Y:,E<M'!M
MR)8M%BR[7+U[ENJ_W<*(9=NLI[:Y<*^^1XY1I5,53?4IU:K[%2LZ=]>O%"Z=
MS6$M=,Z-C3(6E[^I>7$=W:UV.Z?ZT<HY-R'GW)*V?Y%G<Y7Q.>S$6*@S&7R&
M3AQD4]A@FCQ\5VQ.RG',*]<2LKMC;(((0\'Q,ZR;Y/+4R<(G")PB<(F?TQGT
MQZY]/TQ_K_Z/U_3]?^GA%6]T^\J/4CN0_C<$@TZ3 WP69294[11I@>WE<5?P
MUR^;R5BY.: D(D90'Z,%'C<P$,/!)9BJ@Z%.GB*NFV2+*O(_VXL;I7UK/796
M=)N[G,""8AL4U<G1$>A<" .R3-H1F4Y>NRC,\]'(Y=("0P*'CC)TQ(R8MNX2
M$@M#$@%$4)KX\NTSHB\+W8%::BASKQ3$NOZF=#326&FEN'+AZ_= W'?XZ_W#
M[A',69UV=B3%]68S;1VXD#>2IH2-QJH(7R/3(M(2'S*]G(XTD]6KT%1KKLO7
MC2U;,F+5&?3M*G2%*U9TQJSN2Y2C1C>.;RA.R3PVW %8M&Y)GM'AQ@:2F#A5
MR*52!H$7*^4SR[=%TNC/:R@Y'9LFC5Y7GT(G1"&5XM3EUFT<O.P?7,D<K@20
MGT<KHK6K!8@A+0Z+]Z]ES8:$565R;=C4VSG9$BM(\8W]FQX]_P"1_J?_ $&@
M7"*<7")PB<(G"+JV_BB>M5V]S^NU'TCUEA"EJ6C6MAF^PL_BHX]%@*T0IP!7
M\RC3R;'RDN-Q\&.:/#I'49'ABY/4[+' Z0_E8693BTDW$D6WOPRG2OLUT<Z.
M6M7?:6L5JKF,Z[+';1BH=:5P67;%H(<J*G0@L]J^@,GE0UGJZ*1PTUP/(/&A
M9'++*R[!)NNV56(NQ0J.'K*;*K,&2JN^<9W45:H**;9QC&,9VWW3SMMG&,8Q
MCUSG],8Q_#'"+Z\XQG&=<XQG7./3.,XQG&<?ZLXS^F<?]'"+TU22TS[M$D],
M^GIZZZ:ZY]/]7KC&,^GZ8_3A%^G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(JX)GY4>HM2]FK.ZJWC8#.GK&@SRL4HMM*$B;X=
M9S&SXL,.CGT;<Q\44:C5A98@K&B <\[8F<.&R)C5C@$5%OG1%8_PBUJI3%/+
M(P)LM5%:JMZJ>ZDJO;J06+[HUN1TQKKH_@26PO.D/>ZZZ::ZNH]J.7UQIKC"
MF,:X]"(I3-/JJV"NK5%:JK6VBBVM592"Q?=6S6[=JLR;M[!4V%YWF:*#)PNT
M12D>22:35=9OIKJDKOIL19E'X\ B0,3&(J##QF-@6#84#CT?&,@P,,,9):HL
MQHD2.0;,!S!HCIJDV9LVZ+=!+75-)/33&,8(J5?P_/\ H*S;^=+N?_7F5<(K
MPN$3A$X1.$3A$X1.$3A$X1.$4=9UV6BE?SL?796"7,4/F=WJ8%:,5;)9 %/Y
M%B6QHID.98(;L7>HUDZT^LVRHGA-PFNWU]ZJ.^N"+=Y^2QZ)@B,HE9T/%HV&
M9*$C)^2$V0,,'8(Z?(N\*E":[9B.:H:>NR[AVX212QC.=]]<8]>$4=\WY+K'
M_P UZY5B0FP];Y--;=LA0G6-,(8TVUUV<@'+\2\L2T-56ZB9$"1@,'>5K)4-
M=VV+7"*[86T(JS_*CXF6WD,ZX[LNR/9ZT,F:B>R6X@C*M(W$H?6C,H#@TH9:
M PL$(HR8KJQ>)/D]W)R:3:>2QLHBY0"' PDH_$J$6]_#[XVJY\9G6(C6-;6%
M-K%&6Y+V-WEB4X; FKX4:DD A0%P&': 63%ON+;H1ILNBHYT4=Y6<+XW5SIA
M/&"*USA$X18M,!LA*!\HQF5*Q BBOJYV*)!AAS95LD@XPHRRS+:;MM-5E-T5
M<N-<?-IE#&FF?:IOZX]F.:2/K!8-9X<'&011RDM .V=9 6C9(/;[C7Q\$J7P
MEO&4[ODRN'9FZKXS$*C[UO'ADKY(RV<3TW-E)8UKV",DQN\A<X;:U851KN8&
M*TA\IFLKQ*2TPBL7E.^R8(8!;"MS8 >1<CFJ W'^7;)N7*F45G6ZCC"?MTV4
MV]/7.)B'69:%6Q:L>XEM5Z]@D0QPMC,T#'N8T1_=H<XZ+B7:^"3K:GO4&'"4
M>5YS$8'#G$4L'F,OB&AV0MY&6XW'Y*S5BLS26C^[E=%$P/9"UD1=MP:-Z%<7
ME<[9R"J.N2K[KS9I 38K"T(R#-'80.VD+$*QW92#[K'CLBT$EXH$,KKHLE,1
M\F_:2%=)'9PV8[MD7"NE']1>1SXW!E^$OOCO,R%>*66I'YVQ,Z3>2":812UH
MI20P^"1[9W-'9K"T.*]2_@V]&,9S/U196]3>)UKO%[/$<MD*..Y!:&+L7[#9
M\:*>3QV+==HYG(48V26&')U*T^+C>\12V6S/B8Z//AKM'L7V)K.T T\O.3-X
MQ6Y& QF.(,HW%]Y*P"XCQ)!H("R L-("QH;1J.01=Z;Q8@;6V3;+,) *W24^
MHA?2_(9S-T,A'=RTX@HR4Z\#6UZ_G9$('M;'%-)&^..+JP!W]SOF)#7,GC(.
M]F?CIX?Z7^F'+.(WN.>GN*DRW*:O(\ME))\KEVXJS?.3JR37;^-I6ZURU>=-
M9D? YN7K8^,.ECLXRXU[?'=Y%JH@40(Y/# >'LJ4;99N)K)7Q&6SARTVS[MF
M2\PDSLK(LCO?Z[)"DR*8MKZ_&T9-TM=$]=KU\=3JO\T<7>P6ECK4[Y+-MS"=
MEAM6'23^/?R(Q((V_9K&C07@#,<RY%FZHQUO(>##ME$\>!Q5:KA>/Q3@=18C
MP>)AIXOW77Z7W'577)OXIYY7ESCCMTXQ]-6?Z?\ \9ZXQ_ZONRGZ<Z<K_#0_
MSI0_VJD^"?UW*_\ F+RG_<FK9<B<25J*66B0D&;-ZJ(X;CY%(7\6%*);*:X<
M;K&!D8F#M!1)'.VZ*6@)QJNIKJENJVTVRMIG3NG;&36CAEEV-,GG?7C(W]1,
ML=>RX$#9 $+MGX):/D57%Q8J6XQF:NY"A0+9#)9Q>,K9>XQX83$UE&WEL)#(
MU[]-D>[(1&-A+VLE($;M:T3';!AE?QZ%3X1#6"T3!!0@]_$)@;E*1CZ-NHB\
M=/$#4#A6X?V[)MLMD4%#/U&%E_E6:Y;I_58.(ANU:<%6Y%58:T,43'UK,M@2
M]&EKG.$M.J8OLWJ 9=[.RWJ.UJ]0\GQK.\ER>>XY=SEEF9R-_(6:V;P=##OH
M^>5LD$,$E#D>?%[8=*)9)&T?&8X^C)O*[P[FY**BIPB<(G")PB\9]?3/MSC&
M?3/IG./7&,^GZ9SCUQZXQG^./7'K_#UQ_'A%UKO'DV[!L>Z\6"3*966G8,>&
M7TT[K2R?=Y(#>52=E)"J\S^R]?KIUS$6K+SM5ZQ1_IJ?1^GJ^G=:S@K$I6TA
M:2$B22<($5_5YTG7G8VJ)E2MK"G9NOIZR9CY*+8E2(1T[:L"P\VVT1*"G#4@
MSVT(#&:N=VSA/??5/9+;.4U-]<D4<Y7XY>I<ZNZ;WW+Z_*R"66*'E@Z81LA.
M)IO6!<M.ZCTH&9SG>L4SB<-;V')J/3UJ@O,VHI$TYA>51WU&JR[ATJ1:A>>'
MOI$0KA.M7\8M-ZWVE,DDQ6<.+VMS>UY(WF-5AZ*E<+DUGXEN)D<KJ0TI'H_5
MA*#/2JD?4B008DFT2*-=2F2+.?)\(&1_Q7=_@(-@U%!0G0[LX($"V*.C=D-%
MC:%F;)@P9MT\:IH-6C1%)LW1TQC1-%/337&-=<8X19/XQO[-CQ[_ ,C_ %/_
M *#0+A%.+A$X1.$6E;CMAS $ 46AP9":7'8:K\=6<#4>*LFSY8=HVR;F,O)-
MF[U>,UC!DG[!_-Y7LS<[M_K0T8 ,S<ZED/C)TBT3843$41UWMU,UBPK2M6X8
MO-$9G-(=4M@V%*K L0O!RP\;KO&JQC<U(0^%B6Z+>,04,]SK'8B!;B0:AI^7
M<NBA@BD'1LT%3:MXXZ%BYN(^R"P\=(LI[6UB5<82*#@0K=WJ@"LN+1(T^8:9
M<Z))F6+!R'<.DW;1L_5=,7J+<BV[PB<(G")PB<(G")PB<(G")PB<(G")PBXT
MPZ?L1;]X*%[FR39JLLR$)O&P_<BYTUSE)IJ]>[:M&NRVV,:87<;823]?=OGT
MQSLA9&^6-DLH@C<\-?,6.D$;2?EY8P%[@T?/5H)/Y+AQ(:2T=B 2&[ V=? V
M?@;/QL_9:FJJTY-8[P_H1K$G#!D>,R&-.BA"3QHQA:01HHF+?,$&8=RNY^!3
M?ZA9!]OC5'=-O[=M=-U=,<E<IBZV.9 8\E%<DL0U[#8XZUF'5>Q$962%\S&M
MV/I:Z,?4"=C8&UCP3OF+]PNC:QSV%Q>QVWQOZD -).C\D']!^I6Z^0RR4X1.
M$3A$X1.$3A$X1.$3A$X1.$76F\@G[?!O>"2-QDZL03-I0]Z].>EE@1[O17U%
MT;UY"#W 1I<Z%_\ 6V16Q#RUJ;2PXUE)9TKO5MN_M,B1@%7D>4BY2/*N-2+L
ML\(G")PB<(J/?P_/^@K-OYTNY_\ 7F5<(KPN$3A$X1.$3A$X1.$3A$X1,YQC
M&<YSC&,8]<YS^F,8Q_'.<_W8QPB_F?>9OOUY&!OE(["(]6NQW97-,1*5@V5)
MJU(<EQ"!CD'-201E/-( ] (.1+AJO(M#R)I8.NNW4>X>^]3/[V>$7]!VNNN,
M171AT]M<O*KXL=BP$F1LGN!VP-,XJ7W:-E]'L'KT6,"5I!2K+;.6J,ECD.8S
M=XTUU2D$I-N,JN52*4G"*/W9,:*-5P^"'K7LJH@!E,H)/'JQBT6E)8@%(@2K
M0H*)IRNJ[99"1&S)99XJ7:AA+QJY:-M=#2*2BK5WC6K<%./RV'/9'L@N9#--
MK32XEPACD+&AK22]P#!KY<"0IK!<?RO)+AH8B&O/;Z->V&QD<;CC)VECA8R%
M^2MU(YYGRRL:RO"^2=^R6QEK7$?M0+)D+K;48'MFQK2%"\(CP\IM*)Q6+%A0
MUD#&-QX]FSB]7U(.)AFK9-(@D3=!'[ITX=NTU3BR*2+9GQ7M0W(72UWO+/EH
M>^&:+YZAP<&SLC+VZ<"' %A^P=]]<Y? Y+CV0BH9>O7%DALCJU7)8_($M\SX
M70R38NU=C@G+XI(W0R.;8C.G&(!S"[@JOD\Q-6'-PAFWXO)Q</D# .R#C(V"
M'/CS<C 04DW<[.VAMZOIN/(FE\Y^C;[)[MA^$EL:[;+*8B\?8LRW;<4N2KV(
MZTS(F11P1,?,'TXIR[LV9Y!8^4_PMUU9H_.RKWRW$X.AQG 7Z/"<OB;F;QMB
M]/>MY7(6:^.EK<CR.*;$()L?!&YMFK0CUYY0YLMDO9L"-AV_++,@4'6;-)1*
M!8XJ^UQD9'TU=R,I,YSM[<)@HH+3>R0ZOG/KC#<.*>KY]-LX3SC7;.).S?IU
M"UMBQ&R1_P#5P@E]B7^4-:,/GF/_ "8HWG^2I.&XIR+D#)9L1B+=JG7.K>2<
MQM7#T!K?;(YFXZOBL='K_"WKE>/Y [;(!J5\LA+L':W6N,CNOM2]@M'S6Y(V
M37-1026'2<D!2A\^;K[)0V,/G5C, .'CIGDFXF,?BZ#9YJ)2PU=JO$=T-;^H
M\F:R.!@9A<;FN[<I!(Z6M'*RP^$5KC7$5:SW7FP]G-\AM0UVM<(_I<7-(]H_
M@RJ^FG#O57+6O4OFGIH:\W!LK4CH9FY2M8BIDGYSC<L0?G<O7AXO9R)@AG]I
M'@\GEY)8#<<9H&P2-DUEX<J3LXS3ECY[)B+J2".95&7,(B%ENYP$B$BC"D7;
MJ(D$ 97+!&8QI73*""0Y_N8A^R>J6Z8G#G.7&^!Z88K(2XN]^W8\L(G68#4J
MWW7(:L]<UVEKVQ2]&VJY&@&/,M4@ B/M]2M?XY>>\1H\YXL/2J[P%]^+#Y6+
MD&;XG!Q[(9O%Y=F7E;)6DOTQ9?@\JQPDD?:K-HYP.+VNNF(>(7BD'D)@4>;)
MDG46A<78:HCF&CY<3' #+.==_I6+35?9F.;YSKIO].U1QIZXUW^/3TUSZ;9>
M^I2A;Y'5JE=FHV=W100LWOJQO8LC;L;TT:_/07Y^5H,_R/)RNJPYC/9>R7VK
M#J\=W*9*?3F^6Q,8Q/:ETYS?),_M\EO9VR%JCJU(HP>Z_P!.:1PZ!-*"ZGK-
MB8T"$QY'<<0TA0;&[,EJP76V:/-=M%,;-W6$U]<Z;XSIC.NWI'\?GKS8?&""
M:&4QXZ@R012,D\;Q5B!8_H3U<"""UVB-'X5Q]7L7EL;ZD\Y=E,=D:#;G,N5V
M*3K]2S5;:K'/7BV>J;$<8G@(<TB2'M&01IWR%(+DRM:K3]F5Q*9Z] *"[!S%
M!T?+@Y$V')Q0::W6/ 7SAXV>+/7KQ!3Z5755%!9CJEC7.J&=]%]=U=O;&7Z-
MBXZ$QW?;LAEAG:P5F2DS0O+VN+W/:>IV 6 ?WOW^2KMQ3E&(X[!DFW.-#,VL
ME2R&,EM.S%J@V/'9&O%!+"R"""1OF8622,L.>3N7J8R& G:0Q!ZV',6Y)]J4
M((-$$GI+5HFPU?NDTM=5W>K))15)IAPIC97#=-3?1'W?'KOMC7&<R# YK&->
M_P CPT![^H9W<!\NZ@D-['YZ@D#>MJHVI();-B6K7-2M)-(^O5,SK!KPN>3'
M"9WM8^8Q,(897,:Z0CL6@G0^[GVL=.$3A$X1.$3A%XVQZZYQ_'UQG'IG.<8_
M7']^<?KC_KQ^N/[N$75N\.,'*P>X:] R:O\ >!R8-'K1:$ 1'PTV?0!0#G+D
MWL@+_P 8),G*.T[9H--T$F)^3BTI?:X_#;,BSF1OR*NQ%VDN$3A$X10'\JW]
MF)Y$OY'^U/\ 0^<<(N6\8W]FQX]_Y'^I_P#0:!<(IQ<(G"+IT?B4/*3/.D78
M*@ZBB-&4O8K>55G"[<<R^??M!2E3+,3N]^\>P9FXB,UC3#:&S!A#,Q^4LW+%
M=\^"2(^S3?(8<H90(KQ?#W*D;XZ44UW D,<" [+[&1!8P<'@=7NL;A$4 3&6
MBHC5]?-2;L@^!P*,-TG1!N.7(/7I63&I%*3C\@9-.G/"*U+A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A%HRB/_%MF_P#;G;?_ +UNN3><_K,9_F3%?[LU
M8M3^&;_*K/\ M7+>?(192<(L:E;J8LQ>%H."C4B-?5(Z;#Y7+"D,%X9;:JY7
M<8,"(7/'>SI/?".J+/(/5)?517?=\WREIHMDU64WRZNSV:\/4D25:L5R7OL=
M6^&:Y18&D=B7^<EI  8[9+?B0R!NXFL>[8^))'1MU^9[-CE._P!!U^?U"PBD
MY[,+.@$:G\HB$:AS*9QF,2V-, $W*35UL'DP5L:13.*$8%!DA9)JD\;HJMF&
M3C513YMM7^NJ>GS9N:H5,9?LT*UNS;?3LV:EF2>E%3:)JTSH7& 1W[QEC<6.
M(=)X' :W'LG756EDGACF?&R,2L9(P,E=(>KVAP[%T46B-@: </YK;G(E9"<(
MG")PB<(G")PB<(NKCVE@!]EY0K^E!2NR;0!+#_65[&Y-MX:[([[B9=D/6<3"
MF"K7LKJNR&U21$O&*<=(@H[N[AL5;"!DPSJE-2,\TW(NT=PB<(G")PBH]_#\
M_P"@K-OYTNY_]>95PBO"X1.$3A$X1.$3A$X1.$77/[C_ (C+K/TZ[36'U?F+
M")N3E:$]1$G+$3UWL7 E^O'8Y(6+9\-C'66<"UU"2)_?1JI'Y,?:I),OD(.6
M*[C5FD16YHQ2=]G$TB5JC2U;T$[T27%TDHX^CG%K,-\X51?7N_'K[; (62UP
MDLE2 -[E8V*SAG<9E^P-R&H0Y%A]I1>%XM*.%\]S15-NZP3>LHG633'7M@/A
MS,]%AH1T.V'2J,.SWTS@8BB^'MWSG&K/1WIAEKHPU:HZ8,N4QE>1T,^1HPS,
MUWBEMUXY&; <.T;Y&N;MK@X; V""/@A6G'\&YMEJ<.1Q7#^4Y/'V0\U[^/X_
MEKM.<1R/AD,-JM3D@E$<L<D3RQ[NLC'L=IS7 3J3SZIZ9]_R^NFN?D_=_P I
M^[C]_P#<QC3]_P#[[]W&-?U_=QC'IS.^_P!E5R""00002""-$$?!!!^00?N%
MY44T2TW45WT333UVW444VQIIIIKC.VV^^^V<:ZZZZXSG;;;.,8QC.<YQC'."
M0 22  -DGX  ^Y)_(!&M<YS6M:7.<0UK6@ESG$Z#6@;)))   V3\!4[>4COL
M^H2EP2] 2JLIH=EDU?5_-$5<YF;(0#(1&1+.T=G$?--&@@]ARW;?"W?O-W7P
M?,IJ/42UW43UEZ@\Q?A\5$[#6*%J:Q;=2M _W4R*%]:=S@70RM;%-V:W37O[
M=>QZ$#8]P_A#_#E7]1^>9&+U)P_+,#CL-@(.2X)[-8*Q=R%;-XN."1L63H33
M7<<899O)+6@$/D\;39:]S6/QOH%VH[0]RNJ]L+/X95;LB!>R*KQ!9 L;BB6C
M/2N@2@]FC&M6,GV.ELKEM]EWCV31(=G5PU2T4_R+E37'X9R+D'*./9(OJXY\
MD#Y\?'()9:PZ^QA<Q@@#+'FDW*27NGK,/9H!^'$2OXDO1[TB]"O6'AL=;/<Q
M@JY"MB^77:4E+'YEYG/)\BVS._*NL8@8^EXZ31'!!B<U9!AF>6?O(FFL;QT>
M._M+!^Y,%D-L51*(A!($\F JP#P6R004F =GZC/+ FJ)2!3E&5Z?=%9$ 155
MCJV^N6Q)1J^63;?<$TZ!PCA/(:G**4^1QMBM3IOM1W9HKT4,D+IL9.86B2G;
M;8'D=/ "8206R%KB!W ]:_BA_$[Z0<A]"^18OAG,L1G.1<CAP=OC>-O\5R%^
MIDH,=S7',R,SZ?(^/289WM&8O)2,9DXVD2U&S5V.E]LYW:YB< A,%2=)0^*@
MH[DAOJL3<BQK9L0,.=<>GUILGJG]P-$-_P!=EB!5T\>K[YV46744VVVSZ,K4
MZE0.%:O#!W/:1T<;6OE=_P .60#O*\_F^1SGD_))*_&[,\DS_(7POS>8R.4%
M9ICJ17+4LM:C"23[>A5+O;4*S=Z96IQ05XVZ;'&UH 'U2M:6(BL_DT-'3A95
M;"*C2328E%!VC)1%?"KG0D*B4S<J.DU<(:)L]A*22J:BRFSY'9'1)Q]6#9$?
M]RQ032$@%EBQ)68&$';A)'6M.+@=:;X@""27C0!Z</'AI+FL[>R>/I-C+VSX
MG$U<S:=.U[.D1J7,U@HFQ/89"Z<77O8YK&BO()'/CQ"F0DWBU=Q2(SD9%6!&
M(1J-QALXB<H+R9D50! V(Q0BON8AL.7&JN%VN^^C!- EIHEMIG9]G?UTQBXN
M*W7HUJUN.NQ]:""NTUK$EALC88F1EY,M6J6%Q;OH&O !_C4WSJ_@,OR?,YOC
MUO,6:V;RN5R\L>9Q%+$STY,CD+%MM6-M'.YV.VR*.9K767257.>"!6#=..SE
MVS=TG\3I!%RE[L;?&NEHLG[L>OIM[%-=M?=CUSZ9]/7'KGT_CR0<UKAIS0X?
MHX C_054HY9(G=XI'Q/T1VC>YCM'[CLT@Z/YC:]6[-HSUVU:-6[77?.-M]6Z
M"2&N^V,>F,[82UUQMG&/TQG/KG&/TYPUK6[ZM:W?WZ@#?]N@%S)--,09I9)2
MT:!DD<\@'Y(!<20-_D%]'/I=:U9.[F@5;$6 N7+RIJZ*98ICE!-<V-*A[MT3
M<N6C :B6BD4-BMC#I=JMJB%R]P6VU^%7Z/"3EMNK)T</>R,<DM1M5[8@\R"7
M(8^K(QD36ODE=%:M0RB%C7@NFZ>('L.^VN Z9;$<) D\@+M %L,T@)<2&M#H
MXW-[$@_3OM]OC1&\C)MUYS%6RD>E4M@_WA >29'1 82/D[1JI\3K5NL$L>(G
M4!RKE'.&[YD9C&A-IC=1+V,7FGN3QXG-I6G"Q5J7O"Z2-\$LTLE9[AMG83XZ
MW Z0-/U,?#9,3] [>PZ/TX&6,=))(NP!#VM:'@??1;-&\-/Y$.C[#[?!6I^K
MZDR,5!"9K.+)EEA&YO$8T==YD@VOQC0.\79*+O= K>"P>'>UN]4<Z97T+;E]
MT\-&V&:K7&77U,KR84X<O=I4L=5Q\-*W9@9[:2_*Z9C7AK#,Z]=N?4P-.C"(
M0>[NX=IG7'H^5U>*26>29TL;'DR-A:&DC9ZB&*+X._GMV^PT1\[D1ROK,3A$
MX1.$3A%KJUK9KZD84[L2T9#I%H:R.PN-.C.XTP6U2-V'-8]7<.8_0@1Y0GOL
M9F4J !=%TV6[5EN0U>DEV8UN[>-R*E/J9X[+9J[NY NPFW4OJGU8A4+%7(SE
MAJJ>T%]WS.+73L$2F-CP_:&SZMH/"X:H,*):2(A(42)4DW;?6QL8WW:%W3M$
MBOQX15565Y8J?K#M!?O7$S )$^8]8*KD]N7;9;"R:$:Z1>-Q2AG'8$GJ'IX[
M:@>^IOG6,9#AE2T-K4W'!L@/L$31D8Q0(O61%ITQYMJ[ 1,FH5ZP7ZC<D5(6
M(2G]!(%*@<32'U75G7B#=IIC;*DAUL72#FPC>GK+A+@7'@\A<2HM,RZD/0%:
M+,EB.2+(O*7W6Z@N?'5W:@KCL_0(:Q;)Z'W<1@]8R*WZ_CUGR-*SNO\ )"E?
M-QE>&)"SF#HC,61L2I'!J(?=Z8V(LTQZ#C=PEKN12S\8W]FQX]_Y'^I_]!H%
MPBG%PB]%%$TD]U5=]$DDM-E%%%-M=$TT]-<[;[[[[9QKIIIKC.VVVV<:ZZXS
MG.<8QPBH>[/>.6$>5*<B>RL\KZC9!#1[* Q*A5[5CE@%S9:GX/:25AR&7?\
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M+/#)-#.RK.)Q#-!(8I(I'- :'M>UP^"X'1()"^(9FSL;(QKPQS6N87M+>S7
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M&OIZXPIJGOGVX\?C"B4?W'F,);/W+7778UP'Q]SFH,9&3\_9DC_ST2/E;/\
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MD+XCV;[2/L07D@A[-?'P>I[7U-VC1IKG5JV;MM<_QU;HIHZY_P"O">NN/_\
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MW1)"<6$-L:BUX1*H/'=Y/54_J2"NQ]BQ23-H_)9O%\2]@ZV'/W<7E$1=&A#
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M^OZ@'\EQ'&8]_O)7@Z^'O[#8^Q T/D;(W^A*LKY@+L4?[SZL=?>RV8QM>E8
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M38W.V\4+C8GWJ]*[':EILGDCD9$9F,\8D=&YK?@EI TI$U#^'OKY&6*;]G;
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MC#.SC*"' -(,W*C_  [G5]XT-[=OE7][%M'#+6$/8-/;HIA".CLIN,F6I%G
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,$X1.$3A$X1.$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img29677477_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_18.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1T@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '02^="@X0DE-! 0       \< 5H  QLE1QP"   "(   .$))300E
M   0MV9>?53;01#W5P=W'7#,93A"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!Y
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  0X   &_0         !                          $
M!OT   0X                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   0X     %)G:'1L;VYG   &_0    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   $.     !29VAT
M;&]N9P  !OT    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     4X0DE-! P     $LP    !    H    &$   '@  "UX   $K
M&  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)
M" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( &$ H ,!
M(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)
M"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@%
M PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A
M\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!
M  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:B
MLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ .MNZ%UW.^L74+K<
M[(PNEN#64"JZP/<UV-Z+_LS&7_9\7T<M_P!I]:S$^T>O1_W'L5*GI_UM%O2K
MKG9;G&,CKH&0UK'.LM8^K#PZ=]K*VX+F;LG[/]F^T=/WT>KD79'IKM4DE/#]
M1P_K==U"^TUYC*O3I.0S#RAZ5H]3&^UU=--MV)9B/IQZK/2=Z%%V7;?G^IE>
MG]DKL)AXGUNV=5^T#*^U.Z9Z5!=<PTW9HJVNR,;T[J_V?^L?H\=E-./[/UO*
MN]9]/H=7U'J6%TO#LSL^T48U(W66$$P/ZC Y[_[#4!O7NDNZ;3U1E^_#R-OI
M6-:XD[AN;^CV^K]'\W8DIPK1]<LCIW7\9[+&6[0WI%E;JZG2=_MK>RUS_8ST
M'^O?D?I-_P#@OTE-6=UOJ?USZ0Q^387>\FBE[6LL-KZW=4=A;<7>ZBG[76WI
MGVKTV59%G\UC^I;^CHZROZP])M9ZE=Q<V6@G8X?2#WSJWZ#&4VOL?]"OTTC]
M9.A#=.;7[1N=!)TDM\/WFI*>9RA]<L&J[(LO=5BXMV3F,ON>U[6,_P L>GCW
MM8]UV5B[?V.^NK;993ZWZ+^C>G5?R<OZXOZ?TJ_$QS]IR;#?FUD5@55/>VVO
M!R&Y'HV[JL2Q]-EU/Z7U\;_A-BZE))3Q6WZ\Y#L5UPO:7/<W*8WT*F,/KX%A
M-;J<KU;L2NAG4?LEEFS(N_F<JKT\C]+:JL^OS,W %[*G8[KBS+],,(].OT*'
M76$OJ>RO,K;F]0Q_1_28]K\?%O\ ^%ZM))3RM;?KI7U1[F-_4/MN[8\LL]2B
MRYU5CM]E[K<=N-A;,BJJEG\Y_@O\$IE_USN?UVEM?HL--@Z/8_TM+0;65;'5
M/W;+*OL]V[);^CM_J>DNG224\+DX'UDL##T^GJF.R,@8@OS6O?5D'[ <3)SY
MR;?6P&OJS_U6Y_4O\+^A_6*::KG3Z/K1CNZU=Z64;+:+G]$9D9++F,(=>^K&
MNJEFS(LN?7=79:[(V8#\?!^T_J=OJ=<DDIXS*?\ XQ*67-I_6&EY%=K&8_J
M-LS:Z',KLMJI>W)KKZ7;F>KL]"B^_P"S_IOYJOE._P 8XRLC)JJ<'@>BUE9J
M=0!ZCGUV85-ES'9&^MN+]HOS:\>VMEF9Z/\ @_2[M))3R>8?KKB=);]AK-^8
M[-RW6 N98[TG69%G3FL^TV,K;@O=]FJO_2_:<7"_F:]_\T'J'3_K,WH5K6NR
M[LZWJ5]SFTW&6T%U[,6MD9>#9]BV-QG>CCYF)93ZGJ^B_P!.^BWLDDE/!W8/
MUR?7FQ7G,SGU[J;&9K#CBLMQ?3Q::B^O=G5/JR4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MU?_$ !X! 0 " @,! 0$            &!P4( 0,$ @D*_\0 21$  00" 00
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MVN@%A<\[06O'_))0O5D+).KVE+V30<JLJ21^12PPAVJ)240O.]!I*MHHW.)
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M/;-27LY%+1NI:/1#0VF!<5(FQ",='9E8"L_T*HFDL/L)H)Z) ?;MY:_&5IB
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M=-VF\ID=>T_8\CL<UVRMVLH85),#4DC"43DPZ*X+NDPQ746%R&2+/WK/9&*
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MOV;%81M(8JW*)#M2[/U C3U2[[2_PB^ 2J9T?@JF_97N5<UU3/K=7LU9OV+
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M]TRV&NF+-R.V231V8.&J"S+9%+.F4DMFJFFR&4D\Z:933RG[=,Z:>W&/;CT
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M8]82F$$)BG&^5' S0:SU'KJ;;Z*;;K,M4<-E=\[II[YVW2VVSOIIMG/KKKG
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M&RF-<*91PZ15PEE3&FF-\Z>W.^--<;>OMQZ <9A%XR*<8>"XZ"&N]=-T]73
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MRC<OE"U=:H).4I@,C8$H]+DX^[170W8EV;50<\PLCENZ4PIIG8"17 ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M(2<:+@GLR2.BH7-B\<4?K1<-)FHI@\<-7*C9\L/0VX!Y5SXS)DG!&400DG7
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MMUU">4DE>SMB\> 2;D27 $-%195^ ."#( ^Q&G0!^.R$26CTA!&1[(H&-BR
MU^V1<M5=, 99X!6UWP\B\,Z=0H,>C ^'7'+'=@ZP8]!6-D#0IJ,:Z!CY%X2)
MMF R2D&^S)\&1%.&KL<TPDY>ZZJN-%M=$%8+R_F]3C%2*:NRKE++KOP<U-EZ
M.*:OJ*9[WR-9'.].Q\21N:YC=.>FUWI%VH^SK]E_/=<L_?QN6M9S@N&AXRO(
M<=R*QQ6UD*&65U_&U8*M26Q<Q-:1)Z]Z2Y%-#:F5\5=59$YCED9YSH=Y-8;W
M!%31Q,PL-H\S'I''H_'@!:S1Q8A+U#S9RIKN+0)"(NY451=HH,M&[-L^V77=
M)Z8VT4SHGOT</Y]5Y-';=:BJXF6">"&&&6_'(^RLS7*BQI)%7<JHY$8B-:_N
M5R)M%]+E/M%_9-SO0^Y@8L%D,YU!HY/%Y/)Y/)4N)6J5;",QLL35;;DJ7LQ$
MUDD+Y)UDGEK(R.%[NUS4<YMF,A+8 @#AS*&76 P<F6RUPK\.7.!S)=YE#"WQ
MJ_%E;X?C^7XE/C]WN^/?T]N;!-0RI6IO*8;M"$C9\)I2N)Z#Q1<4[&39'KCV
M-<7X5JNO'IF$-YQ';$8(4C!=A-S1N+3$G-(A5 ]0L6LYA65HB A$:= !F,D
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M)R>+1M1I#01QC"FB4<P!VE>^/_KY5@WKF/@S66AE>J^ET?N0%<GT'Q,6XOA
MJE.7AE0@,=-) XT6*[O@>I-FJV&O60Y3=NZ2:_#N!XLKXL^E\AK.3U-+*K'3
MB+2(?(DF#F?L@$]E$'D4Z!A1%GS^OI9,01N012=VV0C@*;6><9/]M)C9#!2P
M"3+:5%CI,H!)^M*<;0.P;6GN=Q*6TV:UO"HB#!,,#!4,J6IHV[90R'I-D]4F
MRJ[:5RNR9)E=HV9M6;"4C8Z@@JC'TR#X#.' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' *'_ Y_%;RG?TTG
M?/\ K&N^ >R\NW>CL%U0J2'2"DX[(:],O[BUA[V:S*.UQ)(K)06D7ES_ .$"
MTS)9$604?.Q3(FT<DH\'<:L&ZJ3G+5PKEFI<_27A& Y7EKE?-6(+\,>'6XRE
M3L9&M:K3K:J1]T[_ (:O"Y(V2OB>V.Q,WR.:K>Y$[TBW)LM<QE.*6HQT3W6V
MPK+*R&2-[%BF=IK?(YZ*JL:Y%<QORHJ+I5TOC?$+Y >R/:Z,6P[NT$>LYU'9
MG#@@<] XQ6T:#Q9@9'D%7^TA26D<6?.M,J(IO?D'C#*Z;5NOJEIE;9-NK[.K
M? N.<5M8IF%G@QK+%.Y/-!>LY*S-:DADC2-*ZMK6HV>E5FI)86J]R*J]J*YO
M5QC,WLG%9=;8LRQS1L:^%D,;&-<U57O19&.7W[^5KE1$]>_2W?RXDY#123EV
M6=-7@J/&B33*FF%$\.6(URZ0RHGG.,;Z852TSOIG.,;:^NOKCUY1A+BG:@KU
M\@]E4M$+B!L2<F%O^LD!O@QBX:\K:MVDQL[=2OY:3IJJ'</D6Y#>&V37!"S6
M+&?S  SS7\L:588R6E0I_-(VV [&VN]%]U7UYJWN"BRB9^/WR>D!NO>MI 0_
M_,XJCI;6^DLK2PBDEAC*4GERM5QR+.+X['IM1I,'&JPE5B1N.;G)17<&7FP$
MHK2OM]&*J$#&EYN LMBV*\;V%;3;KO.#B=IK2F,KJAQ?64+N&4KNR)]9<R7C
MC6.1>'&K+R+ D##'9D[-MVA%L!'J,=F^X.2(%S8CFK85*(M8?7_KU8]1.8QN
MN,)6#;_6^.6S)K!UE3&6D"(=I#IM.1##8$#(2./MHM7ED,OO4D>D@\NC8&7J
M?[)6:&H3LS?MB'FET5+4D+,6%6%G!H.G66;A8PBM'LLLES!@>"11(C5&TE&J
MBZEGSO"*\M&*/WK=S+8RSCEAS0#',0[1]BDNT VL[!6T1@$+M6L.N,VD8&O(
MDX@LSL^<]2HS?Y B@7<VFTM2*/GLQF@T'%,B*XE4$#QP'N,E)0H;E;N1UP![
MVW.]-FP*S;&@L/Z\1N9!(/8L@J=A*CUY+PI<Y-HMU+C7<8RH[C[*H9IN%BF:
MY,%(R,,HE31EY/QHX>ZBXZ,%G4L"@>)9^31V;C+"Q0])))U?-!=S-*T-O+*:
M*6*;G5-5XZE!&,G:H2B2>HIM*):VWA,+("IW(%S6VP\V_'@VD@CC<J!YFH?(
M58V=;2JV70P?8MR53=+6EOOA(CFFHG.9)/>S$KH:M'@/3,7E*RT!%M(F6)6-
M8@4>90$2%LT@<:C\PFKHJ&  6'=?+C(7;5&EAEH>E##;2;7+7YV)CI.VFK1G
M(:5M^>T\=R)D[<6"3,CBQB!/2@EPJ'$N]6+]LW?L&CU)PCH!6<EV=[1%:CZX
MV5"[CKJ66KW/KT\3B] J1",)MJ:DDNZW7+=]2OHNHQ=:SDZ)A\IJG:M;26L)
MP=:2M;\SG8]FOWH#$37 ^N&>06WK=L( A6&D8<U[VGF]8H=,W1$*H@X>PZFI
M5&&_>?28$M-GN=R+*.9FF8$^U&J(C51>KWZ4K\&[/8#S-R>831KU<FMKUK"!
MT)F[<C9L8C3F>D?SS%!9NBHC'#URO#2L!U4&JM$93(QM>4[G:0MUK:U+#+F"
MC%*:24./0+2JMMDA+;;NBNWSAF4&1D)3]IU\;8,U&>'%9W("D3(2,+84SKLX
M.CYK6-A//J-6S+_DJ8B39RW4)-G[YZ!(;@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@%#_@<_BMY3_Z:3OG
M_6-=\ N4M*EZCN\*PCEQ5I![0 "BFAL:&GD9$R@8P,)M'3#0FT9&&KM!!]HR
M?/&NKE/357#=TNEC;V*;XSDL7F<MA)I+.'R5[&6)8E@DFHV9JLLD*O9(L3WP
MO8YS%?&Q_:JJG<UJZVAT6*M:VQ([4$-B-KD>UDT;)6H]$5J.1KT5$<C7.3:)
MO2JGXJ<2JZ)I>C&9<?3-50"K&$@<M7IQG 8H&BK8N[9)*H,W)%$,S:)NUVR*
MRJ2"J^N^Z2:F^FF<:[9QG[RF<S.<?%)F,K?RDD#7,@??MS6G0L>J.>V-9GO5
MC7.1%<C=(JHBK]#BO4JU&N;5K05FO5'/;!$R)'*B:17(Q$151/2*OX&4'+9N
M];.&;M!)TT=H*MG39PGJJ@X;KI[)+(+);XVT5253WV343WUSKOIMMKMC.,YQ
MS%'H.J#1F.1V-"H: !" L2! V,9"QD6/:L (F.#&"0H<"'"FR2;%F(8#$$1[
M0>W03:MV:2;9)+1'373 '0BJOK<$XB3L+ H>*=0&%.:W@S@?'!+1:'5\\P U
M>0F,*(M--@45>:Q2+ZNP(S+88YUC@/59MOJ*8X0 \)+^L'7"P*\AM23FB*CE
MU6UVN-<P&NI'7T7,0F$KAP[^/"%8I&7PQ</']A0 J3!C?M3-KAB(?NQK7"3-
MPJCL!P-.I?5]-Z%(Z=>Z;U>QR$;UL!<:UU%<;B("H%/QO,0'^@OVM0&D<E<J
MCR(Y+75NW!2B2AT-$QQXLV> <VO^KW7"IHE,(%5M%U17$+L%@H+G$6@L$CD4
M!RL<L,=AMV9X:#'L6Q)#(E^]'8T=)J8T9NET-/:FIMKD#^8GUHIB*G('-E8-
M'I7:M=PX'" =SRX" +6RX$@(^]B[)V4FB0EF_=&=P90T.<%$M6R^S0_(&B/P
MLS9)NY ]V^JJLBCX@3)5]#'Y$L>?2DH_>1L0X>$9*3@"-4D3[UPJTW5<F']8
MMF]?/"2V^[MQ#$$HTJKN(3U:8 BK'O'AUSC_ & W[#Z@$B<A::)YC,4?0^I&
ML6B+EL,B @6Y%E 5:AK),IQL?" 36'"9M8,K 0Q%NW0BHD0W#QI(&!D^XNH]
M)7+#3<1*1 !%W!MP7<J2N-0JMWTA;JR>PHS:4T3V:SJ%32*&&$]G$0 'YP+D
ML8.#).2'M2A-HJ79L"+0#E]=^J]2]8XX-CM9C'"'T$;WC"Q1X@"8NB#)S8=B
MVJ_WW%14)&HJ(3>3NU9L92#1B.@8P$2*:"(R!"!6;4>F!R!/4KK)'[.:73':
M)K"-VRQ(GRK6Q(W$1,?ER3V68>YEVWWH,W9/%&\O7(.7\M8J*;L905R@8/-B
M!1HT>( >R8472PH?$!(NIJY&#*^2E:$#8#X;'V32%HSML_935.*(-F"2<?UE
MK0H2;2/ K5I]Y1?NTR'U&KA7&P'W-:4IYC'Y)$V-65\RBTQC@:(2N-M(@!;
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MGNK7]==CN 2GX X X X X X X X X X X X X X X X X X X X X X X X
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MS(BU1*!B+)\FW(,VCU#1?5)TV07U42T V#^ . . . . . . . . . . . .
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M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'D+"%('8#.
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M<Z5&<N9<KX< < < < < < < < < < < < < < < < < < < < < < < < <
M< P/V1DEVQBJR[[K_4 F[K"=N6PE.%%[B;T4CH%))N&Y<\TL-Q#YQJ.)!4LI
MN&#;0%NLY7VUV2=MMD?=L!KY^)@Y%;5[JGB!!VM9L]HZNK!!:2&5^8DKWZ-U
M5M)3$<#236,5 ]K:'-&3>3.0[6/R"PQI(BT%;L6H-7;YR:6F +?/*1U&:=T^
MD%]TV/KV+6+:+FM;%>T,PERS%L-!724KF7PJ(25L]+*I"!A8<E+2;<::(XV3
M"+O?NS7=J_9M'C<"#]^]-^W)GO9#[>H@#/($E)E^I8:PNP ?M U:58G1U/[3
M-*Y:BL;JZY%L7<MD<@$RR0LZQ,#4YHQ''Y7B6H2VM'P\FW*@0 K7Q9=\XN.H
MJ;EZBBC>2=%HIX^*VB=;"[:A*N.WC3J#V7N*VIU.@IW=R@#@F#\6L(,\K\=:
M2P,KM,T#*4A3 ,L-"3H"P:M/%)<4YZD==Z[L/N!VYZ7V' Y/V;L.71#IE> J
M) EW?92_I==C"&R\Q^5C;&7.*I'2)O%11(3].*3>K2588H\'/F:VH'B_PZ4.
M6KND?(A7[B6RV?.(+Y;^Y4.7G<^)Z&YU-5HPSJT(K+9J93;M$R\MD>['8Q(R
M:;1KH_,/'CO1NAJKA+4#85X X X X X X X X X X!QW;INQ:N7KM75!HS;K
M.G*^_K[$6[=/9997?TQG/M33TVWV],9SZ8SZ8SG@& (7VRZX6++$H)![@ATG
MF*R^K;6."GJRY31QN/5+)HN&V6^NS5148BH_1U<Y1RLUU^9+WZ;:YR!ZNY;:
M85)&63Y,.[E\VE9A"'UA7(ER@U.V)/"+5X\'1P<NXUW0',6S%@1D$KDCQ/<5
M#88%D,O-9T$A'F^ *I+G\7G4J?W!USL?M%0U-7Y?]\]ACZ]^6))(6U?-I1@;
MU)O!<!!@3,AC=4=6U?HU[ PT+$KXR1<-X:+DDG=%IF2/FR0%R<3B,<@,0C4#
M@P49%HC"XV'B4/CHIIJV#1R.1T8V#Q\*-8([):(#! QFT8LVB6Z>J31NFCIM
MIC7&< 1@@%(]CHS=$DMF3WM3DD:3D-7T:F49"=;YC%5W &NG,W="$XV>?=FI
M9H"*O%IX4P0($@DD:;IM6.K<4WVT7W7#_J3#X!@ZQ;-GL+DT8!A:M;2IA,#N
MD:!&-IX/!94,:Q>0RQRD]'.0CU5HU0'Q@FEHZU77RNY^FTPCIHMMNGB+U^Y5
MGKPQ8Y+++,R00RK<CAW+\//9<CF.B>K6HRO(B.VNW=OI$7:6#QCB?',]B<OD
M+W+Y</9P>.7*Y&BG';611M%<QC,+"Z"U%?@9--)9R]1[HECC2.+RJLCG,1K\
MQ"ER#H8/<E1Z8HFNS;K$!B3W0BF/>*):[N&:9!-%MH]T;*YV2U=:-T=5\:84
MU2TQMC7&4C<]T;'2,2.1S&J^-'(]&/5$5S$>B(CT:NT[D1$=K>DWH@]R.M#;
MLQ4[+KE2.>5E:V^!:K[,#7N;%.ZLZ25T"RL1'K"Z1ZQJ[M5[E39AL%_?+6G_
M #&4'_K]V2YBX?Z^R/\ 9&&_YW.DXR/^BKA_^\'J1_ASI49SYEROAP!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P",?;ZSE*GHF6R!2F
M;UO,*62VATKB'6^/M)7;@V*RUD^#F9=&HRL6#OCF8V@XU=N60!9Y(<)[_4B1
M9%PW^EW I,\4(6MK$N:E,)]V:%M5WT3H*==?Z/Z\Q7KC(NJ?:0)"I5K7 <Y)
M>S]?63+G$S?%(^+@@$2HA#X#&:](2HFZERSE4GNQ0X!LG\ < < < H?\#G\5
MO*?_ $TG?/\ K&N^ 7P< < < < < < < < < < < A#'[!B=5VWWAGTV)9%Q
MR/'J06=K(M71$@]=O*EC T."!!QR+DK()-(C+Q@ B\9#-'IR22$F,!!&#XJ1
M9M%N/Q_1/^O_ .@9&IJOI89DSWL'<XW ZT9,'7 PN"JNFA)K0]7OG;,EB!LW
MC)5R.=SN5.AP@_<TE$N'#$S(A@**"B1B(5[%"COD'S>G_2MTQ_[Q<O\ _"+V
MBX!)?@#@#@&&K3_C;U]_GE>_[$[EYB\C_G.%_M1W_E64)UP_^I>I?_@6O_C_
M ((9;?/F0QD[)$GC4>.'MEWK]^^<)-&3)FU2W7<NW;I?=-!LV;(Z;K+KK*:)
M(I:;J*;ZZ:YSC)/>R-KGO<UC&-<][WN1K6,:BJYSG*J(UK415<Y51$1%55T0
MNO7GMSPU:L$UFU9ECKUZU>-\T]B>9Z1Q0PPQM=)+++(YK(XXVN>][D:UJN5$
M-(SKWV?[5&^ZM2(/[WO$H)E%^53%)"DZG\T=L#T#3M3VL@!754EN@1B^C<^?
MPV'N?E&ZI%BN$T\:O'7R:HX7/\BFY9C6OR^6DBL9G'5IT==M.9-33(_)#)N1
M4?71LTW:QVV:DDTFGNW^_?4SI'T=H= ^:R5NG?3ZG=Q'3?F.9QCX>-8&"SCN
M1OX=NQDJ;F5&RU<NZ7'8U9;,*LM*^E3[G=T$7;N^\VP/Y_AP!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P# '9:K+6N6L7$"I_L-*>L,
MC*&PZA:TH/#8;,YDA$FZJN9#'XPA.V12/1XP>;[)M6LN4$%GL>]N[L<QW=Y2
M51 C[UC\:?6OK!9!"^!:EJW/V7.1YS$Y%V7[&6M,+@N,O&G;A%VXC[<F>?IQ
MF+ -G""6V@.$1:,BTTTTT<-<I))Z:@6 \ < < < H?\  Y_%;RG?TTG?/^L:
M[X!?!P!P!P!P!P!P!P!P!P"*UA]A;!@]F1ZMQW7"<S#>8K2%.(205.ZF&B32
M47#M3)=PHU/3(<6%Z)(N?A03(,4E7"R6_LTPGMIOL!WW:B<C8+UANN4GC6D-
M7_<FF;(8NJ0P@2TEQV,$!D8 @U&"F[DE*BDD>CPT;&@OJBI@ZY8L0B#M\Y:I
M* ?F[>$ 3WN*>6CJ9BZ1G;8C"AUG$2MB8M!E<;N+L7[*HIOO$R4TQ*TE!+9X
MTVV&[1YX<]BR&=F.PU33.6^> ?J*< C-:'7 E9\YCLXW["WI"5(9(/S5"8W#
M$J.Q'(G(%8*?KL@2'8EU)2T^_P!RD;EDH2>-I$?-L4G9UTZ'M6.S03J. D4*
M9+CA8T>Y*/S;E@P9LG!HKJ/T*%UVK=-!4H2T$,!0K5^_4TV=O-1@L:/U<*J8
M9,&;;"3=,#G\ < I6[S>4BN.M?8:)5+(*QFTC*53)0M@DRP8B!;L"K&3U7,0
M[8>Q2>KZ.$W396:LUEU'&NJ6R;-SA/.=MDO6JN7=0:.!S5;&S8^W/)CIXKLD
MD4D+62,L8^U$C&(]4<CFK::JJ[TJ,=KZH;Z_9[^R%RGJMTRS7-,9RWC^+J<R
MQ5_C52G>K9&2S3L8CF."O2V;#Z\;HGPRLP,[(VQJKT=/$KD1&OU/*I7COM5"
M:_NJ<,M1592T#'YQ *>PZU(-7")%NV+!Y+:;[1)!M)2[;.R+H)#4$=XE''6F
MA8AM*)$W"$(Q,<:]W(JE+*VV^.A9AAMT\9W(]KDD:V2*?(/1$;/*WTZ*JB+6
M@<B2O^(G;$^OKES."#H]G^2\"X_86YRS"Y+)\?Y)SCPK5EC?5EEI7L5Q"NY\
MDN)I2]LD.0SLCVYK*0N=2K)B,7+D*V7R"!22QV5M+&$D\>E'4'MCTTUQZ9_/
MW9+]<?I^F?TQ^O\ #^F/\WLA1/O[(>D_JC#?A_\ 6YTC61>]>E7#]N<N^H'4
MA%VY?:?R<Z5^OK]/W&=N9@KP< < < < < < < < < < < < < < < < < <
M< < < < < < < < \_+4C2\5DR$;=[,)$M'S*0%]I]#[V1I0<YT%N]/N;=X-
M]S9]E!;7[@T=,?73'U;==O\ (EL!2[XN?)3<G:J4H]=+9 ]9I/8U-5JBWNFW
M*;[DUA;)^3S>,[BHP2E6:4@];QA$,'ETAR^<E2$7/$HC$#*R(!!535TP3P!(
MCS$RCL= O'?V8L3K+;0RE9C7%66#/Y'.=H\[/3!*'1&!2DVY"UHZ1+BV<3FY
MT^TCHU*:D43&(S'EY _#"LR?4$1' 5I=A>W'8V*^0P<&C-VS)HYA'8;QO4I
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M^=SIELC_ **N'_[P>I'^'.E1G/F7*^' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M7#865$FGFC9F<RU<BM.EAOMM/^-O7W^>5[_L2N7G.1_SG"_VH[_RK*'SP_\
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MVZ1-N73D5$];E[R)F0' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' .DD<ECD.!DI/+I $BL;#-\NR\AD95@#!BFN-]$\N
M218FNU8,6^%%$T\K.G"2?OWTU]WNVQC)$5?HF_X'*(JKI$557Z(B;7^Y"@3P
M%V77!AGY-XP)L"$E)+(?+OWHGX"/#I6">G#D$($ZZT834.);/U7Y.)/M\XT9
MR1DW7#N=LXU1>[YSC'.=*GU14_0Y5KD3:M<B;UM45$W^6U3ZEP=W=PNL/7+;
M=M<UVP2&',()ND(;L4V/V(0;J^GL6#UK%T3<_-I[8VUS[A$;>XQKG&V?37/K
MSAJ*Y[(V(KY)%5(XV(KY)%1-JV.-J*][M?ZK&JO[CT5J-RYW_"59["1(U971
M1/>R%KU[6OFD1%9"Q5W\\KF,32JKD1%4_-)OOSI>3E3NK= .KNZ]N!:D4[1V
M**KJ/KAH^T:"JYWM@PTB =4&;C8\NV;,8SD>RW%%EV)%%)++1^LV<ZJ[Z?;H
MI6R.@>Q\,S7K$YEB*2*2&5'=CF3PO8V:-\;]I+$YB2,<CF.8CD5#Y\3&6_"_
M4K&V/&]:LT,S96))VN6O8B?+!*U[47PS1ODAD16O8][%1R[:W9.NE)OUP[ V
M!9H.T.PED.J=G8]S9-Y-95L+C+8@)6R3&5W6%)0*?=>H9$R;?1))VP.7*T!;
M+CFALTQ>EDW#U:28_ISC\I>JXS/\LEFL9"5*C'8A$Q^.I/L=T3++()\KBLU*
M^NY\<S8UK7)5>Q/AK%>34B6EA.;7>+Y7'6N)=.>.1U*MN&S9QG);F Y-R?DM
M:%S5FP]NYF:%S&UXK\:2TY8\'@<1#9AG=!DJ>1A[HW5#^'FK10KN_"W@"HS#
M%ZG"K"36S1Z4 KV?/&BD><:N6;.5N34%W%CG&FVNI3+&4"R"K73;1FME;;&N
M93<Z)8;I[6L\D@YP_.SQRLKU:6:KYN>A"VWXH5?)7LY7,P67P]LLD2S49-22
MIM6MC3<WZD]8K_4+C'\F[/0?B/2VL^2G-;Y7C*/$(+;IJEF2=L39^-\(Q66K
M-O(Z&M)'5MM@5D*^5CTE=K<=C\+BX@DWD#3IG81*5(9URA,+*DU*3R9M\:XQ
MKC&DWEEYSJ7IZ8QZ9^/0C[,YQC.=?7&,\C$^1NS1.KNY/5BJJFEIX^#)4*;O
MQ]TJ>*IU%7]ZQ;]K[^IKLW$8V-W<N1Q\CT^DJPY2>7])+%!)/X)WZ^OT_'2\
M[U@69?N7V6+%P&P<D]N6=N7XER[U=KL'2YMQNJT7=#""P]=5MMZI[*,5]VN^
MV-LH[[:9TSB]^-NYJS&\<MXWE&#BJT,))0Q\,O%K=AR4[JXZ5_FF_E%46:5%
MQT*-E^'K_*Y_=#M41-D.-\3Z-S<,=C,MP+-Y6QR"7C^:S&4K\YEQS;>2P]3+
MPPSU*3N,V/@Z\Z9RXZ2M)+8<Q4A1LJ=B]VXSV6L>;:]1+[:/J!L%)LKUSM%J
MN3<%J1-1MFU4K0XBH0,,'-H_<WX=LEG9R19-X\5=N66BJ"0M^MOAHK1&(HPO
MSV,\6<@AE=EJ79+69DH+D<JW(NQ]23[O?%%9:]4=!(]Z1QRHUSG(U-E%XK'X
MV7-XZ&>QCKM-^4J1S8ZU%DEBN5G6HVR49O%59W1V8E=7DU/ BM>NIH]][=8+
MQ12P;&>]U/F20%ENST;67NOF(52U.R-'9:I9@S3R%&0&'OY6FEG;5/ZY(&T^
MFT;*D7Q%/5LJ2<YMGF'&[%/C^=GCY+R.X_)7*%R_7R^<A=C[MIGW9CXY[:3Q
MUX?)%3H4HX=RQM1U6!4:Z3^E=//JG';G%:\%'A/#L/9X_1AQ>!OT(;E&SBL=
M/R&YF;5."S=R\M9(K-_-9>:3XEDLCG7Y8XGMU"UFX>T[#T@XW20=6;%(\^6V
MSHF)FA#$#.;;XS[<Z?89IH!,Z[XS^F=-F.-L9_3..4>[$9-J*K:5B9B)OR5F
M?%1:UO:35EEB5->_3R@G8K(MVJ4YI6I[5]=OQ,>E^B^2NLL?O_:^OHUAN[U?
M>*J5=KKKD5LV5VX0L8M*TW<J3K0=5I*":D=PPK77:,/R@9Z_<CE&NC93Y'#M
M;;*^RV-=OCQIC%S\=AYA]S8A]7%8N6*M7>VE-:Y#R^E:B8]SV2:KT<[4K5'/
M1%9(RK7A:]J(KVN<KG+-,5@N;/Q:,Q]G U\;?9$^6I;XMPNW+82"5\D*9"7)
M\4O7+LD$KGOB=>LV7PJ[4;F-1K6[/>0$9-]?M8TQ>JMH@4IW 1@4./&HMRUC
MCZ%88-2!4CED]9C'" Q5-R^>_;W39FIHJO\ 1KI)?!M3"2R1YCS31-EE9DO)
M+ C'6622-M=TD21R2(^=CW(K$8^5'2HO:Z3;E<0"1EB.=\<3G,MLE<R-]74#
MV6&O5K'5OAV,2%S9$18?!&Q(U1OC8U$:U-=_H[X[*6J'MC55D@NQU(3,C&)&
MY(1B*Q3MW%Y_)76^\4+L'37$3:==8DM+E]UW+AXFB/.Q;+%CILHKN^W9[_5V
M[R;-X2? WX:73JAA;DT",DRL/3NIAI(7+-&B/CR469L2TMP?L'.='961'NC1
M&,DTWWSW>KTT*P\CYEU)RF":U4L8_-<KY/D,4Z-7=Z-LT[\+:<T?Q/CF:U_C
M:V9K)/FD:U5VA.4@8LK?["^.VO;\M_6V2\0ZWNB*AE@5,+3BB9+,Y-+T&$ >
M0=N'F,C873$FI0:Q478&16C( *59JQZ/M5E'F&;AP\L3C_4+(X'$+BH;?(FQ
MI#)%"VEG:]*M4=)?9==-4K/PUMT4KT;)#*K[$K7ML6'(UG>QK,+<PM:Y9^(?
M#0<Y7-<]9J3II).V%8D;)(EF-'-;MKFHC$UV,3:ZVL^8?&FL/AD7AXMJ&',X
MM& D;'L@0M87'F+8(*;"VC4.%6)$7 X,V2:II#Q:I=\NT9:(M%"3I1/+K>"7
M++KERU;E=-(^U9GLR/GE;+8>Z>5TKW33-CC;),Y7*LDJ11M>]5>D;47M3+Q,
M;%''$U&M;&QC&M8WM8C6-1J(UJJY6M1$TUO<[2:3:_4P;#JCMZ/VB<L4U9=4
MEV\J&0P+(08BC9+'W&1D*7E2['((PZO:0Z"2+S>6/,/'CT2:;YU:M,(L$\X5
MV4S=O*XF?&08^'&Y2%U62Y-7FES=:PWR76U6R>>%F#K^6-B56=C(Y8'?,_ND
M7UKRQU[+)WS/GKN;(V-KV-JO8NHED5.UZVWZ55D7:N:]/2:1/>Y,\C9[3#<Z
MHR'6)(!,FD!BQT"0$@D6")1VTK BPL253"E([]R'AX](1PQL^5#&RS!PX3:X
M4<)$'.5L[J;^_&8HYNYCZ\M:O#CG1SL6*9;&+Q]J66)9HK'CDFL5Y)7,2:&*
M1K5=IKHVZ1$0\TM6.9[7O=,CF+W-[+$T;6N[7,[D:QZ-158]S577M%7?OV94
M$C4@XP>*0<$': YFW9).2Q%Z7)N$VR6J6BQ J27<D"+Q377&SAZ]<+NG*N=E
M5E=U-MMLXN619I9)7-C:Z1[GJV*-D4;5<JJK8XHVMCC8F]-8QK6M32(B(AZ&
MHC6HU%54:B(BN57.5$36U<Y5<Y?S55557VJJIV'.LY' ' ' ' ' ' ' ' '
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M8ZL^62&NL'8^=S'2KY:L$[NY8V1L73I'(FF-^5$1=KM5E?S &$' ' ' ' '
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M8-WCD,\?AG;\.]=#%EMV3AV*?O1KE5#=9B[<M=TEMP/)V_;,$HFL9O;]F&M
M$%KX ]D4A)?"J[<_3-===$!XL<VUW>&#IE\JU#QX$/27)G3C\>'&-G)!\V04
M I@ ^8+J]&05<W?!^J4Z#M^Q550KLYV3E@('5,9EE4U3(KQ3ZO0.?7)E(XQ-
MV<?2G.23;<+'EI,;C\+CTC)IJJ:L6HL@!?-P"-O;CM-6?3*@+ [#6NH4<1J#
M#/E91N.-,$YA.9.]V^FCD&A8CY$]BLGDQ+9)BQ0RHDT9HY=&"SI@$&DB#0"
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M*1QJTT:;@64< Q)?569N^E[0J'61YB"ECPF01%&4?E2'SK0"N98+-$"B\+L
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MX*PLR&B_S7*)G8QHJ^;@T1F"V5Y],VK(MEZ.%R8T*:,B"X$N^ . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . <$F,&FASX09'L2PDFT78$A9-HW?CB#
M%TGLBZ9OF3I-5L[:.4=]TEV[A)1%9/;9-33;7;.,@?8Q8LAC)H.&LVH\>P;(
M,V+!BW2:,F3-LGJBV:M&J&B:#9LW1TT20013T223TU33TUUUQC '*X X X X
M X X X X X X X X X X X X X X X X X X X X X X X X X X X X!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img29677477_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_19.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1<N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %Q*^608X0DE-! 0      !\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @   #A"24T$)0      $-/)GTL]C>HHA4@U:H05G"LX0DE-!#H
M 1D    0     0      "W!R:6YT3W5T<'5T    !@    !#;')396YU;0
M  !#;')3     %)'0D,     26YT965N=6T     26YT90    !#;')M
M $UP0FQB;V]L      ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R
M3F%M951%6%0    - %( 90!A &P ( !P '( :0!N '0 90!R       /<')I
M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M     #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         !.$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ,U    !@
M   "FP  !VP          0                         !
M  =L   "FP                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   "FP    !29VAT;&]N9P  !VP    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   IL     4F=H
M=&QO;F<   =L     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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M_P TRH-]1FW<VO[.Z_Z(?ZE[=[K_ -)].Q-5]7+J1;Z?
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MADG\=;K2"$]\5Q<%G\IDO1B\8!03^%B'<9U.W9,[$L5Y5 C:K\."6C=9DVG
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MK*Q05<OF;_KO9E0Q^.@V1,.@E82;^0.B* ^1,D"+,S&'H@9(]]4-W+QIJX5
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M\:Z0D3G&R8.1E0B*GGE[[-UT1^BRF/\ BZJ*;:Z_O<8SD"\?/[5]X[3\7^)
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MK5XDDY;H.$]%M=5T4U,;::@IRK5YZY&1<$P4\,6^U9ZGY3*>?]'[>6/+\?\
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MSPZG.SQEJRM"WO#F[ PFI(M(I[)7'T:G2U>Q%!R[E$^@D1MB$2NPX@ 9,O\
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MTI,"[A]AQ]?5FE88&84W0Q>H&L7F, LI[E>'QMY'+6-R<:]1T+FXXW:+89Z
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M&-L>W&,^S./K]OX<>?EP)KUX8<<J9SGAGB?SC\?[?U_5_'G[> UC+36E]"O
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M#_W]DOM]G_;[<^W\/ Z\GRI7T,IX''V;]<Y=,)93' PUQZ+-X]Q^+[?+^O\
M[N!/"K7;K7A1<NXX':?>7MSX#@8-]\)\<\6^62HBOGGR\LYSY8SY^7GGR\_P
M^7V9_;SX&;TLLIX^2^],9SKY^CG.//&<9SC.?/.,_9G\./Q9\\>S'X.!GZSY
MX-<OYP8_%_1[/9^W]? >#^E77VY9+' KG.<^W;.<Y^KVYSGV?9]?]7 IQE*M
M)>7EK"93&<XSC.,^6?;CSQGRS_O^KS^W\/U\#^=?5<^]?/.,9QYYQC/EYX\_
M9G/V>>/JS^+@5^LNF4Z9ZE14_;]O^W@3=$Y)M=L>OO6KR'U_CX#^WKQ],/8?
MM^WL_+[/R\#IBN-<>GUR62J.!JL\^6I.?,PV>_>WM_GZ&_ZY .!2C6?&?.7U
MIYY&V7!1P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#GIV1\-#K_P!DKF']
MAW<KOVD+O1A25:G[-ZSW;,:1E$[KIN_5)-89.G45<:H2 0S>+*J-%U&Z!AOK
M\W13*808#DV@$36%X,O42R)[-)T2D_9Z.IV;7M7U5:L,@O9FU(9#+6K^H(4S
MKV&1NRF@(TU.3-JE%FF6)1<W('3XLJ^*O7CK=V5?K+@9[V%\++K3V%"T+$BL
MDO6IH!UIQ U*3K>B+BD-5P"$2*LG#I>NIH)C(C19DG/8?J[4:Q^7Z>B>8M=4
MTTG>=]<J; 85/O!_Z^SZ[GG8Q2\.ZT.N4E6L&J4K/*[[3V!"Y 5A,!!" HP:
M1*B=DR3G[K. Z4GD^-GF&Y^9/BLG>MLE"+A;8#.I#X6_7R;W]$;]LB>=EK16
MKRWM;\KJG;'[ 3J74) ;B1=N"0^=Q2M";I1J-(!2;MT0 #,D%HZ#6<+("PS5
M@ILSX!+/;/HM2/<5S6$AL)Y9,&LVDS1@[4%U4E81VJ[>KIW)!Z8J3-X[,0"G
MRN!4D&HH,S8@DT(C7R2"6=FVJFOIY C2+>%OU+C/6WL'UC< YW-(OVKW+O\
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M_P#G.!*6EKL/HDF'O5=_!L?_ #G!1]$DP]ZKOX-C_P"<X ^B28>]9W\&Q_\
M_7P!]$DP]ZSOX-C_ /\ KX))+!)#Z))C[UG?P;'_ ,YP4?1),/>J[^#8_P#G
M. /HDF/O6=_!L?\ SG &:DF&?_6J[^#8_P#[5.!AK[=Q]$DP]ZKOX-C_ .<X
M!BD,JV6NQ#U5.SW3?7$NL!#9/$1 JXV4;3V2MUE_2WWQG&7*J6[G*>/WB.5?
MD4_^#TUX!E?T23#WJN_@V/\ YS@#Z))A[U7?P;'_ ,YP!]$DP]ZKOX-C_P"<
MX ^B28>]5W\&Q_\ .< ?1),/>J[^#8_^<X)+5/MY=!]$DP]ZKOX-C_YS@OK]
M!]$DQ]ZKOX-C_P"<X&M>W0?1),/>J[^#8_\ G. /HDF'O5=_!L?_ #G UKM+
M2'T23'WK._@V/_G. /HDF/O6=_!L?_.< ?1),/>J[^#8_P#G. /HDF/O6=_!
ML?\ SG 'T23#WJN_@V/_ )S@#Z))C[UG?P;'_P YP#";!K:4!XSL2=V*Y*MF
MAZ&[K#MXL%9:NM,S$!I\GERWWRLCC&=L;^DGCTL^CZ/U;9X!M?P!P!P!P!P!
MP!P!P!P!P!P!P!P!P!P!P!P!P!P#YINGW>*>]7/ RO7N5*/N_=TVJ.V.U*@-
MC.9.<+KER#CM+)H#"QQ@X]</S&D7!/#0O9XU9K:JMH\/<,QFS3;"&Z0']._%
M3[^U9!S[^WJ($:MF_9#I/6\)NJ8]:+\ZUPF=Q'L=.E8G;<:'US:TS>2/$NJQ
M5KG &8LI2^ &A1@.6+1MB[PN-5 A?Q'.]4]ETP=BS\3T.Q?HWX[/0&(PL'4(
MLJ_L2Q(VWJY]:9Z-.&+B0.64EFY*0NB4?""QR0)HX<[,!3MK\Z35=;']O<&6
M:>,?W1L&*=51%4Q&G#MH=G.NEK=QT'%3T'?_ &A!P^OP<X;PBM^O;F)5M- L
MM?V"Q.[+ KTN%\I'XM!S:;@,*@+M^BR4* 72Z?%F\1\<PMDG!J)H"FB/7CP[
MJ3[UW56W8 %:SNP1)TZ2FS.S*9&LPL@C2;99QB-;*1\V>:BB$?0&[-"0HL]D
M>'<6 B/NCXAG:9WUJ[YU-VNJOKE+&S3I?U3[GUB"JR07O&0XN&73V&C,&S5E
M@RT'.8%/9$<BKYDF2TF,)*UXU-JM%=7H/0.55 - .MO7;M7VQ[+]N.QX2"Z=
M=8;U/ZG]D2/5F8Q69#I^^[ 3LS'H )D!RP(Y*V$B2B !MZR2 (/BL:+1$GK(
MH^B=>.I Q(HL<J@:+^,7&[9K'L*([CVQ';RN[P\ZPHD1%K"AW6CM)-NO]M=7
M;-6L%\1>]DV$,BDJAK*V]W,>( 0+4>5-[?,$6SEP^08B1V%B0&![^(YV_H&Q
M_&X['2>95[=W7KJTPHB34W4:@.> WXQ2[*QA)>D48\0>2EXVC$9^XTJ8EKY:
MKA'9*32_0B:B6\18;X#I@9-)_%8\1FIZCL,[-NO$7+G1UR].H74MJ6+UX[#]
M5ZQLEOV)G6T.L6!*Q"R9!))@S-5V_30T$V(#)R$6_ FQAXA",$$%0;H"TF_%
M#\3:J2=VO;/C'2Z3POIWW;HOK'>3J$AKB!R:VX[V$*P!$*4K4>9E)<9 "$)%
MV('6=.Y _EVAY\HLE]S!Z %125 ;>>+#*Y=+^S7AA],'MG3RF^O_ &TN>WFM
M[2VN)F6K:3S%"JJV1E4#IA"P(^\&GH^QLR3OM!1!L%*CBIO";5B/<?+Z8TV
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M4>MF#94H<)M H0:FN[522W?F##]B)%L]=\N"!-ZT8-$UG3E%+<"X\ < < <
MC&X?O!(?YZAG^NT=_!^WX?9P"3N . . . . . . . . . . . . . . . .
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M_P 3*YHOMMC'M[N/\?9CSH>L\8\_LQYYSCZ_XN!-SE*G&??*4UPF5^@GMO\
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M79V2.)9*!S[NUV3NSN!)AE(7C#X155U7[UFD\0AI*/Q>Q*ZB\X6JF "$8Q3
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MFJS6=.G#55=0/+3UU])[.5%]YR_\NK7_ +5)G^W^[@I)W ' ' ' ' ' ' '
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MMX X X X!&5P?>"1_P \PS_76/>7Y> _M[DF\ < < < < < < < < < < <
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M!2D.9.B96/D2\:D1G=&)(/E--<X:U3I59]"G<KQ":W>VCTXGD3C8:;2@HGF
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M ([@%/4ZQ?? 3^#(;^C^ /4ZQ?? 3^"X;^C_ /=P!ZG6+[X"?P7#?T?^WY>
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MH=0%OW(Q HDV<.FK?+I-++=1)10"1> 1C</W@D/\]0O_ %VCO ).X X X X
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MXJ/&/G:.?;Y^>OE_/MKG[/Q9SCZ_+/.DML_WVK_ZY=W7VXTR1]]> _[+H_\
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MDI+&W"J*3*7Q<;)DMHZ1D\4<F@# [Z AV11(*)M]@)^X!&-P_>"0_P ]0O\
MUVCO ).X X X X X X X X X X X X X X X X X X X X X X X X X X X
M X X X X X X X!P"\03PJQ':6^S5U3.]FM7#I9M!8-'1FL:<2)5V_2&HC&N
M7BJ&[;0:H]);JLT?E_39X\FVZKQ-5UHCS6-H^'5?;]'?%>7!\U0PQV:L]YK=
MA4"<W%"MV4.$FYN<\CK7;_P[NVW]M6NV+3:%O816EC=X%9PV,$23LH% _P!V
M\J?M3DU.;>5#28_^Y>!A_575?M4^0^4QG'_!U^WV]'/M_??OC7MS[?JSCR_!
MSC9^&;&SBAB_JK=QIS_TH-W%4;WFY+!M5SKGDKAX+L[C"H8+_:1J%)P[UC"F
MWPBE&I*?!3D0\6_<BD7*^GE3N*>2SMKOC/H5NPW_ ./]?LR9QGZ_;]?Y/JS=
MA<W8J3M%$J-2ADYIYN>:EI5V:[7%W?=<5I#$X93E#NJ2ZMKV7(P>/?N3:O0Y
MQE$G'=IUI,5@^AW>-ZP,<J[P.^5W;J/$==BZ2RS/5TDN@FO\EIE3*2FWH8PG
MOZ*]717B'=^8X7)J)N'G-R3>&#GCAD;GL?;ZV/'!'!=G>&HE%**/<AFL)[L+
M<N-4;*1K]RYCHPKHHT[7OE\Z9Q[%Z];>7LQ[/^(9USCVXQG.,9S[/9C/-2O?
M@6Z7M1.*^7B".)S>[#9N&?%J+Z>U#N_8OZB]J;%5BK+PY<;962AA_P R^6R;
M4*DG.&SI3C/'!,G<=^Y^S$<&.TQ?8UD1=Z,U\,T7D&59HKNL(;8036<I&5\M
MTU5<::J+ZMU\I:[;;ZI*9U]#;6;Q\(-GWFULK6+:]\@=E:PVB2L;*3W8E%+-
MR<I)RYM';&ROUQ>)-DW2\76Q\#[&M/G7:UN\-I%M&]J*%QV<4$,<OE.%N&*+
M>:DIK]LSZ*(?(0.Z[J"-B:;F30H1'DI".PDZT49IOF'HCW&JJ[=%%TV=_-'&
M$EVVRFGIHJI*?)JI[IZ]O6<"LK."S3G#9P0P*)XQ*%;J;6"<E@?#U[O$5[O=
MZO4<*@BO-YM[Q%!#-PPNVM(K5PPMI-PPN*2;2=/(MU1?><X\_K]>[7\_]*DS
MYS/ L$2;P!P!P!P!P!P#3#Q$J:@O8/I%V6INRY#.(G!IS6!<?()/6\,D%BS8
M V9+M##<N#@45'E)',U&#X<U<O(R&8K/S8U-X/1RCEQ\ND!\WT,I>6V9-.V'
M;'L+>W8*)5B0M_H"E2G:&K.@%E0HM++2ZD Y[+!UE,.KQ6'VQ+&57@"+N/P9
M:PII%W,;D,H04$MTV(;<<,0 FXI6O83N!U-JNV>RT3N^4=O3=Q6?UDZU,DX!
MI0XSL=U\>7'";8K>R>Y=9J0HN2I.K1[ZE8];=@9AZE83)Y&X>SBL<-JD[$'L
MBP&Z7A/'NST(M2_NMUM505;P^*'+9G,JOF2T]9U?S2R;N7OB41#653.R):2=
MUY>1.\ZS#@+K"DJ@8"HE54.)1RJVS?84#!^@!W0X X X X X X X!A%??P"_
M_EO9G]I$KX!F_ .4_<0].)5VVZVQ>B0$E.V]2];]M+(5<NH-+$8''B$NZ]&X
M?5"Y:>% *%?O<R&QB8<*B&92!\2VW3)?.F"2 XAL@!SD//;JQ1]AD.II_O"\
MF#KPR[G?]BG-@J]CW\P%=RL;U/O5V(H,M%-=2.=@D2"MW_=V*TZ.8!68- ,D
M["H"4H GEI@D7O'3>(-CL/1I%_W9E$#W\/N2)]1VL,GG:"TGMA=H)O(;WUN%
MM+3D?+2+2;3-^V=TY\C$K77>5^%KPQ*] <?$0S24),@/VF,DO#;M?1PV$5]=
MT&,5K<G2F'R1^I+NW!EM/J;DT&KAE:LH&UB*'?X*L1I0.E*3T&F!"2J/9/\
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M0_SU#/\ 7:._U_5P"3N . . . . . . . . . . . . . . . . . . . .
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MX)#_ #U#/]=8]^W^_P"K@:UJI)O ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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MSMC7?'GP"9. . . . . . . . . . . . . . . . . . . . . . . . .
;. . . . . . . . . . . . . . . . ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img29677477_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2C,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *+"^$$%CA"24T$!       '!P!6@ #&R5'' (   (  !P"!0 (1DEG(#
M$X($(X0DE-!"4      !!8DM@SC]A!;)Y"%I_=0\(5.$))300Z      #W
M  $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $
MEN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V
M]L      MP<FEN=&5R3F%M951%6%0    * $$ 9 !O &( 90 @ %  1 !&
M     /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '
M0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'
M1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M  $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G
M)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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MP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M        UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;V
MYG       X0DE- ^T      ! !+     $  @$L     0 ".$))300F
M .             #^    X0DE-! T       0    >.$))3009       $
M  'CA"24T#\P      "0           0 X0DE-)Q        H  0
M ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M     ! #(    ! %H    &       ! #4    ! "T    &       !.$))30
M/X      !P  #_____________________________ ^@     __________
M___________________P/H     /____________________________\#Z
M    #_____________________________ ^@  #A"24T$"       $
M$   )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M             '.P  !V0          0                         !
M            =D   '.P                     !
M       !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M    !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M   $)T;VUL;VYG   '.P    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P
M    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M     '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W
M)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'
MEP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M  5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !S
ML     4F=H=&QO;F<   =D     W5R;%1%6%0    !        ;G5L;%1%6%
M0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M    YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M    EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6
MQT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F
M%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M   $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F
M<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&
M]N9P      .$))300H       ,     C_P        .$))3001       ! 0
M X0DE-!!0       0    &.$))300,     !XL     0   *    "=   !X
M !)F   !X0 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]
ML A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,#
MP,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!
M$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P
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MM)B8>RM[ZSM(=N]S5H*%U5=U3Z;!NKL:6/;XAPVN"2GENGX^-C8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_%-$%?2$/_)W>Z(D6Y1]FF[6&U9A:2.PG<;=%;!<Z96UK%MTN-ED/3V"R4N
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M-W:^[B\Y;HC[=MTET;Y#99>9V&0QQ8#UVLUU_4KE7XM[9EJZF%:BX5JXK,Y
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M\44SZK!*UD8+GL:R8-&I(BD:]]AW,#CY<]EI![']N&1-T64+UC3&L:\E)I#
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M/VFC)_QI&N1B&[QL,7"PLI$UJ8CY:R@[C$(9LK5D*A5@C44'%B=-ECJ?.$M
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M(N"J$"+)D^'+DMIEMEMY:67QQQ'AG$&#XS74'%%+B-'CD,O_ %T6*B;WTO<
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MHJ2JK)-(Z6GFJ'_]L,;I"/$AMAWE9K,>T"LXOHM0QS3(U&(JE'KD/5:]&HE
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M-S_>-RDI"/,]5 PIN;'F"^/\GVY!J?@2>DBP@((JX 8!2;S#8A [BH\=?PG
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MH_\ 7P/.K3PSB?)L#O"6]O\ \0IV^T3AMV\E8S_NI''_ /<<]48S3OV^T'[
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M$-:O+,=X]Q+%@^FH6G#J-UVNR/+JJ5IY23@ 1-</Z(@"+D&1X6;DB?AT\.
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MA^N@#.NO</O??Q\!?91)4P#Q^@?OD=6DCG\1OX >'TTU_65L?D/#[[?/[KL
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MP)W^O-710B::*-NADE8P=+O>&_<\EB2^R<U0'&U3=;FA\7TMAR5N@4K<M(J
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M#D/W]?;^>K"?V&U_^1UVY@W^Q*E8VW+4[=1^_51A"<<  =?#@./J'3GCIS[
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MO]EC>N^_6YW\UV@EX=.OOY_'RU87MZ7L>?Y;E5L--CKIU'ST'ST\M.P$P#_
M &J9W'8?F?6_)793T)OM;;7O_8>2Y=POL_$=/C([O$??=5R'H!IS._?H=/MX
MIZ,!\ '\1_7Q_?&J',-R?_E^_P#E,AY6TT/ZVY&UB1\D[@?]OY^&@S'4$_\
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MRU&+RN*\EQC4AC.9+']SCVQ2?U'7>5R2;H@7_P!QE%2@7SYXU;)8Q2C^HQO
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MMS,%JW%)!\#+'XF17TO;46-N=R1F%[6&,CWBA,8L-U-DQ3BN0RS/0=?PC@F
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MQ[9X*0Q!M3A3IND6MEET42PURRFDW=E!5PT,V1-"13YR!UGJJ;=TY]7GH21
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M_P#GO*BBEY$ #S'PY^'ASX?\]-7.-@3T^O=Y[=RFC;<W\A^9]=ZF"1  ./$
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MK:.EM[S5TU/?;MYXH;^':/:H,GVE[M,HD>;+V=M2(''(=RCY_@Q_[N>7[V2
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M55)K'Y_QHR4?PX$44]$W&Z022#5:(=&Y*550&<88ZA3)1;*>,!W9OST]MO\
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MUY_#W!J0D'4<]=[WY?<$?+0*)PM;P /B /R(_58?NUOV O-WN*H[(6,&0&W
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M Z,5N+H%E"$,9503ET<,S)7,_&&.S$'\Q?F+C87NK*G"<1H(HIZVCGIHY_\
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MKDZ<E'(+CGT/UMZ[U!&#D!YZ!P/A[1Z>(^/M\ \QZ]1"1VQ\"L,Z$CHH,0Y
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MU\=?6_._,^)W43OQ'Q^^JZM45%\,4IRF(<H&*8!*8I@ Q3%,' E, \@(" B
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MH@/GK(%B&V%@>?+?EK;0:+0.C=$]T;@0YCBT]Y!W%N1W'=9<T2\_S<>?C_\
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M%@ T"PL-1H!;D!X;[KG27.<7.<7.<27$DN<XN-R==23<FY^>RGR ="^_KS\
M^O'T]G&KU*-/7+D.>VRF"8= ]X_KQ^FK7?A/KFKV_B"FR)0 H?\ N'D?AS^_
M9^NH';'Y^8V^JS&#0=2+G[_;R7F[-%"X2&10)RJ@7NN"@'4Z!1Z*< '(F1YX
M-_\ A<B(@"8 -89,IRG<DV/1QW'37Z'O(MC5])V@$[!=S !(/[F#3-XMOKU;
MX+Q:11X !Z<\!X?C_;KQX_'4KSTVWOMSL#MU(.AV[B%JQ?+;^XWV^5KB_.WE
MMJK6]VF$<"Y2IC*TYNC[*V+C9.4?UN[4A2PHV^G#,!'DE%X]2":R"!V+TT9&
M&?EL<9(5U S-L^?D; U*Z2Y_'8:)U&ZJJV8@74H<Z&3"8:N;$&/<+Y8&4<4S
MW9RP-(E88,V7.6Z.$SI)(H7!AK-<I#:%D[ZE[VAP8V-E.UTCB;N;EME^(AQ
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M_7E_CQ7%3@!$0'@!\/=S[/(0#]!Y#56@@6._STZ?3R3D;CR!O^6GDH!;@>!
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MC9C\&27$N<2YQ)))))).Y).I)YDKW%K6L:UC&M8QH#6M: UK6@6#6M    T
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M;D=0->>W3O62TZZC?NT[M.8OR_13-(P>7_R^73\_[]-7>O7KKT4RCDS=TP"
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M>(PYK0TZ7.HN1?0:[K:NJ?=,&#7C++-VL5#G+3-[C*YDCGO M8$LR-U%\QL
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M=;=?7ZJ-(/0!Y_QQT#^_SYU:1>/3<:V[QR/2_/;>YLLMNH'JUM/+3[]ZF)!
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MKLY;'(-D%R"9N?UW(-LRE:8=PD84'#&#3<)"<3 <=[P]3F6O$O\ 33L<\_\
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M!^-<GGW'3ZC7NMSWZ*A>=;[=]AIWV[N]<#J@ =1^7M^G3Z= \@U4- ]#]/\
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M-'VEW<E;94#.DMO.WZ:=543CWDXMVA3\/XH<IH]/Y17+DNWK&+YJ/71^?+7
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MI%FH00,DNIU ,AM+*X7(#1_R.NNV@O\ *]^Y?1G#?\*/M6QV!E3708/PQ%(
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M5NJIRF4<C/4%S(@_4:(,+)82KOQ[D1#HA&L?0ID<+N^:I:8@QQL87S2N9&T
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M>#L.B-35\1<5UD&"8+0TQL,].RKDA#\XRMBDD<QD[LL8J7/+&F<\08!@50S
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M[9*.5UA::EEIY- 'RN9=AQZ[D]PNXN5R@T<X9VY-YO/TGAFVX5N>!LJQ;E]
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M5 0\1$./+GK[QY\?9]/(-7!O.SCKII\^MN5NNO.Y5I<!H2!I;2_CKNN'I/8
M_$>GN_#CW>.JAE[Z6Z7!YWZ6\]#X*A>!M<GU;7U9<#*#X=X ^''/M\^?'@/=
MY<==5#=+DG7>VVG?MIWZ?(E6]H>0_P _X76*GLZB/M\O[_75;M%]!M;2QOSV
M'W*L))W*X"81Z#^_W[]6EUR+#NUZGZ=U^A5%U"< ]_Y?7]^&JAI.I.^_7UW=
M%87@=_V^:Z#J\AT'\^ ^7GJ\ #;U91EQ.YTZ<E"F4$?#\?T#P#5P!.PNK'.
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MQX<YMVR-NVP%US%;@V'?Z6[&**HJ)HFXR,-IO>(HV2&/W)M0^8Y;ECC(7M#
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MA [H>8\!R/Z!^?OU*&.-K?"--3OY#\SW^*LO?G?IX+5S[32++E7MJ.SMQ*[
M'$.X?[;F3YJ?@Z9T['N+LYYL@IF[Q>7$/'-4S=X! Q2D[P" =>#XI/\ U\3
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M5X'6YUTN;_38*TN)Y^032P^7G;O[CW\U:N(G /?\^GS'2_+7Y$#Y_I=._O\
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MU,R:Q@*A'Q^8\>N'JYA\"-VI+"*RYQ\BI$.8?(-6-Q"@><K*RF<[^T3QYCX
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MXI@, ]0'1%<S$0L-7V"$5 Q,9"1C4@)MHV(8-8U@W('@1!FR21;HD#R*FF4
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MN/1JQ\@@[C'KUFX(M"!&T;UOL_N:;;@?-M >Y9VUW"6E9G'L^T5>1-.N"X(
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MR+ZK]7/_ *?E112>SGC"FA:!6T_%<4M8[+8F&IPV(4;2ZUG93353@+DC/R!
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M@H8Z*24U'PR[E9-FBY T]/+V3[G5KM'#['R^U^=E[E[ O:F/9?QFVHQ![_\
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MN7P$,>B[,3^7NKRS1KZ,I^>2IK" =T#B'H588O>L););M#6S&$&U\S<.KLQ
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MQ--N$Z[$I)>&F8DZ0.S#%::7!C'(TM?A]0T$^/T45#!Q4U_MQ;CM;PL98_\
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M<XX:ZA9CQ'<'38KFL;7))7RC[0X!1^WO&';#%N!\*K#T=+354=$+Z[B*FZ;
M=5G<U[6IDT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1:C6^3L=MXV6MW.
M3LETE6.R/2LB6NISSN\R;JGU.2CR6MZC#R[%O4D)A)2198SCFK=9^\ D>ZF(
M5)LLS2E)DS\@:B>BG?,]S;/:]S27$M;8.LT_""+B-HN=BX 6S.)*^Q.!/;1P
M7A'!V%877"7#*[#:2KIV8?$VLK(I#21F6&1U8Z B.3$Y'.;&PF1D$Q<UQCB[
M,JHG:R;+=ENUS8554<B3MTF]R";NO5K&.3AF[G;[E?[17XLZ,LQ?PV0\A6EM
M5<9F@NXM88RO2S"'KSU*N&@HY1=.*K[KTWV?-Q!F,#W5L<D+:4QU[Y 6-%.7
ML+2S*'6G,C&F-FH< \'*T%S?B'VE5V&XI_J.(/@DH??\2GKJ&D%0ZLDBGF?)
M(Z-U1*V-\\;1*\/D>T/RN;?,_5U/^RGQ9L-?]ESO*M63[C+@XM,.XKVZ*6E8
MUHPFL<1,&V4EL9-,?L&SV6-*MU)MR6?JTJH"+NVWAN$*[ATON%HS)T/%-5CK
M>)\'BI86VB>),+:QQ<RI>\AE2Z<EK<IR#LY6:MB@.8.(D+CRW#M/A!P#$9)Y
M3>1I9B#G -="UMS"V,7-VW^.-QL7RW;890K->PXVU;0=PNYC),-EV?L-HL%5
MK4M)X=Q[*M'E%+;(87964E>%I^J7%:5CKC68]=JL2I0\IS'?>2TZQL4TE#.1
M8[+CZJQ"+!X8HX6-IJJ2-E?*R1SS&]N61D+1DC/922,/\T@%P8(W,9G^+7\&
MT]"_$Y9'2N=/3M>ZCC>P-SL-V.F=\3P9&L=8L!.7,7ASK:7==HIV.VYF6SW*
MV[;C$6O-&/9BHC--6]HR',3=AH2-?.G%M,>I6G-&3;3;;BN=D"4C!D3EP2*1
M9[&L(B*9LF;=7P"KI9GRND8WM 6W^'(TC+H&?$X9B1J#?74&UA?]!_9![4N#
M.'N$X,$QBI=@]338A(P.E=55[:UU8.V?6CL:5S*"G8\&%\3OY<=FR&1[Y9'+
M9,V5X3N&W/;#B+"UXLT-:YZ@U=M$*R4%7?X;9H('.=ZG$G;?>,@$FYB5'2S!
M:P&+'K3OH2R+R.;OEW)UMC!&Z*)D;B'%C0+AN46&PM<W(V+KW=N=25\[<<8[
M1\2\58SCE!2S4E/B%4Z813U/O+W. $9F#NSC[)LP8V04]Y&P%QC9*Z-K0VZ7
M4JY1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T16D;LKAL\FL?V_
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MQ;)*]H.O4$C0_AY *YWL?)>8ANTGVHN(0ZQ7+N]R\0[*B8P>DAYFD6F,FR*
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M\715.\4BO5G\A4&J3$!7K3>*A6Y^UN!:5>#G[+"P\Q9'8& @MH",D7K9[,.
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<4=W(J>K1"DQ,"Y9R!7*)6Q%=3HB:(FB)HB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img29677477_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_21.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1HX4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &AR^9H0X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   )@   X
M0DE-!"4      !"H<CR.\+B]1))=K(K5'*#I.$))300Z      $9    $
M  $       MP<FEN=$]U='!U=     8     0VQR4V5N=6T     0VQR4P
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _@
M.$))30/R       *  #_______\  #A"24T$#0      !    %HX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              *8   '90         !
M      $             !V4   *8                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     4X0DE-! P     #V,    !    H
M #@   '@  !I    #T< &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( #@ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MJ]?7U#*#<7#KHN%AK9^>^S"J9^CI;N<[VI*=U85GU:R[+[K1UC-8VY[R&,?
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MZSU/U?\ 0>G[,?T%;]6>H6
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ U0)> P$1  (1 0,1 ?_$ !\
M 0 " 04! 0$            ("0<! @4&"@,$"__$ & 0   '  (! @0"!0,-
M"0P&"P$" P0%!@< "!$)$A,4(3$5018B46%Q"A?1&2,R-CE3@9&3H;'!\!@E
M)D)T=;6WU"0H-SA$4E=8>)CA\2<S1H32UBDU0U1697:5EI>D_\0 '0$! 0 "
M P$! 0            $"!@,%!P0("?_$ #\1  $# @0#!@0& @$# @<   $
M A$#(00%$C%!4? &(F%Q@9$'$Z&Q%#+!T>'Q%4(C%C-2)&((%S1#<H*B_]H
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M>?RX1>1C'Z1@^KYUZ[W4K,.WF7-6.DZ=DK>D:YL_85'022\9,95C43-Z-9]
M?6.;GK+$R^ES UF4L+%9>);VZ<955F6.$6$2@ZZ]BKI=I+@"6@M:70=(+M1:
M"8@$AKBT&YTNC8QA2+NF4S5.R[J9:L7ZT97U>HWK&YCC_:>P]=[I:9CJ#V(9
MR^ 6*\5EK-R]\DW3A2);6N+I4+?JM8)R1KWX]#5Q%R8QS@@2DDQ/ 0/ 23]R
M2LG5'/%-KG2*3"RF+=UAJ/J$6W!J5'NDR9<1,  9DZ[=H.ZO3[HQJ>O=:8#K
M_>>C&2]N^RE2R,^CV&_N[HMB9NSTO3J,SRM2(16@I+/8E&1<M:NX<RI4P19N
M46QA9(-2FQ)-@-^/@.8'O]%@ )F^QX;Q)'E%^'&\0O6_#/5)*(BI%4A4U7\:
MQ>J$)Y$A%'35)<Y">[];VE,H(%\_7P >?KRHN2X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%53ZR.[]INL/2+2.P'5V
MZYW1)?+2PTY<92YTE:]STA#25LK%7CX2D1KN0:5>+?O7\^9Q,SUG86)%I$,E
M647 GDY)&8AGUZ\%00US26APU EKITN N6NTEKH($'2X.O8@W$9O4$[;]C^N
MG;.KR5HU[=.NO1!GA>.S5GVK.>I].W;-HW8K3KU\KEGB]6O,[!2DO0(16KHT
M!J#B%*^.P6F6;H&"!WHNE"GI]_W6%[9WR[A&WZU;A7M@CVG7ZA^L+GGI?*=7
M@SJE.H.R9]/UZD1EEUQUH:\6II1='6N5X1FZ^A&61C4F<'&E9.X!^1599:C<
M3S4<8!(W )'H%:-D7>:UW+M UZM:5U@TK$+)-42XZ+4+):K12)^%M=8ILXR@
MGCUDC69)Z\8B[7D&J[9*0(BH"2GZY0,!O @ P#($@>A(O[*,)<QKCN0TFQ!N
M)X^/DK$>19)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"(( (" AY ?H(#]A#]@\
M(L&,>K_6F+:V)C&=>,,C65OAG-=MC2/R6@LFUGK[UPW=O(*PH-H!)*:AW3IH
MU<N8R2*Y9+N&S==5$RJ*9BI-[[F3XF]SXW-_$K(O>[5J>YVMVM\N)UO&J'ND
M]YPUO[QD]YU^\9Y%/KQ@*.6*X8EA^0I8HND*"V0IYM3B9@LB9T1\9-6AEA@J
MRA!?)D>B4\4("[(1S_\ 7%*<"Q5<OK+UFN4[TNMEJU1@(6K5FOI91$P-<KD6
MQA(*$BF>GTQ)G&Q,1&(-8^.8-4B%3;,V;=%N@F4"))E*'CCKVG]TZZ]E:]5?
M[6*Y_P PP_\ T>WX1<]PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G"*'?=;I1G'>_*@Q?6[WLU3SQT]!U98+([VG24+PW
M369NV<3="+PLVA.P\=)1[*78,54$BMI1LB[ YCD* $6#M9]+C--T@:=0];[)
M=T+WDD#!TZ!N^-6#=D7V=[BA2+,>UQ+S84%:>-HEW[N2!DE.J5.T4U"<91$0
MA(MECL$EN#Y1MSY;W)WW/"=@!99.(<9#6M[K1#=4$M:&EW><XZGD%[H.G4XZ
M6M;#1^EYZ5?6U[V8/V34L6T))K[A!=G'F M[^U1ZY/NR-9J;>FPFXNJ&6N_C
MIKTQBV;-P )W)*M+RS1O)N:\LX2*/&ZQ76]%_5]87K24/L'2S=0 / ?^D*G#
M]_O^0#_F^PCR :0 -@(WZ_17@3XCZ@JU#E43A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$53WK=?W-??/^5YC_P!:=.X16AU7^UBN?\PP_P#T>WX1<Z)B
M@( (@ C]@$0 1_@'Y\DB0.>WHBU\A^WED;3?DBT\@/V$/I]_K]N)'/;=%KPB
M<2!N81 'S]N0$$2+A$Y43A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X158:-Y_JPW6L?KX#I9N@>?'T#_Z0J</CSX_H_I<NN!ZX_J'
M/S'.]O;AU=6FB<A1*4QBE$XB!0$P )A#[@4!'R(A^8!YX1?)TY;LFSAX[72;
M-6B"KERX6.":+=N@F95994YA I$TDRF.<YA "E*(B( '"*LJ+]77II+:JEEC
M>WS::KF9+7FMR<P2Z%,7E5'/R:10E#J@HFQ5<^$B2*C<K43&((F*D;X@.NK_
M +>2E_VG]?X5G*9BG(10AP.4Y2G*<H^2G*8 $IBB'T$I@$! 0^X" ^1X0=<?
MKY=<3OX53A%H(@4!,80*4 $1$1    ^XB(_0 #\Q'A$ 0, &*(&*( (" @("
M _80$/H(#^0APBZW;+G4J'#GL%ULD)5(--=!JI+S\DUBHXCET82-D#.WBJ2(
M*KG 2I$$_N.("!0'QPBZ#"]A\(LDM'P,!L&<3,U*N4V<9%1MO@WD@_=K")4F
MS1J@\.LX74$! B:1#',(?0.$68^$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1;1,4H>1,4 \^/(B !Y_V'DU"UQWMO%)W/+?PZE;O(?M#E1.$3R'[
M0Y"X @$W.PYHG*B<DB8XHG*B<(G")PB<(G")PB<(G"*IWUNQ\>FOO@_F#S,/
M'\?YU*=X_P _"+I7J6>K=GWI:T7"I&[YU,:,MJ,*X1BHR"F6<6_1- QT098P
ME=MUDS(G!Z43+'.D0@I^P!.<Q2\*1/&+>//PXVZX]!]+WUN\Z]3[3[1FE,QV
MPYV_J-.?6Z3<3\ZRE%$FZ$E%QK= $F3,B7M>GD3&36!P/M%L<ADQ$P<Q):")
M_-%B =N-^ \+^7$+\^(X?NNL^JGZ]&,^FII<%B:&<3>SZP^AFEEL4+$S32!B
M*C"21EOPTLE(KHNE59=\5'YA%@D@44V:B*ZB@ J0!-: YQ<UUQ8CC)L+\IO;
MU"$&+$2-IGE%XOL?,G8V*FUZ9?J29%ZF.$.];S.*E:C-5F</6+]0IY9!S*UB
M<!NF\;@1ZW J$E%R+-0CAD^1*3W>%$%4R*I"',8$.8V0=Y-IFY(/T-K%-K&)
M\#/0GTA6.^XI?!0 ?  'D?L  /U\_P /_EPT@%K "8L2-A^]U?-?,#$, A\0
M#D$1\B ^1#P/ZP>0\_V)OH(>?IY\"',2R&EM1Q(<2YLV=&]K"W(\9W-E9V(B
MW*]^?G_:^Q1#^Q /H  (?3Z" _L_A^?\><C;=V(  CR\?&9\U%CY76\N1M04
M9;0J<E<3"4I:R>PQ99H5#& A4@CQ<@X^,8P@4$?9\41$/!.9*3/7Z]<]ED/A
M5>>KM?\ RCWIUU#[ Z?UUT/,=VEK;E5C/69R6KT!7EJ^]?$:-G@J1;I[8&JR
MR I.B 4RB"1Q$#_J  <*$'[WX^ABT".<['F9V>F_ZH&)^IM5-(MV+5'1:G'Y
MC/Q%>FD="C(Z-<O'<S'*2;96.+'2,@55 B"9BJF4,F('$H% P"(@3]MN'7JK
M*>%4X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X158:0'GU@^M8!
M]QZ6;MX'R/\ Z0J<'^GQ^W[?M^Q%X%?4<V3LICW>C9<^?]UMC;C';=?UW3..
MM]X3:9G#2U@<RL(T;MFTV=%<K>)?MDTV<?[!0;HIE$A ,0A2O7]'W_E>N#JP
MX[^QGHX,[O5-*H^_NU,3T:?KR%FAKG,Z7H3%_)3JC-N>QJ63VF=K,%CE9*J%
M_P"YFB""2A?)#>"QM>WG;CO^J\3E<[QZW*WJ"IS3-:C^D+ZU1L @P%Y+E5++
MKRR+(C851?\ L*J5R()B?XOL*8ON]WY\+*WC[_POZ6=<_JC,54H-LSB^J\B=
MG!Q+=JB_D=(:+*$18(IE^<=$*[ 5Q "BL<J9@]X&]OD! >%CZQ-N&_[^Z\./
MJ#>K+ZGO7GMYLN5)=VK/$.(#2K$WF:?0(:(<5+.V+A^+MG6JZ_FHDLC,-HED
MX3;M3._A+&022%=85E#^TKRVZ_:+?TO47Z4O<+O!J_2+,=%E*"[[>KSDW:BK
MZ\^T"IT:PRJ"$ZX1&.>5I^R;IM5:\!31OU6 S@R)3E$4S ;A0^%KS<3^UXMY
M*J_^4%W'M?)M:SLI'O8OJG'5G-;!!+5&!T!J-&NDHTE!E!<+O*A)_"4? V<E
M05%Q[5C-TRE2*)"B/"OL>1_;^-UQ'\G1[,V2@Q][U+L=MV\7VJWFG,H"%9V)
M.[Z)4JE-PEKD_>9H9FA,FBG;^.2#WJKE0 Y""F4Q@]H<(?+]S;;@-]I_E7 >
MKOOW1/L#T,U&-O/9N=J=>I4O6;H[0R8S5'4Y.8B'"Y8BKQD+9V[,Q3S#AX!5
MSK)$*W32%<Y_800,4OR]#_9_7=>23T,)/KOHOJ'Y-%Z/M/8:KV^(UQE9>OS)
MT^A).H7,L(*SV-INB>X3O&LS-))?!%Q$$_#SG!1  3,H0X%3X7]A[2;_ $/@
MOZ8;]\SBV+V2D'"31A'-'#Y\[6,!$6S-HB=PY<+''Z%2113.HH8?H4A1'\N$
M5;9_60]+PAC%/W<P@#$,8I@_2LH^!*/@P?1N/V$/N'T'\O/"*PRH6^LWZKU^
MZTR:86.J6J)93M=GHQ8%X^7AY) CEC(,E@ /BMG*"A%$C^ ]Q3 /@.$GJ"NQ
M\(G")PB<(G")PB<(G")PB<(G"* W>/U+NH_IXQ%8D>RN@+5^1NBC@E6JT%$/
M;':)=!H!OFI!.*CR&4;1;=0HH*2#LZ#;Y@2H)G.L;V<)^]_"VWZW65>I'<WK
MKWBR]/7>MV@,[W42OU8F3 &SJ,FJ_,(D*HI%3\*_21?1KWX1TUTRJIBDNB<J
MJ"JI!\@3KKFL[WN^TG+Z?8M"T>V5ZBT6HQCB9L]NM<LR@J] Q34 %=_*RTBL
MW9LVY!$I/>LJ7WJG32)[E5"$-)N1X<OK,_2QLG7LNBXEV(P[LE6Y.V85J%2U
M"OPLP>O3;ZJR9'AX2<(S:2/X5-,E"HR$2_4C7[&2;MI%HV4<Q[UH^;E5:.45
MCWSWZ\T68Q2()?;[0$/(#^L'G_']0\_Z/M]!_/'2(;/^IEOA?ARC8<1P0WF;
MSO/'SYKCVDQ#2#^6B&$M&/9. 59H3D8S?-7$A"K2#1.08)2S-%4[B.5?,%DG
MS1-XDB=RS53<H@HBH50:1(OL?#>#]K7^X5+2():0' Z21&H D&#Q ((,<01N
MN3 /'GQ]//[/R^@!_JX@R3.\>D>O%18_IFET;09C2(&GSJ<M+9'>0S?0FA&,
M@U-7;H>GU&_!"G5?-&J+XXU.]567!Y%J/6'LE4VWS7SC9XW0FB"'.(<2+7%A
M)!D RTF]C!(@Q!!63F%K6&61587MT5&/( >^F?F-8XNI/U,<0RJ&5"PLJAOR
MZE-[N_>P?S.;QX\?X?V^?K]?(>?/Y?8.6^HF1!V$;']0>16$6CZ\>NC*W>/S
M\_7Z_E_B\_PX(W(L3QW^DIR_F?>??>5J'[_KP 8@F3Q,1/HJG*B<(G"*K'U3
M.PM/I>"W+):AVTP? NS3C^:W2Z34M0[$0N!3-WJ52UFNV6Q5(+069C[35835
M:Y3;AG 6N-1*W24DGR"SI%JD_50(JXO3!=Z3;.\$1L<_WMS+=[]NF3=CM$[6
M8GF7;FG;+E>;2;[3<Y+USS/&,JBYQW+L&./T8TY'6716L02'.K*FA4YM^$FD
MJ^)U]_X_;EZ:A'P'D?RY"8!/)$\_8!^@B'^CQ]/\_('7 (()$HM/=]/(@(?7
MQ_\ '^'^OZ<!T@D@B)MY=;>Z;=<U4_ZW7U]-;>_ ?=YE_C__ &I3>4$$3P_1
M%11_*@>JFJ;16>I6ETI!!_"T^H25<>,UG)&X?B$HE'/""!UE"I)K*HI%! 3@
M1-7X:A#*@<$RFMI$F 3!<9AO*8!W-A^RR:USR0-^'7/=0&] OIAZB-'U#5=5
MZXV?&,XE%J.%0G7&N-9BR1#MLYE6$D5DR85PYA5DD56B:PKBHHDV;F$#B0[@
M@#QM>RJRH&R"UQ;J((TEIW@[AVUXA'->S4'4W#;29$'F1N+<9OZV61/61],;
ML_7IB<[W=N+UC>ARN@66I4&;2R9"S5Q&%<-:XK'UTS.'G4#?,MEF< J+]4'P
M*$=*?$*D*1_"?Z.^%E+L'VF#,BQN257YKA\"_$&O5#'4'LIU&BL15^8ZIK-2
MNUS6NIAH;+08$KH\S?C<*P5*%9I!> 6O!U&=A: !I:387YR85A/I;>G7ZF/3
M;)C:%U7O'5!K6^QE:I]ZE*[J[2]V!]% :/.ZAO@/($(PJ;I6.?ID?H_%=MBJ
M% $1*8ACJ:-\2<9V-.(K9;V;RW$X'&99C*^'Q%1[*;*59S'"G5<T-<YSVAS>
MX7!D07&=4#Z\(,5I:^NYK];6G4VP#3<"'7XR2-P8\5GSNSW4]8;HYE#/0-<#
MI-(Q]HG$*;#J4>+TE>;9RKQLNX&10:2KS\.6.DBB=1)NY4]GQ  QP43*IXZ7
ML!V6/:[M%@LN:/FX2BYN(S-P<YA9A6$:N\V2S6XL8" 3WQM!7+CZ]+"X=]0U
M"':3I[HL1>0'"\1XBVQ5<_IZ^J5ZD<CHT5UBS<N1[98=*F[+9H!]O,O8H-S$
MS$B9Y8IQDVL%?0='-$"J1\NU8.6:@,15*W:*)-")(D]A^-'P\P&#P6&[19/@
MF86AA*5+!X]E"2UK&M%+#5_E$$ MAM.I4#I<2PO&KO'ILES1V)U4JH=KU6@"
M TW$[6X;1(M"O TC>/6]K.>VR6-TVZ?NE(VL3CE63K'9:W.I1M\E%.USR4=#
MO,Z1(NY3^%\5I'B\.=5Q\-N97P<QP_,H,P =0V%2VDQ:8F?.WDMD(!G>. (!
MFXWZV\87\XV9[C=F'>N/=2D=)LA+H-H5F'*'S;A-%&3))"N='X7N%4%T7)?@
ME<&/\Z42@8%BG !#*W.\[1PO?R,6E1?T*<^]4WO= 9+F4K;?2;[(WP[^@U%\
MYM5%NM!F"SYGD(Q6"=3C3O1?MTY,AP>_+N/<[3%82K$*8!'E( ) ,@<=I0P.
M(\_TX;;+R >O)WVTSMEV=4ITSC=@ZZTNB,85^3,;K4H" T1S;WD: R5HN\G&
M)'>R[I4JPM8DKA^J@TCTP B/Q3J'-$VX[B_WX_I[J]+T._7$P+-.J3G.^Z=E
M-1KC2[">+@=#ALDF'#*X4EK'LRQ*EHEZ'7'82$[!&,XCU'\D@+M9B5L*BASE
M$ZA.NNH^JY'U_/5GH5MZNX18/3^[INHVXJ[ HI:&V3668K-H=512FS8%+/,U
M$XN5;1J$HHQ/['344_G/AIF BI?H2.,>O7E]%7'_ "?3O-W!WCU+\PH.U=LM
MFN],<T_19$]'N%ML-D@[/(,*TX.V;KME5U6C=1D(GDD73LOP@.U^&0P*G)Y(
MOZ(7")PB<(G")PB<(G")PB<(G")PB<(G"*J7U+_4 TSH:\R.8K>,S&I4K0ZE
MNS#S7J+>[O-S&]P5;K1^NN/L5*2HHG4$M3L\Q.J2EHL$7+,DX>I/XV/1:R;Y
M!Z@1<YZ:O8CMUL:/9'-NY\!D[?7>O.ET2HO;7B,1:X;/)<V@8O0=:D*<1"UR
M<TN[MF62%S6IULD8R1-%N7*#,J+<BZ+AX_(K.SG @ (@(^1 / ??ZB ?F(?;
MSY']WGD)B+3)CR\46ON^H!X$?(^/(!]/I^W]W]'+S\/X_>?)0F(\5N\_Z?'Y
M?[?Z^0&9\"1[*JK'1S 'K!=:P\" #TLW8#"'YA_.'3! ##X_(?'C\ON(_;@F
M)M.D GPDZ1];)UUU^B\"OK&],;U2_4MU:)J]GKVBLNP&KSDU1Y9I8XP54):6
M5;.IBLV%1T[3"+=UMR[^456<G*T,U3(5!4ZJ:J) -G$B"S\PO,;@[<1^L3"@
M_KK]UZK<<].B+P7TG22-T[T=O'%3J^!VR:N57P:[5N2S]L,FWDG4U7:A6CU!
MU,2+%B]>JL'C-.?0</ED7PIJL@5*1+'YC"3I=(!B8.\3YVX^*"YV@D[&YWL"
M01P7@)J>8R;W5ZY NF-[95QQ>(IFO86=-FC6!G +3;=,T^C#"B"Q9!)B<KM-
ML940*X I#*CX$PY$M!(D&+^E[P;\%;&P(U<&\?/P%Q[K^IK6_3@FTJ] D;>H
M#W\(V3AHM-NG_.K2$@*W*S0^$F*:N8J+)^$_:3VJ*F6)X\&4,<!,-WXSR_A+
M;P!UY^GIZK^?[ZPO7SKQ1.\USC\B[B#LCFT:)*5S87NL,[8-]RS08=TE$6QU
M?9YG28Z)M,/^((.'"$G5&;UR4J2K3Y!0$DG"[U^_OM_/@H#.P@<-MO#^87KO
M]*GT[*-+](LG?]>_4K[2RM$6&>^<>XU+1M)S@]M)*K$M2-:KEWSP]D:LVTF!
MT/F'YO>\43%TD!"*%(!#$["-KW/GN9X\!N38*H[^4DH;IU'I6/8&P[,]CMES
MC<&-FE;I_/1)4ZR1!U8!VP281<(\C:=#OHR03*J9R[%)Z(JMSD*!"E$_N*C;
MAP^W#P\[\K+IO\FL6[,]D66S]>ZEVEU[ <[R.#BK?75,ZK^?R<,XE+3-NT95
MA.HVFL22C]XO]7;-11Z8[=,JA$TR)^T.$,6L#N-O7K;;FK@?4O\ 2?L^@=>+
M6GOOJE(UZCJ.8MRR?[QD^(U*OO[\U.[/6&DOI<"QK<]%,GJAC-SM&WS9EO8=
M4R+@"_"(3;U\_I[>425Y5O2KZ"VW6>S*\]G?=KK#AFP87KC*"QLUDM1;!*ZC
MHT6Z.>'?Y_761D'ECJKD4_B-Y9H"P.SG(W(U,)AX3K]N?K]U[8G%O]:'KK2Y
M9]K.<=6.[%%B(*15M(4.SS>5:.[A6S)<TJ9M&6*)4JTXHLS*L"K152,\I^XO
MQ%3?JF(8X2/#<\/#Z^-^:_GO6KN]"2_<=KV-9]6^N4+08>45BVO70,WA3YDK
M33/51<Q4TQ13(M*V-1!94QK4=<TDB\]AVIB-4DVW">:_JL]2-5Q[8^N^277#
M%JHEGDG1*VI!U^GOX]W%5-N,6W\U@B,>LJFQ-!J>^.,T.":B(MQ(=,IBB4"D
M[S]+VX=?M*DAPJGGQ_\ (1_T<(G")PB<(G")PB<(G")PB<(O'-_*2?2=[=]N
M]BROL?UGJ+[7X^(HB6=VF@1LI'-9RNK,Y.0DVD]&,I5ZP;O(Q^1Y\%^#1<SM
M)VFDH9N=$3J%*;3,;]3UM"FS_)RO3>["=!\'UV:[(1R%0NFUVB"E6&<DD&LD
M^J\/6V#EFW<S+F/7<L$Y.54=G5^3;+K"W;(I N<%#"F0K^JL[]1NB7BW9#E5
M@J-!GM;BL:[2=?=STK):LT;RMGT7,\UO*<S8HVMUQXNV9VZ>J[I2)T>)J*ZY
M%K"^I*$;%$<SB\6U7<9Y+%H@1R)^_D%%KLIM!]TG\1M),V[^5+ITVG=-BMRD
M<ARCLWB.SV[0TJA4U\0=O:OF;&I]L'&.1*[G18F?DX>O1,$OH*-'))K257;.
MG(%DH]16)]R=4I5$BMFNO=6JR%0Z =C[=7?T3U31<_M[[88W;GZG6)+69S,9
M9@G;=TA,@<5IS/5&5DY)&R6-"5"YP5F*U40338^^U[3QWX[#>T[!74=);:"0
MXG2W5+0X"'QJ [QEH(:XZ2X$M:1TZ5RG;*NAZAMPK]>[CU_M'NG6[KEHN?76
MKRO8F0K#^5D<UR.#UQ&MM E)?'Z_K59TN+F&\93EX)E=JM54W<;4X=KGOXG'
MEH) .T2#<-)F'1$@F+F0.[,:KAJS:]S6. %,M^93<=3*+GZFMJANDO::GRX<
M_P"8UG_$YPI&J"]M$C)7;W,-<S2U:KF].?>HS/\ X+UGJZ/IX3>*:AV1OL*X
M[024]L$M=WW8&_,[1*Q4K-DM#[,#>_M?,.L6C,H*YB*RW9)LY>/2BXU8UT>I
M^D5:Y]YY#38![#S%T[90-I9R*D8[CX6UH$Z>]3ZS,V*IJND4B2=;&XURSPS9
M^T%5L#V'?L14!PR<)INNN7JFD@ F.]J<(<"8UN;W@"2TR"0UP!+2' :7-)GY
MPB<(G")PB<(G"*B?U5NONW6"X/>P\)F_HXOL-SG(8U&\ZCZBF1W>WZ%6'$18
M+._D&S:V0,4]B6F?HMIB)- 1!E@D3V62G2)-E59)F14BP?Z12$E*[54]'3C/
M16:TK4L5U2:SV:Z%XGJ&6[U;8JE:+5J/:I!FXT*L5L[C-8*UIC"W)N*(.#3B
ME76124:G3<&(O21PBQ:WVS%WC+2I%IK&;.8[&'3UEKL@A=ZVLRRUY'1@34BU
MT)XG)F0ISEA$&_$WR%@5CU6C'RZ<%31 3@(V)'.#]XX6MMLKI(:#I(:9#3!@
MQ$P=B1(F-I$[K&45W7Z?SF+3?8V'[.85)X+6I!6(L.O,]/J#C/H2825;(GAI
M6SDE31;&8.J^8D1BG+A.0<"^9? ;* \;?%D"_COZJ*!/J\Z-0=8]*;7-$S"Y
MU?0J!:TLME:S<Z9.1UCK4]''UFIM_FXF:B7#J.>H$707;J&;KG^"Y07;J_#6
M24(5W18[0;#D-_O]5 ;^0GQGA]I*AKZ]6+[Y<L5Q39<S28IYKB%&GI?5)%9_
M#I/8]O*I5=K%KLXV1**\GY,5?WILBG43'P80,'/9/A!2['XW,,3E/:/#LQ.+
MQ]2@S*VU*#JK-3&O>\%[6N%(D-DEQ#2!Q,+J\T.,;2^;AB 627#5HD3PB;GZ
MQ$";P@]'O"/4:K,[$]L\GIN777--'SJUUR 6T:\,*RT=?!M;1BN\+'UM@^GV
M\@A(5EZW2*Z:$;JMA464/Y%N)MS^(N%^%.$KULF>S%Y7F>$JT78EV4Y>:CBR
MI1;6:QSZGRZ+Z;J=5CM37DM< T#>.#+ZV95:8?6KTRUX,,?4ETBVT'8@[@"W
M 66WUG>V79VX5=/J?V#K'7VM@C<*U=3M<JMUGM%JAG,3"O%F1)T99G'L4&,D
MC/&52%-I\<WPD@\@7W&/LWPD[(]F</5_ZER2OGF(:_!U\&UV98;#X?#5F5*S
M-1HBD7O+J;L.&D.>6F7$\(ZC.,QQ+7&A4%*SVR=6IP(:Z]B.[!W(;!CQ*GYZ
M='J%=O=$Q.LUJC]4*/K]9RRGU*I(?H)L4) 7)BRA&1X5-S:8"U@!$'TB6-!=
MLDU<E2$#"(F AB 70?B%V#[+Y9G.*Q.+S_&Y5B,QQ>(Q.O'9>^M@ZIK.%9S<
M/5PS0=-(U"'%X,C:(*[;+,9B\72IEKL,6M8T%FHBHT#@221)B1( !G=8A]8/
M0.S793K] P+OHKL.=/\ -;U%7J7L-NEJC9LS"N@R?P\XNYD*=:#OVDE'(/2K
MQ[IVR,T!(RXJ$ ZA0#ZOAK@LN[.YP[$93VQ[/9B_,J;,(<,ZEC</C7-^=3>6
MTA5I-!>6AQ !<"6AMP97+F%-M>FYM?#URUK7'4US7, B3(:;@$#>#%[*M+TU
MHW.,^[]Y3H.E7C,<ARVA0LQ86=AN$M(1LS/WEPQD85G6F+M0PPK2/^3D0?/'
M,JHV(()?"15.H8"%WWXG8GM9CNSV)RW*,L_RN$Q](TL<:0+\5AM%6G68^G0:
M 7L=\LC4S6X$&61<]?E%'"T:P<V&5N]=Q :6%NF)<02Z]MP.=U[D%-&H!Z1)
MW\EMKTA0XR"?3\K9HV1;3$&C!-&:KU](&=1QGB3AHDR357/\+XHF3 ?:0WD"
M\_(0R_,&XFE@#A*U+&5:K*+,,^FZG4=6JO#&TVLJ!IDO(:)TW/JMEU,,NU A
MNYD$  3ZP+@\MK+S(2^0_P FCF-R'L:_L^>#:5[(2YKPR8ZDWSUU82KF>'D7
M%03KA8DQ%W@B\79"F#%9Q_7#MC>0#F\'X5?$* X]F\: T3(KX"+#\Q_]5M$&
M9X;V7R#,L"7:!B:)=M&HETS$1&_UX;+U)5F4@IRN5^:J[AJ[K4O"14G7G3%,
M4F+F#?L4'44X9HB1+X359@J@HW(*28D2,0HD)X]H:'6HU</6JX>NQU.M0JU*
M-6FZ YE2F\L>QT6U,<TM,6D+[000'"\@$'P-PO$/ZPOHZ^JCWL[I:IJ%+SK'
MIO*$Y9K&93.'M-,J=F7IK&/;ILV\^8K=.3>.$W)G11-)*++F*5'R;P0H!QI(
M^_TF>O">:M>]%_TUMNQ3KKHN*>H5AF$OF+*W,'N5,X2+ID^]_!'L68MB/+SD
M(R2?K+JR1$OA%?.5#E)[A3$ $>$D3'%0*_E#?IF8U6<7QR3ZY4:NYQ.S>I/$
M;+(.7$JI"EAD:W)KI1[!L4KTD>[7D3(+_$3*E\1NW61$Q@$I>./7WZ\.*JHV
M],KT^NS1>V54_FJT,L/;"UVX+-Y'/KA+T>T-TTH-PIY86=2(<M8Y4%P1.5.0
M;KL'ABE;.T%D%3IB28ZE>E.>[P^HST%KUAF=MG?YT*C2(%]-R%6[+4T:Y;9I
MA$-E%'"%'WK*&+JFS\J[,EX9H6ZM1[EP*@@5, #W<)OU:W/U\1LJFLW_ )6;
MVM<=A(F2T+'LI4P&7LS*/DJ- ,Y=&X058=OR('?QMK<RHIR$^S:J L<'L>6.
M>*D.DFU:%4(=,B]]U>G(^SP,+8XE8'$7/14?,QRY1 2JLI)JD\:J (>0'W(K
M$'Z"(?7A%S'")PB<(G")PB<(G")PB<(G"+R&=F)*43[$[HFG-_RIY),FMZ"4
MB77N+JA\'3(6TR@%)C)W!BKGR\H  44RY05-6@C14#WB/"*X+TB'#MSE>L'=
M/?5(>F+H4>4A_5,:Q372"%_1MD(ES L4(IGHXB/F1,J;WA/_ #  4"_4Q%;C
MPBVB8I1 !, "81 H"( )A^HB!0$?J/@!'P'Y (_8.0 #;G*;K01( @3R7W '
MO HC]?!1_LO;Y\B "(>1\??]_ $3'']=_=0B1'MX<E5CHHB?U@NM)1_X_2O=
M1-X\^/(:'3@^@"/V\_7[>?H7R/[:#9XX:03XB38^ W/]JP>.XL?->6'U0/1S
MZO8KV^K0V'8]7DY7MMI]HMJ#%E*T]-S33VRP.G2[B1:N*Z*A(E6SRA(F(7.L
M'QT"+>]0RK-<3>A=D.P>-[6Y=G6:47FE2R?"E\%CBW$XH,=5^4U]Q#:3'.<
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M=%B&"7"9%PT21<[J^>N]F<0FVS82Z' ,GYVK55ZQ>J.6)V;A1(AU6YQ>-D2
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M=F\KS:EF1-#%8C$MBM3Q-)C?E-?I%V5*+0&.W!86[1/095@V8YO?K5*=6E<
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MV-,-#21N2#-N$B3OLJS.KG7[MEC6G)S$YTXL>GU"<AY.OW"B7NJ,%:_/PKA
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M5!1I"@0T X76&/=WB[4XW'3MK8(YNTNI4FX<.^6!3GY;GR1\YNK_ &U$&.'
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M]Q+262U!5K/S2/RKZRSL@O.3WX?\0%@CFSYWY%FR%4 .HBV(G\82D^,8_L*
M$\UG?7<HI&X9K=<HT6%:SU.OE<EJS.Q[I%-4#L)=FJS640,H4PHND2JBJV7)
MX.DL4IRCY#A.7"/?JPE>.20_DCR5?T*5M59[#Q-PHD7)C,UK.K5!2,0^GFR#
MP'"%7LEDBUCE9M'#8OR;F4CT!7$H^\J29A$Q23X<_+8?O]/>=&-:OV;Z)6[]
M *'#7:Y4> (FK;NC>ISRD_H==KS=(OSMIZ@:W+. 2T"N,FZ1G:>:6%^M+)(
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MY*?V'R&8ZDWKJ_$RZ)=8S;1[-<YAHH4Z*5IK5H&/,SL4"+A-%9RVCE"EBI%
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MENSHNDT'[2?SVRD79IFLVBUR#L)M/'<"]P#!M,P(!Y#',ANESF/)+&%X+ \
M-J%IJ-:14=K8UP94(8Y[7.ITRVUC*8BZ0&79M!:1*P\[HD+0:?$WV;KS$D9
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M-)F;CZ].R;J(7EK25X>()*N7;$82M04%',&IG77N%=+M(=!TDEH=!TES0TN
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MP8]G[*)W%V>M>G/7[-E76;9K!=''2W6]=I^J5]S7KYB]0T"KU#3IZKU*S/\
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MK]?ZS>;96JI#WQU4MX?1LA2+7<;NI3HQU(V;26/XO)"E&QSQPLC%M%.$4O\
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MBE55!30D&ZT:0BLWX1.$3A%4]ZW7]S7WS_E>8_\ 6G3N$5H=5_M8KG_,,/\
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M*3&2OE]>KL:Q#J!&-'0L47SA%4BDF_\ EXUF5,#O':)1*(N,^ $<+<?-8@0
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M_;X_9_#Q_FYCIG4'7!VX0(%O<2B^*Z"2R!T52%414(9-9,Y0,11(X&*=,Y1
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MLW#U<2WY9JN!(#39PM![PLH#=:>C>L8#JL1>F]_K;^+(DM&6&*1:R1#R40Y
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M*"WJ2].P[X]-]@ZT(3Z=7F;O%,W-8G7 *F8L+/ OT):&-)D1*952-7=-@;/
M3*8Y4EA5*0YDP*)%Y(O3%_DW?<['NZV7[/V1D*#3<WPZZM+NU7J]G+99>[RM
M?6%6$9131./0*PC7C@$UGKN0.W<(MB&33;F6, E*3;K?D?'P7O& ?(>0_H_S
M#]>%4X1.$3A$X1:"  (F^OG]P?Z/X_["',3 ,P2? 'Q]$6GGZ_8W^(/'^WY\
M:C([I]1$?=%NYDB<(G"+BY:#A9]L#&=B(N:9$62<%9R\>TDFI7"(B9)P5N\2
M62!9(1$4E0(!TQ\B4P"(\@F3RF!^OH47[R(ID']0I2@'@/!2@4/U0 "^ * !
M^J4 *'T\ 4 *  '()U&+" #XG?\ :?Z4(!WX&1X+Z\R53A$X1.$3A$X1.$3A
M$X1.$3A$X15.^MU]?36WSZ_^69@/^+4Z=R @[(K1*K_:Q7/^88?_ */;\J+G
MN$3A$X1.$3A$X1.$3A$X1.$3A%M$I1$#"4!$/L(A]>2!R\?7FBCGV9R7*]=R
M2\US5HYNI6U*W,$>33=- LU!HBT4^,\B72B2IF[I-,#"GY R1S")52&*/M'9
M.R><YOEF<8*IE%4C$'%46"@YQ^16EXAE9L@.89DQWA'=(749OA\O.#JXK&4@
M\X=KJK2ULU&D D%A$$N)MI,@SLO'0WZ3XHM<4FD?&S*=96L2;9B>50:H.OPL
MS\J3921=HL!114,W]@NE"-?8B;W&(0P% !_:+LZS-N"UU,0SY_X<N?\ *>YU
M/Y@IES@QA?J<-4Z)=>!SE>(_]6.-=[&8"F74W?D?J^;!=I!T\=Y(B9)'BKL+
MAZ>?6*Q_ADE:^E^B9U8_P],A=%ZX71S%J$*")?#\#0,G'+J+N0*58PC&' YO
M:8X#X+SPFAVQSQOSJ>%[;Y9C</\ ,?JRWM#A YTEQ[C75*;M.B-.H56F-KR5
MZ90Q^,HT\.W$]G\2^I58U_XC .;\L#<D]YHN+AID7-X7G%[\9[K+S;97/89W
MV3N>69L8L?F#C?965E+,R*X1;*3#Z+*[;MA;,3R:1T&;D"*+K)-$E%7 F_5+
M[UV'KY93R9F,JT\@P^8XX?,S Y%28S#5"TEM%M1P<XO>VFX.=)C4\C2!O\&8
MXZI4K4H=6HM #F4<2YK:K' R9T[;&QMQ$[JY3IONG?&\XI6)6Q>H10\LLD2J
MXJZ&7:]@$3-.RQD(FBUB9,]QC@:RDJA)- 34*]=G,N!R*$7.HH B/C_:WLMV
M:PV>X@X3L/C,SP%4,Q)QN59M4I!U6H7/K4SAZM<,IEKK:*;  ""T"2NWH=I,
M%2I,HXK,J5'$Q=M2D][0),'7386FWYB2;S$\.2[?]W.\77;&9><F^VG5;1"3
MP*U%C$YWG5DC- D5)AHZ06DXT[Q^>)CQC2"995V9(Q$_8E\,@K'(479?L+V2
MSC-L/1;V1[29;\@C%U*N/Q^'J8%@I/8X4WM8#5?\TV:R03)FTKF.?X5]&M4P
MV94,6YK2T-;1JLAT<W!K3<\)GD"%(KT%.Y[O<,.G<#OLVXDM%QET*T0ZDUS+
M2,W09A8RS-<RRQSK.CPTFHYCU3^?*;8[(I_R$VM_'#L>W)L[HY[@*#:>7YLT
M-K!C0VG1QU,:7AH'Y16IAKQP+FNM>WW9'F+<5A@RJ^<2U[M0))+FDR'<8Y$$
M[7O<J_\ YX6N]3A$X1.$3A$X1.$3A$X1.$3_ &'D()L#',\?1%5AHW]V&ZU?
MM#I9NOG]G_A"IWV_PB/^#_#QRG?PF.O-7@?,?8JT_E43A$X1.$3A$X1.$6TW
MGQ]!\" ^?S'S^X?'U\?P_9R$$Q!B#)]BA,74+N_'7"X]L^M5QP>F71&C.[NZ
MAT9J77,X(DZKK%^1[)0RAFJ2BP(R/P6Z:I2%+[TBG2.;V',4=M["]H<%V7[1
M8;.<PPE3&LPM/$&C38&@TZ]1FAE0$N:)IASRV38F03 7QXRE4Q%!U&BZFPO@
M$NN +&PO<D";>B\]\/Z4?8OTXK?3>XV;20[>]QZ?;RUFSRBN7K&SS="7;K,[
M4V8-WC#X4L0T2LX%Q%$'YE5,H*MP,HB!>>^U_B?V<^(N"Q?9+&4SE+<VP[J6
M%QN/IL=AJ>,!#L.7%M2:;A4#=%0EHX'\U];PV7XC)JK<75+:E-KH>VB7$Z"(
M.K5)@"+B0" =KKTD=7^V&*=N<[C]%QRU-I5N)"-Y^N.3)L[93Y9,0!W!6:"4
M-\Y&O6JHB0053^"L0 605.0Q3!^=.TG97-NRN/=@,UPSJ) 'X?$4Y=A<51/Y
M*N'J@:7M<-P>^PR' &ZVJA7IXFF*E)P<T\/]APAPX&Q\"+@D74E/C "ADSF(
M0?:)R![P$QB ( )P*(^? "( (^! !$ \_MUXEP#B[NM!LZ)$0-_'>W*ZYKSX
M?65]?(_M  \>?'Y@'U^O^'_%_'Q]1U&X(T\[S'&/KX^2)Y 0\>? B'[O/C\O
MW (^0_Q_3@$EL[<SM8&\<O7[(M?WC]/X^/\ /_\  >7D22 !L>/GX^_HBT$0
M+^L(CX'P !]P\C]O'^W^'D<X-EY=W3$"./".4]"4Z]EM$3"'D/H8?/M 1#P/
MT^P_Q'[>?/\ HXES@")$';_R]>2+<'GR C]!]OU* AX#]_[1_9]/MX_/E.JP
MC>SB+1;<(M! P!X* "/D?O\ L'[^1_;^[\_\X8.+VAP: YW^LSMQ)-]MO:R>
M:W!] #G+YHM>$3A$X1.$3A$X1.$3A$X1.$3C9$X1.$3A$X1.$3A$X1.$3A$X
M1.$48>SG<+!^H<-497:K%8&;S09N1K]"J%'H5ZU+0+G)PD*\LMA"MT+.*]9[
M7),JU7(][/6252B@BX.+0^8DGC<5VQ%R*O3U7M=SC>/2-T77\CMD;=\XT>)R
M"UTRT17S!&DW!2>G4U9LZ(V?(-9!FL3]=N]CY!HTD8YZBX82#1J];+H)MA.P
MVGAY*3N.7[2KAJLNB%9K@"LD A Q'D!4)Y#_ 'O;A]0\^?OQ/4%)',7V\5SW
MQT/[\E_E"?T\*R.?CZ<T^.A_?DO\H3^GA$^80_OR7^4)_P#BX1/CH?WY+_*$
M_IX1/CH?WY+_ "A/Z>$D<^NB$^.A_?DO\H3^GA$^.A_?DO\ *$__ !<(GQT/
M[\E_E"?T\)(WFW-/CH?WY+_*$_IXWVX;^"DCF+[>*?'0_OR7^4)_3PJGS"']
M^2_9_P#6$^_[/[+A$^.A_?DO\H3^GA%^53Y9<BJ2@M5$U?)%4UOA'34(/T,
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MM>Z0[9E@9HKI0"%57220=K''W*"X.8 #T[L]\0<>S#4NS^>Y=1[5Y,]S*5+
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MIDR8$ ;[JTZ+])CJ<2,CB/0WSYU)@U3=_"[.[T1('!$$RN?A 2^% $_BE,)
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M@[\K=1YV6(/$ <C('#TO'/\ 9;_ZDUU& /[/?OO_ .L]O8AY'Z?_ ,?<"&"
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M#R6Z96-%-4(%>)G/TQG8B:4M#^2.F#@LFP&+^6(F+5;XY7*BAETQ\E-"70(
M+@\D.)-FN$'AO[SM:2508D"P,>8CE$;^2D@7,\[ ! :#2O(F$1']%X,?/D0\
MB/\ W"'U'R(C_#Z^1'DTQJC_ &,\H)%S;>_JL1-P?'U'C^OB.2WCFF=?E0:7
MY_+_ (+0G[/^0\M[<^I_A6WM].@@YKG0?:@TOS__ $O"?4/S_P#(>53RC^?[
M46^OW1W.,)T7M!?R_@MP'LIL+/6CPTK2X%LUHAVE'KE,&N0RI2N1>,50KX2A
MESI,A!P\53^7-[154A)(: ( +B3Y\[W$W_9(/$S:-O/]#$?NI1FS;. \ -!I
MGD0$0 *M"#]"B'G_ ,A_>'^KBX!=Q N1:\'UX%"9(:;SM-Q;SV^B%S7.! !_
M0"EA^S_@M!@(?M^GR(^. 9 /-4B_ QQ_9<!;<6SJTU6RUG]#JA&_I% 3$%^(
M-ZI!G78?BT>X8?.(D,S(!U6WQQ63*)B )R% 3!]^.\#(BPL/&4L=]N/!8PZV
M=3LYZ\83EV)%BJY>"YI4H^K%MLQ3H!G)SP,??XD'K9-%T1%97W_KD*NJ >T!
M]YA$>&R !Q%Y\9GS0[[?Q^O\^&V;@S7.@^]!I7[1_P""T& !Y_\ N/U^WU\C
M_CY+PZ3<S/'P'G-K'?S2 -A"W?S:YS^=!I8^/I_:O"?]A^G\.46^G"$4=>S7
M3/+^R>>Q>>2$9 5!@PT//[TZD(:I0BCN2;T>SL;$M751*FR509SR;0T<Z=(K
M@JW27.JFFH8H$'Z,+B*N$Q%/$T3IJT:E.K2?_P"-2FX/:Z(W:YH-Y&W)8N:'
M M-P001SD1U_<QY/Z,OIO&%0INM< )%P/\4 L-P #B81,(&*6>]H%$PB/@0$
M 'QX\> YOY^+7Q!(T_\ 4%4L(+7-.&PAD$0=Z$&V\@R%\9RW EP?^'9J!D&]
MCX>/C//FIXUK%,GJ-=A:Q!9W36T+78UE$1#8\!&O%&\='($;M$#NG;9PZ<&2
M23('Q5U5%3B'N.<3>3<T6KF&.K5Z^(?BJQJXBH^M6<VHYFNK4<7.<0PAHDD[
M 1L!%E]+:=$!NEC0&V&EHX6X"3^N\P52UVQ]"J [6;Q<MOF.Q\[3ALQH]O$4
MZ#S6"&%J</%L4632)C3)S[$%4O>FL\774:IJN';I913[@ >R]E?C5B>R^287
M)J604L7^'#S4Q5;,:WS<14J/+W5'CY+X-PT-U$-  ; @#J<;DM'&UA6=5J4X
M$:&AH;RD2V9WXPL^=1/27K'5VYYO;9C65]?3S"A:-G\#$V7.:S')J1&A6.'L
MQU'+TCN2<K+03^,<DCA< N;Y>1.B"B22":9M'[9]N,9VLS0YE0P]3)OF-:,3
MA\-CJ]:G7>QC:;:D$4VTW:6-)T-EQ'?U&Z^_"8.GAJ#*#O\ E%.=#B "+DBV
MUI(]9@$!<KZAGI?)]Y6F>0D'JT7B-6H[B3E'L+ 9E#RQ[).O2$;-))\]0EH-
M1-*,9?'0:L_AK)_$=++&$3"0"=SV!^)1[%.Q];$9;5SG$8QM*FRM7S&I2%"B
MPESF-8ZE6$U'Z"YX+3W&BXLOES#+?QS&T]>AH<'.@"3!$$VN1R-M[\^M>GMZ
M3:71BU7V4D-D8['5+[#1K1[3YW,(F-;L9V)<&.PL;-\YF9U9%R1FN[CUFJ22
M2#A!R)U?*J*1B\_;WXHN[:X7!TZ>4U,HQ6"JO>S%4,RJO>^C5: ^A4ILI406
ME[6/!+B6N; L3-R_*F9>'!M5U4/.HA[&@-/_ +8X>D[J8?;GJ>W[#=?K[C>?
MO:?D<[>V3>&<W=O1XF4=QT(=XBK+MF**!6*R+J29)'8E=)N4SMR+*&+Y$0\:
MCV3[45<@SW!9OF#<5F=+!/?6&"_&U6-?5#'"DY[G%S7!CR'EKFN!( NOLQ.'
M%>C4I- :7@MU0 0#N>=Q8Q>ZIYZX>@?:^NVVYEL43V5AYL]!L"$B^@G^;)K-
M+'"*E.VF8!Z#R7=H C*,%5F_S!FYSME#$73**B91#UKM)\;<#VCR7,<FQ/9N
MJVGCL.ZFVK^-:31K"'4JS6BF+TZ@#H!O$&Q7383(W8*JRO2KS4!(=/Y=#CW@
M!I#I@D"383<G?T,ES3.P#]:A4L?M_P#9>#_[ '^CP'Y>.?GD:@77&ETV%K<C
MS]9_?88%N,<3NMW\VF<A]J#2_P#_ !>##_0QXB! ^OG>55U"_P"%YW>*+=*4
M6HU&)_2^J6&K_BK:IP:CF+"?B7D2:0;I_*) HNR*[^813%1,#G2 HJ$ PF!I
M!$&8DFW#R%O+H*$NL1!B(!V!G>?V$KK_ %3P)GU;ZZY#U[C+$ZMK'):7&4UI
M9GK%&,=3*,:*@E>KQK=9T@S45^*("BFX6*4"@'Q#??B"3)X6 &Q  B0;3;RV
M]*9X<=R>?&W'SG?AQ4@S%\A]@\A]0'[#Y\C_ +??[C^7,2':3'YMQR!Y>4?J
MBW<S&PG?BB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*"_<;OUF?31
MU3H.Q9UM&RW>YUC1=!:9[@]2A;;;8C+\BCHV4TS39Y"Q6FGQ4?4ZDA,Q""XE
MEG$W+2,DUCH"&E78JI)$7(;!WUQ7*<$Q'?XJ,O\ L4/V9E,X@>NU&R.NLYG1
M-AGM5K3JZ5"*K$19)BJ1#!1:H1\I9)5W:9ZOQT-&1;T9!XBZ(BU6(HD6?UO.
MJD#FM"TV)SOLA>HZQYAH&UZ/7J;FL*\MO77*,GT5YDNF77<XF5ND.C!,:9HD
M7-UN0851]<IAXK S$A$Q\A$M2OEB*95#[R8?IO:*:ZE4Y._OM"AL82W0;.]H
MLQ!9G-4A>=KM?*>HV^=+&_IDY(\M,2*K^KQLM6$C_B$8>Q!/1$K$,R;KF^U/
M;2E=3*Q0Y2QTS2M1N6L:''Y7E&2X[ Q-BTC1KP^@YRSJQD"QL%@JM>:MHNLU
MF>GYB6G[)#14?'QJGQ'9G2[1LXQ;_L(@!T#Q$ S]>*#8+H3#U#^N;[HVIZ@A
MGMO984A5'UB=,'E94)HK68CK8OGKK/5:DD[6*:_%T9N>A)124FI'.+&9(J,P
M>+5))CDBP1*^L)UPJ77O9=\TC-.RV<.>OVCCE>OXI/9*67V:C6H]4BKXS7GH
MREV.T4>(JLC29EC9&5UE[Y'515!0D6:7)87+"'>$5JK-RF]:MGB/N^"[;H.D
M@. %."2Z1%4P,4!$"F]I@]P>1 #>0 1\>>$4?^T/9FA=3LL-J-]B[=9BR%NI
M6=4NAY[#M[!H.D:1HUB8U6D4*D0KV1AV#^PV&9?I)-RR,O%QS9JD[?/Y!JT:
MK*E(NM]<NX>7=D\2M6WUV)OM(C\YL^E4;5Z#H-7,STW+KYD+YVQT"EVJKU9[
M:TW-AA1:%=HM*M(V,DJS>QYXI5VN[(W BY/JEVNS;N)G=ATS+HF_0<)6-/T'
M))B*TJIKTBUL[=FDT:!LJ#RLO73B4BDTI IDTVLTC&S3<Q5&\K$1KU%9JF12
M9 ?/GZ?8?'^+P/GF,V)(V='L1"+0#>?R$/O]_P!P^/\ /RS>/"?MUX\-E 9'
MOX^RB?2NYN17[M?H?3F!CM&2U3,\T0U2>E9ZAS%:H4E6U+>%'7+4;)/!'K7!
M1E8_C1[J5KT7(507;*4CVMC<RL3)L&E54L//ZPAX_/Z#_@ 1_/[?XOK^W\L9
MAT;ZK^4 ^\Q]E.?A;Z K=]N4 "P543^Y'<K).C>1.=HV2.T65JK>2919FF:T
M.8O$LD=XX1;F?RAV8-8*LPC,RZ0.IZW3L!$&<K,XEF\=SLG%1;ZHL&]E?5#P
M+J[KI\FNU.VBSI5F'RJQ[3IN?TN*G\PZ[5W;;JYH&8S.Q3;RSQ,Q&H6:PM'
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M9FOL3.\NOLLG:2XE@<ULG2'.#G < 7!K X@;D,:#R&R]"Y2@0I2A]BE H?P
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MI1,)%?E#,E(V'BHY4Q#JL(UBR5.G[A3.HU:I(',G[BE-[#&3$2^XI3>T0\E
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?3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img29677477_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2TL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    +1"^$5-CA"24T$!       )QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1Q
MP!6@ #&R5'' (   (    X0DE-!"4      !":B:U=*&VZ(0+(RZEG!3_;.$
M))300Z      $9    $     $       MP<FEN=$]U='!U=     8     0V
MQR4V5N=6T     0VQR4P    !21T)#     $EN=&5E;G5M     $EN=&4
M  0VQR;0    !-<$)L8F]O;      /<')I;G13:7AT965N0FET8F]O;
M +<')I;G1E<DYA;65415A4    #0!2 &4 80!L "  < !R &D ;@!T &4 <@
M      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90
M!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6
MQT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M   !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&
M)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M  #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&
M]N9P      .$))30/M       0 69>N  !  $!9EZX  $  3A"24T$)@
M  #@             _@   .$))30/R       *  #_______\  #A"24T$#0
M      !    %HX0DE-!!D       0    >.$))30/S       )
M ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&
M9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M$ -0    $ +0    8       $X0DE- _@      '   /________________
M____________\#Z     #_____________________________ ^@     __
M___________________________P/H     /________________________
M____\#Z   .$))300(       0     0   D    )      #A"24T$'@
M  !      X0DE-!!H      S4    &              4G   '9
M !                          $             !V0   4G
M            $                         $     $       !N=6QL
M   @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   4G     %)G:'
M1L;VYG   '9     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V
M4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M    !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V
M)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&
MQO;F<          $)T;VUL;VYG   %)P    !29VAT;&]N9P  !V0    #=7
M)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M$       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O;
M$    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15
M-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6
MT    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;V
MYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&
M]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M "/_         X0DE-!!$       $! #A"24T$%       !     0X0DE-!
MP     (D<    !    H    '    '@  #2    (BL &  !_]C_X@Q824-#7U
M!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q
M!A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0    #3+4
MA0("
M       !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W
M!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !
M1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U
M   "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#
M $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6
M=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M     2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.3
M8V+3(N,0
M              6%E:(        /-1  $    !%LQ865H@
M       %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-
MI865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W
M=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                        !D97
M-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&
M%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D
M="(&-O;&]U<B!S<&%C92 M('-21T(                             9&
M5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S
M8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&
MEO;B!I;B!)14,V,3DV-BTR+C$                                  '
M9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $
MP)5@!0    5Q_G;65A<P         !                         H\
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M]M____[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)"
MP)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,#
MP,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,#
MP,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( '  H ,!(@
M "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@
ML!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@% P
MPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6
M-S-1:BLH,F1)-49$7
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M\>A^_4GYR3^OF.+?#/E(Y+\4><#X]#]^I/SDG]?'%OAGRG^7]_<.2Q[VB/\
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M@KD05 H2IUQ-G+*UF":"&-RO80I',,I.9P,WR6K&,LM*Y[6:0*##"RR5 QF
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MG+@*H8'V1</(-U]A--5.=>2"$Q.%38='3>:);0D<S0LRTIL(88L^JAQ#;?\
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M\,MJ5O45H==2.SG:!I&97PG>K4VQZPY,DC#)8+T8Y0A<FKTE2>YM*U>ME*5
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M*EDS.T;=T*SOQ;A$3:P1T W55Y*N4K6MJX>2XUR7%XO/N9:-@=$WW%[114'
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M_L>^X-,;I:*.=TL=FMLG2ZK[!5)5;FU:FS!#*[&5'MI4FW),2,W3 04=IL/
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M7=Z6U&\OL>AY#2\(D=C-[RK>X&U]&.">1E4ZRK74S9\=!6[,V)COF<F$SHV
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M^O7X]8 ]=?7K\>L >NOKU^/ 'J'Z]?CU@#UU]>OQZP!ZA^O7X]8 ]=?7K\>
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M7K\> /77UZ_'K 'KKZ]?CU@#UU]>OQZP!ZZ^O7X]8 ]=?7K\>L >NOKU^/6
M/77UZ_'K 'KKZ]?CU@#UU]>OQZP"5_!N];[DXS]-Z_A6\[_X_P#^;T/_ ._7
M_P ?7]K*K7O]1ZS_ +JU#_I+MRST7_7&E?[QPO\ J:S^H%GS(?0HP!@# (KJ
M>%N)UJE0L6<@<P*E:L\U2J5*:%JT]0I4GF"-///.,BPC#CCC1B,--,$(9@Q"
M&,6Q;WO+2-<UI8A5U;4HB(B(B,[)B(B(VB(CJ]T1'=!7SI&E3,S.FX,S,S,S
M.)1,S,]\S,S7O,S/OD_#[ WA[\#CEK^H"J?V4S/KW6_F^I_797W3'JC2?EF!
M])1]L?8&\/?@<<M?U 53^RF/7NM_-]3^NRONCU1I/RS ^DH^V/L#>'OP..6O
MZ@*I_93'KW6_F^I_797W1ZHTGY9@?24?;'V!O#WX''+7]0%4_LICU[K?S?4_
MKLK[H]4:3\LP/I*/MC[ WA[\#CEK^H"J?V4QZ]UOYOJ?UV5]T>J-)^68'TE'
MVQ]@;P]^!QRU_4!5/[*8]>ZW\WU/Z[*^Z/5&D_+,#Z2C[8^P-X>_ XY:_J J
MG]E,>O=;^;ZG]=E?='JC2?EF!])1]L?8&\/?@<<M?U 53^RF/7NM_-]3^NRO
MNCU1I/RS ^DH^V0NZW4>)3B=RJ=CO#DBF]R*[ELQ05G&*TXH;K=DTE40%J;7
MN6Z3,%<UE(W0L#.TNJ5Q4#-2@UM&%6I![1"%882]>ZW\WU/Z[*^Z/5&D_+,#
MZ2C[9M?F^JO%9UO4+!>O/W.O)<_K*1*'-"C?"N<H Q+$3LR+S6QZ8G^/R2"-
M$BC;\TKR1IE[,_-;>X$>I)_PXDRE,<<]>ZW\WU/Z[*^Z/5&D_+,#Z2C[9OD7
M!_#@=>T+CKED(=>GJ(5 U3K6O7Z-?3N*>GT[WK6L>O=;^;ZG]=E?='JC2?EF
M!])1]LTY3_/?C\ND=H CW"-21G=3VS+:>>]V1Q_#8 %_?8<%O$OD<%%(H0DU
M,:_<M.)7S>FK-L]E>]$JA(CAA)V+;U[K?S?4_KLK[H]4:3\LP/I*/MF&= UW
MXS^;)#SG&K XPH)6OZ?O:.\\UP;&.;::=$::=R=E?WUM52<Y6UM@FV.!21U<
M4I<4!3LL*4FI0 ;#2AG'$/7NM_-]3^NRONCU1I/RS ^DH^V25UPCPWL'O-<=
M\K[+]G8O;U054;![.OIV+VM17V?9UKZ=[]?3'KW6_F^I_797W1ZHTGY9@?24
M?;&N$.'!!T,/'?+&P;#[6AZH*J-AV'>O70M"U%/38=Z^GUUOT]/I]<>O=;^;
MZG]=E?='JC2?EF!])1]L^-<)<-;$$&N/>5MC$'VP@U0=4;$('_[80_-7UV'_
M /BUK>O^_'KW6_F^I_797W1ZHTGY9@?24?;(V\Z5QXTNGG#H)LKCBZA$JCFO
MH:><S6%N3\V4VV%JK#KI(QK']5&A(6IUVY1@TJ0(@MSDM"UKE!A:G1S4F" L
M9SU[K?S?4_KLK[H]4:3\LP/I*/MD2Z\ZA\%%EW(QT:R<^TJU2^5VS(:)ASU+
MN$U45K>8W!&'9:QN=>QNTGFH$T <9*)S;U*-"W_. H;@IT0E2;-5*TI!SU[K
M?S?4_KLK[H]4:3\LP/I*/MDL^9*X\:/6$<M&45EQ?0:)LJ*][6YXE/SNYMII
MH4'3JG7LMAE:QI+0M;N6JC:A88 UF<51J):J2[V-6V(#=;)T]>ZW\WU/Z[*^
MZ/5&D_+,#Z2C[9)3[!'AOV/>?8=\L>[]GV_;_<"JCV/8]/7VO:^:OL^SZ?3[
M7KZ>GT^OICU[K?S?4_KLK[H]4:3\LP/I*/MGQOA'AK0/>[X\Y7T7[.A>\W0=
M4>Q[._IT+V_FK[/L[U].M^OI_P!^/7NM_-]3^NRONCU1I/RS ^DH^V1PYXK3
MQJ=-.703577%U!I5/-?0<WYJL+<GYLIML*56% 6Z/N;VKC0T34ZB<HR8GDB
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MO8!>FM^R+6HKO81>F];]-^F_3>MX]>ZW\WU/Z[*^Z/5&D_+,#Z2C[9"6>O\
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M8\MR]3[D&PZ&=[A*I--]T#8P:$9['L!V(.M[UL6O7(,@P!@# & , 8 P!@#
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M?GM1)7/Q4=+-JX@"E"XO?.R!:F-UO92E&LZ@IA,J3FZUO6Q%'D&F%&!]=>T
M8@[^C> ; _>4O%#^ ;SW_1$7_.8 _>4O%#^ ;SW_ $1%_P [@#]Y2\4/X!O/
M?]$1?\[@#]Y2\4/X!O/?]$1?\[@#]Y2\4/X!O/?]$1?\[@#]Y1\4/X!O/?\
M1$7_ #N /WE+Q0_@&\]_T1%_SN /WE+Q0_@&\]_T1%_SN /WE+Q0_@&\]_T1
M%_SN /WE+Q0_@&\]_P!$1?\ .X!"5[XIY1X^\OOC#US#0U>TEJ?UAWK\]/F&
MT;:OG'\VZWK7;#\J?]L;[_35M[=MH];]-%[<%._IV/UT!Z'L 8 P!@# & ,
M8 P!@# & , 8 P"K#RG,,_L'GJX:W?*LI64<V+ZNCTEF4OMCK:3<HHD\YCUT
MP!<GC$@F\<C2P^+0PN(IG64F2C;^46ZO[2WPE:UA1O8UV 18\(9L5,5]):C3
M[2#SO2:I=K T[Y.+$\B0TVMFV/\ #[D"6=C&"I F^AVFL]KWH4WV6X%J];U$
MTV\ OVP!@'4DL#$FV?M.RM)&U1!J93LEN1E;4)C_ $]\G/V D/OB#O37O2C/
M:+,]->V'?IK .K*@L((C!D((AT5)AAI)R<V(E1YH+C!B=0>)2>08P 1A:ADG
M*1"4'%"2; 8>(1HPB,WL6P(X]RHT;=PKURWMZ5,A0(N6+S2(T2,@I*D2)4]5
MR8I.F2IB EDITY!0 E$DE  646$( !"$.M: S3D?^"GS+_-]IG^SF.8!(3 &
M , AGY&71S9/'WW$\LKDX,SPT\C=&.34[M*U4VNC8XH:BERE$O;G!$:0L0K4
MB@HL],J2G%'D'%@-*, ,.A: K8Y;\-7$-E<R\Z6+,$?1CE+9_1-1364N)78G
M5" MPD<JK^//KVM+0H+=3H40%3FO5'@2(TY"1.$S1*<DHD  ! WM^\:^/_\
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M!_ MY"_FO4!_91$L E#@# & , 8 P!@# & 4^\#_ ,8MYK/YP')O_P!3RN<
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M0TR3,DK$HK>;N]?R3Y48-+ H0:?V405ND M+C_BD7KLE3O16QZ]2@[P"J_\
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M)*C<4Y@RUOT 61*E25"E4K5JDA&C1D'*E:M4<6G2I4J<L1QZE2H.$ H@@@H
MS3CC1A+*+"(8Q!"'>] :!:>N>4G^NY9;[%TWSZ]5- G/Y$G-GM-S5TXUY#7G
M8D@=-,JFB21G1R/N8A." (4#LY)%0A+D80E;VI)T,#5_7\UAUB^/CJ><5]+(
MU.H7)>4KT<XY+X<^M<FC#^VFUA*@E.#*_,JI:U.J(P0!A J0JCR!B ((1[V'
M>M ;1Y'_ (*?,O\ -\IG^SF-X!(3 & , J1\RW\'7G[_ !?_ (0C@O\ [O\
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M&#$!H7S5L-DR;Q:=E,53MS\[S!PK) 68U1EO<79[<H:7-HJHLQ"D:6DTER=
M*JV*EI*UM1'%'KT U24!@/>^UH"@DVVWR3):??YT*MKA\=7+?DTY8>3NDZUY
M15497,U@SES9/2G!;,:S9D[PV+H'SA;+O"H:=+34ZU*W+%;>0\K3EC6#2<"3
M541?K)I\1_73WSLW4O"Z#L.>^36T(['KRB%GLLA+YCF\FFSM6JFI(_'CV F-
M)GYDW*9%'TTI:@-QB%ZCBY*D WGG>^ ]#_(_\%/F7^;Y3/\ 9S&\ D)@# &
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MF'O:4+RL0B)^->!":@DF 2[\/^QB\8?#XC :+,WS]"MF "+VP@'M,;L0-#]
M^WH(O76A>R'VM:]?37KZ8!9#@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M.KJP:LYHB46.YSDE?)W6P7BN$UK%2H,_:YK!)>:C)BHI*SZB9Z U&!8&0O\
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M^FO7TP"R' & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MHQ^OU[@97R1_!3YE_F^TS_9S', D)@# & , 8 P!@# & , 8 P!@# & , 8
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MV(L)FTYOMA +80[$#0O701;"'>PZUO8=;WZ:1[H_[^__ (@L@P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!6GY=P0%;P3;,>LJ)
M*YO&9M*Z-K\J/@ME91#,9)YY>];Q*$NDTN%$C<3J]@+!,7=C?9M(=-ZSW,=;
MEZ<M.,]03Z 0W\*LXKMY=K4C,/<[4?)(JYZY4MNPU,W["L[JV/1246*\] LJ
MNNF8FQM"-KUU810$3V>,@[3E-(U)XNN=6YLTSHP*4?K]?]OR!?I@# & ?498
M!@$6, !ECUL(P##H0!!WKTV$0=ZWH6MZ^C>MZWK>OMX!%'O#6@\/]A:UK00Z
MY?OC6M:^C6M:JZ4:UK7IZ>FM:^UZ?:P#+.2/X*?,O\WVF?[.8Y@$A, 8 P!@
M# & , 8 P!@# & , 8 P!@# & 0=\EC)#Y)P9U*PSVPG*J8J[50]H7*P62)2
M"?/\9-/.1@:UD:A$5DD1?Y;*#W?:!#&8\W2)M,=GY6W(CAJ$QQR10!"/Q7W[
M>]F29&UW?V).+T%**>GTABU567P]!N4)[#EU*]!O?.EDN,N<H;;=C_$RF/SJ
M(+69[AJM*@TF2R5C>??E*MJVI$!=]@# ,0L&!1"U(),JRL%C2R>"6%%WZ%3.
M-KAJ2D3_ !:3MBEF?F968C/3*P)G)L6*D9XTR@@\)9PME'%CT$>@(.Q[Q.^/
M2*UU/JF8.:8RWU[9C;%6N7QH,IL52G4IH,[@?H8<RK%DQ4.<1=(L\E$N3"]1
M!:Q/#6K))-1KRMDE>P!)JGN?*;YBJ$ZIZ*@K=7\$;]29ZTTHECN[+7)^D!BE
MR?I%(I'(G!XDTIDCTN-&I=9#)'AU>G S1?Q2XT)100 18\0G\6/Q'_J!AG_=
M_P#F#O\ %_BQ'NC_ -_\_P P6/8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , \_WFWZ!LB$/%%T(BM62471UQ5W?;_;$]8.-#.UR
M)B_PW=<-5>4Q)*Y51&9,;9#Y>9+I*]R=Q<&O1RY%&B6I,M0:4F&F ;I\*MU\
MO6=S4UQ^C>>V7FZUX]!ZMD74,#B7-4OY]A^K<E;"O2NZAC5R"&1IKFY(':-O
MQ9!C*ZR74?;=MR(Y<%,J0&*@+F, 8 P!@$4.\OX$'8?I]O[&"^?[+Y1@&5\D
M?P4^9?YOM,_V<QS )"8 P!@# & , 8 P!@# & , 8 P!@# & , J0\NE[K(7
M5-=<SLE?TW.W_LM\G%9B-Z#N5QH6HHE%(7 W2?RF2O5D,9)LC:9.3ML:$$!U
M'SFYU(E:Y"[I',A0TDIE@&BO"+6/)&ZQ!T'5E@V#+N@[)C\Z9[.AUO\ 3Z'H
MR9U!\+>4X=+0C<5/1$,@4D$FMX&22Q13 ^,I7.Q5;ZURMX<5:MQ!Z@7R8 P!
M@# .M>?\#NO^C5W_  IN 5Y^(/\ BQN(_P#4##/]P=@%CV , 8 P!@# & ,
M8 P!]K[> /M_:P!@# & , Q60SJ$Q)8RMTJF$6C+A(U?P$>0R"0-+,L?5WJ
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MY6!G8MDU9.'FX]N+E8]J_P 5=^/>E=U-D;QNEB*T?G!R0K$@U)J("I,-826
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MI"B?B5)2 !QWNBRRO>#%[L  >@= 9W[_ ,N_\G^.K\]Z0^K_ /H?_P!O\_\
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M</5]0UO%UW%?46HOLC-3)?JYUEM;0V+%%M'2JF=Y6J;86BEHK>N4E8FNI?\
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M'>PCUL.]A%K0@[WKZ!:UO7TZUO /TP!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@%87;_?ZBFE-G<W\Y1LVS.\4]'*KDJBG71E?2&^5Q,M2Y
MH7B4,#H%"!AF#E"RFIP=#:^ _L;Q)U:=%'VY<G5NA9I<1[K+%RIQHF5TV_%G
M57BIK;,+ N?&YYE>-$UMEQMDI6BTO,\UN:8:<=ZVEU4UHV+.5/%<Y<E,!9LB
MJO*S*:[F3%LR)AUQ89JMWLL285&KWXQ:MD5OT%X^2NM+'B'2BITYKN#G.R;:
ML"_Y!=2B&2YBZCGS'942?H99/'-L1IV3*&A56,>E*LUITW2B1+'"%M41:XND
MC"9[; /A4],/&Q(?&L5;<-<;5J<1L:YK:=:P=8R+\[3M0S;8Z<-EX,Y%.53F
MU0U[Y.)BO4V%QNK(3Y>1D3%R_NLWK:5.4E]7!]'S]'JQL7.QL2O=IBC,7'NQ
M[L.R5HBG,R(MC+5JG/1K"(9&JYAT5@$,;-,T1A4>:(K&&@*I:N"UL+"@(;&E
MO"L<E*QP5!2(4Q! 3UJM2J-T7H9YYIFQ#WF^ZW(MLON?G;:TO8\PL2S3[YF%
MB%B9_/:([^\UJJKIK6JI82M(V58WF(C>9VC>9GWSXF49R.@P!@# & <98L1M
MR14X."I,A0(4YRM:M6'E)4B-(F+$<H5*E)XP$ITY!0!FG'&C 646$0QB"$.]
MZPS*L2S-"JL3,LTQ$1$>^9F=HB(_.9,JK,T*JRS-,0JK$RS3,[1$1&\S,SW1
M$=\R4C=]7E<R#HNHH&]]+R7BCCFQ(0<.M.MZE;Z\E[-*^D52@9D?@%V2R?L4
M@C5:P'Y+)"X1=(6B+;+17F*FA;.689!369PKBR<K4*K[HQ<NBA+='QLA8C#S
M5KK:W/?(EN#WY>/"[5:9#T=3&BW)JLR+X2FOL\I&-B6553DX]ES)JMU33.3B
M*SK7B+1"\EJQ[V:)MU"5MFJ_IX[U54NUUF@?'_PV\]/\_1VP;(OFS&JBI_?$
MDMJ><V0UGC"'G^[9[6=S.;HQ7C6+C(HZJLZMZDO.215CN==7,;D".-N+JYJE
M#(:BCSK\,HGX\1BUZ%>V,]7HN)B:IIVF94RUFA95];VUXC61"VY&-A66ME:;
MC9>[8U=M%=\636]<Q;F:Z_6:5O6V;<C)TS-U*A45=9QD2NJS)BN.55&3=7$X
M.?DXT+&0]%S5\(97CT@9P-Q@# & , 8 P!@# & , 8 P!@# ,5>)S#8^-^*>
MI2PMRF+Q<Z;2)"I=487)EAZ?X_WLG<6W1PEZ9BT)K<BP.9B;20TY L(*-&<G
M- $#R7=;R[I>R*66VK6\\N]]X0ZRORO+ZYWL[H* ;G$GY5NIFL>.3&IG.;UH
M $T?9[XZKU?1,8(@0\1E3(*=.<XZN504]O3MK-*@+O?&!RU?G,%7/[#=(*R@
MR-V^1?F]2M2/"N=,3-(REDD?+-NB>6Q(8A#I/8-Q7Q,9.I?)?[IG:H9%&)@B
M$9B;226@7*#P+/L 8 P!@# & :LO"YJ_YVI^R[UM5W&Q5S4T,?YY,G4E(<O4
MI6*.-YS@MTB;TP1*'!P4 )TE;D"<.SEJXY.E*U[9H< \T/6\L;O)K,I/&_E"
M]N,NJJ3KBL;&H2ENK9PX<VQ*G8JDLPZ8V9Y V*2U;.)#$[XTQ5T2Q11?#ESK
MH=<;89*B//:5CVX/+:!</XL>E.@>I>>IE8'0)-=O*QAOFU:\J^WZE8)'%:VZ
M&J*'."!#%[KA4>E3D\.R&/21Q-?FAM4Z<UK<\)X^%Y:U2E$O)4G 658 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8! 'M#NEFYA"L@T7KVS;6N
M!94DXMTIFK:#I)XFKFO8F>E8U5K6 QJ)E!W)WAK1)71O(5QR&.3C.'Q.0Y 9
M&H7PARHF'D9#+7F]-DIC"HHMR<[)5YP<*<Q\BO#G*FKE?*6MBY+V315;-%&/
M==;"K"19+HHAFQ&L5[8RLFRBC%I=%R\N<9:+,M,:;(Z*O77D4*DW,BV79%-2
M2S-/&GSCOD.S.XDD8L[H">6ZYHS3R919;W*Y+,&>8Q6V5K23,JTZ&\<71<;;
MVEV8*,M.'RG3?(:D5*2FB+M"[;(XM:&4-R\I79+AIA0BM%J="EL>OJ60NL8^
MHT=#$UC3]4OI9:]3TC4ZVNR:<A&:IF:NS :M)FO$@MESDR\I%31?;UV1*^>E
M7Z=?-]VFY6'1;RLT_5M+MJJQ;*G_ 'TPMD9O4:(LR?3/'(^UQ1B:8XRDFDMC
M,A3MZ,*A2I7*S"TY82]J%[@M-/7.3BJ%H2EP<EYZA>XK#3UJU0>J/--'K;8U
MUCVM"++LS<:T6NM-YF82NM(A*ZTCV4K2(1%B%6(6(@5I%:(D2[0BJO*QI>Q^
M,1'*QVF6=VVW=VF69IEIF9F3NLYFXP!@# & ?0TTL@HPXX8"B22QFFF&"T$!
M998=C&,8M^F@@ '6Q"%O>M:UK>]_1K-7=:U9W:$1%9W9IB%55B99FF>Z(6(F
M9F>Z(C>3,1+3"K$S,S$1$=\S,SM$1'YS,]T%6LT[ZX6ZAYTZ;CR*13.TX.BB
MRBM)M"HE6L]%.[!9K<(7PN-*JDCSBQMBZ?LDW7*%3;%)K&]J8D:L(,6*'U&@
M3F+ 1<O&]8Z=76JV\=3LJPL?BFV1CY.15CY.+==39*MBPE.3BZA79E177-+)
M9O,;J2L:YL'49F6J6S3ULR[>H^]%E6+9?5DU+97,Q?,6XV1B754,]D6JU>T3
M,25K>+CQ4V$V0Z<-?14SLB&5C%;$<Z3?^-CHVE<>9KWK^LV\+6WVM*(-;9$_
M1E2&V5QS--5[]48J_:VAQ:E+4W)-. E[@5:K9SQ<2[+6K)R,CK9-V)9$68^E
MYV-<V$BZ<[1&2E-69A7:IBM-LT759E"5TKAHM;U[I"9637B3;C4512F/DJTK
MDYN)EUQF-&?"3T'M]$RTTO)KZ<VU68UKV6OD,S+Z*;'D#A5%3RF0U_7"F>.,
M%B2M5$JKBJUBC"R3&LR+T:XA'%3N:A8&M2K 26@:BE)A"0)GN4Q>M;$6#</*
MR+%5\ATNRK)L5[83]Y>ZO8O6M6&GE=8E<O=TXF;+I3IIO8RQ,C%HK9J\=7JQ
MJX2426CA2G%)Z2-*QM6C-"U\YB$KAN;S"+,QYUFKR0E])W-;-C\BV#=E=WO6
M\\9(M'>8;28K9=Z6ZC9HQ5<9F-A5))FR0Q55"N?>@V-<;,8HW#A\CCZ]"_QE
M$[R=++&%].5Z4M%%#:A6RZEA/D9]^7BI,S99I6+TU]9:-D6\+)R5Q8C+]#B&
MHYQZ#?BUWO.1.]U<66UX5^^!E+C8=5&4T0J8^I9=MT+@ZG37+5V8K7\:(RVB
M+91YRJ,AJZHH/1]64\:[2KF!66R)7)"SV!#HU-&Q"\HSF]W0H9,SHWE*B=$"
M@ #T;BD)6 3K4IH C(4EFEBUZAR5DT^C9%]'42V*;7K6VN=Z[55IA;4GW\+%
MV==]IB&B)B)W@AT6S=37:R-4SI$O4_\ '4_N>MMNZ61X9)F-XF8WB9B8DSC.
M!V& , 8 P!@# & , 8 P!@&@.H+CF//](S*WX/2<TZ$=8.!I=W*KJZ7-:2<N
M\2 \H"YHZQ1*[;"3(7V,14QWDC7$4PBW*7+&LF.MQZ56Y%*B /-Q=7=:OL!\
M@_07.]8#Y=:K8G3A3/)?<\R61644_P!B.U<2"90Y1QIW-7J&-IK INI+E>WJ
M<(ZF23%^--#*#6>:%I69[2HD( +2?'7X[6RAVNH[AE+OTG$'2-5S(&RL^.;8
MN:,6K5_'!EG'M+A84%K9\BK0F6RUK2G,J-CB#A+Y/*3(Y$ A;4"=M7J7#8 +
M?< 8 P!@# & ?B:I3D"( >>22-4=\,E :: L2E1[HT_W! 1B#LX[W!!YWNB]
M"'[HDTSV?8+&+0'G8\F3)V3!ILKZ N3H&&D<*2#I>CN4)CQL='V1165A\@=#
MBA]46K8]HS]S(;9$SVEJ93I\4MWPYR5HA$?C*%8VO1^UBL2L#[<)<:RRY9/R
MS=*/JU%T/P[R/+[I5\<2"?4G)XUT_)H;)(E+*0!6\PMJ0+V]FLCG)%'W QUB
MDK:H>!3:Z!IB1ZXY,QMJ1$0!9WY"K]I;FCE^1.MH=&2/DYO>SF6)0.PJQ;XB
MY6(V2(E:D7H4<%B4LC4KC[RC1M[:H/ER99'QM33 D\A<5[G'420;XW@:.Y0Z
MTOJ'7TW\/]R*H3*+2E\-=K'Y6ZIK%K!':K["K2.)TBN2 U&"UKBB@UX0MJ6(
MY#,86R.*^..D=4F2B*#*8$Q1JT"V' & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P" WDQC-WRSD*>-E#-\R?Y&0_U\[32&5M(#HG9E@TVS3AB<KA@%
M=2=,J0*V692VOD[ZTLRA"O0N"DP\QM;EJ5<N3GEQ<CIQ=I]F55;?IU6?39JF
M/1RFV["BNY9V1)5[JZLEL?(R,9'1LG'IMHAIZDH\K&F>&:E+UTYMF#D5Z=?=
M*K53G3PFMG=U=*Y>N+::KG1EHOLJNG:*^2UT4?0-"=O6&RQ6'\_7Q4W(G.=)
M)HU6UE20_I3F^_#+*LF7/CA<='+95*)<T3^QJH41H#/N7H%Q2V,IW\8$C0^N
M @ $AFS1%LYV7E]"U;5T_3,-$F.AJFD447OD1GX>T1=C59,XT8K95==CNV5$
M),3<SPXNFM</%QXMK=6SM1S&LC>[3M2LLQZ\5\+)CE%>1;1&7Z3%%CI"+C3,
M_P"9A;\(G%8Y!8O'(5#V9!'8I$6-JC4:8&L@*9M96%C0D-K2U($X/[TE(@0I
MB$J<O7K[!10=>N]Z]<S==9D6V7W/+VVNUECS$1+.\S+3M$0L1O/<JQ"K'<L1
M$1!K55736E52PE=:PB+&\[*L;1WS,S,_G+-,LT[RTS,S)D&<SH, 8 P!@# *
M&.J.DG_LR,7KOCSJB34ZAX::>K=='PN);11N['&X:E952>FP%-KO'I0BE-'O
M4BCDP-?"TREL1RL@M(V*5?QJ!S94M7E7V5:7?VB3ADX":5;;AXK+#U/J->90
M]M.JT_G19IM>1"5<IY1>MJP_<]-CBTU6:EC:';O3E7:CB)E7<I2R-+R,2R8M
MTZV(GCD5YMV)U'E998J:N>$-'6Q/C;GV%]OSKE/O"OX1'.>*IH]LBA4/0M'.
M+!65CWD]1>N7.,'OL7LM-*@21MY@6K9F\M[17CI7S"%_4Q-*^)3#&EQ(4F^D
MLI73]2S\M(=*LM<^G!PNHR/7@W5TZ9AW:FN]GI4SIN#B7:=5:U=N-7Z,UE:3
M6L64:W3FX.-C-*VW4-AVYN:RP\/EUWOJ655@SM7%%D:AD9*:A=4KUY+VWHEC
MQ+17>M:%GP.F(!*;0LZ2(HE!86TJ'J1ORX"D\I$A3:UZZ)1H2%3BXK5!@@)D
M#8VI%CDY+#B$2!(I5GE$CJ[;4I6&>9]JRNI%56=[+;K%JJJK1(9WLLL=41%6
M69FB(@GUU/:TJD1,PEEC2S*B)74C66V6.\JB5UUJSN[M"JJS,S$0>67JOKZR
M/("=5+_&^9WRVN>FYTN.8UUSN&:JQQ/LF/P-')XI(4[A.(A&VZ7T#UA329*L
MLB)TE/RES<^-BHDUN4#GS,@3%Q^FR;YF76TOZE3+C'IMEGP,3.:AJ]?TG+HY
M5Y^1@66)IVL8J*V3B<K9P>>]CV=NHOMXN-:JKZS]$G)M39,G)QN4OH^I8EW&
MS$Q\Y4G+TS+:5IR.*+F0B2J+=/XN^=HI5_-];6TJ$.171<E70=39MEK$TT:I
M!-FMF$\J:[33-NFB-A>G:80B'O:"#N<WD\7:9M*2&%,ID.]Z D3)KC*AJ)G%
MZM=W.,3*R[Z41*,[4FT_%IS-4JI263'C4GKG+LI24Y66R^0GI,V;5>/*W_TC
MIO5"/F8^)1:S/;@X$9]]F/IUEKQ#7^@Q,45V/S5%3ACOZ/PEK,-:UK7IK7IK
M7T:UK[6M?5D,E# & , 8 P!@# & , 8 P#2]H]&4-2<DKB'6]<5<UA*+@=7-
MAJYGG<K9XTJG#VT)TJAP;8\!V6(P.*M,%>WEB3EFA&:J<&]"3L:U>D(- \NG
M6'2O?=X)H]7$M'>T(?.<+;M#GOK.1<1#M]!*JDLUZF,'F_-'6?[D51&.-JW#
M3-A<WFOFJV@:AR#7_P"ZN\J#K//7-K,V)Q@7><$<L,D/+FG3+K6<[H>9].?)
MTJLGG*2R&/.<3U*XI+WDZ"W_ "^OV./H(M!.GK&@Z:%/]T)X4-*Q-\V)/2[2
MJGQK.>30+-\ 8 P!@# & <54L3HPE[/-+ -09LA(2,XDHU:J]T:<!&DT>84
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M@>93+%B^+PA-,9X6)ZDGPX +Y, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M'NB@$D$D@2*P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M5=2J9 \LO1;^PHD+U,V]P',9,Y6*. ()T7!5%F%HIPN:%3@C1I4P%Q. , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@$8
M(QR%34"O1_Z"KA)*:WF,W.5K;-CT'EKRQUC:;TJ2B2AE,]K(!YL-<YFFUL!P
M9F@:FN4K32B@.[NY)@_#[8_]&JLHJ_T>R79<=_;IHML=7LNQ4;?T:RR8GJ13
M*562[/96UG%US?,Y#UVV?YZN$6;U]BZVJM95*;WC_/UI$Q"=6&>N%A*W5-UF
M3^# P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , U>S7!5$UETWJV$
MVU7+]:,$3A#,X1'YC&I!-8&:M+T%"IED/;W4U[9 B,-)&46[I$(5&]@+"/6S
M-;P"A*"D=C>(>VJ3Y6A+S+_)/6?5R.0*H)$IA+DD0NZHKX8$+0]W39#E(W4F
M1H4'*4ND#VJFDD/7B=U]42*3)F=L'(G!W2$2_'A^?Z_LC_#_ ) OVC]05;%;
M$G=NQNO8@P6A:3;%&JR)XT,3>AE$W00<ES3Q)-)WA,04K>M1],\."1M-7#-.
M)1FEI?;VG2I"B,@V/@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P"$W?%Z7%S)239T%5L/+L&*U-8L2E71D,1,RMZF;GS4'Y1;+4>:Y3)%
MB;_TP@25Q;;' 2>4K*<F"(/S0$HHYP*5$ >9EMY]LJ&)*V.Y9H"96W>;=<Q]
MZ>.CRE\O,;,\P"]:@NFVC)K9%6^0J5$.34-L(;(Y*94QS5RGX50'\EL),BQ2
M.0HW)BE ?K]?K^9ZX*BIEDITNP@,\IL65BL:U)O;3B98\W>)R;&W:>*4:MSB
MD'.>AF&1:NVHU$5J-PUOV%L90&'Z3AWLX6\ V_@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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I@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img29677477_23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_23.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2'64&AO=&]S:&]P(#,N,  X0DE-! 0
M    (;J^AC0X0DE-! 0      "<< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M 5H  QLE1QP"   "    .$))300E       0FHFM72AMNB$"R,NI9P4_VSA"
M24T$.@     !&0   !     !       +<')I;G1/=71P=70    &     $-L
M<E-E;G5M     $-L<E,     4D="0P    !);G1E96YU;0    !);G1E
M $-L<FT     37!";&)O;VP     #W!R:6YT4VEX=&5E;D)I=&)O;VP
M"W!R:6YT97).86UE5$585     T 4@!E &$ ;  @ '  <@!I &X = !E '(
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q =F^9H         IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8
M  X             /X   #A"24T#\@      "@  ________   X0DE-! T
M      0   !:.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             %>0  !V0
M 0                         !              =D   %>0
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   %>0    !29VAT
M;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MUZ)8WT:0;;6T5S21-COYMNMWY_[RU7_XM7O=O?UG(+^-^QN[\_EV[=_A;?\
MMQ/=_BXMO>'V]:R'.: T'TVB UOIM@-+?S$N+%_5^PJX9^/VAR+?KI]=JJ[+
M;*Z!75&]XJ):)=Z8][;MKO?^ZJW_ (XOUH_?QO\ MD_^ED7+Z'T:C,R>FYO7
M\MEF.YC;*W4E[7N>QF0W8RKU?4^E7^9_.*O;T#ZLU"A_[9O?5DEXJN;CC8?3
ML;CW^YVW^:W.M<[_ $%-ME:0EAZU]B#')TO[6?\ XXOUH_>QO^V3_P"EDO\
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M$9\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!=P'Z P$1  (1 0,1 ?_$ !\
M 0 " @,! 0$!           ("08'! 4* 0(#"__$ %D0   & P !  0+ @D'
M!0T)  (#! 4&!P !" D1$Q05$A87&!I76)67UM<AF!DB,3E9>+:WV HV05%A
M>=4X<:'C\",E,DAV=X&(D<'4X?$H-4>"EK'(TM/_Q  = 0$  04! 0$
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M;WQ\Z3IS[1U]?C#8GYCQU5B_PVA[)7^&.L\EX^Y[3-[X^=)TY]HZ^OQAL/\
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MY7JK%^KJZC[)!\/N'6>2\?<]IF]\?.DZ<^T=?7XPV)^8\IU3B_PZC[)!\/\
M=]WV#K/)>/N>TS>^/G2=.?:.OK\8;$_,>5ZJQ?X=1]DK_#[OY!UGDO'W/:9O
M?'SI.G/M'7U^,-B?F/'56+_#J/LD'P^[^0=9Y+Q]SVF;WQ\Z3IS[1U]?C#8?
MYCQU5B]MNKJ/LD']/+W'6>2\?<]IF]\?.DZ<^T=?7XPV)^8\IU3B_P .H^R0
M?#'6>2\?<]IF]\?.DZ<^T=?7XPV'^8\=4XO\.H^R0?#_ '_?]HZSR7C[GM,W
MOCYTG3GVCKZ_&&P_S'E>JL7^&T/9*_PQUGDO'W/:9O?'SI.G/M'7U^,-B?F/
M'56+_#:'LE?X8ZSR7C[GM,WOCYTG3GVCKZ_&&Q/S'E.J<7^'4?9(/ACK/)>/
MN>TS>^/G2=.?:.OK\8;#_,>5ZJQ:HB=74=D]7_A(/ACK/)>/N>TS>^/G2=.?
M:.OK\8;$_,>.JL7^'4?L3^Y(/L_V8ZSR7C[GM,WOCYTG3GVCKZ_&&P_S'CJK
M%]_]K:'?_P#DK_#[OY!UGDO'W/:9O?'SI.G/M'7U^,-A_F/'56+_  ZC_)4@
M3^B/O'6>2\?<]IF]\?.DZ<^T=?7XPV)^8\=58O\ #:'LE?[MO\7^5[_6.L\E
MX^Y[3-[X^=)TY]HZ^OQAL/\ ,>.JL7^'4/9*_P /]_W_ &CK/)>/N>TS>^/G
M2=.?:.OK\8;#_,>.JL7^'4?9(/NV_P 7^5[_ %CK/)>/N>TS>^/G2=.?:.OK
M\8;#_,>.JL7^'4?Y:D"_TQ__ ,'6>2\?<]IF]\?.DZ<^T=?7XPV)^8\IU3B_
MPZC[)!\,=9Y+Q]SVF;WQ\Z3IS[1U]?C#8GYCQU3B_P .H^R0?T\O?^0=9Y+Q
M]SVF;WQ\Z3IS[1U]?C#8GYCQU3B_PVC[)!\,=9Y+Q]SVF;WS] ZGZ>+$$8.D
M+\ , M" ,%QV*$01!WZ0B"+4CUL(M;UK>MZWK>MZ].MXZIQ>VW5M';_5(/A_
MO^_[1UGDO'W/:9O?/;'X">MKCZBY7G+==TJ<Y]**=L@$/:)P_JAKY*]11TC;
M4]-:22.9^QK'MV:%ICJG]^+SC7!<W&MQ*TU0J1FK%/%]>XFGB\K"ZE$V"*Y6
MYSX(VHV)DK9'L<L3$[F->U&JK&HC6N1RM1$=PIUK1F4M9+'2I<D6:2K/RFS/
M7>1\;F->U)%];G-57)QKWN;MONJ*JWJYHYN P"G+SV_S8%[_ /E#3/\ ?'!\
MV_0O]\U#_0M_\K,:OK+^]Z[_ *5;_F8C_/<ST"</& , 8 P!@# & , 8 P!@
M# & , L=X:Y=HV[ZLZZN"]#;O6L7-42JR0MD5HA9#T<LDZFPYLLB"@C>YC%I
M0C."W>K2KBR2"40Q%Z5[,4"UHL&M<SF4O4K6)IT?0FR9*6U&Z6\V9T47H\"2
MM7]3+$J<2[MW7B3=4[O6;!A<;3N5LG:N>EN90CKO;%36-))%FE6-4_61R(NW
M<NR(GV]Y,B;^(JOW&9W51-%6#8TIZ/8*^H3H"FJ]G*:-QY8^4S:RQJ9YY$K"
M8$;8:O9;8J92]-LB>5*%Z3M:Z-K4^BXPG4:4*4T-!JZPV&E>O5ZT6-DL7Z%R
MQ LLB,N56N?!+!(KN%]6VC'1L1S%<DJ+O+P[$O-I:NZ6W3ISSOO,BIW*T,O
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M]&U',K=>[#9Y!S_U6"(E6LU,L+5)$C?82=!&(Q#5C+&WP\[:4E#(6+2I2H.
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M$%6FRP^>7ZUB_-$DDK*S%W<_@1[5<UJ<$:(JN5"J?-L-8& , 8 P!@# & ,
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MW6\WGHLS!POAD9-#=GEJ2*YJHVE/LO(E1.]SV.:U6N3N:WZB=VZK5+FU&L#
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M#]>?-?WG:'Z:X[2\/X')>2K\R.S[*>,H>:Q\ ?1E.P?KSYK^\[0_37':7A_
MY+R5?F1V?93QE#S6/@#Z,IV#]>?-?WG:'Z:X[2\/X')>2K\R.S[*>,H>:Q\
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MZS.VUS(Q6"R.,:F<S;UD!DD#/:MM[:>M2/#<\IG-.]-C:N3B3B N.P!@# &
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M0G1K"4>P)_M_F%K^O(/Q:KZ"JBTVQWZ@J/E.5OEGPEJKLNG(U-NEVB,)D"%
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MM 1ML QHDRM5ZP"0%3<:)H%S1:_.,VMZ66F7<S=8#5,+ -@5*56\)4-@PI+
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MGF , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# *R>MM;WY!O$UO6M^C5@]B>G?HWZ->GD
MR9ZUZ=_Z/3O^3T_R_P F 62N[NTQ]I=']^=&]D8F-N6N[T].ZU,VM30TMJ8U
M:XNCFXK#"4B!O0(R#E:U:J.*3)4Q1IYYA918A: Q^)V)7\]CY\L@TYA\SBR5
M4Y(E,EBDF99$P)UC,8(IW2'O+0M6-Q*EJ, ,MQ(,4A-1# (*D)6P[UH#4EE]
M5TQ6$4C,S6OSA-6.8(Y2\1PVJ6-SL\YTC,$:%3].I:E+AA#L$^,Q!H1FJ'=S
M),,T<M.;8^T%.DF>F1E<0/MC]44[5SA$4,B>'E<5+V-MEH':+QIZD['&H.\2
M&/1)IG<R=V=(I11N)N4DE3(VH7)<9HQ22-X>R4PXY$Y@\, &N&SOCG]])3ZC
MYEAO[H^F1,RNX^U5M*SGVWF2<H;&=8I+*L1FH""Y7%'AEJ*S7\MZ H2$)8_#
MU;ZO"D:76-K'H#84%ZLJ&QIA7\/BZJ6'"MFN3+3JR3.4'E++#K!B21FADA=#
MHU('9L1ISG!F9["B2IR;EQ:%0 YP7MJ;2IVC,K0,8$D, 8 P# XA:E86"Y2%
MG@5C02;N\1.2IY6U1&71^2.,9/6C6%HR9 A9W!8I9C59C>X%IBW$I,,\:%8
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M8&!=)'U\T!L;$>I&Y-)1*I1\(P"TU+I*68L$G+&!;A@# & , 8 P!@# & ,
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M2% 3I4B1*1+RR$R5,0662G()  HDH "RP! '6M <K^$Z\;_V^>-?WEZ<_..
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MRUJ88'<L2;:T)C8()NPKP"1ZVKT))LT.TVMGZWZK7P\ [' & , 8!6%Y0?\
M-_BK_>,<A_V[-P"SL8 & &68$(RS B , ]:$$8!:V$01!WZ=""(.]ZWK>O1O
M6]ZW@%;_ #SXD^!N6.B)?U+2%$-,/N&7Z>=#>0.STX-,8U)!;'(]0J/+URAH
MBWOL0C K/=J8&R4QIZ!OVB;SSDA@%D6 0RLOQX\47'?T5ZCL[G"M9G?4,VV#
M8K%>6@PYT">Q[+$PK'1&!06T2!>P;))]Q+GYN<E;/Z@C3<<FT27H($M'6.1Y
M^.;%#XPLKRH95@7%G/=6M"XG-+@#6P@7-AJP@X:!8$.]A"I2B*/#K>]:'K6
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MTOG3HZFHWHI<MB*5.G84'L:+X1.P+HL 8 P"M6(_SM]U_P!1&DO[ZK6P"RK
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MM92]U4IG,V6-@K8AHW5L2M"EO:S5+@UKW=.^M2UJ* E#@# & , 8 P!@# &
M, 8 P!@'02PE HBTE(=5IC:UGQ]Y)<G$G6A&H$!C<I L6E:V6=K9B5.(P\&M
ME&ZV(O6MECU_%V!XY?'WQ'-+<N7F=VK.4RC= TNN@5WU/-K(X(Z2HV%!A;+*
M>7US[+.>;(L*_)HP(;$Z!B//\3+>!@9$C1*(I=G0SLE9$S4>A:U@'LYP!@#
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MTQ3L[1"6OJ>3,#SIA5#(>TI"YC<D3AZM8@(/()/#[044+0@Z N0P!@# & ,
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M;T;JU.*0S1J5>W."<M6B6IC=?L,3JDQQ1Y)FOV#+&$6OV;P#L, 8 P!@# &
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MMM2\L[&5\A%$JQ,N0R5I4<L>S)8703M9&DO+9+?-L.+C & , 8 P!@# & ,
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M^-;6];UP[S1Z=?R;^2F+?_ X!/9L;6]F;D#0U(T[<UM2)*W-J!(4$A*A0(B
M)D:1,2#6@%)TR<HLDDL&M! 6 (0ZUK6L YN , 8 P!@# & , 8 P!@# & ,
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M7OR)+<R.0L26;4[T:C&\<LBJO"QC6LC8FS(XVM8QK6-1$RC,DB1@# & , 8
MP!@# & , 8 P!@# *TO(Q9G!;=$XA!.N^L&?F:7,LI:K2J:2Q2XDE;7Q#I2W
M-\AC":;5^F1:=G\U.I87^611T-5Q9[C3DSO+TU.20\)@M% 9OX\WOC,VEUL;
MXWZ$9>C6!-*Y#,[&GIUN(K<LR06)8+LL?9#*[7=M*-.Z.42-=I0,*=Q:&%,4
MC1%(6AJ2-Z I.4!1_5<,K:N?+0\'2&*\^2"8V=V];CW$['M#ACO$70('IR#*
M7WXEU]U&_)&;GI<5$X]''@R).J).Z0]N@S2I*95J]B;4B\('I4NCGJB.CHZW
MQ&_J=K2YXPTNQ;ZU,-FPN/S5K;'DI.>CTYMZ.0(%Q*-:-$J5(3STX2QJ$"I4
MA4;,2*3R3 .I7<M<U.<_KNU5] TVJLJHF-'&:MG1U;Q$4IKR.MI*@AJ8X8]>
MZ=+HXU,Y"Q:4RH&HY*F9RUJX+86DTL5:- B;$?YV^Z_ZB-)?WU6M@%E6 , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# .N>&Y&[M+HTN&QZ0.C<N;
MEVRSA)S-(UJ8U,IV6H!L(R!Z)-'L)P1:$4+T##O6PZW@%47#W![?1%K12<'=
M91WH%KY]H1]Y;I&'1.JZGK=;7]8/TAKQZ6D6G(JW<5BVSYH2554.;4CLYMT3
M:DQI4@>@1C3W(EBPD"./F'U*8_?W(-C-,VF,/8X_6G2\6=AU9VIS5Q!9:I?+
MWV@'!LT1.KX>$3G.X0$N(+]22#1U&)J)?=0^2N[DF7M#.@<P+C>9W QVYVHM
MT.<'YU-<*EKY::YRBQ8S;\E<#%,6:SAK7^UH6:?$+(>%(A[.<IQ&#C6"4*QF
MO+28-"L(%L#:<GC,=FL;D$.E[&U2>)RME=(Y)HV^H4SHR/[ ]HCVUX9G=M6%
MFI'!L<V]2H1+D2DHPA2F.-)- (L8@[ A@/QE<%&5NGJ0?,5<#@::7'SHMK$2
M\B<A2I5% 0-4YGRG;MN6*@JH(45!E3>J?#FQ3"R28F>B,CY);<$#3/DF96>-
M0;A..QUJ;F*/L/D%XU96-D9T2=N:6=G:YC["V-36WI"R4B!N;T1!"1$C2E%)
MTJ8DH@DL!0 AT!:C@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & 4I>2;H";<]V(X)Z!;F9\N.Y*;9J[7)8O0[N[6M7C_.Y5):[H6UV^]D,
M3?( 48\6,ZCA$8I^[W!E9I:ZLPUD D"-^0NL4G0&P^4I&_17A:YND#YI7MKW
MHW0B['@V>I&3;A-6,-=()0^1"F;=D;Q5U)6+)I+63QI8B?FB?UO Y*S+'!6R
MK6$E2G&[N8$*^58+>=_71S7T3?7'/?BE(]O\9OE/);![WJ66\K5[.91"W!8E
MLB)<U--U.+VTQMHW*'+XAP]-'5SC$T#HD1F->S$)Q80/1]@# *U8C_.WW7_4
M1I+^^JUL?G\_G[0658 P!@$=XGUQS#.[EE'/$,ONJI/>4+*4FRFJV69LJ^:L
MH4(M!< *V0A4-5Z]L$( 75,4 Q0U[,*TX%)O6E_" D1@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# (1^0V.UN^<L3ARMN*U1.H!"G&,361PV\;:<*4JJ4M
MK0^)$RUAE4Y)5IV DUT1."E'%FB>IW&OWB:&QM'*$I",871N IN\<58<Z],]
M9R&VJKX\Y=J:E:@"7**VD5/U_6](7+ 9.G=(.YU0B>9125ZN,UM)CG<?U/7"
M:&RRL&BB)FB;VD%8SBVX0N6N3X!E'D2ZEB-J="VESB]R %1JN9WEOAZYZ<O&
M#-O)0WV8TW#350VDG=6YQ98H%AI1='C)(YQISB9[G)5DN(2M,E< (404#?L"
M[7CF*1B"<E\RPF%2&9RV'1"A*EC,6E%BQMVAL\D,>8H*QMC.\S"(OS8S/<7D
M;BWIDZIWC[NU(')G6FG-ZU*4I3F!P"2& , K!\H/^;_%/^\8Y#_MV=@%GV ,
M 8 P!@# & , 8 P##YS8,'K*/*998<L8(7&D9A)*A[D;FE:FXL]0+X"=/I0K
M,+ 8I/'K82$Y?PSCA:WHLL6];S$NWZ6-KNMY"W7I5F*U'3V960Q-5R[-17O5
M$W<O<U-]U7N1";T]IK4&K,G%AM,X;)9[*SM>^+'XJI-=M.CB3BEE6*!CW-BC
M399)7\,;$5%<Y-T.=%)=%YU'VV5PR0L\IC3P3M0UOK"X)G1K7DZ&(L0TRU(8
M:0;\ T RC-!'\(LT RS-!&$0=?=6W6O01VJ=B&U6F;Q13P2-EAD;ZMV2,56N
M3=%1=E7945%[T5#'S&%R^GLE:P^=QE[#Y6C(D5O'9&M+3N5GJU'HV6O.QDC.
M)CFO:JMV>QS7M56JBKD69!&# & , 8 P!@# & , 8 P!@# & 5K=<<LWE8-P
M0?H.J)]QX2[5<W)-1!LZUY+:+=.K1Y)5G*ELOJ^YHS/:WL> K7,W;<8O;U"Q
M^0:6MJ5<UGLYOK &@;[YJKGJ>)'S"0=/7W6-JNTI]V>[(=3-&ET_7T.5(=JB
MG%S"N?9Q9$_F3Z])A-J%8O?Y0D;4:)F1)V]@2G;5*U(&FZG[$NB>]P73S(_\
MF6S#:VKR%UD^-%INKG0YC<W#E3A?"8<ME>F#H.22-;";&U6+ @JQOB\!6S=G
M<3'LVU8_#6U2UJRP+$L 8!6K$?YV^Z_ZB-)?WU6MC\_G]X+*L 8 P#S;<E?Y
M/)%>6O)O)/( FZ*D,K8 RJRIQ!ZQ/C?L3RC?[22R%$[I)9+MO*@MZ:&5-)7#
MW>%,TI%#D<%&:M]FTE&6J ]). , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M B=VK5=AW-0CU ZSBT!F<B4R.'2#4=L"S;4I1.JU#9$AE[4MBEPTPF<)_64\
M8Y0R1Y_BDN:FIW)0KVO9"UO&G5#.( A=SK6W7L8FU-(TG!7+7/$>K!N709\N
M68];3OI*Y5=62F7))G8\=BBU/3\;E,N>YM(DYTE4/MKV440"7*=RIT:'I?[4
MD6 ;XZ>[!Y@X-FT<5S".+FR;].6=!T\Q=(C7DY=U;L7[F30!-/Y.\Q"%2-(^
MN$5CL18HZDC@E@94N9T+>0THC4B30M 3W97=!(&=I?VHTT]K?&Q [MIQZ18@
M..0.24I:C-.0N!"5>B-,3GEC,2+DJ98F'O9*D@DX RP@=G@# *PO*#_F_P 5
M?[QCD/\ MV;@%GN , 8 P!@# & , T5:'3= 4J]HHW:]L0Z!OSBUEO2%JD+E
M[&L4M1RI4B*7E%>K'\).-6B5D!'Z=>DQ.:'T?Q<@\IJ7 86:.OELM2Q\\L23
M1Q69FQO?$KG,21J+ZV\;'-W^]JG0M)=$_2/KRA8RFCM&YO46.JVW4+%S&U>=
M!%<9##.^N]_$W:5L-B&16]^S96+]IK7Y_O&'VCZP^_/^HR-_3W1G^4N)]J8;
M5_8X=.O^:[5GL"?$(&>02?<E]BU0PP^,]@5-$I#$Y0&3-GO9X5G,#OL;>I;E
M")T"B($H(- 4H]<@6@(5>H,":2(CX"H1I6B=(%[26L<1#1KZQP].Q6M-M1++
M9XH)52-\;HYFL^M_!>KF/1'<#D_@JCE5/1/T;=.=,W0AK'(YO*]">LLUC,SB
M5Q-OT*E S)4N&S%:CL5%GD2*1CGQ<NQ Z2'F-5DB2<4*,?FW#]Q\?\F4,UU2
M[]<U;+GD3\\R=W<$KP>0TI5[UI&6-M92510E &Y*4A)%\,T)0U*TY:KV03[1
MHH.;HG+Z/TG@8<1)K#$W)4FFLS2I91L39)U;O' URJY(FHQ-N+97/5[U1.+9
M('I^T/TV=,O2);UC2Z%]6X6BF.HXBE5EI127)JU!9W-MWY(I$B=:F?8D;PL5
M[8J\=>!)).5QNE[\_P!XP^T?6'WY_P!1FW?I[HS_ "EQ/M3#BG]CATZ_YKM6
M>P)\0V95W3-!76]+H[5%KP^>/C8VC>%[7'G+VQ6E:P*4Z,:XXKU8-A3A5*TQ
M A^G?H,/+#O_ ,+626+U+@<U-)7Q.6I9":*/G215IFR/9%Q-9QN1/4WB<UN_
MWJAJFKNBGI'T%1KY/6.CLWIW'V[:4:UO)5>3!-<=#+.VNQZ.<BRK#!-(C5VW
M;&]4]1O/)PY\, 8 P!@# & , 8 P!@# & 4J^=V+0B=\=Q:"3:4*XZ"97 9'
MXZG,I:?] Q1Y?%-&7B<>=.JQJU2&?KV2"QM/(+789)'FJ3?$2Q(!")H[QQP8
MF)S,3 =1PU<4<E//79U,1:]$CE?#8?T'<4DNQ-"992?.J626P[3],?,:$E,B
M=9*L6U15T]C[JT2B9;>%CNBE30]R=Q2D^^D/K0(-\Q68_3SJGFZ0RSR8<[S7
MJ)59E9Q$JGJ+\@;Q=U*R[DNMN>4,$MA ZPQ3&89#YE?5N7HX#LQO:5[ JL(@
M]S+?HZ^NC+7DD5 ?Q@]$G1O5'/W(\)1V+T99K)5T.<7CW"WN[PE>7':UUTV.
M+V<E2-L?;'=V4:1LS0Z.S@H*0#2MK8@5KEYZ9*2,W0&%.'>''K9.JFK=3T'7
M8YA>3)"9'5:!$YGN:"5LEF[6!K-P+D+:D5QMI*LDUO7)J\ _.[6=.5B-2BBI
M3LK(,)"!HN(_SM]U_P!1&DO[ZK6P"RK & , \^W+O^4(T!U%Y&))X_8Y3\_C
MRDB26##8+;;D[-ZELF$FK1,\K)"G7Q$IO(<(NV*TL=>3F1Q.=G0U7[.G+7H&
MLQ4$)8'H)P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'42$PXE@?#DSB4S
MJ"F=S,(=SR-*B6LX"(\13B<FWK>E!2$>@J3"-ZWHX!6R]Z_C8!YC_%;T;8;)
M;]6:OSL>LI35%LE6]":<<5/<9_3[IT[>$L8>13E9+$QK4"%16OQ ?858<G:H
ME,4L3DD05=.,M4,T+:1G[(<@)B]:/7=EI] 22B(ZUKJ'IZ)] 0.TJX[1=*0J
MBV(57M:0[EKXS*@-S;/I0>!?9SQU(I-A+>N4P\*QLC*]6F8UI:\Y$M !:;R_
M*K8G7-M!32^8IJ#7;+*<K:16Y#0HCFS49L=XB#0OF;)[J4&J%#1MOD!Z].)H
M4J%*EJ$#;<H4'G)AG# WK@$0I)W]Q/$H$ZVB_=1THDKYDLM\IMTE9$[97-I2
MVG&$'O:30+UK6I6F'26-LVAOD@;4Y9IS(Q%'O;GI*U)SEA8$;/).],\D@_"D
MBCSLVOK _>07C5Z8WMG6IG-H>6ATF.US:ZM3DB-.1N#<X(CR5B%<D.-3*TQI
M1Y!IA1@![ M0P!@# & , 8 P!@&BK0YDH"ZGM%)+7J>'3Q^;FPME0NLA;?;%
MB9J*5*EI2 HWU@-Z3@5K59X0>C?H,4&BUO\ C;R#RFFL!FIH[&6Q-+(3Q1)#
M'+9A;(]D2.<](VJOJ;QO<[;[W*="TETK](^@Z$^+T=K+.:=QUJVZ_8IXRVL$
M$MQ\,,#[#V<+MY70UX8U=]K8F)]AK7Y@7&'V<*P^X_\ K\C?T"T9_DUB?96&
MT_V1W3I_G1U;_O%?<'S N,/LX5A]Q_\ 7X_0+1G^36)]E8/[([IT_P Z.K?]
MXK[@^8%QA]G"L/N/_K\?H%HS_)K$^RL']D=TZ?YT=6_[Q7W!\P+C#[.%8?<?
M_7X_0+1G^36)]E8/[([IT_SHZM_WBON&RZNYFH*E'I=(JHJB'P-\<VT;.O=(
M\V^QJU368I3+!H33?6#V).)4D2GB!Z-:V806+?\ X.LDL7IK X6:2QB<32Q\
MTL?)DEK0MC>^+B:_@<J>MO$UKMOO1#5=6]*W2-KRC7QFL=8YS46/J6VWJU3)
MVUG@AN-AE@;88SA:B2I#/-&CN_9LCD^TWIDX<^& , 8 P!@# & , 8 P!@#
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MN8M ..5GG.8B"SU0@  ],. , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MK8,B/NFVXQV<Y6O3%2Q8:2J7*6]"!Z'< 8!6K$?YV^Z_ZB-)?WU6M@%E6 ,
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MPKBXV=(K?9*[(V)B;S'-WKM"V(A.+LX(T))Z]8F2@.4%^N/+!Z1Z>H%FV ,
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MJ@?H,H8(XYFNDMF<>9EA,D<%A 'I%P!@# & 5@^4'_-_BK_>,<A_V[.P"S[
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MUZ=;UO7[-ZWK]NMZ_9O62YI"HJ*J*FRIW*B^M%^Y3[@# & , 8 P!@# & ,
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M!,C-GI._F1-12WOAVT;5N7FBO+!N9E]SSEZ)<PJC/=_NC;ZV(W)2E:)'MI^
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M).SOZQZU*Y0TQ!/,%13FC&WZ98Z:0K;G5*WIW,D]<HV;M&!2K&F]2F5%>I-
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M!K6ODXUCCD>V2&;$<N& , 8 P!@# & , K!\H/\ F_Q3_O&.0_[=G8!9]@#
M& , 8 P!@# & ?Q4IDZQ.>D5D%*4JHDU.I3'EA-(4)SP"+.).*'H0#"C2Q"
M86/6PC +81:WK>]91S6N:YKD1S7(K7-5$5'-5-E147N5%1=E1>Y4+D4LL$L<
M\,CXIH9&2Q2QN5DD<L;D?'(Q[51S7L<B.:YJHK7(BHJ*A'JG>3.>J"D4CEE2
MUDR0^0RK1A;LYI#7!6>%(:?I48W-FG%8L S-8U "S1MK2!&B$(DGTD[T25H&
MOX?2NG\#8LVL1BZ]*Q;W2:2/C5RL5W%RX^-[TABXD1W*B1C-T3ZO<FW2M;],
MO27TCXS%X?6>K,AF\;B%:^G4F96@C6=D:PLM6_18('7KC8G/8ENXL]A$?)M)
MO(]72+]&O3K?HUZ=?R;_ -.O3_+Z/^?-A.8C & , ;UZ=;U^W7IUZ/3K^77_
M #?[< I*JOQ83^ ]K[Z(76LS+X$W3Z0V$VIB=/ YTZJ7M0X*RF-Z]<E+; %
M-<3"G-S+<E0G!.3Z0(21K# ).+8OHMNX_6[M2ORT4E%F0M9&.-$E]-D?861R
M5YU5.5P-=*J/D21RO8Q$Y;5>O![VUA]+W3>I.@;LSKZ.O5M1VM-XS3-N5ZT4
MT]3BH15H7Y#'JR9UMSU958^I4?4A2M*_ZUA[8&NFN'55_!%LI23A9#(JKF:
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MST)[-6*Q:QD]IB(VQ+2F>YBOV1[6JV*;>>.55EGFU'&Q@# & , 8 P!@# &
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MR]!8L596S59YJTS=T;+!*^&5J.14<C9(W->FZ*J+LJ;HJHO<?W**+)++))+
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M +>G_F] =_W)^_\ J-'1EI\N[[T#:U/KNJ.?&:'5[ *KE[!:JCAF4#9)V\6
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M:*\4U.C@RIJ:79$7TVK3*SIR.7JB&TQ0]LXTHF%3LA.Z[-,"D D)\AOED_I
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M#TC5&:[YD<Z7>&^1#7(34[RJDJV\++*7MY+>4X(S&<+(E&<>L(5Z<BM(]IU
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MSH9[+FEL M&K<&2-'J@.:Q-\%M=-IC D:TNVTNX4/M(FIPTF W9@# & , 8
MP!@# & , 8!UCNR,S^D"@?6AL>D(5"98%$[H$CDD"K1FA/2*@IUA1Q.E"4\
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M$RU$UV/-Y]6='LLOE1*"02J%4TVS(J#QB1OK.U/;^VL*-S<6]NV:2UH )\X
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P#\C& L S#!! 66$0QC'O00@ '6
MQ"$(6_1H(0AUO>][WZ-:UO>\ J!NWR>2YCMM!&.7J3BG4M>,/.$$ZSERN,VR
M4RVO:E'3N42Z-+'[DN#"BKG'KE=*S3Q+W].FAWFT.4J3)+%(FR:&^/!9H -!
M0?C6)=6VL?8//UM67">()=<G.'?R>'2FH6%\A,_N!^5(KT)LKC"X5$Y1S.E-
MRYX*TU=)QAV@:ST.LDEK;&4T?52QY6E@7U,S(S1QK1,<>:&QA96PC29M9V9
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M=:&$.] 9%K6M:UK6M:UK6M:UK7HUK6OV:UK6OV:UK7\FL ^X P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@%"MH^,)^CUN,#-&ZZ^6_DITMU\L6 ((3=$D
MYNZLX$F5L/&SK?<.>;;B[U%E$GYSFI[B[R&84P&719W9!K%B>)I)844TLJ0"
M[FO*_AE3P.&UA7,=;HC :]C#'#(9%VDL9;;'XQ&VU.T,C0B"8,T[9"%O2)TX
M##S3E!OP-FJ#C3AF&" S' & , 8 P!@'4OS Q2ID=XS*&5IDD;D#:L9WZ/OS
M<C>&1[:'%.8D<&MV:G E0@<FY<E--3+$*P@Y,J3F&$GE#+&(.P-;4?0E2<W0
M8NLJ1AZ> 5\F=G1Y;(<VNCZNC[ H>#0'K448;7ET<D\6CX3@>L0Q:.A;(TU"
M&=[K:4>CSM& ;?P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#!9]:%
M9U2UHWRT;$@M;,K@X :4#O/I:P0YK7.IB92L V(W"1.#<D4N TB-6J C).&I
M$F2J3]%[*(-$&_7JV;;U95KSV7M;QN97ADF>UFZ)Q*V-KE1NZHG$J;;JB;[J
MA9FL05VH^Q/# Q5X4=-(R)JNV5>%'/<U%79%79%WV15/Z0.RZXM-H42"L; A
M-CL*1P-:53W Y6Q2]H3.I"=,K/;%#E'E[BB)<"4JU&I-1&'!4EIU:8X9>BSR
MA#6*UFJ]([5>>M(K4>C+$4D+U8JJB.1LC6N5JJUR(Y$V545-]T4K#/!8:KZ\
MT4[$<K5?#(R5J.1$56JYCG(CD1454WWV5%^U#-LL%T_&C2]F#*T8#9H @&,K
M0P[,  S8]%C&#6_A!"/98] %O6M"V >@[WL._0_/Y_>@_/Y_<ICYLPB)$J20
M4Z4QPF;+V=3(D,.->VPN5+8^B4E(ECZDCPU6G=0SI%AY"12YDHQHB%)Q1!IX
M#3  W<2&58EG2*186O2-TR,<L39'(KFL63;@1[D151JKQ*B*J)LBGPLL:2)"
MLC$E<U7I$KV\Q6(J(KT9OQ*U%5$5R)LBJB*O>86P7S1TKD\LA,7N:J9),X"0
MN4SJ(L-AQ%XDT,3-AVD[DHE;"WO"ATCI#<HWHA>:[I49:,[>BE BS-Z#EZ2C
M=BBBGEIVHX;"M2":2O,R*97)NU(I',1DBN3O:C%=NG>A:9<J22211VJ\DL*.
M6:-D\3I(D:NSED8URN8C5[G*Y$V7UF3;L2O](XHX[G,/TWSQT)8X.O\ C,R^
MQS-Z4)%Z].SQ15[;ZB1.AZ%J<UI*!H&L5FI&U>I 4(E&H&7;]'L;RMY$W% U
M7SMY3]X6(K6J^5.'>-J.<UJN?LB*YJ;[JF]SG0[1NYL?#*Y&Q+QMVD<J*J-C
M7?9[E1KE1&[KLU5VV13,<LEP8 P!@&J6V\Z>>+5DU&M5DQ!PMZ&,#?*)97B-
MZ2'R>.L+J:W$MS@\-Q8Q&( *QO+,(HE1L"G9+PTJ-DZ(<T)A^4ZE;95BNNKS
M-J32.BBL*Q4BDD;Q<36.]3E3@?OMNB*QR;[M7;'2U6=.^JV>);$;$?)"CT61
MC';<+GMWW:CN)NV^RKNBIW*;6S%,@8 P#\!-+&,PL)@!&%?!]: (P[&7\,/P
M@>L#K>Q ^&'^,'X6M?"#^W7IUC9?N]?J_:#]X P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M!?(US'4+/6S&@5I*>>:4L*%563;KB=&5$5T\/,8,<) \J4[LY.IB"'*6\:E
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img29677477_24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_24.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /U!/(# 2(  A$! Q$!_\0
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M[#_P)'UQ]H3^]1]H3^]7R2OQ4^/?_0L:3^('_P =I?\ A:7Q\_Z%C2?P _\
MCM']IT _U,Q__/V'_@2/K7[0G]ZC[0G]ZODG_A:'Q]/3PQI7Y#_X[3A\4/C[
M_P!"MI1_ ?\ QVC^TZ O]3,?_P _8?\ @2/K3SE/?-*'W=*^3%^*'Q_'3PII
M)_ ?_':E7XJ_M ]O"NCX^@_^.T_[2H"?!F/_ .?L/_ D?5^ZC=7RC_PM3]H(
M_P#,J:.?P'_QVG+\4?V@L?\ (IZ1^ 7_ ..T?VE0%_J;C^M6'_@:/JS=1NKY
M4_X6A^T'V\)Z3^0_^.T?\+._:$/_ #*>D_D/_CM']I4 _P!3<=_S\A_X&CZK
MW4;J^51\3/VA>WA+2#^ _P#CM'_"S/VAO^A1TC\A_P#':/[2H!_J=CO^?D/_
M  -'U5NHW5\J_P#"ROVAO^A1TC\A_P#':</B1^T0>1X1TC'T7_X[1_:5 /\
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M']I4$;+@G,91YE.'+_B1]>_:$_O4?:$_O5\B_P#"VOCP>?\ A&M)_P"^1_\
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M3]H+_H5-&_[Y'_QVG_:5 7^IN/ZU8?\ @:/J[=1NKY4_X6C^T%_T*>D?DO\
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MDG\!_P#':/[2H!_J;CO^?D/_  -'U7NHW5\J_P#"S/VAO^A1TC\A_P#':/\
MA9G[0Y_YE'2/R'_QVC^TJ ?ZFX[_ )^0_P# T?56ZC=7RNOQ*_:'SQX1TC\A
M_P#':7_A9'[1)_YE'2/R'_QVC^TJ ?ZG8[_GY3^<T?4^ZC=7RR/B-^T2>GA#
M2#^"_P#QVE_X6)^T5_T)^C_DO_QVC^T:/0/]3L;_ ,_*7_@:/J7=1NKY;7XA
M?M%M_P R?H_Y+_\ ':7_ (6!^T7_ -"?I'Y#_P".T?VC1%_J?C?^?E+_ ,"1
M]1[J-U?+G_"?_M%_]"?I!_ ?_':!X^_:-;IX.T?\E_\ CM/^T:7F+_4_&_\
M/RE_X&CZCW4;J^7O^$\_:._Z$[1__'/_ ([1_P )U^T>?^9-T<_0)_\ ':?]
MH4G_ #?<'^I^,ZU:7_@2/J'=1NKY?'CC]I!O^9,TG_QS_P".T?\ ";?M(_\
M0EZ3_P".?_':/[0I?WON#_4_&?\ /ZE_X$CZ@W4;J^85\;?M(G_F3-)_\<_^
M.T[_ (3+]I%O^9+TD_\ ?'_QVC^T*/\ >^X/]4<9_P _J7_@2/IS=1NKYC'C
M+]I(<_\ "%:3CZI_\=JO;?&+XR>'?&GA'2_&.@Z3I6GZYJ,=F)(TWN5)^;:5
MD.#@]Z<<=3;LNO<F7".,LVJE-^DDWIJ?4H.:*GL]+%PPVW:D9QG'N:UX?"9D
MY%VO_?&:](^)<7=W,&BND_X1!_\ GZ7_ +]T?\(@_P#S]+_WQ0+E.;HKI/\
MA$'_ .?I?^^*/^$0?_GZ7_OB@.4YNBND_P"$0?\ Y^E_[XH_X1!_^?I?^^*
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MB@ I'^Z3SZ\'%+39 6C8=L4GL!\8_M:V=K:_M$?"K46.R>XMYH)'9OD(5AL
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M"WV)5J1>M1+STY[>W/'6N&T/XTZ+KWQ5U/P!;VMZ-5TV)IIII% A95VYP?\
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MD^.&_L72/ NGNPU#6)%N+I8S_J[=#PK?[S ?]\FJ'PH\-+#]FA1,1Q@*H/8
M<"O1P-/FJ^T[%YK6^IY2J2^.L[_]N1_SE^1]"?#/3/*MH21CBO9-.CVQ+[5P
M_@O3/*MXP1C&*[^W7;&!7N'YN39S2444P"BBB@ HHHH **** "BBB@ HHHH
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M<MDW*D95ER?TK@/A+JEMJ/[9'B_4+:3S[.:SN)D:)L[UV*?IG'ZYJW\.=?\
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ML3_PS/XM!SMW6PR?^NHI1_=RIP^8YM3C5K=+-(\(\"_&KXRZ3\"?#T_P_P#
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MQ7:Q7HOW<US5J5*"DGT.VC4Q3E3JSNE.][VM9[6]#EO#7[2OQ&\:ZMXD\/\
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M\*>&-('B3QKJ@!@LF)*PJ3A-ZC[S,<X'3')KRS]IZ:+4?VIOA79::ROK%N\
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MG^V5[>JMQ11A3BZ=/D^*YY]:I6:K5%4MR-&#XM_:(^+5EI \::9X*M;/P,S
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MAD1B0"K#!''M7S)\/_V(G^&WCZUUG1OB'JEOX?M[U;S^Q1'M\X*3M20J<'C
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M!YIYF$EW?S\RSN.A/8*!G"CI^-=L.E/2MI8FI42CW,*>#HTI*<8Z]#S'X)_
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M-P_B?P2K SZ9<OB>U3(Y!]NQ'_ LUU7@/XEZ%\0K-6TVY'VI5#364PVS1_\
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M=;++*DOB=CCGGV4T]*=*=3YJ/_!,?4/VK_$>JN@\.>!_)3(/G:C*2<$<\
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M/\57'!8CI"QA+$Y5#XL4GZ1;/K6]US3--CE>[U&SM4B&7,TZKM'ODUQVN?M
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M^%=!:Z2L:@;1^5=)\X<MHWA.*W"_NP/PKJK/3$A4845=CMU0=*E&!T% #%C
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MJ*C\Y?[U.5P>]*S0#J*6DH&%%%% !1110 4444 %%%% !1110 4444 %%%%
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MVW1[_!<B51@U8KDO#^K"XB4[NHKJHFW(*^V/D1]%%%, HHHH **** "BBB@
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MHD>V-C&/O*OZ5]!>$O'_ ,.OC_X-=-"U/1/&.@74)26Q79)B(C!22'[RX!]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 DG^K?_=;^5<-7<R?ZM_]UOY5PU0*04444&0[:*TO#JG^
MTA_NM6=4VGZM9:7J5L+R\M[/SRT4/VB58_,?^ZN3R?84F[:LVC&4GRQ5V=C1
M4$ERL8RPVCL2>#]/6E2XSC/ [58;.S)J*0.#T-+36NP@HHHH&%%%% !1110
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MKRGXA3'3]5L77 8W!7\-N:]6O"!U]:\4^+ETJZKI\1SYGGLW'3  !KBRZ_\
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MJ")!M%%%%!D&?6OEK]L[2HO$'B+X7Z9.TB6]U?W$;-&^UTRJ#*D#C']:^IF
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** $:N%^)%NT^A2E,[X7648]CS7=UAZY:BYMI8R,JX(/TKEQ5#ZU1G1_F1
MTX>M]7K1JOHRCI=\NI:1:70.?,C4GZXZ5%/7,>#=2&DW5QHMY)L(<FWD;H<Y
MXKI[C.>1M/<5\#&?/3UW2U]5N?85J:IU=-F]/-/8SYNX[5Y-\;FVZ*7^Z5$8
M/_?P5ZS<+E6Z\\5X3\>-8$C1V:NV9KA$VKZ+R?U(KFHP=3%48K^9?@;MJ.'K
M5'MRO\=#HOA3=-]GB&<\5Z/XQLI+W0]\0S+$1*N.O%>;?"F(^6AZYXKVLV_F
M6?3/&,5^D5J*KTI4I[-6/B,-6="M&K'H[F?H^K1ZQI-M.A);:%<'LPXJ*Z^\
M>,5R4MQ-X/U9I(0S6DK?O(3T/T]ZZEKA+RWCGB):.10RENN/>OSNM&I1?L:J
M]Y?BNC1]G'DJ15:E\+7W-]S)U"188W=ONJ-Q_"OG?QIJ!UCQY';*24M4PZ_[
M;G<?R&*]5^*_C"+POI$[NW.WY4_YZ.?NK_7\*\;^'NGW&J:DUW<$RW$\C22-
MZL>:[\APDJM=XB6T;I'/FV(5'#J@MY6?HCZ&^&MH8[>+*]1V%>P6/RQ@5X(W
MQL^&_P +[J'3O%/C?1=$O\9-K<W2^:G^\HY7\:]J\(>*M$\::+#JGA[5[#6]
M-E^Y=:?<+-&>.F5)Y]J^^/C#<I*YGP;\2O#'Q"NM=MO#NL0:M/H=X=/U)(<Y
MMK@9S&V1UXKI^M A**4#/YXKFX?B-X;G^(%QX(35$/BN"P74Y--V-O6V9BJR
M9QCD@\9S0!T=%'/.>,=3V%+ZGMZ]J $HI=I]*3@]"#^- !12X(ZC%8WBKQGX
M?\"Z7+J?B/7-/T&PC&6N+^X6)?U- &Q2X/I678^*M'U+PS%XCM-4MKG0);;[
M9'J4;@PO#C/F!O3'>N$_X:C^#O;XG>%_3G4H_P#&@#T^DK'\)^,]!\>:.NK^
M&]8L]<TMG:-;RPE$L99?O $=Q6S0 E%%% !1110 4444 %%%% !1112"]@],
MG ]::SJGWFQSBL+QOXTTSP#X:U#7-5F\FRLX_,?:1O<]D0'^(G  KY!\1_M!
M?$3XB:A-/H=Y_P (KHGF?N(XU4SE?5FP<D^G3^==E#"SKZK1'HX7 U,5K'1'
MVJUVB@G<,#O3Q<#.WHWH1S7PJOQ)^*F@S+=Q>*YM3V<?9KN)"CKW7IW]:]U^
M$?Q_M/B)9O#<1KIVLVYQ=6&[@>C1D]1ZUI5P-2FN:]S7$9;5HQYD[KR/><CK
MFO(/VGM$NO$7P<\06UFNZ>)$NE0#EEC;+#\B?RKTC3]42X08.:35X!<V\BL
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M.<Y+/+I*O3?/2EM+]&NC7XGK'6BL^QOA,@S_ #J^.>0:[#YKR%HHHI@%%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJH&,5MJ JXKA.![Z;!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH.O1FYTJY2,83:O6(\G..OM7):M^S[\:?CY=:7IOQF\5^';+P-8W<=Y/X?\
M"EO(DFI/&=R"61^B9YP*ZSYM%C]JZ\BU7XF?LLWD(;R+KQ4;A%/&%:UWCGV!
MKK?C3\9O&B_&/1_A+\+K;2T\4WVGR:OJ.M:T&DMM-M V WE@@N['H.E;7QN^
M">H?$[QI\(=5TJ]L;"S\%ZXVIW-O<!@TL/D^6J1X!&X<=<<5C?&_X&^+]8^*
MVB?%?X7ZSI^D^-]-LWTNZLM8B9K/4K-FW"-BOS*0>A%(#PC]K?P]\7]#\,>
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M]_W:\U9J*S@^RV-M 2':*&.(LO"G:H'3\*EH,^H4444 %%%% !1110 4444
M%%%% !1110 4444 %(PRII:*0MCSKXF0-_9B3+_RQF5^F>]4?-$\,<B]'4-^
M8KJO&.GF]TNYB R64@#WKA/#]U]ITE%/,D)*-]!TK\]SZG[/%1G_ #K\C[C*
MY>TPKA_(_P R6X^96&,C^5?&/[4VD_V?X^T;4%0 7-H\#R#.7>-OEX^AK[.N
M.,C\:^5/VPM/3=X;OB[!X[N:V"X^7YDW9/OQ7S5"5L0DO,^JP,FDS8_95O5:
M^OK8CE9H9=V< =5Q7UG>99W/O7Q!^SGK TWQ4(78JMU!A?\ :D4[A^E?;37
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M%4 8P!Z<#\J?2510?YZ4444 'Z4?F?QHHH 7_/2DHHH **** "BBB@ HHHH
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M:&*W0$<UV4?RC'M6;I=D(% Q6F!7"<'2PM%%% !1110 4444 %%%% !1110
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MBC\&=6\0R^++?PI$FH:#K$]P)9GT^9"!')("=Q4X&:!\I]1D *6+ (N=S,0
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MSN$:YTQG+(V?FCS_ $KU>ZA\U>/2N%\4>'1>J<KEATXKS,9@5C(KD?+);/\
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M/FSQ7PYX7NY[KQC%>6<#I;N!'*S=_0_RKZY^'MTYMX\\XX->[A9.5/WMSZ7
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MQU?3]8AW6U[!>*1@[9%?J.F,^E9^K> = U9B;K2H!(?XXQY;_F,5Y7J7PO\
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M,O\ O) >Q!.*];^&-OY=O#CIBL,PO]8MV/:RY6PR?<]DTT$P]/X6_D:^#/\
M@E?_ ,C3\;?^PE'_ .C):^]M.7]T!T)&T'Z@U\X_L<?LM>(?V;]8^(%YK>L:
M;JT?B.Z2XMUT_P P-"H=CA]ZC^]VSTKS3UTU8^FJ^$/^"M$]P/A_\-K=F9='
MEUJ8W?)V[A&NW/\ P$R=:^[_ -:\[^/GP/T#]H7X:ZAX/\0;X(92)K:]A'[V
MUG4'9(OJ.2".X)H$CK/#.GZ9:>#=&LM,@@.BI80+:P1@"$P[%V@ \8(Q^1YK
M\_?V_+CQ$O[9?PACTG3[/5KF.U@?2['5G,=G<79N7)61N, E4ZXKH;#]CG]I
MBQT%? 4/QKM;3X?QD1++#))]I6 '(C4!=P'^R' QQFO=/V@_V0;#X\?#/PSH
MUYXANH?&'AJ)!IWBJ9 9GD"C>9@N,ABH/'((!^H/2^YX-^T/X!_:M_:1^'\G
MA3Q'\-?!EG!'<K>1W5AJZ^?#*N0-I:0@ @D'/8G\+7[?&CZMX?\ V"/ VE^(
M%5-;L9=.MKU4E$JB5(2IPPX(XZBMBS_9G_:?\72:9HGC;XW6]EX6L9XY6N-(
MS]LG\MLH"0BECP/O''J#7L?[8W[/>N?M'_!JW\&Z+K%II^H17\-V]YJ@8JX1
M2&)\M3\QSG@ <T#DU?0^;/\ @H(/^,(O@V/^P;_Z1K7WAX$_Y$;PU_V"K/\
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MRKANM6;B7KS6=-)P:U1T)%.X;K67<'K5ZXDZUF7#]JWCN;Q1A^)+P6>FSO\
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M 4444 %+244 )M![4TQ*>WZ4^B@!@B4=A^5+LQ3J*  #%%%% !1110 4444
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M/N>!.FUNC;CN /K4Z7 /?;DCYL<5C)-[Y]Q4JS].AY!YJ>5^ACROH>(?$/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRY;:BT5D:]XNT7PQ>Z/::IJ5O8W.L7:V&GQ3-@W-PRLPC7WPC?E6O0(****
M"BBCZT %%)N'X4GF#M0 ZBC.:* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#
MSW(]<=:7Z\5QOQ:^+7ACX)^"+[Q1XMOULM.MEP(U(:6YD/W(HES\[L>,#ZDC
M%(%JSQ?]OGX+^#/BA\$[_6O$6L6OA;4/#B/=6&M3J" <$&V?'S,CG "KD[B"
M!Q7Y^_L<_MC:O^S3XA_LS4EN-4^']_*&OM,4Y>S8\&> =F'&5X# =C5CX@?$
MWXN?\%!OB=#H&BZ>\NFV\K7&G:# X6TT^+A?.GD. S 8RS=R0H .*^J/%G_!
M,'PO%^SS_8NA3B]^)UJIO$UV:4I'?3$9>WQDXA(R%S@Y )-(Z%9:,^T/#OB+
M1_'7AK3=>T.^M]4TC481/:WENVY)4/?V(Z$'H01VK)U[P^EU&X*9K\P/V0?V
MNM;_ &5O%US\/_B!;74/A#[6T5Y9SH5N-%N"0&D5<<IG!91[,*_6"RO++Q#I
M5IJ.G7<-_I]Y$LUO=6[!HYD(R&5AP13\C%IQ>QX5K&B7>@W?G6P8!3D;3R/<
M>OTK>\/>/(;[;#?'RY\[?-Z G_:':N^UC0%NE8%:\N\3>"'C9I;<&-QT*]_8
M^M>MA\:X6A4V/%Q67JH^>B[2/0$D#*K*<ANA7D'Z&GC/U'K7D&G>+=2\,R^7
M,&2/^Z02G^(KO-'\;Z?J2J9'%M*W]YLHWT/^->Q'DFN:#/"G&5%VJ*QTJL*<
M#4"2*XW(VY3TQ_0CK3P?4_K2L%R6EW8ZU%D4R:0(C'VJ>6[0]T<[XY\3R:)8
MJEL<7DYVQ^JCNU>:_9PTKR3L9YVY=V/))K3\579U#Q7<DG<EN/+3VZ52R>?K
MFOP#B+,*F,QLXR;Y8Z)=#V815.*2(Y+>.52C(/F]J++7IM$D\EI,0YX]JD7[
MU8'C!2NESR@[2D>\'Z5Y^2XR>#QU.4';FT?S9K&TERL]<T'7!=*OS9^E=1#+
MYBYKPWX>ZXUQ#'EO3O7L-G=K';AY9 B#G<V /U-?T9!\UK(\:I:-S58]<?SJ
M.65(4+NRJH&26.!CUKD_$7Q*TO0K=YO/0H@YFE.V,?U/X"O#_%WQNO\ Q!(]
MOI$3RACQ-,-L:^ZKW_&M9<M/WJCL94XSK.U%?,]4^('Q<T_PW:.$N-F[A64?
M/(?1!_6OGS5M3U?XB:EYEP'M[/=E;16R,^K'NU6='\&WVOW[7=]))=W+GYI9
M#DGZ>@^E>R^#?ANL*Q,8N:\;$8QU/=CHCW\-@8T??J>\_P CF_ ?P[):-GBR
M>IXKWGPSX62RB3Y *MZ!X92S1<+BNMM;-(5&:\SU/5$M;40**MTG!I: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH &^Z?H?Y5SXK?;[I^A_E6$
M.@J &T4^B@ JWI__ !\#W6JE6]/_ ./@?[M &CMHVBEHJP# ]**** "BBB@
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MZ?H?Y5AU+ ****0!5O3_ /CX'^[52K>G_P#'P/\ =H TJ***L HHHH ****
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MDTI4:1K]9U, 0?>;?G&!W.<5YW8?M0?"S4=4M;&/QA:1F\E,%I=7,<D-K=2
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MNR_]\J3^%!?-?0\7^ '[/-M^TMI,7QD^-MO)XJU'Q$6N=&\.7DC"PTNQ)/E
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M"@8P*ECM5B (4D=C@G^E3I<QJQ ;=C]?P[4 6%7;2TR.56XS3]P/2@ HHI:
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M!_NT :%%%%6 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)2VBX["O5+11Y>*\]\"P;;6/CL*]$MUQ'7Z<=:):***!A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 #?=;Z&L/;6XWW3_NF
ML>H CVT5)10 58L/^/A?]VJ]6+#_ (^%_P!V@#0HHHJP"BBB@ HHHH ****
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M.*<@9CB::1F4'L"0*86/5OCM^V/K'P3\!^!-+7PU_;OQ?\46,4@T/852VD;
M9G1>22QPJ#&<'M7F>M?M=?M%?L]WFEZO\9_AYI\G@V^E6*2XTL!)+?)YY0L
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MKHE^48Q00,GA$BGBN<U?04NE.5!)ZFNHIC(#VH$>1:E\/8;B3<4!/KBF:?\
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M+1O!&CV/BW5H-<\2V\.R^U&UA$4<\FXG<J#[HP1Q714""BBB@ HHHH ****
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M>=I!X9,X.T]^17A/AK_@FRE]X@TR\^)7Q0UKX@:/I;@VNDSATB;&/OEG8@'
M! P3]*S_ /AZGX._Z)_XP_[]Q?\ Q5)_P]1\&_\ 1/\ QA_W[B_^*HNNX^65
MK'HG_!2"."Q_8[\1VUO&EK!;W%C''%'@)$@<A5&.@ '3%>-^ /V#%^(WP7\&
MZ]X/^(VM>!(?$.C6\VM:5;LTEI=2%<-( K+M)_ND'-:NJ_\ !3KX?Z[9M9ZE
M\,?$^HV3$%K:[M8)8B1R#M8D5-9_\%1O VG6L5M:_#CQ9;6T2[(X8H(51%]
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M]-Z?X;$EN&V[L<CV^E?,W[+EXWAG7OB%X+U)%@UO2/$-U-+&2<LKR,-XXY'
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MX)61&0[<YP00<>AP>M<5\&?@_H/P+\#IX5\-RWDVEI=SW@>^F$LA>5R[_,%
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MW_!1;4;[17CGLO"W@X:=JUU#R@N)9 4AR#@D#J.V*F_9?@1?VF/VFIM@$O\
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MODQ_\\H_^^!_A1Y,?_/*/_O@?X4ZBCF8#?)C_P">4?\ WP/\*/)C_P">4?\
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MODQ_\\H_^^!_A1Y,?_/*/_O@?X4ZBCF8#?)C_P">4?\ WP/\*/)C_P">4?\
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MV2ZOKZ6Y,$+'+1QASA4/H!6+J/[$/P9U/Q=+XAD\+2K+-="^ET^WOYH]/DN
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M;FQ2,AA;)<O)(4*0F7G9C[S9Q\O0_A7 ?!:WLK?P'X9BM!&EJNG0",1'( V
MG'XYH-(Z'-W'[,/P^N=+:S?P?I@@V;=T<1#\=/GS7E<&I>(_V(?&&EZIH>IW
M>H?"_4KM;?4=&O&+I8ECPR>C8R0P],&OMB:&U_L_( W8Z5\Y?M91VI^"OB[S
MO+*_9AM\SKN,BX(]^M!=[[GU]X5\8P:U;0W%O.LL$RJZ2*=VY2,@_B"*[VSN
MA*J\YKXJ_90\0:A_PJOP?%J#?Z3'I\<1Z<+CY<XX^YBOKWP[=>=#'SF@PZG2
M44B]*6@ HHHH **** "BBBD 444F\>M%UT'9]4+12;O<4;J9(M%%% PHHHH
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M]TUFU+ ,FBBBIN ZI;7_ %W2HJEM?]=1<=BW1116@BK??=;_ '6_]!-?+/\
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MO5^3/H"WGWKG.14U<QH6L)<1J0>#720R"1>*^::L?2(?1112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 #-M%8_B'Q!:Z!I\EW=R>6BC
MY5[NW]T>IJYJFH0:?9S7$\@CBC&YC[#TKR=)9_&NL-J]XA738S_HUNQX/OBO
M6R_!?6I<T_A1Y&88[ZK!1CK)B3RZEX^F6XOM]GI6?W=JIP7'J?6N@M+&&QA6
M&")88UZ(HQ^=3JO^14JITKZ^Z7N05DCX_E<VY3=V^XU5IXCIZI2MMC5G8[$0
M99R<!1ZDG@?C6=UT-%%]2/91MKA_$OQR\$^%9'BN=<BN9USF.R4S-GT./EKD
MI_VJO#?VAX[71=8O(EZ2K&JY_ DUO&C5DKJ(^4]D*TSR^*\@M/VJ/"[S-'>Z
M3K%@ ,Y>)7)_ $8KM/#7Q=\'^+MJ6&N6YGP#]GN/W,@SVPV ?SH=*K'XDQ..
MAT-]IEOJ4#17$(E3'IR*XN^TV^\)S>=;LT]A_P"/*?\ "O060'!'/<'.?RJ"
M:)9%*R+O0\,I[BLWRRBZ<MF9QYHS4XNS,_PSXP2Z5 TF&[C-=[8WZSXPP->'
M>(M&E\-7BW5F6^S2-T_N_P"S75^#O%R7<84MAAP0>WM7R..P;PLO=^%]3[/
M8[ZY!\^DET/6%DW<4M9]C>K+&,5H9S7DGJ!1110 4444 %%%% !7P%^VDEU)
M^VQ\*A8[OM8\-SB,QG#9,LM??M? O[9FH-H_[;GPGO@GF&'PY<.%8X'^ME%5
M[W++E5W8J'+SI2=CV'X;I>QO&+W>9>,[SDU[UHO^I3Z5X-\.M2;5IDN)(EB<
MX^53G%>]:-Q"HZUUX/VGL8JM%1EV6R.?&>S]O+V4G)=WNS7I*6DKN.(*.?2B
MB@#A_BYX(LOB1X"\0>%M3RMCJ]F]K(Z*"R%A\KJ#_$IP<?6OSG\!^/-5_9;U
MX_"_XH.UK%:'&B^($4O;74.[Y5SU"CZ9&2#TK]1=0M_-C(QQC!KR/XK?"O1/
MB!I4NGZ_I%GJ]H3GR+N(-M]U/:@KF/"KCXX^%8-(6_?Q/I*V)RJW'VQ65F'+
M 8^8\=.*^8_BE\2+G]IC6H?"7A9)?^$0BF6?4=8="OG;>51>> .?<DY..*]J
MUC]B'X>6^I-/;^'&7YRWDFX<Q_[H3.,5VGA?X.V^BQ16UG8Q65HGW888PJC\
M*8^8O?"/139Q6T,<>R*)%C10, *!@"OJ#PQ"4MXZ\_\ !7@O^SPA*8_"O5])
ML_)B48Q2(-1?NTM%%.S>P>H4444A771A11104%(S;1Z'UI?TK!\8:X=#T*[N
ME4M*J[4 ./F/'_UZQK5(T:<JLMDKFM&FZTXTX[MV*OB+QYI^@R-;R.TMUC_4
M1C+#W)]#7.M\4F50S:3<HA_BW C\L5BZ#H_F#SY_WEU,?,:1N3712:/B/.WK
MZBOSZ>;8^O)SHNT>G_!/L_[/P-!>SFG)]7?\C0TGQM::JH:&3+#[T9X9:Z&U
MU)9AD'->/Z]IQTN9;RV'EN#APG&:UO"?BO[5M0O\P.",U]/E.8O'1G&I&TH_
MB>%F>!CAI1J4FW"?X'K$<GF*"*?6=IMT9D4YX(J^T@ ';WQFOH-.YXEGN]AU
M%9MWKEK:2>7+<0P2]=CR <>O--AUR"X7=%*DJCNC9_E67M:?\R^\MTJBCSN+
MMZ&I152*^60@Y&*LJXDY!K2ZV,_,=Z]N]>8ZKX7UF;X@C4182"Q^T1R>8'R-
MHQ7IZY+  9/3%>?Z1\2+G4/&!T@102VLEP\:3+E6"J#QC/M7A9HJ$W1IUI.+
M<M+=_/R/<RQUX*M4HQ4K1UOV\O,]!8?,>W.>?QII4-P:7^=)7O>IX?0JS6*2
M'D"H?[,3=P/TK0HH JQV*KV%654*M+10 4444 %%%% !1110 4444 %%%% $
M5Y'-)9SI;3"VN61EBG*[A$Y'RN1W .#CVK\^/&/_  2N@DM-?\27_P 5-2U+
M4@EQJ=RTVFH&FDPTC9.<C<0?PK]#*P_'0QX%\3_]@F[_ /1+4K%QERGXS?L<
M_LSVO[5?BS7='N?$,WAR/3-,34%N(+99C*7D";<-Q@9SFOTT_93_ &4[O]EI
M=;L8/'5YXFT'4RLO]EW5FD @N!P9D*]V& :^-_\ @D*Q_P"%K^-V[_\ ".1?
M^CUK]2>@P.E!4Y.X;<8!.XCK[>U%'I13,@HHHH **** "BBB@ HHHH ****
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M=(\3+@13DPS+P=U?FV;4WA<PE5GM(^[P+>*P$(4]XWNNNIW6H+%Y/RFO,OB
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MN2T?Q$EXJD."*Z:UN!(N<YKZH^:)Z*** "BBB@ HHHH **** "BBB@ HHHH
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M--/D?NL]BI.&'P_+AJC7.O>0^BBBO92Y=#QV[ZA1113$%%%% !1110 4444
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M'M6;?,="TJ\GL+$32X,AAA&TR-W)]1CM[5S'PU\5:GX@^UQ7T)DBA8LMT!M
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M+PEI'B0H-J&_M@SKCT<<_AFNQI:0[LY'X>_"/P3\)[&:S\'>%=,\.03#$O\
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MKQP_Q+^$O@_Q7( )M8TNWNYL=#(R#?\ AN!Q]:[&@E[A1110(**** "BBB@
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MTXU;X+>!/$FL2:AJW@S0=3U"X=?.N[O3H999,<9+%23@ #\*_-3]DSP-X?\
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M,_\ E(U\0O\ KIKG_H\UT4_A9$MS]1NQ^M)2]C]:2N8H****8PHHHH ****
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M.E:ZAE,C32*BB95_U#%6+X;CY2.M'*PN?0N1NVY&[^[GG\J/;O7BNCWGV?\
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M-,DC.(XT&%7(&/I7T%UY]>:&K.P!1112&%%%% !7Y]_MR?\ )Y'PP_[%J?\
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MHH ****@J(4444%BT4ZAN]*Y,AE%%%:$%6^^ZW^ZW_H)KY9_X)F_\D5\8?\
M8YZG_P"C#7U-??=;_=;_ -!-?+/_  3-_P"2*^,/^QSU/_T8:YL1_#-J7Q'U
MQ1117FG:%%%% !1110 4444 %%%% !1SVZ]J** ./^+GPMT/XU?#O6?!WB"+
MS=.U2'8'507MY!]R5,]&1N1ZXK\Z/V?_ (R>(?V!?C!JWPI^)PNF\$W=QYEM
MJ!!,=MEB$OHA_%%(/]8H^Z1GKFOU'^OUKRG]HC]G#PG^TGX-_L3Q+$]M=V[^
M98:O:JOVFQD/4J3P5;NIX(]Q6L)6T9)Z7I.J6>NZ=;ZAIUU;W]E<*)(;JWD$
MD<B_WE8<,._Z5X=<?M;:;;?M70_ T^&KUM0EC$HUK[4@@&ZV-QCRL;NGR]>M
M?$EK>?M ?\$W]6>WGM5\4_#:>=F1?GET]AN&Y\K\UK*?EZ_+G/6G_ _XS6G[
M0/\ P4F\,>.['3;C1[?4K9D-E<R+(\;QZ>\9^=>&!*D@XK3V2U:)N?JI5.^^
MXW&?6KE074>]37-OH:7MJ>3:/=KH&MZCIER?)AN)#) Y''/;^GX5>U.18E9V
M((09)Z BH_B+IH^QR3E/FBP5;TYK URYD?PC:R%CYA #?[7U_*OA,=!X6;H;
MJU_OZ'VF%MBXJL]+NS_S/'?'VM&^\66UHAW>2#+)[%C\H_*O:?AF6^SP]NE?
M//A?3Y]1UF2YN"9)Y7W.[=2?3\*^G_ 6G^3:Q\8Z5]K@\.L-AHT^VOWGR>+K
M_6<1*H_3[M#H?'/CH_#GPE)KG]A:MX@A@E19[;181-<1Q,<-*$S\RJ.2!SBO
MFS6-6\!_$+XS> =:^".GW5OXV_M=)=>U+3=+GL;0:9M;[0M\'559F^4* "V[
MFOL&S4QJ",@]L<5.ORY XW'+%  <^I/>NGFLCE/DZ^^%NM_$SPG^TCH6EP-%
MJMUXOCOM,6\5HX;F2!+>5%W$<HYCV[AD GVK'_:2^,?B#QU\$?[.;X>:]X8E
M75-)75YM>A2*.W;[9"/*MR&/G.SXVX&-N3WKZX\2:#:^*]!O]'OC+]CO8C#*
M;:5H9-I.?E=>5/'!%>7Z5^S'H%KKFD:AK/B/Q7XO@T>=;K3-.\1ZJUS:VTJC
M"/Y?\3+V+9QP:M235Q&#KGA:\\4?M"_%#3(EFMEU3X>6FGPW6UE02/+=+][&
M"P+ D9X'UKQ'P?:^"[SX6Z;\//'7B;XDV?B*&WBT#4?!,(FD$C(0A\G;'L,!
MP&#;\!?IBONSEQ@D[<\9_P ]CFEW'S%<;?,"X#  M] <9I>T\@L?-7]O6'[.
M?Q_\8ZCXK2[M?"'BZQT\:=KZV\ES%#-:1&)[68HK,A((=21@DGTKN-3\%^ _
MVJ/#.BZ[JNF:VUA:O.MAYTUQILCKD R;%96*-M!4L.@S@9KUQE!4*5$BM_RS
M8 _GG@T;BS$DD^Y[U+E<JQ\\?M,^";?PS\"?"7AWP_9W4MEI_BC15@@W27,@
MC6[0L2W+$#^\>G>NI\=_'_X>^ ?'6IZ3XQTZ^TB\BB4Q:E=Z$]Q#J41R=D,L
M:/NP?E*G'->O;BO3'TQ2'!4!AN53D*R@\^WXTU(5CPW]D+P]>Z+\.]>OI='N
M/#ND:YXAO=6T;1KE#$]I92,/+#1_\LRQ#-M'3->YTI8LQ)R6[EJ2H>HUH%%%
M%(84444 %%%% !1110 4444 %%%% !1110!X-^V9^SA!^TE\(;K2[94C\4:4
M6OM&G8=9=I#0'_9D'R^F=I[5X/\ \$ZOVHI]1LU^"7CA)]/\4Z&DD&EM>KL:
M6*,X:S?)SYT?( ZLH./NU]XX'?D9 *YQ^-?%G[9W["MS\3M:'Q(^&3KI7Q"M
MY%N+JU6;R!?NHRLJ./\ 5W QC/1N];1::Y9$'VF,\9ZTOMWK\F+[_@I)\6/#
MOPTC\&ZC:M9_$32=0C6;7[V(+)+#&Y+PS0$#YR0JENC YZU^B?[./[07A[]I
M#X<0^)=$'V>YA(@U+3)3^\LKC +(3W'.5;N#]:F5-QUZ#N>IU'<<(:E/#$9R
M!TJ.896LRCP?XN*R^,K25E^1K<(K ]P>:Y*O4_BEX=_M:S6:(;;JV.]&]?:O
M)XK@M"[LNUE.UU]#7YOG&'E1Q4I-:,\/%TY<_,]C!\777V6.,@X<RH![5ZA\
M,[Z22WB!;/%>&^(+Y]7\016J!O+MSEFS]YS_ (5[O\,[ I#&Q],U]EDM!T<#
M%2W;;/0H+EC8X[XD>#;GQU^USX1L+;Q+K/A21?!EW+]NT258I6Q=#]V2P(V]
M_J*])L?@CHGPQ\*>.M9AO=6\0>)]6TBXCO?$&NW7VF[EC2%]D8. $0$\*HQF
MO3-.M8]R3&&-IU78LI0;PIZKG&0._7%:+)Y@VGYAVR,YSUSZ@BO:YK'58^4_
M@%^U-\,? _[-_@*RN?%$5_KECHMO"VA:7&]Q?O,% \E8E4DL3QS@"ND^$_P&
MU/Q!\';V#QC=ZUX0UWQ+X@N?%%W#H=\;6YLS,S&.!I!G.U-NX>OTKWNST'2M
M/G$]II=A:S#.);>VC1A_P(*#5[KWS2<KBL?+'[0_A?2O@O\ "WP!'/XAU6]T
MJT\>Z7?7&I>(+UKJ:%/-R^9".%4#TKVGPK^T!\-?'GB"'1/#OC72-9U>?<T5
MG9S[Y&"@LV!CT!KN+RQM]0A\FZMH;N'J8IHED&?7##%5;7P[I-A,L]MI6GVD
MZ_=FM[6-'7([,%R,]/QHYAGC/PI!_P"&K?CD-I7_ $31!T_Z925[MC'%1K;Q
M17$LR1QI+( 'D" ,<<#<0,L!GC-2>GI4MW=QA1112&%%%% !7Y]_MR?\GD?#
M#_L6I_\ T=+7Z"5^??[<G_)Y'PP_[%J?_P!'2UT8?^(B)_">O_"7_4Q_A7T/
MHW^I6OGCX2_ZF/\ "OH?1O\ 4K7I]6>:C7I*6DH*"BBB@ HHHH **** "BBB
M@ J&YA\Q34U%)I25I(:;CJCA_$7AY;V-LI7E>O\ PU%Q(W[L_P# 37T+-;+-
MVJA/HR2-]RF_>=V%^Q\[Z;\*Q#-Q$0/I7IGA?PBFG@83%=O'H:*WW*T+>Q$7
M:@74BTVT\E5^E:% 7;12&PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ H^O%+534M0M]-M9KF[FCM[:)"\LLK *J@<DD]J.MAI.326Y7U[7++P[
MIMSJ.HW4=E8VR%YKB5MH1?\ 'T'>OA_XN?&C6?C5J%Q8V,TVE^"E?:(/NR7@
M!^^_L>PJ/XR_&"^^-6O265K)):^#[&8B&%20UVP.#*_KG^$=A[FN:M8UCC5$
M&U%X '85]-A,&J:YZBU/L<OP"P_[VHO>8^QLXK.$10H(XU_A7U]:T8EXJ&):
MN1K7H-L]63)XDXJY&O%0PKTJY"E8LP)(X\U:CBIL*5;CCSBL[F,F"0]*LQ0T
M^*&K215#9E>Y$L.:AGL0W49K36&I5A#=12OW)OJF<+J7AM;AC\M4;;PFD,F=
ME>CM8HU,%BH-1JGH_OU,^6[N<W::4(E "XK1-OL6M-K<+T&*C:*J1I'0R7BZ
MU7>+K6K)#5.2/%7S&BEJ9DT>*J2)6G(M4Y$ZUH:)ZF;,E4IEK4=>M4YEK2+-
M4]3,D6JLBUH2+5*1>M:+<VB9TT$<RLDB;U/&WUKH_@]X\F\#Z^F@WLS-ILYS
M9R.?NN?X/I6"ZX-9^L:>=0M0%;;.IW1..H;L?PHJTU6@XO45:E#$4W0GU/O#
MPKX@2XA7YO;&>_>NXM9@ZC!KY+^!/Q&?6-+CBN6(O;7$,^X]2!PWXU]+Z#J0
MN(T(.>*^.J4_95/9R/S^M3E1FZ<]T=)138^5%.K$R"BBBF 4444 %%%% !11
M10 4444 %+13JEE1&T4ZBIN6%#=Z*&[T6)D,HHHK0@JWWW6_W6_]!-?+/_!,
MW_DBOC#_ +'/4_\ T8:^IK[[K?[K?^@FOEG_ ()F_P#)%?&'_8YZG_Z,-<V(
M_AFU+XCZXHHHKS3M"BBB@ HHHH **** "BBB@ HHHH ****!$=U:PWUK+;7,
M,=S;2@K);SHLD<@/7(/!S[U^;^D^$M%\#_\ !6;3-(\/:5::+I<=OYB6=C"(
MHE+Z<S,0HXR2<GW-?I+_ )ZXKBG^"_@>;XE+\0G\,:>WC15"IKC)_I(41^7C
M/;Y.*UA)I/46AVE(P.TTM1O+M]ZRU6I6AQ?Q(MQ_PC=^Q_N?UKA=3MBOA.U1
MCRH5CGWS_C77_$_6K&WT>>SFO+>"ZN$(AMY)5624CD[5)R<#TKFM642>&%S_
M  P(W'L*^-SFTJ]U_*?896I4Z,;K1R/*?"MDHU)B,8,AP/QKZ'\(VX6W0#KQ
M7SOH]^D/B"ZAR T<G*@\J#SDCM7T%X.OE>W0AP/<\BOLJ,G.C&7=(^4K4W3K
M2BTUJ_S.\CX0^U.P>N.^*\-_:H_:&U7]G7X>CQ!I/@C4/%[-N1I8F"VMCZ-<
M,,OM/^R/J17YH>'_ -NOX@7_ ,?-#^(GBF6Z\2VFFM,;?PQILS6]F@="H$:@
M-G'7)!/O6L:;DC!NQ^T'_P"NC^+'?TK\^-+_ ."O.A1:@T'B#X;:EI,6S=_H
M^HH\NX]BDB+@$=P:])\(_P#!4CX,>($MTU4Z[X8F?<9/M5CYL4 '/+QEB<^P
MI>SD%T?7WUI:\^\!_M _#;XF2-#X7\;:)JTX 8V\5VJRC(S]QL'(!YP..^*]
M!8;>""#4-6W16@E%';/:CW[4A!1110,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ I><<?0_P"?6DHH$?&_[2W[ FJ?M*?&:;Q;?^,['0-%2S2S
M@M;'32UWA<DL[,VUV+,W)'3%=I^S9^P[H7[-/B0ZYHWC#Q#J-[/:FVOK.9XT
MLK@_PNT2@9*]N>":^E**T<VU85@Z<4,,J:*7L:SZH9S7B*T$EO)\N<+N_*OG
M R>;%?MW,C']37T]K*[K=_\ =;^1KYB@ \FY]W?^9KXWB'X::OW.#&2T1SMA
MI(FU^:4KDLP-?0O@73Q%;IVXKQ;0E7^T 3W(->^>#U'DICIBOK<++FPU.7=(
MZ:>L4=M:QX0#VJ;I4</RJ!4E:FP4444#"BBB@04444#"BBB@ HHHH *_/O\
M;D_Y/(^&'_8M3_\ HZ6OT$K\^_VY/^3R/AA_V+4__HZ6NC#_ ,1$3^$]?^$O
M^IC_  KZ'T;_ %*U\\?"7_4Q_A7T/HW^I6O3ZL\U&O24M)04%%%% !1110 4
M444 %%%% !1110 4<^M%% !SZT444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 444$[03Z<_7VH[W&([;>O#9&/K7R+^U;\6)->U0_#_1+@BW
M3YM9GB/WNA$&?0<'CU KWCXW?$V#X6^ [[5R/-O3_H]G!D9DG8<'Z+R?P-?"
M6EV\JI-=74C37MVYGFD;DLS$G))^IXKVLMPZF_:R6A]'E.%4FZ\UHMB[;PI"
MB1(H5$& H%7HEX%54JY#TKZ"6I]-)MJ[+4*\5<A456MQ5Z%>:P,66HUZ5<C7
M@56C6KT"BLF]#&^A/&M785J"-:NPI6?0PDRQ#'G%6XX>/:HH4J]$@QSTK-LQ
M8L<([U8CM_12?I6+XI\76'A"V1KHM-=2C]U;1<.W^ ]Z\[NM9\2>+F9[B];2
MK)^EM!PV/<]S[UU4L+.JN;9'CXK,J6']U:L]5NM4T[3O^/J^M8.<8DE .:JM
MXJT+'_(7L?\ O^*\QMO ^GKEI8WNW8Y+3.6)K17P;I;<_8(0/3!KL^ITUHY,
M\=YO6D[Q@K>IWD>O:3=MMAU.TD;KA9A_C4S1K(,J0XQG<IR/SKS>Z\!:7(S$
M6:QY4C]VQ%5%\+WFE-NTS5KNT9<;4:0LG_UZ/J<'I"6IK3SB:_B0/2I(_E)'
M(JE(@;-<9%XVUS0V"ZO:)?V_>XM5VR#W_P#UUU>EZS9^(+;[393":/'S#HR_
M45RU,+5I:M'NX/'T<6[0=GYD4L>*IS+6C,O)JG(O6L%*YZR>IF2K521:T9EJ
MC(N,UJC6)G3)5*1?F-:,W>J4G>M4]39&=,N,U"O_ .JK,W456K1=S>XSPSK)
M\(^-K6Z1MEE>'RY%Z#.>/UK[&\ Z]]HAB^;)Z?\ UZ^*]>M6NM-DV'$D9\Q#
MCN*]Z^"7BXZEI5C,SX9EVMSW'%>)F=%>[41\UG-+6%9+U/JZQG\Q%.<YJY7.
M:!>>;"ASFNA7D5X)\PMA:***!A1110 4444 %%%% !1110 M.IM.J65$****
MFQ8NT^E(]2TR3[HIDR(J***L@JWWW6_W6_\ 037RS_P3-_Y(KXP_['/4_P#T
M8:^IK[[K?[K?^@FOEG_@F;_R17QA_P!CGJ?_ *,-<V(_AFU+XCZXHHHKS3M"
MBBB@ HHHH **** "BBB@ HHHH **,T4 %'UXHIDC'C!Q[\_TI6$I)/4Q_%7B
MS2_!>B76L:Q?P:;IULNZ2YN'VJOI]2>, =:^&_BE^UMXQ^*=U=:;X!9O#7AM
M)3&-;(Q=7*C^Z/X%ST Y/<CI3/VL/B+<_&#XIOX#L;@Q^%?#N'O?+_Y;W7/!
M/]U=VT#UW&N2L],ALX8X+>)8H4 554?I_P#7KP<;C'%NG#='[#D.08?"T(8K
M&1YJDM5%[)='Z];=B7X-^$WM_B5#J]]J%]K&I^5(7NKR4R,<J06YSZ]S7V=J
MD"II/D ,^(=HSCTKYF^$\*+XDEW\ VY^;T&17U%J*_NRJ]UVC\A7S$VYSGS/
M9!GM7FK4Y26GEHCX8^,OAW4-%^(^I^(-#U.>RU7$=QLS\CC:/E(_X":^D?V>
M?BX/'7A'3]1F"PW3 I<1 _=E!P3^/I7E_P 7K5?^$EC.W]XUN-_O@D5P'P)\
M2/X'\;:MX6E=EBEF-U:;N <C+#WX_E7NY+B6[0J/<UX@P:QV4>VC%>TI6?\
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M.)2['&> ,G^5'+S:#2O<^.?VKO%[^*/B58>&87SI^BPBXG4?Q32#.#]%V_\
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M8OXTF/;\NM%% !1110 4444 %%%% !1110 4444 %'5@.]%-E;8N><G]<=J
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M8U.>3S6XC;AUKO7F? =&UL.HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^^ZW^ZW_ *":^6?^"9O_ "17QA_V.>I_^C#7-B/X9M2^(^N****\T[0HHHH
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M4LKBPE'!++\OYU[DN7$+FIZGY[4HU,+)QJ*R[GMG]L[K?;GM7,:Q?!LUQO\
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M>DI:2@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*(HX%78[=4[5-^Q-S)L='2!5&T"M:.!8NV:D*CM12#<6DHHH$%%%% !1110
M4444 %%%% !1110 J_?7ZUH5GK]]?K6A4%1$HHHH+"H[DX@-6=M07:CR?QH!
MZ%&BBBK,BK??=;_=;_T$U\L_\$S?^2*^,/\ L<]3_P#1AKZFOONM_NM_Z":^
M6?\ @F;_ ,D5\8?]CGJ?_HPUS8C^&;4OB/KBBBBO-.T**** "BBB@ HHHH @
MNHPRGZ5XS\9/A'X=^)FG^1KNEI>M&#Y5Q]R:+V5QR!GG' KVUE##WK+OM/\
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M$LL$R%'1AD,I&"OX@UUU4[R .A&.M5%M.Z#7='P#\1OA3JGPUU*YN-(MWO\
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MB.O)E(YD2(NT<4ZEI*S*"BBB@ K\^_VY/^3R/AA_V+4__HZ6OT$K\^_VY/\
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M>U8'P)_;D^&7QZ\3+X:L6O\ P_XCER8--UB$1FX(&<1L"1G'\).: UW/4_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#KXM^ +7P-JWB*%I=$OM/OOM=K=,@R\#MCY7 X^IKE=!_; ^)WQ"UKX@Z5X
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M\-Z5KFES"XT[4K9+NWEQ@M&ZA@<=CSS]*TZS]1A1110,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***.F.],"*:\M[=MLMQ#$V,XDE53
M^IHCO+>9ML5Q#*^,[8Y58_D#7S;^V1^S;X-^(W@WQ3X^U@:I_P )#H7AZ?[$
MUIJ$D,(\H/(FZ-3ACN8\FO$OA/X;\,_LL?LGZ#^T+I.EZCKOC&ZT>UBN[>^U
M64VTHN9TC<[>0I QCZ5I&*:N3?4_00XYYZ<4'"X#<9.!GN?2O%OBM^T%=_#?
M6/A!8P:-!?#QUJ<&G3R-,5^QJ\:MO3CYCSWKB/%W[5'Q _X7KX\^%_@3X:6O
MBG5/#MG!>17,^I&WC:-U5G\W(XZX4#))Q4\C87/J!6#=AGT- ^;HN?48Z?6O
MB6W_ &\_B%XB^%>H>//#WP;6YT/PVSP>)I+O4@ABF1L2I;+C+A1R2>AXKTWQ
MW^UU(L?P^T;X<^%9/&GC7QMIRZO9:7/.((+2TV@M+<2=@#D<=<4>SD%SZ-_
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M$1/X3U_X2_ZF/\*^A]&_U*U\\?"7_4Q_A7T/HW^I6O3ZL\U&O24M)04%%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(S_\71_P]$^"O_/#Q=_X(S_\71[.?\H<R/KFBOD;_AZ)\%?^>'B[_P $9_\
MBZ/^'HGP5_YX>+O_  1G_P"+H]G/^4?,?7-%?(W_  ]$^"O_ #P\7?\ @C/_
M ,71_P /1/@K_P \/%W_ ((S_P#%T_9S["YD?7-%?(W_  ]$^"O_ #P\7?\
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M%W_@C/\ \71[.?8.9'US17R-_P /1/@K_P \/%W_ ((S_P#%T?\ #T3X*_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH 5>J_[PK;VFL13\P^H_G6\5.:@TB,VT4[::*"[$FT53U3BW_X$*NU2U4_
MZ+^(-!,C)HHR/4?G1D>H_.K,M2*XCW*3SGM7#^)M!2\C<&&/D'I$N/Y=?>N]
MX*X)_6JDUF)%(ZT!J?-_B#X9QW4S-Y"<_P"P/\*YJ3X1AF_U"?\ ?'_UJ^HY
M-#1V)VYJ ^'XO[H_*D&I\P_\*?'_ #P7_O@?X4?\*?'_ #P7_O@5]/\ _"/0
M?W*/^$>@_N4!J?,'_"GQ_P \%_[X%'_"GQ_SP7_O@5]/_P#"/0?W*/\ A'H/
M[E :GS!_PI\?\\%_[X%'_"GQ_P \%_[X'^%?3_\ PCT']RC_ (1Z#^Y0&I\P
M?\*?'_/!?^^!_A1_PI\?\\%_[X'^%?3_ /PCT']RC_A'H/[E :GS!_PI\?\
M/!?^^!_A1_PI\?\ /!?^^!_A7T__ ,(]!_<H_P"$>@_N4!J?,'_"GQ_SP7_O
M@?X4?\*?'_/!?^^!_A7T_P#\(]!_<H_X1Z#^Y0&I\P?\*?'_ #P7_O@?X4?\
M*?'_ #P7_O@5]/\ _"/0?W*/^$>@_N4!J?,'_"GQ_P \%_[X%'_"GQ_SP7_O
M@5]/_P#"/0?W*/\ A'H/[E :GS!_PI\?\\%_[X%'_"GQ_P \%_[X'^%?3_\
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M?\*?'_/!?^^!_A1_PI\?\\%_[X'^%?3_ /PCT']RC_A'H/[E :GS!_PI\?\
M/!?^^!_A1_PI\?\ /!?^^!_A7T__ ,(]!_<H_P"$>@_N4!J?,'_"GQ_SP7_O
M@4?\*?'_ #P7_O@5]/\ _"/0?W*/^$>@_N4!J?,'_"GQ_P \%_[X%'_"GQ_S
MP7_O@5]/_P#"/0?W*/\ A'H/[E :GS!_PI\?\\%_[X'^%'_"GQ_SP7_O@?X5
M]/\ _"/0?W*/^$>@_N4!J?,'_"GQ_P \%_[X'^%'_"GQ_P \%_[X'^%?3_\
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M]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%%
M!]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1
M]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%%
M!]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1
M]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%%
M!]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1
M]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%%
M!]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1
M]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%%
M!]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1
M]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%%
M!]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1
M]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%%
M!]GB_P">2_E1]GB_YY+^5%% !]GB_P">2_E1]GB_YY+^5%% "K;Q?\\U'X5-
,TXHHJ6-!1112*/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>img29677477_25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img29677477_25.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1Y"LH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV/0O[',>^X:#SOM&<8)&<;?;UKTFB4)0^((SC/X0HHHJ2@HK \8>)?\ A%-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M29<O?CI)]H(L=&3R0>#-(=Q'X=/UKI_"/Q6TSQ'>)874!L+R0[8@7W)(?0'
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M\R7'E X)'3GK7(_!JRM;[Q5>1W=M%.@LV8+*@8 [UYYK5^.2+'>:*B*%189
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M9!VSD'I_6B2HP?(U\PBZTUSI_(H?%J>*Y^'+3P2+)%)+$Z.IX8$Y!K*^!O\
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M^I::;Y@F(1D81L\MSWQ6=*BG>35[=#2K6:LD]^IZ?X=^-%CJ%[':ZO9?80_
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M<9.3"BBBN<Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOMLBXFOG\SG^Z.!7D,\MY\0/'.^. A[N4#8O.Q!ZGV%?3-E:QV-C!:Q ".%
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M6'<$@@UU5YX7T'4'C>\TBSG:-!&ADA!VJ.@'MS5FXTC3KO3DTZXLH);) JK
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M .N\G]:^A[+3K/3K06EG;106XSB*-0%YZ\52M?"^@V-Z+RUTBSAN021*D0#
MGKS4*LES>9;HM\OD>.?&[_D9[/\ Z]_ZUWLVB/X@^$=O81?ZYK17C'JPY KJ
M=1\.Z-J\RS:CIEK=2*-JM-&&('IS5^"WAM8$@@C6.*,;411@*/04G5]V*70:
MI>])OJ?-_@GQ1!X/U*ZM]7TWSH7^5T9!OC8?6MBZ^(M_JOB*.#P]I-J()"$C
M@DMU9F/J3CBO8]4\*:%K,OFW^EVTTO\ ?9!N_.I-*\-:+HC%M.TVWMW/5T0;
MC^-6ZT'[S6I"HS7NIZ'&>/M:\4^&M$L;G34@2'R]MR4A#"-_H>@KD+/QWX5U
M31PGBG1!<:BH(,T,*C?[Y&,5[K)&DL;1R(KHPP589!KG9O /A6>;S7T2TW$Y
M.$P#40J02M)?<7.G-N\7]YX5X'TV;5O'MJ^F0/';Q3^:3U\M!ZFO2OC?!))X
M7LI44E8KH%SZ J1_.O0]/TK3])@\G3[.&VC_ +L2!14UU:6]];/;74*30N,,
MCKD$?2G*O>:E;84:%H.-]SQ;X6>.;?3[>U\,R6;O)=71 F#X W8'3'M7-^*M
M*U'P/XY:_BC81_:/M%M+CY6R<X_#IBO=++P3X;TZ\2[M=(MHYT;<CA.5/J/2
MM>\L+34;<P7EM%/$>J2*&%5[>*G=+1[D^PDX6;U6QXWK7QI-]H,EK9Z<T%Y-
M&4:0OE4R.2!3O@WX5NAJ#^(+J-HH40I &7!<D8)'MBO1X/ ?A:WF\V/1+3?G
M(S&#CZ5T2(L:!$4*H&  , 5,JL5%Q@K7*C2DY*4W>Q\[?%C_ )*))_USCKWJ
MW_Y%R+_KT'_H%0WWAC0]3NS=7VDV=Q<$ >9)$&;CIS6H(T6(1! (PNT+CC'I
M4SJ*48KL5"FXRD^Y\Y?"/_DHEE_USE_] -:WQB\/W-EXC36XXV:VN54,X'"N
M.Q^HQ7L=CX7T+3+M;JQTFSM[A00)(H@K#/!YK1N+:"[@:"XB26)AAD=<@U;Q
M'[SG2(6'_=\C9XH/BMI:>&EB318QJRQ; YC4INQC=T_2NA^%NLZWX@FFNKZS
MM$M(EVK.EN$9W]!BNJ_X5_X4\[S?[$M,YSC9Q^5=#!;PVL*PP1)%$HPJ(, 4
MIU(<MHHJ%.?->3)****YS<**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFO(D8!=@N?
M6@!U%1?:8?\ GJOYT?:8?^>J_G0!+147VF'_ )ZK^='VF'_GJOYT 2T5%]IA
M_P">J_G1]IA_YZK^= $M%1?:8?\ GJOYT?:8?^>J_G0!+147VF'_ )ZK^='V
MF'_GJOYT 2T5%]IA_P">J_G1]IA_YZK^= $M%1?:8?\ GJOYT?:8?^>J_G0!
M+147VF'_ )ZK^='VF'_GJOYT 2T5%]IA_P">J_G1]IA_YZK^= $M%1?:8?\
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M_P">J_G1]IA_YZK^=.[M85E>Y+147VF'_GJOYT?:8?\ GJOYTADM%1?:8?\
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MHHH **** "BBB@ HHHH *P?&$CP^';R6-RCI#(RL#@@[3S6]7/>-?^18OO\
MKWD_]!-..Z-:"O5BGW7YGA?_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%
M>ARKL?IGU>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$
MAUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#
M6;11RKL'U>C_ "+[D:7_  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP
M?5Z/\B^Y&E_PD.L?]!.Z_P"_AH_X2'6/^@G=?]_#6;11RKL'U>C_ "+[D:7_
M  D.L?\ 03NO^_AH_P"$AUC_ *"=U_W\-9M%'*NP?5Z/\B^Y&E_PD.L?]!.Z
M_P"_AKW+P3-)/X<M9979Y'B4LS'))KY[KZ!\"?\ (K6?_7%*PKI)*Q\[Q'2I
MPHP<8I:]O(Z:BBBN4^0"BBB@ HHHH **** "BBB@ KGO&O\ R+%]_P!>\G_H
M)KH:Y[QK_P BQ??]>\G_ *":<=T;8?\ C0]5^9\\T445Z)^HES2M,GUC5(-/
MMB@FF)"ES@=">?RK4\1^#]1\,1V\E\\#"<L%\IB>F,YX'K4G@'_D>-+_ .NC
M?^@-7;?&+_CSTG_KI)_):RE-J:B>37QE6&84\.OADKO\?\CR6BO09_A+JB11
M-!>0S,[ $;2NT'J2<U-=?"&_BLS)!J,4TX4GRO+*@GT!S3]K#N:?VO@M/WBU
M]3SBBO0=)^$^I7EJLU]=)9LPXB*[V'UYKGO%/A&]\+7,:7#K-!+GRYD& <=0
M1V--3BW9,UI9CA:M7V4)IR.?HKNK;X8ZC>:%;ZE;7<3M/$DJ0[<'YL<9SVS6
MA_PI^]^R[O[4A\_^YY9Q],YI>UAW,Y9M@HNSJ+>W4\UHKO=)^%6K7H=KZ9+)
M58J 1O+8[\'I69XK\"WWA>)+AIDN;5VV^8JX*GT(IJI%NUS2&986=7V49IR_
MKKL<K179^'?AY=>(=&34H[Z*%&9@$9"3P<>M<QINGOJ6K6^GHX1YI!&&(X'O
M34D[^1K#%T9N:C+X-_(IT5U/BOP5/X5M[:6:\CG$[%0%0C&,>_O5ZP^&E_J6
M@PZG;W<3--&)$AV\G/;.:7/&U[F;S##*FJKG[K=DSB**]+B^#]XUL&EU2))B
M,[!$2![9S7#:YHEYX?U-[&]4"11E67HR]B*(SC)V3##YAAL1)PI3NT9M%==X
M;^'NJ>(+9;LNEK:M]V209+#U ]*V;[X17\$#26>H17#@9\MD*$_CDT.I%.UR
M*F:8.G4]G*HK_P!?(\XHJ6ZM9[*YDMKB-HYHVVLC=0:BJSN335T/AADN)DAA
M1I)'.%51DDUVMA\+->NX5DF:"VW#.UVRP^H%;7PFT*&07&LS(&=&\J'/;CD_
MTI?&GQ%OK+5I=.TADC6 [9)2H8LW<#/3%8RG)RY8GAXG'XFKBGA<&E>.[9@:
MG\,=?L(&FB6*Z51DB)OF_(UQCHR.4=2K X((P0:];\"?$"\U;4UTO52CR2 ^
M5*JA22.Q ]JR?BOH<-G?VVJ6Z!!<Y64 <;AW_'-$9R4N60\)C\1#$_5,6E=[
M-=3SFBNWTWX:W^J:#%J=O=Q$RQ[TAV\GVSFM.'X/WCVH:;5(HYB,[!&6 _'-
M4ZD%U.N>;8.#:E4U3MU/-:*T]=T*\\/:DUE>*-X&59>C#U%;OASX>:IX@M5N
MVD2TMF^X[C)<>H'I5.22N=%3%T*=)5IR2B^IQ]%>BZC\)-0MK9I;.^BN749\
MLH4)^AR:X>RTF^U#4UT^VMV:Z+%2G3;CKGTH4XO5,FACL/7BYTYII;^7WE*B
MO2[?X/WCP!KC5(HY2/N+$6 /UR*YCQ+X*U/PT!+.%FM6.!-'T!]".U)5(MV3
M(HYGA*T_9TYILA\.^$=1\3K.UBT"B$@-YK$=?P-9FJ:=-I.ISV%P4,T#;6*'
M(S[5Z7\'O]3J7^\M<5XV4MXVU15!),^ !WX%2I-S<3"AC*D\?4P\OABKK\#G
MJ*[[1_A5J>H6J7%Y<QV8<9"%=S8]^>*CUOX7ZKI=J]S:SI>HG+*J[6 ]<=ZK
MVD;VN:K-,&ZGL_:*_P#778X6BI[6TGO;N.UMXV>>1MJH.I->@V_P@OI+4//J
M4,4Q&?+$98 ^F<TY3C'<VQ.-P^&M[:5KGF]%>@Q?"?5##,\]Y#"8R<#:6W =
M^M9_ASP!-XCLYIX=1AB,4IC9"A)&._6E[2.]S+^T\)RN:GHM]^IQU%6[_3YM
M/U.:PE&9HI/+..YKJ]3^'-SI6@/JMSJ,(58P_E[#G)[9SUIN21O4Q=&GR\TO
MBV\SB:?##)<3I#$I:1V"JH[DTRN[^%NCK?\ B%[R5<I:+N7/3<>E$I<JN&+Q
M"P]&55]$9>O>"KOP_#9M<W,+2W3!5B7.0?>G:UX!U?0M*.HW;VQA! (1R3S^
M%:/CW5#J'CR* -F.UD2,#WR":[KXD_\ (BR_[\=9<\ERWZGC?7\5!X=3:O4W
MT]/T/$;2TN+ZY2WM87EF<X5%&2:[:T^%&NSQ!YY;: G^$L6(^N*Z7X5:%#!I
M3ZQ(H,\S%4)_A4>GUK&\4?$S4AJLUKI#I#;PL4W[ Q<COSTH<Y2ERQ*K8[%5
M\3+#X-)<N[9D:K\-=>TR!IT2.ZC49/DG+#\#7+6=J;J^AM2ZQ&1PFY^BY..:
M]<\ ^/+G7;QM,U/8UP5+1RJN-V.H(''2N8^*&B1:5KL-]:H$2[!9@HX#CJ?Q
MS3C.7-RR+PF/Q"Q#PF*24K:-&%XG\(WWA>2$7+)+',#MD0<9':N?KVRYB7QA
M\,$D;YKE(=RGOO3_ !Q^M>)U5.3DM=SJRS%SQ$)1J_'%V84445H>D%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&EM>18\R'3%=,^NP8KDOA9K.H7^KZC%=W4LZM&)/WC9P<_\ UZZ.3_DDB?\
M8+3_ - %<=\(?^0[??\ 7N/_ $*I27+)G)2IP>#Q4FM;_J/^)7B/4K7Q1':6
MMU)#%;(CA4;&6/.3^E=?\0\2^ ;EV'/[MOQW"O.OB?\ \CM<?]<X_P#T$5Z)
MX_\ ^2>7'^[%_P"A"FTER&LZ<8+!.*M=K_VT;\,N? T'^_)_Z$:\H\*#/C33
M?^OH?SKTKX4ZI;3>'FT[S%%S!*Q\LGDJ><C]:6P\!Z3X<\0)JUQJ'R&;%M"_
M'SL< >_6CF4923''$PPN(Q4*E[RVTWW_ ,RG\8?^0=IG_75_Y"NB\/7367PW
MMKM "T%@9 #ZJI/]*YWXP_\ (.TS_KJ_\A6UIG_))O\ N%R?^@&I_P"7:]3E
MDD\MH)_S/\V<7\/O$6J7OC18[J]EF2Y5]ZNV1D#(X_"KWQ1MDN?%&BPMP)E$
M;'V+X_K7.?#;_D>++_=?_P!!-;_Q;E:'6]+E0X=(BRGT(:M6K558]6K34,V@
MJ:M[O^9V/C74Y?#G@]GT\")\K#&5'W 1U'Y5Q/PX\4:I/XC%A=W4MQ#.K'$C
M;MK#G(KM;._TCQ[X9^RR2J'D0"2(-AXW'<?XU7\/^"M+\'33:G/>%V"D"2;"
MA%[_ (UDFE%Q:U/)HU:%'"U</7A^];?37RU.:^)&C077C#2E4B,WNV.1E'.=
MV,_E5_\ X4_8?]!.Y_[Y7_"N-\<>*!K?B1;FQ=EAM0$@D7@G!SN_.LS_ (2S
MQ#_T&;W_ +_&M5&?*K.Q[5+"8_ZM2C3J<C2U3_#\#V?P3I\6D:?>:;#(9!;7
M3H6;J>_->+>*()+?Q1J4<H(<3L>>_/6NB\"^-FTG5IUU69Y+>\8,\K')5_[Q
MKT+6_"&A^,-E\LV)2,>?;L#N';/:I3]G.\NIQPJ2RS&RGB-8S6_F>3^ X))_
M&FFB,'Y7+,1V !KOOB](@T6QC.-[3$C\!S_.MW1_#>A>";>6Z,P5R,-<7##.
M/0?_ %J\K\=^*%\2ZP#;Y%G;@I%G^+U;\::?/--;(TI5'F&8QK4D^2"W^_\
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M%% !1110 4444 %%%% !1110 4444 %?0/@3_D5K/_KBE?/U?0/@3_D5K/\
MZXI7/B-D?-\3?P(>OZ'34445RGQ@4444 %%%% !1110 4444 %<]XU_Y%B^_
MZ]Y/_0370USWC7_D6+[_ *]Y/_033CNC;#_QH>J_,^>:***]$_4159D8,I((
MZ$'%.>623&^1VQTW'-,HH"Q(T\KKM:5V7T+$BD262/.R1ESUVG%,HH%9"EV+
M[RQ+9SG/-.>:608>1V'HS$TRB@=D2>?+LV>:^W&-NXXIJ2/&<H[*?53BFT4"
MLAS.SMN=BQ]2<TYIY77:TKLOH6)%1T4!9#XY9(7#Q.R,.A4X-237EU<,&FN)
M9".A9B<5!10'*KWL/>620 /([8Z;FS2B>4)L$K[<8V[CBHZ* LA5=D;<C%3Z
M@XI7D>0@N[,1_>.:;10.P^.62)MT;LC>JG%237MU<?ZZXED[?,Y-044"Y4W>
MP4444#"IX;VZMO\ 4W$L?^ZQ%044":3T9--=W%R<SSR2?[S$U#110"26B)!/
M*$V"5PO3&XXIBLR-N5BI'<'%)10%D.>220@N[-C^\<TL<LD+;HY&0^JG%,HH
M"RM8GGO+FY_U]Q+)_O,34%%% )):(L1W]Y#&4CNID0]5#D"H&=G;<S%CZDYI
M** 44M4AZ2R1YV2,N>NTXIK,68LQ))ZDFDHH'8EANKBV.8)I(S_L,1237$UP
MVZ:5Y#ZLQ-1T4"Y5>]C=\(7FG67B&%]5ACELW!1Q(NX+GH<5ZGJ/@SPWKD,3
M6%W':*.<VCKAA[BO#Z>LLBC"R,![&LY0;=T['FXS 3K5%5I5'!KYK[CW*_U'
M1O!/A1[&WN4DD$;+''O!=V/<XZ5YYX)\+Z=XG>Z:_O)(7C8$*C*-P/7K7',S
M,<LQ)]S2J[I]UF7Z'%)4[)V>I%#+)4:4XPJ/GD[N7_ /</%FOZ=X:\+-I]C-
M&9S'Y,,:,"5'0DXKPWJ<TK,S'+$D^I-)50ARHWR_ 1P<'%.[;NV%;_@[7/[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\
MII_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_
M  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\
MII_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@
MT4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^
MT\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?W
MGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK
M2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W
M\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK
M2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W
M\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>T
MEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_
MS\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_
M  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\
MII_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_
M  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\
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M^%5:5_TT_P"_AKT&BCVDNX?VGC/^?C^\\^_X55I7_33_ +^&C_A56E?]-/\
MOX:]!HH]I+N']IXS_GX_O//O^%5:5_TT_P"_AH_X55I7_33_ +^&O0:*/:2[
MA_:>,_Y^/[SS[_A56E?]-/\ OX:/^%5:5_TT_P"_AKT&BCVDNX?VGC/^?C^\
M\^_X55I7_33_ +^&C_A56E?]-/\ OX:]!HH]I+N']IXS_GX_O//O^%5:5_TT
M_P"_AH_X55I7_33_ +^&O0:*/:2[A_:>,_Y^/[SS[_A56E?]-/\ OX:/^%5:
M5_TT_P"_AKT&BCVDNX?VGC/^?C^\\^_X55I7_33_ +^&C_A56E?]-/\ OX:]
M!HH]I+N']IXS_GX_O//O^%5:5_TT_P"_AH_X55I7_33_ +^&O0:*/:2[A_:>
M,_Y^/[SS[_A56E?]-/\ OX:/^%5:5_TT_P"_AKT&BCVDNX?VGC/^?C^\\^_X
M55I7_33_ +^&C_A56E?]-/\ OX:]!HH]I+N']IXS_GX_O//O^%5:5_TT_P"_
MAH_X55I7_33_ +^&O0:*/:2[A_:>,_Y^/[SS[_A56E?]-/\ OX:/^%5:5_TT
M_P"_AKT&BCVDNX?VGC/^?C^\\^_X55I7_33_ +^&C_A56E?]-/\ OX:]!HH]
MI+N']IXS_GX_O//O^%5:5_TT_P"_AH_X55I7_33_ +^&O0:*/:2[A_:>,_Y^
M/[SS[_A56E?]-/\ OX:/^%5:5_TT_P"_AKT&BCVDNX?VGC/^?C^\\^_X55I7
M_33_ +^&C_A56E?]-/\ OX:]!HH]I+N']IXS_GX_O//O^%5:5_TT_P"_AH_X
M55I7_33_ +^&O0:*/:2[A_:>,_Y^/[SS[_A56E?]-/\ OX:/^%5:5_TT_P"_
MAKT&BCVDNX?VGC/^?C^\\^_X55I7_33_ +^&C_A56E?]-/\ OX:]!HH]I+N'
M]IXS_GX_O//O^%5:5_TT_P"_AH_X55I7_33_ +^&O0:*/:2[A_:>,_Y^/[SS
M[_A56E?]-/\ OX:/^%5:5_TT_P"_AKT&BCVDNX?VGC/^?C^\\^_X55I7_33_
M +^&C_A56E?]-/\ OX:]!HH]I+N']IXS_GX_O//O^%5:5_TT_P"_AH_X55I7
M_33_ +^&O0:*/:2[A_:>,_Y^/[SS[_A56E?]-/\ OX:/^%5:5_TT_P"_AKT&
MBCVDNX?VGC/^?C^\\^_X55I7_33_ +^&C_A56E?]-/\ OX:]!HH]I+N']IXS
M_GX_O//O^%5:5_TT_P"_AH_X55I7_33_ +^&O0:*/:2[A_:>,_Y^/[SS[_A5
M6E?]-/\ OX:/^%5:5_TT_P"_AKT&BCVDNX?VGC/^?C^\\^_X55I7_33_ +^&
MC_A56E?]-/\ OX:]!HH]I+N']IXS_GX_O//O^%5:5_TT_P"_AH_X55I7_33_
M +^&O0:*/:2[A_:>,_Y^/[SS[_A56E?]-/\ OX:/^%5:5_TT_P"_AKT&BCVD
MNX?VGC/^?C^\\^_X55I7_33_ +^&C_A56E?]-/\ OX:]!HH]I+N']IXS_GX_
MO//O^%5:5_TT_P"_AH_X55I7_33_ +^&O0:*/:2[A_:>,_Y^/[SS[_A56E?]
M-/\ OX:/^%5:5_TT_P"_AKT&BCVDNX?VGC/^?C^\\^_X55I7_33_ +^&C_A5
M6E?]-/\ OX:]!HH]I+N']IXS_GX_O//O^%5:5_TT_P"_AH_X55I7_33_ +^&
MO0:*/:2[A_:>,_Y^/[SS[_A56E?]-/\ OX:/^%5:5_TT_P"_AKT&BCVDNX?V
MGC/^?C^\\\;X5Z4JECYF ,_ZPTD7PNTF6,.OF8/K(:]!F_U,G^Z?Y5%9?\><
M?TH]I+N']IXS_GX_O.&_X55I7_33_OX:/^%5:5_TT_[^&O0:*/:2[A_:>,_Y
M^/[SS[_A56E?]-/^_AH_X55I7_33_OX:]!HH]I+N']IXS_GX_O//O^%5:5_T
MT_[^&C_A56E?]-/^_AKT&BCVDNX?VGC/^?C^\\^_X55I7_33_OX:/^%5:5_T
MT_[^&O0:*/:2[A_:>,_Y^/[SS[_A56E?]-/^_AH_X55I7_33_OX:]!HH]I+N
M']IXS_GX_O//O^%5:5_TT_[^&C_A56E?]-/^_AKT&BCVDNX?VGC/^?C^\\^_
MX55I7_33_OX:/^%5:5_TT_[^&O0:*/:2[A_:>,_Y^/[SS[_A56E?]-/^_AH_
MX55I7_33_OX:]!HH]I+N']IXS_GX_O//O^%5:5_TT_[^&C_A56E?]-/^_AKT
M&BCVDNX?VGC/^?C^\\^_X55I7_33_OX:/^%5:5_TT_[^&O0:*/:2[A_:>,_Y
M^/[SS[_A56E?]-/^_AH_X55I7_33_OX:]!HH]I+N']IXS_GX_O//O^%5:5_T
MT_[^&C_A56E?]-/^_AKT&BCVDNX?VGC/^?C^\\^_X55I7_33_OX:/^%5:5_T
MT_[^&O0:*/:2[A_:>,_Y^/[SS[_A56E?]-/^_AH_X55I7_33_OX:]!HH]I+N
M']IXS_GX_O//O^%5:5_TT_[^&C_A56E?]-/^_AKT&BCVDNX?VGC/^?C^\\^_
MX55I7_33_OX:/^%5:5_TT_[^&O0:*/:2[A_:>,_Y^/[SS[_A56E?]-/^_AH_
MX55I7_33_OX:]!HH]I+N']IXS_GX_O//O^%5:5_TT_[^&C_A56E?]-/^_AKT
M&BCVDNX?VGC/^?C^\\^_X55I7_33_OX:/^%5:5_TT_[^&O0:*/:2[A_:>,_Y
M^/[SS[_A56E?]-/^_AH_X55I7_33_OX:]!HH]I+N']IXS_GX_O//3\*M* _Y
M:?\ ?PTR'X7Z1-'O7S<9QS(:]$/W3]*K6'_'M_P(T>TEW#^T\9_S\?WG$?\
M"JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"F
MG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\
M"JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\ "JM*_P"F
MG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#1
M1[27</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3
MQG_/Q_>>??\ "JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>
M??\ "JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*
M_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"FG_?P
MT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\ "JM*
M_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\ "JM*_P"FG_?P
MUZ#11[27</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27
M</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/
MQ_>>??\ "JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\
M"JM*_P"FG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"F
MG_?PT?\ "JM*_P"FG_?PUZ#11[27</[3QG_/Q_>>??\ "JM*_P"FG_?PT?\
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M  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\
MII_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_
M  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\
MII_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@
MT4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^
MT\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?W
MGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK
M2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W
M\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK
M2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W
M\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>T
MEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_
MS\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_
M  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\
MII_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_
M  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\
MII_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@
MT4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^
MT\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?W
MGGW_  JK2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK
M2O\ II_W\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W
M\-'_  JK2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK
M2O\ II_W\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-'_  JK2O\ II_W
M\->@T4>TEW#^T\9_S\?WGGW_  JK2O\ II_W\-=9H-BFF6ALHL[( $7)SP*U
M:J6G_'Q<_P"_2<F]V8UL77KI*K-M>9;HHHJ3G"BBB@ HHHH **** "BBB@ J
MI>?ZVV_ZZ"K=5+S_ %MM_P!=!0!;HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* *LW_'];_1JM55F_P"/ZW^C5:H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DW^ID_P!T
M_P JBLO^/./Z5+-_J9/]T_RJ*R_X\X_I0!8HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** $/W3]*K6'_'M_P(U9/W3]*K6'_'M_P(T 6J***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JII_\ Q['_ 'S5NJFG
M_P#'L?\ ?- %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MJV'^I?\ WS5JJMA_J7_WS0!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *J6G_'Q<_[]6ZJ6G_'Q<_[] %NBBB@ HHHH
M **** "BBB@ HHHH *J7G^MMO^N@JW52\_UMM_UT% %NBBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH JS?\?UO]&JU56;_C^M_HU6J "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 9-_J9/]T_RKS:'XMV$$0B.EW)*\9#K7I,W^ID_W3_*OEV3_ %C_ %-;
M48*5[GOY'@*&+]I[97M:VO>YZY_PN'3_ /H%7/\ W\6C_A<.G_\ 0*N?^_BU
MY#16_L8'T']@X'^7\6>O?\+AT_\ Z!5S_P!_%H_X7#I__0*N?^_BUY#11[&
M?V#@?Y?Q9Z]_PN'3_P#H%7/_ '\6C_A<.G_] JY_[^+7D-%'L8!_8.!_E_%G
MKW_"X=/_ .@5<_\ ?Q:/^%PZ?_T"KG_OXM>0T4>Q@']@X'^7\6>O?\+AT_\
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M5S_W\6C_ (7#I_\ T"KG_OXM>0T4>Q@']@X'^7\6>O?\+AT__H%7/_?Q:/\
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M3_\ CV/^^: +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6\51^)['5731[+3?)D0%;48#Y!Y-9?Q"^.:^'=7ET?0[2.ZN8&V332'Y5;T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]\U;JII__'L?]\T 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JK8?ZE_]\U:JK8?ZE_\ ?- %JBBB@ HHHH **** "BBB@ HHHH ****
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M)&"3C@<T >1_##XNZ]XQ\8II.H0VJP- \A,:X.1C_&O6/%2A?!FMA0 !I\_
M_P"N;5+8^'=&TVX^T66F6MO-@KOCC .*C\5_\B=KG_8/G_\ 1;4 ?.'[//\
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M/H **Y:]\?Z)8>,[?PK.TXU*XV[ (\I\V<<_A74T %%%% !17)ZW\1-"\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW17/^$?&6D^-=-EO](:8PQ2^4WFIM.[ /]:A\3^/_#GA#"ZMJ"I,>D,8W/\
MD* .FHKSK2OC;X*U6\2V6^EMW=MJM<1%%_.O0T=)8U=&#(PR&!R"* '45Q_B
M;XG>%O"=S]FU*_S<CK#"N]E^H'2J>@?&#P=XAO$L[>_>"=SA5N4V!CZ T =Y
M11UHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J
M6G_'Q<_[]6ZJ6G_'Q<_[] %NBBB@ HHHH **** "BBB@ HHHH *J7G^MMO\
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ME 'T1X<^*&A>*]<?2]'BO)VCSOF$)$:@=R?0]J[:N>\'>$=*\':'%8:7&""
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MZWTG3+;3[5=L%O&(T'L*MT %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA:VL8BC#MD[1ZGO0!X=X]_Y.4\,?]NO_ *,>H/BJL_@[XSZ-XP:%GLI?*9V
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M5FE6!B&:/!#=/3(/X&M;Q+\+?"_BO65U;4K:;[6%52\,I3=CH2.YKLBJE-A
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M1Y7.2[!ADD_6JOPC\<>&-'^&FEV.HZU:6UU&9=\4C8*YE8C]"*],\1^'=/\
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MP#"!VW'\ZTJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M* "BBB@ HHHH X_QU\.=)\?+9?VE-<1/:;O+:$@<-C(.1_LBM/PGX1TGP9I
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M3_\ CV/^^: +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=I^@1:)#;)]@2'R/*(X9<8.?7-?.NJ_!+QCI'BV2[\,0I):PSB6TG-PB,O<
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M>'[)[F:\<),58#;&.3^9Q3_A5X)_X0KPC'!<(!J-R?-NCUPW9?P% '=4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 59O^/ZW^C5:JK-_Q_6_T:K5 !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ,F_U,G^Z?Y5\E2G]Z_P#O&OK6;_4R?[I_E7B"?!K6;A?-74K !B2
M=_\ \36M*25[GMY/B:5#G]I*U[?J>;9HS7I?_"E-;_Z">G_^/_\ Q-'_  I3
M6_\ H)Z?_P"/_P#Q-;>TCW/;_M+"_P Z/-,T9KTO_A2FM_\ 03T__P ?_P#B
M:/\ A2FM_P#03T__ ,?_ /B:/:1[A_:6%_G1YIFC->E_\*4UO_H)Z?\ ^/\
M_P 31_PI36_^@GI__C__ ,31[2/</[2PO\Z/-,T9KTO_ (4IK?\ T$]/_P#'
M_P#XFC_A2FM_]!/3_P#Q_P#^)H]I'N']I87^='FF:,UZ7_PI36_^@GI__C__
M ,31_P *4UO_ *">G_\ C_\ \31[2/</[2PO\Z/-,T9KTO\ X4IK?_03T_\
M\?\ _B:/^%*:W_T$]/\ _'__ (FCVD>X?VEA?YT>:9HS7I?_  I36_\ H)Z?
M_P"/_P#Q-'_"E-;_ .@GI_\ X_\ _$T>TCW#^TL+_.CS3-&:]+_X4IK?_03T
M_P#\?_\ B:/^%*:W_P!!/3__ !__ .)H]I'N']I87^='FF:,UZ7_ ,*4UO\
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M-'M(]P_M+"_SH\XS1FO2_P#A2FM_]!/3_P#Q_P#^)H_X4IK?_03T_P#\?_\
MB:/:1[A_:6%_G1YIFC->E_\ "E-;_P"@GI__ (__ /$T?\*4UO\ Z">G_P#C
M_P#\31[2/</[2PO\Z/-,T9KTO_A2FM_]!/3_ /Q__P")H_X4IK?_ $$]/_\
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MQ1J%1%& !Z5)7/.;DSY?&XV>*GS2VZ(****DXPHHHH **** "BBB@ JII_\
MQ['_ 'S5NJFG_P#'L?\ ?- %NBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *JV'^I?\ WS5JJMA_J7_WS0!:HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *J6G_'Q<_[]6ZJ6G_'Q<_[]
M %NBBB@ HHHH **** "BBB@ HHHH *J7G^MMO^N@JW52\_UMM_UT% %NBBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH JS?\?UO]&JU56;_C^M_HU6J "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH 9-_J9/]T_RJ*R_X\X_I4LW^ID_W3_*HK+_CSC^E %BB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0_=/TJM8?\ 'M_P
M(U9/W3]*K6'_ ![?\"- %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *J:?_P >Q_WS5NJFG_\ 'L?]\T 6Z*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ JK8?ZE_\ ?-6JJV'^I?\ WS0!:HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J6G_'Q<_[
M]6ZJ6G_'Q<_[] %NBBB@ HHHH **** "BBB@ HHHH *J7G^MMO\ KH*MU4O/
M];;?]=!0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *LW_ !_6_P!&JU56
M;_C^M_HU6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 9-_J9/]T_RJ*R_X\X_I4LW^ID_
MW3_*HK+_ (\X_I0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** $/W3]*K6'_'M_P(U9/W3]*K6'_'M_P(T 6J*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ JII__'L?]\U;JII__'L?]\T 6Z*** "BBB@
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MT>3=?\_ _P"^:M44 5?)NO\ GX'_ 'S1Y-U_S\#_ +YJU10!5\FZ_P"?@?\
M?-'DW7_/P/\ OFK5% %7R;K_ )^!_P!\T>3=?\_ _P"^:M44 5?)NO\ GX'_
M 'S1Y-U_S\#_ +YJU10!5\FZ_P"?@?\ ?-'DW7_/P/\ OFK5% %7R;K_ )^!
M_P!\T>3=?\_ _P"^:M44 5?)NO\ GX'_ 'S1Y-U_S\#_ +YJU10!5\FZ_P"?
M@?\ ?-'DW7_/P/\ OFK5% %7R;K_ )^!_P!\T>3=?\_ _P"^:M44 5?)NO\
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M HHHH **** "BBB@ HHHH *J7G^MMO\ KH*MU4O/];;?]=!0!;HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** *LW_ !_6_P!&JU56;_C^M_HU6J "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH 9-_J9/]T_RJ*R_X\X_I4LW^ID_W3_*HK+_ (\X_I0!8HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/W3]*K6'_'M_P(U9
M/W3]*K6'_'M_P(T 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JII__'L?]\U;JII__'L?]\T 6Z*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JK8?ZE_]\U:JK8?ZE_\ ?- %JBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI:?\ 'Q<_[]6ZJ6G_
M !\7/^_0!;HHHH **** "BBB@ HHHH **** "JEY_K;;_KH*MU4O/];;?]=!
M0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** *LW_'];_1JM55F_X_K?Z-5J
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAC_GYF_[\-_A7A5%'L(A_JY@^\OO7^1[K_PL_P ,?\_,W_?AO\*/^%G^&/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %5+3_CXN?]^K=5+3_CXN?]^@"W11
M10 4444 %%%% !1110 4444 %5+S_6VW_705;JI>?ZVV_P"N@H MT444 %8/
MC+Q/!X/\*WNM31B7R% CBW;?,<G 7/\ GI6]7SU^T;XFWW&G>&H'^6,?:K@
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M^^:MU4T__CV/^^: +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 55L/]2_^^:M55L/]2_\ OF@"U1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML?TK@U^/&JZO96D/AWPO+?:HZ%[F--\BP_,0 ,#+< '/'6KMW_R:\G_7@/\
MT96C\ -,MK3X=B]CB47%W<.9),<D+P!GT'/YF@#&T3]H&**2]M/%>D26%W;H
M2JQ DNX_@*GE3]>/I5*\^.7BZTC75)?!;PZ,Y'ERRB0!@>GS[<?I6=X^TJTO
M?VC='MIHE:&Y:V:92.'^8@Y^H4"O9_B%!%-\./$<<B*RKIL[ $< JA(/X$"@
M"SX1\467C#PW;:S8AECFR&C;[T;@X*G_ #TQ7 >+?C6FF^('T#PSI$FLZBCF
M-RA.T,.JJ%!+$=^E9?P8OYK#X):_>Q9,EK/=21CW6%&'ZU!^S?I5LVGZSK+H
M'O&F6W#MR57&XX^I(_*@"Q;_ !PUG1-2@M?&GA2?3H9C_KE5E('J%8<CUP:]
M;N=9@7PU-K=FRW,"VK7,1!P)%"[AS[US7Q=TBUU;X::Q]HC4O:PFYA<]4=.>
M/J,C\:Y#X4WTMY\!M5CE9B+47<";C_#Y8;CV^<T 8Q_:*OKK342P\.J^J/*P
M,8D9T6, 8/ R226X[8]ZZ,?&P6/P_M=>U71S'J%W/)#:V<<AQ,$QN?)'R@$X
M[\UB_LV:9 -.UO56C4SM*ENKD<JH&X@?4D?E6U\;_ ^K^(;?3-8T*(SW.FE]
M]NG+,&*D%1W((Y'?- &3)\7_ ![96AU2]\!R+IFW=O(D3"^I8J>/?%>F>!?&
M^G^.]!_M*R1X7C?RYX'.6C;&?Q![&O(K+X^:C9HVF^+_  RS97RYC&#&Q&,'
M*-Z_45Z5\,)O!-SHL\_@R!;>-V7[3"68R(PSC<&)]^1P: .ZHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &3?ZF3_=/\
MJ^59#^]?_>-?54W^ID_W3_*OE.0_O7_WC710ZGTW#CUJ?+]0S1FFYHS70?47
M'9HS3<T9H"X[-&:;FC- 7'9HS3<T9H"X[-&:;FC- 7'9HS3<T9H"X[-&:;FC
M- 7'9HS3<T9H"X[-&:;FC- 7'9HS3<T9H"X[-&:;FC- 7'9HS3<T9H"X[-&:
M;FC- 7'9HS3<T9H"X[-&:;FC- 7'9HS3<T9H"X[-&:;FC- 7'9HS3<T9H"X[
M-&:;FC- 7'9HS3<T9H"X[-&:;FC- 7'9HS3<T9H"X[-&:;FC- 7)(Y7BD62-
MRKJ<JRG!!KW#X>>-W\00_P!G7P8WT*9$H'$BCN?0UXYHFBWNOZE'8V,9>1OO
M-V0=R3Z5]">%_"]EX7TT6]NH>9N9IB.7/^'M6%9QM9[G@9[6P_LN2:O/IY&Y
M1117,?(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 54T_P#X]C_OFK=5-/\ ^/8_[YH
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M_9VT6\TZVN7UJ]5I8U<@1K@9&:J>)/@%H^B>&M1U.+6+R22U@:549%P2!T-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_A\6*6/]AZ:;1'WK";5"@;&-V,8SCOUK41$CC6.-51% "JHP !V H =3)O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ*** .&^,-TUI\*==D5B&:-(^/\ :D53^A-><_LTVR[?$%T1\Y,,8/H/F/\
M6O3?BMI[ZE\+]?MXURRVXFQ[1L'/Z*:\K_9IO%6\\063,-S)#*B^N"P/\UH
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MRX8_=!&:^5_A_&=>^.<-R@R@NYKAO91G^I% 'UG1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!5F_X_K?Z-5JJLW_'];_1JM4 %%%% !1110 4444 %%%% !1110 4444
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MI)SF[MA1112("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J:?_ ,>Q_P!\U;JI
MI_\ Q['_ 'S0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"JMA_J7_ -\U:JK8?ZE_]\T 6J*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_BZ[RB@#C_'VK6W@_P"'&H2PXB"6_P!FMD!_B8;0!GT&3^%>:_L[>%Y$BO\
MQ/=1D&;]Q;,1U&<N1^.!^%>N>*?!^D>,;*&TUB.62")]ZJDA3GIDXZUI:7I=
MGHNF6^G6$(AM;= D:#L!0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JS?\?UO]&JU5
M6;_C^M_HU6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -\U:JK8?ZE_]\T 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "JEI_Q\7/^_5NJEI_Q\7/^_0!;HHHH **** "BBB@
MHHHH **** "JEY_K;;_KH*MU4O/];;?]=!0!;HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** *LW_'];_1JM55F_X_K?Z-5J@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &3
M?ZF3_=/\JBLO^/./Z5+-_J9/]T_RJ*R_X\X_I0!8HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** $/W3]*K6'_ ![?\"-63]T_2JUA_P >W_ C
M0!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JFG_\ 'L?]
M\U;JII__ !['_?- %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *JV'^I?_ 'S5JJMA_J7_ -\T 6J*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "JEI_Q\7/^_5NJEI_Q\7/^_0!;HHH
MH **** "BBB@ HHHH **** "JEY_K;;_ *Z"K=5+S_6VW_704 6Z*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"K-_P ?UO\ 1JM55F_X_K?Z-5J@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** &3?ZF3_=/\JBLO^/./Z5+-_J9/]T_RJ*R_P"/./Z4 6**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#]T_2JUA_Q[?\"-
M63]T_2JUA_Q[?\"- %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *J:?_Q['_?-6ZJ:?_Q['_?- %NBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *JV'^I?_?-6JJV'^I?_ 'S0!:HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\^D'_?;_ .-'_"Y=;_Y](/\ OM_\:\WHH]A3[![>IW/2/^%RZW_SZ0?]]O\
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M76_^?2#_ +[?_&O-Z*/84^P>WJ=STC_A<NM_\^D'_?;_ .-'_"Y=;_Y](/\
MOM_\:\WHH]A3[![>IW/2/^%RZW_SZ0?]]O\ XT?\+EUO_GT@_P"^W_QKS>BC
MV%/L'MZG<]'/QCUDL&-E;DCH=[\?K2_\+EUO_GT@_P"^W_QKS>BCV%/L'MZG
M<](_X7+K?_/I!_WV_P#C1_PN76_^?2#_ +[?_&O-Z*/84^P>WJ=STC_A<NM_
M\^D'_?;_ .-'_"Y=;_Y](/\ OM_\:\WHH]A3[![>IW/2/^%RZW_SZ0?]]O\
MXT?\+EUO_GT@_P"^W_QKS>BCV%/L'MZG<](_X7+K?_/I!_WV_P#C1_PN76_^
M?2#_ +[?_&O-Z*/84^P>WJ=STC_A<NM_\^D'_?;_ .-'_"Y=;_Y](/\ OM_\
M:\WHH]A3[![>IW/2/^%RZW_SZ0?]]O\ XT?\+EUO_GT@_P"^W_QKS>BCV%/L
M'MZG<](_X7+K?_/I!_WV_P#C1_PN76_^?2#_ +[?_&O-Z*/84^P>WJ=STC_A
M<NM_\^D'_?;_ .-'_"Y=;_Y](/\ OM_\:\WHH]A3[![>IW/2/^%RZW_SZ0?]
M]O\ XT?\+EUO_GT@_P"^W_QKS>BCV%/L'MZG<](_X7+K?_/I!_WV_P#C1_PN
M76_^?2#_ +[?_&O-Z*/84^P>WJ=STC_A<NM_\^D'_?;_ .-'_"Y=;_Y](/\
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MO_C1_P +EUO_ )](/^^W_P :\WHH]A3[![>IW/2/^%RZW_SZ0?\ ?;_XT?\
M"Y=;_P"?2#_OM_\ &O-Z*/84^P>WJ=STC_A<NM_\^D'_ 'V_^-'_  N76_\
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MO_C1_P +EUO_ )](/^^W_P :\WHH]A3[![>IW/2/^%RZW_SZ0?\ ?;_XT?\
M"Y=;_P"?2#_OM_\ &O-Z*/84^P>WJ=STC_A<NM_\^D'_ 'V_^-'_  N76_\
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M\:/^%RZW_P ^D'_?;_XUYO11["GV#V]3N>D?\+EUO_GT@_[[?_&C_A<NM_\
M/I!_WV_^->;T4>PI]@]O4[GI'_"Y=;_Y](/^^W_QH_X7+K?_ #Z0?]]O_C7F
M]%'L*?8/;U.YZ1_PN76_^?2#_OM_\:/^%RZW_P ^D'_?;_XUYO11["GV#V]3
MN>D?\+EUO_GT@_[[?_&D7XQZR@PME;J/0.P_K7G%%'L*?8/;U.YZ1_PN76_^
M?2#_ +[?_&C_ (7+K?\ SZ0?]]O_ (UYO11["GV#V]3N>D?\+EUO_GT@_P"^
MW_QH_P"%RZW_ ,^D'_?;_P"->;T4>PI]@]O4[GI'_"Y=;_Y](/\ OM_\:/\
MA<NM_P#/I!_WV_\ C7F]%'L*?8/;U.YZ1_PN76_^?2#_ +[?_&C_ (7+K?\
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MW_QH_P"%RZW_ ,^D'_?;_P"->;T4>PI]@]O4[GI'_"Y=;_Y](/\ OM_\:/\
MA<NM_P#/I!_WV_\ C7F]%'L*?8/;U.YZ1_PN76_^?2#_ +[?_&C_ (7+K?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO/L:N/-1M#N<C\%&<>-)E&=ALWW?7<N/ZUM_%15'Q&\-D?>/E9_[^FNK\">
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MX@>!'?RQ''?0LC1YW&)QQU]C@_E4/GIRC)JUM"UR5(RBG>^IYY\"O^/W6/\
MKG'_ #-<Q\6?^2A7O^Y'_P"@BNM^"MK+8ZUKUI.NV:$+&X]"&(-7/&WPMU?Q
M-XIN-4M;RQBAE5 %E9PPP,=E(_6M.>,:[;?0SY)2H))=3 ^!K/\ \)1J"C/E
MFR)/UWKC^M;_ (J2(_''P]NQDPQD_4,^*Z+P/X)M_ EA=W-W>)+<2J#-+C:D
M:CG S^>:\=\3^,&U#XA_V]9G,5K*GV?/=4/'YG)_&DOWE1N.UAO]W32EO<]&
M^.1D_P"$;TX#_5F[Y^NQL?UKPFOIS4K/2OB5X,"P7 $<P$D<@&6AD'8CU'((
M]ZX/0?@I>V^M13:O>VKV43ABD!8M)CL<@8%.C5C"%I;H5:E*<[QV9Y"Z.C$.
MI4^A%?2W@013_#>QCTB:.&4P,OF;0VR7G)8=^><5S'QHU32X=*ATT0VTFIS,
MK;]@,D48[YZC)&/SI/"'@F>#PPNJ^'/$]VMS<0B1(P%\GS,?==3GH>,T5)*I
M33>@Z473J-+4WH;CQ_H*7#7UK:^((\9C-O((77Z@KS^ )KPKQ1J3ZIXEN[Z7
M3_[/FD?,EOS\K#KG('-?07A&X\:R7$T/B>RLXH$3]W-$XW.V?0$C&,^E>1_%
M^2TF\>.+4J76!%G*_P#/3)Z^^-M*@_?:LOD%=>XG=_,])\5*-6^#/G2#<YL8
M9\^C *3_ %KYWKZ'\5N-)^#(@DX?[#!!CU8A0?ZU\\5IAOA?J9XGXEZ!1117
M2<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$*Z^]Z3JBD$3^6G9=OW<8Z<=*R**.6/8.:7<ZAOB)XK?4H[]M7D-Q&FP$1H
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MM:HZ"S\;>(M/U*\U&UU'R[N\(,\@AC._'3@K@?@*T/\ A:?C3_H-'_P&B_\
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MQJO2IPY(J(ZD^>3D%%%%:&84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P# ;_[*O<**/K%3N'U>GV/#_P#A2-U_T%C_ . W_P!E1_PI&Z_Z"Q_\!O\
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M_@-_]E1_PI&Z_P"@L?\ P&_^RKW"BCZQ4[A]7I]CP_\ X4C=?]!8_P#@-_\
M94?\*1NO^@L?_ ;_ .RKW"BCZQ4[A]7I]CP__A2-U_T%C_X#?_94?\*1NO\
MH+'_ ,!O_LJ]PHH^L5.X?5Z?8\/_ .%(W7_06/\ X#?_ &5'_"D;K_H+'_P&
M_P#LJ]PHH^L5.X?5Z?8\/_X4C=?]!8_^ W_V5'_"D;K_ *"Q_P# ;_[*O<**
M/K%3N'U>GV/#_P#A2-U_T%C_ . W_P!E1_PI&Z_Z"Q_\!O\ [*O<**/K%3N'
MU>GV/#_^%(W7_06/_@-_]E1_PI&Z_P"@L?\ P&_^RKW"BCZQ4[A]7I]CP_\
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M_P !O_LJ]PHH^L5.X?5Z?8\/_P"%(W7_ $%C_P" W_V5'_"D;K_H+'_P&_\
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M_P !O_LJ]PHH^L5.X?5Z?8\/_P"%(W7_ $%C_P" W_V5'_"D;K_H+'_P&_\
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M_P !O_LJ]PHH^L5.X?5Z?8\/_P"%(W7_ $%C_P" W_V5'_"D;K_H+'_P&_\
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M_P !O_LJ]PHH^L5.X?5Z?8\./P2N0"3JQP/^G;_[*D7X*7#J&75\@]#]F_\
MLJ]OF_U,G^Z?Y5%9?\><?TH^L5.X?5Z?8\7_ .%(W7_06/\ X#?_ &5'_"D;
MK_H+'_P&_P#LJ]PHH^L5.X?5Z?8\/_X4C=?]!8_^ W_V5'_"D;K_ *"Q_P#
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M&Z_Z"Q_\!O\ [*O<**/K%3N'U>GV/#_^%(W7_06/_@-_]E1_PI&Z_P"@L?\
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MK_H+'_P&_P#LJ]PHH^L5.X?5Z?8\/_X4C=?]!8_^ W_V5'_"D;K_ *"Q_P#
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MK_H+'_P&_P#LJ]PHH^L5.X?5Z?8\/_X4C=?]!8_^ W_V5'_"D;K_ *"Q_P#
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M/_@-_P#94?\ "D;K_H+'_P !O_LJ]PHH^L5.X?5Z?8\/_P"%(W7_ $%C_P"
MW_V5'_"D;K_H+'_P&_\ LJ]PHH^L5.X?5Z?8\/\ ^%(W7_06/_@-_P#94?\
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M/_@-_P#94?\ "D;K_H+'_P !O_LJ]PHH^L5.X?5Z?8\/_P"%(W7_ $%C_P"
MW_V5'_"D;K_H+'_P&_\ LJ]PHH^L5.X?5Z?8\/\ ^%(W7_06/_@-_P#94?\
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M/_@-_P#94?\ "D;K_H+'_P !O_LJ]PHH^L5.X?5Z?8\/_P"%(W7_ $%C_P"
MW_V5'_"D;K_H+'_P&_\ LJ]PHH^L5.X?5Z?8\/\ ^%(W7_06/_@-_P#94?\
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M_CSC^E2S?ZF3_=/\JBLO^/./Z4 6**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!#]T_2JUA_Q[?\"-63]T_2JUA_Q[?\"- %JBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *J:?_ ,>Q_P!\U;JII_\ Q['_
M 'S0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMA_J7_
M -\U:JK8?ZE_]\T 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "JEI_Q\7/^_5NJEI_Q\7/^_0!;HHHH **** "BBB@
MHHHH **** "JEY_K;;_KH*MU4O/];;?]=!0!;HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** *LW_'];_1JM55F_X_K?Z-5J@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_9=#N_P_R#^UJ_9?C_F>_?\ "RO"G_01;_P'D_\ B:/^%E>%/^@BW_@/)_\
M$UX#NHW4?V70[O\ #_(/[6K]E^/^9[]_PLKPI_T$6_\  >3_ .)H_P"%E>%/
M^@BW_@/)_P#$UX#NHW4?V70[O\/\@_M:OV7X_P"9[]_PLKPI_P!!%O\ P'D_
M^)H_X65X4_Z"+?\ @/)_\37@.ZC=1_9=#N_P_P @_M:OV7X_YGOW_"RO"G_0
M1;_P'D_^)H_X65X4_P"@BW_@/)_\37@.ZC=1_9=#N_P_R#^UJ_9?C_F>_?\
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M#R?_ !-> [J-U']ET.[_  _R#^UJ_9?C_F>_?\+*\*?]!%O_  'D_P#B:/\
MA97A3_H(M_X#R?\ Q-> [J-U']ET.[_#_(/[6K]E^/\ F>_?\+*\*?\ 01;_
M ,!Y/_B:W-(UO3M>M#<Z;<K/&K;6X(*GW!Y%?,NZM;P]XBO?#>IK>6;\=)(B
M?ED7T/\ C6=7*X<K]FW?S-*6;5.9>T2MY'TI165X?\06/B/3$O;)_:2,GYHV
M]#_GFM6O$E%Q?++<]R,E)<T=@HHHI%!1110 4444 %%%% !533_^/8_[YJW5
M33_^/8_[YH MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5
M6P_U+_[YJU56P_U+_P"^: +5%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !52T_P"/BY_WZMU4M/\ CXN?]^@"W1110 44
M44 %%%% !1110 4444 %5+S_ %MM_P!=!5NJEY_K;;_KH* +=%%% !6%XP\3
M0>$/"U[K=Q'YHMU&R+=M\QR<!<X/KZ>M;M?/G[1OB;=-IOAJ!^$'VJX /<Y"
M _0;C^(H VO"?[0$7B'Q/8Z1=Z$MC'=R>4)_MF_:Q'RC&P=3@=>]>TU\/:SX
M=U/PK'HM_.3&U];)>P,HP4YX'U& ?Q%?87@KQ#'XI\'Z;K"$;IX1Y@'\,@X8
M?@0: -^BO./B=\49?A[<Z?#'I*7WVM&8EIS'MP0/[ISUKB]6_:1CCM+4:5HB
MRW3Q*UPT\I$<;D<JH !;'3/% 'O=4=7UG3=!TZ2_U6]AM+5.LDK8&?0=R?8<
MUY?\/OCE;>+-:BT;5-.%A>3\02QR;HY& SM.0"IXXZYKE/VA/&#SW:^$OL2J
MD#QW?VGS.6)0C;MQ_M=<]J /9_!WC+3O&VG75_I:3+;07#6X:50I? !W =AS
MWYK@?$WQQ?P[XWG\.CP^MP(ITB\_[9MSNQSMV'U]:X'X+_$>70+BU\*+IB3)
MJ%]N-P9BI3< /NX.?N^M;7C7QIX<L/B9=:?=>!=/O;M+F-6O9)R'8G;AL;>W
M]* /H-3N4-ZC-+34.44@8XZ4Z@#RKXB?&-_ ?B--)70UO0T"S>:;KR^I/&-A
M]/6N2_X:9D_Z%-/_  8'_P"-US?[0W_)18O^O&/^;5Z5X2L?A8_@_1FU%?"O
MVTV41G\^2 2;]@W;LG.<YSF@#F?^&F9/^A33_P &!_\ C=>K>+/&A\,>!?\
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M0SG[/J$;(8\\>8HR#^0-3?M$_P#(^VO_ %Y+_,T ;_\ PTS)_P!"FG_@P_\
MM=:NB?M'Z3>WJ0:OHD^GQ.0OGQSB95]V&U2!],UJ>"]+^&\O@C19-1MO#)O&
MLXS.T_D^87VC.[/.?K7D'QBM_!MOXBMQX1:UP8S]J6S;=$'SQ@CC..PXH ^M
M()XKJWCN()%DAD4,CH<A@>A!J2N-^%5K>6?PTT6&^#++Y&0K]54G*C\L5V5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 55L/]2_^^:M55L/]2_\ OF@"U111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM76WG24J+=LD*P..OM7=?'(8^%5^/^FD7_H0KSW_ (:7OO\ H6;?_P "V_\
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MH **** "BD5E<95@PR1D'/(X-+0 4444 %%%% !1110 4444 %%%% !1110
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MX3ZAHK(\.>([#Q-I27UB_M)$3\T;>A_Q[UKUXDHN+LSW(R4E=!1112&%%%%
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MT'3)A-8:)IMI*.CP6B1L/Q K4HH **** "BBB@ HHHH **** "BBB@ HHHH
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MB6,]F*MMW#TR"/R%<S:S^'+_ .,6O-\1Y)O+%Q*D(=G\M6#X56*\A0O3MZT
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MLUQ+;C>Q'WB.,UT]4M'TNWT71[33+48@MHA&F?0=ZNT %%%% !1110 4444
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M4-8MXI7&UIKW[1&6ZX9=S#/L10!]:T5Q7PO\<-X[\)K?W$:QWT$A@N5084N
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** *LW_'];_1JM55F_X_K?Z-5J@#Q+]I'_ )%K1O\
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MX=_[!EM_Z*6L7XD_#W_A86F6=G_:G]G_ &:8R[_L_F[OE(QC<N.M>=#]FV<
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M\U;3K?4+'[;-:W$8DCD6Z."#^%<_HFC_  QTOXJ6FAZ3:ZU/K%I< QS1RJ\
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M 4444 %%%% !1110 4444 %5;#_4O_OFK55;#_4O_OF@"U7SOI'_ "=-=?\
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MX)[ >U7?V:/^/_Q%_P!<H/YO7J'Q@_Y)1K__ %Q3_P!&)7E_[-'_ !_^(O\
MKE!_-Z /H"]M8[ZQN+289BGC:)QZAA@_SKY9^#]])X>^+XTYB52X:6T=>V1D
MC_T']:^K:^2=!!D^/T7D<9U60CZ?-_2@#ZVHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MJS?\?UO]&JU56;_C^M_HU6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *JZCIUGJUA-8ZA;1W-K,-LD4@R&%6J* (X+>&UMX[>WB2*&-0J1QJ
M%50.@ '05)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,F_U,G^Z?Y5\>R_ZY
M_P#>-?84W^ID_P!T_P J^/9?]<_^\:[<'U.+&=!E%%%=IQ!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JS?\
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M +Y-'E2?\\W_ .^37V&47:?E'3TJM8*OV;[H^\>U'USR#ZGYGR+Y,G_/-_\
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M:MU4T_\ X]C_ +YH MT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !56P_P!2_P#OFK55;#_4O_OF@"U1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 54M/^/BY_P!^K=5+3_CXN?\ ?H M
MT444 %%%% !1110 4444 %%%% !52\_UMM_UT%6ZJ7G^MMO^N@H MT444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% %6;_C^M_HU6JJS?\ '];_ $:K5 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ,F_U,G^Z?Y5%9?\><?TJ6;_ %,G^Z?Y5%9?\><?TH L
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'[I^E5K#_ (]O
M^!&K)^Z?I5:P_P"/;_@1H M4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !533_\ CV/^^:MU4T__ (]C_OF@"W1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %5;#_4O_ +YJU56P_P!2_P#OF@"U1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54M/^/B
MY_WZMU4M/^/BY_WZ +=%%% !1110 4444 %%%% !1110 54O/];;?]=!5NJE
MY_K;;_KH* +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5F_P"/ZW^C5:JK
M-_Q_6_T:K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ,F_P!3)_NG^5167_'G']*EF_U,
MG^Z?Y5%9?\><?TH L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% "'[I^E5K#_CV_X$:LG[I^E5K#_CV_X$: +5%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 54T__CV/^^:MU4T__CV/^^: +=%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% #)O]3)_NG^5167_'G']*EF_P!3)_NG^5167_'G']* +%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 A^Z?I5:P_P"/;_@1JR?NGZ56L/\
MCV_X$: +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54T__
M (]C_OFK=5-/_P"/8_[YH MT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !56P_U+_P"^:M55L/\ 4O\ [YH M4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %5+3_CXN?]^K=5+3_CXN?]
M^@"W1110 4444 %%%% !1110 4444 %5+S_6VW_705;JI>?ZVV_ZZ"@"W111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY&_Z @_\"?\ [&C_ (7(W_0$'_@3_P#8UY3FC-'U##?R_B_\P_M#%?S?@O\
M(]6_X7(W_0$'_@3_ /8T?\+D;_H"#_P)_P#L:\IS1FCZAAOY?Q?^8?VABOYO
MP7^1ZM_PN1O^@(/_  )_^QH_X7(W_0$'_@3_ /8UY3FC-'U##?R_B_\ ,/[0
MQ7\WX+_(]6_X7(W_ $!!_P"!/_V-'_"Y&_Z @_\  G_[&O*<T9H^H8;^7\7_
M )A_:&*_F_!?Y'JW_"Y&_P"@(/\ P)_^QH_X7(W_ $!!_P"!/_V->4YHS1]0
MPW\OXO\ S#^T,5_-^"_R/5O^%R-_T!!_X$__ &-'_"Y&_P"@(/\ P)_^QKRG
M-&:/J&&_E_%_YA_:&*_F_!?Y'JW_  N1O^@(/_ G_P"QH_X7(W_0$'_@3_\
M8UY3FC-'U##?R_B_\P_M#%?S?@O\CU4_&1B,?V(/_ G_ .QJ.W^+S01;/[&!
MYSG[3_\ 8UY=FC-'U##?R_B_\P_M#%?S?@O\CU;_ (7(W_0$'_@3_P#8T?\
M"Y&_Z @_\"?_ +&O*<T9H^H8;^7\7_F']H8K^;\%_D>K?\+D;_H"#_P)_P#L
M:/\ A<C?] 0?^!/_ -C7E.:,T?4,-_+^+_S#^T,5_-^"_P CU;_A<C?] 0?^
M!/\ ]C1_PN1O^@(/_ G_ .QKRG-&:/J&&_E_%_YA_:&*_F_!?Y'JW_"Y&_Z
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MK$O[GA8+AC]ST5CZ>A[?3IZYG(R*\*O0E0GRR/H,/B(5X<T0HHHK W"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *J:?_Q['_?-6ZJ:?_Q['_?-
M %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JV'^I?_?-6
MJJV'^I?_ 'S0!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 4444 %%%% !56P_U+_[YJU56P_U+_[YH M4444 %%%% !1110 4444
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M&@>-- \3WEW::1?BYGM/]>OENNWDCN!GD=JWZ "BBB@ HHHH **** "BBB@
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M76IOW7"V]RY^YZ*Q]/0]OY>Q@Y&1TKPJM*5*7*SWJ-:-6/-$****R-0HHHH
M**** "BBB@ HHHH **** "BBB@ JII__ !['_?-6ZJ:?_P >Q_WS0!;HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMA_J7_P!\U:JK8?ZE
M_P#?- %JBBO+-5^/7A?2-7O--N++5&FM9GA<I$A4LIP<?/TXH ]3HKR%?VB_
M"!/-EJX'KY,?_P 77<>%/'_AWQFCC1[W?.B[I+>12DB#UQW_  )H Z:BBB@
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MT:+2;/3;Y;1$V%#:)\_');YN2>]<3X"\0:7:_'%'\-":WT?47,7D2*%^\.F
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MDN]5EV_9K@(I$?S8')/K[5P5[%';_M-V,,2A8X_*55'8!, 5/\7?^2R>%?\
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MP@UZTEDO/*DD7S$,,I>*0=U8$#/TQ7T1<?$*!/A2?&,<:EC;!EB)X\T_+M_
M_P J .W9E12S$ #N32@Y&1TKX_T?2?&GQ>UJZD6_,K1#=)+<RLL<>>B@ '\@
M*=9:UXL^$?C'[#=7#[8F4SVPD+Q31GN,^W0]10!];W-[:62JUU=0P*QP#+(%
M!_.ID=9$#HP92,@@Y!%><_%K1$\6_#*6\MAF:U07D)']W'S#\N?PK&^ ?C*3
M6O#LNA7DNZZTW'E$GEHCT_(Y'Y4 >P4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 59O\
MC^M_HU6JJS?\?UO]&JU0!XS\==4\3>'VTC5='U&\MK ,8[A8)"HW9!7=CL0"
M*[GPK\1/#OBC28+F'5+6*X*#SK>60(Z-CD8)Y'N*Z/4=-L]7L);'4+:.XM9E
MVO'(,@BO)]2_9V\-W-PTMAJ-_9!C_JPRNJ_3(S^M $GQL\5>%YO ]SIAO;2\
MU"5E\B."17:-@?O$C[O]:O\ PGT":7X.)IVHH0E^LI5&[1OP/Y9_&H- ^ 7A
M;2+Q+J]ENM3D0Y5)R!'GW '/XFO5$18T5$4*BC 4#  H ^;/ACXF'PO\8ZKX
M8\1DV]M-(%\X@[4<?=;_ '2#_*OH,^(=%%G]K.KV/V;;N\W[0FW'US6/XO\
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MH \!^ 7'C'Q<??\ ]J-6[IGBWPG\3_$-]H'B7P];6EY:DQP?:909'(8AU5L
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MV'^I?_?- %JOG?X8_P#)POB;_M\_]'+7T17-Z5X#\.Z+XCNO$%A8M%J=UO\
M.F,SL&WL&;Y2<#D#H* .DHHHH \#^.W_ "/?A+_>3_T:*]YB_P!2G^Z*P=?\
M$>'_ !/J%G?:O9-/<69!@83.FW!ST4@'GUKH  H '0<4 ?-VAZFOPJ^,^J0:
MRIBTZ^+!9@"0%8Y1OIU!KU+QC\5/#&C^&;J>TU>TO;N6)EMX;>4.Q8C )QT
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MKCSCIDLV#D)+<.5'X9Y_&MZ3X<^%9-<M-8&E+%>V@40/#(\:H%&!\JD#I[4
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M)'J#MHEJVS,L$Z1HZ-CD8(R?PKG/!WCA/%/Q+?3]!\-Z4NC0$O\ ;?LQ655
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M[]3^E>CZY\*O!_B35Y]5U72WGO)\>9(+F5<X  X# #@"L[_A1WP^_P"@(_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z+PAX0O_%^JBVM@8[=,&>X(
M^6-?ZD]A1X0\(7_B_51;6P,=NF#/<$?+&O\ 4GL*^E-"T*P\.Z5%IVG0B.%.
MI/WG;NS'N37/7KJ"LMSHH4'-W>P:%H5AX=TJ+3M.A$<*=2?O.W=F/<FM*BBO
M.;;=V>BDDK(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *J:?\
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MV>M6AN8(WWJHD9,'ZJ16S10!!96<&GV4-G;)L@A0)&N2< =.34]%% !1110
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M$)_$&L2ZWX=G@AN9SNGMYB55F[LI ."?2O;:* /FK0OV??$5_J<4OB.^@@M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?_"C_A$?$?\ T M1_P# 9_\ "OJ^BCZW+L'U2/<^4/\ A$?$?_0"U'_P&?\
MPH_X1'Q'_P! +4?_  &?_"OJ^BCZW+L'U2/<^4/^$1\1_P#0"U'_ ,!G_P *
M/^$1\1_] +4?_ 9_\*^KZ*/K<NP?5(]SY0_X1'Q'_P! +4?_  &?_"C_ (1'
MQ'_T M1_\!G_ ,*^KZ*/K<NP?5(]SY0_X1'Q'_T M1_\!G_PH_X1'Q'_ - +
M4?\ P&?_  KZOHH^MR[!]4CW/E#_ (1'Q'_T M1_\!G_ ,*/^$1\1_\ 0"U'
M_P !G_PKZOHH^MR[!]4CW/E#_A$?$?\ T M1_P# 9_\ "D7PIXA<970]1(]1
M;/\ X5]7G[I^E5K#_CV_X$:/K<NP?5(]SY:_X1'Q'_T M1_\!G_PH_X1'Q'_
M - +4?\ P&?_  KZOHH^MR[!]4CW/E#_ (1'Q'_T M1_\!G_ ,*/^$1\1_\
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MHH *JV'^I?\ WS5JJMA_J7_WS0!:HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *J6G_'Q<_[]6ZJ6G_'Q<_[] %NBBB@
MHHHH **** "BBB@ HHHH *J7G^MMO^N@JW52\_UMM_UT% %NBBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH JS?\?UO]&JU56;_C^M_HU6J "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 9-_J9/]T_RJ*R_X\X_I4LW^ID_W3_*HK+_CSC^E %BBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 0_=/TJM8?\ 'M_P(U9/W3]*
MK6'_ ![?\"- %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*J:?_P >Q_WS5NJFG_\ 'L?]\T 6Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JK8?ZE_\ ?-6JJV'^I?\ WS0!:HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J6G_'Q<_[]6ZJ6G_'
MQ<_[] %NBBB@ HHHH **** "BBB@ HHHH *J7G^MMO\ KH*MU4O/];;?]=!0
M!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** *LW_ !_6_P!&JU56;_C^M_HU
M6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH 9-_J9/]T_RJ*R_X\X_I4LW^ID_W3_*HK+_
M (\X_I0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/W3]
M*K6'_'M_P(U9/W3]*K6'_'M_P(T 6J*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JII__'L?]\U;JII__'L?]\T 6Z*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ JK8?ZE_]\U:JK8?ZE_\ ?- %JBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI:?\
M'Q<_[]6ZJ6G_ !\7/^_0!;HHHH **** "BBB@ HHHH **** "J=^&+0!3AB_
M!]*N54O/];;?]=!0 >3=_P#/P/\ OFCR;O\ Y^!_WS5NB@"IY-W_ ,_ _P"^
M:/)N_P#GX'_?-6Z* *GDW?\ S\#_ +YH\F[_ .?@?]\U;HH J>3=_P#/P/\
MOFCR;O\ Y^!_WS5NB@"IY-W_ ,_ _P"^:/)N_P#GX'_?-6Z* *GDW?\ S\#_
M +YH\F[_ .?@?]\U;HH J>3=_P#/P/\ OFCR;O\ Y^!_WS5NB@"IY-W_ ,_
M_P"^:/)N_P#GX'_?-6Z* *GDW?\ S\#_ +YH\F[_ .?@?]\U;HH J>3=_P#/
MP/\ OFCR;O\ Y^!_WS5NB@"IY-W_ ,_ _P"^:/)N_P#GX'_?-6Z* *GDW?\
MS\#_ +YH\F[_ .?@?]\U;HH J>3=_P#/P/\ OFCR;O\ Y^!_WS5NB@"IY-W_
M ,_ _P"^:/)N_P#GX'_?-6Z* *GDW?\ S\#_ +YH\F[_ .?@?]\U;HH J>3=
M_P#/P/\ OFCR;O\ Y^!_WS5NB@"IY-W_ ,_ _P"^:/)N_P#GX'_?-6Z* *GD
MW?\ S\#_ +YH\F[_ .?@?]\U;HH J>3=_P#/P/\ OFCR;O\ Y^!_WS5NB@"I
MY-W_ ,_ _P"^:/)N_P#GX'_?-6Z* *GDW?\ S\#_ +YH\F[_ .?@?]\U;HH
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M=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\
M/P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^
M^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT
M4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/
M)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^
M?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]
M\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3
M=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\
M/P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^
M^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT
M4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/
M)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^
M?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]
M\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3
M=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\
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M]\U;HH J>3=_\_ _[YH\F[_Y^!_WS5NB@"IY-W_S\#_OFCR;O_GX'_?-6Z*
M*GDW?_/P/^^:/)N_^?@?]\U;HH J>3=_\_ _[YH\F[_Y^!_WS5NB@"IY-W_S
M\#_OFCR;O_GX'_?-6Z* *GDW?_/P/^^:/)N_^?@?]\U;HH J>3=_\_ _[YH\
MF[_Y^!_WS5NB@"IY-W_S\#_OFCR;O_GX'_?-6Z* *GDW?_/P/^^:/)N_^?@?
M]\U;HH J>3=_\_ _[YH\F[_Y^!_WS5NB@"IY-W_S\#_OFCR;O_GX'_?-6Z*
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M=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\
M/P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^
M^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT
M4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/
M)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^?@?]\T>3=_\ /P/^^:MT4 5/)N_^
M?@?]\U!:QW#1L4F"C<>,5I55L/\ 4O\ [YH 3R;O_GX'_?-'DW?_ #\#_OFK
M=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %
M3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O
M_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'
M_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'
MDW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_
M #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#
M_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK
M=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %
M3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O
M_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'
M_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'
MDW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_
M #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#
M_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK
M=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-'DW?_ #\#_OFK=% %
M3R;O_GX'_?-'DW?_ #\#_OFK=% %3R;O_GX'_?-)8AA+<!CEMPR?6KE5+3_C
MXN?]^@"W1110 4444 %%%% !1110 4444 %5+S_6VW_705;JI>?ZVV_ZZ"@"
MW1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 59O\ C^M_HU6JJS?\?UO]&JU0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% #)O\ 4R?[I_E45E_QYQ_2I9O]3)_NG^5167_'
MG']* +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A^Z?I5:
MP_X]O^!&K)^Z?I5:P_X]O^!&@"U1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %5-/_X]C_OFK=5-/_X]C_OF@"W1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %5;#_4O_OFK55;#_4O_ +YH M4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5+3_ (^+
MG_?JW52T_P"/BY_WZ +=%%% !1110 4444 %%%% !1110 54O/\ 6VW_ %T%
M6ZJ7G^MMO^N@H MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %6;_C^M_HU6
MJJS?\?UO]&JU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)O\ &C_A;VL_\^=E^3?XUYUFC-'U/#_R(/KF)_G9Z+_PM[6?^?.R_)O\:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%5-/_P"/8_[YJW533_\ CV/^^: +=%%% !1110 4444 %%%% !1110 4444
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M7Q7X3LOB9=65[X-BO+Y;F-6NVGP68[<'&.U 'T&IW*#ZC-+34(**0,#'2G4
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M&(]J /9Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#E'YHS3,T9HY@Y1^:,TS-&:.8.4?FG)(T;JZ,593D$=146:,TN8.4]I^'_Q
M745CTG5I0MV!MBF8_P"L]C[UZ37R<LC(X96*L#D$=J]G^'WQ"74ECTG5I0MV
M!MAF8_ZSV/O_ #KQ\9@[?O*>W5'LX+&7_=U-^C/2J***\L]4**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JF
MG_\ 'L?]\U;JII__ !['_?- %NBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *JV'^I?_ 'S5JJMA_J7_ -\T 6J*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "JEI_Q\7/^_5NJEI_Q\7/
M^_0!;HHHH **** "BBB@ HHHH **** "JEY_K;;_ *Z"K=5+S_6VW_704 6Z
M*** &331V\$D\SA(HU+NQZ  9)KXI\2^((?%?Q N-6U!Y%LKB[&[:,LD (
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MZ?E0![U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 <7;_"?P3:W8N8]!M]X.5#9(4^PKLD1(T5$4*JC  & *=10 4444 %%%%
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M]0?<5E>/="7Q+X$U/3W3,K0&2(=Q(HR,?EC\:\@_9W\2R0:AJ'ABX<[6!N(
M3]UAPP_D?SH ^AJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** *LW_'];_1JM55F_X_K?Z-
M5J@#YZ^.&IS>)/&VC>#K$ERCJ9%'>1S@?D,_G7L=CX&\.65A;VO]D6<GDQK'
MO:($M@8R:G'@_P /#7O[=_LFW_M3=O\ M1!WYQC/Y5MT >5_%OP!IEYX!O)]
M+TVW@N[/_2%,,84L!]X<>V:SOA)XH_MKX5:CIDTFZYTR%X^3R8R"5/\ ,?E7
ML<D:31/%(H9'!5E/0@UAZ3X+\-Z$;@Z7I%M:_:$\N7RP?G7T/- 'E7[-8!T7
M7P>09XO_ $%J\]\<&^\ ^.?$^F6.4M]8A*CM^[D8,<?B&%?4&A^&=%\-131:
M-IT-DDQ#2"(8W$=,_G4.K^$/#VOWL5YJNDVUW<1#"22+DJ,YH YCP_X>'AGX
M*/8,FV<Z=+-/QSO="QS],@?A7*_LV_\ (M:S_P!?2?\ H->T3V\5U;R6\\8>
M&12CH>A!X(K/T3PWH_AN"6#1M/ALHI6W.L0P&/K0!\[S^(-/\+_M(:AJVINZ
M6D,L@=D7<?F@VCCZD5ZC_P +W\#?\_EU_P" YKI=1^'GA'5K^:^O]!M+BZF.
MZ25U.6.,<\^U5?\ A5?@;_H6;'_OD_XT 6_"GCS0O&<=X^C32R"TV^;OC*XW
M9Q_Z":H>#_B7I'C35[S3=/AN$FM$+N9%P" P7C\36WHOA;0_#4=P-&TN"S$^
M/-$0(WXSC/YG\ZX+X7^&;FU\8^(_$3Z/_9%E<G[/:VIZX#?,WXE<_C0!ZM7)
M_$[_ ))GXA_Z\I/Y5UE5[ZQM=3L9K*]A6>VG0I)&_1E/4&@#RSX 0I<?"^XA
MD4,DE],K ]""B5XEJD>J^'M4USP!;!C#>:A&H7NP#$ICZAE_*OKC1M#TOP]8
MFRTFRBM+8N7,<0P-QQD_H*J7'A#P_=Z['K=QI-M)J<;*RW++\X*]#^% '(^/
M=(BT'X&7NE0@;+6R2+([D$9/XG)_&H_@-_R2ZW_Z^)?YBO0]1TVSU>PEL=0M
MTN+688DB?HP]ZCTG1M.T&P6QTNTCM;526$48X!/6@#YJ\$>+=)\'?%[Q-?ZQ
M+)';R274*E$W'<9@>GT!KU*Y^/O@J&%FBEO)G X00$9_&NFN/AGX+N[J6YN/
M#ME)-,YDD=E.68G))Y]:(?AEX*MWWQ>&[%6]=A/]: /#[>/6/CA\1+>_EM'M
MM$LRH.>B1@Y(SW9O\]*]3^-'A.[\2>!-NF(S7-A*)TB3JZ $,H_ Y_"O0;2R
MM;"!8+2WB@B7HD:A1^E3T >#_#GXV:5IN@6NA^)5GMKBR00I/L+!E7@!AU!
MXK4\9_''PP?#U[9:09+^[N86A13'A!N&,DGKUZ5WNL_#SPIKT[3ZAHMM).W6
M15VL?RJOI7PP\':/<+<6NB6_G*<J\@WD?G0!RGP"\,7NA>$;J^OHFADU&57C
MC<8(C4$ D>^37K5(    , = *6@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_$DUL@ # &!10!XK\?O!$>H:*/%5JJK=60"7/_32,G /U!/Y'VKR7X4>#/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***]8^&OPU-\T6M:U$1; [H
M+=A_K/<^W\ZB<U!79<(.;LAGPU^&IU%HM:UJ(BS!W00,.93ZG_9_G7N*JJ*%
M4!5 P !@ 4*JHH50%4#  & !2UYE2HZCNST:=-05D%%%%9F@4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5-
M/_X]C_OFK=5-/_X]C_OF@"W1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %5;#_4O_OFK55;#_4O_ +YH M4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;_T!;C]*/^%<^+?^@+<?I7T_11];GV#ZK'N?,'_"N?%O_0%N/TH_X5SXM_Z
MMQ^E?3]%'UN?8/JL>Y\P?\*Y\6_] 6X_2C_A7/BW_H"W'Z5]/T4?6Y]@^JQ[
MGS!_PKGQ;_T!;C]*/^%<^+?^@+<?I7T_11];GV#ZK'N>+> /A7/]L_M'Q%;F
M-(F_=VK=7/J?:O:%4*H50 H& !VI:*PJ5)3=V;PIJ"L@HHHJ"PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "JFG_P#'L?\ ?-6ZJ:?_ ,>Q_P!\T 6Z*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ JK8?ZE_P#?-6JJV'^I?_?- %JBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI:?\?%S_OU;
MJI:?\?%S_OT 6Z*** "BBB@ HHHH **** "BBB@ JI>?ZVV_ZZ"K=5+S_6VW
M_704 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K-_Q_6_T:K559O^/ZW^
MC5:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!DW^ID_W3_*HK+_CSC^E2S?ZF3_=/\JBL
MO^/./Z4 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#]T_
M2JUA_P >W_ C5D_=/TJM8?\ 'M_P(T 6J*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ JII__ !['_?-6ZJ:?_P >Q_WS0!;HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "JMA_J7_P!\U:JK8?ZE_P#?- %J
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M JI:?\?%S_OU;JI:?\?%S_OT 6Z*** "BBB@ HHHH **** "BBB@ JI>?ZVV
M_P"N@JW52\_UMM_UT% %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JS?\
M'];_ $:K559O^/ZW^C5:H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DW^ID_W3_*HK+_C
MSC^E2S?ZF3_=/\JBLO\ CSC^E %BBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH 0_=/TJM8?\>W_ C5D_=/TJM8?\>W_ C0!:HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "JFG_\>Q_WS5NJFG_\>Q_WS0!;
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMA_J7_WS5JJM
MA_J7_P!\T 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "JEI_P ?%S_OU;JI:?\ 'Q<_[] %NBBB@ HHHH **** "BBB
M@ HHHH *AN+<3A<L5*G((J:B@"I]C;_GXDH^QM_S\25;HH J?8V_Y^)*/L;?
M\_$E6Z* *GV-O^?B2C[&W_/Q)5NB@"I]C;_GXDH^QM_S\25;HH J?8V_Y^)*
M/L;?\_$E6Z* *GV-O^?B2C[&W_/Q)5NB@"I]C;_GXDH^QM_S\25;HH J?8V_
MY^)*/L;?\_$E6Z* *GV-O^?B2C[&W_/Q)5NB@"I]C;_GXDH^QM_S\25;HH J
M?8V_Y^)*/L;?\_$E6Z* *GV-O^?B2C[&W_/Q)5NB@"I]C;_GXDH^QM_S\25;
MHH J?8V_Y^)*/L;?\_$E6Z* *GV-O^?B2C[&W_/Q)5NB@"I]C;_GXDH^QM_S
M\25;HH J?8V_Y^)*/L;?\_$E6Z* *GV-O^?B2C[&W_/Q)5NB@"I]C;_GXDH^
MQM_S\25;HH J?8V_Y^)*/L;?\_$E6Z* *GV-O^?B2C[&W_/Q)5NB@"I]C;_G
MXDH^QM_S\25;HH J?8V_Y^)*/L;?\_$E6Z* *GV-O^?B2C[&W_/Q)5NB@"I]
MC;_GXDH^QM_S\25;HH J?8V_Y^)*/L;?\_$E6Z* *GV-O^?B2C[&W_/Q)5NB
M@"I]C;_GXDH^QM_S\25;HH J?8V_Y^)*/L;?\_$E6Z* *9L,L&,[Y'0TOV-O
M^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8V_Y^)*MT4 5/L;?\_$E
M'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8V_Y^)*MT4 5/L;?
M\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8V_Y^)*MT4 5
M/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8V_Y^)*M
MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8V_Y
M^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?
M8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S
M\24?8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^
MQM_S\24?8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW1
M0!4^QM_S\24?8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GX
MDJW10!4^QM_S\24?8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C
M;_GXDJW10!4^QM_S\24?8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q
M)1]C;_GXDJW10!4^QM_S\24?8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&
MW_/Q)1]C;_GXDJW10!4^QM_S\24?8V_Y^)*MT4 5#9$C!N),4BV)486=P!VJ
MY10!4^QM_P _$E'V-O\ GXDJW10!4^QM_P _$E'V-O\ GXDJW10!4^QM_P _
M$E'V-O\ GXDJW10!4^QM_P _$E'V-O\ GXDJW10!4^QM_P _$E'V-O\ GXDJ
MW10!4^QM_P _$E'V-O\ GXDJW10!4^QM_P _$E'V-O\ GXDJW10!4^QM_P _
M$E'V-O\ GXDJW10!4^QM_P _$E'V-O\ GXDJW10!4^QM_P _$E'V-O\ GXDJ
MW10!4^QM_P _$E'V-O\ GXDJW10!4^QM_P _$E'V-O\ GXDJW10!4^QM_P _
M$E'V-O\ GXDJW10!4^QM_P _$E'V-O\ GXDJW10!4^QM_P _$E'V-O\ GXDJ
MW10!4^QM_P _$E'V-O\ GXDJW10!4^QM_P _$E'V-O\ GXDJW10!4^QM_P _
M$E'V-O\ GXDJW10!4^QM_P _$E'V-O\ GXDJW10!4^QM_P _$E'V-O\ GXDJ
MW10!4^Q-_P _$E(MAL&%G<#VJY10!4^QM_S\24?8V_Y^)*MT4 5/L;?\_$E'
MV-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8V_Y^)*MT4 5/L;?\
M_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8V_Y^)*MT4 5/
ML;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8V_Y^)*MT
M4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8V_Y^
M)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8
MV_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\
M24?8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)2+8;!A9W ]JN44 5
M/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8V_Y^)*M
MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8V_Y
M^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?
M8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S
M\24?8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^
MQM_S\24?8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW1
M0!4^QM_S\24?8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GX
MDJW10!4^QM_S\24BV&T86=QWJY10!4^QM_S\24?8V_Y^)*MT4 5/L;?\_$E'
MV-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8V_Y^)*MT4 5/L;?\
M_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8V_Y^)*MT4 5/
ML;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8V_Y^)*MT
M4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8V_Y^
M)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\24?8
MV_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^QM_S\
M24?8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10!4^Q
MM_S\24?8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXDJW10
M!4^QM_S\24?8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;_GXD
MJW10!4^QM_S\24?8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)1]C;
M_GXDJW10!4^QM_S\24?8V_Y^)*MT4 5/L;?\_$E'V-O^?B2K=% %3[&W_/Q)
M1]C;_GXDJW10!4^QM_S\24?8V_Y^)*MT4 5/L;?\_$E2V]N(-WS%BQR2:FHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>35
<FILENAME>pyxs-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-29T06:58:54.3329+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://pyxisoncology.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:pyxs="http://pyxisoncology.com/20211231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pyxs-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pyxs-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pyxs-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pyxs-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited" id="StatementConsolidatedBalanceSheetsUnaudited">
        <link:definition>100010 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2" id="DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2">
        <link:definition>100020 - Disclosure - Operating Leases - Maturities of Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited" id="StatementConsolidatedBalanceSheetsParentheticalUnaudited">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2" id="StatementConsolidatedStatementsOfCashFlows2">
        <link:definition>100040 - Statement - Consolidated Statements of Cash Flows 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100080 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusiness" id="DisclosureOrganizationAndNatureOfBusiness">
        <link:definition>100090 - Disclosure - Organization and Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureLicensingAgreements" id="Role_DisclosureLicensingAgreements">
        <link:definition>100110 - Disclosure - Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureJointVenture" id="Role_DisclosureJointVenture">
        <link:definition>100120 - Disclosure - Joint Venture</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100130 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>100140 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>100150 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100160 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeases" id="DisclosureOperatingLeases">
        <link:definition>100170 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100180 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>100190 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100200 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100210 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>100220 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureRelatedParties" id="Role_DisclosureRelatedParties">
        <link:definition>100230 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>100240 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEvent1" id="DisclosureSubsequentEvent1">
        <link:definition>100250 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100260 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100270 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100280 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>100290 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100300 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100310 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesTables" id="DisclosureOperatingLeasesTables">
        <link:definition>100320 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100330 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>100340 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100350 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>100360 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>100370 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" id="DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Organization and Nature of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails">
        <link:definition>100400 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Related Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" id="DisclosureLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" id="DisclosureJointVentureAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Joint Venture - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails">
        <link:definition>100430 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails">
        <link:definition>100450 - Disclosure - Fair Value Measurements - Summary of Changes in Level 3 Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100460 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100470 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails">
        <link:definition>100490 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails" id="DisclosureOperatingLeasesAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Operating Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" id="DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails">
        <link:definition>100510 - Disclosure - Operating Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails" id="DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>100520 - Disclosure - Operating Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails" id="DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails">
        <link:definition>100550 - Disclosure - Stockholders' Equity - Common Stock Reserved for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100560 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100570 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails" id="DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails">
        <link:definition>100580 - Disclosure - Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" id="DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails">
        <link:definition>100590 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails">
        <link:definition>100600 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100610 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" id="DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
        <link:definition>100620 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails">
        <link:definition>100630 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100640 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100650 - Disclosure - Net Loss per Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" id="DisclosureRelatedPartiesAdditionalInformationDetails">
        <link:definition>100660 - Disclosure - Related Parties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" id="DisclosureSubsequentEventAdditionalInformationDetails">
        <link:definition>100670 - Disclosure - Subsequent Event (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="pyxs_LicenseAgreementsAbstract" name="LicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_AggregateMaximumAmountPaidToRelatedParties" name="AggregateMaximumAmountPaidToRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" name="AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" name="AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_AggregateMilestonePayments" name="AggregateMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_AnnualLicenseMaintenanceFees" name="AnnualLicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ContributedAmountToJointVentureByEachEntity" name="ContributedAmountToJointVentureByEachEntity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ConvertiblePreferredStockSharesIssuedValue" name="ConvertiblePreferredStockSharesIssuedValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_DeferredTaxAssetsLicenseFee" name="DeferredTaxAssetsLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ExtraMilestonePayment" name="ExtraMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" name="ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_GrossProceedsFromIssuanceInitialPublicOffering" name="GrossProceedsFromIssuanceInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock" name="GrossProceedsFromIssuanceOfConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_IssuanceOfConvertiblePreferredStockShares" name="IssuanceOfConvertiblePreferredStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_LeaseExpirationYear" name="LeaseExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_MaximumAmountPaidToRelatedParties" name="MaximumAmountPaidToRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" name="MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_MilestoneAndRoyaltiesIncurred" name="MilestoneAndRoyaltiesIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_MilestonePaymentsPayableUponCertainAchievements" name="MilestonePaymentsPayableUponCertainAchievements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_MinimumAnnualRoyaltyFees" name="MinimumAnnualRoyaltyFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture" name="NonCashGainLossFromEquityMethodInvestmentInJointVenture" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" name="NumberOfCommonSharesIssuedUponConversionOfPreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_NumberOfFinanceLease" name="NumberOfFinanceLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_NumberOfOperatingLease" name="NumberOfOperatingLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_OneTimeMilestonePayment" name="OneTimeMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_OperatingLossCarryforwardsBeforeTax" name="OperatingLossCarryforwardsBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_PaymentForLicenseFee" name="PaymentForLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_PaymentsToRelatedPartiesPerMonth" name="PaymentsToRelatedPartiesPerMonth" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_PotentialDevelopmentAndCommercialMilestonePayment" name="PotentialDevelopmentAndCommercialMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ProceedsFromPromissoryNoteIssued" name="ProceedsFromPromissoryNoteIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_RentIncreasePercentage" name="RentIncreasePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ResearchAndDevelopmentCurrent" name="ResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost" name="ResearchAndDevelopmentLicensedProductEstimatedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" name="RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ServiceFeeIncomeFromRelatedParty" name="ServiceFeeIncomeFromRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_StockIssuanceExpenses" name="StockIssuanceExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_SublicensingRevenuePercentage" name="SublicensingRevenuePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" name="TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" name="TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_TemporaryEquityIssuanceCosts" name="TemporaryEquityIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_UnderwritingDiscountsAndCommissions" name="UnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_UpfrontFee" name="UpfrontFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_UpfrontPayments" name="UpfrontPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" name="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" name="ScheduleOfCommonStockReservedForFutureIssuanceLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember" name="AgreementsWithPfizerIncAndLegochemBiosciencesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_AlloyTherapeuticsIncMember" name="AlloyTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_BiosionLicenseAgreementMember" name="BiosionLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_LegoChemLicenseAgreementMember" name="LegoChemLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_PfizerLicenseAgreementMember" name="PfizerLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_ScientificAdvisoryBoardMember" name="ScientificAdvisoryBoardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_SeriesAConvertiblePreferredStocksMember" name="SeriesAConvertiblePreferredStocksMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_SeriesBConvertiblePreferredStocksMember" name="SeriesBConvertiblePreferredStocksMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_StockOptionsAvailableForIssuanceMember" name="StockOptionsAvailableForIssuanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_TwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" name="TwoThousandTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_UniversityLicenseAgreementMember" name="UniversityLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_UnvestedRestrictedStockMember" name="UnvestedRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_VoxallMember" name="VoxallMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_InitialPublicOfferingPolicyTextBlock" name="InitialPublicOfferingPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_NatureOfBusinessPolicyTextBlock" name="NatureOfBusinessPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" name="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" name="ScheduleOfCommonStockReservedForFutureIssuanceTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" name="ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_LicensingAgreementsTextBlock" name="LicensingAgreementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>36
<FILENAME>pyxs-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-29T06:58:57.8649+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="pyxs-20211231.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited" xlink:href="pyxs-20211231.xsd#StatementConsolidatedBalanceSheetsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited" xlink:href="pyxs-20211231.xsd#StatementConsolidatedBalanceSheetsParentheticalUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="pyxs-20211231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="pyxs-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="pyxs-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="pyxs-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusiness" xlink:href="pyxs-20211231.xsd#DisclosureOrganizationAndNatureOfBusiness" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="pyxs-20211231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureLicensingAgreements" xlink:href="pyxs-20211231.xsd#Role_DisclosureLicensingAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureJointVenture" xlink:href="pyxs-20211231.xsd#Role_DisclosureJointVenture" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="pyxs-20211231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:href="pyxs-20211231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:href="pyxs-20211231.xsd#DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="pyxs-20211231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeases" xlink:href="pyxs-20211231.xsd#DisclosureOperatingLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" xlink:href="pyxs-20211231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="pyxs-20211231.xsd#DisclosureStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="pyxs-20211231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="pyxs-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="pyxs-20211231.xsd#DisclosureNetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureRelatedParties" xlink:href="pyxs-20211231.xsd#Role_DisclosureRelatedParties" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="pyxs-20211231.xsd#DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEvent1" xlink:href="pyxs-20211231.xsd#DisclosureSubsequentEvent1" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pyxs-20211231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="pyxs-20211231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="pyxs-20211231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="pyxs-20211231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="pyxs-20211231.xsd#DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="pyxs-20211231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesTables" xlink:href="pyxs-20211231.xsd#DisclosureOperatingLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="pyxs-20211231.xsd#DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="pyxs-20211231.xsd#DisclosureStockholdersEquityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="pyxs-20211231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="pyxs-20211231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="pyxs-20211231.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails" xlink:href="pyxs-20211231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosureJointVentureAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails" xlink:href="pyxs-20211231.xsd#DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails" xlink:href="pyxs-20211231.xsd#DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="pyxs-20211231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="pyxs-20211231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails" xlink:href="pyxs-20211231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:href="pyxs-20211231.xsd#DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:href="pyxs-20211231.xsd#DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails" xlink:href="pyxs-20211231.xsd#DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="pyxs-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails" xlink:href="pyxs-20211231.xsd#DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:href="pyxs-20211231.xsd#DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:href="pyxs-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:href="pyxs-20211231.xsd#DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:href="pyxs-20211231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" xlink:href="pyxs-20211231.xsd#DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="pyxs-20211231.xsd#DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosureRelatedPartiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosureSubsequentEventAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesAConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesAConvertiblePreferredStocksMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesAConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesAConvertiblePreferredStocksMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ServiceFeeIncomeFromRelatedParty" xlink:label="pyxs_ServiceFeeIncomeFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="pyxs_ServiceFeeIncomeFromRelatedParty" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_18"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_19"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_20"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_21"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_PfizerLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_19" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_20" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TemporaryEquityIssuanceCosts" xlink:label="pyxs_TemporaryEquityIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture" xlink:label="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureLicensingAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LicenseAgreementsAbstract" xlink:label="pyxs_LicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LicensingAgreementsTextBlock" xlink:label="pyxs_LicensingAgreementsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_LicenseAgreementsAbstract" xlink:to="pyxs_LicensingAgreementsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureJointVenture" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureRelatedParties" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEvent1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_NatureOfBusinessPolicyTextBlock" xlink:label="pyxs_NatureOfBusinessPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_InitialPublicOfferingPolicyTextBlock" xlink:label="pyxs_InitialPublicOfferingPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LiquidityPolicyTextBlock" xlink:label="pyxs_LiquidityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_RisksAndUncertaintiesPolicyTextBlock" xlink:label="pyxs_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" xlink:label="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_NatureOfBusinessPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_InitialPublicOfferingPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_LiquidityPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_RisksAndUncertaintiesPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended"/>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UnderwritingDiscountsAndCommissions" xlink:label="pyxs_UnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_StockIssuanceExpenses" xlink:label="pyxs_StockIssuanceExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pyxs_GrossProceedsFromIssuanceInitialPublicOffering" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pyxs_UnderwritingDiscountsAndCommissions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pyxs_StockIssuanceExpenses" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetIncomeLoss" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202001Member" xlink:label="us-gaap_AccountingStandardsUpdate202001Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_NumberOfFinanceLease" xlink:label="pyxs_NumberOfFinanceLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202001Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pyxs_NumberOfFinanceLease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UniversityLicenseAgreementMember" xlink:label="pyxs_UniversityLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LicenseAgreementsAbstract" xlink:label="pyxs_LicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LegoChemLicenseAgreementMember" xlink:label="pyxs_LegoChemLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_PaymentForLicenseFee" xlink:label="pyxs_PaymentForLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AnnualLicenseMaintenanceFees" xlink:label="pyxs_AnnualLicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_PotentialDevelopmentAndCommercialMilestonePayment" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_MinimumAnnualRoyaltyFees" xlink:label="pyxs_MinimumAnnualRoyaltyFees"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_MilestoneAndRoyaltiesIncurred" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_IssuanceOfConvertiblePreferredStockShares" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ConvertiblePreferredStockSharesIssuedValue" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UpfrontPayments" xlink:label="pyxs_UpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AggregateMilestonePayments" xlink:label="pyxs_AggregateMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SublicensingRevenuePercentage" xlink:label="pyxs_SublicensingRevenuePercentage"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_OneTimeMilestonePayment" xlink:label="pyxs_OneTimeMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost" xlink:label="pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_MilestonePaymentsPayableUponCertainAchievements" xlink:label="pyxs_MilestonePaymentsPayableUponCertainAchievements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ExtraMilestonePayment" xlink:label="pyxs_ExtraMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pyxs_UniversityLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_PfizerLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_LicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TransactionTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_LegoChemLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_PaymentForLicenseFee" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_AnnualLicenseMaintenanceFees" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_PotentialDevelopmentAndCommercialMilestonePayment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MinimumAnnualRoyaltyFees" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MilestoneAndRoyaltiesIncurred" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_IssuanceOfConvertiblePreferredStockShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ConvertiblePreferredStockSharesIssuedValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_UpfrontPayments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_AggregateMilestonePayments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_SublicensingRevenuePercentage" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_OneTimeMilestonePayment" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MilestonePaymentsPayableUponCertainAchievements" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ExtraMilestonePayment" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_VoxallMember" xlink:label="pyxs_VoxallMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AlloyTherapeuticsIncMember" xlink:label="pyxs_AlloyTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ServiceFeeIncomeFromRelatedParty" xlink:label="pyxs_ServiceFeeIncomeFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ProceedsFromPromissoryNoteIssued" xlink:label="pyxs_ProceedsFromPromissoryNoteIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="pyxs_VoxallMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="pyxs_AlloyTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_ServiceFeeIncomeFromRelatedParty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_ProceedsFromPromissoryNoteIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ExtraMilestonePayment" xlink:label="pyxs_ExtraMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_ExtraMilestonePayment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability" xlink:label="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable" xlink:label="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ResearchAndDevelopmentCurrent" xlink:label="pyxs_ResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="pyxs_ResearchAndDevelopmentCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LaboratoryEquipmentMember" xlink:label="pyxs_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_FurnitureAndOfficeEquipmentMember" xlink:label="pyxs_FurnitureAndOfficeEquipmentMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pyxs_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pyxs_FurnitureAndOfficeEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="pyxs_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="pyxs_AccruedResearchAndDevelopmentExpensesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_NumberOfOperatingLease" xlink:label="pyxs_NumberOfOperatingLease"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LeaseExpirationYear" xlink:label="pyxs_LeaseExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_NumberOfFinanceLease" xlink:label="pyxs_NumberOfFinanceLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_RentIncreasePercentage" xlink:label="pyxs_RentIncreasePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pyxs_NumberOfOperatingLease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pyxs_LeaseExpirationYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pyxs_NumberOfFinanceLease" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pyxs_RentIncreasePercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SecuritiesPurchaseAgreementMember" xlink:label="pyxs_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesAConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember" xlink:label="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pyxs_SecuritiesPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesAConvertiblePreferredStocksMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockVotingRights" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesAConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_StockOptionsAvailableForIssuanceMember" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_SeriesAConvertiblePreferredStocksMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_StockOptionsAvailableForIssuanceMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandNineteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_OperatingLossCarryforwardsBeforeTax" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_OperatingLossCarryforwardsExpirationYear" xlink:label="pyxs_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TaxCreditCarryforwardExpirationYear" xlink:label="pyxs_TaxCreditCarryforwardExpirationYear"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_OperatingLossCarryforwardsBeforeTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_OperatingLossCarryforwardsExpirationYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_TaxCreditCarryforwardExpirationYear" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_DeferredTaxAssetsLicenseFee" xlink:label="pyxs_DeferredTaxAssetsLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="pyxs_DeferredTaxAssetsLicenseFee" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UnvestedRestrictedStockMember" xlink:label="pyxs_UnvestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pyxs_UnvestedRestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ScientificAdvisoryBoardMember" xlink:label="pyxs_ScientificAdvisoryBoardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AlloyTherapeuticsIncMember" xlink:label="pyxs_AlloyTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UniversityLicenseAgreementMember" xlink:label="pyxs_UniversityLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_PaymentsToRelatedPartiesPerMonth" xlink:label="pyxs_PaymentsToRelatedPartiesPerMonth"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_VoxallMember" xlink:label="pyxs_VoxallMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LegoChemLicenseAgreementMember" xlink:label="pyxs_LegoChemLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_MaximumAmountPaidToRelatedParties" xlink:label="pyxs_MaximumAmountPaidToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AggregateMaximumAmountPaidToRelatedParties" xlink:label="pyxs_AggregateMaximumAmountPaidToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_IssuanceOfConvertiblePreferredStockShares" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ConvertiblePreferredStockSharesIssuedValue" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UpfrontPayments" xlink:label="pyxs_UpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ContributedAmountToJointVentureByEachEntity" xlink:label="pyxs_ContributedAmountToJointVentureByEachEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pyxs_ScientificAdvisoryBoardMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_PfizerLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="pyxs_AlloyTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pyxs_UniversityLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_PaymentsToRelatedPartiesPerMonth" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pyxs_VoxallMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_LegoChemLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_MaximumAmountPaidToRelatedParties" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_AggregateMaximumAmountPaidToRelatedParties" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_IssuanceOfConvertiblePreferredStockShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TransactionTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_ConvertiblePreferredStockSharesIssuedValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="dei_LegalEntityAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_UpfrontPayments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_ContributedAmountToJointVentureByEachEntity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_BiosionLicenseAgreementMember" xlink:label="pyxs_BiosionLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UpfrontFee" xlink:label="pyxs_UpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_BiosionLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pyxs_UpfrontFee" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TransactionTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>37
<FILENAME>pyxs-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-29T06:58:58.0852+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited" xlink:href="pyxs-20211231.xsd#StatementConsolidatedBalanceSheetsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited" xlink:href="pyxs-20211231.xsd#StatementConsolidatedBalanceSheetsParentheticalUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="pyxs-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="pyxs-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails" xlink:href="pyxs-20211231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosureJointVentureAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails" xlink:href="pyxs-20211231.xsd#DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails" xlink:href="pyxs-20211231.xsd#DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="pyxs-20211231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails" xlink:href="pyxs-20211231.xsd#DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails" xlink:href="pyxs-20211231.xsd#DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:href="pyxs-20211231.xsd#DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:href="pyxs-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="pyxs-20211231.xsd#DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosureRelatedPartiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:href="pyxs-20211231.xsd#DisclosureSubsequentEventAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesAConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesAConvertiblePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesAConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesAConvertiblePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_PfizerLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TemporaryEquityIssuanceCosts" xlink:label="pyxs_TemporaryEquityIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UnderwritingDiscountsAndCommissions" xlink:label="pyxs_UnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_StockIssuanceExpenses" xlink:label="pyxs_StockIssuanceExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pyxs_GrossProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pyxs_UnderwritingDiscountsAndCommissions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pyxs_StockIssuanceExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202001Member" xlink:label="us-gaap_AccountingStandardsUpdate202001Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_NumberOfFinanceLease" xlink:label="pyxs_NumberOfFinanceLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202001Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pyxs_NumberOfFinanceLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UniversityLicenseAgreementMember" xlink:label="pyxs_UniversityLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LegoChemLicenseAgreementMember" xlink:label="pyxs_LegoChemLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_PaymentForLicenseFee" xlink:label="pyxs_PaymentForLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AnnualLicenseMaintenanceFees" xlink:label="pyxs_AnnualLicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_PotentialDevelopmentAndCommercialMilestonePayment" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_MinimumAnnualRoyaltyFees" xlink:label="pyxs_MinimumAnnualRoyaltyFees"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_MilestoneAndRoyaltiesIncurred" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_IssuanceOfConvertiblePreferredStockShares" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ConvertiblePreferredStockSharesIssuedValue" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UpfrontPayments" xlink:label="pyxs_UpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AggregateMilestonePayments" xlink:label="pyxs_AggregateMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SublicensingRevenuePercentage" xlink:label="pyxs_SublicensingRevenuePercentage"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_OneTimeMilestonePayment" xlink:label="pyxs_OneTimeMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost" xlink:label="pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_MilestonePaymentsPayableUponCertainAchievements" xlink:label="pyxs_MilestonePaymentsPayableUponCertainAchievements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ExtraMilestonePayment" xlink:label="pyxs_ExtraMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_PfizerLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pyxs_UniversityLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_LegoChemLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TransactionTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_PaymentForLicenseFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_AnnualLicenseMaintenanceFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_PotentialDevelopmentAndCommercialMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MinimumAnnualRoyaltyFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MilestoneAndRoyaltiesIncurred" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_IssuanceOfConvertiblePreferredStockShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ConvertiblePreferredStockSharesIssuedValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_UpfrontPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_AggregateMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_SublicensingRevenuePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_OneTimeMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MilestonePaymentsPayableUponCertainAchievements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ExtraMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_VoxallMember" xlink:label="pyxs_VoxallMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AlloyTherapeuticsIncMember" xlink:label="pyxs_AlloyTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ServiceFeeIncomeFromRelatedParty" xlink:label="pyxs_ServiceFeeIncomeFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ProceedsFromPromissoryNoteIssued" xlink:label="pyxs_ProceedsFromPromissoryNoteIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="pyxs_VoxallMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="pyxs_AlloyTherapeuticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_ServiceFeeIncomeFromRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_ProceedsFromPromissoryNoteIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ExtraMilestonePayment" xlink:label="pyxs_ExtraMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_ExtraMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability" xlink:label="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable" xlink:label="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LaboratoryEquipmentMember" xlink:label="pyxs_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_FurnitureAndOfficeEquipmentMember" xlink:label="pyxs_FurnitureAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pyxs_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pyxs_FurnitureAndOfficeEquipmentMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SecuritiesPurchaseAgreementMember" xlink:label="pyxs_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesAConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember" xlink:label="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pyxs_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesAConvertiblePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails">
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesAConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_StockOptionsAvailableForIssuanceMember" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_SeriesAConvertiblePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_StockOptionsAvailableForIssuanceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_OperatingLossCarryforwardsBeforeTax" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_OperatingLossCarryforwardsExpirationYear" xlink:label="pyxs_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TaxCreditCarryforwardExpirationYear" xlink:label="pyxs_TaxCreditCarryforwardExpirationYear"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_OperatingLossCarryforwardsBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UnvestedRestrictedStockMember" xlink:label="pyxs_UnvestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pyxs_UnvestedRestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AlloyTherapeuticsIncMember" xlink:label="pyxs_AlloyTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UniversityLicenseAgreementMember" xlink:label="pyxs_UniversityLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_PaymentsToRelatedPartiesPerMonth" xlink:label="pyxs_PaymentsToRelatedPartiesPerMonth"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ScientificAdvisoryBoardMember" xlink:label="pyxs_ScientificAdvisoryBoardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_VoxallMember" xlink:label="pyxs_VoxallMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LegoChemLicenseAgreementMember" xlink:label="pyxs_LegoChemLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_MaximumAmountPaidToRelatedParties" xlink:label="pyxs_MaximumAmountPaidToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AggregateMaximumAmountPaidToRelatedParties" xlink:label="pyxs_AggregateMaximumAmountPaidToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_IssuanceOfConvertiblePreferredStockShares" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ConvertiblePreferredStockSharesIssuedValue" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UpfrontPayments" xlink:label="pyxs_UpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ContributedAmountToJointVentureByEachEntity" xlink:label="pyxs_ContributedAmountToJointVentureByEachEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="pyxs_AlloyTherapeuticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pyxs_UniversityLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_PaymentsToRelatedPartiesPerMonth" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pyxs_ScientificAdvisoryBoardMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_PfizerLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pyxs_VoxallMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_LegoChemLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_MaximumAmountPaidToRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_AggregateMaximumAmountPaidToRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_IssuanceOfConvertiblePreferredStockShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_ConvertiblePreferredStockSharesIssuedValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TransactionTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_UpfrontPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_ContributedAmountToJointVentureByEachEntity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_BiosionLicenseAgreementMember" xlink:label="pyxs_BiosionLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UpfrontFee" xlink:label="pyxs_UpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_BiosionLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pyxs_UpfrontFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TransactionTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>38
<FILENAME>pyxs-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-29T06:58:58.2824+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited" xlink:href="pyxs-20211231.xsd#StatementConsolidatedBalanceSheetsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2" xlink:href="pyxs-20211231.xsd#DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2" xlink:href="pyxs-20211231.xsd#StatementConsolidatedStatementsOfCashFlows2" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="pyxs-20211231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="pyxs-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="pyxs-20211231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="pyxs-20211231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails" xlink:href="pyxs-20211231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:href="pyxs-20211231.xsd#DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:href="pyxs-20211231.xsd#DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:href="pyxs-20211231.xsd#DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:href="pyxs-20211231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="pyxs_ServiceFeeIncomeFromRelatedParty" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ServiceFeeIncomeFromRelatedParty" xlink:label="pyxs_ServiceFeeIncomeFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseExpense" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="10" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture" xlink:label="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="pyxs_ResearchAndDevelopmentCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ResearchAndDevelopmentCurrent" xlink:label="pyxs_ResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pyxs_AccruedResearchAndDevelopmentExpensesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="pyxs_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pyxs_DeferredTaxAssetsLicenseFee" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_DeferredTaxAssetsLicenseFee" xlink:label="pyxs_DeferredTaxAssetsLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>39
<FILENAME>pyxs-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-29T06:58:57.0799+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_FurnitureAndOfficeEquipmentMember" xlink:label="pyxs_FurnitureAndOfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_NumberOfFinanceLease" xlink:label="pyxs_NumberOfFinanceLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture" xlink:label="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LiquidityPolicyTextBlock" xlink:label="pyxs_LiquidityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TaxCreditCarryforwardExpirationYear" xlink:label="pyxs_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LaboratoryEquipmentMember" xlink:label="pyxs_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_PaymentsToRelatedPartiesPerMonth" xlink:label="pyxs_PaymentsToRelatedPartiesPerMonth"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ProceedsFromPromissoryNoteIssued" xlink:label="pyxs_ProceedsFromPromissoryNoteIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability" xlink:label="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UniversityLicenseAgreementMember" xlink:label="pyxs_UniversityLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AnnualLicenseMaintenanceFees" xlink:label="pyxs_AnnualLicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ConvertiblePreferredStockSharesIssuedValue" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AlloyTherapeuticsIncMember" xlink:label="pyxs_AlloyTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LicensingAgreementsTextBlock" xlink:label="pyxs_LicensingAgreementsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember" xlink:label="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_NatureOfBusinessPolicyTextBlock" xlink:label="pyxs_NatureOfBusinessPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TemporaryEquityIssuanceCosts" xlink:label="pyxs_TemporaryEquityIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ResearchAndDevelopmentCurrent" xlink:label="pyxs_ResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_RentIncreasePercentage" xlink:label="pyxs_RentIncreasePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_PotentialDevelopmentAndCommercialMilestonePayment" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UnvestedRestrictedStockMember" xlink:label="pyxs_UnvestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LegoChemLicenseAgreementMember" xlink:label="pyxs_LegoChemLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_OneTimeMilestonePayment" xlink:label="pyxs_OneTimeMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_InitialPublicOfferingPolicyTextBlock" xlink:label="pyxs_InitialPublicOfferingPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SecuritiesPurchaseAgreementMember" xlink:label="pyxs_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_OperatingLossCarryforwardsExpirationYear" xlink:label="pyxs_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" xlink:label="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ScientificAdvisoryBoardMember" xlink:label="pyxs_ScientificAdvisoryBoardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_StockOptionsAvailableForIssuanceMember" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UpfrontPayments" xlink:label="pyxs_UpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LicenseAgreementsAbstract" xlink:label="pyxs_LicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UpfrontFee" xlink:label="pyxs_UpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_NumberOfOperatingLease" xlink:label="pyxs_NumberOfOperatingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202001Member" xlink:label="us-gaap_AccountingStandardsUpdate202001Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_RisksAndUncertaintiesPolicyTextBlock" xlink:label="pyxs_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost" xlink:label="pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_MilestonePaymentsPayableUponCertainAchievements" xlink:label="pyxs_MilestonePaymentsPayableUponCertainAchievements"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ContributedAmountToJointVentureByEachEntity" xlink:label="pyxs_ContributedAmountToJointVentureByEachEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_StockIssuanceExpenses" xlink:label="pyxs_StockIssuanceExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_LeaseExpirationYear" xlink:label="pyxs_LeaseExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesAConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_MaximumAmountPaidToRelatedParties" xlink:label="pyxs_MaximumAmountPaidToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_UnderwritingDiscountsAndCommissions" xlink:label="pyxs_UnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable" xlink:label="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SublicensingRevenuePercentage" xlink:label="pyxs_SublicensingRevenuePercentage"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_IssuanceOfConvertiblePreferredStockShares" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_DeferredTaxAssetsLicenseFee" xlink:label="pyxs_DeferredTaxAssetsLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="pyxs_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AggregateMilestonePayments" xlink:label="pyxs_AggregateMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_BiosionLicenseAgreementMember" xlink:label="pyxs_BiosionLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_VoxallMember" xlink:label="pyxs_VoxallMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AggregateMaximumAmountPaidToRelatedParties" xlink:label="pyxs_AggregateMaximumAmountPaidToRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ServiceFeeIncomeFromRelatedParty" xlink:label="pyxs_ServiceFeeIncomeFromRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_OperatingLossCarryforwardsBeforeTax" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_MilestoneAndRoyaltiesIncurred" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_PaymentForLicenseFee" xlink:label="pyxs_PaymentForLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_ExtraMilestonePayment" xlink:label="pyxs_ExtraMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_MinimumAnnualRoyaltyFees" xlink:label="pyxs_MinimumAnnualRoyaltyFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pyxs-20211231.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common shares issued upon conversion of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Common Shares Issued Upon Conversion of Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common shares issued upon conversion of preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating loss carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Authorized Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in Joint Venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Outstanding, Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, issued value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value per share; 190,000,000 and 40,300,000 shares authorized as of December 31, 2021 and 2020, respectively; 32,792,867 and 2,177,956 shares issued as of December 31, 2021 and 2020, respectively and 32,222,881 and 1,289,342 shares outstanding at December 31, 2021 and 2020, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Financial Instruments Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Instruments Carried at Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Convertible Shares Issuable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock shares issued upon conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Issuable Upon Conversion (pre-reverse stock split)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average shares of common stock outstanding - basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted-average common shares outstanding, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FurnitureAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Office Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FurnitureAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Office Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FurnitureAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Furniture and office equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of related assets, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation permanent differences.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Exercisable at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Fair Value Assumptions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets before valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, par value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Investment in joint venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Interest in Joint Venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, accounting standards update, adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of cash, cash equivalents and restricted cash:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 16)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfFinanceLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of finance lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfFinanceLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of finance lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfFinanceLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of finance lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock (Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Series B convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities measured at fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash gain (loss) from equity method investment in joint venture.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-cash Gain (Loss) from Equity Method Investment in Joint Venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash loss from equity method investment in joint venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, accounting standards update, immaterial effect [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Series A and Series B convertible preferred stock into shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit carryovers expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Diluted Other Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock outstanding percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation and benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Shares, Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extra milestone payment for which derivative liability recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extra Milestone Payment for Which Derivative Liability Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extra milestone payment for which derivative liability recognized.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Office Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PfizerLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pfizer license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PfizerLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pfizer License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PfizerLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pfizer License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PaymentsToRelatedPartiesPerMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments to related parties per month.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PaymentsToRelatedPartiesPerMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Related Parties Per Month</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PaymentsToRelatedPartiesPerMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to board members per month</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Description Of Principal Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investment, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromPromissoryNoteIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from promissory note issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromPromissoryNoteIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Promissory Note Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromPromissoryNoteIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Promissory note issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial recognition of derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Initial Recognition Of Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation recurring basis liability initial recognition of derivative liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Lives of Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Estimated Useful Lives of Property and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of estimated useful lives of property and equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UniversityLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">University license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UniversityLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">University License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UniversityLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate%</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective income tax rate%</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective tax rate from continuing operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Purchases From Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to purchase licensed products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual maintenance fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Maintenance Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual license maintenance fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock shares issued value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of convertible preferred stock value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of voting membership units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Series A and Series B convertible preferred stock into shares of common stock (Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Operating Lease Right-of-Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Liabilities, Operating Lease Right-of-Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AlloyTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alloy Therapeutics, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AlloyTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alloy Therapeutics Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AlloyTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alloy Therapeutics, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and development credit carryovers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Equity Method Investment Equity Method Investee Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LicensingAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensing agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LicensingAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreements [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LicensingAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value $0.001 per share, 10,000,000 and zero shares authorized as of December 31, 2021 and 2020, respectively, zero shares issued and outstanding at December 31, 2021 and 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreements with Pfizer, Inc. and LegoChem Biosciences Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreements with Pfizer, Inc. and LegoChem Biosciences Inc. [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreements with Pfizer, Inc. and LegoChem Biosciences Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NatureOfBusinessPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of Business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NatureOfBusinessPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NatureOfBusinessPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Liability Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Aggregate Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current income tax expenses (benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental schedule of noncash operating and financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share - basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Outstanding, at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Outstanding, at December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net operating losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross cash proceeds from issuance of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding at December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development In Process</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting pronouncements not yet adopted policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RentIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent increase percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RentIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rent Increase Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RentIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent increase percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Series B convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Outstanding at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Outstanding at December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum lease obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Future undiscounted operating lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock in initial public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential development and commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Development and Commercial Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential development and commercial milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnvestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnvestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnvestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LegoChemLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">LegoChem license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LegoChemLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lego Chem License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LegoChemLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LegoChem License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OneTimeMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OneTimeMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One-time Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OneTimeMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">One-time milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_InitialPublicOfferingPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_InitialPublicOfferingPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_InitialPublicOfferingPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Less: amount representing imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: amount representing imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classification and Accretion of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classification and Accretion of Convertible Preferred Stock [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Classification and Accretion of Convertible Preferred Stock [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in deferred tax assets valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets measured at fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Net Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Common Stock Reserved For Future Issuance [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair value of derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain Loss On Derivatives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of related assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScientificAdvisoryBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scientific advisory board.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScientificAdvisoryBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scientific Advisory Board [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScientificAdvisoryBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scientific Advisory Board</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options available for issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Available For Issuance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Available for Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, term of contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State taxes, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LicenseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LicenseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Reserved for Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of operating lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Exercisable at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202001Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2020-01</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202001Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2020-01 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital stock authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Units, Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset obtained in exchange for new operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Outstanding, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting commission and issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks and Uncertainties [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks and Uncertainties [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercised (Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Equity Method Investments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Equity Method Investments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development licensed product estimated cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensed product estimated cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestonePaymentsPayableUponCertainAchievements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments payable upon certain achievements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestonePaymentsPayableUponCertainAchievements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Payable Upon Certain Achievements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestonePaymentsPayableUponCertainAchievements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments payable upon certain achievements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Conversion of Series A and Series B convertible preferred stock into shares of common stock (Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Convertible Preferred Stock Converted into Shares of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity convertible preferred stock converted into shares of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Estimated Useful Lives of Related Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other (expense) income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liquidation Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Liquidation Preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, liquidation value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investee Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Outstanding, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative, Gain (Loss) on Derivative, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from issuance of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Level 3 Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ContributedAmountToJointVentureByEachEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributed amount to joint venture by each member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ContributedAmountToJointVentureByEachEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contributed Amount to Joint Venture by Each Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ContributedAmountToJointVentureByEachEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contributed amount to joint venture by each entity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuanceExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuanceExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuance Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuanceExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issuance expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease terms expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stocks.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stocks [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesAConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Nature of Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumAmountPaidToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount paid to related parties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumAmountPaidToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Paid To Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumAmountPaidToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount paid to board members</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Accrued Expenses and Other Current Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of accrued expenses and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average fair value of options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty obligation period for licensed products upon first commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Obligation Period For Licensed Products Upon First Commercial Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty obligation period for licensed products upon first commercial sale.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Transfer to accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfer to Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation recurring basis liability transfer to accounts payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SublicensingRevenuePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublicensing revenue percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SublicensingRevenuePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublicensing Revenue Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SublicensingRevenuePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublicensing revenue percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of convertible preferred stock shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Convertible Preferred Stock Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of convertible preferred stock shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-cash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments And Joint Ventures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Common Stock Reserved For Future Issuance [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense weighted average amortized period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reserves and accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate maximum obligation to pay future contingent milestone payments for normal approval</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate maximum obligation to pay future contingent milestone payments for normal approval.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxAssetsLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets license fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DeferredTaxAssetsLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized service fee as other income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Other Revenues from Transactions with Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Losses incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, accounting standards update, adoption date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">External research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common shares authorized for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate milestone payments for first four licensed products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock public offering price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share sale price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of common shares issuable under exercise of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Number of Common Shares Issuable Under Exercise of Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum number of common shares issuable under exercise of options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total future minimum lease obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum leases obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BiosionLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biosion License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BiosionLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Biosion license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Shares Issued Net Of Shares For Tax Withholdings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of restricted common stock shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_VoxallMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Voxall.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_VoxallMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Voxall [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_VoxallMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voxall</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Outstanding, at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant ate fair value, Outstanding, at December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumAmountPaidToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate maximum amount paid to related parties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumAmountPaidToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate maximum amount paid to related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized to be repurchased under a stock repurchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Derivative liability balance as of January 1, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance as of December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability balance at the beginning of the period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock (Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ServiceFeeIncomeFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Service fee income from related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ServiceFeeIncomeFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service Fee Income From Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ServiceFeeIncomeFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service fee income from related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from stock options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amended license agreement amount incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards before tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards before tax.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value recorded in earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone and royalties required</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone and royalties incurred.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone and Royalties Incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangibles</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income tax computed at federal statutory rate%</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity (deficit):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Shares Converted1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock automatically converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of preferred shares conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PaymentForLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for license fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PaymentForLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for License Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PaymentForLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for license fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Joint Venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basic and Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extra milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extra Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extra milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Conversion of Series A and Series B convertible preferred stock into shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Convertible Preferred Stock Converted into Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity convertible preferred stock converted into common stock value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MinimumAnnualRoyaltyFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum annual royalty fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MinimumAnnualRoyaltyFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum annual royalty fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MinimumAnnualRoyaltyFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Annual Royalty Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stocks.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stocks [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock issuable upon conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common shares reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Equity Method Investments [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Equity Method Investments [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (expense) income:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of restricted stock vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from equity method investment in joint venture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Equity Method Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Equity Method Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit carryovers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Derivative Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ESPP Withholdings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in initial public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" xlink:to="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_FurnitureAndOfficeEquipmentMember" xlink:to="pyxs_FurnitureAndOfficeEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NumberOfFinanceLease" xlink:to="pyxs_NumberOfFinanceLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture" xlink:to="pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_LiquidityPolicyTextBlock" xlink:to="pyxs_LiquidityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TaxCreditCarryforwardExpirationYear" xlink:to="pyxs_TaxCreditCarryforwardExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" xlink:to="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_LaboratoryEquipmentMember" xlink:to="pyxs_LaboratoryEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_PfizerLicenseAgreementMember" xlink:to="pyxs_PfizerLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:to="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_PaymentsToRelatedPartiesPerMonth" xlink:to="pyxs_PaymentsToRelatedPartiesPerMonth_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:to="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ProceedsFromPromissoryNoteIssued" xlink:to="pyxs_ProceedsFromPromissoryNoteIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability" xlink:to="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_UniversityLicenseAgreementMember" xlink:to="pyxs_UniversityLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AnnualLicenseMaintenanceFees" xlink:to="pyxs_AnnualLicenseMaintenanceFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ConvertiblePreferredStockSharesIssuedValue" xlink:to="pyxs_ConvertiblePreferredStockSharesIssuedValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AlloyTherapeuticsIncMember" xlink:to="pyxs_AlloyTherapeuticsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_LicensingAgreementsTextBlock" xlink:to="pyxs_LicensingAgreementsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember" xlink:to="pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NatureOfBusinessPolicyTextBlock" xlink:to="pyxs_NatureOfBusinessPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TemporaryEquityIssuanceCosts" xlink:to="pyxs_TemporaryEquityIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ResearchAndDevelopmentCurrent" xlink:to="pyxs_ResearchAndDevelopmentCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RentIncreasePercentage" xlink:to="pyxs_RentIncreasePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_PotentialDevelopmentAndCommercialMilestonePayment" xlink:to="pyxs_PotentialDevelopmentAndCommercialMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_UnvestedRestrictedStockMember" xlink:to="pyxs_UnvestedRestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_LegoChemLicenseAgreementMember" xlink:to="pyxs_LegoChemLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_OneTimeMilestonePayment" xlink:to="pyxs_OneTimeMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_InitialPublicOfferingPolicyTextBlock" xlink:to="pyxs_InitialPublicOfferingPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SecuritiesPurchaseAgreementMember" xlink:to="pyxs_SecuritiesPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_OperatingLossCarryforwardsExpirationYear" xlink:to="pyxs_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" xlink:to="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ScientificAdvisoryBoardMember" xlink:to="pyxs_ScientificAdvisoryBoardMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_StockOptionsAvailableForIssuanceMember" xlink:to="pyxs_StockOptionsAvailableForIssuanceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="pyxs_TwoThousandNineteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_UpfrontPayments" xlink:to="pyxs_UpfrontPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_LicenseAgreementsAbstract" xlink:to="pyxs_LicenseAgreementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_UpfrontFee" xlink:to="pyxs_UpfrontFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NumberOfOperatingLease" xlink:to="pyxs_NumberOfOperatingLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202001Member" xlink:to="us-gaap_AccountingStandardsUpdate202001Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RisksAndUncertaintiesPolicyTextBlock" xlink:to="pyxs_RisksAndUncertaintiesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost" xlink:to="pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:to="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MilestonePaymentsPayableUponCertainAchievements" xlink:to="pyxs_MilestonePaymentsPayableUponCertainAchievements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock" xlink:to="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_GrossProceedsFromIssuanceInitialPublicOffering" xlink:to="pyxs_GrossProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ContributedAmountToJointVentureByEachEntity" xlink:to="pyxs_ContributedAmountToJointVentureByEachEntity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_StockIssuanceExpenses" xlink:to="pyxs_StockIssuanceExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_LeaseExpirationYear" xlink:to="pyxs_LeaseExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SeriesAConvertiblePreferredStocksMember" xlink:to="pyxs_SeriesAConvertiblePreferredStocksMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MaximumAmountPaidToRelatedParties" xlink:to="pyxs_MaximumAmountPaidToRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_UnderwritingDiscountsAndCommissions" xlink:to="pyxs_UnderwritingDiscountsAndCommissions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" xlink:to="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable" xlink:to="pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SublicensingRevenuePercentage" xlink:to="pyxs_SublicensingRevenuePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_IssuanceOfConvertiblePreferredStockShares" xlink:to="pyxs_IssuanceOfConvertiblePreferredStockShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_DeferredTaxAssetsLicenseFee" xlink:to="pyxs_DeferredTaxAssetsLicenseFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="pyxs_AccruedResearchAndDevelopmentExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AggregateMilestonePayments" xlink:to="pyxs_AggregateMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" xlink:to="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_BiosionLicenseAgreementMember" xlink:to="pyxs_BiosionLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_VoxallMember" xlink:to="pyxs_VoxallMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AggregateMaximumAmountPaidToRelatedParties" xlink:to="pyxs_AggregateMaximumAmountPaidToRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ServiceFeeIncomeFromRelatedParty" xlink:to="pyxs_ServiceFeeIncomeFromRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_OperatingLossCarryforwardsBeforeTax" xlink:to="pyxs_OperatingLossCarryforwardsBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MilestoneAndRoyaltiesIncurred" xlink:to="pyxs_MilestoneAndRoyaltiesIncurred_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_PaymentForLicenseFee" xlink:to="pyxs_PaymentForLicenseFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ExtraMilestonePayment" xlink:to="pyxs_ExtraMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue" xlink:to="pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MinimumAnnualRoyaltyFees" xlink:to="pyxs_MinimumAnnualRoyaltyFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SeriesBConvertiblePreferredStocksMember" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250549494024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 29, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Pyxis Oncology, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001782223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1160910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">35 Cambridgepark Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">221-9059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PYXS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,841,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Portions of the Registrant&#8217;s Proxy Statement for its 2021 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2021.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250549718712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 274,735<span></span>
</td>
<td class="nump">$ 8,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">1,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,466<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">278,673<span></span>
</td>
<td class="nump">8,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">280,021<span></span>
</td>
<td class="nump">10,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,951<span></span>
</td>
<td class="nump">1,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">6,592<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,708<span></span>
</td>
<td class="nump">3,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">18,708<span></span>
</td>
<td class="nump">3,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share, 10,000,000 and zero shares authorized as of December 31, 2021 and 2020, respectively, zero shares issued and outstanding at December 31, 2021 and 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 190,000,000 and 40,300,000 shares authorized as of December 31, 2021 and 2020, respectively; 32,792,867 and 2,177,956 shares issued as of December 31, 2021 and 2020, respectively and 32,222,881 and 1,289,342 shares outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">352,999<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(91,718)<span></span>
</td>
<td class="num">(15,743)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">261,313<span></span>
</td>
<td class="num">(15,645)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</a></td>
<td class="nump">$ 280,021<span></span>
</td>
<td class="nump">10,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesAConvertiblePreferredStocksMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,942<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesAConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pyxs_SeriesAConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250548104152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">190,000,000<span></span>
</td>
<td class="nump">40,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">32,792,867<span></span>
</td>
<td class="nump">2,177,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">32,222,881<span></span>
</td>
<td class="nump">1,289,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesAConvertiblePreferredStocksMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,724,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,724,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,724,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesAConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pyxs_SeriesAConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250549375880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 51,054<span></span>
</td>
<td class="nump">$ 9,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">18,663<span></span>
</td>
<td class="nump">3,846<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">69,717<span></span>
</td>
<td class="nump">12,894<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(69,717)<span></span>
</td>
<td class="num">(12,894)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ServiceFeeIncomeFromRelatedParty', window );">Service fee income from related party</a></td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="num">(6,231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income</a></td>
<td class="num">(6,027)<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment in joint venture</a></td>
<td class="num">(231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (75,975)<span></span>
</td>
<td class="num">$ (12,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted</a></td>
<td class="num">$ (8.95)<span></span>
</td>
<td class="num">$ (12.45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares of common stock outstanding - basic and diluted</a></td>
<td class="nump">8,493,273<span></span>
</td>
<td class="nump">1,030,556<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ServiceFeeIncomeFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Service fee income from related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ServiceFeeIncomeFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250547431368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Pfizer License Agreement</div>
</th>
<th class="th"><div>Initial Public Offering</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Initial Public Offering</div>
</th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>Initial Public Offering</div>
</th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,724,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">$ (2,874)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,915)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,828)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,828)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,724,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="num">(15,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,743)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,289,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,081<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series B convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,660,103<span></span>
</td>
<td class="nump">12,152,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue', window );">Temporary equity, Conversion of Series A and Series B convertible preferred stock into shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (194,023)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock', window );">Temporary equity, Conversion of Series A and Series B convertible preferred stock into shares of common stock (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127,537,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series A and Series B convertible preferred stock into shares of common stock</a></td>
<td class="nump">194,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A and Series B convertible preferred stock into shares of common stock (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,056,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">$ 170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (Shares)</a></td>
<td class="nump">70,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(75,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,975)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 261,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 352,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (91,718)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,222,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity convertible preferred stock converted into common stock value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity convertible preferred stock converted into shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250553660312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_TemporaryEquityIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Underwriting commission and issuance costs</a></td>
<td class="nump">$ 15,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_TemporaryEquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_TemporaryEquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250549527416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (75,975)<span></span>
</td>
<td class="num">$ (12,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">647<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">6,441<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Non-cash research and development expenses</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture', window );">Non-cash loss from equity method investment in joint venture</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Changes in fair value of derivative liability</a></td>
<td class="nump">6,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,444)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">4,643<span></span>
</td>
<td class="nump">558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">5,092<span></span>
</td>
<td class="nump">1,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(615)<span></span>
</td>
<td class="num">(421)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(35,326)<span></span>
</td>
<td class="num">(10,084)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(540)<span></span>
</td>
<td class="num">(1,483)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Investment in joint venture</a></td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(590)<span></span>
</td>
<td class="num">(1,483)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Series B convertible preferred stock, net of issuance costs</a></td>
<td class="nump">151,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock in initial public offering, net of issuance costs</a></td>
<td class="nump">152,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds From Issuance Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">304,044<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">268,128<span></span>
</td>
<td class="num">(11,532)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">8,188<span></span>
</td>
<td class="nump">19,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">276,316<span></span>
</td>
<td class="nump">8,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of noncash operating and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset obtained in exchange for new operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">274,735<span></span>
</td>
<td class="nump">8,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 276,316<span></span>
</td>
<td class="nump">$ 8,188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash gain (loss) from equity method investment in joint venture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552619080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Nature of Business</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Organization and Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pyxis Oncology, Inc. (the &#8220;Company&#8221;), a Delaware corporation, was founded in June 2018 and launched its operations in July 2019. The Company is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The Company develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since the Company&#8217;s launch in 2019, the Company has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates and monoclonal antibody, or mAb, preclinical discovery programs that the Company is developing as monotherapies and in combination with other therapies.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has determined that it has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating and reporting segment.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reverse Stock Split</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 1, 2021, the Company effected a 1-for-</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6e0eb586-b179-4054-af6f-b94a1fcee934;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.359</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split of its issued and outstanding common stock and stock option awards. The par value of the common stock and preferred stock was not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the convertible preferred stock conversion price to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The shares of common stock underlying outstanding stock options and restricted stock units were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All issued and outstanding shares of common stock, restricted stock units, stock option awards and per share data have been adjusted on a retrospective basis in these consolidated financial statements, to reflect the reverse stock split for all periods presented.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 8, 2021, the Company completed an initial public offering (&#8220;IPO&#8221;) in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company raised approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in net proceeds after deducting underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and offering expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon closing of the IPO, all of the outstanding shares of Series A Convertible Preferred stock (&#8220;Series A Preferred Stock&#8221;), and Series B Convertible Preferred Stock (&#8220;Series B Preferred Stock&#8221;) automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,056,145</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock of the Company. Subsequent to the closing of the IPO, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of convertible preferred stock outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the closing of the IPO, the Company filed an amended and restated certificate of incorporation (&#8220;Amended Certificate of Incorporation&#8221;) to change the authorized capital stock to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">200,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">190,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> are designated as voting common stock and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> are designated as undesignated preferred stock, all with a par value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, the Company has primarily financed its operations through the sale of convertible preferred stocks and the proceeds from IPO. The Company has not generated any revenues to date and does not anticipate generating any revenues unless and until it successfully completes development and obtains regulatory approval for its current or any future product candidates. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to expand its research and development programs, business development activities and develop its product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company currently expects that its existing cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">274.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021 will be sufficient to fund its operating expenses and capital requirements at least twelve months from the date these consolidated financial statements are issued. Additional funding may be necessary to fund future clinical and preclinical activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company plans to continue to fund its losses from operations and capital funding needs through issuance of equity securities, convertible or debt financings or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250720352840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s fiscal year ends on December 31 and its first three quarters end on March 31, June 30 and September 30. The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Section 107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expense, and related disclosures. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, derivative liability, research and development accruals, operating leases, assessment of the useful lives of property and equipment, valuation of deferred tax assets and liabilities, impairment of investment in joint venture, and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, the management considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the year ended December 31, 2021. However, the extent to which the COVID-19 pandemic may directly or indirectly impact the Company&#8217;s financial statements is highly uncertain and subject to change.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Actual results could differ from those estimates and there may be changes to management&#8217;s estimates in future periods.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to risks common to early-stage companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key suppliers for active ingredients and third-party service providers such as contract research organizations, protection of intellectual property rights and the ability to make milestone, royalty or other payments due under any license, collaboration or supply agreements.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risks</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company&#8217;s cash and cash equivalents are held at an accredited financial institution and the Company has not experienced any losses in such accounts. The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company&#8217;s cash equivalents consist primarily of short-term money market funds held in accredited financial institutions. The Company believes it is not exposed to any significant risk in cash and cash equivalents.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all short term, highly liquid investments with original maturities of 90 days or less to be cash equivalents. Cash equivalents consist primarily of money market funds as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principle or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, the first two are considered observable and the last is considered unobservable:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the related assets as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:73.139%;"/>
          <td style="width:1.898%;"/>
          <td style="width:24.963%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Estimated Useful<br/>Life (Years)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and office equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of remaining life<br/>of lease or useful life</span></span></p></td>
         </tr>
        </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and amortization expense is included in research and development and general and administrative expenses. Major additions and upgrades are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are expensed as incurred. Upon retirement or sale, the cost of assets disposed of, and the related accumulated depreciation and amortization are removed from the respective accounts and any resulting gain or loss is included in income (loss) from operations.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates the long-lived assets, which consist of property and equipment and operating lease right-of-use assets, for impairment at least annually and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. Management then determines whether the remaining useful life continues to be appropriate, or whether there has been an impairment of long-lived assets based primarily upon whether expected future undiscounted cash flows are sufficient to support the assets&#8217; recovery. Recoverability of these assets is measured by comparison of the carrying amount of the asset to the future undiscounted cash flows the asset is expected to generate. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. The Company recognized </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment losses for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lease right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are initially recognized and measured based on the present value of the future fixed lease payments over the expected lease term at the commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. The Company determines the lease term as the non-cancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease ROU assets also include any initial direct costs incurred and any lease payments made on or before the lease commencement date, less lease incentives received. Operating lease ROU assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. The Company accounts for lease and non-lease components as a single lease component for all its facilities leases. The Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> finance leases as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investment in Joint Venture</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investment in the Company&#8217;s joint venture is accounted for using the equity method of accounting. The Company </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">apply the equity method of accounting to investments when the Company has significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">equity</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">method</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">investment</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the equity method, investments are initially recorded at cost and are adjusted for dividends, distributed and undistributed earnings and losses, and additional investments. In the event the Company&#8217;s share of a joint venture&#8217;s cumulative losses exceeds the Company&#8217;s investment balance, the balance is reported at zero value until proportionate income exceeds the losses. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingencies</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company, from time to time, may be a party to various disputes and claims arising from normal business activities. The Company continually assesses disputes and claims including resulting litigation to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the contingencies, including an estimable range, if possible.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company expenses research and development costs as incurred. The Company&#8217;s research and development expenses consist primarily of license fees to acquire intellectual property which does not meet the definition of intangible assets and costs incurred in performing research and development activities, including personnel-related expenses such as salaries, stock-based compensation and benefits, facilities costs, depreciation as well as external costs for outside vendors engaged to conduct preclinical development activities and license fees. The Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and efforts expended pursuant to the terms of the contractual arrangements. Payments under some of these contracts depend on preclinical trial milestones. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of expenses. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or prepaid expense accordingly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company maintains an equity incentive plan as a long-term incentive for employees, consultants, and directors. The Company accounts for all stock-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The grant date fair value of the stock-based awards with graded vesting is recognized on a straight-line basis over the requisite service period. The Company recognizes forfeitures related to stock-based compensation awards as they occur and reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs. The Company classifies stock-based compensation expense in the statement of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company values its stock options with service conditions using the Black-Scholes option pricing model. The Company use certain assumptions to determine fair value of the stock options pursuant to the Black-Scholes option pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate, expected dividend yield and the fair value of the Company&#8217;s common stock. Since the Company has no option exercise history, the Company uses the simplified method described in the SEC&#8217;s Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-Based Payment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(&#8220;SAB 107&#8221;), to determine the expected life of the option grants. The Company lacks sufficient company-specific historical and implied volatility information. Therefore, the Company estimates the expected stock volatility based on the historical volatility of a publicly traded set of peer companies. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. As the Company has never paid and does not anticipate paying cash dividends on its common stock, the expected dividend yield is considered as zero.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Prior to the completion of the Company&#8217;s IPO, the fair value of the Company's common stock which is one of the key input in Black-Scholes option pricing model, was determined by the board of directors with input from management and based on certain assumptions including probability weighting of events, business and market conditions, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. The Company used 409A valuations to determine the fair value of the shares of common stock. The 409A valuations were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;font-style:italic;">Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">. After completion of the IPO, on October 8, 2021, the Company uses the fair value of its publicly traded common stock to determine grant date fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For restricted stock awards issued pursuant to standalone restricted stock purchase agreements, the fair value of each award was estimated based on the estimated fair value of the Company&#8217;s common stock, less the amount paid by the grantee. The Company recognized deposit liability for restricted stock awards issued pursuant to standalone restricted stock purchase agreements. As the awards of restricted stock vest, the Company reclassifies the deposit liability to additional paid-in capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes in accordance with FASB ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (&#8220;ASC 740&#8221;), which requires the use of the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between amounts in the consolidated financial statements and the tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income tax (benefit) expense in the consolidated statements of operations and comprehensive loss in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Classification and Accretion of Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Classification of the Company&#8217;s convertible preferred stock was treated as mezzanine financing and not as part of stockholders&#8217; equity (deficit) because the holders of such shares had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock was not redeemable, except in the event of certain deemed liquidation events enumerated in the Company&#8217;s certificate of incorporation. Because the occurrence of a deemed liquidation event was not probable, the carrying values of the convertible preferred stock were not accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares of preferred stock were automatically convertible into shares of common stock at the earlier of (i) the closing of a firm-commitment underwritten public offering resulting in at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of gross proceeds in the aggregate to the Company, prior to deductions for underwriting discounts, commission and expenses or (ii) the date and time, or occurrence of an event, specified by a vote of the Series A and Series B Stockholders. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon closing of the IPO, all of the outstanding </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A and Series B </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">convertible preferred stock automatically converted in</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to common stock, resulting in </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> outstanding convertible preferred stock as of December 31, 2021.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company follows the two-class method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the diluted weighted average number of common shares outstanding for the period, including potential dilutive common shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s participating securities contractually entitle the holders of such shares to participate in dividends but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2020, the FASB issued ASU 2020-01, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments &#8212; Equity Securities (Topic 321), Investments &#8212; Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The new guidance addresses accounting for the transition into and out of the equity method and measuring certain purchased options and forward contracts to acquire investments. This ASU is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> this ASU from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and the adoption did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have any impact on the Company&#8217;s consolidated financial position, results of operations, or cash flows.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(&#8220;ASU 2016-13&#8221;), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses on available-for-sale debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. As an emerging growth company, ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2022, and early adoption is permitted. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is currently evaluating the new standard and expects it to have no material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC did not, or are not expected to, have a material impact on the Company&#8217;s unaudited consolidated financial statements and related disclosures. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552451112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_LicenseAgreementsAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_LicensingAgreementsTextBlock', window );">Licensing Agreements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Licensing Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The University of Chicago Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2020, the Company entered into a license agreement (the &#8220;University License Agreement&#8221;), as well as a sponsored research agreement, with the University of Chicago (the &#8220;University&#8221;) to obtain an exclusive license under certain patents resulting from research performed, in-part, by the Company&#8217;s scientific founder, as well as a non-exclusive license to certain know-how and materials relating thereto. Under the terms of the license, the Company has the global right to develop and commercialize products that are covered by a valid claim of a licensed patent, incorporate or use the licensed know-how and materials or are known to assess, modulate or utilize the activity of certain specified biological targets.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In partial consideration for the license from the University, the Company issued to the University </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,919</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock in 2020. The Company recorded the value of the shares issued of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">as research and development expenses during the year ended December 31, 2020. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t incurred any expenses relating to the University License Agreement during the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Pursua</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">nt to the University License Agreement, the Company is obligated to pay to the University an annual maintenance fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> commencing on the third anniversary of the effective date, potential development and commercial milestones of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as well as running royalties on net sales of licensed products at varying rates ranging from less than a percent to the low single digits, subject to a minimum annual royalty of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during certain years following the effective date. The Company&#8217;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until: (1) for licensed products covered by a valid claim of a licensed patent in a given country, the expiration of such valid claims; and (2) for all other licensed products, ten (</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) years from the first commercial sale of a licensed product in a given country. The Company is also obligated to pay the University a percentage of certain sublicensing revenue ranging from low- to mid-teens based on the date of entering into the applicable sublicense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assessed the milestone and royalty events under University License Agreement as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020, and determined that </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such amounts were required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pfizer, Inc. Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company entered into a license agreement, as amended (the &#8220;Pfizer License Agreement&#8221;) with Pfizer, Inc. (&#8220;Pfizer&#8221;) for worldwide development and commercialization rights to antibody drug conjugate ("ADC") product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates. The Pfizer License Agreement became effective for the Company in March 2021. The Company&#8217;s rights are exclusive with respect to certain patents owned or controlled by Pfizer covering the licensed ADCs. Pfizer has also granted the Company a non-exclusive license to use Pfizer&#8217;s ADC technology platform to develop and commercialize the licensed ADCs and licensed products. The initial licensed targets include CD123 and extra domain B (EBD of fibronectin) and the Company has the option to expand the scope of its license to add additional licensed targets that have not been licensed to a third party or are not the subject of a Pfizer ADC development program. In March 2021, the Company entered into an amendment to the Pfizer License Agreement to include additional know-how within the scope of its license. The Company determined that substantially all of the fair value of the Pfizer License Agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development associated with the agreements. Thus, the Company recorded payments made under the License Agreement as research and development expenses in the consolidated statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Pfizer License Agreement, the Company paid a combined $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for license fee, which was recorded in research and development expense in the consolidated statement of operations and consists of an upfront fee equal to a cash payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,152,145</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B convertible preferred stock with a value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in 2021 to Pfizer, and is obligated to pay future contingent payments and royalties, including up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">660</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in milestones for the first four licensed ADCs. Additional ADC targets may be licensed for a nominal upfront and milestones. Additionally, if products are launched, the Company will pay Pfizer tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to mid-teens. The Company&#8217;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. The Company is also obligated to pay Pfizer a percentage of certain sublicensing revenue ranging from </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">thirty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> percent to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the Company effected a change of control transaction or sold all or substantially all of its assets relating to the Pfizer License Agreement within 12 months from the effective date or closing of the IPO, the Company would have been required to make a one-time payment to Pfizer of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such event took place during the year and the one-time payment was not required.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assessed the milestone, royalty and other events under Pfizer License Agreement as of December 31, 2021, and determined that </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such amounts were required.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">LegoChem Biosciences, Inc. Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company entered into a license agreement (the &#8220;LegoChem License Agreement&#8221;) with LegoChem Biosciences, Inc. (&#8220;LegoChem&#8221;) pursuant to which the Company licensed worldwide (other than Korea) development and commercialization rights for LCB67, an ADC product candidate targeting DLK-1, and products containing the licensed compound. The Company has the right to request that LegoChem use commercially reasonable efforts at the Company&#8217;s cost to modify the licensed compound if there are certain technical failures of the licensed compound that the Company believes are attributable to the linker or the payload used in the licensed compound, and the modified compound will replace the unmodified version as the licensed compound. In February 2021, the Company entered into an amendment to the LegoChem License Agreement to include additional patents within the scope of its license. The Company determined that substantially all of the fair value of the LegoChem License Agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development associated with the agreements. Thus, the Company recorded payments made under the LegoChem License Agreement as research and development expenses in the consolidated statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the LegoChem License Agreement, the Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in 2020 and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in 2021 and is required to purchase certain initial quantities of licensed product from LegoChem for an estimated cost of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recorded upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in 2020 and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in 2021 as research and development expenses. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> expenses incurred related to the manufacturing of the initial quantities of licensed product for the year ended December 31, 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company is also obligated to pay up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">284.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to LegoChem if certain development, regulatory and sales milestones are achieved, as well as tiered royalties on net sales of licensed products ranging from mid-single digit to high-single digit royalty rates. The Company&#8217;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until the latest to occur of: (1) the date of expiration of the last valid claim of a licensed patent covering the licensed product; (2) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from first commercial sale; and (3) the expiration of regulatory or data exclusivity. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assessed the milestones and royalties under the LegoChem License Agreement as of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and determined that </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such amounts were required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company also entered into an opt-in, investment and additional consideration agreement with LegoChem (the &#8220;Opt-In Agreement&#8221;). Pursuant to the Opt-in Agreement, the Company settled $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of upfront payment for license fee through the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">303,804</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B convertible preferred stock in March 2021. The Company is also obligated to pay LegoChem a percentage of certain sublicensing revenue ranging from thirty percent to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense, which percentage may be increased to up to fifty percent for any upfront payment from a sublicensee under certain circumstances. LegoChem exercised its option in December 2020 under the Opt-In Agreement and paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to the Company in April 2021, in exchange for the right to receive a milestone payment (the &#8220;Extra Milestone Payment&#8221;) of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the earliest to occur of certain events, including the date of pricing or offer of the first public offering of the Company's common stock or if the Company is the subject of a change in control transaction. The Company determined that the Extra Milestone Payment meets the definition and recognition condition of derivative under ASC 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#8220;Derivatives and Hedging&#8221;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for which there was a binding contract and firm commitment as of January 2021. An initial derivative liability was recognized for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million with an offset to research and development expenses in January 2021. The derivative liability was re-measured at each reporting date, with changes recorded in &#8220;Other (expense) income&#8221; in the consolidated statements of operations and comprehensive loss. Upon the Company&#8217;s IPO in October 2021, the Extra Milestone Payment event triggered resulting in realization of derivative liability, for which the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million within accounts payable as of December 31, 2021 and subsequently paid in January 2022. The Company assessed the remaining milestones and royalties under the Opt-In Agreement as of December 31, 2021 and determined that </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such amounts were required.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_LicensingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_LicensingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552661112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Joint Venture<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments And Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Joint Venture</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Joint Venture</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Company entered into definitive transaction agreements with Alloy Therapeutics, Inc. (&#8220;Alloy&#8221;) and Voxall Therapeutics, LLC (&#8220;Voxall&#8221;), to finance and operate Voxall, a joint venture company formed in collaboration with Alloy to leverage the Company&#8217;s technology and Alloy&#8217;s ATX-Gx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.025pt;font-family:Times New Roman;">&#153; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">platform and antibody discovery services. Voxall granted to the Company and Alloy, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the voting membership units of Voxall in exchange for certain initial contributions. The Company&#8217;s initial contribution included $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand and a non-exclusive fully paid-up license to certain intellectual property owned or controlled by the Company and the execution of the services agreement to enable the collaboration with Voxall. Alloy&#8217;s initial contribution included $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand and the execution of the Alloy license agreement and the Alloy services agreement to enable the collaboration with Voxall. Voxall is governed by a board of directors consisting of an equal number of the Company&#8217;s representatives and Alloy&#8217;s representatives. The protective provisions under Voxall&#8217;s operating agreement require the approval of both the Company and Alloy before Voxall may take certain actions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounted for investment in Voxall under the equity method of accounting. The initial contribution was recorded as &#8220;Investment in equity method investment in joint venture&#8221;. Additionally, the Company has recognized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million in service fee income from a related party within other income for services provided to Voxall during the year ended December 31, 2021, for which Voxall issued a promissory note to the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Voxall has incurred losses since inception and the Company&#8217;s share in the losses of Voxall aggregated to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million for the year ended December 31, 2021. The Company recognized its share of losses of Voxall only to the extent of the carrying value of its investment in Voxall and the promissory note issued by Voxall, which aggregated to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million for the year ended December 31, 2021. The remaining unabsorbed loss will be offset against future income, if any. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As the Company has no commitment to fund the losses of the equity method investment, the carrying value of the equity method investment has not been reduced below zero</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250553982424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables present the financial instruments carried at fair value on a recurring basis as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively, in accordance with the FASB ASC 820 hierarchy (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.787%;"/>
        <td style="width:1.206%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.566%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.206%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.529%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.206%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.529%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.206%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.566%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Measurements at<br/>December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">272,210</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">272,210</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Measurements at<br/>December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,996</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,996</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s cash equivalents represent deposits in a short-term United States Treasury money market fund quoted in an active market and classified as a Level 1 asset. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> assets or liabilities measured at fair value on a nonrecurring basis at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the years ended December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of the derivative liability was initially determined using a probability-weighted income approach and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of the derivative liability are recorded as expense within other (expense) income in the consolidated statements of operations and comprehensive loss. The significant unobservable inputs used in the fair value measurement of the derivative liability include probability of payment factors and the discount rate. Refer to Note 3, Licensing Agreements, for additional information on the derivative liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables provide a summary of changes in Level 3 fair value measurements for the year ended December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.246%;"/>
        <td style="width:2.671%;"/>
        <td style="width:1.206%;"/>
        <td style="width:24.079%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Derivative liability balance as of January 1, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Initial recognition of derivative liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,369</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value recorded in earnings</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,231</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transfer to accounts payable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company paid the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of Extra Milestone Payment, for which it previously recognized a derivative liability, in January 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552562696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Prepaid Expenses and Other Current Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.657%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.254%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.244%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Insurance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,763</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">619</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2,466</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552659448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net, consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.503%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.228%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.052%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,804</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,264</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">213</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and office equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,123</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,572</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,116</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">469</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,007</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,103</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense for the years ended December 31, 2021 and 2020 was</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552570808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Accrued Expenses and Other Current Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.648%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.254%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.254%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee compensation and benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,963</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">External research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,381</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">712</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">982</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">167</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">266</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6,592</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,997</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552617400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. Operating Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating leases, respectively, where the Company is the lessee or sublessee, for office and laboratory space. Lease terms are through </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> finance leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of lease expense were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.422%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.984%;"/>
        <td style="width:1.994%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.984%;"/>
        <td style="width:1.994%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">650</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">497</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">146</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease cost (1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">730</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">713</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other information</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use asset obtained in exchange for new operating<br/>&#160;&#160;&#160;lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,186</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of lease liabilities, included<br/>&#160;&#160;&#160;in operating cash flows</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">663</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">484</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.25</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.25</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.00</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.98</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:3.0pt;border-bottom:0.750pt solid;margin-right:83.704%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Variable lease cost includes common area maintenance charges</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></div></div></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Maturities of lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.019%;"/>
        <td style="width:1.939%;"/>
        <td style="width:1.206%;"/>
        <td style="width:16.039%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ending December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating lease</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: amount representing imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total future minimum lease obligations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">165</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to above, on September 29, 2021, the Company entered into a lease agreement for an office and laboratory space in Boston, Massachusetts. The lease will expire on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2032</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and has scheduled rent increases each year of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> option to extend the lease beyond December 31, 2032.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The future undiscounted operating lease payments (base rent) under the lease agreement is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million over an initial lease period of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company will record the right-of-use asset and operating lease liability upon obtaining the possession of the property, which it expects to occur in the second quarter of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552534968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Series A Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2019, the Company entered into a securities purchase agreement (as amended, &#8220;Series A Agreement&#8221;) with certain investors to sell shares of Series A convertible preferred stock (&#8220;Series A&#8221;) at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9681</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. In June and July 2019, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,724,925</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series A to institutional investors at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9681</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for gross cash proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, less issuance costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, resulting in net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. On October 1, 2021, the Company effected a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bc1feaae-b4f0-4232-bfcb-7aa66a503921;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1-for-6.359</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Upon completion of the initial public offering, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,724,925</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series A were converted to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,573,659</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Series B Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 5, 2021, the Company entered into a securities purchase agreement (as amended, &#8220;Series B Agreement&#8221;) with certain investors to sell shares of Series B convertible preferred stock (&#8220;Series B&#8221;) at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6458</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. In March 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92,356,299</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B to institutional investors at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6458</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for gross cash proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, less issuance costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, resulting in net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">151.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In addition, the Company granted </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,455,949</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, or $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, of Series B convertible preferred stock through separate agreements with Pfizer, Inc. and LegoChem Biosciences Inc. On October 1, 2021, the Company effected a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_01b30c23-8e47-433b-a192-0adf8d0251a5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1-for-6.359</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Upon completion of the initial public offering, the entire outstanding shares of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104,812,248</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of Series B were converted to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,482,486</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552595400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stockholders&#8217; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the closing of the IPO, the Company filed an Amended Certificate of Incorporation and authorized </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock, with a par value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The board of directors has the authority, without further action by the stockholders to issue such shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the dividend, dividend rights, conversion rights, voting, redemption terms, liquidation preference and other rights, preferences and privileges of the shares. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> issued and outstanding shares of preferred stock as of December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company was authorized to issue up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">190,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,300,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock as of December 31, 2021 and 2020, respectively, of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32,792,867</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,177,956</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were issued as of December 31, 2021 and 2020, respectively, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32,222,881</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,289,342</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were outstanding at December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Voting, dividend and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Voting</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;Each holder of outstanding shares of common stock shall be entitled to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> vote in respect of each share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reserved Shares</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reserved the following shares of common stock for issuance:</span></span></p><div style="font-size:10.0pt;font-family:Calibri;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.41%;"/>
        <td style="width:1.796%;"/>
        <td style="width:0.641%;"/>
        <td style="width:17.811%;"/>
        <td style="width:0.641%;"/>
        <td style="width:1.954%;"/>
        <td style="width:0.641%;"/>
        <td style="width:15.463%;"/>
        <td style="width:0.641%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A convertible preferred stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,573,659</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted stock options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">618,494</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">888,612</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options available for issuance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,289,259</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,585</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,926,969</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,383</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">424,595</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8,259,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4,718,239</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552419800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 27, 2021, the Company&#8217;s board of directors and stockholders approved the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;), which became effective on October 7, 2021, when the Company&#8217;s registration statement was declared effective by the SEC. The 2021 Plan replaced the 2019 Plan as the Company&#8217;s board of directors has determined not to make additional awards under the 2019 Plan following the closing of the Company&#8217;s initial public offering. However, the 2019 Plan will continue to govern outstanding equity awards granted under the plan. The 2021 Plan allows the Company to make equity-based and cash-based incentive awards to its officers, employees, directors and consultants. The Company has initially reserved </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,852,807</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock for the issuance of awards under the 2021 Plan. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The number of shares of common stock reserved for issuance under the 2021 Plan will automatically increase annually on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022, and continuing until (and including) the fiscal year ending December 31, 2031 by lesser of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the total number of shares of common stock outstanding on December 31st of the immediately preceding fiscal year or number of shares as may be determined by the board of directors. The maximum number of shares of common stock that may be issued pursuant to the exercise of incentive options under the 2021 Plan is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,705,614</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, options to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,515,040</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,508</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> restricted stock units were outstanding under the 2021 plan and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,289,259</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares remained available for future issuance under the 2021 plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2019 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2019, the Company established the 2019 Plan, under which the Company grant options and restricted stock to its employees and certain non-employees. The maximum number of shares of common stock reserved for issuance under the 2019 Plan was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,042,408</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options granted under the 2019 Plan include incentive stock options that can be granted only to the Company&#8217;s employees and non-statutory stock options that can be granted to the Company&#8217;s employees, consultants, advisors and directors. The 2019 Plan also permits the Company to issue restricted stock awards.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The exercise prices, vesting and other restrictions of the awards to be granted under the 2019 Plan are determined by the board of directors, except that no stock option may be issued with an exercise price less than the fair market value of the common stock at the date of the grant or have a term in excess of ten years. Options granted under the 2019 Plan are exercisable in whole or in part at any time subsequent to vesting. All the shares of common stock were issued under the 2019 Plan. As of December 31, 2021, options to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,411,929</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were outstanding under the 2019 plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes stock option activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 (in thousands, except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.848%;"/>
        <td style="width:1.456%;"/>
        <td style="width:0.603%;"/>
        <td style="width:7.894%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.456%;"/>
        <td style="width:1.206%;"/>
        <td style="width:7.272%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.456%;"/>
        <td style="width:0.603%;"/>
        <td style="width:8.979%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.456%;"/>
        <td style="width:1.206%;"/>
        <td style="width:7.958%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number of<br/>Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,383</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.64</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.4</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">348</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,351,820</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.12</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.6</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">574,838</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.41</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5,926,969</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10.03</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">16,414</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,033,510</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5.04</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9.2</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6,125</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average grant-date fair value of options granted during the years ended December 31, 2021 and 2020, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.57</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.62</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">per share, respectively. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding and exercisable stock options and the fair value of the Company&#8217;s common stock as of December 31, 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The intrinsic value of stock options exercised for the year ended December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company estimated the fair value of each option on the date of grant using the Black-Scholes option pricing model applying the range of assumptions in the following table:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.968%;"/>
        <td style="width:2.05%;"/>
        <td style="width:20.466%;"/>
        <td style="width:2.05%;"/>
        <td style="width:20.466%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72.88</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103.41</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79.40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87.40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.81</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.38</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.56</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.25</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.00</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.02</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.08</span></span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense related to stock options recorded in the statements of operations is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.973%;"/>
        <td style="width:1.493%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.216%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.493%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.207%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,976</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6,372</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has an aggregate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million of gross unrecognized stock-based compensation expense as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, remaining to be amortized over a weighted average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.9</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years. The Company has not recognized and does not expect to recognize in the near future, any tax benefit related to employee stock-based compensation expense as a result of the full valuation allowance related to its net deferred tax assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Awards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2019, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">994,650</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of restricted common stock to the employee co-founders and certain non-employee consultants. The shares of restricted common stock were issued pursuant to standalone restricted stock purchase agreements that are independent of the 2019 Plan. The shares of restricted common stock carried a purchase price equivalent of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.01</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The compensation cost was measured based on the fair value of the underlying common stock less the purchase price of the restricted common stock and the Company recognizes compensation costs over the requisite service period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of the restricted stock purchase agreements, the Company has a repurchase option whereby it has the right to repurchase any unvested shares upon termination at a price per share equal to the lesser of: (i) the fair market value of the Company&#8217;s common stock on the date of repurchase and (ii) the original purchase price. The shares of restricted common stock issued to the Company&#8217;s co-founders and non-employee consultants vest based on a predefined number of shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognized an associated deposit liability for restricted stock awards issued pursuant to standalone restricted stock purchase agreements upon issuance based on the purchase price of the awards as the unvested shares are subject to repurchase upon termination. As the awards of restricted stock vest, the Company reclassifies the deposit liability to additional paid-in capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,508</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of restricted common stock to employees and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> certain non-employee consultants under 2021 Plan. Compensation cost related to these awards were recorded based on the Company's stock price on the date of issuance.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes restricted stock activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.494%;"/>
        <td style="width:1.484%;"/>
        <td style="width:0.594%;"/>
        <td style="width:13.525%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.623%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.683%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Restricted Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-vested at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">888,612</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.01</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issued</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,508</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.58</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">306,998</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.01</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,628</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Non-vested at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">618,494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3.04</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate fair value of restricted stock vested during the years ended December 31, 2021 and 2020, was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has recorded stock-based compensation expense related to the restricted stock of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively. The Company has an aggregate </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of gross unrecognized restricted stock-based compensation expense as of December 31, 2021, remaining to be amortized over a weighted average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Employee Stock Purchase Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 27, 2021, the Company&#8217;s board of directors and stockholders approved the 2021 Employee Stock Purchase Plan (the &#8220;2021 ESPP&#8221;), which became effective on October 7, 2021, when the Company&#8217;s registration statement was declared effective by the SEC. The 2021 ESPP reserved and authorized the issuance of up to a total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">424,595</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock to participating employees. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares are issued under 2021 ESPP plan as of the date of issuance of these consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552561576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company recorded </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> current or deferred income tax expenses or benefits as the Company has incurred losses since inception and has provided a full valuation allowance against its deferred tax assets.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the expected income tax benefit computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.543%;"/>
        <td style="width:1.605%;"/>
        <td style="width:0.594%;"/>
        <td style="width:12.526%;"/>
        <td style="width:2.004%;"/>
        <td style="width:1.605%;"/>
        <td style="width:0.594%;"/>
        <td style="width:12.526%;"/>
        <td style="width:2.004%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax computed at federal statutory rate %</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.70</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.60</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.90</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credit carryovers</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.90</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.50</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.90</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.20</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Effective income tax rate %</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">0.00</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">0.00</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company's effective tax rate was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% for the years ended December 31, 2021 and 2020, as a result of the valuation allowance that eliminates the company's net deferred tax assets.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Significant components of the Company&#8217;s net deferred tax assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 are as follows (in thousands): </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.169%;"/>
        <td style="width:1.512%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.3%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.512%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.501%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,918</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,515</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangibles</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,648</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">187</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Derivative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,577</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock based compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,003</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reserves and accruals</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">804</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">257</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">License fees</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,716</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">252</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">299</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets before valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,811</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,557</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,748</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,343</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">63</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">214</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">214</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company's federal and state net operating losses in the United States were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million ($</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million before tax) and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million ($</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million before tax) respectively. The federal net operating loss carryforwards in the United States can be carried forward indefinitely but may be subject to annual usage limitations to the extent certain substantial changes in the entity's ownership occur. The state net operating loss carryforwards begin expiring in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2039</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In addition, as of December 31, 2021, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of federal and state credit carryovers which begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2039</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. These loss and credit </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">carryforwards are subject to review and possible adjustment by the appropriate taxing authorities.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assesses the realizability of the deferred tax assets at each balance sheet based on the available positive and negative evidence in order to determine the amount which is more likely than not to be realized and records a valuation allowance as necessary. Due to the Company's cumulative loss position which provides significant negative evidence, which is difficult to overcome, the Company has recorded a valuation allowance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021, representing the portion of the deferred tax asset that is not more likely than not to be realized. For the years ended December 31, 2021 and 2020, the valuation allowance for deferred tax assets increased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. The amount of the deferred tax asset considered realizable, could be adjusted for future factors that would impact the assessment of the objective and subjective evidence. The Company will continue to assess the realizability of deferred tax assets at each balance sheet date in order to determine the proper amount, if any, required for a valuation allowance.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The U.S. tax attributes may be subject to an annual limitation under Section 382 of the Internal Revenue Code of 1986 (the &#8220;Code&#8221;), and similar state provisions if the Company experiences one or more ownership changes, which would limit the amount of the tax attributes that can be utilized to offset future taxable income. In general, an ownership change as defined by Section 382, results from the transactions increasing ownership of certain stockholders or public groups in the stock of the corporation of more than fifty percentage points over a three-year period. If a change in ownership occurs in the future, the research and development credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#8217;s effective tax rate.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to tax and will continue to file federal income tax returns in the United States as well as in certain state and local jurisdictions. The Company is subject to tax examinations for tax years ended December 31, 2019 and forward in all applicable income tax jurisdictions. Tax audits and examinations can involve complex issues, interpretations and judgements. The resolution of matters may span multiple years particularly if subject to litigation or negotiation. The Company believes that it has appropriately recorded its tax position using reasonable estimates and assumptions, however the potential tax benefits may impact the results of operations or cashflows in the period of resolution, settlement, or when the statutes of limitations expire. The Company does not currently have any reserves related to unrecognized tax benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552426664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.906%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.196%;"/>
        <td style="width:13.198%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.196%;"/>
        <td style="width:13.717%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75,975</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,828</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,493,273</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,030,556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12.45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s potentially dilutive securities, which include convertible preferred stock, restricted stock, and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.64%;"/>
        <td style="width:1.938%;"/>
        <td style="width:0.603%;"/>
        <td style="width:10.536%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.938%;"/>
        <td style="width:0.603%;"/>
        <td style="width:10.536%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Convertible Preferred Stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,573,659</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested Restricted Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">618,494</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">888,612</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,926,969</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,383</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6,545,463</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4,682,654</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552562136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. Related Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2020, the Company entered into agreements with several Scientific Advisory Board (&#8220;SAB&#8221;) members whose members are comprised of the Company's board members. The Company paid monthly amounts, ranging from $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand per month. No board member was paid more than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million individually for the years ended December 31, 2021 and 2020, in the aggregate, all board members were paid less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for both periods combined.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company was founded out of Dr. Thomas Gajewski&#8217;s laboratory at the University of Chicago. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2020, the Company entered into the License Agreement with the University of Chicago, as well as a sponsored research agreement, which had previously purchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">309,885</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s Series A preferred stock as part of the Company&#8217;s 2019 Series A financing. In partial consideration for</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the license from the University, the Company issued to the University </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,919</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock in 2020. The Company recorded the value of the shares issued of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand as research and development expenses in the year ended December 31, 2020. There have been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> further expenses incurred for the year ended December 31, 2021 with regards to the University License Agreement. Refer</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to Note 3 for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to IPO, Pfizer along-with its affiliated entity and Bayer HealthCare LLC ("Bayer"), were principal owners of the Company. Subsequent to IPO, Pfizer and Bayer are no longer principal owners and, as a result, neither Pfizer nor Bayer are related parties of the Company. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2020, the Company entered into the Pfizer License Agreement. The Pfizer License Agreement became effective in March 2021. During the year ended December 31, 2021, the Company incurred a combined </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (which was recorded as research and development expenses), consisting of an upfront fee equal to a cash payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">illion and the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,152,145</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B convertible preferred stock with a value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in 2021 to Pfizer. Refer to Note 3 for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company and Alloy formed a joint venture company, Voxall Therapeutics, LLC (&#8220;Voxall&#8221;) to leverage the Company&#8217;s technology and Alloy&#8217;s ATX-Gx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#153; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">platform and antibody discovery services. The Company and Alloy contributed $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand each to Voxall along with certain license. During the year, the Company provided services to Voxall for which it recognized service fee other income of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">181</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand. Refer to Note 4 for additional discussion.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552436648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">16. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Legal Proceedings</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of business. The Company is not currently a party to any material legal proceedings, and is not aware of any pending or threatened legal proceeding against it that the Company believes could have an adverse effect on its business, operating results or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the normal course of business, the Company enters into agreements for research programs with vendors for nonclinical studies, manufacturing and other services and products agreements, which are generally cancellable by the Company at any time, subject to payment of remaining obligations under binding purchase orders and, in certain cases, nominal early-termination fees. These commitments are not deemed significant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, COVID-19 disease was declared a pandemic by the World Health Organization. The COVID-19 pandemic is disrupting supply chains and affecting production and sales across a range of industries. Currently, the Company has not suffered significant adverse consequences as a result of the COVID-19 pandemic. The extent of the impact of COVID-19 on the Company&#8217;s future operational and financial performance will depend on certain developments, including the duration and spread of the pandemic, including its variants, impact on employees and vendors all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Company&#8217;s future financial condition or results of operations is uncertain.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552611960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">17. Subsequent Event</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with Biosion USA, Inc.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 28, 2022, the Company entered into a license agreement, or the &#8220;Biosion License Agreement,&#8221; with Biosion USA, Inc., or Biosion, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pursuant to which the Company obtained exclusive, worldwide (other than Greater China </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(mainland China, Hong Kong, Macau and Taiwan)</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">), licenses for development, manufacture and commercialization rights for BSI-060T, a potentially best-in-class Siglec-15 targeting antibody, an IO product candidate (now referred to as PYX-106), and products containing the licensed compound.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Biosion License Agreement, the Company agreed to pay an upfront fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and are obligated to pay future contingent payments including development, regulatory and commercial milestone up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">217.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in case of normal approval and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">222.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in case of accelerated approval. Additionally, if products are launched, the Company will pay Biosion tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to low teens. The Company&#8217;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552782744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_NatureOfBusinessPolicyTextBlock', window );">Nature of Business</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pyxis Oncology, Inc. (the &#8220;Company&#8221;), a Delaware corporation, was founded in June 2018 and launched its operations in July 2019. The Company is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The Company develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since the Company&#8217;s launch in 2019, the Company has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates and monoclonal antibody, or mAb, preclinical discovery programs that the Company is developing as monotherapies and in combination with other therapies.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has determined that it has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating and reporting segment.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reverse Stock Split</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 1, 2021, the Company effected a 1-for-</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6e0eb586-b179-4054-af6f-b94a1fcee934;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.359</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split of its issued and outstanding common stock and stock option awards. The par value of the common stock and preferred stock was not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the convertible preferred stock conversion price to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The shares of common stock underlying outstanding stock options and restricted stock units were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All issued and outstanding shares of common stock, restricted stock units, stock option awards and per share data have been adjusted on a retrospective basis in these consolidated financial statements, to reflect the reverse stock split for all periods presented.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_InitialPublicOfferingPolicyTextBlock', window );">Initial Public Offering</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 8, 2021, the Company completed an initial public offering (&#8220;IPO&#8221;) in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company raised approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in net proceeds after deducting underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and offering expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon closing of the IPO, all of the outstanding shares of Series A Convertible Preferred stock (&#8220;Series A Preferred Stock&#8221;), and Series B Convertible Preferred Stock (&#8220;Series B Preferred Stock&#8221;) automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,056,145</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock of the Company. Subsequent to the closing of the IPO, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of convertible preferred stock outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the closing of the IPO, the Company filed an amended and restated certificate of incorporation (&#8220;Amended Certificate of Incorporation&#8221;) to change the authorized capital stock to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">200,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">190,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> are designated as voting common stock and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> are designated as undesignated preferred stock, all with a par value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, the Company has primarily financed its operations through the sale of convertible preferred stocks and the proceeds from IPO. The Company has not generated any revenues to date and does not anticipate generating any revenues unless and until it successfully completes development and obtains regulatory approval for its current or any future product candidates. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to expand its research and development programs, business development activities and develop its product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company currently expects that its existing cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">274.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021 will be sufficient to fund its operating expenses and capital requirements at least twelve months from the date these consolidated financial statements are issued. Additional funding may be necessary to fund future clinical and preclinical activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company plans to continue to fund its losses from operations and capital funding needs through issuance of equity securities, convertible or debt financings or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s fiscal year ends on December 31 and its first three quarters end on March 31, June 30 and September 30. The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Section 107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expense, and related disclosures. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, derivative liability, research and development accruals, operating leases, assessment of the useful lives of property and equipment, valuation of deferred tax assets and liabilities, impairment of investment in joint venture, and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, the management considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the year ended December 31, 2021. However, the extent to which the COVID-19 pandemic may directly or indirectly impact the Company&#8217;s financial statements is highly uncertain and subject to change.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Actual results could differ from those estimates and there may be changes to management&#8217;s estimates in future periods.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to risks common to early-stage companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key suppliers for active ingredients and third-party service providers such as contract research organizations, protection of intellectual property rights and the ability to make milestone, royalty or other payments due under any license, collaboration or supply agreements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risks</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company&#8217;s cash and cash equivalents are held at an accredited financial institution and the Company has not experienced any losses in such accounts. The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company&#8217;s cash equivalents consist primarily of short-term money market funds held in accredited financial institutions. The Company believes it is not exposed to any significant risk in cash and cash equivalents.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all short term, highly liquid investments with original maturities of 90 days or less to be cash equivalents. Cash equivalents consist primarily of money market funds as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principle or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, the first two are considered observable and the last is considered unobservable:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Level</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the related assets as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:73.139%;"/>
          <td style="width:1.898%;"/>
          <td style="width:24.963%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Estimated Useful<br/>Life (Years)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and office equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of remaining life<br/>of lease or useful life</span></span></p></td>
         </tr>
        </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and amortization expense is included in research and development and general and administrative expenses. Major additions and upgrades are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are expensed as incurred. Upon retirement or sale, the cost of assets disposed of, and the related accumulated depreciation and amortization are removed from the respective accounts and any resulting gain or loss is included in income (loss) from operations.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates the long-lived assets, which consist of property and equipment and operating lease right-of-use assets, for impairment at least annually and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. Management then determines whether the remaining useful life continues to be appropriate, or whether there has been an impairment of long-lived assets based primarily upon whether expected future undiscounted cash flows are sufficient to support the assets&#8217; recovery. Recoverability of these assets is measured by comparison of the carrying amount of the asset to the future undiscounted cash flows the asset is expected to generate. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. The Company recognized </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment losses for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lease right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are initially recognized and measured based on the present value of the future fixed lease payments over the expected lease term at the commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. The Company determines the lease term as the non-cancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease ROU assets also include any initial direct costs incurred and any lease payments made on or before the lease commencement date, less lease incentives received. Operating lease ROU assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. The Company accounts for lease and non-lease components as a single lease component for all its facilities leases. The Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> finance leases as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment in Joint Venture</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investment in Joint Venture</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investment in the Company&#8217;s joint venture is accounted for using the equity method of accounting. The Company </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">apply the equity method of accounting to investments when the Company has significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">equity</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">method</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">investment</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the equity method, investments are initially recorded at cost and are adjusted for dividends, distributed and undistributed earnings and losses, and additional investments. In the event the Company&#8217;s share of a joint venture&#8217;s cumulative losses exceeds the Company&#8217;s investment balance, the balance is reported at zero value until proportionate income exceeds the losses. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingencies</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company, from time to time, may be a party to various disputes and claims arising from normal business activities. The Company continually assesses disputes and claims including resulting litigation to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the contingencies, including an estimable range, if possible.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company expenses research and development costs as incurred. The Company&#8217;s research and development expenses consist primarily of license fees to acquire intellectual property which does not meet the definition of intangible assets and costs incurred in performing research and development activities, including personnel-related expenses such as salaries, stock-based compensation and benefits, facilities costs, depreciation as well as external costs for outside vendors engaged to conduct preclinical development activities and license fees. The Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and efforts expended pursuant to the terms of the contractual arrangements. Payments under some of these contracts depend on preclinical trial milestones. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of expenses. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or prepaid expense accordingly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company maintains an equity incentive plan as a long-term incentive for employees, consultants, and directors. The Company accounts for all stock-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The grant date fair value of the stock-based awards with graded vesting is recognized on a straight-line basis over the requisite service period. The Company recognizes forfeitures related to stock-based compensation awards as they occur and reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs. The Company classifies stock-based compensation expense in the statement of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company values its stock options with service conditions using the Black-Scholes option pricing model. The Company use certain assumptions to determine fair value of the stock options pursuant to the Black-Scholes option pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate, expected dividend yield and the fair value of the Company&#8217;s common stock. Since the Company has no option exercise history, the Company uses the simplified method described in the SEC&#8217;s Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-Based Payment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(&#8220;SAB 107&#8221;), to determine the expected life of the option grants. The Company lacks sufficient company-specific historical and implied volatility information. Therefore, the Company estimates the expected stock volatility based on the historical volatility of a publicly traded set of peer companies. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. As the Company has never paid and does not anticipate paying cash dividends on its common stock, the expected dividend yield is considered as zero.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Prior to the completion of the Company&#8217;s IPO, the fair value of the Company's common stock which is one of the key input in Black-Scholes option pricing model, was determined by the board of directors with input from management and based on certain assumptions including probability weighting of events, business and market conditions, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. The Company used 409A valuations to determine the fair value of the shares of common stock. The 409A valuations were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;font-style:italic;">Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">. After completion of the IPO, on October 8, 2021, the Company uses the fair value of its publicly traded common stock to determine grant date fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For restricted stock awards issued pursuant to standalone restricted stock purchase agreements, the fair value of each award was estimated based on the estimated fair value of the Company&#8217;s common stock, less the amount paid by the grantee. The Company recognized deposit liability for restricted stock awards issued pursuant to standalone restricted stock purchase agreements. As the awards of restricted stock vest, the Company reclassifies the deposit liability to additional paid-in capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes in accordance with FASB ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (&#8220;ASC 740&#8221;), which requires the use of the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between amounts in the consolidated financial statements and the tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income tax (benefit) expense in the consolidated statements of operations and comprehensive loss in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock', window );">Classification and Accretion of Convertible Preferred Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Classification and Accretion of Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Classification of the Company&#8217;s convertible preferred stock was treated as mezzanine financing and not as part of stockholders&#8217; equity (deficit) because the holders of such shares had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock was not redeemable, except in the event of certain deemed liquidation events enumerated in the Company&#8217;s certificate of incorporation. Because the occurrence of a deemed liquidation event was not probable, the carrying values of the convertible preferred stock were not accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares of preferred stock were automatically convertible into shares of common stock at the earlier of (i) the closing of a firm-commitment underwritten public offering resulting in at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of gross proceeds in the aggregate to the Company, prior to deductions for underwriting discounts, commission and expenses or (ii) the date and time, or occurrence of an event, specified by a vote of the Series A and Series B Stockholders. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon closing of the IPO, all of the outstanding </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A and Series B </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">convertible preferred stock automatically converted in</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to common stock, resulting in </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> outstanding convertible preferred stock as of December 31, 2021.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company follows the two-class method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the diluted weighted average number of common shares outstanding for the period, including potential dilutive common shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s participating securities contractually entitle the holders of such shares to participate in dividends but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2020, the FASB issued ASU 2020-01, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments &#8212; Equity Securities (Topic 321), Investments &#8212; Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The new guidance addresses accounting for the transition into and out of the equity method and measuring certain purchased options and forward contracts to acquire investments. This ASU is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> this ASU from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and the adoption did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have any impact on the Company&#8217;s consolidated financial position, results of operations, or cash flows.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(&#8220;ASU 2016-13&#8221;), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses on available-for-sale debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. As an emerging growth company, ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2022, and early adoption is permitted. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is currently evaluating the new standard and expects it to have no material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC did not, or are not expected to, have a material impact on the Company&#8217;s unaudited consolidated financial statements and related disclosures. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Classification and Accretion of Convertible Preferred Stock [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_InitialPublicOfferingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_InitialPublicOfferingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_NatureOfBusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature of Business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_NatureOfBusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements not yet adopted policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks and Uncertainties [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21459-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552561016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock', window );">Schedule of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the related assets as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:73.139%;"/>
          <td style="width:1.898%;"/>
          <td style="width:24.963%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Estimated Useful<br/>Life (Years)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and office equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of remaining life<br/>of lease or useful life</span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated useful lives of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552422248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Financial Instruments Carried at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables present the financial instruments carried at fair value on a recurring basis as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively, in accordance with the FASB ASC 820 hierarchy (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.787%;"/>
        <td style="width:1.206%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.566%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.206%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.529%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.206%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.529%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.206%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.566%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Measurements at<br/>December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">272,210</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">272,210</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Measurements at<br/>December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,996</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,996</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Level 3 Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables provide a summary of changes in Level 3 fair value measurements for the year ended December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.246%;"/>
        <td style="width:2.671%;"/>
        <td style="width:1.206%;"/>
        <td style="width:24.079%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">($ in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Derivative liability balance as of January 1, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Initial recognition of derivative liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,369</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value recorded in earnings</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,231</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transfer to accounts payable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552574952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.657%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.254%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.244%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Insurance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,763</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">619</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2,466</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250631144392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net, consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.503%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.228%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.052%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,804</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,264</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">213</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and office equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,123</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,572</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,116</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">469</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,007</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,103</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552550888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.648%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.254%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.254%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee compensation and benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,963</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">External research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,381</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">712</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">982</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">167</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">266</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6,592</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,997</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552476504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of lease expense were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.422%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.984%;"/>
        <td style="width:1.994%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.984%;"/>
        <td style="width:1.994%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">650</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">497</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">146</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease cost (1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">730</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">713</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other information</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use asset obtained in exchange for new operating<br/>&#160;&#160;&#160;lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,186</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of lease liabilities, included<br/>&#160;&#160;&#160;in operating cash flows</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">663</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">484</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.25</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.25</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.00</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.98</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:3.0pt;border-bottom:0.750pt solid;margin-right:83.704%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Variable lease cost includes common area maintenance charges</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Lease Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Maturities of lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.019%;"/>
        <td style="width:1.939%;"/>
        <td style="width:1.206%;"/>
        <td style="width:16.039%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ending December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating lease</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: amount representing imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total future minimum lease obligations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">165</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552660280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Common Stock Reserved for Issuance</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reserved the following shares of common stock for issuance:</span><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.41%;"/>
        <td style="width:1.796%;"/>
        <td style="width:0.641%;"/>
        <td style="width:17.811%;"/>
        <td style="width:0.641%;"/>
        <td style="width:1.954%;"/>
        <td style="width:0.641%;"/>
        <td style="width:15.463%;"/>
        <td style="width:0.641%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A convertible preferred stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,573,659</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted stock options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">618,494</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">888,612</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options available for issuance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,289,259</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,585</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,926,969</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,383</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">424,595</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8,259,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4,718,239</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250550774168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes stock option activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 (in thousands, except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.848%;"/>
        <td style="width:1.456%;"/>
        <td style="width:0.603%;"/>
        <td style="width:7.894%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.456%;"/>
        <td style="width:1.206%;"/>
        <td style="width:7.272%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.456%;"/>
        <td style="width:0.603%;"/>
        <td style="width:8.979%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.456%;"/>
        <td style="width:1.206%;"/>
        <td style="width:7.958%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number of<br/>Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,383</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.64</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.4</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">348</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,351,820</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.12</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.6</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">574,838</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.41</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5,926,969</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10.03</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">16,414</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1,033,510</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5.04</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9.2</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6,125</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Fair Value Assumptions</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company estimated the fair value of each option on the date of grant using the Black-Scholes option pricing model applying the range of assumptions in the following table:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.968%;"/>
        <td style="width:2.05%;"/>
        <td style="width:20.466%;"/>
        <td style="width:2.05%;"/>
        <td style="width:20.466%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72.88</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103.41</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79.40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87.40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.81</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.38</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.56</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.25</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.00</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.02</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.08</span></span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense related to stock options recorded in the statements of operations is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.973%;"/>
        <td style="width:1.493%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.216%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.493%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.207%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,976</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6,372</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes restricted stock activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.494%;"/>
        <td style="width:1.484%;"/>
        <td style="width:0.594%;"/>
        <td style="width:13.525%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.623%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.683%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Restricted Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-vested at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">888,612</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.01</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issued</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,508</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.58</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">306,998</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.01</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,628</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Non-vested at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">618,494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3.04</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250553551784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the expected income tax benefit computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.543%;"/>
        <td style="width:1.605%;"/>
        <td style="width:0.594%;"/>
        <td style="width:12.526%;"/>
        <td style="width:2.004%;"/>
        <td style="width:1.605%;"/>
        <td style="width:0.594%;"/>
        <td style="width:12.526%;"/>
        <td style="width:2.004%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax computed at federal statutory rate %</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.70</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.60</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.90</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credit carryovers</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.90</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.50</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.90</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.20</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Effective income tax rate %</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">0.00</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">0.00</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Net Deferred Tax Assets</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Significant components of the Company&#8217;s net deferred tax assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 are as follows (in thousands): </span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.169%;"/>
        <td style="width:1.512%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.3%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.512%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.501%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,918</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,515</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangibles</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,648</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">187</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Derivative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,577</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock based compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,003</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reserves and accruals</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">804</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">257</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">License fees</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,716</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">252</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">299</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets before valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,811</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,557</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,748</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,343</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">63</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">214</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">214</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552455944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.906%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.196%;"/>
        <td style="width:13.198%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.196%;"/>
        <td style="width:13.717%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75,975</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,828</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,493,273</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,030,556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12.45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.64%;"/>
        <td style="width:1.938%;"/>
        <td style="width:0.603%;"/>
        <td style="width:10.536%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.938%;"/>
        <td style="width:0.603%;"/>
        <td style="width:10.536%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Convertible Preferred Stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,573,659</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested Restricted Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">618,494</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">888,612</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,926,969</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,383</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6,545,463</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4,682,654</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250547529848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Business - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 08, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15725743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Capital stock authorized | shares</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
<td class="nump">40,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (91,718)<span></span>
</td>
<td class="num">$ (15,743)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,975)<span></span>
</td>
<td class="num">(12,828)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,735<span></span>
</td>
<td class="nump">$ 8,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock', window );">Number of common shares issued upon conversion of preferred stock | shares</a></td>
<td class="nump">20,056,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,724,925<span></span>
</td>
<td class="nump">22,724,925<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_GrossProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from issuance of initial public offering</a></td>
<td class="nump">$ 168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from issuance initial public offering</a></td>
<td class="nump">$ 152,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued | shares</a></td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock public offering price per share | $ / shares</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_UnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions</a></td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_StockIssuanceExpenses', window );">Stock issuance expenses</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_GrossProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_GrossProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issued upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_StockIssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_StockIssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_UnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_UnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250549634104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Lease </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Lease </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_NumberOfFinanceLease', window );">Number of finance lease | Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from issuance of convertible preferred stock</a></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="nump">$ 151,581,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202001Member', window );">ASU 2020-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,724,925<span></span>
</td>
<td class="nump">22,724,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_NumberOfFinanceLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_NumberOfFinanceLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202001Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202001Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250547491784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Related Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of related assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of related assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives of related assets, description</a></td>
<td class="text">Shorter of remaining lifeof lease or useful life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250543838072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,054,000<span></span>
</td>
<td class="nump">$ 9,048,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,000<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,077,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,951,000<span></span>
</td>
<td class="nump">$ 1,077,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember', window );">Pfizer License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale', window );">Royalty obligation period for licensed products upon first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_MilestoneAndRoyaltiesIncurred', window );">Milestone and royalties required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_SublicensingRevenuePercentage', window );">Sublicensing revenue percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_OneTimeMilestonePayment', window );">One-time payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember', window );">Pfizer License Agreement | Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_PaymentForLicenseFee', window );">Payment for license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember', window );">Pfizer License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_AggregateMilestonePayments', window );">Aggregate milestone payments for first four licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 660,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_OneTimeMilestonePayment', window );">One-time payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember', window );">Pfizer License Agreement | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_IssuanceOfConvertiblePreferredStockShares', window );">Issuance of convertible preferred stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,152,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ConvertiblePreferredStockSharesIssuedValue', window );">Issuance of convertible preferred stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember', window );">LegoChem License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale', window );">Royalty obligation period for licensed products upon first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_MilestoneAndRoyaltiesIncurred', window );">Milestone and royalties required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Payments to purchase licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost', window );">Licensed product estimated cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ExtraMilestonePayment', window );">Extra Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember', window );">LegoChem License Agreement | Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000.0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember', window );">LegoChem License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_MilestonePaymentsPayableUponCertainAchievements', window );">Milestone payments payable upon certain achievements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember', window );">LegoChem License Agreement | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_IssuanceOfConvertiblePreferredStockShares', window );">Issuance of convertible preferred stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember', window );">University License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_AnnualLicenseMaintenanceFees', window );">Annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale', window );">Royalty obligation period for licensed products upon first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_MilestoneAndRoyaltiesIncurred', window );">Milestone and royalties required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember', window );">University License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_PotentialDevelopmentAndCommercialMilestonePayment', window );">Potential development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_MinimumAnnualRoyaltyFees', window );">Minimum annual royalty fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_AggregateMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_AggregateMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_AnnualLicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual license maintenance fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_AnnualLicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ConvertiblePreferredStockSharesIssuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock shares issued value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ConvertiblePreferredStockSharesIssuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ExtraMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extra milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ExtraMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_IssuanceOfConvertiblePreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of convertible preferred stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_IssuanceOfConvertiblePreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_MilestoneAndRoyaltiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone and royalties incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_MilestoneAndRoyaltiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_MilestonePaymentsPayableUponCertainAchievements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments payable upon certain achievements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_MilestonePaymentsPayableUponCertainAchievements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_MinimumAnnualRoyaltyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum annual royalty fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_MinimumAnnualRoyaltyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_OneTimeMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One-time milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_OneTimeMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_PaymentForLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_PaymentForLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_PotentialDevelopmentAndCommercialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development and commercial milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_PotentialDevelopmentAndCommercialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development licensed product estimated cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty obligation period for licensed products upon first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_SublicensingRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublicensing revenue percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_SublicensingRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250549645048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Joint Venture - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ServiceFeeIncomeFromRelatedParty', window );">Service fee income from related party</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pyxs_VoxallMember', window );">Voxall</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Initial contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ServiceFeeIncomeFromRelatedParty', window );">Service fee income from related party</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Losses incurred</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ProceedsFromPromissoryNoteIssued', window );">Promissory note issued</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Equity method investment, description</a></td>
<td class="text">As the Company has no commitment to fund the losses of the equity method investment, the carrying value of the equity method investment has not been reduced below zero<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pyxs_VoxallMember', window );">Voxall | Alloy Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of voting membership units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Initial contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ProceedsFromPromissoryNoteIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from promissory note issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ProceedsFromPromissoryNoteIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ServiceFeeIncomeFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Service fee income from related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ServiceFeeIncomeFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the principal activities of an investee accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pyxs_VoxallMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pyxs_VoxallMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pyxs_AlloyTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pyxs_AlloyTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250553467848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 272,210<span></span>
</td>
<td class="nump">$ 6,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 272,210<span></span>
</td>
<td class="nump">$ 6,996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250553458616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized', window );">Extra milestone payment for which derivative liability recognized</a></td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extra milestone payment for which derivative liability recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250554066216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Changes in Level 3 Fair Value Measurements (Details) - Derivative Liability - Level 3<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability', window );">Initial recognition of derivative liability</a></td>
<td class="nump">$ 3,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value recorded in earnings</a></td>
<td class="nump">6,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable', window );">Transfer to accounts payable</a></td>
<td class="num">$ (9,600)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability initial recognition of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability transfer to accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250550603448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">$ 1,763<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total Prepaid expenses and other current assets</a></td>
<td class="nump">$ 2,466<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250547432040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">$ 2,123<span></span>
</td>
<td class="nump">$ 1,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(1,116)<span></span>
</td>
<td class="num">(469)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total Property and equipment, net</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pyxs_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">1,804<span></span>
</td>
<td class="nump">1,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pyxs_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pyxs_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pyxs_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pyxs_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pyxs_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552529464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 647<span></span>
</td>
<td class="nump">$ 469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250549723912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">$ 2,963<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_AccruedResearchAndDevelopmentExpensesCurrent', window );">External research and development expenses</a></td>
<td class="nump">2,381<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">982<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 6,592<span></span>
</td>
<td class="nump">$ 1,997<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250547451912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 29, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>Lease</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_NumberOfOperatingLease', window );">Number of operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_LeaseExpirationYear', window );">Operating lease terms expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_NumberOfFinanceLease', window );">Number of finance lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Dec. 31,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_RentIncreasePercentage', window );">Rent Increase Percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">There is an additional five-year option to extend the lease beyond December 31, 2032.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future minimum lease obligations | $</a></td>
<td class="nump">$ 33,800<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_LeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_LeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_NumberOfFinanceLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_NumberOfFinanceLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_NumberOfOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_NumberOfOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_RentIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent increase percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_RentIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250549537992">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 650<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable Lease, Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">75<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">730<span></span>
</td>
<td class="nump">713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset obtained in exchange for new operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 663<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3 months<span></span>
</td>
<td class="text">1 year 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.98%<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Variable lease cost includes common area maintenance charges</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250554002824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 29, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">$ 33,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing imputed interest</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total future minimum lease obligations</a></td>
<td class="nump">$ 165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250546074648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 08, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 05, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from issuance of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="nump">0.15725743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share sale price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesAConvertiblePreferredStocksMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,724,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pyxs_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share sale price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,724,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,724,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross cash proceeds from issuance of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from issuance of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split description</a></td>
<td class="text">1-for-6.359 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="nump">0.15725743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pyxs_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Series A Convertible Preferred Stock | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of preferred shares conversion</a></td>
<td class="nump">22,724,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pyxs_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Series A Convertible Preferred Stock | Initial Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Convertible preferred stock shares issued upon conversion</a></td>
<td class="nump">3,573,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pyxs_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share sale price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,356,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross cash proceeds from issuance of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from issuance of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split description</a></td>
<td class="text">1-for-6.359 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="nump">0.15725743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pyxs_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Series B Convertible Preferred Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Convertible preferred stock shares issued upon conversion</a></td>
<td class="nump">16,482,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pyxs_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Series B Convertible Preferred Stock | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of preferred shares conversion</a></td>
<td class="nump">104,812,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember', window );">Agreements with Pfizer, Inc. and LegoChem Biosciences Inc. | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,455,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from issuance of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesAConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pyxs_SeriesAConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pyxs_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pyxs_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250547472840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 08, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">190,000,000<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
<td class="nump">40,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">32,792,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,177,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">32,222,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,289,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250546063992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock Reserved for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">8,259,317<span></span>
</td>
<td class="nump">4,718,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pyxs_SeriesAConvertiblePreferredStocksMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">618,494<span></span>
</td>
<td class="nump">888,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pyxs_StockOptionsAvailableForIssuanceMember', window );">Stock Options Available for Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">1,289,259<span></span>
</td>
<td class="nump">35,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">5,926,969<span></span>
</td>
<td class="nump">220,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">424,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pyxs_SeriesAConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pyxs_SeriesAConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pyxs_StockOptionsAvailableForIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pyxs_StockOptionsAvailableForIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250547715400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 27, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common shares reserved for future issuance</a></td>
<td class="nump">8,259,317<span></span>
</td>
<td class="nump">4,718,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted</a></td>
<td class="nump">$ 7.57<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Gross unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 38,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense weighted average amortized period</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Number of restricted common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">994,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,372<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of restricted stock vested</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common shares reserved for future issuance</a></td>
<td class="nump">618,494<span></span>
</td>
<td class="nump">888,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Number of shares authorized to be repurchased under a stock repurchase plan</a></td>
<td class="nump">48,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense weighted average amortized period</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock public offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Gross unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common shares reserved for future issuance</a></td>
<td class="nump">1,289,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,852,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Number of shares authorized to be repurchased under a stock repurchase plan</a></td>
<td class="nump">2,515,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Number of shares of common stock outstanding percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions', window );">Maximum number of common shares issuable under exercise of options</a></td>
<td class="nump">7,705,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Number of shares authorized to be repurchased under a stock repurchase plan</a></td>
<td class="nump">3,411,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common shares reserved for future issuance</a></td>
<td class="nump">4,042,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Number of restricted common stock shares issued</a></td>
<td class="nump">48,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common shares authorized for issuance</a></td>
<td class="nump">424,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of common shares issuable under exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pyxs_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pyxs_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250548035416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding at December 31, 2020</a></td>
<td class="nump">220,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="nump">6,351,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="num">(70,396)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Forfeited</a></td>
<td class="num">(574,838)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding at December 31, 2021</a></td>
<td class="nump">5,926,969<span></span>
</td>
<td class="nump">220,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable at December 31, 2021</a></td>
<td class="nump">1,033,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at December 31, 2020</a></td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">10.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">8.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at December 31, 2021</a></td>
<td class="nump">10.03<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at December 31, 2021</a></td>
<td class="nump">$ 5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term, Granted</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable at December 31, 2021</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 16,414<span></span>
</td>
<td class="nump">$ 348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at December 31, 2021</a></td>
<td class="nump">$ 6,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250547515048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">72.88%<span></span>
</td>
<td class="nump">79.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">103.41%<span></span>
</td>
<td class="nump">87.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.81%<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.36%<span></span>
</td>
<td class="nump">0.56%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250549581656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,372<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,396<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,976<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250554168216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Outstanding, at December 31, 2020</a></td>
<td class="nump">888,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Issued</a></td>
<td class="nump">48,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested</a></td>
<td class="num">(306,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Cancelled</a></td>
<td class="num">(11,628)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Outstanding, at December 31, 2021</a></td>
<td class="nump">618,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant ate fair value, Outstanding, at December 31, 2020 | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding, Issued | $ / shares</a></td>
<td class="nump">15.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding, Vested | $ / shares</a></td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding, at December 31, 2021 | $ / shares</a></td>
<td class="nump">$ 3.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250550700712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Increase in deferred tax assets valuation allowance</a></td>
<td class="nump">$ 21,400,000<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">25,748,000<span></span>
</td>
<td class="nump">4,343,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Current income tax expenses (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense (Benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_OperatingLossCarryforwardsBeforeTax', window );">Operating loss carryforwards before tax</a></td>
<td class="nump">48,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit carryovers</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_TaxCreditCarryforwardExpirationYear', window );">Credit carryovers expiration year</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_OperatingLossCarryforwardsBeforeTax', window );">Operating loss carryforwards before tax</a></td>
<td class="nump">$ 45,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit carryovers</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_TaxCreditCarryforwardExpirationYear', window );">Credit carryovers expiration year</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_OperatingLossCarryforwardsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_OperatingLossCarryforwardsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250552855848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax computed at federal statutory rate%</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(27.70%)<span></span>
</td>
<td class="num">(27.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit carryovers</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate%</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250550575320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 12,918<span></span>
</td>
<td class="nump">$ 3,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">1,648<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Derivative</a></td>
<td class="nump">1,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock based compensation</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves and accruals</a></td>
<td class="nump">804<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_DeferredTaxAssetsLicenseFee', window );">License fees</a></td>
<td class="nump">7,716<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets before valuation allowance</a></td>
<td class="nump">25,811<span></span>
</td>
<td class="nump">4,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(25,748)<span></span>
</td>
<td class="num">(4,343)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">$ (63)<span></span>
</td>
<td class="num">$ (214)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_DeferredTaxAssetsLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_DeferredTaxAssetsLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250554360648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Summary of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (75,975)<span></span>
</td>
<td class="num">$ (12,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding, basic and diluted</a></td>
<td class="nump">8,493,273<span></span>
</td>
<td class="nump">1,030,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted</a></td>
<td class="num">$ (8.95)<span></span>
</td>
<td class="num">$ (12.45)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250546054552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</a></td>
<td class="nump">6,545,463<span></span>
</td>
<td class="nump">4,682,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pyxs_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</a></td>
<td class="nump">618,494<span></span>
</td>
<td class="nump">888,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</a></td>
<td class="nump">5,926,969<span></span>
</td>
<td class="nump">220,383<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pyxs_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pyxs_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250547024552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,054,000<span></span>
</td>
<td class="nump">$ 9,048,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember', window );">Pfizer License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember', window );">LegoChem License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_UpfrontPayments', window );">Upfront payments</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember', window );">Series B Convertible Preferred Stock | Pfizer License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_IssuanceOfConvertiblePreferredStockShares', window );">Issuance of convertible preferred stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,152,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ConvertiblePreferredStockSharesIssuedValue', window );">Issuance of convertible preferred stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember', window );">Series B Convertible Preferred Stock | LegoChem License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_IssuanceOfConvertiblePreferredStockShares', window );">Issuance of convertible preferred stock shares</a></td>
<td class="nump">303,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember', window );">University License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember', window );">University License Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember', window );">University License Agreement | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pyxs_ScientificAdvisoryBoardMember', window );">Scientific Advisory Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_MaximumAmountPaidToRelatedParties', window );">Maximum amount paid to board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_AggregateMaximumAmountPaidToRelatedParties', window );">Aggregate maximum amount paid to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pyxs_VoxallMember', window );">Voxall</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_ContributedAmountToJointVentureByEachEntity', window );">Contributed amount to joint venture by each member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Recognized service fee as other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Scientific Advisory Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_PaymentsToRelatedPartiesPerMonth', window );">Payments to board members per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Scientific Advisory Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_PaymentsToRelatedPartiesPerMonth', window );">Payments to board members per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_AggregateMaximumAmountPaidToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate maximum amount paid to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_AggregateMaximumAmountPaidToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ContributedAmountToJointVentureByEachEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contributed amount to joint venture by each entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ContributedAmountToJointVentureByEachEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ConvertiblePreferredStockSharesIssuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock shares issued value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ConvertiblePreferredStockSharesIssuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_IssuanceOfConvertiblePreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of convertible preferred stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_IssuanceOfConvertiblePreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_MaximumAmountPaidToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount paid to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_MaximumAmountPaidToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_PaymentsToRelatedPartiesPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to related parties per month.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_PaymentsToRelatedPartiesPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=pyxs_ScientificAdvisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=pyxs_ScientificAdvisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=pyxs_VoxallMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=pyxs_VoxallMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140250554066088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event (Additional Information) (Details) - Subsequent Event - Biosion License Agreement<br></strong></div></th>
<th class="th">
<div>Mar. 28, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_UpfrontFee', window );">Upfront fee</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval', window );">Aggregate maximum obligation to pay future contingent milestone payments for normal approval</a></td>
<td class="nump">217,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval', window );">Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval</a></td>
<td class="nump">$ 222,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale', window );">Royalty obligation period for licensed products upon first commercial sale</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate maximum obligation to pay future contingent milestone payments for normal approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty obligation period for licensed products upon first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_UpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_UpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pyxs_BiosionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pyxs_BiosionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>pyxs-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pyxs="http://pyxisoncology.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pyxs-20211231.xsd" xlink:type="simple"/>
    <context id="C_a9c9231a-7100-4362-8c03-86895d680666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3bfacc42-7016-4be9-8736-1d6d637d68e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_cab37125-1fa0-46b6-b525-727f58de2829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_52f84543-c5cd-4e24-8f62-15582b3c85f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_6eaa700b-aefd-44cf-9c29-31f008101fed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0419a777-abc4-43c5-941f-c166c8f4b73a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_404bc14b-3eaf-4e94-a492-dc8d161a716a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c3e89383-fd3d-4b7e-82f6-24ca7bf96cec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f0325835-c766-40ad-a049-921b9832afb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_34a68bd8-42d2-4884-8c43-a95f93b476df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ede49b60-05ec-496a-8366-21adc55138b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_1ca021f9-876b-4a5b-8dc2-fcb1ec552bde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_f9b6d952-91a3-4a16-ba7e-88b297d8e0b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-08</instant>
        </period>
    </context>
    <context id="C_1004cb6e-29cf-4ad9-a179-5780de31070c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pyxs:VoxallMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_35ae1bff-4ac3-4b11-b994-17b32b210d6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3c5d682d-d0a1-45b0-b0e4-16275df3e997">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pyxs:StockOptionsAvailableForIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_43a98943-5b0e-4436-8f96-5a50552b1f8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c05c67d1-e528-474e-8817-657f048332c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2021-09-29</instant>
        </period>
    </context>
    <context id="C_83f1f8d4-1a3f-42eb-89a4-fe5b4d42496e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2ae77749-d3df-49f5-b129-e03c49c1d9ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8b24eb84-4a1e-48e9-939f-d50285a9ebf8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cb6bd2f8-ad47-4a35-989a-57aedc56c9c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_72eb1cad-9bfc-44a0-9b07-b1629f06a05d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_2479e14f-6aa9-4a28-be71-a2c03d3cde43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pyxs:VoxallMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_4a74247c-2b25-4a52-afe0-244e457c4f7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_128e59fb-2071-4047-8fbe-17d937e7523a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="C_805ffd5b-0773-4785-8a81-7d324e3eaafa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:AgreementsWithPfizerIncAndLegochemBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_53514985-e3a7-4155-9770-bf7e144b7596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d95ea6c8-6b64-4ea3-9e32-ba4722916902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pyxs:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1083a66d-cffd-416e-a565-3d03312b0250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_75951ce6-a95a-42de-8088-a5a897b8380d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pyxs:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_60a4f247-f1f7-4230-bdbf-18fce866817f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_673e5066-a0a1-4324-b5c4-c5590d5143fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_f4093bae-844d-47d4-af50-d208ea9824d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_be0b2666-2fd2-42a7-9eb9-036c72e9e2e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8f0edcc6-6967-4a4a-b278-e69a383ba6db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pyxs:ScientificAdvisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2bb52469-04b7-49d0-857a-43447b7272be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2021-10-08</instant>
        </period>
    </context>
    <context id="C_37f4df29-d5b8-4d2c-bf7f-5a96e5b924a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_71c85092-8520-4659-ae48-430a857097a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5a87e6b1-9e03-4ac3-8a39-debc18e92132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="C_60a0d615-609c-4658-97f4-896f92d22495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d16739b1-097f-4ebc-b79f-81d904a831e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-08</startDate>
            <endDate>2021-10-08</endDate>
        </period>
    </context>
    <context id="C_9848985a-6cbf-4efd-a97b-7350766a6a66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5a579548-3c9a-4e1b-bf3e-98869a574f78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_86a53aad-9b46-45bf-8f94-a9e963b999b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0492f1f1-cdba-47c2-b6ed-3d308a2cdd45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_6a491c51-e3ff-4f01-b86c-22bb7f1219c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_b54da75b-957d-4884-98f7-3495f571051f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a39c61fa-aca6-4bf1-8634-94e72b3a3719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_add39c44-72f5-4ca5-ab44-474e2dd8f88c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="C_c75ce941-68a1-475c-964a-d8c55a132c9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_073f9fdb-14b4-4632-8088-b25125b7ae60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_86efd6c0-cd6e-4044-a8a6-91df62d66a91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5fb2e8bf-e772-43b7-b907-59150f324329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pyxs:VoxallMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fc3376eb-8285-406a-bbf7-1c82c1b22a7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="C_13a4aa5e-911a-4c5d-9086-7de944870e14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7063a67b-e132-4dc0-b804-27e9078dfd3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_54d4e58d-90af-4c17-b083-9fcffe474079">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d8091fae-ef00-4700-b4a2-77ed5956ff06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3e0e6445-8830-4b8b-9312-a6c3f7385eae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202001Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_762248a9-dd67-46d8-b8ac-e8d11ca59329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-08</startDate>
            <endDate>2021-10-08</endDate>
        </period>
    </context>
    <context id="C_a48bbe71-5e71-4138-9877-1babd6034c0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_cfa6104f-d54e-432d-8bca-e8247807eec0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8e920cab-08bd-4853-a2c7-07b631b559f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c3a5fd86-4b2f-48b5-906e-e21ff053ea3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_152d9614-3fcc-42d6-ad59-684db0e1410f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_40efd25b-f2c1-4224-9850-278e0702aecc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6ff4a3a9-acf7-49fe-b336-139827d87918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pyxs:ScientificAdvisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c8cf8329-d1fb-4956-86aa-e52d9990243c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0961fd9e-e455-4080-b194-733e8f9aaef7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bc36a634-547c-4f28-b1db-420db4a8e3cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pyxs:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2a39c163-dd87-4565-b3a7-3a9cd35c9839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_928733d3-c3c5-45d1-9947-05d14b5ad5c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_99104f1c-d368-4dd0-8b3e-c298819aba0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pyxs:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_eb20c638-f7e6-42c8-bbb7-04213dfaf5a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="C_ea790169-f5cb-46d5-bb2a-a27a9d87e6bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-28</instant>
        </period>
    </context>
    <context id="C_931efd56-1c76-41f4-bf5d-55380b0d9598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_8e0fe443-9856-4876-8a03-0c6ae852fad0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_503f6a97-2a52-4ea2-92dd-c00d66d8adf2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a1a3afb5-1db0-4c36-83ed-2876af7a7097">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_529d4c7c-54dc-4be7-b79b-cb508fa84d76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5c40a4a9-f63b-4608-bd08-8d0a1321ed5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b4f7a85e-0b7b-4341-87a1-c762f3633c3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_d235112b-d87b-410d-8d79-ca05e714f0dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_dc7688b9-57dd-43d0-a91e-30eeb4979d67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pyxs:ScientificAdvisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c358130b-d442-4714-9617-ad3cca7aaa47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_b5d21c61-6321-4216-b894-327d183af8bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_98160ecc-3034-40bb-a317-ac57984c3f17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0fbda7d4-a5aa-4836-8bfe-59b19b15fc3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pyxs:ScientificAdvisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e5fb5e1b-3838-47c6-bb70-01be05e587a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_249a52df-36e5-49ab-92ea-306c0765acf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="C_5221cef4-195a-4dfd-95bb-66e798f30b97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_ebe69ee7-b47e-44a7-9ec7-718a9ea1d455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_8718a804-c532-497e-b1b1-1415b90f394e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_856072e1-a9f5-4feb-888d-6f52cd2b0837">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_14084414-5d74-4992-ae92-da97bbd2c4d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bacaab47-1993-4379-b4c5-c1e4533f5d05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pyxs:StockOptionsAvailableForIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4173faad-0fa2-4056-a8cc-cccd57e2e301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:AgreementsWithPfizerIncAndLegochemBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_2b011e3d-095a-448f-a28b-10116452cf0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-08</startDate>
            <endDate>2021-10-08</endDate>
        </period>
    </context>
    <context id="C_a4512320-e5eb-43ea-b73f-15322d518ab6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_77b69288-abc5-4593-aa39-850f6b1b0b7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6b8a4a3d-2a4c-49f1-81b4-0e6c37ae21f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_5062dfa7-6cc0-4b79-8af4-5b4183bdb254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_1af731d8-74d4-4ca7-b3c7-e479981d947b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3014eecd-3b62-49b1-859b-5132c70a7d8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_5dd6ea79-1ed6-4fd4-bfde-295b989544d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cde6dc02-fc80-4fef-a5f9-c1c479dca2db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3f4cbd78-d94e-48b1-892b-e716976eb7fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8e0bc3e3-4b08-4944-8059-6999b756147c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_6e2e4e5a-08b0-4845-8a93-3b94cd5895c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_430de8ee-a6be-4373-9634-ddf883b01c5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ed7e79ef-96fa-4eef-919a-c352a3235260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_b6ec6f8a-bc22-4323-8647-1e511c65aa13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_93d8ea59-4f70-435a-800d-684dd2b13280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7ab4cd50-7dbc-450e-8807-5e18ae9fabd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ffc2f537-c19b-4a4e-86aa-33adffaef56a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_37efc727-3d91-4336-9a3f-f491d3514c2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-27</instant>
        </period>
    </context>
    <context id="C_668767af-d588-4269-bdd5-6d6317ca1174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_aa4c513f-59f0-4418-b2c2-d90b9bbe35b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7e96f6dc-3ab3-4489-961b-e2b6b8303a96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_ea67ab21-1afc-421d-9c63-09eb80e2cfd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b95ae457-b724-40e9-a605-8b606684a52e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pyxs:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_002caa9d-21b8-41d6-b0f1-07bf5d365ac2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_97f1d379-1c6e-4fb0-8b48-b544858a4c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_dca5bfc8-d2fa-4c60-8e05-95c561295a9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-28</startDate>
            <endDate>2022-03-28</endDate>
        </period>
    </context>
    <context id="C_8a2e39db-f489-43c1-abbc-dbbecbeb09c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c093cb7e-c886-49da-91b1-6affab2f3890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c28b8bc5-5c32-45fe-b131-2c2fbbfa9d56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_0326a5ad-45a2-4a64-829d-d01a89aa86a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1662ef99-8778-4709-9b9e-c988faaab66e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_32d8b9f9-d8e4-44c1-b86e-a4702ec224b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9b924cc1-929b-4476-912e-1c2d54d69e3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_19b30afc-5afa-40c6-8463-3498cd194d89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d1f92bd2-7f9c-4761-a7cd-fb5f0d37b59d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f604ee67-0407-458c-8c83-3dcf27014aee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_22452cd4-facf-4cb0-b0d8-aef2986fea43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pyxs:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_52a59c4e-168a-478f-9c0c-bb44fa171b44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_72b2f27a-fcc2-48bb-89ca-eed397dc0270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="C_4a0f2d3a-54c0-420e-9bb9-0592cc6ffcc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_04691b98-e0da-490b-a8f4-4b50017b84c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8b95c8e6-2fe9-4e6e-b9b7-23db66016497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:LegoChemLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7f621107-7e12-4f37-bdcf-0e86434b9852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <startDate>2021-09-29</startDate>
            <endDate>2021-09-29</endDate>
        </period>
    </context>
    <context id="C_766b7d60-5964-4d51-abab-3b2019b307a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5a174817-ec5a-4adc-91c7-b3f0391f3a67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_eefec595-540f-41d0-a397-d2a35572ebb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2022-03-29</instant>
        </period>
    </context>
    <context id="C_cffd11cd-91be-467f-9b81-32cb6d435261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pyxs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-05</instant>
        </period>
    </context>
    <context id="C_de03779b-38b4-48de-abf6-4dfbb5df89c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_113a708f-879e-4c63-8e7a-917c6c0f4303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pyxs:VoxallMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pyxs:AlloyTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_822a9797-c061-4b8c-ab9b-33b711164570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6b5b3558-a3b0-4002-902a-e67ae5cdd4b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d3f40a67-c272-4dd9-b239-cdb25247520e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_84680f37-2d8e-4647-bf6e-6e10f83c3b7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Segment">
        <measure>pyxs:Segment</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Lease">
        <measure>pyxs:Lease</measure>
    </unit>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_72b2f27a-fcc2-48bb-89ca-eed397dc0270"
      decimals="8"
      id="F_01b30c23-8e47-433b-a192-0adf8d0251a5"
      unitRef="U_pure">0.15725743</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_6e2e4e5a-08b0-4845-8a93-3b94cd5895c2"
      decimals="INF"
      id="F_b487119d-da19-4ae4-9043-40f7baa15197"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      id="F_0a1acadd-79fb-4921-bd24-0d8d565584f5"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_2fdfa06b-df8a-4632-9899-328796781364">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_04691b98-e0da-490b-a8f4-4b50017b84c0"
      decimals="INF"
      id="F_7234ad04-fa57-47a9-883c-6986dae56233"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_eb20c638-f7e6-42c8-bbb7-04213dfaf5a7"
      decimals="8"
      id="F_6e0eb586-b179-4054-af6f-b94a1fcee934"
      unitRef="U_pure">0.15725743</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:EntityCentralIndexKey
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_53b8bf9c-826e-4b8e-93dd-782095518f7b">0001782223</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_d7ecb9f2-df8f-460f-9821-26cf851cc9f5">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockValue
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      id="F_d7c513c0-dafa-48ea-8420-1d541d060cf1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_add39c44-72f5-4ca5-ab44-474e2dd8f88c"
      decimals="8"
      id="F_bc1feaae-b4f0-4232-bfcb-7aa66a503921"
      unitRef="U_pure">0.15725743</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      id="F_50960eda-5271-4ab9-851d-c8014b79d8e6"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      id="F_e37b2c3d-2209-4ae4-a26d-141353a73f83"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_9c8d13d3-b0ca-4be4-84c7-a6e6a68b50ee">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_adad96df-1da0-4e0a-8978-a64a9257f83b">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_7913ce1b-ceab-40f6-a242-f237a0102cd4">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_d51a5ba2-0b0e-4962-8e7d-a4e3e95156f3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_e35fd5c8-6287-445c-88fb-a91123c1ade4">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_bda25842-fa93-40c5-b8a7-ba9ab8c03528">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_8e759407-d189-4b48-9021-cb141cbb2c4d">001-40881</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_c382e615-b0f9-45b7-b606-76db1dc7ce64">Pyxis Oncology, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_d36d799f-bd76-4989-8a09-8f5ff7334457">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_55d4286b-e416-404e-b912-ab76efb8c31d">83-1160910</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_a76c60f9-4029-4e95-829f-f9d66195b956">35 Cambridgepark Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_cc555a07-5cd5-4cc7-b7b2-3fe9ac12facd">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_64c05801-d0f8-48a8-9be5-d5ace39cc6af">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_2a6d93fd-ea83-4e0e-8e00-a73741c3bdc4">02140</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_5a1aad2c-8ab2-4ca0-9442-56bf970148a8">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_906f1026-2d3c-43d0-a668-ea1b0e6957f0">221-9059</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_5d32de20-d9c8-443e-a5d2-f3d5f8730774">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_4a2c3897-7fad-491a-a047-e45143c1a958">PYXS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_f29b98cb-e0cc-49a1-86aa-d72f025d6d1e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_1bf39aa3-3b0c-4fad-ae42-cd64f93cdd4d">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_38cd4a01-4e74-42af-a777-88b956c88230">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_13d24af2-face-403e-9a5a-74945d03538b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_8e6688f2-d6ee-47fc-a565-4e8cdee1b6ce">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_1738b628-01f1-48ba-844a-2764ee003577">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_6d4616b0-287f-4467-b4c5-889460d21d76">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_7954223a-efee-44b2-8921-cd51a1a2f1ae">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_855efb69-8c0e-4159-b792-949bbb01ef8e">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_78596760-1baf-4a82-a6aa-d5b232181a93">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_66d16560-0a5f-43b7-91ef-534df1f2f95e">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_002caa9d-21b8-41d6-b0f1-07bf5d365ac2"
      decimals="INF"
      id="F_81ed7600-3b22-40f8-9e88-f6ab8d702eba"
      unitRef="U_USD">0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_eefec595-540f-41d0-a397-d2a35572ebb1"
      decimals="INF"
      id="F_55c4d2cb-f52a-4908-b149-7a73a869c458"
      unitRef="U_shares">32841747</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_12f96385-f3df-4631-9689-34ca3658999a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Portions of the Registrant&#x2019;s Proxy Statement for its 2021 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_16c5b53b-094a-4903-b18f-3b08a07be810">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_1b820805-0e30-4644-9525-4fdf9c795de0">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_7a065e93-6eff-4f13-b6ea-23fc541ebeff">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_b216c834-a954-46de-957d-29b837624214"
      unitRef="U_USD">274735000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_849d248a-cc94-4645-8eb6-be471e35ed4f"
      unitRef="U_USD">8080000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_3e70cf33-6753-44ce-8382-4f5b015ba8fd"
      unitRef="U_USD">1472000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_ca748584-5125-444e-9b5e-3ce6b96dedeb"
      unitRef="U_USD">2466000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_a0c7fe07-8ace-4c6c-95a3-2426fcad3428"
      unitRef="U_USD">23000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_15284b59-3f57-48da-ac6b-fc84494a6cc4"
      unitRef="U_USD">278673000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_6c6e41d6-2544-4351-90c0-e8830f2e0fca"
      unitRef="U_USD">8103000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_8a220c01-5233-49e0-999a-44a0777fcb66"
      unitRef="U_USD">1007000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_9be5bac6-8ed1-4cb8-b992-443d67885d96"
      unitRef="U_USD">1103000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_96e5e1bb-2e40-4bbc-9660-2829c1c7d951"
      unitRef="U_USD">232000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_6b7e6d80-c7e5-4b53-9fa2-1e048f09b58a"
      unitRef="U_USD">836000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_3e59304a-a2cf-4eb2-ae9b-a5633fb5fb45"
      unitRef="U_USD">109000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_c6277e78-eed4-44f1-84d6-58ba92faacc3"
      unitRef="U_USD">109000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_1b95e06a-7912-4614-83b1-3e90fd85795f"
      unitRef="U_USD">280021000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_a39a782a-d527-4c6f-b979-cc48a44a091a"
      unitRef="U_USD">10151000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_e3d2ca42-50cc-4821-860b-def8324ebd19"
      unitRef="U_USD">11951000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_6fd98350-a859-4d1b-9933-73839c738057"
      unitRef="U_USD">1077000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_97911dda-9040-4138-8620-6e9d6b0d0a92"
      unitRef="U_USD">6592000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_91fe08b2-4543-42f9-8620-fdb2ebfeca33"
      unitRef="U_USD">1997000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_846937fa-8781-4f1d-85f0-2c45912bea75"
      unitRef="U_USD">165000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_21b2d2a9-7bbb-42f8-a4ca-c11990e65ede"
      unitRef="U_USD">615000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_88561de3-b415-4704-8488-6d6fe8eb2daa"
      unitRef="U_USD">18708000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_94fb4a91-9619-4ef1-89f4-9fdac515e4df"
      unitRef="U_USD">3689000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_e20a49d6-48f7-4a44-af55-2bba6bccb232"
      unitRef="U_USD">165000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_b6e17582-0dff-4af8-bd4c-4981ec7bd39f"
      unitRef="U_USD">18708000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_fa66a669-fe37-46ee-a0c9-f236651c0590"
      unitRef="U_USD">3854000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_de03779b-38b4-48de-abf6-4dfbb5df89c9"
      decimals="INF"
      id="F_f5580615-b442-4c65-8e92-6b30ab07e684"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_8e0bc3e3-4b08-4944-8059-6999b756147c"
      decimals="INF"
      id="F_65401b66-38ab-4880-bfea-6ed03553dbb5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_de03779b-38b4-48de-abf6-4dfbb5df89c9"
      decimals="INF"
      id="F_8e738fd0-de97-45fc-9b35-005fd128e97a"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_8e0bc3e3-4b08-4944-8059-6999b756147c"
      decimals="INF"
      id="F_73635248-2c43-4489-9c5f-f4c317518864"
      unitRef="U_shares">22724926</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_de03779b-38b4-48de-abf6-4dfbb5df89c9"
      decimals="INF"
      id="F_ef673e1d-735d-4356-a908-656dc855cee4"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_de03779b-38b4-48de-abf6-4dfbb5df89c9"
      decimals="INF"
      id="F_504ad540-8915-4e3b-9731-fba0c79767a9"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_8e0bc3e3-4b08-4944-8059-6999b756147c"
      decimals="INF"
      id="F_27ef5f75-5ea4-4625-9c55-7545d148d497"
      unitRef="U_shares">22724925</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_8e0bc3e3-4b08-4944-8059-6999b756147c"
      decimals="INF"
      id="F_61578d20-a23d-4d1f-b62f-516c10b3cfa0"
      unitRef="U_shares">22724925</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_8e0bc3e3-4b08-4944-8059-6999b756147c"
      decimals="-3"
      id="F_730ad7ba-eec8-4230-bf9a-56dae659696a"
      unitRef="U_USD">22000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_8e0bc3e3-4b08-4944-8059-6999b756147c"
      decimals="-3"
      id="F_c20eaa5e-a4f4-400e-9d5e-b73d4f4010ae"
      unitRef="U_USD">21942000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_04691b98-e0da-490b-a8f4-4b50017b84c0"
      decimals="INF"
      id="F_2c6af2f4-7acb-4dbc-b263-303c91022a7d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_6e2e4e5a-08b0-4845-8a93-3b94cd5895c2"
      decimals="INF"
      id="F_962c6c2c-948e-4ca6-ad27-36ab63248ec3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_04691b98-e0da-490b-a8f4-4b50017b84c0"
      decimals="INF"
      id="F_eaebc958-6edc-4ab5-a4f1-81edc618d9f0"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_6e2e4e5a-08b0-4845-8a93-3b94cd5895c2"
      decimals="INF"
      id="F_e357f22a-c7f0-459d-aa75-4e4361a78ea2"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_04691b98-e0da-490b-a8f4-4b50017b84c0"
      decimals="INF"
      id="F_dc50d673-d83b-4d24-ba46-1b6cfca8a25e"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_6e2e4e5a-08b0-4845-8a93-3b94cd5895c2"
      decimals="INF"
      id="F_95e37cb5-d7e5-46cd-9f30-59b6b86af103"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_983767e4-0975-4c5a-a102-e915fdf196e5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_d2488bef-1317-4048-aed4-8d670147ee0d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_283d0ffd-6d59-4914-89b5-c466c270631d"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_8c838cd1-4a80-46e2-8e4a-06e3bc41125a"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_fc9e622c-692e-487f-9845-313f2cac1689"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_9a3d4c5f-d903-4700-b920-0c0301f7c75b"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_1bf4ab27-2fdb-474d-94c7-eb341be473a8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_e6235a5a-519b-4665-861b-4a4604fd4061"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_3372c316-790c-412e-b62d-741d85ab75f7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_ca763d8a-dafb-4ea2-9dc3-f988b65d4209"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_cdc44667-76af-4499-81ee-d57814e3c081"
      unitRef="U_shares">190000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_2dff5d80-f392-4a07-a1cd-509a2f1a59ce"
      unitRef="U_shares">40300000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_068580a7-0d3b-4bb2-8271-093adfaa19eb"
      unitRef="U_shares">32792867</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_eed9987e-4d5e-4fc7-8760-72f74d307f49"
      unitRef="U_shares">2177956</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_a3f76fac-61fa-485b-9fb8-e4578c666cab"
      unitRef="U_shares">32222881</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_1f7cf3a0-d088-480c-a18e-a57495662d4f"
      unitRef="U_shares">1289342</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_542af9fc-3ab7-4832-a24c-d15ef01937ec"
      unitRef="U_USD">32000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_ef5a056e-fc9c-4e31-98e3-547ca62b0eb6"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_702376a8-0b80-4577-bbe2-d0b3c5dc2ff0"
      unitRef="U_USD">352999000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_7c35bbe1-34f9-4639-86c8-0357e6e04cc5"
      unitRef="U_USD">97000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_5a11eb69-e81d-4c7e-b25f-6478f8fe915c"
      unitRef="U_USD">-91718000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_28682d48-a9ef-455c-9816-525c80f41f16"
      unitRef="U_USD">-15743000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_05fcaa4e-8652-422a-b610-37aea175a378"
      unitRef="U_USD">261313000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_92c84fb8-f59b-4897-9319-9368090b9254"
      unitRef="U_USD">-15645000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_32f1ba3d-a265-4704-b509-1f882ab2c155"
      unitRef="U_USD">280021000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_8761100b-4571-4d34-be21-5e60fc20b94e"
      unitRef="U_USD">10151000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_0e401272-2eeb-42cc-9e8b-8a4fc2fbc5f3"
      unitRef="U_USD">51054000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_2ebb1532-5db7-43ef-afdf-42effcabda34"
      unitRef="U_USD">9048000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_47ada345-f81d-48b1-a412-36ab9ec6697a"
      unitRef="U_USD">18663000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_8a6cfd03-7f03-4140-b9d8-4d88baff6bf3"
      unitRef="U_USD">3846000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_28cba468-6582-4cd1-b75f-febf07fe4703"
      unitRef="U_USD">69717000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_ecea12e5-b008-42af-8634-372e39c4258c"
      unitRef="U_USD">12894000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_36fa9b6b-55d1-4256-bef5-718826deb2e2"
      unitRef="U_USD">-69717000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_28084cf4-56fd-49ba-8550-4ddbd39ad5e7"
      unitRef="U_USD">-12894000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_1ec70c38-1ce9-43c6-ae9e-cc4e63cd0745"
      unitRef="U_USD">23000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_92fdc938-0bd5-430c-ad66-bf4c91c60d17"
      unitRef="U_USD">66000</us-gaap:InvestmentIncomeInterest>
    <pyxs:ServiceFeeIncomeFromRelatedParty
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_dd504bba-09aa-44a4-9621-021eea9fe898"
      unitRef="U_USD">181000</pyxs:ServiceFeeIncomeFromRelatedParty>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_24fed7bd-45ed-47dc-81f0-04f10c134dc4"
      unitRef="U_USD">-6231000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_fd481415-1141-459a-867a-a712953aedae"
      unitRef="U_USD">-6027000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_a1125698-3d7b-426a-af81-59b19e89cb20"
      unitRef="U_USD">66000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_3b6c6336-e542-4a84-866d-f7376e8c6b2d"
      unitRef="U_USD">-231000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_5f7c6d43-3cac-46b3-b70c-08e7fd9eb3b8"
      unitRef="U_USD">-75975000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_b6003a08-2414-44a1-972c-3930848e0726"
      unitRef="U_USD">-12828000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="2"
      id="F_781125fc-974a-450a-b4fd-0b91e76b04ab"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-8.95</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="2"
      id="F_adeeb1cc-53f1-4753-b569-dc15c4f625e3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-12.45</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="0"
      id="F_f818b5a2-28b1-4a21-8602-60a51b3ae04f"
      unitRef="U_shares">8493273</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="0"
      id="F_78912931-2377-47f9-8998-fe81d9b9ee93"
      unitRef="U_shares">1030556</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_5221cef4-195a-4dfd-95bb-66e798f30b97"
      decimals="INF"
      id="F_d7208de5-81eb-4fbc-95e5-620891b34754"
      unitRef="U_shares">22724925</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_5221cef4-195a-4dfd-95bb-66e798f30b97"
      decimals="-3"
      id="F_a51bdf40-3ab0-4c0e-8aa1-33f300bea1b4"
      unitRef="U_USD">21942000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_b6ec6f8a-bc22-4323-8647-1e511c65aa13"
      decimals="INF"
      id="F_a162c3e1-3467-4f76-bd0d-2a774b6dda99"
      unitRef="U_shares">828356</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b6ec6f8a-bc22-4323-8647-1e511c65aa13"
      decimals="-3"
      id="F_aeada01d-666e-4d3c-aca4-057495456b89"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7e96f6dc-3ab3-4489-961b-e2b6b8303a96"
      decimals="-3"
      id="F_0c68e98f-b564-4836-b269-0d49f9763c8a"
      unitRef="U_USD">40000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6a491c51-e3ff-4f01-b86c-22bb7f1219c0"
      decimals="-3"
      id="F_b9e51892-442b-47c6-811f-cda3f5e2ac45"
      unitRef="U_USD">-2915000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_37f4df29-d5b8-4d2c-bf7f-5a96e5b924a3"
      decimals="-3"
      id="F_19ff0f75-5411-477d-a088-9b83b05b7f72"
      unitRef="U_USD">-2874000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c75ce941-68a1-475c-964a-d8c55a132c9f"
      decimals="INF"
      id="F_52d9cd53-fcbe-4147-9ae6-6f79b75b4e35"
      unitRef="U_shares">49061</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_cb6bd2f8-ad47-4a35-989a-57aedc56c9c0"
      decimals="-3"
      id="F_a915a22a-78f2-4b82-a614-730f03f31f71"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_040a64ee-3626-4215-adbe-68f06d989a8c"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_c75ce941-68a1-475c-964a-d8c55a132c9f"
      decimals="INF"
      id="F_962f3d75-f158-44ae-8511-fa3346f668f6"
      unitRef="U_shares">411925</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_cb6bd2f8-ad47-4a35-989a-57aedc56c9c0"
      decimals="-3"
      id="F_e1d1d574-9918-4db3-826a-d6bfce5bc2d4"
      unitRef="U_USD">10000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_104e451f-2bf5-4d94-b541-156b2311439e"
      unitRef="U_USD">10000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cb6bd2f8-ad47-4a35-989a-57aedc56c9c0"
      decimals="-3"
      id="F_492a3c1e-6565-4404-8271-7fc9bab921da"
      unitRef="U_USD">44000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_e4679cae-f0c5-464f-bcba-9ee03803af7e"
      unitRef="U_USD">44000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_a9c9231a-7100-4362-8c03-86895d680666"
      decimals="-3"
      id="F_1d10b89f-723a-4f8b-8a0f-71c1edcdbcaf"
      unitRef="U_USD">-12828000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_b1921b5d-39bb-4335-b137-b6f27267039f"
      unitRef="U_USD">-12828000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_856072e1-a9f5-4feb-888d-6f52cd2b0837"
      decimals="INF"
      id="F_67552021-f07c-4c1f-b946-17bcbc298c68"
      unitRef="U_shares">22724925</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_856072e1-a9f5-4feb-888d-6f52cd2b0837"
      decimals="-3"
      id="F_ee595d94-e02f-4e8b-b29f-1c1f6a6890f3"
      unitRef="U_USD">21942000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_766b7d60-5964-4d51-abab-3b2019b307a8"
      decimals="INF"
      id="F_f3ad696b-8759-449a-a01f-9928e07859d0"
      unitRef="U_shares">1289342</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_766b7d60-5964-4d51-abab-3b2019b307a8"
      decimals="-3"
      id="F_1dc89f10-384d-447e-8c99-2e284cd3eb88"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0492f1f1-cdba-47c2-b6ed-3d308a2cdd45"
      decimals="-3"
      id="F_fb85e2eb-4c3e-4b3f-bfdf-599084370ae3"
      unitRef="U_USD">97000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d3f40a67-c272-4dd9-b239-cdb25247520e"
      decimals="-3"
      id="F_80cd654f-98bd-46ae-b2cd-7fa3112b5924"
      unitRef="U_USD">-15743000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_fbdada60-45f8-4ca6-ac79-859b70b67289"
      unitRef="U_USD">-15645000</us-gaap:StockholdersEquity>
    <pyxs:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b5d21c61-6321-4216-b894-327d183af8bc"
      decimals="INF"
      id="F_81431cbd-f407-457e-835a-dd36e7baa22d"
      unitRef="U_shares">12152145</pyxs:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_b5d21c61-6321-4216-b894-327d183af8bc"
      decimals="-3"
      id="F_de28cc03-c55a-4570-af94-ee7bceaa52b8"
      unitRef="U_USD">20000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <pyxs:TemporaryEquityIssuanceCosts
      contextRef="C_8e920cab-08bd-4853-a2c7-07b631b559f3"
      decimals="-3"
      id="F_637fb36a-a282-458c-a533-274d6f6335fe"
      unitRef="U_USD">419000</pyxs:TemporaryEquityIssuanceCosts>
    <pyxs:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_f604ee67-0407-458c-8c83-3dcf27014aee"
      decimals="INF"
      id="F_8f71a00f-7364-4172-ab1c-917f5c0bca90"
      unitRef="U_shares">92660103</pyxs:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_f604ee67-0407-458c-8c83-3dcf27014aee"
      decimals="-3"
      id="F_a1c222ff-e95d-421b-901a-02dae88f3511"
      unitRef="U_USD">152081000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="C_822a9797-c061-4b8c-ab9b-33b711164570"
      decimals="-3"
      id="F_52d5e0ba-02c4-445a-ab9b-0003bebdcd79"
      unitRef="U_USD">15704000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_8b24eb84-4a1e-48e9-939f-d50285a9ebf8"
      decimals="INF"
      id="F_68edf472-a22f-4a66-a330-91b06c24ef00"
      unitRef="U_shares">10500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_8b24eb84-4a1e-48e9-939f-d50285a9ebf8"
      decimals="-3"
      id="F_15ce4fdd-942b-4c26-afb7-768e2afae3e3"
      unitRef="U_USD">11000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_cab37125-1fa0-46b6-b525-727f58de2829"
      decimals="-3"
      id="F_14c3561c-7850-40f9-a346-eafc9c168c76"
      unitRef="U_USD">152285000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_60a0d615-609c-4658-97f4-896f92d22495"
      decimals="-3"
      id="F_3cc5c48c-34d5-47c0-9c03-36468c2856a7"
      unitRef="U_USD">152296000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <pyxs:TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock
      contextRef="C_f604ee67-0407-458c-8c83-3dcf27014aee"
      decimals="INF"
      id="F_e797421a-9e2a-435a-b382-644fa5b65da7"
      unitRef="U_shares">-127537173</pyxs:TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock>
    <pyxs:TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue
      contextRef="C_f604ee67-0407-458c-8c83-3dcf27014aee"
      decimals="-3"
      id="F_36331d4b-17c0-4f4e-806e-0dc58d7b5ca7"
      unitRef="U_USD">-194023000</pyxs:TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_d8091fae-ef00-4700-b4a2-77ed5956ff06"
      decimals="INF"
      id="F_517512d5-59a9-461b-a892-b6b2e8dce59f"
      unitRef="U_shares">20056145</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_d8091fae-ef00-4700-b4a2-77ed5956ff06"
      decimals="-3"
      id="F_e3106c54-a977-4f20-a065-c184034836ff"
      unitRef="U_USD">20000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_5c40a4a9-f63b-4608-bd08-8d0a1321ed5b"
      decimals="-3"
      id="F_4d634b35-6626-4c21-a0fc-9868d908b548"
      unitRef="U_USD">194003000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_50ee77cb-40d2-48eb-a3d2-ca90740e31e8"
      unitRef="U_USD">194023000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_d8091fae-ef00-4700-b4a2-77ed5956ff06"
      decimals="INF"
      id="F_5f5b8c54-a14a-48a5-a457-e0de372f4dd7"
      unitRef="U_shares">70396</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_5c40a4a9-f63b-4608-bd08-8d0a1321ed5b"
      decimals="-3"
      id="F_e2156b94-c23d-4344-ba52-3caa78e45170"
      unitRef="U_USD">170000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_16f3b4bb-24c9-4222-82d6-a7744ede1d76"
      unitRef="U_USD">170000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_d8091fae-ef00-4700-b4a2-77ed5956ff06"
      decimals="INF"
      id="F_0f27f295-a75f-412d-a0d9-b12d7f8ccdfc"
      unitRef="U_shares">306998</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_5c40a4a9-f63b-4608-bd08-8d0a1321ed5b"
      decimals="-3"
      id="F_f97770d5-5716-4e90-aa5a-955ba8b49676"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_df15c236-db6c-486a-bef8-9f32a460dcb5"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5c40a4a9-f63b-4608-bd08-8d0a1321ed5b"
      decimals="-3"
      id="F_800ca1e2-618f-4f78-8439-26a0594b7da0"
      unitRef="U_USD">6441000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_78243338-4e37-4160-a0dd-ecc351ebb565"
      unitRef="U_USD">6441000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_5dd6ea79-1ed6-4fd4-bfde-295b989544d7"
      decimals="-3"
      id="F_89701edd-8e62-4576-bba9-7cc9c1ce6719"
      unitRef="U_USD">-75975000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_cf2631d6-e024-4e30-a6dd-92a2d7294976"
      unitRef="U_USD">-75975000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_84680f37-2d8e-4647-bf6e-6e10f83c3b7f"
      decimals="INF"
      id="F_90b9c22e-4676-45be-8655-7c3468da98a2"
      unitRef="U_shares">32222881</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_84680f37-2d8e-4647-bf6e-6e10f83c3b7f"
      decimals="-3"
      id="F_556bca05-21c4-4856-87d9-58e7b1fece34"
      unitRef="U_USD">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_aa4c513f-59f0-4418-b2c2-d90b9bbe35b3"
      decimals="-3"
      id="F_662b1f47-7baa-4414-9a1b-c6ef536a09a3"
      unitRef="U_USD">352999000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_98160ecc-3034-40bb-a317-ac57984c3f17"
      decimals="-3"
      id="F_b6c00a64-549e-4301-afda-50b84b0b45b7"
      unitRef="U_USD">-91718000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_670080b5-16fc-4ca9-bb48-1f1f75cfe9ec"
      unitRef="U_USD">261313000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_c3a5d796-3fc6-4477-8a64-36282aae222f"
      unitRef="U_USD">-75975000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_895f1389-37c2-486d-83a9-c326ef4c7bc1"
      unitRef="U_USD">-12828000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_08e220a2-f979-4778-b9e8-f88f0bdccdd0"
      unitRef="U_USD">647000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_d4d0f5f7-fa70-4b09-9d05-2441867fc5d1"
      unitRef="U_USD">469000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_acf685b4-0908-4f2b-9bd1-bd367ad58ef6"
      unitRef="U_USD">6441000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_622fa3e9-2070-4a66-aaa9-baf62ba734a9"
      unitRef="U_USD">44000</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_6ffca598-ac0e-4efd-b67d-a2b51239e1fc"
      unitRef="U_USD">20000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_17cd7340-6c74-464b-9d2a-06832e2035cd"
      unitRef="U_USD">604000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_07b36869-1aaa-40be-ad42-33472cfd1ccb"
      unitRef="U_USD">365000</us-gaap:OperatingLeaseExpense>
    <pyxs:NonCashGainLossFromEquityMethodInvestmentInJointVenture
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_bef55334-2e1b-477a-a707-b6b8e1393344"
      unitRef="U_USD">-50000</pyxs:NonCashGainLossFromEquityMethodInvestmentInJointVenture>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_9e6ec0ec-ee27-45e3-90c3-e9f22d7089e6"
      unitRef="U_USD">-6231000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_0511b958-6d44-41b9-96f7-7de0e13ef4e6"
      unitRef="U_USD">2444000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_cf4c7109-e5b4-4cea-87a1-f74e9837950d"
      unitRef="U_USD">13000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_7755b041-4c98-4a08-8387-cd0e3441fc3e"
      unitRef="U_USD">4643000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_33d8fe3a-a2c8-4e1b-a264-3dcea8037777"
      unitRef="U_USD">558000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_d9439ce4-5449-4ef2-aa84-a9cbd1595ba7"
      unitRef="U_USD">5092000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_c196b9a4-79d8-4522-9326-b68e93694797"
      unitRef="U_USD">1742000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_801b56e3-3c15-40d3-87fe-63d2787c88ca"
      unitRef="U_USD">-615000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_a97dd8e5-4259-4f29-93f8-1a11b2922546"
      unitRef="U_USD">-421000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_f4f643c3-488d-463f-be00-713741edfe58"
      unitRef="U_USD">-35326000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_6c522bf5-2818-4d9a-91c4-dd2637f37ad7"
      unitRef="U_USD">-10084000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_81f14186-0342-4c1a-bfdd-0042d1d55367"
      unitRef="U_USD">540000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_62f013e2-09e8-481d-81ad-2bb722907da5"
      unitRef="U_USD">1483000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_7df1474b-262e-40b4-ac8d-50a804ae4771"
      unitRef="U_USD">50000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_609d8991-4b1e-40a3-8037-7640b6857365"
      unitRef="U_USD">-590000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_e7d21dd0-ddc2-48d3-9165-e8ae2f094768"
      unitRef="U_USD">-1483000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_9ba69741-3c92-44cd-a933-884f7e10d57a"
      unitRef="U_USD">151581000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_fb6b79bb-dfc9-432a-803b-a09aa47d2cf8"
      unitRef="U_USD">152296000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_abb1e9b5-9272-4b13-b224-9d852fad8d02"
      unitRef="U_USD">3000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_4569a5ae-b35c-4be9-a45d-666ace4c46c9"
      unitRef="U_USD">167000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_50ae19ea-ffc6-4683-a5fc-b87127679554"
      unitRef="U_USD">32000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_d438ef1f-eb55-4889-bf6b-44b64902ba0a"
      unitRef="U_USD">304044000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_b9c008b7-959e-4dfe-9f38-fdf05263e9d6"
      unitRef="U_USD">35000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_8586458f-b294-4173-9c06-9627bf5601d5"
      unitRef="U_USD">268128000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_36b5cded-4685-4591-b15c-a46f8badf2d2"
      unitRef="U_USD">-11532000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_ef4bf6a6-aca1-4667-b1d5-3605ff27f260"
      unitRef="U_USD">8188000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_37f4df29-d5b8-4d2c-bf7f-5a96e5b924a3"
      decimals="-3"
      id="F_e9d3a33f-4370-4b85-b29d-7e1d335bece0"
      unitRef="U_USD">19720000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_7324655c-670f-4091-a2c4-0711c7bbcdde"
      unitRef="U_USD">276316000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_45fdc56f-daad-4670-9415-68c57442fbf0"
      unitRef="U_USD">8188000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_49fa73ee-cbdb-4db9-a0de-0687e2ff9dc0"
      unitRef="U_USD">11000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_16bfb2d4-7e2e-4c6b-a100-8b3f0a19eb29"
      unitRef="U_USD">28000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_c9d1787f-d493-40e1-a2e0-1eecd842975d"
      unitRef="U_USD">1186000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_ebfb343f-650c-4d3d-aed4-67f6955826ce"
      unitRef="U_USD">274735000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_0d8c6365-6539-48d9-a424-f87634df8fd7"
      unitRef="U_USD">8080000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_d3fba815-9ccd-4300-925d-14775336e6d0"
      unitRef="U_USD">1581000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_04cc726b-bd7d-4613-ae48-a6bd1219d692"
      unitRef="U_USD">108000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_481610ae-1531-4faa-b633-80dc6ce84d88"
      unitRef="U_USD">276316000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_360767c6-8f72-4320-b046-21dd8c565980"
      unitRef="U_USD">8188000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_50c32070-110c-4c2e-9afb-ef595a192aa1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Organization and Nature of Business&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Nature of Business&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pyxis Oncology, Inc. (the &#x201c;Company&#x201d;), a Delaware corporation, was founded in June 2018 and launched its operations in July 2019. The Company is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The Company develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since the Company&#x2019;s launch in 2019, the Company has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates and monoclonal antibody, or mAb, preclinical discovery programs that the Company is developing as monotherapies and in combination with other therapies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has determined that it has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; operating and reporting segment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Reverse Stock Split&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On October 1, 2021, the Company effected a 1-for-&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6e0eb586-b179-4054-af6f-b94a1fcee934;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.359&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reverse stock split of its issued and outstanding common stock and stock option awards. The par value of the common stock and preferred stock was not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the convertible preferred stock conversion price to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The shares of common stock underlying outstanding stock options and restricted stock units were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All issued and outstanding shares of common stock, restricted stock units, stock option awards and per share data have been adjusted on a retrospective basis in these consolidated financial statements, to reflect the reverse stock split for all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On October 8, 2021, the Company completed an initial public offering (&#x201c;IPO&#x201d;) in which the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;168.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The Company raised approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;152.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in net proceeds after deducting underwriting discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and offering expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon closing of the IPO, all of the outstanding shares of Series A Convertible Preferred stock (&#x201c;Series A Preferred Stock&#x201d;), and Series B Convertible Preferred Stock (&#x201c;Series B Preferred Stock&#x201d;) automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,056,145&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock of the Company. Subsequent to the closing of the IPO, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of convertible preferred stock outstanding.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the closing of the IPO, the Company filed an amended and restated certificate of incorporation (&#x201c;Amended Certificate of Incorporation&#x201d;) to change the authorized capital stock to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;200,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;190,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; are designated as voting common stock and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; are designated as undesignated preferred stock, all with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;91.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To date, the Company has primarily financed its operations through the sale of convertible preferred stocks and the proceeds from IPO. The Company has not generated any revenues to date and does not anticipate generating any revenues unless and until it successfully completes development and obtains regulatory approval for its current or any future product candidates. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to expand its research and development programs, business development activities and develop its product candidates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company currently expects that its existing cash and cash equivalents of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;274.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2021 will be sufficient to fund its operating expenses and capital requirements at least twelve months from the date these consolidated financial statements are issued. Additional funding may be necessary to fund future clinical and preclinical activities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company plans to continue to fund its losses from operations and capital funding needs through issuance of equity securities, convertible or debt financings or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <pyxs:NatureOfBusinessPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_aa8e54d9-852a-4f6c-b57c-cc37bc961d79">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Nature of Business&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pyxis Oncology, Inc. (the &#x201c;Company&#x201d;), a Delaware corporation, was founded in June 2018 and launched its operations in July 2019. The Company is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The Company develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since the Company&#x2019;s launch in 2019, the Company has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates and monoclonal antibody, or mAb, preclinical discovery programs that the Company is developing as monotherapies and in combination with other therapies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has determined that it has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; operating and reporting segment.&lt;/span&gt;&lt;/p&gt;</pyxs:NatureOfBusinessPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="INF"
      id="F_ccada53d-8214-4fcc-8fff-440570b7107f"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="INF"
      id="F_89197659-e9ce-4858-9c92-e0630d3d84ed"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_99e345a9-8152-48ee-9e1a-6700f098c49c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Reverse Stock Split&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On October 1, 2021, the Company effected a 1-for-&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6e0eb586-b179-4054-af6f-b94a1fcee934;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.359&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reverse stock split of its issued and outstanding common stock and stock option awards. The par value of the common stock and preferred stock was not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the convertible preferred stock conversion price to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The shares of common stock underlying outstanding stock options and restricted stock units were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All issued and outstanding shares of common stock, restricted stock units, stock option awards and per share data have been adjusted on a retrospective basis in these consolidated financial statements, to reflect the reverse stock split for all periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <pyxs:InitialPublicOfferingPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_badcd654-1e35-44dc-9bf2-3395fefefb7c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On October 8, 2021, the Company completed an initial public offering (&#x201c;IPO&#x201d;) in which the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;168.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The Company raised approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;152.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in net proceeds after deducting underwriting discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and offering expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon closing of the IPO, all of the outstanding shares of Series A Convertible Preferred stock (&#x201c;Series A Preferred Stock&#x201d;), and Series B Convertible Preferred Stock (&#x201c;Series B Preferred Stock&#x201d;) automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,056,145&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock of the Company. Subsequent to the closing of the IPO, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of convertible preferred stock outstanding.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the closing of the IPO, the Company filed an amended and restated certificate of incorporation (&#x201c;Amended Certificate of Incorporation&#x201d;) to change the authorized capital stock to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;200,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;190,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; are designated as voting common stock and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; are designated as undesignated preferred stock, all with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share.&lt;/span&gt;&lt;/p&gt;</pyxs:InitialPublicOfferingPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2b011e3d-095a-448f-a28b-10116452cf0e"
      decimals="INF"
      id="F_6120adf3-28bc-45fa-afb2-4c551959185a"
      unitRef="U_shares">10500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_f9b6d952-91a3-4a16-ba7e-88b297d8e0b1"
      decimals="2"
      id="F_91a5bd24-78e4-4863-99c1-6d5bf9697fea"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.00</us-gaap:SharesIssuedPricePerShare>
    <pyxs:GrossProceedsFromIssuanceInitialPublicOffering
      contextRef="C_762248a9-dd67-46d8-b8ac-e8d11ca59329"
      decimals="-5"
      id="F_211bd13e-82bd-46c7-917e-f68c85bc23fd"
      unitRef="U_USD">168000000.0</pyxs:GrossProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_762248a9-dd67-46d8-b8ac-e8d11ca59329"
      decimals="-5"
      id="F_01984122-8302-403a-84f0-f7e6c58ebbc3"
      unitRef="U_USD">152300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <pyxs:UnderwritingDiscountsAndCommissions
      contextRef="C_2b011e3d-095a-448f-a28b-10116452cf0e"
      decimals="-5"
      id="F_d7624d22-9682-477d-b812-83542b73a4be"
      unitRef="U_USD">11800000</pyxs:UnderwritingDiscountsAndCommissions>
    <pyxs:StockIssuanceExpenses
      contextRef="C_2b011e3d-095a-448f-a28b-10116452cf0e"
      decimals="-5"
      id="F_2354df97-9b26-4651-a27c-1bdee6a06601"
      unitRef="U_USD">3900000</pyxs:StockIssuanceExpenses>
    <pyxs:NumberOfCommonSharesIssuedUponConversionOfPreferredStock
      contextRef="C_d16739b1-097f-4ebc-b79f-81d904a831e7"
      decimals="INF"
      id="F_c3b4cf24-795b-4074-b7b6-eecd4ade0e76"
      unitRef="U_shares">20056145</pyxs:NumberOfCommonSharesIssuedUponConversionOfPreferredStock>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_13a4aa5e-911a-4c5d-9086-7de944870e14"
      decimals="INF"
      id="F_a793bbe5-b79e-44b7-be33-ba92345f72c5"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="C_2bb52469-04b7-49d0-857a-43447b7272be"
      decimals="INF"
      id="F_939c204c-6d65-4065-a2e1-987cd3fc4f12"
      unitRef="U_shares">200000000</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_2bb52469-04b7-49d0-857a-43447b7272be"
      decimals="INF"
      id="F_96eea108-c658-4d6e-a50f-db52829b39b1"
      unitRef="U_shares">190000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_2bb52469-04b7-49d0-857a-43447b7272be"
      decimals="INF"
      id="F_86e09246-6d9e-4bae-b115-5a1a9c384251"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2bb52469-04b7-49d0-857a-43447b7272be"
      decimals="INF"
      id="F_a441a29e-e02d-43b9-8e8e-7d17abf99261"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_2bb52469-04b7-49d0-857a-43447b7272be"
      decimals="INF"
      id="F_6508b6ae-df7f-42b1-aa09-5695482fab4b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <pyxs:LiquidityPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_23050be1-32a6-4ed3-b02c-9875798b10d6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;91.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To date, the Company has primarily financed its operations through the sale of convertible preferred stocks and the proceeds from IPO. The Company has not generated any revenues to date and does not anticipate generating any revenues unless and until it successfully completes development and obtains regulatory approval for its current or any future product candidates. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to expand its research and development programs, business development activities and develop its product candidates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company currently expects that its existing cash and cash equivalents of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;274.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2021 will be sufficient to fund its operating expenses and capital requirements at least twelve months from the date these consolidated financial statements are issued. Additional funding may be necessary to fund future clinical and preclinical activities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company plans to continue to fund its losses from operations and capital funding needs through issuance of equity securities, convertible or debt financings or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</pyxs:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-5"
      id="F_6c3723ae-898c-4671-9a2d-11b258bdda46"
      unitRef="U_USD">-91700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-5"
      id="F_3f5e1cbe-1cc5-4bad-9004-1eb452affac4"
      unitRef="U_USD">-76000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-5"
      id="F_c1aacec5-563b-4887-bc8d-8379a49feabe"
      unitRef="U_USD">-12800000</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-5"
      id="F_bc216805-209e-41c5-b9dd-96c12161da83"
      unitRef="U_USD">274700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_5ce32211-f35c-4ce7-8228-0fcca59aed0e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2. Basis of Presentation and Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s fiscal year ends on December 31 and its first three quarters end on March 31, June 30 and September 30. The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Section 107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expense, and related disclosures. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, derivative liability, research and development accruals, operating leases, assessment of the useful lives of property and equipment, valuation of deferred tax assets and liabilities, impairment of investment in joint venture, and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additionally, the management considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the year ended December 31, 2021. However, the extent to which the COVID-19 pandemic may directly or indirectly impact the Company&#x2019;s financial statements is highly uncertain and subject to change.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Actual results could differ from those estimates and there may be changes to management&#x2019;s estimates in future periods.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is subject to risks common to early-stage companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key suppliers for active ingredients and third-party service providers such as contract research organizations, protection of intellectual property rights and the ability to make milestone, royalty or other payments due under any license, collaboration or supply agreements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentration of Credit Risks&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company&#x2019;s cash and cash equivalents are held at an accredited financial institution and the Company has not experienced any losses in such accounts. The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company&#x2019;s cash equivalents consist primarily of short-term money market funds held in accredited financial institutions. The Company believes it is not exposed to any significant risk in cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers all short term, highly liquid investments with original maturities of 90 days or less to be cash equivalents. Cash equivalents consist primarily of money market funds as of December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principle or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Level&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; 1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Level&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; 2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Level&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; 3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment, net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the related assets as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:73.139%;"/&gt;
          &lt;td style="width:1.898%;"/&gt;
          &lt;td style="width:24.963%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Estimated Useful&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shorter of remaining life&lt;br/&gt;of lease or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and amortization expense is included in research and development and general and administrative expenses. Major additions and upgrades are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are expensed as incurred. Upon retirement or sale, the cost of assets disposed of, and the related accumulated depreciation and amortization are removed from the respective accounts and any resulting gain or loss is included in income (loss) from operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluates the long-lived assets, which consist of property and equipment and operating lease right-of-use assets, for impairment at least annually and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. Management then determines whether the remaining useful life continues to be appropriate, or whether there has been an impairment of long-lived assets based primarily upon whether expected future undiscounted cash flows are sufficient to support the assets&#x2019; recovery. Recoverability of these assets is measured by comparison of the carrying amount of the asset to the future undiscounted cash flows the asset is expected to generate. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. The Company recognized &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; impairment losses for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;lease right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are initially recognized and measured based on the present value of the future fixed lease payments over the expected lease term at the commencement date calculated using the Company&#x2019;s incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. The Company determines the lease term as the non-cancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease ROU assets also include any initial direct costs incurred and any lease payments made on or before the lease commencement date, less lease incentives received. Operating lease ROU assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. The Company accounts for lease and non-lease components as a single lease component for all its facilities leases. The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; finance leases as of December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investment in Joint Venture&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Investment in the Company&#x2019;s joint venture is accounted for using the equity method of accounting. The Company &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;apply the equity method of accounting to investments when the Company has significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;equity&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;method&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;investment&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the equity method, investments are initially recorded at cost and are adjusted for dividends, distributed and undistributed earnings and losses, and additional investments. In the event the Company&#x2019;s share of a joint venture&#x2019;s cumulative losses exceeds the Company&#x2019;s investment balance, the balance is reported at zero value until proportionate income exceeds the losses. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company, from time to time, may be a party to various disputes and claims arising from normal business activities. The Company continually assesses disputes and claims including resulting litigation to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the contingencies, including an estimable range, if possible.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company expenses research and development costs as incurred. The Company&#x2019;s research and development expenses consist primarily of license fees to acquire intellectual property which does not meet the definition of intangible assets and costs incurred in performing research and development activities, including personnel-related expenses such as salaries, stock-based compensation and benefits, facilities costs, depreciation as well as external costs for outside vendors engaged to conduct preclinical development activities and license fees. The Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and efforts expended pursuant to the terms of the contractual arrangements. Payments under some of these contracts depend on preclinical trial milestones. There may be instances in which payments made to the Company&#x2019;s vendors will exceed the level of services provided and result in a prepayment of expenses. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or prepaid expense accordingly.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company maintains an equity incentive plan as a long-term incentive for employees, consultants, and directors. The Company accounts for all stock-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The grant date fair value of the stock-based awards with graded vesting is recognized on a straight-line basis over the requisite service period. The Company recognizes forfeitures related to stock-based compensation awards as they occur and reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs. The Company classifies stock-based compensation expense in the statement of operations in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company values its stock options with service conditions using the Black-Scholes option pricing model. The Company use certain assumptions to determine fair value of the stock options pursuant to the Black-Scholes option pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate, expected dividend yield and the fair value of the Company&#x2019;s common stock. Since the Company has no option exercise history, the Company uses the simplified method described in the SEC&#x2019;s Staff Accounting Bulletin No. 107, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Share-Based Payment &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&#x201c;SAB 107&#x201d;), to determine the expected life of the option grants. The Company lacks sufficient company-specific historical and implied volatility information. Therefore, the Company estimates the expected stock volatility based on the historical volatility of a publicly traded set of peer companies. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. As the Company has never paid and does not anticipate paying cash dividends on its common stock, the expected dividend yield is considered as zero.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;Prior to the completion of the Company&#x2019;s IPO, the fair value of the Company's common stock which is one of the key input in Black-Scholes option pricing model, was determined by the board of directors with input from management and based on certain assumptions including probability weighting of events, business and market conditions, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. The Company used 409A valuations to determine the fair value of the shares of common stock. The 409A valuations were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;font-style:italic;"&gt;Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;. After completion of the IPO, on October 8, 2021, the Company uses the fair value of its publicly traded common stock to determine grant date fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For restricted stock awards issued pursuant to standalone restricted stock purchase agreements, the fair value of each award was estimated based on the estimated fair value of the Company&#x2019;s common stock, less the amount paid by the grantee. The Company recognized deposit liability for restricted stock awards issued pursuant to standalone restricted stock purchase agreements. As the awards of restricted stock vest, the Company reclassifies the deposit liability to additional paid-in capital.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for income taxes in accordance with FASB ASC 740, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (&#x201c;ASC 740&#x201d;), which requires the use of the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between amounts in the consolidated financial statements and the tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income tax (benefit) expense in the consolidated statements of operations and comprehensive loss in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Classification and Accretion of Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Classification of the Company&#x2019;s convertible preferred stock was treated as mezzanine financing and not as part of stockholders&#x2019; equity (deficit) because the holders of such shares had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock was not redeemable, except in the event of certain deemed liquidation events enumerated in the Company&#x2019;s certificate of incorporation. Because the occurrence of a deemed liquidation event was not probable, the carrying values of the convertible preferred stock were not accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares of preferred stock were automatically convertible into shares of common stock at the earlier of (i) the closing of a firm-commitment underwritten public offering resulting in at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of gross proceeds in the aggregate to the Company, prior to deductions for underwriting discounts, commission and expenses or (ii) the date and time, or occurrence of an event, specified by a vote of the Series A and Series B Stockholders. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon closing of the IPO, all of the outstanding &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series A and Series B &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;convertible preferred stock automatically converted in&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;to common stock, resulting in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; outstanding convertible preferred stock as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company follows the two-class method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the diluted weighted average number of common shares outstanding for the period, including potential dilutive common shares.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s participating securities contractually entitle the holders of such shares to participate in dividends but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2020, the FASB issued ASU 2020-01, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investments &#x2014; Equity Securities (Topic 321), Investments &#x2014; Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The new guidance addresses accounting for the transition into and out of the equity method and measuring certain purchased options and forward contracts to acquire investments. This ASU is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; this ASU from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and the adoption did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t have any impact on the Company&#x2019;s consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&#x201c;ASU 2016-13&#x201d;), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses on available-for-sale debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. As an emerging growth company, ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2022, and early adoption is permitted. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is currently evaluating the new standard and expects it to have no material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC did not, or are not expected to, have a material impact on the Company&#x2019;s unaudited consolidated financial statements and related disclosures. &lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_db3f7fbf-fa77-42a4-87ed-877642f0bafc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s fiscal year ends on December 31 and its first three quarters end on March 31, June 30 and September 30. The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Section 107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_4ad66a1c-ee51-44d3-8016-0208e8199d14">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expense, and related disclosures. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, derivative liability, research and development accruals, operating leases, assessment of the useful lives of property and equipment, valuation of deferred tax assets and liabilities, impairment of investment in joint venture, and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additionally, the management considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the year ended December 31, 2021. However, the extent to which the COVID-19 pandemic may directly or indirectly impact the Company&#x2019;s financial statements is highly uncertain and subject to change.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Actual results could differ from those estimates and there may be changes to management&#x2019;s estimates in future periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <pyxs:RisksAndUncertaintiesPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_11fc562b-0650-4be6-869f-d4de0cb9c6de">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is subject to risks common to early-stage companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key suppliers for active ingredients and third-party service providers such as contract research organizations, protection of intellectual property rights and the ability to make milestone, royalty or other payments due under any license, collaboration or supply agreements.&lt;/span&gt;&lt;/p&gt;</pyxs:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_7ba62724-1cb8-4e49-8695-ad5f722c6f15">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentration of Credit Risks&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company&#x2019;s cash and cash equivalents are held at an accredited financial institution and the Company has not experienced any losses in such accounts. The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company&#x2019;s cash equivalents consist primarily of short-term money market funds held in accredited financial institutions. The Company believes it is not exposed to any significant risk in cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_b3e2d0ab-d6c3-49dc-a187-ac52997f2377">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers all short term, highly liquid investments with original maturities of 90 days or less to be cash equivalents. Cash equivalents consist primarily of money market funds as of December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_a3b5b8a7-690f-493a-824e-3b9abf682def">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principle or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Level&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; 1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Level&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; 2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Level&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; 3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_b9e3561b-756b-4b18-8503-3b249382c134">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment, net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the related assets as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:73.139%;"/&gt;
          &lt;td style="width:1.898%;"/&gt;
          &lt;td style="width:24.963%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Estimated Useful&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shorter of remaining life&lt;br/&gt;of lease or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and amortization expense is included in research and development and general and administrative expenses. Major additions and upgrades are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are expensed as incurred. Upon retirement or sale, the cost of assets disposed of, and the related accumulated depreciation and amortization are removed from the respective accounts and any resulting gain or loss is included in income (loss) from operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <pyxs:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_4d3b7541-fac9-4e45-b26f-5a7c6c144c4a">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the related assets as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:73.139%;"/&gt;
          &lt;td style="width:1.898%;"/&gt;
          &lt;td style="width:24.963%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Estimated Useful&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shorter of remaining life&lt;br/&gt;of lease or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</pyxs:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_152d9614-3fcc-42d6-ad59-684db0e1410f"
      id="F_2a03809f-8887-4e34-9bf5-71692969b4fd">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_ea67ab21-1afc-421d-9c63-09eb80e2cfd0"
      id="F_78d0f3b4-c251-493c-a041-d1e3865bcdd5">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_c8cf8329-d1fb-4956-86aa-e52d9990243c"
      id="F_f22eac62-a7d5-422d-9535-3e3eea40fe36">Shorter of remaining lifeof lease or useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_5495aa31-2ac5-4bff-81d8-a914175ca7a8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluates the long-lived assets, which consist of property and equipment and operating lease right-of-use assets, for impairment at least annually and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. Management then determines whether the remaining useful life continues to be appropriate, or whether there has been an impairment of long-lived assets based primarily upon whether expected future undiscounted cash flows are sufficient to support the assets&#x2019; recovery. Recoverability of these assets is measured by comparison of the carrying amount of the asset to the future undiscounted cash flows the asset is expected to generate. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. The Company recognized &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; impairment losses for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="INF"
      id="F_7d7b200d-023d-4f57-9bfc-82af6dd7a1c8"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="INF"
      id="F_5e48f387-cf6e-4851-bcf5-129b9c074a6b"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_455378d3-045e-4aa8-868a-002dd1f0a38c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;lease right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are initially recognized and measured based on the present value of the future fixed lease payments over the expected lease term at the commencement date calculated using the Company&#x2019;s incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. The Company determines the lease term as the non-cancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease ROU assets also include any initial direct costs incurred and any lease payments made on or before the lease commencement date, less lease incentives received. Operating lease ROU assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. The Company accounts for lease and non-lease components as a single lease component for all its facilities leases. The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; finance leases as of December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <pyxs:NumberOfFinanceLease
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_a014d39d-b70f-4056-9f43-7d3dd9955e94"
      unitRef="U_Lease">0</pyxs:NumberOfFinanceLease>
    <pyxs:NumberOfFinanceLease
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_181929bf-a4b1-4cef-965a-311e1c28c454"
      unitRef="U_Lease">0</pyxs:NumberOfFinanceLease>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_8bd7d98a-0c4c-4272-9302-d6cecab2159b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investment in Joint Venture&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Investment in the Company&#x2019;s joint venture is accounted for using the equity method of accounting. The Company &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;apply the equity method of accounting to investments when the Company has significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;equity&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;method&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;investment&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the equity method, investments are initially recorded at cost and are adjusted for dividends, distributed and undistributed earnings and losses, and additional investments. In the event the Company&#x2019;s share of a joint venture&#x2019;s cumulative losses exceeds the Company&#x2019;s investment balance, the balance is reported at zero value until proportionate income exceeds the losses. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_63503608-3851-4e63-9463-b90ff689ce84">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company, from time to time, may be a party to various disputes and claims arising from normal business activities. The Company continually assesses disputes and claims including resulting litigation to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the contingencies, including an estimable range, if possible.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_ed83cf87-3d5d-420c-8598-acd76c5706d0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company expenses research and development costs as incurred. The Company&#x2019;s research and development expenses consist primarily of license fees to acquire intellectual property which does not meet the definition of intangible assets and costs incurred in performing research and development activities, including personnel-related expenses such as salaries, stock-based compensation and benefits, facilities costs, depreciation as well as external costs for outside vendors engaged to conduct preclinical development activities and license fees. The Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and efforts expended pursuant to the terms of the contractual arrangements. Payments under some of these contracts depend on preclinical trial milestones. There may be instances in which payments made to the Company&#x2019;s vendors will exceed the level of services provided and result in a prepayment of expenses. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or prepaid expense accordingly.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_8c8af615-9852-4135-a198-ba96eebb15f6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company maintains an equity incentive plan as a long-term incentive for employees, consultants, and directors. The Company accounts for all stock-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The grant date fair value of the stock-based awards with graded vesting is recognized on a straight-line basis over the requisite service period. The Company recognizes forfeitures related to stock-based compensation awards as they occur and reverses any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs. The Company classifies stock-based compensation expense in the statement of operations in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company values its stock options with service conditions using the Black-Scholes option pricing model. The Company use certain assumptions to determine fair value of the stock options pursuant to the Black-Scholes option pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate, expected dividend yield and the fair value of the Company&#x2019;s common stock. Since the Company has no option exercise history, the Company uses the simplified method described in the SEC&#x2019;s Staff Accounting Bulletin No. 107, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Share-Based Payment &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&#x201c;SAB 107&#x201d;), to determine the expected life of the option grants. The Company lacks sufficient company-specific historical and implied volatility information. Therefore, the Company estimates the expected stock volatility based on the historical volatility of a publicly traded set of peer companies. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. As the Company has never paid and does not anticipate paying cash dividends on its common stock, the expected dividend yield is considered as zero.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;Prior to the completion of the Company&#x2019;s IPO, the fair value of the Company's common stock which is one of the key input in Black-Scholes option pricing model, was determined by the board of directors with input from management and based on certain assumptions including probability weighting of events, business and market conditions, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. The Company used 409A valuations to determine the fair value of the shares of common stock. The 409A valuations were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;font-style:italic;"&gt;Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;. After completion of the IPO, on October 8, 2021, the Company uses the fair value of its publicly traded common stock to determine grant date fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For restricted stock awards issued pursuant to standalone restricted stock purchase agreements, the fair value of each award was estimated based on the estimated fair value of the Company&#x2019;s common stock, less the amount paid by the grantee. The Company recognized deposit liability for restricted stock awards issued pursuant to standalone restricted stock purchase agreements. As the awards of restricted stock vest, the Company reclassifies the deposit liability to additional paid-in capital.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_d7a57aa9-8590-4331-902e-94ba50851b61">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for income taxes in accordance with FASB ASC 740, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (&#x201c;ASC 740&#x201d;), which requires the use of the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between amounts in the consolidated financial statements and the tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income tax (benefit) expense in the consolidated statements of operations and comprehensive loss in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <pyxs:ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_6e710380-89af-40b8-b43c-b7bd3d6643ea">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Classification and Accretion of Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Classification of the Company&#x2019;s convertible preferred stock was treated as mezzanine financing and not as part of stockholders&#x2019; equity (deficit) because the holders of such shares had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock was not redeemable, except in the event of certain deemed liquidation events enumerated in the Company&#x2019;s certificate of incorporation. Because the occurrence of a deemed liquidation event was not probable, the carrying values of the convertible preferred stock were not accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares of preferred stock were automatically convertible into shares of common stock at the earlier of (i) the closing of a firm-commitment underwritten public offering resulting in at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of gross proceeds in the aggregate to the Company, prior to deductions for underwriting discounts, commission and expenses or (ii) the date and time, or occurrence of an event, specified by a vote of the Series A and Series B Stockholders. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon closing of the IPO, all of the outstanding &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series A and Series B &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;convertible preferred stock automatically converted in&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;to common stock, resulting in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; outstanding convertible preferred stock as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;</pyxs:ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_4a74247c-2b25-4a52-afe0-244e457c4f7f"
      decimals="-5"
      id="F_999368f6-aa31-4d56-9a89-9e759120a7e6"
      unitRef="U_USD">50000000.0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_13a4aa5e-911a-4c5d-9086-7de944870e14"
      decimals="INF"
      id="F_32d3e388-2945-4dee-b2e2-de8d2bcfcaa2"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_8f0241cf-b40f-4f06-8c23-f16e99782dc6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company follows the two-class method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the diluted weighted average number of common shares outstanding for the period, including potential dilutive common shares.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s participating securities contractually entitle the holders of such shares to participate in dividends but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_12197a84-7146-43ff-ad5c-74e0d807f918">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2020, the FASB issued ASU 2020-01, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investments &#x2014; Equity Securities (Topic 321), Investments &#x2014; Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The new guidance addresses accounting for the transition into and out of the equity method and measuring certain purchased options and forward contracts to acquire investments. This ASU is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; this ASU from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and the adoption did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t have any impact on the Company&#x2019;s consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_3e0e6445-8830-4b8b-9312-a6c3f7385eae"
      id="F_9c4953ef-48e0-43d6-b354-1259e09c3a58">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_3e0e6445-8830-4b8b-9312-a6c3f7385eae"
      id="F_da9bc9ae-3089-4f21-a3a7-51d656467cd8">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_3e0e6445-8830-4b8b-9312-a6c3f7385eae"
      id="F_91418e0a-6701-4a77-a105-ce450b3d65b6">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <pyxs:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_df007390-d93e-4cee-b774-bbe099e2aeb0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&#x201c;ASU 2016-13&#x201d;), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses on available-for-sale debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. As an emerging growth company, ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2022, and early adoption is permitted. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is currently evaluating the new standard and expects it to have no material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC did not, or are not expected to, have a material impact on the Company&#x2019;s unaudited consolidated financial statements and related disclosures. &lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</pyxs:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock>
    <pyxs:LicensingAgreementsTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_31d821dd-e6f8-445e-ae53-edca3ac7dbe9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;3. Licensing Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;The University of Chicago Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In April 2020, the Company entered into a license agreement (the &#x201c;University License Agreement&#x201d;), as well as a sponsored research agreement, with the University of Chicago (the &#x201c;University&#x201d;) to obtain an exclusive license under certain patents resulting from research performed, in-part, by the Company&#x2019;s scientific founder, as well as a non-exclusive license to certain know-how and materials relating thereto. Under the terms of the license, the Company has the global right to develop and commercialize products that are covered by a valid claim of a licensed patent, incorporate or use the licensed know-how and materials or are known to assess, modulate or utilize the activity of certain specified biological targets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In partial consideration for the license from the University, the Company issued to the University &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,919&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock in 2020. The Company recorded the value of the shares issued of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; thousand &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;as research and development expenses during the year ended December 31, 2020. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t incurred any expenses relating to the University License Agreement during the year ended December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Pursua&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;nt to the University License Agreement, the Company is obligated to pay to the University an annual maintenance fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; commencing on the third anniversary of the effective date, potential development and commercial milestones of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as well as running royalties on net sales of licensed products at varying rates ranging from less than a percent to the low single digits, subject to a minimum annual royalty of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during certain years following the effective date. The Company&#x2019;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until: (1) for licensed products covered by a valid claim of a licensed patent in a given country, the expiration of such valid claims; and (2) for all other licensed products, ten (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;) years from the first commercial sale of a licensed product in a given country. The Company is also obligated to pay the University a percentage of certain sublicensing revenue ranging from low- to mid-teens based on the date of entering into the applicable sublicense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company assessed the milestone and royalty events under University License Agreement as of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and 2020, and determined that &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; such amounts were required.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Pfizer, Inc. Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2020, the Company entered into a license agreement, as amended (the &#x201c;Pfizer License Agreement&#x201d;) with Pfizer, Inc. (&#x201c;Pfizer&#x201d;) for worldwide development and commercialization rights to antibody drug conjugate ("ADC") product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates. The Pfizer License Agreement became effective for the Company in March 2021. The Company&#x2019;s rights are exclusive with respect to certain patents owned or controlled by Pfizer covering the licensed ADCs. Pfizer has also granted the Company a non-exclusive license to use Pfizer&#x2019;s ADC technology platform to develop and commercialize the licensed ADCs and licensed products. The initial licensed targets include CD123 and extra domain B (EBD of fibronectin) and the Company has the option to expand the scope of its license to add additional licensed targets that have not been licensed to a third party or are not the subject of a Pfizer ADC development program. In March 2021, the Company entered into an amendment to the Pfizer License Agreement to include additional know-how within the scope of its license. The Company determined that substantially all of the fair value of the Pfizer License Agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development associated with the agreements. Thus, the Company recorded payments made under the License Agreement as research and development expenses in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the Pfizer License Agreement, the Company paid a combined $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for license fee, which was recorded in research and development expense in the consolidated statement of operations and consists of an upfront fee equal to a cash payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,152,145&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series B convertible preferred stock with a value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in 2021 to Pfizer, and is obligated to pay future contingent payments and royalties, including up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;660&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in milestones for the first four licensed ADCs. Additional ADC targets may be licensed for a nominal upfront and milestones. Additionally, if products are launched, the Company will pay Pfizer tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to mid-teens. The Company&#x2019;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country. The Company is also obligated to pay Pfizer a percentage of certain sublicensing revenue ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;thirty&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; percent to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;If the Company effected a change of control transaction or sold all or substantially all of its assets relating to the Pfizer License Agreement within 12 months from the effective date or closing of the IPO, the Company would have been required to make a one-time payment to Pfizer of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; such event took place during the year and the one-time payment was not required.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company assessed the milestone, royalty and other events under Pfizer License Agreement as of December 31, 2021, and determined that &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; such amounts were required.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;LegoChem Biosciences, Inc. Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2020, the Company entered into a license agreement (the &#x201c;LegoChem License Agreement&#x201d;) with LegoChem Biosciences, Inc. (&#x201c;LegoChem&#x201d;) pursuant to which the Company licensed worldwide (other than Korea) development and commercialization rights for LCB67, an ADC product candidate targeting DLK-1, and products containing the licensed compound. The Company has the right to request that LegoChem use commercially reasonable efforts at the Company&#x2019;s cost to modify the licensed compound if there are certain technical failures of the licensed compound that the Company believes are attributable to the linker or the payload used in the licensed compound, and the modified compound will replace the unmodified version as the licensed compound. In February 2021, the Company entered into an amendment to the LegoChem License Agreement to include additional patents within the scope of its license. The Company determined that substantially all of the fair value of the LegoChem License Agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development associated with the agreements. Thus, the Company recorded payments made under the LegoChem License Agreement as research and development expenses in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the LegoChem License Agreement, the Company paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in 2020 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in 2021 and is required to purchase certain initial quantities of licensed product from LegoChem for an estimated cost of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recorded upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in 2020 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in 2021 as research and development expenses. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; expenses incurred related to the manufacturing of the initial quantities of licensed product for the year ended December 31, 2021.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The Company is also obligated to pay up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;284.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to LegoChem if certain development, regulatory and sales milestones are achieved, as well as tiered royalties on net sales of licensed products ranging from mid-single digit to high-single digit royalty rates. The Company&#x2019;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until the latest to occur of: (1) the date of expiration of the last valid claim of a licensed patent covering the licensed product; (2) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; from first commercial sale; and (3) the expiration of regulatory or data exclusivity. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company assessed the milestones and royalties under the LegoChem License Agreement as of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and determined that &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; such amounts were required.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2020, the Company also entered into an opt-in, investment and additional consideration agreement with LegoChem (the &#x201c;Opt-In Agreement&#x201d;). Pursuant to the Opt-in Agreement, the Company settled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of upfront payment for license fee through the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;303,804&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series B convertible preferred stock in March 2021. The Company is also obligated to pay LegoChem a percentage of certain sublicensing revenue ranging from thirty percent to low-double digits based on the stage of development of the licensed product at the time of entering into the applicable sublicense, which percentage may be increased to up to fifty percent for any upfront payment from a sublicensee under certain circumstances. LegoChem exercised its option in December 2020 under the Opt-In Agreement and paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to the Company in April 2021, in exchange for the right to receive a milestone payment (the &#x201c;Extra Milestone Payment&#x201d;) of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upon the earliest to occur of certain events, including the date of pricing or offer of the first public offering of the Company's common stock or if the Company is the subject of a change in control transaction. The Company determined that the Extra Milestone Payment meets the definition and recognition condition of derivative under ASC 815, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;&#x201c;Derivatives and Hedging&#x201d;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for which there was a binding contract and firm commitment as of January 2021. An initial derivative liability was recognized for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million with an offset to research and development expenses in January 2021. The derivative liability was re-measured at each reporting date, with changes recorded in &#x201c;Other (expense) income&#x201d; in the consolidated statements of operations and comprehensive loss. Upon the Company&#x2019;s IPO in October 2021, the Extra Milestone Payment event triggered resulting in realization of derivative liability, for which the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million within accounts payable as of December 31, 2021 and subsequently paid in January 2022. The Company assessed the remaining milestones and royalties under the Opt-In Agreement as of December 31, 2021 and determined that &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; such amounts were required.&lt;/span&gt;&lt;/p&gt;</pyxs:LicensingAgreementsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1ca021f9-876b-4a5b-8dc2-fcb1ec552bde"
      decimals="INF"
      id="F_a8620594-7dfe-40fb-89bb-bc3a2cb3778d"
      unitRef="U_shares">48919</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d235112b-d87b-410d-8d79-ca05e714f0dd"
      decimals="-3"
      id="F_89169314-4259-4bcf-add5-0688b1469d3b"
      unitRef="U_USD">3000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1662ef99-8778-4709-9b9e-c988faaab66e"
      decimals="INF"
      id="F_5390a0bc-7a88-47bc-8732-80234bd5ae84"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <pyxs:AnnualLicenseMaintenanceFees
      contextRef="C_1ca021f9-876b-4a5b-8dc2-fcb1ec552bde"
      decimals="0"
      id="F_d1243f0c-9309-45ee-85bd-9af1a93e7dc1"
      unitRef="U_USD">10000</pyxs:AnnualLicenseMaintenanceFees>
    <pyxs:PotentialDevelopmentAndCommercialMilestonePayment
      contextRef="C_ede49b60-05ec-496a-8366-21adc55138b6"
      decimals="INF"
      id="F_9c6e7cda-2c8b-4ad8-bfbc-bc3210fc4fd0"
      unitRef="U_USD">7700000</pyxs:PotentialDevelopmentAndCommercialMilestonePayment>
    <pyxs:MinimumAnnualRoyaltyFees
      contextRef="C_72eb1cad-9bfc-44a0-9b07-b1629f06a05d"
      decimals="INF"
      id="F_7be22d89-bcc7-4f9f-980d-ee1aba721001"
      unitRef="U_USD">3000000.0</pyxs:MinimumAnnualRoyaltyFees>
    <pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale
      contextRef="C_1ca021f9-876b-4a5b-8dc2-fcb1ec552bde"
      id="F_7055879b-7000-42b7-98b8-a05432f0f9ff">P10Y</pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_9848985a-6cbf-4efd-a97b-7350766a6a66"
      decimals="INF"
      id="F_9767cc2b-75f7-4c6d-bab0-1177f47c0d10"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_35ae1bff-4ac3-4b11-b994-17b32b210d6c"
      decimals="INF"
      id="F_225eb254-4ff8-4e19-a62f-79adacbfda59"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <pyxs:PaymentForLicenseFee
      contextRef="C_9b924cc1-929b-4476-912e-1c2d54d69e3d"
      decimals="-5"
      id="F_c67ab746-9845-4ca8-9a12-02da2895777b"
      unitRef="U_USD">25000000.0</pyxs:PaymentForLicenseFee>
    <pyxs:UpfrontPayments
      contextRef="C_93d8ea59-4f70-435a-800d-684dd2b13280"
      decimals="-5"
      id="F_03dfd7a8-bd09-408d-82ec-da33061b2cb2"
      unitRef="U_USD">5000000.0</pyxs:UpfrontPayments>
    <pyxs:IssuanceOfConvertiblePreferredStockShares
      contextRef="C_34a68bd8-42d2-4884-8c43-a95f93b476df"
      decimals="INF"
      id="F_ab16d50c-f84f-4d56-be1c-d3d197284be4"
      unitRef="U_shares">12152145</pyxs:IssuanceOfConvertiblePreferredStockShares>
    <pyxs:ConvertiblePreferredStockSharesIssuedValue
      contextRef="C_404bc14b-3eaf-4e94-a492-dc8d161a716a"
      decimals="-5"
      id="F_cf93045c-9bb4-4e12-bf4e-ae75f95275b1"
      unitRef="U_USD">20000000.0</pyxs:ConvertiblePreferredStockSharesIssuedValue>
    <pyxs:AggregateMilestonePayments
      contextRef="C_71c85092-8520-4659-ae48-430a857097a7"
      decimals="INF"
      id="F_209f5733-e5d1-4a1d-ba5d-2f67ada13756"
      unitRef="U_USD">660000000</pyxs:AggregateMilestonePayments>
    <pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale
      contextRef="C_a1a3afb5-1db0-4c36-83ed-2876af7a7097"
      id="F_0969149c-7ce0-4dbb-bc60-603718a98f0a">P12Y</pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale>
    <pyxs:SublicensingRevenuePercentage
      contextRef="C_5062dfa7-6cc0-4b79-8af4-5b4183bdb254"
      decimals="2"
      id="F_ed24da66-598f-4196-b4de-f075ef13fa96"
      unitRef="U_pure">0.30</pyxs:SublicensingRevenuePercentage>
    <pyxs:OneTimeMilestonePayment
      contextRef="C_073f9fdb-14b4-4632-8088-b25125b7ae60"
      decimals="-5"
      id="F_7c66969c-64e4-4dbf-8ce9-2b486bf2264d"
      unitRef="U_USD">20000000.0</pyxs:OneTimeMilestonePayment>
    <pyxs:OneTimeMilestonePayment
      contextRef="C_8e0fe443-9856-4876-8a03-0c6ae852fad0"
      decimals="-3"
      id="F_715327c6-91ef-4736-a997-8ccb1f147509"
      unitRef="U_USD">0</pyxs:OneTimeMilestonePayment>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_8e0fe443-9856-4876-8a03-0c6ae852fad0"
      decimals="INF"
      id="F_9b306df5-41ee-4362-9df2-1d72fb9c93bd"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="C_3bfacc42-7016-4be9-8736-1d6d637d68e5"
      decimals="-5"
      id="F_756a5c83-7e62-4aa7-b6ee-6178a969e780"
      unitRef="U_USD">500000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="C_7063a67b-e132-4dc0-b804-27e9078dfd3e"
      decimals="-5"
      id="F_3f7a8dfc-781d-4efb-8143-1ef5737b2686"
      unitRef="U_USD">9000000.0</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <pyxs:ResearchAndDevelopmentLicensedProductEstimatedCost
      contextRef="C_8718a804-c532-497e-b1b1-1415b90f394e"
      decimals="-5"
      id="F_d8c226b7-ceb0-46b5-83f7-8f62920aae8c"
      unitRef="U_USD">7000000.0</pyxs:ResearchAndDevelopmentLicensedProductEstimatedCost>
    <pyxs:UpfrontPayments
      contextRef="C_60a4f247-f1f7-4230-bdbf-18fce866817f"
      decimals="-5"
      id="F_7933c980-8675-43c3-b9aa-86c8a1db3639"
      unitRef="U_USD">500000</pyxs:UpfrontPayments>
    <pyxs:UpfrontPayments
      contextRef="C_8b95c8e6-2fe9-4e6e-b9b7-23db66016497"
      decimals="-5"
      id="F_2d6d29de-569b-4a63-bec1-7f62e1295613"
      unitRef="U_USD">9000000.0</pyxs:UpfrontPayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7063a67b-e132-4dc0-b804-27e9078dfd3e"
      decimals="INF"
      id="F_725b09c0-f28c-4e77-b6eb-738e4b465666"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <pyxs:MilestonePaymentsPayableUponCertainAchievements
      contextRef="C_86a53aad-9b46-45bf-8f94-a9e963b999b2"
      decimals="INF"
      id="F_c5c41f55-8e38-45b5-af54-cfff21eaeab5"
      unitRef="U_USD">284500000</pyxs:MilestonePaymentsPayableUponCertainAchievements>
    <pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale
      contextRef="C_3bfacc42-7016-4be9-8736-1d6d637d68e5"
      id="F_caedbcdb-d1dc-46e6-bc00-74836e15e523">P10Y</pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_5a579548-3c9a-4e1b-bf3e-98869a574f78"
      decimals="INF"
      id="F_58f72048-fef6-40b2-b609-93efb2e4f6a8"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_8718a804-c532-497e-b1b1-1415b90f394e"
      decimals="INF"
      id="F_e0099029-7a65-413d-889a-57c94af1d2fd"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <pyxs:UpfrontPayments
      contextRef="C_ed7e79ef-96fa-4eef-919a-c352a3235260"
      decimals="-5"
      id="F_7efcf7fa-9517-43e0-b7a4-83296125168e"
      unitRef="U_USD">500000</pyxs:UpfrontPayments>
    <pyxs:IssuanceOfConvertiblePreferredStockShares
      contextRef="C_97f1d379-1c6e-4fb0-8b48-b544858a4c77"
      decimals="INF"
      id="F_cfd48cea-75ac-4ecc-83bf-aa388f3e5945"
      unitRef="U_shares">303804</pyxs:IssuanceOfConvertiblePreferredStockShares>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_52f84543-c5cd-4e24-8f62-15582b3c85f2"
      decimals="-5"
      id="F_ef64171c-77d4-443c-9947-54982459ea84"
      unitRef="U_USD">8000000.0</us-gaap:ProceedsFromStockOptionsExercised>
    <pyxs:ExtraMilestonePayment
      contextRef="C_32d8b9f9-d8e4-44c1-b86e-a4702ec224b4"
      decimals="-5"
      id="F_301f0f08-0a44-4ac1-8462-329b3ece893c"
      unitRef="U_USD">9600000</pyxs:ExtraMilestonePayment>
    <us-gaap:DerivativeLiabilities
      contextRef="C_673e5066-a0a1-4324-b5c4-c5590d5143fa"
      decimals="-5"
      id="F_f7d11e74-2f7b-4ba4-a451-a7cc0d964427"
      unitRef="U_USD">3400000</us-gaap:DerivativeLiabilities>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_5a579548-3c9a-4e1b-bf3e-98869a574f78"
      decimals="-5"
      id="F_0d9fe76a-c7cb-4ed2-a97b-a2bef08cf19b"
      unitRef="U_USD">9600000</us-gaap:AccountsPayableCurrent>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_5a579548-3c9a-4e1b-bf3e-98869a574f78"
      decimals="INF"
      id="F_a1826480-56aa-4cb7-9c5d-6a018196f41c"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_4fb90442-1db4-4472-a4d1-7b61ba65a009">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;4. Joint Venture&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2021, the Company entered into definitive transaction agreements with Alloy Therapeutics, Inc. (&#x201c;Alloy&#x201d;) and Voxall Therapeutics, LLC (&#x201c;Voxall&#x201d;), to finance and operate Voxall, a joint venture company formed in collaboration with Alloy to leverage the Company&#x2019;s technology and Alloy&#x2019;s ATX-Gx&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.025pt;font-family:Times New Roman;"&gt;&#x99; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;platform and antibody discovery services. Voxall granted to the Company and Alloy, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the voting membership units of Voxall in exchange for certain initial contributions. The Company&#x2019;s initial contribution included $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; thousand and a non-exclusive fully paid-up license to certain intellectual property owned or controlled by the Company and the execution of the services agreement to enable the collaboration with Voxall. Alloy&#x2019;s initial contribution included $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; thousand and the execution of the Alloy license agreement and the Alloy services agreement to enable the collaboration with Voxall. Voxall is governed by a board of directors consisting of an equal number of the Company&#x2019;s representatives and Alloy&#x2019;s representatives. The protective provisions under Voxall&#x2019;s operating agreement require the approval of both the Company and Alloy before Voxall may take certain actions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounted for investment in Voxall under the equity method of accounting. The initial contribution was recorded as &#x201c;Investment in equity method investment in joint venture&#x201d;. Additionally, the Company has recognized&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;million in service fee income from a related party within other income for services provided to Voxall during the year ended December 31, 2021, for which Voxall issued a promissory note to the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Voxall has incurred losses since inception and the Company&#x2019;s share in the losses of Voxall aggregated to&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;million for the year ended December 31, 2021. The Company recognized its share of losses of Voxall only to the extent of the carrying value of its investment in Voxall and the promissory note issued by Voxall, which aggregated to&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;million for the year ended December 31, 2021. The remaining unabsorbed loss will be offset against future income, if any. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As the Company has no commitment to fund the losses of the equity method investment, the carrying value of the equity method investment has not been reduced below zero&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_113a708f-879e-4c63-8e7a-917c6c0f4303"
      decimals="2"
      id="F_13a357ea-f1a5-4277-8ad5-5ab8d09c57f5"
      unitRef="U_pure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_2479e14f-6aa9-4a28-be71-a2c03d3cde43"
      decimals="-3"
      id="F_5fda7134-89f3-417e-b115-928fa945a350"
      unitRef="U_USD">50000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_113a708f-879e-4c63-8e7a-917c6c0f4303"
      decimals="-3"
      id="F_d00af995-d067-4ea5-8ad8-fba6e86193b1"
      unitRef="U_USD">50000</us-gaap:EquityMethodInvestmentAggregateCost>
    <pyxs:ServiceFeeIncomeFromRelatedParty
      contextRef="C_1004cb6e-29cf-4ad9-a179-5780de31070c"
      decimals="-5"
      id="F_ddd8b262-9b83-4432-b188-dee8568f5d7a"
      unitRef="U_USD">200000</pyxs:ServiceFeeIncomeFromRelatedParty>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1004cb6e-29cf-4ad9-a179-5780de31070c"
      decimals="-5"
      id="F_412e1a13-8d0c-4c06-beee-e6b142d0014b"
      unitRef="U_USD">-1200000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <pyxs:ProceedsFromPromissoryNoteIssued
      contextRef="C_1004cb6e-29cf-4ad9-a179-5780de31070c"
      decimals="-5"
      id="F_d00ddd47-e3e1-4788-be88-88d259e3ae91"
      unitRef="U_USD">200000</pyxs:ProceedsFromPromissoryNoteIssued>
    <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities
      contextRef="C_1004cb6e-29cf-4ad9-a179-5780de31070c"
      id="F_0d3838cd-c35c-4934-b011-41ae10a050c4">As the Company has no commitment to fund the losses of the equity method investment, the carrying value of the equity method investment has not been reduced below zero</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_0b091083-448a-45a4-8348-0ba68fc9ffd2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;5. Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables present the financial instruments carried at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020, respectively, in accordance with the FASB ASC 820 hierarchy (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.787%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.566%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.529%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.529%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.566%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;272,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;272,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s cash equivalents represent deposits in a short-term United States Treasury money market fund quoted in an active market and classified as a Level 1 asset. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; assets or liabilities measured at fair value on a nonrecurring basis at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of the derivative liability was initially determined using a probability-weighted income approach and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of the derivative liability are recorded as expense within other (expense) income in the consolidated statements of operations and comprehensive loss. The significant unobservable inputs used in the fair value measurement of the derivative liability include probability of payment factors and the discount rate. Refer to Note 3, Licensing Agreements, for additional information on the derivative liability.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables provide a summary of changes in Level 3 fair value measurements for the year ended December 31, 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.246%;"/&gt;
        &lt;td style="width:2.671%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:24.079%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Derivative liability balance as of January 1, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Initial recognition of derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in fair value recorded in earnings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Transfer to accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company paid the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of Extra Milestone Payment, for which it previously recognized a derivative liability, in January 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_f51f6ff1-212d-4fba-9c92-dc81bbc0d277">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables present the financial instruments carried at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020, respectively, in accordance with the FASB ASC 820 hierarchy (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.787%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.566%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.529%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.529%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.566%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;272,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;272,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_2ae77749-d3df-49f5-b129-e03c49c1d9ad"
      decimals="-3"
      id="F_10d37615-4b54-432c-86fe-ce999e4865a9"
      unitRef="U_USD">272210000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a4512320-e5eb-43ea-b73f-15322d518ab6"
      decimals="-3"
      id="F_b962b705-920a-40fd-9ec9-764164d78396"
      unitRef="U_USD">272210000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_c093cb7e-c886-49da-91b1-6affab2f3890"
      decimals="-3"
      id="F_6d99f600-7ca3-4592-88e7-ffabaac17dd3"
      unitRef="U_USD">6996000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_928733d3-c3c5-45d1-9947-05d14b5ad5c6"
      decimals="-3"
      id="F_8a120273-278e-4f2f-9362-e8405af6d935"
      unitRef="U_USD">6996000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_736d4d81-691c-4069-9e7b-3b06884b5fbf"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_72370c76-a218-429c-b614-84ace48b9da8"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_61ecf1ae-b425-48ad-947e-323185041875"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_67f2377f-701a-4d8e-806f-4052785058a0"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_8a0fbb6f-4c26-4838-a31e-ceeb26c651a0">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables provide a summary of changes in Level 3 fair value measurements for the year ended December 31, 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.246%;"/&gt;
        &lt;td style="width:2.671%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:24.079%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Derivative liability balance as of January 1, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Initial recognition of derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in fair value recorded in earnings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Transfer to accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <pyxs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability
      contextRef="C_430de8ee-a6be-4373-9634-ddf883b01c5d"
      decimals="-3"
      id="F_6f34cb26-7a69-47b0-86dd-34883e531dfc"
      unitRef="U_USD">3369000</pyxs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_430de8ee-a6be-4373-9634-ddf883b01c5d"
      decimals="-3"
      id="F_8576f082-796c-4973-8265-22bf097a16db"
      unitRef="U_USD">6231000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <pyxs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable
      contextRef="C_430de8ee-a6be-4373-9634-ddf883b01c5d"
      decimals="-3"
      id="F_d59b8f7f-4a0f-4838-9c70-94468b03e78e"
      unitRef="U_USD">9600000</pyxs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable>
    <pyxs:ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized
      contextRef="C_ebe69ee7-b47e-44a7-9ec7-718a9ea1d455"
      decimals="-5"
      id="F_c9a49af9-0ff9-43b9-bad8-c67264e4390f"
      unitRef="U_USD">9600000</pyxs:ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_58965979-5214-40a6-a5d2-583ad065fca8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6. Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.657%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.254%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.244%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_da3b3f68-f8b5-49fc-bf09-2a985773d4c2">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.657%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.254%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.244%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_a3aa34f0-a5fc-4af9-8e5b-3e3dcd3755a8"
      unitRef="U_USD">1763000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_f8781bca-07c2-4db1-b190-d389b0ce6403"
      unitRef="U_USD">8000</us-gaap:PrepaidInsurance>
    <pyxs:ResearchAndDevelopmentCurrent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_01276319-8c6c-44db-b7a7-10c38d873e1d"
      unitRef="U_USD">619000</pyxs:ResearchAndDevelopmentCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_0ae5a769-0a60-4000-8d23-9ca6caea620f"
      unitRef="U_USD">84000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_1d78ed3b-b87d-45f8-9ead-466aa38e9f11"
      unitRef="U_USD">15000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_b5df506a-3ca1-49e9-8088-41189c66ebf9"
      unitRef="U_USD">2466000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_69cdc881-b22f-42cb-92c0-0fdee04ef1ea"
      unitRef="U_USD">23000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_14048b97-f474-4912-8f56-cfbf0f621024">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;7. Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net, consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.503%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.228%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.052%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation and amortization expense for the years ended December 31, 2021 and 2020 was&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_6c2c8558-ca3b-40fc-b4bf-eaf39a27451f">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net, consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.503%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.228%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.052%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d95ea6c8-6b64-4ea3-9e32-ba4722916902"
      decimals="-3"
      id="F_54853b22-7863-4342-90d4-9dbdcf67e6a9"
      unitRef="U_USD">1804000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b95ae457-b724-40e9-a605-8b606684a52e"
      decimals="-3"
      id="F_f00669d8-de94-460c-bf48-53bcedc4f50f"
      unitRef="U_USD">1264000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0961fd9e-e455-4080-b194-733e8f9aaef7"
      decimals="-3"
      id="F_54af8afb-1683-4ea0-8489-5b94ff1adf22"
      unitRef="U_USD">225000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c3a5fd86-4b2f-48b5-906e-e21ff053ea3f"
      decimals="-3"
      id="F_fb22ff9c-31fa-4962-b471-5196fa0a7516"
      unitRef="U_USD">213000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bc36a634-547c-4f28-b1db-420db4a8e3cb"
      decimals="-3"
      id="F_9ef8762e-de0d-4c05-baea-762b06bb7be1"
      unitRef="U_USD">94000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_75951ce6-a95a-42de-8088-a5a897b8380d"
      decimals="-3"
      id="F_8a7ee766-8ac5-457c-93ea-653b6d8fb0fb"
      unitRef="U_USD">95000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_2daa52a9-da18-4e89-b1c8-c9f201ac10dd"
      unitRef="U_USD">2123000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_58f90ad6-0017-44bb-bbd9-4093d0aa9f19"
      unitRef="U_USD">1572000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_0863952a-2e2e-40a2-908d-5e68a854ed38"
      unitRef="U_USD">1116000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_98dd5569-b892-468e-af66-95dfb000dafa"
      unitRef="U_USD">469000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_2c607ec5-89de-4ef2-a656-a4b4739df546"
      unitRef="U_USD">1007000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_276547dd-aad9-4354-bdbc-3eadd3ca2f44"
      unitRef="U_USD">1103000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-5"
      id="F_f7392682-2ac0-4f60-8209-2615dfa24cfd"
      unitRef="U_USD">600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-5"
      id="F_0b5cbf4c-7445-4613-a7eb-1309bd5b44e2"
      unitRef="U_USD">500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_7bdecb96-695c-4068-95ce-c8857a150661">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;8. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.648%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.254%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.254%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;External research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <pyxs:SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_12436fe0-b9ad-44c3-9418-5cd919327abf">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.648%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.254%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.254%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;External research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</pyxs:SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_b0f6c015-1a54-4ba2-bbf9-8a46708ba5e2"
      unitRef="U_USD">2963000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_ac366af7-2327-49aa-9059-0fa8bd8a39e6"
      unitRef="U_USD">1002000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <pyxs:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_8cf6e534-80e5-4a23-8134-48ce895f5345"
      unitRef="U_USD">2381000</pyxs:AccruedResearchAndDevelopmentExpensesCurrent>
    <pyxs:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_52b1f0e7-45b8-4138-977c-39cb2b9c4be6"
      unitRef="U_USD">712000</pyxs:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_d3de9c81-b65c-42c3-836d-7c54f9380079"
      unitRef="U_USD">982000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_d43ebc3d-f7f9-46ca-bc02-f94464112de9"
      unitRef="U_USD">167000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_b0a5bafb-e030-43d8-b216-eabd01ace1d7"
      unitRef="U_USD">266000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_0d49b3f0-5bcd-4e20-982a-b0a60a05f80c"
      unitRef="U_USD">116000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_754fc51e-c652-4454-b033-6ebfe0893084"
      unitRef="U_USD">6592000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_a0844b55-0684-4f2e-8402-61ff08cd438e"
      unitRef="U_USD">1997000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_6ec2c4a0-90c5-4f37-913b-cbf4932c663d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;9. Operating Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; operating leases, respectively, where the Company is the lessee or sublessee, for office and laboratory space. Lease terms are through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; finance leases as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.422%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.984%;"/&gt;
        &lt;td style="width:1.994%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.984%;"/&gt;
        &lt;td style="width:1.994%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Variable lease cost (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Other information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease right-of-use asset obtained in exchange for new operating&lt;br/&gt;&#160;&#160;&#160;lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash paid for amounts included in the measurement of lease liabilities, included&lt;br/&gt;&#160;&#160;&#160;in operating cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:3.0pt;border-bottom:0.750pt solid;margin-right:83.704%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Variable lease cost includes common area maintenance charges&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Maturities of lease liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021, were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.019%;"/&gt;
        &lt;td style="width:1.939%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:16.039%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: amount representing imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total future minimum lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In addition to above, on September 29, 2021, the Company entered into a lease agreement for an office and laboratory space in Boston, Massachusetts. The lease will expire on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2032&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, and has scheduled rent increases each year of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;There is an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; option to extend the lease beyond December 31, 2032.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The future undiscounted operating lease payments (base rent) under the lease agreement is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million over an initial lease period of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company will record the right-of-use asset and operating lease liability upon obtaining the possession of the property, which it expects to occur in the second quarter of 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <pyxs:NumberOfOperatingLease
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_9397d920-ef60-4e07-9282-2ef80973541d"
      unitRef="U_Lease">1</pyxs:NumberOfOperatingLease>
    <pyxs:NumberOfOperatingLease
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_9b5447c7-c235-41fb-966e-3705e33bd98a"
      unitRef="U_Lease">2</pyxs:NumberOfOperatingLease>
    <pyxs:LeaseExpirationYear
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_d8ac6f90-b787-4c13-9354-d45ae1d62fbc">2022</pyxs:LeaseExpirationYear>
    <pyxs:NumberOfFinanceLease
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_590868f1-2322-4f64-8960-20225ce0db46"
      unitRef="U_Lease">0</pyxs:NumberOfFinanceLease>
    <pyxs:NumberOfFinanceLease
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_ec999906-9f69-4bcd-ba7a-e12e92627dde"
      unitRef="U_Lease">0</pyxs:NumberOfFinanceLease>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_b4ce9c8e-517e-4ca2-ab7f-87e5eee8fb32">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.422%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.984%;"/&gt;
        &lt;td style="width:1.994%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.984%;"/&gt;
        &lt;td style="width:1.994%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Variable lease cost (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Other information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease right-of-use asset obtained in exchange for new operating&lt;br/&gt;&#160;&#160;&#160;lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash paid for amounts included in the measurement of lease liabilities, included&lt;br/&gt;&#160;&#160;&#160;in operating cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:3.0pt;border-bottom:0.750pt solid;margin-right:83.704%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Variable lease cost includes common area maintenance charges&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_92f6f19c-863f-4485-8b7a-1c72a065b0d4"
      unitRef="U_USD">650000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_a197c38c-62fd-4c26-baab-cd4100670cda"
      unitRef="U_USD">497000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_6272b7a0-b41a-4f82-9c8e-1a6d41c2e56c"
      unitRef="U_USD">5000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_dda1cd69-2811-44c2-ad08-b437a9aca4d3"
      unitRef="U_USD">146000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_1705cc8f-18fe-443e-b8d6-3e583f9850d8"
      unitRef="U_USD">75000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_17b2d502-1157-47ab-87f7-2134a0019cc3"
      unitRef="U_USD">70000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_19039eed-3064-43fb-984b-eff365018cc9"
      unitRef="U_USD">730000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_8aa65485-1154-4b2d-86c3-1bcdd79ed339"
      unitRef="U_USD">713000</us-gaap:LeaseCost>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_58420ef6-273a-48a0-bccb-a3d8f8182616"
      unitRef="U_USD">1186000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_ebbc539c-f417-40f9-b2f8-5c101fe70230"
      unitRef="U_USD">663000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_c21f6e60-f5e2-4e34-b122-d27d90243763"
      unitRef="U_USD">484000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      id="F_ef90a04e-7dfa-4463-b4ad-af6b7ae2cb67">P0Y3M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      id="F_d06d2084-af84-44a4-8581-9bca0a7e342d">P1Y3M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="4"
      id="F_99edc8e3-2fcb-4bd9-a57b-b15089737a32"
      unitRef="U_pure">0.1000</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="4"
      id="F_e3879ff2-9af0-4584-9724-fcf07d315bd0"
      unitRef="U_pure">0.0998</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_e13c7abc-c69f-468b-885d-e110abda8d05">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Maturities of lease liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021, were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.019%;"/&gt;
        &lt;td style="width:1.939%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:16.039%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: amount representing imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total future minimum lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_85fd8b00-53a9-4bac-ab44-2176d7185dda"
      unitRef="U_USD">168000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_de80709a-33da-435d-93da-d61baa122261"
      unitRef="U_USD">168000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_ecb18948-f04f-4007-b2e1-d4b5dd3d64e6"
      unitRef="U_USD">3000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_1a5d05fc-9c85-4d00-9da9-ac1e3afc4d07"
      unitRef="U_USD">165000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_7f621107-7e12-4f37-bdcf-0e86434b9852"
      id="F_271dcf5a-3573-4ef5-96ec-54423ddaa5df">2032-12-31</us-gaap:LeaseExpirationDate1>
    <pyxs:RentIncreasePercentage
      contextRef="C_7f621107-7e12-4f37-bdcf-0e86434b9852"
      decimals="2"
      id="F_5c5c519e-4287-4e8f-b386-83c0ef108104"
      unitRef="U_pure">0.03</pyxs:RentIncreasePercentage>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_4ea7eca8-f1f7-43f5-bcc0-3001ec7874e3">There is an additional five-year option to extend the lease beyond December 31, 2032.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_c05c67d1-e528-474e-8817-657f048332c3"
      id="F_9c46cffe-f79c-4776-9815-f2dd3c6d72a0">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_c05c67d1-e528-474e-8817-657f048332c3"
      decimals="-5"
      id="F_d3f3fea5-6f85-460e-9ff5-39da0bab8f94"
      unitRef="U_USD">33800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_c05c67d1-e528-474e-8817-657f048332c3"
      id="F_74b10833-d3b9-4b7a-a1dd-1009887f4c13">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PreferredStockTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_52e3ac2c-9d3a-4664-9916-455111558b45">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;10. Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2019, the Company entered into a securities purchase agreement (as amended, &#x201c;Series A Agreement&#x201d;) with certain investors to sell shares of Series A convertible preferred stock (&#x201c;Series A&#x201d;) at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9681&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. In June and July 2019, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,724,925&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series A to institutional investors at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9681&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share for gross cash proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, less issuance costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. On October 1, 2021, the Company effected a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_bc1feaae-b4f0-4232-bfcb-7aa66a503921;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1-for-6.359&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reverse stock split&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Upon completion of the initial public offering, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,724,925&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series A were converted to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,573,659&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 5, 2021, the Company entered into a securities purchase agreement (as amended, &#x201c;Series B Agreement&#x201d;) with certain investors to sell shares of Series B convertible preferred stock (&#x201c;Series B&#x201d;) at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.6458&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. In March 2021, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;92,356,299&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series B to institutional investors at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.6458&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share for gross cash proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;152.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, less issuance costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;151.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. In addition, the Company granted &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,455,949&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares, or $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, of Series B convertible preferred stock through separate agreements with Pfizer, Inc. and LegoChem Biosciences Inc. On October 1, 2021, the Company effected a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_01b30c23-8e47-433b-a192-0adf8d0251a5;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1-for-6.359&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reverse stock split&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Upon completion of the initial public offering, the entire outstanding shares of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;104,812,248&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of Series B were converted to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,482,486&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_931efd56-1c76-41f4-bf5d-55380b0d9598"
      decimals="4"
      id="F_f5359e4c-3e1d-433a-88a8-b310ad448b35"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.9681</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_c28b8bc5-5c32-45fe-b131-2c2fbbfa9d56"
      decimals="INF"
      id="F_4b41dc18-5211-427f-a6de-961508ae030a"
      unitRef="U_shares">22724925</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_931efd56-1c76-41f4-bf5d-55380b0d9598"
      decimals="INF"
      id="F_c92a6d74-246c-4003-a0f5-382c506b3b73"
      unitRef="U_shares">22724925</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_c28b8bc5-5c32-45fe-b131-2c2fbbfa9d56"
      decimals="INF"
      id="F_69a4ab3b-a3cc-4df4-a3c3-34c97ba00d6b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.9681</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_931efd56-1c76-41f4-bf5d-55380b0d9598"
      decimals="INF"
      id="F_811e19fd-2000-43dc-be95-31121db57bb8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.9681</us-gaap:SharesIssuedPricePerShare>
    <pyxs:GrossProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_b4f7a85e-0b7b-4341-87a1-c762f3633c3c"
      decimals="-5"
      id="F_c34c7866-a475-4fec-809e-209015080ce5"
      unitRef="U_USD">22000000.0</pyxs:GrossProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_b4f7a85e-0b7b-4341-87a1-c762f3633c3c"
      decimals="-5"
      id="F_f5034021-d8bd-4389-9eb8-905e7ce7a357"
      unitRef="U_USD">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_b4f7a85e-0b7b-4341-87a1-c762f3633c3c"
      decimals="-5"
      id="F_04a9c40f-4adf-45e6-b1f0-0047daad39f2"
      unitRef="U_USD">21900000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_add39c44-72f5-4ca5-ab44-474e2dd8f88c"
      id="F_3257e42c-1a0b-4622-a8a1-8438e616c2db">1-for-6.359 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_249a52df-36e5-49ab-92ea-306c0765acf5"
      decimals="INF"
      id="F_f112e245-66f2-4aa0-82ac-2f30e604d148"
      unitRef="U_shares">22724925</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_5a87e6b1-9e03-4ac3-8a39-debc18e92132"
      decimals="INF"
      id="F_6593539a-1bb6-4a91-821f-654d8382b131"
      unitRef="U_shares">3573659</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_cffd11cd-91be-467f-9b81-32cb6d435261"
      decimals="INF"
      id="F_950d99cc-4f0a-43c5-a83b-c00ada1dda72"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.6458</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_a39c61fa-aca6-4bf1-8634-94e72b3a3719"
      decimals="INF"
      id="F_c2d6a6e8-9507-48f2-adc4-1652f290a55e"
      unitRef="U_shares">92356299</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_a39c61fa-aca6-4bf1-8634-94e72b3a3719"
      decimals="INF"
      id="F_f6fe1dac-c636-4dc2-b1ab-5cb406279cd0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.6458</us-gaap:SharesIssuedPricePerShare>
    <pyxs:GrossProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_52a59c4e-168a-478f-9c0c-bb44fa171b44"
      decimals="-5"
      id="F_d202c9e5-993a-4b15-bdf6-e609fa041573"
      unitRef="U_USD">152000000.0</pyxs:GrossProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_52a59c4e-168a-478f-9c0c-bb44fa171b44"
      decimals="-5"
      id="F_2423d8e0-a419-48ec-8b17-b1a1c7118d76"
      unitRef="U_USD">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_52a59c4e-168a-478f-9c0c-bb44fa171b44"
      decimals="-5"
      id="F_b00eb146-799c-4cf0-9730-3d3a7b57d115"
      unitRef="U_USD">151600000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_4173faad-0fa2-4056-a8cc-cccd57e2e301"
      decimals="INF"
      id="F_aa5ca3bd-c224-4fc3-be23-1a9d4c3cb821"
      unitRef="U_shares">12455949</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_805ffd5b-0773-4785-8a81-7d324e3eaafa"
      decimals="-5"
      id="F_edfcb1e0-c983-4af7-91a9-e3a33f0403da"
      unitRef="U_USD">20500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_72b2f27a-fcc2-48bb-89ca-eed397dc0270"
      id="F_b10691b2-ba4d-4b77-ae42-d312326a9a5a">1-for-6.359 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_128e59fb-2071-4047-8fbe-17d937e7523a"
      decimals="INF"
      id="F_da79018d-32f7-4ac1-aa25-8b9383f44b40"
      unitRef="U_shares">104812248</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_fc3376eb-8285-406a-bbf7-1c82c1b22a7a"
      decimals="INF"
      id="F_afe94c45-0b72-442b-89a1-7a1901353e27"
      unitRef="U_shares">16482486</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_fa47b434-7845-4029-b10d-1eea566d471d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;11. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Preferred Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the closing of the IPO, the Company filed an Amended Certificate of Incorporation and authorized &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of preferred stock, with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. The board of directors has the authority, without further action by the stockholders to issue such shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the dividend, dividend rights, conversion rights, voting, redemption terms, liquidation preference and other rights, preferences and privileges of the shares. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; issued and outstanding shares of preferred stock as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Common Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company was authorized to issue up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;190,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40,300,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock as of December 31, 2021 and 2020, respectively, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32,792,867&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,177,956&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares were issued as of December 31, 2021 and 2020, respectively, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32,222,881&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,289,342&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares were outstanding at December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Voting, dividend and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Voting&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;Each holder of outstanding shares of common stock shall be entitled to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; vote in respect of each share.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Reserved Shares&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company reserved the following shares of common stock for issuance:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Calibri;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.41%;"/&gt;
        &lt;td style="width:1.796%;"/&gt;
        &lt;td style="width:0.641%;"/&gt;
        &lt;td style="width:17.811%;"/&gt;
        &lt;td style="width:0.641%;"/&gt;
        &lt;td style="width:1.954%;"/&gt;
        &lt;td style="width:0.641%;"/&gt;
        &lt;td style="width:15.463%;"/&gt;
        &lt;td style="width:0.641%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series A convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,573,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested restricted stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;618,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;888,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options available for issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,289,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,926,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;424,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;8,259,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;4,718,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_2bb52469-04b7-49d0-857a-43447b7272be"
      decimals="INF"
      id="F_b46ec05e-448b-40a9-9113-131e877d0b71"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_2bb52469-04b7-49d0-857a-43447b7272be"
      decimals="INF"
      id="F_65e6ae05-f86c-4f73-9427-8f554d330dcd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_9a2acca6-a511-461d-b3bb-d17797a94f49"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_04deceb8-bfb0-4542-8913-24659043f9b0"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_99a61f40-bb8d-4ec8-ba68-7c878cecbaaf"
      unitRef="U_shares">190000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_ada70c6e-aca4-41aa-97d8-d06e3947a273"
      unitRef="U_shares">40300000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_d7f9b731-bf69-4b3d-9501-cd3f348a1c9b"
      unitRef="U_shares">32792867</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_d721dda3-6f5a-4a55-9e13-d32f825b02cc"
      unitRef="U_shares">2177956</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_1caefe84-694d-4b74-8df1-03b0fdd83fa2"
      unitRef="U_shares">32222881</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_e7cc0989-3a00-49b3-8eda-686989dc6f85"
      unitRef="U_shares">1289342</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockVotingRights
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_d787032e-b062-4b0b-9e12-586772169244">one</us-gaap:CommonStockVotingRights>
    <pyxs:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_f69fed3e-4011-4f8c-968a-4d7a600a5416">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company reserved the following shares of common stock for issuance:&lt;/span&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.41%;"/&gt;
        &lt;td style="width:1.796%;"/&gt;
        &lt;td style="width:0.641%;"/&gt;
        &lt;td style="width:17.811%;"/&gt;
        &lt;td style="width:0.641%;"/&gt;
        &lt;td style="width:1.954%;"/&gt;
        &lt;td style="width:0.641%;"/&gt;
        &lt;td style="width:15.463%;"/&gt;
        &lt;td style="width:0.641%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series A convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,573,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested restricted stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;618,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;888,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options available for issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,289,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,926,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;424,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;8,259,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;4,718,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</pyxs:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ffc2f537-c19b-4a4e-86aa-33adffaef56a"
      decimals="INF"
      id="F_c476fabc-8b9a-45e7-8262-687203d8a044"
      unitRef="U_shares">3573659</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b54da75b-957d-4884-98f7-3495f571051f"
      decimals="INF"
      id="F_1a5f58e2-9ecf-484a-9cd4-d2e268bea3aa"
      unitRef="U_shares">618494</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_53514985-e3a7-4155-9770-bf7e144b7596"
      decimals="INF"
      id="F_6b1c2786-5114-464a-a125-659d0d0b7768"
      unitRef="U_shares">888612</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_bacaab47-1993-4379-b4c5-c1e4533f5d05"
      decimals="INF"
      id="F_f29b131f-9d46-443d-8927-3802e28d0435"
      unitRef="U_shares">1289259</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3c5d682d-d0a1-45b0-b0e4-16275df3e997"
      decimals="INF"
      id="F_85382ba3-2c7d-473a-a702-50e6ddd03e68"
      unitRef="U_shares">35585</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3f4cbd78-d94e-48b1-892b-e716976eb7fc"
      decimals="INF"
      id="F_732801e4-c411-48c9-a8aa-2ffcac7a6159"
      unitRef="U_shares">5926969</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_7ab4cd50-7dbc-450e-8807-5e18ae9fabd1"
      decimals="INF"
      id="F_507c0746-dce3-43c1-8ad1-87021d7fccee"
      unitRef="U_shares">220383</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0419a777-abc4-43c5-941f-c166c8f4b73a"
      decimals="INF"
      id="F_15f3144d-eb47-48e9-9efd-2fe327bb34bf"
      unitRef="U_shares">424595</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_0b29d293-12f7-476a-be5f-06154558d7cd"
      unitRef="U_shares">8259317</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_c264e250-0828-45ff-befd-98ebc91dc2f7"
      unitRef="U_shares">4718239</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_af664d18-ec5a-47f8-a85e-ba1c99bb15ce">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;12. Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On September 27, 2021, the Company&#x2019;s board of directors and stockholders approved the 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;), which became effective on October 7, 2021, when the Company&#x2019;s registration statement was declared effective by the SEC. The 2021 Plan replaced the 2019 Plan as the Company&#x2019;s board of directors has determined not to make additional awards under the 2019 Plan following the closing of the Company&#x2019;s initial public offering. However, the 2019 Plan will continue to govern outstanding equity awards granted under the plan. The 2021 Plan allows the Company to make equity-based and cash-based incentive awards to its officers, employees, directors and consultants. The Company has initially reserved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,852,807&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock for the issuance of awards under the 2021 Plan. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The number of shares of common stock reserved for issuance under the 2021 Plan will automatically increase annually on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022, and continuing until (and including) the fiscal year ending December 31, 2031 by lesser of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the total number of shares of common stock outstanding on December 31st of the immediately preceding fiscal year or number of shares as may be determined by the board of directors. The maximum number of shares of common stock that may be issued pursuant to the exercise of incentive options under the 2021 Plan is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,705,614&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,515,040&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,508&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; restricted stock units were outstanding under the 2021 plan and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,289,259&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares remained available for future issuance under the 2021 plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2019 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In 2019, the Company established the 2019 Plan, under which the Company grant options and restricted stock to its employees and certain non-employees. The maximum number of shares of common stock reserved for issuance under the 2019 Plan was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,042,408&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options granted under the 2019 Plan include incentive stock options that can be granted only to the Company&#x2019;s employees and non-statutory stock options that can be granted to the Company&#x2019;s employees, consultants, advisors and directors. The 2019 Plan also permits the Company to issue restricted stock awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The exercise prices, vesting and other restrictions of the awards to be granted under the 2019 Plan are determined by the board of directors, except that no stock option may be issued with an exercise price less than the fair market value of the common stock at the date of the grant or have a term in excess of ten years. Options granted under the 2019 Plan are exercisable in whole or in part at any time subsequent to vesting. All the shares of common stock were issued under the 2019 Plan. As of December 31, 2021, options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,411,929&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock were outstanding under the 2019 plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock Options&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes stock option activity for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.848%;"/&gt;
        &lt;td style="width:1.456%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:7.894%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.456%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:7.272%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.456%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:8.979%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.456%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:7.958%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,351,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;574,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;5,926,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;10.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;9.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;16,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Options exercisable at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1,033,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;5.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;9.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted-average grant-date fair value of options granted during the years ended December 31, 2021 and 2020, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.57&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.62&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;per share, respectively. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding and exercisable stock options and the fair value of the Company&#x2019;s common stock as of December 31, 2021. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The intrinsic value of stock options exercised for the year ended December 31, 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Company estimated the fair value of each option on the date of grant using the Black-Scholes option pricing model applying the range of assumptions in the following table:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.968%;"/&gt;
        &lt;td style="width:2.05%;"/&gt;
        &lt;td style="width:20.466%;"/&gt;
        &lt;td style="width:2.05%;"/&gt;
        &lt;td style="width:20.466%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72.88&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103.41&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79.40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87.40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.81&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.36&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.38&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.56&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.25&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.02&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation expense related to stock options recorded in the statements of operations is as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.973%;"/&gt;
        &lt;td style="width:1.493%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.216%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.493%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.207%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has an aggregate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;million of gross unrecognized stock-based compensation expense as of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, remaining to be amortized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years. The Company has not recognized and does not expect to recognize in the near future, any tax benefit related to employee stock-based compensation expense as a result of the full valuation allowance related to its net deferred tax assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Stock Awards&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In 2019, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;994,650&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of restricted common stock to the employee co-founders and certain non-employee consultants. The shares of restricted common stock were issued pursuant to standalone restricted stock purchase agreements that are independent of the 2019 Plan. The shares of restricted common stock carried a purchase price equivalent of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.01&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. The compensation cost was measured based on the fair value of the underlying common stock less the purchase price of the restricted common stock and the Company recognizes compensation costs over the requisite service period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the terms of the restricted stock purchase agreements, the Company has a repurchase option whereby it has the right to repurchase any unvested shares upon termination at a price per share equal to the lesser of: (i) the fair market value of the Company&#x2019;s common stock on the date of repurchase and (ii) the original purchase price. The shares of restricted common stock issued to the Company&#x2019;s co-founders and non-employee consultants vest based on a predefined number of shares.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognized an associated deposit liability for restricted stock awards issued pursuant to standalone restricted stock purchase agreements upon issuance based on the purchase price of the awards as the unvested shares are subject to repurchase upon termination. As the awards of restricted stock vest, the Company reclassifies the deposit liability to additional paid-in capital.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In 2021, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,508&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of restricted common stock to employees and&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; certain non-employee consultants under 2021 Plan. Compensation cost related to these awards were recorded based on the Company's stock price on the date of issuance.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes restricted stock activity for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.494%;"/&gt;
        &lt;td style="width:1.484%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:13.525%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.623%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.683%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Non-vested at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;888,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;306,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Non-vested at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;618,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;3.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The aggregate fair value of restricted stock vested during the years ended December 31, 2021 and 2020, was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; thousand and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; thousand, respectively. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has recorded stock-based compensation expense related to the restricted stock of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; thousand for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020, respectively. The Company has an aggregate &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of gross unrecognized restricted stock-based compensation expense as of December 31, 2021, remaining to be amortized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On September 27, 2021, the Company&#x2019;s board of directors and stockholders approved the 2021 Employee Stock Purchase Plan (the &#x201c;2021 ESPP&#x201d;), which became effective on October 7, 2021, when the Company&#x2019;s registration statement was declared effective by the SEC. The 2021 ESPP reserved and authorized the issuance of up to a total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;424,595&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock to participating employees. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares are issued under 2021 ESPP plan as of the date of issuance of these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_37efc727-3d91-4336-9a3f-f491d3514c2b"
      decimals="INF"
      id="F_823cedeb-8682-4358-8991-8385e4e85cdb"
      unitRef="U_shares">3852807</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_f0325835-c766-40ad-a049-921b9832afb8"
      decimals="2"
      id="F_475bc1aa-cf3e-4231-8c36-a372a51b73ea"
      unitRef="U_pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <pyxs:MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions
      contextRef="C_43a98943-5b0e-4436-8f96-5a50552b1f8d"
      decimals="INF"
      id="F_9614102d-1962-4690-a86d-c942e4009c16"
      unitRef="U_shares">7705614</pyxs:MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_43a98943-5b0e-4436-8f96-5a50552b1f8d"
      decimals="INF"
      id="F_ffdb890e-f18a-4ae5-8e28-dc1a1e5cfd55"
      unitRef="U_shares">2515040</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_b54da75b-957d-4884-98f7-3495f571051f"
      decimals="0"
      id="F_89b2b060-e4b4-4067-8d4a-8435bdb036cf"
      unitRef="U_shares">48508</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_43a98943-5b0e-4436-8f96-5a50552b1f8d"
      decimals="INF"
      id="F_38f3f7ab-e6e4-4dfb-bee0-91356bcd9643"
      unitRef="U_shares">1289259</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_be0b2666-2fd2-42a7-9eb9-036c72e9e2e4"
      decimals="INF"
      id="F_66c8d305-2291-485f-b302-29ad3bcfd099"
      unitRef="U_shares">4042408</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_503f6a97-2a52-4ea2-92dd-c00d66d8adf2"
      decimals="INF"
      id="F_f8c70d32-a93c-42aa-8707-8b07a81f7a79"
      unitRef="U_shares">3411929</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_4b4b4de3-fb20-4698-b541-6918521a7830">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes stock option activity for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.848%;"/&gt;
        &lt;td style="width:1.456%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:7.894%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.456%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:7.272%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.456%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:8.979%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.456%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:7.958%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,351,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;574,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;5,926,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;10.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;9.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;16,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Options exercisable at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1,033,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;5.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;9.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_8a2183e7-2c7f-44c5-af07-1acd79c9e8a4"
      unitRef="U_shares">220383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="2"
      id="F_0c6c4275-5f30-45f0-8eb0-3c1e44420fa8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      id="F_8641f5bd-f09a-46fb-bf92-b97eff841804">P9Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_a1484c89-1529-41a4-9f7f-09350723584e"
      unitRef="U_USD">348000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="INF"
      id="F_ca4c13db-e4bb-4d01-b290-8bd8d49cf66c"
      unitRef="U_shares">6351820</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="2"
      id="F_087a716d-598e-4df5-8e79-7b2421c37350"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_d53bade1-0ea0-4c18-84db-95902169a3ae">P9Y7M6D</pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="INF"
      id="F_2a176a23-7bd8-4966-acce-12f87c15194c"
      unitRef="U_shares">70396</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="2"
      id="F_2a308223-134c-4d59-85ed-ae05c249f63a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="INF"
      id="F_c3e1fed3-d662-4765-be14-640cd588adee"
      unitRef="U_shares">574838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="2"
      id="F_7fbb5340-deae-49c2-8cd0-a5f5edecd165"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="0"
      id="F_93448da5-25a8-435d-a5d7-d54f3c4b2c44"
      unitRef="U_shares">5926969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="2"
      id="F_82f48f31-edd1-4c4e-8144-cbd5d9729583"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_fec7cb4c-f0b7-497a-8219-12f00d7edb39">P9Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_78fbbd79-1867-4c36-b9ec-51ded077b259"
      unitRef="U_USD">16414000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="0"
      id="F_c1510c9b-3363-43c6-962b-874bea3dd875"
      unitRef="U_shares">1033510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="2"
      id="F_407e6f7f-ecd1-488c-ab65-ddee90864310"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_9fcffd35-5e31-444f-b5fe-2f771147b0f7">P9Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_1c8b66c6-2e11-4ee2-bda2-dfd490ad10fb"
      unitRef="U_USD">6125000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="2"
      id="F_c86ce4ec-74b0-41a8-a7ec-b7f708c35b5e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="2"
      id="F_380412e9-9fec-40a6-a246-54fd3bf00060"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-5"
      id="F_e1977fc7-657d-44ba-a7eb-db3da8fb1922"
      unitRef="U_USD">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_ef7d2d59-0e56-4080-832a-49dcede3a447">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Company estimated the fair value of each option on the date of grant using the Black-Scholes option pricing model applying the range of assumptions in the following table:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.968%;"/&gt;
        &lt;td style="width:2.05%;"/&gt;
        &lt;td style="width:20.466%;"/&gt;
        &lt;td style="width:2.05%;"/&gt;
        &lt;td style="width:20.466%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72.88&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103.41&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79.40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87.40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.81&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.36&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.38&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.56&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.25&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.02&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="4"
      id="F_15da046f-918d-449a-9adc-1ae031ff36e4"
      unitRef="U_pure">0.7288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="4"
      id="F_99118d62-4313-4807-9f95-7d066ab059ad"
      unitRef="U_pure">1.0341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="4"
      id="F_232da12f-6f43-44d1-b6c6-b9fce78b38b9"
      unitRef="U_pure">0.7940</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="4"
      id="F_bce1a0db-34db-42bc-bddd-52df4640e5f6"
      unitRef="U_pure">0.8740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="4"
      id="F_c5d3039c-81ce-457a-9e8d-370661298596"
      unitRef="U_pure">0.0081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="4"
      id="F_3f4a75cf-8aab-490d-bfa5-72020f633f97"
      unitRef="U_pure">0.0136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="4"
      id="F_76d606c2-dbae-4925-b2d1-6ca34a7db03e"
      unitRef="U_pure">0.0038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="4"
      id="F_4999216b-ebf3-4046-bd79-1f1eb1a06a30"
      unitRef="U_pure">0.0056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="4"
      id="F_20c76b8a-c162-42b7-be85-ba3234d5a699"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="4"
      id="F_7dcaafc7-9d5d-469f-bc4e-55c6aa3369bf"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_77b69288-abc5-4593-aa39-850f6b1b0b7e"
      id="F_00c2f259-ceb5-40c1-af54-44b15cd36c00">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_d1f92bd2-7f9c-4761-a7cd-fb5f0d37b59d"
      id="F_8e65a3a9-15e1-410e-a171-a69f04a88b54">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_8a2e39db-f489-43c1-abbc-dbbecbeb09c3"
      id="F_e9ed3331-90ee-4e7c-ad26-dfecf18807e4">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e5fb5e1b-3838-47c6-bb70-01be05e587a5"
      id="F_a1617b2f-5604-44a1-9b14-abc9507dc881">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_5b58c966-8e1b-4b22-ac0d-1756393d7ba6">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation expense related to stock options recorded in the statements of operations is as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.973%;"/&gt;
        &lt;td style="width:1.493%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.216%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.493%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.207%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_83f1f8d4-1a3f-42eb-89a4-fe5b4d42496e"
      decimals="-3"
      id="F_42f2ac11-cc9e-41ee-a424-bc9ee7de1d63"
      unitRef="U_USD">2396000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_86efd6c0-cd6e-4044-a8a6-91df62d66a91"
      decimals="-3"
      id="F_b2714f49-a838-49e4-924a-579715566c9c"
      unitRef="U_USD">10000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0326a5ad-45a2-4a64-829d-d01a89aa86a2"
      decimals="-3"
      id="F_113883bb-88d7-47db-8115-c9116f664ad2"
      unitRef="U_USD">3976000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1083a66d-cffd-416e-a565-3d03312b0250"
      decimals="-3"
      id="F_39899845-6702-4071-98e2-b1be003fd94f"
      unitRef="U_USD">8000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_fd092daf-f7e1-4f21-9d01-7f94859cbecf"
      unitRef="U_USD">6372000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_df2d4cbc-e749-461c-955d-f9b5453f53ba"
      unitRef="U_USD">18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-5"
      id="F_5c654034-4656-4159-b464-269c8944ab5b"
      unitRef="U_USD">38100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_4b7561e2-8f4a-4fa5-b48b-42e5db0c3114">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_c358130b-d442-4714-9617-ad3cca7aaa47"
      decimals="INF"
      id="F_b47d778e-e5dd-410c-a736-fae5ea54c0c1"
      unitRef="U_shares">994650</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_6b8a4a3d-2a4c-49f1-81b4-0e6c37ae21f3"
      decimals="2"
      id="F_400af050-f2dd-4173-af2b-133615444780"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_cde6dc02-fc80-4fef-a5f9-c1c479dca2db"
      decimals="0"
      id="F_46e25817-eb12-41ef-833b-bb2e26436075"
      unitRef="U_shares">48508</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_ca663547-9ffe-4645-be5d-04bdd521c5e6">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes restricted stock activity for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.494%;"/&gt;
        &lt;td style="width:1.484%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:13.525%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.623%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.683%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Non-vested at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;888,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;306,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Non-vested at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;618,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;3.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="INF"
      id="F_0ff95b7e-ecea-4847-a6b8-72f853d1097b"
      unitRef="U_shares">888612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="2"
      id="F_431b50fd-6493-42a7-9d6c-ac7b7bea3601"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="INF"
      id="F_d99ae751-9c92-4f58-abed-3d484ccebaa7"
      unitRef="U_shares">48508</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="2"
      id="F_e8a67940-dc97-4bea-b505-81fa51397cb2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="INF"
      id="F_43fa601c-289b-4219-b091-7776e168fbbc"
      unitRef="U_shares">306998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="2"
      id="F_c4867b80-9223-4bda-a015-fd6f1e17341b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="INF"
      id="F_c47d098e-1cd9-4946-8b27-a348f7592fd2"
      unitRef="U_shares">11628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="INF"
      id="F_60d485a7-1245-4f03-aa1d-82c3b37d2164"
      unitRef="U_shares">618494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="2"
      id="F_8d7e8d29-a703-40a1-a676-2f8671faca5b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_166b4d7a-f692-4d9d-9756-2087d4b2d406"
      unitRef="U_USD">5000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_ac70f771-060e-466b-891b-ea89dd07d2f0"
      unitRef="U_USD">4000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_668767af-d588-4269-bdd5-6d6317ca1174"
      decimals="-5"
      id="F_5fef466f-1a02-4128-86a3-bb7bd3e66d4a"
      unitRef="U_USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c3e89383-fd3d-4b7e-82f6-24ca7bf96cec"
      decimals="-3"
      id="F_38084a94-d7de-4fe4-80c0-39deec653a30"
      unitRef="U_USD">26000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_b54da75b-957d-4884-98f7-3495f571051f"
      decimals="-5"
      id="F_079d664d-e252-43f0-87e5-9a6bddce7563"
      unitRef="U_USD">700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_668767af-d588-4269-bdd5-6d6317ca1174"
      id="F_e308d357-30a2-4a47-9032-102627bd26f2">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_4a0f2d3a-54c0-420e-9bb9-0592cc6ffcc8"
      decimals="INF"
      id="F_fc282523-38e6-4971-850b-94b916577447"
      unitRef="U_shares">424595</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_cde6dc02-fc80-4fef-a5f9-c1c479dca2db"
      decimals="INF"
      id="F_3953ffb8-87d6-415b-86cf-36602ad0bef1"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_e5f3d89a-2c2f-4cfb-b91d-255be911645d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;13. Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the years ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company recorded &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; current or deferred income tax expenses or benefits as the Company has incurred losses since inception and has provided a full valuation allowance against its deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of the expected income tax benefit computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.543%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:12.526%;"/&gt;
        &lt;td style="width:2.004%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:12.526%;"/&gt;
        &lt;td style="width:2.004%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Income tax computed at federal statutory rate %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development credit carryovers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Effective income tax rate %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company's effective tax rate was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% for the years ended December 31, 2021 and 2020, as a result of the valuation allowance that eliminates the company's net deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Significant components of the Company&#x2019;s net deferred tax assets as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020 are as follows (in thousands): &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.169%;"/&gt;
        &lt;td style="width:1.512%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.3%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.512%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.501%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Derivative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reserves and accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;License fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company's federal and state net operating losses in the United States were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million before tax) and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million before tax) respectively. The federal net operating loss carryforwards in the United States can be carried forward indefinitely but may be subject to annual usage limitations to the extent certain substantial changes in the entity's ownership occur. The state net operating loss carryforwards begin expiring in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2039&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. In addition, as of December 31, 2021, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of federal and state credit carryovers which begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2039&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. These loss and credit &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;carryforwards are subject to review and possible adjustment by the appropriate taxing authorities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company assesses the realizability of the deferred tax assets at each balance sheet based on the available positive and negative evidence in order to determine the amount which is more likely than not to be realized and records a valuation allowance as necessary. Due to the Company's cumulative loss position which provides significant negative evidence, which is difficult to overcome, the Company has recorded a valuation allowance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2021, representing the portion of the deferred tax asset that is not more likely than not to be realized. For the years ended December 31, 2021 and 2020, the valuation allowance for deferred tax assets increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively. The amount of the deferred tax asset considered realizable, could be adjusted for future factors that would impact the assessment of the objective and subjective evidence. The Company will continue to assess the realizability of deferred tax assets at each balance sheet date in order to determine the proper amount, if any, required for a valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The U.S. tax attributes may be subject to an annual limitation under Section 382 of the Internal Revenue Code of 1986 (the &#x201c;Code&#x201d;), and similar state provisions if the Company experiences one or more ownership changes, which would limit the amount of the tax attributes that can be utilized to offset future taxable income. In general, an ownership change as defined by Section 382, results from the transactions increasing ownership of certain stockholders or public groups in the stock of the corporation of more than fifty percentage points over a three-year period. If a change in ownership occurs in the future, the research and development credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#x2019;s effective tax rate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is subject to tax and will continue to file federal income tax returns in the United States as well as in certain state and local jurisdictions. The Company is subject to tax examinations for tax years ended December 31, 2019 and forward in all applicable income tax jurisdictions. Tax audits and examinations can involve complex issues, interpretations and judgements. The resolution of matters may span multiple years particularly if subject to litigation or negotiation. The Company believes that it has appropriately recorded its tax position using reasonable estimates and assumptions, however the potential tax benefits may impact the results of operations or cashflows in the period of resolution, settlement, or when the statutes of limitations expire. The Company does not currently have any reserves related to unrecognized tax benefits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_1af731d8-74d4-4ca7-b3c7-e479981d947b"
      decimals="INF"
      id="F_d07762c2-4f22-4753-a9cc-ba7bd2ee29d7"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2a39c163-dd87-4565-b3a7-3a9cd35c9839"
      decimals="INF"
      id="F_d8fce774-2c6f-4769-88db-c7d4282f45ae"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_1af731d8-74d4-4ca7-b3c7-e479981d947b"
      decimals="INF"
      id="F_d0cef481-9a51-4210-af55-441e9d68c3f7"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_2a39c163-dd87-4565-b3a7-3a9cd35c9839"
      decimals="INF"
      id="F_00c3ba6b-5a01-41c5-ae1c-a7b7499d0afb"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_cb0747ce-4cb3-4310-b647-5ed2832f6110">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of the expected income tax benefit computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.543%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:12.526%;"/&gt;
        &lt;td style="width:2.004%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:12.526%;"/&gt;
        &lt;td style="width:2.004%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Income tax computed at federal statutory rate %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development credit carryovers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Effective income tax rate %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="4"
      id="F_35db2a8b-48f9-42d7-83ba-b85fa4e3f7d2"
      unitRef="U_pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="4"
      id="F_974cfdac-ea1b-49ce-9fe2-98f0c951f20d"
      unitRef="U_pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="4"
      id="F_b21740f8-f965-4b1e-9e33-e72d8641ee25"
      unitRef="U_pure">0.0570</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="4"
      id="F_3726ff14-fc64-4ae9-8042-00582aa48345"
      unitRef="U_pure">0.0560</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="4"
      id="F_9a1070d6-0a08-4e76-a4f3-375bce685c50"
      unitRef="U_pure">-0.2770</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="4"
      id="F_b6210427-9d53-4116-8460-66ef6f6c41e4"
      unitRef="U_pure">-0.2790</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="4"
      id="F_77b0e56f-3746-4ff5-80a1-6015d2f31b34"
      unitRef="U_pure">0.0190</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="4"
      id="F_bd36ce12-19ed-4a51-9b86-8be72874cee0"
      unitRef="U_pure">0.0150</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <pyxs:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="4"
      id="F_f9e6d7cc-1f46-4578-9ffa-7db9cd55fa83"
      unitRef="U_pure">-0.0090</pyxs:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <pyxs:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="4"
      id="F_aaec76b1-35c2-485d-8b70-a175e5f03b7a"
      unitRef="U_pure">-0.0020</pyxs:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="4"
      id="F_74c898ca-ac3d-4932-b3b9-5abd09cde422"
      unitRef="U_pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="4"
      id="F_75d2af73-3158-46f6-b90c-f5b741d842e9"
      unitRef="U_pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="2"
      id="F_6c25c259-63a2-447f-b283-efdf556b3efa"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="2"
      id="F_ef6ebc64-2b44-4f8c-b1d3-ddda2c2f0767"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_f32ef832-0ca8-4c4e-8f52-bced104976f4">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Significant components of the Company&#x2019;s net deferred tax assets as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020 are as follows (in thousands): &lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.169%;"/&gt;
        &lt;td style="width:1.512%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.3%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.512%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.501%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Derivative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reserves and accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;License fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_a1ed4bbd-c551-4787-ab5f-7fd4e7a85439"
      unitRef="U_USD">12918000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_8556998e-3acc-4c82-afc4-10798c99dbe2"
      unitRef="U_USD">3515000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_71867427-0601-4aa8-940f-55a0a7671a47"
      unitRef="U_USD">75000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_af1cce98-e7cf-475e-b239-0dabb992cbea"
      unitRef="U_USD">47000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_280ac9d7-ff04-437b-80ac-b144d33c2f26"
      unitRef="U_USD">1648000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_2f2fd2fe-3d47-429b-995c-ddd346fe0e0b"
      unitRef="U_USD">187000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_25b1d606-2993-4aa2-9796-f9364dcacf6f"
      unitRef="U_USD">1577000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_4ca2aa4d-7136-4864-aeb7-364d4ecfb5bc"
      unitRef="U_USD">1003000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_c1bd1532-a8d2-48cd-a885-f15cd913d308"
      unitRef="U_USD">804000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_34a18394-8bfa-491e-bc45-c5de67e12d4a"
      unitRef="U_USD">257000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <pyxs:DeferredTaxAssetsLicenseFee
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_5f0a8bb8-45d6-4ddf-8dfb-821b036db0e3"
      unitRef="U_USD">7716000</pyxs:DeferredTaxAssetsLicenseFee>
    <pyxs:DeferredTaxAssetsLicenseFee
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_89888dd5-b85c-4893-a38b-86cad0ddf39b"
      unitRef="U_USD">252000</pyxs:DeferredTaxAssetsLicenseFee>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_c6254a91-82c6-44b1-ba2a-02e68608c122"
      unitRef="U_USD">70000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_a2cdce77-df7f-4f1c-a101-6c51ed653529"
      unitRef="U_USD">299000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_2b2123eb-e41a-4127-80e1-fa9431b80fdc"
      unitRef="U_USD">25811000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_f3dbe049-aa02-48ff-ac0c-32ad9dbfbdc0"
      unitRef="U_USD">4557000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_a5b41ed3-77d7-4822-9555-0442b30824f4"
      unitRef="U_USD">25748000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_8fe0abfd-cccb-4b6c-a5cc-511970936f86"
      unitRef="U_USD">4343000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_8173056a-6300-42e8-b2d8-6c4af712ab8f"
      unitRef="U_USD">63000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_0e309d32-2973-43b0-b719-803e4f4c1cf0"
      unitRef="U_USD">214000</us-gaap:DeferredTaxAssetsNet>
    <pyxs:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-3"
      id="F_162cc6df-7d6b-4aac-809f-ded13ed5c8a1"
      unitRef="U_USD">63000</pyxs:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <pyxs:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c"
      decimals="-3"
      id="F_7e08990a-706a-48d6-a35e-092efa2138dc"
      unitRef="U_USD">214000</pyxs:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_529d4c7c-54dc-4be7-b79b-cb508fa84d76"
      decimals="-5"
      id="F_e3ae27f2-ed6b-4280-b1bb-30ba5bcec374"
      unitRef="U_USD">10100000</us-gaap:OperatingLossCarryforwards>
    <pyxs:OperatingLossCarryforwardsBeforeTax
      contextRef="C_529d4c7c-54dc-4be7-b79b-cb508fa84d76"
      decimals="-5"
      id="F_11ee892d-bb7e-45bc-adac-ddfa685366ad"
      unitRef="U_USD">48000000.0</pyxs:OperatingLossCarryforwardsBeforeTax>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_14084414-5d74-4992-ae92-da97bbd2c4d3"
      decimals="-5"
      id="F_35c00873-a11c-448b-9996-6b072de062ac"
      unitRef="U_USD">2800000</us-gaap:OperatingLossCarryforwards>
    <pyxs:OperatingLossCarryforwardsBeforeTax
      contextRef="C_14084414-5d74-4992-ae92-da97bbd2c4d3"
      decimals="-5"
      id="F_4af52255-e94f-4ed5-bd0c-487456ca3ee6"
      unitRef="U_USD">45900000</pyxs:OperatingLossCarryforwardsBeforeTax>
    <pyxs:OperatingLossCarryforwardsExpirationYear
      contextRef="C_f4093bae-844d-47d4-af50-d208ea9824d5"
      id="F_54c3a4e6-a555-42dc-94aa-a3a9a2746fb4">2039</pyxs:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_529d4c7c-54dc-4be7-b79b-cb508fa84d76"
      decimals="-5"
      id="F_d034628d-707d-4c87-b5a5-8cf2054bb42d"
      unitRef="U_USD">1000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_14084414-5d74-4992-ae92-da97bbd2c4d3"
      decimals="-5"
      id="F_2e3225db-b5cf-4e89-883c-2426ec42f8e2"
      unitRef="U_USD">600000</us-gaap:TaxCreditCarryforwardAmount>
    <pyxs:TaxCreditCarryforwardExpirationYear
      contextRef="C_1af731d8-74d4-4ca7-b3c7-e479981d947b"
      id="F_91d6d207-f2f5-4d1a-a359-867b280cf9b6">2039</pyxs:TaxCreditCarryforwardExpirationYear>
    <pyxs:TaxCreditCarryforwardExpirationYear
      contextRef="C_f4093bae-844d-47d4-af50-d208ea9824d5"
      id="F_96e7a75c-a1b4-40c7-9eae-5d682a8c9366">2039</pyxs:TaxCreditCarryforwardExpirationYear>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_cfa6104f-d54e-432d-8bca-e8247807eec0"
      decimals="-5"
      id="F_8658173f-308c-4fca-b1ee-e7120495f533"
      unitRef="U_USD">25700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-5"
      id="F_082c17a9-213b-4944-802e-068106fe0dcb"
      unitRef="U_USD">21400000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-5"
      id="F_5be6ab0a-7062-48ef-ad43-956c8ad0877e"
      unitRef="U_USD">3600000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_d0e7c447-a9e1-436f-a34f-1142083cf159">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;14. Net Loss per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.906%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:13.198%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:13.717%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,493,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,030,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;8.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;12.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s potentially dilutive securities, which include convertible preferred stock, restricted stock, and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.64%;"/&gt;
        &lt;td style="width:1.938%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:10.536%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.938%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:10.536%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,573,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested Restricted Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;618,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;888,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,926,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6,545,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;4,682,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_024246b6-c4b0-4235-8a55-fadcb7eb83b8">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.906%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:13.198%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:13.717%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,493,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,030,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;8.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;12.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="-3"
      id="F_f23eceb6-b445-4cd2-a3fa-485cd2569335"
      unitRef="U_USD">-75975000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="-3"
      id="F_cc3d2626-8576-41fd-a8a7-cd8e1545a3b0"
      unitRef="U_USD">-12828000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="0"
      id="F_08e3ade2-fdd7-4e75-b20e-8cbd01ee0934"
      unitRef="U_shares">8493273</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="0"
      id="F_a610686c-1ce7-4b92-a754-5daf63eff550"
      unitRef="U_shares">1030556</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="2"
      id="F_d2cd6497-c092-4aaa-ab03-a17734095d12"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-8.95</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="2"
      id="F_effef5bc-d973-47fa-b0dc-4519e6d95172"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-12.45</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_4135e090-e607-48af-8e3c-17d3b1548abb">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.64%;"/&gt;
        &lt;td style="width:1.938%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:10.536%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.938%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:10.536%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,573,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested Restricted Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;618,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;888,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,926,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6,545,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;4,682,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5a174817-ec5a-4adc-91c7-b3f0391f3a67"
      decimals="0"
      id="F_b7646b5d-9c2b-4208-bb76-14f16a9eea57"
      unitRef="U_shares">3573659</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_99104f1c-d368-4dd0-8b3e-c298819aba0b"
      decimals="0"
      id="F_f47d57f8-300e-4562-bdf9-a7a6688a4c7e"
      unitRef="U_shares">618494</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_22452cd4-facf-4cb0-b0d8-aef2986fea43"
      decimals="0"
      id="F_495fe011-73e7-43ef-9fb7-67a2291993d0"
      unitRef="U_shares">888612</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6b5b3558-a3b0-4002-902a-e67ae5cdd4b2"
      decimals="0"
      id="F_8d7b0cf8-6c45-4e21-8771-003c50f6970c"
      unitRef="U_shares">5926969</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a48bbe71-5e71-4138-9877-1babd6034c0e"
      decimals="0"
      id="F_58869ef0-fe09-431c-b3ba-cc8acb181d30"
      unitRef="U_shares">220383</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      decimals="0"
      id="F_58643769-a064-4224-92ab-90ca60e6a09e"
      unitRef="U_shares">6545463</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_54d4e58d-90af-4c17-b083-9fcffe474079"
      decimals="0"
      id="F_27d27e26-b3a6-4f92-9b1c-1e8b83fdb900"
      unitRef="U_shares">4682654</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_736597c8-071d-4bda-b715-dc90208ef3c6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;15. Related Parties&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In 2020, the Company entered into agreements with several Scientific Advisory Board (&#x201c;SAB&#x201d;) members whose members are comprised of the Company's board members. The Company paid monthly amounts, ranging from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; thousand to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; thousand per month. No board member was paid more than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million individually for the years ended December 31, 2021 and 2020, in the aggregate, all board members were paid less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for both periods combined.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company was founded out of Dr. Thomas Gajewski&#x2019;s laboratory at the University of Chicago. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In 2020, the Company entered into the License Agreement with the University of Chicago, as well as a sponsored research agreement, which had previously purchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;309,885&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s Series A preferred stock as part of the Company&#x2019;s 2019 Series A financing. In partial consideration for&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; the license from the University, the Company issued to the University &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,919&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock in 2020. The Company recorded the value of the shares issued of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; thousand as research and development expenses in the year ended December 31, 2020. There have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; further expenses incurred for the year ended December 31, 2021 with regards to the University License Agreement. Refer&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to Note 3 for additional discussion.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to IPO, Pfizer along-with its affiliated entity and Bayer HealthCare LLC ("Bayer"), were principal owners of the Company. Subsequent to IPO, Pfizer and Bayer are no longer principal owners and, as a result, neither Pfizer nor Bayer are related parties of the Company. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In 2020, the Company entered into the Pfizer License Agreement. The Pfizer License Agreement became effective in March 2021. During the year ended December 31, 2021, the Company incurred a combined &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million (which was recorded as research and development expenses), consisting of an upfront fee equal to a cash payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; m&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;illion and the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,152,145&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series B convertible preferred stock with a value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in 2021 to Pfizer. Refer to Note 3 for additional discussion.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company and Alloy formed a joint venture company, Voxall Therapeutics, LLC (&#x201c;Voxall&#x201d;) to leverage the Company&#x2019;s technology and Alloy&#x2019;s ATX-Gx&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"&gt;&#x99; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;platform and antibody discovery services. The Company and Alloy contributed $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; thousand each to Voxall along with certain license. During the year, the Company provided services to Voxall for which it recognized service fee other income of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;181&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; thousand. Refer to Note 4 for additional discussion.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <pyxs:PaymentsToRelatedPartiesPerMonth
      contextRef="C_6ff4a3a9-acf7-49fe-b336-139827d87918"
      decimals="-3"
      id="F_f8805f91-837c-4aba-9365-6eefeab7e37d"
      unitRef="U_USD">3000</pyxs:PaymentsToRelatedPartiesPerMonth>
    <pyxs:PaymentsToRelatedPartiesPerMonth
      contextRef="C_dc7688b9-57dd-43d0-a91e-30eeb4979d67"
      decimals="-3"
      id="F_47b8746c-389b-4ce6-b21e-19acb5239254"
      unitRef="U_USD">5000</pyxs:PaymentsToRelatedPartiesPerMonth>
    <pyxs:MaximumAmountPaidToRelatedParties
      contextRef="C_8f0edcc6-6967-4a4a-b278-e69a383ba6db"
      decimals="INF"
      id="F_e7544bee-4793-46fd-b080-9524e4628a26"
      unitRef="U_USD">100000</pyxs:MaximumAmountPaidToRelatedParties>
    <pyxs:MaximumAmountPaidToRelatedParties
      contextRef="C_0fbda7d4-a5aa-4836-8bfe-59b19b15fc3f"
      decimals="INF"
      id="F_1d1ba1bf-7b5e-4911-afd0-e19c479ac2f9"
      unitRef="U_USD">100000</pyxs:MaximumAmountPaidToRelatedParties>
    <pyxs:AggregateMaximumAmountPaidToRelatedParties
      contextRef="C_8f0edcc6-6967-4a4a-b278-e69a383ba6db"
      decimals="INF"
      id="F_e3ce6af7-cac8-4d07-80d8-ef77532da01b"
      unitRef="U_USD">100000</pyxs:AggregateMaximumAmountPaidToRelatedParties>
    <pyxs:AggregateMaximumAmountPaidToRelatedParties
      contextRef="C_0fbda7d4-a5aa-4836-8bfe-59b19b15fc3f"
      decimals="INF"
      id="F_d1ad85ab-ab40-4898-9c77-da4c1e00e907"
      unitRef="U_USD">100000</pyxs:AggregateMaximumAmountPaidToRelatedParties>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_40efd25b-f2c1-4224-9850-278e0702aecc"
      decimals="0"
      id="F_6231df14-93b7-4890-8d47-104274aa9c04"
      unitRef="U_shares">309885</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_3014eecd-3b62-49b1-859b-5132c70a7d8a"
      decimals="INF"
      id="F_8fff1535-1472-4ec7-8939-d65acccf706e"
      unitRef="U_shares">48919</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d235112b-d87b-410d-8d79-ca05e714f0dd"
      decimals="-3"
      id="F_31417b2c-6407-4958-a6dc-5eda4725c179"
      unitRef="U_USD">3000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1662ef99-8778-4709-9b9e-c988faaab66e"
      decimals="INF"
      id="F_2153b565-bf6b-4221-8650-3f33af8d4c75"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_93d8ea59-4f70-435a-800d-684dd2b13280"
      decimals="-5"
      id="F_ae4acb28-4dd5-4136-99e0-997a95e6d901"
      unitRef="U_USD">25000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <pyxs:UpfrontPayments
      contextRef="C_6eaa700b-aefd-44cf-9c29-31f008101fed"
      decimals="-5"
      id="F_d4b4166e-cb8b-4944-bdc6-10d24b3705e4"
      unitRef="U_USD">5000000.0</pyxs:UpfrontPayments>
    <pyxs:IssuanceOfConvertiblePreferredStockShares
      contextRef="C_34a68bd8-42d2-4884-8c43-a95f93b476df"
      decimals="INF"
      id="F_7c42a8b5-7923-4b64-83fa-552b6c1e5705"
      unitRef="U_shares">12152145</pyxs:IssuanceOfConvertiblePreferredStockShares>
    <pyxs:ConvertiblePreferredStockSharesIssuedValue
      contextRef="C_404bc14b-3eaf-4e94-a492-dc8d161a716a"
      decimals="-5"
      id="F_d32e8870-e901-453d-93f8-cc6d3d08c8de"
      unitRef="U_USD">20000000.0</pyxs:ConvertiblePreferredStockSharesIssuedValue>
    <pyxs:ContributedAmountToJointVentureByEachEntity
      contextRef="C_5fb2e8bf-e772-43b7-b907-59150f324329"
      decimals="-3"
      id="F_1394f864-8a3d-48e1-b5c2-39064d4b54ff"
      unitRef="U_USD">50000</pyxs:ContributedAmountToJointVentureByEachEntity>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="C_5fb2e8bf-e772-43b7-b907-59150f324329"
      decimals="-3"
      id="F_cc544be4-823a-4af0-86dd-dd9e75d310f1"
      unitRef="U_USD">181000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_7c426c0c-76af-4458-ad18-023ebbc06198">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;16. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Legal Proceedings&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of business. The Company is not currently a party to any material legal proceedings, and is not aware of any pending or threatened legal proceeding against it that the Company believes could have an adverse effect on its business, operating results or financial condition.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Commitments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In the normal course of business, the Company enters into agreements for research programs with vendors for nonclinical studies, manufacturing and other services and products agreements, which are generally cancellable by the Company at any time, subject to payment of remaining obligations under binding purchase orders and, in certain cases, nominal early-termination fees. These commitments are not deemed significant.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2020, COVID-19 disease was declared a pandemic by the World Health Organization. The COVID-19 pandemic is disrupting supply chains and affecting production and sales across a range of industries. Currently, the Company has not suffered significant adverse consequences as a result of the COVID-19 pandemic. The extent of the impact of COVID-19 on the Company&#x2019;s future operational and financial performance will depend on certain developments, including the duration and spread of the pandemic, including its variants, impact on employees and vendors all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Company&#x2019;s future financial condition or results of operations is uncertain.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_19b30afc-5afa-40c6-8463-3498cd194d89"
      id="F_7f04958c-9e9f-4f5f-8821-5dc097e49fee">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;17. Subsequent Event&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;License Agreement with Biosion USA, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 28, 2022, the Company entered into a license agreement, or the &#x201c;Biosion License Agreement,&#x201d; with Biosion USA, Inc., or Biosion, &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;pursuant to which the Company obtained exclusive, worldwide (other than Greater China &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(mainland China, Hong Kong, Macau and Taiwan)&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;), licenses for development, manufacture and commercialization rights for BSI-060T, a potentially best-in-class Siglec-15 targeting antibody, an IO product candidate (now referred to as PYX-106), and products containing the licensed compound.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the Biosion License Agreement, the Company agreed to pay an upfront fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and are obligated to pay future contingent payments including development, regulatory and commercial milestone up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;217.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in case of normal approval and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;222.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in case of accelerated approval. Additionally, if products are launched, the Company will pay Biosion tiered royalties on net sales of licensed products in varying royalty rates ranging from low single digits to low teens. The Company&#x2019;s royalty obligations apply on a licensed product-by-licensed product and country-by-country basis from first commercial sale until the latest to occur of: (1) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; from first commercial sale; (2) the expiration of all regulatory or data exclusivity; and (3) the expiration of the last valid claim of a licensed patent covering the licensed product in a country.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <pyxs:UpfrontFee
      contextRef="C_dca5bfc8-d2fa-4c60-8e05-95c561295a9b"
      decimals="-6"
      id="F_2cf68fb7-c0a1-426b-bce2-d8b01d3c558d"
      unitRef="U_USD">10000000</pyxs:UpfrontFee>
    <pyxs:AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval
      contextRef="C_ea790169-f5cb-46d5-bb2a-a27a9d87e6bf"
      decimals="INF"
      id="F_cc054cd6-fb94-47cf-978d-a2d43c717c54"
      unitRef="U_USD">217500000</pyxs:AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval>
    <pyxs:AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval
      contextRef="C_ea790169-f5cb-46d5-bb2a-a27a9d87e6bf"
      decimals="INF"
      id="F_d552c3ed-7cbc-41d1-a7c7-96967fb64264"
      unitRef="U_USD">222500000</pyxs:AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval>
    <pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale
      contextRef="C_dca5bfc8-d2fa-4c60-8e05-95c561295a9b"
      id="F_67b2ed84-abf2-4561-90e6-ceeef55a2f41">P12Y</pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_1705cc8f-18fe-443e-b8d6-3e583f9850d8"
          xlink:label="F_1705cc8f-18fe-443e-b8d6-3e583f9850d8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_17b2d502-1157-47ab-87f7-2134a0019cc3"
          xlink:label="F_17b2d502-1157-47ab-87f7-2134a0019cc3"
          xlink:type="locator"/>
        <link:footnote id="FNT_1d02fe45-14e7-49c1-acb0-ad6b9e3a7f80" xlink:label="FNT_1d02fe45-14e7-49c1-acb0-ad6b9e3a7f80" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Variable lease cost includes common area maintenance charges</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_1705cc8f-18fe-443e-b8d6-3e583f9850d8"
          xlink:to="FNT_1d02fe45-14e7-49c1-acb0-ad6b9e3a7f80"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_17b2d502-1157-47ab-87f7-2134a0019cc3"
          xlink:to="FNT_1d02fe45-14e7-49c1-acb0-ad6b9e3a7f80"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>106
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M@;(@XDV3U*Y)\,1(,F/*D.ET6C 0^LO=.&)7L!+&CMW3)O"Z)<E?C25B5[@
M&0&:2$_((@NB?Y%]$;#H7'*R@FEW"%<FRA%*41-0M/F!R4[:;%D+G1^&V7=%
M"K;AD)!MJP2I?R=H5>PX;>V.$[=')&3$ V[-KSKD:-Q\Z^T=]]A]COS83)/
M3BF*DY_J;G4T-\@/I'KUZ\6YWAVSVR2:Q'P%H<[).6B>*H[*B@LC-_GAT5(:
M(Y/\9\09])%] 9ZOI#2["_N!ZL#R^A]02P,$%     @ C#Q]5(0(&]&?!0
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MG)#=G#Y@TI=/L)%;)06Y>[#;,UOM'UAL:2(!(QL=XUW[>E**8O=:G"B>YAO
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M=4S].%IY]65TAE)+/UIT0J]HXXXVGJ3]$RH,0F%A68;)S)4V0:F=G(VMY(*
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M!3&TL$JB&1==;@F&M_YY4)1W::=@]$$(!_U:+],%N=<G02W(/_FL$M-<WK[
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MX2SCR@K _]=2FL.+':"YKKK\'U!+ P04    " ",/'U4+O[C,\ )  "+&
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M9\14MC8/HO95N^-EB:#2=@-!DX,3%_B@IB$MG;#XZ7T[UF1A:*;NGHCB(_>
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M9A1)'_:0;0-B:>$<G9!Q.VJ&P^[H(1>S_X:8,"A679!3.O&USYE(PJAL22]
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ML"PQXTS['V5R?P,B'G6^ \@-0<>LZ=N/7O,Q:C/+M*[VON:C%)K+ RC'&S9
M:@<^?B[<-05 .*QAD6FH% C+XAM(U5^YE=H]37WQVT8'-_=3\BU*N8ASB3<]
MVNSUK3==V[2CWOWIP?'O33,BAX(K$ *3.2&JJUW>ON-OYF?GL^0.1.]?)7&@
M>O#TEW9'#'IQ<?[LY) ?Q;' V&=7+9(97CR;:1.G?QFB!*O?V8I?#:H/?G'^
MZ;-"CB?>CQE>EFNJJI,6YTG.E=%$? LGXUR^YS*&.TCY[85X)X^!C@8]/A5>
MA?X"?2L=EP5B*UW6U9ETY_^"-"\XC*NF+$W?#96\-!G96MHL)ZL,UU\"BCK_
M=*9BXYHUBFEN&XY0B"[1?Y1...FB4B49/#%</?1:D5Z289#M7QY:.>Y('D1!
M_<U6I&*/!'F'<\L^9S%+,V\QY<; .M[.371;:U2G51LOB[XX.__LF%Z??S8_
M?S%+7K3S-KZ18ZXO/OM![%G0R<^>?96^BBEY19H^20PX.&'ZHF2_]LF*PO2-
M*EF2;15SXOH2M>0:[VKZYJ#PYK-PWPT]0HN4#;"NM2E#[X(F6T.[L&2MXXT*
MKD]K9T"3] #@,?DN?:-,5B/1$S*OV_:]K!%:*]AN^ONGZ<YB;P7YB4$N289W
M,O<^D.8<!30(2;<Y<FKSF"5.7X_0)(@VYQ\ N >U<Z)KCK=9$+Y>#JEW]^EQ
MS<SJ34=.P?J<JKP".9L;[;&X#,%%$^Z>UW@TQ+"9?/("3NHI+Z7-\LB[I3.Q
M:J^JW*3)C$SJ6C_:Z%R(T>&7/D:KX-@?;A'>3SK%@ HY/![BJW,]*H31]B\A
M#A$W#*<;@@MLVKTWB'Z<I9E4L0Z^Z%>LR^1=ZLF[U],.&;8F3Y/FL)"9)9WH
M;)EEER]OKY_-_L$B?WQ3RNWK:[6[ QM&#Q>2ZMA,[?%CF34V9I3W^OT?V';H
M3R0\3_Y.!=24_QH'O]2T&>1/5H1/PQ_\N)2_<Q$?E[\6\J.!EN.JYXJ&GBT^
M__2)1'K^EZ'=\5^]6+;#T&[YQPT=,]OA ?I^U1*TUU^P0/@S**_^%U!+ P04
M    " ",/'U4PYP".@X.  "?,   &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6SM6VMSV\85_2L[JJ>59RB)I&1;B1\SDIU,W#BU)D[ZF$X_+($EN3&
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M.<!55<$/C?0XT7<]-J-JBI"1-KZ3'<X9E!(5;IJ3$_:S:KT;YD*:+="Y_>E
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MP+X0-^8DJJ%0W(Q0VFM_1\C&\O9=J= UQ4734MPF\.[:W.9F>$\&'[)I P<
M)[XBY$W&N>.;AOA*SHK1L6/<>.>T7)$KXIV >RXZ1#HX]U_[:\=U.FUOIZ<[
M"\YC!?*$H\@"II/1\[.!<.D>D%Z"K>/9&]T0)_GX6.+J1(XG8'QA4?3VA0/T
ME[&K?P!02P,$%     @ C#Q]5%<;I,<^!0  @0P  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&ULM5=M;]LV$/[N7W'0@B$%7+_(:9JDB0$G;;$.S1 T
M:8=AV =:.EE$*%(EJ3C>K]\=*=G.B],!P[Y8$LF[>^[NN>/Y=&GLK2L1/=Q7
M2KNSI/2^/AD.759B)=S U*AIIS"V$IX^[6+H:HLB#T*5&J:CT>&P$E(GT].P
M=F6GIZ;Q2FJ\LN":JA)V=8[*+,^2<=(M?)&+TO/"<'I:BP5>H_]:7UGZ&JZU
MY+)"[:318+$X2V;CD_,#/A\.?).X=%OOP)[,C;GECT_Y63)B0*@P\ZQ!T.,.
M+U I5D0POK<ZD[5)%MQ^[[1_#+Z3+W/A\,*HWV7NR[/D*($<"]$H_\4L?\'6
MGS>L+S/*A5]8QK.3@P2RQGE3M<*$H)(Z/L5]&X<M@:/1#H&T%4@#[F@HH'PO
MO)B>6K,$RZ=)&[\$5X,T@9.:DW+M+>U*DO/3CT):^"94@W")PC46*>+>G0X]
M*><CPZQ5=!X5I3L4C5.X--J7#C[H'/.'"H:$:@TM[:"=IR]J?(_9 ";C/J2C
M=/R"OLG:U4G0-_FQJ^^ERY1A;QW\.9L[;XD=?[U@XV!MXR#8./COX7Q1$=?B
MB:M%AF<)%9M#>X?)],T =AB FQ*A,(IJ3.H%>#%7Y%J0U!X\;THM=":% JG)
MWR:*9<):B3D(#P5KO@N:N5JHXK*&-DD;L5XZ$ Y, 904K.9HUXD!H7-^&?5)
MPM48JDRM^F2&2BXS-B>S2*SV9<#Q<79]#K/K"SA*1U!*M,)FY0KVZ;@O3>-(
MG7MUTMOEI_"]ST@&8 SQF;;/"=P8+U1OYAQZUR,NXHH*Q=Y28RL:4@I[D+Y-
M^^EX1&\__W24CM-W#][:W?_']&'_^/APA^&XQQF\,%4M]"ILO7W'Z7$EX/=&
M4EX"!HM=3G.LC9.TQ'$&5QKK7WNT%7S5TE-&K[WP1($;&UP@/(]1P??&\$&6
M[[ICM\\YS91P3A:!'>0\=+X+]G+ <"VEE7^TB8M$$ M*BKE4TDLR7L7P/4LO
M;?03AOD7Z/78(I6L=@5:!W/T2T2] 4@278*(L8'\&^,;RN5-L,W[*Q2D"+EQ
M_0C" T>B]APM)2C$K_-^!4O!J:$X"*7(%G)NJ,9S:!Q;%52<9MX>?KT,ET=(
M1F8J!%'3KLC*8%IRVH/!$$CD=>(!)9P5Y91FCGME*"Z%);(0.\BB+""3-FLJ
MY[D '>0R8TH,X*(4>H&!./[?^R-(/26,ZCD2 N]I+G"QL$F3(4$+^^WJJ\Z1
MUD9FM#-*,M8<',.()44&:;RP@B]H%UE'%6"QY%N?S1OG8M2=7&@B8R:(^HTV
M<^Z(W.3(0MV0IL9%*C_RJ-H4\(O>$5S5Y+B=%#Y?BU40+:@\C(T(@PZZ/TQ#
M&S9$] L2$<$;^(TJ"B9]^"PS]H#2,UM8C,[VJ3];$'DNV=O0A^-,Q<.)T3NQ
M#7;U=G,G";'HYBG&FVU2V[6FYX/A IB.^KN8?]+[@W?#A=Y[LMO;WX,'79N.
M/!/:N5#A!HCWQZ]"-PRVJZUU'^Q]BL422+;0,H:E>#Y=D_[D\+@7B<P8MIQ<
M<Y26";RFD#GJL.EDW+MI6P9GBJ^FAN- *0X\VH?C_N%H!*]ZYP\ /VT'F]:]
MU;))CXS<V(/CP2&-:DJU'GRXIUX%EY*RYJD)PU4D5>3#LI14SM+S77TG*9)4
MNFT$_N9">];_<+EVD21,Z0">FUV&6V-AA781AE^Z5-CQ."&N5]?S]2R.E9OC
M<3B_%'9!<P,H+$AT-'C[)@$;!][XX4T=ALRY\32RAM>2_B.@Y0.T7Q@JC?:#
M#:S_=4S_ 5!+ P04    " ",/'U4X#:]DIH"  #2!0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6RU5$MOVD 0OO,K1FY4M1+"#PA0"DA 6C6'J"CI
MXU#UL-ACO,IZU]U=A[2_OK-KXU*I0;GTXGU]\\TW,YZ9'Y2^-P6BA<=22+,(
M"FNK61B:M,"2F8&J4-)+KG3)+!WU/C251I9YHU*$212-PY)Q&2SG_FZKEW-5
M6\$E;C68NBR9_KE&H0Z+( Z.%[=\7UAW$2[G%=OC'=K/U5;3*>Q8,EZB-%Q)
MT)@O@E4\6X\<W@.^<#R8DSVX2'9*W;O#=;8((B<(!:;6,3!:'G"#0C@BDO&C
MY0PZE\[P=']D?^]CIUAVS.!&B:\\L\4BF :08<YJ86_5X0.V\5PZOE0)X[]P
M:+"320!I;:PJ6V-24'+9K.RQS<.)P31ZPB!I#1*ONW'D55XQRY9SK0Z@'9K8
MW,:'ZJU)')>N*'=6TRLG.[O<:JP8S^#=(Y79H $F,_AH"]2PJ;5&:6%E#%HS
M#RVY<T9AVE*O&^KD">HX@1LE;6'@G<PP^YL@))V=V.0H=IV<9;S"= ##N ])
ME,1G^(9=\$//-WR2+T>*,8.-,M;T8<,J;IG@OS#K0YN9_DE&FDS %3>I4*;6
M"-]6.V,U_5K?S\@9=7)&7L[H?]3B++5K[9FI6(J+@'K7H'[ 8#D>P+-==D@\
M12J/3%LD:Y"IHI8UEM*J<B  Y$I0[W.YAU=<THVJ#1F;U[,>%13+'5%047NN
MJ*ZR4>]:4G*93!$N(.Y/QD-:I[U;TLUT6GC/&3[00*E*YW<<OX&7+Z9)G+SM
M-=JG(X@O>Y\4%1.J9PN_@*0_&H_=.H1_U3,\Z;,2]=Y/$Q=P+6W3<MUM-[!6
M39_^@3?3[H;I/9<&!.9D&@TFEP'H9H(T!ZLJW[4[96D&^&U!0Q>U ]![KI0]
M'IR#;HPO?P-02P,$%     @ C#Q]5(NPUM[F @  9 8  !D   !X;"]W;W)K
M<VAE971S+W-H965T,30N>&ULK57);MLP$+W[*P9"#PE@6(ME.S%L ]F*%D@*
M(^ER*'J@I9%%A"(5DHKC?GV'E*TX0.->>A')X;PW&V<TVRC]:$I$"R^5D&8>
ME-;6TS T68D5,P-5HZ2;0NF*63KJ=6AJC2SWH$J$212-PXIQ&2QF7K;4BYEJ
MK. 2EQI,4U5,;R]1J,T\B(.]X)ZO2^L$X6)6LS4^H/U6+S6=PHXEYQ5*PY4$
MC<4\N(BGEZG3]PK?.6[,P1Y<)"NE'MWA<SX/(N<0"LRL8V"T/.,5"N&(R(VG
M'6?0F73 P_V>_:./G6)9,8-72OS@N2WGP5D .1:L$?9>;3[A+IZ1X\N4,/X+
MFU8W)8M98ZRJ=F Z5URV*WO9Y>$ <!:] TAV@,3[W1KR7EXSRQ8SK3:@G3:Q
MN8T/U:/).2Y=41ZLIEM..+M8:JJOMEM@,H>;IX;7E'';AR]H9Z$E TXMS'9D
MERU9\@Y9G,"=DK8T<"-SS-\2A.19YUZR=^\R.<IXC=D AG$?DBB)C_ -NW"'
MGF_XCW#[L!1,VK=1P\^+E;&:'LJO(Z;2SE3J3:7_)[-'R5QK3DW-,IP'U'L&
M]3,&B\D CAAY>X>O=Q+IDRGJ*V,Q!U6 +1$*):A!N5S#"9<D48TAG#F=]J@&
M6*U0NSKT7!U<,:+>+5LIS:S2VU=R^ !Q_RQ*_9J,T]XM4L>42N3 JUJK9W1:
M!I)D!$D\['ULM.2VT>A]5$7!,SQ@.T_A?-1+^G$R)+[1)"$^8Z;4REE3-8(Y
M]W.DA&2<M3U.+*Q2VO+?K>"$<'$\AE/:I>-S..U]598)J-_/C?<]BB9^C:,A
M7!^U@"\T'XW+G_9YW"+3!M"]?SC,G'_!'NZR!QMFR$ T&%-3"[%G=I+17M*G
MH6=J]&-+; ?PMS<9'G1^A7KMYYNAZC;2MD.@DW8C]**='*_J[?R]8WK-I0&!
M!4&CP604@&YG6GNPJO9S9*4L326_+>DW@-HIT'VAE-T?G('NQ[+X U!+ P04
M    " ",/'U4SB;=T+$"   +!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6RU5$MOVS ,ON=7$$8/&Q#$CZ1Y%$F I,VP 2L6M'L<AAUDFXZ%RI(G
M*4WZ[T?)CI<!:X ==K%>'S]^)$W.#TH_F1+1PK$2TBR"TMKZ)@Q-5F+%S$#5
M*.FE4+IBEHYZ%YI:(\N]427")(K&8<6X#)9S?[?5R[G:6\$E;C68?54Q_;)&
MH0Z+( Y.%P]\5UIW$2[G-=OA(]HO]5;3*>Q8<EZA-%Q)T%@L@E5\LQXYO =\
MY7@P9WMPD:1*/;G#AWP11$X0"LRL8V"T/.,M"N&(2,;/EC/H7#K#\_V)_9V/
MG6))F<%;);[QW):+8!I C@7;"_N@#N^QC>?:\65*&/^%0X,=30+(]L:JJC4F
M!167S<J.;1[.#*;1*P9):Y!XW8TCK_*.6;:<:W4 [=#$YC8^5&]-XKAT17FT
MFEXYV=GE*LOT'G/8'*G,!@TPF<,G6Z*&V[W6*"U\Y"SE@EN.9AY:\NDLPZSE
M7S?\R2O\<0+W2MK2P$;FF/])$)+83G%R4KQ.+C+>83: 8=R')$KB"WS#+@-#
MSS=\A6_+7E@JVLA].I@P\'V5&JOIG_EQP<6H<S'R+D;_+<D7^5WCWIB:9;@(
MJ#,-ZF<,EM,!_)O?#H[G<.7A60L79_!,46L:2P:J $)!H03U.)<[>,,EW:B]
M(0;S]J9'-<,J)1ZJ6\_5S14OZFVJ6J@71**JG$O6-"IY35%BP:V!*TCZL_&0
MUK@?14EO<[2H)1/@XF0Z*ST\QV<:+W7E)';JD_YP&L,D3GI;K0HT;HZ088'T
M-ILF$(\GO289R7@,<3SN?5:6 .S?TG %X_[U+/$*9[,)_.U_"<\:M$*]\V/(
M97 O;=.KW6TWZ59-@_^&-V/RGND=EP8$%F0:#2;7 >AF]#0'JVK?[JFR-#S\
MMJ1IC=H!Z+U0RIX.SD$W_Y>_ %!+ P04    " ",/'U4;J1X9@4%  !N"P
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ML]JD19TU<)(1)<ZM':,GAZW7"RC4A0Y:4FMC 0^=#<5#XU'K:VR-G)VH!S
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MJPJCA#!*-"@?,YL3!J170CV&5, P"!)#!290"3@O' *3"72_9&\R9U9&BWF
ML?O5@0EB -'"4.V9,PB&LCAEY8M&LJR]:@,F2&QH!SZ<ST>LLP4DI MX"K$O
M(9 Y2+9]!7GW/O$"6AT\8EZSW^F"LZB 6?:%*&QR.J=]H^%.N(?:D+M!!0MD
MB]&JMH9I>[@7N\@$CRRYT&__$A:11Z<. BA)>Y;O1RK?UNA:"5V!>HP0S%R=
M"]OU2%*%)#/A N'-17D%^ZCDB3T$9QVF)/($)^;P!*S),GT *N:L0V 4Q\WC
M.<FIE 1+"KJVN@)7-BZ^:2K4[&VB&K-H-:?K=Q_?W#Q9_T0EFD BVZL E,(
ML4R:1@*M+D9"/CD/6;UF95"?=[Y65O^MLC)2=XQPDQUT#FC?=TE=H>\Z8;H1
M!:?JJ*3(1$ZN4_K.82,H(P4LO MXD%=(07@&E?BD>"U$7(_==U]IH#BQ$7J
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M5XOG3V?D\U4J+Z+KTO5EZR(N0^EO@P*QEP/8KYR+XT(<3/?9BW\ 4$L#!!0
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MI^/3XT';K783;ZKPY*^,IP^(,%S3%QM:/D#[N:$FUDW80?\-./\74$L#!!0
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M_7A9[P^J.M)?RQ\?S#*5O=*ENE4P45XWA[HA;)AEM\IF&X !W$]FJNR7KM(
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MADF;XEN,199F9W0QLAZ<$G!O;2J&%-TA/9+YYU(L8 BTN@&>#""@-4U+7]<
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MHR-<&<V5 5-3P!?@_&NMJX"/^#Q,"\S: VA-RAC?NR6$LL!."^+Y&^!-56X
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M%B0G:':@ _2PCXV9!O$.#7S:ROBFW'2(ET-KDXDW7Y-K&^\8-B+AUD(3%:!
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M2X*$C7 <F/W6A=X?8N#"?]4\?<_**'1]Q\=)\',B*IY0*H _8P?.$R"X8PZ
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MHG8.=%\H9=\,EZ ;X_-_4$L#!!0    ( (P\?50.S]07N@(  .T%   9
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;)5436_;, R]YU<(1@\M$-2V\ATD
M 9(VPP:L6-!VVV'80;;I6*@L>9+<I/]^E)QX&= $Z,7Z(M][)$W.=DJ_F +
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M+@3"".CSC'/UO# 7M&]7TY]02P,$%     @ C#Q]5%STL-'1 @  3P@  !D
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M,=?Z<Z#,+5,O7"#[V8,?^.ESV\DG:1;ZA)H0:#TA9CWIUM W[L*(EA)R-'L
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MXO*5=E_<!;ME<NW#_BW@*^C*.AD#6EE<KRJ^I"+.+^L\B#058?YQPYG'I6H
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MGC++,]D-,@5/R&N".T)=*[)79#2<P:*Y5Y KN&$"1<Z0PZW01M4-9(9*,2H
M#?14[-4\4%[;([&&:]1,P_&<##*N3ZSJ?^1I#W<&CXLY'!^=P!$P ;]+66L4
MA9Z$QGITG89YZ^>Z\9/L\3.G? ##^!22*(D_H<\.IT?OZ:%-MHLWZ>)-O-YP
MC]Z5UF3T%T+#3FCHA49[A&:H2Z"7FFV1N_0_2Z91&'L%-[W;+#E/DMCZV/83
M^ A++R[2#O2NO5'7WNC+]G[1ECC$7Q@==TKC[R66=D+IMQ-+#TOL(^R3Q,+>
M$+H'\ [5F@D-G%:6%@W.+5\UCTI3&+GQ<[F4QDZY7Y;V'2;E /9\):5Y*]RH
M=R][]@]02P,$%     @ C#Q]5),E^=FI @  =0<  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#(N>&ULS55=3]LP%/TK5K0'D#:2IFF[H3824-"80$-4L(=I
M#VYRVU@X=K"=I.S7[]I)H[*5T,?U(?''/<?GGIM>3VNIGG0&8,@FYT+/O,R8
MXM3W=9)!3O6)+$#@SDJJG!J<JK6O"P4T=:"<^V$0C/V<,N'%4[=VI^*I+ UG
M NX4T66>4_5R#ES6,V_@;1?NV3HS=L&/IP5=PP+,0W&G<.9W+"G+06@F!5&P
MFGEG@]/YQ,:[@$<&M=X9$YO)4LHG.[E.9UY@!0&'Q%@&BJ\*+H!S2X0RGEM.
MKSO2 G?'6_8KESOFLJ0:+B3_P5*3S;S/'DEA14MN[F7]%=I\1I8OD5R[)ZG;
MV, C2:F-S%LP*LB9:-YTT_JP QA$;P#"%A >"ABV@.&A@*@%1,Z9)A7GPYP:
M&D^5K(FRT<AF!\Y,A\;TF;!E7QB%NPQQ)KZB3)%'RDL@MT!UJ0!K:C3Y1,[2
ME-G24$ZN1?-]V4(=S<%0QO4QACPLYN3HP_'4-ZC$\OE)>^IY<VKXQJG?J#@A
MP\%'$@9AN =^T0^?0]+!!WO@\\/AP6NXC_9U'H:=AZ'C&[[OX0VC2\;1-]!;
M/U/R79![2$JEF%B3<ZJ9)@]"+C6HBBXYH+U%:6R(% F"&Y]_WN IY-I KG_U
M:!QV&H=.8_2&QC.M <N:;S510U96=F5E[ZM 0S=R=+9W5#%:5>V:W!?Q2F/4
M:8QZ->Z:=[C0Z%VA?1&OA(XZH:->H8L2B_=<XA^%7%;X[*G/N*,<_[??T*33
M..E-^W)C%,4FQ ';$A(7],4V"X+-@=092S)LN(I5U'9RPMLL7O!R2.1:L-^0
M[FL4DW^*\V4<V-]?)?)W>IR]D&ZI6C.A"8<5(H.3"5*HILDW$R,+U_:6TF 3
M=<,,[T50-@#W5U*:[<1VTNZFC?\ 4$L#!!0    ( (P\?53(CU-CMP(  "<&
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;(5544_;,!#^*Z>(!Y V
MDB8T&ZBM1.G0D$!#%-C#M <WN206CMW93@O_?F<G#=W6=B^-?;[[[KOO[.MH
MK?2+J1 MO-9"FG%06;N\"$.355@S<ZJ6*.FD4+IFEK:Z#,U2(\M]4"W".(K2
ML&9<!I.1M]WKR4@U5G")]QI,4]=,OTU1J/4X& 0;PP,O*^L,X62T9"7.T3XM
M[S7MPAXEYS5*PY4$C<4XN!Q<3%/G[QV>.:[-UAI<)0NE7MSF)A\'D2.$ C/K
M$!A]5GB%0C@@HO&KPPSZE"YP>[U!O_:U4RT+9O!*B>\\M]4X^!Q C@5KA'U0
MZZ_8U3-T>)D2QO_"NO.- L@:8U7=!1.#FLOVRUX[';8"XL&>@+@+B#WO-I%G
M.6.6349:K4$[;T)S"U^JCR9R7+JFS*VF4TYQ=G+-N(9G)AJ$.V2FT4B*6P,?
M8=ZV"50!5Q63)1K@$FYQA0(2V!=W/$/+N# GA#!#S5?,J0ZWG"VXX/:-S!N(
M(X?W6*G&,)F;46BI'$<JS#KJTY9ZO(?Z((8[)6UEX(O,,?\3("0=>C'BC1C3
M^"#B#+-32 8?(([BP=-\!L=')P=@DU[CQ,,F_]=XHP,G-3O=<O@FX0&S1FLN
M2Y@RPPT\2;4PJ%=L(1!NY+*QSD7)C(*9O\X_;BD+W%BLS<\#',]ZCF>>X]D>
MCC>22#%![RQ3I5M3"NI\_MY"L6GAKDZUX$,/[N; :I(DZ?DH7.V@-.PI#0]2
M:F^=NR2%$W#E!73\-'7;F9%I29+MO#HM=+I%*(V3P6Y":4\H/4CH43-I"M1@
M%4V33#7NPB_9FVO2+@[I/Z)\/$^CZ"\2X=;CK5&7?D09\/#M.^ZM_12\;!__
MNWL[0N^8+KDT(+"@T.CT$^76[5AJ-U8M_2A8*$N#Q2\KFN2HG0.=%TK9S<8E
MZ/\;)K\!4$L#!!0    ( (P\?50B0I)_> (  ((&   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0T+GAM;(U5WV_:,!#^5ZRH#ZW4D5^0LBI$:F'3^C -0;L]
M3'LPR4&L.G9F.\#^^]E.B%((B)?$9]]W]]V7\R7><?$N<P"%]@5E<N+D2I6/
MKBO3' HL![P$ID_67!18:5-L7%D*P)D%%=0-/"]R"TR8D\1V;RZ2F%>*$@9S
M@615%%C\>P;*=Q/'=PX;"[+)E=EPD[C$&UB">BOG0EMN&R4C!3!).$,"UA/G
MR7^<1L;?.OPDL).=-3*5K#A_-\9+-G$\0P@HI,I$P/JUA2E0:@)I&G^;F$Z;
MT@"[ZT/TK[9V7<L*2YAR^HMD*I\X8P=EL,8550N^^P9-/2,3+^54VB?:-;Z>
M@])**EXT8,V@(*Q^XWVC0P?@#\\ @@807 L(&T!H"ZV9V;)F6.$D%GR'A/'6
MT<S":F/1NAK"S%=<*J%/B<:I9"Z@Q"1#7_:Z+R1(A%F&?J@<!)I60@!3Z$E*
M4!)]0DO=0EE% ?$UNAYW.P.%"95W.L+;<H9N;^[0#2(,O>:\DAHF8U?I2@P?
M-VU8/]>L@S.L9Y .4.C?H\ +_![X]'JX]Q'N:OU:$8-6Q,#&"Z\3L:-%K<%]
MJ\GOIY540O?NGPMIPS9M:-,.SZ1]8;(2F*70)V -'5FHN<K;Q'^(PMC==F4Z
M=1JW'A\H#5M*PXN4%B !BS2W$F2PU5.BU'=>]3&L(T6=Y)'_N3_]J$T_NIC>
MBMZ7:W22:SP\TN+4Q1_ULXE:-M%%-J]<8=K>%.C>%&Z[(VVZ MLNZ>,=G7R@
M8!A%1\Q[G,(CYFYG0ICI_!V+#6$245AKD#=XT&A13[S:4+RT0V/%E1Y!=IGK
MGP0(XZ#/UYRK@V'F4/O;2?X#4$L#!!0    ( (P\?51=X28V" ,  '(*   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;+U6WT_;,!#^5ZR(!Y *B9/T
M%VHKC79H2&RK*&P/TQ[<Q&DLG#C83@O[ZV<[(0UM")T$>VELY[Z[[[Z<KS?:
M,'XO8HPE>$QH*L96+&5V;MLBB'&"Q!G+<*K>1(PG2*HM7]DBXQB%!I10VW6<
MGIT@DEJ3D3F;\\F(Y9*2%,\Y$'F2(/YT@2G;C"UH/1_<D%4L]8$]&65HA1=8
MWF5SKG9VY24D"4X%82G@.!I;G^#Y%/H:8"Q^$+P1M370J2P9N]>;JW!L.9H1
MICB0V@52CS6>8DJU)\7CH71J53$UL+Y^]GYIDE?)+)' 4T9_DE#&8VM@@1!'
M**?RAFV^X#*AKO87,"K,+]B4MHX%@EQ(EI1@Q2 A:?%$CZ40-8!*M!G@E@#W
M4(!7 CR3:,',I#5#$DU&G&T U];*FUX8;0Q:94-2_1D7DJNW1.'D9,Y517#Y
M!% :@L\/.<G4-Y(=\$U5T"E8J*H)<XH!BT";Y?$,2T2H.%&8N\4,'!^=@"-
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MYZROT+P8<(J-9)F9$99,JHG#+&,U%&*N#=3[B#'YO-%C1S5F3OX"4$L#!!0
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M@7$.=+[2&K<;%Z ?G-EO4$L#!!0    ( (P\?53^>\9.O@(  %$'   9
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;(V576^;,!2&_XJ%>M%*6_E*H*E(
MI#;IM$F=%C7M=C'MPH%#L&IL9CL?_?>S#6%I(%%O@HW/>\[C-_8AV7+Q*@L
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M:,I&5.X6EVAH5Q .\Q\U&(ZBVK ;H&I8=LYN.39&H"!#EZV;W0B^$K)UGBX
MN9#VC,X^+A?L].2,G3!1L8>M;BRO"IN%2-)<@'#=R;AN9<0'9"Q@/6+)^!.+
MHW@\ )\?AR^A'K'XRQ \I(+T58G[JL2>+SG U]7B]]7*HJ&7]N<(9])S)IYS
M<H"3I,5#A6E14X]R/?><C].++'P>"#7I0TV.AGK0R"63_N9J_DI-AX-WTK*D
M!T*WA9^\DY<D%U$T+'#:"YP>%7@#UEXRKG13(<T"FC^6-+I7*%3=(!3TG!#(
MBT.RI^]DGR?#>M)>3_J!@I4-/7QP7294H[KZZ944&^Y&SF )TX';F_XG)MQK
M3S<:;[G9B,I2@))0T>@SP4T[;EH#=>T[=J61^M\OMS2AP;@#M%]JC6^&&P+]
MS,__ 5!+ P04    " ",/'U4^0\'SQ &  !H(   &0   'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6RU6EUSVC@4_2L:I@_M3 K6APWN$&822-MT^L$T[>[#
MSCXX1H"GML5*(K0[^^-7MA7+@"T[*>0AL4'WZ.K>JW./Y8QWC/\0:THE^)G$
MJ;CLK:7<O!D,1+BF22#Z;$-3]<V2\220ZI:O!F+#:;#(C9)X@!S'&R1!E/8F
MX_RS.9^,V5;&44KG'(AMD@3\US6-V>ZR!WN/'WR-5FN9?3"8C#?!BMY1^7TS
MY^IN4*(LHH2F(F(IX'1YV;N";SZ086:0C_@CHCM1N0;94NX9^Y'=W"XN>T[F
M$8UI*#.(0/UYH%,:QQF2\N,?#=HKY\P,J]>/Z&_SQ:O%W >"3EG\9[20Z\O>
MJ <6=!EL8_F5[=Y3O2 WPPM9+/+?8*?'.CT0;H5DB396'B116OP-?NI 5 PP
M:C! V@ =&"#88("U 3Z<8=A@0+0!Z6K@:@/WT*4F T\;>(<&I,%@J V&70U&
MVF!T:-"4!U\;^(>+;DR<\Y@Y)Z^@(N5YO<P"&4S&G.T S\8KO.PB+[K<7I5)
ME&;[XTYR]6VD[.1DRM('RF5T'U,P5Z5).:<+<"=9^ .\!E>+1925<1"#V[38
MC%E1OYQ1&42Q> 5>@ $0ZX!3 :(4?$\C*2[4A^KZVYIM19 NQ'@@E9_9;(-0
M^W1=^(0:?/H2RCYPX 5 #H(%>@W(M ,(UB#?[V;@Y8M7-2@S.\JG@!^AF#4W
M^G9C1_VPC1]1H=\=]:T==4;#(U\;L=YU2<&HP#*NU0"][Q! Q^T =-M]=4XC
MR(>VP*<*Q"D";X_X0&VD<C>A<C>A'!\WX'^CR89QU6? S3_;2/X"?WU4(\"M
MI(GXVX*/2WR<XY,&_,^J86XX"RE="+#D+ &1$-L@#2E@2Q!6]O*FW,LBW\O_
M@1=U>ZB8SLVGRUKIP\1UU,]X\%"MN^-1T(7N");#]A9#RL40ZV*^4N6MH-I!
ML8DC>:'74'3?C&SJV*. ]2ON.'WH#I$[)+C>);=TR;6Z=*L(+%)D-]_>QU$(
MOBQ5#*-TI:(W94FB?,J)T9)(KYS(.TNA#$O\H74A=UE% Q'DE1"I\MA07A1[
M5@FV;?AN>)QLKSZJH]*9D=T9%435(*Z I=E8UNR7T_AGB2ET3*]TVJ,J\CU'
M%[4$7=A[U=+<WTNW-4,0&B+B([<^RK#2RF&7.%\_,\[0L!P\#\U!PW/03G3M
MD<;MD;8-V??+4!:T<]8=#;=<<83R;;[EX5HI<W"UXI2J1P:IMM9OECHT1 7=
M\Z3 ,!3TSD0A-QHY*_4*1?M>I6/H;MT^<-][PW^P P%:"NA&VUOWH7:RP\A]
M+PTQ0CLSON-,"! &8GW2MGZCIW7W7*[V]7U_#<-"W]X?']T*F9"B<7;_*&"P
M:6YDR!?9R??4VN=&S[<7).@W.FIH&-EIN$;7J"=V$?)HDST]U2F:%D3X6CU[
MO?;ZV/4!/T:W"=>*<D7G46,:]RER#)D^@%KZP GX5@UKT'6VP)F6@,A9F!@9
MKD=V5?IYF]PK[E557JGL@M],@FI3XSZ1N9#I#JBE.YPU,=T%-S(= 0W/DR?#
MYLC.YE,+!XEJ/P+;C5I:2^Y&1[G#[A![KM^0.D/BR$[B'5/W7!F)#:-CYSQ/
MRX:*<8LB?K:&F6GD/6D"^QYQ1_ORX'V'@?O>&TK&=DINTS S;5^M$1]AUT-^
M0Y'@RD&#G7C/I$QFN.XLH5F:8$/#V*[,.TF3F0:I1HPTSFT(&K<0](FER4S/
M=W#BXC5Z:F@;VVG[&=JD!?'YV@0;ZL9V,?]L;:)QGZ)-L*%[W':L\?L\VKW1
M8</O^#SG(,00-[%+\9,V.G)\( (],D)DU'#L1 S]D[8#D9-DZ.GJD1B.)^<Y
M2B&&R4G+F?%SU2,Y/C^!#AE!I%+3D)G*T:^=K<LL"+"+Y!K,E]&_E%^H4(=]
M$*0+\)&NV'1-$W =,1%&5'&I*+[];8%"#*^3\QRR$,/'I,,ABZW%:_N])"#B
MNCYI:/'$L"JQL^K)NQ8Y/CI&CGO4M :5MY79._A/ 5]%J0 Q72H[IS]4 +QX
MK5W<2+;)7V#>,RE9DE^N:;"@/!N@OE\R)A]OLG>BY3\73/X'4$L#!!0    (
M (P\?535'\C%&0,  )\*   9    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM
M;)U66V^;,!C]*Q::M$W:PBWA4B61TM!I?:@6M=KV,.W! 2=8!4QMD[3[]?.%
MT%R )N4AL<UWCL_Q9^QOO"7TD:4(<?"<9P6;&"GGY95ILCA%.60#4J)"O%D1
MFD,NNG1MLI(BF"A0GIF.97EF#G%A3,=J;$&G8U+Q#!=H00&K\AS2EVN4D>W$
ML(W=P#U>IUP.F--Q"=?H ?&?Y8**GMFP)#A'!<.D !2M)L;,OHIL!5 1OS#:
MLKTVD%:6A#S*SFTR,2RI"&4HYI("BK\-FJ,LDTQ"QU--:C1S2N!^>\?^39D7
M9I:0H3G)?N.$IQ,C,$""5K#*^#W9?D>UH9'DBTG&U"_8ZE@O-$!<,4[R&BP4
MY+C0__"Y7H@]@.UU )P:X!P#AAT MP:XYP*&-6"H5D9;4>L000ZG8TJV@,IH
MP28;:C$56MC'A<S[ Z?B+18X/GW@)'Y,298@RCZ"FZ<*\Q?P%<R2!,N\P S<
M%GIWR2Q]BA"'.&.?1<@'8 *60HK8V.1"B>0SXWK6:SVKTS&K[8 [4O"4@9LB
M0<DA@2DL-#Z<G8]KIY<Q0O$ N/87X%B.W2)HW@__$?,!L().>'3^[%:/&[?)
MBJOXW Z^.@]_9DO&J?@T_O9P#AO.H>(<=G NQ >%*$4)8#+G7T )*=C K$*@
M1%2GLBV3FM57K/(4V4RM@66)1=KL+^]94=%;40?&1HVQT67&]*X$L.(IH?C?
M\?[2MC2GMR?%MO1SY.S<P.@TT&HWYC7&O'<9PXQ5[::\'@E:9%_$@4B_$>F_
M2Z2X8QB'18*+=9M2_TVE?1$'2H-&:="K=$[R7)QAEVR2X#3W8?LN.3LR.HT<
M6NYAX(&]L+$77FZO>ZN$)S)<QP^=P/./])X&.K;OAR.O7:YMO=X\UN6"W]@V
M->6A;/$$P?%1TQ)I.T'H#IT.W7LWIGVV;K A7$@%5)87[1=A/QDI4-O9;N[=
MZ#FB:U49,1"3JN#Z<F]&F^IKIFH.\S5<EVYWD*YQP4"&5@)J#7QQ3E%=#>D.
M)Z6J#Y:$BVI#-5-102(J \3[%2%\UY$3-#7I]#]02P,$%     @ C#Q]5#6K
ME1H\ P  K@P  !D   !X;"]W;W)K<VAE971S+W-H965T-3,N>&ULQ5==;],P
M%/TK5EX "9;8^49MI=&!F 1:M0EX0#QXR6UC+8F+[;3LWV.[69*1->*EZDL;
MQ_?CW'-R;YS9GHL'60 H]*<J:SEW"J6V[UU79@545%[P+=1Z9\U%195>BHTK
MMP)H;IVJTB6>%[D59;6SF-E[*[&8\4:5K(:50+*I*BH>/T#)]W,'.T\W;MFF
M4.:&NYAMZ0;N0'W;KH1>N5V4G%502\9K)& ]=R[Q^R5.C(.U^,Y@+P?7R)1R
MS_F#65SG<\<SB*"$3)D05/_M8 EE:2)I'+_;H$Z7TS@.KY^B?[+%ZV+NJ80E
M+W^P7!5S)W%0#FO:E.J6[S]#6U!HXF6\E/87[0^V<>R@K)&*5ZVS1E"Q^O!/
M_[1$#!QP<,2!M [D?QW\UL&WA1Z0V;*NJ**+F>![)(RUCF8N+#?66U?#:B/C
MG1)ZEVD_M;A3/'LH>)F#D*_0Q]\-4X_H'5KRJM(DVUUT"Q+$#G*DGQIT+65#
MZPS0ZRM0E)7RC3:7!14@9Z[2B$Q<-VNS?SAD)T>R7T%V@7S\%A&/X!?<E__O
M[CUW=S4/'1FD(X/8>/XQ,G23Y$T)Z&9]A ']Z*!/C6H$]$3\_*+#H&L%E?PU
M <+O0/@61' $1)M8VL1B2/WZD)BUB5^B^Q ZLJ%-!^\6"0E3'\<S=S?D=6P7
MQ#@A?MK9/<,>=-B#2>QW(!A(=*G9JW<@%+O79*YT8X(0N@A+Y@1%89<F/)].
M40<B.IE.RVC$OQ_&?A0>X3_N,,63F+YIUJ72,#012K!,/9&.;K9F:LJ)NI,N
M1W(^\M,.1'JZ)DE'Y$<X"=+@GQX9FR5)$F'RLD38ZR>N-]TD0T'0Y4X/46KZ
M9#A=)RC"@]&.SZ<4[H<J)J?3JHT]5 &3)"6#3FG?%&-#/PR3\(A:_33&T^/X
MN5HWC9**UCFK-U/<]/,2!V>4J)^G.#RA1.&(^3 E41J-)!H;$N+YB7]$HWX2
MX^E1_+':EOP1H.5NU8BLT$<[M"II/<5//U9Q?$:9^LF+DQ/*E(S?^20(TW\[
MQ!T<)LU)_BL5&Z8?_1+6VM&[B+6*XG X/BP4W]KSY3U7^K1J+PO]00'"&.C]
M->?J:6&.K-TGRN(O4$L#!!0    ( (P\?518AU$MW04  "T:   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;,U976_;-A3]*X31 2W06B+UZ2(Q$,?I
M&F 9@F99'XH]T!)M"Y5$EZ3L>-B/'T7)HFQ)K%MT71X2ZX/W\MS+>\\1I8L=
M99_YFA !GK(TYY>CM1";MY;%HS7),!_3#<GEG25E&1;RE*TLOF$$Q\HH2RUD
MV[Z5X20?32_4M7LVO:"%2).<W#/ BRS#;#\C*=U=CN#H<.%#LEJ+\H(UO=C@
M%7D@XG%SS^29U7B)DXSD/*$Y8&1Y.;J";V\<OS10(_Y,R(ZWCD$9RH+2S^7)
M;7PYLDM$)"61*%U@^;,EUR1-2T\2QY?:Z:B9LS1L'Q^\OU/!RV 6F)-KFGY,
M8K&^'(4C$),E+E+Q@>[>DSH@K_07T92K_V!7C[5'("JXH%EM+!%D25[]XJ<Z
M$2T#Y \8H-H G1A =\# J0V<<PW<VL ]U\"K#53H5A6[2MP<"SR]8'0'6#E:
M>BL/5/:5M<Q7DI>%\B"8O)M(.S%]$#3Z_&8F4QV#:YK)^N-8K> ;<!7'27F(
M4W";5R59WG@Y)P(G*7\EASP^S,'+%Z_ "V !OL:,<)#DX#%/!'\M+\KC/]:T
MX#B/^84E)-QR4BNJH<TJ:&@ &D3@CN9BS<%-'I/XV($EXVR"18=@9\CH<4ZB
M,7#@:X!L!'L 79]O;O>8S\\VAY,>\QNS^0/9C $*^L ?)<-I5MY1_IPA?^5Z
M@9Z5OV(,YRLBV4" V1ZTQ]WCO;I\M<,L!I]^DR[!K2 9_\L R&T N0J0.P#H
M]R);$ ;H$D0TRR20NJ+D'V%;.;NL0; L1"'A))P7.(](7U55L_AJEI(GM],0
M>1,'!A?6MKW8W7%N $/D3)IQ1V%X31B>,8R/BIM(_ 9O"9-<"Y8X86"+TX*4
ML=%-F60.5C+)XK2JJP J_V$+6##V3M%W!]EC'_5#]QOHOA'Z;2Y8(C4@ZL(E
M3X1%">\'7'GU6EA\V^Z'$C10 B.47QGE'!0Y(Q%=Y<G?<OFYHJJ%*L2H7;#D
MJ3SNK86@@\P)X1"VL,$6&K$]?@LJL*OK 1SJ 6>4"66[(2RAO1DU T!@3S#C
M -H@JQ@2N2#&>V[HPDD3W.3,+I1])\LA$E5@JB'+6!NBERW86P[S2:>Q)A/7
M]P:R#FTM5;81VL-W%$#M\J@VG0"=-%//*!@.P&TI*S3"?7?4]ZUL5FG<R@O]
M[53[;:/Q3@%WA[@#>)'&BXQX/VB$*M,5RYMJ"FJM@<]$;*!6&_ASY 9V=<2'
MH3MQ3Y>L1Y?"T(<#G VUWD"SX.A Z@AP(=:4*881%"R(#&E3L&BMLEK(9RD&
M<%V$^@[8I#COC<_KZF3HV4/MH;4&FL7F)[#H5Q! 1:/ KTG45%5:MJ!9MZ[;
M3+DI%JD44[I<2HCY"FQD>Y$2;[52?=Q9NS_6=1L.)%LK%C0KQG=19]@EQ99T
MUE7='83\ ;1:@J!9@WZ0^->SM+$%0]J/M HALPJ5C]_@YDN1B+W<%T62H>1.
M%]QWNN?8O58-!)\'4R(M#,@L##^**>MIVDP"43B1#^?'1773,] )/13:P<#B
M:1U"SO_)E?7L;>#(@Y[M#E6=5BMTKEK5P%NKH=#10G A-]J*9^2SNJP'29.]
M(,TS>6/;_L54-UJ8D%F8[O!3DA49R ?J1]7*(B5UG@];C-:VHQ=^5X^"P/9\
M./  A+0B(;,>E/OR;^]L+0TH>":=K64!F67AOVZ'L-O'+H03-+#%1EHAD%DA
MAI<*_ ,.=??ICI3AF5+E:-IW[.>Q>HZ6"L>\P?A1O%Q/<_2$9[O('7K&<[1R
M.&;EJ+0RVZ1T3TB]J[@_5,U7&LMIO<AZ)IL+1].U<RY=?^\N>N;TO)\:?NYV
M-"L[YVX7CJNFU?IEW1@+IF=+@%QOX@U@TPSLF!FXPT>&]/@=#*<B:[5>BV>$
MK=3W""[#+G)1O31NKC;?/*[4F_Z3ZS/X=EY]N=!NJ@\I=YBMDIR#E"RE2WL<
MR,RPZMM$=2+H1KU\7U A:*8.UP1+'BT'R/M+2L7AI)R@^4(T_1=02P,$%
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M0(Y,'-BY\PKL_4R6P8/>N'F?L#&EMT'X8GG1M>'T4K1IVK_E8,S]AU%3CV&
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M*3,\04NFC. :_8)F22)L'[(47>7E2+0]^N&"&R92_1&:W-]=H \_?3P;&LC
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M-MN@XG:D:ZQHI=!&<4>F*6-;&^1Y"%(R9DDRC147531/P]R#F:>Z<5)4^&#
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MLJOZPLAB^3O0Y6]8C_X'4$L#!!0    ( (P\?52U<6!\%@(  *HF   :
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M[01Z.^KM!'K[9+.;0&]'O9U ;T>]G4!O1[V=0&]'O9U ;T>]G4#O0+V#0.]
MO8- [T"]@T#O0+V#0.] O8- [YC\K"30.U#O(- [4.\@T#M0[R#0.U#O(- [
MH]Z90.^,>F<"O3/JG0GTSJAW)M [H]Z90.^,>N?OU+N.GX=2KSU?:WS^=U(]
MGN\MU\=?EE\G)R_4!>=T6U&?_P)02P,$%     @ C#Q]5-(T9!3L 0  !R8
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M#P72AP;IHP#IXQRDCPN0/BY!^N 3E$901.4HI'(44SD*JAQ%58["*D=QE:/
MRE%D%2BR"A19!8JL D56@2*K0)%5H,@J4&05*+(*%%DEBJP215:)(JM$D56B
MR"I19)4HLDH4626*K!)%5H4BJT*15:'(JE!D52BR*A19%8JL"D56A2*K0I%5
MH\BJ4635*+)J%%DUBJP:15:-(JM&D56CR*I19"U09"U09"U09"U09"U09"W^
M4]9G:Y=_'#\\\];4W2&?#?__FKT!4$L! A0#%     @ C#Q]5 =!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " ",/'U4[%'"%N\    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " ",/'U4F5R<(Q &  "<)P  $P
M        @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (P\
M?53:&Y3]'@<  +P<   8              " @0X(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " ",/'U4A @;T9\%   I%@  &
M        @(%B#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ C#Q]5 65?5VD P  3Q   !@              ("!-Q4  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( (P\?51 \O,D"P0  .,,   8
M              " @1$9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " ",/'U4\OM9>^P%  #S'   &               @(%2'0  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ C#Q]5 )"MI)K @
MD@4  !@              ("!=",  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( (P\?53_"V6LR 8  +H:   8              " @14F
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " ",/'U4+O[C
M,\ )  "+&   &               @($3+0  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ C#Q]5$=F>&AS(   $F4  !@
M ("!"3<  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( (P\
M?53#G (Z#@X  )\P   9              " @;)7  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ C#Q]5.=@<D%K!0  F T  !D
M         ("!]V4  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " ",/'U45QNDQSX%  "!#   &0              @(&9:P  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( (P\?53@-KV2F@(  -(%
M   9              " @0YQ  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ C#Q]5(NPUM[F @  9 8  !D              ("!WW,
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " ",/'U4SB;=
MT+$"   +!@  &0              @('\=@  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( (P\?51NI'AF!04  &X+   9
M  " @>1Y  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
MC#Q]5)"/3 <D!   )@L  !D              ("!('\  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " ",/'U4;8RWO]$$  ! "P  &0
M            @(%[@P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( (P\?52S_;QG' P  *XD   9              " @8.(  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ C#Q]5!0P4;XG"@
M8!H  !D              ("!UI0  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " ",/'U4D)/*E^P#  #A"   &0              @($T
MGP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( (P\?504
MI7D-\P4  &0.   9              " @5>C  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ C#Q]5)5L)HS/!   VPH  !D
M     ("!@:D  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (P\?50@:!79J (  +H%   9              "
M@47B  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ C#Q]
M5 (6L9V\ @  T@4  !D              ("!).4  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    " ",/'U4#L_4%[H"  #M!0  &0
M        @($7Z   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( (P\?526'VFKJP,  &,(   9              " @0CK  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ C#Q]5/D3^L3A @  V 4
M !D              ("!ZNX  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    " ",/'U4?'C>ER(%  !1#   &0              @($"\@
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( (P\?52,G0 5
M400  /\)   9              " @5OW  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ C#Q]5$22(D*O P  'P@  !D
M ("!X_L  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " ",
M/'U4)6(3 E0%   U%@  &0              @(')_P  >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( (P\?5369,"CQP,  &D-   9
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M970T,2YX;6Q02P$"% ,4    " ",/'U4DR7YV:D"  !U!P  &0
M    @($F&@$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M (P\?53(CU-CMP(  "<&   9              " @08= 0!X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ C#Q]5")"DG]X @  @@8  !D
M             ("!]!\! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    " ",/'U47>$F-@@#  !R"@  &0              @(&C(@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( (P\?5052.<75 (
M $0%   9              " @>(E 0!X;"]W;W)K<VAE971S+W-H965T-#8N
M>&UL4$L! A0#%     @ C#Q]5/Y[QDZ^ @  40<  !D              ("!
M;2@! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " ",/'U4
M7BV<X#T#   M"@  &0              @(%B*P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;%!+ 0(4 Q0    ( (P\?531 *TBL0,  ,$+   9
M      " @=8N 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%
M  @ C#Q]5!(@M?)O @  _P4  !D              ("!OC(! 'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " ",/'U4^0\'SQ &  !H(
M&0              @(%D-0$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+
M 0(4 Q0    ( (P\?535'\C%&0,  )\*   9              " @:L[ 0!X
M;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ C#Q]5#6KE1H\
M P  K@P  !D              ("!^SX! 'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6Q02P$"% ,4    " ",/'U46(=1+=T%   M&@  &0
M@(%N0@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( (P\
M?52KJ0?",@0  %$0   9              " @8)( 0!X;"]W;W)K<VAE971S
M+W-H965T-34N>&UL4$L! A0#%     @ C#Q]5!@%82-' P  - P  !D
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M=#8P+GAM;%!+ 0(4 Q0    ( (P\?51 YF#<?@,  )X+   9
M  " @?I= 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @
MC#Q]5&W@N._  @  '0<  !D              ("!KV$! 'AL+W=O<FMS:&5E
M=',O<VAE970V,BYX;6Q02P$"% ,4    " ",/'U4?G6$5T4#  #*"P  &0
M            @(&F9 $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4
M Q0    ( (P\?53W'>UG=@4  *(:   9              " @2)H 0!X;"]W
M;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ C#Q]5'(GFTB6 @
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M2P$"% ,4    " ",/'U4M7%@?!8"  "J)@  &@              @ $J>@$
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " ",/'U4TC1D
M%.P!   ')@  $P              @ %X? $ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     20!) /83  "5?@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>153</ContextCount>
  <ElementCount>338</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Organization and Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusiness</Role>
      <ShortName>Organization and Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureLicensingAgreements</Role>
      <ShortName>Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Joint Venture</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureJointVenture</Role>
      <ShortName>Joint Venture</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureRelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEvent1</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Organization and Nature of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Organization and Nature of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Related Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Related Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100410 - Disclosure - License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Joint Venture - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails</Role>
      <ShortName>Joint Venture - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Fair Value Measurements - Summary of Changes in Level 3 Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Changes in Level 3 Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Operating Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails</Role>
      <ShortName>Operating Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Operating Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Operating Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Operating Leases - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Operating Leases - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Stockholders' Equity - Common Stock Reserved for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock Reserved for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Components of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share - Summary of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Net Loss per Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Related Parties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails</Role>
      <ShortName>Related Parties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="pyxs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Subsequent Event (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails</Role>
      <ShortName>Subsequent Event (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEvent1</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="pyxs-20211231.htm">pyxs-20211231.htm</File>
    <File>pyxs-20211231.xsd</File>
    <File>pyxs-20211231_cal.xml</File>
    <File>pyxs-20211231_def.xml</File>
    <File>pyxs-20211231_lab.xml</File>
    <File>pyxs-20211231_pre.xml</File>
    <File>pyxs-ex21_1.htm</File>
    <File>pyxs-ex23_1.htm</File>
    <File>pyxs-ex31_1.htm</File>
    <File>pyxs-ex31_2.htm</File>
    <File>pyxs-ex32_1.htm</File>
    <File>pyxs-ex32_2.htm</File>
    <File>pyxs-ex4_1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img29677477_0.jpg</File>
    <File>img29677477_1.jpg</File>
    <File>img29677477_10.jpg</File>
    <File>img29677477_11.jpg</File>
    <File>img29677477_12.jpg</File>
    <File>img29677477_13.jpg</File>
    <File>img29677477_14.jpg</File>
    <File>img29677477_15.jpg</File>
    <File>img29677477_16.jpg</File>
    <File>img29677477_17.jpg</File>
    <File>img29677477_18.jpg</File>
    <File>img29677477_19.jpg</File>
    <File>img29677477_2.jpg</File>
    <File>img29677477_20.jpg</File>
    <File>img29677477_21.jpg</File>
    <File>img29677477_22.jpg</File>
    <File>img29677477_23.jpg</File>
    <File>img29677477_24.jpg</File>
    <File>img29677477_25.jpg</File>
    <File>img29677477_3.jpg</File>
    <File>img29677477_4.jpg</File>
    <File>img29677477_5.jpg</File>
    <File>img29677477_6.jpg</File>
    <File>img29677477_7.jpg</File>
    <File>img29677477_8.jpg</File>
    <File>img29677477_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="511">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>112
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pyxs-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "contextCount": 153,
   "dts": {
    "calculationLink": {
     "local": [
      "pyxs-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pyxs-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pyxs-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pyxs-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pyxs-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pyxs-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 500,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 9,
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 12
   },
   "keyCustom": 61,
   "keyStandard": 277,
   "memberCustom": 18,
   "memberStandard": 24,
   "nsprefix": "pyxs",
   "nsuri": "http://pyxisoncology.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:LicensingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Licensing Agreements",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureLicensingAgreements",
     "shortName": "Licensing Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:LicensingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Joint Venture",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureJointVenture",
     "shortName": "Joint Venture",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Fair Value Measurements",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Prepaid Expenses and Other Current Assets",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Property and Equipment, Net",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Operating Leases",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Convertible Preferred Stock",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock",
     "shortName": "Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Stockholders' Equity",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Stock-Based Compensation",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets (Unaudited)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
     "shortName": "Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Income Taxes",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Net Loss per Share",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Related Parties",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureRelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Commitments and Contingencies",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Subsequent Event",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEvent1",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:NatureOfBusinessPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:NatureOfBusinessPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical) (Unaudited)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited",
     "shortName": "Consolidated Balance Sheets (Parenthetical) (Unaudited)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_de03779b-38b4-48de-abf6-4dfbb5df89c9",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Operating Leases (Tables)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pyxs:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Income Taxes (Tables)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "pyxs:NatureOfBusinessPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Organization and Nature of Business - Additional Information (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
     "shortName": "Organization and Nature of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "pyxs:NatureOfBusinessPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pyxs:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_152d9614-3fcc-42d6-ad59-684db0e1410f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Related Assets (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Related Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pyxs:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_152d9614-3fcc-42d6-ad59-684db0e1410f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - License Agreements - Additional Information (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
     "shortName": "License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "pyxs:LicensingAgreementsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_a1a3afb5-1db0-4c36-83ed-2876af7a7097",
      "decimals": null,
      "lang": "en-US",
      "name": "pyxs:RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pyxs:ServiceFeeIncomeFromRelatedParty",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Joint Venture - Additional Information (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
     "shortName": "Joint Venture - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_2479e14f-6aa9-4a28-be71-a2c03d3cde43",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentAggregateCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_a4512320-e5eb-43ea-b73f-15322d518ab6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_a4512320-e5eb-43ea-b73f-15322d518ab6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_430de8ee-a6be-4373-9634-ddf883b01c5d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pyxs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Fair Value Measurements - Summary of Changes in Level 3 Fair Value Measurements (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements - Summary of Changes in Level 3 Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_430de8ee-a6be-4373-9634-ddf883b01c5d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pyxs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pyxs:SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pyxs:SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pyxs:NumberOfOperatingLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Lease",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Operating Leases - Additional Information (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
     "shortName": "Operating Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pyxs:NumberOfOperatingLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Lease",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Operating Leases - Components of Lease Expense (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails",
     "shortName": "Operating Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_5221cef4-195a-4dfd-95bb-66e798f30b97",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_5221cef4-195a-4dfd-95bb-66e798f30b97",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Operating Leases - Maturities of Lease Liabilities (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails",
     "shortName": "Operating Leases - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "pyxs:ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_4a74247c-2b25-4a52-afe0-244e457c4f7f",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Convertible Preferred Stock - Additional Information (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Convertible Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_c28b8bc5-5c32-45fe-b131-2c2fbbfa9d56",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Stockholders' Equity - Common Stock Reserved for Issuance (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
     "shortName": "Stockholders' Equity - Common Stock Reserved for Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_ffc2f537-c19b-4a4e-86aa-33adffaef56a",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_83f1f8d4-1a3f-42eb-89a4-fe5b4d42496e",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_044b8f28-1e2d-4d9a-ab46-6b36bf9f714c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_8e920cab-08bd-4853-a2c7-07b631b559f3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pyxs:TemporaryEquityIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_8e920cab-08bd-4853-a2c7-07b631b559f3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pyxs:TemporaryEquityIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Components of Net Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_cfa6104f-d54e-432d-8bca-e8247807eec0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss Per Share (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Net Loss per Share - Summary of Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Net Loss per Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss per Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Related Parties - Additional Information (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
     "shortName": "Related Parties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_3014eecd-3b62-49b1-859b-5132c70a7d8a",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_dca5bfc8-d2fa-4c60-8e05-95c561295a9b",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pyxs:UpfrontFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Subsequent Event (Additional Information) (Details)",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
     "shortName": "Subsequent Event (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_dca5bfc8-d2fa-4c60-8e05-95c561295a9b",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pyxs:UpfrontFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Organization and Nature of Business",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusiness",
     "shortName": "Organization and Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pyxs-20211231.htm",
      "contextRef": "C_19b30afc-5afa-40c6-8463-3498cd194d89",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 47,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pyxs_AccruedResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses current.",
        "label": "Accrued Research And Development Expenses Current",
        "terseLabel": "Accrued research and development expenses",
        "verboseLabel": "External research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_AggregateMaximumAmountPaidToRelatedParties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate maximum amount paid to related parties.",
        "label": "Aggregate maximum amount paid to related parties"
       }
      }
     },
     "localname": "AggregateMaximumAmountPaidToRelatedParties",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval.",
        "label": "Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval"
       }
      }
     },
     "localname": "AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate maximum obligation to pay future contingent milestone payments for normal approval.",
        "label": "Aggregate maximum obligation to pay future contingent milestone payments for normal approval"
       }
      }
     },
     "localname": "AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_AggregateMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate milestone payments.",
        "label": "Aggregate Milestone Payments",
        "terseLabel": "Aggregate milestone payments for first four licensed products"
       }
      }
     },
     "localname": "AggregateMilestonePayments",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_AgreementsWithPfizerIncAndLegochemBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreements with Pfizer, Inc. and LegoChem Biosciences Inc.",
        "label": "Agreements with Pfizer, Inc. and LegoChem Biosciences Inc. [Member]",
        "terseLabel": "Agreements with Pfizer, Inc. and LegoChem Biosciences Inc."
       }
      }
     },
     "localname": "AgreementsWithPfizerIncAndLegochemBiosciencesIncMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_AlloyTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alloy Therapeutics, Inc.",
        "label": "Alloy Therapeutics Inc [Member]",
        "terseLabel": "Alloy Therapeutics, Inc."
       }
      }
     },
     "localname": "AlloyTherapeuticsIncMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_AnnualLicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual license maintenance fees.",
        "label": "Annual License Maintenance Fees",
        "terseLabel": "Annual maintenance fee"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFees",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and summary of significant accounting policies.",
        "label": "Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and summary of significant accounting policies.",
        "label": "Basis Of Presentation And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Basis Of Presentation And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pyxs_BiosionLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biosion license agreement.",
        "label": "Biosion License Agreement"
       }
      }
     },
     "localname": "BiosionLicenseAgreementMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification and Accretion of Convertible Preferred Stock [Policy Text Block]",
        "label": "Classification and Accretion of Convertible Preferred Stock [Policy Text Block]",
        "terseLabel": "Classification and Accretion of Convertible Preferred Stock"
       }
      }
     },
     "localname": "ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_ContributedAmountToJointVentureByEachEntity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contributed amount to joint venture by each entity.",
        "label": "Contributed Amount to Joint Venture by Each Entity",
        "terseLabel": "Contributed amount to joint venture by each member"
       }
      }
     },
     "localname": "ContributedAmountToJointVentureByEachEntity",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_ConvertiblePreferredStockSharesIssuedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock shares issued value.",
        "label": "Issuance of convertible preferred stock value"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedValue",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_DeferredTaxAssetsLicenseFee": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets license fees.",
        "label": "License fees"
       }
      }
     },
     "localname": "DeferredTaxAssetsLicenseFee",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Lease Right-of-Use Assets",
        "label": "Deferred Tax Liabilities, Operating Lease Right-of-Use Assets",
        "negatedLabel": "Operating lease right-of-use assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation permanent differences.",
        "label": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pyxs_ExtraMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extra milestone payment.",
        "label": "Extra Milestone Payment",
        "terseLabel": "Extra milestone payment"
       }
      }
     },
     "localname": "ExtraMilestonePayment",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extra milestone payment for which derivative liability recognized.",
        "label": "Extra Milestone Payment for Which Derivative Liability Recognized",
        "terseLabel": "Extra milestone payment for which derivative liability recognized"
       }
      }
     },
     "localname": "ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability initial recognition of derivative liability.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Initial Recognition Of Derivative Liability",
        "terseLabel": "Initial recognition of derivative liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfDerivativeLiability",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability transfer to accounts payable.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfer to Accounts Payable",
        "negatedLabel": "Transfer to accounts payable"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransferToAccountsPayable",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture and office equipment.",
        "label": "Furniture and Office Equipment [Member]",
        "terseLabel": "Furniture and Office Equipment"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_GrossProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance initial public offering.",
        "label": "Gross Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Gross proceeds from issuance of initial public offering"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_GrossProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance of convertible preferred stock.",
        "label": "Gross Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Gross cash proceeds from issuance of convertible preferred stock"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_InitialPublicOfferingPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering.",
        "label": "Initial Public Offering Policy [Text Block]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "InitialPublicOfferingPolicyTextBlock",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_IssuanceOfConvertiblePreferredStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of convertible preferred stock shares.",
        "label": "Issuance Of Convertible Preferred Stock Shares",
        "terseLabel": "Issuance of Series B convertible preferred stock, Shares",
        "verboseLabel": "Issuance of convertible preferred stock shares"
       }
      }
     },
     "localname": "IssuanceOfConvertiblePreferredStockShares",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pyxs_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_LeaseExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration year.",
        "label": "Lease Expiration Year",
        "terseLabel": "Operating lease terms expiration year"
       }
      }
     },
     "localname": "LeaseExpirationYear",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pyxs_LegoChemLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LegoChem license agreement.",
        "label": "Lego Chem License Agreement [Member]",
        "terseLabel": "LegoChem License Agreement"
       }
      }
     },
     "localname": "LegoChemLicenseAgreementMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_LicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements.",
        "label": "License Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAgreementsAbstract",
     "nsuri": "http://pyxisoncology.com/20211231",
     "xbrltype": "stringItemType"
    },
    "pyxs_LicensingAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing agreements.",
        "label": "Licensing Agreements [Text Block]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsTextBlock",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureLicensingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity Policy [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_MaximumAmountPaidToRelatedParties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount paid to related parties.",
        "label": "Maximum Amount Paid To Related Parties",
        "terseLabel": "Maximum amount paid to board members"
       }
      }
     },
     "localname": "MaximumAmountPaidToRelatedParties",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of common shares issuable under exercise of options.",
        "label": "Maximum Number of Common Shares Issuable Under Exercise of Options",
        "terseLabel": "Maximum number of common shares issuable under exercise of options"
       }
      }
     },
     "localname": "MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pyxs_MilestoneAndRoyaltiesIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone and royalties incurred.",
        "label": "Milestone and Royalties Incurred",
        "terseLabel": "Milestone and royalties required"
       }
      }
     },
     "localname": "MilestoneAndRoyaltiesIncurred",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_MilestonePaymentsPayableUponCertainAchievements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments payable upon certain achievements.",
        "label": "Milestone Payments Payable Upon Certain Achievements",
        "terseLabel": "Milestone payments payable upon certain achievements"
       }
      }
     },
     "localname": "MilestonePaymentsPayableUponCertainAchievements",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_MinimumAnnualRoyaltyFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum annual royalty fees.",
        "label": "Minimum Annual Royalty Fees",
        "terseLabel": "Minimum annual royalty fees"
       }
      }
     },
     "localname": "MinimumAnnualRoyaltyFees",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_NatureOfBusinessPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of Business.",
        "label": "Nature Of Business Policy [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfBusinessPolicyTextBlock",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_NonCashGainLossFromEquityMethodInvestmentInJointVenture": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash gain (loss) from equity method investment in joint venture.",
        "label": "Non-cash Gain (Loss) from Equity Method Investment in Joint Venture",
        "negatedLabel": "Non-cash loss from equity method investment in joint venture"
       }
      }
     },
     "localname": "NonCashGainLossFromEquityMethodInvestmentInJointVenture",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issued upon conversion of preferred stock.",
        "label": "Number of Common Shares Issued Upon Conversion of Preferred Stock",
        "terseLabel": "Number of common shares issued upon conversion of preferred stock"
       }
      }
     },
     "localname": "NumberOfCommonSharesIssuedUponConversionOfPreferredStock",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pyxs_NumberOfFinanceLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of finance lease.",
        "label": "Number of finance lease",
        "terseLabel": "Number of finance lease"
       }
      }
     },
     "localname": "NumberOfFinanceLease",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pyxs_NumberOfOperatingLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating lease.",
        "label": "Number Of Operating Lease",
        "terseLabel": "Number of operating lease"
       }
      }
     },
     "localname": "NumberOfOperatingLease",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pyxs_OneTimeMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One-time milestone payment.",
        "label": "One-time Milestone Payment",
        "terseLabel": "One-time payment"
       }
      }
     },
     "localname": "OneTimeMilestonePayment",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_OperatingLossCarryforwardsBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards before tax.",
        "label": "Operating Loss Carryforwards Before Tax",
        "terseLabel": "Operating loss carryforwards before tax"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsBeforeTax",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pyxs_PaymentForLicenseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for license fee.",
        "label": "Payment for License Fee",
        "terseLabel": "Payment for license fee"
       }
      }
     },
     "localname": "PaymentForLicenseFee",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_PaymentsToRelatedPartiesPerMonth": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to related parties per month.",
        "label": "Payments To Related Parties Per Month",
        "terseLabel": "Payments to board members per month"
       }
      }
     },
     "localname": "PaymentsToRelatedPartiesPerMonth",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_PfizerLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer license agreement.",
        "label": "Pfizer License Agreement [Member]",
        "terseLabel": "Pfizer License Agreement"
       }
      }
     },
     "localname": "PfizerLicenseAgreementMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_PotentialDevelopmentAndCommercialMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development and commercial milestone payment.",
        "label": "Potential Development and Commercial Milestone Payment",
        "terseLabel": "Potential development and commercial milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentAndCommercialMilestonePayment",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_ProceedsFromPromissoryNoteIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from promissory note issued.",
        "label": "Proceeds From Promissory Note Issued",
        "terseLabel": "Promissory note issued"
       }
      }
     },
     "localname": "ProceedsFromPromissoryNoteIssued",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently issued accounting pronouncements not yet adopted policy.",
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_RentIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent increase percentage.",
        "label": "Rent Increase Percentage",
        "terseLabel": "Rent increase percentage"
       }
      }
     },
     "localname": "RentIncreasePercentage",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pyxs_ResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development current.",
        "label": "Research and Development Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCurrent",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development licensed product estimated cost.",
        "label": "Licensed product estimated cost"
       }
      }
     },
     "localname": "ResearchAndDevelopmentLicensedProductEstimatedCost",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and Uncertainties [Policy Text Block]",
        "label": "Risks and Uncertainties [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty obligation period for licensed products upon first commercial sale.",
        "label": "Royalty Obligation Period For Licensed Products Upon First Commercial Sale",
        "terseLabel": "Royalty obligation period for licensed products upon first commercial sale"
       }
      }
     },
     "localname": "RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common stock reserved for future issuance.",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Line Items]",
        "terseLabel": "Schedule Of Common Stock Reserved For Future Issuance [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceLineItems",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common stock reserved for future issuance.",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table]",
        "terseLabel": "Schedule Of Common Stock Reserved For Future Issuance [Table]"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTable",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common stock reserved for future issuance.",
        "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]",
        "terseLabel": "Common Stock Reserved for Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of estimated useful lives of property and equipment.",
        "label": "Schedule of Estimated Useful Lives of Property and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Estimated Useful Lives of Property and Equipment"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_ScientificAdvisoryBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scientific advisory board.",
        "label": "Scientific Advisory Board [Member]",
        "terseLabel": "Scientific Advisory Board"
       }
      }
     },
     "localname": "ScientificAdvisoryBoardMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities purchase agreement.",
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities Purchase Agreement"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_SeriesAConvertiblePreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A convertible preferred stocks.",
        "label": "Series A Convertible Preferred Stocks [Member]",
        "terseLabel": "Series A Convertible Preferred Stock",
        "verboseLabel": "Series A"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStocksMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_SeriesBConvertiblePreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B convertible preferred stocks.",
        "label": "Series B Convertible Preferred Stocks [Member]",
        "terseLabel": "Series B Convertible Preferred Stock",
        "verboseLabel": "Series B"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStocksMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_ServiceFeeIncomeFromRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service fee income from related party.",
        "label": "Service Fee Income From Related Party",
        "terseLabel": "Service fee income from related party"
       }
      }
     },
     "localname": "ServiceFeeIncomeFromRelatedParty",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pyxs_StockIssuanceExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issuance expenses.",
        "label": "Stock Issuance Expenses",
        "terseLabel": "Stock issuance expenses"
       }
      }
     },
     "localname": "StockIssuanceExpenses",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_StockOptionsAvailableForIssuanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options available for issuance.",
        "label": "Stock Options Available For Issuance [Member]",
        "terseLabel": "Stock Options Available for Issuance"
       }
      }
     },
     "localname": "StockOptionsAvailableForIssuanceMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_SublicensingRevenuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicensing revenue percentage.",
        "label": "Sublicensing Revenue Percentage",
        "terseLabel": "Sublicensing revenue percentage"
       }
      }
     },
     "localname": "SublicensingRevenuePercentage",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pyxs_SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of accrued expenses and other current liabilities.",
        "label": "Summary of Accrued Expenses and Other Current Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pyxs_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Credit carryovers expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity convertible preferred stock converted into common stock value.",
        "label": "Temporary Equity Convertible Preferred Stock Converted into Common Stock Value",
        "terseLabel": "Temporary equity, Conversion of Series A and Series B convertible preferred stock into shares of common stock"
       }
      }
     },
     "localname": "TemporaryEquityConvertiblePreferredStockConvertedIntoCommonStockValue",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity convertible preferred stock converted into shares of common stock.",
        "label": "Temporary Equity Convertible Preferred Stock Converted into Shares of Common Stock",
        "terseLabel": "Temporary equity, Conversion of Series A and Series B convertible preferred stock into shares of common stock (Shares)"
       }
      }
     },
     "localname": "TemporaryEquityConvertiblePreferredStockConvertedIntoSharesOfCommonStock",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pyxs_TemporaryEquityIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity issuance costs.",
        "label": "Temporary Equity Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityIssuanceCosts",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series B convertible preferred stock, Shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pyxs_TwoThousandNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen equity incentive plan.",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one employee stock purchase plan.",
        "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_TwoThousandTwentyOneEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one equity incentive plan.",
        "label": "Two Thousand Twenty One Equity Incentive Plan [Member]",
        "terseLabel": "2021 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEquityIncentivePlanMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_UnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts and commissions.",
        "label": "Underwriting discounts and commissions",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "UnderwritingDiscountsAndCommissions",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_UniversityLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University license agreement.",
        "label": "University License Agreement [Member]",
        "terseLabel": "University License Agreement"
       }
      }
     },
     "localname": "UniversityLicenseAgreementMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_UnvestedRestrictedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted stock.",
        "label": "Unvested Restricted Stock [Member]",
        "terseLabel": "Unvested Restricted Stock"
       }
      }
     },
     "localname": "UnvestedRestrictedStockMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pyxs_UpfrontFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fee.",
        "label": "Upfront Fee",
        "terseLabel": "Upfront fee"
       }
      }
     },
     "localname": "UpfrontFee",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_UpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments.",
        "label": "Upfront Payments",
        "terseLabel": "Upfront payments"
       }
      }
     },
     "localname": "UpfrontPayments",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pyxs_VoxallMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voxall.",
        "label": "Voxall [Member]",
        "terseLabel": "Voxall"
       }
      }
     },
     "localname": "VoxallMember",
     "nsuri": "http://pyxisoncology.com/20211231",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investee Name [Domain]",
        "terseLabel": "Investment, Name"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r189",
      "r200",
      "r228",
      "r229",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r436",
      "r437",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r189",
      "r200",
      "r228",
      "r229",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r436",
      "r437",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r189",
      "r200",
      "r218",
      "r228",
      "r229",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r436",
      "r437",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r189",
      "r200",
      "r218",
      "r228",
      "r229",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r436",
      "r437",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Equity Method Investment Equity Method Investee Name [Axis]",
        "terseLabel": "Investment, Name"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202001Member": {
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-01 Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the Emerging Issues Task Force).",
        "label": "Accounting Standards Update 2020-01 [Member]",
        "terseLabel": "ASU 2020-01"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202001Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r37",
      "r398"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r39"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r35",
      "r165"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r24",
      "r269",
      "r398"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r266",
      "r267",
      "r268",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r89",
      "r90",
      "r91",
      "r92",
      "r101",
      "r139",
      "r140",
      "r151",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r177",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r299",
      "r300",
      "r301",
      "r302",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r387",
      "r414",
      "r415",
      "r416",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r230",
      "r232",
      "r272",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r232",
      "r258",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r80",
      "r130",
      "r132",
      "r136",
      "r146",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r317",
      "r321",
      "r350",
      "r396",
      "r398",
      "r418",
      "r426"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r12",
      "r46",
      "r80",
      "r146",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r317",
      "r321",
      "r350",
      "r396",
      "r398"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "terseLabel": "Assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r233",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalUnitsAuthorized": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.",
        "label": "Capital Units, Authorized",
        "terseLabel": "Capital stock authorized"
       }
      }
     },
     "localname": "CapitalUnitsAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r31",
      "r72"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r17",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r67",
      "r72",
      "r77"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r67",
      "r72",
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r67",
      "r360"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental schedule of noncash operating and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r85",
      "r86",
      "r88",
      "r139",
      "r140",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r177",
      "r262",
      "r263",
      "r264",
      "r299",
      "r327",
      "r328",
      "r329",
      "r351",
      "r353",
      "r354",
      "r355",
      "r358",
      "r359",
      "r369",
      "r387",
      "r414",
      "r415",
      "r438",
      "r439",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in accounting principle, accounting standards update, adopted [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r85",
      "r86",
      "r95",
      "r139",
      "r140",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r177",
      "r262",
      "r263",
      "r264",
      "r299",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r351",
      "r353",
      "r354",
      "r355",
      "r358",
      "r359",
      "r369",
      "r387",
      "r414",
      "r415",
      "r438",
      "r439",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r89",
      "r100",
      "r141",
      "r155",
      "r269",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change in accounting principle, accounting standards update, immaterial effect [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r78",
      "r80",
      "r102",
      "r103",
      "r104",
      "r106",
      "r108",
      "r114",
      "r115",
      "r116",
      "r146",
      "r178",
      "r182",
      "r183",
      "r184",
      "r187",
      "r188",
      "r197",
      "r198",
      "r202",
      "r206",
      "r350",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r174",
      "r420",
      "r431"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 16)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r175",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r176",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common stock issuable upon conversion",
        "terseLabel": "Common stock reserved for future issuance",
        "verboseLabel": "Number of common shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23",
      "r398"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.001 par value per share; 190,000,000 and 40,300,000 shares authorized as of December 31, 2021 and 2020, respectively; 32,792,867 and 2,177,956 shares issued as of December 31, 2021 and 2020, respectively and 32,222,881 and 1,289,342 shares outstanding at December 31, 2021 and 2020, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "verboseLabel": "Common stock, issued value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock Voting Rights",
        "terseLabel": "Common stock, authorized (in shares)",
        "verboseLabel": "Common stock voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r119",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion Of Stock Shares Converted1",
        "terseLabel": "Stock automatically converted",
        "verboseLabel": "Number of preferred shares conversion"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r197",
      "r198",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r36",
      "r190",
      "r368"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Underwriting commission and issuance costs",
        "totalLabel": "Debt Issuance Costs, Net, Total"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r70",
      "r81",
      "r296",
      "r306",
      "r307",
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDerivativeInstruments": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.",
        "label": "Deferred Tax Assets, Derivative Instruments",
        "terseLabel": "Derivative"
       }
      }
     },
     "localname": "DeferredTaxAssetsDerivativeInstruments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Total gross deferred tax assets",
        "negatedTotalLabel": "Total gross deferred tax assets",
        "totalLabel": "Total deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Net deferred tax assets",
        "negatedTotalLabel": "Total deferred tax assets",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating losses",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r293",
      "r294",
      "r295"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Tax credit carryforwards",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Stock based compensation",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Reserves and accruals",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Valuation allowance",
        "negatedLabel": "Less: valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "verboseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r70",
      "r127"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments Liabilities [Member]",
        "terseLabel": "Derivative Liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Change in fair value of derivative liability",
        "totalLabel": "Derivative, Gain (Loss) on Derivative, Net, Total"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liabilities",
        "terseLabel": "Derivative liability",
        "totalLabel": "Derivative Liability, Total"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per common share, basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total",
        "verboseLabel": "Net loss per common share - basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Diluted Other Disclosures [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective income tax rate%",
        "terseLabel": "Effective tax rate from continuing operations",
        "totalLabel": "Effective income tax rate%",
        "verboseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r82",
      "r281",
      "r309"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Income tax computed at federal statutory rate%"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r281",
      "r309"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r281",
      "r309"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r281",
      "r309"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Research and development credit carryovers"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation and benefits",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Unrecognized stock-based compensation expense weighted average amortized period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Gross unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Gross unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "verboseLabel": "ESPP Withholdings"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options Outstanding"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r53",
      "r54",
      "r55",
      "r85",
      "r86",
      "r87",
      "r90",
      "r97",
      "r99",
      "r113",
      "r154",
      "r212",
      "r214",
      "r266",
      "r267",
      "r268",
      "r301",
      "r302",
      "r336",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r440",
      "r441",
      "r442",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment Aggregate Cost",
        "terseLabel": "Initial contribution"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the principal activities of an investee accounted for under the equity method.",
        "label": "Equity Method Investment Description Of Principal Activities",
        "terseLabel": "Equity method investment, description"
       }
      }
     },
     "localname": "EquityMethodInvestmentDescriptionOfPrincipalActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment Ownership Percentage",
        "terseLabel": "Percentage of voting membership units"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments And Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments Disclosure [Text Block]",
        "terseLabel": "Joint Venture"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureJointVenture"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]",
        "terseLabel": "Summary of Financial Instruments Carried at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r191",
      "r193",
      "r194",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r340",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r345",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Fair Value By Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r339",
      "r340",
      "r342",
      "r343",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r191",
      "r219",
      "r220",
      "r225",
      "r227",
      "r340",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r191",
      "r193",
      "r194",
      "r219",
      "r220",
      "r225",
      "r227",
      "r340",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r191",
      "r193",
      "r194",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r340",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r344",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r344",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]",
        "terseLabel": "Summary of Changes in Level 3 Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease",
        "terseLabel": "Change in fair value recorded in earnings",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value",
        "periodEndLabel": "Balance as of December 31, 2021",
        "periodStartLabel": "Derivative liability balance as of January 1, 2021",
        "terseLabel": "Derivative liability balance at the beginning of the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r191",
      "r193",
      "r194",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3FairValueMeasurementsDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r345",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Office Equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r70",
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r161",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r80",
      "r89",
      "r130",
      "r131",
      "r134",
      "r135",
      "r137",
      "r146",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r316",
      "r338",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest",
        "negatedLabel": "Losses incurred",
        "totalLabel": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r56",
      "r70",
      "r128",
      "r142",
      "r421",
      "r432"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Loss from equity method investment in joint venture",
        "totalLabel": "Income (Loss) from Equity Method Investments, Total"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r167",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r284",
      "r285",
      "r287",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r282",
      "r286",
      "r292",
      "r304",
      "r310",
      "r312",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r83",
      "r98",
      "r99",
      "r129",
      "r280",
      "r305",
      "r311",
      "r435"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Current income tax expenses (benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r278",
      "r279",
      "r286",
      "r287",
      "r291",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Increase in deferred tax assets valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r69",
      "r379"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r60",
      "r126"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r144",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investment in Joint Venture"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r383",
      "r385"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total lease costs",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "terseLabel": "Future minimum lease obligations",
        "totalLabel": "Total lease payments",
        "verboseLabel": "Future undiscounted operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: amount representing imputed interest",
        "terseLabel": "Less: amount representing imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r80",
      "r133",
      "r146",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r318",
      "r321",
      "r322",
      "r350",
      "r396",
      "r397"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r80",
      "r146",
      "r350",
      "r398",
      "r419",
      "r429"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities, Convertible Preferred Stock and Stockholders\u2019 Deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r80",
      "r146",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r318",
      "r321",
      "r322",
      "r350",
      "r396",
      "r397",
      "r398"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities Fair Value Disclosure",
        "terseLabel": "Liabilities measured at fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r67",
      "r68",
      "r71"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r50",
      "r51",
      "r55",
      "r57",
      "r71",
      "r80",
      "r89",
      "r93",
      "r94",
      "r95",
      "r96",
      "r98",
      "r99",
      "r105",
      "r130",
      "r131",
      "r134",
      "r135",
      "r137",
      "r146",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r338",
      "r350",
      "r422",
      "r433"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other (expense) income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r130",
      "r131",
      "r134",
      "r135",
      "r137"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r376",
      "r385"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "negatedLabel": "Non-cash lease expense",
        "terseLabel": "Operating lease, rent expense",
        "verboseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r371"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total future minimum lease obligations",
        "totalLabel": "Total future minimum leases obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r371"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Current portion of Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r371"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r373",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities, included in operating cash flows"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r382",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r381",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating loss carryforward",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Nature of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r39"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r45",
      "r398"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets, noncurrent",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "negatedLabel": "Payment of deferred offering costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInJointVenture": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.",
        "label": "Payments to Acquire Interest in Joint Venture",
        "negatedLabel": "Investment in joint venture"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInJointVenture",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r233",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion of preferred stock.",
        "label": "Preferred Stock Convertible Shares Issuable",
        "terseLabel": "Convertible preferred stock shares issued upon conversion",
        "verboseLabel": "Common Stock Issuable Upon Conversion (pre-reverse stock split)"
       }
      }
     },
     "localname": "PreferredStockConvertibleSharesIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r22",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r22",
      "r398"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, par value $0.001 per share, 10,000,000 and zero shares authorized as of December 31, 2021 and 2020, respectively, zero shares issued and outstanding at December 31, 2021 and 2020",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r10",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Total Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r8",
      "r11",
      "r159",
      "r160"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid Expense, Current, Total"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r9",
      "r11",
      "r158",
      "r160"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance Initial Public Offering",
        "terseLabel": "Net proceeds from issuance initial public offering",
        "verboseLabel": "Proceeds from issuance of common stock in initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock in initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds From Issuance Of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of Series B convertible preferred stock, net of issuance costs",
        "verboseLabel": "Net proceeds from issuance of convertible preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r64",
      "r261"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options",
        "verboseLabel": "Proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r50",
      "r51",
      "r55",
      "r66",
      "r80",
      "r89",
      "r98",
      "r99",
      "r130",
      "r131",
      "r134",
      "r135",
      "r137",
      "r146",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r316",
      "r319",
      "r320",
      "r323",
      "r324",
      "r338",
      "r350",
      "r423"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r35",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r169",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Estimated useful lives of related assets, description"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r34",
      "r164"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r18",
      "r19",
      "r166",
      "r398",
      "r424",
      "r430"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r166",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r18",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of Estimated Useful Lives of Related Assets",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r18",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of related assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r226",
      "r390",
      "r391",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.",
        "label": "Related Party Transaction, Other Revenues from Transactions with Related Party",
        "terseLabel": "Recognized service fee as other income"
       }
      }
     },
     "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction Purchases From Related Party",
        "terseLabel": "Payments to purchase licensed products"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r388",
      "r389",
      "r391",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research And Development Arrangement Contract To Perform For Others [Line Items]",
        "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r275",
      "r412",
      "r458"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development",
        "terseLabel": "Research and development expense",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Amended license agreement amount incurred"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development",
        "verboseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research And Development In Process",
        "terseLabel": "Non-cash research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r77",
      "r417",
      "r427"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r7",
      "r17",
      "r77"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested Restricted Stock Options",
        "verboseLabel": "Restricted Stock Awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock Shares Issued Net Of Shares For Tax Withholdings",
        "terseLabel": "Number of restricted common stock shares issued"
       }
      }
     },
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r214",
      "r269",
      "r398",
      "r428",
      "r444",
      "r449"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r85",
      "r86",
      "r87",
      "r90",
      "r97",
      "r99",
      "r154",
      "r266",
      "r267",
      "r268",
      "r301",
      "r302",
      "r336",
      "r440",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r380",
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use asset obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Components of Net Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Summary of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r232",
      "r257",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r232",
      "r257",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule Of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r5",
      "r80",
      "r145",
      "r146",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule Of Equity Method Investments [Table]",
        "terseLabel": "Schedule Of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r35",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfRelatedAssetsDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]",
        "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r233",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r238",
      "r248",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Number of Shares, Cancelled",
        "negatedLabel": "Number of Shares, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Outstanding, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Number of Shares, Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Outstanding, Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Number of Shares, Outstanding, at December 31, 2021",
        "periodStartLabel": "Number of Shares, Outstanding, at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding, at December 31, 2021",
        "periodStartLabel": "Weighted Average Grant ate fair value, Outstanding, at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Number of Shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Outstanding, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Number of common shares authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of Shares, Exercisable at December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable at December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of Shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding, Ending Balance",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding, Beginning Balance",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r240",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Shares, Outstanding at December 31, 2021",
        "periodStartLabel": "Number of Shares, Outstanding at December 31, 2020",
        "terseLabel": "Number of shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding at December 31, 2021",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Number of shares of common stock outstanding percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r231",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r233",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r254",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable at December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable at December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of restricted stock vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Common stock public offering price per share",
        "verboseLabel": "Share sale price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r377",
      "r385"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r78",
      "r80",
      "r102",
      "r103",
      "r104",
      "r106",
      "r108",
      "r114",
      "r115",
      "r116",
      "r146",
      "r178",
      "r182",
      "r183",
      "r184",
      "r187",
      "r188",
      "r197",
      "r198",
      "r202",
      "r206",
      "r212",
      "r350",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r44",
      "r53",
      "r54",
      "r55",
      "r85",
      "r86",
      "r87",
      "r90",
      "r97",
      "r99",
      "r113",
      "r154",
      "r212",
      "r214",
      "r266",
      "r267",
      "r268",
      "r301",
      "r302",
      "r336",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r440",
      "r441",
      "r442",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r113",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r43",
      "r192",
      "r212",
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Series A and Series B convertible preferred stock into shares of common stock (Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r212",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock (Shares)",
        "verboseLabel": "Stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r212",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Gross",
        "terseLabel": "Vesting of restricted common stock (Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r23",
      "r212",
      "r214",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of Shares, Exercised",
        "terseLabel": "Stock options exercised (Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r44",
      "r212",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Series A and Series B convertible preferred stock into shares of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r212",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r22",
      "r23",
      "r212",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r44",
      "r212",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "terseLabel": "Number of shares authorized to be repurchased under a stock repurchase plan"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r26",
      "r27",
      "r80",
      "r138",
      "r146",
      "r350",
      "r398"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r198",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r214",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders Equity Note Stock Split Conversion Ratio1",
        "terseLabel": "Reverse stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders Equity Policy [Text Block]",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split description"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r367",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r367",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r367",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r367",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r399",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEvent1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Credit carryovers"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r16",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity By Class Of Stock [Table]",
        "terseLabel": "Temporary Equity By Class Of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r178",
      "r182",
      "r183",
      "r184",
      "r187",
      "r188"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Carrying Amount Attributable To Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Convertible Preferred Stock",
        "verboseLabel": "Carrying Value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Liquidation Preference",
        "terseLabel": "Convertible preferred stock, liquidation value",
        "verboseLabel": "Liquidation Value"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r16",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity Par Or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value per share"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized",
        "verboseLabel": "Authorized Shares"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Convertible preferred stock, shares issued",
        "terseLabel": "Issuance of Series B convertible preferred stock, Shares",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning Balance, Shares",
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "verboseLabel": "Shares Outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of convertible preferred stock value",
        "verboseLabel": "Issuance of Series B convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r89",
      "r90",
      "r91",
      "r92",
      "r101",
      "r139",
      "r140",
      "r151",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r177",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r299",
      "r300",
      "r301",
      "r302",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r387",
      "r414",
      "r415",
      "r416",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain Loss On Derivatives",
        "negatedLabel": "Changes in fair value of derivative liability",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r117",
      "r118",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r378",
      "r385"
     ],
     "calculation": {
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted-average common shares outstanding, basic and diluted",
        "terseLabel": "Weighted average common shares outstanding, basic and diluted",
        "verboseLabel": "Weighted average shares of common stock outstanding - basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pyxisoncology.com/20211231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://pyxisoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21459-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r459": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r461": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r462": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r463": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r464": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r465": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r466": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r467": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r468": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r469": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r470": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>113
<FILENAME>0000950170-22-004850-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-004850-xbrl.zip
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M=9NGT"X_#?<"+_#K[>: S'\;X1P2%G(V>>8D9N'ICCE@W^?*4ME6T';?17/
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M*;EUTXU3:,.?I>-MJ.BHJ.9Q=-Z/=W[.R=./C584H:R#Z4'4I'O%8RN^ 7/
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M"(03Y/F++QI=2:\2(XF]'6F^C$C#3I4)!.30;*]35519'?3JU=2 5X^6T*L
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MM12:&JW^T!8NX$JP19R1,<2C>#G) 'U(I,FD^+J2WZ^F2YFZ[6R5&$\%-HL
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MMD@-(X&VF^F*58-374VO_[1[_>CP\D\L6K@3R9:_^&@M]'(!QK06=@G[-)J
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M,Z.D[-<TNACH^D*%&E3I!;H1E#ISKP'*6Z9X"M_Q?/V(EYUL":1>T(@7?/3
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M;3?V,/RO/-6'(4)WTY#S<IDR=#4=+^TL Q9W*=)=R6_;LIE$=0$,H3OD#I(
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M;5L^HWFW%&ALSMZJB'&*$:\Z 0;),)6(5D4]J"8*Z,'I@T.IP))4CGZ*\CO
ME"WNYLU0DUGU*MP4JOJ9I]A)G$RO76$'S:D$">E:]/UI?"'&6B=7$!PO0?EY
M(( *=S1,A:_KR9N-23K6>T@1;-OT(NG.'#%7,4\0"FP=\]BKX9);;WN.15P>
M-^+.4*11H=[F>#GVV% ;CRDWLW5/I@.=?=[.3>43RGJNURG%:<31,4"V2(6N
MJ<)&=/"P9!ZM&L,&-;-][*7?]'=%$9<GB/4D!N@A8DT^(%&28WT8H5<G$M4@
MT^M!BHL!,U@GA="'\?6*EV )A<[9\<I*<8-""3G UPA%1"IX:;F_09DDZ)@[
MPY.?*#$U+ 5R"#0Y6*AJ@!>%IR#:OC6=[2/* ?N<&$0+T*'$/I534@-OR!A1
M799L\C?R.Y:([[Z;\56X_T<H;<F/"-H'O/"V&V*=VZ'_=:>!ZJ?RLW!B_WG@
MYR(3YRCY\#_H+QCWYP,BLOX2=RC_0:;_N[[$[[Y#\(O#(=_J_?K:<'>O)A-V
MEI*DHV+A@J\]*%OX<&4N'__E1>1(O.SM\-&I)>U5RY].?WC].G34QCEB!K:?
M:M&UA&PJ)$NJTV^/%U/>;E18KG#<]#;RUJ&(](0'T5LR,EZ.K;?(GMIN?GKX
M]8,:1?72F5/SGP?HE%(C3N%^Y]9_K??*U_;C62E^O)KE-""/@_ZQI/(_@QM_
M/'U;-T3:OT'!?W)I'XD;["FSO9M$?9_3/I[?8Z#),M<U/UEEIQ'58X_K.7%:
MI5/E= 9QSH'$/O*$>(6IH[OGN 3LS^E1G&D^D8-J9WA7BB!+RLP7C/31H'#)
MN@U.W;GQADR9L;X#TQ?]).7PFWS>F2CZ5D-JWF0^Q*D>W6/8-*]R21I@2V)U
MY-JT*L*+%Z?YNC1S0\<H(!4N;QPXS%,UTPYD15<]S@<10;C=]HAS@;L#^H@@
MH^7>M@1\43 7Q(G BR!#N=0>CO*;QD.#&%Q=%__TXN7$X  /'-OEA2".+F'*
MT0.SOND=#>U AWI0I;W$<BR"NU5QZ'$U#=2SR(;5%);-W4K5@M*0OT%;: 6Q
M>I(O?B"N5FE+?* :F ,(E"4\2"'"]_FL,XZ&<0"DN5,]> ]:;AY"JT.P0S"D
M3Y)*L&#56<#X$:[ H,BC8O& DM!BA=F'BZT*B@'[2C\"_68=Q76(& 9%(R63
M!<O8DNXS/%N2UJQC0.[FAPHT ;TA=Z8GETFB 7W$K^@\/B!#E!Y.'?32B>3X
M-,6)>!W\![B*/H<)\8 <L#)7 B^]VV9>?+A7)P>"KNDDJ=?A\GF:*EJVY"I[
M,;+@^'DU @WYC$O51X.5-V*EM>AJ3<A6984-%WCU<+R8',<1DNJC<<F0W J:
M58(#YK6D9N+%>"DDNE($;>=H%R.[3\$,F^" W$*;8KU:L5\[$&*&EQO0$ZO1
M)KLH4/-B,[STDV@4#9@@;L=Q%3$=!Y*H(#I>6HM7EE<%&^1.ISN.$%/U)$.<
M ,':2GL<W$N'9G*79FZN)%AAPNRVL_0WK/HU@W4#1$TG(29AB0 DMS*1 @9]
MS%2RP)=)U*JFPP)M:&!+(BRD*1P&S<W1EIN<?48# :8C'J!R::V2M8:4LI.N
M=Q PO[6&:NQ,HO)N(JK!2S*S489T=0D 936D4QRF_7RE (R#;>/Z>>" [ *N
MOA?3W;Z;K[T:,&VT;4Z78JKQ^2#RVQ8>NH.O/N IL'41@5%CRDLR>Q0]:^DP
M* ]V(7*ZL]%59NQ%S9R +U1M!?\^3]*1\C0TON!68JC6>.66OB$B[K14!$R(
M]9P:FK/L)2K3 M=<#C6)6J\2TT?.Y014229%8"1".'XG=<"SU)!)?-B#"#M5
M9E>A8I#A\6: S-E<#)@'?O&<3/@.9)CX?P<N9^WOO3G0W=C\;W'C-?'_#Y@?
M7@W_7T5>6;ZAM!^4.I.]@*OXDW7_R:TC?A;"_^N:'?6I)..S[K2M.PU$D\A_
M)\Y_'/WSN5Q:V%%SK.;@WGD,4YOH>W?D%9=AD+G.$48N;YLXP+ 5UWGY=^#@
MM>K1FNV+,^_7?#5\2W^T1_O9@_[]Q&561YRUE'>N<AU^-M=L^4=+85#6=\![
M3J01VWC??&9[R<%[[\Q'KH:TY@]8VBZ<&SDEJ7NTRMIW!M9VVZJ%:JU]>&N-
MOT./X9E5U?PZ\A39ZLSP/=<PYA'*-R^/\4O-=Z;;GSVYIQYS>FGLKRXKN\/9
M0$:YZ0OS$>U.:?&!I_D)_LW= R>2.FQ1^S]J=SA_=2X%]8;@I@Z=GUKRK&*F
MP[,Z6!:I"_48K_OD4?YU>TWIYA:3=9O"7"_2^75;?CEG&M>Y(T.;N/_8R$"_
MQ>.AP15)K\U&H'F*._'S$$''TI86["O8F;@CG@!UB]NONM?D.Z!N=5Q\^V9Z
M+._TL:,V^,BZ1_=RZI0OA.W\V_5S@RNO^+XG+\Q)F2D'X.5Z554F*RSGG[HP
ME?5K@][Z-<]W#.J5S\&=W_#-@'ZD2;S"U;MYO")B99974_2N^?M&#FQ+OA=L
MN.SKK(SY(5H$/W24K>=/92.Q5GZ<RH\OC[V 8_NO*T1Y5X3RR$_T.?F[%Q7X
M=RGV'UA3>[FC&  IA[WO\N<YE_6B5G>%\=O36?YL^_P.-J(K%N6?NQSS\)TU
M'9LB ';MC_+:VI'=58\?)(*"]?W=R5'6:) ]RE_!<Y'AM=[T@K18U+P>W,&Y
MM"XM-,A6*7J4VL!P7)S+<06:&A]W<^9$L!>B&.3'!9$\C .#F-8CQ'S8K^'R
M(D4.Z2G&IOG8B\;(N3%B/00;8UN->6(O";7S4PG'E1N/D-NR47Z@5"&MVL<-
MTL#[+ &]%F!3R*F*4]?10+4]+OZ1*/4&+AOP<_#S7G;\(:A) #4O [_OR!>^
M*7[TMNW\ ''.XSZRD!60 B(-$:MK6?5@1JO?P@,TRXP::*X1IE0#V 5A>!MF
MWZRA^),@W0<PK&3:8!9176YIA40\R*2S;ZKP'/SY"2(A'=#E^.0=H 'A6429
MGI-?I08XFH#&]]-TLOW;>/GLA862#JX.K;,"< 1'VTF!,6+/$O[C)7ZOZA#5
MU:1!WUEIP042Y=:K\X;P4I-=B".R1;C?7M?Z4J"V$$%P&(]<*<X@LR?W/%EX
M60G\.S% 3[$*N.V$QWQ3?YPDI3Y K<I$D:*>ZA(<*\YRL=<S2SD"Z(F=%+DH
MD$N[G\I681XO>^=,D29XH=Y <Q;BW@,!D3$A 6404=/43EQ.CPI;N_D4'D5-
M;LN.K "6.IIRJ;$X>"JQ)O*]#!>656'E2CQ4JT6WV= @;,KI9AOQYT%S"$7[
M2L_2D)*MD;AZ6[E5F;V:GAD;&15+-/Z%U40(PDWNS5<%/"BVGKSQ&!S;-9.N
MN=Q[L6B+7+,E)<NCF0V?URQ-!+CHPC[G4N LS3@UU;,:8U]+ PQH?10"#0><
M+5K?G![EP^  VFTB[BBZ/>"V\O*8Z/++.[%;U1P!M^7XL!0\=*WWXJ.Y$T5S
MK==<R0=LW7U6SG9T<:4'XW&E0-J!W32902'(ULV@5Z+"P]@*8 A)/.(AP" K
M>*DX[4 HBD>WE3L6YG?P8?;2(6'3P4FI"*34V8D&M&K\^10@3@216R$E?2XB
MD$^SW.**\O/%)=.0;!5";Q^Q^T?X30QT*4#8&UD>%1A3(1VK_!;AP'+8I5G_
MD6C05Z%I"1@<-YZ05M.Q+>R%%7IZHE@)@4&$4?X=V#HT?^J:/X."MB\+/_X(
M<2_XWPE;D_^0,3^12O+78B'YB3<891%;3D?GY1S@H.5_!;J_+FX]R,V,]G>L
MP[#_NU'!]8_/Z>T-V1O0N=%R4&JUI:"[#=!R7;DOSBB@.ADH^>T11,?=I<2I
M?&K%NXU._I&7@H)67'2Q.[NT-/(35??1Y_V'83 >OH_,K1@NN>]ZWU"][/H)
ME;;6[X!DD^'TR^2WE:'[YO=\!TH%$0\>*%AD_$#_O!F+-]MY4T?;Y^PWZM,)
M)"<NE337ANC-=UU.JFIUY!'<%H#?]\YL[)CS'8!OF')^^'@2%_%PP2//VF?O
M[^[8PQJ?+-DX%3N,T7&[,'7+NNZ!1T'J:/J77H_-GUBL[HJ%E><T8W:!7Z6J
MS#GK5KWT3L:^\ _WWAB^K3T]$J348$>FS+H3MKY.COV6'IUZ ,D+&M:;85 J
M]WY5*C3=A,/5FML*!O4C<IR?[LA(ON_R.0=48YXNFC^^\'Z)6KI:PI+FMC6O
MDYC?,F*%YU]JGQI&&AU*6%A5HFZ$F.IP/'/0<EM!6'>8NZOS/K=5 4IH!ZV8
MR'*H/G3Z0!XWTP= &$>N&($]O)K@6^7 *P:@W3AU+7?W23QLN':_QF=Q50BL
M>1]FN]VUIX6?Z7IO&?%XF[GR7,#&)H$P5;)YJJ9C:$Y_".2>HGCBMOW08QXI
M[]",_"'^T9.N2+W^[77[X'N)#3,+!'<"GUV5K(?:'7NZ^M66FX:KE@'%'76'
MVY9.^1*NW\Z/DEO>Y!O?8B-?(<?*3IDO8_2[]&YO<]:;:DKHO,]X2]&U.A^N
MJ; B=MZ<-$[]$E>B/U4PPGDJ:T$VX(+(G=<SGO<(VE7#>1S G#N6^R)^>E7O
M0M;FU$N[/G;2E)^P^=CB=<AGH<"B$?L9+-&P_*^1U9]I*LP/23H+SWS9K"OY
MLUF4I2PG?S2)_CQK=B%G'T?\3V96C;0S85%^Y?9UB,8LX@HE0)^HH[B\0(S=
M[PJP2<"+@%'ZPQ'O1Y(Z/ [H5/#MW&2.@$+[7E:]G\J=;=JX^GU1>Z\F'ERS
M"0UJ317$Q7$_X9[7L9!=2OK=OX?.2*V2]&/6,(@'";2 +(YV8 "O*<U '9&C
M)VUA>INFB59_DB';>>/A@A-K*0M$6S?'I:2Z5-GG9WFY/JK,!W.2# $)#)%F
MAIUJX,9*UWTNE^XZ)P B=R@:%+PFP&\W:W9B?:4(T&(*5B<6H#]?5]P$C1 U
MS8TUU"I%[>,%H)M;QT50C9CHJ\2I7KK#^ P&-$C:VNCS0KO\2UPAP_.U(!@>
MD:))8)"2CV-@N-!P#M3,)LKU4&#HSJ8SM_6!C-4?3"?R(U(>R<R2_%3T_=2=
MQJ5(Q$HF27TQUY%?D^*UPX*/L9O?[I=,OPVD<<-XI14P')MHWWV"K:QO]=@-
MNS'XOK;LN71Q%O'0(%E(Z&.V9*'JL:V#^=PU&>Z-*^LQ/"FRJ!^MPQ[S;.,5
MI!#;%<"08'M23%&3U4EFF_C5"YRF4JG3%P'M2MY!Z 4"4K-(B?9BXWIW>Q&$
M0&>,*G(S/'/A?O"]ZZ&FV\!9_CK,7$7GF*2?U:B36@%L#<@)1^9_DE@;<WS&
M\WEBY>MC^FAHXX3CY^/AXR)(%$WJ-$+QP4M4X-W<$S@F$<H&9](91#S.T(<&
MLN4U158X#DNVU702U:?J&4J*-$H#K6&26F](EUW6E)N@[M*0Z$XS_A[ZTWH!
MW3![=J>G%AEW1[6.!72:L77FN4Q*8>^-%:$I1 V'@"1%#Y1#1*2=3,TBJMER
ML+5T#S#"$"\*TT=78S0!##*/)QP/G1!!<-H4YU)Q"A'XI/Q[L2(.!-F=;=A6
M*M$LE]1) 0NV""3'Z7KF[J&7=Z<< @;%' P\9/QP8P4^]++$20"!\4JUZ+ *
M*PK@(L!2"$5:;F" ;IOEF<YR\#,VH),?27IIL#*P3D=JQKBT6G4E>V%KK%@/
MC[LI&1(0D0;H3E3 T58L9XL(9M764S;7N7L2D<T@JD%]:/B"3!6&%WA)RN$H
M>[F93X*TJQ[4F$KL:KS.36KT1=6#!MRL*L <HI[<W+B!V%,2"/C9/I;4.5''
M%%GG.]A:FI 14G*A'(R($>,19XI8 @BR3BEKG9OBNJ@@^]G!+V-U!U883:O=
M^)%-[=M,^E:W:M0T"O\=$!U3@GJ?9YCX1]1_ZW]\*RSU;YYC]E]Z%DM_GD3^
MXX0(I23-POVSTLP>Y?S>?/?ZK]PQ%S<]R6Q:_W3>C_-^*IK_XH;MGWWXB!]T
M #I_-+YZ_\+]]WV5>!XM4>)Y1)NQ-OSSYY?)OD9$BP'#LIY/;V%.YK$=BP@1
M<U9=]81TT!<?[,"0NE0J8'BG<$*?M=>9=ZL.>AR\HQN-:AB\>UNEH\>$_PP?
M,(XT"GYQ>(8ZE7HAX=[#,5I+\)CF<LR=(]'OS+\N'CM>8Y1D+AJ?V=Z?1@U?
M5D W ;ZLK[FK1HO1/A:8T.RW^N2+$E1>R)&I;9"O2 ZRX57OO6MWK\1'F#\O
M(_TB,=E]XSC\>./Y'6SMGA#&NV2-QC4C%2</7Y#_HN.].S3C777[R\4,OD=;
M9<EU$$1%RZ6$?]?DU>-WFX_%CU5E7!_<M<4Q+CWG<.4D)&.*2IM'>.TZM;C]
MC?Y:@>?&,O4U!_0_>E<:?7('S;BQ;)95<XZ<7^L.@ &-L7-&,[Y7AE^DOA,^
MZ;"/]5[=ND(2Y1H-7]5LM$5(\.WTFG+LU-9-N+=:F+SSN5,ATF-^^R*OGGM/
M&WGV*.8'>DI?HA*<();SCW>L0M -$8V!T^MO;UAB%,NZ<[AA?7D), (;!%UJ
M';CBF^=J<.GLG/U%)UQ/UTQ'WJB/F1!%-B+6K3I45C"R, WW-<1SU[45K196
M)V['V0X%(=3^('88)ODORO6GR^LO^"."H;SUN[G[-[%;_@-;,_\S23=GHVHM
M JTSWH 6GD7:_4/0C@E9U'9AVIE<Q7@(&J0&+@8BLQ0'\&(G/U"60+ML&1]C
MFT74T(E^/. =%="<,J1(X3A$\-OK6:%^()3?8FP-0C38)Y^3VU[_-)6H/N32
MR<>0.G&1)H@T]+XW?>?C4?'2NBW-!Z/O!0+($;9#P(N<OH/?(M@DI+)\NRAR
M\0,NQDJ0:Z?&#'K*S5F (X>!1TJ0LZ-:U#I2^1CR>)]+'P?P:A@D>40!W6P4
M7KICJ_X6')B8>LD-CWU=&I",8:;*%W/P5,RL>2; #[2D'-[)"GAR7-2(];QM
MD4H\6"?%])&T,,Q;*4>O@7%G[0ONF>A)_+/D@%T!3L66LP[5P/:H,(;O6V,7
MZ/<2*34&;(EJ"\%F C?"&1->=FL H%3YN=1XI6H!N"O'13'=V:%PP](<@U[0
MRB_Z:M+.PH+E*[.(\"$!U670G4DD7"'.?=V*M-.Q7['HRO)-MP24S7>2"T$P
M'PRLP@"-&B/!+@*MG.W8,#I#F)V:ZD7;B6GM%'A%XL5952*8Z;:B#5L'QZ7D
MU1C_-G%/G&,]X%(7Z,=H/J Q(0$WL[68%#45-A'!CN"SMPI\TLXV<G:JX>!$
M!M&4VLE)\'WS401EIE-@3A&\"CH:J>M!\:-CB1J)B-3Q BVZ))RK ';$26N5
M0,^4+W>S7AC_U+O6&P/1CO*-(J(T_!+D9OB>8BN(GPJC.:M(:L)9Y^Z'Y&I
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M2$S,<20FET&"GJOP5/"[<[51]6 /<RGX$N;5>/ZH(Y-XR$+@R"!I!S=D:B.
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M6J0/2L_8'$ QUT%[77EB!0J]VU"R[.<.>$%<VY/7 "0V/M5'!Y!0PCLD/SE
MW!*R07BN3%:D%@@NR-)Z\",JF")U6) KP4)4#RL0]R,TM0J?5":(X6R#+7#
M98M.=1C=+ ;58TPU5&K".[V]9 '*V@37&8D7"P,;W-R #$^K""^D3@_NY(<'
MIBRP&.8Z  FLZ@<1Q9&"[ !/NT0T%NEC!J^;1_M97Y1:/2 :;$IMI[N*4V[$
MJ'/K6;\:+I^LU?>;A$8L@JV!+C%W[EP Z3];=TZ*3D[/5*JI2P8"C.5CD$Q2
M\QVY#.L()KE625.8KVX0@9XNO@Z%V"3TP.E]$:T"7C#57K#:Y;6+8O>5U7!
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M2,MOW!(4>907=W6,YG/*HCE$P9.U@J37.RZ??]2RQ:WF-_!L G(UIO3%#]>
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MSP\0F=XT$%(77E[$H6*I9SSTPNN148\%@A>2J]0*2/@HYY;2Q\=UD#,#51\
MBHDLRU>MU_3>'?.SCM9(Q>KC&6#S" :'HDM]16?X5QU>86?5"WA>RF>2H+,0
MEX!W$F![0X0(8(EN5R(<X$_ZD'XZWRQO;4$?1F6MK_J\>:'-!>1(6\433$]T
MF4Q$H%1# M>Z'T'NJ$-FI21\$-@@B$<CCCXO<F5F]B+TS!IER:+0@J8&!'%'
M'J)8I!$&(<NVSRVQ5 +#.VIL]'KC !['S+[W8J*I6.PV$5I(CX;J=;;*>BE#
M\-1(W4 "O9#;%4W9O'6,W!A:"#;ED*O<I03M-]6:><H:J)P;OW&/T",X$ .#
MFJO/_VC&N0A9 [:^25I-@JF [[)V"!7!HC)9S-.TB%":UVI36D0<;5.?:YKJ
ME36!B2GAF6;C43[>[9"#'4C29Y 4PQF39K'@[G00#QP8\S5JA-!U2;,R*:J1
M9CVM7>>[9&R]$4<S^]]4A;'+!O?'A+D"/.:J)!=?A_@-/V4(4,+*YOR<ZW0T
M[M:I&!,0OR^")<A!S]"+AQ?RB+]25:L1[]V$9^1H%LWHG"(E7^OK,41(VND
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M1P,U*H?QMDA.0"^U.^GI-%OJ:QNS3X)YA^BL*#L?-+_C&ZT9YA!U@9[B.R_
M0V%)*S1TH*Z U2:O!/<Y!2MWPD82VSF*6ZSE@"QS[HPV60QE@N%"J5%"*$4P
M"P1,EURXOW6V,*6/1G#R]-][2IF'XBC4(%_%<O:F9K91;G3= )>Y&A2==)KP
M_;-[PB- HQ)X@BE#51^)'=]PS$3CV3FJ"B8>+#DQC#D\:,$+EV:8;$>=]U
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M9,[9A>"[&ZFE(%1;JB 4&>L0FIP2UXPYY1%LC%UZ*Q+,!38T (W^F$0^N)Q
M@@LE3C7?G^'8Y+Y-)KJ#F4+0-*=98!4YD>WR!DHFF-O,6'5:1QW??K&(+#DH
MXK&&N4="WR%4 \[?S]48Y*+@T1ZZX#$W^Q=I3MP-QW1#Z,4?"[,%6A)63ZD3
M':EU WD'H/+[/8F84;OO>"\7/F!H4;R^-NGPEJ\WBYX0TS%6I(.QH*I+ K5.
MCFQZ%O8!<! U$!^:IRN2L!NVAP6#,7!1/X[(I  6*.8 \TZ.E4@YW7G3&&R
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MD14SZ*C=J<]1\HKXCOI>UN$8=QO]S8\T:HHN*YMDUQ5.0WOKK[L;E/?112>
MIVVA-38.LI2=M:$4GRDE!GEI[UW:3SN4Q8K^/>Z_28]5_H^PF,LO,@=1*+$8
M]W-_\CYN=G^!@:BY]9^.$O)75%Y90DP23DTVSLS8//-.IU\U>]!3TJO?[++C
MO&%5!>&+PL4;]YA:<U#X-4W,VD;KS7U?OZ<PEJ2T7P]ZY3-EV_;<HB3B^2U!
MWXX@#U%3"DDIV&JSP7N>G9/?S8]GXUU=%0AML[Q/?V#R*6N)G;^U2S]KQ@F
M7U)/5D8U(R\OKF3%]2IS;=N^Z.\&NS8LCR>&1/M&"0=+WF7:NSS=/W.[JOI*
M-0'&\K#9/*M7L_^!K<*[V-.NYS%EKX7]2$WM"SS2:.5WDQ9LU?:DM;$9&V#W
M,SW;9DOC&G&W3Y_X,SG>UKKLV!UDTI5O6\F27B4 F R)0.1?MM;Z!5(E_W[9
M?FEV%S]G"U<3_J&ZXK"E.()_S;I5.0*CGZ.BY]'7[O\7I+H:-ZXX/+>ZTJC+
M:2IU$GLO4:GZTY8JJ%[K+</S+JTY3'6&M4J]!JSMSEK2U64"F;U\HB;X!W!I
MS\T/^^NA=R>GO^^X'_#]Q:"U+#KK8OGDB&A)9WCUS>.[CC2(<8+:Y!\K/TGO
M@U=]9*AMMWY+BWEZZ%CY*?.V@*NOOD28O[()ESK*'[;)F;NW_NR[1*X@<7^:
M=<JU1Z*9XS:!*U9EH-'GONUI \F#(%K3VI>9\!UGN_NB-D?%H<\[#'W-S,^A
MT&G^2"1Q_@HY_SZ=/-0"">:(_VM2,='E%^/A!^EKD2PO4QDA)0<'LA\?LWTK
M?LS5QA&\>;ZK0.$X2R._V'TDN7:HZ2U\:6UW>D=.C5_ORK0[PB]/SJU\8L%:
MHWZH0[/]3BDWK@&+'?IZ2<,05A(1];F\SL,)_WH'K!39I'.E\*EOG,9P=]!R
M_6.H*_+OI*8!6<CLT=G2LHIST^C %*4M&5\D8HX.!(W_$1VTB4 Z=;>"9Y\4
MT5.039Q&\V/:CJZ]9?.'66U*(,_:1O6@TI68TSF4IDFIBKPY[>VV1^8V.)4$
M:&V<"G"*Y4ROI2F]#?+R4YY86[LT8?!/F2,A;?OJ]B1ZSJ6EG-3+R+QKL3YN
MA\4.K.<>HD:*/7+Y5-S(CF3XIXJ/9[PSZ3$OP=?^;,R>\7_2FKRGKR+#L,.]
M;?W'A!=',M[*>L^-DOPJ$@J<LGIY]SOWC,;:'7J[Y)C,N[[Q/_I<H]\ESC9J
M:FP=?12:/^QSZ4/C\8%LSU7'>@[)S60=[OCSEMF#\R:RN9>N%I_/S71\OZ?Y
M+OS;BK;(&435'\LZS^TQWVK2:?8F-RO(+O!MT:=[#_RAQ_>D7-K6:;/QTJX&
M1ZO@V(L'("]>YY=N'5E!.G_UU=97_.@EL0DOC$HW;%J 1O].5\U3F=Q%IX9%
MVFK>5^X_<&D0?T$$^Q\Y,JRP\K&KXUNABZ4M_?*C,CLK^Z<YH5/1(EKR*UQJ
M^QG96@@T[3RM)E$@F78GCBVI7C2:[11)@$!X_D#\-\..W5&$.EE=G,8J*-G[
M_I1+F\^5R2EG&7T(%]!J,D<=)GJ$,B(3!LO *]D%L($\T:DS&D!OJH*.#MI@
M"RUQN[' @3G1D5F8>M2!KQF?+K"0=D+)RG\1A3(96^ #Z13IU8T1 6'$3=0X
M;C0UA*SP S"46AUAWP@N W?1@("!S()AIX,(FVG@ I9DZ*ZE/KSY(TL<L&+
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MR7#165C PQ?7$\V:3IJY>-???NE4&VZL5H P5^7KO:L"](R;K866@U5P%:=
MQ-)PO5/V5OO =(SZ$==]!G7FNU7Y1F&>*HZ=6X/;:)V/-HZOBVSTWUY\LK[S
M2]*6AN.ZWIW.6\G]/BX21JMBKD@2N\Y?SA6X1]G=I+]J6W,L  <JH*=B,>!V
MV@>0^M 04MZ;CYITAY0C/O(!21675HJ7L0 VB%*\?\'?C1HL%YA&$TDX:3D"
MHVX-4EJP?A$]FP&8A4)OM-B[VZ37&"P[RI!6:(4^_LA+O_F9&R>'7QH<AWH@
M6!LV'SI5[,QR9&>*CNN>'F;L;R][L;WLT?7WY,T!6UQQ)62\.M]FEZPIXBN[
MU<1R+O>,,%R"=L'?RTPM^7BEG+UVTS27CX!!P6_$V,1"'WJFTP/"RCU*%P#.
M3W8X53DF#J(D2/'<CB2?I>F "$ZWZV_CD N@&0Y4HM,,SP+ZIH<CD4VI#D^X
M_M2HLWG<-V]=M,=>,!E)YLU2'R<Q[!L!'#C=,8KH#%8M@$=C+<8QW7TH@!RI
MPT)N#9X0G7O56RBU0H,DE#2(SD$27\T4LN[@PAG2MLS=Y]J^X'*<:]F*%N(#
M&W.TZ,VS%LJBD2 =Y4I26\ 5GE$'>KA AP&8IF,A@BQ_(TN&KWDR(U3:_2@C
M,@8YN7&@Z L.]$[ZC8\+5;[5^3T"6FOJV 6Q]0\XP)8?H,DD<%]7AM#AO7GO
M,Q/9DMU3+M36&ZBS^A3 H8% ?(+HXQJ:?L*!3/!PH3FW(1':L!H&U3)\ 8TK
M7B+YM88 6F6H*4&;F.$&G;U*$IGIG3FR>;WHO%K_LD:NP?4VG1JGYH_L$./F
M6G8T!C;LZ#+J+#6"L,5Z@ H.1  >T]UF&_3M':.;..!^ VF(/S5N(,V*->T#
M<A; 04X^SI:[:;6[4^O89J@[*F)PW(@Z3&1L@3]M)Z]ZSD!VM1U>&HT!ICGP
MN(+.&M4^*'!3FVRFYA;*%"I9"\%G/>)3&3MAUL\>@=6N6?-XV(JUD+-G8@4;
M97;V<35/0KI2VVFU1+M9CJH "1=*A$,H2AYX"W:413&@3S%FX4<[F)8^H,K2
MDR]18O0C_IN^%KD_PBT:TTLC[2;#310TIL]TBT(E:*!1+$@=L6341<C"PVH<
MD6(<BKHS@9$H]T!N%U&_X#1) #JA@)HD5 "WDU=NF#[Z;N8'H.U1\ /8N>('
M\#3ZN>!!UWR-;!XT_1H9\+]G>Y8^79S+]0L!R,Z_!W\O\'FVO]5-5%X1]O6R
MXY-#(+^U]$]T'8?N$Z+#)Q]3HH>V[BZ1FW1^L\1E<X7<_E+G#YVC+V=6#5<8
MPBM;+>(W!%+6/K/U<''8-B\, O_\C>45]S5D;T_H]A+L[7D7/W-U3G_T/^OB
ML./,\PJ/P^K8S&;5+O4/@A_ \3\D-Q9?7V-[Y^S1AVDUCQYTJ5W^\/I8VE/3
MU9KB18\'OZ%+WI\K["!L].[8MNG*IG2R)7TDQ=V_7*V*.3V4;+CKG&^#S=9A
MQ=??-XFOCJ<6$I%_9K%VM5#4^@>Q];-L5:CUEQ[A;VJA_)PSOUH;<U+_P>+X
MTIAN5>JJ=0)YY8L.3M!\N[GGT;@M5JND[&(<GRTW-?+.B3+(O9J8Q7I=DE^E
MYVD'W1]<4!.X6>:&1,GV'T#Y\ACF"W;:6=T0A\:##1<<['9'P\Q1/MQ&QAO_
M?7M#H+ZED>],A4G"]O<%.I!A[%!\F*\8<UU<LFA.SA4L8*2%6A,8M6C2 3XS
M<>BPUL3R8L;2*Q'*63D>Y[YG?6KW2[?>;/E*4VDT,?.+RE6S0WV-H>/?1N^4
MA_*[EIT(JEZYL=Z^>),IE-P7;REQ*+LL5/?YNBR?)90CV$.;Z[^A-2?O3;Z/
M@_KI=(^K-!=!1%68D&?[[F[Q@YF WHR.[HC[,[_WW1.XHT8"*9,Y^^V;T-MA
MN=[JO^F%YAL8%UB"_%3Q?W +18_=BQ,PYZ^]=5ZOYQ%W;G/[WK[O];S9AY#7
M^X,N5EA6%/ZQ;_6]JPQ1G *T9/.1Y*^]:+E#2B.3+Q_*>D\Y_@"Z AMN$3Q&
M'G_YEJ<^MO/=[N]OJQD_ '+8L]?ZWGDNS_:-7]1/-ERE47"CQ'?+T9N(8OV5
MUVQ.M^[O:9L>^B/8(C-,'EWR+/'0?<&ALY6$_K[O8:K?'4A'HI]8ES<.?GIE
M^L#OE%FUIQV>PRVVV+38'?=W2<Q/8F.^C/.;RUKQ[RUUOQKG_F9O0?O)FLQC
M#>?_SJ0]2/W#U#J+;A^=51SP&T9 =VB567%WW_)AN,Z 5]F1PE"FEX>L?IE>
ME D"M-V\,6*3D935)UD!GM#^X=%^W9S+37"PQ_/ECT4W5:&AE"V:ILJS1&</
MIQH]LA?( AI]6X*A"%$G/+1X19"')K^:YME OU#<7SZ<+;SN]*CKC"P5+F*Q
MA;SV#+X6>(HH3G_U\B 41_1MH03X-A>&)@!U/*;*,&6IR;;UUS%K]"LB*G(\
MJ]RF5*$ZL=#'Q#'WM%6M#*#90ITP2HYY0-F3,O:Z"'2C(]HUO5J:^0,PDL2I
M5,K'<<"D&,\>[,%#$6[AC"B;-C(DVH6O:HNUYP.KHC&JT'34C X,C0>MI-C/
M7B48Q>#UKT#E=]2K1:UC9A0.OF6K4+VCY?AGWJ..I@L0+=V(G;<9H2J4RA.:
M+UUT_GBQV0/B?[O0\6H0@M;C9"T\C#-H?H"$=-'U:PBC.7_.GM,!0F]<FCIY
M#VL/4T*%2U/3A;A![=0,1R)&=>"4']Z" X/WTF3I=!?F#$^J25>DB ?)=E+C
M>*%QJ\%9_EZ>$=*0M\-V.E2O^[1!N-=J(T]1GK67S1@037<&2(QD(FK[]6A&
M>!!7=1HJE#L8O.T6P[VT&CW4D(BZY.0/JP\(9U7V3(6C'H?3D(T&2!E"OU :
M2>IG>.23H?TL!0NZG&SA-%<3#59S'D*H0B@R#W"#4*  @,\4IK.F[Y'H@!@6
M\A$-"1R=&YPA!*C[\%Z*?<Y+U,FFOC+#F!O:J:#N"6?CKCPM7!1!7@F-:+ 4
M@KRS77+,V9!RX9W6Z$;46?-.QYAX!A!H*;>I<F 5"1=\>2#UF#E[RO$-UIT3
MC5'R[2/&%F;>'/-X?>0%X6PG1E%?7X_A7U[(:L%'PKH5TT[?%T0J]Q,GBS@F
M>9*XW<R'DI=6TA10F7B@/X7@HU^FT("\N>::FZQ9<"_CE082^K;(IF8(%/U*
MI*@@^1X:!Q>!C#-S[S:DIXKHDA0 !XG81.0C5.%Q[#0K+XE0:JHGI!]%B:X;
MQEK"O<#2ED*E".]4OOI$FQ  ^*N'G;2Z*4HV;?(8#)LJ3#%UM/0"4;,9]NU,
MDD@##\"@<:@SO7GQYE"R6["7Q2BF^6(1*#J;$2G#K8/B@)'$ NHT%WI4^PPP
M[-*>Q_2:G\(*C^5")6S5W*8H@/<X1F!ALQN8<#67JU4D'-N=)-J=R62L'-B+
M@YVQ*(#QEG?R41(.QDMJH4P&+H'#7TV1U9&@2Z>FBM*B,9! A!Z-$9 D@BF1
MD$IP.9O*VH!E2*51K+LT3?H=!=3719LT+U"'D(" :'H[[?P#*"]UA, 18W"@
M1AKAS?"H[,$H#!$\/-%%#0KJQ4"X#O3,0/IG(2E):-S(V&]1H!L]ZN3)!:S(
MINZ"/R+<)C"*F_51AWU.?:QH/_LDD2W%3]'\%U7S5+SSANF\=U-BA.'X&V&T
MM804W!P5I^ A6_\G\P+$K\*?/GY>>,ZOAKQYP3/6'[L011>ZW"\GA_,V%O=8
M?<6W5;("I\'%:YOF-M<XUYJ<TM&BJD7''T!QO47%:B=BWR=7.<1U67^XQ-)\
MQDC0L0V^L:8@V-S^M7O,AA%'+';HNZE2X/+A$AK)*)]B<#*-LE;X;4GWRC8&
MVG,SM>S,@'F6=!!QS,>B:.VU<\LIW".%([ZD@[N")#\I[HATN-NV//^R#\U2
M]2"K:^;=A^W\/1)VDGO@WB=+*$8 3UL77T19#@U&P "?TB?%WH*19&E;HU)J
ML0"][&6\'!919#Y?!B/_XI,D_E8P^SM=@@WYEVK:X@;SWUPCL>(?Q,K"E$8&
M]N=/PYXJSM)F:KL)B,N*Z[;V,T4X;S>I+0:UF?D53MI--S5/>7$ETVE1$0&1
MJ'?XMIB'.D$?;\L5#SH[FC'"_;'J#XF*5>BKTC&-579;UF^7?S0J\+VN9W6Z
M*)]2WU8:2U[:=\^_8DOYN2.!WR/*]JA3N3>\'0R5+I8LS?T[<?8/^V)X(^6;
MR9?L+-_654W/QN[B7R=, 7,J<RDE;S*L-]UZ2U]7VO^F-CX DV#0=6-ZP^V
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M7=8-MI3#)#:2, 9%P #M %M"40EZM*)*8B5[V 6[54-*RPH/DA'?3@P4](0
M&R#KZNZ]/U/4D.1-Q9'Q,)RR'01U*8$MV6<]Y?CN W*YJY%W%^]&]=(C@[H4
M:8RB(J).G^[*C*9X'&5@(!4U.O*B&4X+%!0W_G),ZM8'H&2B1=<[U[ZNJ XV
M;"<.< \N-- SI^^P"(BEEV*D$2,6O>G/*3+- ZDGAZ*0I!2"\1 A0=,?<.]J
MTR1!I'.G,+)MH@'Z=6.!2R5B@*S*,D(^I=U\[2:PRH "*YJ'G1/$@3:H#$#
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M!48_=;SS@YG_TLK^EL:>75![^/R]!6+IS]8CMZ>8)5A9G(RY]CD'8+LK5V<
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MG]E"-KSLY-9GA25.NTE^]U/\=CWK.OW.6&LJ5*.OC%25/-PC<!ZV_'Z^6]?
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MDZ-7X,"[4QS.MN?BG3T[MN_ MG1//E)4NMWP#'R?7YN_\H:_Y!&=9M%]^@?
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M[#4;V1N$8#;O2]'Z'M)C1G*2B[*>MHA^O8E?_&E5'[-G14?4J8.#/92I#Z>
M)LLO/P##ZW'OM7/N^M!+K1UWWMO7'R(3I/0H^NC5O0]M7)HWCEF$#_3KDTME
MTMV7T6VYPI_BHT5=DNQ_9IFMLRP<(] :?CR9-YU_\&E!A+R<E:(5(Z-H>R/6
MU5ETA *R;Y)$X?@\?HX((+435V5R3:<4S[HGF4@S[]W6J/-V1'+4?#=,=;TO
ML,U@$N^D0O7:?3M/>:/L#2H R7/SE5/9*DVC(_'V+QF *D*19J+1YNOXYB9Q
MLG<2]]CPPC@J,@M4D*=B6@N@5K,>$*$VFDXV?1E0SS'<0-\Y2X2$;TUC!)B\
MQX.9P0>%-C>G+Y)42P#CPX69Q!U&J[,)+[GN2) )!LVG#&96W?,8'L8MR2#P
MZ<H6=R=)$!9E:7NWI!VBQ'9YD9>2VQX_BJN[1:>)H,U<ZVB\?;\X0\[63SP[
MRV?E%M4,XX#I40>E2(8'/9I8'SG#DQO34N"I1'9E9%A'^Z[P#=KY4#Q>U\-1
MNE2X-UJ<V6#$\)'=>>Z:I< CDXU32/>G$N!P03>*1@8:6X#08D$KC9R'!""K
MV4R1BI.5AX0U#10FUO"+!/YN:"$I"@F2;R/* 6TTV*%&7O 0# !'LHE.\;!4
M:ZI9="UDI4%?,G,P"6\C?DV30D%Q;"0C1L%=%@I 2 XI+8#)!E5T?BTWR]&(
M2W4)D*+*QH8Q5Z-(HRI$HJ0$@1S&*; 3N=RM\<O4SW..6RS[ 5PETT+*RJR?
M"6ZSD \TY=:?8/IL:M&/4<\TZPMQCY,3,D8H092,N8*+WHBS(Q2@U1%Q!>+L
M0-H7#I.W/V<HN)/:RN&]M>K Y=5=!0).T\J?A&6<%&YC;4G.\0K2+NV]^OEH
M817Z"]<E<"@]S$MOAR&7;V0DE!D2ZIU^9"J82!2SX>AW7]P! D0+=3'2X7 ]
M6@Z+ A2WF%#Q!B)G+0K(2M,_-[Y@S/"<!@_RJ9BJ\$Y6HRT,I^6Z$9TM,)CE
MR09&XOHS<5#MZ8,M #J=Z,%4E$(IWI&N(!C-_:A'8HL&UM1)U1>'2.121[?F
M'.+;1.,>Z0L!&IFI]I8*;4(N#5 IR)@BZ5@8RE'@DK&M&2M[,MY3AO' !Q1>
M-HY?HL<#K@$M&]_WEQEA^-+ODYD>YDXRQ;^\_.AYBU9%;AU,) /G%P^RC4HT
MAM! 15MGVN-))_,&'G.*"SC4U,I,UB(\1+UBD,@T[>-@/KK NW$D;%V ",5T
MV41U&R)&R5%A2^,T!.#]729VQJ"A'@'+\&PXPZPNW^*>;Y/Z79&,\]H9P< 4
M,7Z?*$)Z:S3P]ZL:<55'\7$($3A)+KH%E&C#()G70H6 3%ZV8(#,HHF7LQF
M7S^7TJP9HTJ#(D0F#= "JJI1%W-@\(P3!:1"(_<S[,Y(@>4:(U+I>!);8T ,
M@D)A%4.P(#%[DA>806F#G<<.5X/C>#)P"->^QF:2V,R2E:)BN)%A8B-?@W=H
M5@#.JNXEZ]"\6\=58<A&#$^FIA9BR))BP+12H+(?!NIAP<7]4 :@T)^'XDLS
M-E9*!A<N'Z4\#_&._=,M*H6$G>\9G?C^1^YBSVC1?,]HY]O_2T_+SX85GN2G
MU="\D<*"912>2OW9Z(E"+3 V*#J9S%V<K?&KC_0G([:5@$M*_EFB N3X7$K)
MZ_B"S* TN3^S>T%>AZJB'CWZDM SLOQJY'7[E^D\K98X*/-P?-&GRZ_YW9U?
M:/E9+]UZ/A[P])4(AM[N(5].+7[ZZ6E?Y9$OQU+]$IL:XUE_-7ZW.U<2C\YJ
M1)>LN]:FC[AMVFC4P0V/Z8%^.A+;%W]V9/3(7]F%@VQ$X[L'_3N+G3@DPS?>
M3D8I<VN+/UWZV'#S],"N&;:= ORCG;CJZ\,\9<EA5.BMYW^4D^P2HOH'#^Q^
MB[VRRU6R;OHT_-U57;PN,^*RG>?(D9&745Y7APH=;N6J*]-.S%=.3_[4SB3/
MET4] 33' T<'DV3MF@Z'4J\LK5,'C8?YIJ[N</G..;._S\0S8L182(Y=<V79
MEJ\&,M-OP\9"/<_Z>- ?*Y+3ZC6VWQU7VZK9)LV"KKZK'S00>S+WH8BO"8[J
M?RSJ516V'=#KN?!T8N.'*UZ>D&6,O!$=0Y?TNR^-JSP6&H]^&UV0?_J#0YWU
M6+C1#N^QLG:U<9>EW5-=-XQ?<K[J-.]/DSSK*(LL#/HC)X>+0@I,6GXZ;H;\
MJQCX[RU!0.D_S;/G3SFB1Q6#/R1(<_0_A[8O-\JB*39E.64VFS:B"?K$-]D#
MDK L]5HEYRW2B]U7[Z7,/4^:17 [+]\QW7<Z'E'^X<JV=8(3_]TO"3G?=_JO
MYE(D*&Q[B.G[>%\&0[-"<O/P5@V-;CO-O:VG10-?MQD;8]3\WB54QJRCEGIX
MX?\YIE[I\P^@SOL'$#*YGP^'>Z)V?^K,?T38%/=0EP3YHW^Z<(Z4VCRYUXZJ
MY^EU&**77N=M-V:Z2WPW-O&CBO_3]0_BOJ?>;W=4;SILN>CV] ]^"K?8]KH
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MB:/&ME;NU5L -#^9U:&65\"-$T J:G@!2@S/M-)DAIR1ORM"A8K7LB*#6!3
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M6OXX]G)3$W8S$C-W M^T2\D6]?8H]+UZRYF^-EO>_I[MO6F6 =MPS=I0W1_
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MT:M.JA[C\VHJ:G>OO_S%^;J3BVL7NS>YP59B5D47JJ9!R:_%JT!O]PBZ6QG
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MN&-<- &X5Y[JO,X-!^_IO01O+(B=43=8?\Q::K5;I9^8PBL?KYP%:!#O'W&
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M)JQP!HU#<; :_=]=;UK6-P^H1=L;YP-ZB<][#SI'7'D+PAJ=:?XX;_"N. %
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M</?Z[SRT:G.#P&Y#Z9,?J1/+B,$'#[?MA-^)N(<-R77Z&:3DEMD']-HHGUY
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M&;8;UK?Z%>04Q)W9,JYZZ"+SKB3*D(PA:I ;\L]K[,?\GF'KES[;1FK:T^3
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MDZ^0DUZVCS$,%(9FBH& 3.)XY?%@"LE_]I/Z#]K5BVG+*0J1:'9J'\L<!!"
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MGG\@V9BW2%\!\<GJ%9X/AV0-9P#_[G/:D;'!A(0&40^GW^$WW<]=KY.[B'M
MGO%"J0A/I/-/Y@;#LBGN#'[IST<K#)Q%OD;Z*7;AVFJ5>&+T3EI0"/([XJ[
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M(JY((^.)#5X*$7:9337-(8TJAQN)BO;]U"H^\<&/,)DL@;]ZD)-O&'QCZ>M
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M/T9M*X9==(5MA])U+?M_4P2/MFV=@DN#<I!,.#EF1:Z61#;!#Z"W/F? U8/
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MXE<VFR% R9]&<<UOAZ#?)^>HSF'(K?JW(8T[0?LA?,ZFM33HD;TCBT1KY+Z
M@M"H4NRT2!H[RNMH['VI086HZ]Q%S_G57>&WJ51!\QE0DL7NJ-SU[F:_?']"
M-@(=A]</"-W7$).A.AW=LC"<7JE,Y+F:6';PTE(!HEUE224Z,6IT)TK"BL;*
MRV2-#\KU+2DSPZWPPA[T56[F_]/'_NJ_BXQ>2-+>>B7XKQ248 "JF^X,H#]]
M@VVXX)4*E A([98"_6[P#OG924C.%XYAE]9=>+C+<N=CHV[.Q7-2L)S]>;.F
M5))4*89LH>X,T,0&[B$BQN;D%8(\IK6R$(??X03^9I8ZY]:0;.I[TU7G9B @
MEB2PXC;!OZV!5_OH])M3/#SO@.<7S6DJ%OD1VM;JV,S_L'Y0HFX@R7I O<U;
MAK+I#)@Q>C^XQ0$:=)$7FVM\)#HDH5[Z 4AFFFX+_AG2VXN\A1/)[6R])F\X
M_R.\1>GDUN2E"?98D9!DX)@%"Z/:H,5EM-?(9G*? ?F63P\[%BC!.SG0KZ%7
M_;-[V@D\8]Z"GO,"8(6O 14UU[28'QN5KXU@]W-H5UM9\+S08IQDB/V=% 4M
M;0YO+R2E7L@2;UT/UZ1)ZU<WAK[Y&2)+ZZERZ \'R<IZ^<8[)%+SY'@O,Q"C
MXJW5%!N*EJ&2:HJ@QM/[7%=[2,(/<MU_=GHO2&,E3 ]\*]-!I)#).DZ9'9&P
MV$:CIX36?';5(*H+]_ WN7JA"'NQ^:]TX&7ZJ__0DOROXP9O\^0OQ3K] A9'
MRCL_<2Z.%P8LN8MU.T-FVQ:'5,.>#BOS:Q"7 KJT*@:ZMS].2M'%5H6Q)2JC
M+&Q9/*F$Q/KNR"\.N?(T>*@[.EKWE&I_<27+3KXA,Y\D1US% CQHO^F;$WB0
MS[0S!F^,GPBC)/Z6YW#30W5'6=53HXN8\CJI(T <Y;D8'6BH_L.3ZM;5 E[2
M9)R\GBJIBGABYD$.R2*+S:27)HTT9[+1=1W850!*JD?EHIA_:?!50WA3;'+L
MHB%P>=?_$U! $:$.]/']:2SE55:_S/LE9W\YWI*]J"?[$7"36[B9F-O@LER=
M>+XZ6.+FM01IHA<BHC!^_?9N)_ [\4N_@H5D<(D?/>#38,([YV.Q'O NYP8,
MN\*[B\Q29(+U:@V"-RY&16J0'YM\4.$2J..]Q"-3";<8=O$6TN#7GE/0=>&7
M@2L'J# 7VC_>!P\G6@=#=PBR*L%U&F2DS7:S.O4'PG36CKO@[9V/,TS@&1W_
MXR)PLI.%U-LL7J?K_N/M$$=<C]LS-DC=Z%.M"/@V-O$<J=CAQHOQ2F.,':%$
M([S1+^.Z#OR!A657Z6-*Q-?:@J%2(0FHM8[ZG@^4M8<ND*P;M@\:&7^'#QK7
M3FWP?4417,Y7]YYFAX,>E$-R'M<6D[<$J/A*0N,E_2ME[%!6XZ,S%+#%C-4S
M /OS_,946_2?$P^UE.+,O-!_U,Z ,I<+Q;9Q6G3:X"0&'-T'?VLZZ7!XP5!2
M;C9#+8U[^S$[8@MTPE>*B)[9-4!6#G]_=P8H,?SP-]6#:V'L4X.WWLS7WU\\
ML)I%?!OMP<$X(=TA6@OYPK/6CI<2#TPE=LG[/=48#JJGJF2S,Q1*6L49[XE*
M@ALZ0&,M1AC3,!\4A?/U+HFD88MM1>.?ZN;,09ZR(#MSO013U>3$P<RBC>S1
M?7";EOV[KZ9[HK-:_IH(/0:UO3[_PTAYXGGAZU/<)NG>@U]U.):]^5AHK+);
ME2%Z_I". P(C&OLI\;G?78$]F?7- $%<NL]BZ1.#=\THT&F.CH0@B%!7NX?D
M'\A@(63$(IS/;^D!PWIK%0W^917\>'ZFORGW/A.&-.,<2>K#5FT_(]JT"6*;
M<@1O*/+X$'9*,MYMJE4SKTP8)/@<G']_+/\YN4 1G?%6"S0/[O\8:;#AK5!P
M$(S**D,<V)X[R<_C6U?.$=J_&<!" BH!7K-13H=*I:/I*_Z,ZYM[9-C9P/,R
MW;B^/F7(1/!ZR'P)V4V_-8U&XQ&HA4-?77LO,J^%%/;M]0QV%[NW73QWZO"
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M0H.Z%G[0F\R6[(=1OPA%HKU(IJ==EF0S)Y(RE3N6#JL5]6P>I]\V)\I[K"
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M8/^NRS6P%1NPR\@]KD+@LM-Q@D2M'!-:!1N7A%6Q;>>8XS;5-P10UI3?Y,$
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M&@:]V3K]4=[QK1GQJ^$MF@'F][0]W^^6]ZNM\D175FTGI9Q*4=O$^?_%V7M
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MZVH3H'W6?\3#=))_&OEV9%W_?W&V>?__T]E&UUA_HA2@%W-;F3C#0AFINP9
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MBFHF"G]4 /$16JK;Q.K7)&4\6ZHA=GD./P<,.G=I";&+M_U#%A0]D[K0'%<
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ME[0KIZOLSJDGT7JG;1LMR!'E-4M^D_F?]M[D$^3XZL?X3A,=4^AYU D\1E8
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M<DNE.W,G!3,=<.32<'J6I>1>7?:O7;>8!Q.\G.-S[/&6#-^8WP>H(Y(^-S.
MGUP$LP+EV:TK.OFH1'-/*XX/857O1B#N7WXII;$9UW;G92LQ!F%B_7I:@>>
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M"4G'4MJ?X=CWE\B@O45YT.D8X 4 GM#X4A/#.7L(.K[]5RD4X+0".Z<^<;U
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M";T%#J29>*6/)(G@KQI.(WJ0><J.173^E2MZ(^#MKF$I'V[NERO5Q=P=]&T
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M7BI+'[_YM>'7^]3-Q 0Z/CM[41NQ37F;4LSG,N,=+M6QRKHIGECL9-^0N\C
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M.6H,+#>Q/Z+,0_6S>+N]O,HO]Z%L^, TJA)<']N5OI)LQ,'=>A&J_UWS06P
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MRE;]U;'K\P]5%OW44X&0Q3LIADB>/=WNP*Z7WKQW.IYC6 .DIC5S(#>TXJ\
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MW9#UDZ+01VS+ZB&J@A@4B!5'C4U8>64ZDZP84B&'1B+JX31H<)0W_B)R$U?
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MY>:N:*MML[:H^.<"? J>&&> R<="2FI9!P&.1;80UW 67*_@P6Y=PHQ@QA*
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MK8&!7DYR]&,PRK/JF8A?2!I_4"8K>6,SN!P6*HG1(%97:MM[,;!N!+[]7C+
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M/R)$Q\(J9TL)YVI\<<%_SF-I%K&,Y)@(#B\'\_?U!"2\8[*CN00#,<EM9^8
M>E2LIAM9%/1N:HSG,*:>F7(D)/520$E%CX89$_PSUI<.,'V08(T5PEFEY]A
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M%^PL4^TS:JE<S=B_!JR#_)E6R"+JYL=3OCVTTNSD/_['=$FA93&)EH53FG%
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M$/L?Q_=95:Q,E?[:,_K%'H2;[%$QN51>Q3>K!GIFSU$VYM6OES#QU8HC$6H
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MR+C(<UR'-JTJ)@L'%T^2;U8VM'0D">ZLR\74VSF6HCBUB,JCZ&>$.!D=K2.
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M"]^ZT3 2_^-8\\>G7$'N;W?R?]&'L?Z QUK_CC;YWYUKU(E"L;!]:E CE_=
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MU *RS!AHG_U3@&DDQ99L5"O&;FK9ZI(66?^?W2<$(Z0KZ1HXG@$5.5\#F-?
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M0])-$R0S/G2Q,9U57;D?'D=R')_)(6);QG,N'PR3+[7%"P5(KDP]U^"_4.P
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MAG:0<OPXIG2M2#(Y%PUJ3I2^I?Q^H4,*@]]D#6KDI8:ZLCV>3-B6&S"6%RY
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MD5["!ZF;O%\W^NA_]_D'U,QNLLTCVP+4A[0C=E*8/JF@I4B['%(._U8T_&^
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MV-PW#<N5C6##Y7)#HE@+IT&P&NYCLW;;JR(^,8"*;TS\Q*G''$Z10%*[7JX
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M4Y^I'TZFFVA2^+=Q'[@9-99_O;"T9"AT@9W+TPXH@,ZV-NKY'0>U:WJ=*94
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MX8='=(]UZBTUXE+65VXGY^[1%V'W+_$U>>=KI\ZF]S[T>L%Y61GG,>.0&[_
MQ^_7$V%R9O)A:3GR<^UHX3;-F=[G*\]7/TR!K_X -L7+F$@-GYK5,&:9ONR?
M_ZI6<-_.X=AGE[&J'M3S@H.MJ]E'34)<%^:_QEDME%N59U>V6X[;]# >5H7<
M-AO-^@%@OSH]&9B]>Z8R*GR3M^83H8MOI*MW-WI<UKBGG7NL])H%;!_W/Y78
MC:#T7[]X_U,JWQA@6%:E$Y@\WYE$K1)[%W/B0U5@</9A/6W0H/'#K$[NJ*%
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M:B51TGI"5FU3=KMZ^IO%OBJP:B:&KS/4NE#P/ OA*_>8EIOO#SHP:9Q(DWE
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MM@XL0S ^GG6:>XZWB-BP-);+SVGD>7A4* M(,O1C(;;,-"H8I:$6I;)?Y>+
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MPZVJ'N6=ERH].X/5GADSXXVLKB0+/>QP]4<JTF\]-9KZ@3)M=R\'GJP']P^
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M"M=F;OMO.GI%7%>YKU4.&W!U/M'N^%QUA2+Y$+.8\/*GGD^JS=4YQ[]0, R
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M]AAHI#;E RBE U;]0.%F:SHQK)!U@->/!"F#5UIYFNF*$2Q%\4ITSH^XS)R
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M#0$B-(,-9F%&CN<KPC)N?9&' ?/TF=&Z05Q0LM"-MS\('"#/BQ00T',Z]RK
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M!((E*.FF+# T?_3Z@[71?5V0LIQ7$S_[3BG'TEW$\DT0@=]7H[ H";1\5/7
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M][@SD/0;EM;GL4TY&%/#KWJSHQ%/0U^!J(I>:XG03?&5"YR]&XSD_";)U86
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M\*2_ 9V6JPXW\1K\><+I,)'E'VHMOWX5-^Y?M>KV2CGM;6V:MF316)4?]'6
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MT-CQMDS.9RU-)J:.J?J) U5'E+\\2OXL]'&%AN5E+2Y+564T&WI:5*N4"-0
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M2Q7_O(.U>,L^Y%"VV=20<K CG^SUI;[>W=Q[TJU0D+VG:$)5GZBB;]D]/RT
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M7C"ODPTKK.F,YS^*7_=V0$C8V'J?VYFV&YP-A5;U"+++B^<XIO.WESO9<6H
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M=1@XV=XA04OO[WEO6K?.%:R'%<Z-?\Y?&%Z3?L9%48]085]V&%V9U_HY//A
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M K^6C)2T7?L1O?X/-+C4TX$JP<[[CZV(SDA2C0+P8N2H64_9YH[=(OC!RO7
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M)LA\;MX'02N,]-ZZJ_=.IX,+H\_+,$EE5\GXXEV#!(**>E_306%=?_M#"[>
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M[WNV9V,%Q1 IZ!T +1[*Q\C %B8=^B<;T(WA]G+HM1O=S,AA+P6(VNUS>)X
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M&B).R73G%\5JFW<2\3A[I!&@3M9J'CG'2G!_XY9^-C^WP=ZT0Y)_VAPF,K'
ME\ )DYY#8<)@7TS3X$SQM?!(-_T<+D:NUH(*/$T*R9\5MVRA<>P%DS:,6 AC
M[:$E&^9E&)3BFW%"\\2>-.R]Z44, \ F/I;U#7S=M!#41E!QE5E5<6&5%L<U
MP5L&[M!"*#FY$&VB+4HOC%$[F"!?9Z9]"(>FPX37Z9Z=X'BB)K2K0_GV9IQ
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M=)W$!U02+Y$^Y<W/%BK[77S1NOE\]5 J-46N25.)IY<H)/!7=(DFE9IQR;C
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M@ECOG5?0F(>$OT34LZO;-^2E@GUG>=B3^Q][ *.TDGRXP[ +JB#70T*<+?Z
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MTV@%'>\47L&XZ;7N&(XR#HZ"&,"_*1!1A%&?&RR/Q-P1.(\)'YJ_6:EU'MW
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M,:>M]HX9/-Z*^G&K7=QV%S/(2%(K-_C<C&H+& ^:="QYRS)I])#$]:ATE<@
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MQ*TLK#R'GN7K/BNAG>"O6^Y&%^7GSR4#9M,AT8%H,'I+OS-IMK7K][B8R?<
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MBI> ),+/9\ @\F&Y;RSNI79#1V$6(;TK6'.04.JS7V*K-V01[Y,K,8F6OZ>
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MR[M HJ8TX3LM@';*3*X-/J)1X./MB#-?_[;-%%OHELHS,KO^]2R6Y&Q\FR9
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MK,Z.)\)?B5TK*HL Q[.BZEU!*(3PGBQ1('8N857:5O+;*1>WS>:@:=UQH]N
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M%'-;UY-4ZHL1]^I U6EK!#H4V3XLF27\V\,TRPL_LIK.XR%Y0-PF:RMD51M
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MP@A9BG\4D[*V3%ONQ]@8;QNA!-WN>1J97YKC\O;'C^3WX.$LEX-<\F-%E'+
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M\PN_TFZKH])W4#%ST/]$:.*M(@4.(,Y[A ,R$4?(@;\JCR4/Z&VQ_-K"#G7
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M=TT]9<J&7]25! Q/=.6FWF-](RNYLF8:;&J -&K70"=UZC@/;);-W'M(8*>
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M18H-U=27-:FZO&IFN0\M6<F$JG]^*A)K :F''85YJ8J>?(9,0;XUZ'W 'N"
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M?VQ3PD=S?]9O[&X=]-"[Q$NT,^E>T8>EK12^X@-.'D@&X$5FZH3JPRJ+Y.$
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M>BU5/ZY)KBF85  R\5QQ9<MT?-;AMB%ZIY5(LU3]WM)5N+5R7]P]P>/7U]U
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M&G>?64U>/F,$\?I8+DRQ1T\T9O 6ZSHB3'!)PKV='O:%&V5%VRJ&?$[L7R5
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M) ^;%-;UT<$"Z8Y1J&M5OE,;Y<DB/=%>/4H!EMOC_&0 2JL8'V9H=<1Z9+O
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M+"J0+?Q,W(]'E/7@Z2J,@>T?K.)FB:=6IYI.ZN3>-3^L)SS972 5C:^F^O#
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M+5H\<(5\#E?/A0<&4BIE5-"F=A:4>S34=KKPK9MB=9XUJ318O_Q8_ZS3K.,
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M+2XN;'E@8/>2G5,#,;&?D5=K:3*<TTW]QH:KP.A-X9.((X,O$!;L>?\KR.$
M&Q9-R7L\AEZQ9^<PB2@9N)5Y#RJQL[6#\_R+H1W3C5':I^[6NY>MEF&=[P_I
MB>8)L >V5+26OH_" \<D!N/?4',1XD<RPL@I,P<^1N_RI-?*O>42"APPUGT8
MQMY, Q<V98$]YX+C"9*+?D/YO"MHOO0Y32X#.C=DU8P+69ER&'0Q&INUO4CZ
MHA['T["[$-'NAP!O'+XR8#75#SE[)_B%SL0J\Q+Y;G\<A'+[NW@=_((]X[9X
M7,_39&*11,K4/A JK69+GG-A$>/IF$Z\D6#'X[(E&1?8]\"I)'7S'3C'<27
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M N2&],UB#PX(!G./FZB3(5L)L$PG\S%\ETYEUT8 &;$6/TNZPC &N+!4-CP
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M?LU*$T<V5<$'.JK19UOX^LU!]$0+G#?P0.)K%!XXK<,#:YKF#8MS1[QI5_#
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M1_L8  8-1V$MPHJF,$#?3>B.K_2X#73E??UQ0T'>U[1)5YQ+S"7F7Q6C>6!
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M7HEDB*,)F".P-!7(,NE68QP9%#AEW6MA)"Y126,,>MO9A W*L*WW]I"+M[?
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M;Z 2=C_FS0:US,K2% 12B.^* 7R%S2$+H _ON/6?D8!-BR.>2B@.RE(('V"
M#8VQUC0,0*)7@0&R2C! OW;-QOS][G=HT3+BAP:/F4,=I@[1T23)M5&Q*NL*
M9^JT_N5MA">45N"-;NBJM=Z.#W0QH@T#Z$=!F7)G ]%8(S6JV3]GUMXP[\'W
MC#3?5KLR"Q]NZ*G[AY][S^$,W?*1\NF4-*7!LQ8\-Y>S<TPCK51^'ZTEN^DZ
MUB!"?[.@E$-#8OH!HR01N"E)Z2!;V'!71W-06$_DXK(%&9= PHJ8GK]W6BE]
MAE#5\L%_ICQH_+9(4>*[T3E<@&$C1",VV)-8;R.)+5:EJ+8\:'3IN)NQ=U$$
M 32@6G0K(<5'_G;+1_+C7\H*/.)A36<YJPTW[8R,@*/V'H]2 U5+#3MS]-7J
M8J]EE@<A9A"O%H]B=;_QGXD:ZRNO$0W*-= LVTU9D*ZFZVY_Q_F7]/ 3T^7Z
ME: ]!1QUR!V]HN&/1I.=U.'*LP<%J:5;# K(\'D6=(]]LBBCSRN>[[4WSO%)
M81PO>S9)-/E8Q6T\VKEEVK0U-*3N??)=E71G]O?$UW^Y\7%Z@RRF2.?'_*@
M'O&B8Z_8CRP/\Q'>EO+RH3?^XX=W7^W)W"8+Q1&O_MJ789:3Q4>^;K+*A\-J
MYB1*4E*$,&B*KG_D Y_=XBE<WY3&.M%DF(>%4":EP5VL^:@L7YLZ,+7L??(/
M%Q'LX_OIHK_<UPHE(&[KN1(_NSD$N$IA88 175M_T=L6\=# N>IAT_(SFI*$
MX=;FDL]KK0+Y9GON,T,.F;KHG>*?40LFOK:46AMO6^^:0MG>X-QZU"!Z.#NY
M'IR*$@Y0,9KAV(P^.MW5Q6F==IN1*!ZX%^78/F/UPU$Y[,IQ?LXOJU3PV6&
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MP887#Z&4)N4+.\0N/L,3LQ8/K!-V)(FQ\0]_=)Q2+G_-Z*#9%'6U?HOM<T.
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M*E.G?8D/JT#<V,BI*+E#LPM*H V4[3\$D^#\3\@'PX6?E-(OD ]_H^%_@O@
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M=/= X!6S 3O-:=%MN+KR)U><U2:Y0_,O'@HCA&_!ABY"B$J/HJD1);>01-#
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M='RX=#?J<9&$-JO"*,31.28]#>*>;(V:\,J)Y0UC**YZ;Z K&Z>C;([(]77
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M$6J&M'V$45CUM6=GR=1D5#?(00C@"@0<3$JBVH)W:5=>\Q+\^,?$3 Y)K(C
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M/YP>?(W^C4VRBS,=P?T5(<<9*EUA$GW=-_1HVJO4Q^52K2YBBUAPB9^#@*:
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MKR-;G%_^R'&2!D*_  3H#>,?Y=9]KHV646JTD[JLP_; #8]S,MOB@J/I,TQ
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MH@V^ $>1.$-W]!')UP8Z^9HB]F.YWBBN<=34QCAI!@RTHT0A4M?A_/.7WO>
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M!47)R<^NW\"[N DV>^[;3XH-.!D2S+GK^TE06C\<M+8U)+D?4/%NPB\B'=A
M/2@]*]R]*@4OXC''Q LRZ.:BL=/N6;65R8-3LLE<5W-R>,,Y7ZNF9E%ANN3N
MGV8&[P@;(!YEF!_U.^^TF@D$4/S*G0A,P*"V*W:AP^U^=T5,42)+A!14?*T
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M?:G;)J%KMVO/X1G36[!>\>E="RS8RAOP)9UO3O>7<(&9+5*W#$6PHDHPPM+
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M^E0$=()R:- J]Y5/&A>O<R'\12M[)Z;2GNI"PK%3Q9O,M,)&OI2=H"]L&QQ
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MCM0;<.O6;^_OG/,_W_>_]Y[[,)*\[YHU,[]9,VO-V_*\'@\=?P:0J*NHJ0"
M0 R@-] ; #A>9FK5O8% (9 W$"[,PGP" '$%-2TL+ ":F)[5WL3[LPE@H@>:
M C#I.%3_LL4  -!_WU4Y3F5)>MLR-&2B%KE"KHHZWJ9,XS[MDSSI M*>])_L
MG$H2N+@YP%$Z[B@7=Q2ZB7/"4W1V,X#"W6$_]D^V^JH*BB=;-3@*^J/O9/\/
MF=.VEHN"LPT"X7RR?_[4KH&#UXFX@@/J!_\['M1-&PR#&BH;&Z)91 !] !0
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MIZ0A)Z<D)Z<A)3RE/S9_3T B @(B8B(28F(2"F)B8HJ3+V**[RJD_Q4#Q_4
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M:8FHC?_ID^%+6[3P%MG!AX6O6?<%Z]20=:JQ40&R_ 5'!%_&<RR(FP/F]Q-
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MI.UX-H4NAO!KL#\A@L%T+VXV20 _%2GO13KT-R>([!>HV(1K:D.:8B7B(]S
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M%D+6I*"0M) 6FV(E^QE*"TU2@\:I67-E!Y&U<[VXC9UDC&D=] ( >B$/P!G
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MV_$LR;3.J9%GJ3\(.#HZ!N@ZAPJG"=(W01K]G)B;'R:U]!.1M^O3$P!;*9+
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ML.7N,:!V;'EY=6UM<[FW!OANM1<AL]J_AQCT==WQW.$BENGP'1P/R\A_UQ+
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MWEHWVHT)GBB\(JJ;QW%-W5*6:I/L;^LI<*8CGYY5<BV\N  U>YQJT/)"2 S
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M2 $"$XPA21WDTWY/;[FNJ/>"GFQVT_:S-J1N]B8C;P,+(QAF$COVC37Q]"1
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M:I(]>=;5*B83$+&)\'6I8WSJ78'P7^[M'BP%9L%5"L_;/G-H:TI#53[M-)[
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M&4:&J9$E+ H9?01DD)A-'"1Q#@S'(\1\97Y;]3VW7F0\#.FC>%H^ P$[3B@
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M/0)L>8YAV<9";R#Z30],AMYE5_9U?Q3=\X3+9OT0Y'96M/"@$31M-_GTK4=
M1=($N69\]PVX=G8::%M:=MCZ"+B^7#Y:LL/_HU#XD9_6*!_0T?R[?4\PXX:E
M5;M".^%\\3:DP"B4+]#G'@35_0:R\)"/U(LY\+YIE*G(O_W8RZ]6)Z\ QS!.
MJZ05*2R^262?J$H=#Y=L]05+3 N> NT"H\(#@>"8IXG+*A,C,2:@3M&W.J:2
M<"PE_A>;7AEZK X%]EM!.)M,69Z& ("YD;3@''1A'C$#'G3)=Z0; ?>TB&?=
MD$.U#FG7BY"^53JG$2]'=GJ6<$E%$[XS^8Q3*LE2999@TB57.C]_824=0^;$
M)CP<4\S\<T!>[P4@K!)_$6G" FWR.18_I[*V#F[2KR1GG9_.L9@7*<LX!-V_
ML*PW9-2@+Q-JA?(H=+CIZ@3HI%MJP[!+FKVG-)+'Q5+_\94Q'O*P2G:1]3AO
M"7\+,,B!23I$/,2_5%.Y05C>K-M@TV#-:7^(+\M@W:DQ6' "9*>KZS6VY)J4
M-KHMK<1JS;&*'Y\7MY+>D+>^EB:WS;ND+#-2+!0*]U_O5WR6%+DS&U9^=QV"
MG$57^Y\WP8&O'!#U+;Q1CO+Y25\'9SGR/^J@@V*&>RB85/ )?7,^U#=E! V>
M(MI_$>7Y+]ON"HHB=E3Z]"%KH,[5UCMW;8T%J[+2LKQB!S<#'2 Q%^@C;F9=
MNU28;'R<,E\E"F9<%9L%7<:;W2A)#T;HEZFIU.7Y5"6RG@'V>PKF\0-)_[6K
M^>60(F(7X:-Z'LN68JK$%?_8('.;"@WW)-2/\.'M >V,9V&^5P))SL'6RJ_E
MSS_D)S^OVI72DD1UU.JLHW^/2952RR&4%L+-X0Q[+5F!K4EHJ\NA'<1>:;H^
MA,M5UT) ;&W'@ .+CXZM<"M<FM[_XGT7&S9WHN2R+C/1QB*Q8I#J O>-$*'\
MN==[8L^@ZF'UCJ-T#=YXNF-7MXMZEV\IU)P&O5)KOK9P+\I9PKIQH_B)[G[P
MV$7I<\ B%:*#Z-YF.\07YP81X//0,3O&D6[!%G[-0?6A]E'L 56&IJCPS6:K
M>H9\%L@U-OK^;!Q(OE=JX&A"V/TD>14CD+-)[YSEAXK)V;HVQ3315K^<,2.[
MG/B\V6?A<OL!% G]<J:Y'!W5Q,LRX5WP5!OQ(431;2GF(&\AH:B(7_!U[%=R
MC"86AM-+OH:[^=8%NR10ZNC81?2 9.SQ1E&<)7_I,G9T0W=<[GAR?ZAY2<=*
MG1%Q>DAMAMA74[28^G!_ICB\=+_TM]$U!W*N9/M:\S9\5^<;W;>T^>^"T"FH
ME^C(Y-R_UQ?DOB3J\4B[S(N/M5B>\CB'[.U!+/:VK]R',G/U'UCQI92*!";+
M=W3:P]EJ*)C*,Y(O^:!:Q[;?"G;CIL9V::W\?/]:#K#X3^4 KU6&(?R<XV,/
M)N);J/]5VZ=2SA>_&![B5I>.T5C$M,_^1\V?X(D0;X?6MS,EKB\ILVB=_V[8
M^O?1[5M62_5Q([CR<./C8L:(:2H>=C]O&LRZRM4*52SVVLGL9)TH(G>["$W,
M@-6Y*9,,TI4G6CH)@M\ ,3'.#22QN=WBKO2O5;W[S872=6J,WY8] CS:ZKZU
M2*]D8X+DVOO#2>_74J.8^(#-0:#0S)@I)Z_,[T73 :\N1!6@:8DF7>&@^KNO
M\-^!VFSY,$_V":OX;/,V3-[PU%7!L42[R>WR?W%\@=M_<?RU_Z\<_V^C%&X7
MDLC9A=YSRF**]"]4?XQ@!5AU,U13]LEFC9:^_&*?!V<6;O(>C#F-L2=5YF1G
MK)L&1@8>%2:E,/",R=7/R;WA@8V]._5!J!ARF_!D;[:9&RL;)]ZA8&>/QZ'D
M:'L;*+/*3NMF8J'\+?7M>JP.,R^7&U!V+OLSE4LO=?F,DDX^%42H'=D0PEAG
M[9_!+]I1/F/H3*%O]3UO=V&[F'74(33<(!\/-I$RV6SWMJ\&S:V#3#*'?F/=
MQ.QLZ&M"0D*2P.YV+7,2>9+92Z=UP9*V6V:(8[EC>9%C@-6AS$LHF47C#AFS
MQ]NA^<W71G;.:K$B)PJ?X[.9E! DYZ?CEU$Q49'@$,TR-7YA28'\F70S//<=
MG?QIJ'/67]+&Q\?.+5FQ,+R1;ADR3OC@O+;V7GW3W$7?W#ZC3L FU3_]DU(*
MO\#:^:%X7V/;X#[^,S!+UU^RG/U_RG+@GV% ;DUIE[J$D+?\Q+<PQ!WE@-\9
M+2(5K.HKN?49M*.I">?>%VM^$JQ!U&'\N56 &C1/3AI7SUW9,R9-B,>?;PSD
MIR3Y:B9ID//S4KRC VMBYOE7\W71\?Z]=V+CU#9$*AAZN2^RHHPZU&5,C70Z
M6FR09)MFF;,4%&A"^-0(G%<X!'*T1&!8$C@_OZ;G_##.2[L5OWD?F7YR08I;
M,OU</.ITO"VCQM:3"JM!%]LX9=>S^*W<R[P3OWRHG)/T7E%>!0WV*_2P9I3;
M&HI(4,BK3!)3J.]W%]-^DD"NXI@:&\)YW.+G<Z/YC7EHAM\4O@2:' 719V+9
M0>5\:U[E>'!8B@24QP@*YZB$#*JY=VCBA0^BP[>VVPLJCL0#S--G!OI+])G;
MUSUL^N-:\92J@4)4K[GDJO%Q H=.GHL(;447ND1ONS(G?Z>/;!!ED2Z*M]4\
M^%:3,H''E"=TN[C22.;-15.N:%WU2U_1,0BHJS>VEUU(AK_SAL,H/:BPD36A
MDLHYCO%U" %>4'<^*$YCLM+EN"LK8<U5#FY BK'9>SHJU?\RP&HZ%?"YK?@5
M/29NV&:X8&$0?GB@&8QW>\R\N#?,3X-'DDJ._8RLH;F\]Y5&"BU-%VG>62+!
M1]X<*P=;KA$]-+*Q S@4# <.GX\E<E$A1WN594*[#N2OAGG=(E8&VKSAN9VM
M0<G$[],%C?G"P,]CUC<,^>V=Z=FYZ+K46KH'DTAI^UNUF^KNUS,@2WWWCP!E
M-K- UO7$<6H(PLXPW[ILH/FX=C--=$Z$-2Z^A;L?[7P:D5-T<(Y1,4Q;R\!@
M5(C^ZQL5268K=EN&0?Y?KBS*P#K2D 4C\LBO3:95^,;0P&6]A$*O]U;*-,(F
MJ"(>70ZM4JL%13'7<01OTSX("_.U*]K&"<:;!> *O!P*S;7-L>/S_ZB!N8MH
M\KZ?&8U'^#Y;GQE:A; !-A^_J((+8:T@>\L>/WGZ(LO(:/!3'$5+L2DF80\'
M]TF_Y/0 I?P8$UZ==1^'U@Z\+EEWQ*1[W&N$(A+P>)NYSY#6)81!XT6_AT=,
MGI=S9(NIY\ "J0R==%DI@^)!KFFXA Q3F)S)P=M2^NX0$MR5GTQO=6I7JM!B
M&%Y7OM'Y/[/9RT#CNV>B8Y[@!PJI(G21O\YT&I^BY]LTV%+0X?)\F0<DK9K8
MX$]2>R:TCI*ZT-X7HET;5_E_6QJRMI&W3J+"XL93:Y!4PYO3Z;YEPCG[X;(Z
M%L2066)"FD;ZK3EEHF6,,ZT&/_1<IJB%]YF>'V$/?# 3*5P0<56GKE\GL72(
MU*IF)A2OZ45S2?I:KJ46[;D=5/%U B!*] /L\"9+L[%02^=VM,UC[=!MLKN8
MY1NS))2AH+0K,?\HH;'BE=B+=FUD8N/$]$7\/8]3-%N)LKZ@VCSF4:: @PU:
M=6W;@R\2$N4CS5:WMR,,Z2X5Y6KT%K1KI^O<T+ETFS3C,J==C)IG0UPV<3CM
MVEDSWXG,& +%PB6G.RQ[Q] \FJ7(Q!%5SDRF91!>&!2W-Z$7#U'3..!&D_W\
MZ^J R(%ZF=$_+A1P>B EIK#U[[:>D+MCM$<47KB:,C <\EK;UZBB?W&@XN_8
M5JR6^( T7;\]()J, &HMLT?1/2I*O.H/5=+Q4.YK=54^L1NXU'R! \'NTQPB
MIPHZ+7+42W>#Q4;.^P@30SI22(C9EF62\5W'<VTDZ9YY^-$1YG_#TO5#_1YW
M.^+'/;(R[;MB./9-R2OS)8VL^\%B>AT5JEB59ITI8S5VM\N:J90^K#OG9;&T
M4[V:HPM=G9EA*[_#$N%^;42G( 'C0QEI><+D7DUAW^#90UE<\DX#>;B =83#
M4#JI98BC ;ZP;6^[ODDX,/Z\QG*T8",P^90)B"#'S%R4AHTU!<UXC84SX8^(
M4#<"AVV,@C/+[CE6+B8))+"?%[0O396CCAV3HZXKH_[.XLGU_>-X(8.28_K:
M)C]4+7UM/I]?[D M_NLG>650PT)#S?Y$IM1_MRS4'Q+Q+/+_$GD*E3";/9!'
M#!EYTLZ6.$?(I4.LX&\^0LUW%*MUDTUG9:B%S7MOF)>)DV@DFF+)/<D2N39X
M>J:E?8DC=,[\<(T2P^H%S:HK["D$[-?FUT7A%^6O+-S,Q^8%<1S-UYT4X(,M
MQ!/[+/D=68&"IZ!",ZVM:@M72AB).+F9;7!Q$VO4.PTA6=+)JM@$7+8?MVJV
M,EY:@HZZNZ<RJ&25]R=#^>>'3!.9_!K.K5=89U?[F_0FVB8<9E'X0:A@LZ@F
MK*"TU)F$C#X&:X6W4NE2L^%L0==(Q=>29O;C_.+7ZI;72%*?O[YV+R-/Q^D_
M&TUUX8WGBF.;F'L.#$G)0.\9N3,/5U!1*M15C*&D>8<P,=G"))A5%E/7LG9<
M%0_R/3@N5 CW-OK!I\Q4W'-(F"TMU\6&VM?8=9=&Y]'3&=^5NAB Z4C;1W*@
M4[0_Y4;_(Z2UL5^?Y3N5!RY_'RJ"E-9I[!L5*W[6)MDS5=9X4XV6A&_[\I9"
MXV$&.@:+&3DAJ>9O^.84$219]&Q<6MOSWX6E(X(.I\2F#BW,@#\JPYJ(M6)5
M7O4__PB,SZ7>^:[4G#:IX*-(N%""_K&&U>IM,"U7IKSYFPXG[\#H[D$!5V=-
MLAH)7X4\M.DRE9\315(2,[I8>-QC!+S/-)20A[H\XXAS K=Q8Y*0OS>;?%;D
MPB[=&+A-?R[##.9/T"-CE>H]&9?U8R55B%M:*H71 ZGI2579"G"&9EC[]^1X
MA,QO'P&N+PZ+6&5(=XL0/6M_=U<]8/YJP)G!848F\/WRPW;WX"$A'"6=J8K9
MU$HR&BX5>'75F#DC(VN6HEB5A7N- 2_5OV#=2)Y2@'X=?=*B]-C[VWD#]O@#
MAN"[&]/!9$OL#G9,,8]>9+/2[-1?%5A$>#<*6]D1.!_C"3%8-^F!D8F\EO7G
M^71P#>KZ$^2O:1L? 7&WG"M#,L^1L\,#"LJ$@/A6*#CU+55!%I_,'P'D$@9:
M>G3::'JZ4[S]J,M,^EITQ^?*52XLK!OL-<%^G:]IF'+,\=\Z)BTM17,DQ;Z1
M;PX>?4C,<'#-I6EW<W?H/[TNX.WYN<:/KR/SF1W]*#7,?YE+FU$MHG7.0$$V
M#_T#X;H9@XKVNZ:U;&8I7QEBI-%_V&G6( HZPGL$R!T?7@7@9S'?_"4NAM.T
MJ)L-J7DYJ+E][X?,,%"<"J:&%XW+7*2*II,IARF0%,8)5_(V"_%F55,P<=%F
MB66-,C#[V9GTLUDD(NO>LSOJ.GYY56BKND!A[5*A@'6G6WX=Z#V\?8+/V<O9
M5%J-D5&=6D0<7.LQVN/N_*G5E<]$&P\W=++3_M"_/U['\?I2-%T+UP:CK[."
M^3BY5F\7BC3XY?B"?NUBW%:I7>N:G"J]67DM944_KLKO.=MV#'EI4T@"-7>V
M$'M*QGSBI'#E"A&5>ZD.%L4G%21[1@66/ADH8=NK[%94:Y0R4=K12#\7&:^W
MO):R_H/7_;2;%N[^J58,W=&?5UV8\^*P5%Z^=Y.>%:@;FI9_]V%,'VX(75N0
M.1IS:N+_>9J%L-Y&!U]OJ5[ H!5>A]&/2ER_C((^#OBY@2B3@\5,$: JWMHM
M]AD8VJW%B]$PEUTN5U97.S4^KGM5N./AWZB$.V'>K9I$5-:AI^,1N]_8:OT.
M"/SX0XJ?";ZYG0H+OL:DUU4BJ#;+)TK),5?X^[V=+:T:WTD#9A^]M JFRDDV
M9:(M5"Z0G N*QD?B:QYY@3GO@\GU0#-I;A^>D,2BDSO\Q;-,CI<GG41_SCN"
M1*=]IY_C()\URL"55D/J#!8RGD\WOM>TRIR@#FRO5@MGSS7_A!6F1R5P3@?E
M?&=4)&.*3<7&Z-=()2^V5XO_S+>\@YZR.GKF^SP^Z@7$O.ZS-ZCT3=-RG9EH
M4[$H[]%=ZPOK?\F)_[E$_K7]WW+B1X "S@L)@FN?V3@HSI,E&O8Z\# ER:;1
MG+181JV=="MU65@)!1*1>L1P:7UAM<*W\7 $J:U]J4QE2M:T9F"J2@&'DXX:
M7&8Q__M<[[^)CO[]1\G77S_-MW+V&HJLJ2,._=U'T"'5A,(8@A=C'O!68AY*
M^E^;=F\_B,OA7:1F3JO;,ULQ1.U1[<FDZA\"GU?+#+(9M>X;(_+6WUF_BINV
M+"RX2QI(WHW_1#LU->8!LFM65E8L[]O>'4U%[TJ^<2GQ''DK\X&^]C0%2RI1
M7H/-0@\HHM0E;&QJ%^VO<*QT0O(C17:09KF@FU[8D=V7AKCPP=XHA+F337U2
MZ+8NS8!L)]_L6V].STJW"-W+%R]JL])S)O+K,^M:+[TDBRS>[PVA?ZW1%ADY
MZTECEK5P+B_\@FHT*]H!G=4[24MP4Y286]>WYAYTSZ0*#0O5O7H;'8\REJT\
MO(<RCA.?V<L4[A7";TS?YG[XTV0#?G[9,+BB];#[//.$'PRJ7TH#^_" N5[_
MSU3]8"+^"-!',5Q_@/S*5(GY3_4 IV7QZL?[>[H>R J>CF_-UG^;S/]+Y/;V
M]+X OR-%; 93R:9C;"*ZIVZ?WWP%3T/:MJ=U2):[/]_Z=4^Y+:6J:^#$[DNL
M,8]*K&PQM+TN!F9*>7LRF<YB<H7MX'<)RI!:!F@%57I%@VT&50\#9R:]7X!5
MTF;PU0%'\+;B6]7LDNIY"8HB6KY"^N\7Y -L2%/9Y!#PPR.@/!+J^774)KT_
M("UOK-54[CP_S/']6\G71L\CHJO>&7#U1<Q,R9'3#+8BSIHZ6DAQTD2B)O#R
M%[C%2.94QR?QZ_#^M/@Z *]*Z_JO/0;B0M<4(W;U]-1Q$N#QOKTL4\O2@$.D
M>9U-_*D010]>V]Q?@NSP$6 QO>P1.*;8D!<'@E GN2[U)G>_CS=&7.>O(Y1F
M@*K%9^;D)+G"K*B_-\SLEA0TIMI\+]*P&6'V/'?=\-(U2]B?-<YA8+0$?>HV
M^PG_C98FENL9-U<D6\@"^P;:,$WB# UC-SFTR;$J[XU!=V@OM(11W2W2UC @
MAE K(=[=,4+-*0AQ5R^_I^M]<7T&J.]$8%BK>2AEE-.#VB-VOC5]ZVO8-J_9
M2I.)BV8&ZJ:J <M8,Y#ERD5^/<A<VUZNAQ:K3&"H.R!9.]]W+!!!GHV'R +_
M=7B5K\8\%: 3["_^L@(X(]ZZ#S8$&UK/1,J/*Q;43EM\3?4./_V+:136-/R]
MEN(1,+VU]:=U@%KX-1(R2>Q:]RS>''7'\E(3\D781$1&F:41!SHJJJ7KMW5_
MLIE RFXLHH$-S%]D?DSSE#,R2>W7$,WCNU;//M[ Y^_VLZ.$G2.]\L7_-/ 2
M8C.Q SW_U/,(B*#Z:J7RIT_6B^>$23!)<N?]*TO2VW>YPZ,2;K?7HI#MC:>;
M#9]NWLUSVF?$AGP=?>CL1**Y&.G);)81&<OZTWS+>/D+SNU'TV']W]1^=^ZJ
M/&H/\:IEWRR/&:XM^M,$S-WH9]L<X>FT[.:<.LD_\/"'+$;%?U#!!?^AXO,W
M*F^4(:(4_WCQ'QGUV":]E?_RNXE8T+_*]V;EOZ+]=S)I?\B0/)$!_CL6]Z_O
MMZ/^V[O^+LCT;S S#!_,Q7]CU.60<%+ IH_.S\$<@:B5<\)'44_!7/=9?)J!
M^8"G6*Z>/@DNJJI000[ZXA5OJNHS0JLD5".LTB=Z1*97_RE2=O\@#0[L$5#V
M^Z+C(Z 8^@5\?L-]$_479,@)V=_4!PJ=C_%?)" ]_ 6ZSZT>]R3WR/^(W5^5
MNWKX1PT-=CO_GH7_K?+_5"^*?VA'W/^#W=G<_=9+^:VWXV_;Z?FOGO]OC.O?
M/LDGYTE2WC^2\OZ'I-X^'J;_2.E/Z[A_PF/ZOS=3P[_Q0_N;BFCGTR4]#_K?
M=\$.;]C_WUG\_W8DC#O!^U>[9?^"6=1^!*GN0JZ\7FH2E:.M-NO7S B/9]2E
MTD6?A_(TX?H2Z(C\R57V?R+AL0,T5H&+$]2W3MQ5@;V>9=T@,][ ANXEC7Z;
MC=@#C(9P:J Z^#P=2RN!5R=P7ZIDOS91*6='=L]_)N[3?;B8<S O5V>^D]DA
MJ;^=MJ!,5?DA?O8BJ&A!W?0Y9W:A_V8)EQ)P]49V J<EBCOFM0-=I@0O\R>\
M+_C=]OZ4LW;.OZC%W"1_[!9$:KW#;EP+<4;RBB8P_:C65[OZ\K2%J']=GJIL
M R)G!(\=.*^R6<A>;!_YXBL8(U]"=>9U92G@<\G,)4MBQF)!ZHQ8#H:(75<J
MYT]E_N0!*'9M>>3&5;JK%66WTK<J26,Z_/PN^)8$[-C.G,/01/Q!6O59-^K0
M/FLUB2HX0\/$>;;@A_?6$^21)]X$PU7!!E\W9X+@DF*R.*?3]U]-[(W-;.+B
M=+%8H@-)%2\AQMJ9]J.O7VN& .KD <5K:X54-3Y+3\L.FV5FB$M.C08Y6?9X
M*==U8>E^07B6-,M 8\"!,7FOF*F]6WB=@DDL$E&+GG\$CNS\-X$]G?K)_"PQ
M>R79VCA<O2RL?#$BJT? %*'7W^,LS^FX4(61K:PU"4<:0<?Q"%M4'A6:KOCT
M3J1H:A2JJ@XUK/FTE_:8G8W7+:-V=<O7(K#]];+#DVF?D7.,D\B\G&L9-;O0
ML+F))M?5"N%]H.[<*9>\I[ :2'!S;UBT9Q87<14DGGGBK1#%92[#5<UG2BTW
MP$)X+L(5^,U$:8&(P\'I.<UY+<\&7O01OG@>S0:V#=[RPW:,2^5WXO0$!GVT
MPZ00=6"\=0Z7)OU1\0)B1K02.^R@'B9@(;QT_I1N;=^+TA6>9^:.L7PK_QH3
M-\Z42&Z>X@)+FJC82>&>.^$D4&YSO",;TU12"4VWB#<E:&)&PX<_JF=E903'
M)L_:?URV*6QY([NU [0GD44SYFNDP!ICTI[9!]+S?=:K2C,&:7_3T__0Z$,7
MA"D\[NE>!BHK&-L[AUD*#0>,# U$*D&PJBN.ZXBZW#.IFXXC0A1EP YJ<KNZ
M+-^*=/XY@GH_.SUS+)-W))IY? ._G(7W[!.60OIT:2+5^]B/94*L4]@!^.R@
M16KRB_H5C,,&DGW0Q2I$'XY_'\\P)O^JR5#"US7T3>_8G5Y%MIB@%,&:E3>K
MYD@664[8"1>$@&E+!7-4ZIK8,"SA=WNRG+N(-UW0W_W.5+VEDU;6O=#@YN@A
M5.^.'=L" /^_$7P9:20=SF9Z@%?\Q?OZ^+P!]9G.K2&%U#[8SFCNUF"ZM<+V
MN\$%!'T$W^W_4@'^;R 8^L,/BZ,1$0Y%@BA1O/)W"^ZZ,L&8WVW*=:8:0J>R
MA*H9"0B$O 1!'VF9LV<[2.@DIC(=Q4.-Z1I+S/0D*"U00^L&5?&YY0+@Q<1=
MFP)K0[2-ZGXRJ9 )84!3Q>PDOBK*-Z'5-FY"6:D"9]W[U650"7*E%&@*X8R'
M\ZVE% /'HEY^^^ 0C/W2TFTC88; G]F99D_J#0<71+3DOGV.B7QYEFDQT(0/
M>_+F11C-L(<1L$L)QXL]MT9)L*?B8*:WJ#II "M$_\L<NU;S.I5^%+IH%4K!
MFJ()@='+MA7Q;$L#\=9W :[YQQWZ.C2)R]J;='KOY)+S9I%$NX_J,H[$:=10
MR46#Y%>O;K"6+())B7I97F0GUS2R)/<EM;424*&WR_91_Q(MT%P;7$>:! _D
M?F@RP/U219OO((0K93\H:KS14ED/PLILM)+A*!D8Y\>;<@U\/9/Z.HJ6OZG<
M)H@S=N;,T[/\AT+ 1WB5]'BX>G)E%KY-&S?^*>^".A;BH-72AM*]X9<97T->
MUXBO682;(W4WSH81=Q"F6[J:1N3&RK\LL'5T]M29&$HIGU8+9J@P%11P_F&^
M*-H5WKA**_N2"Z*X*$,;2;I2B7/MU)(>+[UP1M7$O,Z?_I%XS"GRY7=M%M\/
M?CB=0!O W ^S9W#;_'"?(G9]IZP=20-CQ'2'U.&(D_/]Z%T53/S:P<_-?'=]
MI1%Y*_W1#:9652X+>_1JSR$LN_6/ );KS.S.=$\I.DS5C9RQN,!I&OR+^+I6
MGKI6NZK\#$G9.N>>E",N!+[FS[;87BG=$RU][-3TFWE.ED[E>0')S5+D*@XE
M_98:.+Z_JM;.IJ537IB_? 2T$<)+TVZ;E[#OMCX"T#0DTZMV-TIM64405^D8
MI#$59QF.5W(1TY2'W7\49BF3E)B=%0U:?@B)/=[>F8TI&! H:>;M*5Y=^.#R
MP4(!&."N;M*QA#\0MFEFM(R7N$E(F&+ZO"SF:E4-7YHVWC\': 625^-BV>K#
M\),W*Y9#07N=T_F#QI>GTO-#8K@I2E$7?3?#TQ]U[(D<:Q^57#W,KMI-W^R@
MOH]_%E03OU?M"(XOY.=ED&O;KX=YV]R<T[#_WU+\<GWM8F8.P3,[/]6(O*(H
M<EB;-*L+BKJUY4CE67,ZE9D/K_*I3?4M(YA/UG^"_!?;TD$ILIP^]J_!%\-.
MF!FJ0"8)TC2L>9JR 2!/7S)1#[JE9VDYV%^*()S7#+^1)[<O>6V9"^^0PI\_
M%K&<>:T&L5C-'",HY_6I]-0BLFO+NQ<]A+<$ID6LY&+0R5"*H^2?0.+Z[FG]
M(9' Y]"!B#;FA!CHSG1(>VFB^E:_1.V[1%0=HT3WA%=.K!]]*XO^^N;^&9RD
MQ=711$J41=G1U#5P --(\C.= '0P-"N\EH]:)>9"VB&)C8'4]C/]NTIL)KC/
MK0--67/K2QX$,JT:] S0[[P-EH'91'1$PV-*3- W@Y>*7"GQV_7YABH_,]6K
MK =^ L/9-=1/*G)Z]<-"(9N%775N]1@.[]34PAS<0J7DDF@I3+@1&>7SLD@S
MY$U]/9R@;#Q8SZE7#B@'F37:E@G?V(?.@S[<W87K*O*D6I4/B@QR;Z2>&^+.
M_.?YZY^S "AXG(=#"F=GD.1H#WCP?Z%?IN>=5V@^>5>7=Q)A*OA>_[-?$0L4
M%SEM\K",;O/J+4)Y<'9A"$.UH*N9TUGJL^A*09W8H.M05(&>O7>66]".>(,Z
MGIE\.C?OJSC:B",?OY$:O>JKO?Y<G.VU<W/[IX9;4<=M_!CMZHO,VA?/@5 !
M6<-X%RHJ"0VQMVE8UMQT7U3R?Z*HED<+AE!R7T8/*<!K<BLK22%QJ+JY$8:J
M<(NY"?X@1V;YPG9?>[RXZ:MKJO6A<MJ#@./8#HDGBG<.>_%\<'ZWYO+[_,/F
M_.[\P=2>5]KMHA><[<A?]TK0$%38;403'0/+',,NLKFYP 8<YEYJA+2):O*$
MHZ2>5O-^:2-ER702653VD1"T?C20K5 T,]];K?'GK8,-@B_UM?$WEIC#$W[1
M?*N,SV[#56)UH[D['U:<RL=;N695+(>U*:ML:WD/.^\T:\H"B[5V,^UJ.;\]
ML/?UQ+::GEW/S!72D:13) D4+L,P,33)NNU "N%EJMV!4_A<U#PUM504"-:(
MV1MTLA'LKLQ^J)B7,\]\>5! K8=US4#ZV%#5=W+4L09R-'E)?<3JFX)T@LQQ
MZ7M/<X?</E0-!%6\J8=93ORU=N[O49QPJUO4P\[O. X1C:1]E=;P$1"%#GDE
M]NLR&_T.,K%=5ABI,Z1"1&61XNC7*F_U1@1:8ULY;C4EE85RP6]M,L'$_-*L
MZCAZ/C)BBHE5[6K$MZ ^5C/'(UYJ3&;T4A&^KEN8!NYG.O6>=4U"F/SZ[C/7
MP-G1#7Y;L'$O"QMJFJ<ROE#+V^,C@UR%:G7.E($6Y-CQ5STYSP.*HQVINHT3
MO56X/ML1J^_@QR-RDIT,6B'0KMVY/3/^./S12#N)H6F9E*FX&)_8VWP<WZ@?
M(XR4A 6U9U9./BUDMFMR,G^T.,"Z@/9"LP'IW J6/HQ-U>I[%'W29Y5(E)'"
MEGZ*O[/ZJJ:OQNMLFV2">E>)$Z4@[=7)T=)T-XY4JJ-37Y]T0_,;4%@<A0M-
MX#X2C4+VKZXN#EJU%5G<HD-&5^34C8&,0(<+UDE:::F@0GZ$EVNDDW _8K4U
MT(RA5]U<JW1)JY*;&-9*^DLZ.+H*'^7A9'P'UBFT1L8"?IUFZB(6H7'&FB8D
M>^;16EP089*FF6HK<?0U4=3%_"2\L)^.(EAU'Q\ Y7 EG%A2H4;TGO)UWQB/
MS;MK_VSDHE$T7\@3)XL&()!\4JK19)1./D<OJ+\3+-&C'0VMRRZ9=RK0L\/P
M&&?2/=T@I_3(X!#KS>,(J$'/$$( ?V:<(@R.=SA-P,M#3"RCEZL_A$ @69R7
MRC<C5D'4$^6 "0OC-M.)S"]58T+YW[3/>#'IN^VG4=('(Z7B<I Z<J7:VJ+K
MP+9"LA%-?90RZ"'OJBG(+I&8L<WA,%,<1SY.O>XJG); V93KW"@^*KX>AEN=
M!P:LXY9&Q*R:-=,!:S\ETG?!T/8Y.39*';[+U[S/EA\8.MCY=1!!+-)K])):
M]U;<\VOLB?UMB8H+FIX@TV *^Y=R68=VCGA"&/HZ/V[J1K>->:I%3X8%W\2"
M.6S(\8#YDWJM7#+2VP#MOEG%ZETX9^NX1#KY5(U^)T_&<_P):?/4%=E<]4V!
M1T ?#+UUW8(4 =M#;H%V<^_G0P#0R5D.NXR 96UD9G)'K2XS0R=OS?_$CTV8
M%-;_/GN -@R]F&11%;K+31(XMOD<J]/_V-G/AQ+J0!,5HHT.C*B)<UU_VQ_<
M%,EJRSX]4E-D91,ER[IC3;-_GV6/+\*Q+M:>DJ3R0@N9T)1%<1"$UVO-_GR3
MF]UH\[P1_=5Z/#.%CW//>T\_G?ZB*%FB?K; 'G-T0M KB9-B'(3,?9?BYWP8
MT?^GI:EQL@^<\ME7\D= L*HU_/"__J1CR6+])TGNS/52%N]E&X1OZ<BYP5_I
M,I%\S7EZ+_1Z1HK#PS34FBQ$,.7U?L8LNE[ /I::4Z!A2_9K8TDWS00%[&UD
MF%-Z 8A]OSM*YW^2J1/ONP\\'RQ@?@04"K\R/?IXWRFR?LZI8,\<1^D%C9FZ
M-*^FUR5<;W<(>\N>\>65&M+EN5QFOJOZFKQ#OA8\LY'O\)"<OJH%AJ4C>'M8
M37M%8($42D04J&+F6^^ZJCUG*!<Q3,-.:P5VXN\FYODY=J%!>XVEEBB8TS@O
MG?VMW4H8Q0:I^Z_[^/^T8^]I ^V*-9NI=FP/6F?_J*'H$E4JAQXW1&FA9+QO
M)[FA%R.7(\5?0WH%+:I,#6BG8+7"K':AXHL)'_-5]?TXT:O)J*?E&L'OJ'KR
M?ET3IZEO/^YU"A$7$G[U\@Q-$Q%RNLDE0RB I,&"OZ6!#BZ6*=@OD13+__CS
M4^C<[1)&[B_\0LLVU5[BINR]A(U7&%<K;GSU:O@[3&O;9H[<SS$#FJ@K>BW'
M^J)F*N])73)*:\7D1_SE(A^VGO_\EYY:0C(.6I2-DD,O_9C\!?>'7I:!9P3W
MO1H@&!=ML#,5,B_JZE*B#!=-MNC-X/%ZILS5U5 COB(X'+5UV9&W^MT;@YR]
MK)>R,1DVPI.O 2&?Q8O#7R:F>^#XL^,SZ<*O*UZ7#X3F*]:]P6A>M>.[<E6"
M[M7WH'1\D&=[0)>7DW<5YV4@DW]I>39LN=NU351GN6(!U7;0=OWESOO ^8+D
M!1TN CX__MKXUR@+S7OC#W'%0ZGL)_DH'>6P=7_HK"4[#ZJ-_610%:2>U@'(
M[T$#@@Y*N[,X*@@3CP6KBW63:.F-RV,< F<TYGGK#M/#XU>)>CS-XG256 K7
MSJE3'XI)H3<VW<US+*H:X_R:)O[+-NHYYS0DC/&[J4MW(_$Y#QBQH6=J__5Q
M1Q0\7G"+6;_+Y94^Y!X9N0XB!7\'$9V&7 KH='[":Q*COM$T'GUW$5'K$[QF
MOCE>[9BI2J,MP?,(2%]A'S4S+8"C?#V.%)+$S[Z J_K9W$IAF>>[ZI:-B62H
MB=!$9 3 %6%,*=AQD6-*E(E<O8]A)+M'I].Q?<M!J*[INFI(8ZL/ZZ>R2C$P
M[AMU8G7]R[Z,^3!N]G=^RK;T* G1^GTH,O9<N]D&LNG7OA:ISIV?=N/*N1/2
MCI"\+#,;=HTB5>Z"%R+0/X:MT51O+8I'?+P7"F^GRZA^K8)7MK<IHZTU/^DO
MX<WZR]Z=WPB;-**/'ZJ;XDB(OSYOLQE[XLD9C\/^]?.WV?(Z4KVJM0:ETO$Q
M#4[3@0_Y!]OIG0BZI!\-LM=N>ZF.NT HJ2^BNO":9F?RGL%E#GA03W;Z,'I:
MJO*1*"H3,W?W<[9))N[T4['OK(=^\C\'1^(]&Z6B*CL;FI)3.KXK%'@V(OR=
MU=W,0AS?1Z=N:-=@\?WGO5\<DK&2RL0MHWL]VH2X7,8HI][8R3M1 M;O<'?$
MDUBZ#"I$F!@@7>^K.Y%#L.A$= E5%CN&RK8G+R2:X&C*L0A'ZUD $@?V^!"&
MS%@GGL)J&=K2-%QNCJ8ZJS3#&3<5?KT>RS/F()Y5+:M-TIN5"?E11&4E:N14
M'&)5IT0&PLZ9S_8S)G"7#TNS>X1$Q8HD)R%=+IU0=OYQ<JPN?CL\QX3M3G*3
M#]HB+LES53?ZPJ*=5:DM)CMM,F@XW&/71R_K2EP<S.U"\Q@8=J<YM ?/ZP1X
M)100=JPXXPS59Y)4TZ.:&($DH;EA6[L2UW3/-LY1:16&T&8YF!-2KM'?.U%R
M=3^?1:-2<GF-U%SO^O:M+UUPIPT)0C5<5!@_=5VB'<WBV[$^![X/)W=A\?L6
MA7-I@O?&Z.*-T;.K3$UV2"+S_9044_NR\0P'%'XUP9)&A4T:*H+88OK7=N_2
M\W3L)ND8] KE4RV[=8JZYO.Q>XNB!_*:H#2A9)6([1"REM4>I?O5V(E5^U[V
MMQU>]NYBHSA\R.F^>:B"+I0QI4H :@'9M=RA9L-)&9JU;-5C[4SN,<P@QT4"
MZ'O_8;D^H9:FF#RU/O[MG'!,FNB;-J%GI\_V!Z/(BN*-+5X+MTEP1N+((VPP
MCK*6(T"SL2<T,FOG3G/=!2(D9-<]2@>>$S>:)AE[Z2^?,+<R<L[7_IQ356:^
M-G#WZ_W06.9D;&<;WJM>XLH^NO^+IO<'LIG\_[A$W65G_?U8@>?$@4SJ3W8[
M&M9X3D\_W4B<'\=3$(X+K6Z,@YEP#GPG6*8FE%WW)[>&9#13#W2>C$#<'[KR
MO]A[Z["XGG5=$ @$)SB-N].X->[N$%P2&@D.#00-[M!(XQZD<7=/<&@DN$."
M!D]P""29WS[GGKOU[+.?N3-G[LPS_5^]5:O>;]7ZGM55M=[OJU_I%/WTODH)
MK70&*V^(6=I!8C<_# NN>=[C"H-7MKQG?N$.?X>TB@U0[<V75]J5V/,Q5^%0
M,9\]#%.%3H4#:M\JP.PZ>U-ZK3.%>%A$ %^@3L_$BV5$/I<,9Z>=DE$X3U-X
MAAR9JI,*KB0$X(*YXN937S>N$'LSD-XGY]!F[<Y&#;$/130RL8=R6L0[:L6$
MH&ZCKI/JD,O_[6*)/EF[Y]PR>X^G$,*!8B_C/;!0R(97'UF;K^GP"[?&53,?
MOU_PERN/6YS(\:(I?!6;NZ1 )G?_I%P3D3;-<(K:+-+-8471+.Z2X., :AMX
MIZ:9V59M_OS!77PC3/T/_C@3B=%5-:V'1/K$.:K4V%-*,.;)1,0[E'+V(,D#
M47&4[^.$S9K>T T\]3"6=%4%$I:H6^J/;7^G7L<X[;F)+6Y2Q#TBK3-7IZR,
MF6VKI>_LUTMF$%5(CNS7K,LG;,9ID,O77>JTH73/XMWJ[ZT_L)H N@5:MLP%
M63U_9#W\;//8!)=XN0@29:NF'U\EUVJE47=UCX/D$7YC&P:IB:NZE-2RN Y
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MU,6=?_32/19- <?)11AX<616>#3%^CF:#MNT88B@F##M*RY%^::^B=;J$AP
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M.#Y^@1P?>P,6YT54Z?E4!2F82X/(,6PV&H%]VR<#+J[9\*9*"3,[,0TZ[1[
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MS/.W8>;4'".1^;TWD$.6:^V$)Z?I>FB<-2<NYUM*C)1\0NB4A+-F_0*36TQ
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M*R=9W<?C[1R:DVENG;K1L4JZ+#^:>8.J"FFOJX'[WV::9D)<T=KP8Q&L_Z1
MU[]BO\OA";4+=Z4GR<!."18\,Z?9!OLC.!P3&_6C)<+HZ97Q%($*_/@Y&O;N
M2ML_VW\$U)\CU-_U59VXI[L(/)  (5K[>6OKM9HY807WNY7LXO7/F*G:,Y'X
M*-&939*B48+$3G FVTV^2P3UCIL[34'G1CH[9G>;3U[?21D6\4VEQMV1N?,4
MJ%=$T6VJR=-'$ S/\,C>H\W<U8=,?7"N+IMTVQO<!'>>V61[3LSCNM\I1/JC
M"C(L ;A)E- %%A@QF,>:5:0\9RSS]D@:'):7*!3;-A]5[1DG'%L"7@$-NF<W
ML*&TXZGC#24&6)=U^-R-\=*"G+)E,GF>'W6M'63J8H(:)N>P/(W1O0;,EXU#
MB%F>M4".U!$2=:M5:R_R<_"S<T4/!?8[D_O97H6/?1+;,9J>]AI=$>P;ZA=T
MM++3KBDF+=DSTHRS9!IG9VKKJ;QT#%3=[8EO+ZUC\OS-?'QG"*04R<=?\OJD
M+513R01S&U-<HE2X3OM;$0V[GAIPZE_4.*J0>R@YGO2F9" V+L6"Y,QW>_G9
M69//6CZ]?L$=AUX+1: V"IBA3^F&&A';SI&&'LR:ZUJ^3GUD517!P &DZ PD
M].9/KW4IB772K%=1Y.BF2W<6U"T7)&"DHEM3J0Q2=@,W<SN-7]URGX4VG]@U
M&VU7E.5[.$:2U9XS$C"D*@@LSES8;S@'Z>+[LJK-+%LB%B-&*Q*J#QHA;V\^
M4 '3F10^:[MEJ,RQNNFO?43CAS')9KKJF:%V:),O[TB-OP+@O!ZT6<R9NT^U
MI[O+VT4T@(KJC:U:<_.;^RF;Z6)C.]"Q0/2UA@9M*<U/B[5I[/X'?[$&12X#
M1?^ ;DCYBNF=C0'^O?>]F/JQV-NCGL#@#CLD./B(K3_@OX-,?[]+\D.HQQ)Z
M^4Y9AA(-SFC@%8@T5S9@'5M-X%6IN;&1^&81"%-;H=_:T(?_U4\J-IC[QA_$
M<#8QC8.:C[VA:W888J$)E%=,$K38&7>#O2P4].\/[M4:<22*KFIO4F==/>J_
M<U,5ZGK9?\BHGP!_@B-O[WKB^]1:O9S9<(K*GE^^MH?N'_+'_8@Y(9B++WJ:
M-O/.XTN11IM"EMOMOO6%TX;M/3-H+7<CSC' 5IZ>X\T('<C;26?WY#"?5=1<
M:=9X8( KD8T&WJWJLX<]@L)DTS%RR1U.[+6TCA0D+C2?+KD2-]I=*2-KINMC
M;BY;[\A"NK"2.FG]-8VT_@PA^-U" QV+?&=P %HE4T*$VUZ==HQY30_#](.P
M:IS.D('H+WN3(V;0Y**87N=&.(;^A%87CXJ\LA_4MC4\9];25\I-W!Q50-U5
M3/D ]_N._D\18UXMO0"2,PU6Z?H$%Q:E#8D_SJQ$=D)YOKT#;[8_;L*DW^!!
MRG;UWI6T:"^@#Z^__9+<"?1][T9H]PI(G59:Z".,L%$3:0?7?^D='U,&IQ_,
MEXT*0N370_66][#08_3B!F?&C,G>'K*HN@$$A/I<"5A16 -33;T>Q?<?\<<E
MYE)VZB:M^,?)*W &]VZ5RPXO&#+%6"DE#8J[LY-*0]MMO)VX$L8P"*MJ\?'0
M.%M"?OY\!8R38!#&HRU$-#=#T[B54!E3B=UA@;234H46"-^L4X1Y>7AYQHW4
M2]Q\<ZJH(2IYEICRZ^12?OP?D]**D!3Y -;XMNKJ 7\J/ZX?E0HSB,P+>I8T
MCPB5#:=B'4A9MU1H.2J 8L:LPMZY&N+#I>"B.@210D.$P<%#*FIKWSA&HC!Y
MS1NT3#3)BVOSELHJ*;#L<T09YP!NAB_%)O$+O NK--^5<]9CY*3/['V7M]'V
M_SK"U> +54E/R<.G,YYK B'A'FS(1]@.3TH-KLK2J6NWBQSZB;P_=]I)S?63
M<1?!H\V!DCXF%_-+;R,Z]5Z6_),XW,W\I/(A[Z!%(RJQJ$VBU#28P=6V 17/
MA7I0*QVQ0D<$A)'#O3%5XG(9\W&_62+OZ.?/4GPN;BND%BI\ZE\,,CCEHMV/
M"5974^M$8&^,K>%(S.']P_DGRC _?G,GY!P@C1L1UOD<$RLN<\_[)IWZD]%P
M.,WL&J$(HE4,C"([J9-<VN&A0A9+A8D<GU$*;,Z2AJOV-<PB0>,<WE:L+Q!A
MV  RZ(O D>;WL]I<'99"'UNPP(_KETD'UEXZ<[I%8M(HUZK7\&F)'1@NDZ]6
M^XI_G,C7)#'>H+:!50*+<5VMUS*7XO'W.RM9O\8DWZGLFCG(TDX.2&1)9X0D
M=-EUF$V"@ VJE6-: DE2WI424/M29SUXR73[;@,#G85'C3W/;WEFG3'?>5=A
MF40X)D4';.8!%Y&NBW_]'RSTT@[^%]*-;@6:*1Y*D#5=_5Z'V/+W6<BJW_\9
MWRK?T#AS@X0:)C[?T9LEHMF*/(8<E6&<0WL<80'':B([S_.K=) R\U*["2"5
MJ@LQ\TLE5@Q-,G3_8CSL)\=!%7B8>)L&%3['XT!KT5DNR>Y)5<1C5H*3LM$+
MK[1L=77LVF@ES71W>0[7XH&Q/ [G$#<3\K&1,4EIWUE^.$M^GM[NTNE.Y:LG
ML%AXVI%$<CF(H:\]V3W47HZ^2FD0"$T!C]D(/=%;MI _M1F)TGREPN<>,T@6
MNZ]A[12H!F#WM%5Q,Z-DA,^'Q7SQ4D@D#OZF^!]U$K^Q73ALPK-7%AH1<HM+
M91(]0,G&4+*T\CT.B9DJBH<P>AEU^HW>(>*XAQFD1-.5L)D/\NSVGIM%/-12
M%L]S_W9^O^ON^RM@S_1J;QJHL=G:UDLUO-*;>J]:ZV^_4#KCQV:78575SOCG
M\$!6L<;GUAFDU'78FF)3#TD<5[N4F"THWE'\.2264)%FP3Q!$SG'8X0H:<?L
MCSZ(W&,N53<2"N^:V(S*'$P;[FA$'[';6XO\I_Y8A]'8A1X8N$]>->\[L6$8
M\(+YL#)/_Q(LWG-\[;NB_N.2#$]?L,J+[O"DO)9-73%CO6/DU/AA/]!OFP.&
MMM;V]$Z)YI"<@!&Q^!Z2B-2-IDL'Z$J.<G#2MT4=<H9/R9*_[QT$G'( 'X]G
MBQEMT?.Y/8!+:,[>'B"-E.KQ\7GJ<1WHV#F':IE4SI6=P70Z.$$P-M7$>*;X
MA5!PJ8;IRB&L^? ,%J_WR+'V+')U,=H2F]) <>'+[BM#R2T0QG>7J&G?Y<5)
MPX_=!5^8NJ\GI55S1C >[DJG>-9W.EL!I#9*T<PWNW\'_Q45GLQ@ :Q^_EYY
MN*;'L'ZL:Y4UW-N0E(J,+M.7G7^EGG^%70(:DO[RI1=R'\O*6O]S72+]RY?Y
MQG9&,MR+LO167>%>;9O3U"/DG%10[[,*[%C4"-'!STMB=/P:L9:P=Z!4&3<9
M\UZ:)*G4%Q3HYNJ$E$)!I>636I LA7%OL0 @),8"Q&)WED!:\@5K=N\,SEL(
M5J#5-8=UD6B@$05[T+U]A0>GTY_PT\U!&XOMNQ^[M2W<!ZG2PV/ZV.GJX,4U
M>]F1:H;6N:U[7FBS7 X3)I)#HN(J2YQ-RQ8O<N DQVI4KEBW$BW7H?!Q?8+#
MC 0[4)$P8SZB3&]^/!NMB(\IC;RX0S$URB[$L91=Q.)J:<]"[K!^?"Q#)4.T
M6-F#K<'%,<S2V"U/R\'(7Y8>34%00OEH0[7\IP$O6X*IWDF[EU'WV7@I5D,]
MFU-T]P[+<2EIE;Z*IV4CNGH]O;&W_MO=<7?C!]80<VXV_Q@+=3O%2%DV><,)
M+A3QGI7'=25\1(:&EMPH+*%4(CCY""392FQYMNTX^F"!K8!ZM3C6.,L^Y@##
MU*V1MK6+S;7+HQ;/XU\_=W=F@"(Y-=CGNP87A0P/@J+D1YW"-P=0(\W5&"7Y
M#I9BO[]^QJ@5KXT$ZRQ:'PR:C"D[L4$^9EY&;JOD$OD:@Z\]0XKLM$.^,$-X
M#?=0A'$9WFZK.="WMQ+;<%YIPSIST<[>K,V"<[;A5G>)(L4JWQT5N_'//%)7
M/;2OPOS=-5)XA,;'W4"3HQZZVG\] TD4V5%9:'W $%X^8%CU4%,+\^R\R8A]
M()>!A4.5+&@,J7,(-;_$Y(HKY*/Y>+2#F'%ZB]>L\.79TON6FJW*C 1)Z$,'
MB(=%-Q_ ?5N$H_S:6O6R/EZR4(PXC<W<U'7(N$K?>:^]/:MHW;63A[8N<%X7
MO60'"<HBNKOFG]&I<-D-:AB^J4J+^;]G>PF1#GRV6@NZWODL$3+P"JCUK2*Z
M/+A]VCKT<MWWW3=)4&R]CKUAZ/A^,L662>8@2&=5E9!T,W^A0#(W["<W(.#*
M0Y0"%ZK=TA9WI*N!S,B;T>BA-D?'_&';(,11.G38(7C@LZTE9M )4#-OUX.<
MMD92M<BH9"K53H)H:%5D](S4 KEPS9W5/BY[]_<7N^#* FNG:%J\U?+I\9S#
MAF9Z),J35P"#/7 P?MGIJZW<QQE*Q8S*E]FPZ"VE&P7\?D'&Q.2*S%%R@^)9
MZ90H%ZCSQ* <M8?:=__81X5#U"RMJ*J!480^1!5I;.=>&L>TIZ>GWU^VZ<*L
M-Q@<(E.#M TB9Q)*()R1WV]$=Z981>3 $;BZ.4<=O.IU/U;R#Q0.?'9DZ[H$
MMF_F'<9"C]*W);E);R[FW4/2PA>$)"?B!>PU5MZF'WZH<HHN\2*>PTR%E5;*
MY<G DKD-2;Z?<28I>B>0MN!#$YCK?HFR/5!\#/5TL_0TDF4QEXIVH#.NV;0O
MST+.OJ*,:YY[-U!R;BS=J3.9 78LFFQ=S@0<KV$K_!SA#-!,214>]2)V+MLR
M%TCAQ_-4PN^86%_ZAL_N8O/.'@_7^$* X3MC3TW6EO'O^( #ZB%'KH:J!'=!
MSJ&-UK48OJ=2,>]NQ(-GN:]W;[T)+6&KF2S(#;Z,8[IVMAU.7V&BK6"QN(P?
M,$P'R_8@>YO/?_[\^=!J=R_L,Q#0-=W)8%NV7LD9?"*M(*1!DG"+B(>*;@\?
M:F/S<7\H:XQ';$5$4G#O4YB]P;IVKWP> =S5< U.MBLS1C;Y%7]0?&MIS1OA
M8@FE]?04S\0\'C$EA9X2X4L.!R(5=I^1\0_IV@/6<RA*4LW2@71>P/R IJBI
MU%HW$! _%+P=*%?;7&&O!IYBHFC[Z9:TYVN*PS+F1L'WC:^1,AU8?@%:?@4P
M6F;4J8@G+8^4P^DHI'PE$U3[VN;4BJZ+3[2V*;4=ES:=X W(2-,#+%+F>_[)
MUG#O<H=9,=:Y<25:.FU$\$V1C&23W$@<;J#FB?*;S^I1X<F5*>+!=?YPPNKY
MZ2+I+"ZYE@B(T<*=7!9$4-)#9ZYE1L[JI/($MGSHZHE1YF,=5XVK_!T#PYW4
MV)Z+S:8=XT56=)<YQ@O$B63)'H4."8OO?N"P_V!7IR]*$=:Y?4.UG,[ZU[=]
M'G ^_(-R*"P7^PIHI9B:#1MYXK6I]Z=B_6IKBEOG-I9-15D\*;3P!_) PM+-
MW8SRJ]F3Q;K!GG!T2KQKF"E("+S.T-@1#'L^+W[S_:A^H,U^Z(V0A<]9=Y(+
MJSVDEGIXQSMLK^+-_J^K_2W<,#$8*;8@F%]A+EB%$3=<8=M-:C4OO(B-.1D@
M&Q+YBQ/_0.QD9&RH7/DS[*ZJGO\0A&1;YY+"_['@1NXM(=>H$SC.(%O[AL9N
M6DM(Y@LMZU0B /@;'_.0DE&0C+XYN$&9GC4*0> GK'C9#;O/:"6A^F=\JDG<
MY"IT0;LD ?Q&UYHT?$P(66O80L:Q]>?^23QO=_,GG@/WH;W0A/INCQ-( ^JP
M81$6/UR1<5ZT P0XPOPM*\4B5G#"TSJ:>CF4J%P,5J,B1%31\WL[/+_>E\,'
MXD\#7;2GNZ!(F,NUPDQY1+!#)L@4F#JZ[\[ZWAZRS/%/6)O@2BAU)L5S[MH+
M?_(65;P!):O,]A0RI%=16%FWNCU87%?ZZ%4IY=$0>\T:Z1/9DDVNG(,G'8@Q
M-8@0'4<0?>$]4*ELWJ$VLO;QS8['=4;R($O-VC*]R$^YQ>D]D4/U;5,7,M\)
MYCAY+NEBKR%.5_PZ?\2Y+L-RS*AU!:(@I^W3V7_VX,<;Y58\O Y)?HXTD!Q;
M9=]_"K$,Z!FV^L@X==B)P3-I5M&)=B"#!)0*.(\0<E\*J3&P3&WA4^@20]F;
MUO =Z2<]3%I C\@Y241PX?N?(27^84O[/\M6DE8?Z#RSS:J6K3@>QK([]"T'
M762] AYKWK\"/GYZ!>B:OLS0O@)@(I7''ZHI@ 6(J]Y3#BI<,AE WDQB\_(*
M=KU![)::W@M\Z!G"):2MT[*?R_ \,.90BY$MAYIH4W<QXZ L-\=X]7-W;^4A
MI.])8NWT7JX@<N$\-R7\LZ" ^QZ25<<HY2A=;:9]6UN::<'S4O;L][U@7T'4
MM\PT'MUPX67<LE\)))>EF633S-Y0=(8(%:$6Z5DTER X(@HL>T&TT72%.I?$
M8BW.XB[C#;V4W.+FC]"D,!4&W34+J7:,'ICMAQ]3.6GJ8NBJQVH1")?WUE15
M6]BAPNDG'A7:FB#O%2HLP3FCZFJ50%Y<,7/3;HOS$=@W2Y?2/"%>W0=)FU9.
M(5NCSTGTZTO6)>=2OVZ#-8R?<*S?T&=A( _@6&^NZ73.TQ+;[$MQ>4%Y]XC%
MF3^J1?KR';3=;52.<,9*A-T33H#N-4O7O*YA;>-L>>>1'%@:?8OSPH.XZHDI
M&F%T*7-Q!O;.CJFJKX#=5.&@/VG!SS?).G=GJG]2^8-^Q?2_X ?TOK0$/4N?
M'?W%V?I? 1=Z+I3MEH?JDIZO@"5*O4))+U!&^:.Q1,)^BEYUW442+9W2EG9W
MJ95RD)F5"[6H7U'&[H/W351W"VNTI**I!6YN!)1<3W61E[VMKONL39Q'HX%_
M)7%WY3W11MZ"6YR!?PK04$W=* ?TR6EOPY:6D:K^CGRR1CQWO)^TB\=U4?;A
M&ZO65A*8J:+/X/KX2RY8CJO>4&A:9:+'G\R.XL^B?L4;7Q:_]^1Y>_3 \CLU
M-WM6U)A*M7VN:G%N,^,_KP!/5+X!N" ,Y%'#'(K']M[;Y92C1*U70.3E:.95
M^\Z%\1;%P^WM\POJ,>6W#?*$]-@ 0CI+3VN'!/0TMY(C847UT%27%%"M6&8T
MK&&*)%V7P4H-':&1H_VN,VGE#>R-&Z*>MRDO=(7B3W6XS!C=QTUPBW!U*E_X
M#$(5>8(B"@Z2_?/"R5NI]CPR1*8'I'/#+85CXML$UB[?7UF=O])J&1-)K+1S
M XS./:<[JI:76.;%B'6=+#ENFL7;.SVG,Y4S^.H*; 0DG-DEZ*J OV_.XRJM
M:O/P">*9/WP<#&./R?PDSFM!GDW\9QRE?.PJ_Q; 2Y8&WIC6.[Q*WWD3 @Y?
M69?-V2,'^<O5@];EI3[74>>X)WR.X]E!HXM8Q#07KYC0_ZRQ1J1JS"^%7<-7
M<Z24[[I:LZ(M-#J4=KIW >4V4&J[WZ1=?9.>.E^7,Z"'CAWO5AMVXM& 67.>
MKJE^=2#D]J"E,6OB CIC@=RB:JZL_5M82XF?U$&9O^__'P X8[+?+.U[^73X
MR:>4!D_="&_\/L WOI0DG?@4V*$E8R"H:Q51I4Q63IO]Y^J)O8$L2@#2V(_I
ML1I#^%%Y^Z(BWDJ;7G1_![.2_:.]8/O5F3?G3[(%QEGQC@0C$1?UD\8_Z86Z
M.W[&W/VL.CX*J[5IVQVZC9\[O?<3^OSR%DZ?OZCJIT=-<9P N0S[Q%/:L:2>
MT.6CT[/0UZ;HG#EB,;RY[)/*42\<4D/AUI&0'YI<('9ZGT7>QT%=WE=.U9X$
M4'LE:.[QS5OD!QAF=)0]B?>_3UPHF/<'@?JF[VJ"?F1"EOLX52:J]_=_GM24
M4NC_->&VD91UUGI!806&V5B1.6('CSBV=\CC2N_]ETNB24K5[",8T,((S>K]
MPY@;.^:6=9&&<:<Z9%B#O<>@A(,\:9O'Z0; ";9XMYH.5FLR:]36W%YZ#)^;
MW0/,!@X4SK8SP_,&_I&//'69S&P! ?;[^NF?%RVDSNP,+=+27-?R.Y(S(Z?Q
M]YF4\IR-0_@P:CYU4&::X="MNLTC7HLRW_ -*U*[[E]P'^$^]?1\U<=MR9O+
M,8MJ>H)/</MPF*<WY&BRN'F?KPNGGPMJ%(1OMXT4U@7-:<:FNZI(\,,^S;I=
M[B_&7RYS.IY_O3=%0/-G/U=5BV#/]M3-_#)G;B/>E&"]ZIIW0\VPU\>[_FF<
MTU"%XLLCV<WX<WO5N717 Y2$C BS'6=OGK[-*D(CFSP/7ECS<4DO+#2=%:U:
MVLV;FL0MXIYG"6N3O66%W"LQ-B-#3N*CZ [[WM0TUX(]$ZQCY+P<TMK6_>(2
M^@JH0S$H-#C-QUKYF5 _2R#.L;IGJC.:P+_$;#5M0J\>=J91+SC23K_A;>*W
M=;;X&15ZUI[\[0"\;(B9SBB]$2W:1:BSN:[MIL^CQ.HJ%,I1]!3\.2H7ZY!D
MBHA/\' +U/'XHA&GF9838P+JI;\-@B_4K*WG2,O^4#)/2-ND^&X/R?T(#"8Q
M"P:C/P#\ Y\2%MO7UQPOV.LAI]^$@C837^B?TMX3Q#WYW D>[WX,JEFZ?R_T
M1]EJ,;JAO'DXOG[@0FK\+JD"8Q>#+OB\'#UGBBR:#NM4SAZ1E65'66$_JF4<
M*!M+A]8 C]+;"04EK-VL&WK]6JP6V/Y+%! :T:U^<3->B]-8(MIRZ7Z<J^XG
M8JPQU#1!F()=6^]I7 :T'# !G6O*=QCJ,M'W#-<9+]WS##]//5+R?ZC,H$"R
MD/.5L Z3.\ \DM>47[&>(UP<U>(X$,FWIM?OG;&W+55IYY+!QO*%@URZQ_,)
M'FU].G:O-K-D\@=KEU<KN3BVV/<ZBVYV<VPA>C=:<PQ6%OW\?9+'',:R!YTH
M>53XE+:]1;'$\( IQVK<41'?/NC11PCC..2R?*X%9/?AQHWB&=!J5-A&OGM'
M-SC.;Y9<K..>L,@TI 07Z2T!A2,&1.ETU/?)\CWG!#$4_G!J:JM]O[."=OHM
M+ URW"M8_RQX=,7NEU)4]%Y00D]Y=G"M<4K^X\Z;A#8[JS%&VE2!@AL_:*4O
MJZ23P]%!%)P9/=A!A5Y[%F>*2R'JW4S<)YP]CC^E*X\;JC+'KX"HG4!PG9>/
M8]@U^,)A=0XB:!$TE'; Y&;_"MA48%P0X6_3G'4M#2++*=%H#'5+)[X_<8O-
M<3;J'15DNIX+-+F87MI:N9Z8U#?\P"1O'<48E8M2V/^1DBU_?"+T^4<U@N;5
MEDS.$$5.6#EOB=6]I%XW9F@6(R'V\MKJ*DH;!\RKVRGOB-^:^*8V)]2M=DB1
MX.9+($VHP35]M>JTDK^+\GV!1J%.\XJBAHZF<C%,5F@HHA1SI"_ J\%%(_-Y
M8Z;G9"'>Y]_#62S-21$M=?\)&DT6*Z;YK_;%FK]GNB\]$)']WE;%3X4B$QVP
M1&"1.;KLRZ%P 6ZM5FS!!8\N=92V+>J%U*\LT.;,6V!C:&53EQ'S3'!)HQ)_
M*'JNKEFF[&CFB.<GJGH :;9V_BA%/;D7E$B5!.^3W%"Q9 /I?'[[8[@PDHV6
M@F+-I['BP\6AFEWE>KN3445%\'>$YZG?$+R7^A9[[WOO(9>0CLTG+X.-3_W:
M<'%.OFE+*VM=L]>4=B"Y\?GB8(<":BMJZA$UXS-0&C_Z)3*: 1[Z.SG"DAW.
M/+A,_] EPD4$?/Z1J,K?693D'J-V^TT/<49_6-S5T'3>:UV%;.#GI]/JP5@[
MF_E0RM72[ &N<JPY"/#<\#N8Y^8ZO#4_E[V,3 >G85H]\GJ5^+G M\WV]W-K
MORJ/'YT+!OQM4\\831*-AX<K!1:B4Z-^]&F&D?/@:Y6/8RHH<F"8OA7/J5_P
MCH XO0(J)K?'9SQY! 650<QRT>$MA.-HKI_$#N="D7_*A:KMTLQ7OP)^1!.K
MU1)$L#I]:'_*W6:^EXIAKSG(],S7C(\1HZ[8GD]9G;LU^9S0N="_R%KK%9A=
M.'OV@T(DYG<$^W*&,=D-/<M. (5'3NPJ2$Y5H:+-BT<7=E!'EWB.(RM$QD3$
MY&'M[2<U3.XHBA"^JIX7(E()GQ+*O[)0H0CVP<T!Q9Q91<V/)#J"S%:D*[R0
MSY1( [33/N5/ P_0@)P]2U</Q$N,#88!JQG[[1XND)?))1/^E)..YX/$@IQ2
M7/X7+-TA2H63@D=R1F<5M41B!Y;Z)6C[:$LFH_,72#3^K+>P;0I?)H([W"R]
M=US_[B-/9!@SD42#5IPS?$](FIE:V1=)'QA_IW#9/1!JYLQJ\M _=@^LJRU/
M%LMUS$^.9*(G<4NS*"UG:%O,!#T2OT2^-%%\7)DNQ$J,GG'EY0:#QJ[<V9I/
M;*W8^R8TT[WZT"H%VGKN^GE=_3B^/O*J"G/2[<<E:9[5*T]3D$8)" R#5P]#
M#<<LO=V]A U:\O9KH44C"$:XL7#F'"-AW>NZ%".@%@JJTJ69DZZNB_Q-_AKH
M89K/"8N(XGM. 8_&G]$O22WO9ZG4ODY/?!W]ZD.<.A+N<]OLX/!)<8E9<;2W
MDIVN#V7A@'M4N%WKMQ\H^/BZ_((DE?A&!N@T^R#RI=([,2,_CD.6[=T^,OFV
M^FB>QN4%F[MZ!@[R;N\@*_)=2E_6OK9(91^O@K@@T4KE$07_P96PJ=;QO)<3
MV16/5KXP3ISMH$>#R=D>_^4'J%*/SL^GAF^.X)*[@$+RY@IZ#3UW;T8N::"K
M%&#[UZ,%<9C>%[.PZ9T_7\/]S\U? 2N]YX$UPPWAT9!7 ,XKX/?B*^".5/5E
MRH\(*NC8\@J F!Z<]MZ?[[\"NOCR.;\W-%FDRM]:M:-9O5,QSML@Q05P,0^%
M<'*R1\1K5E^[MH.1>LV LM:E7/3!PR/E:O3^,5# AX%O)8<W?5RA7K]2]JH=
M4S87UQ*V G%7-^_*%K-K],\R=52K+.9BK<"E7@5D<:>-P_4,)?5Y>ZR,Q#!=
M*UNCO+4PB]926AM2R_WS VOIA/@W2%8>Q#+X_5V-=K%6;Y2EU\-RZTELV34L
MHA&8"E"!?@.D=,<9L7EZ[('6=<8##N.[/^55*?N'J^4.*'GVK';S-!]$/T!%
M]^I[70*=OFT'E3ZS38KY_R[7T<TYC?=F,A5BEFLMU<IC46_ =55*B=/M:5MB
M6&G;!.8S.#;".U@\)FJKLN-U##D+I,KHD5XO<GV@]*!?E-H?JUM0A,9%E,S3
MH6&23^CM878@BQHUH;B9/"I+% +Q\FH.NG%5TXXD8&W]V;V^S^(J+47^['-_
M"EH8UODM"I0=P_,:FH?W#-,R[7L9.R6.0;_O!7P;[($^.<>.K-#6;TBPXQ;+
M7"5?UR\88+7K>'U5]M%ZFEG)1CX5\:9EC4&.,J1U;W FJ@!V':LU4[[7AM9Y
MO;&64UA=-6Q$'XGN $O]DE+)T;%K<\G#L4(M'#*]N@"!NJ6GM^U6(LZE^7*<
MIJRN7O113'>9A[F?G3N: O9!9V0&#Z^ =-Z#QMZV/>BFJ,O0<Z.A[9/E2N'[
MW\*FC7\:#JZ6!EM!0>=!-OU/O:9_$4CW*Z#H^[WSC%R/EFKA@6\EP@'6[PH2
M<1<OK9JXZ<)4CB!/#PV&MK19&LOQV)3L%42?V8)\M<&^/=X<[HAG@8"W=K]E
MN-Q*K?9D+/E'*5E@T"BIT>TYF+-'O*.*8-E#96OW 7?7-Y5G?K&ZAJQJ#J'C
M%:8Y5)5?_*"1<?4&D<!$E[[6^+ ?B2IYC<N!!*Q60R*>XRK7'U%NB"CS;10S
MS/>4O>#A-:MT'!%B_<W6WXH%,X"GS92Y8L%AL06L!&9$42?&_D6F*95!\K7O
MM3_H)K.>-8Q2^6\THV-6R_8+K!<\/<JRBC6T?#_POA$Q]GT%#(6&7]*,'XQV
M[S!!25==_$'MO;YT&>L_K2D._!)/$G''[A"BFYU<,)H;/XOX\7@XK$>AX+,0
MZ]*[R#@9?YU5U"$3(4ZZRM$[,X?G;$9^7D-?6NHJ5/NQ(G12AY7XABP]QD3,
MG2UWN[WKUSBWBL)QV_U3@/?JD)?82V)J0O&76?-P]YS,6/)8FU_EFQR\,0F%
MC=[]G<N<M./DA^"2O7CL-\$&"RE,(3O" U%A45' #19;-[UBJ=B.1#"^E$QE
M#NLMDO^RV/?5A]YZ@\=@'HE@-6PFVZVX[./C(.YW/Q'O_QWMX#_I](C>(KB3
M%U05]R'%U43;%N]%>/SJ:$QLI S"2*-6G?P'IRH=#7?_ >T'N::W9*VSB>R9
M._T^HY;N0UA$\ B(W-W/\C.E D,V'(/&U,HIBXIYDYA)*>/1L;]1LQXL&NS+
MJA"RIW>W7#KCG?'K5FA=1XA#C6%HL^PM2OS"^91#+I$K7&':WZ/K,4IRNF?V
MMSCW46\F8Q-V5OK1]QGSWW=Q[;?_:J6BSCJL%S-^II?1I]K$>R\A7?YGR4I$
MX"J<REY!FY&/?4=,X5,'2>G?EC=R:;:ZVWO?!/+??&$U6-M\%OKI4X4I(WXS
M?J/>Z&_G^OF;F<$CEM&V)<V"'H)ZC39WHX;DFI&*B[J3F"BN_7'GL0I?R"8T
MW3]B$-O%\3N982Q,W\:MZFQ0H/F">\403R8]9/ X@Z;K7G?QYT6\$D?\@(CL
M,4<U>LG;+FN8)AMMLS<],TP(@>W=Y[_5=\94LO[L9)LV&^DS44A74>M.ABC@
MN>-3UU/=D XS2ZJ*$V&7'Q5(8 R<JB*?K70'ZAFO.FU'X^58Q:(WMU:G+0^&
M(D^  WH/@Q**/>S?$'Z(,Z7G_DMV._FSZGW=H8]H<%4T",<Y@H!M=<=.*AGF
M4#Q/5&T^N4F:!W=$:9FY],*)_GW;L4<Z7MAZ_8YX4SKQ(9-7+"86:.3)=>4L
M2HK9J/C$Z9 5&I,IJZC9RLX0.EH<*P+S=:,UD^"[9[*1]X2O@-.\;X^AP3Z"
M,8'LKX EX<);),"5"_ZSX2N@P>/](3K<]B;SK_97@-%AT"0^PD"/YK7+2^?D
M*R"+">6+3^7NUA^/[%< E]I;Y&O5D?[?1[PO9D64F+N%L4%WT[;/ Y)B_]H@
M"O]Y@\S^FX/\^RM!::@E&,S$\SQ5ZZY3]4 5V6?)F)C'\]"D-$B#KI<6RF%D
MY2O05;T+V'1C3-,?66<@Q-%[:_F?L_K_+9_XGQJD2_G_78,HK&3GZI%-.-J_
MLY_!=V@9U(_19N/ZV*#C?A!)6FX_3D#I$.[P5LT^DMQLV+RD=V3&$>[N_U*P
MK& U/$DNV3UL?X5W/4AE>WZ.H85[W1#W1_IMJA2F0/X)+0%'^EZ:]=&VPX ,
MB=%^YMWUJ+"<-"-U^P1ZHN3BD-3\3=Q F1 M0H?*/_*7:8Y?$\Q?\7K,+[)6
M/Z?';<=S*>L .8:R*@V7:^436HJZ^!PH8MD[O>ON50F9+S1QQVI_'O,QW\A4
MJ3^\"?C&'<53:(_63A.\U5<(Q\(*MP-_! 1]TW2_1N9''-DID2NQF#UG0>1.
MXR$2Z'2'**4K&F9VKUB4:?"SZC %*-L#;5G4+(K)N=C_QO6QFO(ZLBY5-=E>
M ?"Z:51Z-T!MEZ_<HP'BE<+(5/-]MM8R5ISJ;.[V>8-:,Y5V=2.#C$B33:?]
MYH_DK??SLW2U*[299AA=,HG,R7!=T\"HJ&T#G%DM-F>=3_B6")89AIQO&%03
MI.S41I-3],W"57*R*IPD%0'A[] R6MI@Z8BQG('RFC60#T6\_V3PP'^XB:*7
M85NWE0'9J"X_G75OM%YNXUJL%CID9IX+=!W-^J)T)9^*P,'S291JPLVJQ!8K
MJ>==1(.OQYN-<W";I)Q,/*7T.#]RC0<_FIFW]]_?2Z'2J63CDX(W7IDT!>/%
M4IETM^Q+;$+ZWN$>MINI\H$V#8U2=BJ8)&L@O^I^9W<$!.!CII?7$<U  Z,T
MB94X:C"DG^*&K+Y]RR+9CK,[4N](G8 9<SU)K>G^[+HL8.33"1\U85ZU*+D2
M)_PAGFN$&:H_XSWT5LR.&!K.E, E:V0!#_T[ ?6/>RZDSSE>8BI3R_/_*A%(
ME+\EOHV9!OIL,A'J F\.,E?6\<IAB21XA;Z$(EKQK3;-+>M-Z6]3Z<0'FO<$
M[&[=)3<*<K$\U(-='[]13Q9Y"5)!([8II).&<X7#C=<4SA8G$.6DB!\U&P+_
M7(7D"4@2_,D8-LR&P'G_<[:'_WCS!*5>Z!YKQ.\RU:8RK"?_EIFLH;XIA^A'
MF;^)00=E\QN/E'TV?R2IGT<5/AD*ME]JTX?&M#9_[+T!.0A7L^FG?6H1#>4K
M!8D_W*&X_#V)'MP20EJDN++G2@-*-5!BD1R/<M.TLL[1*3GJ*$=T7JYQ3P\J
M2I2Q#SP\A/'TF-.HD@W6?2MV][33JQO,X7A)X/,OG?TH":%VDT,QZW':]>\3
M#>YF29:S03>F=K,EX%DV<)Z+5'QK  U7F&7*D=CR.I>?6(F(G@H7]"+O1C H
M*_?^/6WK1(PX^S?MI)&3A4Z38](+$C-0)B/2XC:_KJJDVC"7=#S$93\$UU+R
M]2V)S/P/!.9,FV7\7F>I0*_\9B%X=D0F<UMS,H.EUJ,FY@!/HWWD34_59!+W
MQ12^TQ3+EC?1[VVS=_4\=O4CC.CC)=0^X[:5B()T)%EXDO%=>;;9T,.^E5@H
M(W\A1Q6#[A0DR5*:D4C_E^R;&GY"!<7^S!_!$Z07_&H8/BP1]<#6)V71[,VH
M9XK-,MG-(H&*;)I^!29,M!H-4PI^G,M""SX4'LJZ+/CY]Q=E/RW.M% EJCEO
MS=P;3SOFA1MI[*%FYL"@9!O-V:,'&@I:=7"_5>1^Q?')=/6-0=M<NE@G+PDM
M..S]F\-DD7LN[Q&X99:_3\<+_T!A?GB)X @6U])3[VLO?*J67)$O/&W1D;Z6
M^@I@'>.W!D3*,]2Y5D[JQI3KZYCFK% E?!!+*5)@_C)<]R,^?P?59!6[DW]Y
M&VY5&C"Z3*/'B"YKD6S/1LI.,IRU^YXT;')H,DMZF:1X<FIRQEY/E*? *D-B
M/9M7Z8>_^4?^&9I:;TOOLU#XM;\3L^KX1HJU+Y'Z&!BC+=LSMK9GB=R4/G$G
MX&/E'VE'S!:]3R,NM1I,:I%\.,$EW%$78I&=V,@/"A@F&C#,*\](8O]<Q73"
M\_)!A.;IM#V7IG.^;9^\0MSA)KX(P1BSLT1B$]0KK0BJV,RV)FKYDK>4G]_)
MX5ZM49#H.M,/0S#@F_=17[9<.RY:KSC_.;W^?[G))[DVMMKX]G!RK2:*BLG;
M ZHY6<J2,4WOBZL:Y]F85'9M\[$=*4$J!F+-!HLZQ$/=1Q8+OEG]WE22+# Z
M)U"LZE:,.=%1]]]J.1=O)A0XCF,B%#8JLW+55FZBMMR47C>N[<IC1,F\\DI1
MU+RR]9#WS)O1MA#MFBV/S*L1Q6ILGFWS3HIYC+3K.47=[G%._X+_X'<^Y_R^
MYWN^YWN^2E_&=DYQQN4;V1B%L>1*M]>"#U3QXSEAUH=5U86W$O& ]J-_>16<
MS$/'I'4_.M 6>LT.YT@;)UPWM2L^BP2KV_7U8Z]0;J560=5MLT_,?N/'NH&G
M%0^FVG/F"Q.1H;Q2E'N\MC GM+XM6_>BFSEVE<60QVH] N'VZD"B1- "&$XT
M"@EOKE*F^.^\W<8J=FFPWQM)Y7E^'%-Z ?I]_66R%&5F.3-F(5O/HDL=L[LC
M7;04\#2EO8.7%98VC>VOW3"]IF7F$Z!?[9";$\5P2_NN^"//(OBA1L@'U4/S
MW"*7U[LGE=J^/RJ1E4/1!=[4NSQ0KL3C.2 "<S/N)IN;4.(PRTOE8JZ.J(^P
M^7_I-MY*SVG=E]@"M?8&'@-*3M+K9$AXOPG904>D[= NQ-/IL6*>8G[A5!W7
M$/).)^4\4"_0)QE^SFYC@O7DZRECS9D2#VH)R?\TO]1LK"']/,-]*7:9&%^"
M9C?!M#3.!-RI[IQ$\(U\S+<__F-ZT67H\7J07S+\;%UAAL(T+=&TDHU1*99_
M%:0SL52-SEY>R>GM *)["L8CPS*&:&'ZD7W:A3>&K?9\U!(O-+RZ0U4V?NF_
MP!G=;14(CK'*Q_RC[<+81MULX%+W9AQ\Y$(6 E*15)E0X<4^[-VNV)-86_:#
M66YF()PZ\S=CA/S9F$\YY22HKR_USY@3T5<5[Y<<0!1&F^F'I35JCD[D6T0S
M4,J!VT^UJ'$;HEK(/*:Y20BK>T^K@\544J?*6YL.@@4%^HFD>5W=$7 ^2NU^
M?C+<4&-K<]D^E=9AF<Y#-F.#=Q!$58A"]J*J_3"^V4](;TS13W6G>]\?"K81
MN*4]T#O(/OS5!K^RG]S')%2[H2W#;9DN!N:IE:PZIG4M*$202[J#UEE<N7M+
M]")JYOWG-4"-+(NF><*3 K=UVB4VDX';L-]]03<2QO/H%/SIS'3QC"L!$.9\
M.T<PBQHO0 N1,921XN<5[7*52G'<-N+ G@FPQJ:JB;;R98FBKW/(:02Y9K5X
M^S7) P1M6Q%IY8*ZY4\Y!B&/\OP2^U*N-_5HJ.D50ATRP\88P+L<2"JGC *,
M*88!GO/O6*R['$=Y'S7#,\[K:_@H>WC$\3<ZWV)!8W/VQ*?!UIX^@SVZ+=CE
M@+' K-RR<*\$Y# MI=NZ'UAOV%L1'&3+6(']E O#T5.$_WV*8&[)V; 1?3WZ
M@5([M?!>*4+O5:6] >P]9#%FUA%+$5CID^73]QN+?!H]:T6J5M@T1/X;3C >
MUU$5-\^$+ \=CS#04+M2((C_XD%U'50'X$\">."H0Y(G-F9'SF8QRCI.M0S*
MG#):FS)A ?@AK4Z<[J1ZJ9@!*K+D-$W0DB)<.S-585W$7"HA+L &!MNIY+%9
MWNM7NL/,N\\KXH]RA&M&-'J>6?YTUKTD4I5VX@$_HY#6>^63SM:\Q:0%NPI5
M.>BZ%Z$A  R,X ),JO0&NU-$:C!?X/[HFL$Y7!KT-Q\B2C>#A:)MZ\J4+$&]
MY:R'.UO;"0G]N?3EXF$NW6(D^FA8TM;#_?(P$,:K-@;B^G!]HQ*UPW( \&DN
M!^I+GG W(1H()5W$FF"G8VU8E8MI?_IH@)X:\;ZN=3=U/7O+U"3M\%,EL*X1
MIP'4JU)#A0&)Y-?__ASZ'U!+ P04    " ",/'U47WG9L^>- @  ] ( $@
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M.$3Q-[!O"@1'<C"0J;HI[AYGEO 1NQ$/0,""OWUTV&(#\(3Q]0@4"?0(OFH
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MBU=%.>:N9[\0/"M_RP_EK<MYI_=2QV0,?[*HX#FC!MZ6?+#%"N"@P+>P],O
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M+6E-[FG_TVTRWK;L0&,8Y1BYV[72R(38F@W7M/[V+>TDW-7/X2#Z3G6;[.'
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MA"'=+P3) O,-$T;"-LJ#7@F'7:'V,\A?E2A,$CD;I()((9[.7!;0QW*-?OO
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MQ<Z]M<>6R(-AQ"A)"F3 [#Y#.\*'3'HQ%314?E8JG%:R^Q.\IJLT9\GB4[(
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M^A;RY<^O334#ZW32D^ Z%4-;.KT3)32@3BTSVZUXF8WFYMN$*1/.KE9QY4N
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M1=4^URL].[]P=H7?)^.ZT_Z>HC5:O/$_-O1&RP@5+&CWO^34M?P'$*P,$-A
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M8$7FE6<7."P-C8,Y$?-Y$>?.!M9%5>IT02IN8J!6NPK"WEV+&']]N[HS]]2
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MFK5+U<*"K^Z./\VB!GA$>7U.:K ^N/M03^6#1)O>UJ0^<LW'.3_\X2+/!;5
M$@KU!"P/&E80:$I=(7M!?-8EAD\) F\N'L@";+W2,V/"]3J;<TO9*Y3U7:P[
M>9.\4>0@B5T;6HNZUIQ&PH0F465'?(\:; ^^V^9G5'_O*YH-9MT0C*6OWFY7
M+ !'6CAZ]?X;@QTIZ]DD\X5,#P.='ZM<#)U)_(9I'Z+:)]2<LC)7^D)?0=H&
M0FW3+77F5:XV66GF&\G0IDOD\.HM_^$'(TG][RQ<0]DX19@U;? 3YY-NS=/B
M/N+N?0;&##)+?@Y]V_0V3GP1E27)SHRG=$9)=)&57X#0SW:*8]>$)'FBU7J?
M";M9R86RM:+\A*U;-JR(AP8DAN5IO#!+Z4LM"9PF0P@JL*;8]X<FRZ0BW-P&
M4* EEX.9UOQO5H4-017ZYZ1<!9M$E@D9)L5QQHU.56=&7QE?!B]$ AX0 CJ#
MSI9DI>DX#:FXZC;OX%<)8E];9>/XB/51M8ME%H[L+'JZ$M+P/N@X^V99#K==
MRR^+3C-P@V>G@X*Y:P268L'%;1V+/)7O%Y.=A5T=H?\ &)OLR6--Z'DVE,,B
MH37VAJR4*(S6L3Z'[4[;?I%_OO>7?S?^T\%]VJ_:%\W_<+'E5'Y;*XY&_$NL
MU^_IY0]E=Q\7W\+V/X!-0@!L_'=.[&>,@*"S<:%?=H#7]P!1%R',.A#YN1R+
MX]/K*:47Y/>UUU62B54"V80OH5Z?*>(!B"M36_"G,%$I+ QB/_4J/<Q?Z:]6
M&^WD8HS.,S!?9QK&(+3Q9N\%!*;^&.MP"48!VK=TL8HABPP:GTVY(I$(7U+J
M _]$/MP^8JKC'#:(LZYA/<VXZ*>+3J'Y'PJ\7MW703+H"@%G4:I?(C14I6&B
M3?D+ B/H.3 A&'#2[;__,(AB+I-__/:BS/5LK9.P&H;]48=$]0<[,2"#W%=;
M?^<#L\NFM_=(652Z;6C!D7#$H1%%OX9#:8,Z6Q?D%/C=-3XQ4'(+5XE:7-U&
MT$08GKQ@8VWV6X02S8ZLMEK=.5]76_*N()RU-I)>\ "SU>G8SWN\$W7DL9\X
M0FN>*2)"QI4.WT70A3:;)V@T\5H*R61 +A*HU#J,=1N:"H/E>'N8:SQ7V[IW
MAV^PJ PTQ6:1UA#E&M6=V:/+B$X[5#&PQ_?93$7)$4UL;JZ4W\1YV\?W1]M,
M):714]K8L:%Q5=)\7TC6E*))UQFTU6Q:6^_,I;M;YN9/)JFHV!4;29V43&$"
MT<)+1W4)NWBOLEN*_@$TEF=GE^J[\70TZ(SGG6'=W/8M(\&!$II*!&XZ,&F;
ME0)5&W]9P&4T_>V7TQ3'ESG@M#B<:Y)LTV]7\+@>J%#.7@/C>N-)O,Q2#.#L
MH"*LW:=>K(8UZXNGDQI6-K?//$JHZSETG%MSNW>S. "??X #=0EWQGJWW$CA
M9;F4L<VG.#=4D!=?H7E&O))P)5K@:.Y[)6GF09+\NJGB)2RS41"XBH+1#3^-
MU?R9NY7U0CXWP4G&\14716KH&A%5_&N3J6[SHXZ6 ^[L("/"T9'P",VE@&CJ
MD9\'RH9Z,K<'1;52OL2**=O'U!+-T?V CKK$'K76:XC3*,R+SDG#X1QA/W90
ME:P#3Z#U[@-O3U+CAXX7A23M"H/5N5OCV 1$U6 L<RS"9/(E^L)D@H=46L,+
MV::VC_;7LRSU3$S:- "&3'YRO).FIK3P2-V.#9LJ)/),3H62_VN7RQ&6 E4P
M!I(PEKRZO#EP%\F46 $H016,1!4;C+0>S _G**N0]?^=I;,8@\5/171/0XM7
MWH3W3S7AI?,D.3NOY<[97C$E\(,C#^-_TB#]P21/K0W_[ZY@\+@QGC??CI92
M.(%I29G^TO$:9Z:TR@6'C9ZM<<0VQ[],MGGB,<G/PESA"<Z&[RAZLHV6(4QR
M ::)2I;E8 W/?)7.-IL,+&DMAY @C,-;KFN8E'1@FJM]$/^C8AR+E(2KZ?7*
M4V0B"#X5=UP#/8SI&:5="'JGA&WN3I>I7!C+><!U"U5;5]C0JM1N.2K^]1\Q
ML<YOK,G'X2#GJ?K&'+OUY /_)?+%C9@RY&Y$$:@CU2I5=D!!T=5KW-4;T%-#
M\AM+24JN&A.AUTQG>G4U(E;8@BM6IZ>;P4&R8A(.$Z=:;HJ#X%22%EMQS-IE
ME[JQ53(N O_0YT3%FM%117]FX0(GSE"/C>H7ZU(%OS]!E\*,WN#%C]P4Y3 _
M=HP=N.!K,6KC5I:,"_Q#Q()?%(?1N W?2I-T!\[SC5TP\3N:P*3.&C]8R%Q<
M2JL$L_D(I&M7[<94#'E3"!6HDJTT.TY'!#(-2=KA.0.$-3<[AE!64Q:KY1MK
M>*&:QFW V2P.RV62/[^H6JAR?[R7:FEJ1 SG<B$QFTSTB$=1PV<,'6Q[8''.
M98HE$'7)6HOH]<;)@7O<QLP7.3^'>5"$I8V%,"*Y U>(7UM^"%E" [27J]ZL
MUN-W:SNW\&W.*AR8+XE  FX'YRRHEBURE!5*:Q8UV+QO:-9<41I0EZ;?L6RX
MEK' 2 KFXG;05#D!+CJ)N*1BQY__[8K(?[UJZ]\N^NW,;=]&PXG[>7CC-S3U
M9Q'&D@+C@?J*%;>YXWC;FTSTXFEWN<DLCP[<LH B>@A>QF_J"13H_*8G1-ZU
MVVYP8SL6@?Q$;:S53^0!>3C,P7.-<Y+:K5H H]B]JWJ+=&9MA[!"IHY6FRF!
MNA0X]%_>];?'/P!A&<,T3(=HVJD'I9+DSY(SIUM[_E3L5#_T>*YD_DY4H]2:
M:/4S@8 I*?.R:Q)5IIH?(K&;/""98ER7 ZI)J.+2]:,3PQ[&P3=Q#H*Y9UJ/
MW=&[S*]V,=4;3GNP&9LVW0RR#4=>^B3#[A-M(N6P>']K7;E<1]D/4I"16<S#
M1KU/2E"4] E<FT_#-7LA)Y08M0N&(AHWAJF:R)<4.+K\!^\M;::D=3Q1T=%%
M6D\,X+Z]&@^]\Q!9?D'RG$*V^/S:^,QBKF&<]/U/@V;U2A/M$>[9_R$2SU+3
M+>NQ/-;7!#*PM*"2Y>6X)RJ!NZF2.]SN?PS=)9BM301L.)SAV0N]6J#OMF"=
MQ76>CCL3M($TN,S8M5?XB=0IF1%#.:>&GFB<:DHA$,^9;T8<<2QV'<5X#>W+
M9AQY"OZ<B6#IKK6G<%V=:WXU9%$GX?/0N2\)%:*CZ:(]@KD0DUI5BVZ/WMY]
M!\S1QD(%<0=&CE*;QC?%VX2Z+X3,]P3VG=6.A8?,1J-?3-R3T-CN^8!UMW7)
MZ4(,2!.?*6KRB'-:P<SV[@H&YGDRTGV^.]."^JFU]O4,R="$JU.+#]9UU]%6
M@R7#T;JH<* 76:Y5G\[9JVJOJQ>BL,<>AL^,9Z=1E4TG"XG4L4!.8<AG+0'\
MT]DO4P1$Q#I?YDQ_:0GKI?F?0[O^ 3#10'D<JTL0?PMW8EBJ(_!0?XRB'_O,
MD? ???)+_\%I/LB<:?72+-S"F?9AIBP7 >LZT\_H/@@C^^OAJX\^XYQ6=?M_
MJ>-=D:56!$@36V:9.D6#%P61)E0 654Z<8">$TT#)Z,,!A80B82$D5J7AM)H
M6,VO7VK=B_C5]GAPI\,!'F>(NCM",> -FI3@M,-K1!EXH2^5*>V7X5[J@S5'
MO.=;N2'R];#2Y_[ST!&P]X)9VX5<P3$[*3VU_E";*P\MG#6/<US#'4E$"6.G
MUMC^UVIUTD5FYN@3^>8\?)@ <0%7[7+=;FOW=YR=E'!INSL+)P*#OSVUX^:A
MSIU.PB[) G<(K6VIM[72>!:^#2;/Z);RI*,G3-/D39Z] 1J/60%6!JDAU<3<
M7QN7*B>@P#7+/2ST^PW:LM-"<"H:X(;(._3043[E%C>NRGIZ=HW@:O!;=>(O
MMKH-U<OSW;G>9&"F.1]-@A=R#R\L8).D6R#5T-#>B2[L399ED7H&CGJ.1OT3
MWABV8& H@ DI,N/@$SP39#*6BDK]R/NJOL RJ.\(/5SU(Z3S@?QB7P#NJH'1
M+:B]\E)4S?[^K]1M<8.1ES1YC,Y((VNC1_0]JI(-,]:UZSTD^DX+0LH+G&P5
MC5EVLIV>"F:1+D4D0[ @T'#7R,&7"'VP+OP);DU'GJRN:^3):FT-?9['FX0/
M2]T>M&H/VWR2<6 (9S?C5F.\I1<I,;P[.D/]3,C0?:"U.)=.YNN^EF3 6K'T
M=4=VRD"P1+M-SA":K,PC)?!W9(_+NITMDN\USJ7X8ONO2F@)=(]I7;OYZ%L"
M),/?84)7_EAC0+HQJV4Z5W??L%*^@TA16S9B8.4<:^2%""F<JGNX\Q[JC)+]
MGYH/@DC#]YO"#UT]\@6<%,EUA+/F.N:)2V.]Z+,A'E+ETD-K&ZRB1&/]LN-K
M54]B_J<S/TY.2DMM''!=<=TT/R\G^]YF$O,X^/UX$!6[48X_."?PL?)1@-!%
M:F-O\J+@!U]J9].1Y76CZ<0?QO.OM030I:LM7A=%[VZB&MOF[1)+S[*:V[#/
MQ5%-==4S6<'(<PR*K&20P@AW]=>SY#3G^6WGH$MIY/P5B\FNA4;YHJ%'\VI^
M)K3RT"[39%IXSGR1C=3EP.GD^8S)4C_0] ,HKU26$^3V\P?/%DCD&$0/Z4+>
M%J*^E H%),4&OXYK!'.K$_;XCQBT-K8DZ[&9)^)#+P]LK: *@SI)I:Y5DB)#
M8JJF')X"U7JC[>H1U//WV-A__GQ/IWWWH+K*-\X+,>6?_VX2[Y;42*6['XN[
M1S2Y5W'QG/M7;9JA68ZU&R;6^/#IX709MOV6LK_?C$R0;FS8;,W_H_R#]@/A
MD1?L/!N7</AGCH_N6]L XAO[T6RT#GA$H7,"44/B[U$*OWEJ,-E#10 :#>UV
MZ$^E[5%.R" :*N>SG]?DI:IO0H3;1?1$IS,=DOE$8KRU66R!*. B>"O9-VR0
M7)+HW#'0+TC4[\[I0.3O^#TV!6)^72>Q6GVY!.9\_UY<EP[. .CLQ;G_6^X_
M@&CU)6M$O !3Q%)#0%[O\/;WES5*SN;'P6U'7TOGLS87SHOH$_ <ILG:#.9<
M(:M22DU=,X'Z:#M?N5,Q8K&P"JW"02'!;JH)=)27D$MB?Z K+^!U$^=Z"7Z9
M1F-Q1N+J8%52#CZT9;DL7W.9U0E-2H]HVCX1&4F)#JN"D$N$F;)UPD8I!(];
MY=A0R?F$CO5P;KK-*NHP\@X^$4N+)VYJ]YH\1BJINEDA^E;N6I,O*I]LZLZ
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M?&F^[LWKGK?\]BFMB7:.%?W9=8*N&\BRA&I7CQ6]+7G+$PM1*2FYJN<@-&3
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MC'-_[:8H]T9K%C[DK;"H(W2<HI 2RJTK+(U31.D-/*YYFE$4GF3.H2*TE _
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MJ">'Q36'AJ=_#:+@C\U$*>X$V2G\3G+RBI7<^AGSG>3854@)Y<_<XKE@29;
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M5CFM[^Q(ZZ)Q>1_YYGBT_9HL[>!(URU)7.D;&S].> HAE&^3V'; ;Y!UA'\
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MG^7L_4M*1SU;]XB@?H(&([NX=S#C.(5GZ94>UVJBQ]3%B0QK'>P0'YIS1 ,
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MS/:HHV.!,4T<C6\K(RI'P5$BN;M6[CU))T*@$PF_&;N,5Q$U/@_(5J[KT#?
M:-"M]'=;-&F>Z&\Q2/$V^-<X 2'/*A4KQ;'5=@QRQD7QUJR_:86DM*XJ<Q*M
M[;DY4RP5=2WZSW/R+D?H;<QIG,E=C45O"V1I2R5^9R;?(1T[,9KZTW^%3!;[
M\,2:#5$'VPAXL9^F2)C%>ZV)U)5LA$\[%X3UU5T1'M_+J6O*:7B=W@((/#Q<
M78R&W6&*%E()(Y?5!5"\OMB:%%X@%XR:'+D@.^R1Y]IV1LS(*D==+MX^NHN=
M:M_P[1_J)9#-;AI_&5_-X] A)FM5#Q5$S.[8.%^H3WG&)T.?F<G6.KA(%UAA
MFG*9B=6ISE6@VUD=^XT?;[(>DW%6;=F13$LI[B6[!DZL+,AMF.JS*ICQQX\K
M.VX\%<PMS;23G'3__%D('>I<_IDE%ED[GMN* M0"?\?#IO[*<ZDOP2_@=WK(
MVS)FU@'FXFJQHT;'9P&]#<HRR#76[ M5!PDHU:>;49M0!,KQV=/'6'OB%%@N
ML;@=XB]DN+N__??J; C__&VD(;A@GQMH.S2*9>XD\"!Q@--V.#5\D=QF19#,
M$FK;@5R_4T^U>JI.@1.#/PZB70\3"?#3FDB?T[FH;&I1,&5%1<6KJ4509')E
M\J A,Z0H985B"5H!R.1<4("E_U$9$>".K&L08W;@P+(^K;6@(^BRH0ELC0,I
M,Q1QKE=R,@G2@!]45JCW1U3;@*MR$1>:ICL),U2S--CVX!)#/KL2_U7S_3-:
MY6;!3F8ASHQ<U!95/,=/I"H0J5%YF$B#M<2/8)PI6'&5%4?J/@N$,2'QUL#W
MYYX\[6(%1_L2)\.K.K;T2F$FK"#XT"E:$15AFHJY/,2"4"K:'9MG9K4]E0)N
M*EB&O52;*=?\?%J5;/1S CL+.D_E./R=7)7R\XQ5#'@B95(7/C;5*\?MRP@N
MW[J6>C*75WGYL<TB(DD1=/AM]!["I%*3$U::3SMV8QS*CM' /F[GCI*)5.?!
M(J?F,4X1/=7:Z!4AU)I.:$D!63G!]I@1-$_D6J#!8@XK]W1IRU(W_F5X4@/"
MP\A1=HD)REB>,Y(:,(VU=1@F>+IR' ^,^OG9(ENMF!)P@:\YI2V?P;W!F,#L
MHU4&9 '!E[7#4?>=H!P>CDX*S$;/#+>(SNV[4Z: *\XR@*/^^<3Q\UNBV_<O
M3*O">_"#7'NA0[B0^J6?12?M9HRXH&Z-W>GDR+, %R9I.'Q*_2_@@^C \H,N
M:$A*4HQGQBM#NC/AO(,2I)Q^U4$!@?*L?NHGEL"?*BHDFGAK//.E+]\5!0GJ
M,KI"BG%=@O?_ 9CDX,L=VG34,.]BB==Y><>Y[7IE:\QS[,'?[$H,@00*:!YB
MLU0J:C=X#CO(GT@+UR0Y541VV:A+=DJ(.=/"4VRNV;23!3[$&]*JI#%20.0L
MXW;3Z+_OQTLS_3F1L["@P+>@"$89XS%Q^[%1E*1/"JPJ@H="RY#T2/^3$)A?
M]$<Z3N/^[\T7KP<?"T.>BW5WKVZ7U.\VY\.EOSELXW\*?)1;7XCBS43=A5LR
M3S91=28PZL9ZD@I$OPOC;#V*#*'Q]J!'6?/2<35N>%GF=&'\!UB5E#O]!\ +
M^P>XQE2X&8WIJ.CX?=;T8XO#^O[=]P1C<\$S'*X3)^V4R&1OVB:3B.LH$/[A
M7:S6T?GHYMV,P--Y0<B7#UFD16#TZ](=U'Y[AG?+[ /&X++_TW'KD&.SQ138
MZWC[YRSIT)<3D:?7;O_74]3]V;U8T_OSTZLGT@XM&,$>@D-OS3^ V/FR]X3!
M$&K(@\"^P.W=7H+IZWN.QQ+7A&#R<4*9>D\ ^O.17PE5$^OZQ9/WY?&UT$/-
M8ATL$"6EUQDGXN9"[+*WM.,_T+R2WQX_>2^9K4"0.T0O\C%Z?R[55W'GFA6G
M*+3X())Z"9PBLBJ@+&C8[<%;+IC[YM@A>3#O+BD>XKIB_E:&VAF*:^\-2RE$
MT\,#%?_"1C(XV4W,\%V<T^CA9%3VGQ%N3R5*E1F=\3Y32EDY$Z>A1:-ZV%D!
M,$I:[L[S3]OJ/U/.B72W78CVY VNO_YXO<9^6+D3^0?@.HX_^GEWKIYL<+>2
M/UNF>4<J:WQS-;0Y"NR61$W8JGL@WQDM [UW=YYR"KC(J+QU2QPOE!VT_A3
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ME_?C9HYUJCUKDW O')>[<5V /G,KR] S'_8%!NH_ !TC?D1(C1XE%T>BEG?
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MU'2^H^NJH>R\,BFB0'CU?\K.*AFBH8CA!4&#M"A**TD^1] EZ!W(#AB; AT
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M0D0$EA-7]3F4>UU9,ZJIBF07J2D=8YZ1 E6)0YY37-5(Z0IJC@ !!O5\<ES
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MVKYP'+Z"PR*UUKPL1^O1:A-P%8U@I0..5Y&)PPW36Z?(1>U-[.A?'6-.8W-
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MO17VV#:.9AC=KOV#<>[6_NX1>X9M:-*NAE!KEKL>*")&/+PE=W_W+"V5^ ^
MX1(8V-/U\<&30IHQ+)@($?)\^6SM*VN_\!)R%/2+>2+/8\U#15UB/RE+D![Z
M;X_[#_!E8OD29IW&,*OGX^[L]1_ 2$NZ'H_N+/@485_NZ&G9KD[ RDYH;F.)
MW6QNJS;5=1BTP4$]2Z7AG*M8NUI#&$VM)\&)6_0\P2*12F3[H;Y_5JX+[@\^
MK"A?6!;6=ZZWQYJL(%@S17\F1*/F O(-IB E73_4RODHEBEZ#R093)X?J?9
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M1U+]NCR1.1A;SS<F_'^F;)A^(3 >VOGF;=1R4#[ZK:7_-#R<%/?^4:F%/29
MW":M12Z6$UZ^=='MP*U  (9^TK A)Q8!QXV;,!HWQ\WNX"@ER -_^V]3L5'W
MM3/%UT[=+72O=FV/3Z,><V:AN@G6)X.+'/M''!MP5E[%@?R&Y15Y1TM=/R<1
MN$0($2[/<)\4Z&2PLF;<$9TZ'H,M&T.=0GX@1O:V;T&:8]/';X-ZB(POU'"Y
MN&YH>[ .0^]?P[HV*;I0Y:!WRMF\9EPC:N#^1M:FG\I>YAO[EX0-BHSE+KQ:
MY2 XA>DDJ<N=2Y3&S"JDW>D*=7"?V?#KQ@+<0@-1X&Y_9"J%T]ILV*Z!.5JS
M4MOP05:[S60B5H:^@BZC%SV_)8Y"+>TQIM^6>/D0@Z'YJNPQ9\T)J)6+Q77X
M_MU7?* S<DPH()]8<%:(ZUN3V)!.1EDTS\\+V-=V(B0M"2\4K;G(N/"\AIJF
M"J_@;NUH[@+D X7N_^75KJ_,X2Q-M-=1(+MM17$M-C(#57I55,<)5'6AA4&;
M55194=/LD9<TRLU>K3%7>K.DR9]49$QJPB=78WRYV>PT?7RNT-XRL=]NROHZ
MS_B),[6$4%-\Y'J_W]G/'=0GL.N[%MWEC7TR/CJP<S[%60;Y^ALJWIT[TJ70
MJ,Y2:#BXUB.DKN>[CYG3)6EVJQEJE<=O2X^8OTRD.W%)>S70B'<.':1"Y'8\
M*(AA$^]3G@Z$PZX!)[],LD:#2<>9+2UZ8+O?PJ$NSM8?]I;S;LX%&\=S5)>/
M^4[FS;VJOSBQ*5_+F712J!K] YC[:0634)+1T$<@R<5M#9RL?&>;.'DD,YW
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M-T$1[XSY6BF[&D<(US$[,4C6U1O SM@^0H7 AX-^\5"LD6D?NT1>TBU>@QV
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MZGC<@$XJ K$S'%DLP2%PZ'RN> <%M]Q<#] ,EJ/2SRD"X:35(8./+Q;_?5L
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M=00BO,8=/0\I=MQ$BQ9$X*TB.MH4#]QF+%KO?IX$(QA]1'3_?02L!%!KDD@
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MQD@KN::SC"ABUR('KSFOKL+:H1. (:?ZYZNG^\V+0*#]+'GQ6HJ9UR\_$!,
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MQ@53) _H^6\88JSIF_ 5F>AA$,7/XR(I!D]X%MHRZM&QY;'_\X<#L3*D'@,
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M6:VOSJ+0!#S(GZM*IW(.I+:(\33.KI=6[A?R65MX1R@GRV([:EM,H($7K3C
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M=.CS#_#TGBKO1]1.7KDU0PPECUO81M#-_6G[#*>W0'<Y)@!=>VQ4.N1[Z3\
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MD*X3L>?':L*:8C7[2U)>%"9DY- ^C_ZSY)+>P5+K5=I2!$!$!^#A@>KA[8\
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M,7AJYY1C+?S1-CDJ(A-N#;0*.#HZ0>JNW(?!G",8NAI/)+7RU/<I)*^.YO]
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M*]0-CV1!PFC&GBT+@'5$2FU0N)VKZ1K&7855I'L[@5,I! #'(O5=\YV!10H
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MXS?KE?O-?Y/#-42'72&.L4KM&'L;()NZZRHUK%FTIBPQ*9XAY8^]*X4,<BI
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M?GZBE(S80GA]7ITG4FOJ?1D;ZC/QV61:+/-P@BJ(--W,*I%1EJ;_#27398/
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M=? ?H!6]#B('&NMF*+W MZU2JW"D>NS1(J#)LG'R8!O-]Z,D&F;T7K+Y<5*
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M=DU>/L5=?ULBR3/%FJ<DB.SYY_0*?WM%*#V1#XBC8/9PM2^_=URJ@:5OJES
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M^/P1MP##]S_H2#Y=*+DJ4?Y>:DT] MQRN*$J*@H=;4<H3&""<+W%Z5-]Z_N
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M0H1<R["W13DIP4;XO-#IH)M/FAP5^D_SW+3;X"Z\Y:/U&7+(=9,+,-%DE9;
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M>B_"2$9$)-F>%@JXA-(R1;N%FWH76I)(2&<:3=):N)T$JG4M@:A*X1U< ^1
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MN'G@/ 0<(TA*^M .=A\K7_WMCK'H'%G*GX^L 'AC1"-_XO&AO0+'0+RCOP?
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M] N[GEA3_IA0#;(&2U8A1P^-'Z&$)"E]LA<E1RS,V.(KYGY'/)?J)T4&U&=
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M]BE,3MK52JW&?T27N^18VDQA,-.[. 1500,LMA6_O;.X("8Q_H4HS8CU=>?
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M"Q$C;IRP8Z2=6_Z_^QNKJZ/+L2K6Q=F3(9&J*8)F8/TL[ZQNB\>S//)/R"M
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MD8X-+#O-RN,.]O8&Z<F);\Z+Q#+_.OOC&4>8IM+40=[P@T@$_X@.7 B[H*3
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M^HM+NSQKO^![RV_0]X;\(^T-/M#>.7ESL?L30.CK<[OSD?OLZ_X)6-PV$&L
MY>&^^?36>&%G9RN\_^X^S,UB>MMTEWX]J__J_>[+^;/&EBEN@I\OXV[WYNSM
M%L_K;17_-&'IF\"$\P-7=\'AGA^H>+1+A'F.#_%'IP?JX^OK[<?38K\S]KT
MTH+$FB]M3&W*'<"\"<%'CG\IAS>#Q]<?HKFZJB6] +IX]R-[HQTJD^G,RV7U
M_DD#^T$\Z((&'>*$$O &:O%W>W%?A/ *?!%?W0\QZ+#=]''A6;0Z5F%GMX]N
M<]SL8EFMJ2*NK/ 7Y;W[(F;6["\+\/+A=?IP]U'P[K=3M9VO$%VSJ2CT%N2%
MOEAF?2O_?U+I\_^T=0< B(B(P/_SX/O[/R C$_2!__@+O2CM<JSDVP^][?,7
MZOL!V5 R$P=OUK1XQ609.'^>6L$N?ID(4FNH4_IER6DEH507I/YQFN^&\R=
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M=4$H2!MS?W^C.3:D''9-T[^+Z.IUL2QZG.OZKO/X&!Z^%_N@-Y*)%#EF7D&
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M0Y1J,*)K[7*I:QDQTXJ/%SI,-U,E,5^'$9MIJ=2Q8-OOA% )0<>4N$["F!Y
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M(6D]G9U*E<;'@N*81Y%68@*L#:;3K1-'XB9M%AHQZ[0KV:&;<,KI1ND7O%Y
MAK'ZXF:>/7F!;N>++N^GS>64!.OQXENYJ[4V\WD6S0IF$IZV13I"EG8=20]*
M07^0.D;1"3U8G)EB1XRFLLP8Y#FX:CZN D:IML*PQIIUQ1%QZIA9QI=YSZ1&
M(%&E!!AV'3VT3YML'#[\[)Z3&11W*Y%BPEL%A0S.V-194$%1NM>S#"I%K?YR
M2NA&$[C78C&N9.K0=M.40R9P[ QLT1<;1)T"G7?EW\M+=G]^ZQ_Z>,D%B#F'
M4*@IGPZ3P:,[ U)Y[C1UA<K7N3>U=*2XA_2I/77!T4M@.3ID=E-0,@#^VT*E
M'#:M(GTS;+@KDC9^CEQE[Z@S7.^? .H-A[_RNZ:D](!PZ_8Z3=P^G4M"2KVQ
MAQ.Z7NE*X@"1?R),AF(PS>+MBZQ5I/66I'-V#:>0R>FCLY6-] (*S4E0OI&8
M3!-VP4LH_K,Y9M1OPC,F*3RO<M)0IJUQ*VO\GO2[+4W-4;MT#L9_?F"-30F?
MP X]&UH[*661OHIZ+ 4$M9-*)!)#[4R*V*[&A>OES@*HV-3J.\3]<TH!@!Q_
M?VP(?VJ/737,AE1Y6/_[7IEV*:%>HABCS%X<:&A.'I08<2-XV6+(W$] DN22
M*TC-B?MN\_>\G87[RH5T97W3O' /8_2X4[WZB%S+M D^NK^(YUY@1\\BY6\4
M02ZQ]EGQ0 E>PNU%C3&58MRV4^;_E!J3:]9*.,Q;+/W%C=Z?0ALL;4M-;50W
MR/UD66;'$:R53JT1,XDJ9VI<B3DBA>DZNO;G3UH%:5S+\J\"U*PR1C%+!.YQ
M/=G!AP",6W*>O<L@H6OGK*V;X*&GBC$>1]Z_7;PE_N8C('9Y#+#3)#Z_;80
M1)J?9:J_3NBPIQWOG>@N27%SPG-<(&O^F2AF.2KRN('$S&?@$A7"M1CU6I#'
M I,9-!SR2B*?#4F12%/H$S#".?W5'9B9"X"JT:0)[-@9^%3+98JQHP0B^P/Y
M*'D 9BS;.AC5\^FP7C"W$9"3F\ 8W<Y:M[ T\3\,TA)-4.+P=#2C/\RS&0]K
MZLB=V^[52*+0HZ+$+//0H[PE!@ZY,@R!T021WP?SR+\_#TQ7>!J^C8/Y',3J
M.$3.%97C_(9)LG<?!G+1OC3[8QWW;ENZ?Z+UN 93'U%;<9X6'8-OI]5*$VC-
MY9<#!F7C,:1B.$9MV<($F-J#%?BU**^C,CF\JGKD*%95&G1D-A_2O^<IX_D#
MLA:<BF,3.R^DXL]IJU!-4&FK?_*Z6F R;NB\L@V1!YCRRRZ!:Q8JU4(3G/E_
M A3:20Y)$^JBI73XUB(9SMB?A<>OHW3$I"98G=%<J]@=W*G5+AL/H<.;>O/*
M>B2DAXJIUB7F'^V5;"[DZSXPM<PJ(S\!(Q3Q\ZS'=YG"MW*MH$QS%N%QL.]$
MV!;[@NY[:>Q2*CPW+9//&%4,YP7UK6DKNL[]Q,(2XA"NCE>NQ,'NO3@;%1LU
MM 3_KW0L)1<:\9SBOASKJ''&(>-_R$S6.&,(F5I:V3\LD@0  "<A JO^ZP]+
M!H"2X@% *RL8TAY]"U7[EAH*EX,J10D <)!E^N/%:V=,M?L'C\=#0"LD"4N'
M&+C4V?ZHURQKJ!DM/.#0-V5388K7"S?%P!/%YP[/=ZYZ"D;E)U:>P5<:N+)>
ME+,T91XIUAH^"9*D=N7>)]A"EK28<R8C*-%6=*3Z?N:'\,;5L97^;:XQ7:)Y
M!T$>>T-S7[CNN,E^C,Z-K@*"[$)8Q@L1;K2V1]#:S3R_25HN &X,*][1],\]
M(=E" D^*#IED3#AV,=)SZ++X*(IXW+\;6/]<4BR2B."?BBAR,W!8!0.YK%A>
MKGO:5=$.#QH/A]1T)H"MLW_C(6MI.% S$D146Q<0OX*OF^=8.\VEV[:S:&L"
M-?_9SY$/9@Y3QD0^N[/7E6K9VE6N;@;L0 ,M=,&!'-!6JS(; P2N7(Y#HB9#
M?[*,TC(NRP%YI4)ZZ2PRI?,1A"T>964MMO]4N&(J6YUV[.#]<R,+,JP$.%3<
M'=Q_:#N2O"+L% 9WPJ&QQ9JAZ-& 33D;7H#%\>YU0*;F?-BY#%3N3F&^H<UU
M"+@MLFI1+'H0G"C2-RJ6/7JIQC61UBR2AJD9)9.181WCN[D75-.L3GZ,-X,T
M7J99_[L*_R5^F+)!;9KAD)BTO=B%]P>)*<3G:C;Q'%CJSA:)5M-S.@7SU1))
M-)HW#N0Q@3@:EW0' 286*LQ&'?2I'6GA%+-6'K;]O%@#U.6?@)E*V[O6RCAB
M<UQ]$1-IR=%J)[+6QCA8,BDX$702+9PWT$_;H*B5D"%>A2%=%N<"W:O$R'I)
MT]C]]@">D#2L*,W0Z7.&7RU_67TN;DJB$TB"LMVE@]P3N];SSD7(S_TLEZ%Q
M::/FFD<6ZI*4;*.M6M82>25G-K_9%# [&D:A4Q"9$9 ;>33\/:E5NJ5E*N\M
MI\4]$3M-4=6H6';(O"BW+]W4U!7CJRRX[;>ZH-!B^_8W"0FUP['-&32L*!L;
M=SX\'*2#645R#?7RJ#R;'L'&9Z Z?W%N.V.=*?_B*V_-RG\B0CXQ,=B/G9_0
M5C9(FP<TUPT>N6@:W&%I3&=XNOD$A'1@:*L-XUZ:F:MT3-:7EBNUF/!::YL2
M>I2S_0D.C;;HJ420K^GPS\;<67'X=Z%RD\;IC.[)CZ5+6;)\Y&!=38*]I[D7
MMRX":QC@!*E<CQ9\8"YX!*">+$CJ=]HY[O@%LV@Z:V/6WM#A+X/O'B/[[QD8
M[G.4'T>IA>YT"W^(" %OC)-0BSGQJ!'V6/?RJ#]:L?7P=T,;1/T]G/0\"9IQ
M/.?,<BU+8N;7]?9*8Y5(?:7\>.8L2_.3&<:!\GB:>KQ7I-<12[.>(P>X0(BB
MA:+%-X]<939?P96^BF98OHIDK-\;,U*.(TZAH_3_(.W)%T2;):+3RJ$"AR"
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M);8A35N2%0RD_40@J=K/7JD4C">PJ#3>*:@UI][4.?.MNF?_)CV T''JUE&
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MIG&O*VS_1X-E\@R44SF!U]D*8]>]6\TRF@K4I56O"[(N-44+%35C::[BMQD
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M=E5<M<9.FYX*1,I(O&"!,[,[/%IZB %_H2GDH8F8\H04>YO2V,GZO%RS1QZ
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MMSDHZO/1Z'OD?$;+M*TP'_K<O<ZU\=F_R1?N+_O0-.FRSWH9S:OR"^W\[H5
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M\N7(\9UC?-\P%;.CFZDCGV<P^=&R6U9X"POO,YK&C6.C>N[*#S?4@]H4=4X
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MC83VBMF^&5SYHF36:+KY*?QI1%ZH/V/=E>94!_*X-B6\*-GYS8^FV<T=9EN
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MES[T1JK6QP[9,S&ONZMFKN2%X%&QIGV9QOL\38/R/W0(5:Z\LPC6?'Q5C$3
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MJ)F>CMJB>,9B/*JJ4=08P180=XU1*0@^=O,P9B$_HKP4G9AH%J!JVF/Q]+T
MS? !$X%M2LV-!!DJQN2/VCJK.=/V1B@H0D;IZ[4"XFXG *CA4U1VR%*WY%7^
M8F4\*F_F<AJ#^JS@3C9GKLA1.W4/;3H8^G%#+.4@=O9ZJHX.NV5RR-&J3P8K
M=U0E:<;8-GRC[#.:<$RFG>IS 65-?O]P5_L;K,M9-;/3)>0MF1S8CZ(N1;9E
M.+-'R[$S?+UK+D 8XR_]D'Z%\8U%H]D+AJT,O!")@_"A?.SK8[(1[C#]A"]0
M%)8<EOJI?@P#'9?.*[=?W?9TI-3U6R^7'I/4#.6]@)Z2S\#@.RGKQL$W)Q""
M\NS"8>!P/"-6X3+Q^#V)&S8E*0M=I@.!!JF?^.!F[5.&VJ'DUPSI])Y%7Z'T
MXK@W2A,YSW>C#[:1+M@%UXQ;?\B9]28 =J'A_I9K-\DK/XC_(W?K%RBZ;WR&
MW3Z,4>;86I&):I)J!CCVZ$H6W0G5)2/88!JOCY:[W$FJ/->O6A,DQY<4'?%L
M"M&'IJ+^GL'43ZLB24Q2^"KKH^B/]E6+R9*5.6L:G^] 6X@4]6+HO&5DTPG:
M8-UD>OP8X5YK? DO^KU1E*,Z+Z.HU=X>E /<.+Z](ER?,QL$)\G*I[0@.#!A
MQ?/!?M0*X]^)T.]MA9H>^DO>P8@'7Z8+I^@S49.EL%[)N4F*I6E2^@8+FZY_
MMM'AY3]*6F+WS<WC495'G_:[Y]X?WX2)HF[^]<<Q#.&[C8=>SBI*GR/$MY5'
MM?(ASRSM%5\8:?%\8(%RN$ LG'09>YTQ;-%"%%'EE&R;U7*R-_-GF/B<MEOD
M]$K:CXNG^4X +??;C:@T)W5Z7O!CY8SSUGZZ(5)P0<_9CV=LOA*17IE)1)EP
M^4HE5)]5 /N2A-FX[8>L/J?^$IG,F>5-ZPJJHS6M#<]U61;VZZZ=LYMC),7:
M$X7%7[1*.-U%:0R7M5O5.:[OA(LN1%09O.WU_'"#5U>I09_,GK$-MB4X7V9:
MH'N=S'9084"(A$$A^GG9@=I#Q@>M]]VMY8\%/[I#U5K[=>NN'6AW$H;Y7)<N
MS4HNND<W-\A74B_?(S"AA;/\'K]F%,8W3%U6?M"F/JKY>6>0?)3$2+QT/Q#Q
M1K6K@BS<7&U["^LPQG+$;B]S@8>037A6.IXJA(+1.@2TU2K+/? @('^TJ.'F
MT?6),H<NF%$HO OGM4O)F"N0S719/GC<AFW4.CNX')1MU3)\Z[%Z00S^J(_\
M/RPY5'5WHP]552=G&!8N/I\Q)$WJ_23(TH$AXWPK-#_S<VWHJH(NL'75]=J1
MH%#JPO;-\"?PUV:"_>-VLCEO8^+Q-)S[0P(&)B_4U%TM+!#.#?\BEVIJ1/ 2
M!*GE'U9[S5YJD>V8>%$"FXF!O)#T:8@Q;&SE0IF$\F9]1'^EX\NQT&.^FHF5
M4!_C]U0O29^[MZD5-"\6'/3'*?1'T]Q_T,(I1#H00A 5]XX&'R]2Q3<:FRDA
M&=#4_3#6,ROWF3%30=%D:;>VM8!5><\0ZL@U#('#I*U<Y3&-1)&D=KOD+&B-
MM0U^H#!5[P *X2@A#NH:(WFA?F?)J\>0H_E1L5CJ*XP L-%PE^$G,:]$V?HE
M':$A?-QZ#\VU3A;L-RMLJV-IVE3W"<OR*S031(P"A;IF;Y2E2J5O+D\&ECRZ
M6+KJ-*_0?$O')"@YB*:4(12V&8,.#HGK*+6>4F4XQ/3CDH%IAI4RI.;L!+\1
M5<K_>NR(,[O2<@_;@UY!<XCQ8P6>V:W!RU/%)H#7$Y(![:'4F(5/+CWR:54-
M+G?<KF_B&J8 CBSW0I=KW\NY(G;9C8Q3M;M7Q (G4"DT+GGX74L,=GXRD%JR
MQQ[O$%Y]MQW\8/=QR=%ETAZC#J=0:$@UW]IRD/=NX5MWAZW&CY&+7PKC=?7?
M<'$]K2[Y$I0-=\&9,KR+A]-0I,F!UHU AQ]N";G:<1:5WQ!G H,3&1]5=JM%
MW0N0#\Q>.)X%/%1_&NX59FQ:6H\W7#W40_&XLD&9:>!ZL/?RFX\T:]&#(G[6
MX;'B15_:FD/T7)=38TC'*0C[N\;5S&12J<(5#"'WXA?]02*JG+AS+H_Q!UN$
M@?=9GI@/.5UMZR>BIZ6N$::P&M#)>%8D?.D2-76T :\5]4-+.>#K-,O..2@D
MD>/Y=&04$)*#?D&4=0HQYF/^EULS-HM%+@G2$L\T=L38/=JANQ]4--V&+%]E
M/J6-NGMQN2) 2>91,6B#\!+0&: 02)-Z#"=.(#;88DZNM[JL:N_'?WLG"4BG
M*2.HEU.?P_]:G=OT!&!M*?@5*D4%(&U-(*QN&F[NCQ&S;<I.4Q1JK#'U:QDS
M&8GHEJ_N6D^\H.P^L02+GFA$S/62A'8E9EIW%;14S;NGCF/@7Z:,GACX0&/%
M4OJP=-".-)JJ">T2YACCWJV5+W'4R8PS!MM=!74:]SYOH[E]WT'A7-W?/P'8
MY/;N'<(W/YT .,II43S^>G>+2G?7_P0PCSLI]B4=47/T6ODNL'"_Y@0 #\*^
MOWI3Z@0PQ7'GG>()8%;@?C)R5Y_Y>5#QT#GW<Z+8:NG4I-8)( 9/X_1?>1D=
MJKH,&TF(]3"G' Z< ';:I*N$-X_=W&F7$/<+(/-/=AHTI?Z;__OC;PX)[NBT
MA'Q/EG!.FYR/N7$OV3.,!C:;AVG7-[-LF2.8G:,(O5O"^1*R9P5#[X&RQZ_Q
MB:?P8$<8CUE8AGNM,%*P8;*E$MEH:HB^S\G=;C<<-*+8N'POB]#A!""WQQ.W
MFA)+LFR[GN1+T6)K[D(^))"TUNZL'#N$:LZV',SP*D?KZP<WY;TYAG3JUQY8
MKH*?:"Q\7 .X6UN7BKL1!K,#,%DAC-"9_'9"G\B\6FR7 5)0F.'11MNB#/:5
M(B-)>7C_$L.[U?Z7*Q,<2^(,Q4\^,[3R'2TP99GS*'+CB-N2OU*VG$2Q%JIM
MN)-O>Q"QXD3K,T9&B5(@PZ".J?_</B0[SL#-]Y;)A/,G\B)P2:CWWD?\^(]<
M6;>OO.=[PQ03N^"T@N>"7[9DO";D^<7\4>+$LU'^6.W)RC9\/5Y,7IY^:4WR
M)*:MX7*V]3(+LVA+*3=OKL?Q[[C3OUQ>$M"-KNVVDG;\X$!:GIM1>--JW#0Q
M%OEB=+M-R%'/[RT[N4]L$ET!5Z"U6ON*?H6&!9P:WWYL-<R[ A]%[CXM[0?$
MP;L30&B#R E@(5YJFIOHKR,G%=Y7M%C-S^V 9P%?O*I/D%W4J(UW_X%W],M1
MP$,9?'HZRB/UPIQ<!D\P1HOW,X_+FE.EAX^?56@))%M5LY7D#+VC;X-5<^I[
M'";G^XQN>5(*/NY\?<. QPTRO/Y.CG/25U@O33<+#K=UZF@#>=ZA6M NSAI4
MU-.L5;)_66DE%AOO4GMH+MJ@L17"_O"6ZYU==G7M)VS49?J;G0Q%[@J,#O=%
MN7:K"#O)KOC5.>4R#%&2EVN*Z3/(RQHC'E&\XX"$3'?@HE(G N^/= DS@,#-
M8(R&4.S_0\Q;!L45=5N 31(([NY.\.!NP=W=79J&X"$X(5AP=X($IW&W!&D<
M @TT;HV[NTR^J:DW;ZJFYKU_4W7J_+GWQ[W[U%E[K;/7V>FB1=_354=<<DZ.
M*JK)VBK@:]X4K+*#I\:K5QW2_,=. A9-R$W+XK1!63:LLTU;+FK?< U9X!N)
MYT99!B2XW%_6X%[I^J'*2JIH".VG0A1DLE-+51RE=2-C.TL<?>FCGS(J"-EU
M]#CX+],8#7M$G=.JN-3N=<^Z?M !^?O/CR7B*W<8F,'OM%EV+;4=1#XI44_U
M9AW%Q+"&@B-=%(SR77IDYS](8T1BK9'H\E[+'I"!H^/X[/?O@ <<1.R54W]7
MP:7YOZ4<SZ59$ZU'--*V;G+MBN[4&*H.Q5GY3$<7^VTC5^A=4JGW[I+V=^SQ
M&DU7#:(\WN;G5=)G,59($'UE^3P',@9M^\:- MF:JEK^Y;4[>F=W?H:\@>=&
MI+K_D2R0]NZV'9Q\J2SQD87R8IC-$9QYJ8W:#J:MT&QF.%2H3L-0"K,FUB0"
MK_LL"V6Q7(X*W.,68HBGEFY!2V6(IGIK0CD^PMF_:2_F.?4\KM16>2?$U$V?
MR2:F%TLB&W^D3DA8 _'J4<!'7[_FPFQN\4\^S:,1>)FB"[HOR#9"J4U*_Z'D
M8V6@;/DC4Z>P /SX=W+"8V X"18_=N:LT8[(9U0Q\][=B_@]>Q0@>)[+K*Z6
MMGP8(+SF;ES+$C7G6,%%M-3PUE,S0(*X(^;JK/%3>X3 ]N/=,PHCF__/5\#2
M!';\;]:%QTQEOJ8G872L#E;$(LY>*?6QI#Y3CL(,69VZ8(%U%&<]/3)#<B-5
MJJ3!EJ>%OWMOI560UC"ZV]QRE3#=M^/62B$\J=T_=L\#>&Z?N]]NQ4U27QQ[
MKC)Q1RM>:?OLEW9ZRU#/=90QZ^WA0U7#.SUB6T@[2LIZ8":[=DYM+MDQ3.W#
M< NQYZ%XU8NW^/[CW&K9X..RY^6BHEUVHY,D%Y.?4-#9AMWQK2D&D2'OC2K%
MG+(N/XS%,29D.SE-]E/\1X.Q+'%Z$U_U?O]$'KH,+"2PIBP$[^,Y-"4[1OOJ
MQ+CF1DP3HP<M3/<A(+JT^;<<9L3AW2QW;S8)(()X#RA?Q!!6<*4+-***XGMI
M\:"*2<T<+8ZWN\!#I^5J9>-G(]A0),]=NC7_KAN.3BZ:R!UK=/3^AYZ/EQ1[
M*0>KT]+L)*_K>$/H;+[<@ L/3HF+D^%06N+TAW@OZC<FG2XJM ;<EKC,9CEQ
MV%]S5G)RR-S8);[Z)>R%@ _-DZ,9?\/1]-O-WM32ZFR;<S45LD3S49J*$,KM
M-.>W@Q&;R5 ]PM]E*!ZA<%M_E]N ]+ARC+6E(4S8>(R;;K22S*(LR+%E^^>+
MKYC<6WH@3D8/&M?3$>0,'P[79J[H9-ZX6<M)C0*C2,[V%&FT<"W#U6FVZF?O
MR(< $C9[?PN->A2P(K("I??46O?05N,*J<2RHPL*"<92FMI%3$#&XRL&[]D
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M.,^%2X;FJ5'9J<])3D[OF93]9<Z]\[EC[]]KP,0_V(H+)._%%N;OT_AMOX!
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M]FTM!9/15]8M=;BV[*\X#T .^!9&J [T%]@JTN\$8+!?9/%U2KD_/M?'EA_
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MV:+I2HES_-K$2;:ZRUC:UNVMGBD#1@]B_ZK"7R"]D]"Z9N%6R5\=A4WGIK?
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MY5DW?)850MF5$Q;<P\9F4S=Y+:G/DNK[H*<*!17YG 9WJ^:TP/9O!>7-.TQ
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M_Z(12SQ:%.0-D:B_( (=Q@BATZ:,;C+2<7Z6:9)$J4,!D2)3!;A9BNTX[!7
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M>P1J[/C"DMK<']@%VF.N'!&U<PS0MZE=>;YSV\[FFD\8*FEDSKE[AWGK:DP
M+Z>:U[/;OHJ*V$F;=SNLH\/R?=U3=@ 7(5[H%@F[#0T/(\XH,<V6W/55?DAR
MR?B(35S"]576%YDSU?/GL=DQ!-_L5P6PA=@-T:2R7=O80FZZ=RITHCI>9"X(
MLR#"T91O$+^*/I_(E]AS"7;J/'W _H6CTAW[QS+&3L/3C@*BB?[L+SY:JI;V
M9:4R3/(L]F)%MW4DQ*#*PL#7E0_&@WJ9@T%D)DM-8!2?IE]UZ#5-0V4D.=LY
M[V)=^*W6?UICX[%%E80Y!;G!?]_^$4'%,[__.E)I=Q>%H&[2?W<R4=R'63!9
M27U*C"[(B*1ABWNDW=YD1TA:]W*HT> ]U8P-FIK"O#UMK?6DJ9,!N0P9+TR%
MU6/\=P=%6V#LHL!$(L7/(2NQX8'"B \(Y>GB*Q\0#&2_>)?'"+FF#6@NSQ6N
M:VE+:@/IYCL8&OT>8!BSM"N5C8"P7+??<'4Y-,'=:-+D/%>+*VN7R"ZG#N'1
MY@J9G63/#3"=08.CB'O/HHIRCBM2S6(PXX,M<B2?FLL43U7Q"9Z_J=4(PI&_
M\SG;CQ3=?65,1\*:RBA[98-S1:=466O^S$6W@QN^-]\PPX/_Z<C:@3>9BW,R
M!2>E.VF\1_-V+!E)"H2SHJ)] 9$B;R9@RFB%]4(K,F?U2@RI.-HV:5!4QUR>
M=J7#JP4^/DC@,3[LR0@4 XK?I7P;O8I<;/'T"O"^/):U/3<?6"[9#ELK-,3=
MPZ.B:0JKJ?C+OPDUR"@W/GA$SR=-7]%,H>2"T80[4W$;*G3QX>/R9V\A?GS;
M% 0X(_>ZE8<$G$)-*7RG"'KHUE+QY<X/'VYVA-SDVV6$*(FXL("U+="3I$0=
ML#X&,Q64$8GZA?$!>4;S)SB_^PLH?_O+C$Z$#_S\N>?Q+>,A!]YQ7Q)G$@=]
M\*5GG*.>?^*-+-94(D<9&?-W_FJG#(O['%2@"W]]1HKPA('HD>X1!J/%.S0D
MU?[4RE(TM*?1EY"B,U&SUKN'XU#;0*56[[I=0[;%ROL/!]U^731B2A.JJ*Y&
M,QIG]7>>O0MR4S9JDM,F8V.:3U*$!8C1;S3["T+!Y-&S^GX\E$=H^_OQD6OQ
MF)#:A24*U@EI=E:<&!5RBL[<IY?YN+9^*Z&.[;>Q"V'<OF18W:0?%/_QAHJA
MTSGVAMC:CN]>4^S:;[I>*'U??F[7))IG+9)^#R\PUZE%L7\O$"E#FB;N!AC*
M*RBY*%QDU-/0V=@-JA+W+*>H?RKJ2EI9':))R2H.14&8DOAOICV)5(VGL</0
M!UK=N=GU;+7<2NJM:MGUDCB%HJIB;04/VV78GUHM-@<$S]SL#$%LE%!''%6&
M/'PI/FU]$DCWF])NH9Z&C?.'%IS+J GP]CK_>ZEQUKHY@A3/G.E9Y.-$$40?
M;:XZ/IE!)H1WW*L85/RTI-VQ&<!ZL!1XPX>3R% >B#"5:VGXISQZ!TU+3Q([
M&N95K(%/B47BO/=M9YVV+K&Z_RWVM^F)(7S/A/-QX^:I/^\G5EDKOJST?4^=
M6#I"\EJGE9<#5B5-;E?L"DT\X#>MS&-APP0?7*9KXCOXP.36]P\MFGU;YS>N
M\76F5P_63T;6^XK7BN5I2^T2E165V:[NV;9YC#7[TN76OSKS=-1?M/,M2:M]
MIJ_5Q):C!L:A!"9FI;,KN7A-,U=[?*WT.F;&_$M)X=%5P.-[R*#I"-AU!M*1
M;V/N"^QN/P4ONH([]KO;8 $"$'X8R!OBUOR?VWUDP&:>_]B$W'+L!2?$\SI0
M;8HMW\X'787O*+Q\S]\8[)<Q5&%XL FBQ)\T3H6Q6$HT'$/N84\2/M"3_QAA
M2H-;63F\<<NJG='XI7/HR*HMIML6QILFRBVI$]:QMMY=@A<&Y_/P+(3\X4*#
M2R5<UQ/B&0]?4!ONJ+Y1Q#PY:#4,?_,O$MV[QZB<X;&]&81:,7"R,BI_1%)V
MWA5:<^[X)ACE>NO:O&2__Q+DPG=&./K_"R7\7_7ON^B&D=7[EFB9^CO/0MJD
M*GI"1N87V,]3LJOO-9Y8RZ\?<?0OB^YF)CI>=%[R P%P[4WNUJ1]RNW-D#;.
MC1A/&=/>1SG<RB]W2?GTM;\W.;X-,4YKG'>Y?4?VC"'H<(XFAG/239CF8[/K
MRLL3:-N! $>P_VK60_'D']0$W?5[X;Z[?06D&6(%=ZK_5Y\JQ]57 $,2)<X'
M5>@+S4'E8G7LW)>&DO2 3Z@<)_5A<5+W-]O]P^@4HNQZ,G\^(B?6Y^OP.P?W
MPG5[ET#M67N(8IX2GT<#3=G4*.^>8/'"3+F'+C%-P)?,1C6S&+CTIT633)5&
MHRFV$>$P_RG;U>]91(YXSC.CU1JV26113FO7:")K[/GQ@RWPY_5#$55>=54\
M=5-/=54OJ"HOA ^JR@?A@YEZ0;ABO6 FUJ3P__C%K(G_8RPS0UBG%2[?U%X\
M;LC9EM,U)2Q\>)88"+]0[$_WOH,$+>>-RF>[MIR_B-7%!DVJ7Q2OKN5XW5 %
M'CSXJ)LS'9]O\Z,7%6X$M+H&<D7WE(_V!D!3E'/C[N6EMN'ADRW7B'4U!X9N
M7U^8ZSW^D;"8X9&H1QS=(/,UVB.7W BW^(^F 5)B-GN-+CEA/2D?4*(?^ +H
MN=K'PP8VQU99DO:YO3ZDX&)1N=S;$$HE%3=YURO1QSV O/'_3(:,$.TX.->K
M7US)GK*VMBF[=U]O)4>^&]R5-N?9F:MGTAOY"]"[H4<]^7[5)\]A4NC#IHL6
M19E!'F=:/X4P@H\O<*$TP4#U[8(FT&J?XSCY=P<T"6VXR*NI95:/?-;*.PS2
M'ZIW_!,7G]]]1E-*:F&8D68;0<?NR/&6%A^*NAVZ\/C[]#(/J$#$>'E--W%<
M8O0RI3''10R03Q:B8Q_O(2/$GO_$RK*Q&>MM^.Z?"$\[]E1DUW"8I2<IBM5V
M+6D]]*^3*XM/C-&]E?%;G-79/<D=R5M^!<Q?_5':+FF;K3"LG:L!YK[#'9GK
MB/,SJ:L;^C'8@]IY?@+"XXZ<:MWZ5>:(37NB'4MF*@='^QC8'>GTQ^;&V-.H
M55=5"^:%!V4!@7DAC_M@C^LE$_OJBP%Z]R+ZV(-$A8H8/Y-.[PJ/7I8:\@HF
MB2XL6R<!H$GA(^^QOC5X#F@NYFOEU&;K5*0YS54&WB#X(KL;I@L/TT+WE_ZG
M]HLR>S:&79_A8UVAT%? CR\]U]I!2CFU[? 7+^]7P/_9'F4[\4%)]W]L?8)H
MJ2INWIJ%U5E=+J2;L)XC*PU2P')47A3>< >TN/\H457J^L'[_O]@[:V"XN#"
M8$$((1""!'=W=P@.P5V'88"!!'>".P0(KH,[!&<&=X8 P=T97(*[NR7WOW?E
M<>]6[;Z?.@^G3U5WU_=5=\+(;O4!S>NT4,\_I/ZB,)/BA3-3@\;G-.RN3&K!
M5'=).3<CA8WV(H"\O?%!-G5[5GF\V_+D?+7"54FO[,\ F:$29EG-CXLUC%[R
M]-</8:?Q([QCD(M!)U5J5:IX=X>P:S]V(_+\7GV83_;^ZTO$3RMS7RJ:# PN
M&T7GLTTE[XC]7<) 4MIZ#C1R!U;HSC[G#AE#4AB8Q[P">9!8^VNL)V8U25WD
MUE/DH:MN R-: K58^DPEAWNRWJD&V1)9'W!1&5?$MZEC' (P6.\_=1QM\>>3
M-](?'(>M&XE123(\0DWS1.>N)17O53FP,P^Q16X!(XE\RD2L]H)5>:8Z&QSI
M$9.YE^,!4D(!)G-X(BZVGPZV#XU*!V'L&!2C6KV1[XE.'3%&BD(4H-N*X1&'
M101K#I=Z<P +R!K3\5G./66M.5\#O$/$RK\J:I9-67_L_;9]1K^>^S0OM'R_
MY5#^S-1#;I,XSFM9U+;9]N'A*G-DCK:,L_60]];U8?2*,\HLSTKP:YF=K7;T
MR!5TJ/+$KLBP6MY-V\JZ0>[M;IJW:'"6?\I+1NV!D]'I^L\QD]Z]4BUABM7<
M&RM6TPCZ$404W>9[(=BI#8D+]U@&2):,YC"T##MP=^UK@.0M;WO^X(>7KH2'
M@.X.7ZJ"$L9N2=H*]'Y3OSD"U)K%^0:0.KOUF),W9U'[NSEJ6:44<N' JSX_
MBWJ9U6K)$2W6I%E!K47/GC3'0@ZBZ=*:P>U$IUF 4E!"]=[FT*"H2A6N0)EI
M7CMKC%E$AN&=? V:G2NANG+5@T0-BJVU"N/N)M_7FLU)\Z1^9'P'F@=\AUM_
M"699<OBJ%'5"V^0IF.'[X%_>K\)R"A&/I,&W,[1 CLG.=YD'E6Z_.*Y5C:,Q
M5O![>SA%Y"Q?A0GB6T8\43BA=)7H;\D,[$($-SS0"]&^ECX=14YOPPMQIU97
MN Y;:L=P@W7.JLO1EW[,:^F\+YXG65%R<SLK14=/_^#.)3T]2S-)L,RDC'_2
MZ-EK =1"CR;?)<',:MX"M1JH6D2Y6[Q;:76FD5.1>ED]U[\6?QM%E>HO+U0D
M[*NOB-SB1E$:%NT_]UG>XITQ%_3T'Y(CJ/FW6>%S4#NU5HAH>1>3OOF!$5=,
M?;72 ,0H8//9,Q6)+R]Y&2&7MIV@1'>949ECO(G4'9J';TP>:$5BIL7;/+ZC
MMH+GOXK>A/0#;R]K<$NQNFA>HH&I731M>>_I&18S<FI[4XQZ-UEM%X7L0__(
M(+[S/58].?K,]X AJ6Y9@( +\K%;+[YV02M^M6GQ/?67J$/T_=$-$OSZFAPE
MZ#,;]>K[!3T+-LDC9M30 ?N'5$"C_T[':+(\^A)1<./N1 H_#4W&;^V=[$(V
MFK>^JD0TQN@=8N$9G152:9T($2LC[;/ON]DME>:_VAACEG6'AE14Q 9X!C[T
M!0>'OD]L^"%%^%6EB'EL66E(FG#&D\MP!Q0TU-V 913<%"AGD2MHX39)=:/U
MH8ZL,%78^L55>9?@ADC\,65@,&=5@E&K(?%#]F*UAG,[6ZD$=7+#HC$-NOZ.
MA8[ O!M[H@A&=SGPBVG^]Q(3#_P97--T>V-FF0TR(QR&%QRRNC=R=-K[WZ+C
M81:R)8R04EYO <!2P^20F)JQ"RP*\TQ!?BQ-2WOF'U*RS%?2=^@"6$M7XEHW
MI: >\;X959:H'M_LR@;LU@W9XO"?^Q8 @*/BRKT,_)!4S?&@[:,0_O4WEC_*
M*-\MPR$!9*\'3/'N3H");VB0_LJY8C^I%N\C-CN#SY#O,H_13Q5%KDO^:2X=
M7TH6)^9C-+YH%^EL627PAT%="QQYWE-]T^ZE*688G"%(UF=GVI#F97_N>"IE
M_7:WZR=[O2O!&_,-(6,*;FCSR'94,<.QZBZY'<OJU4?&1J7\KGRC8'(8*_DY
M!G]@F"\>:]0E(S!F+885\L6;]J]FE8'NDUG_H>%G9$.W="4WK(U91(4!.,G5
MS5ZZB,!2B^Z*AVX9_8Z8/+I20Q:(^PW43!L^U()"8]WHV)OTY%Q1&7S<[]=>
MGS'\R;VD=\S]Q@1ZUHXD9R=P1?UMA,%M63DE'IJQ@EO;_"7)XT):AU3Y.V[?
M+.A&J?I[:(J5C6H<V/PK0QXR,ERJR)Q0K0=^?JS0S?NA=(^:9X8EL)]<E*_V
MM5Q#;5<R9;_Y#2@"O_YL)]:J!>QC.2$=Y3 ^>8O+6L"!;;'KO++*@1ICWNG[
M\00E[9JH )8&-/74V%5QLWBG:<]UQ/FQH'"*6=^OW?4\J_?[$.E9T$>KD_<5
MID!E2L5['R7T;1^_, B'3#EY5X)OV@G<\:R^\!P:0JP_T68FKZN8\_'[1+1&
MX3R^D1#FD<.((=9TY-R7R)]<@P?]^B'H]5H%_3GM!,J6J_&C+=(.7/!:L3<M
M6,#\'94WI#,X=W6$UL[ I!@:00TCNVD;M7:K_J]N4?BG2%&2(X$YW%P72@0P
M8-W:.(\#+:Q,*?<C*K>LSXB/B9JY/B;YLT!. WYVKV9,JCRCM.]V.AI%@O(;
M2;F,T!#JEDIW<!1M,7G!97*CT+3^F;:ZWMU"@. $4I>&!Z</99'=M@0W<61/
M38\V<@*G=PK6^N3FY6'TLF,=K_9]>Q9D=^HNVUINU@@MQK;S88.U$RS5XA\,
M_W\CC@G:KZD7*?(I-ZLO"G#<^S&(;MW&[\0#.H3T5X)K&]/%&$+*_XJ3DN 7
M#:L0L+A$\4Z^Y9FS N/:O6:'1[$EIWBM8B >:-HK.HN/VO$N^6V!V9-V@6I[
M3L1[=B4W6Q+9M"I_\V!F]4[1N3]"6%1US\QU/NCJ']6FU.&F16.9/::=IZ@W
M))136OVO4#DF>+MPL4_U_.%S?.&?MDE#_2$)AI2SH9@UPC4[H39"!44AM=9[
M.L:Q_'3!FM-H48GVQ$CVTB?F)T=<\%Z7=85D1I%K=IF!4)[VH;5#6:4,LWA+
M+]2<#GH3Y[-=-[-\YMKRPRUY#6!TZG;+"20NO8DQ>$6M@1HME<7AAUT[@D0<
M>2U> T[#ZP5Q-PH1&A(IT<0+0\@F9P\+AZ$2$7U"W#0N'OG#.R>1W,J)\*-G
M?K[,Y*0Z/#UC.TJ3:&=R2$?:R!YV2&I<'6^K9W5.^&M!X3:/[&V54T\&;_*K
M\G5U_L!C\[PSRY3>Q)B(<662WY)N^W@]UY;',=O:,+ZKSJ\["M+AY \_/\%5
M'0K&B7QI&S?5G'\Y$G5IHR.;$-SW6P\#-=U:!FK,4&.O<KXI$@!NW8_3?3SE
M5 9F@*[]W3EHSG16L^E,V=_I2XAI]T2'^E$M6K^8HU%1<<"[6WIO/=X\[VJ(
MJ.[R;Q=T^2C;2O6:O]N#]2/3%_?OH \=D1/548O:,T=Q%B29*2:/&0Z]U79)
M&(Y<<-VN%0^%C./Y088&[M0T1$\_+' "+.;MMITX?8P/<:<YOHVR$^+6V .;
M-2O$LCK_CH[X$;6H>(&+4.KM6SD43.P,<B860JTTDFFA#Z?-B">]?<5.&X;4
M"D;G<>YXA6\;GA?GY3_NPK#H]C5CHI.+O7MJT3[6GJR[A[0<J;HSA.@VI<S#
MTQ2V!BT2MM^L$WS#S3;7(2J'<0JQO@NG+[Q!:%7IV/R!\$S!O!]=X+GB>7B5
MWY::8H/Y%D <G15-5M&LC.[J;HC()*7(!J6))3HSNH$Y>;?M3IYG3G!9I<^X
M9N"804=T[ZD(\6&KF* M$^.CH5"U/HRR+?,#A]+3K<E.D8FUY ==MN)S]\IP
M<M+[.W]+"9O/@H+Q&>8AXI',W/S$@BR@(YP0 [8VA-<FC/)J#:P2XO$(].$A
M@T9&8@(4)L/;G(R#P^7%GMR$ODY-XJ^LA<<!>QE&=MPXH%<'1\_<_O8C<"MH
M$;UO44;YO43U@+_F[ Q=4WS3VQBB:V$SHQKU.K@827.3$<7CCS/G\%Y"<LKW
M6?%Y?2P/N^9_PM_3'!;-0\I#_W>R'FW@YMN5VEH"77_V'<X*U_@U<17$?7I;
M4=DA)JTZF[OTH-5AD_)>V9UHUCU5-2!9%]RT\FD2V]YX07!<47"HRLTXLLH-
M\$F_C3A%3P\@+Z]!*)'R.LB0.#1L!KE4Q5]A<!W8YU/:,2O*N). QILO[B@*
MCNNY 7"UM;5J)-T?X+LFEAW["[<!1&"00,DRM%>69*E]\?;S6 CIW#7;8^G0
MIH(/SZXBV<'C475>Q(?.NC^C?&0_L90&+N&E](2)=9 JC,H&MDJ.(.SX+!&I
M3ZG)\4;KT"X=*(S^986P"NAEZ&=J<"_1931P+*(:ZZCBH+## 514M!9]R!^W
MY7.6/_65[K.K="FBK_M*-'?J7T$<W5]7FK5_7 T_SK]ZVC8VE])\EHKU50$P
MW_YAJUS ODW1+86'%OBT-Q00TN05)>GS5:AA.XY4&,6$L8/T+GU+XA55FMO_
M/+.MAK*LJW#$2[>\L$N\"@D;8?U#TFJE/G:Y1 ."<2>LQ.A.RC]HA.^)K:N[
MR5=Y&M>FU<Z<%!.F--<I,"F4CZ]45Y3_-AYK&$\PLVL&M_8Z\C'B]#\*H0A6
M/(3_9^*46)S5;[LT.6>%))2),Q58RE]<\Y$5$$V2=V(*(64S\]K:KC[=P^)G
M"J@QWNLX0R439!%(=4)TLLU:T1.U;^5"_/5N=Z12DC=KGN3I3T4@8VP@ TIB
MPNV# YA6F*.8MPOHAT=8#&W;;N_;)#Y)A2\:]90_&2@2'(X_--@6%>L 33[]
MW7@-ND5MZ/&!1]3<AM605<!NL'_3:WNGF%D=T5(%B)F1D9-\Q4I@;AS_O;:C
M*O*5E&1(U&F.-O4?TN?PJKKFCP/X@S01*9,#\J8 TX (9Z*4Y#PY> IF"#DE
M]'W,W!=1#5S;',BD*!DG/LM088R4M==RDK5NQ9NG!,S6M<&W'S>LE3"<]G^;
MIUHCF5P6I.2RVMR1/Z.E^.QHL^R(UD7/E[ =4RU$FJ'05&Y.F60THBR']2Q-
ME<NI?"[TCE<X]GWQ'[LPF LW2;Z7:92QWKY\^(=T)RGJMUTX$TFX:^/1,EO)
MN?YM<_8]]3[9.(;+)_^;J,A5CETWG8\='%WG&'),_EN984/4?-&.V#7VZFHY
M2NY9ZK#[6'>[ OQWHWL[)QH_=\^2ETU;4T7J^:<@<ULD:+ UQH?.SPO=]UYM
M8ZGVM>(#O&\1 ^5'+#5G_Y#:3M( E$]J+'_0'>U?G)>N!@/DP?-@\9':W8G%
M+(F<&WF3#HEBZ(B%ACD%"F[;XDSS/ <//4VHT]"-S[NK $:/\? ](:V?VQ T
M%"I\A%"!JE/>KM;K!V59VX]7!# MK1BC'(<OHW4H%0/CX=<=[6\:%>2RL1;+
M_87M'!L)T4><+R[5(N3/T#<A%(V]Q$BJW,C$4WMS4Z=X'4&OIITCR;O_O8W0
M/R3IOX/5^/(\^K_2)O_6_"U^71!C;<\M-JW_._C,E%4$TUSX>U0*?*63MC-J
M3ZPR@M.0Z@;@(>*FM6[I.U/WR&4Z%*AE!(T4JC0'Z5/5)O!&-'K]/K-7^7"G
M=S/N7C-%YJ<TB/Q,,0[CX$S*"LZXVN<9K5A*/?0T3O/.CBCP91CCM9VKYT;1
M;PA1_(DH(,9].FJI^<EM.7M-9Z[=.*(TUNKI:T_'YR3/+*"^W7>CW:Z'-(CM
M(JI@M4&C2[$X(CSI,8MXU:A]D6\"$N;5&E8'@;X<:00%:?*-1QV+#N?$+Z&?
MD3GP8WZ[G:#<7?DBF)MY>4V>+",B)UX\_(&*?VBUWTMKT#[X\LX\_X8B<'8?
MUUT9HJXLD=)DC>ZO]\5CWB8F'77YY,]$; [AEQC'X3-4^3F7SK@.1^>XI^;W
M;N[^ _PC?*'U#4C.DJ09U\?5;FA$^V),'2$MAS%D<J<DJ;ON88E#A5,&SQB0
M*1H=?9(LU2$:=6',8G7I-D%)"7I[O7](U(0ZUWJ4\9LQ=!^L<3TUJ!:;6P3"
MN=67"#/WK<A$^*&\6[KO!1,5!NF #D-><CT83;V .;_G&"V:W/.AS*WR "8=
M+$L3>C.!&H !_@0H?X'B0+&0Y%+"T7DAB7;VR.E/M?E5!/ZH:49"E[\#@_\/
M.6D?#W!;ACTA%@.&T%02C=-&M &X\V[J/"^Y07/1C0>,XZAGN(!_+%3 /#G
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M*9J^2S9WI+Q?&,O+&.-O_:%&?]6??TATOSSTW$#MHF)K\TT;PN5PP1]W51\
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M7M%24>CU:5_C]+1@S.=OM6& $>/*.T8<QJ?),/DP C%OR(_C)M \?EBX+A;
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MB.B[#5!U(3FC6 \HTX:877195'6IFU S7N!%>$>!2C8V][>XC0XZ%CAN^Z>
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MN9@**!]7(#T+GAHD63!)UZKS%L,= @0J(^4< @(%3 V=2E&!51]U:W?'Y_[
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MB1;N[-HP02.3JAJB3G;5E\M 2 _ V@(<#2J,6O:$>PT3K=16V>S-<I;&4>&
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M0W1>7+-\&BVFT1K1DAW5@KG5\A]S*G-61#SYL-&]-,"3!,7O=HS6F==I[Z7
M$H1/AF]*@#[IM_DP$."&U38G4GP'L9_>+BJ&00Z(W1^;KE_2\'O\!7G;K,9
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MWL/6P NQC^RWDU87.L?4':""JR6[;=VHZ&;W/>;W4 FS>O<L*MO3X?W)E5+
M[5^-EANC\H0075;7U7X<7]@*OKQHWFVZ(>3&ZV')+4=6<_--L.[]4;SDAT'6
MV99O9J^FN]LT !%M 6@C$@Z7MF=[XCE"&R8D_2)%;S0!CT&C#1KTKR2D<MD/
MZ:Y.K.S2XE?J@9+"O.G#Y,>))690.XGNE/;DS0R[%5:[4EC*D+U 8K[@(.&F
M\?5BI;GO!T)/4]O,!/FN/ZM;M+C( H"<^NRGUR;OR9]QY;O.&9=]L)HU&7,A
MWE<R%_898AGX]<?\<W\4 *;8:_%"99RI8077+IR!7#QO('KD5OBOB)O4NH0Y
M_*A98Y9X[#@5%E[BH$V+B5(P81?^!MUL@[II6V&.,JBZK]R_EQ/>'[\::NWH
M!H& UQ.MO!G4KAM-@[#@(",@;_RH0F%VE%N:<[:_<['/;% %TGN4=1(Q_[@_
M2 BDJ@8R_C]-M4!S] S3(% 0FEZ1 MXPUH$L!$"0Q0$S2V4Q$-! P-3_4=Y;
M1<4!/&^B@\6PX 1W=X);".[N#"X!!G>"! CN@[OKP.#N[NX,[D[0X&Q^N_?I
M/MS=\]^[3]NGWOJ<ZJ[6KTYU?U6R4%]AS= \H2%NHX*CH8&!E<AH1W[5.!PO
M)ZZ@R93Q[[(%9^91%)I3[NCT #^KK)2_%^CV)M4XIA@3F$:4$G*@9_);U"V[
MY9;><_U<?N1JK]R>%(*!LJA''6&C2.BT$)5@R-"L@P6V5ZZA4FLG&,HZ5$O\
MB7,X4-;<JI!^SW_"_5ZEM4F_U#^I0>!S*B3%*Y51[6"K?$C'9$XX8J\<^I1@
MI$-5CZA%TIF2&LOOB<DM8V1.$[N9]C)0&)=+L'-RNY0[;7K[*C+YX';$Y$=Z
M\>H7\_>Q+VF/%ROU3#,(Z[QF$OM']L7/J861%*:UV^UH0D97G_8RTXIE0[_&
M.K9VGS> UAEC?EV''&3"Z@NVE6XI2@M-#0?:G1>98'^ZO\H4Y?0$I)U%' W9
MO!DO9L%ZR6C>5<YU2CJ^D'M6L]1ZNV&=/S-Z/K=DS#YOW+"6\FDS>(<8Q_JR
M\1ALQ?B06",LQ5XM7A*^*T-2%MIWOGS^VYL!M*;1F))N;><NWK5]\CT6V!J8
M)9 J&)6<-VB0J!^3)V/=#8R7LYO%.8N6F@\J.9"]#:\I,.1-?DH.M<<L.=J,
MY+(JBM8=JD^3)6%X0JYL./_LS:WR6>)=.O=RF2ZGLG-0'9!Z<70/RR'=K=X\
MJPW$^E,SBQ05\<<$"4RX!;:@>,#07"-A':\[T6_BQF3OQ$=T09$?5P%#,7PE
M7>,)_TB8ML;S\T[3W$5U>Q$AU#_QV3'?!-S>)FDG0R.C:EE^5HM%3+@3Q5@_
MS:]3'DLZ_ :@7'9Y,J/%"M/G4& /Y/W"%B-IC&LZ,YVW)\'T%>;QG$"D'GO*
M-#X#54<$8A*>)C59[/EUG6@HRTY5SC.+T8?$+*PWRXZOL(2O>=5QU(QK6IFX
M.-<@:Y2.DCJ30+5I0.&E-T(_]</GYB-#>@QUN116=+A>_- S^S;O/IP9<^@
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M,./5ZFO?L\!BO&JL*%3*Y%!](O<D%;64OL"Z["]N.A\JW@!C1UIO@#/,DC?
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M@)#:W,9=75<R9DUZ^0YD@?,MEVQ4)M_Y<?'7W96&].'!'[\>(G9A)9FYR'"
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M^[MG@ZO\<_H W:\9"/QZ E;,I*?1GG(:$Q52-X(5NG#!O<KNS%@L!3QRL.^
M3,[D/ 68#-/)""WY)"5IZM/=1\35VMZG[[G5'DF#TCY^!C8_EB3):W3^SDLX
M/_;PF2='^Y9!LL<:W@ :/&^ @:$OR?_5WV'_MPD*P91_;=V)'%HUA=FSBT_4
MNZ2NC2&*&-4O=(@3!H#?/M,IRS@PH6^>EZ&?UP[=(9QN\=_IN(&2HX=9JJMH
M:*\2KVR!EV\ UV?SJUOWY<QYLD"W0F@&VBC/U[:5]B0I)%L33164ED"!]Y@
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MZ6SVJX:S]D/V.7/1U'X@W?$]KQ^#40MS*L@H-+:.^I[1),LP2.<O>X11NH]
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MBO!@7/<+ZW>\DX[\H!]Z*80)[C>L(KC<80_=/LG5&"D@YI$0_T+].TY#O^3
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M:!1/2H!5=F=CQ!D=[Z+S2#W+3&..'3)W%=L[)PH]"Y%F?/A87$%J4Q (O]I
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MO:_ FE(0^CBU<W+MH+"^:^K-H;Z5>UA:44/W]/JGFXH&UA[A]QXU]LR\_4P
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M*43MJ!QGOLEVR,J+MN^N0_;124.V-DD1H5?+BHDAUNFK$K)Z?$2XIM:G'KT
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M"FN-<CQ?\-T=V?>OS=#)&+FX%I)!^XVC'# >)_67/-3)'PH2<-E[K;E!EAS
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MD)@SJ+V)*(^AU[M>\$H KFG'U393]97QWI<E,Z)*)@WO\?;'ZP$#*NUZ\-C
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MY<;@H'3' &GITDQ&2 5E3WJ8;:A\FFVH89IM1&0.*?.C10+^-=W(*MA$]::
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M),# E;3$CBWV$:'8K?N%'L1<?:4QJN/)Q:^D73'L/^/E1Z!G8%NE;V(I1")
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M?6SP=JG!_6)D%="4S'XF!9QH8QS6GD,@(O-+E5ZK(O2\5,2>.:G..M2[V&#
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M5^CA/M0947/'-<A^%99F1$#KJM ) BA2BN@\&/"$HPYQV_WM!^:9V4W(S<C
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MB#D])9<5-#IM?!;-D3Y@6)Z!JR%Y^ZPAD?RX]UJ0K6B_0*0^>MCC%"%*4*^
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M>;Y]>0W17!!AC0LE&L!0B_$;[NE6IJ*O)B"K3K%1(,[1T;67M,ERU0?%0DQ
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MJQ_[H?30297B=<=TXXYLPR;G)[-ZR,#)3/'D\ FF\]K]=R\*N4[^R=&XB\=
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M#C(X08*[ZP!)<'<)FOSG?.__K?OPU7VX7>ME]U/WKK5K5]=>M=J@B'.G6^F
M/=:)#.-A7@?LH2"]?Z8X:(P,KNWZG':55Q_'<=U2S.F[!GI +.I'%9,F#+O\
M185O[6'\(D )@?5,2,4P_&K;X-%3WU=VBH)GU&(9$EW#V(%LV@Q<U6R=DM$L
MZ.:7TU)4[UK]>A>FZA+S_&\#8OD^]#<MZ<L_.-FBQO^D]WOP;W[JF#73]>][
M6!'R7>_E) ='=BH/F&O @%PNT:[(5E3K'_DD]](.[DPJ."OK"S>I_EK'-\7Q
M!8#!^#10'MZ>A,@&;(:K@SFP;Z(#43E\V-IF+>F9:#M0D?_LVBE6Y580Z/G(
M4QU8 Z'OIZ>#N3OTG9[^(3<)%B0XM)[CH;:M+;6D.F,NPN\L%MF+S<J)O3#,
M38\6_#*, KV@KJAT760=+0$33I'Z]P4E%4>Z.F $1YJT^O)EV X2N6%:H3FE
M#%MPD[X;OFAE7?ZB:(*/\KDD[)!0.?0NR@V(/GY%_EFV+,2>_@\N<-GR@G\#
MM_?Q-]C;/Y!#-;@VR2K?_><T1U[>]P*GGU4Y*C.2SZ)),+?K]@"NXG985]#?
MBN"&G FO#CNHQ>_CMDWQK?/JHK6XJT(7/GI%6YLL.3W"W:_-#FP=W\\FN#)O
MB)>739U'[O3=#U-]&J.RY"7G-E01Y&J.JLI$XY,F6D(5W/PF<GDW$ZE#L5&+
MA*!1EW7,QT<G&'A?]DQ^YLY!#4RG-B!CQO3T09U+BL[@)6#C8R34,'O:8%02
M<"6@&/3YZ4:$KV,GF#"8_!_<,)IWL8K^>?>"5S(T8F+H);_RTZG>G'>BW5H@
MCOGXH-ZRO)X&E ^#*G-2-_X1JM;>T*\ "S(3KC"F-=IFU7VP$PW:+&.0;<GJ
M_' ]BF+_>N]>O4_*+O)3[H'<F9QN.:H<@E5:_=X^"CNMW%AR,3I;<A<%7RVO
MVO5!&NH=6ZK(9L(,<(2G=!D._ZC^L>),C_TH:>-CR0D-=D[M&),!VQX.)F:K
M![OEH+5WJ$K(0$Q.VS2=2\\Y>AL2U:R>/G?-8+0X98-L@#-J5H99ZDA/98_6
M 4='WKM-+,Z&3E\64]%/ S89=1NM[3=&DU%$W8V6Q8K3U[5*:P7\^ZBG;7B.
M/0<&^@E=/ID0AHQXN?#_@U-\32YG7]+*_G8*XFHY,:8/3JT<NFZN)"/\Z0"S
MM01JJW.\ =4DG80(EQ*V+\! F.FWU7=BN]E'T62YWHT%]<P.C=/VUX@JYLP;
MQT9VA_HUL\C,S6#OFUBBC:\7/"X:VFNZ2[[%.] I[;^IU1:/2$GWUOI]'UUD
MESW' W_0V]AEF)_)?#*6+5N@_;J;H3W[8%4GTI!&&WZVZE-4R^O*'3^ZJGAV
M<7[<5_C"/6/B$]^=7].<R3D2W(?,21;,'$^QEJG1'MV!8]74G@,9Z1[)<\KZ
M!V?JP:%<6=M7]:*V[0VU#L2'A*OFU'9E.MW=>3R2VYO:-$-]GN=[6-<6/ U;
MSP+KAFKUR>+PJD9#G@=.XM(@.H"S6A@!NG<U?"JX6&'/,A+/5)+2CDL1W4^Y
MSOJ7A./VTIC+7TV*3]US%!P7P2MNE9.'=6+N;1O#D"&K_)STX%Q3*@5 ^VH7
ML6Q#5H7SDA$?&UMPI&&$(2#&\/>B8VG<EP,]T!=;@@P ,!.8&Y,;<VC)9!MT
M&'1H&[2?+F'DDPR/N?GG 01@@'?B>/EZGUZKC-NI%+@K]OVS1L)R,*2F&0!^
M>"VD;MN4<C([L% [HA9W:'?/C(SKZA*P@/C4$7^BLW'G:2=7HPS>J*^=L[30
MRPW^E/5 ]V>K\\9*-ZW!FH-W^E%#\D<S']]-&WE#$G87&]0FMV[IW,>O>_*J
MA74,:A."+?!@SJ2^)& E:;S8 6L :5^V-!]0+WAM^ D#SY0'WF54".AS#G/4
M;1B8_E \'W<8(24PA*=7&"@?_U$^C:=-@G9L'06=9/SU_^-#U,CL\$FT:@1F
M61[<4 05(A#ZG#KL*WY1W3[CT>#)F\5G[;-FV>LZ5,?A=0[;QE;;N6KR$07%
M\<J==(B>O]L>,JXX0SJ6;1849HQ><CEK@HNH)ITAL&=%A2+YQ?=(*TYW)2D
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M3-5U:GS2?M*GY;$@-YHCP7&_G@D?3=Q(C ]5:5]B-E&#5_UGG@WEGS7-]C)
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MP$"?)>UI]:2FA2DAS_JU!JSL?(!JNN.*VI\A.57_/W-VOF!5 @*;F1&]X<;
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M+U<9 ),)@&4#5(5^Y)F9>?+XQ#/5U#QN!FD.%.RK00Z&ORNW5_F9DL;QR$R
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MW,<Q79*(#$R!B/:J3<RLV$&=K[EY;^4U^O$DWCCZL+'NC\LF,UM)KM_<"P3
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M@9 #C*.4^L4X[3!EJ$Z5SIZT;Z8\#OD1Q_3#15?*ILNFY &+U-,8"89:UB"
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M>WXX9H'#4>4LB&$O!CQ S.IRDZC5YGVOU;<Y-6_$<=9H#*5%\URB9[$3>*S
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MIS"[5WF2Z$3ZV6D"A3M+V1$@DP^=:.D?0G&59>*"I_NI^RAF7$"*@'J)0Y/
MLE-BBF=J>C*YO%J"$]%KACDH(7[KYQ8>PO\ 8IK9-CQ#'KX7O;H(("'3M35H
MR'KS3',DQ,3XJ\@N63=1W"HL0XB(^F/OY<X(@THZ]DA81O728:I_8^>2>*(G
M^A"LK^(+S$&5CN%X5\PAS;HL3N+  C3!X.6Y%FL-%/JQ[&[GMBSI6F[*'@%Q
MG=7MC/0ZJ9K3E;R<J&D8Z6D3./^MY].\P&&W\'A@>Q[=JM+U#V$MOZ+BW+2T
MSO>C20U(*PR_4383;-N \1X#_F//2R9W*1:'EBRQE?6U,RJ_D3\^3$<N"7G9
M"W^D)!;^7E=HB#,C[ZRC,3V4F;P^+7H6]?=4X;)*"N2V@UK3+;'1:8T[*N#%
M=,&8T9%>R05 &[5&!??S8?LRY4XFRO&*7SPL2ZO,3Y-DTSH]G<$0=ZJ'P.FD
MK"(WK_V0K^Q:5%GI44 Q9L4)XBN$=V;NB\-#^!NF'!Q+)J>^?.G\Z#LRU)4K
MS=SH!H&4W$VUN!*L';(;(Y?9)$2U).)Z)&*4A^-0!9>WQ/$L3^F" "I:)VKD
M*#GIXX>S']$X5:3BKS/U8"<9B#R5I_[3^F9:%$*'A!B3%6P*+61+21A/,PPZ
MU 36*_2V"AGV\Y'$9QX7.1WJ52FFD@W$3> E;37=VJUX]"HA8WO3@+V##: (
MO%-S6^EWAV:EV6+-;GIRN=.W(G(.+H= /^&$)(I:)3TU=,DS(KNXIF.IK:#)
M0/<6%U/+U8AY+;AV>N@XN8'>L3G7;QW7D2#C!^FO10O,1P:N?0$#Y%^U=[_T
M 7W>M9R1=;P^2U7YXE0*T_*GJQKG#! ZUA%?%W\CG!(25"?'WIZ+P*Q]K#U?
M/$C),<^0QK581K.7VN=W^YF0N$+K5G7 ?4]K5E0VJY;+K6C"R>>RMO+D_8O&
MZGT!-8Z&.+C@K/B$E&[OJZG-&>_<EG#O7F_7V:]>J2@6L7()._*);U0<QV>_
M& MU"]8I5T< ?&V$NM4</HS,OP>YF,,&-D3DNJ#9971-DWY3[*)*$<PF1 /<
M(_SN>X3=*B;C7^545ZWQ1](+AHLCH+LO'&>^K2ZG)=HN!M74O].GT>+-'BMF
M"+K-7:1ZG%5S9?9<="9? QD<MY'3NDT=IM'(A*8_TGO%9FVEG-<-6EDW>D_=
MM0/WP+>I'"%R\8'@AJO/<H!]>97S=J&&9>%=GX8?2V>VE8WS3V?(-(7RI7TN
MP+>->/FS=,G6J3C\%7L/_Z8A,16PJ]6:!&Z>'R8]@MM4[\??&8>S*D53HH&Y
M;EHN$BQ\F<*M8S!7)GVZWI=2HHOWE7YWA6K.B6D+1I><2U"GP7WWU99Q-[#"
M1JZ@-ZU!S'#ZJZLP,U/_@=H'TSZ3K#;K&_J(.,XS5B:B0KNTTB-HF\OF8IP]
M^P1%8O;96T!EQX@;"5PB9= 6UC.R(<%C[V3,[E1PQC$E9S,85'&7CES[Z_:C
MV/R7<8R@/-M<WG0-B#V__YHD$K-)+D.Y+D_G?F3JJ@O'Y0@^HUI/\S\$>S_2
M@X;<?)3YMZ]E19G[>?#G-XUYWWSG/^_JR,O"2%)_QA7FM9<KBO(PV/U@J)>7
MP7!7)#6E() ID$TS]!U>QL0R*O_D(@IM620*_H<@S+O<#6I@E%A[^#BOE(#(
MF-!?<:;8]6.I*44,P40UL(%749^/#(G?*HGJ QK_4NT!! ] (3KMLN#'PJB_
M>U3Q-C#9D-EJ?/OU+D(@_T/9C993_GKO)^G[3'66H*CZ'DUY\4KN(+P<]'H]
M\NU3^.>%.D=W)8Z?EY+B_ S9LDM66@13OZ?<4AV\D")(CGS'F3>65/P2*37E
MC73]@!TNDO;Y,9E^WH;[N2L]AJ8YW369OL-.>NFF?NL-:Z4,+&5^&\,1G0T?
M29W>-?R1MD_Y-&=8,@I<OBF>C&YFV;3$*'[7\@[0$BB7J@&!ZL)RU$I3/+"F
MC=R+7Y4IZP.KFSL%:S?/SR2Y-&MC?^B=)\U)-Z$U*6_AH9JGYAU6LC:],JP(
MB$<R1DXB!*M#Y/? +=XII>M;6GIW(TZL$P)R"D>P='V[7'5EF&.7J:C^I/=S
MZOF@ V1EP^\_ZE5+"T#:,KF^>J;1BB%\'FF =J28> *+;+.7C0T6.3%Z.X-F
M'R>20!&3:K<5RS-BI]@S!9L,5:Z=&>+1+NJ&07OXX!S&?7]EGIVRRJ[:1<SC
MW6-Z(DY;('PW<?LWN:A@<U(C4DD*)XH\)"8*/R-MM,R0W#5)DL=37;N5&H8X
M$W$:.1DMIDNWF^/^J+1,ASO6XP;@Y*;MFANTX*:7O57J9X;+<'9KQ>GC?MN1
M(<_6ZAEY(3^.N[/O6+V+?=-N]#=H$2N?:U)J])?&1.5+MYARI^!H&:94(?HX
M%BV7[QZ/:U'E%T^3BQTN.A.5RE"5!JW"_([U/.YJF0V)WZ.]2K43;$9G=B]E
M/<8>6NKZ):LR-BJ&X8[BO@-?1K80%F)L &+O0"6R*7EI0%V%%A7V_OBX+7@G
M=X]@Y]/>XRBLS#>-PP@,4A,HA.=X%E2H[]+E!Q&#E0^9HHOT,A+@/MT?)"40
M-1\YZC-U(I1>IRE1DJ3H*JUJ38C))G7B1?TXV4LRG',)%;M27;ZCV3H4@>"@
M5>?JH.#6+2M)@8^MM]\*F8YA/81!2VN6ND]GC>_9DI57,R+6178%B,66Y_M6
M[B1*+@*B[''C96]L?P<,[W$!#95H"YF^K(](60Q5/ R$+%6W%"VI&0-7SE.#
M ]W0[?\A$.UV;,G^PDI!KSQ9"_D))4Y]SE"2ND,1$'%";8J>^*;B'#:WC0#,
M3:SWRDNTV<JZY[^)1HTC4/)/+-R_#&I*IM.%P *+3<]\@A7^^@F83_PFM]8;
M<K(=\VL37L:UX/+G!=XZ:55AHUEB+:X8,Y1%2$4;V8*YLQ(5E$[G:C!$SC\5
MT42/R>'+>:71?3L:QXL^J88T-9]7]KN1:Q-OIVP^OY7A^<KZ!D?7H6JP5HO>
M8EMCX'3;A#&A3$9^UXG'DK%#7#5,_,J22U;79,,8*PX.^_M,N9H(JA^X@)C>
M^'W2U-$VRDIW[3V9_-M3?8([=;0_Y?0/H?!IP-D!+;NOOW"%]MOR0G%<*Y*C
M_PQ).*V6;OID7B,W<E8J9A"#NZ,13UPYK1W)/P17SRET#T40/#3TX\?)BLI/
M/JS-AEJ-U"U/\FV_D'<="GK.$Y9*/7"E>\YXJF>=O.2KK$DBJ/4R**B8\6TX
M,;[L?=%M\&]_2A.=R3:1+PWI0 K5P[[@[8QY7$'4?3&3R_5^5Y@GKY:N,Y>N
M7,:OTY97CFL6T- 4V/#BRI;!0GWPFFGRAM3S']J]:EO7(R2O$_"W&FRY+I'-
M'H]!].HM.5C&Z,X>:8$<8;5*T8@9ZYV=.8^S426$C8*&YI$$QY2%.>B* 75U
MP >=1R<CF:LU9U2]GI+7=TA5-Q?N@DL&Y^6&.1&B\-$/?(#S*0TK)B)HHV.?
MGXX%AVQ32D+NDPI MD+H.6*X/Z<E$#1Z<!'QE9[Q*TA'')H/A%P^/A1.Q*]J
MIQXZQCM9W+V7$VEX:!%ZL2\3'BEY"6OPC?0SX7 @J$3[#;7*+#6276?.+Z/T
M8$O<>4<A]&5.=)S,]>PJZ7'42G4=X6EL_CX>L5E7IW1N'L1I''F[_Z[(Z>_!
M:W41WDS'@9XKC_6*2V@=H$[VGBW!3!="P.X2TYQJO]JHD ]'H<GS]01&FF@-
MS&3=FTE0CVI?_TFQ_R9\_NSS);]*?$TMHQ"='Y/K3BJSS+NYW2:0< ?E+[(Q
MB)4OUO>Q6\UH;G37/]F"=,;+@^H,88]5GK)5MS0D##"4Y-HWRV)<?#0@GZ0H
MN3A2)4$4G0Z8F.)K7W]2],G0Y'_YX>NW/IS,Q%9:LFGU1IAHY$FAH,"U34[F
MM[-.\CTNA<!B2Q"XJ4%\3==@$1&/$T+)K=X;]]3]YVV?N]:6.,2+>K@0R$^D
M6_9 (VY^6%/G@NIRDM;?O=+=T^!ZN"H.4->\=T$/EF6]UDA9EFF?2OX8GLV
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M;I17MR?S?PC\/W_?![0%D_U/3()(NY)Q!U(>F<M8SXCRTQK2I_\2R;QHLPA
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MW;&MD[VB5C<(3V<U^XCKA?WM0%P@6UX=5!\M/.D=SES?/]&+*I X7,:]^<=
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M=ZQ^?.IO 4.4VM,[FK*2L*U+/-)B:_:$8QL6(FE1UH0)W&@>!>6M2LJ87*(
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M%P+XQ48HQ0,$7.;W=SH(>%8NTL-P[>88W&_UK9KI5FHQ<@5^8WM0A2R6"PR
MY VJ8M3;-E)$@E&EJ,7&G:0RR04PHQ(KS&5U5E76B4E6 4AI9^.BU&60?(;[
MH@J-*CAB-/M%09(;:<532MMQ?483BNJ>/@'++Y4N<R8*%[/)>))!G>O<TDU;
M/8M!/A:DO03GM#7D"6*[TZOG\(LP%:U'FBJ5,Z$;A2RT!5EXNMLM)'OEP-X$
M\@O]&&,FP 4V,FT@ .PR-PU=18,F/2Q&&DM+FW&?N<%G08>N<IUM@;#A$Z0
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M/$-,0SPJR@Z7OP_KE16TEKFV[(?Q"!1[/3_S8W*2]6E8:F*FSCL'+OR_>T'
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ME'5W,["6236I:7#:N&#1[PK5J?>X,>7\/E*T8=$H*J="T42P7VD,]]SE=FP
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M?]4]4=Y^DV_'(S#XW^=D_QK_=?)Q9._TXO'0;N,39-$WIF[9!,K&Y$)Q>H0
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MA=S+T]7<7.MEQO^3V?T]=*9VGI4?"/\?%V._&I'P731R<EM!D).PYADQ9LS
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M/G_7$@6>M=, ^">GM/F-*W9F"X"<,T;F:5L\^D<;9?%,"W36_CES@E.M(2?
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M#(SD29X.M(M!^O21+XGD^W>Z_7+_"[\+F;AG?@+O8R6=1E@"-9@[%HTX+BX
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M^2.BS=,L2BR;K0:M-VT!=@3V( <51T>G:.<2ET'737<"#S%/8Z]H[V:?S=M
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M^&726RAXU-R?5;U"6KQZ"G6*^=L/#Z&@8J)C8*%A(WOY"5$ *&BHJ%C8J&@
M5.1QVHN&3KB)04/$):X*=[J#21R37MKR:IYD"^LR+1TWO00I@]K)%. B&M(J
M(1HA0!3PD3.ZB?,X<\THVL!T\6/NL6#^GH.Y[0POOV6@V9M1"Z,8.KX#O>MR
MCIM-+$0,WKS&HX5NH-9EXA+0^CB5-[T[Z)/3H_BC2QY%7YVJ&5=N3'THG/%6
M5I<[N+*6^*S2]K!)?X._(SG/;G:(#B/UB2Z^/95A.)OF77])M'NPA4J""1^!
M#((7P:7==Y*VFV5G;GW*S]L;OV?7M60XJT:H7&,9-9J@MQP79NEL= +P7N^-
M)-;1D$E.@=!<%)ODH'YVK&9#L =EOE/U5;"O6&D7^X*=U_.-KV'OJ55N!:XW
M1@]/CA[?:9"_4R:&.;&G5>#=I4])0^Z=O=1*/ZI.(5]E8'L[NKL@UALT,? B
MLR6.@6C]7M05=GS7YYW5>>Y=4I 3P+"PB^8&=/ZCE/?Q5 ZJ04V0?3UL&/P4
M>LQ?JJA, GP>+P%Z<S,)IF]5U0YXJFL1KZ!C34&-]Y9I9N-FTW30D=.'5I>4
M'-R=K^/5@IT\\8>'AQ8"G2Y1[R(L[AS<^N"77$SOC9VX.TDQW*%TWT@-<E!F
M5W'AVM8TJ2DP2Q\X7,3#PL-IS!HXU\S('6U<<?.!<")HVE\J,H[(=D@)_K:L
M63_LFC,OP0F 1/Q61GSF!/QBB3!M/)W<T@L&[6[[!WO<H])K$U4("2F&B*,6
M'&U-JR\W>V>NL79NHT@]ZKX:Q)IQ,/D!EOGZ6!=ER:?K\T#Q>]]EHJO\RG;6
M>WUA%D#\3_?OF&FLU3!FD[I?X"*S .Q&J^Y9)OJWRK&UVGP"030P,%*W1]]=
MU+I?6\7NDG>X[[7.\3IKW*J:/5G)$6_<M>A1GN&+$J)TCA. ;RCP_E5^>^ 1
MW9I_%_B%19:"!5%_5_)=W'@J]]7'2T\F'I?NOO.]C(-7<=/-2LFT4G9<IL_;
M%:#N,-(\%B9!HQ0[S<W0<75+NCV*8>^1UW*RPGT:5IBZ?UJC]O/LG"Z@,*%*
MNM7*C/]ZDI6#FMM>^*ABJI(EG-O1?"Q(B=[QY?#C;=V6_%05YE*N!_!%](NF
MN/1@>O+8:?P<F?H[2\H'Y?93B]T6$FV[]$ E"WX$;%])SW:,LZXD:A'?'Q^2
M[)JF[NX$L/4,=C//-$%4YBHW8QJL!RM"&]?@H\%LH[5 4<W.$K08K4-.XF/9
M%DL\_R^VKH4.,5_:G$ENO"\+3M$;^OIRW(Z]4,%)0*+<OZNC4?6= -4#K>M/
MNPI4&"X75Y*VTTJ&2+<HA*?(0B@>5!+?N70)4JM. _^\-31]SZL=CCN ]E)I
MXO"320E4N;%1G5,UL%]E:(BERM_='2,&RI/03/M>;OA1$-^53N=G91K#*YT\
M*=41IG<6JC92M<3HZ=D_(M8.50-[6\7#JE[G)[1"-9-  T2,* $J;PEA!@,4
MG305>\[+CA&F,RFF=\H?EFJM1>LQP2%7",:?0D-?H3'07 A8K[VW)QGQNO9E
M2>N2@M$>'7<2]^+JUSXY0S][3 &#U6C;K)0K-@D:M7D*$3S.>!RMM%[R<4,/
MG!7-"Q87%-VUR>BAB,F+8,T'][R"4]R>LU2P:%\R V\.C?%K=/@XK'YZF>&Q
M,-9M<ZR8F<N41#2&Q5+#\$37XE:^@I^Z0'M4C)Q,UX<!KNA,;RQ/CZ\S2\05
MWGZN5AO$6BM!J$4OCO'+\LC\@_8QXM?#=M'#H]SS):? Q))I21>AKR5,@W93
M+Y>ZH&,%8L(3+4QL!QM5P,NYK+8T$F3EE2NLW7<;RRJZR>1?]QFW0V\VRH=J
MF<8ZMM-W0;ES1ADIM:T$]@7C%_?G5/%JO%37NLQO.$R^>3*2/F&SKUQ*3$)?
MV3@@']_!9/+BNI()I8.! I454*/NE2".O&X\!V5QQ:*-E:!N(P?6_NCQS&SX
MK-N-L (?C&<5B!MYAP-F,.]YGPR# ,K)O8EM19;T#[84F\?I=M=9$*Q6.EX"
M_)+C-E?DL*EP,I4@BUL2!WU3NIT8G8SUJ:7/HJO0]X9V*'CK;_OR==HH*,-"
M3&"&P$ U/36NA"S;%EV-%(3V@%/$NSL-FZ*\AOHG@*>H1EU8%E)NL[INF^"C
M?A^M,;#[NC#CG#'N[I+/[5SC5E2W=+?MK8P7MUS\L9>]/![>K2ZJU%:"W^SK
ML\=ZGZ\_FW>D9Z2Z=QOXB#&WGC13_[GFA2X82<_UMP5"/'<L^%/\Z'NH(#?>
MO#YD$314*X!K#X"N&4_?U)XHQ+#</8Z4O.&&GO!L1HROL5%MD(J==6+UWO@\
MX:V2G:JF=4[N!9Z[K$?7=UYN-*=->?06&WB(>M_ &AQT8D-QF/$IQ"DCG9 )
M&[HREJ1_69/].<[3N##K1.,[YM>>1YIR96&%)>D'Z# /\)"GR.&+ZM5CO='#
M=ZC/E-O K%A;KEH%9\;WUAV56]?CUG(?&9.LA#P*X3$/M[">RKHC==A+9&*3
M2*%<]46'4_P5.:CO?@,!!/J(W<G8R5I\,Z_ '$_>I#.V1 .+#A11&RO %;(M
M^G[^.>)%WQ&U$7:G5I)PS>Z<BXNM._[SZ*/CT7[33+YB(X[CRY,:)DP>>+/L
M)?FA4Z@14*5^>]\ [-1G]*5W'*?(5)QOS+O=7L;!ND!J#H^Y).5K;+QC^?)Z
M@]NL\/BZA<Q:*1O@HX$+!?,=F[=W4QDB/7P<GR;O2$5E$ 19)VNG[#W5H>$/
MW;XKI7Y@XM!UG*VGT/+*WSVY_PDZCVYI0,F<XCO,R]W<BWW&<$:GB#JA8&/9
MF)T<OHA%#JFXK<8("W)US]TY/_&"T7J*,-H&8VPO>$X=<YTDJ;^J1%C7@./G
M(;E FB\MCP><4F[@P2BBWSBEL%>\NXK_-ES:7'6E4KL*J&:'9E(I$&D7L/A&
M&)5XPH+M13)5+2X-*6M-'#6[K.\-V]J0R5ZR%$B4HY]DP6@Y>G@PL3&V2L/M
M,1TA9B=+8CET;^C5%^X*+9$TDY(&?I=N).HE#[-Z7*J-AVM+-*"&>&','J>.
M4YG4&#Z_/58!VWBS&]YA6 \I+_]8Z;C3', 0HZ$G&601,YG<K$[*U?T"FH'!
MXHE#=SWVTT8G'2V/),/=&TVWBEY!K%C3IH8KX@.TWS1T'1-J5(2-9%OE,!^&
MF)"&%,WI44$T9@9X*U5EICY:FY''?$A5)4 UC[57?%XQ@+A+\U:T^_'F:I.5
MD-S:)53GP!OZ^_RE6;N=TREB; JF0=:25?A&UL],\JP"L(VEHG+*"K%]7?7E
M/(AU_9_F-F6OW0RQ9KW!9& @]_B"4I-:8;;UD&]JBI+Y"/869*DIIK,Q]SUJ
M3E\\[<W>X<(OZ!3W/W9/A^X=11<8\QMBO9UM.@$,\3IDS7QF&#6>PE9N'X'T
MMN2LW7CG4FO+@ZM$7]5IPN>_+AX8[$]+*Y4W(V%.+WU7*MX*_66H$(M<5"B>
M@/\Q[T#E:(>__8A:)[8!?&)PF1].KXN]>2]4YI(Y>E2OPNT'VN8. YVTM4DE
M2=N?M!VN]PY'!%/Y\.M5.X05ZT_P!G\<GC>.IX!L^*L[) LJL>R\#-/5^$(1
MAZ.8[F"B#DKLU)5(:7O<_DX EWRJF'F*^-EQWFJUVA[ !NY3;5V -]XRR3J4
M>P+(XAN>8+RHK_.(?!CL)'VW[<%&P-5._6!NYR:*Z4^@A'EV\'L3GYL3>)\U
M?.!#R5J:NQ9&[C=AX)G@&U01$^.W@PS)O IA)P"UL'N&OB67Z:PUS)]$<S]B
MOC,_F[/RB(DAHIQ$OR9#6XU4#'*G^4M5ZJ?PV;5]QZ.P,8XGGZ<+]R!,-_?8
MZW+L:8@].@ITEL?SQF)W9??00\%"WO3]H@)7WP$#BRJ-@9VP$7TNKI>F9:@]
M*Z)"O/;-GF\WNEQR#Q5']1Q=W_,^M;M6/V/+ZD"P7E01 =#WB5!1E(O1Y63
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MH1$AKK A\($Q0V)6LL8N^J,6VO:GV8\KY-5#7P]B5]\; $1-K?J-3(=W[4X
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M:A:)]1W)(H-50(IZ+*A-.H$86A[03*L4G<N>PB)"YRON Y$VHA?2@2P701S
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MCY4]L.:8^%M:@T^QWY:CN:C7'R7/!)9+RKI^1*_<V74%<QC,W=NJ/N&+\VQ
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M&DJVBMC\)!EUUZB=EF/7EZWFBP;NK:\FH]DNR?J4%C_9;91Z*\L9X7  -$/
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M4?&!:YWJ2*/W@.BTH^(SM[9R2#1WIM>1(Y#@(+_.97A5?&QLY+7-+CF]F[7
M:!>IZ%6S;JJDX$P&8] =#7EH:HC-_)8+DF_(#;>OF2;7"1 SC/Q#1Z7TI@=D
M<*3(&AF!S)R4"7EG2W7O=#"YYK2I<]=.%YZI<SV)Y8/":C*#/#$EU["X"Y*V
M)]V%4 ,*T47I1#@I!3B09>)IJ.1K$H,YJ&DA'Z"K[Z0"T?CX!8T#H:01"7L/
M5F!4J6B\M/WAN '?J1UKZS0":WKKTFPIMA3 NEK(%P(YYQBSA4!2.[+)G=/
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M2M,X,%W5TE@PK<F]2->V_;I&6.] ],?C5&N?B_- 1ER(@(3)'L@2Y-O)Z8$
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M>[-/F/6#,192!6Q#.<VEW22!6^U0IK56W;\42]KC\ PRWLM]@OX8LO!UL,=
M24<:5$NZ3,SU\DN1<89$"3^WU<?GJ1#V;AY_OAI3*N:#ITSC^'FAK:P8XNK
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M=RVVV&N)G >Z'H3WPTCLEQ<JV'[!24^C8^YW*A[K)_E8-%)J7,L*"RE\(9(
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MH3I.B=[@\B9KO$@??YH=K!>PC$%D07*'@^N^_<0]*^A=Z1RVH+P82I^ I0Z
MY%/&3%5WKKV*%E;6!*EHO?:/;S5'H\G4T@#^UA/^C3_ICSW]ETA;1PU&]S_=
M(I&]+$@NH2WY%8"F2:ONT\4LYA=+1J-N)B:^4W? J1XPFHLQ8T$G!A#"W**(
MQ>\@+==WMSM?Y:B[T'3V9<;1U=VY)-S]BK.8>?OIS]#E"0.2W;@3 PBD?\?,
M*'&$6X^JH^\.";]43W7-F9BH3_U7P4#_.\6/ 8R=Y(#\X8>_4";!?D(S]5I
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M]DFR*L:S<BS1MZP%%-+(A6+P!Y'W ;^]^G7P<0;UD<E;D;TH7?W4GB9E(V6
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M*";U*._,P9&4\_0I.&\92%#CWJ%$_D6PS[7=54HAX%?]76"?2?\>(H(/>KJ
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M#&^)"V7RG+VF4[,8(FL)S,A#?@5M)>(-0WD)6);DE:&A:Z01U&])6T@CH60
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MIHV'UNE^J G!$#:\CX3"A*!LC;,H2R^ A4A26TJBZJ*0,./27F#SH * P8J
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MCZ!S7$];5CG3%,R0.AUH<R/[5./[FA/6Q2J7*3N:G(Z;28L2J!; >ZYSJI]
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ME7T+@PE@6;!O*YA\-FQXR/-0.?)GI!K7+N!FQXY%X\2*$MC^L].UP7T.G:6
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M9\&M&MCX,F-MW-YUP\$S5G+Y_BL+[)M0!--CD/YXY&!7VR*QE'*%JRQ[RF.
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M3"-'H(T<#W=/-IC_9_==OQZ!/@_Y/@BAM4D:>HDNT"1.EF#$@$I-U(9E^);
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MZ:"56GXB."] Y-N[U@W6U(G4X)5%SJFO+M'EM:P)>&_&*M#!:M$N3Z<"ME]
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M?[80P1\!<REQ-L^0HGJ..[E46'W$MM)VW]X8_$I;9VCZT,H@4<AK7*G3CE3
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MK;(SFE0L@:%&,;70R&/M+$'5 _.NL.,NRA3<G9[VGTNWL<VY[M;9KVQ%7FZ
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M!Y9^9QV^+Y.G_/8E'S4?N.]7;[WOG_<@OPPR1U@HBCM^%F\=?/SWR424;XF
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M",N;4>0T4$MDR+O[Y(<Y)-#R15V/4(6+JRG#RP5)(7\V7GC2(5C+*L>-<5&
M##?#'O72JX \2A_ 7ZK&FO5>T6[\:JPG\>O4J&_D8"R3]0ID4;8(;)YUS$X
M8.LOWUF]?.#A\>V-M_+]4UFPY?[]<DV/PB=^(%7BF5,(CQ#8R'T2(,PF_H^E
M$82#7S^,*I<CN4LF^$['5,00A5$0C3:AWXY5T4X:85QS3N%GWTA07[7-B1D
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MN(367>NUH]>=22&/MFDJ2ZSP,E;/*<$!'+1EC](S[PUHBV+F: B"&=N3/^.
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M;I*FTQBGX#S4!@ ]B8[AALW(2/T6>DZGG; UZ\%BMSJE*;!V(7;%P3NXC^C
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MTOEJ+$$4U87;?5U*[=^>S8NZ5;N.T%9DKC9^:C8V/+,+N>QFXV%:$Y*TSC&
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M5=)3_*\A@H_<5.5GFU^J"/7S;BZ*A32!'JJC(^4_"4PZ-7TI<'D_-7+1K$3
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MHU_ -)9IHD$7-C]]@C2I5O'&U"74G]_]"?;-  FF!^'6E-*$/Z1YPP9C-R
MD,@0=V&'P34  ANB$M)=)"6D2PM QD_M'S'#T[2#5K]'U$:K$=4.BEJY4#*
MM:,O;HPY1R,*+_,G7GAA1#'P:X_A:/_18XDC)%#4X1HL!CC;"\\\2*#5'YV
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MG+D>%WA4U%UES<R:9R(7KU-:.U#YT3QOK:)*(H[QN1\?922>I+X!NEO.O7,
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M$N&\;>9/%1@YH1AYO5WJ7XZ?->I,].((7.%1O;+QA#M+0 C!K?P=HORV(LV
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M:%JOT/U:N71B=^6H7(;V!0J,:]U-4\K+[)J/7F-_UBY/)F;7??@8#5)/\EG
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M2+G]/(+7X8ONC<406D@$I!2A$S_&S0M\N6$Q_+91JVJ6K**J;#([B=\"[?#
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M>:%C(9 $H@L/W^%06OED0]=JUD^%>C2=\,N/9K@> @KZUY\TQ7;&-&/;U#2
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MK.ITN_0,&](R63?K'6K/ZC)H-_7E)<CMHYGWL!7/M),OT^N3)POHO4H-)][
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M+H2VD8BNE&1)DE1:,V4=#O,-.-1 FY-.,Q0'\5^ FIH&C2H$MRD6%_TN^(
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M9R29>7.7R.?C)^#A3@=W;?3EOC]]&-K=G$J1&H!<2%+FCM/E&WS^+[-KLVS
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M<UDD]NI@W'3HIKR=T?-@G#?QLSC:X;868;/I,*HM:.Y>B&\1M%]FKTI>;;B
MCMAN.\E-)%<FY+]$(NQ28_V;(I?"2*LU.W:F-.Y1[5?PN:Y?NKB+5W!_6+/#
MBZO?(,ZF_.%X2%5!R)Y@LMD7C#"77Y8-%^S=C8I$:W!]Z?:8Y1DAVU(?[:DL
M-ED@RCX"=%P@^OY=5)YS[-\DZG!6Q,/)IORD[%A5_B3/CS:^C!KX$2<<6C,3
M$RQX-1K+@E'GL=ON?RFU_,2IH2YG?S6_Y]7:\>CY]48[_!+-S/1!IUG=O]1T
M]4,\* BF*F5Z"/;]]6"3&95U:II>T@%N[UBHI\X^[_PF --PC$(TT/?G/Z7
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M XGKB+]6=I66P;H8E$.HA,>+FB_@B+5T+K+1([?<;[SX?_M;1_M: @ E(0(
M2$A(!P.0]_\/A_3E?U0]!;OZ.AS>/#BV?[\C7R_R;-1;"&UP;>\Y:EIDP"3"
ML>FYHE;>^*509W,ZV;*@*:-V36I!):K%UB33#W93-B^:W@@&,0W@51S;^W\:
M!Y4[,?AA$=6II<,. ;>)A$7N7Z,?[^^6AP2E5QNXG[UN(0/^J->MZ]3>PG\!
M,B$^BY2929__6P" QRO@M$8<L;'2R]SZ3M<FNA# K(;NN.ID=>D%1<3OY>(W
MN^[K@!X :K#ZZ>+D!@PL,A(**BQ_PV(E]W<XDA8].77U<^K>Q)M-]BA)+L/
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M8%N7$F=PS* >7&_+L0<YJG/P_"AF$=T9)(;>YE:+EC:4R6QC"CDCD<JDOB'
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MR2-A^GD#BIZN]I'  !]T/3GT[AW_ *!J.R]-SY]0-^VW_%*N5K'<\#QQ\_(
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M&\,;?GV<<M0-_B<0;63P5H@JW6,@9-B8Q2/RJSRG9K%,,V57J]-MC"=5BYB
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MX>#%@@1( Q!8!0 2,D$CS!)QY$]JK&]OB\<ANKDO$K"-S.Y9 ^SJIW(# *&
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M7?-]SE'IRHQ;!K48YQ_\.-9%<_A;S5Q=P$2X!-9&/<R$B"$<X@ 6(5022<
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M+,(H\'E SD$F0G(Z87)Z 9KB$OM&GGECM].TJ,33,L437=T.3Q'8*O,%6)5
M)WS,!N"6'2LM;%=E6PG$=*JN<MJM3@[TXR%!DL,7N%M$D[O^2+4SF2G%Z_&V
M6,@OJX^=J>V:6&'@XVK"C((.X^9B49!N[0)L&G6&G0Q1S6B(_.H*W#$NY!ZX
M9AE/(JJKN,$9%:#Q)KG$5[//9:M-);^!(5DL8P(8$*^:H?\ 6&,,CR/("#S(
MV",R#KDY 1^'(#_#^_/RUFHVWP1TQ]/[CIY[FM*E7KCON/CW^O[["J2J7D!#
MOR4?E\N/AYAP/RY'GRU6!V&3T.#G&!V'T.#GT.]6$BX/HPS]>H'4['Z[53E
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MK"LS,2S,68G)9B22?,DY)/QJHHMP#N(?D'X<!_M^/PU'I\?V(W'2H5[R(CY
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M^VU>&4BXZ<C)*%F&+63B)A@\BI6->I%<,I&-D6RC-^P>(' 2+M7C595NX1.
MD514.0P"4PAJ#*KJR, RLI5E(R&5A@@@[$$$@CN*C#-);RQ3PNT<L,B2Q2*2
M&22-@R,I&""K $$=Q6G7[-3;I;".3NI#TV)-^\?5C;AFUGE'#9Y%P=R^2H62
ME)&,=M%#'X*BD5A!T*>411 $335IG7(!XW!CGX;J5K^"O[NU&ZPSNB$[DQYY
MHR?4QE2?7->X^'M3_P ZT/2M4..>]LH)I0!A1.5"SA1V43+( .P KK#U95F:
M:4II2FE*YB?VJ'*4RVV2X3VIU!X*5NWD;GL=8\]Q*/)G]3J3C]YWP>S*/M#I
MH7U3&0J^$!+X%1*?_67EUI6+,6U*+K,' UV&:@UAJ]$1D%$-2E*!6T7$,D(Z
M.;%*4 *4C=FV03(4@ 4I2@!  H &JYVVZ8Z_!?Z;?*I5SW^&<?,_7..G4;[[
M5MY48[N0WA'@.  !_#O_  []_@(_&-2D[=>IZ^0Z>6XZ^6^^,YQL57&'^@0#
MMVX_3R_+OZ>>I<'?;=NO?'Y#H.G7<U'8+C_;CZG\^^?TW&*S3#,^ )V#TY[<
M>@?Q^?P]!U(QR1Y#'GC)]?+UVVR>E148SYD[]_L^?KFLE,44T$C+*F*FDB0R
MBBAQX(0A \1C&$P!]TI0$1X^'8.^H(,G(&=\*!OEB=L 8SY^?0XST.ZHK.Y"
MH@+,QV 4#))]!5B2\TM-. *3QIL$C#[JW$>!,'</;K% 1 5C@(@  (@B0? 4
M.?&<^;MX%@7)P9&WD;KOL>4>2@^0R3@G; &BZC?O?S8!*V\9/A1YQGL9&QD%
MV'3?W >5?YF;\MT0  #X>7S-_8=O/CCR\M5"<Y)JSJM((<<"/ ]P ?Y<<=O(
M/3R\^/( A]_?P[TJIIIAQS\/, YX^OP[>GP$?+RYCTZ_#^NQ[_I4,]<=NNV?
MIZCY_"O64 +Z=_3C\>WGV#D!Y$/3SX#D!A]_?]Z?+SQ_?KC.^_UW.*^@)\!R
M8?3X>8=OA\N..1\_@/?2F/K]_7TSGZU MDV^LS=1"4R/G^SRQL)X8NB<?C]G
M.1-SF,2U.%C<9.*G<C3\#68NTUJ%L[C(=U7OZ>3,D1$&4K>A5J'K-T@V:+F,
ME^=W.I:S)Q,RO8V3<+6[?AKJ[OEO'F_$(50_@HX(I;9!%,_/)/=@<_AB.%T8
M934SK6KSZG?6K:);_P#AFVD2VGU._CN6>XN(9%:XFLS#%/!%':2^%&OXM8EN
M6CN&CN$>)8C/+2;G&R\; WFC3\9/0,Y&LIF GX1ZWDX6=AI%!)TS>,WS-55I
M(1L@V4352625.DHF<BB1P,!3AT >%<1*RNDD4BAD93D,I&596 QTW!!Q6X6U
MRT3)<6\@Z9##WD=3U5AG#*PV(/0[[$#&W%>G&UAC$GR >S/W2=-Q-R9LX*!1
M42$> $2" E.F?@/&F8HB!3>(I<1-$T+E#N.JMV9>Q]#V(['S&"=ZL[J*\A65
M  <XD3ND@&X/F-\J>X(.QR!6A( AV /QYX]._P"&J57)7_C SC!V!QWV_K7F
M42^7I^/U#^G_ !I4O+Y?0_IZXSUZ;['O5/51YY[=O3@/K_8AZ_EJ(.,>6?GZ
MX^7WG>FQ'4D[Y![8Z9Z=">OED':J2X0#@>0_O^?^WQ -5<@8[;@8&.O7&WKL
M?7&=CO3^_E5NO&P<#P''?Y?GZ=^/A\_0>[ .?V^&Q\_R^1P#40<?IU^.Q].Y
M_4&K)D6O'(\?$/\ ;TX#U#RY'GSU1Z'X?(U6SY>0/R_7X_+IFK!DVOB W;R'
MZ_3UX[^7Q[_CJ8[CF[YPV/R/[9/E4:QI,M $I^0^/';O^H#^' <!^6HJP!Z]
M\'I\B?(;]!C Q\X,,C[Z=^X_N-MLYK#%C8@(''CRYY'XAR(?3X\<^H>?QG(V
MQY'/PWV SMGM]XJ4;_,8([9 Z]CN.N-QT(VVU2S'CZO9"IUMHMKCDI2KW.NS
M=5L4<L0IB/H6?CG47)-A\93% 5F;I8A#\"9,XE.7@Q0$)AN/,'\_O[ZU ;9!
M[8.QZ#.XV/;N.F>O:L-?LS6<[!5L;[G.F;E.9.]R1L<R[.J4;WKQ)FF,'Y!F
M'LC&/HHJO^<XCV=P^V9P%#< SB;_ %=H5-)+V) H$8)'D<54ZU<'[5U<Y:+Z
M;>/\80[@R)\^;N<-XTE" (E(O$,X2_7\@*B'84TK)2ZTMX1 W^80A@*/@$2Q
M1>=T0=795'_\1 _>J<T@BBEE/2*-Y#WV12Q_(5F2O0,?58""J\2B1O%5N'C(
M",;IE J:$?#LD(YD@F4H 4I$FS9),A2@ %*4     #7?(T$:)&H]U$5% '14
M4*-O0"O!5U,]Q<W%Q(29)YY97).27D=G;?XDU60#D0#XB ?GJ:J:8S\ ?Z?O
M522 ._'T_+M_(-4GSGYX^@!__2-7:?PCUJK-2]@\@^/8>>0X'CR^OKVU1E.2
M!Y#]R.WH!V![],5>1 @#IT_OMC;\_4]JJZ(=P^(C^OI_(?QU1;ICN1]<[>>!
MN1_3-7*#?/E_7^F:JJ(<F[!R(<!Y>0>8_AP :D<[GML!G?IU/IW'6KV$$X&"
M<DGOVR!L/4=_WJ*K?KO8O.#;<&+,32M,%]*TQ4UI='CG[NUT6<EG*R[-ZR>-
MY=O$M9*0AG2$DT:2,2^<LS&0EU@42D690Z_[-O9_IO$-DVL:S!?+%%?C\(B2
M11V6HP1*OBI)&T#3O%'<*\<CQ31K(>:('FB=CK/$W$5UIDRVEF\!DDMSXI=7
M>>V=B1&ZN)!&&,9!17C8KRA\$,H&7^GON\NVY1I9JM>8VN-I;'%;JA5IQG(N
M2SMP</U9%BXF7$(JB+= B98Q%29=,W(-R2DDU!%HW0>I(-L+[3>"=/X4>TN]
M/FNG@U6ZO>2VDB3\/8K&(I%A6X!YG)\9EMT=>?P87)=FC+-E.$]>GUE)XKB.
M)9;.& -(KGGN"Y=3*8BN%'^F#(0W*'<!5"L LH38G! ^(CQY>0<^7Z_+7)!U
M[;GSWV&!TZ]#M\^HQ6]QC&,CH/7KN1MY]>WY@57&Y?\ 3V]/3\P_ ?N_CSQV
MXU2D8C/?'3IL3CZ]?7I@[U>0KTS\/IN?K]>]5= G(@(C_+MP' <!Z<=PX'MY
M\:L@=RQ)QV!VV SC'0]=M^N^.M92-<@>0 SC;X?7O^U5IN3U\_3\1_OL/R#4
MI[G/GW!SOC],?#'09%7J#.%Z=/,>OITW^(P,G!JM>YI.&RK98OB363,FH7U$
M#@(=O, ,'8P"'D8 'CD-4RV-QG(.W0CJ-S^8'?K5WX0D4QM@JZ\I!V)!!V!.
M-]P?C@BL5.8Y:/=JLUP^\F;@IP#@JB0ARFJ41_\ 2H7@W'<2CR4?O%$ K%^9
M>8?S9^7GZ9R?I\JUR2V:WE:)QNI)YL$!E.ZL,]B.FYW!!W!K1_?16J[8*50Q
M3L\I6<KU^VR-@PV,8W*]1FYU.J34'9J]9F"LO76Z]*G:G/R,)95_WA@GS<DF
MQ)%20R3EM&R6H<6WCV=K9M:07EYJSW073+*R6-VN9"ICG_%&6:WABT^*&7GO
M)Y)X_!7D:,O*4B>5[V>REM5LHY;C4;B1Q9V<2EDN6BB=W6[//$D=DBD-/-++
M''$WA,"TOA1O2>G%%RY,+V"-M";%R>BYGOT-2B,48UU6ZK O8NKR[J"QS)M6
M3-0E693LO.LTV0MV:M?>)R%/30+&5Z/(,O"\QGM+IIA:L]GJEU!!^%+S6]L#
M!;/-#9W4J1M)&)I)5=XU5%?GA4%8@3-I<YOOQ<DHL#+;:A<V[#3C-+96\@6%
MIX+6ZN(HC<*LQ<2RQ(L2RJ\&Y@)J1<$0.!@, & P"4X#P(& P"!@/R'W@, B
M!@[\@(\\\ZV0G(((R""".N0<Y&_4'.^=M\$]:S:H,=.H(.1DG.Q^(W&<X&^^
MU:W7+:KCMQC:ZT[#U;I^$;':)./M+6XT>EP,6[1N4+/M+/%S,PC'M6)IU(91
MH"+QJ^64*>/=.VZ/LP.4"Z_J?#]I=V$EM9I;Z=<>/;WMM<PP1JT%[9S1W%O+
MRJ%+!7CY".;9&(788..U'1Q=V,EO9NMA<K+;75K=QPJ3!=V=Q%=6TA0<OB1K
M)$BO$6PT+,@PIP=:JMTYHZ1O-MO^7[H264M4_ 2*](H,2>%K"474K,QO%=C!
MFK$O8+<T ES)+R\D:M259*_92ZT0L*B*LFXE<78<))!=WEU+<Q1)J$T=S>:?
M81+'9S7,;K.;@-,))XI)+KQ9I?"=><R$N6DYI'IV^C3)=ZA>2W!C76!;-JFF
MVZ*VGSW=L$87<0N$DN;:22X,\[K#*B,\P+!ID$S24G1YY'S]?E_4/KWXUNH)
MV['8GN,_?3RK+LA(Z ^>/O&WH ?2KOHT*+J15D5"#[%@0Q4S"'8SI8@D  $>
M?$":(G.;CN0QT3>0]Z4\A"A!D$[X'D#GSVR2 ,]0#W&U_I5ISSM.?X(AA3YR
M.,8WZA4))[J2F?7([EOX>2&_TCY#QY? 0_OS[?(**MS#U\_[>?GM@8WQ6;DC
MQG\_4>?]?[;V\NEX1,0P!R/^GMVY#@0^H#Z=NWIJHI.<]P-QY]SCT[_WVJPD
M3<XQ_4>OP[Y_I5&73YY 0#X#_(?7\=7:MD>HZ$^6V<].G4YW-8^1.5N^#^O]
M<G'3;RWJ@N$^!$!#N'(>O/ER ?3S#^6JP.QW[8/789V/ZXZ=/B#9.H!VQY_7
M(Q\/D=OD:H3D@]P^/X!R =A]. \OEW^FIFR0.@P>VW3;N!@ _'<XSTJQD&^?
M/S'T^HJDKE 0Y^(?/MY /ER/_ "//GJYC?(4]QMT\]L#Z;^@^=8V9>O3J?/J
M.OUWQG/]*(N3L8//U\_S\_Q[?SU<GKL<$C;KU7?.WV>WK8N!^V.V.NWR(&/^
M3IQO?P4?<9M;S)BN/46:6R1JJ]BQQ+M!\#^!RG2'"%RQK-Q[@H>U:N8^ZP4,
M<RR E6%J9RB F(L<AJ%Y#^)M)8P<.5YHC_,LJXDC8>6'5>GF<]=[O1+_ /RS
M5;2Y;!B$HAN5.ZO:S_Z-PC#(R#&['![@'J*]VU7-1-QVVC!>=?9(MWF4,85&
MUS3-L42MXVSO8EN2V1* ")A]C$65&5C2<F$?"T 3=^0"YLIS<VEO/WDB1V'8
M/@!AOUP^16.URQ_RW5M0L=RMO<RQH3WBYB8C\XBA^=9K<%[B/'KSW#Y\#Q^'
M]\:R*'W0?+!)_(C?XG[W&O2C<C/4$>>XW&?F03\//I2ERCR/S#MSW]?/M]>W
MP]=5AMD>N?D?[@_O6/<=#Z_K_P 52G =O+GDH\=NW//\> [?RU.A]X;XSM]=
MMZMWQW\CVV^R 1C?Y51E [#\A_V_IJXZ$]MP0.WF/ECRJS(Z@^HJFJ@('-SZ
M]_S#5<_L/O:K208QZ''S^Q7S_OGX_P"W^_XO[[>7]_[?*E6@_0?8*Y,ZLW6(
MSY$$.>H5ISC3!B<B0!%B_L<.^>0LH1HOX13<F:'Q.LNH9%02D0DVBH@)'2!A
MXMK\JS:SJ#H05_$&/(Z$PJL+$>8YD._?KOFO:? EI)9<'\/P2@A_\OCG(.00
M+IWNE!!W!"S*".Q'0=*ZZ-8>MMII2FE*:4KB_P"LY;#Y]ZX&SK!31P5_6=I6
MWN=S5:6A5/&2,NE]DY06'M$@$2IO$@B\1R"9SE*H5!\0Z9NX:G098#?N=O0'
M'R)V-0/3Z?3._P!!6XE-9<$2[!_Z?3CX!Y<? .P>?YZJ]_+[^\_D!4HR%]2.
MN>Y)QW]=S^9K:.J,_"FER' CQR/'J/'X#V^/P[CZ:@>PZY/K\3][?/I4 />/
MD,>1Z#U]>XW'SR-@Z^TX*F''D =N.?AYCW[\^7\^-#L#Z?>>O3TS\*'<CK[Q
M&>VWEV.,=SZ';FK+\0W  )]WY_'\>WGY 'X^O<=42>F3CKU/^[/WVSG8=S4[
M?8'[XK^VU^*2+:'1-P9<"N7@@/\ ]$IA!%(WF'!U2F4, ]P B??PG'G)V,(S
MXI&R9"C_ +L>\2=N@("GH06K7-?NRJ):(3F0"27'=03R+\V4L>A'*O8D5I'E
M'=G6<-[@L/8.L]7?C'99BUGALCI2B2<-3'CF?;U*N-)^*-'J*>XV*UR4)74I
MK[4:MH^3G8TCM$4%3KDR)&1@'IC)['OT![YSTW/PK6HT]PL#OGI@[_#Y9/;-
M>_%^]S"=PQ)#Y3N4XRQF=7&41EJS5>47E)YS4J7/W60Q_"RSV4C8!NC(-W]G
MCE8U$&C,'9%C>)9FFW(#DTA4C/Y$;>O[=//Y9F*D$@ G?'3OC.,>=?;<-O=Q
MAAJG9L6J,C&Y&RAA*"CYJQ8_:!86T>R,YLE4@',?-W5C7Y2L1$PS3M;%XK!J
MR"DZ '3 \8FD*JR(+W(.,$]@=OCU_O45C+8SL#C!Z]>A\O/Z=*R[,;M-N5>L
MUPILQE6"CY^@QELE;4V5:3IV4>A0X,EENS)O,HQ*D),S]3KYRS-CJT')25FA
MX\IW4A$-TDU#$AC?ICN,^7GDU*(GP#@XZ#!&1V\NN?,[G? P*],UNQV[5E&9
M6FLG138T EC961:HQ5ED)0YLPQSF6QFSB86,A7DM8)2XQC)Z^BX>O,925]V9
MNE73)N5NL*;!/WY>?KOWZ [X%1$;>7S]>O;O6?H>483D3%SD6JHO&34:QEXU
MPJV=,E5V$DU2>,UE&;Y%L]:'5;+IG.V>-F[M YC).$$5BJ)EA4O2HE-[N'<;
MM,E%G<>6&^8KS==6[>^6>VPV0G55QM[C#+1< 5_865@83M3;6NS,(((6/2BB
M5)&:&$,[M\R/L6/OVD<2R75O<0KIDWX!G'XO5]2N+A8M.T[38R5ENFAD5EGO
MYG18;:.,P@GFEN)1&G+)K>M7.H+*;;3-1GT9ELVO=2UF9T.DZ1IT$V9+F:"X
M1X9[Z=1,ELD/A-B%I+N46T0CEVWV#_O>7;#16=KCIMD@P=6%M3'EE9)QMDL&
M/U)IT^J=@G6)7[\R4D_CW?LU'1S,PFDFR-@0CHYI+-V:68X:=VTJ+*3B%99A
M:37((GN[9I"Z7<JEF96G9W8<W*S+ROR*& J;A:4RZ/"56^-LLLZV5SJ0*W^H
MVGB%H]2N48F2.2^=I)P).61HV24I&)!&N_M$FSPLXDDJ?AC)"1HY 1$"$4,;
MALOZ !DU1\!A'L5%541#D $,M=1>)&2/XDRR^H_F'S R!W(%;KI-V;:Z56.(
MIR(Y/($G_3<_^UC@GLK,:V0UB*W6OX(<_7T'X:4KS+)^8^@^@?Q_#S'MQ_-5
M)AT\P,'/?U]<[]\[; 8VI2Z78>WZ?#X=O7^/8=3J1L#GK_<=-R<].HW.U#C
M((/?!SU[YW\NIVZ9&.U"=(AP/S_OT_#] ]-3[^@R3Z9'ZY_IV[R_M\_WP=_U
M)WJT9!OR!NPAYAZ?/N ^7;@ _#C4CCO@_KY=3G;?;UW.:G4]L@^1^8VQ@'US
M_0U8$DA_J#CCS]!]?+N(]O+M^7J.H+UP?YACY]1\352L<2[?GQ]OT]/7GOZ
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M]QY>M9"!<D?#.WKWSYX_/ITJKMR" @'F =N1^7D'P[@7\.=6Q&!@YZ]<9SG
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MF.-ZC))"3P J60(N<OC5[58^^_H<_7/GMC]M\XJ5OAG[ [@CH3UJ8JH-@X1
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M&/DC^-=I9:S/5.*>P)@140;OD$'QN5&R:9H\V_8;YSW/;R]2>GG@=JHJW*,
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MLDE2Y.OA959%HL_0CE"\WXGU3A*]N[.UU29KE[>8E(&M;\6HD2:-A=)="V_
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M!^8_7Z:K)UZ]NGG]_?>L=*.OPS]_0?MWJA.P[>OGZ_Q_'X_#5VO3'<;';O\
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MTF 'GG< &2:0CF=CCLJA4"J.PY%%%LBDW;I)(-T$DT4$$4RI(HHI% B2221
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M,/3CY^7IQJ0=&'H#]-_CWW/0?6JE659&(L9Q8X!PD]$'J0\#W]L;A<!'CCQ
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MVT;5$TX:L]C.NG,ZHMVR@1DNW*I )YRC,.59.7PRV%#<Q K&KJ^F/J#:4M[
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M]KFZ2*$&EIVG[X<$Y :RB8^%RG5[$_D*S9(DB@"!O=9>26JIWJ("!%TH\I%
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MLG*.>1@7? YB<5>2!^W \?=]1^H<?KV^/\!JU6/;H/7R.1M\]P:]9#<" #W
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M%A/#E@D6ZC)_9J10*_$VITQ5$HJQZUH*S4L!XU0Q"B:.^T@9&.4#B@)@ =1
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MEWQZ_/';(!&V*MWF'Q./LX/[ #\Z\*JX%[B/'S^//E]._/EW^6JRJ!YDCO\
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MIMAI%@SR$!)UCNI9;V8@)XKQK-E[A\*#&A"*0$B18@B#=N+;FY]LW$6I\?\
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MB*+9/4CH6B1-8JD>I<'MGNRUD%O&?N4C#QJKU\+H%6TQ'B+-JD].\205]O\
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M^G($'E;0X(^5PS'H!HU'I16M/@:@8[G"@,'@MV+;BW 2N3<TBN3=%.$QW3N
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MZ>J>K[?MB'F_W(I*OE^5L%T]4NB,:HI59Y594EOFGS;82]X=-:0O$5*<Y-.
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M;2W[.IVVZJ_D;9V9$[B7!RW7QHK0,USGJ<H5ZJRT0,A<+F4VL/K :$,4/6>
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MG7X$CZC@*<F[A6[I2^_W+\!1 ?3@/#BN^M?&V,TLQ=7L:![)_AX!\BW1:Q;
M'Y48^=0+XDW5:LV3@K!/?CWP=G^^-<_^*O<+@.4<^-<V&W3JY2K@[5*L=8L6
M0,0@?_, ;N7O#8_+ Z\K >[O"9D#M\=,KNIAQERFA>)9V^Z>E_A3TK\%A@U!
MC/(%Q-V\P^3N;KARX> 0&Z1-VI_=E+/FS,JW2SKWVKX>0%S?SEBCS\@'!+X(
M?M_Q !!Q[^?N@U>X+HD%PT^"YRD7+A*RP422^?<PQ6+9)M'FI?DG+1PSFZ\7
M!QQSU:-V27"V6RW%E>PFIS6\OP6;GE@5>HF;R6?B<4;M(?1-LB9_1/P#((+8
M@J(2G)0#LI6^ =+)XIG7B<QK! 6W\B%>ZFX_48\<-QY/NL7%%9UY'T]%V?8*
MY[X 5G='?PA?_Z&]M6Q LJ@ZFL )[05'4+$147F<4"+*[WIE 5,ZM%3M_LA<
MX:$*<2.0^)/<L7,!;)^>7A:J+S@?K1VFY"L8N5U))M5M7\Q=QM1&6HU<R9 #
M:,Z\A?2XCBO"";N:*_B#"OXH6;(TD3/OR>"O[Z>"OX5+2?-+"Q+W"BO5))]A
M>BW2]"(KERSGG[IJWT'?_,*L6)"%I8*5&OD-E3DJ)CJ<OR3 'F72!QLL8?M/
MF!2 R38!,?)'IN9$QO+_X:#V\;?;H=7:IU%_MX7;%P"JL;Q+GM)@:+V[:CCP
ME\1-.!V#2+M>TV2"H(D&$FZF5/K#>_ ?KT[3(N;D1/I_M@I:$^YKMO>9MN?8
MC@?IZT@!.]+H2%ID D;)V>:% *\ :[@A;?)>E..G#ODQ@.Z(#Z[4>- A_S&E
M_L[HS^_U06-Z2%/"Z^_N/I4':^*2I,JF2MFE6Y7Q2Q-#'00IW+#2C[#2(^W7
M^%<%!3$$%#2MJL5Z#7V%KA/B*LR0+<- =Z9A-CDB;I"6L6V=VG(Z>FX6Z.=K
M<%LMUN;:AN5R&@>G%*BM*5?6^C?WDTE$).>0"5II1_93Y0WK"ZQG&,'[IS]R
MWO*ODSRRG*[P9W")5VQACY<,$B>QOU^*NK"^$&2N?]W^[AUX]]DM?T+U?N7^
M,\^WSNJ48^PLMY=HW:_;E[G9ZO'LJ;?U1]+\ZOK=Q0W-S1'_"4^U GG!_')4
M5*@I23:)7@T+BIZJSIMJ^*FQM,7$V_=4F^3H07%"3IJV]0^)6<5H_H7L[.U^
M/"1+$[):4LALR.@6->$^H#EF@P4!9^4-Q@52AIT>&=EH6\)OMZ7W382)OE@G
MB,,8R+%!( .+F+Z2OR4R"$M'QP*?GE-POXTS-G*3MSHV3R4E)$YL]-O;P8$K
MSXU) X?=K[<16 NM)XC#<RANCCK'&[/<6YHN=V9&#CYU,1IH_W1@[(Y7&2CZ
MW-HW:U4#11A2&G,IQY4T%F1+D"1Q+C1+9\_&/"+-3?0FP>].6II%9"*CKE2R
M[(3$TS2@1_4XMF!&ZQ9Y=P\L(-]?1L>(Q>,5&B$)88<M=(?-Z^N4E*KY-R?5
M+JX:D:L>N<>>B:T1LYQ!J(GY,QLIM]L[N+X:?@\A"R&"GF$W<6L/FQJH'*NA
MS(LZ[Q@$.V84"A7$ZE]2%D;X&3Q+7)O_WWKBEQ$>AVF_VGCQ\T?6M5>2O!0
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MD)9YC9Z-&XKFHBQVG].NIS!M[D+![5&A?FZ[CSPB2LS40]?/PYYPJJ:X!0)
M%.OXTEK$1-D!-^:;$AK+8A+NC87%OT5\?.)>- )(WV@XD-#("U!O?EV?:X^(
M2S!992C;3 CP)TJQF?SK$*>QX+")M"C(D!$;4PZ 3JZ(_?]53*MTLJX?R!P\
MO"EVSE.PDA>1Z93.DVE5G8I(/IKX,^FG=(IU(B8,Q>^8')!!.1@0ZO;K+2X1
MX15 )FI= Y?@QHT;2-\QEYVI*S%6Z#&GBXI&@L@MEE00UI0"KSJ%,8XZ0.^
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M&\6GEEK_;F%KI@3_E#"-=TJ,2ZP"'.$ "2,0D6\@FI47FW0V<8T2#P:![C^
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M[=/5S$P8NJV)\S&C.%&>-O,R_I+HU]7;[2-7%I?1?A#'Q/+NOQ.76AA-\/3
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M-V_:]SKD&"27'U:M@,FQ0U=&LD;<UUO9;HMWAWV(:M?BV*956]5/YL,**5,
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MO+ ]24I%.8/>3_] S'K[\FSF"-0@D]SD5>$+I*+\VB\RROH7@#_.Z]&N>HP
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M0<;Z)'72.2%7%QTN:\Z<K$I+'+\(],10\X N'*@(KN&$2;-A3.A7<;WJ @\
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MKA[>;A-8N#G"-!^D)1[61[_6,6=FNO-"JOG%]$9:Q!)\F)O*NAUC]0K?)'?
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M&C*(F9@,,FCEM?0UK8-!]&&F75APH%)*G-;UL( ]=,J?^I0EB9U[C@. 1L+
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MZUYKKYE]L;_/?'\).'M12U<+@(.#BQ.($P@ ?-]@V3?V0**1OAY(;PY)$3&
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M1Q/YA/Z8D^0GW.-9RW[29OIK&^_C29OXIS><$RO>LW_X^J,H +@GNKLGUSH
M43>W(PGLZ$CPA]$/3F%6]B^.Q,G1]NCXDR-]<A3^DW/B\_/)M??/J/^5\-X=
MB__[92>Y(/J1YY.X +@7?GS^D+'_RM./-O/Q%9[TK^A/"*__*'5SOU+W=_J-
M=ZQWK/]O%7[1G\L% (&!'9<=[C&L"Q*#</7]E]D*1HO_#/.XQ'\K+\"_U"%
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MQP.*?](^U@=0E?V1L(*CC_+1Y4L  '7IB!\+8 3@?)_YO@$@4W-%ND"<- P
MN-\W 10G+8#KU6.[[_. "  9$1$1,1$9,3$9%2D)*14=)1D9)1TC#0T=#0TC
M%=D)_7'Z9\(A)R4EIR _2T%QEI:"@H+V^$!!^\.$ZK_BX/M] !714? %>#A
M "X5#AX5SO>%HXZ2?'^$HWH4Y1F<$_HCC7@ '%S\,P2$1,0DI#C_*L0!X.+]
M%)X%X.#CX.'BXYXA)" Z@T<F>22DPL,_3RU^1LW$F0;H<TV"@#:EL%Z=DXO.
M](&+I!0J;%2#D#O5[/W2-MA7FKZH(9Q',\W<%?2P&"W#,&;Q"O*A,:)G'+/\
M48LWO>1Z4\:CB=<[I<V]DRN[EFY^D9EE+7U3;_9DM:W<_:-NW&[MGW[[B0J
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M3<KLI7>#X\(>\/G^5MGL//-&S>RTRD)]S<P(9OY<OT-]_-MQU1WW<27@5XN
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M5^HSL9)-K11WKP9!N8AH=N-K4D"%NY/B@XHRT9^";^JT)<SQ?*;B&@/F5RK
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MX.=KC\9V&[B-TKDVI6WZ034ZFKHY;Q$9F&OD1*Q"VS*!5B\G_3=E)I6"#^5
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MWE!U;;8C@0O_!=+YC2* 24/,@^2 @5BQ3Q]=9Z! ?R;=SZ-/S8C:V?H]5N-
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MQUW=(TFJV RPEB"/PXNW,?98O\^G#GLV6^F_=#.'?9O*,,VS>[W;C;EUT4]
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M4 DON%'C"?@D][^JG=P=X1G(1U7<K_]/TV.^8#?$V1(CS[3,#A5X&R8S(B+
MG#FIBAD'W"E:.[GP_+*]@Z4')NK__CU+#[XB7U0!X8$^3+N!DVP!E+M'KIEU
M5B)L\ ]MX$@CU=B&2@89Y\X]<-!L$"J(^X#D$[IH$OVX_@.M.SM2IC6FS30P
MQ7?5?S?1N\GV%)A8!P^J%71S%W!;>\_S3L)'0> ">KS>X+E<CJ<'3%)0DN2(
MV_$5K!9VWH9T))OZU P1V21<E[;)J7,T(^=+<: &^/77E5UF_<'3%WC+8Y?+
M_W.-W5B&8:;K)SW.H0\7"KXEQ&O+B*+9O4EO2^7FWO\&3@*8^+_>2D"#'Y^K
M<Q2/3ZJ.QVM/CC-"Q%"$S'5*E8;/A F5'+2<]F?-^[,4"J_(25Q6B>,*Z+I\
MG3J'2S-Y[@FK!N.&D+)/MX<"I5C]TA_JST]_J(A#T&39N.W&HS:6W3?308HA
M2%%!]E!QR8;+J_6D^#[X24\ZAHSUP6#5[.U2PB^R@3HJ+FN9Q?2=4Y8DTZM>
M<LKC1+Y<(TS1&2I;ZTE"?XTC+RU_^XJ1Q$CO@GA1G7))+G5W3=4:PTZJ]4!M
M"A8:+(1^TG$MRZ+FD3=HBH)T>/9 3O&0F["F-#EUY_BQONXL'\%JB>4/26*B
MHN4U>W.7 KA5&89/+VWC"K*E=.>E,4(%5-&.YO+E$7A^Q</&S)O:XV?EG@!H
M/;6&B%;<+"1I5:-Y=T_CZY::'YPW<QQ39',[AKY:3640$_:9R+OBHI/>M.L@
MG%IDZS[#<UO+^\5[!K7L #47X!HSP/0? NBW>W6TH&NG2H9?-3-KM2/<$2['
MN:@BT3;7')@O;#NCM0(WI$^?SA-TJLXY2=L I MIJ',F__#OWON*>[CBP/9^
ML'[ R.N8@:$P9#IVB%-> -E<?AQFO$I$P["KC"%E0]0W$I*+A<#O3I=+;7XK
M5$(MLJ$H+R()'^ <R6?RM_+Q/BBG=(%R/LW;CYM\K-17+O5!/%I =(CIV,-@
M'K4TGXM62;=WI_;YQQU.6";H\(0<%7*\4K0[GIE-1>,Z08[U[B;?'.CL$ (6
M>E -A1ZS7Y7C3,F*^4P[P=$G4:8<CG0D\U<!HNW6T&319?'=YF:L!8_,*^3U
M]R.[FP(+]%]PZYW$NE";6LA=6A/1S) +O!C9Q"4KJ;KJC:-C3 3WS66T6\BC
M\W#;-@QE3JX:7]9X3NX/JA<YFJYEUZM5$<,.A &IFV*G#/W"N6T)\";S>>*%
M8]N]8=1%4_V 83$Q7.I4F6&\=*_IH=K/KUY61GRJ@<1XW4)-:F_N4C+*(G%)
MG$Y<KT:.DDR_!,'7&I_L@T^1FK;"5I.GYW5N&[E[S)G'A=X08C2<HTNEU U#
M03,#2+2""=HWM>D_G3 Z\U=-ST@]KAZQVHGF.E"$PG( .\J/G*V"=J85U(6F
MPFZZ%X\ 2ZNS9:N'EKJFY00KYL-G70/:6Z)8Y9-%]J!NYM^GT8TD]!'=LKJQ
M=<6Q8P-X\9:@*:]=Q8?DX1+8]Q*6)09G.M* GV/Y_;E10W'=(5[3==^=?E'K
MEI'HX/[YXSWI*8/ Z,7<Z%U<P:N WEXI7RS"#^1]D@O(.:TC^P7G3YYJY7'U
M1F#W2FFT?4<OBHO=99,DS#S(3L[<I)!+CHM!FE069.7CJO;.H;+\F 6Z!L@P
M_!^WYK^&.,HA4JO,$Z/J#]GE#@ZOJ[K,MVS933\-V?QF-\:*+K'I]O:>Y7E"
MQL$1>,X_W&J466?#5MQ&)H=P2/2\9?23OF3-4&[.K1.NQ#!X:4T6!F8CUEW)
MW/9=M"Y]1QF$3-PW:NTM.!A">TS((? !QUC(N+;XRZ];3]J)6X1&9(J0BW^8
M1#T7$S *?F@\#RM.WL,)E30L4E"HM>-G>(+*$RR=B_)=<!!&):&$@AF:N9(Q
M?F(Z&.'49ZR/KC'ZK_'F[B4?2R_XTZ[&^BSE\U^("&E7'=*WM5$6'CD>B]EZ
M+Z\E2W<F60_HOA\,FKH#F'C)F?(.,A8F-UXQV'^)@LN-=B4$TGB"\=)/)<8D
M58'MRB"&WWHV!MH5LEL9G4YZ2W-\8&^=9L+I=.1$DW<,>Q:MM[7.7)3*591?
M').KH402E!*5@LY;*LW?<27I7SKM@4Q_(AZ)3@[ X]9\_MZ2:->9,I!); V0
M:GL\=RK%LKH[%T\&[^;JU3N+PV(N1-/]5KT?]81:0OZ\<MKPP^_'Q<"!A],K
MN^4+IK3%\]D3 W_"%ONN[#+$1#O+D7?#,:=>IM*[HHX2A4=($4+L03]4H+P[
M/LPN421:'\/@$(+56 NXM^E[\X9\.%[Y<+[L2651U5>HJ8&@K]WJ3T>M@+V&
M\@0J+-N?H4<EJ=GT1\^,SW7?,_7FT9[3%F-94B]V"?CS;OU><WKF6D(24N49
MO/('6>LLW83#E3%XY64ME3O3UUUY35>(Q=]VH<PI@..EMF<V2"O1B*4WRJJ(
M/$SN6:&M[!A2-;"Z/';4E/;H4*AK)6R)%K<#Z:H\P6B.NZE($8;74F*7 2EK
M3(Z90%^>8ML?5N$#260*I@9LSP%@2Z<W)OXTN:C*B*O)8?'3$4L+Z/8"A%3&
M35&K^^]0Z*>9[2P_GXAZE'B6FAK(,_(<LJSOD\G$AEFG,%_/SO._30HJV(Y;
MK$64^IP_-:L;W\%XPV>1U4;C2_2S<-\\!L=R\^YSH.AX(X$G;48!7H[M*JU;
M9#I<\G..N"8(]&X34D;MZ#48-*1)MPC.:Z0[R*0H&!X@)+BJS9=GLPO+*!XC
M<'YL+V^"S0E*3[!'@C%HTS^C<.YUH/C7 IM.NKZW0C$*\(T4Y";)Y79^CTDE
MRS^/H  BPF:$4AC18/@[5&+6.G.Z2:DFVQ0[VB#Z;#&GSAR7:DL#F_\CKO[T
MC75K+697Z9'Z[//-![<!3H,1H3M'W_M7N:>"%Y00UUBW_^GQ7B 2(%X!B4](
MI^^)*>NZHTAK$/7UQ!GW[Y7KHRI,5"A@V4HITX0MHI1?PE=86H!.9(=[$V6M
MG]_70N !&8T5JA[Z04^<"">WCVR=HM?CZ,6A=OI8H)*X"X1#2KSE1*QHT>?#
MA"7'Z!9W#MP$M#BI3\%@X%O^I4P:7#.+T-$(G@4GZ%QEDM071P&0BL]68*MD
M-AH=!.Z4ZP ^$)FA"15$I7F)%GOWFMBYL<(S7.^0N9\G D&&O+NA"99\E>&J
M!2'$&Z(%Z26V887T:D8SE1KP:_6YQZ/@8C1O<QH>-85M04BJS!0[;3HY"4CD
M093W:R6C+"SCC[IJHLF%?((6-J2U->908?[U0\$!)G3PAQQ4A?18YPEMWE%I
M+5$)P9AV ^O.0DE*@\/.+"4R,Z/F1N(%O)KJ=MH8BG@T(YW?:TC;/^25XH>*
M>6!',?ZG[-O+QK#Q=U13IR$_*,2\#S@5(&>.['L#/_XB^(V?-1)CEY'* GX%
M'(EZ5R@LY88>KG/RUQ<]"3?DB*G9<*H5<%2"6=@EQR>$C3QW#7!4K(CTM'B@
MXRY0^8Y^KS1S# ^<(K9#$C=VO;?FW/+MN;Z^^Q;%U=UN9-;#8;*H4.=QX0ZY
MDS#G30X<K"KBV(:Y[Q=$:U*<;S:Q942C&X(_EE?+<?,@1>80O_<Q&DR/!G$R
MQ +>9IA1Z'[HS\(CX>E$'.EU'F-2SBP$,5:7;DK@+8*LXO"8>=$%L;A]RZ>I
MDUFWVY=5,@L[I+$W"#@5++/+D^U[657@Q?3Y+I!IZH_NV_ R0M>F6$<@S!6T
M8G0#%[,P:H6+'BPX.D#Y\CQ.<OV<P#8W,Q"^!.6_"$%\KQ!<?U?0Y=)@X(H:
M%%32G.HY!S0XAN1P)ML__?&O3!<<S[:M:'.QACO$^=P=P'.?;,)-(' '2 ?<
MJ1'2N2,"=VH&.T!XG@Y$I@-YP!;4$(^"!0K ]0 7R;_\>ASQ@ 0*CO"!#PR?
M+%S^&;#FPV8K?.%C?;E;P7:N*VCF/QV"DJW!Z]?09I<#I8Z_""M9.JA0[#1L
M+/Z/*9VY D$/T>\1S<>WT!TIVTU;Q?FG0CA7E:4<"+3Y:#B;@A4_DLG9.9B?
MI_L:_7"_$N<C%]3X1TVZL_L,FT20X8_0LYI1ROPT'E8L%50BIY*PTM5BY]8<
M03KUI36#8X((EKZBX1X!?KIL)GL.I1#B!NRI+"AI\5R= NUTAN4!3^4<[S6?
M-T?#6K;_62*?3EY')>L=2XL,LLO/;3W39!*C"Y#R+@&/5\E C]2E$4^X\!B!
M>H>XKP;^BM=QVNX[R!+,5DP)6)))^Z/I$SOK[#-(J\=O<BC+ES-ANRAG*K()
M@H1%S.A1)?&;!7Y93RKJT"E*#QP=#@CB!NO>#/4/E]<VQE& J77!V7K&<B;>
MTIC; K/'S[[F+XE4?_3:"/EGW(XG*A(!:H@N]'A\C/ C-@M20T]?/:+A)"]!
M>=W-9 *&GT'4<H8:.MJ4($-$$/:\[>[CEP$4100@AY72P=725U%?0OP4X9-*
MD4>Z@WT&C%!5NC[E0@HSHASI43SDS:G/JSIL8\K?S9:K>K6X#2E]B2CHK>QH
M(^(CY% K*.772G6R0^R3BFTP&5\RQ_AV"F3Z,-0_T'S1WC6\Q@JVY?%73B%W
MLIR:*&]4V'CS-"OK3"X)DNKRL/&1P;>C0[;L&'IP3^^I]N4)U^L(X[Q"ZN.>
M.Y=1S*KB-01Y>174*(L>W@T+U<[]F99T( IDS>IV)<S$[5*F%PSL=9Z01R!8
MVGD)#Z/C["A50$;:#=&1?(.--W:TL-L:8'5$4/>_PFC=[A%C3@RTH>@)$>D[
M3"W'V+BBV:RX4)_ S?H23Z@+24AHL@)E6?GSC@U;*T$3QMS(N5%EF.>]CCH[
M(+?[Y.18K!3:-KFYZ#1(*Q.5F;ZDG68]";M6$-;UGR5?<SV,GT>!EZX$;K 3
MZQPU#,2Y_D6P7O.;04]R>OUW-Q>%U,CVR-+46+E[3$F3% IW4D5 8T+57'5J
MV=K94B_._.#ZQWN]ZO6SHY@DQ4GO^0$)_&:;R"QWQ]#O+->"JGT4X@&V6''<
M,7([*;B8_J=.O96[0_+B,< E#KB]=S@"/[?>3 >VST D^*#>=SN&-BL+*YO/
MWPM&-Y^^4>%^*O@_)BCF)<HS=BH5*Y&JU0$NHN1]S)*A]Z;#3.:HJ/3\M:6E
M_)Z7"NB_HZ.L<1I)-(M02M-\POGN?!1=\O#'#9B!]-I+1G,Z,IH#;([9V:70
ML3^=I9#U [2J)CVX,EN<T+3@^->MST$\9_<.)R?Q6# :2CRL^+:2^K#Z&;D#
MD^PG,UM_]'7COOV,!K$B?TGD*>R%S@S,X/,*R'U)'6=3D-[3YPVE];\(8>,U
MJPH.J<+KB?+$ZO*'AZ<JF5?,2N6?%]]77N&5$1F-<\ $_9M[/,+O%:[D=ZAV
M??8C;JECW0.^6^=E:UF.RU$)"AN)8X0VZUY:3TP"$QJ;I(U7[IYQ?G]D>!I[
MX+J]GKU0?1':U0U2R:_H=X;OM_%R_[I*;_I:=::5\BZD%G[:;("UNA-SM93>
M'AP_%>C3G2=/..Z)UP ]CF^:;WB6O"O>&G781?H0W(XPW*$[YR1?#:WJ2>(1
M!.)]E?RNM>"$YYAM;S5O'] ^\<T\1SIRYTKW%(45(OE+J!_8^"&GT,*RGN:K
MJ.=DVB_5NE4:_K>KE'&V#R:7M!/M)KRW-OD'PG$^!G4IN_.;]6. ,=WT?/VD
M6MAS/[@QH89!DCXD'BM@Q@.)TT6*'N[[XWQ6'=)/?"S/S0-#"D?ZV!A5[HVR
MG.?-N5XO#;Q<^C$Z_(X@>07(P(-)W\DBDB8]%+W4:-B.$Y!9\FC?;*;*5U9G
M2UAF<$/,;==F7#27HI["?X1[121103#'C;"=KF3_*B^[7"R9%EOR-&+6*#($
MGF1GEZ7,Q690;4;^/$V8)&G1O]8&^&E[K-'X6^G'1).L]J]!Z=-T_-%-TZB9
M&4YM@<72+=T=I?7&(UW=(XX? B:MF3-GJ;)S DIMM>-HZR6 AN I67I-D(I2
M9=;B_E070[87IQN:^0<?,AO&]QRI7U*<UY9AWOOIS2YK6A$\;*8?!<Q/F*/[
M9Q(*F8_0D1"!54P+[V\G%F^;DFL+=TT"C8"3:IV5VC9/1::2@X,5>/Y( JM+
MN>*7#T!OZ8;[H>_!)S(VAKH?4H'?C)?XA$O06VOIS>CIW6[?+3@A$[\7.$K<
M-:QWM"<'[+<Y?=F35F10@YW=&V9Q$$0/LHF1*?Y%J(OO]&)$T\)S,-D@$X?L
M-6Z_]'%YE>]5-;@C#Z6YUW:D2'[^)65U*<5QY";E7RY;7(JT,L*P-+E/-_^L
M6PLSTO3CE)?U-R-_N_)'8PX9K,<R@::P$Y.GNBY9'A']G9B18LSR($*AS2\_
M(;I8J\#ESCBQLT]+@TWUIY9Z1ADS'>2-K-*1C;K=4B#SN;YI785@(@MZNH88
MD7@/B3*-;A>L@2^2=N#=!)A\G=?BTSPQD@(24S?E-^V?;0,OCA\(V8L55_';
MZ,97#HFCO1GE<)LX[ Q+YZI*YGFBM%J]W8$"$4C6Q19AL8V8VLE?K2T)HV/>
M1C<2'!T:'1_/H@L[%H$4[0A8[/6K%Q9(GU?%ZU38%'<%6)%GHZX['[+D+Y<:
MA;,4#.1R=XNN(7-O&:W8>6)D?)N=<:6<[(,&!DH))H-:3\AGC=JP'0RC3N,O
MY(<1U9OR3_V$O&SQ[PHX0C]\=)AD VEV5&_OD)B1G!0*Q(< !837<13;(? 4
M0-_N2]!%]'F+ 4%W,8M-EXN07/=9IF"94^99LM\W:]V9GR<+\TK&1M8R)TQV
M?5:8:)L?#6'";C0DAX=*&:$6$1YH:-2 ']JWWW:#%B+O.A%IF=X/6JONGE6;
M:>0@>/DYIN$W=T5)<9?NM79SFNH"VU@S6-[;2WC4KC>Y+66XZHY<1><=Y&B;
M+L9:W%J5GCI5F<:DQ#M3TXEN+]QIX[@.;Q: 0*=B9D03!H0@?-7(J(W2D![[
M"*JLBFH0U=&DCRY;A#Y]-NPI2?7[?TH#RO5&';P@6V]-9WC\1:CGA>"Z]-)O
M7N5XOD(PF6IHY3/31%J&I!0XK#\Y(OVTC_(GS,AQ;V?!N6]4*T,W.^19%UC*
M&JVJ'&40&A1PCYQH7=FXR#38$7ZHM:A&<Q2C(U3 DLJ;4QYZ6BYWB_3=TDM6
M^D$RZ#?^6V]7 MMXZO9@6^?W4?!M;\;6D ?&3:KKI>OSVE/CY0>%D3S8FM]W
MFW<)L>*1G$L!P]6IW:3DJIDS\2%3#2QMT_TT\<[O1NH3[>Y=S>9_I7=3)H8-
M5$P6AV34T!#A9R8K4T92/1^D4/C)ZHM+UU%VZNRJ':G!Z$?1V*M)%D1,@O+1
MICBO[*&6L 5+#3FOUF)OT;05;0Q/Y6\.^!^4V&,V<[V-Z)TPYNA,6)4N]1YL
M=X*B;5Q;'EQH&GTH/>)FLGJIN7=SS=D73@>#EKY1,5$;0XB65HTPV(]A+/I)
M=^@[EA%;78[[9T8U-"5^*WZ&:K)AU&,UHIT6 HB3LZ$'0QULU.]/P^BC$1,2
M\3PG5%;DE-F917AV87;'<Z"1<RT5(V_1R]@(5;&(M?5S@/UR@29L58O=>_R-
MD>V#!)>5%V0ZE\L:)1X!@CIT[-_4GY)',&EU9<N@0>_/Y+WH=LFW6(O+V8=2
M,R.0G61%[V_EW==%_>76?<Q.WHF[N>AW%T[WG6!M7JY@+PD%05]=&P([27=,
M?S*?0O(L&GE\6ZIF-+TUCYK@1F&W@>CM[L,$*BBM72R"!:1HGJP8/ 5T72HU
M.V"\*%2CG:_"+-?&1+/XJ#W6O#$3!=.78F.VU*QU%#<7CGFP[#&@LBYB-BW>
MQA*V*G'G4*,YN[?]!&2@2_-9T5FN=6M!:C&4C\;,-Q!RC(37\@A"F%E',.9G
MGR$I48SA*KCI^B[6EA:7) @\RV9^8Z@['5*)R2PAGIL>S+DYNLK 6SVL -&4
M;,.4KWL#OZ$-J C!O,P!;F%-U>_IJ-5^+T]-JEC1+VVT>Y^TA;0E=+&1J!KG
M0D6!$2//(A91)T-X4P5+NPP:<,1E_<8(.7. 4(UG=GR2[L&O5JW8?2[;<>J,
MVF#E[=.^&:51RR;\^<SVXG'H9A$?LSVQ.0<3Q54H0)? (3'/I2TCE;K&@GC1
MG>"7G'HKO6I\HG3Y_-Y^38:Z3^;JKYV[^GBYA4AV/:D99<)8CK1LI$ Z+GS
MB\ 5'X0KVP^SFX]UY7['3E>TWU*?.34Z?%R8O(K)2$*,P_<K*GL0)[;!TR"8
MW/Y, I2>HPTNQDG;35$0)@DI9F%85EUM.*UIBN&M+==ZQJSVT[Z+2$U-B<*1
M<M'P1G:@$^BXJ_MU]9;K4Z9>GJW:8J1@8!>362J-1!,GVK=<]ABBK,8N)3<Y
M:N-E9H%J62TNH_-V)RF_]N11R_%U*)O/+_O0:S2,(-\??834T>1+/;5;]L<D
MQXU9YD:5;[K$DV)5!\V[A4&ZFD&:VSZ>YX,@S2) &\KS*HZ\%C41A%W7(:8E
MU^T!N<.4(FW-GRR1&\U8:!69C4^$$N'1D&K1?2X)3W: (5+I+2@IJ*&7]?99
MM/-#T$%,3\1TEI=^[&E<2)["<(@.K.U[25J7Z&TT_NC>M ;!#S>7J?AE\YO4
M9.=P+EN61V"L)P7'J906)V#C1?%<X\<0J/"]V)2M4=Z.BD%*0;>6^CL\W3[2
M'G+KP<(4^1.^&E&3=^&$+N81AGQYF3$!'(OJDO=.1*L/(V^B:]_^=QJ>P.A(
MZ(GN=N5US&SK53,*M8SXW^1JC5"/V_F6@6II2Z >8@V%U\8>8TNY/U]N>,%D
MPMB>I-5$XC>MX>*TNB/Y'(#*PZ>DY3H TQ1ZA-[.?I,LKUX?SY>*6?]/H(C2
M[D!/]IYORO@I-P55J05F$=)FO'J?_!0YWH?-V.?(?7F+.BDUS)[=_^5ZOTO6
ML@N'/'3'2JSZEBA3S^>"7\<J#;#XPZD_.'T6!U4#4J.?5Y"A;(V'NBBPP5G?
MQNDK\:8EE$)=C.X4Z0E22S1HUQV*A#I^O-#WN4UA/EVZR"4$9E;)+<9"!-1,
M+S 0P^VUL6EV[M26 #= [!(T+0GK',1[GS;YZW=;D4BQB2MH;H=K,,[\M)5@
MWAFD\&>W+PIG!KQQLJ?6UPJ[>SYS;RQVPIA.<.7&3'3JHKP,0;;W:L^\&4H%
M^=\--"1\9).@9*J O#*A';\,B(.!"\'Y+[Q<J<%O$84@#P0G\Y!(()UVB-59
MQCL9+/[PJ3G"S*]B-=UM=',?QO'MUK":02>_N:C5K>^=/#AK+-T-TJ5.L?7S
MH+V)A.;<](DR$Q.8_&DUQ&Q=5N1Q:L\,N?;0Z(NXZ+K1_[W=V"+^BZ T,?KH
M<MQV*]9! 4BF  1+U%X9+7W/_ARFW>:6%7TD>9@C4GEC,7M_1>3_-D 7IGW,
M>EE=59Z2^QU1VBCG@'1+\T9!^6#.R UT070#3_4@P[=L2%Q(KB7:4I33[:#T
M>5PCX!-&$<8SF/>]N6@4HTZ.A!TTKE9E(8_"UNC!BK.P/!IV3@]!I: WIZ,!
MW^;+X@2<!EUB.PE==::I.R-F!DJ#1'^6(,OB:+I/L$?FB)I"X:Q+)DG(/*EM
M<)$1'O#3:W>U-8\0MYY8.SA,=Z*%D5O7T05/EAY!.!+&3\&_?8685&/-EO:K
M]0TC2R8UJ8>2@MW69L4N=4*C(;#?%V@7L%)7^F9?G4\P=VTJ$"5>TL*9?E1%
M04^2$:JQ*V ;6S=OOY0J^#TMP_46GHJS\K;5J1S>Z;Y&2*<MM2CYO+!B$1;3
M;4637/X2F21!"AR3W ,PXJFGD).<B0I*$(%322:KQD@FW'EH(0PA.;2WKF,T
M99IIMC1TC>74N#:W]S;V;%*.K2Z8W,JIOQ4] O=Y@)+)UN8=DUA:I=S)VG0V
M\A6/0(M1'[C $U#PLP,]OLW5(=,^:O"O=P:X9DU8)W-N%E<D<WNG;\JDVSG%
M <[57<@$CNX_.82!-+8<QMORKS&J:#QM[)48V&1H<.N+<<41'(*]/_XZY=FX
M_N#S/!)#L+ _D\9%I*DFA8L'9S4<&>Q'S9>\FFP?3H$7Y+;[]<TE6LV$.CEC
MO>$H6EW)[^00&&_B(0.=VPHRK*F+K;D5J&MV&G =PQ/#I\Y3B"97Y'J$ 9L3
M(2B6X,_&!F/8OPF;[! ?QT9,456)6Y-)?8LO8U><9?]#FOJYB,C:_'?%#L^A
M8[F9E32-I".1!=6@H6[4Z$I\PK$93RRV_:3ADBF#%VNY"IIS@]8:P"AG'E-7
MW'SS>+UMC!@GP4+T\))9:9?+3VN>B!2OF"W#=NVWU7QN.@:0.PIYP-#6PXE^
M"$BDAXNLA[AYDDZOI1(VE.SQO<H2]!/D;9R1 =N[M,:7'!R7 DF@&%Q3/<F1
M=C%S+Y6BUG#'3Y[/X=N#?936G$V./[)9M?MV[>3LG#XLG<M#*1"'(>R_/V8>
MKVT !D'E%VZK$@@I(>DA*E<JZUUJ49MT]='8<^LJU+Q>728%Z+:;.UK0SVC"
M2DZP$K/S6[6DEJDT]K38<&:+"6X:?UK1<YGN]QY<%8,34S-%KA[R;9L><J-\
MP9-JJ$VU)*,'2"470WW38S%V)4ZPCM'-E9/H1XD4/ \)):DED7%ZC(6 !+],
MJ',7>1?%L@LIJ1Y]1"I6\[LG\A1B\R.S2P2.@LPDSOX48M9R8(,CULB\%PCU
MDM0IBEJ25*O*<-Y4#6_'CN[^+A B)3R"3=!W>!?^H_"FY*OMVW-MSU#V(1F3
M(R[.[507H[%C8/X@XV7'#N)0B>K5'G=3E@S_.CI-B=P@_>R""UW%NX^VT$[V
MY!AQZK0L+FB'\Q?ID'+9VD,%1JP5P,3#OW*(7/[DF@ZED0F:$' A[GSMJ.O]
M.PPI;D598V8$YBJSNU\*RO0'=+./EW.7/UEJ"S;DL6.(G*FQ%L1H-Y25]:XM
MY&O>U;T*V9+/U16QG<M]>7&)KFLQYXSKHNOR9S(=JU#^$C],GY6] C5*=>8P
MEQL.3X)]UCDSELH>I761[\^GAGA*T<OS8D;7(<SIUJN)/AQ&ZF^F.QI#\%+<
MBG4O1'K/QSC#9QC[" )!Q3.84^7# GYFT=81EN44S'W2GF.*I2HC<8Q.>,S&
MO9FJE8T.Z)J%8MU*U^ZD+4%CJ'=MG\WSW*=\OH:>6/9M7C:SO.T/MBCFC*')
M]!XV"[>QZWRDRK?.B9[U0"'!#9SI[K[E]W]V]3OC.$NMS2.D)C8BN[8BNT,M
MQ!I ._YZF1=D<B&\;'O*95'*<YSUJO*+'OX.&X-W<S#:?5Q!#9!^,^I0I=19
M$K715\8\9*%!W$Q3-Z3G@!FN.*A8$_,U]G4X*@]+.7Y=*$FR_/*:)^L]!A6>
M:1:*B%[,NYW<IH#=V*:/V-FP]L/PX4$O#:/.E^ES<QAG;'9U+*S&7]%'03-M
M0<RVV-X.VG58GF-C=#LMN"(RXI:/:S!<K[0D5/HU5?5GB.RI_.H.QRZ[U-BJ
M+3!,PTD/AVPCF_DBUT+.MI$5"(G=^= ._/7T#?,:]B>>C3(C)*W)\V</DCO4
M&V@6*BMHW7@)_82]UI\L/_M-+NFQQ@7S(&!T82/W$8(+N^JV8+,'MT\07Q(9
M:4^N/M9JMW(HT+M,%"8/BS:+1/T<0W)^O0U8XB#^/(>H^*;"H;W'G6*.4BF=
MDHBR<+\4[7"-T:_'/3]KFL"M1E-=FOS@0[N*A-?KN5O<D 7WY1@6;YH?C^)?
M!/:D%=.X^D1^H:[@YZY*S*U#Q+/]H"*/;VJ<B[#K^,\9>\256OQ5ZY/Z7E4U
MFI[UN2LQYPA0.OZ$Q)9O0;^^">2.FU^NM;ANR!J2!,3RT)$=BOP$&AR>VIFY
M)*\1@ZD%-4CGO*?5X99+2@$V1C?3;@4+XDF:2T?,,2/E Q_Z.5!$I8C/&W<*
M'%GA<HZO%_B)Z&DCT7]8+41?=!5HU!BC.([.'67\=<C\G-,[MHF89;.J06+"
MGW(1N?^ DSVPF[%P/7F0HY,*=& (3N_2V?\B!%C]*"]V*NXC?^.=/'8JT+Z8
MZ!0^KS82FV0A^[0B SN3X;Q.2[5-:]@L]"93-00<7!@T)-C+?0$;GI7DD8M;
M<R&/O^#K."U+4L9\@&M>-I<U=Q!U>LR^%G01X+!N?@LV]72,,2]4DP1!JV/]
M',7=A:6MG==[@+]4KLFCAND<L\Q&=$'QLOTA1)N9(8YKQ< &#N,V31^-PF,]
MW%3+XA&971R=QHI>O,8C>EDI9WP67?J8T,K*DA;9\9-,PT0Z*$0/ET2><YWF
M^FP/HY$&F#Q2I5A-C1_7;]'@&E;\Y?$]+ZSO8YR/$Z*"0;*K44>YV >C^2,<
M9P5X5#17&G2-, W.\NQULX*D-GYS>;_B,(WU'N$0KQ5F^A9A9+W.^&W]ASI=
M0VLVB<BWX97@)W0)O/4/[,A9 I9B9N:C9*8A5[5K))_,/)31<)WO-AV+]4?I
MU"18#[,+BW;>Q\3Q>8KI&$39NKL0-F,XC\'C4GU!\X+L5+2B[DK W]*\L%6/
M=9'9% (*6V 9,V>XNI&WN/5GG*^<G+YC[796\CF3S+*'O/4R:U*T:ENA7>']
M9 0XR.3VSMM"ZD3[EI:&. Y%*;N98-,I1(X<BUOBNO2-594D,TU<!:0'TO;%
M7.5>EEY"&@N62/]&K+1B9;HYR#>!H>1-V<:8#\_GGF\),TSIPV25:B-W]5+W
M(RL<:XDG][OC8"O"3Z+*.2O@JRR!,9GL5&J*H"S9:B' W,^D"JSWCGLYY2>6
M"B6(:9N2P]2"AJ#]L-OCA-H?;VE-M!+;'1YF_R*T(/I3HBX:-(9<XD;TM6"L
M33AI&+R9C]2^O;%[(W;1?H,D^4L%US$_:=M$'GB'4&;*\S4:+?&-B;TQ'5*B
M3N)O1R_'>3&BM[RIL9G3!#C]S9;I@X])E8N2%@X2WI>4^#&H?>6#!(;K93#H
MZ']0GK&Q'W&[4?:;_ACJ\8CB$$S+6>*TVI;*H 8[WRN(;4@TOXF=*SR3X]P\
MB8!]! Q96'.T;?:_J\]N=(X]IZ!/W]6J>E#NO(#K?R#<H.M)@SAELIN/2]>%
M'XW>*0(U2)DP6,J6.D:_G":Y=QHTVV9EGIM8Y5?9Q1G'/_(4:+Z4&O6U_UN6
M9\?11O0,'-0QS0<.NO-Z\4AX7'\ZJ_^+L 2V$7X5?G$;X"S_082D15N?_1)J
M*AJ.![=$V929^!0DVL7Q]DR#X7OMG4EKFD]L0.7Z^:A_B='-,I!ER V4PQ%5
M/#FG<#)UMTWL"/D7&_7NJNXE,U^F-^EU\2^"] $%8*_;XIOU:,*WW6]5?Q%F
M;8E1*XC_\T.4RV\WW=W?TE]KOFET)0VP$'6B=DI:3ZNK>)_CJ2'/ZA@Z)\/J
MRL>JD[.=P">=_^#WN@MD]5_!.]<FMW7:(7L_>84_2J O4?^G-RK=+HYL/S5-
M$4(HZNI').I&ZB+-P!_?WB?^V-1/FL#"M@L^>2ATY?E]CXMZ*SIYPNNR1I68
MJ2Y5 ^6+#E7H< ^![MQ)FTU455O@:7 )+:FH27O]_J9W?LEN! [<,'Q\M.EA
M@,*;,Y/?#8WV&^,:\MPXXRUW$LM3T-MNA'N2G1[G6\0.IC527*XZT5( Z"B\
M]']?4=W[T"L13^>20RH>?'KST$F/Y31,>]2KV([_2.NN/8:+4M?*3.6/4(UP
M>AMN<?V6]"HH!0W,X"H,'/&NR8)(:2'CO))&:7 G_I'LZW3WFHT*CL1>MMI^
MU;U!9PK+#/I69#G/RQ990UBFX7)&\-T@Z9MS!-N\:8O&2XOJ%<CLZ!@&@$D5
MX.B2BHC&.><V1T-)+'8JJ&#X%\'4;P7KU,R>UFYKKC=N@6C,065#,[@'QIO%
M_IK>9B\8LB&BG(*,9"\P59Y;QTL&4&+CHI#7GDR931\B64H-?8CV4J]_*?$J
M]R")DS;;Z>P;GZ)\ T(.BW">=&#C%)P6?6QQ@QLV#RD0/=A%06[(Q@)(M)2/
M#WYMD9J8<ZB\/WRE$Z1XG>)PGP8IU(\X_$4('YB;]V!=<2!9]%P@7ARS?:-+
M_T<\/7T^#]RJWT U+>@)6>C<'@ECUW%70"1-80<&?SP\6P[RL%>QZ@'7EW'-
M*/U,'K<<LR>SOW)1:ZSDM 5V:&J76EH^,W\A@$#L6E@0[FS;NUGKL^ ,\BY"
M8N(6]&0,VI8FEAIEQ);.LU4,%_Z8^A,.3T^?A9HFM>:#OD_HF/<,N\"]59I=
M]&X?:242L!B9?9/OS.3C+%I>Z=RXU&7U'!(OE+)%6-D]0<L_#[?1[0>:P.W:
M[>Z39=<8IT,<#D%0!R_M>LL3+P<)V>P5#?N"KP&D1R$ <[5"*+OI@MV7^O+L
M?$LHON>ZL+Q;,7MG_Z&OPIF<T6*"HWI"UDJ@:/M3_+H25P(T4QZK#5J8!L9U
MH-B)0I8]W/U]YS5]H8B]0F9'9RQS2SD&4J#8FR/0;W]B\6WMW-UGJ5"SX/XQ
M8+"X>+7.Q1J/Z+V.1EWECTG681 97WCLC3!DF\Q!!EM657PO8FO=Q[DOBOS'
MO/1/[?PP )BZ]LJ5S#VBPPE>0XI9'>[,5*J-R!*S"OY52U-.*RC%E^%0>U,:
MSL]J8+..5]ER>WI4:CN&T)M>,*+<E@4LW1TI!M)T>AG<.9/HSV5NQBP/?'32
MSAV821L-'E(#P];P[#1O(660WXN>[M,MYJ:):G$:YNGIO.L^%A_H&BLUH%=J
M\;CBI+SL>A7RI]OS]O'<<;>D=$O9L<O)>E*'[JGC_HJJA5Z+DY7RD_$_AH.A
MU&CU4U-Y=10*>0%\'J8AHV\FM?A?.CIHKSA16B^AXW4+]4B(<!!)VA=I2.FB
M"'.8:8V2S.2I'K< &AN&O@:*4IJ=5#!=I2O=#4?Q 9G@ G-*'$>XIC,P#.V2
MU"2BKF;],!!NDS!?VE"4O/[[064.+.Y 3>RUZ+-[+,&(2>)'Q>FZ"/VJ5YOJ
M;<Q.;Z=+8.*+9-=@47)\J<L)_&A[_/L/Q^TV<\KQ9A$H]CIY]>']E&8N/RJ&
MHSJN^N#\T@"K<W+]9ZGCPQO8>;:%(5_2&!C[UN3H0UT_T<._):2(U:F.J*J$
MK@:_@J!QGO52;^-N'>297]=_Y-6BF0I*[GD0NA_<<1"5Z05-20,W,K?$BHA3
M3EOB-B,>X]6]]BWP47=D98RR_?F,#(@VL:V64P/GVHS.T&J_T= )*7*??C;1
M^8N@?UL>B1$-WE?">4KI"NF719#_]6G"]S$*_(_8O)7TXW$'JLV(<X\K#AS[
M*D&&5_Z!CAH@LU)=7N */N[V72!%@9GI2R(P5P>/[=7>&]\U,PN(R9\'7R#%
MA';#]4Z3912YP37:>VV >X9ME>>#:QOF.[,NZ\84O#5LM?6@D0;(3<S743_:
M_$^[(LT;00N>+^T\Z[_JB^=HIX9+U&OGFYQE["%&8UM'3+9 NI(@FB<0<]'Q
M> )TJ1:]]4KQEUF0GFZNTC^<R=YL>N>\RN-NL$N':ZU>/"[;EY9&8 _[I)-,
MBM_X\Q.2[>$8<71GP&'LAR#*!BG ZP?5$8M3' (4,?CT%B(J!T1PJ6$.D7.-
MYK*6_.0[_"R<M-D9Y.D&A3N%+ZR0PD5NI^4[7 3"NOR>ZY/H#^NL982&KRG5
M4#11:\0<)$A>:00%:]@8W+ ##EA';@.;.:C]282LDJO?3L./H56VY2<WYJKT
MTY*.!X&I3B\1IB*/CVYA)"=4?Q$H]-?/.LC?.J;[\)S+?1QB>EB&5;M#]S!)
M>J)RNW[(RA?#J79&MQN_O^(I)+09;[WI>:(.*XOV523=@ I$Y-7MYOZQ-] ?
MN)]P'D)KY1%V1<=-\O5IX?CJOY\-$&,U,Y+8DM_++VTH'W]N/E_("FJ9&"Q(
M&0D:$'X4 *7Z[,S_>DFQN>>](297%7)6L?V+0&YLOOR=O[,]<SP6*G'?\6X3
M$_VL>9_GH60K>E+RJ.?D4QMTJ=I'K73O+X*Z&,5(T[QJ7?A57EYK)!.Z%\""
M_8?L3_2A"#LJ?]QI!HSQTPO/WU.+WX2Y-PV/&_YL3\<<9#,8$K!FW]ZWM-0%
M6(_5.<6H:UM#;Y <R9K1:#O%WA@#38FZHH$,%KLG;-K:^EH"4H)5EL]$87'X
MH*@(:HA^J^5FJKFD0V<N;L 52<^8D;?[=V0D>#/O]\H!(XW$D];M+/&-H[6(
M*U'1OPB$,NVD0E.&$U.+O6*K'WHZDH&YKS.3RI0ZJEN W"#<]64N6"_ZL8F+
MHDMEHJZG2Z.6R@]>E-H$AM7.7L8>#_EJ9?;R+XI@%+,D&;\#0.+G\5J*O1Z1
MMEM[T3?D0YJ^/C,,L%B?]P"PN_1\J6E"<:'6%4(B:>=E<)KA8I?JG42@AEZ-
MQB5X<_DEJ]151"Q;AK57>)<U;=CT/D GQ;^]]E3*"0F,SY*S,J2MM-J1=L4Y
M"0XN(Q%-4;P[J8L!0'9*E;GCP&FJ1(U'MI;)%C3V9K,T,K$+LPH&8\I!9%]7
MS9)#>4,1V]Q9!JWWWR0YC'O.V,\=99C(]$HM1QA&<?2G_?GS$BON5&$7"OFA
M[VYFS;BO[1E"(\R7:8^QA9Z82_(D2.XUDA2 $"QSBW482T=Q-NK-%OO*;WR0
M/$Y3M[M(0;3#(&2U+#02)^M4T0K<8OPH*U#_+I+F'J=HY,2VZNOEP%G>6!&F
M4@>"M1G6<E\D14R2C0K[^7X[5/3:MR%>5[7&GY\R<N"G;;B?H_2=$S+1MY+;
M9WRU\7I9=#E%^=([YIQJ<Z2:%PUVK.@<74%Q,_"V<)/;0+@!J/BE-]> MQD!
M@A;#6P]>#-1-%<#9SQ9#H<;I@FCWQ M9+S>BL4HF4G^LI5-FE8R19%<QS$-4
M 07>JTYD=PN.K8?K5S3A'3D"AMO>YY.O.]6/YD76D'A%*IG$=T5_F<N.<".4
M_?*5PX-L4U%<P'#WE[;M\\M9])*&TT:'Y\^1R6&6+Q_E0?%Q^H&W"3-U4??L
MBC^KZ*X=1$M63R$B5 ZKT6= M$!]8Z0/8_(#9AC6F<R#^+;#/(CYBFD@O*"7
MC:&-H;YH_X$2-RS X^%S LR!]==;H]AZ)O6FMYUQLH()XX[9#^%2RI\;7([7
M,<NZR>R8FM#+-P<[$]V.(LHY-KK<R SO%$BU6%_MD::$:+YQ [9ZN%*,5;:\
MK'D<:.U14RE/=,R6H73I0PEVFLWFA'E;6N^JK'F3R6KW2EA("STZ?ME51Y9L
M*LH*WWJGE"<V5L8 6B#_?KU+?D$^8O4Y)48(7XFB\>TDO9J\[74H8V(?&2U[
M!J$WNV^;="G7NL2@Y0>4Z3R"SRIP^Y0IS\]:A)).KL!8FM]IEUYR$1DXA;8N
M1KC(G'D(>CN\=3^\>34H/N7*$EU>B[/R-_$/T9PS17!G3/<O=OIKR ^*R>0R
MS/LE>4@PWOY%0 KJ?/J+L)].^>?;Z_Q_O%3I=CHY@R^LK"Q\R-]RZ5I9N+E[
M[O59>3&^V+Q]_5A1C]I9^^#:$*YZ44FK<1T[[F"=BNS0+F[:ECD1^GR*IJ,@
M+)Q]?B#QEJ:#-9V%;M!R8?E+N&WUST('^T9A"+]%C8PGX.SSOSB+X%>MWF9\
M6,;5Q_6"PX"=<,,VL,OIZN7%GX3;CT^8B-L$O_[36RXC(E&SA^1GZJ"ORF'S
M-IW/\N'H0:NM.KJ?L["DOG9PNT4CQSBWF]%AY2S4"&R<G-4A^G6I'"LEK+S5
M#>"XF9[^(,5YHU17XZEM$J@%EU%7<[J5)#3D@%8=Y=TM$1W:%I_4Y#KD,L:R
M5%9W'9 QE<//(!V[F(DH4/FWEF^N+Z\4$+ 7DQ&>DQ'_IXW%'_XB?#5O%1UT
M&J%9$O @8Z'F,<%*_6Z\75]GFYH@=5[**^E W_>5]XO7"F:DN9XS: JY0\FG
MZ[L<=NHFYJQ+J^^WBAN^U6>B)F*;6%V(* J&5S41+4^T62)Q3UP+4EZI][KQ
MPDK1H= :G G\.UO$CW>MQ]Y[?.)S1'%$M8;TCN.7;F*)QC4JU1EO^ ;.[,(B
M(EK3C_P[A16+H]AU%]H$HG>\:=+\*50J8)0@+(2<A/H)!H.1/7?)D[<<D" 9
M(6"S"(N.@UW-\/QX)9]7)T&^7(0S,9-?*1^O_M(9"8"K5=W TNN4DA^G6XEZ
M]6PZ4C!4'PN4C2DG$>/,1.O<K=ZD^'MF&]2:/:\_9^-J'<F$1EJ'8WBH.^L7
M5KP?-N2#]9HSU_OS@1<S*8YJD]B,=:BH[6:J;O4=#1*XV+G&AVM(B[^_#[^*
M[MZR>KMP62_EM F5O1%_Z(M:Y>9U7:!D'2WU686=T+<O_5:>PHG7KR,8&O:)
MQ;\8+A].[73IVVO$7%^F"!-[94U0K<OD<ZV/:[==#'G3B&CI_17&\^2L>"*L
M(E$[CD>[.>.-?*;4[#BT5H([Z]+FVVHS>"T3XY3:\I7PJ94ZZVY\76S>ZG&_
MJTG,L&_Z5J";-IC*9GM<T9!R/87:.-;K6L^\F<03&4RH,#DLG-AG%JPZXB'
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MG%Y2-CZG=.FFH4C%!<ZA8\U:S\![E+<PRI1-X\Y)(<9,^8S,BP4^KXKPG+L
MZC#?R:ILOB>4^BZ":J$$G^J:@!I4M;' D?O]5"R*\4*4MI5K<?G )H-_6T)O
M^7?[;MY+TRW0FTMR):=+,LI*G0*S;5 XBT OR4DH)[L7J&)3ZW:6AWS.UQJV
MP&JV=?K7MDYH35"GVA2M.> (2B$94:73[?% <>ICHT"B G6S5Z9:CC&-U+LC
M:7/_]![JO2E&;/J)@L THFJX1ON/#8W<GHU1M?[2ZRD)AFZ+QY;#5EOA OZ[
M7DL55Q$ID@EY=3V?RN,(HE*S$<=51\4?3!O-R*GX%_S.5E+Q"6%Q"=*T//;
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ME11D7/WIN#&]Q*%A/C0F:1GB)J+Y$S%8J[)]HG&B5?SDS^!%I\2NP8 4U__
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M>[G(CGEAC-QS7%2- 7)WDPO+IMGW6U=]0]&YV&#>SR*U1:T'U^;"G!Y"6-7
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M$"FO[/2+: [;@Z^=5>ESOI S7'9.T3?%A%'T^/;?I/ALE_6?&"MHG%T/G+^
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MZD/4M]X 3$^=+V^ 32CO/^W3KRTHWTNH']%H!4__&\!6GRI<$N&] A7DO?P
M F6RY%/4H2ROLNJ2?O '53'?+5F\#1+'\MQ]$9?^IXM\4/T_N.^G2_L,%]A:
M:,8#[!7^$2$5 &_S)0SPE!I*A5/GE;_25C;C@0DR0O7*5XLP0AH')O\S_HRH
MMJTE<OX863; \5&IAJD(9K-\&\HK:W)D-_:1&X<8=V8>-ART*!>.;3GINX/N
M]TO YW?0A).83-N6S&U6I>C(?9".VI!!D1.(8$MI3F)+)9YPI6 &<6YB943
MKD,U\,GG/. ]O]C0O?2SD/XM9:&-U2T#]B2GX#D_')9R>"!?>),?M;% 0B(J
M*8%:Y*+I*)%MWCB; X*X.JEJ9M^T]57_9]^25K&)T[[&EGM;O?-8PF;F7DD;
M=-)XNA(QEJ]*V'9@D!YW<&+FQ&$'S"_)9IX:MCRDTZK]G)#!-[J;GY#LF2B6
MRE&3&)0L'A3DB6I;*_Q$9 )%@6?]5+I9FM4=,"66^^[> _=;'(=\'\T-RPH%
M*;GS7Z[P>JEVCBS3,CK6$-LCK_%KMA:1Z_JF6*)',V%5G $D!CX;(KM/]K]H
M'&O=R"E$GI21+U4(I)UU<6,C<1&N+9B_BQ*,(^!E(]N?\DS".<4IX!T2FWWQ
MUI-YAZ^;6-??Y:PHUY"IVK'Y0>WSH* Z==4$DWH*=*U.+>]"WM>A018CN=O9
MYH@@CFG#Y?.!]V\X2R#!F-$>LKL8Z+[H6>U1<BP8_<"@GWBJB7A&=FQW8&/?
M?^-9GSJD7 G#CV^4AY;GY%I<C)YX>SZ[-QULI\:?PB8W;9J8M2&T56_ECJ*"
MSZ HO?>UI(NZO^:#)RO(;AA#Z/]AZRV#XG"B;\%) @%"@"#!G0&"NUL([@&"
M.X,SN#N!X##XX"2X#^YA2' GZ "#N[OK_OY;;[?JO=VJOMW?^LNM/N>>OGUO
M(RA_ZH-SRY[^3&"] (R@U%I3_14G.2EZ'@1(A_K=H>G];]@?*[K1W!;DY,CT
M[XQ> -AZ@!.6\>T[\IWD<P66LW:>09['L--.@?2!+52K]'T9U^FZV0(,X(/O
M1Z6.QG>CRQGZV5]UXMK +HV_7ETISD)I6222I>14";7 M 4*O.DI7SUC4V3\
MF7>^?,G7%& 65C&DR0=?XR4I%N</@>\H$B<8J;2Q$JEN6+^JT% 3ZM;26[W]
MX+D&]*@2;*&PA5.C ]/B +[.9VN%K95'A[GBR2 .\&VVBN%HB2JBOE"V:&3V
M'4//-0EF"9'QM5"E335UXGC\A^(O*NLSBQIT0B0?365I2./ZR 2CAC ',SY^
M_L!/1T +WZ:IV>HK7_-L/RE ^4=?'.50[!F0\^3>Q\[.XK$[6^4H?!A@0PV;
MTN^!DM&9126F);/I%X7UMN^2GKYZYA,8JU[E?OS)D[4Q>T%H;W7>:OB[=MN%
MH)9G*IDNH=:A$>1 ?NPI HX6RD3HN:<:[H2@FBX)'FXA!=Q_]NRA&!8=]ZV0
M[MG4!1[ZWCL<:AHUWH 0XAF75_^3UXH'DL^VV(YB4Q4$TSVA?BN RN<L,U'A
M7\K9+&^+R!V+\(86W,55:Q\N\" <]/D<$487<<TS;1@TL <09?K8G)*12Y-+
M_!3)..R_.9NORO&^L6IEI?1-$/(7$;<*;P])49+&Q"^+Q'%JJJ17+D"L9\D
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MJK7_+4S4VFK)@3WZ.O<+VZH<L!Y(:R/O!<OL=K_\I0<GZ\Z5[>[4C39ZS[P
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M@/+JH"?,G65-*C^MB.=ECL?]WX^Q=](8TVUP'.Y\^:GF;]$*XK.<A@P7*"-
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M)IYIE*Y_1%R**X^TTI%%_#T"1,AMY75:.EPO=5;E]G0^J*%3#6MEH9G=!03
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MGLX9WD^G+CBU5DO$)6<;%AMF][%)>?]WW==$;G9<JY#A=MM2Z*T.\X:L("+
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M+Y11*T3O,=%KJV <T=]GD,!FM75J"*-H1SX2ZO[<':0U1GJ:9G7-,4ZM+3S
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MYZH>LX+G>V2*>4EVX'-[T@N@BBWT%%0;Y+?VY'KS9&+V O"'-'29B[U&'+P
M&G@^6SK[Y\D@'$U9%7@"TG?R64@]83'>3UCQK8@? 7?B6;Y5)F2B-RAF0?SF
MO:0,72US[6HK^P/4R%ZO+0TJ=(=:;-BY-9('9B\:BQJ%T+,I&:'T#AY>H0%H
M=AV7U(Q+7F&;/(+NTT/W2:9TC\<7)H5&(RO2.K<#:TXW+L>([@YDV,HE\OF^
M!<+)JO[X47GV0KSC)WRK\%(EFL@OSM529I(']@)H="[>."+X#%[C4CW.=790
MVW6;A=L0KOG*"4ZL,0:^2>QIGV6/U)HX@\X;U)0ROIV:BN<;+1LX<_F':T+_
M?*[\]1=-_[F'&$^%P+_SX"FP,=7Z0]F]0+\@Z/AR8-WF!8 '3L=QGCK[3M+9
M@;=P;?)Y$A;:P%(]8O6CM.(4=LPA:KRC;W'@8S>_';5MW(J@$.V5S_+ZYC,X
M?KEG8^:C/2,<4*,<*<)MF>8X]P@>)@WN<$ZLMRB%UYD#KHY.OB>"\YQL/ [D
ME-/4J9> 8:VAW:=_8H7;0=?!@:@"[8<+5PNW1Z ;DS#_'^EU__L)3#=ZRZVX
M*?'?*FQ3E$W[PSXPNU>^ &"S]1Q'F?O[!#8K3DNB%60#WM:!?NNTDU?9/;/O
MJ%-E%]O6:.,KQV]E3A0$::./APH5DB??2"C![DM#%Z0=R06GCF4Q2J-I=#87
MGBJ\OLMH\I?M 7%'7'(<F]@$;5 E'0[WCD!-ZX*Q[2Z,-&5&J;8*7$13ENSD
M/ZBC,P8=)DJO_%9VX7'&$@M6D,M"E0AISMYK5QI9W1*9)K!8G0)N#+CQ-79<
MIQ6[?KN=YCPR&N_;-F4LQU]%6 VN602Q+X#6J3.!%T!F#MO30:#&"V!"$@]8
M$"#^&B1/;N[-D:@ONNN7&C,NEH$2ZY.G?[R$4"JV"/8.I/A6RT)/'R0_Q%G-
M@"]O%#XUUN"X7@#5E<TITZ2DJ"B*T&M$_6NQJ=5*]==:[UNZD.W=+EQDMN8X
M8%@/,=F3$^JI7M)$:Z<V?9L\0ZV^8IWS4 \M(![N>CBVZO7L.$'J:*SW63(E
M+>,;&M2KD=QFM[99*8]5P"D2!".1GW4ZIY1[!*5R144IWSZP1['8\$E PMXH
M)=57KSE8!7X^&  CUX(/K:NI=&\#'K7'WW[CHR_<=3,E!6+@3F&/^'RRO_K6
M$\#X$(9J>-0O."/*7%NIEE64[G/CEL?7]>"2F8/ \&>#;;F,;K5:K)^/S/-R
M3F Y26/%5%MYDZU%-6"!GX99!;</@37C 6.=U1-_[AB<C(B6R>:1R$F<C"X;
M<$IPFIX?=!6Y?LJ*:="91$,<S'TRC-L@2!$EDWJP<'L#(10F):GWRHK@5!)T
MSYXZ@;GA$NYOWG%;TX)GYD/\<S!;M4]TNRX'QNV 59O$JH1A:T^>7UH+K;BQ
M(9M#-.D 477&>.R4/&%N<2?I7Z4_3U\ O8,;U!RWH5M971^-D*G92*NICX"?
M.C/J$Z*::F<[EIQ31#/B5M<<+<YN%T1'3-;VL03==/TP#S[A<B%6SLD%MY.K
M38#T&OU'2Y P"F&JL2R&KS8; I$_%_#L*J04PU>VW%(78!'4-#PFYV-&$J#>
MS2 QPH&]<1DF/CI$C9+]>'*5LG^F=12ZJK,_1'0 Y=4X\I;$J=B=-E5+"*O_
M8+5X >F0QR#+3YK!/Q8]W3AA6W<L^T;I%%'R9\/*Y$22/+;RIC9 5[3V?CV.
M$?G,H6.K9VI9:K4MSOW#:F?\1I/%P+XBK8%W[60R>(G3S3WCL6JE?#(*6QCO
M7P#8RWM'J;L83&'[_#/!FJ[IV3->(<ES8S:NUL43N5X<0PAR979ZI@3L>BCO
M_ CO7'AO',8U3:)<G_UA_:59J=DC37U Z/X-R3HB4<-SN9@QK%3 R/_./TAW
M:WB8<4DOXC3*F7#8BB.AEW;F:$PC,;CAHWS"V?:?DS98 $\,M?5A3EG;R<<*
MT%]AT@?>L>Z/EN++:H7<I)^&,&8/-%#E1E'5Z>8%I=N!?PA=Z,F_F73?'^>_
MAS8_-E.7)_5;\_P>Q (NETO8:FR<KGO7MX)3?WBIM+U;,EG4.!#LL/H9;#9Y
MQO7IMIQO>&EXQ\'C60T\L=2/ 8ZYJ9INIZQP@/K3)R>39DZ2)$^UUMPREF"Q
MO/OT3'5_1VJ9<^WST\5]_@7@X!]!]RGCVD311H13S^$:^J!<Z&4^(&0[7KL\
M9:PW<3Z^<S*EZ^V[4BGFH+A!E=T=OVV67)\:^T"I[MB#.A.$(FI ZY?:6O^>
MMHA.].J.$\W*4++D4?998"]@YB?M^JTD:<9&L]66\-$HU,=+YW1@CT5OZ,-]
M%_J/#R?3;5MN^+XSLK)$*>LU!EN[OWR!AUVQ/MAVT[%T%P*+N)JW/7/O6](V
M$1A$LD=5<4C_0KEP6ILCK\V$JA*UJ2M=Z=^^;4W.V9,-4P)D95 C(<3<"R#&
M[OX%<&9*]IRZ^P(8\)$Z>@&<LU=2W@8V/*Z^5F':>L-2&?(7[F],HMC:8?C!
ME/'"RLZ<="Q"Q9 26TG/% P2'#[GFC(B]2BZ!=ZT_O P31U-&)\=E>+#/-/K
M6+*M*[HFKE,TVS@G5\<2%3W^_=QF5DQQ>O8"B-I>S3CG?*T]LSPO1I^] 3N[
M]>*UVQLG-.*==M$$S66!K;:L3,6C:.F5T&K=QE5#'PH*B*7N<AM"5PL:S![7
M=E:O0:$;!L_A+X#8Q]W_]]Q9FXZ D17&7$TZD5+P3]/>;1>^%8Z5':<>J4LH
M: 99P$\_RWMX&G8\Z6W'R#P<%=<(<? ]/ST(-/B%@;5&&W+V5CCDAH)9,H2R
M.K]%\V IGB@.-K572&KC6O/(*B09F/N,V:SUK* Y[1I)%9DF/DO6/6??N_0+
M2VK,'$WXO "H2BUK<AM$[@7HVNZ@1">"\L 046 ?V2C'U\9IL1W)G_N+1!(<
MCY*K4C=1N>J-$>J6@@DR(O/T? *A/JSZF!2P_8LON^@?QQ83D<C-$=<"GC^T
M,)>YW?-Y5W2$-$3@.?0<8=&,T9WQ\8,HZ?LJFDT8%&?O2N+K%*U.IH_?=75^
MD7*I)0P(/.C2B+I/[&_MG/%B47@U7&'G;&F53W:^4JOW!WKO7+='-91'CQ:O
M:.4E+<9!OVY_'_KW%J@XDK'6\&Z64_3PZ.3O",L;1MM96_(1WNV,)=6*]Y%J
MO<0F<?(D[ CS@[:5N$;39G<H>>4PUDS)WQ> 6MZ 9\H6NW71$*^RUAQN4_$?
M#N^47S3_-)R&MHA9J%;S_*^/Z.-]ZAGI[6SAH1UR19][D!A7/Z?>EM_C$E3/
MB_\<K^NM-Q1DIOV+$)V"DNUTD":I(^JKXD%@D,-$Q2WWH7A.@Z0,?7,G3D!]
MB?G\L3Y7A8;JRDIB/#J;64J%;&IN2_PPJ7YQOCJ"5E(GW#=2&5>P!=YVPD',
M\5M#;_&HVP[XS%AP^ +H]PN\URAX 9 N_ LK7@!#L);0]2,5I4RU&HQ,@I&*
MV1XC%5KIUQ-TS.KR D 1?;$W7Y6\^+Z8L4:]TY YHJ:[XK@:R:XY61*9*.R[
MU^ 4$M)@?1SC&]3;:SCHB5NPMO?W31P^R27S!BU54%/;W/,=<&V^ ##&._FW
MEHD2R[.JU1Y/*7(PS+B8:8HM6;V&,>A<RH&N@D(C ZV=\9;R*=CMKQL"B?_P
M59@?5."=5/0S?3*R1U8HRVI+,B)N;/H6_Z$>954L*CY6M=JJA]M5]HX6+$\P
MZUEKR '1<BMP2N-?/1[URPW*>/<@^&:SD+DM:C#O=YO%CQQZ%=$W]%) CXNE
MCT93ID:/XB$TY9=FLV@7%*NB+P#6DB-4%6P>T E\<(BI4X+4"FJ77GU\B/OC
M.MWO>I.&)J%;U*A0$H]E*3LJ=O%IKX9=,!7Q![?\X]S;"<X /3-U9\C6C!1Q
M=D.$Z@99/ON^3J2HDF4X2"= \;38!']J<8T)[>V?S=C>$#$ANJ$<*##0>/'D
MLRRM<PW'3%E&LQ6-&"4(OD4]LG*;\ZC5# ]<EEE%?I6R@;D)XB,\5G!B!#*X
MM3,+2NKG]Q**;N 9:R5#4(2[1]#I:\=@.2'4H=2.LENB.G\-9NE&%HRJ96P&
MVU\M#'^W/XI#%#03,A)(.'9A!A?K=A+H6#"YDHG J?JUUJC+V;.J*4B-U3^2
M4RM/MNL9'N763Z/GT:M\'$5>,(.?&"VX71D:S7#I\@;AS%+1CM6V[5AFD$],
MC1KV]_,+E'1C*<DF5@^OH8!CIK_,2DRUX(RQ9OVS.6%.(4@9)J:\*05=FU#.
M-5 7I4/?P?NC<UYW 3;:_&8WEU'UW 1%R2TZ.E:"+,&!T9(JM?#@_GIKZGKO
MX78PB[C83/@ K_9:?7(T'<)!2;=>L.H/>^!N+5=J??U[=ZS(L</9H!;*1ZY/
MS_0O #+^)]<_MR?,7S9(79E=,QA+<S/H[7@TZ(:KY@9M'$0SHUAQ11*#6M'+
M\'UIT"FFIXW1ZPYK_]Y..;4EVE5,H_&'4WZBCVEW.&I:;IU+%KLCW<+?I)C8
M'21,+!.@;F,ZQFL75$V?_+0R7WDTCEF>,>Z'<UEQNPOO)!)#\,Z84AI<BZ^N
M_R9*KMC8G^F1OO5U[3VNS5Y;3SUSPBDDN(LT_C>_$<\;3R-A@X-A(!N0XKT0
M,9&RB/[UN/+@MP6A8B\5E0 _19IKLLF#T][#:=E"F88C]A CAR42G<0=D0[Y
M_>XJ7,9/P\0&J*G"ULH3!.BFFU^"6YQ*#7D4/+&SJZ4G=#RW=84*-BD<.:4B
M*V*S%4^&#>95JK_FX:9.VCH,GHRE$%TZ?RGH\X4W#UPV<D'RFY>O[&:77P!B
MO7.= WNVM+URV'2!GTS28?69CB2MQH<\\,C$BU&UBP;TI2DH*F62$D2EX)<7
M2#SU;8UH.P74X:2.9=J%J:0ZIG T:K6FN?NJHR RF."Q7R C:]0A<'$-Z6LS
M(,L%WYFEJ!^/O+*6"-0EQ+GA<6ZL."C-[\U M YE)\GC1F(:F9XDMTX,[BOP
M/,8*3MP6N@4]RFCLU4H59-J>(;!UE5TEDGOB39P:?R@RM3M16HJ9^CNIK]:_
MU7"(YX/%?X\&3&,N__@7E.T"5_F%FMW20@.)IGHY+'#,9Y:*,F5$Q5A:AM-+
M#'Y6?U*DT@FO_6[0GJ+4HIL UE%JVM_;-O$9^/,HJDZ+*D/*!7T!=*5W?!F#
M'&Q(83 X_(M$ GW.D3O!3D<^95($+X"O1VX;],R]4)(3KL!XH;C?HS/I8JVL
M=\1&/NK]I-FW*Z\->VAQ?QC^^7-^_E>:4OT&YVDB,:;VL0]A=JJ]&/KL<7[9
M403M?FOBG@[2*SB1^.")+ %9MWA,N"YU?*\65E*ZCN2-I"*#-.<)D"_C+,A-
MZ8]!PLI#'J9(HDV54MU>/<T37@$UT[6&_.<'E,S)TV^^YT'0FI^N7H?==1Q>
MB^B%;Q^*6ESR*ZST].]NAO=;?4SJ[HHB/(!BFV,+]0],#AU^J\CX03\K>]9H
MAO4.\&1($F.\B- ,' P73XX&[=^KH&)9^!0MI/#LW5AO"^C(34%FUU("AR)D
M?Q6,(*]-]NOYB:[RX/,^2U$ND1\SO/^<'J HZ+@06Q.D<6LG,WB(DBYM?=T]
M8H-,^['^"8RRBF7F$^NFAA2 0ECB[LZ2?4;,HY&,:,W<TA1WU$X\]PS#3N<L
M.&D91*\>?903F'Q0$.]Y 73/]CX3KK_[+X,P9#1(=T+6G^]'P!!SQ[.9\561
MV6P[U6*&QL5RG-)H8?J8:R\698)\0UX1AG[=K)E"OGAPA\?>E:HD@EW">5]P
MV#6_3^_U,UWV[E-QOD7HVH'%"^#MWYC_,F+Q[RC/N!@/HQ7;\7RO)CN?S<I]
M77PQG!T[OK:>1.8(?5@OM?X\4#FG7V*-C%S6..NT.R'YS:F/&/Y^/>CTC*ZL
M'4^5Y#3<GH7DE@XE*.XNXD/XWUXJ207*JZS""%-1Z["3E!Y6N29-"J:NA_V(
M;TMBY?M':R)+I)/HK05G!'"I8XH+C.<7@#;.+3!"X[\,W;NI;L+4G FWU3K?
M:/_'KCXD38F)NOT CD7*H8:B0%66S"-/.F4)-O>CO\Q?58 ALJW6@M\ 4YE"
M;4USJ./\NM E5SGST T62.BBR [QTW,9]=]:](+_M+^[63]JCCF9KOG=_& +
MN;H+EOATC6^WP-T9EEJUW/YAXW?2W#'[O9.9J LCR>L6>]N!G:\TC I:@K5)
M_/EW1$*RU"Z5"W3Y9O^741JB;3NX$ZO;5A;8F!K.L790GA)-IXDZ-KJ1:OWM
M!E.$!&-^3N;'HG\B^3'C::O-  I'#8RE6$?; AFQ(ZI3(U/7M-C=RE8I!5L#
MDN?%/#=/;S+1&QOM/J7QWX_'%ZX<8G/'AP1RA".+L6-^<U_V0'QF 0O?74@@
MIWG_^7RLV:L0Q[K.*#1,$,;\1[E(<$W/-BC"WYMS1A=DIE?RL,04LJ9["0_F
M-]*A["-4>;M?%.M0F0DG/ZS,.8S?)'>)?X(JT4D4!V[Z-"(2O+ 38L@=T&0_
M@ZYO,8Y3)/D6A3H3YIL&B?)"<AS0S) W[[BD39$=_BBQ?M:@R3?^6-26J6LM
MYUNI+,&8-M R\Y8U1S% ]'T9_X# P,.FF)6QE;'=#%6N$GM*DDWR.2X_9J+7
M$'4PTH8B^6/RN1(MJA(U+?*'S@D/Y,O7?7NL]V4=2D,UJW>^NQ!!N+=XPRZD
M 9>SDJ208:O=RYJ^Y'=CH=FP!N+6X[T(92!QIANIY,] HD6%:*BI2'$>XMM*
M;S296SA#"K-/S"EXD1Y&L2.F8/9O+0H7U$/T#"E"/N!_;+BMR)A/XK)+"24E
M3N)6^:T;8+;#0V JT?=A5)_ ^+02HH6UZH#;L,Q2UCHC1ZP6+X"ENZ;FE0=:
M475I:ML5'OB?\D+#_#!<FW0E13)4A=8MY!M 2Q[R8P:O"GL)J76*C.2KY!-_
MP-//(_7FQPR!_YS&BQI0Y=HY[?J72*M:3<QY$]AYCA-)XT/_/*1KL9;AJ2Q[
MX92N 2O64Q8<P^38CE[D:D622!>&G3,<]WY#\!4P3ICA5Y#HH-@FS)8H_:.E
M7Z828_TH/9D2 -\0_@H*0#FT!DC1M&\T_C^]'L[:2N0J7P$MC1!D:\";^4O
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M<A\V26'K4B:')4&ZY:L?1.E)6JON)V D3!QD8N+9)[=/O^[R)>D<:%1?17[
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MG8(@((V"A(#(?\"CYYSOG._6=^_]/_=Y6#(S^UWU6^]ZU[OVGMF/^VSR;!Y
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M%P!5]L?K-QG]KSS]&%.?'Z$)_8K^AU@4.3S]E;J_TA]XYWKG^O]4X1?]WBX
M,"_H>=FAGMO;NGK![#S_8;>"X'P_PSPO\3^4%^ ?ZA @_ZM>?X2A]ZL<+Z:
MZ0F%@,">1E"-\PV%\B<<C L9\H $^<*Z&*@I_L$WEH.'JY?;GUB8KAX0!\BO
M7JFD?VZD?<%#C@F 7G!7%3 ,[ &$@^TNHO=U^]GJ<7\HGW/.)6HN#HS_"_-'
M\_* _NF$<9'\/W,T/1W^?%+!!$+A!D"'/_$(06"D'=@'KN:I:J"I\;-M8?]D
M_TD9Q]'5PT\."G'XF:DK/R:O^I-]GET[L#W0ZZ)OX2# 'O"_43?ZR?ZS.IZM
M@X(KU-7C#\DE_F$@K_)+<!Z&EBOL_!,'[NJ&/#EY@O^8.%PH,I%_X>+;7C3
MO_#Q/,[;W#^P+W;0C1]VY^4L\QGP.Y_XXA#E1^=!)[T8G2\HQL7X7!] \OJW
MA&4A7T#DX3P 4(=\D50"* $H9Y-G6P!\.3M76["U@B8 ]6P;0'@Q M@%G]N=
MS0#" /C8V-@XV/@X./C$>+AXQ&17\/&OD%%>O4IV]2HE,?X%_?;Q]X1"@(='
M0$A 1$A(1$I(2$AZ_D9(^L.$^#_BX*P50(R-##X+#849@$J,@D:,<C:+G"CN
MV2L4&624&"@7]%L:T0 HJ.@8F%C8.+AX*/\H1 &@HOT4$@%0T%'04-%1,; P
ML3'0\ 600F(T="82/@PY7>!59O<0?DS2N*=5\BRL9'IMM@*"'G>&%+#8XO4_
M+^R /(7(LZM#KRDF&-@IM>? A2F&#3^ =VO".D:\%K\H7T_,O5N;]&IT:2^O
MKG-L>=_('A&>G%_?-?[Q0$3%V,'[WJ."ANZ)E4-B "HJ,EKTBYBP,#&$+D)@
MXB-!1T;@SGP5@S\DCO0\@C:]H<\"K+8+'G?B%?3)0)Z".VR8YP%@71-J'T8&
MD4-AIV0H# =_^!7"/X_@^N\AG$T#\-$N,(D!,H -V*JEM\0&A4[3N\U([N3Y
M<1V.IM9#H<FYB.^ONZP/ JQ5N,X D/W25R<J%2JGW55Z!06G+N1[)>4(\\<@
MEO*0V/&J@>IQZ5))<>_IOID['V&])S)3+4,CAT/K2Y9Q:^5CK(F?3U6N;'C-
MRI]H^D:6C.0N"5RYX6<4HT^SY04?<9E,MI5^[%>ZE[&JB[!L6#E.M7HR=;,R
MQ>>)>;V7=2U^19U$OI\!A46'YE1V67E/U]YVQ<'M#8:<;K#@XHF,>5_S>*#T
M/>-1OV2*6QTU$M)#RD(L7LE$&E?6><4^?>_0H9EHNM7D(J7[Z%-'S\R:R7AC
M0B/,=?7@^*7*%P1K >[0?C]+@=<WA^HN\UJ17%/SDJ)A[Q-G?R[/T\@]AHWW
M<<>:9X#YEVJ:IK.N1:>>:_A!FG?G=AWSMIPYA5L:O%2 +IUSZ^PGEBYK3YSV
MIHR4GKP!'2=_CXZN?EDJ=6W<+^F=Q93C=="]X2L!Z^^SNO2=-V\/5HRHGMJM
M*L _3FS19*!GL#9T'*;%9SK<"/1H*]Z,X/$R:6RP^\A_DCE1%WD&X/3S.:R+
M\9HR:;X-:FFJGP)+-ZR^S/'SLN[M/_[P_<EPQ:MN&4AOY?MT4[(00VU_EPHL
MIF?T4<W%KZKVIKQD\O9W7BX(<^>Q)NZ8!SU?DB";P)NV.!1AC]KC %VI" $*
M-3VN,-I47W70/6%+AO8T'STN?B$9,SQ=_+;B]9M6BNH"4-.'UR\U>&.T7LK?
MLP3R%&U6\-=_W,>_K;*7<O"2@?P,\-6JC#5QMZYA(R]0=QMT6^<$MA7#63.:
MW9]A&/T>O-U USAISL]1G'Q;[#O>-Y+4VQ,23R8@+D$1!,*$,:!3+B[,<<.J
M,1E$/\>)U$RU^;'$[:(U[@QDO3P393#EQ)>2SBR*[NFAO/-M_,6^'4,EK<;C
MH]Z&\5;G];>G1BO[/)]?/CVU37-Z-K)Z/!2]7>>=EPBMCW@R1!47WY_23N>_
MWM549/\Z@CO0VQA<WC,5_"V H?9[@6O1!&M\I@#[&6"1)-EB^K8)Q)=LN@MT
M'"S\>GK5\V;U=)&_AW-%WDSJ^N;>C98S0,WW]*/B(ZTS .7B399KQ8_IL;+'
MC9R\ '[1@0B@/O@U0OEX)N(@XHMS=WV]:>KJ&2!TK[DV7K_W(T-Y8P;;2V#I
M^Y3-=PTF>*F@%]=-XQRTG*5'0#=A>+,'3A6G/-/N;B]3*VY_D5NGD]D0\",K
M<Z[>'F@HLO9,U^PRE_/:["R+>Q3J,%DO0C47+6W/EGB<69%]!M ZYMJ,5]/&
M0ER9N#Z13K8B(+:_G=]E7[GXL-\]4-+,B:<"X:5=P@:XI$NZI$NZI$NZI$NZ
MI$NZI$NZI$OZ7Z&S!9D=1SC<39R'!^;)#3S_B9$;Y.K"XP-TX^'CYN4!2,KX
MN %!SF XHRW8 0*38O[4_)*9$6(GQ6PLI,FKZ:8 =H2H^GF ]?VT#$!^SB Q
M.V89:5Q)'W$?%S<7,!S(Z.,"A7F*^T@Q7S@71QZ?LWF8&2]4X,Y2S!<_;#*:
M:.HP*KAZ@!F%N(6Y0+S"(HPB8MQ\0B(B@B*<C/R\?$(\O (\ KQ<_ +B@KSB
M@OR,OQ&S-"[R7=+#SEY<3U'Y-SCD2(KYMWEY>WMS>PMPNWHX\/")B8GQ\/+S
M\/-S(36X/'UA<* /%\R3Y8>3GWX4P9X@#\C%O4S&\S'0UM4++L7,C,OX!_IM
M7BYNOX#^-H%_9V0'^F7CYN4!O0C-#L0#AH)=P#"X)]*.[V_MW'[>ROY[R%_B
M?PJ,C%93\]^.U\7E;RT]X4H(^+]MZ7G^RSN/'MC3U<L#!%9"(*?"\O>N],#V
M_QE72/7?%^A\C9#3$%?P  /AKAX&KJY0Z1\%]/N-?@5]8<8;QA"8G:NW)[LD
MSS^J_YTGL"+R)<W/R\_'Q2O,Q2=HP"LJSB<F+B1TDU=(7(#W#TY^:/Z##TU7
M.XB][]_X$.(3%Q+\HX\_:/ZC#^2VL /"@?\A+W_4_8,?.Y"XO:N'"Q N#7$!
M.H!YP&Z>]I(\OW/_H/JK6L0O;IL@XP)+"TKR_!W[SX%J:HJKP3SA0-CY'3-I
M)(,; K$3MP?;"HB(V-MQ\=D*"G'9BPCR<@'Y^82YP/9 ?GZPH"!(6!1\$?N?
MS?_B6M$5Y'6^"Y"R'PW#SA6$=/][6$ @""P@*FK+!0+9VG/Q\8%MN43!PD N
M.S$QL*B@F(" J(#M3Z _./L+T(\;=T#H'W3.YV*'!!-15N*34U"2EU=40+[S
M\<D)B2F**0CR\RHIR/,I"PK\=/\W+OX"HPKQ1-:=K_2?-L)%E]$'N_^9^U,
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ME(OGAZ*@H92AH1#_?'[H*P##^<- 4=$ :+\_2!@;!PL7'0,3!0T/%:F@<_Z
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M^+*1V@?[$L9@T%R]+^NGB5A#R3O3="REQRL59JO&6#<'4OK+[G?&?YN <-]
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MN[A07,O_P1!?V:0G2[BO^V-.CGVK:I=HZR(.T:C3VW8BTYQD=.(9!'><KIL
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M]>F;KB@/N="/;S**<T3$<S'N.2-;0_GT%K([4,Y8U@T(E$^OT#<B.\7$>7M
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MN)9F/(MW&=<W7K<+<:RSX:N+O6LCV3TEWI#1QU.VM_2,B:ZT9WI4 QMX>VN
M(3EO_^$S0"@ >QM5U,77Q#XROCW.$D5%]I1",E@WWFIPS[7N]/:=9]#$K@]9
MG).*?,:$5V&=KQYOZCPD[BJ?@^7?;Z!7K#?E1VQX\<9ST1;7?]\2'.#'K,F@
M__)V[/L#GX[[^VF;:+8*)T=CV'Q]FH2Y/1Q')U2<'_M153LX3LF[3.]88'_F
MQQ?%SLU8D,_1C#3&_#Y'67\2/+E*IY)"/]KC4;$PL2WBMB$D7KKGZJS?O.VT
M9HM5$%.<DL)N>?V:SU/!:<70/EI*=<K.JMT=U@_-/2RO9ION%Z;JV1XB/A..
M- 8V%DC.>S=T=MY<7(#4M1%LB(!-#LRK1!#.IDO".&:*S!@+^;KD5>RE09(G
M&*\%HA\Y3N!5.W9.'0[Q*=#%^QVMR[?&9&K:3&A_H-O&&#*%#V&'.UI3>+W;
MSS(WJ>1;IGHOE1'+T=E_7,_'8CT]*ZN2(7\U^HZN$KW2C*V@EHVSPYV/NI9Z
M:'9O"8,402V*?@_HDV5(NO""]"-$"B5NZF7+ (Q#3(<0[V&F_3<&UD3<"&]R
MP]H4=(=F1-IEQT:?BX#?Q3V(UP<8"MW6,A0^_&"[:Q=59-%>&NZ^?=>P)(Q.
M+/)>$B'YYW?<P=BJH>284R\<)T-CHY_<F]I57?^$VIL RIZN#]H2"I[XS"9@
M<.4;^RY>2)G_%:TQEMF07-K)*0"/;STY@RU>>+4<CO16-:09L^J%(>W]):O5
M3BEZ&6/EKZ9?\LA0%Z'->*4O++Y4^5C.&;4^G(YH.';0Q%TKRW,WQG!13U26
MEV?$WUR-M2_J!I<JWK)6HYZ\59:A>&I+3<%U[V;M<$"WOHTAZT!:P](<TTF_
MNSY98#)-MT5-OX5SY9B+?$H-4V;+6FS@2BB8A(C8<B>G/A8_F5TS)RENCUIH
M%#L._$CI.7"!'L5&F&UG\0Q0U>(:P*,EZ=N=?>-59W4-</AH.5 _KG2^0I6P
MXCYQN+'IV*@5[V!I4S6NI;>>[I:YA)4H-X2*=J<KU12S$$6W2I?83<IX6T:W
M.6'2K^7)9FY.H_W,%.G4;8;=DI,7^B5$KP<XE@CB=&>F+708FNYQG(I\HLSJ
M)'6/+>D9 R>D#72M^Q D%K5ZJ'9_D-BH=;(+J"VWIO^<BH[%GLA UL@RK$:9
MFA".^98&^ZF .A:W18(W*T[$NUZ7[A=NS9H/6OI,X87TBSO7NK&=!+KVZ^Q?
ML2*N*$.X5Y6O!8X_0,/]KB%"I#FKK(?'EM*-Q=P49FM[1Z0*)79LV*_:XX/!
M:_)^ULT-'C=BOQ"6,>ZUH\VR+1F:6-'(B,+!\M0!1JFEY'8G\%-!MOO;9N(V
M?636JHN=B[JM_%.8G^@G\+A[YX42&;MX(H'7WP"U&VS1D[ZQZ]PWOT)?\ZP9
M.\PR<? >Q!6[%\=?%M5<G4$%TY9T%1JXL&?F:#HHMVVHVT%\JWDV0FETUH!(
M.["F7G8G"%9J%4*_C:$P\8132HN-:D/R82ZW;=SN=<+82;$X)4X5](2VAX4)
M-]"%C#64J_JQ%#,)KGT/D,)XW6F'^RJ5C],B9?"F9_<86&:S^3;?"]J=,X#?
M^Q<1.[G>!<.B#18KLV$&([JE$M)V%D#5)7):F#P)3];@-?(Y/WJY9/>4)CPT
M!GIQ-_J3P-JGK6S=&L^/][US6WBS9MWK%@\X03U8AB7@5:,,N=AQ\JOL&L.C
M#PH/9-!N8=)T?^\2EF)ZCV*M3L9H&'9?6IA_T$?_2N45A6!?5_[3+/&X]QU/
M9K;GC-:]7%9;WC0VEZ=M>6 65#@Y#JIY6RUC"+(<?"TLHOGP.AL:SVLF&&8.
M>JK&O<Y3C7X_>JHCBXNZ>]=TT)I'D 'BAS?\O8M-:E-H>>RDAY5$\GM=PP+:
M!%,*W[4M4A;F=-G%K%2"D_2V-SV;1;0\X5K&NIC;'IF]2[B3JV\SI2OW1+HD
MK4N-6VD(\=YGYK6S&M0$Y3\I67G#FM!/2ZR@Z3QJ1NF(YX;6KEH/O\I_[^ZM
M*%X^"QH=MQJJ=X0KLM,J!<FSSP*\DM,:/YF9:CTW0PB*Y>9K:S;&2L1+A07V
M>G/<L],\^?K-)E2^HBVPLE?T"-!#'"'-_-SQSEL&7+<=-U;S>A=L8</T@[+,
M6FL+QV9C1];EZFD0U"7*4,[%6TW3O;YI*\I[ @J"@J0S&[L!)S0-<MG8=4YW
MN-)%U 1I&F"9][/NL#M'D2B1)DP8#*M)"4THCHQ8PD<L0);ND2#*>89;'_'5
MZG7CKFEB"YA/)9E)0R/J^Y:E]G4E"^\<WTC^WBDXI"DU[3#3TO2I(G]Z411M
MS8=6#1,2'<3IN; 68'V5(C)=S/Y)6T450U1Q+RS\">&3ZD<-&@%^WP<R4TY%
ML:;GW0XUZJG7(D18ZM4$$38+Q7C\4Z0U^7JW[(LAU51JDFOY^MKL)_"!-'_W
M&)@4X(2ZUJFS6F-*&#:430T4I*Y3$MZ*TZ9O>9![QVPUW@\T(9T&*6]:G) I
M 'QY&0=D^)9!=@;866 X S  EM+O*R[E3./$=;$4=%9:UB2C:=ZE-O"_SKE_
M4.,VE/ZQOP':;'D;7%U8D'W?^9BMOA$9'^=]@+*0@MZ"8N)8N<A8>:Z*0&")
MBT%7BCXVL(]C@=8U;*3KJ_9,5&5FRLS$3$460^ODD@]_L2@1.F_>F/:"(3![
MLLI0L::^>9F-U.F.^7:F]XCF:;I+1N#T1D-!>>, X*,HM=A,LJLEK]WR_&GB
M5&@#@8YI/UUR5Z.QO7-A9E_]E 4DG[1/8BUC)[]Q1JRK<0\MSQ_[;H)TEY$R
M$P73#:KR)H)X*0#[U,ZQ\_;!ZJOV+5+F$<O &7\ON3Z?[F97#61"LOR"4$8=
M ;B@<9(4.9R'[BT&;@)RI?OT3>FNV>FP&B[=#K#WP%I!"V*6JW[@&%+ON5'^
MK)7!7AZK;VO6QN243M A;G,V?P@]HP:4(:*].M6DK4DKZ!I%^MY2%Y9M!HFJ
M/UBD?S9/O6B2B2NA#WQ5NMU$]05K<NKZ+9<U=0Q[+ZFGAAUE&VTFH0KR^ +E
M*@?1OM?8I<%T=EG$9M5.DYX^Z^K9R]Y\%).<OLSS4 HKPT&G>C(K6:8LTY@8
M0S>?-UY80W8)"%E!96:"7#?&6C7.3,L5Y0\F65.:E?DO1?)/BB*7-5_([J>C
M8-5C+]JT(]HBU^(G)STEY_/U!Z9&6 -UWTXX:'RJA_<_>32343\@)>6YCJ%P
MQ+#C /*E?32A WGBP>95H(P2),=NOX])8:!0F?>$_8Z:%J5JYH1PKDI_, X'
M^V?>,T#2.*V?.-42.#'1\1WM;$U<JP6@+:>#@)[VEO#BW8>V@XY#6R1#F)$J
M57+"I5-U*AH@1?,Z6+PC8W)*UX.\_"9GY%;J!FR\5\IAP\>-38B^PQQ 3MZJ
M$!-V!6$C30L:"L"]MM 4H[(0$!0!S%Y=L A*/ZEJE=Y4:77BF[24N]_J?5R1
MLR!*W8]&[[AA#<J@JVQG4%\TI@91\Q3WNM[UZJ[3<(D9";X-6'2?;*UMZVJ]
M&X.ALO15$8W\E6IM"W0%W,*W200;DGD$7>'PU^U^*3: V!_P;!5%8QR,C1RB
MI68@)Y&JHNMOL.679@L5Q+N9@=#)YC*K54._7X3L'\VS@F,#1Q,6F^6>D6Z$
M^X,+GPP=F\?Q,\K;7 MM:_(+10T38J:^#PPIZ;]'] <-O)S2'4C_/O"R[A@4
M[*X%P+A&/2\8>R,5X.TS0?CJ,>WKR@F3$:AK/BU?4$1X"4AS)VJ__8'+U@SE
M#'UJET"KF,*]*T2=A6V<5'C4G70T_/1BQ?@I-;!,J:MR)<J]N;--[(M[0ZSZ
M(YKNQ\[E?*TR&>$$L]_S1.B[/?Q$^C6Q-X=:WNXYU\^X)$\W]_FZEP1LM9R
M:=G#OM2?.(@?;SW1$9WN;ET5<9M&)\ZZBS@LOJE;6D>=?P;@CO!O (6Y302V
MV.T9SU:;ONW/?^AW4M?EAN68!LE.@[!F/F!-3LN/5]LH?Y"?F;:(_(:JZ1X%
M1X81Y36![)5>77S()>X2Q4J5)\!Q?I9$H_#AS6A<\V#87466#[KOONS5#ZR]
M$&AR$9K,J3T<0 SU;Y;7ISM(.+<(/%X)]D/ZL'0O;^QJVHAT1G8O2N0H1@-9
M,6N1((9\OI@1RE.^5LF.'DG.R+N)M6'RW-^-A"19Q34^ Q[I$:\Y;VQIQN5-
MP]2*?0X=1A1I"\JE/-=B)B31:J\1L9?I#K:&@.M<,PX4]*#4,F,$B5V-^G9N
M:VQNF=Y=::" M2C/>J$)&K\3]U6L25'5I]B;DZIM'V8^M1C,HKQ.YU<!"T2"
M)#83[(9'7+Y$@JAFQ%>@BY3=%?FB6*U#J JL.>ZHW;ARAOS5A5%V4P_5N3*\
M1C@*TPWB1[P$\M,@2<(3$@Z67A,3R+,)@ J;1,@A6@6/MJT-@[?F$#]5V*EF
MV;VI&&C\,"O>24R?IK3^ZZQ+P\Q<<;/?<5&]!]9A5EM1BYLFWVM]UC4Z\R:F
M'.7C%H_PE!%JQH6YH@6ON!&<@BA]7<W:"9RU2.=(2$46K79_W*>&P">;3$$C
M24'0B!-SAH: N4^W^_>LL48"6LX ,T?2/-[-!R\";UNA[*LR5_G:G*+WY=C8
MM8^87A<GB,6BMPN*IED9P]BS5VI./BZ-OFV0U.XS*WD&<*]_CM;08=14W\%E
MSE0BR13>" G3[X *M]\FIUG =]X!XK.=QF O:L<LGL:X-NS-TU$VPA5IW%^W
M*X& TUBZ?>UF$9B\_NY.+V;F=G1[!)T>:B1ZO]QZ-EM?!&UY7UON_7:C5=I2
MX8-V3'72BP@5>G7,O$0L-3ITROD3=.&NR2ER93+G9^1%#C2?(O-#$_<&A&<F
MK*??%M*5*Q/T?R/K.3!E#S\#J-TQ=;PWL5#1+'$J3!]P6S?\^[<5UWNX 4&;
M*ZZNY8$^6$R(57$Y^X$XM7X''%A$^$9!=@_WPZ85)5U3-J$I(3U]S9K\M4_E
MTZ[EGN63 P*/W0BSI2BC%._-:QA)$O+?Q.-81&-I-\%@N#O^]AGX<X\SXDUE
M=3.(AB/_ZF'1DXG FDR4MS:";KG\HR8'"N9@S?%^!(&.?;B1_LB2,;N(IN!N
M_O?9P),5:\1<RJ&#=,H\+<M.XV:I;1N84;Y706S@F1OKU_IKF*(#J?LC-WF9
M0Y.+5S16Q"8D\NJ]!@+=UUJE!X-#NL*%\6CQ;P 09BO*MO*$CC= F@*/MS)H
M>&T?$N@@*TW" 5EX5 .>CQ>1Q5_JC757)K;VD?1]I;E^K((P$[79[E?/8JMO
M40[P)BC<$GR78+<3N4(Y1"'N'.D@VB5C\9EP,(4WOTY%GQDC>:S%>ZHEM[OV
M=C$->Y1;OFY'KF&[J3XU).I+08/$HJ9[0T4#?;![BM(B\V/@?.,J4_G^"'P?
MWBI[ !,:"?!SS:> S0JYYW\]%4'N+&1C%GT+^" =VM[;0]F/H\B\Q,:\UPZR
MJPC&\6:DS6QIF:5,M<P.,X/$6!P[S?;Y+4Y(IYQZMDJI -RP_L?^L)F6L'JZ
M+20AANXT$35:^65,-<XH>8X$JH+F$*!4[B=0/+LZM3BP9.<(UKVEZ]$,^[3\
MGKIQ##U(<AGJ4DCOWUV1\+W<5S3"]"IAQ?-,R2N&3["HD[8D[KL0>SX5PUZY
MBV7C1T/,LG\?.A9_9&H!>_2JH$9CHZ%Y F!"+,^E$,EL>3#CV&-.86?EFI_.
MWA)ETJ#;'U6K;3VM[Z)W*V C_V5=O7N4^_%*L"RB1=V1K:WM5F/$'.K<],ZJ
M05-69&*QAF"<.;'I9B;!%6P_S&B+;<X<Q2M3L9CA,Q(<DBF"RZVS<3:A*D5E
MK5)^LU\*#&!<O'S^:=9L;G=3CM6LNS@67:'8@&*8*C<+."&E<W:[;=U,>0GS
M%9\3MTPJ?KAE$>8GFY \?('F,D!_O;$MT+#K,]_]NQDFGGBBID7HA"_+LC>>
MI&1&*A.A?M#GF$T_1%%&B>JJ35*:><1SG9.X&)Q;-?G%)4,U!IMDC]#.N9H4
MFE$K8\?9D\(B4.CW97*3P\FTE+S3C+,7R_G1C8/F1S>H';EN('O3@QSFT?O*
M,ZANO/'HGZ>4N=U2Z+T.W?SJ6Y?D)?/. 'J-3&)L,E?H= *VA57-ECD&">P.
MB Z[)HG=:&]-QJHLOJ>VU_TBHDD2-.(RM&<\ 0@<#IKV:N>CCE<[>%921$WL
M=.AO$>MCT2?"D\AEZ71'2R\%/RKDQMXST9-:8P4$VU2=CN=KSFCS)GU<2$9P
MG 5**^V_^(<:&=#QU?SAD6AAMH[3-N3*QKM5S=&DFAM5]'(,;RSZ8J=O"J!_
M8PGG7-IY,62ZHW8+Q"$]-=P$ CY36?-,^IPMZ_.$,!,OQXH_^Z"R1+W][H&R
MDNCC#GMWL9M^G\/8?;1VY-Z:!_*K/D]6\]@QYGD$/16AYI@Q$'&)$E;3V-IN
MI9A@(:M:W9GWXPF?H<+7,2I':'.LO[?E-':X>W"+!I+$FVS4GJI-@[RNKFB@
M<=[8".:8?QMAMO;$>-W/GDBXW*BOPFR_J#2YK8:IFOTK#?%=;"=VINO4W#B;
MO2S93SUM=SH9RB@(KCFQAW836!1.[78,S@3[&DL+7%-KHU(DBO=J7<17XX+(
MF@#[^/6N44P<8:1\4T-?RC".5]J2.S34^.H\KJ2AKEA9"V<0CE-]DHS]H4ZS
M"1^!"M00/W3BE5$P]3+,Q#BMT3#@/Y9<2"\6M=+C'KFG=0;P&'9XJTKV4)4%
M(U1;,&5D1XP?TY3CFWG]*[;6S+M'^ \E:%&Y3+Y+E-^4A,_)\&WB7].*JM=J
MJ83VHT>)%99PT8@W5M2'1=!8\C D5\5T.NFI\^.U#-W;U.JYVS4[6;7BX<LG
MP;99R$A'-O-A,",Q\L%CVZXPY2[UDG8R_X68C0;"E,B8Y U&/XP%E*A[/919
M3]$SN@!D<O%KUWIE&?1P#.MT:ZX'H(U;68DM'^(XXRN8"[^,,JY.O_:F*:1I
MO(9Q=\A!NJ9IS[DB!E2-H^>):7M+5CXBCEBZ0SD$*]VRL <N9AA'0_'N:3"7
M?[ HVG_U#]UG\XG#^O=B^2XM+E).5$Z"QWJ2I&Q X[=;4R$B6Z 5MKM&KE?+
M0;L"$!P,\L@GL;2B.SDZBUCXQNM6ZUL=Y.6M;:" Q_#7LQDZ8S;0#_?P+'>:
MLF]A)N%6<%XW3'[PGD^_QD\2O;K_E8.)'3W(Y=7B]:@VX.[PPI+2=,R89 QL
M]7[X$F '\+QYSTGSZA,-%).K=SCGEVX:L2BP:9A#^EURRWV'IKNR>.1?/5:(
ME_$*KN&\\3R:C43$BD]<;(&W(@G>S#>=?:1S[0V5]_B+V&*F!DMY7S4V?PG;
MG7D2F.(C@(*24E(08#Z4\4H5-1SEZV:8FN->&''<YD-,8<[@B:TXCS%+7DS3
M>;*Z]U>8/P]DR(?21UZY9^'1C2"L! T:"<L.YN=0KU(>480]J+?A5Y=K>?T$
M4U$_O+Q;L%W+:J.X7-#<DL@(K__HA1:?'GM)=;E>?_DWVM$I/]'\BL)\__<L
MIK2?M+I?Q3TK!\%7\B?\D).NJ9BZ+37!>?H-9C;N>6?AZ>+-'O=W#[O)ZF*?
M)AM;=XW=*5.#6KP:C[M>X7<K3I.@*&G'V-!."Y2L[#MPSU<H_!#=8.C5:T[A
M& 'ZN.Z<G7F,TJ'.^[=&):?ZTK:Y4.69MPT,*1RS^I4W9Z2GO&:OYPL/::QF
MGM+*/#%<&IKQ*BS^ +[CPQ1.Y=K-LEGZQB.[*U[)LJ]P29E9J&+;F-F%8GA9
M>NBVW;M/"MLVMFUV AER.0F=2[N^DDG<;$Y)4!:^ZE=C+L\XK%XKCJOA+678
M99KU]"SX-UN,>J;;\Y-,H@(67C]]9()/FPJM:W]):#'OR38'QN?:*=D!N]Y;
M/ IBDY;Q;EY\/S*3CC[*G^?DRAZ^A:TZ]3E-KS$SM)."=--NBK[Q0*CSJU%)
M!7UJF,AC%:@RMAZO9=B[H<;:5X^'F0RNZ%0YB]T%.]['5H0,HJ3T OIKM)FS
M;QZ/7K?-%6(_#+1*T]:0W2B1Y_:\OEQC$6]_ \S& S2S%Y7!:?<G!@?NMI1J
ML_ &I/52%CBPD4 (:R))RF7C$YK]7M\WS (3.#]<\+^BS*(Z'=>KN<M/93P,
MTG^0F-B?JU\"-N%+N*6X^!#WM6]JL*':]<Z^)$*Y>9-OQI^&1;\2WR%>HE<0
M5V=@H9K0C\K*IQ_EA1@M.90J3;GWIVWDA<[R3O(6XJ145JJP/"1(,78O2- W
M8A7:4*A!.#6&9S/R#7,"7GNY0JU2HQ&LRQ,8,88O/X/M'CBSAM%W62V&$S@F
MW3[)5F-9[Q>Z8[S^H;.B8VU-YEX5JEJ*I5K7! .;4*@_<RMAT4MH0?;V0]2B
M*G9B(O*)8U%:E/[T $AO/[L"KL56)\=[$\H>UQD+6>9;(9ZFQ,FD&2K+/)L$
M=3U.[\*$E.-7@A%&*H$WJ)O<>2KLV&=8[=Q"M6U7$ _TR&L;&3XNU-V06(K4
M@";BZZZB%G2/J*2;5)CQ,C>YR DR/]P6Y)W8<D+IG.GA,2,[B5]DY?_PE+JK
M8!>HKUQ7>RJ^KI=DCF[6]20B:I([I_!53UJ$"O&,7FBEKM"^\ /514M+AJ@^
MS+MHO>-6"B7L&F:PCWZ U]+=9=<K-M2V0#@N;(T]J.EEL)?Y0#[TUYT+BS-2
M*9-Z1C0O4<B.KW6F=?'6/F_2 /:X,$_BN!J8#T9D \;[0Y\)U%KV0@K);O-W
ML>ITY!!,Z+.3W18D<N*[24DO3QF, ]?YZAVE1@ M-V)HZEDPZLNJ#I8=ECJJ
M"QTCDEA^;XY&5.*:HE%L.&$?#%-QW7S&AYE8^_%;&>C 0M,O+TN5)L(6#84C
M%(L8XI+Z7-U&78:&MW<=G3Z-%,LWAH6X79CV@("\G*[/C"#-:_JF5D]77T*_
M_V1@PXW[*BZIK#I!+ ]+>PLLAI*6'K<E1^.+B14^@LY Z<!7WP,0]3+Q3;@2
MBAKETR^QMM_V4U^%23/0D5CQ*_;ZC/(EA4C3+W\K5""5S=-7L@*:>[5A-C=6
M@%4_&5$RG%1P=P$V<;P):@8331!C]GM:"ZQ>SJNA9?I3VPS7V4+?LARQD:<+
M#)11G^(9#Z-<;?3HH.C;-G\4DNQ^-XG^L\<&2M)_]JRAH+4[[IW7=DNBG#W%
MU;IT08 "G27YU'C2ERT=$/7VIB?Q[N:H#69?"9;:0(<67D(1O> *H<TN@E\6
M7T/Y<ZW[ GF!&8JN^Y4K+[*QQ',7=S?B*RK7NX:OT MW[CBT,/'BN=F_6:4S
M0: .\Z&$LY R4<>^VB(1#9>:LV3,Z(SJ[(J.7]\6N,9L6'R,$I4E37GB3TJE
MW_?@M=_N]YXU.__<I EC%-Y'DU' !DF> N_E/-@S(9\THXK)/&/6:A!"P*=#
MKHJ(O!G;=["<$*;S14]<"(K^*L9'JX +5N5U4+2-?P?FU%6D=< <H+F%X6HR
MEBN$X^W(G7 8ML<XIE0,R,V4HN)W>>[!;2;+ZWF(=K=0VYW9@A+11B1Y96$Y
M*@<M-R!X;%%#[747!\/-%R^+%FCZ<\%Y]BGRS@>& 1[\7+TU,,M8WQJY4KTC
M(U.+S87A:#KVF-3V9BA&):*Y,$G%@W'G^/N<F=%]RG=E./>WLJ]1W[T=O_6*
M'#N35A3!6>Q4>\RB+5 MGI5Y9(Y=M+M([:"Y^"TB"O1,215B-]ZN@)$\[="A
M/OED&:KW*F, [L'<4&V\)9BYU[R?U^ G,MX"'AR0BU]ZSI;BL%3=".$U2A!2
M=MZ/3VR 6'MTD@JO/4LX6I5]P-SS,3=(^8#C&>U<3E$@1_ZQ%;D=9J:9;0U5
MKQSXS4<;]Z=U^PBFG&07WE[E.XKK=ZSQZCS*T_/K9SYMS=!L1 4*C'5]+>>)
M4'*BM9TVLH@78_N:FLYQJ#@A].+AY.*6IACB843=1*W4"\>-]V(;+[[1WWHL
M@-E/ZY?19' 5)R:=@;H#X5B0Z@"=@)7&?+J;$>V<$@4;,FN>5H_OH*$FU9!X
MF[#:?\6/[WU'RU7CM2?UNL5G /*C":ACP:OR[V^^E$].N&JL6!S[V:OK%42$
M&!&G?<@/UR=^%_<M';U\L2Z8\Z5W3OQ19.>BQH=0_OV#^\SI=ZR=;,,MFL>J
MS3A6YNJ)M"TK,P'M87Z62JI @UF((+9ZH)ENG<)Q-)75Z_>,5HQ+NI17.>H@
M&HG*I>;7$/"Y9M516;N0KF-'6HT^AQ -TR;)YL36G7IC.2<:X88'$Q6Y!YSP
M,+<\/Y/]'%HKE!<54!ZCR'<![#3E^M<K[,I<E-LM';F5PI9#WF_75DO1QQ>6
MW\)3&I#]*+&ZQQIV]WEB5(/_<Y9J&PV&,T!2G+!:_Y9H1I!RU?TY#Z[.-LKF
M-WF4#U[8WN^4;R+ -"BUHO;)I8U+21%YW;ID&,@2/);A5]G4F7</^K:X!)>,
M)5B,3H8=QR+,3XH;TY'UB0[/PJ"HU?K5N,"O(:'=K-1THK;RU>%/XBQ/'I6(
MHU7AC6F0)AL=*!4YF.A-&4B]YH;"L%\=8P\KP7JB//*<\PI).'0$UJ! I=!G
M\)WGC))3&8%/RV(3XB/(TU@_Z'V^<HME_:[QC3BUI67AA, !<[N>,OE)*)#4
M/,@QT2OUGK[:0K$I0TM/U&F?BDB_??J-_#6U%@4JMVP)FZ L^928R&Y@62QV
M0M4L9!QW?RELE#J+T&8;?L/(B)Z3=5W/YM5,(TDW/X&BJL6D76HJ?Y_'N@GD
ME?U-_6T_\ ,;*KV1G1U"1)?GS9R'+_X?YVX9% >PM>M.( &"NPS.X);@3H)[
MT,$),H.[>X(DN WN$%P''31(D,'=W=U"<$C(W?N[M[Y;7YU]3NU]JOM?5W6M
M']UKO>_JIT.,M5^7GH=)R_Z>V0?A#=]T&9KV8J6Y8+C%&2F9A9NHH8()%7HL
M0QF"2Q/?)@F#"W'HY*G>8P_-=K:K^5VAV5.DK<AS@G.8>/BA_LA['0OW%8:+
M%J>E[QFHZG\.8EH#]F<A^+WAC[5R@X/O?RU' G?;@PN[?]9Q!^FY5+(7YX0U
M.?=O>R@7>9:5N;L+;[7QON3ZK>N)+?M>..O>,.QNDMBM%Q8:E<'!QL(2+3]K
MB_/2-8:M0'/TQ;)>Y[O'!UV<D_1[/@,;2[^:XJFG!)*A:UHBTNW[]Q7::6$Z
M=#PS2JBQI!SMFWY)5I7F-0:XVE[GB?8_S]&C.;8GBG\!Q]6U5=CK9B(:(P(B
MF7&M3X/4+?%]B0_)-4D#GCM35:4H$^18O)8P-MD0N:Y)?QK3E["):U_S+NOH
M'_$&*3U.9SNBUCK:GGL3ILY8(;ZS,V 386.38)?;V:PT:0SZJ27-,0_#E_4X
MZJ$9)H56C@:UR;%Q^2%E S-T]]A;_W<6./PW[F>2[Z6?U5@"_@*J[#M?G'YO
M]RZL-=$HIY_&_"!&7Z/:U8(([\@<+43T)7(PO2KZ:/P7L(4RPVM  "4..-5F
M<*1*C$=WK40[+CK@,N9(M3/^P[1%CJN7VFHJ8('U<R#<**;X U(>43%370&[
M^X=!#*O!2A14OL]=/%7= &56G\M>*#8SCQ@CM:,,8SS4/9MZZH<'H;&G^B5>
MF1N@W*@*9"O)J/-P5'2QR9O82ZQ=]'H)>(P1[OFD0M6!YE*V,)W[I'"_(Q"/
MU SJ^\KTC%[)ELK@JIJW@*WC 3V&M\W1J*;"T-(QR:FFH3( *\[52+_$W#H4
M.$)\KLY/5K5;-6:G"(T%*1\OSQ=:%^O:*9G;=0Q6=)3!G?7(1]>'^BWG%QLX
MW>61G:0RE.0+ F#_*2@D;:,K!:XC>W,QO?:[)2EA2DG$RV!&+Z00&<D_G&DN
M^W,O8H$[83CR0!CY:*[3./YH+8Q<?CPYB?^H^:6EU [SYA>>I=845@0EH9NY
M\^/0BTYLBZT:#KNU(N3XFO*SX8?,"NK>7:.$=4KHPDO.>4[K*P#VE>D($!S&
M:ZC#]GM:<!$7N7PA=P>^V:\^Q^0LL-ZY&SIZT7977?3RW>]Q]KC4^4<5#A6,
MHE3R82U?-X2Q&^?V_:F?HWP2.K"*29?12:1U2,X;[:/#RX+&FN:IJ++WR+2L
MH/K%)@[D+4GC"OPJ-'+97AG"44%E:B!]3J%\/IAGX,ZT$PN!^;A6OF'H3G@[
M8/5AK-E&KI;@F&>I<W,W@DP0E-E$PAJM'_CY9"Y>4R3&J:5'%Z=K_GZO@;G6
M,X4G-8&!NDC4402_U^S]H.+.6<'<7L+(A99"4>A(H9GE\>=Z71L[H@:ALPC?
MXBFMV80&4A)S:[304@.K+0A&-<T(9]I;,Q]&308!^6G-BNARZ_&?4;^FHM[Y
MK8TV\8Z+F(\!!GAPIV[9N"=QJDY)&N5?8"'L<5O&BLSL!Y,B.,<GLF_8^3XG
M, 1["V:I:+$^G")M^*FT&3@B=?#%76AVF)@P*5/:80L _Q7W#D$'S+&Z_-KG
M[_+[4G2WG"&EYNP2OF\PC7>7N69;%EQCRLXEA[]E.I&R9>[^4!SL94WAM]S]
M;;-U7K!3^"I'!25XV^"!W\N)MZ<?3XDQQY2?S)V_&N=[?2:;15:.-GBG7(I\
M:/D;:Z)?E"-K:M,Z$18=NS>=\?P*GN!O'\%$C!VW?-_,\$%P;(XC>Y,)-JW%
M:HK:]'SJTQ:#2$F!>P;C70-A&[#1!T^U?X^#ZP7I-+-^2JS%*QK+%X2D8W2N
M9;][[ [+S #ZWJ;<O&2.FL5AAC3);U>4$".F.9%Q24V9C=;TQ8X/9^+>#-"S
M_A#5P6TDG;KR:Y<R5^X;BS\-WJ= ":4>T1<&0U[>C7)VDBU+&NUQ;:F&'1,U
MZD31D^RRH-=-)46)Y\W&S8'*C]R%9(;C'R+#A^UR*HV4[%__F$]$=/'EQ%MU
M^:$2"'0_;N5*.9YX]0"^FA>9C_DO^W98A*NN$6 6X-+TEI?KF'?Y7J<3SEBW
MKD:S[EME!$O.VD7$ZGRL^91<\Z-=(NA*B"5=#7CC9F\_7QL\F='N)NA@P;_O
MIW UJF'0Q@ZBDG#[SE^%#D:KF*)0C7'T_7!@B^597:V"W1H2HY6I)!/_OK&B
M:8F>J^D\ZNPJS!)-7EK[-B? ,52 8JO?V@T%QDOXMHEXO%U85-)>?U%=LE!W
MM&NW/"+)FFN6<>GI(%_1";")^Y]/XG>;[O?5>^\>;<4._D!,?F(E-Y;[Q5U@
M]HBXZB;XOP<49%("@;X41*SDW3V.U&\GL^3E@>U2Z,N\ 9=PN/8,V&5M^@CB
M;)&U(\+YT9KK2Z:*<$#*J66DA3YC9FQ&Q0@C^ZUBG<3/CCAWDLNZ/Q45.6-V
M)S8>^I6&*X1B&C(6@JTT\VJ43'82!(9Q\ATD!(,+(H*1'>REVZ6$E06V?CP9
MKM=C8$ EN2(5PL\U&XT5R+[8WJ3$'BK$J(D]5N"TX! U7!12>=)YQ%SR:)MM
MW^2:][W$G2\[0,N*M_E7XOL%7O2-9H%2Z8$*D;-8*_^Y6'<8R> :0P5#S>1V
MAS("N#]7_<JJ0W/"@8"7T:W EF2P3Q8L>QW5%9Q,U>1TTQ#F-*DTHV##OC1C
M_?JX I<2GCO$&3+D'-L(9M+>@,ZJ![K#'QV;VB'"XZZCFH>B^5/INU[\[$
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M0AD&TP[J6&KF$GZK(P_^VY*2Y5V\?9;Y* MV-W1!71R:E&7$JC 5'?4$-PH
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M"S5+EHH^)[/M,;G))GZTE4H3-VPM_JYATO'1G6 T$J-<AD[Z=MB(\=W'\1T
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MD-W7<YD9<\B5C 5SPRWQW3C>"2Q(D#W6YJT1E:W=@J>==L:/(W'IH #R_+Z
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MDW\$8G^RY%-:L^>5]O4J;EHVEE)5X7=7+;2'LT4\":7.+FV>,@\_DFJRANO
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M'6B.4))7X";O3A$&,LUP[7%P&RC"VA:#BVMS8)8A/X-I8#42O#6&3Y3!>^X
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M[</Z'Z%H?X7?D6]6%I*3\,%N30>7)]V!K3FMZ2>GI_\(> @^W0$VW?@#K[9
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M?.YM3FVB4O NB3RR6YO$[R3B'!T"@]KM,M'B6@)+9%A-'4T>R0T1$LK&8Q.
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M:K-C3EY2J5K865MXW./%\\TJ/#"YU*QHCO25V$K!(\W*R%L/$MWYYIA'WSH
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MIE D,ACE3!HW'!^'>G6_(N;_WU[MW^S_!U!+ P04    " ",/'U4UX'FYTC
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MIX(+#/R;V[C6<$<7F"/XPB2BCW4AK:AEJO$]@E+G\L@\?X@2\2]1TG&#.4+
M'N<9NAB\&PS\8W"(2%A#?W;T[3VT?N= P8J_=\"PWSN:UBX>/SO:]C#/GQUE
M5Q>EGQU$L'\WK6#C;/];(+X[^",_*!?GMHR,MA"XM3QD%O"CJ4+!?Z$IN/Q5
M3@%J:V@$AJDPZ[O  +\T!1=;QK^CZWNXP"[HNMXN\M"7/\C8GB ;& 2J!(0!
MSYV^<%+77M?CQ]0Y/__M>#&M-$%VL+\S;XA8%G]'-[!Q^4[7A=K(F_XD$]I
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M6WTCV,;C;XEYZ&Y$*TR]292C3@PMNI-"7,C:VVF.%2KL9&RXK:I_C?G550&
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M^*U/PU27JY+/  ^*(US+6IHZA&+YOMLXMIR3C^D^ T0',NRX2=>49?P2L\/
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M<8VG1WL(QDJJ#VY<4V:ZDOF&Q>Y6]FL,'1,P-_]>>9)ZFCUOHE;SI"BX:F)
MYIZW21*M_\%'.:$!PB35@CCQ9Y^8M$C<)4I=2.NY0?5@(K"%&"OY<#]3(<L&
M^6:\4EC=4PN6A*1E<1WEFA&8@0&-8R''VQJ?M;@X-TW2K=?-(YD%BX*9@0-'
M/C;=B%IO6;W6A[:H#N1TQJ4P77AGP7!,>K1Q!J!99R@_"& ]+:\.3M%!G7O.
M*S@_A>N'CZ'#ZYOOG#Q[.U"VV3L:W?"C:HSVD]JG[V_GB]5YR+]8'\$>_3(\
MY3 V0%)BASO9.:FV0[Y6%>.(=VO./E'R"X5KH@.#BA2AQ[W! _*II0#WE]?-
M1KP;>Z),83>9JD,Y\Z8;8,.F7CA%.6I,$68@96-3(Z%B1Y:DU(WZ"([:>L>R
M!M?:\0ZA3-11\255B:&Q_2N\3;L*&1O*@6GZ$8FRJ293&>P,-E<]"%/;5=,\
MV54BG@?2ML](T7JP1I4E?#J*3+HC'WFK0[ VYT'C=$F3+EIFO3,M>SP[+P:V
M59%<!W7L;,!^O?VG>@,.:X.3ELW#Y@^MNVZL(:O[8Y;A^>H/CRU#5V<#?'S&
M#-9,Q>E\_6SN"Q<\5$4Y,%B2?6CT=9L6GW(M;/?T0]WB<3IIFWV+GU]@UN,/
M:V'X6&T'\V/WH6N2,E6SN?_&'@MZX:N X.LV9X"ZI$>[&7RS#TO6*SH,/6[T
MX1=(28-*N!1FMCZMX[+E/5 KJ#)A4"G0,*DDI6U(U,F.H[$FXJJ8 U )G@$Z
MU8D%<' =6>Y6OXKN6<FYD\JXV/9MLHSVP)[/\C4>Y^?7)\J[O$'9H S?H(DJ
M\1JA&>T0S?5&C-6=?CSOU_9$%7V4+"0 VE&7Z_2C+["ERP8I(TWO],Q1LG5%
MK$^)R[9BY"17/#\QD:EMU/33AI0G(*Z3:J7%,>6Q+P=>E-]T1>>TG'X03"+]
M):.3;FTPEM5^H:,3^]'=3I$4TO+)6A9#IP+:S1+"/'5A9-883QZGJ5:O8N%C
M\+T*V[KAG-J;A9OAXW0V]=@A:S[!L8]=GVK0PYBOEPXWAE@(4,9%WG(B3%X/
MOQ?.K%6(SDD*QE?-?LDM,_M@;(  YS"FZ,2QFB?^#N':>S W>:74@-^SX?EZ
MK;G:Z-2YINNPK[3T6FH, >(/WCUX$<,R+62EJ'E?/31G4'S]6A52P=08#W..
M_F1G^W75]Q8Y.L#!R8[R4C/XUY'^$+5\,MD,U'PCX;8R9XIB[A3=[D-QMD!1
M-D/34?C[KN?+:>[<.5^U=J/53GUSUMO,QA2ZYHK0:AN4X3M9Q82WZ_EN&UDA
MF<G$-EU3MRLQA*]T++]^-RBB9.FG]Y[)A<)4K4LDZDK%0,0R1Y<JM>)]TE>:
M4_F/4>472A^4GV1OG&CT.ZFTEG$G%UC75R+NM@BQZ=;?Y1DK%K[Y#/1]'>&Z
M=Y-U?8GWGL/K\8GN91:D?L<&>TZ1AX7/8IAN);WB@^F*KUEV(M\J>&P>LL[N
M(AD^1P#6V\5E"IC DO-.DPDG"E,W\-,<(LO2D@USNAJ2@F%#8L&<\C#B7IH
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MKB^IAWW+0HOLLE2WU6OOE4O)F$V32H=C=7H0"-[;;_;T*W95OF%,UB-T__.
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M>$0LP!-(4F[7[_V^5IA-[49)OY3]+:>]3V^9RP"'Z.>[DT0/E??2YP^\G,\
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M3(TJTU4S9?J\A/,AQ6<9Z$:%K:+W/B^0Z2KP=*:2_6Z7#/ O@Y1P)/S?P?^
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MQAXJE&079=0N0RZN2C$)S1:,/H]9@PI@$F8SX^>S!G3BRL=#(Z?M<3E6J_9
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M1U/A6B'GE[N0@OI:UP=P)Q*&EP@RIBHH&&J*I66RJ:J_5*0=:8EK6@H(VET
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MZW(&L1"B4HUDN]Q#LZ]UG.3"]E/!Y9(JC/N'WCCJO*&>KJ"NGBW<BDPG7UN
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M'"JN5S/'J^M,/T70[GKR<&U3'IF?2M+(_P,1Q5G^A"VEI9:;M:(R<W+A<1E
M,, 5;(M+F(V>68N:-0&/GB<&CA_#ZC%1S7IC!FMG:NQ;(T)X6_)JNS[I+S:I
MGJOZRN<="!F_KVF>4^'+,6DN!3@"JS=54[-IYL5<^!&NX]P1Q(^VLL"O.QI:
MR9PAX4I<D)4BF-QI'T]0C^L%1LJ-EE>4BX6S?:%SMZL0Z/;VXCYCU#PM'U:4
M<6-:%Q23JL/X'7^4#BLIM%/25.+RJA91EW5FGS%_B%! $N=C]BD#MY&:2"G$
MN3OV9=%,_WQ1/&-7MGG6U<%]H.IQ;[CMM]&Z)5/ I,&31#-C\E0MU$7#+2Q%
M,-\@L>:JRZL'BLFT*3)ELO)MI5[%A/JFPFBF57%'2 T!R0"5%^2<\BPFR*A4
MD%_X1S'A9GY#K YA<;6I!]3W/H.ZW._)1"/B(2J<)3&RC/"?Z :I'93NC\F4
M.=%4<9("(8W.85B!Q&1VK/O,>&)HSOE?U[\J]/[.(P?7"2Y38V1-%36[]$60
MSRPV^WK:'PV,K_TJUTM.X$J;($,,CZ:!-TP&@R![\SN44QEM8&K4QBP&275S
MO)Q2P%98WZP=M2U,/;2GW[!EY6%M>'ADW@2_"FEJ*S](XL)J0O9BZ8Y6=<%+
MW(61-/4E-G6LE0HP] (GK)UGW^PVSN6P!:UC7/>EI75&<?-$SV, NMS$5@?#
M/]PBYUQ4L(;<Z_L G4X/G@LM*?T:+X$%;G?,3Q7S;/XH@JJ[;_V[9N(27#E"
M8-P>(W=!AFGZ&JT[UP;>\TZ%?=6S*:K<Y2-,H^2JV^IZ=S\*UY*$!MG*#N=_
M:,5J+M?&$V>/4C_I$9'BA[2CF^1"Y^+:I8R04,*>B2@TA7)58NA=YZ(HZIF7
M26B?1 ID2E O;LO*?]>:7[L)R6#-$&S"60*I]81([@=8\UP_\;OXCE-W;B(K
M2=(W)<LGKRAF8^TI00!%WQ.G%VT+D^8*H'STNHZ.;:A%[7@Q[KO4L^C+O(UG
MQQ?5U<X;BV+IE9<?XY31UR)65>AE*1F<83/'8_%RQ(K"R2$*_7*Y4)]&60Q%
M=FA$F(5@3](::U[NGM^:A_;E+%"KNDB]R.6GY'M2M].WM&7T;O1/K8YJ]D;#
M3#-P!^!6+!)FR!AS"HEUHS,F#XT4SC^94HVG8VD3.^G.(P9SM]9^;W$I#F;1
M0*-/H)ZWT@$C9EP9W/$>I]^#=X=^<KL;+3HCUD2DZ$V7V)OV)P2M3\)]M5,_
M$,PGRWC1U6@EL_SU\.P^A+F =#/2#-#/K[TB3+3*AGD8'H1#KDXQUE^FM,W)
MT=1?05]?<N9]U_OQPA%U.7-L43%.5@<K]):S9BN"M YKTXSTX)S5.E77N[>@
MQ7=\1"=<?@(AQ=_,;XK;YFNO+%[N<M*2?N9YJMJT+Z7T-=KOFK@;#TZWWDKV
MXF4^NUV<.T("BA;9[#1;ZP7MMO)K_GPTR0N <Q9OF4_=\F>Y2[>HK2<P48$Z
MF6?-NN5[D7?0^,$ R>TN.L1HU- QZ\2W#*;]E.;D?C:E1()HA[PD6G8&%1)\
MS_$]0-IL]"_GYRN#P!!EC=A8WO7=1BB[V\W1(V.XCN(0N=7:HBOS#'UO\&"N
MIL-$1KC-WO%TIA)1>P8_NT'7$+.11#M=R3/)8OG(6*.S[=S*?)VEH8#T SJA
M]=4I=JVW%S&9&,\4;1QB%4-5"E\,(1T=F!;_/MWM4<[T7QKBME-"9HSOUQ9T
MRG7]=,.;H0GA0@-58(H$K)00S2<(EQ&#^82W^K6Q76<M-"5*ZD7-K]_&.W(#
ME0Y8*E_:;X(X-XN$3+ZY(2ZHHL/_ 6-M"-M.-5-.UA^/26G!4G,UOXML4)SE
M>5K-?O62UY"1M+Z@TUAI:ZK:Q:*O0$[R6KIFA8SFT^F.66JDZ98'825I"R0G
MJT1DMZJE14@;#T%  =H--1DY):KHKI'59RK_@,$=OJH=2""(C'-=Z:D$":MY
M6-_J9&WQB"N+I@L2X&MA$F.TP\]J24M/C.F43'8D*UH:#Y7RY+'@=S3=?K=M
M4A*>2MIQ*\]=YO%5C7!MUJN.W#V3BD?\JDFO^B1W:C_ &,9%)%K?O+[RL_/:
M;'V8REFX'DN%-Q+=NT1Y4V!IJ;\Q60(%_!M07RH&"T<" \18Y]$#/E=O;WKL
M1CS4U$ZK[>["0G!IH O/YV%H,0L0+S,Z^!J2?*?J"R]%H6?*L\DQ'<*%BNZ'
MN@B6%<]P@8.;<='Q0FU;EQ&BX$B0N:K5QW!D<\W.%0"6VNBA#6:'5;#A[<!(
MTV)\9\]:6\B\Z,_I\9)2MS(88]NY/@FZ G:H\MGF6=>U]Y>YG[O'_@HJ''#:
MF7\'[RW7ZGV>],-%^B!\#P0*?E==NL#>^2(<LM=7_ ?,<:R?_M^8R_?_@*&3
M]A5_]*4&_1>.WQ#_3N_\.ZT8LM<;^&EX=/*^;1@;)*C0Z'^#_IL-_U4X2/,?
M^=5_P%Q)^_[2?:8^ZT=>O*!8D1L#0$$%@>=ZW ^!8#[Y)F^[M#=FW ^>#Q^&
ML5/_$\(_Z/? _;^R YOO;F J5YA[P0L=WZ<C_H!Q?R:\"3/_ X#Z;X#_"A9X
M]<+SS_J-?%*)!3)_*CY]*GR)'-A7?13M64<P2M5G96U87!<T^8KIW%0Q=SC!
M8\A/-\1ORK0Z+Z5+';?'X:%KECQ::5W6#L'ZR#?\] <L [P06LR_\ ]8PB[&
M(]_(<[_B[KCCZ2?8/^EVQ],_8,]._ZAB(-10H-3G3N:_2=!W],_F[)T[(RP4
MGN@G^JL+?L.]8R-]$/^#A@\DKG3:>4J<.]A%4:TQ](/\1(CX3-S%_!NZ5_7O
M8JZ_*/XC _$OR84_$S_ZB/\[R?6X;_Z Y7[.55_^$^C]#UARTL[Y6^'G]M\5
M?6/Z6XA [.;?PK__@)7_3XUMI&%GXC!+UI7"90V!F,R/M-Z_;#)O8=VUR,[S
MV:YH*;]6=D1@:G?15Y+P>I5W$>_W07 RC93TWX<08\PZ)]8_W8VZ?FC-@1TK
M>K9>3-DRE6=N^ MV\>-SAC>2J2"Q5]B>-$,:5YMOLU:+7F=+AU!6MQB<9QLC
M[;3Y5\-$6P$R=/D6C]CQT\KYCE/=3VBGYBZ==R+Z.O%<50L"%57V%F_I8F].
M8L>NSDFR2EBAFG.)+\Y11V<H'(OJCNZ9.Y+52:N$7JC9(&[5(R]OFT.$F=22
M,0OX?.\C;>B'7_^ /?6UNC42 VV4Q;BIRM%D%N-6% GB+<_!QDFNE]2GK83B
M-@G-J\C<>GJ%U.G:Z(DUW">B,>KPG+XE41M,'"IR^5D_(0MQ]G893U"L-0&F
MTG59;&*L)ZXG9@$E&;)IF3?<J7_ 7!R\>:OF.#EYS;8,"&3&N@$^SZ4_(-/6
M\LF[NBA-QO;&.,/7'CF=:@9J>,E\^HP;VDJ2TR!>P',NKQ:!Q$S+"\6J7L6C
MR/A,=1Z3?@7HGVL-)[+>>:44(*?!LKZ."L^*AES5B^2S.M,#]CU_@Y$NXA5K
M@L8ZNJCQ]1T=8U2+[1;J3DJ0>=17I5%**9OA*$ *$<!>!UL"A*E=]2;E[5)8
MVK(M Y@C2#U8S/<[E'C+B<#*C:[D+<M0&\,,2U7?-=Y"M(/#_YSWU';'&SM_
M9.&+KS0.YFJE']Z30LR-P<_@_DEC"9_/=S:.&J3/JHG$H4WQ&?"X^"S,=#49
M>US)R1EV=#84F9:@+(;!TRI%558>84O@FM9#7;>UCZ1627>IDZX8J;XC<#E]
M!MOBJ9O=(U+Y6F;VH%SA7(:RDZICD+4:A&>'Z@#@Z>=P$3&2X:;(;=$UE<]'
MCVDYOSUL/"2)H,E1RYVT(<)0'9F[[3\+](!44]&!^^;IJ'^\E1<AR 4AY9[N
MCK6A3B4?HZ6N4;[!XJ"'#V0<J2@XJ_M(IM 0X?:2FM_"3%.D6I@+)R3TYC57
MC2N FZSE6CI<8?=B !5P9J)!W3QMJ9=_5'+AUZ8*M:H=*ZCA:7YAT$*WXFA_
M^DXOZ9QZSEP6CD#WP*,NSH(&UZM7]M,4LE6BVJVI"423L]\U72O;==.MMB13
MJ@.@SD OF=%(AZS,W6'-<$.)5-]";81]NB/DR=M4B?'GH*>FB>(SLZL+2,Y$
M:[M2-FD0HYX8TW0@Q*I(97]VQZ+!W#G!FSEU<3W*]W:>@YNJ]#21\U'TC%%5
M'P0H!#3[QQ]>.]A"W\?$*+.=7B6#X#A$V,WW7,ZOF5&$]EO].^.3]#'S)BCG
MPS=X ^-;O.8..;Q29#E?MK,=SBC2QBCUZ']F*RC(8=-Y#G93LX\MCK^,9T:.
MTRR/2 I@59R6?M\L-!@9Z:<RUM*-EF_5ND3B&:)^@;Z9X/'97V>(& ;^C'VF
MH[FZOF"JCKM5IL[K_$EWM"6'>,'4O*>'I'/NA5.QO: R8Q40KBNH6?DCW7Z%
MR9H22!\T_R$42$V/P4N$C\==,ZDF)W4T5>(^,=(8MIDD LVHUZF>JS&S<#1K
MHSXG].$6U>"L8*T^4>4R&6 .Z@OIG,W/%.0F/W/_<#4(.[UW1N4RM]61*6GD
MAAL_& M#P+ELMP8[YF&:X+X>[J;,R,D@0&V>/^V=KQY)W>;*8-2$K^GI/G35
M<&XIDJDP<0%4*>(RW-0OM&QT-$P^1$;NHG[DUIJ%DW6I87;Y(K?4[I_D3XYD
MBK2XVN.*%Z,6\B* .T?# PR0^PGVUO1'SZ\P.8:$Y>#*]=0I[MR+%6$,<.]Y
M^,3WW&PQJGY/QM]-\:DOJG?SZRWQ>VBL.ZYNB,[5G%GMZ-%Z65DS=AFL-V3C
MW\^_F-UKS@?':H$HJF\!D=W&9!355%I.HN)FT2;U^MVN0#>%IGI+IM=CERW?
M*EH UQ&3^E2;P+ANS_<*-?/\-(/6T_A[_LOWEVXCHB>ER0)YE\H<##P7/._4
MS%+\"7P(MR_FIOT?%NM<L!2V)/B<;+E+N3[X.A,=O+2 EB--2CU6EW<T94<Q
M>&5NC(UP,?18@12'%/M9E<,*#X.W>E.-95R.4#E\/"^&.',IV[@X693!:7X?
M7$(Y%+-),4ROX9NY3)*)3G@SVWSU+<9G,7MU1?^_&CDUM2Q0SXD\Q;U8FT\(
MA^_5>Z(YH0#FYPKJ_%/B3&YNG(VH,*I3CX].W^4#9Q[I0>;H3A_R4NT;@S!Q
M"D/JJNWY31QN5+> <SBLL*)9 ><\6U5.55&IWC: +GD$^4')4723SID2S45M
M5"W=5H"J>0CL5NI"3^"7G6UTPX8<RDJ:A'Y!&NC@S+?SE?%"%6W?])(<!]MP
MW:GA)L)62M=XHZ0I-7_G<@>/SZ$@^KQJM>4CX Y_@F)35A&&3UBUM)<L/<]A
M['0F(]C*6 XCC*K+FS%V,!R]$$KM(4C/?8BK>"<F"-.2D4=0C8AWJ#T&>44/
M*!!YXI@)4G^PC>QP#5>QI[L[RLL=FCD4,T"^94WZ[)L=:/%[M/!53!T$%*P2
M!E4+'9.6R HMBL0-/J'I,J0PK==%&W,42&VW))X=W8OKV-QVE:I%OZH*UV\]
M,L@"RAF.RPH1S7^/J%0<(^B@41MZ%72;$]:5+(]'E19"F1-D?8UZ)MITMX+7
MBAG)J]N?@1$RUQZ10B;;$T=#I\)1@SW"7-]XK=FQGQ]1CW4W63I:<"\P<-"'
M5J#E93 K6^4U/74+'?4HC9ZKB'*KO<1H>3B5(R+'635^W4(S;J0YC)LRGY&7
M67'+"T*,<6^ "F_PFJ\C*"G&O*T^U"M/\T<Z/"YK]JV<..#J3=N/RF-B7,9@
MG'39#E=6[^Q4Q=W;! 4B&]L/N"-7(X>>F+$L:BNFEM_RRR+?VM$S\;3ES,?F
M'2:,XI^^E_^HKX$F-%YAC31MB!K9(,F?U3Z(Y.I9A"O;S&-2_&BD22GR&N(\
M_XPUKV+N/B'6W-FJ?_0WO*MDWZV&>AR;3O7Z]\!$T[L),P,8G"2 Q1U),JR;
M/"LN1I$J)<TXA0\?I)BZ(2:;W0!E+@L.@RL%EMOC_1@LT&Z+$E,;P+'*;X0D
M"[7//X_+*,;<&^(!3 ]4_I:($"MO\3H]5L0G3,E?12?5WV=W8B9K92"=<L:(
M1Y0+12B=!*(/DWG5^=7[W0#R^:W$DES=K-_1YC3<U-,N^%*A@J8G&<\D[UB!
MI1I5_&  ->"CN50^ED=)2=0T4P3&-"X#C?9<6IAFH"N("Q8J'RQMIMQ]VD6#
M9'.C887S(9((IW=V6RPC"UEKV#KZ8W[1HG@2"S%Q*V)?PU#%)\I%H.@*S4C)
M-O*;I=^_=C%^P3_>J[JU-XF8"?^Z<K8!%2NGTV4:]S]:^\JP.):EX4T((5@$
M=Q*"!W<G"2$X@>#N++9H<$L($MS=@D-P%G9Q"!IL<9;=Q6UQE^!?SCWWO>=<
M.>_[V?/4C^KIGJGJFIFJKIGJ*OX,!_V5W8-L@P]1JW9/W@N&WO7&FJGX8@=_
M3=;I.S&I5-?S4F:7]9N6V?"W!Y,AC\6M->SR[MFE /+RYA6>#A:6)3$0N##C
MS(+F@I5?BS=6!EZ=T#L?%/([)_&$E3C4$_P>T8"K]_P3]F,>>J=/#OTR^K7
MIQ0_/LN\N2/J)UYMR:X(?F5!A>=\K-9CCGQZPD?L+(X"?MEJLAA3<Y2L697Y
M1*"R""2S8N-"%\B)HJ35)XL/AA(]#GKZ\G+#60(IZ7(;1NDGM.QLUXL*44"*
M%=PW-$"*ZD4GW(<D[]14-E8,)7E#4T>;(%XDD?+W:H4>9$4^$+2YKJCL;K79
MTMS3A;@%$W<HZ^5"FHJ*GY1O(+P(RQ:Z?^R5:C[7PA)8/5+9-5_AF34-PP7&
M84X8?V^TEQ6Q(O*_41&Z)FFJQND5:69>S /5:3TU.\5RO(!J1@>39AL1YW\0
M_TSF(/*%S(G!?%O8 Z,\V"HH]$S=;1BKJ@(Z,_+AR)C(N9\Z-TBF,*=%T&->
M ]#TXU(&GA*92Y$8AQJ)F?J$'AV5,N7$V<B;24U97Y6U(JVH&S<),.=E)V^8
MHZ5E.X\MT2P!5=VG=\ITB>&U.FG25 ".?ZM@-^DT=U,R'A,Y[?V,$8O+PAP@
MF,SXRJIG;&0[H^Q4(F<"L\V9^VZH@.-&J4^C$AM4E8'HKO3"D\C.LP"IJQ/<
M6X!!7O-?[00D.V[R'0N7G53P'=?@DH8J*0G\%A^KNLM;@=RK<((TV6;/VT(:
M>I!H,A1YCU/$4:='].JT+I*)"3/#B6GH-7+(TCM=HA_7^[J_8XJ8.+%N=\_"
M^A?%#T]0K_!LXJSK];Y9W0)$)C!DL3<:2"'=ZZ5%%=3"1KZ<N-+X/+DP#36'
M5T06+(5969ZGMH5I6Q7B*3UBU:N'$A,_0Y>:\ O\JJN1>A!-]W0KXZ!I1#>S
M.HBA>3'=1A_84R=I*_;\0O_GBUH?SL7+D[,. <VSTKF^^CGV'>K=RX?7!06!
M3Z2)<J J)9"5>IZI":I8%M&D6X""8,60*TU:7T[+HO5.H3O*7T;X"*F3<2G>
M%KUUNBQI1/GNRPUKN"4">0L([<IS.]"!E)4E)*1_?R7Q/GTY,%H<?MRT;SC0
ME30BM4CY:&-[]S%*!]'MV2J#XR2-]S!6KUNG.R(^OW"L**"=\CDM,?-Y9ITW
MGULPI5U:WYQ 4<$MX,'!/9<*I]I*D7,O4319;W*2>.HAS+=YM;KUF4<%RDH;
M(5V;&_8 .F[$.O# +B\LNWH89T@D"QKIK^B/62%!A10<J RT8P.5F3;549$V
M;?.Z0=-QF4OP%QF$S)P3\L\5BP]X@'@C\X*8!YD0.;$=B#U*1A0H/$X.\[FV
M.6X^0F=<\D97#N\?#3@</.KFTNU]]#-0B3FC #-.9Z5L-5-+#H[M?,US1=L\
M:V=Z"PA^&N;FJ.P>/IZQF%&X@QZ.*!!XG?]EFIV!43O/=5[(!JXN(2<VZV;I
M2[67>01-<F&&N40[)$.'$1GGYT#AM5Z+Y7>/D?H5I]5&N4ZZC$LVL'ZP]KO5
M_62=8597RY&?C_9AJU!()G*@<\J?M5M'ZF[8@6>>G AG-@L;,?430M11NBD_
MZ< B:>;VYZ&LI]E%Z6E]J+,PM ^01J_/K1<L@A8Z]?4WXLVB/GB+:-YY\!3:
M(K0--4MSU.D/\RA6RZZ,A<\_:7WRD]32PV_N" QA(_5&UE6KZ")0AHP)3L7Z
M9^6YRG*"VOISC%6F9VW5T6RG]W\.+]P"V)($Q-JP)I_W\)YZ+J,BSKU_/?5N
M(?;SE.%7?8QQ<0%42.5ROIL0:5T?R?WKN PM >1<@LW8%&ES3NC*F+9"1/-X
M3?TVEO&HRWK!M,*R@80<^U6UTW23V;"OSU&TV(^;9N#P\ &0;)AG?[X\[Y,@
M01CG3GHP55RRM'K]* 6H,ABBE+G&S+9-Q65?/",I()2\&X[5/*M>*F:Y&:&K
MA.#H!5M ABZ?^#!!Q, ;2_-5+M #3TOIU6@PZLH#W>18%S7&F&L]]3Z1*\[K
M>\7]ZB50JDO#;/;QJ7==T)ZPLHMZAWJ6OHU,]J(&X@J-FM[:DO ;7-X([H*3
M7TJ4FWO :8>BV5RX\5BZBHO$S)N'".2;:70LDLA9''^ "7>BK?7$G0,,XEN/
ME?BA<+(+DZJC#$_0:H;GFC1Z%7WBJWUE9"2V09^,5-LL05RF7%KE!C-_5>7'
ML*X'OMT_/>3U8 **LAFA4>+;%J<U)3Y)H><SFC1\XP:G/0*'\"E)^SF=8:CD
M\,FED]Y[Q+0.8K>/.=?%LT&*,.&\P2PP$MI!*;)5Q[ZG,O?5+;;S'LZ0 S\>
M;Q29*8A)D'[C>VM@6/GE=)=K;\&T-]I!_)?9'\<,BIY#VYD-#!-PBEW[S;/=
M F10(>"VGF6GU^A+/>WW&HO'>>WS[%?/P!4C#J+D>[HOVQKIT^P3WG\_+;"(
M/B@R:7JR;C90!>_QN6[5J2\S<(JX-O3KH^']Z3=S?NWG-P],>G$"^8!N!)<5
M"7M^@WE0/9L6Y4:T9\:'^KOM7MFZCF<+YAMBS+M?G.NY-F'Y[&0G]=0?-;#Y
M+!N)<]\"2&EJEFD\+WW::%Q.CLAK3\MO]H!FAV9!KZ<>$K,V6,!1$4/9'7.X
M^[NCS88&FUM$JD(S+]RF1D6D\)+8A8MT]BU?1L[ZV%_I^>ZA4.:9"523YC>I
M;)%.C2^:I?GY>I!RW) &6#HH OA+;?]Z'\\O/3<,W.;&:J/&R,K5>:KK0H6,
M0XA*(J9XLG"T^V3W?93VW3KW]SY#>J804]S31AQP6]FRYVZQ;[^&2A%FY%[7
MQN7%>2RY!B5X]$>DB\Q-M[HTAFYL6!]OV.Y$BVU$>*+)DY=1&>AA(9A8=7;I
MP$!:LQ\#BJ47>*WGN);QF'Y+I "O0*RF3^4JI=G'\&"%M%1/2*!#'E=V,8#!
MM;$X@:4-U7*HI^Z,%AQ<@5K;A^\V0_!ZEV8#6[L"[6>S-AZ-H6LTQBF+D[/<
MA@?ZB>?)84[HU0TOH4M^. W,32MX[RS]=  <=40[%"E#);KS.FM3I9^4/CX!
MV>$#%/#E7\"'^J):*1I ^'D4+88[)MZG33&=XE-%LD1<??S$[X=K ;3@ZVR?
M:S[B[:"S&EU/L]'N/K.-RFRHA.>Q><IQ2VJ/#Q@=<?,06)YWKLG!3.=BXQS7
M+9)?,/8NKJ1>K_>PS"R,4L@]-\Y9S=G3Y;O9F'EDFZDW=:3;X;;TV39<8KY0
M@7)@\^*Z1G+I=)G64JP9'&6:N 3W%%^9I;;@.U@5J))O_DD6O5E>HL%@ ,<C
M7EJE/V<QFT@T.Q-?V3;%K=_&_)D;9@UQA]F',PD-QP>=P!%;@MFW "V:>4DP
MU7<C@?(+7&_99W7R9+K)VY^6\=A7A\^YW(? OL%SS,9U*IVX\F3NST#LT_I%
M! ZD8S7:?3UG6,:B6+0DHR;B@6V4>XVI/:BEU>JKH]4*EVC+,8.65K]Y24G.
M;G2TA/DI]<V)9UU= )*?0*6( 8]KRMH\86Q#F"VBI[W-T,$M"88<?5/ %_=)
MB2EB@J65.+V0A[\;:BLJG?@!+A[7)@!GW8H\..XV6:8TLSL';7C*MLX 1<ZO
M_:-IM03</_MD?_,WL\F0>S-N$^>SCCQ24AN./:Z&>XS*^;(;RM%K9BY<?=>>
M3MZ;M=RK^X!P5P#+2;NC#!C2K"L+(#Y'%6DF8D!$A-E6+RSKV8']3",H?&>N
MXZ3! NA@]37H.^YLB&<?JW'"+S<W7H+^(+FKDFS[%D"T@\H<MFLJG]OR;38H
M^QJ\]2&R5(B=3LY!QHQ(FX6)T$4.!LJ6]<-.'/DDXZ!C&HQVQK!+[?Q8Y<)5
MM7:X(A/.=&:R=;J=\B,ZSA@%5'[+K2J#73<YQ15,. IZC_(5G/>CW&DIJ"N#
M9)^<[J)69=R"<>@+**"A4(:P<YOWUO1S0ID-^R^Z16V[DB2>WP+(6IM6M$0-
MLC$CG'1T=-[D0 +FA-;*RK87';Q@%'T-[SV&H76D<S:W@(%2O4NUU",P[!9
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MY%S0@5L N]1OT4'@\YN*O]H!B,L6FQ[P%)_;MO";L =]O#H?2@@^IC/ ,*)
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M% AZD!RR%%3OX!8K@R?/+UI7,Z]2.\%K+[>2Z;,RS-C6,'Z@#W\GLT[!CXY
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MFSBN!KE[([.#/@._5;O.(#/QO@;8;F]HW:\#0HA@/\_I9VR>"\V"Q/%6WYS
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M-.?YV=A:\Z7Z&'?!IO$"JL2SCVNC4BU#I^T'(EPH@VI?K37\5M*A>,6#9)@
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MA+XL:E-9$0(4"M$S,)#F*%.N#0B)(2A>)?@6RKV4CS8Y.+\G01DK576!LQ)
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MGK5/QP-797]SV(N3+>%D]SV PFQYPF<&R &4XY'C%0!/!@RSAEC(:0"HQZL
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M)M8_%^?K9U>&_ZL%]$^B?Z<9_%^YM/L7T;_3#/M7K^[^0S5_]?@OCOVWWR
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MQH AKS-11.WO=;L5<!5Z@&SF%WW5$J 8WF=Z;V"?W?B^>,#=G$DZLY' *&O
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M3LQD*X/H_82'JBK9%&0+]U(E5\3H<=,-#$39].1NN:I\],T>CE<:(?BP,]5
MX#0X7."RF)WNNED= ZVXKAB*XZU:>/^ZR= 2G0AMD\]]!QEG\,QHR^V;0Q2L
MK('?*!2#];$G#GTS>8LU.:!<EYI6%:9'5S6MI&:Z/J2.("<CN:(SE_6_H)IO
M/ZLS@-BD6&QP.4??B7SA(-RO>\<AZ +JJW*5"<J=SL<YW@-*KYCWAJ]L9@DD
ML%0R9KIS7U]O?AAG<4.;672?PJ)JP;:R[:."HVAUXKA+;'&CJ2TS/62.O&T
M\IFH*:T<L;$UP7G$9Y2G_^ICQE[3.GSUH^/PCC[F_L>8>XHN"V4LR]/KD0,P
MU^"R!%PYYK==TT/K;*WJFII#IAU4Y$.1W1\LN;C3J!G(ADK=%Z[9#ZH>>K'D
M:%&X"TVPNN5ZMW+SM;3;J2G1?R:N2AOX;+^W.MQ7G'D,)-S,'ULTB$GO(RYX
M'=,CE+#$IF_%'&2F86>M2%7(_BQ8'R5J28:G^EMNO]=%:=UO&KEO=LN>PVL^
M>CX8NT*-^V;Z\<V-@%2;%?'Y]O1T\\J"JN>6"<_+Z6>$'IMN\S=\<'\-L@QB
M%!RXF4>:K39,I?WU5:FUAP:;S-,W(UK=9>,H3P(#;6^H;RIC9H;'>!=.31N3
M:;\S#$_E(=BA]^DUB.;PA$<62E?(VJ+KYJB19I:UUUC9<9,L4OB\J\P):FP4
M0BO.&Z:@JABJ;/1O#1H;9H]4S0N:9;R\,O\!1"',]Z@M^QL+UW-Z5]FE@'?3
M-FO$74WTJ[YLC(Z!+\)]P#%UU[,DL S=^EXP+N;&0JN?7.E=70/CWDMUN8M7
MI)(L[T)'6T3E*O'8\9D_1[=MII$>U^X V5%JVHR*5WKF Z]7VT?Q]R.,MX.7
MG$DBV=@0I*$UFS<GZ*VPHC>P42(Q"(;8BKUI-A!0'H(OC0$7QS?JDDW* %/S
M%G\UMF$PU>U,F<4"-@G%T=@:=O_- Q6?I/BJ#NL2N?T+@J Y1<RM[A[/J,BO
M"0&:+9>\#%S(O</]UM=B6:]<.7J>XU6T2[JU&2:]H:>P8#@G=@^R<@6B\:$?
M#2>NH;5+0-7Q_=?].^3O[GT*ICE$[Q%K'DEY<E#]OODC3[X*S61N^F.TD4+%
MQLM'MG,ZX[4N!E\KY?PB"XHHCS9=\93, [O$NO,_:(+&T\M,B+9MRU^"YQ\,
M%5R1[_$?*'FNF)\O*.TM;%-/7-5WH]UPP0V0#TW+ )O@H+T!DB7NJ\V@8%KU
MA)#/6JM'5Q6U-+C:N%MU:.4-ZB<=9F]%[XA]R'SC7N=+&:.M)$)D-E>T&8HA
M_F1]O31!9ARS^2/G))9,V[OA:ONYOM*[14E71/!*[TU?J82^R\E2RC2Q3E2A
MC^R0CLA_8YJ3HZ/F<0RP4; J\3R_FHPV8L#^ !##I=-R19T8;\<!-E,PIBI$
M7&D3&WC1W7(H&U;QB]:Q_$6S[_,0D4.^##N/7<N$5<Y::U6!G/J]YKP=/K]X
M=BOT ;L6&WW9+O0#BV,/\DY;,H&.2CT[J72CN!IA%C/\&;IT(Q\>)@H*(2'U
M>WH*RLADF57Q*P??6BD;&2.5T\!!8R*ZV.R?&V\HB].>_&3W=]BWKOG+E0NC
MA,GM^M4U$1'-,(AI>:GQ4^>7^T$#9G8!P>R(W=T-O@XK$;\.)<99@/W.""O:
M9RS50PI+AC!.,F+6QYPZUGP%3=E?#06+'N@HM; "M_WS,I(,W/)ZE2-=B)"9
M:H*\D1.01%295VV2S P/=7.OOH#'O?X:9*">CK(L<1_POM@OR0BDW!7&C5#<
M?JU84I- L'>0-1I7&KQYX5GQ,X2<:W"+B6HJ5! QID9R5U@8MWQDVGRJA.FH
M7T*HF$7$-::D0EY%K9EZ256*#P!,K^>9<D<R.>=;K4(P @L<9VEIDNTCY6K#
M(.;D'>!ZTWK-@T?WJU[L<;ZN.P9PCH&09Y\=(&&=OD;7E1_H"<%8KPB,R)N4
MZ5WM3S_)M#D:A>VM80;&Y^%VP?H!,VLL.[N$NY= K@LA[%_(LI;N7NK7HY*K
M'Z.-,1!0&<SI?6^=QH;!&649_:3=5_ 2^\58ULE]Q3R=4HB+H:>W&#2?CKB1
M59SVMHO*?I'B9)_\HH'_4B&EO;((GHWF&HD[U5S\0S&0A!(R1LJ+[7(1 \%]
M+U^Z 7PO&6>2DQJ8Y$5/X^0PIQ?\NFB+KM2\!K["0B)(>8>0/2S%-.@VP2K5
M%T_)/ U4-B8N<OC5!6'?>SM<0I6!O$;&%W:+WWS]Z%A=4H?.^&5-QO]PE/2
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MXPL=3N] ;X?K^3D;'NC==+%Q,>](&MX^],M5\:5:[7.9CJJ(=JS8QJ0NNJ5
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M 3?T5<4JJFZEFLW_E,9O]S;?7PI\T+KI+)E-L#1:))K;X5X7HZ\'[0P3C&)
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M2-=G,:_^1N[%,F2X'+?TJS7*:SSHWCL\-I6'Q_L)B=".=R]<]L%<#&$$;A]
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MI7+&CGGO HQ4\WDL?9*IMA^Q'Z)"L8G>*3SFG.IYQWS]X&I\0>M3KYTH33U
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MB+6YM.*MDQI&.5:>?/=DF[WB0WAKS"<D2MQTO]B4&KTEUMN=]M:1=:-ASHI
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MOHQI?VR4QWZ=&M=YVP,13$<6#2>II:L)6Z1(E40/*HADDQ'#4C !0!&= ,
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M1#UM60R!.VII)NF<)PTV?);S?D?YTT<*7::5@H!O/Z"13R5(A'XUDGV# MK
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M3LU"(K]Z+B[+OS0+; 3\^5WJ]Y;'B_'CSU]$++2$LJDTVQ9UK$K!H_76')O
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M0?J*:Z^GG@'3]_G-\Z<BC;M%N=8JL9(L-3(5GU/E'!J%8;(ZSPY9R#G6*P6
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MXIZISH1ABN[!D$V;A<U PB'Y>0B1CT$S[9;GJIN/=AW,0P^V.*)-0]$0*(U
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M]DZ,:#CJY]>S)J4!O/ZN,*F?<0B-9#^?\&K@\HI-#G24MW2%EW%/XSVVIV\
M2L4<9$*T,1Q)D[3:Y568,H 8$F0>X2H46$5R+UZ7NZ>_M77-Z^?(U?1G'(W1
M;H=H]'/#5'C!N.S&O$;9KP+&[RH6A 09->,4D@ DJDX%>GV:F(O/]2_+E!<%
MS<83>4@?C2T>[HY2X?2+,N@7U)=WS2]]*V]HODKSJ3W6?SMC-!C%PQ$79CT
M\F:6$:J\^:/4U_GU"N'Z];/$CL1C+##N/DP8J.M6H'UBZ*?[WD8DR- \IDQ1
M01@V.L8;0%Z:^TC*MZ;&9H>G-ADWH:D5PJ>@UR0M*=6EZ%H?VA9 IO;6@3/=
MX'OOY):IE54JSJ<CR_:8Z=#\)%4/@NEL@$ \#'V<Y+G_J6A\]_I5V>#6A:!=
MZ((B#6)IH'#P9UXY;B("#[=P<7-#W3$9:E#)@G1:R)K7_[M___>73<;^P]\?
MEEQ;%PK&#E\_7?T%F&\FKM:?WZ_>E3GS+FS_4D^;Q[)GH^!Q<8>M'^VHR:+'
MXDF=LT1J>%&)@,1Z=3?0I0U*ZMYPT=8$:&D/5,C,J@8'#UO7_FQB&YZ?_#GU
M"\. G8-OE*2\#8^^S>9Q,MG-#ST"XI/9=)WV'/+V%YO=S0^Q=QY#<ZK( 35F
M>B]G3W--M2,CK:>1EW?H.4?)./S6WQ#N-M8)GT%)7NMM4OPM_UK">@5B38MB
MT0=^>G75)D'[*_ES9*SJOC=>4N=DJMU0HM7E\1!N7/?RUZ2^\1JYD?FZ9%]E
M,=9K FBL\X!%[JC2V*A2^>[WMI^\509?\H+<K-U3C-:$N@N%@Z91R)S*,S!^
MSN+;0F$NKF(.9D)C1J:#\@QOZ'^87RB<NK2/"V,LVABGLG!AF8WI6JDC(<9E
M0+X.";+J?81O207LUS_QGT>\$T@K<KE?XK]&%8A&%(BS-_!!JV3.^0LX='FF
MG>A41N&N7.5723-:2R4+H$[Y3(;!:&B3KA&L)@ND=/DD?5G'[Y(/4^5W70HJ
M?]?5U7*CGM MF'3&%QW$7LK/,;;,D;,CT*5FL\YN%I=F.4E())>7]!%S7\)]
M=XHS-/79JGQ2SZ[AGN=PN,JU*IOV<^YKT4ZNY]R#&OTWIV\@O<.'/Q,'=2T;
M0=].<<US%^>#C#[U$U:G!SC11G%^X\ ]4#:1% IA_$IPM*]##-:QYM2X<K&'
MB/M 2P>O31LY_@(2[DR %K#KG Q[1S7E2W:<S20B/4+55CJ&ME9K:0)CH[G:
M/-8>)U .FQ%?)>T,:'-Z;+*R*^UCB+B3)E]?IUATQ:#GT_X,\\NU:HCS.GM)
M0VU+T.$*\H)H':7_@^%Y&CH/HT#PI2J'P$D%GO.@0^J[24::H>AXJY*MFC*3
M:(28.0?R6/]*IA^U/T0"ZH*J(B3-\N"?:>INO+F3L/8*F54Y":L7$MY(%O,_
M[,9#,30E1[6J\"^)V/E^0'+.K\H7=BWX"#\Y24[=;2H4[[$VSXBG^$>UKQ:
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M*//<37CU.K1L^R3=4-^F*,0DQNDYS<DS\J$++<9D.^YXB0$ [0>5%UF.,[#
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M#:2L\*#%OQD+5LG*&6EH@DI(C*P]@S]AY.3#%NI[-*M8\#_=<GQ/L^$7<?^
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M>@_.[#Y!(\"0QMC#H,?0O ! !Z!)HYE_A?]F A.I"0,;*!J@';)D\R'9S>@
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MNL'=[&&2O\/]ZJ&,O=OON3\Z[.%GCHG:6SA:2S!X<4-A5A;N]FX,D@K*UO1
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MMAPB)3$NSB2/>%4!A;+0CGASRXI0JPC3*L>/<C@K9#OD\B"5Y#R2=DV:JE/
MEX/4;;^3>>2#?G4&QXUI+3%XD4?,UFV51![)$\F54CEEI2EU3!="\XH2_W)!
MG9%3@%">>*%R7Z4/#3;7A"D>O?K>';*3">,#,[Q7&P*P)^:QH:S0^3(9C^Q@
MR(9TG4GV%?6][3LU&;#N.W)W2[(Y/O'MH-0W"LI;&.;[)KVU]CQF[IMZR.[H
M.%]!L^)HQ[.HG[,C.EW](.\F7CV&G1R<:1^/JG,L)^Q!J 5P)8:ZD)$+' KH
MTZB"T;[LN/SP92_:'?*'=U[B?>:@21-;>=4>\,9^HAX#W/_1P/9#S#W.:SG%
MLIT$D=42BH487I67O"RB*N=M0,?4F<R^0NN/2ZF,+"B4V8)95?H:7.5-8)Y4
M-8UINY>G0SG%>KI-7CW1\>9X%[&?.,';V4GL2I1DA:V<:*"K;WU9;[-X[L7*
M=/O)D4Z :WE@]#X9%LFLJDJ9-K-"IG9AJ.FQ)N*X@= ]L6S'U^SYSCVGFS0^
M!\E%M?@P8O=DO9==D?&E$*[4BID (02[\],$VI>*($S!T$;MWE!]?$-NN_M.
M($HFX+*^4T6]H^GL<\A#ZR;YKI1[C4HI?(>!%@7.7P+!0]37QDM]=3TY:RA2
MW*T27GW@*W?)[N;,:!V!>EK$)Z7 ^6,]20.'<:[AXLB[I/@/FBS'YQ^V68=8
M';H^%H9-']6LW6\U;&K4[W3,(QJQD=->@7$:8<T-*"C<[M.]N(9=4=R<Q4Q]
M'QH[;:2L]ZQW.Y_M+:=_W8ZG,U7$O)5+#F^]-TMO+I755 +)W I>HXI3N(E0
M7[5]DB+"N^+ZCN-;F&V[MR1;UU!+%I%M04>[JDX1=(Y67U)&;XY#/F:PA^MY
M#&+76G+\'9YYE53#<OX\F;'QM%VL? A^]HTLCXJNS,568"%%Z35MRYZGVJ3U
MNDI8].HJK+O4[484_]X5>=M'"BY4COWNOB>A[2LPL.!Y<O/-):W,3C5/HA$#
MY:7^U@^$%GR%]X.8$'P%RYZ95V^QW!R].S9)J=R-R6J9<= .NU@Y./O%O3L%
MUE]S+&$)QR THJ,83.C2BHX+L1:B'=4--RWC*,K(O/B4M><NW@3^U46!;!:B
M1&FY] P>D[N#'\D1M2GTU@W5]*TFC,OKSY>H[,-,=825CEQO9XX$9MD1T\I-
M Z^9\$LW/:B#:C3H4 /0VC*X&YH&\2$%[]T&5"L@KGR(RF>$*L*^5=2>'&,%
M9 _AW.B,)&M\1J]?"I'W=!2,&LI25O*5::V/&B^Y381I%VTODBUQ6LQ=;S*%
M/TYX.CG6'V9S::GJ)L56LP/N_HNDW:5 DO=I1[5<#!-TG^>VQ1Y=>G7D_=*8
MH9K#R1JO?7_[A.N9TDP33?XR>+*]S-ZWBC9O.K-!8I&H!X657O_*<=0%1B!3
M1NEP;DFPD:>"<SDZN1HI,<.AOD2%;IZW;]^4IZ/A*>"2-EGW<OT@NL>QPO79
M(%8G\DH)RS[6:/BU9<BC:8:MOI 'I6"98W<S4AVVZQ]B1ZA#Z<2PMBI29Q.6
MUHY <1"/<J6'BC@]Y@U^]ZONA6Z1F,ICHD"K^6KG>3V2."L>Q6<O^E9(AD4\
M(&Y28R$$5;$IT.>WZ]BD$'%NMAT#IF^_*G.+@+6F.'5\Z&+NO<(_WI&1CGZD
MLCTSI:MLU%FJ]8:'8,\A"^\NPT$#E\\MS@O0*\%S )Z@)^;>8E4R!I?8.6=A
M'<[;VQ^OYSXJP$F4P28LYA^G;.^K\UVYV%ISW 2VK%EM S<8S#LD"=IFII03
M5G-$!.79G>0Y#&IC@L>7^;9IYKU=B2\9"E1<'6$6X'HFN)BOKZIL,KJ[S[2N
M$&8L)!I Y)KBUM?U]DTH'=7!UN?>V<A*3=7 -ZEI'7G:+HAKOEI5CKSH)L4?
M_7"4,E9A)1J6TS;*$^.U-CF)UIJAX^M5;Q9"'E3(\0IMJM_>%[T8?>/EB,>B
MZ0SM]%[5C"T"OT ST2.<7$NAC6F>Q:D /XKTL9J&L.7=_(SF=P(:3$RM$JQX
MQ.:*\C:*/-A!7*Z<X?_>Y:C"ND!?J!E3F2_'I191+]K2KSN']AXAXF44U)5+
MB1D]&NUZL09"WS&#*<IC+":C2Z[4J:;;KW,1BPQ-X/GTDZVV_D-R?=L#';8%
MUJ$YCNWW'B1-0A:&SHL0SSA^TOSMVR>4V(%><MJ1A:Q8E^<P:^X)O@#0$^J>
M%/JFT0[@%DPS%/4#8?= \T_FL[^0=:05!+TTD9>0ZQ#E,=%A9+ 3/FC=CF?7
MMUK5SV+:3UYAV#;-K(-J9AI5L:MHQV6QD60!V%4TD3\HS21/J+^]P3NC# O*
M'R''9:S_24ARUNI8OR\E4)NY\:Y".'8+QQAJ1YS,HXZJ/B$J_?QRGPP,3O]P
MKK$^(>V7!98BQ[GE(XZN7&@B'C4L%"YAVK'X^, JSYH>>G*N$+"HD>FPVT#T
M??Y/UMQ-#XVWC!LL$GW5X#8W']QCQ"KQB408=L: JJPO;-K%$9$]KY?:_M1]
MA"-2!ZO&-'TJTOLAGT1]15R&T232W>Q>C1A3 0S>R'&;1IFUZ_T^XM &<_ME
MIXA:^P,+RM8&I<B,4$;&ETN?,35PKY-_26-:2L@KC*NTCVY5OD)IQIXL%!!.
M0^TJ&'@)K-UG5E3N-<<;EOWX(0&HM&.7I.*M;O.;%@@SRH!Y\$#MA^2UBE6R
M>M2*?M##0R&/IAU>$<>@8X]YYI$F6=C#I"DHL,/_8&; _41EY4:HMY5Q7:)^
MQJ)Q3<&@M*)JYCAFX4L)"%\G,X8Z]O2[I8T=WD4NR5#<4X!FZZ+@:O1(58;D
MJ#):26,KD'V;^BT39*Z_(Q/4CPAV:.9X2;YT:V;F2,N2"*RE2?N&+CH,V#U\
M'4(I74\]+"M3?P?5A*BJ:S*^6/X_>3X@EC,LWL[NJ.(JGVZI$;Z5S\JOHQ?@
MSA6B=!C,4;9C:>,IS(F;V"Y/P!]RB:->.8EG4<F%$ I )UR0S5F825SW"L5W
M*\*%%B6D" 0!)+W2J#U9[;H-7X&&]N4%-DI4)A0N/>XL,Q_)96"_?#3ER2?\
M$3$-QRP]J8&JC< N30AVEA8SLT0U3V<,Y^MGZ01R2(^^RC<--VQGNR-YTE"H
M6USY_BX:^:B#OQ?ALL33R^WPO3I##EO3RVUFBL3*]";B T3UU[5:9AHGQ@1)
MES]PXWQX("]'<$&C5D]XYA <L5\Q>YR%<^$3L:,']M(QA4MEW=J,074% T.F
MU,D-#:.=(^9KXRU7ZS&-\]7I#VXZ[Z D$K:WU=0MRG>SH'+R=$0WDYEFTOA1
MC,GBXQD\;'Q^@!-"8;_@K<P<'6%C?604[A8P"XP03W#"UAE@D5!!I9:8'^T!
MM="D&'8)KM8,/R1HQ@T?2#@\4IMUJ*=983-E=>\[X-@Q+%6:8$AG<\4S(VIA
M>+N<]V82O5YW)D<&3E^.R.#'T"R@Y( 2W5[)BTB.=WJ<*JCF%3YD<Y,>(ZU=
MM:IDO??X@C03$>_[!_B8^V#F!QH1F@OC\<+R@N[:0S>H#.%+, *[/(1P _5^
M9?.A1;9B:.+,WB2ARW7)R_$(Y0R6LV-+\'_@5IHTTQ@O! H&5ZWZV;D43]8]
MKYF ,%GE<ZU:[;KGM-]X)@R_7&@)ON 0-L.CBK,$[A>X&X:X_*XK+[7\%*!B
M6=V1[],?LG?7+-&T@ESB"8$C57QS.-?F&RI?W/<'=%!#Q4NOQ0U[;W/&AZ='
MA.09/LGUX5L\X*\3T)@>'^O30HM*.-Q.>%@RP+@!,<>/9./ILFH3&F]*-,M:
M%6^L\:%Q'C!L"C>K@ 9QI5@8\X0+B9AZQ9>-0SP\C^#".6'W-*"+=:5[6S8C
M#)4>W RRF;$)' :O1]/00IX2Y&1G\8CDV:8'L%]2\GRW@LO;V(PP-O,(N&-5
MU;H0:G_2:"%.TT9181U =:VK([#?Q?:RZ 8\-^?9DP"*]&>^5)<WDHUSTW$3
M,HR3@G*]^^\TEN1XEW1,,\]</G+T;JQI+-?-X2H]?#U1$C/36JKA7_CXF85\
MPWA(XFC<AD0,SV)>NB24,T2W=VL8JRR.*4=0O, 8C_3H,>?B?M B7U!VCML'
M.\A6*M=0;&58@B(P4:1=TC2MGVA68L803Y% 4FRQP&4L\=%)IM9%N_X(;TAX
M ; ;=3E,P1B%\-5"M[J)&*@<7=XC=(:U9H/GPW(YA/K>):.DN0D9V(U^/!A[
M^%9<:^>\/5:)@H.Q*E:=9V%AY%@,TX!7P19?D=Q^ZZC,9O='+ ]7@=<-8LHZ
M;9UWR6"WJ=2A3Z([!KWI+LD^'E7NEY<U7A4FDC5=K1%<1I&Y!QDG@&07&5P7
M_=CN;F]C9[RJM%5:6V=(H6QW!T .D!%RX12??E:BP0(K;*OM*3?)=K(I?E50
M-D$=* 5_ROH9?GG9DJK!'NA<4A8-R@WZ:,<F%G:5LJP2RD%J'BZ/2<:JEB":
M)JPJO<Z": _'07J!9Q>:LA>.V8X(%*;!,H<HX=8 >)\+J\X.\.(YN_-@@C$E
M]%D?C/(GQWAML.?"\P7&KRG'R2KA,N;"Z0B@C?&Z\3'M9F+)1TT&6_FX9(-X
M#!Q$(OE@X-Y^@>546:2M A=E>:1MK$*A8=FU+K44\!L&N130E3"%-U'!)*W:
M@(AN +I_R64 &#7C8]/--"W!%[U'/4QO>P0CHU>5:3_27C_J?F=Y5#O(/$1/
M+ASCJ<--\A];NKQWZ3676P$H2PST*,,BM$^W (0?,()RR.!=)53^LSRZ'>.4
M;,R;'YWP3-?=@[V$N!Y-^EZ?UHT.>N!'O<&G9UY@K-)@7Z=2!AP6<'4-"O:N
MZVNS?4#CC@NQ7WVAVR+59GG),KKX2M7P_),[/48AH[IJ-+ZD)BP1V?H::%NY
M=M-B+-ZFDU@I;$28@71AXIC7C\9OWQ03FB63[J[?;ZM'/,H?O#K#*"!N[Z%P
MSZVG[:9H XC(GIF?<H6(""49[9J@8*YZ1H9N1 E#LK7((P9L7\PP2[?W4Z37
M&7H,/Z0IK.E(9)+U?IRB EB(/938'KX^P12.V\"+W9;'T@E_<X-JELF=7E<P
M' )5;\B:!P!"W]54[I#7/O7PW2%BK,![5KZN<NV3YT6?0CPCK+MRS[GX$V=8
MVD.K;QH]?5V-1I+-:VQ5\8)2EH)03Y:50&+ZC@!]5QI=VW(S<T>*N&_L.IT5
M>;5PKL]->78;H>W[13C<+U_1+8Y#6^[JE].$X@.E!#B27[/HQ)9 [YQ4F7,9
M&O+Z\K@-OP%7;S-L^\1,LYB'MI$T*#W8<.B0!/<)@1Q CXO)23(SBW&:%G;E
M&28^M'@%Q%P4]L/DN ^%?E2[W)"?Q)948Y4&TIV@H&6T0XW05'9!2#=-4-X&
M.FQ)8UYK#Q3T[=L:FIKS<;\[$#[Q&J]M 69?42*KP&Z[$B=/WK6+6L6;'ETN
MR3"U%CS:HRZ7P=(A2/R<>TJ 6]XZ3"H"P45">K<2/9:CU/.BDIVR)9;X!"V<
MSCA47SI*^T5T<-([XNHH&4%H@A&X*(IQ+*F),T'M':-7=%C4!=09:M1";QKY
M+:4QPQW/ZU*1"^^<OP@$F\<3OQ@;LW!W'=&0N)+XHLG&+$&+\C$%LP@M#55H
M!BZO79G(_DKTN(E!X=7_R':&O(62^18>.\VQK(&G\15GV\8>EG8NJWQ>+E1Z
M[BXO55X*I+EZ=Z (03P\8+NU.;"2R0S39E"?TQ! B51Z$_?,X4JH 4E9.Q7A
MF##1/(HS*_N'8 #&75.%K&9#N_2#2,B<6MLC[O9W!OM,C@Y<-0YJXGII@\FB
M!I\%"#8HX*ON)ALT)"ZMRA#S*,RH)=G799+]E]S+RV>RK%M--F/C._&*M K>
M*C!JMUD^JFV7-[B2S<P^$7:;< 1O#<+./_*"V<(I-"(BW+9S#=_1A9<4*.E%
M&>#>@2ZX%=XRX%);;^))[7^);'8/Q=F4/Q5!]>;"KN\3\X,O4\()(HV)SIWL
M$2V!.G4X&N09;>RY?'5UN28:FCTT(2KF^+GVVE6/E5S8,U)3_4GVEK=IMYY,
M;8TES3;Q#U'=@JM4#D!%M[]D?#G0RFPS7BW8NOPXE>61?7Z&\?Z[@\G[(#.H
MTDN/GGYZPA<0!5)YS!%[,ZY6H 93K(=636U4$LUT:><1PE 98NKH*(VVZ=IT
MNTL80;;H8YR/W;67',9(D=T]DVS;ZX*K9#=#1UQN\K&DNW6RC<O)A[^D<K]Q
M@+[H\"/8FLIL>YI5F,BX^GI8:ZR.JGAL\?CB8*8#QPNBI_<9+?,F/]]=G(V^
MOA2#.Q(59;MNS9M2[1A\O$$=C;%ZI7 LUJ)IS2('-2\V<(]:(WB_02!PS];O
M9@?P5K>-33J/W>7U;/=R9<8FBJ7P]-&!LSODI9MMFP)\;K5+Z%Z=CUK4$6I
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M#Q!X@DSJ21P>U!Q8^WB) O>.4&-OY6Z9]YU5ZP*JUI?C#T*ME(R@%!:7GY1
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M7Y2T=[+2%2]JL_O5G+KNN-'\+W=XA'*K]LHB=PPGP('A]/NV;_$V=[OOZQ*
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MQ4_$P.4<&R>,2J,D1V>)P9K2]UL=F^L:0>S,*"<_K1T]\47JNH(!</[T[@U
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M%%-4A!2*/U3PGK W%.0.&<EVUE!W\X+-F>_A^$<JIS(3@>I/;^VX"XC;'BP
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M.W;HN%ROMXH4BJ-8+%?0<%FM=XB+=+J<(9>3!D 7J91$4)>HE"1()Q7)!=-
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M^^#+%M=QXR)4>8%[O2FI>+Z1LO"] 90\+?XM,#NN4QD/(F#<7?7NX6%/P(]
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MU[$GA[1[.4.F-+FP?P/)V6;.H+7"+#+7@OD/P+'[>%5#+[,&UPCWYYEPYKK
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M 6<Y!R.J'7T_CL[^UX*HX@9M^(T>)?&#$*-B77SC1&5O'OQ2[8M'A8'N_]^
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MXC![ZS.?V.#XDB?B/T&")*W=/]G\@&.ZRC;Z!W>FM5Y!AJ)LAXM2065JRN-
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M1$RH.15DKJW(55>2_;-<&R9A2>#7PE/2;Q- TE!B"TS._P VJ$1E1"&[+/\
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MS-(VT>),G]+J<;6L&;8&)R<&1VI"8$P--EQC*;6;Y726F0L2HJPLR_@C?X)
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M[913H$C#G/%^N:(C\DY/)]&*EN5O7,D"&HA6@P8>9\2\QI\!7%.UWZR159:
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M[FWAQ\*;R072954: 6M.3%.;\+TM$T)/I/A'.^6T"EO&%$</)$I__XI8' /
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MXGI8B?>PA\3 TY@X62 UA VE-MX?@@HF?_"D2B .B6?C'J.SC Q\QXR(XX\
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MF4B#$G1?Y3<SKNN@17'1A:J(G#&"JFQH@=RUVIM7Z[1DWZO9TA^\X$YN8J\
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MM2%$,>W-:49G4EO]$XP3[LWV1,6JG]_IV><X\:TSL.3AZ9V;6?(3]??Q9[F
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M/ (>WH61A3J\]N$I;LY?;,_/9/K<.^]V$E=&N00U'_[>&^Q^H0 _[PH*I4V
M.@W['P3Y?!;R!#JFYV:.9HR0WUYT5S;L Z].R)3OHOFFE^*T@[O&^(--]V>7
M/20X1?!?()S)(0Y:EDF/&/>:R^+8KC*IP!.)2 WSZ.(=\F.%(B/&_7<SW!$Z
MU&].TS@21MST 2Q1IJX*V$0A+%.7QBQO'>8/N,'/)$A.'0._0?,\Z;2^A#S
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M7/BP?A$3TR#";E'X8(*?1;^96FQQ'E=B>$T!)S^UZ>>'$ZCGC>VW'](KXP/
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M1I+B9[C\0<B-)/)M'5Y.2]A@3<87Y= 7CS3(O[ 3O@ND^L$>\"T4( 4>O0<
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M8+ 5Q>(V!""!:L;,P\J"6T?GHK?VG]RT:!?F#(-*1$KB.KGH4O((<R2W2KY
MBS=7)7FCL0ARBM4"O(RZMV^H@]>4ZG[29M953SF7=(P8/."H4R/YZDN/>YG=
M3:O WS2Y?@\HP9BV>?&C1D=YRJ7>\%@94C+XH3*6M70T"7&2M*0"*3. W%5
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MM;RORC[YG6>K7CB[4%7!+>R5U46(C][&F4AB6^"N@ ZGL*.31T.^*97+9P
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M<,W,S,S=5@+PWTH5SK+]_,@ G!S[2MUMR4^C0KWTM7W$*$V5>LC7RD]K:86
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M_@08$ 1W& H_'=HJ!G/8MP4VO)HG&^;8M!'=KZKX9EDA ADR:&TX&2]+]F;
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M1/R&ZUA',<UE6!QX,WX% Q*8LM_W.2W;L?XQ<]2W9G]L,8BZ!YKJ/68D:6(
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M$@MC)SIW:_4U*&P;Z0[,L) P!C;@/NL\L%/SG^DAHYCDNJ99UF@F;OZ-^H.
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M0:8*9]GP^4%UC/O':&*)V2=1EN^FX1LWW:VK8(MB;]V+B0"]R;]Q5XGX$@;
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MWVLD'91H0E7&;"[8(C,*K0A^74P2Z\F2-AE\P!^W**8 WZQGZ7UQ:A@GY$A
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M$^CC+E=.+!TO#A,9BT)6S56+!^CWNYHY$OQ"S?\!.L+<U=GKF;C_\%,7EU>
M;4G;XCQRNDU>W8E+!:;J\R !BZ3X$>NLR8VZUK *)B7I+E#)&L0\]AQ<_%>%
M*=G-&]O<HNS$]QR<E*Y:%-L#[&=W"G1+O:UN;?.LNS2\05UW[AY]3UN]LR"/
MX X4(Z_1;;5).*I!:PN87YX6%>"(KW/$T=J.WO+4LGXG0OA D!O"C-+^:T#;
M=<UPDK[@\44N8%:_ZH(=^; 56/LH2T.AS@"O%"XEM\"84 J0N<F4I%^ 1E)Q
MWD=#9_5H7E530UKA8&=S(%#<O?W0V>H)6?X&L[V6M+_.S1 G0D,JR20*,Y<V
MD"BE3$?C8^_PW;]TS;DW!!$R,Z']8"Z)4>;@.MRA;0_L^%A-AP_!X?$S.2\S
MT=/E24+("E.%6$9!GMZ$M0/8$Q[?F,Q*PW)YD;Q86 NMC060*0K;7<68:[C0
M)S2L?<<5U)=O3WIB9-E(JTW&JX6R5N3"?CY-?<;@U"\.<R%]FRB@*76P:_ +
M^ ]A)U7\8J_-QK5BN- A2\[KZ+2T.#OU K\OH9\SV)LPG,6+PRWG$YW 8Q$6
MY/9#@50(E@5>:=<)75>X/+"3/%O9N[2OX!N0H79GK"%JB?M1GL\[//'%PM5C
M[(6S^*WK$']",(-7VWR +BS@ER6.;<46' *FM<83H9(#6R9Y_$/?:47N<(G@
MN.IEVP:'D!(%+"0!C8TQ:78)J%&H>3&*D%2-"U[GBMRAU#3GJJI\8JMZB_^_
M 8'_GQ*K@MJZN^_ZNS:KE46XJDUWHNX_T="^U%;>7[:5E_-XMM-U\XR2>R/J
MZRR9./TC2?&>F\5Q+UCLEV IQ5[WG-=\J5Z<(O-O#P MC=H=T1,*9#W!2X7D
MN0G!3L-(NEK0PY;C93#/:6^T,=X!\TRT&1_H>24=-BBF\!\@=\QC19$\6!2V
M )6D'T5Z:RZ2? WD[W/!#RX7Y=LZX]3I2XJ3V/$F\28IG$O\%/J\$_1_MAM=
MO9U'T?\+_^>5L2)'^71;^D*$K R:QQMRW'\(Q/MB2[YT'#"^9%R;,I6!^@WR
M:J4$69: >$Z$E-(.PN57S NQP]KME_ D:P0$X+>_4([_K[Y\_M+F;TL= D^4
M*E(O!.Z0@05$9<2"G,?'CQ][G0IP@7*0<RIG3B0^J"+Y"2(-(8.'/3YVC7MG
MI3:-]P_M@;T"R[;2APGI[</"18)/?STP,@AUPHE4[T@C14@MBSZ9'[CY'<;?
M]9U2WV>1^T5$L$-WHB23.0-*=R;T+41GD[9F]\IR-24.=Y68-K$^16*(RA*4
MC[&GDJXO\7[9"KD'^K?V'RJS#%=!4!TQFO1)C>Z53@C;G3$CAS?<G1 [' &;
M>9_=D\<][JSM_ $$FY>N3+;I2O]]:0SX1'!+HG^>=?4SK:>&B_['Y& [E\</
M\NUPHU ,!V/:R1DP-0'VCV4;J43;5>3C+DG6\,B4S&C!K8KU4L.)9II+==(6
MD21]*__S=GOU\!N53!\Y0]^W7<OPV#+\77L5/@0]/6B>6LO+9PO@4=9$Y\^$
M"-D89OW0;1ZP& 6ZQ ZN4=_5GYP%%3,NC\2N1$5J/E!1:1E<2;D=:4J3KFOK
MS.RIO;T;YZ5GZHF@$UUU56%9*;B5.;XY<@ RK(E=3=?_OJ%SAD^R3BK->7'$
M-)O3E*BO*2O7-QN<.7[XV=IAX(VC+R0F*60TH#WH:%_5]K-V(YD,7Z8S^SFO
MY,)R"$ C]X,&IMDH/DF34N=J'OD#@7Y3P=*&IIRIHF2H2H#WN/4PK44*\3CA
M(U.9J!#<=_=+EN3EY\;H\]3*XO+O.W;\>FQ#?_*'9JLAV:R9Z&';M>F7$W!/
MQFC#UW?H=)9FTW 'MX_<R???!+U.DF,Z53]B6C+ $INR!O5N'J<UY,D:_?!=
M.*Q<&SY\4$ELRV9%#;:\]!:!Z\J3?E*U,8+<:1&_Y]0U-A[<[%G9KMF]+).D
M&ML_M9+VPNIB@\^I AP4':(B\)#X.H5U#9;2^Q@(#!P:F2[:5=$!$.@D /ZH
MA&#8%H]#NQ7LY/&7* <"H:=D]R:%JT\)CC7P(VZ7)?5T>H\FS@6?6ULR;*=C
MIFCN:#1/M'/2N(+0%ST'7KB*LRP/$]*.LW+\L%#1'0QVW-A01SZA<QEIPN2)
MU#1!>Q1KE;W"!%,W[0S6BD*%?=).;XICG+#"S/B:@3%3"E>3Y-:8M-H;X'L;
M$*-+@.>>:+^TC6CFBJ^Z/22_VM@.W5-N>)GX5ZY]I--W1"%HBDG'7M/0-'N$
MUB#\[R3-:1@N3<@X]%'\METSVQ0%Q!P991!KP$:<[/_TPG#L(5+NIE4;9L9(
MPI!^>)P2'28J-'1B@X5" +/)=\H=UL($N]^F$!< E2._KKW?D:P5I@)XVX(R
MSB)?9^>'2U&',,><' #DX87\O[W9D7-L=VV;J<VT]"9WGU#B4Z?'M:>6ON$C
MT0[+7J[/CK<K;D^G+PEKGS:)SZ3&"X9;7OF)RDHNCZ3U<QLW2^07PGU%GF.5
M[]#]&JQO"2<B&1>= E?"0?JH32T3!_X^ <I'72/*?_>4[ZM_$O#G8YOZ)8C]
M_N_&)" HJ*ZN@1" 79+<^7U$/\#8$T_NNF,ZNM6VM=1F>R"F,M'+;QMHK_&S
M P\&L[Y7%L\'40"('6YE#=0\(!6N[W7=>*V8':L:K]>TXXX31*Z(?A3.!?7$
M6;NU\(E2(>(ZN#C;.W2L^5G*BJMC4VDVL;+#E["-&OPF.8!^A"'$&#*##!_9
M=')@<?ZN(3A6G^@#^_KV'P A*Y<SD/1NO?ZA+%B# SNE1:Y-I0ML_*BH2!!,
M$+M#%?'V_P_HA3_DZQ]YR*X[EAR<&MJ#^6FGHI?$EK_,\[<?MPWM3C?5@QW>
MY=D6V95^-_PUDT8X;"5I"Y_$2ZO9W//]62_HRE 6OK_]GMDG2B#XY)@-GH+4
M(#?H=;T@HJ+!=;DDWM;0F-L7E&O>N,$>(A*_MD50V!8*^Y"KK1E\L[1].7;+
M(@U7U^HJC#<!/\WW,3XLL\4G52-%2&M*%_'F42I'#TC''_".8@^D8K28I1HP
M87GP9IN2SW1BL_\XRSD0IW$'2E'RH"_W%O$826U4ZCM$UV#X0>(@.->I4ZBM
M%G=PE@YXT>,N5L6'+(? ,V&=F_*4Z]'JC7!#$BX6DV2BJ)*>=K]UO(1_ZIA_
M6O"@_@-@)+DP0PIQ+B[O"Q+9C&(.H*E'([FL.._0X+VS&MBFD0GM,KJT9HP
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M/;"K'&%%M/C]1T"3U:T<+OT>%Y1/I'O*08>DXA5D -\M>7!KU&F@UK:3 '&
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M]Y9RF(K4<% 67I8]/,0BQM9NOV[H:3U;!^+-G&/0Z"WLO16L_* @Q,][^'\
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M+)-F\&+O1F/?DV_G707)(MZ#"ZJ7!Z-%73/)S3),3VL=^3!T$.#_.40 @#L
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MBSNQ(]:#)SS\>Q]%*[#L_W,?TO?:5@OH4:-;RM8%>F;U#/:QJC<.\S+ZUI3
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M9:,>M$VV7O#F]"V7GB+HM$85>*/*1B;#<^]HX,46*ZQM23#5Z?1W2QC<FEX
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M"3O%^P5XS!.HO)QV9W=(W/0%NZTGG[U4X[,,K7855C1BZ-0 ,8]CIYW4-X:
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MZD<U'.L:X2.9B0HM(!!'C9$=?$<FBL /V4!N>3S2K2J2LPB9Z-)P#3]<"R.
MQ";*@B@(\NZ(Q>RXW(+Q1OP-:\$RV/Y)M&<#'2%35EGN2@\$U1;11UED:[K-
MT+NHW*^(8]/1D5EJZ+3V;MN"S&&QWM)L0Y,V6T?6 RO-+ C+!6/T^&Z^&0:U
M#6M+C&N@J7X<NM<DR!%G)D#5U>C=4A'6#[U4Q17.Q)6&)4E89<XB!NS*8-/!
M\>G/__D8\<3@OFS&'M)\BV$P-YYG58'3-*J%/[64R<5;.4/++?S,:-'J-R(:
M54J6XBJO)3/9;1.[P+S$([F+7K%3H:G-8W79.@<Y+4]*D%0P1(5+J4ZKH3)'
M&,=UZD"S2>$&0NE?+9<@P6_\)MK2L65K7YB:P5MMO(X3%^#&.E@=!:>-CT%:
M0+.O.$OR(/TF511K6V8$O5NU44U':VT_Z9.[+[WKDI$C4O&81T7#^^W^^-E8
M+2\#"T.TPS(&<8Y^,H<@4!=2ZMO%^;/LQ)B=D@\175&2PIQH-!DOUD8ESR:Q
M)(Q[&P>\'G")-]V5Z.\)5HL?HO^U!K7 WLJV(*4BOHK$JVUE\ZHY6Q\F?(;W
MI](T,W1C##EV)M2>U?9=-V;B*7?T4A#-GJ,C*4^- .3NT5"MV3J_4D7*ER5:
M(1=J-\U\51K+UU$F19 CTH&H;BIAO\5A&:Q\=[&Z;'^%?N75<&,/?U!;<_#1
M9[)=:2L!/PUJ7&I$1Q'26D4XS9"8'A'C2\N%B=I$88JQ,,K5JQ$U\\QH3\M*
M3,])RO%!OF B*=U.P;44L-_Z,"'358VKW_/M&!\UZP9Y-G7;(ZO&D-OV3RQ=
MW)R0(>PP4Z*",>1^G4$S;$+0QE#NOBFRBB[J. <IO<^84"3-E)4X6^1))*S\
M*KMK:%_3N_FVES^(Y\4@$=-H_WA)8JWM<-9(IU1?5%@66295PA*3/+ZVZ6X6
M1<E[  @D+;9MY9C@N.\2 P]I;LU\ 9BN0 [9\9ZN72HT[=>/O9BU!QF=OW+8
MF68_Q&"\5S0JM6S@=Y'=@=7/,^95QT%E*#6C>H-$PA>V$0<M<C5I17%5-1-D
M-E$&[J8DE!R\:QQ:&<^0OC(9@VSSC\?M_J%W5DQ>UK\,X :'T1ZFU&1IRZJ3
M"I.F 8Y)64F:!_1$$$E2&_MUEC>5KVUZ^V /"VU^."MPQ65?6WKYW!/=6YE2
MU]8>"TZF!M/ 5)+(S:_"9 ,19J66UHYY#LO7AZH<LI^2(*$N*TT#<+)VBNN+
MGJBC8K>"U'_T"EW!EBPF9895%Y9E6ION-!NN(];PV\#,VG:T8;=2^-*RB:)
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M'K[G/F^-LK"05#-9Z.9S]2P\ E\LSQ[S<?4SNIFFD H<3DV W4Z+TQ)'Y5J
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M%7=':PF\'2^A?=70)WCR!]^I6C51G2](C4%B])L$TM=4F"1@K .@!!T3$P.
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MLV%V4,8>Z<86'V&)!E$6#IM Q5:!8(83+3K"O2XW+O"=HP8&)IV7.1%MN@/
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M9YNP=52)TZ&&8<U7>'F2BKC1;IM; "\IBM0.#]1X[ZL'-IH%^\.<5+ Z0I2
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M.CS"@.=HX,U\TV:PR$H<U1/[.7%I2T5!%N6+XZP5.<R]J.!*@V;.X@#5F8)
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M)C_CL*69G>NTRCYLF+%RC0(89>+S[O_^6.J@0)5!+BK:0:.O&ZJ\L1%"QBY
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M!7/0-.0YL4BM$ORQ$^NX)BR6>@?+\.6L'Y;(P"JH#=A:"U0,]9/SM!@4RY(
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MNVLY_TA)C!59)I2E.J@(X50"Y'_Y7Z#"1!%M%F2^,:OU4P6JB>87WRAH&#F
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M"!"4#149L]]L\MC006OB)#A(NDW/RRG.$R1[$>S+7XB1K^CVJIK!"&*)!QV
MS4&C!8PN_T..88$+U6?Y$.MXM+G#(.9%ZVU$F5_#E-)JV*"B?V</E.*E0JXO
M+] [<&W/-=OD9SH8Z9+Q+=./=EXRS79/@[JVPV2&)A6C!K6B3$%>Z!"HF_^4
MB39%;QJO]98U=?W8N'Q?\H^[+;8!H@2>?XT+8&6<WCEH)Z_@?8H\6V"*8#KR
M3A'Z1=&3H'1*'N8QEP8DV^\^)+36^" 2Y%!]F+%<SW&&1N1<%B.DMH1^Y8V$
MA/JS(<;IE1BDTI,KR7G)G4:G5A5>8R>G%3]6R$-C)I%#:CI&NT7/HW8KG8:X
MG &82*1CU-.''F"=20*;WMHQL)X+SMZL>PW\PFV30ZYL?RP/S]-D<LDTW7:7
M;7.V'U-9TE4D9ZC-M5O+-#JP9*NH)E-AY:45WE'MV@ZE.HGF1_E;U-F'NV"0
MX<W(3;:#0T2@([K!"@[ :%6=N[_B R*PD7R+W\FN6$>K9.O<?YVH:.GO/>VG
M2='504D#1-+![";XNU9OVW^8;>N6C@UYR2,0Q4U LH8N(3#;MY6VM]FCEC2-
M;<T :.MB$8NZVB^#P7M6SPWQ\U4G2*&:(,!DWG^I$X*4=?U+Y=8M=IOR+\]S
M/8A=^\\KS/EIS3(*^T<ZL@/7Y!0+?95?_@Y%L/.!"LOJWQI3%9+PA5D(:D*-
MZ/ OVM0?>EQ]F%V<(K[E&@[PBM;;EQMA>-TXA"NH;NJ\UTLV8F)V(*]5]#31
MGJJ>Y>B:(BA:UDY-IY)-+&G!NT0)T$V!:&.1.Y2/PQ; @ZMP3]PB"E1*_9;"
M04O":+GBT'M!T6V=\M050>K90<YF>[IC:WA]4>SX# N6\'>']62]Y,OO"65"
MCA")?6-X9\DPQ6Z78\O4&M"_^UZ9JWW8P0!F+ 8J3-E5=XZZ!%E<"C,+%4WB
MG4XLH6[3S[J#T1B?'\VK]4EZO$_8J27.%" 0MU.&\%BHD^Q'?*OLWIKTJ[8W
M)9>4MQQ6DNG#'@/^V OZU,?F2S:C<LC5[N(:XT' .?1Q^F.2$_VZWT.,^R?+
MHVTVT%FW&")8B".P'7V[FHDY+7Z#'LAI;L36!C+](&>R#22SO>2<;1%QFPX)
M2T)9M%DZ64)T!M4\*R88TIU8[QI=G;2YX-879M/SM$)'=D-U[K]G[9O6X0I\
M>/33 )I51,&W/X;%84FBT:!ZNY"K7YIE-CH<M$++CC5)Y1+ D_NP["7R$^V6
M(8C/.N$ZMBC'GF&,H=T9Z9VT5]7-L/TM8[B54>PS-@+'H8S\"N0V\,O#JP=1
M!NA7\RVM8 7V(LEP48KWAC+PCX4#DO-M?\<5/R-4*X*.QQT6]'T$--U5@V[I
MN_5<N\4I">I^6F(9\?Z]M2;&FJ.B3I#A6R607G.&H-?\7(T9ER6.LNR+2Q(,
M]/I#1@8L3]>IC,@4((S$>_6S5M2"(PY,QUE3.\]PT\%+RQ[.OEF(J,IY]Z/9
MQ9@CN[=M8S(NJ<!BP]7Y$(;CXV[NI7I&61(71Y2^&"X%]CPD3R,+;XC;&!!6
M]A]<[6PDPQ+O;X6;YF,DX2CV$_(YF)QR8JYZ>QKJR]ZH_E#9(;!M3!_J?>7*
MV:O/C"I[T7@TH!J#C&3(WA5-F%A5ENRV17ZSCT4)=SM4YV-B36N>%2.GT:-+
MAKH#HI_V%)0<27/F2+ID]8=_B*E/D#YV\J%HL KWC(I[]R$X)0>ZW/>BQ?@,
M\Z8%>[,AZ;0ED%P%]CKS)46-18H_<@JJ#*[MJ&9JJ/?Z,6-L6V;SWC/,0#C?
M8@G%M8'4&Q4"Y];65@>%D(S0V-X(5[DJ/1UQ^:,";$VKC LW39=/?U[K_P:P
M1T&GG/G"(<!;Z_GH:G;V^#S-9/84Q([/MB&F\5E*;H=T[6(VP.!#0[DPV[ -
M5)&]BOZT"2H?V4PU4V?%,VI[R>87%(/7GEHY9.CCV,P67CC%ZGL[^,)K0P<9
M]*X3?<7L.U6*D0&5KVZC@I()Y]QT/J_ [)N\\K;>A__&L$5RQP5E[%XT$O1A
MN[!)7R-7MH?O3UKH%2$P@^OV3O;"EN,-PPV.^1.40BVS@2%ONRI=BC"U<CQ/
M$Z99LS)H 2B1W13'O1A/K'@V^CFF)S7SQB\7/!]7>T7&\XRN8Z<F;:I#?VCG
MWF+=94I@PH^IJ$]I,>R>\Y]L/)CFRF"%A8_%X-?7C\!=/-8#>FOMX:#U"JP9
MHH]),<8HH^%W08'5XZ<VWE>K"G;MD,,GMVX+KJM.GZ" D;$]^6"C>#7<4/LQ
MAK2:4K<G8219E<),F'"-;;"*%GNXNK<^E/$&+M*A3*YS$V<NU9#) L1ZZ,,K
M>J<N\_1O5+)RD&8[52!]S0E][:>J[*WI(9\J+.8 T]8^ZWUF:YL=U+E_"2SG
M/C.X8_T5>_?3"MK3^VW1@_X;('QG\0!^W(!NU6$O6HZT9\[[(N)LW77@T[J>
M\+5^J=*O##'9B)M+?*P?OY&3;" -+9F44$T=0WLOK0'FQVJ[:+YL\]Q2]HK"
M O@S7(*BXY/F C*(T9LUMBO$CS> 54$BZ,OXY(%<QU1$AR+Q^=F* J*IOTR/
M!#UHL8]>\BL09KT96T+=B'9[L/P+M4'8R D;(:.#24JT?OM7D7GBF3F/W81O
M0=[M-\U+7EZY_"X[>V5<L[TV]HWEBXQO28?-S!(M)Y3-Z^%'8+\#D&VZ^>!/
MB@9G4*EY<6;NZ?<63S(.+MRO^5&TO+V_V5H]R5I/-E43B22L4<,]8/NG-/5'
M&G@X6UAV<_4SUXC8OP3CG_\2N&MS 1-N-"!?3!25L+E'4WM-<'I[HF5:^V^@
M'C_MX',5;F8;[[2 QF+LB>RH;%Y$NA%I>578B9"6HBL,L.C*!QAM_/?$Q&D4
M<7KKX>DU_:/%.&JP('L*/?5-S^7T;>8M=2K*?4!<RQ0OPQ*::Q;.M$^R1N^&
M+_L0H@"NA\3O)85.@0D-9IE5 W^=:UHAUGQS+=9_?SW37>]=<0[2UEDE6O,D
M=N_\,]VM'8CC\QI[-X01<).0C=+^:@ +PI"@U6=[O_$? (3ADTSC$MW9P0R(
M4?DAP/FU@[QEO0=5?]%EEV/;%*Y^3EF6CWW""LNX617LL/<,_*;6M#RP/*9C
M3"EG/9LOJAV@P67ZKEU*Z#IW;5Q7/IQC0\KQ4EU()1^L+0YF6.LL7O7+'KX,
MG^E%KJIOQ@63@]S=@@K7S+)P)0*1-(I0)U[Z:,E:_QW/1K.=LT8-ZWWXXQ"Q
M#+QNU5D!+'KJN]_%A.?&S:]2S'/WYMUCCRV@I 9[Q[X%^D'6;=;UGZ=-%H6<
M23H/]Y#1 "2:^J/IU]11@_'EU6&MKL+"F+GI\\N#:5N8F;A6UBK^^1-PJ?\?
M^=A\GY/N%,C-F%R!269+-68"[,DLDJ&P\NUS%8^/[&B]_A5;.GQ\[,A[Z4A=
MX@][UL\S7N$*UE2J7ZD,%%W.#O DM,HJUG6RO3NI.R)?F.) ^Z[)B_FS5X%X
M6$> "/!7:9;37P(*9ZRSFB7/;E">=U(EKPW4&7_5)K(/%E188>8[1P)?FP Z
MUK_N@@ZS ARKY1*VE*\H/NB>OL'*2+.D1]4J S,\8?UGPU9C4*&Y9I3/R.JA
M]X103]3Y-]?M&3DWJKXROTG3^\)%?5CC1.Q;[\<>CN7$6Y@5=&?$BI5)'"X]
MK]3P[9O4-GOLXO&2 &SRLD9:V%;Y*KUU?DR4/P3<T.)OF4T<=72,FH+@H(/@
MF@7A8;PE=EIC@@:[F-R/ZA;&6+E)B4ULAT0XY*]ON*=ZSER_O8D1I/_A@O3]
M\BWXQIAW_ CM4#O<$9KU6E8"IJWAAZ7VKV\+<:.U$A'-ES9>W%96N'!CM<9V
MCJS>]U?#HS&(JO<[K =F[E[Q38)@I5<1GS5D/KQ'EC?_+-MF69['I,)5H6PM
MS77FRE+-'Y::$"H=#A<R9_ORUIFH1M,Q5H./GH,W?ACWEA:AU8 PR-8,'G[0
M\GE (=,/RE4HHU74 Q%<V1B53W_M'\YCG=!1^(=EE6]>CGV-&?4T*,O%IYNU
MI'L+J@+DW3W1EAS[+L[FF9Q]17H$3;?[2FZ+,C)^IS"ANLZMBP0R'0;@Z6AG
M:N4SM%I#1ZL#BQ$UYHV]\1'44ML89@_T4-7UQ;.OM"B+=9P@N3LN,[F^4^4X
MTGVT-=PI<.:[:;> 0O)20J)?JMU@3*#<2XOIE4&K*K]D;5-P=,?3!*TU?#R=
MBBO5FE:AW_%GAO337;BW?73=&56A+'AE\>OZ^$K^]K#$O)7M\%Z"A+FC@B.^
M^)5-EC^M((VQO#QZPJ\;W'U6>I9\[3^P!-KLZ!I:]B_P$6_=Y/$O.5%)XR)N
M/*'$?,)"1[+'QUP+V((OV&;09':4[^DR@GN@AY_W9HI?KL>9;.;V3'T$8*0S
MU"9L;D1+E)D?IJ^BU;"7/!84U^,",-EU")'D>$JG1;6-F>"TQ>#O3Y*O"33K
MRO^W">0A8+3%].MNQO:N^C]N1[#B$27;M 2S+C5-BFWHT@'@= - 1I;N"'!%
MK@?#W"8?<FF2-'1[_]0>P,H,^P>5</H"0XOPA4[7L;V;(F)GBM(">ZP$Y;?7
MM]P.+W+EP<*:S7(@Q!NGI'*91_Y0#PH[>4/:68;I+__QQ5??+?_JY\1P^X#<
MYGW$P3YQ@W=*4MPHDRNBHZ=<KZ^3CX]@6)K1VL';J<B3XEJ60%>/3IM"/[M2
MCUNW>#R1B!!R>Y*[(I3TDJS:.B6S:<GWT7GN\2F%@47^D'I??XNZ'!^?;#81
M@)))1P*TCI ;S:KE7*>?,ZSD(B" A/S?TFJP]NN6'["W+YS,^W$??$*E^7FY
M6AZ'@E\X-FK?9N$S25IG&I:+5RLC@G.?O6'Z;L-B%-9)YTW)L$%$<:$VL?I0
MT]KRWXOM!,>-!I/D$^Q+:NJ&\ 4^('B=2J4F..I\;Z^:Z_40!V'9?0(EP$@R
MW^DPMDIH8F%R[6*BPV$L;,A[JCQI'L>WU>+AV>2BB011,TC_*?CD4+4IF1Q\
M(?"7 !R[RVD;J7V: C%ZP2DZ(^5F2_/O[34M[G->J]H[IQPAW:AJ"I3YN6ME
MNJ23OW$DFXDW+L7J2\%B2=)+/G1':J,8&4\_$[F[Q5<:NW9S"S[:BG4\CB=T
MRJ3=28N./Z_DIG:-&F#QD!^173EN4$*QA1O(IB2F:=* -I=>B)VI729DQ@ZL
M,C_VWW,K06[_2L"(LXEU)3KI!-K0]G9T >@-*#?%=\LDF[57=_R9E 7M@RA_
M %Q%'T[9UTTOFL2,[4SF^ 'PC[,N-%]1W5$59N0+M7K4E6GMR76V48BV">UW
M4=,VM_7DC]Z,/)XLA06+3@_!+I*-NY1 <%D0IGZQX2IQ<OZB73,%H\G@QS))
ML6^59N)XLN\ <R3^;XY7G*7<+,0[.GE"^7U\6JZ.Z$%=.ADL)L?)^R3_;3/3
MZN,42Q,7XM*A--_DL0^!5,5R7)81? )([G5*&NOU_^.=\EG=]50(".X4?["7
MUE_<-9.Q(1(L[Z,MIU*GAN;)_2 4T>Z+00R1<I)@_0KCVWPF3-=':X]GR0P-
MR?."B8)3[6D<C?\K*?&_J_\#4$L#!!0    ( (P\?51N02(_C@8! .I@ 0 2
M    :6UG,CDV-S<T-S=?,C$N:G!G[+P%7)3;]C<^A+1T*"$#$H)T=P[=74K.
MT PP,S0" I(*@M(AW2'=(*$@I;2$(%+2(B4@\ <\>O+>>W[WWO?]O^__S_(P
M^]EKK[6^:Z^U]WJ>V7,^S^F[TP\ ?$59!5D $A(RD@>2!P!PNDXNH&[MB'"$
M6SLZ ;G9.  "4@HJJ*B ,R*G;+8,_+4+(*-$,@2@4-#+_6R1 0!D4\!W%?H+
M&?P\F$C$Y]HF4/3=HK 1RK3EBS&A\R&DZ^?CYQ<7DMA.,!LH0LT%X>2"..NB
MG?.D[6%:$*B+PX_K\U933DKZO%6 (B _QLZO?Y&YZ*LX2=F;.SK:GU_C7=C5
MLG$_%Y>R0?S@?\>#P%3-'"#:,OK:9ZRK $T !& &L <  4X &, &  4@SC@P
MP*^&U&&.CI9:$(2+DYJYK<49&P>@?B;@>/;/\DQ-ZTP< 7 Y4S\G+*>?TC_F
M*66/@/[B-HZYBXT]P@9Z8?*LCWDA+:UBH/0]@L+G\LBLOXL2X6^BI.:$L'&$
MPL\S<3%Y)P3TQ^3.(F$.^]G1M(*K_#H"@TK_VH$B?NTHF]O#?W94K1"N/SLR
M#O:@GYVS8/]J6LK"SNJ70'QW\$=^4"ZNP4 @V-'%7,+Q ^ 'R<&@?^))V?]9
M3@H&UM:!(F1O:MHC +\A*7LP\*_XFG![Q 5?W=U> O;B!QO+%6*!<(2!S!!F
MYTY?.*ENI0[_L73.KW]I+Y:5,L02\5?FM<^VPU_QM2SLO_/58182!C_9^!8P
M1R<]:\A9<L_R90.U^A$QW/,!S3.?I!P1"$<'>T>HU2\J.#]&SEWX#?_J#[ZF
MC97U;P>P?PR<^?:3?;YR4-:_^X#2<L(+0 8@_V@O5A7#Q1CNKS,0]_M%Z\OW
M@)T5@0OZ91]?O>">[WC#B_[UG_T;%UK;%WW,']:0+K08\7^QA?2#?2&[>W$M
M#V"WM#P;L3_[1/M%Z3LG/2'Q)X?KXM,0 /C)X;WX9/V5<V'SZ\6UTP^O_T@H
MG\Z'__MC%[' ^![G"[\ R!+?_WX9N_$S3M_[Y.=7*+P_O;\@Y'@  !WR,W1_
MIM_PSN7.Y?^AP$_ZM5P H"[VY\L.^1S6W-$%"H;_8;=:(#A_N'F^Q'^SO !_
M6(< J9_K];L;FC^7X\44T.#V-A80N*Z]\OF&0OH=SI6+L;,+PO.)7'040+^Q
MC6X%<W1Q^AT+S1%F8V7SLU;*:)TKJ5WPSOI7S5P0CG(0* 1FAH" +[SW</IQ
M/\#Z+GS..1]1<+ "_F^8/XH+S/Z7&\EO@O][C@K<"O([#IJ9/4+;S.IW/%P+
MR)D>Q!VA )?75E'^4;8P?K!_)XQI[0CSE+2WL?H1*;SODY?_P3Z/+AAB:>9R
M4;<P72$PQ%^(Z_Y@_UX<V]Q*VM'>$?:;X!)\5Y"2^SEP[H:J(_2\Q40X.IW=
MG."0WP8.R_XLD'_BXIA?%, _\;%AYV7N#^R+'73KN][Y<A;_#/B53W!QB?2]
M\J 27_3.$WKEHG\N#\#[D?*T<Z6SRP^ L[O[&5\.< V =/KN=!V (PEV-(>8
M2*L D$\W +@7/0#8[USO=!(0",#!P,# Q,#!Q,0AP,;")B#!P\'!([E&1$1"
M1'2- .>"?FG^FI"N8F-?Q;V*CXN+3XR+BTM\_H%+_%V%X.\8.'T!(, X<SX-
M!8D6@$R A$* =/K^;*)8IQU(XF=>7D&ZH%_"B ) 0D:]@H:.@8F%C?3'0:2S
M>\*/07P $BH2"C(J\A5T-(PK*#C<9X,$**@TA)Q7)#7,B&B=[W.A$4>EETG=
MI"/1;#7GYH'Y#TBCTT=K?9[=LH#SDF:4!S" GFB#9=HR$7QD@SH?(5\J MN'
M7.:V91F?9CVHC.D8GM_)KGHYLK"K:^D:%)M3_6IT<8]?3L_*+3@NMZ9S;&F?
M (",?.8MZH5/Z&A7>"]<H.$D1#WSP)F6Z K7_2CB<P]:-0<^<].9S\+\HZ6U
M2"S@/%OT:.<.H#/PM@V>.9%)!I;1X4- /OYTX1][P/BK"Z<3 !R4"TP"@#A@
M%R<YT=G&9;\!HN*W),E9&\3_Z13 U-V,;K!\3Z;?DE2:S0O 9OKX XY7M;A=
M]5&U\#[K,=EV7L849;LKVTKY53I^V@2[O8;ELNJ*]U4S*1L&=TWR$*6%8V/#
M7 '.3JL9LV;%SU*/. JL/BU#EX0GHE-&'EB-%#6PUP^,<NM/IGZYUOG"@H5O
M?%E'N"6I>5&L03QY)^^(?1OCZRG L+ET?G[!0B])RR10HK9QS3*MP45WO+HA
M\7WDS'+#NV+^(D0<>"QDJIOJ"5QI)4]_<(FW1:'/FDDS$??3]26UB7&DG!;E
M6C+T-^E0]H*A%4^C8R6[[A.+@RG/4T";9VQ.X<HI0+UXX_FN7?)QL8.R/[.I
MP]/I4;YTR_T*!]S.8]8W#6\;=N)$#3H.>P:X/B>E]N;HA!U%<+-T'0-<,J65
MQ(:6'7T66[Z]S(E.;DX8A#N5[K*MN"T.W]YYR1<$H%2ZNPJU,%R?-"JSI8M6
MU,P_,LH^G Z>6-YU([6?'I^B$TP^9EB#E4&&A_4G6>RN!CN8=2 O^:PR+@M:
M[K(]&4H*C[JG/\)/T^=]MQ**UK9DL'EHO/_>[OTIX%ITBG8<D][7MN5]L-E@
MKQ<Y-S=[&T,G!VG]HZ2B/:%7Z[[Y1RNNIX"'N$][*;^]TO!JL9R_%SN1LLS9
M[[HXNC1XU[5S9/-X_NF[KL.R!(<Q_>FR^%:[Z45NC[" J2/7@:JU?=TC/MU5
M4;614X#D\A'G\17'D=1T4\ E7=(E7=(E7=(E7=(E7=(E7=+_+^ET5D[#&H%P
M$F)GA\+9S,Z/3]@L'!W8W<V<V#G9.-@!(N+N3F86=A $T!QB90,5I=UL:*$%
MVH!%:?5X53A4G*0AUC;RGC"(EJ>JMH6GG84@F%9<#$O$7<C=P<D!@C #NCO8
M0^%"[J*T%\:%SJ[/V>RTP L1A)TH[<6A#5!?11TH[0B# 'G9N%DM.#@Y@7Q\
M;)P\O'Q\G"Q +@Y.+G:.L__X6#EYA'CYA+CX@;\0K1C6V:<(#&PII F2_07N
MK"=*^\N\W-S<V-RXV1QA5NR<@H*"YV:XN%C/)%CA'E"$F3LK%'[SNY$?=D 0
MN 7,YN)W&N!YW\S<T04A2DN+!?P-_3(O!Z>?0'\9P)^6SXV?20M)PR!F" CH
M[$^,BX.+D_5L2AR<VIQG4^(1XN(V%&'_@] ?U%4<P3:6'K]7Y]8^"PH'CQ G
MUVT.7B%NCN\V?B/Y1QMG"0";(<S^EI7?RO[55!QAVHZ.]F+?D_CKCY#2TN=)
MXP'>4C&SL(&>,YE^,[5?E'X$G?T/4?]WL^'TF[3_+AMG V?9X/Y]-LZ80NHP
M1["+!00FYF!FH:8%U(7 X.<XG!QG2X^-#WA+RL7&'@SD%)#CY.!F FJXF,$0
MGD!UD*RT(Q0!<4>(L/_.R'][/F?Q4E'YY^O+P8']KS3A"!E7Q#_7A)^? K-K
M0N".+C +B(PK!(JX^=>F-"'_(*Q_;>I,_.8?E[V*BI "%(XP@Y[_A"!VQF"S
ML0$+<?/S2LD*\,GP\$KSR$AQ<DKR@@1 @IS<G)Q2W+S<'/P7*^;WJG\R"W*T
M<'$X\_T7L^!SL[Q_S^QO5/]D]OMO%F;V?V'>DA\L*,C-!6&UY./E9.4QY^9A
M%12T%&#EX+4 6PJ P9Q@#IX?$']AYD]0\C;PLPWA(?:[V%\L%2V(\^^Y/P;L
M;2Z6CI,9#'[Q@XDH[8_@T_Y)X5SG8CD(F5E<+$:XF2L$+,+^.]X_5K+Y<]K^
M7@#^I/Z/,=RL(=#?54.NLP)_ED;6LW+$P?'#U(74/S8"=[1$N)G!())69W'^
M>_7HKQ3_,8"%M1G4"@(68_^A^(/QIQ2Q?\_1_X+<@2$PF_])]LY0S,[NMV=E
M3<S"$7K^,Q($#+2$.3H S9R<[&TLS,[UV5VAX%]VM=//@"$<@38.9E80=ELG
MB-4/O-^8^]\XZ?]XP8+YN3@L!+@Y6+D%+7A9>01YN5D%.,PAK )\//Q<_+R\
M7-R6EPOV_]#<<?/\JV+^;^?MQQ,/!]^/)Y[_1MZTSAX;]&R@8$<W^/^5&?M9
M)_Z=(G-16GZM&^=5Y%\4FO]W2\M_KY[^7S3I_WQ/_LL'K,L]^7]8QOC^EV?L
MU^^-EQG[;U31O_V !G&"6_Y_I8K^7S3I_WQ/_LMOOY=[\O?<WW\?_O$=^\_?
MGW\<#7Q?EK+G"^OOY5GDXK#CWRV@?U#]*\O@?^>TXD^J?V79\3\]L/B'9OX<
M\=\$]K]^Y@6V^'G6Y.0"L[\XMP5;L$/L(>?NP-DYV3A_?XP'MA"R=(0YF"'$
M?EL9?N7^UP\9?VR(?W#4^&/XS\>_/X>$E"%69A8>"NK:TB ;*P@<(<8IP"<H
MR2$+$I &R<J<_?'Q"T@+RO+P2$ES<("DI/E$V/^)\E]"7/R/GBJ.8(@8SV^5
M?V7_T[A\YVJ"9,6PSI+^XS#_K_;W?Y\N02Y!+D$N02Y!+D$N02Y!+D$N02Y!
M+D$N02Y!+D$N02Y!+D$N02Y!+D$N02Y!+D$N02Y!+D$N02Y!+D$N02Y!+D$N
M02Y!+D$N02Y!+D$N02Y!+D$N02Y!+D$N0?[+(%B_OAX' @6+TKK1BHN=3@*D
M 4C_(9T;^4]M('U_]_ (LC$*$L&/=P]W *C/7R1\\6KAGV\!PL!$1T*^@H:%
M@HI])F"*#P"@ \[?[8M\!>4J)@X:-M+W%P\#, @P"8F(:3A))$EI-<R<L<@&
MKM_DXA/4NA_U)+VL]?,U>@8IA$M5S3#=+7X!D*:>OGO\[!8CMVS@X"@3K[2V
M+L0U)C8NZPR!ZAP<&>6W+B AHZ%<04?%P#P;%B< G+_;& 4-%0WY[ +]XM7'
M!"@TJ%<(.24U/J/1FCG?CT(G2B\CYFH=F-TBD;I)RJU)9XY!QB,-\\_X_7N!
M][?:&#&2:9U"?]M\\DQY>]!LD?DI,)*E[I.V\+VW47(PEAX&SRH?6:>R17<,
M0=('GBR29<D!5LA^S,S^6*%BUT/R9G+%ZO&]XF2/["::AF@?=9;>52R0,BFZ
M#J9Z_?)!TVA2CA6G7B^S(AI4"E>PG4S(.S!^,(G/(."+7!^_2EMA/-6W<$VV
MJK%((Q4[4(F+[FR%2VS^TS$^L6_+)\^\B*J%*"LGZF1+T4W"X EL71&%+ 1/
M'!VJ&F**5 D.UPE#OY'(K;]GPQV"1D\W&WM;]02+Z?5^&C(_OC>.>E5\LV";
M;\.F:F$;G\%*7U1M%='G-BR9TIPV*%S2G%K)T@452A)TP[.O.>Z4*DT=O$XB
M58FC9;HAT\"_ZUG!%:N]^=[8GL5LV#[:+D:3%+OBT&C_F=JFJT;-))^R(B/2
MP/.-/NL46*75 .D^/VA<:>DM<;X"=U.<,P&.^A,;1ALOC%VT/+;>;M"W(2MD
M.7%,6C:*<N.TQ%BB:9],%X46@WFJA>/8EN8TBN=[1L/$8-LAYQVY.)MK:R?A
M!%]?1IL"\3%&X4]<,T8LT"1[0MYI0QYD;#ZA'?+:11YQ;CX%[$KGT:_2W8>E
M=DVN/^T0)K-J>O'<BHE?ISMF<,'0"G'-+/[Y:TY_YBUU.'P?18><E:,RV9N"
MB>?C<)1Z.+-G\+Z+\>/Y'<'N$NM-FTG^NQ&18ZG-X.)<"EV*N[PI5_4" V5]
MNI<;AE=W0T:W-JF5%0,8:25ORTJQ8GT=9.FJ;Y*N]G(TYDH:?; 2ASZ6C"6&
MUJD4D'&70VGD%*!1O#Q(=O\Q=#0.!?0TJW+XZ=N/61.\ILG$/*R/'12Z< (Q
ML:;9U!]UE3%DKZ0KQD9_"LS5MF(B;T*I2!EW&+FJ*-6)[N)?N510E?_.<NWQ
MB@Z#[#-(MO7;4OV.Z^Y)?>ZO9'F_V*62@,#7FI!9ZI8WIR;W[0^W*NT-KUIF
M8O(F[-TL]V"YHR,J&*013=)H.;I'WKAUD -AO(LZ_(1T^6%[["K#2SDI2$(G
MC[QDF?SS!]+#W:OIGJ(O#Y^6%\T)WNV'QJZ\37'4KYJ.[5P-YQE/L42C#^I3
MRE<R)K-??\+IWA&EXZ(G,C>JT9."1GU#@3.4LP9S6D3'-45.>?E)KCK2A.4@
M$O#:%#)H3==I^-CP6.RY76%C@^U:'VU<KH32<&&<4+W3V+*_=@Z4M_YE*M74
M_$.(9(^ ;?B[R7L>VFQ/%#MUHS0U&M"_*"\0NK_,EYFI>:8I]M0E3M;FZ7I#
M$2_76I&*IX]!E)U;.)T,,_(DG758XUZ<78$N(W."-VN0? LK 5.ZRFB"Z#Y!
MV^WK!8%W.K3N\6+D8Q3(T8;>DLI+#(W'E<%P0L&?%P0IFE_+0&,*HT4[JS7X
M-P@<9XD"50D$0/^DD0%-ITY7Y.]MNJ^=L#\'O]67MK>E4!Z AWMY-2110HX8
MNWB%^?0R^U10/MW2E%31!G^DR9HGYS7X8OM*)>5MUD #W9BWC)_3FP5,1H_5
M.'<OZGR7[!$&QF)8RCVY:^F2[W5C:QP>>2E/&^S1=JM8[;Y27HDF&J Q2'GJ
M.H(9N_7Y"?LT[>N) 87*Q[0QQ*FG@'TXQ5J+_N<9=6C5['B32=T@'_DK7M_5
MC6++I@B/'&F)7'.;&'L-W94IH'!"K+5ON^%$OFKRV!LN<)1]0([$[BHAFR_;
MKD*YM5C4H4D^/-D3EZ\3E.>*UCW$*#5UW$$7]G7A9$DIU/;C8!:YXV0V7PRD
M\("$*$A]71LVB_8B73ZQ\=H3"J>4N9=:A(C7]BET?IA$-H#'.% DX UZ\^29
MT2S6D\1#1V?&,K['QR%]O'S';LZCLF3H>.$6,ZS;N]:]J14FY85H#Y]T&750
M?<EV.-@QC=6HM%I&5L'Y1M.[)16>,R5JL]=%K;#6,^Q9-<11WVUTW62>1Y[!
M,%E9[&YDIX9KC4 ;7JX#86]TO8')'?I7(KMAN[H)P ^O>(9"/03R/JF[ 65N
M-\D)5TVPY5D45Q>9\*U29I-71/7:DQ._,7,3I#Q1=?M,^F@^>4%@@0T+<ZJX
M^HB1,J^4FO$V$PF67$1&!H$5$SU0=YE S:=LK6?O=DFMS\Y*'&>*P+OR;MG'
M383>'RM?JA@]\ B<_3!=RVTIBW!%<[^5L[:60#5Q1>'U>"57QGLNEJ6_N,7\
MO88%4J6=[?AUN@KD3YJ=5+^HU_V4,[7(<LU?][5.3' DF5T,KW* NNLN@5.9
MIO;K[$T!!N=;Q(HA=,BFA'0=+Y+BYY"W7GJ$E'I2[/$JJ>7X:Q%INRM79P?-
M)KCE':,)];)9[$3NL\WT/9_?6C=BQ-<N58&LY=BIQ;B[S U'/ BW1/0V  DQ
M9>B>>:IM5/NJEJKCUJKD*X9.N?CL.=[M7%G[=N]Q3]G]5+=T7?9W\YD';]JZ
ML\TM]78\UE#?1F562,NI"5TAUL_1]E.M'W>[DSM(K3A0;X6BL%8R8]EYI.6^
M\3)I&,^Y\<.*=M';S7UT^-"*)A#?(4W7GH-;!XOENG5INH5)AY#-=:M\N08P
M<U2&8IY,VT[+P"HD2],K&+36XB#,UQI1-TTQ>BSQ_(.7'YA,6(2BMNKCY+)>
MH:R148%"IN-(=)S0(2OZ1R9%\$F2YF/_D$<(_^Y2RPZ)%HJN6KY&IT?5C&W<
M>$@/GK$&IMS=+M1_HCQ!2?'^K30D9\16.>5*<HNWT.0*F>/:F(R#J'T;_*H>
M\R?0*6 Y17.V="]"%AOT;H%AFW28R;VAJVN)E'$KFK.'YFM 85BYKM5H3=#=
M[6K[.->T7%+LV,UIWA6EXGVU7 I+BE%OVLG4G>8A:,M8RL011Y.0B7+"2'D0
M\:J.C^8MV+B6]O6A'&(? EC?Z//45R,9N,06^&PO&>8UO49NYU&8V'#[-,YX
M+MQ4C%@+5C^ZF;P7P%'RB=VD,GV&G@E3GH8W6:VOLUJX-K::H;3[JJ7BVZR#
M($PNIR(E#Y+L.?FT4X"KT.R*S@I9\*)N8<W=BN8FZQ2[M46CFJ5:>KE:7>2[
M5?KDZ]!MDP%#IG?>TV7Z$5WK)6U]6-5&_*ANJA]ZNU\LPE2N&,OQ,9&I=Q]S
M[@_&Y;GEO*,S1C?+.DSB7M];T&G8.UF8:)C*YLP1>D35U]U:./D1RXXAG)7'
MK\K9^(%!AX?YXW#OQKG<'OD V&W2G<D5V;J1D_*- [&\% BV9>BX\9 MR5N_
M))Y>JT\Y-5#?VVH&1V_-W_69,+\$QT:!M4FYB:AG,4?4<VX1:.NPI]_(BVRB
M=FR.T5-MWCVL?LC'EW7#Y;G,GHK!OMO9PP1M71ZJR'L>.-]5VRV&DN8J]X1C
M^J>$30$/[2V-+;6%T?%N&&^O._I>,;5A@&(@E=72#%H%X@]0NJA=>>96JI3:
M8XUX9G3-&J-QH?>-%[ ^@,*OZ' PR0E10I,T8LJ&.4EUF]#E-A.-:3#,W<2W
MGV2I7>8#BJ,S"(L%<R)2H7^H=R^N;-_]CDZG;9GQK-4[2M;8*K(9![F\Q]?7
MG]%WSW(SA?0%I6A9'@K#TYHU":ZO'! %/XD/5FCOVBO63VF/28WR3"UNJRH>
M,[U=A']@R<%1IEXTB9+++MF@7WV+$^HGXL[@NCE+>Y_H(%>6.^[&3%AM6"['
MY_#$OW'_FJ=0V&';8(TK1=2RG,S*].U#&ERF\OIP.TF<[NC+(WSKRJ$6FV4;
M=V.)C@^>61%0D[!UYQ3"KM>71TL-''F >V9[5F?AF]9B!8^!DM&@* (T^= Y
M4YQ)]UD&E8W4\(E7*10K :II\E8'':0C9CO?:A%U<Z_UU&@SLX6LGLH-]UU)
M>]G94;#7@+/KBJ4S40=.SIBWWJF V-8[7 G("!?C>M$D>?1RHCG)]GU?&PPW
M?_X>L.;-*EWIX%[LD4N-Z\1=/24DH]@ 'AD?<F[Q?M.[W@J;T<]KHZJ833$J
M2!P3O\GRA#'.4E'L"N0<0C:-X_=QT &1A>,PMCZ9 ;Y/_9VE3+<%W88W1HVJ
M='&5Q$\<*&BP"<M'@PF@BT\K:TEMRF0^]K[H5QW'NAD:J6# P].?:W,?NHQ(
MU9WL V/Y9@:-7)W9J+=G9QF)/=8ML4QQ>;>O/%OTML1C>FLW#KO,M&Y^AT4P
MXPF*!&]$8GAMOHC>K1-Z3MROX+D3!_GLH>"')G&8ZGZ8@"Y4/W,ZE8?&=,9T
MKWHRIYN$FR1GC_'ASY2+3@',K]B$>)NN2G&;5RFM+Q7)6%TE6RL\+GFX5Q _
M2/>VN= TW)5@FW7$R_ ;$LSKB::RVCJ-3+)7S]C&)]?.HO$<ATQ/8Q=^Z(#Q
MO%X]7&%\>E NFW&$5<QFIUB7^12@7J8">5ZZSE&RHGYP//YN<+XP%L2B/#VJ
M)[G*@+.0++0Z59C?FEV.B!XC?>V_&(P6S4>?W@_80'D(U:E&V)$-UZ\/J[:8
M4QA'E%05+-9U\%JNIS&?:&I7/+DJXZ(<;F#0QLA]FPICW'+W:YT"6#TZ*B+,
M=G?5LE]/ [6;R>A_=/=K5JJ5+&"N0Y2K)*4EC-QM6R$@UE#@"HTH*,@SSTD$
MW\*,@,=G,TF 0  !D HXEMF6%L8<G4\ CE5^*:1(EX;T1,B6&)1+TPTTC\^@
MYP3A( .!(H&M*,G'_,<WQZ)=QLH/OV3\SV_((3?GNDY>;+_VQ?.=)1V,QT6F
M67J!%UFZM(/TA7INZYN$>\HWH2.Y>M:IO'_O=O_[AC4,<)W[J2KXA;PIT=,7
M6OBH&<BP>._[RB:UUZ1?8'A\JY69MZ#.,CUL=EEM&BYJKTF ZPJIID379-DE
MB9MIO%5@O\X98Z'![<G[3.*>15)J>4?/,AS%X.GS,@/WV+WE5SJZD @",\*
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M-7QJ3C_@,8ZLW",O=0P9NV[@^>WUT"<%H0>]S_TKWDU 0S>(&NVX>:)-4.^
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MD:J@KFK9N!T\7W:&GG@=_EI.NK$_BG9#ZZL)299[H^"(\^?)!!-TSO;M6]P
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M8$)S6(-*60S^;3\FG+RO1+B@2D*Z:RW9FVC?2,J>W]1#V]K^3'9C]3!Q]%B
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M'/+"PR.BI0?\&UDA]CYMTS0BQ,G>I?]V*,;8.]3;RSOJ9:N5UZ+5&]ZE<NQ
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M9L'N'-:84BM!TF.;$2(QJRQ-< ,A2[TZZY2'NJ9ZW*+!LLBHWF1P1ARTX_<
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MI)-1S[=*E$/U%=+&&E6XX3:IM_*<-H+)%^IRJBBI@5'KC&M9T;BP>$?@%'<
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MN(3V0X+),5<YKC%:<1$GA*.Q?05\PJQ)G)"4R;U BX/9W+X+/87OZW%DP3\
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M*]>I#\;-%G3!8J7=J? \_127C16C=-I2BDA06;=U>1A470-#(GKP)A_0$QA
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M0E _=DS5A9&,IJ7U BOWKS:]:_SN2+S8#)[A[VL@+9R\#67VBI-\5FC53[<
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MX!,I \)OH1+'?_IVAZ!?$5'&^2D444#X7RL%"#\( +H!OT%>BP 4/CP@ C\
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MG(6!CS!(^QUK;\A6$EU)^5^ O$3.<,''B%&\:V0,?P)0>XK87  1@'A' %R
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MI?WQ1*41<Z6N\]'*4'?> IMG$&52S2M,J!V^>>7T6<59B@7'WH "C?7QF*C
M<*L#EQD2_'J\MEM)CV9-]L^!"X3VQ2(I^9\K;M$3]5AUS$],5Z4,+;H= LDM
MK97*^#/# U.CO<N&Z&%!4G)*9*P;!<WT)#)#9;B(2(AR,?_2.HHSS;BFA:Y?
M (BV';<7+U%;M.6]*H;^54GO<;9]N>8YVEJW<=GV^D<I/C5.2L\_S2VP-"NQ
M^_J,SK!R<_NJF1PJ@:(8#? RK[0_X)3H^KH>L25<"G79I;\ )CHK-(W/'-4+
M&D^5X_PDV60#ZL5*5K/\_DIEL]?'ATVGTE))/EIBG)3,*:)KEXOVHKB$'_"W
MWU6=$;+/6TRKN8KPN&M4MSHO4S!Y.N[?JE7A*C7-:-V+]"+PT=-'E,YI\DFM
M$W.+Z!JIINH^ABKNBHAVOTF(]D:U:'7A4J!9YY)-:#T.-*LBFW94134N/%E6
M=I-HFS:M1L%>.QO:</UHUI&;0G\5UZDKWTD.+V^TL:T>QE79U^^7"C)&)T1-
M/'W.YK?KK]GT6E1-;9R[?Q_WH^[DUEQP98-JI>9U&+*T%-$79[:<2SHKGD[Q
M%K<V6F^R(3&L7HV4B(ONC83?XTN;71EW4C9:^US4?I!F7:A11O,)N4CEJ=RD
MX:S1F-.-L0J0(I2;)J2N,([=RQFOGTU+P*1F?=",8%]@4W1L-Y6(JMK+2?!H
M1G;TL2Q^1*\#G2\3VG;JKE?'&SV4'GX@(ZY/6:S1,BX6VY59$E]HQI\7NY!7
MCU]*[6D)#+4,1JHTUD0_%25JYY[7D/MEUNP]7M5RL8ZK-^!4NXU9T,@SM<U9
M(;]1B=R\7M_TIV%CFQ<@M&E9)ZE!.I]&TM+O[4B.8KY,BA8:*AL0XS>R_(XH
M0_F,42$"LVGJDD="<*Z(I* ,@\HXGKE2YBHM/LJL,)86B1*CQ:&)G!9&V5N"
M2!G)!TY%]7NHB[#T.=MW!O/;VN5:1UU9Y!S73-P)A?;=VG(8<+KCJ!T4BX=/
M/WUJF=F\N!HY*=WVETG.@E-THZ8IM4UZ?_%')&RD4[P9AJT_4_@5\><3?L-F
M8E+'F'+JY*9)O7S=W&AL<M#)V/&O]0/-_<DK0:T:'?+-C3T=W^S/>)A;V0AB
M3D($5<,EHEIF#_A2],V_V.3]:G/_KVJ0WW[W@-$9C*/%OFFI_/Q$NN5TP)_1
M49M%!1N9[5F%B'^##V 'COIT/K]]^.;V)+ 1")(@/S$_1MF6!_ N'JOXN9C<
ME$E6C[F2(PO#= Y:JHQZJUZ*33/*"C5VA%BZO2C,.>JBWD6LM=,79H@2K)Y)
M,+?$.SW_$G[H^Q8_AG)E'AB-R6)>4$*_9+WT_93/%1*Z))(H'IF[Q8\FRG5O
M=RR2FO[V8E9 A?,321)Y3:B?!"&\(+"P7 (*G7$1+"U4MB(9"4#@@:#J2&9Z
M'/YRK:"J],.?#QD,$IX1[,/O!BN #7SFSS[YF) A[&0<3TD$=L!DI@<=W!_
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M7_9U'$+91'>,8[@^&RTA)F?%6NJ'TQ^JM^XXM &*FD&2900SAO>PA [%BVS
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MYMDYQ?#>-*)1!:T,77(/FE&+&U?0>1Q^(\/(X$1WRB<R!7![&KV90@"&6(0
M'#)>7NPA;O@1%G:$!B<N#X,3+>!/(@2<MS4\3M-9SD$?3$S _QYAD/'B,J%U
MDQXY"H%J0=!E2X$>X[2XRN"BSS1',E!@^=$U+?J#(</H$_D$ +CB?<1W/KZF
M:SBZ_LIG.):'#B^B91G1'UP<Z# 4?69%?TX_-(<=;2-NM/QI<S.4%CI>PN@Q
M)K0%-HSN[:+'.H=AY&@;CB***0.%0= \R2-#6QBECV[YDFB^=[/S#]<_\%O0
MA7L<)\@>;M11AB4P?3G#L$C"P^]A^VJY-&O)2 SAD$'*R($2V)#=$1RR-R$
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M<8"%003 ),+ (L+XT@B@ 6  ,#&Q %@8WW]'T&D\'%SL4_@8F%@$: $X(0"
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M7ZWZJ7]XYYQK6K.US5?2:BDY;"^02%ZUU8H8F,NI/)V&'!)I]+'A<13K=O&
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M"9>B4G@1&HC'@U7D-<UDZJ%FG' Y$#6K%L<R ,&+^('8C:52FF'>T/.<"#+
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M!S-4I-R EL8R\-=FP_RS?]NQ=@+7]S)[]X1@;';F%IJ1O]- CD@(,DI[%)Q
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MX1+TS[ZN%P!CQ/?H'3RPIZ1.I7>0SJ<W%*Q?AX"W T9TP0 '_@^ F/CO%"!
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MOX.B,37]ANR!;MS*!GO?.%WXD/.[RI?H*< PFPNI7+3-..J<*4>R+X&9*4J
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M6C[KBR8_V$5FTU5\6<1WU,>(*1.43"&)\/0AAO,,@@F)$E+N$07I$;9$XC.
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M6-! N%&<U%&VFL>CWLA;P46!>/"PPL$O02LVCJ?*@(-9C6#5_->,FEZWK'Q
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M7%12O?:]/8DN<-*VX:Z0QI:2CE/$&%5=9&//,D>-_4=JDG>!$5X4?B%C(/\
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MC>P-V"M^&HOEZEMLXVMKIN:V*1\K U?%T$:AG*KGF+]60)+_"XGWWZ,,H'<
M%WLD^F(LBIRIQI2R9LG)<T*HMU7X]79M01%FQ?S.4QFP?*GNH$7YG'[5F=*N
MD0+94R<HO@C&G9X;?5W'I4UNH#\'<.*C.,MZ1+]82&_C5G!I&9S,;PK:+3NS
M/^\XYJT398X40=<NP\Z/$Z5)SI<GM YA2.;GYD5_69,N3QJ;0>I0WMCV-/M6
MD'J]B'^[&&= >FQQ35<67T/K*0^)DSX_9;D*AL\4W+?_6KWVS:)Y@=GB80P!
M6CV?0\W\XR*QG'/C1A9I]<E:K!UAF P396RH^BUP@S 615YB8<AP/-5 <7"V
M5-U<JDKLMV;8.T!LV4X%CQDTD9R0_:8_9<I7I,TJMK>C,<FH^(%T^50 :Q<=
MPG()"A!!L/ORD??S8XV!X+)/ 5'U8C.. ;G_W]!\PQ\TC_]W-/\O?4JG,V9<
M%6*WG1E^F/T%URG2V\1"X]102U-982NV<7YD10^*7&'P8J'ANY;IR6+:*% 2
MUNT8P1JTSLL2'&X260:1 (UY)>B?/I.MZ:I=Y>LPH4F>;D9 8.U=[9F86)T!
MD;Z'Y+0'80VND(Y>6\%PMF(E<_IN>%586772D,%UX':3!1>/R@^1JW7#G^GL
M27WRR\G?0X^OW)1=V:?07X3$\##BP\]J3$HV=QJV4R <4EGIBN;O3#NC+/Y6
M,I,(LN@BD:U(V4*;;'F2RG8XM)T<EF6DZJ=&)M<^$WT-5:JO&PQ-A7<3U70G
M ^>C&P[FU9D;<PV#UO>A87_,3(&.3^?S[/F8D4HK\7K&7\/<'M?1$,# "# D
ML)EZ(%A\Q6U[0U^#;'\1?@=@"J*\ TJP+9X#:Q (_^T^8!JIJ8F&F5LZOF5C
M01*'-<MJ,<F!+6"%L\<!9FU6(NYVFY)$N9WE^O)DRP,4VK).#P]A]AJ-AIS/
M$5',7(T5*%(:I7P_B 6_:U/Q<'UIQJ66"C)"R"^#2K)%2%"$/+*I>@PCK3_X
MS ^_=*Z9@N?570/^;( JBR9++1$-'@\=PH1;-2^RNK$Q40Z!(.";GFKW7\NF
M$IL+!5W)LW9$LLP:-]I_&FPJI(<[)E:W,KE@7LGW$L?B#%>$=T^MBAN)BN58
M9J0A1;(F<[ S*V1_O$*E$-(/C;$PK6H/5(=H%!VJDS!7V7,$4;3C&N]R?R,C
M]Y,[6UB:!LQ&%O3FSX$I%*!5\@?;UZU55)L#?WCK? I(5YPZ4S:WX,;//@9Q
M$YI). ?V_?Z=P!%BG@375UNB>W"TY>1"C1*'9&M!H^8IED1@*XKM6JT+I4M\
M1(NQT*#CW*@WCQ;-MWKYIMR(K,TTD%S@WUO"0)H;G5WLQ?(E=3LY0\7D];G4
M;U^X*,&BSK"7X%NA-XLB;L;7SQHRVS.8W*9 X5'-Q$ST%):SC9?NNQ5091(<
M;Z!H'S#8;E)*#?9Y1[U R<E9]":@QX:H&MG67O(-7G?D99,F]^R \\WAA3U
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M,7[?]B<TPN9RPHC\P48Z4-G.8HZB+2GM0*Q@IL!:AC]W>N)C=ME>HWEIJ;D
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MHX1$=N1,/KB*60>^O#(_X^IRN&J,3B/=^SS15I:O\J5YXG=Z8H"?W4O9^N]
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M<-2 T[F5!I=KI;\[%U^#*;\:4Y*L]DL>_7.?F[@.)RE,K;?D8"H**A!&1 P
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M,G%Z#Q[J/4XJL/,@[4]NUS +QJ%2D]-38?=,0#1SEQJG+O/T^"HXT@)N.S&
M/.2MEN%9_3")1&!M%(^;9!=*]\"93C-15DJ@S.&>0\"2BY,=].H)&#NUPRXG
MYAG:LF_NJ*Q=R1+%J= HE)D ZPXH^_)S>GT6+H#LV#H;:0>A3@@E+*C4^[H6
M,3.V 8I3$<>ZTK]QQ3W5AN;^QG<9(U[ :EPU; T;J;7Y"4DDX^DL':OD\C5G
MVVE]<@!!%V(.0W+.5L@8-X&GD(\S)UK<B!T19>(PX]!T;R5.L%1R&DXF/0^=
M;8M4=.UZ]'#GR(@P<>"Y,4*T2O2<\5Q6D#^3PB]?XP0_DDJA'7?E+B4 1'$6
MD)HXG%,",)UG.'Z\3HC/8M<#\!=1^KV!&T^<F2,CO6NKD3T1#V#Y.-B/AQ[P
MRPXV>L%)[#^RR1WQ5*)C9295S/]'X")RJ%S-O2,!+R_GAL.T!X7C:UYG&+A]
M@_@9;(A >J=*%4&1JT(R,:N'5YKDUJQJ!ABC) )LE.\+3ZL@0B*HA[WZA) <
ME+@,8B%K4]FM!WXS9QHJFMNHS0EE6EMXY6SKU2OY^6YDTKT.YE\(]O8"(#[Z
M:"7<;!S,4@4;JG:\IQMU&EJMH&Q5[G1$HUHK@]N!^9D]L4-'=V-*\\-9?A(7
M#E/5YVVM4*'PO1<9+=-!IAGC3#EG67;-6E\W VD@NQS<,QX14 DH(VRP5*@&
M*ZDI"#/O;8.TOK#R0MNF-$W?6)\<QS,/*N3-?RI.5R@-@Z#'Z9_3'7E+,5HR
M;)EAZ!*BQ3"6Q$V^S/1'I2X.>J:@.%0X=78M? ?J'DV4^-+5,T.+JA J$1<.
M><D/&)FD>8I8C*;>-O^;CO_1;OB<]X9+J$MNXB)2!9V3DWYW]++C?\'"(K67
M2SF'OT7DF[\>Y5.*^9]\=0_QKZDI'W&7D-V_I5$DZ[;% =EI2!>*2@ ;A:0I
M=9M?:9;R[VUTQO65PY;-2N@._8)"K#O?1[XZXE*G7ERAUC@%?C,Z< @8S@(C
M./ZF<U*'LS%FJ.KQA"B%QRACWE=L&F;N;/HF51C(/57\-,CBB@%DYNY(B]ZB
MGX@,^KGC53R[J1YCMC?A=UE_*N"65^W/U>G64@#.H>\OJSY"B^5CZYD#Z4^Y
M7D2<U'#5].(UME.-LO[E!T*H!P7$\&R6Y\Q1_SFWI^+5)@]B+ZREZ4_Q?Q]X
MX%X$A%A$E#[ZP<#@=&U4_?.-L(7UCBM/U].-3J)>]H(NK#D/I$NX?*@8/*-?
M7N=VYY.ZM1&NGB&NX148E0I&.!Y<UHX3M+ F:9;>#Q BZ8RY>R#4(LWFOZ^)
MN;W66Y*$*7<($N.Z:Z\W,_K5-JZD'XQ,)->8!MZ_=J#1N0'O8V,\EI!(#/R%
MX15%&TK1P0Z9/1YT=&#ZUT1-?USD=THC585RS*[S..G5J2KP>NCH7'!]JE4_
M:X-1?:JSY1;HDIR>MS"*0#_8EN[I%%YQ4M9'6Z>&<_A:9C0JR22WE^HNS!:=
M^B-2]XF*[]/[;>&M?::BO$NA/.H9:A-G;QR,?]W_'%<L'P]Q8 G&G]I@/0$-
M>AZ=73@1](1,VD73E]26DE?V-TCEL<L*W#8B<3^7RH(,TF*+!I\8F=8\(/UW
MM^V>+Q@YJT0VI50F9BA$#OS1U?X=N:,8 YNX6!*,>&7<9,*=7\=]*4C"J)J>
M9)5!ZC0YFQ@N9CJ293+2Z*6N5,-E3<+\_-7\@M\BH; OE="WQI@*3;Z*N8:2
MMJQ@G<R(FAHQ_(&\7.IXH]\&*=9]$Z)1ZUYXL]J09H+*4>7<H,U+$\T+-,1)
M(4&!=?8M)$Q=(*+D7)H<''<*"C0]8F&<H_("88)CM![C_OPU _%$&-4BY4_&
MZOGW(>F!['MW;0/]9RQ*;,?OX['1K$4*N_8O_ R=I;[T,B1>KZ.G8XCQ&@>,
M!ML[:$T1 W\KL+ Y%V/=.4PCEG6?"HQS.4/3[X['S4!ISFT('='NSV/79#&T
MZUP"(-Q4$Y&OMU&ES62RMDF@'=XUD&1J#R;H.I3U -2T9!6'_Z;+C7YW)1^F
M>BF^3^CQB0OK=!DX$:O$\\3SEE2>E:7EIY39B<D7=^]WB DS2,5"\CO"SR]Q
M\(?OA1\/SP?E F:BQFZCZJB6AZQLHX?R%((.4/?P<\V-&OXA5M8;GE HQ1IJ
MU@6W[A+N/6RL1?$?*BC<SV\R:C(YH"@HB#_,'_V/PEPF[LVDM&?;_3U;G1J;
M:"6U-S&8\&8[068TBL-[VZ_% P8UV&C@F-T3R!#.&-\SDUQ^3^NB2'GIR=PB
M),9!?WE<5K8@AL%G8-G/W-)C3.C=87-OXH:NFV\JK3X^H6 II^/(/'L=,=O*
M#'M2[?T BG.\,<S#<I:_C9(97!J;"_?/:%1L3S 4!U%PL86JG*OSZ,DP*T0<
MIO4;"[_7H\36$ZZYPSKS/:8_K'QK<17)7G&<U[7&1X&<F<EAFN"M[+L?]O 1
M(,4J-MV%)]8DY,'"N+T:?%CHF3D[Y&?&1QY;?3.?LL9,RC'P%^$-I)%V+Y]/
MME2$]BHH<",GQ,.SHS!3H>+KHETEU!/NK?0T@0I+M^[)\ Q<_;KDK(AK?CP=
MO+K:^/'C"BUBTPKZ9'2J!Z!;G)J&B9Z2H:6=+*"=NPGP<&KTVXL5M]CRM$;3
MA-$/'5'2 F4^0\_+#E*%C''AZQEN^A:+B\2'+^E=6!*K :JJP+NO]=FD8&$Z
M275S9IDQ86\]!C?!4-<($+D'BZW1B0EI'.(W9859Y98(,QY/GA"P.D9=5LZ&
M\B5B02)6J"SUP1*XG<?H[@X3MDE![D888K.SLU'C>8'%N][3@H/9M8HUPR1G
MNX 6)+:/?3OG%PM?H920R;>[L;ISY4?7+<T-TFH;A0,S?I6/C"7&H95:'ZP-
M][-S"58,="+M4+<W+882PE%9D5>-5HMK:$?Y9%7XV]07"'2E)W<5+AT]./-A
MK2/9U;OD/+2%BJVO_<WFCS).EY#@S>A,KG:RZQTVBEPQ&*+(S\+RDR1;4]#2
M\8%_9$]GI>"'42B4](UE.'@ _G!RAF3=3=&M9IC!Y3R2]B10E#=*E+DJW5\+
M"YR\O+:FDMXSBYQ(XS:72MD+I]<9J),OKLKMV:2%W.T>'.K,T"E5-T/=!^2/
MF&'-K.26S,+79 ?-S#.SAI8ERD;RH$N#7WZ+5!QKW4/>$P,T:;;<97T;E7,6
ME-6N[; N)P<.OJ\$-N'>6_\E5OO1FDK<P(7_>X\8(B[*ZFK&?X$TQ8[2\0PE
M"=$Z(>IQCRV5+?[%U$A,G6O!X,P2I/(ZBG&BRA>5?&'&Z<[=&B/.G16T*O(U
M$NOKHV722PS78KDX5&D96!^UP%@ZU4T((0@=YH/:M O/1L'=VLV?(%A#I4WG
MRWF'>E9_EJ&L2<JXCT;3M@N>JS5N/&]NT?ZF([<-OJH]I"DW*4MP<X5]X&L8
MN"[K3I$EYN^^R3U:&YBHD<@O:^0^S']DUE+6L;P.^ION=OWTTKKP)Y-"?-%&
M\:,?6J&/)_ J(VA-V0ELI*?J\B?@E_^,\ST6>+4[V4TCP(N/D?WZ^J.BI3#L
M#]U\!G?%L&BZ%=TL@Q(@[KK-M"'WCX;G%V\\.(#.%43,JQC+C71J8\EKA="#
M8\W9(. )V^ YJ$%&(*G"!7]^\SRK=G:L6-G#(-J[4T8T/,.PF,*HX3OYYB.O
M@ZEFVO#/Q"K(U 6OHS=WB,' @$J'MA]IN)\)+S<+J;B)6>N_Z=J>T/CMLT"&
MOU)EZG+=_J;['+33J1'7B,@MW!<V*]]5'@%E]K\5E5J)%S76_BGZ/J3@W02_
MH/$,!PUTD*'<$&>\8[UJ(+O6ROG2 >>*,*FZK,LH2DFYCD)=-.",3SC(H#3E
M\[S_>5S-^BMI=R$U]1U**T+W$H?1&?W>0?[Q4_CS\@@FQG'.#II8_7K/\)V?
M59[6 !;O<2B#7O$I<T/(3<R=1R6?YA@/1%R)XLUP @%H6_ !$^)@E"*AZ^52
M!+K?ZR,4>#6S/&ET%[!E4<;9M"*ANJKV<B7@95'F8^HPH %#H^;MA(X8RRH5
MDDOM4XS9WV]A7JR: RT[;U\QEBL$2%1+?'S.O/PO7T0,;#00?<HO&)%E*#!;
M:AI+,?LQ<#5Z/QQ)0NHB";T@_Z @?VM'J1O-Q?H&6&B-F;O+C8?.=SZ\%EHX
M'IWS+&DFK5EOX1 %"\'0V%^KS]X&ZG4BG83%D;<6R-NM5&QJ+7Z5D]4)@7$]
MB$T^_:E[J/GI\66]'^GEAZA)_<VG;1$K3[D*;Z7T"D556VJ+C.',.K&>%O88
MK*'C[MJ;Q"3\\Q<$1)L>-&/8$TINH%BE65ZU,2[S\+.V4W%0F>/.5N9#_$-C
MA.MDBS*-\54VF<H0.U7+=' FK5QQ<?H8?"J'H%(SX,1$LT_I4/M,NS [%N2@
M7:7(7\"X-2:Y;T(U1UYUC4KDM#/(E M%9PH:K+3W3N.9>>:>*511T&:T:+\?
MM69CY-./)F5R)&SN7J T3%$9YK/ <F&)@'Q1(VGFF>FQ>;1BU/=H*>9,6?8E
MID]"UNY)\L72=?E #%[BDI+]V!(\MV3^ZI'35!1JHIL4#U,Y<CC"*<W#?D5&
M8K8:;2(X2YNF3Y"+,ZDW495;CY"R-0Z<_:3MI\D:<775!= =Z!&+EDQ(Q9;<
M3L8W&5N:CVS;5=BM5<DYU7NI_;/C^#M*S7N??9:S/NI,?UJ@+K!%[S83EDOU
M7UQA!GS<EC"ZL3=-+?;@6H:C\](ARB9VH:<JDXFCO>^$I"-D#&(+2XDD'6#W
M(^6LW8+E]&CP[71TLK/L/?4O8&4-2 G%<+IJK[V/(6X"T9RSB.<=1EU2@0((
M-H,(MI7^CC%3@[ WM68Z0G FS+(TK;<,9]^?>@]NQSN67&.L&OK'0Y]%][)N
MC^Y=#7CCT9"C>4:<@8JNVF!_CXU3>\=]*>S(A'QU,*G54%ZQP)@SJZVMQ&/@
MPQ"Z:;P^%B/O[EK\\W/B99X]#_[]@W5#WV-I?VD=MZ"^25_$WW01211U3=6<
M7V;>6 0*1VW'%%>'SG:=NF;GJDZ]V!CH\12MVVQ\^C"H8T?_E]<T#W-P@( G
M.RN /3H<O4$%"61I-+V01)B8'I@FZ2\__FRK"-I190SQ9).)DZR6PZ_2!O,]
MFM>AN>E0UOR?@Q,CR<FI40KA3C4C00J$/AF>(<&TTH!-&\]E6V*OO(M-L]V^
M%&GU8[T0%7";'(>*<Q7*$N@!)V8*L2)@_FH)_S4[5"U+!F1N7.$M=XR"-GCZ
MTWUGV?"RCN!'I2J[[;DZ2H7?NGV+8CV?MO=T_^)'JZIYF^0K'$*6^0?OGSR(
M;@]:7,U89!ZEMF[RBO\*U4;04LXZ2/6-VU.'/\%!UZ(UVSKE&KNGWHF;RMF^
M2%D+<BM!#(M.0/T V9=[*X)ZFC4PF7<!-O]#'P$#X/E9SP'CW U9LPUR+R$B
M026H%EN?^?,@Y7TE/BFI>%-_D@DL%!=RSF7>A0053D!?WW@]7Q?-,W^9W>L#
MYDK7CE ZF>/7+5 \YI>UT%JYG=C8Z&'7WIA  7/QM.YX=F^A!"S?>B_R*<I.
M33$X;#-=,ILFWS5[0]]"/'-CT%*G/2WKTJ2VW/Z@SJ5L&V4UIJR6O)'NT<['
MG8*7<H=O%LF-^7J1_0.EY9=$^&!\5-#YFMZ:EDWGI58>)Q/ 9)6(UF5\^\4A
MSQ]1R>3343L  >5!?WFZ5I/?UEX M#PUUUXTG;"ZD*Q7>E@5+?#>A20!2%'K
MU!/,?N<_TB.5VBP69U#1U*Q/\>GJ9_,6F+A<KG8!>UW5*3%(;Y<;_##088K?
MLG.$(8D'H^(M;)28T)<5?M)CX<^17%GW')BJ3KATD?1[\Z*6H\!Z$=M#T1?"
M#?\=OO[/;F9J07V:19L+[JVG,[VZ9.'"F5=D,"2]N1+D$<-UD636F_VP.5^^
M/U G=4I8P19S_4XC?UY7-6&)SJPXV?0 2YK=PO#+]/<-=HWV1GC&>R04W)=/
MV XEM>Z&8[8#;>!?E(;\<E!EZ?'^XU[$V#%H!L+I,_:S@-M(3]NU#=Q)(0 '
M;[,X9&=VD3$RTOG (+-@NA6Q^>PF5PIR-]@!0@O,F,@+JO0(.:T=;=Z MT:T
MRUDIH][8CCC+K7?SM93<M=+K7NK_  KW"$E18U0L8 _78J_)U63&C0UWXG9'
MC,0J+U7(RQV=[S>YWOL\ZP^*;1S:(;'%598E<G\:3SEIK]51VAR'71-7RO?H
M:I;:'K:,DU=P:V-LD/Y(BOL!+I<.(4]ORAO_"E<J&3*RFFSH8SJI2^.W[,HK
M+'!\#'_U1&GV(CI)J>UV\ITJ>:7K.N$6'NR-PO;%PLJ!O3>>+]H,*M*#[KR'
MQ7_VVJZIJ921-QMN2P7UNZ"SR">6>0( US!/!_<E]H4Q.<'"M4B-<.O/7E:!
M/<6%6-6N/I.X54>A\A#+UW4287N)6>(1)],'?\9O;:GD_:YO#$-<UOE<M)X7
M?EVAO@QO$)!!*@#;:. 2>F0[;V^=Q8$E=4=T-!\[:TL$OK+&5PA;E 6;X(G3
M$NU\Q3P#EAR] B;W^&9;[UJI-L\_C1B^=PU7Y&'%A7#RM Q34+9"8S<L3VC)
M,)YA6J8Q8R)GDW&U ]^6JW#\@9K=U78OM7T*4VO.T,3Q_+WH4A&33ERF/V$$
M=N3IW8^ ]Y%7!U:K)X*/OCG XYWU>:9&7<B$RAWQ(4IIX]O%<9B[EMMV!23@
MFZE+A9[U'*7,W4/'1D2R*Z4Q^, VJF-@4J+%$[F5=LXYF:H^P]TR?<JEUSB3
MY5RF[6*-WZZ=\U$_,SS'%O;&+8I\:7JD@J]0UNTGG[E_25O$-1',;8S\W7#*
M6%#43F#L*F57.>:_<7^P34ABM4W:<8F:U09'W.W00PJYY\8YX-U39;%;SV+)
MHM8%NU4-4)%;(R/2S>7,]*MDX0U<AGG:L\A9W 7OVR[D"R)B)J-><FC>)2!J
MT.G[<-?N)H75U6(B>L%L>6&AV)I[R9JVLN/E]ME^BLW<2>R1+&K$8+):DG9I
M@(UN:>AB/X>UH.^I9D>NS_E !?B>MEB&P>F@%%8,OU"Z.7:%5@L8R3'<^C$S
M">XU\163<C$6U4L@ H^%;LFVH3P0D&DL,+<JVU<6DO_]MYV6-[4NIF%[335A
M_AAJZ+:0$FL+X+*VX'* 3F)=K@,[ '^ZT,R3(QWO VXJ9,;=I6<<]X4"'-TJ
MF3&<=T5T,^]PL?_+?4S^(V)PB_!%&S^HU_OSLHX-XAF6\'G%TVOZ2,#ZH,]R
MU@>2AI9$*,SV7\YC"<BMH+[W1;KQ8%9DC"6+U-M:Q:]_W$G^S5,C6?-;8"#8
M-N1DHV2.WWX(;]I\Y G,*2PSEX*F;9_ J'Y!(X>JU^U(SPKK6)'')[(D+!4J
MU;'TZ[<[^XT"2]<Z %NSQ3SRT=?W_XVN+/8COE!VJ\ %W.LYZ-!Q*8/)C>%O
MK*<)'@^57F ('9>8<ETT.R9II >Q'PUN@MO*M#AYIYFO'#<IM=._+BH+5HF-
M\$A?<3,<?C>@Z3K5O\Q4E"KUNE54:[>J/H8!=#W$.&5%)$A<-_JRE&'9=8^*
M-&T:>C[*5#A=W-6+#_UA7HCM5^C39_7;R=__IDNY/7O_,11OPQ;BW;LU_>I2
ML;MR#T\M>DF;/?RFSCP#7[;BONA$R.MN#MR6Z='8-49>8UL%$[&;Y>4G)P72
M6K']RO?^_YCH7Q-?S^^'V]H.&"@'<MI<E_T0-TD%0J#C*=U&@PL5WI&3@ADV
M(#W,BCP8_>ZHBR&SA]1W02*CME+\RJO#!Q#)-?K,&Y=SLQ:B&HO1,LZMR.>Y
M-B%Y0<-1&TNE@PZWY9HTWM^V?KE!2L#,</JD5)M>,];V$FI4E<J4&[&M_&9Q
M^<"&41YHILJD(B[UX.D[A_K5\*]5U5F0P+8K5P_R # 9GLF\.1-QR\,0] "^
MV7TQP^/S8DI 88QCJL=.U2380X7%9]KFY@/',Q/^[6\^='/_>^>D_W,QR@CX
MUW,$#QVWU7-6).!)X!WN"UN.W']=\'2\P<"_+7R%V,%L\V\OJX<R\)>T_)6W
MRIL%=0L83ANK%F(?R_I<$=G'E5&BDLLO[O/F1GC\A:2F<.=@97*&&R)'9*CF
MBZ/?FF:.?4%.-B#G91?#O[XM^M?%BV5I+62"GN!\3@['X,+L#+^MU>(Z346I
M-DVM1"L\ZX2ASGNMW-W;['MMB4VL[7JU@K^VQ0LMRH"15<7E\"F!P?'MN-1_
MJ#X":3V.$:K-U'=UT\]UM[!RCYUQ0CJQ )&0^53Q/@ND]2(4V1N=:Q'C'FT5
M%FN9E6.9NX"\5;-9.: 4K=Y<2^[TZV.;16!?^:/+UK=X IY^HHN=8*&XS1ST
M;VTG6LDOHJ-0EOWZT'P7 QMJWI$;Q)]-Z0+KS8W&-E4P=\Z,HL?1ZKWP.;5@
M)6ZUU_.8R3F.Z4P@A2S?OL/J)0&J3-I?>+SDF36?G@HFHZ9K8OI;:5^RHSF=
MP)G'IK5N;7-6QI7AIUW#VQ1V=E;$U2QPF'@8@[^J1HR^J#@8(W$)+P^YR6^O
MQY1RY8%C]@L\TQ(U3O;D3BSH^ID(RD3KVE&BU1SUN-!OOU':I#SG!]P!NKZI
M"1,.JOF;3O61LJ4]]IE]QVG]<0ES=V>\8'2(Q1[%ID4L=FSBV=?F.,*8\=]T
MV',_GT$76GD0ES(_$EN.?N=.077KXH00'LP"HE*-4.,R3'D/6^Q" 6G3[(@Q
M5A.R?-&($\V>XK=Y!5B2P.UBDEVMJX@<_<O%21'8^ZAT;CS'?<8:^*T76N'$
MV3S[SX86B;S&6O7$1&=1UQNX7#NL?-^^DV"D>\CN(&LJQZH@1]HG[/%/.+8/
MS+3_IAE45IJE!P_08U9]1%_W\^CL\*LNAR>K,C94OPKP5%CJBKYS4_6]XG1D
MU8@$^):10:_8-9+I\^NH1[J3BKFE%+=PFC!F%_?3BO&\9T6Q24T4?-P[;UT:
M7(=4V<U)S_JK.KHZJ(-MI=&-N!FTG/:G>P?054,843;YK2XN+.@^URG:]7"N
M]J^3""[>S4J"38&@4U.8,#-$?]3"F^G$BT7&NI+@NVAK1/F,IW=4+]>*S)06
M3;#Q'Q_@A9(WY$O-?Q2P]8^_M3QJAT%V2D@]N-6AK00T E>WQ"?M_@W$J6"<
MKXR,GG<*"Y]MG3(W//**=JVCV<:SL66O=QOVV%86I/(5([XYJOHP@PB8TZ4.
MI._3PNHJ&WBFQ'&W[%G!:,U@^&??M[3Z/HA T<:DM-+X!"GIME]*S^(>FLFD
MM7A\_*,GX<4'X4I H-#/%/$4#(O*1F[83W+=/>-I[B.752?9>V _,P<Y/KAX
MC_4.J347;F&OD5EL']&\>-9#6%MR7':GF<)0--/$=)7'A\[F[/(C6HHSUAHH
M&9!&"\$0&)&4=7W%)#:[MS8L(D%K(*9OD7."V?IJ^2F'N\=<(?>YBZ'4>N4P
M('0R=7\ZUX(\' N,Z_OF;^&5)E9)EJOZ>8<#KYOJ$X)HPC;S1+?Q;,GV>QDN
MMI*XKFWN;PZUU9W T$JFB?YSB"D%V@V2[J$,'[&&<-?'[H0(G\Q\W*ID**V
ML/@QEVAAEMG6#)O;S( 4<JZE&77KC%)9Z)ZF]S])=0=N"C-M6NP+^H2D=NG^
MP>A+1KSL+K(H1]M&RP,F32"S@?=C?&&IDC=^64'H4U8,'I@UM?\!!\&CB*8A
M99-9\O!G)AY;0)-/^[9-\A\CJ.)A*#F%?[R32[$CV3C8#J[5"_:4SHY7,Y9K
M+VO7D8&<5S@I?XFJ<.X,:G^$5<6$ZFQ8W"[:<#>#]+!5JG/:L.2Q!!I<]@#O
M/95;L*@6^5 ]/<MV_NHHH@:-GAMDE6#P"!1^4S309CBYOQK[[M$(UK^"BP?8
MVVI]@FHI-Y5BVYWK[<>#U'O'%_1J3"F[\16UGPU%!,3J,_JK2S(3?WB*\[I8
MSH8@<RQG(T8GI,8_GZO[YA&ZZLXPUBO6)>P%KY-4'<$"CUZ3Z(KS/3.*0+N5
MOV(7'B)XB3+YREH679*?!-R=@8[7LC9FHYFUO[S*AK@,RZI;)7N =Q0((+,!
MOMD($G0!*2XN[/1DMG9;!K-2>9N'VI<$QX50#\UZSXGYUJ% E'H3BI6PI]FK
MPK%][5'!K8C F*.>RQ(^B2+,&8DVH%9Z7_%[LRJO_0[R"[L+?CX34Q$X6_S\
MJ<#_MX1^><\'>OEK=XZKG_O8$!)M^%-O4Q0V/6T2'__,KIW^E.B"BZ#M$(2;
M!NL.F6HIK,SJ[O;5%9_KCEV_31/[9&[*N[N!EZNOGFOL6P5#T:@2JY)_0QC\
M%NGNP=W9T8/?DQD7U8VBI^93T3V]<Z]$=78W!/WE"O9%_%\5OC?#*Y SE'^(
MZ-_HUZFQ7WE8GO"0>E(/IH)<(4?M/SS&@7@XVVF&(1?&4$>B:40BK?L'(:3;
MH&9SULZC]BR)K::I9,B%<F/$QC?4:NW+AXZLN597,O(*,?@4^!KZ.^3::DST
M9&/5F4?Z#U0KL+ICB3<ZE2VVVJJ!I">4B!3U?03$9^F1=$XUK")JKM"T8,V=
MHJ8'_N]OLQ1R(0_D ^.)RK;]84-'0",/7UPKCB0R2UI%6]7P>Z'[\J!>2^$=
M 7S9";25K<FES2#WS>EV9ZZ)@_HVD'3<U@HKYV2;HE5DY5X)R67%XJ/.CGH:
M6^&>@#E9JHJXWA?P0/A[ZV.^(2#Z:(&=ZYE3H(L;7#@\:2#/.$U:JE!WG$<W
M,'<DHR<&".8_$4BFXXW>YWF17>S1$I;U[1X W SM"NDK.??$VRT2&BOB2@M\
M/,&0?3[K,2=QFY:\Q%KW5LNIE0H[1FC#7) WMAD&S@[$(]82XU)'TEPS)(AR
M?>UCSAV(H8FU4+ZGH'&.,O39N$YY5PL"T>0X:M+T6G\*J%7U\V.XWBMH^^OH
MD5%]HPGA)&ZX<DOI]%,QID;T-V0ZUB(78%.)I-D#NY;;EFRK=0@R.M83*=7R
MM3B^"LTLV ]%HQ-CPT?XC;KV;;W(V*QB+N$*SQ)Q)R0Q9OY\JG0&O8=.CC18
MN%XJR;;SP+3"+LA2UO&5UB68U/83A7T?]\ 6T4VIYOM9G9+Z*N7?]+X_XQ#E
M_?DIG?#NI+6RIFF-BU+*+//I_&^Z\D#0>LBCFX7U KS:$0KJ.T,S7YXN/3/I
M.DK6.6I_!MG]DTRMQWWA*U&+;/61V=%!=<Z?>_F.'^VIM!KG>B+G#O+\&D2=
MPB]>!74.O0&EM_/RV7ZE_M*.D(:_LN64<O5W"_'Q,S*EUQ2FOK'H US,@SU/
M(.56@ZZG3=^,3W:X%J*L-&0&CL/9-@UJ=:N1Y4?/(62C$/GA+9Z8B]89LMXR
MMK]^6K1R&B=* >MOI!PJR$A^'R?M2X]K;JD_^4R;M3VD&@*IL_;!%*% ;.5$
M*,>+FI78F5WO!PF2#S("^A?_"J$%R4[E'62SQ<:/:,X&KS6A+4PO,+Z^HKY7
M[38;D\X]DJ=-;;6 1Z&Z^J%Y0I7%SFJBXL:^;7.Z!P-L39H3_N^G?(-4^Q,,
MTP9ZR8-V8320IFKL9ID(@7A=X;PM(O.DH*.[9K"D^_^(-%XP'\=JK;VP7;#9
MIC')P!)\BJPW"LR^0]G<Y*YX[V&.%!+$#;@=#C)RA?QBTD69'_0?1+Y;UL1\
M]NA)!+<"Z(]\L,WJUW[=&UB2#2FUJB2Y(!TX[4#14V,V6\3@NG <9Y]B'#F5
MY49]7_LAT0EAGCZK/@>X;?1%+]^Z?&M.FOUZR?I<NZ]]P =R?HC=2ICNW)8#
M6^2+3Y&6&[[PYD H,!<XR*L_L!0R(27B7(5F9^ '^M'R,Y7K,M0@:7(4;R?;
M0OKEW";3RAAPDF>G'%/I.(%=@HCI?(N3%=#EQ%E0O%&PKTK>;_LBIS&OY:F$
MH5592OC!IDA7/2#6-6<>,W&HF#58*DML!-4#!@^%^]U/I%Y[2:'#0HU@*QS#
MM_^R0IX@BIUD1E05"+6C'Z.-RI48:EDXWZ:N_WY_.?2;QCN6HI#AY?Y)OB2S
M:?$4DGU3&V* Z%_)>\,LY%*>A7V6!(RZ>5!<FQ$<N$E65DZ.LEB%C\DTU;]1
MFE$KF/G3^(VOQMNVP:T'!K5]FM8[3[F&9AEDP017IU934"TXYN0Z6;AB@O2^
MQ%]B+=.-^)O!RQJ*Q'G=G,+?4V_=T6M+R@F8P]KD.L_<MVHQ+:"^LAT; +,/
MB=/A%[4!>_HYGR;)9W_/*ZK?G] -YF6\>\@M8#4W6_K!5XS'.*ME*I8R?I*M
M5J#;(2%<H#T1NC'=\F-1<3G([\"M#G8.C =(Y^(KA(&ZR*:$X7,Y=N4S@%C+
MHVIS;RY=7G7ALT8GJ6]!@'9CMWP>K]@Z8==76.Q!;-)I.DMK'GE\;"#Z9G#/
MS]D@\<KJ'$2B*;!0C"19L7R@"(AK>?]#T\LQI('58$)!EQG2XLW"/#,4Y5"6
M-\%0>K.<P:[A+<1D9.V;3<TXS!XU/>.IL[C:3IW&^^S>G(BILY]?Y/QVYOF.
M,+[@/VC\D/A98_!HSH&7+3\AF"0O!Z^^R?:VP\+3J=\B-C<G,Z: 9*EHVY2_
M.\3<#Q4,I_Q"NP>\GF4/;N\(!)_?:UT\Q'9^+)^\B/*Y>D,RQ77BXY#=$[F*
M"VY,2=K?I)WUZJ\(C#-\2OQ0AU)+ MQW/6P(4+)%Z<9_GU+\=35277*@;R39
M'=2Y&VT_<EUAJ!JU[W(;K_D=Q[;-UW9<JS&,4OO%6SV('!ENDVZK:F-OM9.J
MJ4&.^.L.=6'+$176$NZ(_MOW>/$(=IFTB34>.4SZ)7/EUX+&W4*O'S@IJ'=Y
M6<S@![^VQ_F&PJ[4T+<<1XDT"FM\IHG )J.S?,1RK'EE-<ZV! /U*JZU)D/O
MYI"34+F=V>#]7-1\A'M7A1NBNVLQ=:H1V%_#,P^NB7$M(?LUXP'=A;D88ZI5
M^M-K8J%-R4&@>+LHZ>U!DBQL8'"^&6<E%;'5!<^$DH9NSUBEEGAV80O?%H:>
M$:O/[7Y_JSAM^*K)S_)&=?CMTN[$.H5O*O"X,4OO":2HHBZYQ9#;L<Y/T;^R
M?[//[*15OOQ2"QD([/&00@U2)'?^DD6"/*:Y3WF":" H><ISG$/9V13ZB02"
MV681H3.,&DBN.-EQ@'OBV^#X]/A49UW$$7+*W'*=*CQ'M74C#X88!.)JW@3F
M_O!I4S0:N3>9+_+)A#"%$WQ6$EZ>M)T0^I-P^E0Q*-?MX-VNXL&?HQE!W2D[
MV)6MBE4I]>&@^6]L ^Q7T\+/M"V\I)0+-J:FIKIE(XYGPG?I79UM[(-S?L).
M7G&9-\KM$PV&=?3P>2+"_CR#:=T&UMOU_*HS[1!AX7V->1Y=YV_SYM]6*^S"
M977?VM@]I5]2)Y?@E,!,R4X*M62KB.T\HR9#1<6#L[5,1/NQV0#NX11KW DI
M\:>+WQHS:*/:!55^I;YOIO:2O&1;:23(?6]OSX-62%B>T+*!]\!:ML4Z#/1U
MJHYY>C.Q4U4K-/0&;-G%9HYSTL^4VN?V'N*3A>=9C]L"6]IM+F=AN[_79^BP
M:!LW7;YY$"5 EJQO/'R5,CA5&^YL ^L?MQU2]U\(SX,8/B*<&V%&XFJR%Q3?
MI0A$N;W6K[2CN!V.*9#+?\CR3<0Q1&DSY-[!?RS9K]8T5H0S)PT8ZD[@!V%Q
MUD?]G48VYB)Q?RVRJA3=,O,:K+FL\F"L<7/]TWX0B['$S"3FYU!GGL"<5XUL
M9N=@JV6-Q602\3 (F16<\[5E+S<1YP@WGZ]Q^?I5<0PHD*Q5"=G$ ?L:/?1R
M=#V%>V&AT6Z6]G>,KQTLRXSLK*H^.ARYXAQRC^P?V$DWFOYV,;(-X&<<I7;;
MND !]$&:.'OR\X->DK+C->;ANIC+-)7]VS=U^0Z<PWHH;M8D)K%<3$RD21&9
MJ'I=]60SN/:K='?3MZFX>76%DOFI*(EP:J=ZMZBB<1VN8H6(3HZ.9GX]BR+4
M.DY5EO8Z$[IE#9?KQ7HVMBGC\RN+2!5O!?Z1RTLG'PQ#)]GBD?$QUS1HB\+X
M-73 YWS.X7R"G7SWD:%YGG:<Q=9" 5\AIFA9PIUCADWB+W/G#8BSMO#CAPBA
M$87C,XG+TK6V<V3<['"!5EF=OW06Q;XU* B5"N4Y7>$8DNE)5S;V4^@?%8^/
M='7^ATP_,HA0,6%)V#?<R2?I0 9W1X!$KPZ[\E"]*\\">?Q?+,;CJ3G[.*M1
M588;K\("JOCYU;A;M3!!-AKCQ9V ,S-U6\;9Y:UA##%_%8]&W\1.@-)RJHO^
M2OOL*:WC+9+[%N<H[N,N[S9%WL>ZQV$B:3=3CMILTZ;SB*8<!.&V86U0Q+V)
M3X?2NCT3_G.\#TOFE:43U57SU(#Y[C8PF1S;V.BPS=KAVI#NF>T?=>-L+GY?
M^(.[/>0'BY/?.FT'B"<K#9Q!>?,@V)Z.;^\R;"H'LTCZX^VBX9*3^P0YBI:3
M)'V08ZJXD6:%N+AULEMB0!/A;M:<B]5;SXG?"05*F4MB4T1X,70K(R,GCZ=_
MICYS8_C'2!M*?+]X60PZ$@H%#<QFCBUW<+I1TH4P KP97JD6O9/=!WNS,E]:
MNFH6.#ISPU\<J*.H\P:RB=<[J4&1LF-U7H5>[L57O<Q5'@DA&B0$54L'?3@F
M5@$!F?A^(=0UO>IP'Y'E&-8B'\7,N9W4NB>=F*QO*^X9<YO<$W4]_;V3;]5X
MI##;?965KD4CRAK:M(!:+:.#4'>T.40QGS 2?H _K'MD:U)J N9Z4B=+\5*S
M\9I.SP7 VFIH+'?V^>!D(RKKTN).\OLJV@53(.JD-F"8\3>_XC.A"=)D?E*@
MO+.LA91UJ[3KOJ2_NURFMA F5MS/2F3&Q@BV%/XXOVM@Y9G;G=K^T603/-YK
M.[NFN@XN4:[V1K<J+JO:.+/UHX\7EM9N=*Q<^+MJW'^K%. *(/;7$Q(+G+LI
MDT=2I($U96WO<2FY#M^)+QFW6W(Z525SL]6MY_%,F8>QMXS]%PI(H,&)30_A
M=@88U/R1K4CI:WBMC7, 7\=?I2M*+:W522"DUOOW(L\-M"^^+$@E/QUW-:]R
M6F\VKS+>,<F-1Z?''#Z#U9*%%SJU/_89D/.GG'J"&_N3_JP#CX#JOOY*'KBN
M=1PYR<3DGEF/IKI<'>;,HI)Q\_85*_<ZJ*G*[EY!O,N89/C#_WN)SBV!W)ME
MB;) -O&8OA.)UZ[-;8T=MR#K$^LO3".D(%R J1Z!1'^E2U? A;D&XFE^3M-7
MZ5YU;"GKA<][X6;;6(M3Q\OM>"1"$8B<3+?"GSDY.6_]:DHL:[.DR1J01K6/
M,L ?D$:"D9%1R#^?P6OJY,A]XUN^'E72F%FL5Y#9I;K$J78>N;\>+#<T)(C5
MV*?=H5(+G%(8/M)?G 0X%G_J*XJWOM$1L;R*6)7OM(>9F(M"2EV^H+9K- ]J
ME)L@W6.=PD[7%)V<%C_*RBK?DR?L#H&5*"SW0)S8[K&3T0.O_ 3]__N9X?]-
MO/_WS/\#4$L#!!0    ( (P\?52\F?7O+P$! /QM 0 2    :6UG,CDV-S<T
M-S=?,C,N:G!G[+T%7%3;US\\@$&J(*"4("G=+:!T(S%T"#,###4P0X=<"VFD
M&Z0;I%L,&NENI1M!&H%W0/'JO7J?Y__\[AO/^V$I,V>OO?;ZKMKKG#DS,$<#
M1Q\ 5V0E920!*"BH*$XH3@# T?+-OGNF,%L8PA1F3<')P@;@$Y51.'<.@*2;
M%:\\N/X< NA(4;0!:"0T4K]]1@4 D/^_JJ Y67,ERBM'[Y9EQ4W4QI8,D_,B
MPR=S L=3*$3'\\<')Y)8UG"HE:V2G:VUG2UR>.&8)V8!5X58V5F>'A\_JTB)
MBAT_RUC90D[GCH^_R9R,%:Q%+8Q@,(OCX\LG>E6ACL?BHE#;4_Y7/ A<T= 2
MHB:AJ89DX0!4 !" (< "0 &P!L !4( 5P!;)@0/^5'0/#H,9JT)L[:R5C,Q
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M0,Y SD#.0,Y SD#.0,Y SD#.0,Y SD#.0,Y SD#.0,Y SD#.0,Y SD#.0,Y
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M\%IUXQ,:SC_VJ$M3MUZ4B+=+SK:85Q(QI3 55\N+V>J8.Z=DQ2NX4U/)JA9
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M"+)NMX.42=",%.(\>X"2JW7:=];O7M;-S#X7]RI$B*?8Z5J\0VN;J -/4=V
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MJC:L+H(U]!Z!!'9P"UM+I9L"HGY-Q6Q$U.;M!OB-ANI^CQ!DS2W7<^;[XI[
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M3Y)A+YE*D$+[AXV1>!G\Y'S2(X_T46Z3S)(N7\;>-!-NT7&O6[8$5-.:I7#
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M#&,E29!G>%L=!K53D\-'9"@<OW?CL?X1PS,A;T"IG^RXB67U]!VRRM^[F47
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M+-6])=(:-<!"X6%Y( L\-D$.8I% Y _QF6_W.-3 ESY?FNZGLZ&!ETO%_T!
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M'B6L!Q836,\@P1??%)^&H[[=!V/0-4N_EQ?A)'(:,;^L^NE,@?RGIJ9WLZ;
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MZ96W_3?A,GX11Z</@-/35U[WHZMW\AL& [:+HZDRK]F.[MI/*AX F_=#^ ^
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M[RI:94"9Y9TH[%B[606?F2#Z>YFMHP= T6\ ;]Y&>/_!]/PWIM]?O]=;O7T
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M)&8_:G0'-> LIWH'4Y<53*+Q@TB,&;O.)N@T(C#37)FX $L3@*_V/F /*,C
MFX-N/E:'8?L'QK2T=(T29::5JT'(YU/O\%:CVL6]]4"E)!O/.G0\E6TV9:%M
M-H65 "*+H9<(B]I^C0QXCWT/ (6@#MV@42(YRZX,6E]@ZUQ3/>RP3<$$L\OU
MV)^!T4:F0F5:NW:[R=#3N/I^#.. K%28M(5%7X]RA%_D'&]?H !"A-F\=%^H
M=H0Q82JAV,F2U=&'28P%TD>:9F)*_.5QUNIL-'.!V'N?^>KI7S8(!E9_?V-J
MJUMMTZFZNGHXR7-7-U==.;+S4RQLRMV9"DCQEWAF8$)@CVLP!QX7'!LP)&@.
M\.0&.+HZ>3O+'8ZU$I?II"GL+1HOZA$TMG9BU_C[*!;K%_!.#4QPT'?09*JX
MJ3&OA:#A4/AS.[]R^X?50VLTN<CE6.)[&KZ,"(@N$9T1:VD5989"'8%F>3,<
MIFN?UPCS-,R*S'#/,,A>OA._E)LM FRSO<RT<"7-ETP$Z1%I!PWHI*%-%FN\
M0;5GBWTM1VA+]-H"*Y@*'(0&H(]"G?-"[#\Y^)_< RG>^5]?47\86K6(YH*S
M6S(;'LP(T,2!!D+XVH'P^C)QZ;XS;J'&#4*;AB(+'6&.V)217;)<32'/]&1'
MX8D4C R-QMW']U^K:3A!UCJ3.APA]?XR/;)@-T5(R<)):4MJU^83^M!$OLQR
M?PZDV!TV<+N;?9;;K ^N?Z:PW#A@NF?5)J$0Z1),\JCD6"1FH3(Q7-%2ND[9
M>IG_9X3J\?VLC3QKI-+*4Y;#?.YD50O=B9*NINJB@G,M/+[N"Z*FZ J>68DD
MX6(W(09N(T?[%X^B_A:H,&Z:ULOP5R1#G.SPGKRX?F?P**F;$!Y/>IWB1D-K
M4B>MBP%10*]VF:[VI")W8M(XD4IY[BGQ<N:$, /E82DQL^ 320?-D=:5/1R;
MQO[@T]/V[+(MB:34.K'H8TU&\*C O;2;1ZSDL:82J]^[:@<ZF-?VH-R!SBM>
M0Z&I$+9GL=%!2=YB94MJW*F7.,?;Y.Z2D0HG!H(>H1I=UN_(SC! V$[PT:V=
MV+[#\!9[ 6\X.B&IZZ;=I^W(>=23N:E4[<"HA#X">-QF/R8-&?>S;#:ROV=D
MED<VVU .5_5WT>%P(YCO4O8TP,(8DK]T-A(I;(6_#NF%S_N@#U755=@QNS(F
ME$+-#L^5:L?$U9[8NUK$<%W$*:=%8=--JE9ZB(EUTGQB>"?@ "&=:29.%H]/
M+-R]>I;>MW"5^43T46@>/ON[<.BOJ,6X3"?!2OI( ]<@=>*>"X,ZGG%;RJ_&
MA<*G&#G0^X$@-Q*FQ,;V_&LYWE_O^V%A0WB%AJ^D".F\V\HIF%V%!Y][V4IM
MK(6[)0!72 .F)0AF:5G>+$QCL*JMN2HSA:.:_ ]V/@=U7ZA'E9[0W:!*X^Q0
MD%HB+9&#_JC'U[ Z<V(-PWCQV7*I1Q-JB214$+7Z)<2SR]OCV_!]W.Z?5R]"
MR=]Z0Z)2Y!YIV@2@7JGVG$E-3M8> +F/K(8;']?8O2T62UK]H+;*4 ]#OGH]
MJE[_G#]$BS%F* HIIBTI9M6:];'%HE;4<1/#-G:.E/CMYKF@EO,E1D&]C>?G
M7Q(Z:%3HPVKECL6&\XN$)$2$#4+U+.S$/NA!H6-$.DQ 6?:^9S+=7+D=>.^'
M7]$F_4-^9/X/\H/]M_Q(^KO\2/''W<36Y*T!/4/C[0Q"63G%^&3Z;?_8L)8G
ML-2F3H'H^QH/Q"_7II5Y95#&V[OQ:>GLCSK(EN6.BW8_. "OY?.(X'[1DKZN
M5+V5[U)Y"LTTN/[Q>5PM)YK/94WNT7O]Y4GTQ 7MDJ=$+QA^H@NJW"B)Z<M"
M!E)B:[S8&[=T(]U)(=WCTGJZ 8=T)DZKMGT;1/R! 5-33K*6<AC>F.32AL%I
M8+QGKP3S7A#C\%:C6Z> O^;\EA1>55%H^*>_Y>>< NV>S\I9"]K%7S].O*&A
M!SRI^N$V^CLB(+R /=+$-&N)2$BPGHG-#'/3"9\SAH&*N0#C/"4'U)V ]W[\
M":1#\L>YL_'C._AR+$Y,9'F!L<%0*P9UI2-+I-4H<?^R'S-\IBLF>5<C?"N>
M.H7I_ % )#; -=.OXR9HXXGAIA8H-'?C(5B/(6S#MHG"WV*D0XLW4-5<4].X
M7T;Y*VE79X]J.Y',G0.[Z;F%8->>J&@>V5O_.X,<]L;<K+?Q^0YX+U;Y70SX
MU:EL]7]<YI]D:8F*HCA])U @"&,<"^2V^W-0+TAVI56<P*M2XZ^3>@V(:Y'*
MQ7*TP_\F/:E\+EMA%8[EF8<XYMV^0GYTWL%U0#."NHHW:%ANWN4^V,%G2TDG
M,4*X]JD3P/">EY<N<A$R=&H;IY_-58*6O]%9B@^ *$^8IMSR.#E,PC0%3R]W
ML=98;(R=T">E=A\ BI#:Y:)UT[!2#SH;9W\(!B5)]9&&2PJ]7_5(J#PF-&79
M86PN.)3J!>_SVIC+P(;-J5?P'!YYABI=15DT\P2P*I65OMX[Y>!NKB2&$1Y]
M8D-K1(V%'D[5K)!<_N0C;4HY3RD6VZE@(VT2\SGBO+\8D\OZ?NCC'%IJJ#;C
MS5V)9AG27,.*9)'AK<E+K#V8.C+JK;]=?Q(J!I1Z;=O*/1X6RZ"1BGT626-,
M*)*M4.V:JQ/U6T/?Y^C^U XK>V_9OW1$7+V?JOYTX)Q%:T9;K,NPC8\M0<\@
MES/I<]'>]D?H>]<84>5TO5&:;==\=DLL:H-^2B:-54HU\"M+?Y6T+)E18_<=
MVBKQ$*VA8=KJ\9/Z-^JI[O)E%.^L:BR%:Y<V)]ZP6)&'A/@#PT)(,#]D,#;'
M0IX;>5?/RHXY[FPNN!:'_ PP,ME;Q!,>GAU%&H_4<BP<7WACJY-=IED+O_VB
M.,4?\A51C+M)Z\6D>SHO5,D]P#H:.>.+R*E."123+-*QC>1[N\N.]J%51NE%
M[1,R?E]IS4&N4E97,;V/AH_Z.3]R&]=3!B7:+Q@/<T0HV9#6E'DT+."9IHU5
M!MT?:0^:+&%JL.>&47D/6-( XX+G7<@4_ZA!J!+M?8XX7T@G]R,ZT@Q*N>I>
ML[C]0/+<6/9^)[8_%1>_[8MPWR8 [I*JK"3WY!WBP]&YU \&,C;9^$IM;)^I
M2!7(T3,4F4\XM<K56UJ^KA0UT*&.8(&Y%"D8O#,4SJHJJ'3L-Y&!*2_CAGU=
M7= #;F"9_X1ZN29,7"3)&8Z+LB=(]%(8;FCK.4'ET).*X2=FA*!<OF9M$UGZ
M_??Q<8(]CD9.U%KR',EE$7/P./;4WK2"@ #^1S1JX120#<=I3CW_BZ+&G>I?
M\?E>&9I2I]_J9&2\==_YKI0@;DH+;9$<#8-E/;/JOVX+#4QT01QDRLI.$4&E
M16GER)E\;:L+*?/XSN<#GE^44O-YMWL@5X'UQ?VI2S'GC%[9U<%1./!CY$F=
M 7?7^#S<D.2:5R[HD.;(5A-_=@ 1/@2?JS/U4&]:"L-HASG6YPZYQN]1SK9$
MLG2?K:$[(,&/K2)G,]#/_WUXDJ1OJ'ZVWUX8P$#-J\#I:/8TM.(V L\M55#L
M1_>T94Z16RH2K5F'F@Y8C^.95&D?VE.)GSC+5PD/%PCTN#VEF;.D9@GG*JC"
MP_N:@2==/_^=_WULXF*$C@'1S)5@#LGA!'QAT,0G%[WPV<GLW%ONR>&:J0F[
M=]3CX[8B"><>9OD!X52DL%?AC/ML=<U9K^@B7@!( $E@5,-7^($ @#@ 0+ W
MGAW$,!-(L&=6"_FSL'P. V/L_3DM&;2VL32RTCB_[,-:7]@50=XH]KF4 <?7
M!]T:3PY9EE3"F]]/Q$)?B_^R0#88+ON",B2*'C,XFY/HOJE1H(Q3]?VGAG7A
MMS4,AF>M,@J#'&&#A"<BU%EVKTFC>\V$4JDC,\YU"V.R:E4H5[-&8],FZ5X'
MUP"3^S0<'>3>5&'B#=()@#>@VXFC8-=;QO9-)Y7JZQ'2T5JVJ_U=$2CX-.,F
MFY5, <J%.,>0B19!B[%$&C6J:7@@ZBA]C8_[.YU&+:)ZUSF4>=_[R0QAS6^8
MU<%*W1(V?1"36O4GC0X\)/KI15A+^]ADA-K&W#JG+WVSUJ-GJG>^[FUBWS:U
M^H;S.P:'RZNUJ?CJ^CGM(["-S1;\PU8$#N9N3+H)@ETCMG<P. W';!)%;'FC
MW6YK386NU0<>[TF#GH:J+,??\"WMO$HGJBYCP3WNQ2AF)CL))>@G-!W"(LXW
M;'DB^^?$-ZU;\U=5-.ALT:S2EI+GQ..2[OEEJ,W,%%;DZ5LA'(-RP802(,9O
M17M]F*OJVF.'K%7TD?$*F1GM.0(2\MQ3UJ'_EI5\^5!RZ[L"2Q0BCM1^:7KA
MRLH[D627DX9ONDE5)43\6W(!$2)63$@9WI/W&I3A;TTS]NRZBGZ6\'+7SOV#
M2./%1Y$791S;,7%@#SS59\ES.JSIC$-%G)$]OL)1$J8:<:E[S*BR@V-S*D .
M\7MD [4M2#^3U/43MU@$_[>EF7WTT9/PQ9=-D:FLZK&L5*;7[U.07]-64_8]
MMQ>%$T)D$3_>53(A;"\$+1IC-)YFE>VI+^1Z5<!RXX621CFK/JW]2&Q#"A1+
M#0'LS*CTRXCUNO0<!XY.8.21M@3?*_Q*#<2DU:8O#WXD\-6G>B.9)+]O9"<\
M $;(8-C]Q.YX5J_7#!]'&1*PD6%2=S#!Y6*% ]Y>_K=-&_T+FY_+T6,<K-H+
MO@6%R+K U\9<96Q3R#3M](^QW)<<4_C1>^OQ:5KSW8WN0L/SU*4)RG/N^X4X
M//2/';4/9%),XZ/P-7%=$M[[!^CJ+,X0*@TWQXCHU>J?.X,ZUZAP(TS3I".U
M9CY$I[0+TR?*2$&)5NFB038C80NK6^]W%D(%=UZFI)90D/WM3#(C.?A<T6\
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M@.#9<Q+G):64E%54+ZFI7[NNHZNG;V!H;F%I96USR];IWGUG%U<W=Q]?/_^
MP"=!82_"(R)?OHI*3'J=G)+ZYFW:A^R<W(]Y^06%Y1655=4UM77U;>T=G5V8
M[B]?![%#PR.C/WZ.X6;GYA<6EWXMKQ W-K>V=W9)>_L'?C& &!G^=?R/?G$
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M0J5"^V\\!AK=3,  .."$";#WL\E7=@B9"?_.P9/N[7\H-1C(/5!0V_JI6>Q
MOZ'W5_PRR%=W""F)?]>3 Q)^^ \)!_]-PO\7H@:4O"5?0^V]_C]@?I4HO1/9
M!Q#U7XR*P-T+'9"@W1<6^PN4 .CSG)H/0#^PK7V +;%953QG4. U?<CS YC#
M2#:H2FOJ\7W(7YOD ,0F -3ZOL( [W,/O/<,/1,ZX G4FU#DGOS?!?4960=H
M[U YH7^U=]G7_R<,TP80P'9B.BB+S^;6QY3K X$]D_JG\QK(793?AOSI.Q!
MVX$\*"CK)"C$=7V?JQ)!\3E8%6#^4;P(8M%XH*]? M";1\T"(*0Z 5X)O5AL
M"P.X*.O /'C@W$Z\UUZ2$NH?L1H\D/FKCDG [9^P22*"?[-O0X B BDX:';#
M '6+/,0:O"AB\<8@@MCW)Z$O>G82O/82MP Q^!\QH',ZD-/[1\[G0$YA3GY,
M']!TS"H)60B\A_8D1L])1,+=<,+R7>IL2;EN^XO9PF\2E:86#/:JD^-G9G;S
M3OFIK-7OGK,7BZEPSU5=%I]*0YF%I4D%:\G87QCWSW$1P-05!\+/W9MW0%.)
M:5O(5X\# BZXEB31.( .!@4$O-GWOR:K0__?FVO^TR?97DSQGXQ_[%UYX+GZ
MS'Z)#BI\=H3;]#)[,9*%#NJ^!9EPQ_S7QX2.5=</44/]YS]$@?Z34Q+\.ZD/
MS<1=^9/!]8=_IT0IF)\V4NU?W5RIUU:L$_?EM^SB<SWGO6-60J#=O5C[RRK$
M5N%'EY2::T(B?]KA1E_!\WO<QOI^+B3'C3#/G*S]K:AJ6JO!>^31M.K1)@E%
MI)R45S^U60Y5]?71(-YO5X4.LM *,BL6W<JUW8Q+M W"2JY:..^<S3-WZQE[
M^V:K@#>M<J'PM#<59QZ0;[W._,;O?61IMEI!XH<"IW6KF,@2M[8$MQZ+:S^"
MAE#MQHZ5M+:W;[;)'W(<ASK)'S(U+)/R?\_F.B8+&UF\XG$/+%MDC8F+>&^;
M>6J='^,8\AAO(;Z&U;Y#8OM"?3>;(_/1<K3$FZ]TZ@?ZIN/P H2I&+\%$X0;
M#.)D!*>M%*6^:CL)]!I0;!OMG9ZJ,\2,9LCVE7[C(^M04N<CS0??0@TY%GON
MZA18%U^ODMK^Z*R>6?DU"*OK+9XGRY)N-LR)R=6ORQ_,L77MM>/4,V,=<C-#
M&^8X8^0-$S0L/ 9S'(=UO<]:=G\7/@'$XF/,E\]#T8/9ZV;RAI5GK(OU*X?Q
M)K_=$V02@H:^UN6/5NE7N?9>*]2G+7_T,6N?RN\KF(55GX/@]">)@_O3$!)5
MHXT2Z*-+!Z$O(;88[( AI#$&H(S#<+.$Z\[QUX0H18F'NG/?$>Q1O74PT IX
M+/-X_T/_)W>-SK^T7P*?7[?G"="N8)%[4"Y-7M]0Y\F3MW6=7TQO]!"_C2DV
M;"P\6V!=I<B_G5>LX+9ZA35!<JLC;WCK;%Q!H6!*F!K[8F9CP>MMO+% N:/;
MUM<0VXOQ"T :JT1WBG0?\*U;])BBIPIXW[(FD=Q6;] $@X8[KJWHY*]8%HI>
MCZI<T5DVLGAYUC[AV>A8$X):H$2"X"1(3@CDM-PGSW8V[C-C'6#X,]CE/$,"
M;)P+*M&RSU8J^G;<:'C.96-?JO9TTGK\>W!0%.KXZGS2/ :[V3S?BR2]6Z6Z
M]9A>DQ\3B[O-]O.D402YY<)AE\T"JX8A_^: 26$@R'$YCLGZ*5I!%M&F:/>4
MMZQ!6WFY"D'F@P7\2&Y<.M:Z6/NMS+O!U+0K8RD% MT)[CK+IL7ZC5()[TY5
M20WYB5)7G+TG$ 3LW+(Q3= W1"I!$"GPW;!*<*CRBTCEBCMVI#*NHVSU2T'R
M8U-Y]V2W^,Z"I-]1X4%#9=2^K@*!1LQ0U$7371[5W%O1$T'/&R6?K.M7+JS>
M>,5N^];X>J.49>%%[G2Y-9=3J#NK,*70P?KWM:0% L;0Z*T8[Y'U^1BY0]6X
MLN:3+T*5MYK\9^; >#]&I"%I>E:E$GZ+?,,C24],JSKZ81H\\';+*?@/B!4D
MV>T8V>"J\,_EF?EE<[1#R$L#M-VM4)<1D:-$,=@G%[4)GZT=BO2H4IY<MG;R
M#(SECG,<[U(I.FC@F4VJ\K;>@J"O,D 5A[E-=4#_NY,34>"51QK-L/[PA9;;
MA)IS]#,7%0<>.-_C*<,A]E@DR+$VV__Z=&-0PDZ'V^KC,QWNFPS_R:E/!_EN
M/C.ZLJS/CJ*#'J"8>F;7GS6)1;"&?.R0RQ929 SCNE]-XYE#L&VWSD(9?P6]
M]%STL)CPUMZ(S4.V;Z-+*=#<]D*W4?_4\^(UM:^RDFT>63YCVAMM13'=1;76
M3T?#&?(?&A5S[LT_LW%260LUTVI:IG@L; 8Y[A=M0*QQMK1IN:+PX-9-M%XV
ME=W"\761OKI9<2!3/R=VY"W4]H,!P%[O3!R'OMTSK%SX6*SF_DJD.= BN_CZ
MG^M1,V$SS-0?!GMY+]K$UGUP^(/P/I>\*51M3)JK4T1F4)/K_>2J[>]LMM2/
M=G+WZMZ6,JPQ%6@_;W"!4NNU.:?=N_K(9K1A@5*YQ;+[+Y::S1"G+-O25^3%
M4G+=+<;,DE%.ORP!^FLL0KW#V!Y!A8UW>A6- 6V1>MGQWERAA]$]O1<3AI88
MA0M'7U"L<P+GKE2-; F1MK7.+04D^?%>K1ZT((0<$RU*,7I<IU/5(_L]+>4#
M:"G7*%Z/24DTW/9-R.#E+VN0/O=7(1I+8&2N8=W$4<4@4/!B?I]EH;;G<"0%
MF/.J5.I<OZUZS H=KHM]\U2X94VKS#$V/6%+>!5)+:C\J0D)F5D7&3\]G>M8
MG#N>/]^!$8/DEU0+),Y>6HBMP8A&FJ_DW -W",X4B-P".UB2X5K,1)JC]0IJ
MSR8E_?4;[=<%0VS;3"PAKZQR'*LX-[&94Q/$D5I/]CF3:#3<<HC"X.41I.R@
M<B[-+>?FF?L.=:U CQPUIC0Q/!!NF) SF&K>'XP=+58.9OPB)K$"C*&.#6$W
M2&4E@7D[+YL)_E&R")Q _P/*=ZM9_1Z#)2<AR\_>UMN%N2:6\DZ"P]EZR5#_
MM6#U)>[*82$+EP4P'CR288HV&ZM,<V#*U:\2=,Z-O145OM+A.=G"M(^U>]LT
M!]#^)I@)'MROZ4:\9DM0#L^E!'U,%'?[F'$YO/HDVZ#:NL-5BB$!0SG7WHJQ
M>4IZF_H(^X3-_"'^9Y>TBXEU60_^SMEO&0E#:*!86#,2@^>.)A"LVT]ZC'VO
M6AC^5,/R0*SLYKVI*VI+,;?]2K!Z0TXC2I]EKYZT$JKEQ/$T$:P$0.1-X\[Q
MM]&9IR;*[B\L&P%PI8-X-;9SPH?>U1;PY=X/3+*/;-<&#VT'OWARN[0Z$3<(
M:;I:X(1LL083=N<R(XG2.& *CML:MUL-D>O#'\'56G(F<$8\8,LXX<'_O<1)
MP"+F[-<@]<QT+&9*>0EQF*;BBA)N4/4K<549K:Y.&87=<UU_'CE9>4%,N-1C
M !)=ICUL(B?WS13^E7BOIS_$7:?3\O-G.Q:A=ZF+ET2?O'-=6C@<KT4JX9M!
M8F2YYKK"\E?V>7+QN=4HOQU)L2;&8.V)Q%I\E)IP2<R"F0(<Z3.PAS=K"QK6
M*/H<HM([N[)B>B*CP5-S$/&8PT!BXVB3-\F);.J^G]KN=8H")7HF(H_8N(OV
MZ55C/5MJ4[1(<M^@6I<IJS;FZ7.^]Z7Z7[QV:<KK=U3LQ[RBG"UV8SH\?<OH
MT/S<XOVY[4XXGJR] GM \O&Z1P?)=KW5K$Z2OO^RM;LWZ$1>;@@3@=Q5C>#0
M%,H.1)E$N<I4Z6L/LUJ?/L[CK<NF?BIJ;U6G"FCKF.:F8^!R?>4]EF*6Y5::
M]^O$)N([0GDZ'?RTBR3RB^ZL#&R8P9(H[,:G%(#2>Q?UQONX)C(H$)^V<'6;
M%K\-5%^@Q=B,\;F1H@744$?:1%H0=59C\-Z6N"'",1W+M[UJOQO=)!;HTN)C
M<VU6V%U8SFA/\[.""B*HY>GEEFTQ=+%[J@I&,R>[#FLQS$YR^2AE/UCU E\/
MACH.364$YLF[NZ8803^ROYGQ=IM;7/YN>T'<-D%AU;3X,8*/)N<&.4P1;1(=
MP9?\?M#4GT)^\)IO8J^U==^R4TU#5.+LD>^R<<NA.SKZ5;$X=HXQ4GM[D-5G
MY\1.EP*[W&_2VHR%I;W\;'20X1CT;2D;NV%0GC-4,7'1CMWQ]?;.8KY[?2<J
M<BOXN_7-#$]?LGY:\*OQ#[J7SA4&RG>E@3L\V;2LVX-R;)O>BL>"ZB,U;HV"
MGL6S'RU1\!X6<(2P./]:-2M^ GL&<86RPR^3,F;!C&X[ 03W(/#;I>_JZ/A6
M(;<Q/2V/8;ZPN.V<#W-U4NYY#6^EMG)S'%\O.'SC.QT2?+-DZ_+64'+@7.,C
MF(@F,*<=#V@#<R[C6+Y51\P> 2W! _U:A$UT'L&.T-0\4-Q-HO#K#>PN'H3I
M]KB1D9I#X&DCT8W>OLG+U@_831W+9J O,_E)V3D3TX$N5F%VV ]):YM?CC[B
MS]<PT=O5IZPL',TNX+]AEF>;CJM'),PU'_=;((+;&]EV_9<V#LO'$)8W,J$2
M3YLS_%8=K0F]$R2667"L)M,C>&5-O<?JB7:&K >/((>:=[^@+1RWYZL*=FJ[
MNY33LP@]EK\P%D#W"-H'KB\>*:R.Y>:/:CXVPYZ)<WR]E3_Z?K> J[G&-N>N
M5A!VN6@D8\+\[-H-#;-!>7&G--@L!F&8<^\+;X[C\VS;!+?$WP8_L*.:UN\H
MMTG3612>FH'[(\7R:#[+6I4REM-LF,.'[+3J<DG%Q/$K)(T07+=RL-%JRF@N
MQS@U1O)XXON'?>2V>AXU X<'WD8<QEJWEEU^8[.7;XSU;* :&DYJ9U"7B=2)
M(;ZF_ 1WVU?NML=%*K<_RFIYZ*\9B3L.2PT9C>7:.LM8KIKK[4($@7YIX*!?
MXL0$ *W2M0F+J61GZ.-5$\?*86"7W--/"+(H,I4W3 X2F:Q8MHCYUL<=&#7:
MIBTTK-PS^M,MSTZK(S+SJ>]^4A0)-3.9T5OF%U+L*,U2;(;__<[?8#Z)\@4<
M'K2$3YJ+H'4.:K+D?3YQS2;AH5S*15K))#OS]/H%\.Z70C"SIE(I-8W[AAX_
M\_L=T"/I@1;L8A%>@R]M9#_3K$ ^KJ*96@?>3)T/.4[HN[%1G"7N%+5CK*Y5
M)E_UB,:"U2P*;.7ODFZN<2A[YHC;JU/Q,=#A;OD_C6/B=)#9-)2(5D?K)%&-
M0B!=#;^V"Q(XF<]_>-_M4(7&(?\T4+<LT3C4GT\6[GZ^ICJW[ORGG921@8YR
M+;:B#GHS\ML-)TUOK9"B6=18>[L/7(/TZCT<6A8;6QE3[U\>EBV)L]]_K@W+
M/]HTE1 @R;.$X*:PY)%6VX)*(@MU%F\YMC@A++=N!Y]\4B)CS/,J9VYHMUP&
M0Y87-BFRCAC<"LYD\GK,,]Q@?I7VP.Q\X 2"DR,^M!9HP6MP)KGY)#W[86VA
MP-BW?IYGQM<>SB<\/NJMDDGBAV0$)8ZV7;JD>MP7XH@V,$M<"(!:+J+,_LR)
M-Y;. DSEJ19LKI @A4TY&!3%@Z@XL[@JSH-KI4"WGQ$P"^0B&VTOWHN&.@*<
M<Q>;7#VL]6K;6MN<#GK^PF;%/%"B+;5,3VE,N)@L1 =)A%M)?6;9=V%ET(((
MXN$L["WHN":6ROZMQHLZH):R#.5LWMU^E0OZD,#J)]WG&@,Z;7<C*C\'&ZMV
MI ;Y*KAO"-G(;G-^EK.KAT\XK4[S;$+PPF0Q$J1=^\0(_#'.0$Y3,M_-5*@J
M0DVH.^DPO*#7M-Q;)<DQ5\"G3<DJ9260_V6P8&)Q#M8VK^X';2C-)'>&_>=W
MBM9,(]LP7(T;[#QT+5W(Z/85-JU;Z:R9>\H]M([]W8X"355<QMD&M7O-;"J3
MW,/#D9FPX'2_Y<7'V%PCK[E8IUF^-;Z2E;&U8I_\XO1JI._<8KJ>8F'=MCA#
M]Q9:EQHUYTQ]1Y%YY+]7<^W2',0U5-I E5G6=O_MU<'.J]8+NU:9>JFDO)TA
MHD2$MGC@>-L7W*KLW=E>W"=?(SO7Z>^U[P(9OV,L66IG@JS?D\)VW@QK\\*/
M]VOJS<4*(./\7!(O*2E#Q10//?K6D'RS5GN/L?%)\QH=E#,V'3H.YEK/C;U?
M6^J16BV357U1/\K&):M5DXP%.OIE,6R3.@4\[ >OB<Q^O%B1_M[O+4M97_7Q
M?:O,7I1B'H\3V,/!/-EJ/<"KXYTY]0/$E1VT[#\E2_1JQT-H')("K/%7<\]%
MJ"P$7#B;+0YN^,F8A0X=#E4<6X& E"&O1'@W?L\9*ZP7WZT'GX]_Y!3/-C,?
MVKA"!V&*]4S*2 ISP9,FP(Q1/H\]9RKF="\<T\WPRXA389MG4[7EL]$JC"0!
M]$)G&V02;J0FVOZF+76S:96?N)<M^$KMZ@CB29[2+X.VBXN#M)B\?(H_J8I\
M%<[30&LG(9Q"\O2$3L!N,L[?S9.J[C8QDMJ XNQWV^B@,49,DPQ!"QD!Y\/E
M##<8?!1C^=Q3(W+]YL..0'/DFZW69=CUT/8+X=0W6\K,M8J.*7/H<TWZU,Q[
MPPUG)%YI/KZ7&9K\<>7[_8*V[ 36&$S ,B;K0_G'UPL]GZ#79/>[1'U+,Z=3
M+G[>RUPB:U."1K3/D,)L"7E16_F^TQQN47WU($L[#T^_VT$\VADZ&ETT;=)/
MH/0]+,H+-&H9@>;8]"QT/O'^J2JE:YDJL57"B),K\,RG_121'Y+-V5Q;K*A]
M*WBN=_M'WG)Z:%T1@LV/#GH%JPRMFQ4V[,$HDE2O8.7@T1X:_&$*O89+D+7-
MI(G9\F3^KNQ$ ]TO5)S@MO#9JYZ;FTK%][;6??II#)301E+&)_<I :)<?!I?
MM%*EK+A"(N]]\X@]Z.3M1PC!66WA.9I04A>FK *%O$8NQ) D/[K;0O'/9J.-
M76[!3JX,W#*4\Q-']G"I<"4VON1GFJH./44'?2&2QL5H]A\QHR>'O:6\4?)>
M"1GJV")!N1+:0#$T2ULL<' :-_JLJIG3'IS8]J->4E/SQ1V^%1/I+FT0]=T,
M'=32Z#0K'V5[)>23AGO-#<1(?9GH,4S!W0[@2;@>V<C!F"@]R_1<F_N'?J?7
M0S[3X9^7CC,O"8B\84-PK-JBJB-2Q<$5Y&MW.**^]NX,J>NU?9)^?5/OHS]5
M.C/&XHZ@%UZ8/ZH\*<.UB*Q\GR:7)\:'Z8NM;XYT)HZDSH3(TTYV[QK&&VP:
MB1N.&[EHI ?%,XD--C[LF\MM?M4$6FD^6<E_T_[GSR^2%;4:+\P_JHK-Y:OQ
MBY6A%4D!N.98FCC)ZX-15N!Z6P_NY]96Q)1\Z4.%]AJWV#CMC0WV6N5SD02$
M->DB61%^ ^MG; X=YMT1D'N?9'RW^^CWXB]SZ%P_BSR]MSI>OMYF12^MW:KK
M[ +6[Z)>T$%N[-$HG@9I+A*X-<6Z/CS?>0@]<7="X4&.J?2IBSRKCJ_(EV@#
MJA">JA/F[8ZB6"X=HG^BCVR#E*G+S1^7K!;XN;H+4:7;WY.76MY)VXFB@SU"
MU!TPX*E;_,]S(VN7M] 0 NO./@:_.RM4+)QB=/[V:WM-1,"C6,MR/;+#K^1+
M!KVGJA=6C*62[ZQ)!1MMVD$3?DTSTZ0G244[4<2^L,4!WV@-V7-J@M+C1H]J
MS$^VW-45#MK<0F<JLW/ ;R!W/M<-X375G.21//>,/*7]SP3"&Z1/9>:"'C:N
M8IL.([XL4*RWR)K3^X+8JRE O8CJ )UMZO[!3P?EW;&[EL)S]GYPQT+^@EG,
MJ4SL.6JIE_*DT<Y]0B/FU:<L;-6R\OGO^!R(M^J/=L:Q0@]P)5,7A)W$=X.H
M'3X3;.?%<,OV"N?$],>]I<M9\%'0@FG9C\?Q'OG49@MTJX.:OM3T.$=" AUT
M8QR2&P3NX+:@IOA=MSQTEM !=^(7L9VQ4IIOC%7"?:Z9]3+CW!D6S"CFV4\+
MY2+A/ZQ.'S:?-9ZMSOBHXR%><S-D,>JZA@/W;@^\:!O-7D7-HJD'HMMW0]4(
MH\^4J@C&GS5RN.[GI2B1U]1ZG(8>CPJ4G)L:65FB'1];'$HL6RD6)_MT7,4]
MZZO6+UF=68H,52>%X6"1BP0T4E.6*3*M^XJ7QSE4D_[)0\6L,4Q3C&K*'[)-
M-/LJRI(Z+-^]\ O%;VD9&9,:[Q K=MR(JB\K26DCL+7/^7)K;YY[+MG$7=8:
MVA;IL.8C\TP+2^Q8#*$3+RT$V\5>O7.JJ$[H@>OE.Y,&_*)).'3K":\95 L=
M%)6RWX3^Z'&\T/:['\ORO3W]ZR9H%$982XK]!QU$,V9R .-78/N24O9WLY5/
ME$1^5S/1'EC]VKNT<XM45@@W(UW[%!CGP&2 W1:R^S(;A3&,[H[P3) &M8,#
M4SJ?[!00/^\DEPXL$;DH"MA/OOI\O8D#77M6\K-W51]BF+0Z?1 5[!UN35PT
MC,A%HDYC_<34CY7$)QQ?=E7+=0OMJ/$FQKYT$#M<F)@ZZ])N29S*(B;.&:KG
MYHR:+G\8=IS^PE .+CW,N,64AOV)2;.?M+VX4YYQJ55E,A-33A$G]3@1L3-3
M6;,:&EZE]L6-G54+F=19@1?&_;N'3X6M.T+IH,, "24ZS+']&'U,!\6O2N\P
M,6L?I5P;?_YA)=3ZHW;O!%7:FG:\C06N0'3%4#"!$)LRPQP+,=/KA7[";F8H
MJ[CVG1_$A:DP0M-T6]!%!2)?C!?7C2J;OF]BW9M"O[SY-C^MC_&U^*-8FN\:
M7VL;,>344AD9D3@=LJS9XD#++0*WXND@%CIHIVM$TX . HOPD1#L/V18$$4I
M:_.\^_,5H9:_P-5E$,(WFBR31H =*VI_15)OUSN/_<WBT)Q5C9$2\AA!O@L=
M4P]M0;%#"0!OCFR2[-KW ^-6+8:X#<YBL\[I1FE2.[_,>WOX6)$R)##LX4U@
M4FN>36YF,\YHI&)$]O87JVO/Q0]OUISHWV(+D1YK=JD=1@"#.,N'O!XZZ!BE
MXZGZ<V3MZ(O0SC'X6,U:#3'TZYB"<F?'KFG;NT#9'1W,7+IYT3&K%Q_F/(.$
M%DCU;QU%DRVE2QP^+Y>] V/67X%Y_#)T0GE(SKV>8*AGL5_^A4F-N=.L!/8/
M<9BT+?!3V"FAV0;;S'=%R^W7B=IQ9"^9>.$81=UMIO@K,\7P5O*E0!3FN[OF
M19P\U[(@Z\7>P9?;TC<7%ENZ)T<EO,!7I:=I[' .8N2+T ON- 6BRN=L]U35
MG?43$[;>;R:^=OJ7.4;O^M@/%Y@]3PQA&U-6,+%8Z5TVV6TL=JEJ9+-KAU6B
M.[P$5Z;$@=A%PB6<BCRL ECC%2FE5YCKCBS(/'$*9Q1^D@^7)EN3\%7"1JW[
M>6%.0YI!22P>TG:(2;WFHB?9I::;ARXM?@KMRL_K@G%75'+!BVK9_/?*'^]A
M&U0*(5Y:(5%;%2[+%)C+96/[;&/#FX]^VB_$$#G#I3*QLY[P$A@!BN>9FV2?
M[<J80;\*.I$1YGZC@'6DH,9)=4+J2OL93? UQUAB=!>,:TO8RV2P@1&G$>*N
M$>TC4Q^+S2B]\.#!G7@&[:IY1-5):;(.7$IL71*YZ'CQU2C%(V"6'0GW(0KM
M1#217'#R)Q%M9S\N$Y5JK(FZ@K=LSKMHYPF SK>LWRS0-5'FMDQK^AC5L-R5
M*SD48%9>0^%$@&B#(A>PVN=L2$*S 1'X2HW)Z\\\ IB8^9'Q%WYU!QU28RI^
MLH[_G!^83#L3^'!JR21"2V3*TO/<C)/?M\[7]34#;7&3[NC.=682LI4.$@KE
M&R,E=9F1NO1J8_%3@==]K@B\N:<@'""B-_A9?OPS31<:05FBG9.G@[(3Z]VZ
M.(J8^(NMC>/4MZ6&VH9>O+,OEO4,H2!A!%B'%Y]KTV$BW\M0Z665)B'!6R=.
M^;\ JYP.XY^G++P\U/ .2J*#B)A9GN2^5YI\,QX*N,"W#66^68L9UNLG.Q:0
M^8X918W4*EDO9Q+#)VK&J0=U58GP0Q!_-HA,<DG?CM^0$M5H!A7V<? K-86%
M^U4;>/MA<XC=P+->@]61.J6;?O9RXV7C<D^&++1R$V.I-]:?0D1D:"HD_PW=
M<EKWJ%+7QOK6AH'%)0T' *RZ:O."Q.DCH2-@SM S!D6_'(4)L1'HV1?I+VU/
M]GAZ/:P[:F  C#X@D6'P6H^H.ZJRKS,6JG_?\T3VVQM L2IR=FNZ$7H&.6<6
MVJHZ(ET$OUHN@QHKM\><A\X%AET2#WJJ/S=5[;O<GC%&/E6&MJHLT!OSGGX+
M&Q"&M4'&K#O-X,9T4'@ \=JU2)U1EZ]C]G8E'<YB9_A]3R/K6[9GZQ'(Z4I+
M3+N6M1$A+T+IV2Q4<.4IO\R;Q-*"2\8KVIL*O4PWO#UZ(&[+'X80[E[A_K8>
MTJN\ZZ#:#=J&<TBWT*^L9O6*LT/J$ JWE%M5A$WB[Q]Z>0:JDZP[.*>NH/MA
MYW>53?,$#*"I[U-$/XG^FEI9]@E*^4C-;9*BB(TJ#1"]6G>J]X]FG8YQ7&X_
M<7Q;R&30FIQ7'(3&*Q-U89$()KU76[$0H]'KJ2>?2!9TG*L)G!=@K]P]/1]D
M?9'L[WC+%LY85]5PSZ@HFL3;RP=6BU>0Z=D2H!#MP9AQNQ[(#VC;!5@$GZ1P
MW/;#[#,OP0D\"C$27S1N3?A)&2*K<K]_>_VD)-@ZJDE]>9HUE/%7ILJPS(?@
M=ZLL_M6#:RW %)5PL4R/\&%[WSI^FC8 %J;PX<C04Z1W+?6W"!:=PC-ATIJF
MD$GG)6_B!-GZ+-GJ"M"D,TO,.,Q>,+HD.WOK_N,W@]<XUV0TGD5M97CA4O$,
M<WV')W[ X-<)(=.151K*BAQWJE6?YK<_[ (QGB);)>0>ZZSQ4.EU3R[\LM&U
MNV!5$S"Q2M,.7#<GNJQA'\^"#_V\5K@\5I7@T55WFE\FBD:,A#QA/]J VA$8
M;3I[)8N$T,=2-%P@[4_\A,)\BB^R:_%O_%BJN.V+-BXC>150SE+C&O1P#E8[
MXV;U58/KQ]*^U:0X>0L\SLRFN"%N'Y$E:_RX<.2U^^B3._WPME2ED!=#9A[=
M4Z:ORRS2,RHI!C16RMU&8BJ>G<C29BTH%WW?,RLGEF<[H[KG[<M45T[54#7E
MMT2?G?=$)0CG.QRF#<5V;1;*.0[,?PO#+9.G#OM=OHA,A5SDFK"6)RO@$ _H
MH)@CM0[E0,S0S]*RR<+=:=9X2:+7C6%]9 >7@7QB.777LM;IM$B#8GJ(EE0N
M_V1/Z@>%6+>O' 8_U;2"13X3I&>M.QM]NM)2(T+% \^=D+&U"\GUBU8HY^TY
M44;PKY.0B''RTO+PVBDD98;R4/A&T)[IL4XWP3^#O-'3;O>$#$1PWJ&UZ%NW
MDO!'A[H_^CDLGF@/-._"-UZ>V<3#I .W]3#H,?)E0MR-*0&".&Q,,)YV7,X[
M1Y+B+S\S'&68:S<VHEXX%0YQ^?X](%M=%MP2>HXD1CZ=(=U6;R^8&B5>J6K[
MVF<&46+?NZ0U<(D.>CH:26NCG2&]^_BC!(5#L/Y8<3Q6-Y)$MC.K?6#TT/"\
M9[96ZM&F>6([UPR"D[<5\G-4ZQ)X!44'%<.4Z:!6E3D7DORL8KZ#;K7WY3GJ
M52M"_L)Q#9C%XZ'<GI=Y_)]=Z: 9ZA('^3K%9@BN079X68P_;:-D9V,Y'P-6
MM+EE="FI6DV,N%."FG/!R!KA: 4S2OVW*QK*B-PHI1KW@&-?;C(G3!\>L7ZI
M5'RQ TPP]332';%2DU'6DO04$)_1M^V?8=^IP"X[JA&QUT;@C$2A-I%C(]<N
M#2HK*+]>3__B)1-E+4 340^**'&Y$JRO+!(Y,(A1WX-CDPO-$VM(=C]V$6-"
M<]5H@E=G)E]I65GUD(SRR>_>)2^^/L+Y8^*6JAZ+R%"S 5I0'57"0SNGV*JP
M<$G$F8T9L-('A7X!AMG+#3-Q[HBQUNLH(1JW]/G;#QG&@FE[0'HW'*://_@1
M@\(GXU>*.[GOF,AE:$.CEE"VN<Y%%I:RW0-AL]-C8K/#*?&:;A\#I4;Z6KZU
MM.P6U0>\3&>*#]L(6SFJQO-[BH]4DPVTX:=$("@50=,*CW<O5A=XNGT%5@)8
MV8N]8=S98,+7^L1\1A&1&N;&IVW6L;:M 7YDAFY9U:-&L1M.[U]"-T,%.O4J
M\LR.;XP-EN55%4<4[N7VIJLUN>CE4>"D :(4R_?@EE#F"CKHA3/O?23>H\GH
M::.N@1#2*S5/M!&V$T(B>A#SC#_'!8/7$!QN,;R[T+OZ\W-!2QEUAT\^,5.8
M^D3[5C-BBVI!'U-)#CO%FWD]"K7Q]7;HHZE(35KC:A<=Y+(G-MSLT?=R/R+N
M>IHB!O)67%/WV^!Y)J25E=@OU]=.9R]MV"73JL]E&%8N&)K >X-+QNS[*JCE
ME#N(<W4?W&@"5<-PTYVN:JSLIQGG0V=E!/5@LUW<[,4AL)EQO)$Y(2XVH&B<
MFF156Q5G5^N_]E/RYJW'XYG#&W30FE[N>$VL]EGW!\_06?6\Q!O6KW43K[9"
M'^ \5F.2AN;WTWKXUF8F+W6-J/0TYAHZ#G[:"M%^L(F. [J"+6 *U.9"FF:.
MD_4L&GR.1&0*N28\_2*CIZ%7TV^=\(/B3'T/S !KW^VL2$_<GKR?[A-DT;CW
M4S$[GJ%;(Q5M-3=23@<]^&@'3,W,?L(W$!T1:OY?8;^/<F4K0 @<^]:C/A.=
MW'=Q)6)1Q_4E'WWC 0=,MB[WW9FJ-%0J:+-JW'_[O;=)-.?)GEEU9 P\D/I>
MODEHQ58BO$$Y6Z^8M&IK>6%,[=PE!K$C9;MQ04[";!Z)@PA7]$O$"8K?AU\P
M/HJ:4Y[;6/M:];#O!,^S+RU,P"$@'/X(PEM,@;+CJ[R #II6X/3>0[6Z[(04
M'605_:W&="%9BN&WR>5=Y2'*#6H&31EN4895HH-X L?;:B[8VK^2Y;;EMS>:
MD,1(Q#VO/V.2[B3B\>"12:-[\KF9!=^UST^00,B>W7-K9N=Y*:/LS+0)W20-
M06I4V%\V<;#.O)OO"H%W%S37O% <)P7@8LS*O\@$K,2M#KPYU@IY<RZ#[$,'
M=;<2H@?0UDRT,9WNHBPZ2 X]=OVN\,*M+[>"\SZ%#@"#B#+XQ:[MT4C<]S/*
M2%Z/C0<5$<MEK!Z?79TQ9G9/M0I3V^6%X8\B9X_$/9L#AJAEHMNHAYA!L8T^
MAV<U:WIRMV:\0LQ('YZ#P XE+;"E<5EZLG>J^R\KC>>T<UZ2R?5)9&CM_N71
M0Q.F6)/>$H)GJR,)H[/P^-41P:XA;-6;<7CMO-COF?+YVQ$" B6!NA<_O.;]
M.'S__"Q?I:?<JM/J60K2+/M]GVAN/FTM1B$L\?'R=P-[>3VGGW_]UN$^5R:3
M$'SPRX5[LMN;,NMB8_ $Q9UGU0RS"Q',,0(?_,S!_M@\R/*M%J98+0AKE:X5
M;"YZ/2S7C,CT4D93,FMZ53!]=JRMZUR:&Y*0S[\\D?14Z[L#8\V9QGIDT![C
M3A0))=$)XT&TL6=]IX.X?[]3\?KM),#U-2?VZ=)K>U31O9W"BB13/4<^=N;R
MG624["4/B06:USUO6YUM.J@3 G8/O3B$V_C8F-134_5%E%^/F:D?80XSH\@2
MFE-*RQS;&BIPJ6%,^^J?[CC9'X'IX$FC0TW'":3JFAC/+@68:63VFF3^MC:[
MRK>S;V8S0MY7Q@2?_4!APURIV+AS)<:*=N&(547-QM A!:LBR]"\6+3I^0]1
M3LSG/SS]WYV<T&TOVC*M:NF=CV.XQ'X-'03L.*G-S2&J^['XR4KS_/?=TK!V
MR 8O=%>P_)]/8>9%'Z*D>OY/"__?SKZA8GCWFSDQ;-V^5;ARJG?\D_?L2720
MV_1S'U+YU'A'*%C::_;[J;V4C0+II8Z\@-=0^$X?MO$1C%5;] J1Y=J3,>7*
MX>)W/8V5#P6$R"TB5Y-6NY=ASJMI-VO-%&*VEW@VY#'0Y^J9"6A(7 -;\STB
M-V/(9(X3Q[2\V;%?=N WNVC4MT?V=%!#'M9G*U.X-\LLK:?LX5?:_&?(0BB4
MH"Y/^*[E$4,*(%XT(CV[VS9!15J^<%XWCO<,M,MJ^5VW/A10\MUCD8(L+3+&
M)N<4+XS3&/_^Q<0B?; _V:W'V-9[.%XKE%"@9_OJSY5U7CT7V:ACAIDJ%BC7
MR9.';6*Q6@5%)K;%W9IS<WIK9!PBSE]EM9@EVECWF^*8.V\DY]7C7_C5K&#Y
MWP.'$*6Q>$K\3P\$5Y6G7OM Z?U2RP?QZ@QU+V$]4?N=05@R\TJ$J.]P0JOF
M6:G$1=?Y)9(Y;I0$@SQ]7^7AQ6YP;^3J^7=LW'30R8=XU#N) K0\T*-(3E$$
MB'Y-'S6#\]W'=/+2S@Q\<[[$7RL6+/<X(9VJ$P)J]C4?K6*N',G :&I)*NWY
M:V;CUEN.41B)89U-FDC[Q!WH23[V.SN/HGF73K2[H.JE"T@UA,AV.DBP072,
M_>7=NU&S=L&UQVX5SX-B?^EKZ1T.X/DQ5$G-J7N=>C4D1LU>Y-N>(G;G9-/0
MN:I2(KA3V,Z:4%44QIN6WVV(K%<3ES_U2/H7ZB1< :L,";=%/MTJ31-)?9R7
MH<W%[$561SGM-C[17*RO*DBI3';[_O&;4T3N"8YV"@?)G*\5$3$BPA%IYGE7
M0^5M^/AE48DGJQ67YI2_4MBH;ROIH+!]<+1O=,:M!KW[LP;?DL1W9L\(9OPT
MC5E:]]NWKHCRWLXI5/6E#;B_OG/>D*U7"QJQA7I10%:F]9>[CW5^P[2G%1IY
MW@FI4"BLX^>LR6=DVBR&D.Y[X-D[^?91SS41^8%ZQD,&'M$:-NU/A=0XJA_I
M:7(J7H39DG9;ZJT[D"R3O]0[=/!R1ZVNMP3F@/V&=D[3F++0Z3+K5:B?ZS:1
M[2(7,M8;Y"&4,.7.JU=OSW?-I;/O^& >2@L,%_%]JQ[_K1T7P<?R=F#7R;T0
M7S2>1K5&^>H1^G;<2TE.1*G53O\@_##%QZX!YE0?(\!RP>';AHMXXG&*A[4>
MZ:(G#A+C>)J4(5<C'AW@*?7]KN=3CC,L*:QL!@SJ3HU!]XL[K*V(?8=?R7"=
M3U0[N7 +>CILZE-ARIUG*:>BVE>YFAI-(/F#>:ZZ*H]'@S^C-$._U>LLQ6JZ
MS4&C;+^GIXS:)O?8+)?9G[&*^OFX7^3QT^CU,$=J\:\@1)12\*2T1;4=7F5'
MC)N@K[V?.8U2PS^S:G=AJKF# <?G%=\H4NO)" IIS[NJM.SMYUFSJ0VTLA&J
MPY5/Y!XTJ!(OV@PT:/B=4;19$Y_)](EHG6O2KAHGC>)^HP@U.PY$ZTA?\KNB
M(@U/%>=-]/U)L0KP&SJH_#B-HS-8<2O_MV=60W7*U"S_4H3.&/';YX346K%&
MS^U77_+D(N6'EKLX;TZB!"@<U/3I6;[68JX.1V&B<Q;NA/>:L5?02-P-57WT
MLUI)_MOJ@OM\,Y U:C;\1'E#XMB*@Y-MDQC>-J:;XPUC_,OFMIP-J/@N6A_K
M2S:6^NXIXWFGO/JJ8?NAPU>2DIY*+2JLVUIVFD"'NN*8DX\(* =P]<"/$$3D
MC\#O$O607,!N<O 3.5?J>OBN\+?C>^0YGCZ@XTF^2\J:BT;PNXE(U!-*:A9D
M+AJQVNV&\[/FG+SFA S:M2BP^JB\F/LM]FQXGOBR@>MDGR#I&5F-_268R5?^
MT&3@AV68<;*SIZ/K]<&)"X<Y6S(OUC<RP0B"@6&XC-&P[W-7*Y:SC56?7^@
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MX7I-!O1#K&YZCW2W^+J 7E,[]Q%0%U.LHK6'^7R?8OZ]_I+JPI7J1RM5'"S
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MC<5K=+LX8$[@NE]6=L\!XZ+E4@Z!IX3Q%OA/:D<.DW=R8RR$,75A^]"34/"
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MB>_O.?Q-&9L^$?J2^DZ '5T,W8]K2])(IJYJLB>]URDOKO>^;GP[;-_+3HP
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M+3%*<[]*8CW#>-\5OB]/*@TTQ3F)\58&HYZP-YA4U9HE<,F%+11[5T#9I_2
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MDL!A1H"\H#2 H;IL_32>#U9Y#K1-KLFYC>V#PVKCJJO>7^Z3&"E*\WI9KT:
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MU+^O2FH#7:^M:L)G$7\6(KWM0ZXGN60%B.^?W?]JJ@ ]/R,(IEU8L//^Q((
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MFD;0$X"EM<H?:4ZZ>BT@7^^W;+<']3,0@E8"Y-&#&,I+#47!UJNW9TRUA/K
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MU!OQVN82TP._W<O]KRJ&*0/ADZ%&@)>#97%EUOFF6J()'$=C-#><>+&3WF(
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MU/JA>,>Q^TN4JE)VD!LSI[3DQDI)GJNS>K<\5I^[/Y3[D5G2\-CM%[]?W_I
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MQ)<!C)!8;*DESZ:G1:XK>C[[8/Y.]HWZD8,B(G54K7&S+J)+IK'Y03*='R!
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M,U1UZKX57#?=#G,Y4O%!Q 3:3=]O>U]-Z(])/^VZ%)"W_91]3,&4@'@XUAR
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MV.L1A+/HD628:8L#Y7HY++;3=I1E< :)6F869O95T&HM,26=0:O.,OUTY\/
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MN]D!ST$?@7&!U)W*7A](9"_[5)I8D5X#]VT>:J:%+[N=B\PY/"[L\A,HW$Y
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M5S3"M#$DX:R5L9$6,O?07\GI'!AC\K?!S%IX<E@Y.FJJN,J+#ICK=!^C_Y$
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MGM?T  O"/\P(]C3*8$3LO[]4&EH=3L+]] T@0I>4B8H_*431#^G]K!J'>A$
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MPU=._MGMX^>ID:F:20N.8>L$P*H!MKXZE UXVC'.(\T 66 _E)3=]3J/CB<
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M +R4N=)'PJK/<4O^=]JHA  PI,4)BIS:6S[N$A#1P?PZ-M$*DQ6=&>4>3I"
M?[6N<RY24=-F'%6&I!#[+3F<+QT9(MA7*[Q:H+F,6ERZJN#K@OG8E?CEC-J[
M/6>_=RQ#%CP<&OR[KE%D3AB-699"=T"DK=!(C&*AA;"/5N=KC[-#I>]!NE!W
MMQIP^Z+?><Q;T>\&E6"[^N4JNG?O%,ESOPZ,G,$<'DBUEFJKK4MQ8?BZH6]=
MD8@V4$4T'("]WID8W> 5I"X(W,@,^-/+PUKJHS^,%3JU;;(SF10X9+]_H-LH
MX^RT%+-I*)>IS*^UPG? NN29W%+)V.E*0[##2IING>TH+HTNQZZ9RO@0#9!
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MMT]F*V0&ZNJPB:/%-O3^DP.I__H<W?%#<'_IEEOSQBGHC['GW_[6X(KAX04
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M3:%$J\/)-MTWWMO=6S"K5-W8,+N?>0&XE?O)_;PL_;QZCBT@X]>:_(K1@-&
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M@T>,QB <8Z/WM+X;?2;P5-V0U!IK#A[5YN?UF][)S;*,GJ3^0"_\P"(H_@O
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M(FZH3IY8">&1;UHG""ED[7*^J]L8$@[PNWT"Q*6=EU4A;N.'+$-!MP[SCO9
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M[E@\^TG.?8O^F$;X$S"-SWY'1V)(4_*G 9%2X9T+0/PSZ.=)<V@KBW?XD7K
MT[YR$6*M4F\M>ZF?']RW HH28.S6>[E%XL[Y>D"I)SDSHZ9VSPRT8X.]0J0C
M#LE+3SME?QG;'-=XRU_^_'J\UC=Z(8)9M8Q1 IN<AG4!OXENKE_GD;G/J^47
M*-8H=3'.=J($9!8YB(A"-+,0Z#$[-9^KSD5/&!,G412OK?4_/K62]/>8\QE2
MN-&X<=2"+!;H3K\ D)F^B,& 4\Z_3SVXLP7GKQ:".=2=\1)D*C )[4VW7C]U
MG']^O:FQGD188Z^7'SKL>WH3;QT065\B@[5 CCWD4*_"R<*7%G>Z2M26(X
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M!_+(A^&X@RB*+UN*V*,T[V,KOP!TUO0.W/AE8Z//M((-'G+<' XD7I]H9B*
M,&&?/"-ZQ2BTGHXOEZ=N3CR^Y)']NC6F>X'/Q55=E>GTA/^=OBA7#B6[_HU
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M)!RB$ZFMT(>B>8BN&[145,^6TE;;=,S+$29!!G(HY_O+A:)?=%V1K\VQOP
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M!=?MT>SS&V,NO(((.GR16>Q.:$YC4GTA<P3/0[('EC# U6?7 TD]S)]>1 4
MBR%%NJAS(0P?;8!DW7@V_Z8W@7:,HOC>6Y7^KS_ERGJ7M7@H717JHKOFL=K.
MBF<*D+5R+#(D[%N1F7S?K4AKT@<]HAR46=7<KE-!U\!HJZ/4M#=WB0 7H_ON
M8M/+]-VCDJC*@ =XOD7-#TV,"2^QWT):64:9T^J+4FXC1>++3K*3Y/MI3LC!
M).?W?S>QX?N[YAZ-<C8$JG6B/L]MJGF(-U@,>W^X0W+?JNP[K\_5*)UZC1NM
MV=\__7T=*-<ZZ*P0S(3B]U\I*R[G5^^=:7<J]=](/,HM)P)@'P@[LKI3T+]=
M@RN^-::M8$@](_Q[KL;UXAJJ3P:KSC#<= O?46G?3: QT]U[+//G-VI<I&/'
M:MX)NOZHR9 ("+;=QQIT 8_$':&GSU!2/O9FS"-SW1-SK\#[77QG1\V+2@G
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MP??0/+[8L?;\IE"#_7A\7<2)IC7HU1\\XG[E1:$D[[Z@3YU&V1O +W-.=RA
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MT3SEX%7/(.GEBW$FTP7Q'9F-I[ZX7\/"^ GAS7"]280(")8K(P)"$4O>>T3
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MBF<HUP]X">/T8<B/^:^'TP\V&WCT]&4$JK%)-7SW7XEPV"%4=WF6Y[+244-
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M(06:<&H]DS2KM?VW>F)R#'X:Y_5P>;R+%6<=?0]#L0P+I'K#A7W$<^J:CXN
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M6P<B +?D1 28=O^A\Q77%PG=#5T-M^/C.'DC[$_=^98GL%-A3S! 2&2W(]R
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MH1HM%QWH/(?N0]T=[KK( /.?*5<,AN2O0]4"/O=\R-W(Z^3N[W)@_9#GL']
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MI?$)B<KK_,";(E\BYXU#-SRS3@!-^43!GZ (:7DGG!4K@8%8/O058YQ05"B
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MX>5]=4_FK]TNOJ5!/Y;&ZA4FGND_H*,]=\7KR[R,4W1;B;_8S#0C2=P5]W!
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M]V%OE"4?J'NZ;,A8MJ2VZ!74+([?F2_F6_TQ%+OI#SLR6Z]I P>V<H*RW7B
MI"(W6 BW/&L://!1"I^>O^?M!O7?<VXLF71ZG4=\*XC1/(Q9MNJ2,V0"C*M
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M*ZQ66%^KUN&])44OZ.4X&L=]QT8TSL34B)2#:.KL"NZX8BRAXN.=+91LIO/
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MSR,;LV;>KAYXQ/OFN]P7GU(-_96!5XB>N6'+4ZGK7ON-JZMP1Z#G.+?AR)[
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MX8KT;IXY[8N6YJ:?KUOHT.TDF1Q<_5GL-X-N:@P9"]Y'SNF%@*Y(36I-33/
MOJ]A?5@RLG55AYXQZ9?]PFOP,:^^67'OKMYEGXO_L:9I!<2CPJ88"4] '/XJ
MKZ5$I+N:CP93'6>W%W)-7UU1<W<)W02Z&)FT&ROO?9AE'*LU((!"G!559Z>#
ME6_T219I+4XQR!O7A!CPZ=S*^)" &!(W%@N96^ KXBH4#:"/K751V]I<0G4B
M7?9F:Y261D\ 4%>.P\%/A;,$W10)8,=C#>7^UZ8=6(O+>A9TO1'[Q0S6KK,?
MZFB+?A*:5HE.>*)'Z>W)PEFI:BBBH7(AC,<NG29;^6GU5D#96/3HAI4E\>S<
M^RD>8AW\$B$WV-7?>W:K)()<H* 0MH'_CI&[N--]RG7+O@1;%?U:!GXG,'Y
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M7P6->NTD?T&MT2G:]'!G]X_>I&0L:["ZBO1@1OZ7MO=NCWFXO->ES@9"=HI
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M=#NV[^'.O#<A5LW55\8&7%QZ0 *CUWQZP[O 8KNJ(FKQ,T8G:?!%S& M,R,
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MMU!EU'G88%A/[S^*P?W7E.#*.-[2Y7X)CF-G+$1WY,Z8%<).%1IEYZFV??W
M%+BT5DGZDNI[EIA0AA3$&,=I[IQ\P?-Y<UW@V+ZS^?U]&PTJH--4ZD"=,E#/
MNGX>U0!F]@O3&_5:5;88:];TFN1\?*7@ALT;MGCMX*=0J\,$LA2>"B!6X[G:
M&R0L3.H&R6K\K)X>*F'K](VURG>P8*D<+=D87<_=N\,"4@;V9WVK4Y]F7Y'
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M/L'L-&8\(=(J92HT%$X5F^VOP<;",'H,<*L;GA.((UK:S&0?2(+O&>*<'RQ
MHM3PQ1?!*RUWAZM)ML=+06;DPA^IVM&!GKI6JH''-/N;>LOMWTR259^#]YZ
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MD,P!J6LP/%<WF(&B K4G *-W'N8ZS HUI5C)X-:E>W#Y=8ZTQCI&Z^>V]9V
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M_%_Y/UV>I:IM*+)\&>WC233'/:&6D<!>MT5ULCLRRSK= _:=8%KZ2%W2,JK
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MMZ.K^:*6[P$EC1/T?*B0(N%/9&Z23QS+7$&.!R;[^KRHK@DY4YMKWI?E8N+
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M[@'T.X;7? EUM+1*."XI7 6$,=2*KP/P9Z>>_-,SWZM%-N*C>ZPRC8!6_,@
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M'/>N9I40*GU<8%]C>;)',&'CPH^V1/$?2I9WQDP1VE2@Q#6>=TY\Q2HE1U&
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MZ$$GL%=#^3\E"'>77I"I%WA.21(*04NW%G/_H@D*_X6CFT0Y*/X'OGR]<GX
M/(=X'H_=QF3*WOGV/%!G7$W%'@F&<J^+K#O.B<W QZ>L48*OO4<<%?&]CP?P
M.<K(G(B)E1]]> ZH*-%5QY6.L];L=[$8F,VYM;\')-.%S$Z$F)ZIEY4ZIDO4
M-<S7X:FZ6 ^Z\AK@"TBN3BF8_WS9-)#)P^!Q+(M2JE!$M7=<Z*KT:^-;.&5Z
M55;8D:I?!*2_TDW1@2=)1]V!QH66F+7&80Z>>QP\-MZ+OW ?8UPCC%0Q7L?%
M-!A=9F^':UP&QAU;/0XTN@=\\E"TX$4-'=I$RFB 5S]H>>?U5]D[&ZVYQK?.
M?>/:3--"X\*PF4+9[UDB_%83":P6J0^% @P_9Z=C8P;7E94X2@2GXL1JUX1"
M!8>,DWA!VJX8BP5U;X.[G3F&MA/PUOJ^&]^*A$[(GK]7P]<XT_UX6SX2#$2N
M:6-JOW];[[?/^Y[N61=^&[9LHOHY,*[CA"GO^BKQ>H:H:XFWQ_"XO<2UU%31
M@Q+Z^2 -'> ]K>^HZZ)^G2K68,*QD]^+G.TS8I"=K= ;'55*X-]8Z)9Y^T:;
M'=%Y6SYSU$K*W8&KW^/P:JD'VVL?/[\A&9FBY.EO%>XI36$EJCW)\RVCY$NI
MJ,V>&?GG/7:[Q[;Q3Y5V-P_G3^U#6VU\5ND-#Y</1Y:IW]=TKG"5$WZRWW5R
MI?-=VQK($$FG$-%3<:7=%%,9/1&G&F.8OQT):"^#Y5":OH8F9+F^AX.;"59R
MV#)@0:3*(8(/OU2QWB]:\/"5XP$L.-A"]8*T@5TDDC_?06+L4SNU%(T3&(1!
MFTK+JPR/@\PZ#,PT$K"OZ2TN+W;!S;"/#N9>H[W++[">LHG["ZNO@"CUCA,^
MEO]^VSY18??Y/.G;8@C-J+ -1&)QXE51"?/<U5COZ79S?0O5<7^.T)/F\).H
M(9\QNRWZ1H@&HN&3,$X[Y?8P<5';1($^MY. =]K5AVNW*Z/\G5SR/[6.@4NR
M&O6AYC:_C?N/1NNQ,5Z?<!9%3;N?L8D% 47UM\;0 ^4F;F7![3GECF^V;"@C
ME)38\V#BET>F,E2(B*8U*TJ>HO2L-^_6L]P,Z_77E7+WL<R#ZW:-VK&.1^ZZ
M<N$J=8[&&U_8!((0IJ8NB24.QU0/WND,EGZABNF0YB!96V=-(VBHN9TH@9R$
M[>6H:-1,5]@X$B3;?7UEN_\N<.4CL,+#$@]9F4M_?+)C-*/]GG$L:7MN->5]
M"*GEX3"U>A4& [;T7E[((^0;#4AM?;3]IKWL;C_.>1^'02([R_2 A-[65ECU
MZ=NVLB60Z5U_F1]U@ED#R>-^S.781-T/6# KXQY4@>RERLF/E@[<;<I3G,JS
M@&>%!MC4,(P/$KBS +2/?_3*#319TGO :EWUR[#_QR$!8X2O?L^Q9<6^J7"*
M!==5J,$G3(+L+9G:LE<Z6G<JAEE9AMM^V@-65[C;#_O8K7V';02^E;P'I(04
M/.0UHEV0F=X?H7@[>)"&5GV+0Q?VVSA^G2!!PP-GGGUGF[JZ\*>A_'7,\N&Z
M^QQI+W9*O;$GG<!Y'EMH#\R@'+4)O&N$O$"./UA-0[5FVOG!:M%V7\G^V6H^
M5L>Q#K)062APGB+DW6G@D>PP[>669,U>KH=I+R;&$VQI^>]I(?X"%CCQ1-ZZ
M0=I8Q]I]ML=;D1GJ[3\#/F(>/86_HR/1FLQS]ZLD[94H6FZJ--]M2/ZRWN+Z
MG!<;S9]76@Z ?V,TX>Y+V7UB$514JR'(YH'Z\3K/W*!\#'>;YE.WV0C#L!^Y
M F;*$U7=/T%<2I;9=K_3UR7(61D,+\038V5/-(L?\$[2/6!;H2H8LV (#%*%
M<TXR,D\Y"^\:0;W22QR<^2K>-#:PD))]I]:2<-/=:1;) JLP.=8_-V7Y1/GD
MFTZO_UJU 4GQJM-.@^[+J]Z!LD 1Q(0Z@@)D0FO]6F&,FFKU)@Q)L]UJ@W *
M\M .G52)"< DP6'YK'9*YZF;L#A;OVLJD_-#@6GJW;=F.7>,4EKR+)O5/(*=
M63PW9S"T\+L[I(JD9$&XI"&LMK!..;C;"1$[GAV4EA'MTD[D%*G;V)2GVQQ=
M&,W"TAB;F#'+@GF[-_( -2*5CC>KI4=KWLSBCA]$3Z-3+4A_/(<4N_5+&LEZ
M/612RZ6L\GB:\4V;IJQ?0/[+\[)PN[>%#73;+264U:?W@(1;52D#"($REV%#
MK7$OQ6JE*&>*FG1-^JT8Q"4,Q1:"1<[3X7OBD&L:?KA&WWC;S^4.[Z$A7ZJE
MN*11RJY:"&52_O3D:[_;SA^#/2Y:"XD1'NX*>.B28#W'+&Z3N!A0SR''8?@9
M:Q5,63?5^3!P<I6/0FGUSCW@JB(7QM+@4,_ES)A2")QH3HPS^E76!VLYLRCW
M<'B+E[TJ,IDXTV:XU=E.U=(,^EH+4DY+V)3D;[R):?%[  4Z,<M<;9P3O@>3
MMEPL<E&S?_P)'YM!"+TDGY1J)W=OD1=O:Z_)AAHV>QJ?+J\$FHA=30^A(_IE
M:4ZU,7V;3V&H:A^"I:Q:/9C]QW9#0WKLVY$@>D='5VL0?47A,PSB.!:W2G*5
MJN\T)1&U%@X14YX+ 9'T]']<@/$O0*Q>K&#>5V8UL=,,I/ \^D7?79"F3/^P
MZ@$\:.C)U;(*,S7\C_VI\.XRP?%Z.S4RB+5H@%)0A>64[](DHV050-Y6[&NF
M.%Y(XGAM44L"9WC3+QKL]6/[)S/SA^$>#(:US[LEY%3E3[M3]=Q36V2\D$H/
ML8=+= WG.X$H()<>\)TFY"ZD!!6;TB))A.]@:O&GN6KBW4$)X".+[N-W#*W3
M;2H:5=,'?>U@1X*IIV&?OJ(#.HFS@66W.\,_O<@.JL!*WUTHI596CZ A,"NG
M#AM.WO99]A1S6]>35.J+$??J0-5I:P0Z%-D^+)DE_-O#-,L+/[*:SN,A>4#<
M)FLK9%4;0$$2H[3&)@V?PQ^%SJ%+!3TVFI82!8->B("+%\S%5@6_L00+<59O
M.E=T361PJNT'(N 6&MW0[(NM'E/S]/C4S121B-'GCT)5*@*L>@@$CM2/>;)%
MOP]QU0PSNY3^<,<ZOP5I:Q_;1PH-S01H,DVS6AK<5AD'LS4XE)NH<W(\TW5+
M3<7E*&@:_? ??+4+?3,D>@#XI(YY^]=MN-<OQ,-&S0B-&[F7ZIA:B@'5S[E6
M<!UHXB>7+!TN]$?O ?YJ3Q\GPG6(,'S-Z>+1M;%0C3Q> 4XNS]3>N=_0Q&CV
M'?J2G8!62%JU?OJQKKN3<I3\"I>^XUKTBN>EIX05;>9@7;<$4,@%O9>85;&W
MMB_IVS!94,((68I_%).RMDQ;[L?8&&\;H03=[GD:F5^:X_+VQX_D]^#A+)>#
M7/)C191RP,KU!:H.#!^C0=;T++,$J+V0G>^[[,7'?5%];7NY#YKV/"+<AKX8
M$<DI-H4.]H"$^,-9_-T,71^ O=YB5Q"(H%<%:2?7G55!J?^U J-T2']#6[_K
M5GLM!'V/ACMB3,%7V$@W\@7V]Z4AQM,KP]DN'J:CD:DZ'!N[FG1^DG6WIUMB
MUP_@4 P%1.J)!_:-\^#LA7X%IGGJ*M(1<^OT5_>#T5Z]QG6O8- RCA&RDA5*
MS'2MJ -&YDI28C(MO^A;>TMEHG-S1^ IPXML$JDKZG,L[)*."P\;XDC=A%?U
M!;P%%^Y<US+1*XS2?AEX:B?7:6B1%RHE;/V>O6&\@L) W) _]-6-_L6QM[MI
M?@!.>6D;]1B277.FSA5MJ6\-KSS:MD/9^-,6=Y0RVNT5A&4"<JX=L?S</G?J
M*)%_B/8]BX)_&-(+4MP)>(V/FU^VG?FVABI1MSIT0T6;'ZWO)9=)2P6U/MCS
MQ[E*E._*6C)".4FH'(^](<804^^@*8N>S*8>]!,I#P/ET&HT3AW9.!2W=JK.
MO?Y$/S;3?$.$Z>NA^443])"EOZW+IN, XUW.BB2J-]9#?](]T\C*==D_68F7
MP(*>F06]8?F=7O%30;8QY/I\LX/HS%%*!<XE5KQXW/WB9^K8<-OC(!XOT..#
MVO19G<(_JL\1C8/6AYRY6; [9I7D]4G/!3,5MP@'&US5VV?='=SB2A)TDYL<
MO@LO@D*ZC9H#9??47>+\J]9QC\<PD 5$6+M&AM?M65L*]P N,.,*+5%%T#-C
M:$FX$,];*Y%[@$9]IM71SP=(R.GUZ@V<]=NNGGO*9\N2!(M I8[I0"4Z!H8)
MYT\D3Y*[6)MK^,_9Z8Q"$/2LB;"X(8'^E/!$__[GWRX[*\'JQS.Q!?S.DIH-
M#1[3XYAPY/3" IZF^G0%Q!G>^+']S)UW0S:<I(S!;KA6GL9]PTG;T$^TL^.<
MIN%FZ $A'QZ VVHRH;I?-A3BI*.^0UVBB[9A_5G6K@XL&[W\X4OG?6^0 P,4
M[804_;L3)KU7"QM)SY5>+I1)]I:R:E$DGU96.WK![NQU)D4%G#UH <$G6S&7
MP$\TP O[3^T+3&N@K5-QU/:J4=(8SU8O$=U1PB.&0QT1/LDG_GG65B_G30=L
M;![_D,.&R<5@557&O82&QBYN]<B+B_-$;Q?$K$G^FPRM*3$J[^2ITP.0ZIS5
MUEDR-5LQ'7+VPM7$"".BC2LG<M/B'>%7LQ#RC>Q<N:(ZY[L^NP?,S[3-U'BN
M$#E<2T%XLXJA4-6]NDRJ[A1IL0K.YAK]# &FSW3,P_T=U_77-%<MG7DG!CRR
M>[O:=YGMJ5)Q-(/UQ_5A]OX-]5"E;"/UOD]E3_!Q=CT,M I"'<_9BD1%\MY<
MY#LT7'N-9&5S(X3LMY6Y-MO8-D, OB,9^M6DV!I*W%H=040(WI!'7#O0D6DA
M G8SG>:T3Y22_M1/2&0B8@Q>\>;^YISPJ#$#]TLI(I1X79Q3>S+-GW^3;3VM
M&(_[= :PB3G;XQ&X,4,&\:278(AD^,P<4C-IYN,193#/YI=#?<("I8NTV&LF
MG,%?/(,^)"-G#DC+*%)"L?53G$?R!'WMS3N07FM-\4M9)&@1OF8;W$V[1%.V
M-#,(U]XEC5Z?"[?M$*=JXQ- @F*[LJSZ)8%^#U2Y+O& 1V)Y_>.'"4:6( +Y
M8E\-N?%-4F-'PS_#$JI/7&[WK%PQK[*]!"Y(-=(T%$,1;>U%SL?N&--;?I#?
MR;6_MUA(Y@=6GS^3P0H9)'I@_Y5[?S67S_;N)'Z]JA.9O:@V[U1E$W\ED/(W
MH)/) O<B=F:>FQ9&\E9]TQE8(<^HLQSIG9T7UM6H/AT+[UBO6+@'S#T4W3-F
MBZT![2MT1ZOSXY5K G]\&8H_SD?A9Q)*V3[ROZ+3&:GXC_),:\H<H"[5-"IE
MQEW>43Z<OS^&YNEF-EB(EYF](<?\!@\:55R]!]Q&/7^HGWZR17ZRO9"K9]=Y
M=YZQ]P"EHB!JZQ*3'>\":/<,EP,:BPI)N'F>$]@/YHRETQKPJXUI-""#L?;G
M"SPZ?,+@#WKA=C0)%@,2O#JZ[0/\_T-+^$T@<;S='^&H.3M+.SWIF,RSF_^)
MZB\G/8-$5>+AD^]>UZJ(VSV4[B"$WG=6[:02S>;LK5$T8;Z(97$3!I(1$/,[
M[N<URLIB,JLHS&8^JEN3///JOY#L6F<D$4N!]A=X09PWQ'FJ-DC4.$JI=%[>
M,RR)56[NQP+PL:^K5J-9K 7#-*M^6M"'-)GI?X5C<YU_F/BFPU=_+3JE+HZ]
MO\23+/R4;HR%+ILX8G[9 Z'<9J",.-YM#AAQWZ=YEHQ.9W-X.M$>96ND$/>M
MC(HQ ;O2%TG4/>+N0AC]UCP[;RG.?D==&#P,9^VP'HYK^ER .MW2)@&1@(+9
M&Z?7&Y[C11K%\\<QHAGM=9^?CP2X]I6EP&&]J2^ZP"FJ%L8^&*$$7D:YE'^\
ML.*/A&+%H4+$^2E/O$NWL1J$W\)5)RO/UB<KN;^E#SWZWKF-"VC#E"Y-<VB@
M2.^B$5!7:QL3^M>M8<Z$++!CLY0K0Y;-XP)5]SW<Q_A!"*-RFM2MU!21$@;5
MTJJ"&$Z\?[>1=$1_#QB,KGCP%/ ]@//$ZN,]X$3,*F0V+&1[<&^ITOE;:WT*
M=),E'>=5>3_\Z<=])=W)0$FPPVGMM?=7$(B+M]_7!E=]G<YM@='P3RD8BV%3
ML'A#F+<_ATS7. LHA)Q$J;<=W04/W -^SG;XEJ->+(%070_P?[N^J/&X\J-/
MX&P#C71VP\LNJ'T4!8NG^"V7E@-34T,*#MCD:;*ZQ/-!.V8,X#O#R>]%O]9M
M<+6DENU#;XGO <DS1ZA6X#U ,:&ZG;%/.J,W8,<+VU05NJK^?1&'"0X OG2S
MDM]9IAOWC(UHG*QM,3/YZDT9P5A8*=^O\D?_W )+?9;YU=0/QB:\RY=1.%;Y
M%3)5;27"<:C*NSR>,1I$2"\]L_%QN4,F9@:+@D[QFS>XS 9/J_@/L632 E9?
M;;/-\ERB<;'P@J<(5O.F@KUV*63(_GC.V<5,JM?%LRG2?8D+W/4/V^74E.S)
MY$U^/TOCG0$""?)V'_>2I>TER(2FEA.J8$24:>=HU@P(NT;)L$T$ZEX B<VZ
MA L%B'DZDKZIYP@0RA(;HX1G;FF_SRM[TC-IF$VLMF8I<)C3Q:&/B4&^"4N3
M:LS8X)3.R;N#2S(_K-7P!.+ 8L4_56W7ARJ)&]IB82T(P4UQ1V>"%=*H6\J7
M_+*!/4>XR\NW C,\O(H*PDR:S8T#<L]7%%1VS-D_>8VO)A*;#Y3OM+][)U4&
M\Z)-"NNBO@>P"Y]UHLGA M"_D:=]1]HHS<S)/*#M1;%5R6]+5Q/Q058"XPFO
MA,PAKWQ'(0C>@#LGJE;Q(KFD)T^46)M;AGOOQ*Z-&AR&/!CB'1J2E<C'TO'+
M<&$&B2QH!IX=N-NFW.TN><5F\GS:_#H/Z?9-39G8$"N9HQ9)K,M+CH*8P:FK
M[U97W%NHGGO C65[VH\PF#/&+A"*I5IS8Y^UY8?26>D07\HS/S4]KS.-\6Y0
MI'FUR!><_U=;H.O??2WZWQ:LI__HH'Y$2C^4/I4H'BI;3:J7P/>@>0AWA1>>
M47UKJ/AJ2!M=;)ILN-&DIR:?"J'0 EZ //O*B0U>RUX,5)BD>,V&TWE*3T8[
M?53UG+VZZQ2CGQMHOM9FM-87LY-+=+R4$H<=;!YPL'4.T77%\?4[(EAPF%%>
M;;\'"'6+NIR/59A-U3H+&K_05.]?/K 1EQ? Q VJ,?U%DIU:WZ_;(TP!:1J\
MY;T'I#@3S9B>=$0^Q.TKGGO 7FO>3'ODS\D?9WORCO;.9!1PL1AA-+^]/KVZ
MX_8P&W\^'L]8,1=Y%O5D0&=NZQ3GD(=?^G;#KW7?K?ZC*^K]APE6KF<#1*)0
MC$@55VO*Z\U:H[^1WZX7\($"M/YZX%NF2ZI@I]KQ"$9_#Z/5AH@9C%#L&3$P
MK2[9:XXSLAPK[V>>-$5':NTE(R@<Q L&HJG*BO,@T=%PE)&R?+L(T'2N&1D;
M\AT9(_;?V/O.L*BZ;,V#""@B)5%!H%! <DX2"T22"$C.H (22D $E%P(DHHD
M(* @%#E*SCDGE9P$).=<12R@J!J^K_OKZ=O==YZ9Z7OG]LSP8SW/9O/N]]0Y
M9^^UW[7.WN=(2J5/!#'?8?)5<7EAOJYVO]!\1)(]!2IP7'D>HP[B *\/]IAU
M5<Y60YZ@]K(MD>FI/KV'MR,6=#=D3WML'Z0);V>E=+B>&J+4 \I4;B<*,RIY
MUE>RW"%A@J6L<GXH1<WXNZC2L<*=91VSLQE[2#A$3Q?-J;9+%*(Z!KK@JZT$
M^A:T*R^0('^KA!XO\B%'L?N/\36(/SP:-'-TRA+9N7F41#7K)6)GU%E1F"F#
MFFR'Q*N;<1/E%#Y"SUR.<C7]IJVIRYEL?'(I'2:^+P5Y-+3_23)1NO>V-0ZH
M)2>@$A[)J#\HG31Y$/U@@22\^K(7^[?ZY0P[?UIJO[ C2:,YJW"[_5,/,Y+N
M%SLL(P.7GJ+QWQ ]]M 3G<_GU$!"P@VQ;#\5#R/*C%0B8DJ<(EHS.:>XZBCF
MZL51/%O.(=8K"K_"*6*DTP;+=[BXA6\[$2R5:;6YI\-OZ7BXYDQQ,RR>7KUO
M4*_;&;9A1JMZZ,>2G_2EWU251N%#@XZ &*-6PW6T[JHM:/Y:]@2;!K$,S2OC
M2%_%"LZ!6238/W]YSWR 6W2%B=\O(L-9*83VLCQQ\E. C^!Q;KM\!_$8AU#Z
M8H:H!UC"4_^\[P6SGCF%UZ_/8.6[&C?Z8:M4UX\"A*34-J?,;$3>WKR,MZQ\
MX\5"EG VDWS0PQM76K:NA?.O:8G#->";VNQ5W]2K]^):(,=LL68'O69GP&AE
M!R_HU[AKF'#5PHN*:AV2V5<%$N#L=@_Z"/]];H$M^Z_."1(>_I>OW@WB)$&Z
MY=\.L>:9M>:YJ_S\68"BL9\N"ERWHN0?>#;#9 4'P2<,76V>JU+SYW$9X7\:
MSMPT?ZL^6 /VK^FMG+^:6=-06J:B%&?;&SM',]/_O*80K8>EW*N;V51YO')_
MO'/)A(0:.=%2U$PN3Q[*P=A$F:5)5P'GH%SI<1-XQ)9:W?.__\*//XR]\*X"
MWIMK"$/ A>KFQ#,<D)1W/'#X";:2BW7&X_[_H4K1T>'Z,/?U-F6NQWQ="XR#
M7IG@X_7&1+!-(-:]<$6&#H, U;%S[MB1]X,/M2Y5"&TQJ0W>V74^9>-.V[XK
M4YWW9Z#BGXE'Q)2WNS7@X^0#&O^625/C7^-\+ZK^V2KZPT2KG,FSI),)SD^O
M2;NU^;H.,VU.U!#I':BUPU>&:8D_BAF?J!=20?ZFX?;6,P/3Q3)MLW_;8P9I
M_B7.ZJ+JHNI?H.K%^@EA7$%'Y/H;#>.O5NQU5@Z#!6?_QI&JBI0_L)&B47R$
MW(Y,M<?V#&UMA;A8]U^"T0YE-PR!, =FO1%EYW)=2F\OI>+H<M3/6'C(%A\.
MZ-/!K)X^ANR-P,3E6%)3_UR4_E,+GXN:BYJ+FHN:BYI_K1IWI2@K<\).XR?X
MV?]HXQY1![FD-'U=K"C;&DGH5](K$NK"]<9'8;!%_08<4.@&V:=0DT@S)#YX
MCG Y3KJ) ZZ2%N, 68G"4_1YA/P^\#QX3$X<.\,()\B[T^45GUB-K.* NZ>1
M&?\C)%U>D9=IQ"YO-:T9\L,&>)^B!@<T!D2@E5PB3JY.P69:#<HTOM4275!=
M4%U075!=4%U075!=4%U075!=4%U075!=4%U075!=4%U075!=4%U075!=4/T_
M0E7_O5E0&1+(;1DSONCZL92_^UZ#1V&RY]5SOG+$F>.CEAIE3K!$FW-.2RC=
M\]CZNO!X.%N!UN+?[[[8H<4!7<5>.,!T%[9ZKX9VI0YZSM%^=.;1_=L2?\>I
MV\]P0!A(YQ@A.2!/M8K(CA/*%_ RU_93KV"[]^E#1B_1 S=,GE:;-VC8DY^^
M+JX/_^IW@MU/29]Z71G*67U@BZZ#.& C#;9ZW:2R@Q>]-PC;2$=T0]E5<[*3
M5#TM]5]0(C?FHFHQL*Y=0\Y^*[1*+K.&T,T//WJ;R,H*^MVCG+1,/.\TPG]T
M$Z91#OFS?MO]YNN%UP.!DBXC)M#<$-?R \EY^#X]ZYQTAIMMJ9D)2P+?_-W:
MGUYN!1[MTF3UR/(?-J\VA,A7OG\FQ.M\HFBNJL8]+FAH$$Z=;V9Y-8L)D5J;
MYQ @'K;L[Y!C9-*V):G,(5=)M-Q)T_=R-!##?CI3LHT=#NS#KL0Z[O?:>.B_
M%8RU\PTIS:ZLU.JQ+CA21NODF09"UZ*Z=> ^"KL_=YK7#)(XD=Q'_O,J 9]Y
M[$PJCN%5'%Y7,G/E:XT':6*I7;P^OOC26%!+ET\UCGX[MS06Y&PQG-8 IWSQ
ME.Q#='-GOA.M?=));+Y#5MI[MW2R *9W.ZK*$L>TK3<5[&T%T**[[ ,FZG ,
M%<3?;BLC?E>L;5.;X %_J,?IR 8H(.XDUH\TR^$MA=! ,#E]W9?#7ANGCK'J
MA!]\W^)S5[8K+7KOPO>K&D#3PD4V+DI1SP6+'BHQC/>\FE@.=IL[4]UTT+Y*
M:6G@+G!X-ZA7X,UCON. VV2LQ%JU"G948ZX.<]LY\]<L:WEB*_*/+#Y8%!W@
M#U8X-)"9->,K6V7+OYJU^F[!IKX0+9=#N?6:X\4G<1>I+[F<.,",J9<MQS[?
MJJ0Z:F)>)-QZ$LKD0IB:)Q&M:@(*H.&YI_1,(4KQOHY&E.J;"O UX8TJ7>7X
M:W:M$B8EK>L$=I[W^E,^&$,%&:T4=E/Z[,4@@W$="#*'K^4VSEMWHH1]MJ(T
M4T)$7PD.485FL?+H)S&P@H/SX*[&M'KA6Y]H$:WTWBV$\2SP-6V+H(1E3)AC
M>&BXQG >ON^59L)ZAR;$#5YA.U7G>NVT;D9I[=P49:9B_(D2;\[55^,SD[:Q
MJS>,ERP!QZJW&*>'5BP\!J"K$6UR% >/#?4\A(?WXCDKA[QI9];C20P3ZW\]
M_,ZP'^C .BF6?]\;-"V5;5.NE/8I=),L%A_5HY5#,+R19.?G9ZLCK#:E+IQ:
M=C!%O-<Z$6U@RC9-J!.7!M(P:J!#N^6Z^H[83SPLJW"HVA8P=G^WIKT853V@
M=?-!(HOAZT>\.9T#IB'9&.9A[OQX(XG5 A,%SQ+_JR=T\7.;90E;<EHFTA-3
M\:O%FHDB"P5>;%HA(P+6YD4'\RMJ-AF-<=.:J?4\,[-G"TVT"]IP,:73$+*G
MH+&[U1'D:$XM9#]Y+S54]SZ%8C_X@82FSMVIZ+OA5N_S(59J-B5@4K2B!DJ\
M=Y3[4I#2]>5B>AB^07QFHDAT3M^S5T]Z\.V>!S))CZS!B!J'U\UVN!U-132G
M14:H9)G[?(B\"1Y%.SGRI83F2'H]EFRXE5?8M))=<*J(ULE9I\YQ='.B_^3X
MP?^MB-3Q?-HH]N9ZC4G>KXG>N.PO);E;3Z4<I_,F% ZK<WOX[+-*#^$X8,PD
MG!J>-#KH,5FU9;=@E:0PD2T>;>KG@/0]47FRM_ZDG9]FM\W21_ISCY@:_Z])
MBK#6N?RM#&B2@[P[B=G5 SF2/JE%OD_=31-&K^A/1F&!DGBB09O+2?0*MT(U
M/XT3DRM('&1L,=7_:"Q#?BFP=><^6G<<UJD]D[:#:,6W:'Q.C?Y^?QN:-XRE
M^[5FB+]>*1YZ1Y</:]KZ)6F\S]!>^?9P^T#6]Q[>$ ?!X*Q6DCB*='YV&WK?
MW/#%(<Y:M%%:/@X(,MW5^6;(L]2GVIE!'L=1]1QU#:2@8_;0<F.:N!:)$;%S
M<KJFXMRLR](K>Y0%-<4;V>=F6Q=U>/GL\B6R;DDL5=K"U)-U!DDX,!X^^C 4
MY.D+K4%'G_MKKL:=3@.G[M<S.0M>,"JB0"W; ]&AH7U)A<'!^9,E[JUG;B^<
M_.5I[M5"U?UI-U%$24;65['D[4$G\S5F_H:4?#;J7Y62^P2I'L#\%;-&B^LT
M4(*:M%]':^3219#%JJ?X-YD:I=B</F9\)\\S+]9!";3.#AK75EC8-EYWV1(@
M3"27R!ZV.&;E@N ;ER?FU#0$#->T6;Q*0*0N+L0?] 'HW163.CM!K9]C!"J*
M' 6BYMF,CH/5$7!:9D/=VNL'N9=5B@Q\P_'#LU ]]WN-?Y7PGH\S+KF6YU&:
M%6&W3%F184?^B^^-2U3HFK8BB6CH\Q"%+ZN#/9\AFYD=XI?N_,IJV,<!=-[E
M\R[:BXOEO]:_\SNU/=#(0[6/^U-J&#)\^"_ZHM>%_5]F>OW2EW% I&$?MBK#
M\\Q,!DV!E8="3N9C^H+&P:)M,TV!A:O.PQKRKQ&W_O;=]%1]KF-8^9"=DZ/S
MT2@KW#\FM6!V3,W;N#&M?G9Y*'QU$H2Q=B_\<;P,9RM\>/9P31(?!S!UQ.$
MD]LX0,9VJX$?UIETWM2$&:MBK/YWJFG_SZKI*HP*+!5R_AOKP8HXH))>/?1
M(HRU.4Y/I$#3"PY?R%WT4<((ZD.(73B_GXF<\10P)WS_2,4SSL2$6#*$D.&
M13G$V;GF_/05XM>(6LHY]Z@/L0HERA[W^AAB[L,LAA/+EV>V!<H1Y.MV*&DV
MS?6'E0$H1OV8HMJW@.M1=X'?_+K?7*U"Y]U%/!S@&3]W8';,X8 #G@GC@ '?
M6D0(8I=K C;6CP/Z#?/3,RCZ$^^W4KU?TAW:%_E:R#S40&MD*A\A0,]O(KA1
M]+R:US^^-P66M\YO,J4B7O9<?5KDU6]O0"@(5S]F#L8!3\O.:0@<9Z[ %B5^
MDZ<+..!!CO+K[B\?<YIG49I0(VP:EL4U0K,<]?!-;*6F'%4)D[]"A_Y>](F>
M&0I$CB9<^NET6H%Y2[Q7^-O+(R6,86/W<< ^F6GP.=,Q:QQXNQT'I!#;L71!
MQ1U]F^_GF12>E3FT\GA>)SH]E\(*=6DM?M)"0["-59CX?J&_>$;9-(.=Q \-
MI\M?/4O<.-RZSFQ>2A*EHYW:KN89VX+O)%#W-X(EZ/!V1L,M:93Y.RE(>)BH
MB./J*H;.?_V/+%0@5G;"ZLP%MLB9BCP8,O 4K:B5N2;[U (XR8T^XTQ$M^(
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M98/F]L;')7BKXL3[4M*[]'*J%<,W;0R82&\/,<4C03?7.PU0PDNC3K>\(G%
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MV.B#G]5458CYVC!!-ODIHXU57TUFQBQ*?VT;=G["H^/Q<PKIOYQH.7_+3"=
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M!ZK*W?7C82]-W-<X2NW<8E=3X=%?_O8U8QP9*R>3#B>K'%/:=3C R X'F!
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M>WZ=J!<'4,$6&]%69]_5S^@.]N4]1U -T^L["_<B',QY8]YRY]?(W7,L_U&
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MFCZ#Q)ASC_E"0N>\S2*V9<ABE\0ZHTJGVQA6=N:5C3^8?)9<Q\(R%L<E.O!
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MTDGP[RFA K^U[7_-E-2_6/-ZB;FC-@IK\X&#8">\XZ>)$>?.W>)4+VZY%@<
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MFX2<*&_SJ#4Z-5&Z!02LD=!H8:(6XA1;NPOCC"?Y9!IVN%\ :ZY?$L;$D7B
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MH'7S(X^X/URT'R"TJE5'Z?3#2J2+?G[^F!78@4X,W8EIJOWPXOI]DY5'5@-
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M!KBP5#8\ %PFF$]'MVB@?WB/ ZR6]&'8XRW%37;+E,D)+FY?N@S],/I[($C
MO OYQHWRJD#P\(>$>"-<7T;B#Q7CNAP?]SN#3X?%W@HHRQHS,QCB+CXJ7\L@
M+H6&8>5<Y,8]!*_/N.S*X(%2%837;RH\+'+@ PI/%14&]^WI-#74/S=XL.D5
M.PW=SAI@!#&\5P+N?QH6.^6_0)UJY61[@:-=<,%P)-V4CWVX9&^30V?N^W%8
M4L,T6^A3;]IK,0ESI+0I980APWM%M]3"W@\_%GR,?#3=[43>\>'X>8:[_MK_
M-[/Z]P(V-*RG68(E5U!>Z=?X>YT8QD6=MI(N7MA*F<;8+Z:#-!<T)35+&\M+
M:\(9U 1M+-E81'9ITQL2^U2*O(Q7WB]@WN/ZQH2OT=W*GEHRZ\KZ"HI]L%\B
M-@:SA5,[4.^L2U89.U9=.DO7(1<TC\L)DH9&P6@N8D(_-%663BG *,+CE\,#
MM383)FNA5/9E/MXM7M(!IY/0*R]O<0;*7[3E"" #+5C(.N#HT7B@A7E,?W@_
M5.X-6]#L_6<9W8O^3IUR6;LEBFC>N+DV"\#%LXMK)S=-N*PO.G"1D7P<2PUC
M!;(+_-T:$*/9PS),"Q,57K'/'[5RC,O>SN-UJ;F<GHEU2YDSA:NB7X4*Q0G,
M/^WTHD][FQ1TT6_7&$'D$6,"CG U;V<]S3PPL+?^(2]%L@8ITC_-*(\Q*0'B
MU!:U/6V>I)FFHCKMP5H*6#[@]#VS9&NDD>K%V0X%#HS#M\]CH BY,^,.'4.W
M$&7VGR43+K4@%/K)ZG<[O(<V(&4N$4*/'MGNZMPP7'H>-A 8+5 X"EN:U,4U
MN\+4@4T<V"=;!CJ?YYE;&@%5MB=18K.Y?W7S'?GNJ<IB?&[^IMOZ+#EJ*:6@
M3>L1_U=3ZH7[3V2["T_I#DQH)KQP=FK4+8:ELISRN7L\M>E!TF85Z:W9#7%,
M6TS)U$,(-_HMDK7K,&E@!QY%  U",F;9X^LI:7%R20439LZO6$1#LEW3Y"^>
M/&Q\.P!9,AV&; X)GP(&L8&#QYJ?R@8]P^+T5_LEOK9^O'HF// 9N*\A71X/
M)+C?)0!?5<0>D3PK?3=B1 VWCKM_;#VWP8T'//  /W!T\K/%Q?.Q2#PP#3T]
M.S;@/*7]=N!1H__I.]B2.!)R>(&PR(CO42(V+$Z'Y3EAJ#GD7=RM$4\_(X_Q
MK3/!1$8VP@ANN$)\TF<T3?N.#U?+"T<1HZ*I#_G,<>D/CN)%W['N;$]LXA1Q
M_'C@*61/LKAL<1N;>(Z W%>$3\F#)&S02X/^?)RB)\0LFM5OO\]:=GA;L7T^
M%0BU@+,6E]C8TT3X"PL>Y*V9KXC-76[=/0\T]3PAZN=PV)K#INS QH((."LI
M"T5RM[(<XR5L%:74/M/ZAKN36QBP'7 _2@$Z!B%VS)DO#H;;?>^\8O):4R^4
M?_$#$I2_#!V#9^O48Y:1FZIC]Y.;7:ACEYZZ?>$F"E[?W>I<-YJ5&RH2AMG-
M<$[:);VO<7ST1G4!]Y Z\+U\B2TFC%377PK-[G:YM/CM+4 %**"CF9?/H)"C
M12LEQ\I(.A6.AQNN=-E-;2O/S^?C 5D14U!,H'C.6R1H0$;T@UKA!M^*))_6
M0&M!WCT-VKEL&RPS(J5U_A7"C_'NJ[(9->9#0^V(S7N!O<=Z9?;'?:5KG.@<
MDR=;W7H=B_!\KIT,"D8\P"Z>>D$G9*PCC3Y=*]P*5Z/W,GB#(8)KC*S!>=4H
MV%]<HNI1CSOQ9,77.^SGZ(46^AO<+9@\8LQ,%G(^'T2.-!3RK##):@^GR65Q
MH8L5%S3WJM*)*@R7'UT>,6MZ"T<=658?'/4"5N!)_N--S3N?4!N->3N?1*)8
M!JV !Z@;:E>JM^"^:YT=S58HW)CY-P]WSO?>,L\G)SHOM36+U.RH?"&2VNY]
MB.M-L2;1&MW7C[N[Q6_R,>%+'ELD6$=EV<2"#4OS$1,^=W=4C"_V4-H^X&"]
MY_K##PP<75P)<V)$B;P$\,PY8<RA<]CD)O2FRFN'^ZYP_L-<N+]!C@]3QS$L
M?@^\)<#M8RZYLQK<9RS1 3OOQ[HC( Q/B4N1>(O$ Y1E-OXUL0\ZVJQ ?+,(
M;?,D5(L+Z?1:6?]\%^.LI,W)W2NONV)%XYJC#I>>V)'4_MG).__N^#>N4Z._
MD"GI_97K=.DWQ.1Q;R- DEK6P?^/]O *^_^+Z(T(P[NYDI )UG%?:M]]O-I,
MUM"ZL$JP^>?Q@*T%F>1 SIT,U\OQJP-C\78I@C\0^2I65BQ/V;8EK3FZY9+V
M>,.PPC8+ 6(F4WE/W[[)X4J&+&P9ZKM6I*T&IXVVG@BI?>S/3:A1HC<0V?E?
MNAO^WVUL)3S@7 %]%GAYT//5G%#BQXEVL=?LTC="6D^7>+$K#8H'<01[SMB*
M:Z'  QFRCZM"G?Q=4!9WAGE:IH5225\-6[U>HHT-!+W/H-X2+MH7I-FJ?%%8
MN=MD'3>R=%Z_7N6 8.^?)Q.6EEGX48,!1FF1HHAX!P\T^1[9?8!_96RT/"DF
M^A(HJ[*H_S<MKL[(0G%:.6.X6EY<I/B> @NS^&[C?VIG)<.T.!=26%CHA#7(
M;JJLNGH]?K&;3?'"%P1',T=@TGH:)?I:;6>KAJ";]HJIX'M[D&9?T.H^0S!Z
M985/CD7K!6VM8^0@",%[K+<=RECDA"I14UG]2L,K%TMP'HT!^$)Z6TP)9W]^
MIVMV]O.RB?+"L,.E]'NR @,;4O/1[$?:EVV+OY&(7P%<Y^CJK^3YC+4@QH\#
MEB0*AZ_%#ZU2DODL3N.2LN9+*!47P.2&Z[2%YH^UX7*JG71J6,U^F90U@1XY
M'JQ)%:JV$I[I5#=F??0$<:,)6O+1EZ8O2,HB^O9@XTT[@:P""C0WV%X$#\ "
MGQY.Q8[F;@FF?\<#U+8E;^1@W$4686!*EVLN\)AZ'6--<_]Z$56WP1\;O;C!
MO2TC6#D"Z^/CC:OMQ[X(DG51&O6H&/BN5\%V[\[9LZ+"&8>%_9P.QX\;24:'
M;IT\\BI_PF"CH]8Y6K\)/4TM-^F5GES>__C-WLK@HG(U"TM!&C?F3-9:&NN(
MIU1%3#=W17#V?6M3.I"B/)M%6=HV1J%"]O7,P6+L7E][D3#@SUN#0L2X[&\]
MW!C"V0=?OT$V':NE=I,S*?U$"@]T)>;#QH[PP !C@VA;(^\0EO>#6KY#%06]
MNIP>[BI-9OQ*T$UX;.==,)4X5UZAS4&P4UU>LLS#TL:S)C/]J'>*W#F7KB5>
M$XY- L6.$=%S<F&VD&'5J9R=K5[PS@S.T),^F/HQE\:PH)C3C3FMTD@E)^=@
M+NUQ<@ 9",:*EJ-(C^.^CVT&N+I-,-'=X>)K4-WP3=E-AZ=4PHOFUHZ=$[@-
M?.O=GF\Y*S* @C[$'ZTR;,WRH?:KHK$0UZP9Z+5[T*#M<VR?:!I\A.-PK*98
M0<99 51?%G>4RT4#DV?ZUKSOUT,@1/+@VVN?H61AE@Q]_GM5<=;]AR&QWS96
MZVF1$(PZ]I)EX0W2GSC:)RO#LKG=0^Q/W0O[ZYZ8!A2#J<$#@47?_CC[^QMO
M>K^G%^O5_I$]^1<K9>Z]Z!(C84Z'9B@.)4L7RH))F0VV+7@Q2NG)K6(%:D=*
MD$-['QMNNT<Z63Y-7\M(Q'Y<<7EVL(M97"2=_)%)&DY\6&J;L_,D%-6G<E).
MM!5X$_,V!T,Z+I1K]51TENM&S)-<9Y'G;BI%;A#4D!P+P;HHE^ !_TX\T#X&
M.=& =?X(Q@.FRSA'8PL*'*./2ELZC=B,[OWA-)/NKW5+%VI7Z:ZSD\0'W0.I
MO<<^1066!7!\"-^%/CVKYU?==#>M+5_J.&5=QG5Q"DH\;F(Q:S]6Y556 Y48
MN7K6]3FUH><J6/VHD[!L!WOTDV"B)ZGXD<I5M<]ZEKY,V-5PL?R00C8@FB1<
M,8OS87'AGVOOIX&JA*8_C7_/:YUV J$RJ&#$_G<'ZP.=AZ'QR%F_QXSA\WR/
M=+&*I$NVT>O[ ?K#BD-"%;?69>H<[;[&S[9^.I0]XQ]FX_K1GP>3>/+-Y4:?
MV8N,>>BYO0,N4C]D'9Q@8NF<*C8=.2B4:N@FI*_T?HWT>:BL#0'< KKV,F@4
M4*N=5%SMK/N5";EVM66F6JJDA7[WJ37 Z<%ZSC [*N)._0#I$Y5O18^B7?A=
M1+A.)T"D[R1\<OVI44Q8KC0P;@H1XYR=E\'/[$XO*W_ FX^5%4C#G,S32%]"
M;DF#4P&-)>T1#R/(>ZSL&LE,1IK 6Y\?EQ+,K])+2[\+H;DXEK1A <:*6Q;V
MY[1:YIN+Z;Q^5KD19GUQ<;F'^&G)E4&<\ :K12M%"27-]=G5[HJ:_N-JDUL1
M(QZ<G9.5C208BA,K?3G>D8>]J8G("4-7[KG98^'=XWN@(?TR\=X/HO7"%*K!
ML3I6;M8>4HN7<S*C 6F#U[WH.GDH2V[X?'E==<*/H0'3SJJ>:U^99-V#H.NF
M+NW]D7*\R>T&@><&+.W&SL8>S)</N\A/J1RJ2"VF^^ZX4(V;KL,N>/A1=&'K
M/CJ9,V??776\5G"VZS"#IM(1CDYN0U!C+KT05/=^L=ZA5%%-Q2,+O4BT+SZF
MNLGNQ/6./T1MC[A19C@#%CG']$+@T"WY,-:Z>4FY1HHSE(2>Z,<L)V9K0=;O
M7OP7!<_<'@$GY5J]LU#+Z@OPC@:IVF>SADX=[FDB%D)89PSL@X^TD]#VG>"B
MK>+0#C33-1*AF]VKSQT'Q32V_#H@@ X5]]/)\@2VV\;W(LC'N3]SO<C:SZ"8
M/.PL.;LV5FK<)+3/I!CN=Y^-:&^ZS1;5:^<#702'U9OXOSJO(9NZB&8W<&!Z
MND=*)[J5LKL=CB"9-IOM7PRXMB7/>%8&I0?WNL)V/):*A0X4RG"@R?TTR57B
M^9ZY7X[@;FDC"?)%V9&LIT=R2N"!9Q>4(W0#)$S&S2VN8JLH/B4DO#N>'RT)
MPZK9(/MIC#<9>0]UB]4O?)'TE)L?M8T4"T=#6TUBV/+PP)#0-<4@WRCB'^"\
M$H[3-!FE*VEU>3X.7G*F&X\B+QR:^5AB8@/O$^TY_8-[Z R/_JA)_B.O^AX(
M[N^%TL/5Y4PXIMR'BH^FUGV-(C-Z/K]$O42+W;S5,E?.^8;S#55NU+7B]PUA
MQ&(#Q?N)[-:Q2ZR'_"TC_DP+J<96XKBPW'X!MR$Q<N93U:4!4!16'M/NLBC+
M@A5?*!+Z82_,S-7-3YF0%IV1F+@=_6,/$B%Y'LN8W#)VC:NQ-FHI<(';61Y[
M7:!ZJ%[DO=UC"XVA:T7L*'.^^Y*KHQ5Y)*L6X3"Z2YB ,_UA_F8N[H\N)J7<
M],^<$ATY?[/SB;*#<%3Z^62DKA'&H$6_BDF[6\H[L8??FBL#V $VU#K5#WL-
M6E-X:D(+["6\8\E(-,G+B+ZK=F6IHW[$O0]G-4^V?V02?KVE #H2KPD0UI'V
M5!H<+2)X4@Y>+6K<2WZ3@V(AQFJ*>[2Q# _P#*4?4,0<&^1;K%=*9R,F]BD$
M'*O=ZWJJHZQ-C^=#1!77*^GL\<#$MLWC49/; 6\R=3D'!YPZ1+;D.351J[<Y
M>3!$0O!J ;-S@\Q[!C-)D#2!5Q@K-"LXPO[I I1)P?71Q=2TFS*94^<Z[@?W
MT=Q3]AT;>*7/Z.M4.F4XJ>!(_.+./65:95^45(%Q5;B'K&=2A1E/'WHL[&DF
M99.O;1'@/X:&(=GE;E:7Q:B%NWR/N0I91*I^B;IBV6G^CB1V=[3QS0!LR>SW
ML,-]KA8<F/&JU6E$SML[ 9OG*FX'?XX;[Q"-/W74IN6*LXK3HY4G+[@.< 1E
M@'1Y\(#VSTI<W;6+M*%=&31I!'P /J+R@9\2_+N!N "R1;<;Q[%Z E07U(?2
M5(;+>P0D$K<K&FH[3#;+*;]M $>AS6E\T# P;<4FA^^L346:LG+"A2M/VK*(
MIL_#C*O0WDC/]#@QA6Q,($54H=.2T8_BV1L%9%YYS4N4GY86WQD,2)=$>)@]
MH=G2Y.]#Y;64#WR\SMD6&VV#""NGT)36E*-B@FK</'M#X<"3;XD]I"G^28 =
M2<\//+ TEHRK!^%BB[:#83L:UV";Y8AC!N]<C>$I+5R?!&-.I_-<&;/!E\Z<
M:2MPF-R7CG[-2A-'-E7!!SJJT6=;^/K-0?1$"YPW\$#B:Q0>.*W# VN:Y@V+
M<T>\:5?PP">S?ER,PW"R\E#NB-7(H^''2XUP-B'S,S>$I"TCNS[J-C-\I5.0
M4;MVXZI*O!)E86[(69GS=B2=., X^["E5V?(8M]]KI<M@%([U-0EQ%_%%675
M[IL3C-2P[TA],I_=H@R]&Y:@XLE5?).Y).N:6 \5__34^JC$Z)-7LU95458Z
M,Z)A@&WPD:ZX(/CNJ"6M@V] T9+CH3[R2@#B;CP?26LCC[_YL+]F!B0<RU?%
M5#:7%*]VYUJU*3Q)@85[;]VL)$Q&$/(LD'QF_="Q<D?C5DQ,&&ZSE!,"T(.?
M.'XFN)(+IW0NM^X.%A;9K*^HD(=CCT?+$SK%H/1Y)6PAA;$WF#DSXO>(%L%E
MWMAHZ:I3&,TIH+<=:\Z%ACTK*4\U44G% Y]#S]2%6>E0A/>Q1'*3L;NNF[_/
M73?V2KR@]'^Q]YUA4739NJ6@* @(@F0: 8D"2A"0T*!D!"1+5LE9DL2F"0*2
M!00D2),1B9(SDG-.DJ')N<D---V7[YOYOC,S=\Z]][DS<V;F''ZLY]E=_?9;
MM:IKK_VN755[9?[4'F_=JHR<( VYL_[4N^=E/'G^:Q?3P/N!K10TS]@)GQ)J
M WL*\@M<3:&FXH;93\=4R/M.24:-?X+$FJUQ9OD"SH3,Q@*=\C9,IK<.-KSN
M>>L(&%8DB;P+X]G1SQ4%N0CKNF( 1.A:PCX,>:SKJ<>>$L0R%_C&GR^,EUQ-
MW"NM_XH8X7_)M,%?EDB)^L.T@>VS[(,:X<UUCWIEGE_R<+Y^",>_QGW3_^O/
M1V,"4O61OBIAK:WT>X].$HH(%F%R-K]N4_VS;:>@QIF[18BRSQQYGX2[K\2_
M$71 TXXDKMLGF1C&2>-126N)Q*XW_8JIB_\S3+4D:>?TH6G+<#9;I$-"]6M)
M$A6Z?]M5I>J<!\&+:_GU&[FSIRQC Z3BC@KW^1BRF6*-RE<8I_$<B1-#0#"*
M\XN !3:;/2&R F_2U9]BC24C"=&RQP'031H<M!>[-@:0'SI\>1=?JG5B[[YU
MH] '#4F<L5N$?,(/):VQWXK_6D_IEUL^WOW $UQ@UR"L#BL2CKWK^3$D-J;B
M[$6XOS$-M7OXDA:T6)D#_$%6D/&I+%BC()DQE"D0'DVZ\%8]VO\9UC"1VL$Y
MF=S@\P"%H0>Y(9]GC\SNBOQ<^Y)LXB5JOYM?;3U?,,&R01;(,#E18K5Q^]J'
MAPLA$1MZ0^B!))(;<N83Q>6OEY(OQK^-(2YAGF0+?@X'2,I:N29^Z&"?.=7W
MMN>1/,K,OJA'5->5",QQFU)TR"^RDGXSK)5:';5=YC8P\<1+K9<B,1%6S3%6
MT2&TN5O]94\(,8 >A,S2\F+7^/=K:TPWC^[^5*>1D<0 &^I(COG2#Y*VM]ZV
MUA+SX>+,L?8&TW,_\9<B-W[]43HEF8!A_K@YQP#4]57:-JO'PNIHF_NA4''2
MYU--!S7'W]W<[/X\8YW\\ACRSCN^5HS6?3>@M1C)WRCXW;K\./>U'P:H>+3/
M/VSDZ30_BX_2F9N]I2OZO6!BG=*_I%>+6BHWPCVD_ '$<MWZF?00GU.H$\>3
MP4-#QN1*;R-<)5T;'-)GZ-OUN!=>%J=!Y[ -4 K 6PU8"<B/BXNN+*Q+C9 W
MF#(F\.%- 8J3G*3SC)>/O\RWTMR*@@VP_[S3,$,>)AD)OCA3Z^(:%Z<*VQG'
M6F^8UYI+X^68RI#5CH;P)MG#!]X\8U3>;7* S>_%M1?9N2[ROCTZR_K#%>:]
M?#\B0TF)%U_3KJB]NJ*0=,/FE0LGO>SKC]8NBW^X%>DE;'KD41G6-;]=[/2H
M^85>31B$U% %&NW*5+X@(VRZ$ &%Q]E<A/*%CR?O1G\0?WW"TH&5M%Q743)0
M4HTG:_W@8%+(TMQA^=DMW \GY((O'KK OT(;R>8-3N\ZVJ* 8 P0F$S(/50G
MC"23*?1O;9(=SMM*T<NF?.IU!0- QER3D4E=<*[W.S:\L%*=!]YS&E&+3E9O
MQ54LI?_BQ)F_-"^CU+V.+]HY,4CL3+X%?SDF6@&\P.FKP]H]'VN".*M<C-"A
M20>M@]LZ<?QR:F$\4]$,23PJ*$5D@N5"-;D'QSP+)Y="]S>CV$[CZ3!O\95U
MF8)W(Q[@M(T/.=_68F*]/=>2Z%H\W^^QB; W/:'UES=W4_B2%N&#:/S6['9W
M0XQ$^-K\&*+<YV":2273):T[P\U6.'[M'_4ZX=_ZEN9\W<-IOJS&+^\DWU"D
MR2 Q@(6DZND=?8<SWDG.V=MZ1/M1MUZ=$G[& -H'LT$3[NL&>(=G+F,/RN!6
M[E(-?:N9-05'YC7J-;O7HAY.==SZ6E?Q@'!?&P#_1\$42S_$3.TN]Y!8>1GB
M^*C@2'M[S[//A,9S=]I_PJ'7?<SI3Z<=](,1\FC9Q^&'"1A JA9PX8MMNDB8
M!,:P3S.^'%C?H[5>3LZX6E!H94KK4Y>)6/:SG(<1:ID=N3Z<:+W-XV0X!;.W
MMU0) G9WPI-N^:HC^E",'_WDIP6NW,, 21%WL4 O%*6'QR(]J!%6HIR[\>?%
MYD6%RG:\IFAM:E3.09_!ZQV#9QYZ&"!2O0 Z1H(!!H+U9<\>0]M;\J!C1=!5
M*2_1CP +<.M*OP9.:.DT?],,T3!7J9JL=4T:Z./LWL_"'TIM)R955\4HA'%/
MP M<X3JMM$R4)K![$,Z6;COL107FIVBT+P8H$*,U9L")&->TB)11GIRH:T'*
MYZT]:6O:$G3\&G/%S.=F7L.R(([NZ4J^^W(%!#0'J8'A+I54!Y(U\XOIYN8*
M!OXX,>S+)""L['NMKX-8:26#$GA8#,P^B)B0N=#;]=X![+ZA/P]53R^B<2 R
M?)>>,"#"O.\Q[/[*Y',O[+?5[ZP/,8!;12W_46#1L).\/&D_Y^VI[H_^/+[E
M#E>2D@Y7T8P(YX :=TM#IFRB*O_;?38#G6JO?W0LY+]E)QB:*_!Y4$!7[:OT
M61X[F/[.V[9;60R')%<FFS)?/H,^3B%-O.DJ0&L%?U3[ P!T\A]>\XASQP#,
MUYC/0RX\EV/?V/:I$_^+&BA)WVX.[#P]WRGN"#];'.L$X3P4Y30_J]J.!>EE
MUE4:$V2\-"+R85^H]JM&OMXU4A(F:.Q<;4_+BKMC9 11Z\?YAAXT@KXV>W5X
M)G%QG=9IE%V<A+FF^0KFE*HHT!=7LA;8A]'ZVP6\/WFK=3Z5E^)[LX7V;H7,
M785<<T,GV,_B>MX0%^DVW,J^NQ18OU+R_B/A$/->,M[L'32+%I+VQ\3$)YA6
M'-2)P)X>-&.[*C06Y,&/D,K>I6H)T!D)"<]JX__B9,>,*O-8>75X?$#:4)=S
MG@T';7$X9543=RWK6EL)A8LI*<D=]? ?^0SP0IY0X8,;AW0F&JM5>./$L/:2
M":'J:F)!#Y-?$5J<L#=*GS$L=!-)1JL-&P=C]6^3%WP[V#@8YDVP/*_35B#N
M\@<[$L6?&,RC3/61*_B=MY*KX^=K/YF>1HB!M/[&Y_O_2C7Q?_:[??^9<?]Q
M&7F/A'OG&QB@QG*#M7ZX [V&5M_3S3HN0._FK1Z*!@?,E(H:?(W[5;U.G<K_
M&ZAE Y>_4,8V?BFS+@$7VQK_1"VS-]:1?D?D_Z:6[?^@EE<Z72O]#:D?6)5&
MH?-;$ 5^5C4<F7B6QH0\@$EBF"X&""BU&9!TX(=H[8ZPR:4G+F__O/C3/_Q]
MQJ#+Q8O_EL6+;ZSXL.>X6B^+[<KYT2@]37\5=!+0\%T6,;20=:0^;U0>-]$O
M,TW+WQ!:3TRV7_ U)W87W+1#@*PZG3E6+WU76:[WO8O$CXJB?=&-$BB&@[&1
MSBU]-J?+\>6A-C<^Q.D]]AW;+CS(PR>3'*H1R7B6::[1.-%+?6)WW60R4G8I
M4$0VIS/E-DLOT,9;\FL<4-(8S'7JX83PJW@IF0K@/9 ,V@9\AV^[>6N)TB"X
M_&N8[7A/:3^717:G,+YFKYL3Q%HVU",EN8(_4J)9%J7=FY$2=\LF)2@R_55(
MF/2\;G1XHRV6>3G"0'N5Z'XW 6-H]U[9* T!Q0>^\0&Q:_87HQ[H^L9IXD1,
M5DJ;R-1/;IG[$?RW'R6R7]%SNC@4^<'- SUN?"&E#RWF5S>#N#?/I#-?1FG^
M<C4LSL[#?!?'>BM.N6EDIB!?^U:ZT.7OMGY.A]4LD.<7!0'L.,U)^/W".KC2
M>>8#4Y_.(HUR"@8"P %R,ZE> M-8\P:^*'ZWV#)*N82OO2KF7]+9#[#G('8Z
M=72(F0CX%Q$KOIQ'3A;YC$1Q%**O$ZFS<2KSM%FP+L8POT>(,[3?, ;X$5>/
MK +//_<0Q0 I3F $DRV:L[KSESI11WG6<Q<]CO)](9PN!@.8E(E! _W[KT.N
M*\WK6YX)N>A+!&& YF/ECR;G+<5$PZ:<T@O>2,U\EZR&4^D0JY224888&7K(
M>O8]13>CA3QS<S>]I.!,G;71VQ^LK?L9S82NB)']SULMHTXQ<F*N$^FC5 -]
M/S;*\V?+6FO>W$ORQZ)%),YL[=C4AG_R['+  ,+W+]0 /LBX\D+\$5\$CNMU
M9:D%DZZTX4?[&  &#4=A+<**IC! WTWHCJ_TN UTY7W]<4-!WM>T25><2\PE
MYE\5HWE@0&BAO9U!&OJE.M:AB_OC5Z%("/NZX;'28,Y+:%LYZL; 5DU@#(2I
MQ+^N'G&K'A>IT=98]:JL[,7^P^OF[4M]2'>-0Q(-A5D-%Z>_MQ:XU -_LQZX
M^E]LE\4,_K/=718S^*^SRV(&__"W]RY7Z/O_V<5_@Q7ZFG?U]M>J2'L.+"CE
M79+4L>>(O\GD52W7N&( >L^+.*!_<26L7D]T,E,9X.D S]MO0/?7<,Z/,,""
M-(I3SQ8-H;M0TK,HRY[5 J6?JINN23-9#H/_1US:!8SV$G6)ND3]#T<-]+6*
M&!4:&MO(K#K7@_*X_F4.[!)UB;I$7:(N4?_/*,)6/;,0*B%[\"QT-]T@)+XS
MA.-+!5:A,P:@W ]B.2(YPRG/GCH(1^I6S:).Q3$ I!XY@ 'P8G4P $P&O%/^
M"\[M$G>)^Q^/&_L--\C5*F)\_6[G%*'8#IIOA41YD_6(T%:U<@V$J'2J/SGP
M19]!=]/09)P7)*(?H;.V:+[E@TO0)>B_&^AB/''KO,41714NM@G.<VTA<<>%
M^$X.;[O]V6CT2_WGKCP,T)<..I[$ *&NM9>X2]PE[C><.=D";5$:GK$-3G$]
M<BQ16;HPZZ=(K>)*.K1Q:10#K P2GFUA@-8_&ZK&$@8N89>P2]@E[!+VUV"U
MO@VG(?%E?M=3N/TBX7P17L)7+9?<3IWGQU"!5<[G[EE[^1X* JVL+33D%I&?
MXJ.>5+&D5O3^^,L[2?F6;; ]YG6#PPTNM)=EQI]]M$C;I3=&%"]ULJ36^K;A
M)O6V;BA7Z5BRF]LP>VR%,3YHHVU,+GB-O)>\'7.F%RU@<. B>[C>=D+86YPM
M*E-)J1H@_$F):YB7QD VE''8L:M:PJ%4VT7KBJ@O?7'.V@ZMV0 RH<&Y\(>&
MEN%U,]Q$U%JB]R$%*-2C41S;=UAM(&>+=%P]VYW_56J5(.H:W-U=8'MQT&3/
MB.UV#OM=CB& >F0,J;> 77HF/D@>8OJFTV\7O>V 5#^3<688[_O>-O3>QI"3
M*(@5*!,@S4XU(SOMK8BWKDWK>%)F_.%CAMIM*L%6]BF4W=P^L]>8#&(YCMSX
M"Z@S'%?Q2@=CDI)(S_/UK[S5T;B*YG5MWN:GBFDY,KMKH_QD-KX/"J5TOQZW
M"!Y8*_ ]RGP,L^?J?63U1M3T^?F4:1;?%.I1U2@OAX.Z3]^SJ!<5:D0]Q+W?
M3XP>;;L(CTRZ5W?-AC^.)3O"?_VVFU^GQ+L3?HM FCH,2JF8IF*9^DQM* BB
M([RB/. DPM"%'AC:MA;NWMR'LU;3V,6GZ:_MNHN/"(M#TG3,W]GK=N:POJJY
M!N)2<0&%NGH6SW$1K][-7,< SYW*06XRTT9XAQ.*8$K6$94@V[?9LJT*'&$V
M08^BO/5,8(BQEO@O15/BZ57-36PF3B&PA@]\:9%AFSV274;VCAIEI?-YIDV#
M;!9EQ).V9[D_V6:EJ#6<:DN.G8DF)R7V>NY-? B.;/NIJL#GR!3_SD@]&P/<
MF*D\(KS0TD;ZYU$F& #<;IT <0AY4S8[#PUA*.''D7F3;/3ME_]G5;#@=3Q_
M\-Q8+/TGIR$2[L(&'+-<4RUV^W5K7([9A&?+I^QI90CF0%O>TN&M@[;(@;1]
M">^QZ%:'D.7">SXZP9^WX$^'9.:)I%6:YW#'947B@H-U4I^P0S41!A]XV4%E
MZV[N.I/;-VO353M6'Q*X:UR[F?7M>OQ +.\Y^XN1#+.2#?;@<O&8EPR<8L<M
M9M!&,CCTE.P0C+H&1>0OS-FB DJY3N?JN\=>+X""F!O=SLQAXR"+*Z2HOA*K
M=9XA<[33^_4>I4BV%0E6\:8DQ;;W!F:G29^OU _EYXFOK31VP+K5V4Y-FT0?
M#-31K3D_WK+T?W'770LQ13MW3(O2]'=I:AQ<I>6,DO6B(-:\/CD2'=XI6IL]
ME-,]993;D2T?S2HY3=U#.@)N"K^;WM\\(5R]Q,A$<V-A>"6\-7)EOB_(FBNE
M.$J>R;R)][7Q4_);IHD+%7DBZ4)Q9X)'@A;L\MK]?&!"W8RR' OKY0C^;S$X
M[(FF/A"VPU@?8<FOYL]42X?TY;DS4-/K C2*-_LL/ 9*MSFU]$<%3]E><BQ7
M5LB[T+N:O)OXZLL($V//AOK3/I17*OE"T[D@)/'! +2]PBLH:=,@I61DSZLI
M47=ME\'<5 7=]5$;>T;OBQ1._LT>AY(AI=<"I17J.?C<9VJP]L+BI&6#[28*
MPU/5DB]/]'0T2H?F,8"6'9WX5OSI$W->)7]]8H+"^3MX[[$\]MQA^T&=>?KR
MC/GC>6RZQ];C# TVPOCPX)<UXX[L6Y\[V(FL(':#A11RWS6PB1IP2MVS M \
MDQ;QW1J:$Z8_X7$^TFP]]=@'4P_9V1>8HE(_P(?SF$O"E0G+S)2'>;TPP-V!
M7NF\YQ9="3$6+7*?!%V3^T"I!>;:CS/RIB$)"L4QR_KI4K4XV2(X"WJD;8T[
MY#KBRV4?7UZ)9(BC"9@CL#05R#+I5F,<&10X9=UK820N44EC#'K;V80-RK"M
M]_:0B[>WP)'[-"EP34M+EN[@!PXX@Y^Q_(VRK9%#R;?<;5)Q$T,O8#%^XQ=F
M*J42J-'C*5/3^(1?PY4FWRW-NVXERK)8><VJ+(\>3CAC#25]^I1Z9/@V<OHN
MEX=0GGE9O47=8(%U<CNM43]WOI*B3&[G$?C#Q$PU9&[@&@;PSR@LWS<4===-
M"PGSQ4JR[.,0)H(+G;-8O)NPK(U["M=;%U4>GDL<?IJQX&JFNS:A$98%EM09
M<IRLU4<+L9,_'R.FIK]Z'?JD/ ]IJ8G8D*C*2]"A$&?!8^T5?3\:J_G]RY=\
MHP&=)R _OGJB8GRV1MD1 =-V=1""7BQGS(!06-W<'3^]ZGF25?.'SJJB[UA@
M%VH"$7/!%J''?#?Y',/>! V-UH"_N;C!!?AT5&T?!%>J%0J"O/G2TI XS1-;
M15,_U^SYJB'CC,8A_$-V%"@6^R#-"A;9ZI?+J_D)FD@('$(PDE_@6'YWK4N6
M*M=;.GM"$6>TW)/41?[,5IML;,)MRORC_[7$T#H3 6Q3YA.UJ@CEY4JYQ,1*
M*]=]J562*FY_"MT0(U7+L3HNI*E*Q3##\.8F%*YG:48ZC>OUF3G$%)SAVALX
M;VW9;-4D5Q@YQSSC22J-NC&GC!NDO'QSR"Z6-5S2,;[-"R6?/,G7@XZC_U'O
M)C.N)SUF+H"R3/*GL&&2>1V:'MT[(D'!>'I%(SV^RDB@9+._D[VH'*FU0/5!
M(B=]$]OH)E.HSAY'!'*4H'2^QZ!IZ(%V7DA9]ZQC&6[Y0,#UR$2=(F,!6?82
MXP%):Q=Y"=O;R*0N!9"]='?   [S0>9T]#BKWCA1N;_3IP'__%./KJR("*%;
MK!1M^[GQ1[:AE-^TS"=L ZR!L >N8<'CFGZ@E<&:R88)!I> %@U*SYNAB_BL
M-!_M9Y-SYY4K'(IEA^0\(N@QP'O59J:?NJ%W7NSANOHH%8M.5_0ZA'W.=3LC
M?.A[].H%#6R]@6)R*"O#HWQ!X0;2N25V](K=#2@WZ)@JXL01Q<8R=A2:J6=!
MV\,4,BTD/5SZSFDHE]-FXE'L;0D#L^,6@XL=\#1C@ .N=2@2%P/,Z_LAV-%@
MI_#3%= ^7S^R&%Z/HD<S),@]X9^0D,OJ.5.<6C3-'$*MR>6>3-'G"PP&T"=^
M";]5-^A$\] ;^MK)0B<+=H<)^DAM8ZV>$!DNB0Q.F6H>K<2Z:6<I@)WO1K2U
M"LEI0(G/RX<RM-HF2YZU1AKK.)PO.>QA@(!Y=<5R'KO(8HGAM,Y/J=MQP<99
M,Q::5_&HM/)-1(A)'D#OZ=QQN=/R>-<U/,7 &@.8T#=[7JU=)K^(4:*$YG&B
M+S^YYB>[1K5#3\]Q7NOFA^\639QIADU@ /G',8.%RMP]]2;NA3_@:9.*FF_#
M_,[(I3KMAW?)I$+':>2*$F]+W>"=.(*%Q"L&W_>Q>*MD?C>'RIO18IW62!@R
MDQY& .'1-TAU4=7=I=W9S!/5\5/U]R2]<C E0W&4EZ(L)]SWC.+B(F0;;LTY
M50S^NA&K8)VI+>O G;\7.$P0=R[I2 :[)6Q@C/7\5%XFB-LC3KEOD4!I2<V#
M(K<^P,/ T*4Y]4&=[H_=/5HJ\$HI/^^0W; <OBRKV9L9K:F7>EWFSGC/A!5*
M%^Q\,I,+7B''YX>E2W:O55U9!M'/A:U0:)S?0.6TK:G"A-4"5*@C[7!94DMX
M_NG/%UW:?[W]:591\#EG;3; 8(]I;?9P&]99^0B*^P0!N_-K>D& ^/]/+Z@_
M##Y)935]<]5[./[406$H$Q'0U&!M:K,_HS-YEZC9+VY9U,OI)'Q)GPM1((Z>
MV,VKB63:<"<Z"N098M@./]O 0?!MB#Y!AH)\N3BLB7_H]W!34'CL<+U9P4(J
M.OB>:-+>JY1]RFQ"P]+2*P'&I=(*>%HY=!B,UV7J\V:7K_EY0O0)G9&#+ZQ;
M,QSUK!\Z#]H-7:IBFG0-AQ%FCJY@K=J#<0_TF!>LW/P+S$WM4H/-LJ(-S>M&
MJDT4>4)]ZVMUD /)Y]5-",O;^<9%D"*BF<<8 "N\>]#W$]M9YQCUL*G\M//W
M,0OM=@0&\-91WT,UV5KXO3AX\/8ZI$C2'GJK!OK-)4>UKGAX]*K*HP?6Q%L_
M>F\<K[,K79PNF0+PQ@SA.3Z[%_(>!F!0/SYW YW?M!1HY/R4?LS[:?%;*_L;
M*)E%,5)S 3NVRO%M("=#J*Y,>GB"C1*V0XL;.!PEZSX?CH<OU_#:O/OKYVA9
MW=L./Q@&:]+@.;G0.PSO!-1?RHKZ!AW:TB+=]EMHB2DAOA),^RKBRX^O +08
M(%3M$Z2U(SBV+J+!@Z(Z]L7NXVK7Q[./';5 9C\ZWBBRCLWNV;V J&( V56D
MH"%G'#S/LQ%2YU3U 6:^P-9,K0S! ,RD."/@@Z2+3(%88U,.36T[M>')A!S<
M:7QBG+JVZK^]]9.]HEU2US1<7Q(\/Q9\?S<K8%LJ@T0*3K:7,5'_($@:!_0Y
M'1D[5QU.MA;3VC)@RT$1Q)Z(H]$JY4Y[#42 8N7R08$=)Q*_/]CG3^ <[6Q-
M=NQ;M@0YC+LFN*/'VN$>A/-XXKORFD$OFR;-57B>AO?=+WQ_?EUIC+1\EPQN
M?*&A#DL''3^_XI8*VI?ECEG<(P&DK1QV7M9A[5JGPTB<7(VCC"AS"OU@8<^,
MKYSZ6)K"N9I$GC6[P=<GGG^,C29E"M.8;"?'!F6R:]I:U&89WH<:G2<=/U$@
M/AV"2WM3;8VN)[F898KWMH&:ZU-(6U'D_8;^&$"S/DEX2D?VR(@9Z5Z^,%A-
M0] X-E]_ 3_&;04&N[L&IC  +MI+DPIA:!"F)ZU9F/1<R1X#F(> X)NSX7)^
MGK)[FSKEPH+E#+O.+:$&<KM.+6%?J*\.]BJQCDIT? RO[;-Q"-&$PH6&A^NH
M]6=:;\ANUOP@M H9PX+OO)\HRX&O[92LO3J[OYAD%,KPJEEI9J%^7N_XPV:4
M M(.8DS1*6Z\Y./N]4BB%E;=52$]X3XU25W? 'EKX.*Y(!WG*Y*V=&6'"GJX
MK[OCCZ*V1C_2G10VW1SE'&-/>@^J1.TC-3D0L[KHQMTOB6$_?>9.B,^ILC:"
M3@6W-G.W.9TTU&4I;]^/'2%C/HVORAM**%=AO:^">TX(0H[E47U1;'OF5_'!
MM>@6!KCCB(- .WV$71=68+2 Z]QZB&UR<:DUCS' :=XHF#;'QB<D&7\N\OV)
M]0.54Z@4JL\4QB=NG?E:#.MA/08@TV$9?D_L'?Q%L*?R"U<3(<$,TK!5.PGF
M.<#;. )Z](@!^_R:/8S\E_K%4>@*:51.+M(0+C1+XM*G.FP[2/IY(O4-Z;VW
MA)5\%U'KUJ$MJ4M$*;M0-4O*HV_6<8F/Q8Y4M5CM1VO.*"OVE4N$$L,;I.P6
M9#^9OBZ&S.IUA6_H0$E)I9MM\2..PZ-A9Z>6.0AFKS<("4W^V-B('B>VUU/X
MV91A+LPG8S%(6+,=,A;N]*6EVJ;4?YW\M>T+:@=D8KQY]HA]6,?-?#DY[NGB
M"6%KN D"YF^@$G8_YLT&M<S*TA0$4HCOB@%\A<TA"Z /[[CUGY& 38LCGDHH
M#LI2"!]@@ V-L=8T#$"B5X$!LDHP0+]VS<;\_>YW:-$RXH<&CYE#':8.T=$D
MR;51L2KK"F?JM/[E;80GE%;@C6[HJK7>C@]T,:(- ^A'09ER9P/16",UJMD_
M9];>,._!]XPTWU:[,@L?;NBI^X>?>\_A#-WRD?+IE#2EP;,6/#>7LW-,(ZU4
M?A^M);OI.M8@0G^SH)1#0V+Z :,D$;@I2>D@6]AP5T=S4%A/Y.*R!1F70,**
MF)Z_=UHI?890U?+!?Z8\:/RV2%'BN]$Y7(!A(T0C-MB36&\CB2U6I:BV/&AT
MZ;B;L7=1! $TH%IT*R'%1_YVRT?RXU_*"CSB84UG.:L--^V,C("C]AZ/4@-5
M2PT[<_35ZF*O998'(680KQ:/8G6_\9^)&NLKKQ$-RC70+-M-69"NINMN?\?Y
ME_3P$]/E^I6@/04<=<@=O:+ACT:3G=3ARK,'!:FE6PP*R/!Y%G2/?;(HH\\K
MGN^U-\[Q26$<+WLV233Y6,5M/-JY9=JT-32D[GWR795T9_;WQ-=_N?%Q>H,L
MIDCGQ_RH ![QHF.OV(\L#_,1WI;R\J$W_N.'=U_MR=PF"\41K_[:EV&6D\5'
MOFZRRH?#:N8D2E)2A#!HBJY_Y .?W>(I7-^4QCK19)B'A5 FI<%=K/FH+%^;
M.C"U['WR#Q<1[./[Z:*_W-<*)2!NZ[D2/[LY!+A*86& $5U;?]';%O'0P+GJ
M8=/R,YJ2A.'6YI+/:ZT"^69[[C-##IFZZ)WBGU$+)KZVE%H;;UOOFD+9WN#<
M>M0@>C@[N1Z<BA(.4#&:X=B,/CK=U<5IG7:;D2@>N!?EV#YC]<-1.>S*<7[.
M+ZM4\-EA@%=+Z$^\4W2PMPJL/?FMX*;P#_$%07QG"32R=#\-N267.*<KMG9T
M"UJ$S)*14>:,%B2=]*9M#M5YX@A#M+0&!BAPSJF_"UY,-9_=;L$ *1K?V/AR
MJRD$!96KM]]!R>H7DPA/MTBU$%!4I$#]1J?2HD5YR\X)LR^Z6E(#34-^R.7_
M[FB@HB-PSO!\J!U=&H"JTL_$ 'N'I[0BB#:T]#G_^0(JIP@)K]XI<43O%9Y;
M]'FA*2PF"(/\,[)Y6:_5S=]MFS)B3CGZ-DNM8WP4MO M!S1:OJR2G_LJ=4%\
MGZ:VI5OT*M*F6$?L9EFY[CTT*Q4UK'F,!S$+E\J"B]@K<&F\U/I",>\R9'-C
MT7<K:!U;(PF,=/PH+:#L<#7;IDXW."SM9U #$H(87&FLJHF/R7"R?=#P_&TZ
M=D2?BBQ6N46#O;U\ IS? [6[]'/9D[=*&I['L1C>+1GP(*YUOCK3,MVWE99M
MS%'@3A/MW<AN1 [O9IU*,JBIVL:2'>ZH,>0AA=C4?(]G.L'8IU#=:EF[FZC/
MB&Z403$O9;2_)?=(_K"+$JJ@^3:I6Z@ 660\R1PZ"X[G=6M"NK3!0<5\:QJ$
MB_89=JT0=*)F+(IQ=#NO1MIY_N<HUW?;&-TMH3T!ZI4LVN@UVCM#I1!PTU,:
MFZWMTIMXLO=,IXL9_' F:6HM.T3)T0OPZ&X5CX*X,9SA.ZK8B29JDRK> QXO
M=S4R3#WJ:+SISNYO C+=[^N9J:D7#O+'<VV%>>8^%2.V?*;TGQ'GVCT"R$1>
M+H8<\[5ZJ".2,B!?N3Y83X"*7DYN?^*Y/<O:AT4Z,35MX!+58.X\/WE87I-T
M/Y)5!OOZ=A:=]Y3*N\70.D/-E6BTI"V.+O+;WNCZ;$N\HQWHQ)0^NLEW^/;-
M C B/R[+S(#2UHJ:16+*VGD!*,2^@B2^YJ1-$+#0%2R8/N:AP/'I!WJ+/HA"
M8%LGQ+-TY?1=,$ZP*(.!MH%+I!8G/;BJ1B::TD3W[<.W-U;V<GSTCZIT4N[8
M3@_I'(I8-L?H<\7L"8436L38B07Q:T])'O=!$W!.-6$HA=V[I8\#SQ-R7 PV
MVUODID_0;P) TW2O(#=[V3-JOR-]DV<D:0,<XWO\!R(\VQE59SFB&3V92CU<
M>641RZCU'.+G1S]_$HA]"KNZ,I.*+Z4\'LN[1&$3'F<Y+'I#.[>.J;;"N,/_
MYY;H^T)0%]_2X3H(FW.4ZX[^Y*.&^)];M.D/P5U\DP9(*W@*2L(0I5UI&0Z:
MSJ&]%\H >FYZ.F:*D!?;RRO@&X^*@]K=%/6- 7<=YLO#8[ZPHV1CR/MCJUYV
M D]6EM#1FRI]UA<Z]@?N%KG3=R]\[[*32-KQ8T/=P_MG7UN<GK"V'1=%K3K0
M'S>#$15U8^=17Z'&I&=D<4?.X\7YFPODL[V0:ZK(R>234Z?,2F*/HZW%;NEC
MJNVH V'HCV\P%%? 19>W@R+X,4!A/GIP?0B.XTV#^D[MW%_$ZSKUQJ[-P-#W
M1$W4S3XDOK2$PUXM)/7+3O8*[&K]PO%+#)!_$7YX=-M:8"<LFO7;TA@@.6C#
M$W>BRS#/<C0J?SP%CRK\*;FOIK UHEQSES_(AD]>IXL\)?K%M>C$AS_:C!D.
M\P07*+?*^_LB59(C]9X3>N=B ,0G"UR>I01ZI3&WA=-1#! 4R;#;UC3Y/>J6
MT?DS4?94!-C'&G7SM;.#LTODE%QR#^?C= O!'WTK\;NS=Y -I80?H).CIH^T
M.V&F?4[/VI;MH93RQ]%48:-4Y].\&;5]4LA%(PSPWE81ZURK>F7C^_=SRT;+
MM1ZY/CED]-R/0MTKU#]DJ;V,4SZ^8QBVOW&<3RB.9'6WS9-\7.!N<:0L\.;C
M70XF(6IO;\70EXUW8U;5L^4<:MZ9?JQZ\H@@0RF%]*#<&UL5Q?\]7"9>P/@A
M]TG",ZO8Q!B:DQ72;@^S$=X*QZ^. _@E\8G=>?6ON"7)=Y+2& WWTQ$!/J:^
M37C?D [-QY8.=C<B&*YXP'A 3L,K*0N\:I'9"OS):Y)#7P>'9_P7VDYQ=?D.
M\PH^,+0:/MZ[H>>97 #V8JIA;Z&,6D^Z7UT7JX3NBY?NCD&A<I^LT#D8B+M(
M+;06Z2H0!F[FPKWO'#M(+#B40:XPD/=EN():3CB8=A>"53)&L;4Z,4#?\Z0Z
MY*2<[_%$T<DUIVUFYWT1YA8Y/EM?44=?AP1RT[XT(!T#:)_,U 7LZH0RS[7[
M*((V'XJ':]P31Y?NMYC[(PVRDYCA^MZ2))JRW?_L16(N[;_>2 ]VF@I.[CCN
MG!XK+1D\TARJ)ZA?5!BJWY@&1]N_09,XS8LR.3DJ2[ZEF?_+D@JZ8^'@1:7A
M^HU1@W-@3/[//HY(PR6ZYDV[/BE+NN.$69GILX[6\*W\>A,LH6]R^0TCY&>O
M*$(T,\?B=#2EP*#T*,O>AO/E-4XU+JSD'X Z+JM]SLQ$>-S$6/^5AO8-/9'9
M9B52 _.]E[KKF3KFJEV.9@Q+GM4.NBTDB:K35Z-T>%+K=F<#G43N'>3T/.\R
M6O\VX/HHQ(\N[.G*5YIU_T XOFI3K))3^C25^9?'/%8:G2L"35>%-(Q)[%M'
M"T\RW*?J<RVU_>L];4N%?.WLU5@A034$B2Q7RS<O$O%BI4)Y 2?AUN!22IGH
M<>GA,"CU&(,D 9%%S]7$J"J39=@"OKO\\/8AE8A8B[.+@W"2RN/]Q ,Z[XXM
M95EXJ(G![?RZX_3U(/$[)^;C[\ZG#+-HV.F#! U_"F9,K5/!F8-F5<+.2UWQ
MF\T+B2@!3<&&%P^AE";E"SO$+C[#$[,6#ZP3=B2)L?$/?W2<4BY_S>B@V11U
MM7Z+[7-#@*'6:0+:/'O7O*S+]NY7XU ILCY)>S QSTG\HED62[:-'X7 9@_$
MMOET[,,TE7I]Y!SS]-.KW\Y) #!E3WE%_"!<*-A5GS5-**)_+ON(CY1D4%;K
M9MGT^#A_"YA<)*7\28%R^,.GWKN';1MJ5&U)3)#[)>4C>IO3C[EYS61I-S6=
M-W272$5[\5+T!R&].PTP?%N4LK5M=L92R6/]=^/7E_?%5'L!\O.+P9=U8V#5
M$]^=?*FE9^YV<I\0S@QX:+> 8-!#I\#L79YUYKK*9&/S=TD@Y'2/S3_MF\'Z
M&-/*B^KXY3>/ZC08O5=%KAFSJ7P:BAJ@;,TUO)Y::BS'DEI%X* JL4N;-]\5
MR#QHTU,2R3GVFK),&G6#<@H#^&4M*)WB@U#7@S' AWS1H-@;M=JLBO(2/3TZ
MK:+WQNCWG&@T7%-WR!M93_T RC8?5XY\AJ2[DP\4::@H&G#HAAU59>\;,4TZ
MFQR5+BC=1OKW6//I24R)Y5(S?PKVW8A^84G,:N1C%$]!*7C;7U/5)]WY>IPD
M+BL[G77YNW>6NZJM>.9'=MF^K<)-N&2H734.% 0>K'/SP9N1]#/AA..<UC"=
M=\X>+;(KS+4.CFIG N_8)Y0JISVX^QUA1)9DCT_]IGM*)]@Z+([VWEOY.(3X
M]LD=A+HWZO/'#0[)[JJ6)765]G3@L9VBVN/ 7URP>>2MN16P"TB^VN>'J'\Z
M(])C-+B-TKGE?D>WDH'\I.P[JKW'6"5QJH#L.'XH^QJ5+*2MS*7($HKGP1O3
M:WY<-8EGUK'!8$BZ;ZP_?/A%7NNS?+:!DN-"2G1'6_^[;WR.V7L<,CFJ7U9)
M"U)=8-J(3;^2ZA/K)OOVA^V>W^PO+N2!] ,3\])O0D*PH+J'E>_;SC/IL5]]
M3A&#"MLA->\)[^LI[NO*[76N/-ANCH1T?%W-(&\5NM>I$K/9/^A4J_2TZDPQ
MSI6CI/;FLR:(^!R:;V#*0VW7KYM6>03[5<C=,!(-<)@ BCTD->!&^3MO15FM
M1WM=C'LUQ3*#,BL/-NUEC_GJP6$H>8>TQQ&/,[5;TO9"])\;+AWT3J%+>P<4
M6D3Z/\6/QS]Y7)WMXGF\%:_745XQH>G98D-8?)6]#%$6GNOQ?%1'=81//('I
M>:6?_0_JN6L_"@3RK$'-$[U>19S17^6MBJBK,F\PKTI*P"=JG#F)92=T:$=V
MX^$LPJ2DWU_1R@Z]ZF.V=NGUA?=8-BFNR->:J:-11M>E4/AJ(Q?NZ20J9<_T
M.-&1JS(8<?4[DC[-_,+YTKY6+ELSWJ/K678=,A3^Y>GZ#%Q/(3IOUL.2VH*$
M/YN\ >6@5;42>!A.+,R5,T,5=>,>^%V@%W3Z:A%+'@E]F92-O7OQK ?#W(8!
M4FKKD M_XS0T\?BVSSJC='!WFZ!*;:@NHMZO1I,PD$QC]W$QS4\_BM=!CQF-
M_6^V M2:[]?T[XWR*LR.5X6V%-IH&4(_G4O+#53M'@<5T#WLR=>S>NUS^SWS
M[@M\A\Z02;=M1ZD28FTK6X]7(\G#PF\*)V5 FQ$WIKU73SI  :2QAKO\+560
MR(F6[)A0,@L*0TUCD KW171DE#5YT!RI*"NRQFZLR,;&I4->%6EOKZV[SE%'
MCRP;-5\*UD[P6.2)E?"43GXE=GI+X^%H*>FH8GZL8NRRTL-N+];I#:]':BS?
ME(/&B9>8JY],2\,U@TH51.79OT@^)TZ1O=KH52$B+H!^F;N%UW*ZX]_$&?M5
M]I:5_<!MBINGU N(W">L]E(7<7W)?6K]T""0EFUD2WMB0945+X2[,2@AH!(+
MG&>/Z.&HZ>#E%K9/F<H/N*;TE;>3]6M&ZE-[6XW>WDEX0?!6,A'^<SG@A_EK
MJ=?(!5AKX6']G0U]^@@#]?J8.:[I9WZ2IRP_4);T07)$BFOXO0I:A7D%-RVM
MYW?N_%P7^Q+1CNT[0G@+S-:2FIV3PZU:7"52 )]2%9O@"N;-OK[ZX:KQBQ^F
MRU*+1.&[!;RC'M9PKMOC>"*J*I;!;^>/7&42PV!.DAI1+4^F)N@&,H89(2)B
M5Z^KTP'V@JUN9Z.2IHHPMI(J2K7L[AW:%)U3KE"/9_.3CTL&2^^6>R=6*K%2
MV[3R[&.MLE_]K7<^P0-3N00K#1?P4>E)=U77T/71^?/4TPBP>R-Q^_]*N%0D
M=%3)YBM^[ 2]NS%Q\$9$22W)Y?3$%;?^N'-.@X]$G3'F0\SD2'P\UX=#*.%S
MX\&"I3*.XVA%];IO+GS]?;L&K7<D#"DCVR)\!GYXH5WRV2X"</F[(-5(C><Q
MR^OPH_EMSLQ(\\2E](C@1Z*+HYD!\%J')K_ZHM*;=%*"9D@CYC'S]KY:0V6U
M08ON3Q/.TL;.NTHMQQ]YF57WHOUO^M]7@5(;>9+&SHLPV1*[U'4.=,DN=],Z
M&T:5V#?#,BVOE_"&VJKTVTQLR%=9NH[CDJEC;VV$B1]D+\KR77M3.6G>,75(
M&)I$)^TN<G6Z8:\/)D 3]C#M!-99XYFK/S.UKEDTH_]\2%=N,DEJO35G,(M
MYFM8^LGBXH58,C/Y9ZNU2_NW4L@OZUB^6ZM*)348&.JV#EQOM:LP%$!96OR^
M(,K[K:]\#JWU\S+3T/Z+['SN(JDWED:Q4A6<XEUT1PRPF3/%DH?^KEH9,+)V
M) Q&DX2.G5\+1V-!C]2@C1%5%^G[=PSPPQ;=6=L8)/I=M0*B#S-LP@#_1[ZT
M#5*A2[I+NDNZ2SI>%$F%IMJ3.HHJPF(G#-"6/8M(MZE??0!%4&& H@*3WQ87
M.VU1G#]T@X037H@%A@N@N"$&\)H]CP;]&?QM:GBNVC9(,^LG @,@5?@-#NZ"
MD?@88%P9 ^!*;:!]VC# E?HSMF-<EDO"2\)+PDO"2\)_-T(",':^&.-Z&Q;Z
MR\47DDC6M^L43AZ^_><)OQ#:)IP_AVW#EI2UH&V)4+G?!J26_Q[#Y27=)=T_
MD$Y!R2>6F'-Q9$]$LOSBHS[<<^U4W9(0>80!O"E_^U$K]-_(HTNZ2[I_4D\J
M_[4G/3'2@1ZI;ZNK*F& <$/TR>^\EO\*AWE)=TGWKTLWC&2UH^M</Z%H0[G_
MVHDTFL[E,4"=V6]2D.)?7JQ>$EX27A)>$OXW(72#^?$.I:T.F/<P?QYM_QXS
M&;(P46Z1D87RT,4 ]<I/BN-+XMYFW!!J^:4*07?__U9*(&/E=-+V=)5M6JT&
M ^A88P"]:W__Q=?_'^QJ[NSNN>V!1:GZ[Q7K_ZXU$_Z>9C2[;H0!'#$ 6U 7
M6GCA5*WXS^I9B-W]>^_PV7^4A!F)^H_V/V -^\N:+Y<U7_XA]GN)](]ER-!Y
MEU<O9U^\ZFJ@E8"A%)SV?ZN>GDUU7'#(M_KJ;6&S@\.L/.T[,)DJ85=[3/GL
MHOL*ZD$!+K1?LAY!JX1F"D=JZ9-<"-M@Z)SP!84+P3J_9LIY[+-J%+A]O[XT
MY\@@_"3I' /@L3?"#HAL43A1&" P#7U7TP^\2C^+)&3& '?TL:I"AZ'&_=L8
M@'"/<,OB/'8!;5H/;>Q$9)UCZUQ$WD4, /]EQ;;H>:73&^5HK(Y?WJ/SVDYS
M HT["M4WH7S/M.N-D1@@;F<6453#>A&4[U[H;%<P,AX\;^RBBO;AN(C1>]!=
MOCFAK]/21WH$.Q=AG@X]6C#N"5YV/_Z_.:3\1W_ E^Y<NG/ISI^ZLX:,GM<%
M(3__D7CX+HRHAHN$RN#%*WOHTOM?7%+\=W/IO]D_=.G./\N=J4&^6B']$OXG
MUIU]E&6C<SY94[22'EU5I34B</99_'5+5Q.48R2]IQ99/P8(-=5D#V _LI[M
M'HRQ5HUSE\A;A+!*&KM F^^*,@P1'W6<IX? XA\?@%?B1PJ(E>T\BJ:.&>[?
M[Z'Q"6))?_&GM:?5%<!HD?"SY;R1/S:\./[&4M;_FZGK$!YRH4]R?I]UNCI"
MHBQV[5_!U$HNLI9@V/'Z]&^MU:O3?Q7X>YJE\YN&3,9S_.610K\%PCOB\X1X
M^AO.1">ITU+MY=;[U(G7>@D+LO)LQOI@);:!Y0J92 N<>9R)?$"D]RG6 54X
MG 7+LA%:@JU_;U<D+,(YA2/$V=[U*;3,=J+9(XT*1]5[K-9=P4,D%^FLBLAU
MXT MMHZ-=KACL30HNH"4O:!$!J]=V)L?(;,:3FT*W]LD$2U?07$3D'MB4P*S
MJ34+<.<6"D_:J35$6WK&\<3 YYC$MG)LPNW$PWPNC?-TP[#!87-M^B['779=
MWKT(:AMIMF1 AX:G!7"?5AXY_,(O/I1>/V+[NJ14L4CN)\4!3<<1]5@L2A2Y
M9 WOL>"@4AOR\UM$B3^PMPF3PA)2%&-S6<BW_'2>(OQJ?[K@?5WSMX_"SE#S
M?<$W+T*K[=!CND?)A*8(YY"2'2KS,<U3[>=E_;I\%>9JK!Z \Y6?#K/Q<QX*
MNRTHH057U!-AT?*KK(-<X*T$AVKJK9\0B*4WDFN75N\J?*PQ.).QXZN!#?_U
M-QG\@.@V@>=.GK7+6&L2=2$RSBEKVH5,J;9:_O-(@5%BP)MW\]_+RP^2"9.'
MMU_,I/&6# M*TAF&?5H']@H^P,AG?W@R*-QWY*O%O]JSG%# E2UL^/K@,%\>
M36FB=$HRA &NXUSTL#'^LV?0#LE@=(TAVEH_>IX=Y!<^=TY12HHHF%3X) 45
ME<%..,*?+')(7!%,)C#]BQ_GN!2W!C317L, [Z.MKG5,WH$D=A7O+" +W4P'
MB](&T40];)(D^D2NU'[J6G3W U>!/J8<E$WH/:2".[5<-J4PV[<T +_)6XR:
M'\7;#3M@S4+?(L0 5#D:!B6U:=W!D/G E ^PN/D:XMLBGU(QP).F<UB-8.K&
M5@$&L%Q[%SLCX]MU)B%^9.IIEQ3W Y53A_1&.#1I!_CO<)9 'M. E<L#,P+S
M]KZ=2<E%K[7W ,YHZEW.:'@MO8B23.6=R7)L1R.;]:;O^7?@_*UD"(+ZNS%5
ME+,WZ8A/_#>Z6F7)6YO6]-41A 8P^=V5HV>"9Z(I5/?"A5V#N D7\17.)#!
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M33B06_E-B;>Z'R83&!R9GLTPGEZ<ORVY8P5]-5_)NOBG5^_7A#2?7F,<:\<
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M6 'I&N$[H1\3+'?T =;A59T[O#(?5HG!9"X:40 ;!!&/7]UW0^Z< 7QNA%$
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M5WIJDI>LRI&9,1U#5>GGO&B.(EBUX.K](2^7IX;SQF;8E2#GG==AI,/0K^'
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MYPX,APJNOB$-U+S+?(\MTVX0JCGKO+%FVDLS(Y# <[NVVHG7OE *H"SL0J8
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M^OD%BAYK'NQI,.-->-3Y97RBZ?=!%9V>;]<'0'L2E>R.I]+V)B8$YE0M=MB
MO#TM1.O*$PI@.DVV,T:<4#Q'5&V$0R1&1?5[AX0&3U3AF-:DQ/GH/K',:7A_
MW<^NQ6TK48#"QQ1 ,I\"0/R/S6%$\ ;1Y5YYMJ?:G1Z,<IR1BBK\<NFE0%H:
MK<XD!8@YD $<Q/ A>Y%C3/W=T'.6+YVZ3VL*<(;DX.#*)-X>D1)D,)LD:E+L
MNMZT8.,1U:J+A]W'P[_\4HJM%CPGW34F:[9 KZ[*7?V<T9!S*Q<@RZ"O@T"@
M;, WAY!9US$!82A$O\W4R(%_3!![[246?2W2=1.Z;SLKJ6#7!&,@W7IKW![F
MR,I7&G3JGCKXZVR/?!$%6#3J1K(LIU<0C5"L&4:7>#59^5;*-EFYB +K:/[]
MU\)W$YN]48U-J M2^7R/94S++Y." )_99R1)JPG1D]_GME2GGBAZM(K)['WU
M^UR #%,\'MA"ID]M"C(95$[HOD42 :OX052)7'V#1G$D9P(%(/$E0[:8D"*2
M"LI'W6]]U=T06!@%E_GE@F;$W3P<[1531?A-/)Y+/ _981W@/BU[6@PAN_MN
MO/9))AX==)H\H;_@'5?P0=HLK$\7FOYY6[%OW:PVL/1=[5%38H;0_2'[Z@8!
MQTF9A3H/7:=CFS#C+6P \I3BL T%.)J0+>7 ?;-?I'6U13:GUWUK5Q?\L<M<
MD]"J0E LIPZ5EW;TN!3V5GP_5;OBD_;'*6^VM7::>NCI- )MBO W9'[!,3?Z
MJ\:^ >GU,CN5]P,4MD2#4FG+!S+ZQ[M]:U1DJ@F"%<^?[C_6+X)F>[4N'\&9
M4/?<QV=G%@SX/VY_K#]U!;@,WXYV65(LK2'X3.:0> VQ@\FJ[^S$-1*?NVQ9
M*E" ,84:V5VC%%]AXBT/G%8]>I%L.Z]X#_'ZS;9]JA=YQ3MUO\8:U.E_Q,9(
M5J#19-_0\XO"5(PST\I<7H#SBC+LNE&<[]E0<]+='G-X"KV6@,*W?@K MOO-
M3I "?,@J*H_BB_E\B5>P3J\<H(*?\15ZXXJ-9+/M6'OHQ2M747^^SK^$:AY>
MDEW)*:I2,;Q>\.&MW_O2/'RT7)35N-],$MTM\3/MU2;1U":7/V]\+H@9,ERY
M="_=F)KK7MR=HQW*00 %D%T@@^[4E#>RW^&PZ$C6!!130J%? N1Q1L0SD&<8
M3CO9?K2WR.;E]%LGG!ZHT8FDO4Z]/9Y:YV. _9Y)AI'4#A9=&MG1/)T02-94
MKSWX=(L"J)_Q0BQU40 HF?=@F>DBI-,@::+V%IBBBI)7#\_AK%][![/ OF'N
M$&%^ B$8T2B9,/T*&WM.GP</8O;!F^AW=E-O#K,JPM2FG-\8JB@BI3?2(*C<
M/]Q]]=_#A^3.]WN7/NN7#2KQD"H^^4&-^],]P]RTH^/EP?UC<CZ><8(6NGD<
MMHSZM %4G?HO_O_/!CGQ _,6SM5&_OC+,>T6PU\L#>(6?+.#3"@<@=Z*8.VT
M9- SRSGU1X?T_CV7D0=^?6)I['PE<WGZ9/=]QZ1*UE RX]:FA*\"T0<67ABT
MO%!M?%U[75KU$K0!,_86$U):^O1+OY"==9P@KVYNZ$6&X]-H>.)H]*S!<8ZQ
MC3*FH2$:H=LH5,;5M#"5+.N+#+0-V1GAZQU*OY-*;Y$4@*MU?]UPX2?UM\77
MWR4C42&[B;]@V^3_P)^1H++])X"V_.U#5F-$:W/'WJ;##V+C;Y_C_N48!-6G
MU;%9AMWLU/T5G>=2M4DF!7 D:AAV!QQ909GQ=6P37OZ"WP.'D3O88GNJ[?-L
MZ ]%>3B^OEB/97<E)=6>WWU83=^, 0V09 @/>YK]F7O.5I<E.)9H<_!;LA!X
MU[PO\L>@2P$[7V<\+)0$=\O$!.6PEY9K'L[29K/GC_2;89T?JM()2CZ;.8$-
M\79(S!_>3]VB%TUBVK3_&!LZK<EY=-7L:=RGK*?'6.N7M7Y=%1SE3?9G]\R(
MB'?SR8^X_*:;;(LT*D0F.75N*LV=]!JHAU 14QID^_.<"^>#N\^E78F*[,),
M'A-8*4([9 3P5"7<OC"30.->D<3W\*K!TR066@;ZNHX;=C/"6A-638XLGO6;
MG([7]\3&;ISH*?UZG2=F$,P?</D0)C,C0*Q 7NZMS1A;3"/!A*<G#L+=U,C3
M&\FQ&__-OW0].AOOTLH%)02.>MYO7A%>SCG]?035=-6Y]Q#KDT]SGO7HW+FT
MXVQGVO?'(FP4\QX\0@]=FAU>-1K<Q^L_U\ 9A=7QGT!>,Q8$32V[3!@UO7$Q
MK>E=<67V*GQKPY)2(9>*]$^"-F##WS<5->>8\]M>S*^,5*):DO^RVQT.K$,"
MN3@)&B$E-3=@](T2-]O$2GA-@A*%RI&5K8Q-I.M$291TZ P!',2WGN E/_N$
M_QC_32O^PJN?.N0YPG>9PH&=^VT'S]1A7;S8-@DK53U*Q;6RZ[24*W=^"CDE
M-/^&_5I9YX:/MDB[^_!04U':UB'TP2"@FZ)X]\R)/@>#\.#W@\ !&JN /<&
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MKP-O8@[V]99:81I_3 6S-S)":S M2NL^<Y$\A;A8KG<E2$JK6[G6(U>8F7Q
M DM]RH[&%J -)E3'K=OJGU>%]>/&>1O+%RL)I3V>+]UD[F*5Y3&=[9W6M^TT
M85=[>-=\0_9G<(J[)NO@=>CZ&GR="-SJW*XI"C-%CDS[R"B@M#;J,K#51K4E
M4:KV4BK8BDT:_M$:H[E\JN^WK>20;WYLP[_X79WB0=P]465 $P%RL<^]!%$;
M_1=TC\=X%'NR8 4S:-X O #A>C%6.<3S[KX'S"7PVP<RO3/[@&=;2JTEJ3 1
ML)RB-3]KJ1\YUD$$]!_X'SJ=V-3WUUVR=)\)V*Q1S*[Y-J&?9I4^\>Z";Q)M
MD@6VX&(S%PN!LS/3T"K72A8/90DW5=/,'2#=HHW\<3K-6[ H3.'\Q,[*NWQ+
MDVR3\?Y TK9,!.C$:B%S'$0@[&I9E0V;[R65#[<2)  RI=<3PW7O(UM9E?%7
MA'!QF_"BE>WFJV3>Y*#4AE6O0-A6$+?",=3FQB,7M+=PVQ0#>(/VJ\1^77BZ
MV->X&UEN&7='> &"00YI.F(_%+-J&.NO.IA5_B3H$V5]%CP'J8")/UT!6*T6
MMU0J;SYY]SS*]KWH)B0'73/R /<=,Z#4E][_:G=BH>3^J.8X;T_;U3H[U2U#
MJ$_-W<_C^-?*F-[$&>5!PY9YE31OS(H/E*22GF336!+W[C..0F#B<7G5IXV'
M]]PHLYGW.A@&1HVRTK(GC)M93"O>F6M.R3\C[UEZ6HJ@MJR[3$MMHEY6>^&]
MZ4[4[<DC[0]";?9G'>[Y7@F_=X6O09,,H >.#CWF...OE6+C9*4NOK,31-\_
MP@_M47L>H#'@#>$T_P'G>D+ +]Y!A/-B'2:P.UR:"Z*>X),_R.T8V>!_./((
M:](,P41XR@X6T.Y/:B L@CE<)5BX[L;@=!*7X=B[WKT'[H[>FVTZW3T*BV_J
M<;@K2+Q!')0!?Q\SX[<Q^H&.8E.X6\2=0,FVDPJ^C;/]W).)U\'L2I#2J=#9
M5BRSJ')E@>>,Y^9L';^/PR.<;&1M%-]O:<7;CQ6<N4Z+'V6/6=LP9%A_-$$8
M<!%J3C.-_*'U:/1L P.D9>90((7A="C#CT1\9)'-G)<'9(0S.W-71_C/E7@=
MQ<GZ12S6U$'&19O"W8IV\Q4%'2,AE%#TZ6 )Q/:[E2(X8:Y-<L\-7,=_IF+T
M)NS@ 'C)> @4N&O@1>)T?R"?"!0W>^N];27GYH#6UP*G/\Z_-Z)]DNIL<'S]
M?MD(!7?KK.FE'&0Z_Q)7$*N8-Q=N)W?ET<4%@Z\_/JYGFH';0XZD?"3MWY;I
M#V?/>BDUR:N/'-S@-ID^V_A>X@U\K,N1"%#)L>GA3!NQ<OE9\LZYG>)-#QCO
M^?.< T6' ; ]I&J!3IN<;+\GU6>V3RMGXS7 8QN:^&W$LJPZ &MKG>+5P)2'
M[7(\D;]?/,@KR!,]$5YA;CZ.XZ#H.$)7]T1,7ZKHK^.X6B/P O$X]ID#^+*#
M7O!*9&O%S!G8$WW<QSG:.3C]=2,Y25*#YJ8SZMD+6ER3'#WP[M)Z*XZ9T2.F
M ^_!PZ.-5)IR5+Q/B1%W0Z('--N@Q]7+KGA25>!YJ#T+5<\S<F:D9$5),"IR
M@R2[+0L9FV7]G/0>^$<>-P/W,K,=5Z!'MV\D3EFLMMYU/=J4:Y,2LQ5N(M%B
M3_D%_K49?B01 BS+\>*8FHUO8Z=#0DGL:;X763A_O&M8OL5F)>N"KF6H84$5
M9R0++)?=ZWS9<ZN#'6QX=#R\ 4.V@$,VS>$4./G:X5S);?,*_\51Z+F+' 8S
MY2.I9%P-^[82:/@[)QL*8Z/KC$;9+LH=?$_M'?V4YPS&B4!3OGW+#,N+0><\
MJ&B3T"SOUH?P+Q_'=22;(":F1DR-T&#EAB.!>*8) YU:H,<_FFZ/'+QS<*23
M+IWYNKC]^R.E7^X9\NPC;SW94,G*3:ZW=1+-DV[G4CWO%U>@ 4T_F6!8Y"JV
MW1@8M1E^^'/?H>-B6TQCL1V(=)+D4,OD[0SMEJ<M_'0:U?'+>+_ :W\3C88<
M6DM_2>E8G2(D>RFCVGQG,;Q!= U2G6[7=^RR.%BPO1XT_MB]5)JZOV*V6TJD
M,]S"O'S#U<%@\[CNE:_H;D=N!R4%#R#),])Y4+Z-U\=-V%H7=&5^OZX[Z+3-
M/8_ T7+A,*G@;'QS@_0(*,IQ.%)$%&]S.-*#*(D1D_#FTAW]\O8S,XACN ).
MC;^*M0]QHO*RT(@;62_>'.6I,+>/#4D17J4&O#Q4NO,.$L"YR# [:%@=,RR0
M.\[F$U5)4XZ>A/*-I6WS.\LV4S+JGT^1\R1.S31?KVUAM:_Y9:#FWNOFZ!.*
M)Y&G 'W8G_]\[ED/5OU#G=GR"#-,?2A-3,Z/SN<Y=][5-!&^&(>XK:0$8W:1
MQKB!.5^4"45I>&;%8.FE%Y%6"]P$7H+_VH8\YP>>>PX<CGNI*@&S4DMK)N*>
MY)C[5=.%TSR#"J7A,;:^ADEJMY 5)DN[7[E".<'5F%NA@5/^G9S)3@2OC#RN
M*2')ZPA-=X\7/G*E61\OL#-I>G6Y1?AC71KG4&9UW+5.QU[OR5_ZW[DE)V<(
M5EK;Z/D,,PEPLC5 !S>3'3_=_A#WY+67$,_9A]N@-%G0Z9+H(]>\IJAH8\N0
MG'F[\)+*<_FW&:G ,\HX'TI%YU<;SQP<'-QU.A$7:UR1L/+6'9B]<L5'@8R*
M8QXA>=S.Y&T)X:V8@4*&2#0TF""*<[2RS>^"Y81?,I'J1H7>/Y&W Z6M) )'
MVR$[,_X$\2ILMO_/*E]JN,6M:-$(F6X2ZH@QT Y9C06:-WQOA@,V52.;,:E2
MQO_Z="&_XI6NO:SW=FWRF!(X2M;3-5?A'F35/S5Q'A5BLQNIW?OU;LGD\I@(
MGQ>)#[D[I7M!=+?%B_8UEO(L[K&G*;NU[@29[KNY+LC-F08B< /8&(NE+[X
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M^67L3?_7(@IDY5F= F$,M#?G7KYP!TCF1Q+@37=@!@2_\9X3?"@1>)M7!6F
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MN-5"!5AT''_\B4W+=:=BVV.DE]&;H^S3=^UIKD'3'5M">]1#WY!Y0#I"^0&
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M7'3>+M]L'>8?P2#?RT S8''\!O87<.\LP+DJZ-L5O#]M4^E49$%7ZF)P3$2
M)T.="!04PY=;4VFR6U*$^F58/GO5:R=\*9I@MQ39EDAEF-\X?C :FG0KF%>(
M", F?6;BQOMPM9B)%LX[PQMV)1VO"&VV9"T1>@_*UM]K""E:JF&*&Q-O-4F_
M+164&MEPT!/M@BEW\U E!:V-E +.T^>QB^%SR;*;8ATLYJ%G;-S(.$7@"0<Y
MGJ^Q8"7,U4S[G.).1Z%K_)9U.^ GR[)K#01 MA&O:E;.TSC\WBVC2%,'M(-4
MP05C'!]CD2'=A54_54DHF,MAW8_(1/T1N2OR+&6(DI3DJ[T&2/"D(@G$B_>\
M_-&SE[61]T?$?O&M":VZFS?VV C]*-Q8)5^W^4X0LB20]M9<ML]>>:2;57S^
MBX]!E%D#R#5!>6^QBFOL!]LHGC>G0Z2BY/V:D-VR1B]SI#6P[_[_(_\ 9&SF
MG[D/GOS.?? XZL_<!VOF=I-$X-;@MJB6-Q2Q?/-/Z?UKO4W;_[%)!_X*/WJC
MTE=5):S])$KYT:.78?V+-$_&O;GP\D:*IOW.5O>F?,NN)Q"!K_MR>ROBVV_:
MVU&Q(8629UV0%C@O+(7SU4C5H<]4+F2C+TT)Q:/'1$ *BTV0]MY.F7JT/EL4
M?S*E?B3:GY,>LMWS] ^?H?]!^0M]AEC$^B:^\^S<4<EXO-F6"I@EXK*;ZRX%
MM\ OW!2WO3MOP!]:5&W9R0/X )QII],^MJEY9I0+G%WV;G_*VG;?[/L\KPXD
MG@MS8QOL/W/^J^=KQ@R/O(_#W5-Q?#59$Y5'Y7)-7,F $:YH#@G"-35)>95%
MW=3>;Y2_# :TMMN_L_1\(VC5'DO"$/PYN)>N*X18.XJ-OH83,-HF"U*\Y%]T
ML!5\4H8D[]^TJV/SA(9_%F#3J!%6CYR+O&/?I:&,DN>,/'YPBJNA=T\?300N
M;(3XC@ M]^&EBFM3&BDV[9MJ^A_XOF-[2]7SBL10>8-#S)7)FR/Q&C5[W+9(
MH<P%%:0.3OET42B_=_KO(")P3XQDQ[DTR1W21O[*EJS=MG0O2$B:[Y,=Y,;>
MUC@_M-@$-&X2:ADX8<)C>^=134';G%P2Y?:GF<,[UR'K9EQ'CXP[CQ7T.R%-
M.>;A5 ),V)H ..7&:\3/R&X?48A%+9=Z%<:K9:\EO*;\M?5Y[H]SY^+)$[[C
M;3H)5XE ATT]$4".UK\?4<:8H+7*@U#!31=U5042@]*KK]$!%V%:\Z8IRFN&
M2\WUAX*G.&+OF&E;'SCB1DN$FV.X @7W+&WI5J91ET;7Y5FT)>=.QK<1."MU
M!8(/8_T!-F_*.9Q4#7OM(T/<K]PF5=_:N:/,R  ?^!4;$($!XDL$EHU+?FTY
MD2[6AT;RU-,Y7U\PRC(+TI1-O'JEKKPW.V*MZ<@),_?C_?AMHUJAISH1GDXX
M1\><%GNT(.MH^WX?N=VS,/,0<%6#:YO"1LB<# 6V7A,3%)$H2T@1I]*5TX6[
M%?7"7>](TI/L9A6AJ7F;L HW\^$,F8ZJ"ZW]262O+.B+I\=GEN.?C$TVO:8(
MQ/)HL$!_>(0<WFJ=EARNX[.)*VQ[V<G*$5?FL! !?>RE.H>P/KK5D$(')\/?
MEG)NI9YKXAGA80]?KX60^.(T0=U$@!PR7W!JA>T-0T](\M9OX/P;O:_(7<0&
M9I4)$OKV]=@/#<HVV[F1<\;9.=[]4@%E$7&L/$(:350\[YFHMB+X2 -Q96N.
MV"=Z%SS;NFEGX3  O&9B.#ZA?//3RWC:S$#N>Q(%#A/N(YWP\S4,7W!SK:_7
M],,>G_A)U@W(-H?(?RR.2CU8RO=Z!@" T#D !MT0;/V$FCE:@VP_6)<[=_JZ
M^0;@:U]GCH3S(D].)Y1YMM.+&__F8@YI;X'=L^+2N,7%IR'D'XK;ETCD-VT6
MMD*XZ&_)O,ZA!MW3@W]K_J2ER7$@F$(C*WO."5+"%6YW;MV8OOA#YHU0P>D!
MO_GMO-TV2+A;M@_>PG;VTZ$X:?IW. P6HIH0R>?:L'>0"D[UIL'?@9-9B9BL
MWH"4(NGMC>L>N)@@\]V]8%L^<N)&N)X6A^7^%:&)S+==B]SOE?@C<+W3-S!+
MX4J?R=(\3F*E!<IPT6&6<RR/I6B4H0\ .6X\T^ K6V<3>N4O;2[3-H;JH ]/
M WF+.KI%C5P;$)P]2-TNU-IHNMXK4VK29E\%Y8&S-',CTQ4S#)XP6_CW-\L8
MJY=4G0G-CC_-?OC.6+:Y3YVD>%[UL-B?H9V^UZ<H\X+MV=RYH#==NRN'FJ#:
MOV;XC[$'E@W].;OI.%3Z9:'-6FBL!=^W@-&,RMF]5/"]]$(\-]K&G@EF/:!7
M"A6T #F9?S-]YG!7/-?+>9^?*C2]NEFX>*-;U#<1*%*$'0009/5P\<W#^C)5
MHF,GN?C2CP6DP%30[8CLD'U6@*_@"1H4(5AS#K4WN%0F<8NGD]XA>%PW*:8;
M+$^MC7/$DLA=6BF/?Y==&C_VF3;6RG6SO=N=$MC@0\I]PZ5Q++5<][QX$K>Z
MW%UOO?.-9O3@9-*;PZ;7\C>/O1_8FR4RTJA:!5W+\^ANQ@^M;';K-!\WY%E+
M=.)@5'/JV>$U*E6B5E!3GFC1UHT[7BUN$V$T8Y! ]V2 7H<"RX4V0C:-OO+L
MO%:;LO'IE=JUKB^U&@X>T?K3Y[!O8"--M&NJEL-I\V;;H5NM,YZ4P(HEDFZP
MWO)^X;!]R3QF<$#\Z_8]/3NY_6'^)-NYS_(0*W+3YTLX[06FD0WNHWS XS-#
M&XP?;>P[%VNY>VC,UFQT"E";3 ?=0U8W-V>+BA,W5[5"INEO\40X,,AW7/.Y
MEEZC]O0D[;+'02EFT_=USCF9!\WATRAY7GHK1 G/=<^XNLN]-\4P;1_I8\HG
M<X$Y;"K8-CWU6TW9X*NTFN*/U\H_DK9=80\"U4+_IANZ)KPJ</=?4<%'K;_'
M;\5?/UDC C4V YW)E74FN8LO'^#K(;V&?8F1ITA2SK1S@:>+)6?G%PY[_/!/
MPE/X]?^RJ#\S+(*#.8\T2MDZ]$_79*M12\WB@W&RW#H?!$?9GG^,/.HQW<*O
M#?#/.T5'-V4P/'M#OF$\@ME"7UE5XXS.^\&X3EWXL^V=;&3]#I*?*;"\GG2X
M\05R\^'N.%]ZS5S??]^=].\7MK&S!@VAG?+4C/]N,F:'9),ZR>N>W3":<>4:
M_D4G/B]W!;8B0YKV/5?6WYC"XL*ZWFW3&QJ._BM/<!=;]^6D>\D^6Z8\_-+"
M6_YRLJ]\I(([J1?T2%'$2B;'+(9E]'/1FJ^A1%//.V'<T=R30+'AXMM7[PK>
M/#GD<3_OE$JS';)MSX*WC6R4XZ_LK2\TJX;=0PA;3%3? *MG#Q?V;+#G_DRY
M6*FUZ=T7>?+>1W8X9*>>S-,,LQ6Z1== \>K6S*:BY%G)7>U-^(W=!W\&S5\.
M1H;';<,.RF,$;O=>=N,Q;?0U5G ]EA]7=1.0X@W:VN/+D/F1S<)90?E:GK-+
MT>W 3^[FLK=HK91#B &UVONR'?:M-D,N$VL$6KD91N"\F_WCR,;XI"A97L_%
M=AQ4U*,/;.;D"!0H+H0Q779Y9ZHSD33'+:YC/*04G#IC'<3-5QKX6=@_?'0C
M$>A+KR "P=[24*[E<M807?&$($<*I1AO&$BR8>]K/:OGLU-KV--I*,1(^=&3
M8#]2G^#><IEC35#Z(V-QBV/YL<_KFFO>['4#5Z*P_!RCG!4W1(VKS3UL<\84
MW*Q$NNQ%@B,4983$2%Z$[( 9/6WZ92!Y93'9NH;6!^TN5?*C6O8/9^=/SBF@
MD!%2&LB\ML_61[;=X:Z7*5/<?KQW)VVXXB.K'2(5]@\9@G/>R[&QBNF=9^1&
MO@C5#+=K[**?RQ)+V_R-UO T*V^N;\>,,>8,R65H@J$"*6]N/B4?4."HA0$'
MBM?>4SM14RBIK(YA6XC6," EK4\MB @!&@9K+J+R7TSW4RLHEU6$=$-N3!G2
M<9O<[2G,-Y+6*.Y_=;FHL%S-0U=I%*T1(OMEB)ZD6\+'\\91Q]"$0HF4+V*#
MRW+<U>WC5#72<,<@/L[E*#"I+-XA<W@[5R>\58%T/#O=Y\XQ.+".>L"9;VO#
M2>4QFI=.Z8V*$NA22+77["W*5?V,5=<JCJ\C!=_'+9Y4%"Z['U,N+Z>>(C32
MU%_-<(G6O[U 30=G@:*V6RE .EFRNDI:7;QAL!:R9IEZGH/JNS<'9D!TA?4I
M8[]0DU18$5[=3DK@;?LLP[.[H(KL1_+LOCB]V1>J<JQ%'43 C B$JX*;(.<F
MVGF"F^)49N<O9.-M\M)]N(/(\]-TT\)-PY7.Y#0P7*77)-.H1(5?;"YJ3.S^
M=&ZU037L <6XAFADNU8RK\K KJRL@%BG[H8M-\_71Q$DO+Q[>26:(,DO.%!C
MU73:54)VVOB448?/=CN-!AD(_N!T4J%$-LSL"HR>SBZ\>)O"=!_)*=X&;\9>
MY/"Q6I^@K=T'!KI6&GE9C^'6M&R]U;(W>C,3RJ_M+S4I7VJ_DG_Z$$;UC?"S
MXU.A";ML7K,+"F:!<HW5//?_5WO?'=7TMN4?I$F-H'1(%$%](B)-4""A2!.1
MHABEJJ@T 9$6(20@ M(%%"YR(31!:D1*E!8D% &5*B@]";TFU!!(,GCON_-[
M,[_?K/5[[\Z=^V:&/SYKG7W.6?E^DW6R]SYG[_/9L4("NH4Q  Y _G]J'L,^
M02'CXP#>) <UO7LX(8:*Z^<3"GF#.C(7#6]F%C(\O.UW]PE-H8V,?7V> AO#
M1AD70#5#,0PIMR:& $*7C NIB!Y;/.(S&-:766XH/'Z GP.9V\5I2!:YGF+4
M[XMF'TM_VWS4^ !T]$H$Z]P9%/=&22!#GZ['J!MC G145[[4D6+E(?)#<"Q^
M]&&C'<@WP2]Q1#1H?W.03H&=7A!!HZC&#\C;[RY]9HE[PIRS)<#NQ>>\9_7'
MJF0D)&82RG9D'C<PW.);ZGN[UHTJ2_A;KSQYG&)>G",5*1G?, '[@N->8R$Z
MA(TJ]?J%'OUI5,')ZC;N=2EIW"S*,:4AI3IH(LW!\-Z]8>2"T_&U(Z]97U*_
M>RM$U3ZZ18@VH(^$E0]_,72L*.OLAC$!H!+,=RQ#O\2)49^T^^;%GA']/? 8
M^&JKR$7C##$"5OZ;D$S\!UU@2Q7JWMB6<"6:1C.C<P2?63/;.E^#ILVJ,9)>
MTJ3K_;NA$W-+J/G<,=IEMYF_$F D4=-W-\"=3=#UR>,KI6_?0R/'5B[MZ#$!
M]I:HDX M)WP>J7$5'MA,F<!O;$8V, &.MXY28- 706C>[F$=R>XSSA/F,_@L
MMCOB6T4ZY,T-)F!AK$"TU[<Y+DMVV-9[I=!CUXJ:P+*HK*V*"A^.?2VU5:F^
M &0+SC#660$V"1UBF1P3]KA+B8BOK HI=\K\OGA/2FG_[E8<?!\I- ]EP4VD
MV# ! TVX3[ T*LH@&1J"E*=(C<O[%T'&IPNLD&;$9MS)M?C@L163$B9@GN@P
M=8(UE*HO;D*I:=:] !.M5K^%WO*H7%YUZ8<)J%@.:L_@V0Y)1I$50IF %5O-
M7TG[YQWTNC@_H01V(!#A'=V>2CJ;J+L32E6Z<W^[P<0OE37FOR(5AC^CR \9
MRV;#W9V22NEUB.QVL]F!P?? P<O7&1\R=1*F57J4XJ@ 5EJ"?4FV; DFQ"=:
MR]*(#?6=C#^<'GR-_HU-LHLS'<']%2''&2I=81)]W3?T:-JKU,?E4JTN8HM8
M<(F?@X"F@!L)Q6WFQFM.?V^8ZJ)FBEF7>OJQ5,Z!CE9Q-[A7VZ4J=HIG9Q8\
M%N/T<^B 4.L<2(2*)O=P]A57&I\N/KR5J_C13C=N(>)G<\[R'47R:!$!RM&<
M,[=J>.K-IZFC8A_W/_#:2BYM>8<)AVB -,EMM<FR41LC.T7/[5-;](".=#Z_
MBO]T,I+_%]IP?6V,68;5BF;^)H9!P93^ECD$^YB(_B79@9<'J_9QE=*^@U/T
M-G#5ZO/ Z/VTNF6L_$O[1S'5_\6MBXDJ'J4Q>G_Y>+3L=;E]/IE$Z'"5%RXO
M;M+/U,@,B5#:1F^@TO4OECWQE)[M?CYY)P",7S2!?=54X*75LDLBRHS@2OF;
M3TM+$ZZ>##/?%Q(,&.>VIAP_[7+V1;R'P&24Z?"N:DA\_'>=0OXI=#Y%TT%'
M&9=?SC.J/S,!V;%! @X:L^ 5GP&']7Y/^J$?Y?-R4!/Z;YB -X^9@!F@O>,X
M'69!-2/&GEU:$^[QC3;*>WA>29U-8"EW(!_9C5N1_H;ZIH-:XRS:'.4,;06S
MK\E=.CFFDZ\C6YQ?_LAQD@9"OP $Z WC'^76?:Z-EE%JM).ZK,/VP V/<S+;
MXH*CZ3-,0%IO/3]\,/ Z!B%04F[H>_\MCX-R:,.Y>/*B*3T=.B%+1&WF,#RU
M#U7>A=$+%JV>*Z4>/!P3O\Y1__BL7_'^LUW/@LQAG8/HG713#-W'C'[@AZ;>
M6B;%A\BK"%52[D6"O]M>%O:-#P87OEN;M7]/4#B(NK^C53XP8=<3]*SM),;/
M8I6%&C7%T#0]Y,#K<4U76;;)%6UOML)1LB-:Y<PXY&+Q28V++?;Q^2)%]9U8
M@"EYE7@5!$VSB)."F)B5N;?Y\]7X!4%>C'S5D#INULN3)G%"/@:-:M>NJ7]7
M])RE&6%)'BTC=G)6)>5HFIQ*DC.>.MME[A3?*>39 !$(;80(ONV]),"3&5)J
MZUVMM_E^K;2P=IEHUJP!9+>N3,^R*;EG\73\2@(H$$O]06A[&5O16Z_NK)!S
M\M5"HO8 %WBS@X2^5"H'VTCNW$!%* ]\0D,3K=!A**"JW(@SE=0<.+AQ3<FF
M66&TC:$\VZICQ02XH*AD\C+=%[TE"P@\%NGMH2('<(J&.IF10(_?[@1YL\(Y
M;?<YMYU]>),#]&+R&I@%LU2Q'1A"K'DNV(*I\" =S;<N("H\%AF$1OCRZ>]8
M>)T?TNX13?.38,VW!LS@G+3P#8,973Q![\;!=M&6""C5JL %<K9/4X>HCWWG
M?VICTL%/*EXF_I7:AA<3D'#<D@G K#(!F?(!>=B260:H9[+/5^/YX]$CB9\"
MMH%7M"4]6VSX3GJ&TYYCV\3;N,.Q]V]&*C<(I9$-%[$.7$WZ&XJ)=T*&?N9O
MG>%[(!ZVA*-T-LTZ.4HF9X J$>58;6AMT/4-H3501(XU'&50V;-PY6Y=-9O#
ME27G7;/G2:Z@*IOW^<I;3O$,#873A]MSV:^TS8^IXI%=22[*HS/=LXN'7K9_
MU-MO=$KDC?KRRPV<T(PE/ D_</ZJ_]L;J63-F?J5F(T?E+/DY:M4FT<NQ"*Y
MBJ^'H\Q%AUL3BP/N^-.Z.+L'#Z?[2&G:3G<*4R*5YRON8?J//]'4 T<AY!V+
M#=(@W: ;T.J19O>N?\;4B@>,,]2L'+C&]:J>4NF,N0U?-GT 6^GE0V!ON]CU
M">N@L,\+T_?/4E1*@X0,S%8P/R$E6J%-"K' $E>>NB-.=;Z:81\:%<:-?CDJ
M']6TH8CHD6'?6MYZ")1V5=Q6WR2)?D&=G\(1,C4%F  M!1Q9=$#D;RDO+1'J
M5 T"1@@.-.M7&%RPLQ53VWHXCBAM5Z>Q:(-BLQ&WR?=J I*3:=%Z*A'[3SLJ
MAD-253%$)D#2!<)55?7N:_+TQW>WBV0410!QK3WUCM3\<5$$"\;&YONHRL:F
MXE;9,J&74Q1*LI\ER,E0X\D&[9TPV8F7PD\OXD]A)(1@M)V<]4S^E \,:%?M
M@Y3CAB]U^YNX!*\.?M/BUY)#F>.J>M;FH[?;V/PV**DRWM]87FZQXJM+\\D8
MXMG3"<^'+MZL>>J3*/WHZ$"9T Q."BFM$Y@_" \T?'_CR#O]]]6)RA\LE:+I
M9@1M4$CVCA.Y"E=L,QOP )<\YS<8)?\%DC^8B8I# B/,SZH!@]@Z%)X331Z>
ME1R?[A6*((,;'+[1="BGLX05/&'"<_B?B.LTK$.>7 9U>QPH[44<.0\>^:CK
M(!T7^WW7'XX8F]<&Z[9*FXA_C!$3W5<,9(.ESZ$D:J5>S6'%?<I'3%0$1;_A
MN>Z>4A_?Q,AV0Y2'9]$\IWW4G-SM3]D,FLX*<"8&77T R<ZA'AD_2U%XRE_W
MNL7&[$U01ZW7J1'#/O[\'X45%SV$EWHDP@SU7["&>86+B7V0BC71/\32246W
M#'(^.0+K5^@1]GK^%/$%_PTF[TCI_2""-6&I?1?J?5.SZX5#@591.\)D'"I*
MQ1,1Y7/6=R?.BL#2A G!<H< E#A4#>TK$Q#MP+4#)0"Y= IGE<PD.\XWSIY*
M>Y+*F3 #SP3FR"\=J<8:+TX:WWKF8:CW#-\GWD QC$- QZG=E=&$@[B12([I
MHP-"#<C.\R5?.T.62Y;27_+(99<I@X0NALM1!<U(]AJ1C&,(VP,CEP@*'M^]
M?UZ(?/@ RJ(-O@!'D3A#=_01R=<&.OF:(O9CN=XHKG'4U,8X:08,M*-$(5+7
MX?SSE][W@&ZY^XC>-FR#V3X$$N4&:K4*W9!*5,F25Q_SKR</#V[%;3^Z4AD)
MR67=ZF*G^Y/40GTD!LI?TDPBGQ&:*P(;T9?Z.\,8AZF>+>Q)QCB@TLJM9_<1
M >,#\?"#XQ<2AT<[2.H9ZKW[9*(\ZP/+7%?[GL!MB,-^@^R]GY('HYIY"MI\
MAUG$I.#$8$@.!1M;O,.7IX<*<O-2$6R;G!+8O*RDO#Y5Z</WL*/II6Q547Y;
M_2A!3>'U.N?P-5B\CRQ%(4152ZM7J8+#*,)+.B8&>7W'[2/4"278QI'U&GZ;
M\*6?@P@P&[F%!TZ@S@-HXK_3.?F_"418IS%QXC^/RE"J8L?G!6US"A(,'TF.
M(_6@Z8%2\2&UY^[>\G2C)S@=3Q)OK<MFJ^)0<O4:9P* ?(';_MO'QK:O^#$!
ME0?\IT4[)VU\6"91PCLL>?9PCI4@!5/LXZ5.^I%+BF&G.$<E ^^5UPO"<[;=
M"-=R\DR/S:<KB<0GM<4\OLH$*&[!RMK$30\V2X<;LM\PT^6[-0OA(8\^\>!/
MR;6QIF=IOD>\0?JN:79QOD!^OBDEXL#YS"EZ=X/INCHF*;$,H$XWT>[&68Y=
M?_)Z<?N]J&(K4136)PX.]W'@TU>Q/IO.EWA)STA:=-CP$L.7'T,  MTVR^Q=
MJTTK1YKTN&2B$W/.9?([XAD@D!CUQ 9OFM-YGW*S5HT1'DFZ$B?!%K,PQ 1(
M]Y<S 0[&N_9RH,+,4^AK;?)J"TCL4$[6C,YX5&>WIEH.U8/K9G<%]7[V"^SY
MIC.BNP;HRRHUU(R,6SSRVG4PK=I:[U3(=Q&OK<Q!]=V-5PX3P#/6,+:ZY<L$
M!$]5VQD2II_XNFUA,&L2)M$%<;.RON<<8[P[*W?]AC#8N"=-^#YJ.8FAPN+9
MF*'95>LD19KI-3E<,32U'%.JY@2F<16"@-247'@OK+;7A^HAZ';A])1^P^$S
M]M"#-@$*8150/L,'*NZG>10AFMT'CB*58QA.JZ4\!%2XASO"D0@5@,33$^X^
M1':ZN0:,JWT:B[3=?=3<U[:=RTQ HA,13%M)VH+=L%HN=O?5$"O&W+JQF*^;
M:$ 7,S-W9NV  '13P#Q+1Q+T9%)ZY5B['D?:RQ8:%E(#KPYHLMP7Q3]Z;9 5
M^(;WHN.<&.HDC630M88#7D^3/]8N9W)[\I,7+U^K&#2S, 5T@$P?K0%AO7*'
MC M:VCL>=JP^K@,2M"7CXWV>5H!#4JJO'KY?^=;HK<8S S/B0Y1X_+C:3N(\
MBD9-V8I:TS(T+?^Z(%O6)]]#[+\5*8V,T9K3.F[06R'!7M:S>+2RTO*ZONCX
MP?Y@B"O9,-H'S8FPIZ@RRDXE#+7)]IVT4)-JN1D0Q(*Q?+^KQE_?NA=ET_8S
M_P%M Y3X;"E$C'IZ:<XF+9[_N['*ESL)WR_?B&P[CK8^0KT[7N0_)A*^8%7G
M=Y#NS(I?)/5#U!$7L+CD[L4*$Z7,Z6P#?J-./\_5GCHSDN&3I1WC<=/JV\JV
MWRX>-THJRF13BF^8)F-T*MY6O@FY68&-VI^2;9!E.'NE:U?IG:-^?^52S5X:
M0;3*&"2VL?T%TOCA!9PEPER;6*GI1&G%<^('JJQU$AE+4\)AAUJ?2(0K&<\/
MO/*O[L1W<KOU5M#"H]UE%OOU[8I1)S&O$&?(?O$/L,+5LKB?\T^N\$T@?5C:
M$?O(S4MA!(FB^9F78JIB5J38EOVQ.H"$Y23[2J,?\6!.[;\X_R'GO?\.OS$%
M%4UPF2T[T$D.#I]_(ZQ]]5?"VL4/])QXX2J^'Z5_[ ;4B_^IZA#]@\/W4NV+
MR .$@CYK>3?KI]%G_'58^>]"\NGH:8OS4=P+KZ]X^^G52R#4W/6S^RM?/RWG
M]#EP9LK!F]&YBO&TNFI>"# _ Y!DT2W,_M>M\<J<E:_4]]G>O(*BP]E1<LK:
M?_=!_)]"T;(UMNNH)N55_YKPF.-PX9H*\F#7K8$ANW@3K)U%Y+$9UMK$,S^*
M(G@.JC$NV "W]RLP@M=G(*R[ZBF(,+;-J;.KF+EQ)7"4,44JV]I-6-%>.W[J
MU,.8X&]'H05%R<G/KM_ N[@)-GONVT^*#3@9$LRYZ_M)4%H_'+2V-22Y'U#Q
M;L(O(AW80#TH/2O<O2H%+^(QQ\0+,NCFHK'3[EFUE<F#4[+)7%=S<GC#.5^K
MIF918;KD[I]F!N\(&R >99@?]3OOM)H)!%#\RIT(3,"@MBMVH</M?G=%3%$B
M2X045'RM *(%%SN0X.O7^D9XJKH$U@ 1ZE_G4EC7XN^?6[K$F:Q_3EU4:BX;
MH4"^X"&FJ7I;U'\0U1*LJ=>,//ZU7H7ZN$.OJ_AN].6P#F'4U^$U42GV(&#>
M]2&X0V/7C28N;.]B6:NET".&E=/E'I5%:;#<Y;>/OVI):[\OLFQ*:J1<S,KQ
M/=D><  N'7P.RK9SH:?65W;.I<Q,K&((]UGTBW<,TFJ@'Q))L./!NVLXTW[Y
M4GF'#19\.J?<;@>K>T;5G_5DHYJ6RK_Q7$IKPW:2?WXX%K&.X:;Z%U-/=U@D
M-8$4Z][5?'VIVR:A:[=KS^$9TUNP7O'I70LLV,H;\"6=;T[WEW"!F2U2MPQ%
ML*)*,,+2P-L33$ LX(X-PI-L^OG3V6Z[X>47_2I@I\-W?N8FH5PL)<S(!"G>
M)'2W7*\T]=;X3\>,L\DCB6T2'->X'^Z? %66E% =]"@R#PR+9]_8Y[+]]"0S
M/;7%:XL;4):-^LB-9]3U[OH(0BDD)F#K@.H8;777B.D<,N8U/N0J=(#=2BKX
M];*\_/+"9$5UY%ULZD5C"9^; :':((UMS4XI3+!J8&3:?0M[Y9H %O$D>P>B
MIT0K:5D<L[&^TX\$1UUYJY[BM5^KSJPD2#\/[G"ANZ(C5NUR[\VJ\G<CTWJB
M&@Y'.:$10K'_-LKAS)K4Q9!'J)*74H33\S3)-BUG]@U))LV9>=M5I1)-%"3A
M]BOS^$W+TDEXSO/2%E@KN.3?VG]57([S>8>(XL]Y"8Y"Z>]OMZB'<P0YLS8A
M)7<NO2-_*2MP!IVO2S\F.'GZM))NP@?.;^N?-8B;3>ER3=4J2#'R<(1%QIR5
M@LQ%(U%-ECG3@(VZ<0P_/#5T;M"JKJGPC(Q<./CIZPHH@.J 3XI<^PP:%6MH
M38O!3CGO4XBP9AL5(Y].S1N.L94)? 6*>21=_?*?,U%0'1V-C;U+QMB_$"U2
MD1,!Q<WE(B\,O$1^/EM4TR1R!\$$O(\!ZZP>I,OU(N6_U6>1R^W#58<[]G50
MCQ:ANTT?12ST^K QCE2<4KHF=BB 3D:] BC_;>F(=R@^A"'E2QAA.TC90/?^
M[9')!&>'(L%'RVVJP\B>,<IV)FK@'.KE0!;B8"RP,4CRN:6WF@RJ%Y8)1(>'
MD="1]D=NE)9X3*632S0ISXU2('3 !J9(\SAA!B%'".03YARM*EM4H$]IENT8
MJ[X%L )N6FB#Y"C;'P3FQ$]0K H+1VX 4J!K/4H/@'T'M\"N*PYA(%XFX,E
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M8K"!9SR0+M\]=?#;X/6^LW>\"T<XPWQV\Q:=+P*+^XONEM_9O^_.X.BBB?'
M8']R[J%O AJZ/QIVS##"H'?.=#B,Y_;%R1OQL^/H/;8=^2<NH^-N OP3GP&[
MD^;^P-Y=0<+?Y':F\ZGW@-_XAW:+%-\R#S7;;FTGH/MVZSO] <RMOSHL:_MC
MO5U\ 0 0=O@Y@,, BJ_/OBX"&,_ ,8Z(<YJ& ,JO2X #NS4 _/*.W-<Q0!B
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M*-JJ2OZATQ_$#3%PI'/ 3^+R0"E9<VE995GY[3\Q*3EE6:EO.G[J^4<=VP&
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M%==Z*E.+ 7HF.[<!:H*$@WX1.[BP,/8XI4"IE4!GA9DHO "@31L!.>!Q.1[
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M5C(S;55;MH'&>*H?XWI4%,2NVW34CL>TQFZ=?>IM=%T7F"LO\-%G>W)0\5=
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M-!='._5\OJ[^J,_*8S^3^OK:UOH:BXFDG*3C?K/)2,=1(_'PZB1[QE8B];J
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MK _I*CLRIZ\NQP!-F==7H 5UWXYM&CJ8?[5TB5P=0&3??Z67T'Y@*(R-K6#
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M59]\9=6C+E0;TGL$ZFD*]J-MKP^8]\;$"BP.G](KU1,.&FL>Z]/'CM6:AKU
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MJJ;"!N]">QVI')YP3\/#'HI<_*Q!R_,*.-$D?55-'YX1GPGF*,\1!VR,,ER
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M)".$-L-,HX7RDU[)O\Z/H,./>!TD]U^7_/U%3[D?E>YT)P#,7?D!>,"KX$X
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M,;KQGDB<-7$/4M-"YK"!YX"O'5M%V<]#=0=C[=7/ LZ2%X$?G^-@U1]]:%X
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MLJ(]$YY$N.\/\]<JG@_J++'N?/N&;R957O<YI*H7DF.ID1DZ]%#B]_Q+/?A
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MF(QXM\3/,L.TY[)1\![YD-) %\B$",?=COWY%QM;]]<(HXIY),D7)0D)7--
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MQ1VU$)&+7^4O0%26ZN/:K&^!'?NL?>@+T*L2^6Q]^0)<:A<Z*6RF2I[5Q+X
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MO$/H<E%A-7=HN+2/59=B_UU')+1HL]1J-[" 3Y9=/UFK)DR]SW9?Q'LF5.4
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ML9A2;#73K&U[UQ!3S#.L^T9B-G-S>2X2]H>#[D.&#E[M\!"D,]\SP#,RJ]P
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MF?C#5H[Z?AI]7L!'Z(SL'N];%U<JCU1V/UHQJ?#Z/I(:7GW?UOC;(;D:0]R
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MMHFK05!O:8C$X*?<R9FK,X0.R[M2\!2HQSRN%LME-.IK=Y@[F,M^9+:ML1/
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MFMB)^&J19: CG1CWL2PBB];B0H=SGDDI)U7<2\2]EZ'/1R&E+!>HJNX<@9_
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M%+!,BZAE..MD)(+41K<#9V1@$J+B^(F,L=4*Q*8GAP-8&/7S8;38;^&>7Y"
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M4!\2-.8T]V0 W)+QUIK$?F3I;C3GH7G+JP.Y%27BR0__ -(CT@2)#87Z!9M
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M)LKW3\,/3ZNIP,@%.72JVJ3W$^:KJ3.:9KR'Z8>)RN=!6P!V"1%P+EV AG]
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MWMEHV5LS\,U'U+^)3SDR/VZS1!K .O,@O*]OF*@Q^70C>Z!6?S?YQI6,.R/
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M9[^_\C<N>'EUS="3.?0A2LO&%S<;0P?<"C:J09&1]VH?:H,LAM>CDV\<#1W
M?^17.6VTN7L&\%ZJTBUB2G+XA:_ 97'[(3!V*'P^@4ZO858D<HV- E*T !&?
MRDY4CGZJDUT?5"D<X%U=:%1@ 10M^,#?8&WR6"9/XN$EVA!(<SGG6I?0MJBH
M(UGIH5L<Z?3]=5>X+N ]8IC#=J7\%T>SI[%G>%QI+GTSR>6]3W82EUREM::5
MLWU*OHR;N::Y16H?#/1?WQ]>!I/$3AV(U!^V'0Z"P,IK[ ]##?R,>W2+=QPR
M\/TLSPN?ML1N<=>^?9'0<2)VGZWUK&^C!OEL2^W'48]*&G^-9U%Y"^?.I_U"
M1SZ!?B&^E9KJ9CF!W$F@A^"[&M )_ E#<>VL78W!HB[ KX;6XAC+D?8WXQ<4
M@?/<[%EC:3O<#)Q3#$>)IZ4Y?_D,+M9.,5]HJOU:W]K7WR=2SR<DV-A_'9TP
M6($L^D&[]\#XV:$2)7-I\)2%Y]4:]1&BYV4A>+BWQT_GDMV<PS@QO^>8_RU5
M#7FDKT(!H#HGL^Q9<('7/FY@X ,4SH2HMC!CI/(L@O^6?5,2G!,8+FL0>;CX
MZ3-E5J>2" .EHOG^9"$L<9Q*DTDMV6LP^)8]2?]HF+IA/9C6U"Y)J5YX]^>U
M15CHFI'*GB]'1..&6%*QWYL::G%1+0O>N;6/:LSJ]9>G73\>V:R$F]2?J'(G
M0PK#0\IJ(;(-MG:07B0FS,4+=N[XZ.77YQ 4M;@$BY!&H],?5Q>X*L+[9ZFU
M6ZH?_\=+K4ZC1[E-857K=W\^3<P99+TE)+EXYQF8$F_VY$'B$TPSB*&@G3)?
M5-: W!P>9W4CRSW\JZ ]:'X!U0K]SU,??4,P#ZINSPR'!71Y@#X^[H-:*@9U
M4RQ^;<"(\_4B45Q!\T+S#SY'OSTM/596*UOL^]MT3 T^@'^ZO)<]BNSLAH:>
M)(IC'_GX7$N_R-S!9K X#$1.K>[Y//D0?&#UP&TP15756)P!<D]-]Y+R6=>'
MW"YG$,6]F=+LVD#3]:J5^Q0ZI^T&!4-:F:RZ3#F/4Q38JT&,\[?<K^&C=5#K
M09_)YK V9:]S<O;$VNI65 GD3.F=+\M6[>ZZTR1BME&"1.N#&6ZS*B98KL=G
M60EWV@.M@^+45LYF'Y\;%U:9&"/#AH39!NU;3:N>MK86XH8N *8OWH#/;$W"
M/GZ8(M/[_+[/PYE6G[_9&,#+YT]W7U9K1_Z0SY\G<T0=\T1--O@'"=D2JWJL
M#-F=O]>9ZHL'/V&_('O73T,%IB\'RY^Z&ME7-%LQ;.%$X4\^?8(^F1;M9A,K
MF?_]JO>3*(5'"??J!X]%$*+^@0BB6[ +Q;Y[Z-1LR?SS ;/F_IB3:4M2;="7
MHF55J\5AS646G.NR46OC]O)* U@VZMJYW=N'?=DN_/(284-[G82>)0<E6W4:
MF#.9U^(B]5K[,O,/_5(J'J$'W<='<H)'6EUTC?M>_2WQPPMC+$8C]#VWC?JT
M/7K[+N:[VWV7&\J-?O@+K;[+YI+;U*FV3 7CD,>5Y8*3J&:Y1*!'(S1 U[*X
M@*IS8(ZA.ZQIFM=;C<BLO*27(DA_.453N$Z/H3>QT 2A6\I_'HZR">:Z'A]-
M6IW#^VWB(VV:!N .^'F$_J#8LVV),88;"GO@MB@JX/.RB(0"!TS('W\[N)JT
M:"\ _P/^A8@(K -O>^ HZ^KL,$$/P*!"K2^WAEZ6YO=Z*KXAAOS+&GQL87W=
M2\%%#)E?.$Y*(R!E7HFKJ/3;^Y(Y1_L+VP]JC:^ZM35<0"\F-VN8QEQ(4?+%
MT%V)MAV+4I<MXL-:.ZWZQ70AC5)"4.D42!T]'/T=O>BUV=[S_*H!?P)9^60T
M?F52@^5[R1XFHG=3N=^<4%.YR [Q>E+[&=SP>G5UV._[T-[]WT<9M(U]UC)>
M,HZJU9*M('O@RC+^@<GO-%?QCY?V)4_1G/VG0E>?/")CT.95"$'S_8L(/R:I
MJXH:K)ETG]&+6%C%EXIQ"2VM)!F:A^PXQEGT*(I9BH(I7H4N8:+7C<'<EK'!
MU$FO+2C#4"72QL'1_++*:M/+^/)=[S#%X=&@0]420J57\IS6#M)^;GIA2&IG
MWXU[WE\@\@Y%5R TY!\WNZ3D-)+U*VQQ,,D8\D>6?=O2EMH%LJ+&I^Z=Y.MS
MRMH[Z&>,?C_'Z(L)378^$1-YZ"&'307B!B\M=-4RB++E429F!@$93YH8[KGF
M;[)^503:^15]G21W\XU\Z8 ]^;GK3&974"OXP50:85M!+U)' J>9TLAOLGI
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MQ0]>?C?8U4OAYB_369@P9'SS4O"'P$06O3G/E\P 55_5B.M.\.HY=RGU]*0
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M3)*<&>P,A<Q-R_!*Y<VL\;1ZK\',4?2P532&)?Q=[K!58MOZ:.] .#!M!GJ
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M9<IX)8$F5BW.ML,_/9W!X9K.!04MEXOZ/[&20A?T3^J $7F>^K4PF7=F@Z(
M,9K7BO%7'"/Q?F9K2N[6RY<1\[I8^+=-3_2[DWH%B;--OUX\:DWUYPDF4Z@L
M23U,R_)DR UHV=O1;/L*&&UPU-ZSV!M):HSVO<&:1NW>6G>'K?[5 X8M=M5
MD5$Y(&;J_X>S]XYJXEO?1P>"%('0+" M$ 1ITC2$%JITZ0I2I K2"55Z ,&
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M;9#KMNM!T6B5;[7JY,G3U;S@!]<O#VY.!]^7M=;YZ/0D--R_0X]>WZC)KMO
M79I>5#J&J-,02O_IM":P2Q@B+[A^9ZY!^Y&5\)7=/^)]PY@%Z]>W=<>T>B>G
M>C3NKZ89VULX7V8P*:P537C*5*1/O&Q2(5Z+=\F@XK*-N8<=S;SWN:]F>J_>
M+9E&\NWM)BU#@(8OU88N<U)X^1S("+^W<@XPR%86R4HK7Z?2&3CC-+.H^3TY
M\'NF(\E/S'C&RLI*%//+W?2Z:0##M-QJ[926<30]+&8H/8%O]&(("ST05MP[
M\@*W<6_&=@:V4,Z/R^Z(E9T#$Z+,&F>QP\V]+_G5!U.H8O>KEU^^@^[?'WEV
M#@Q/MF_K'\U[P^+1\IKOR/'P>C<4 W3$!]FS,/][_-%3J-0R1<(+$*.X%-5<
M7+LR6P&<SPW.&A&1B3@Q8FSPPU&(ADRX\2K^J9D\W3&,PDK28?DTDTX<=)^]
MB>>22':4X%4+)_#:=TD$)QGVVY 1>D)..@C^=E0@+BWVXR1/^YV8_SI&^;(?
M3E5%XLG"?%PM=NQ5>Y*<%W29[=UT^]=_,O JE,6*:R5\E%*LOBMOIMI"_DT1
MPB4)X09'S7I"#GJ3$=O2;0+K/5O2R2$./=R!['B6W<5GVS(_GS^KSP<H\:#?
M1]4]K@98/OKE*3XT7_#9Q,184;PF>S]&BU%S__3CQXH>&_)]VH3&Q_.)\[8U
MI'&(S$A[KP0E!8G1!]^34L\*O2KNK:L<(=_)<2#)YXZE[I)RFY;DE$(!J]T*
M[@-!B1\$&+T"L5HR>7M]^M (73T(GA2?ZB-'S,S7(,]S?]9TA 8C,(PK9%L+
MI-CGQU[4_?.0;?WA9TCQ @\RMA,^+JTC3RZ4FI@;$.,>[_@W467_9YN:DH2'
MRI!_WD&:%#Z>(Q3@.XY?A;!>[D=I2>'15!MM:5*8$.K'O\ 1*1P,\&ZR;@MK
M^76#3C0\#=TSX7/@7DM?:7#,"R' HZ"V,GQIK>Q*D\V^J_&7O@:\C#<_Q(?>
MSA[NE^DM0+"T.$HT""Z5R2_SAQSH'69B\6792-<D)79+;YGM&NN45NMRZ4R.
M%'%QB4U^&%,WWJ(/K)G)RKJ?QDY-^(M CM<06&FIHS]&$%#+"Y ;G[M3<A=[
M*'U26I8]"P4>/MN6RLT"<-[2T\0=BJ/UOW5G (2M ;U#1NLD3[]9)1_JB"AF
M00/>RKGV2";S9T=]H9H"C,!B%!R[P/OV9* [KY.JA)@([X?586<V#S00@]#,
MW,T66%8$0NP?Z/IJ,/6E#87-8(:P8&K4H9/F$A\+H[R:YE9],O5^%S0S65=I
MBPF*G56"SEW945(+[%<"2]DP'5KGQGCF6W6")7KE%C1/[-TXU&$!C/!NOLU8
MZ%9"#9)U0IIK&H5.(([([JQNT?H/@W"= .\S>9_^@?YLF\ )%(4^56+@$1M)
M3^*W%V%%NL9&I6-$#6'N6?!,[HR7;Y&- P@[^@=X.3D?C#I1;0VVZ&^PFZ]D
MH80D%6TM.$VU]]WX*&Y'?<3-Q1_:Q-%>0>O/U$:_V2W-%67#O;LW(K5(E\+4
M,B##K''8] \P()'<JM<>/HQJ<Y)F1\V9+%/*;-OO.BP2&"'H(AR=SV+W6F\O
M%J+,I+QV?>5Z RF"ZTLS$;4&S6^,BN+(C, H$9A8TMI8%_Z),M>WR9CZ;;>Q
M$L%3\=:Z.,0VT)VRF;O$&]!G+)74A))8#%Z60>>1KI+S#".L6J[3FGE.%8;<
M59(GS/6/T?4DR1=4&3# ]TF[49+0?H%UX^$(L/L66<,>3A2% Q6NXO!$115(
M(-:A%ZO/6R8757M*';',EB; )A_7'.P!T'\;F/*ZZY'O5!.Z6V=?#6O51R_>
M'6T<21ML-I5+S!MK(1VV$.3=)?H';,9]#CRT#J(&2 UKL_G'_<NNN@NPS.45
M<=<JT<#?CVN,M?^93&6X^ NYHUF2T>$3L1=.FJ[TT=SQ6=%IQ5_Q@NFK#53G
M@+:+AIT>IV=W >E4(T\QO>C"T4;C*<)KCF06"S:$MI;"AQQ<E_:);C%N'$A7
M:N1</<=$6 ?34D!GWGX653A7P*1&VQMYW$%:"PFR2< =:UYJ ]4_SMU"K@[#
M%U6;8V@0SY;=\3XXJ1H$GTW:<J+_+)4\00ZTH$(.C=_F&5\ A?C1[OSAE6Y4
M8L.V;>W ^R_,": U0? )+L0+-GPW0HF)]AQ(!R6Z<7HF3M18<)D-*4:J^Z<1
M"V329/9_0@_XG)P1OTA94@4A X'+RS:+GL&H)%?4%M:7W7U?:T)-&=3'U')0
M..79J/>-EYK+)F&_BP+9U53#8],:G' 44C74!I+K;U%.XX)H*(:0^"@#"D*B
M^.65$L,.ES2]X3@?%''V5+54=)BGL TG$5^ @$;AG')OT-$16'M)"W#YI<#V
M<@YJ0G(/-355C\R!=;6;>7S"'AP2&4:J'U-\[/@/$((2X7&ECU)0E0>2O)K/
M;N0O]DCQZL'ATQ'XSE"7X#1(7RP<3_"FBF+:K5XSQ):)?XX5_Z8O!+G82_(F
MW(:K_.TF2Z:3:&<%V\:Q-@M/*[E!0"6:M)>U(TTRR%,SRK[PL:1,.C"Q1T)L
MN#3!^,)B04TCW1(M(>U4QYLW^9B =C0(6&26ST9VW[#]U\9^Q3#;.:73.4:#
M=?8601+^)O'6&W;J[BNJC.@YZ9:ZFS3:1NG%-WD!33((63*Y$HC9B\*3OX[9
M)/B52=VM7N,X(:/$[3<50C)R_5^JR;JPWSBK;8GYY-/ [![90D?1= 3D,)8+
M^24/QZLY>\]9+IF/6P**DY;ZTJG%WE/.!,;@*,@/:@(.=GH"_\H6<@FP46 =
MMA$YN=SN708,+/&1]I*!W/=Q#)B%8C=H\.$+2\OP37 8ZSI.C"*"Z<^S/H9]
M*+?E%L:.AAPZL97)O:&.^$)P:Y-ZN>@^3=430@P^]69$62(SVPHH@I.<T8K^
MEV,CL/;D(4P;"J60TPDA?O[#>AX;LKI.4"LH)V%SO,_[1DKL1"^O#0L!B6;B
M"*;[WS""-DF/PANZC(733HNP'<R.L')L4 )[<W*940+<FMETX  0$.R9UZ><
MEE2L:]V"_-D91/\Q_$]W]T-Y>SDECMB^\,=A&?98J5JRGMSNW>55XS ?K_6V
M'89R]!Y[]'//G#7UB2@L(>T D$=+,:$KV.T8V!/U\< VI$^=]U7SP2F,RR=Q
M OQJ/8\?&A:B.<5&2NO;BM-5/SE(P4@M"V01KC102G*< \@:5%)'(7J*=8@&
M!YY;X6-$-*$$9(I9<CE;!S0AH8& GH\1"+DB _1?XT"9B25OMCG5N#"!4B*1
M3?$L_.(A'LC%$5XJ* 4AD)5?U^9@FM!;S1,2';-WD*07]=LU/-A%(HI78$5F
M.BFP8"=/7=Q![91*+F53ZBP-WC8M%9($9ZSK)-^O+^C E'I#%L1A/5) 9NS>
MT6%%+AH>3_^)KHV?-[2EQ7E$;/BD:'UH?)$*5D/E(59&*7-&+><C\9$U2R"M
MR3CJXCXH.+]D3L3KIO7."F(EPH\Q&R";AG/ 9MI#?M<SM_NXXJ]:)O<81&DJ
MYK OO+& 0BOBU(Z"OL$G,:L_^-*F#2/M\H<@ZD3?*7D"%U^G%@46W@VA,W8C
MQ3]+8^)C825PH"24&)N@KM8<<QPAX:9N,>64=H[4<NH!1V%S\#N0;\_[G)[B
M](?W#MO_?WSH+,F]>,/LM+%\<NFI]:SK.<!J?6KQX$_ HL392.,^Z?C!6<3J
MNV[.:K>UU^/F3WV)TINP] %3NU)3=?&4,M9L,GPGFAG&I?,[5^"7S>83KP3G
M8J85Z6R#."CE5<>NU70-WK6M,<Z=80?BMV#E7?;,ON]>T0YJFQ]9JTM.# ]Z
M1SFI1LH'=I(B9TS'Q^*&B&*MB)4YF,@0:=,*]I71?8?>\-*4U_>'\P^^/3C>
M?E)<5N?QY-319BIL$L/R8.5.<%E:@(Q"_^>1RKO&#YU-QKI6'01BEF$U?H$>
M/!C;'-[7\X_$R@(%?_5:9//F*927UCY5L,MX43'_R>-#':4'_3NBA<JU%R9?
MN-YHFKKHEG .!-LH1]+PH34/]N^M<3.'W3P)746T<%^N*XBY 8XH7)LT-7Z\
MUOO%=K;P<T/=5YB_Z6W+U4:E$9T;4:]T:C$NH[OF03I? \^PO]R;EOY*LA.-
M"AF"-B4.PR=< M^'-9\>)&WYAF]]L:8Y:8P_,5T]!Y:X<OV33A5&K%=/'5U-
M_.R/C"J48.= ]? +Z=936V2/[RD,ZUZM'!1^&C$(#I](N(,\!RH^-_3NI^02
MVL[<@]X>_!QQT#]6>._.=-8SC2<=T.#XRVG-Q+89V>F_ .Q[9#7FOVIVQLP=
MNF>I4^28H;W,CDB$ZR5)^TT*S;Q8IL58*7C!G46O:W7/@]"A[N.\B "F8=LT
M*8@7P[R\#<-3\ARZK"P0*IR&  0K725[^:*;%S2<7Z"8\5Q$MDP\+)/"IUXQ
M8 [2\\Z':A6E(>>S'[I-%^<SH!82U5P5YCF>TAKL7 ]A\%EPA"7"F!;^^]A%
M333X)*IF#T?9[DJH^_J<T@Y!6@S$JF7%'Q90@B2X [?E";RZV)#^*%X -#1K
MB=KA<.)L)*6,4*3T'?_1@,+[\V%MY330K/V)1'5D@;Q[A"&2L0V]_-)+@:KJ
M>9@,$U=',' Q:9HV9#@TN74O.*J&K ?$CB.D=$;LM(%Z7@3O,G7;@F<.@5,X
MYC$4);7(C8 )[#IZ;7&0%4 .MSXJ5DJAS,>Y%B!0Y/.0K^? Y^H;;)E< $3)
M8'_K'$AB'^AK^TM&3OZB->GDV6SFH3WWL@6<SG%!^APP50\[63YAP^HA 8W#
M0Z=-7'A[KL,R(T5X028C+2'GT R03?BX'.\3:J#K]'0_59_<AYA+O*HLD?=V
M5DN>IA_C4VL P&NB#PZ6QKFDVLP060UI35'LIS(1+=*2X1Q*_PW4MMQF3V4(
MK*UA8JXO='8]X>AE=U+F5I,NEWULTP(TKQYGC]T2#TR4GUL?E]]OKOIY/)<S
M+5K)?D!@?Q:;][;3G=&Q3OT,CIWE=7JZQ:[&5M&V1PMXRT_%SV$H9%IQP]#>
M5']VO8,D&:JG!<Y97+II-9,!G8$]<FK'NN@)T/=OW C5?(E^ [#Z/BM%VB;D
M=(JS'C?-4H-FI!&853[&R'GF-0C8,G(LNG=5Y?LD>H873JLV[TR1!V1A)W"#
MW&A4R#U86]X2$B-5J[$ X6;2TY _9)!NM: .\9GVEAZV36C&#G)H*NH^8V6Z
M'P/;9U=#0DXE\#;W;G,K@>=M5GCB2<'XX$LUMQ1C$73YRC@8NF?;B8=J2Z ]
MK4<&.\C&I;LH.B#:YA,R3:&1*-%SJ<TS)S&M-P\WB(;0[_?S4\<K%6\[^=3:
M48-"2;V14$8AS^# A \\7NNV +=$0T+W,I)>,W:/A84JEB+)%E Z+KR1PO*'
MGY^!F8;K&Q"QKW1GU9:1':R*JED&'374H%^0WVCJH=!LG^[!:A!GE?+:RR3)
MF,4#)"52C@.2!;Q<1 !><DYQ^('UX5B_@OL(*&)("XC"J8=]W'-B1\JS-%3R
MH927H8IFQU()#?DTTP9!U'.$N>KKC#73H)= 4H]J,G25D(!G8]3;5CIN\Z8(
ME4<V@7AI9C6YG[T,V0RV!*2VF$@<P#8@6WPZV,2,W %-."3$7M4Z?ON,C[!"
M5=/+SBP4["2-H8H' D,]W2STX9UZZGI:^R>\/G?E"4PR;#("<W]C^P9D6E?)
M"-=^;N:  =GH* ,B=WD"25Z=SR&?+IOS[2Y3BQ.Z,SZM/<VTTKW(O<-@[ON,
M_-'I;IT70.8AN\UA;65?%;_C^2!<VJ^@@Q2*74Q3].]^]F'U+[Z_$_SBS']G
M?_YP<MA;J^"K?9.I>1 )VVQ=FO[/],$[Y+[8@2%\0O&/;E%^QY^U W8&)79"
M0MCP 3MW [_4.5"\*Q+(]4::6897JCEP\% [XLB@N><<L*WU5B<=?\.J)?'"
M?KHN1W!II/2@P;*H75KK_!DQVV,PW@W&"L3_U:"T]Y3O3(KPH.RP15'W4W@Y
MPDA]FJ2(&KLQ4E>GV#@WTP']MXZJ1\P^4L1,2GC_0*@:V]5*7CW'T,] -]L1
M0WD4;S.EV!9>9OU"WB<&,H+GRWTN=-^T$\Z!SHWFKZM67ZBT'+) )EFB1J"]
MG)'6Z;?MZG .&EB>M\&BLKKGH/G^*,WN,3V72"?ND,3 23(H]R.9DB]UW=SL
M7E#7$/=$0HBSG"[=J8 7?UA: ;F4UJ2-TZI<A-1.[@%3]J4V(,@7:$-O*S)B
MU9"VW>YTS!KR:<F4'2L^*"DHXJE-JLQB+@K&K9I+EL5&TC4_"^C/O(12F;D-
MJU=B#Y22(++N\6M*]='D:Q;X.RJ\Y>KLI0R,D.IEV>C9H5MN)=OEF,4KJ(GA
MS#AR[;'+?UG14)2]F[@,O#NA'R_!J %@)ZRK(?+1I%PO&3I+D'0W+\?;!/0$
M5B(/"[;)5?>G<D!^9&?%2C6T][&@<6U_Z*85!QFJ02ED#=;UTG5MOO"H<^#6
M&7L\.:0[[XU-'(?R1: 43H\E8[3'#8K?T_1IHR('X V$FD ;]Q'5#SQ3W@$4
M\6W]:9LI\B"L[3^0C:SC./BV=#\,(T,')'7GN.0CQ0,B6">=Y#B2$3GWC7'\
MX+]0=MUE^U2J8>>*YO?0GEE"!#AWN>[%J@VN6#>B9L*!R[\[BSL^UR0V&<9.
M%X6;($&WTN(2U41=YY*9UGO,]X'%(.L&OZ\@*::/H(3X3I::)7FNVVU]G6Y*
M!'L)BC\R252Q/7,\'K(O6.MU?%)J8E0Q_!0VN!-.DCQN@AG,D-M'W9YW(+<4
MF%?#Q\$M$]'*$0)G9&PF17!X\W+82W-:>K:.>RFCL4JX-DX2^BJRY1RP:J>$
MLH'D@  <Q.B;@I((+]DP6XLLM?7.#N9Y1+LDF?PR4[YRTFC?0#*<7TD@=T&J
M1^+H2[;URQA0(2F"G90(0MC:U$,2\(O;L!XF3 !\3]+)[I^(PZE\+MY\]F%#
M>&6^9R$.SM3B&+K$<+@W>4LJD<(SJR PZBP4$V>/(2?8-EQ$18Q'9F(A]LD_
M$-XVFI%J:E$'O6B</]P)ITO#J(E.#F>38,-UD[&C#Y=?HBU W1E$9%?URSDE
M"(.;)X!3/]L2EY+(C",#@NV?47I+[\=&9,5W&GB.[2^,T^%!#=1S.8L(6>H%
M:&!4?!H^@ET=?&R@P<3>Q^%00$$]*1XPF?=Q"_A)#"L:$8?7=7K AG%ASQ?X
MX?(<\7UDY,[+BBI(%@XNL+HC$'&G_GKS04\ -^(M<HTC9"=O 1K"#9J* $6U
MSFC-\DJW_U5H8(3+G8Y"(-#?'HJ?87C/Y+9  %Q$P1 X=[0EAV[OQ2W&/6=4
M6 Y?[]R 4@G(I0K=!KE-M7B&B8;MK8%LEF;\;&([#SK525P"D7Q$^0>1 BR$
MBY8^RZ=.J]TR(ALZ: $\DQ<1G)NVZV[ +$N?HZ2:S9^P%EX-EE3>?R (QZ(<
M-;7E,\9SX&F2Q;285S,[&IX;E:1X0$9DCP)AP%)0#X8S(%@=WVUYY?_;.X7P
M__N=@N?F*?%_+3^K<@X0=:K#%>NL5[BR3\*'5ZT#GD[II=8_J(E]9[E3<>GN
MNX3=0/->]4H$K?)GU07^L:7/#[]_EMF"'B\ZO&Z=X=F[2R\T^BHP6N .ME4I
MVD#F:=-7[V$#E:)E<Y%OD_H!=EJ&T64*[PSC(RF<!)@Z#IJW7"T.C+?V-4>4
MUL$EJSJ)B4_R[$M$$'XWK*+VI:]KVIL.33$DP(X-%46/20'QGTJ'RMCO#^[>
M@#60K$\D7,!S%7?&3:V%G]!G3_Z^]>B-4;M@'X-0J0!#2&O=C]\JDQGVS'?6
MH'K!%2XCUV^DQEQ1$Y0DBX.34Q_"CMX&,/"D?_2*;-G$U!;S^1>_,U&)UU7:
MYVUY<1'V;!>L;J*MK(M]HU^K^8VE^57F#(P553IC1%;'EG[H-XX\],AS/!QG
M?&U1:R&:CJD(Q*9J:L?%S)W0?:R3C3@,^/?OAY=J&C?W%Q2[!L\!+#%,_J11
M+>3AZN:%C%>D#RZO-,GXEX*7.0?JAU'[-<^_$7(>GU#9,L0T4UQH_3VJ>]UG
MZ&$-7L>?N5I,)[R.U%/9_Y'P_W[*W[8%69-FY(?ZY$8EVE6=5J5PO(!('Y#B
M+XBKGV<Y,ZN-58Z)^_YG=$1*0A(&[ 38_%$+A>%X*=5AB&$&Q3(N6[=%0#0L
MJP5D:!'V?C,*WLYOGZM^_Y[[T><6.@)%5B*2[:XT8P.U_]+AX8MD<"!3&])=
MDY(:X1\?VCT=[T:I1S(BBV3(>\N-W(>RDZ4UC>>K:90&'E%Q)%VO?QS84D<$
MY;H?Y.VQ=YY.W7.9I()/;<G]D8X]QL2EK"EL0$. &-&IJC]PIL/$V@,N<2@?
M1W\^K[K2<;0^"$OA$)5%ZM3LX?8J7YBF/C3S&88M+;"2K8X=?<7A@WNZX7F%
M'"G]3*:!TPR!K,LLM:!4F04A-3'72U_ #7@1.-VB4DA5\ J=;M;$DM27E+1X
M<H4EWD()22?[3-R2NIXX]7YFG+5"=0IC#<.W?2X-*(I4@X1RV0-LT'5&&"L;
M8BA 71X+2&J,0=S$)4.+-T&H>LX@JN1328!C^8>) ^[$.[2;$*DWL?].TBE,
M!D'8:A=P"QZ. /]BQ"*GQ0945\>O4>(/VV2P(:R+W-WQO1X,N:!<I_9$Y9-G
M?05*/&-[=7\49'U&9%67?WX9@6RQ2$#SO>'RE5/.D[7)SV(S4_IE.+@>$&N)
MAB?32W-T^S5_875'U,MUM<=FG:?(!?4%1QD0EV/U)%9@/8E9FD6BAY5TEU,T
MF/H$I11&#F&M=[.4JNSKC-A/UA@A]T'X4%T-S$Q&;%,?H?2<<#8+I>,UVVQD
MS=_&"3G[M#[(A9,U7<T)/#I*HF40CQN03GCW3UB!7 %YO/JC0$$^GT+6?*;L
M=IF*3U]JT9LF"J6F,>O$ TH5R-J6H6AOXX5N2B776Z!?0'?K+1G(7$EN*&=Y
M)2K; WTV]JR$,HJA9RAPQ]]\26DI=CV:0FIO:,_R ASC1=8?)C4 *$_0QR"B
MI.+3ZA.V>GG!;6X2.VRY#GE-GHE:9EX0D!NU/]//QMVNDT[5&F<H)$6&JH<U
M']X_+=!;'!^IML@-L7M&4/0JX"]^5N, JG[-2XYX"+2=Y9A)IT4^VY]@5%C,
M31J5HMSVTN<Z)J=J2DLY*GW\^AK0]7EVAOR04'Z(LG0/G&I*R^J.7<1*_VMQ
M(=M_('N<J%L@ P?Z\3X7PDILP*]22F:?G2C!*'U\F'C/I0\7BCW65:,_.[-/
M,0Z__6IA?T<U GQ"3W*C4AY)"G-ZEDAH0$@SQ?8NFOP#&81LDKH.P%1DK@F-
M0$BW2;#&3.;TAJ0CQ;;^]"V%MQM]'@%L4N2! AM7>BQENF(ZSKQVEVLF@NC,
MEB8SQ?W[8KGQB;!M/F^6O-+_!4L)J%9E)EH+LI=^X*AX"QG:-:7>1"5*)P&I
M]D4GJ7C6"A"_#,"6F]M/E9*+$[>+9&UN1.WL^'BB40RN4_TF')U_-10F"@KY
M F/W"F5B\8G!'Q65-$DL1$,/S[!(:-BK;@BY-$<@_1=,6JT&A'K)YR-$J;\A
MK_0]D:F'7";WCR:CU(: <^4H9I#AV[48%-69_^J2&OE!]F15,M?T.> %_CC6
M=D9H?)]V#@S.. &9N (D/$F >T7?]\"+897J#8WBJ>CJ'W)[V;IB?%+XCHR"
M\WK_C=VP;*-_IB\]6W>/#;XP**4^(3L'Y,X!C4<>E+\63N\>&^,]M\#3@2.[
M/&<,QP0?20'V[KO+&K\%SR:EHZ0."S2X\=W[EU@:,EDD+C1_^:7JMNB_L(.8
M\/M1]9X?O72Q^&V!%>11\2'I+X(F<YI+[12L:%* 4/48:WN!VVM1;^^6)RW*
M1H;@E(_?V)/K';O7-Q062"6'K62VI;5,N6_<DN&@?@QI_NI'2VT!(R3)S?%$
M)-OR"_13*N?J'1^KV8A+TO%U'N)[I&+GPI_&W^:Q^?EMGV'8:Q&^W=7=O(/2
M@D<QAIMP)IX=1BP( JE(2LA9N1SG*0G4:1 <W=!\9F\#=N/Q>+6>1Q4EUQGZ
M36M2.=\IWN"95)/&-%]>,=O2LRX*C^LU?SF#O*YS47@>=5( *D=D%+'L^3+3
M;=/4IZA(Y;C_!7-FQQB!U:XH<DXWZ;7K-=LRF!062!INVYN!&1K%#&/-_E^0
MU(;7N%Z#M.W727JLY";O4]G0PQ8KUW/41K#C\ZQSF7:@Z\Q;#+5!?F26GBS=
MZ[&DD@8'17^>^E>,M,OK91.O/-5'P(5%K?$6Z]$QH>4"<P/_%2\9[=7L-5#M
M45]"B2 "EW-L6:!]+*<V6?P:&-BD=VS*$LU9C6X:=(K=728G>OMZC35L&8?G
M)-H0NZ\IXSLS.XE$BH,L1,"L Q>=5KS>[(!^;-IRZ")G][4:@)JJH]JZA-AC
M <([.J32'&UU$U@^YB9%9*5J"JQW<\?K87VXY:9:Q-JFH"EXROGNMCO';T(<
MI5DB(KXP!AQEM_KJQV,7O,2E><'G@+&AS=%?WFOG@+4T.&)KT^&,'>5T,J6\
M>"K_2#$&SW8.P 8"%?59NKO)XE$[^,"NCD)?8-DXO%3/2T,NX3-56J^<R=QJ
M6BX3CN#6OKBM-U+?G1-6>3BM,@%^73.E=>2NB%$H9.M=XKLOL%I[-K&'<A+(
M3+D#GG;Z(/\<\(!W58_+)Z"<22WP_@8^)9PC7*(FE0IW0$#@4T RF7CL-TU+
MJ62ZA?:"P9<A5,ED&[Q1\2SQO=WK?:?JG4D A$!!D$0>D10-/T+;6,*)+9Y>
MA._3"W-R%N;V1V^9J,(#IZ3V=4>2UN+5.$^7W?IGI R'#OI#HH_0I!$W4 '"
M\UU / %+YT4Y30/EFKIGW.3$)6Z/@N&U6"]B 59"+FIR/H7$;MYVO0>LI.9C
M.[ <6J/6WK;'(JEK$\](R6?PO[!Q#BE?SJ^^0->.X'GJZESKGG"RA9A>%A<X
MHQM^.L5^N!#Z!6>C?\)63L@)X*)0S:5FD&:GKWYIJ7+TE8B@Q'-[J0_PZ3K:
ML%:V#.,]R/8IW,G5L(YD<3E@29Y@((FLBY320G6]WC-2W8M."^339$\N*<6R
MO,[G!'0F2\MAQ:%0"438>TI5", I#NJ94%/R' 'U(7&E>F :@=R49#Y S4N_
M!C?2V][.1TJ5I$!1)]+LL4U&>9$QC ZS$7L27F \\U5HJ/9(N8$3-%Q(U@E(
M<KBG3'<>*F69*>$UXZ*8*]4U@C2'=8^8*RK)8A7(9<V2PQU$9.Y+B&N@B\F]
M[!PVY18H[:<[V[EX2PE>K89@#84H5J8-^>AMLD)R9.<?B=S<10:0/6MV,J0;
M^".QN QYQL[:?G?\$G 6^;1UL33_K+=V'8>K/H/Y*9*B'IVE-%0_:N$^!YAD
MI0XKAR^X]6$&3C^^]LV^@737O44M9[A(YK+V _V;ZA0?-=;FC4CB([^V2FK0
M?3MVNUXW/CX25W=ZPT/!*T%M=O?[X,-7._NYAL^+EA^^G1=TKF,YN+Q+VI88
M_1,4CG<R=YW,B<Z35EO#O1VMGM',N.M4YMNM/VL%9X$V%,58&C#SH?CNFZ1%
MW_Y;\.O=MN!5/_>*G,CW[D^G+J)5RYL9^A46OY<?H(<K[PIJW5BFN9K7A,;+
MU_'!CGV_'\0*1BLMU#+$VW#6*E3.1IY^<9E)U2^]QJR=2I,TS^.PJ.$+89&(
MZWYZ:GIH'N)8;VWFRSFN&R*_,E6V 8[P?"=M0\26//VQ_N1VU7HS]^/F+T@A
ME1SOQ8^E9BT+#RL==;0NO_>8^3 &F\!$\<S@?O"_V)<USW?7X3=YQ/Q$POO%
M([)Y+'DT67+V'S-Y 3WSC/M5Z\PRHL&7F)I@\+M-PBK.;=;\N(T52W:Y16#3
M%EG&#(&GSZNP[.F108KY0C/(D^W",OZF+51WCLGN$>:IL#_%].O6RNZ\\&O)
M&=\9Z/#/4W9R*:%]7G$M#J;74)K=^.7)U$.1E\Z?&C%-GUSFZ?>) 6T__I09
M2'@>!&1N39TN#/^TNSNWV1G^\NTYD#!YDG7H%XYIU;=3W&;0ZT[:/2YOM2Z8
M$+;UD).9@GZ-W#<54A"N1/J85;0'?;;SVWWW4!3>=3F=;:6A@Z$4N93I$!8O
MWK&J!@-H*3__.=%>K_1_5.]4X3GU)";GR:OA[=-RY^+GL B1-!IM)8I49.K]
MP';DWX#YO-&.?5-.GE(YI#>IGJ&QQ&H?3L()CEM"+%&7IXW2;<CXVJ[:"97
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MSY7/OIK>)&5Y4E5B\H.,N?8+C7!2PN^AN]AB\H%7.G8$NCNM%FOX^ZQ8QG-
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ML\85&C)F3M[0]NC@[;I0;2;>9[J[/FN4;,HJTG[<;^-JL\_3C\BJ3T\^E"_
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MI/%0U]<T^+*MKQ793Q5O8),?E"/2?N.V35I'-<G6*;+3;F08:+LZ;*-!\L;
MFWC?D]1;&UXR0=RI+%@HFW:=O6V*Z])=5 Z)C_F\51T^5XM9<3\JCG(M!=K^
M]0ET0[)-7>D,*\M/$M5>>+%FWZ=9,.=],#A^\>#)P3JG+6JL&O!Z9']_>7?<
M/E\[%!0;O$FVPNW=H7+,(YO&6AOPKB(P01.OUGOK<]L4%PT\_0!$;>JH'B+(
M#]=?]WN?Q"+V.2=3M-XAME6=:B<92$H+$795J!*M.,[FM30SZT>.E;7?6G'#
MW*N&%6:C>?)C"MX/AS=G"9%F3;V:P?:IV,2Y/C:%[/EV$#0AR+7,S:CS73\T
M&YIX5A"8=7[,?\7Q"I\TDX)SM/C0V!>F?[*$E_K3):,S Q-J^/F?EA5Q*ZOR
M!\N)-ZU3/OAF4E\QT&J./GBXETNJ*0KV@/G%O_1K)6S0Z]?$:40M.I*IO4=H
M.:P//_Q 6(!#W7M:+9*6HE:TQ3N0&]B\)%Z$D1\?YS\1MJ^KFS&@E;%D+6=
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M=OZF/44%MWVDY0L[[4P1H: N)I:=F9P3H%\!0)B!L%U5RES* ^:'';S*@#O
MUMU@=!-Y6\O8B\TBV[8^$RC5D8T-VALR$27RD$94$"4F $K:.Y.DZ+L[<M^1
MP5?>Q'CR9)(2MA4]"":Z7M5A$MU F35.NB]&"_$EF4RZ!< ,BB4N(FB\<<(Q
M46SH#^[W*G-NDOY@!/"K;4S2NR(D%R=:/5)!4Y':![*/EFL')7SY6W>X=D62
M]=]D%8 >$@84L8D%AY#GPU0Y>$AESJBB_:&$Q[ED)#X,R8]B,_'0 @7@K*+Q
M>7!?)&&G%5_NHK"Q1)&<4Q_4"()>@F591E-M0_:"%\?RMS9@WP+WBB0_%JF(
M4!1 ))"3>Q(>9R*KMHK:(H4W^]#"CEMJ-P%&CZ(PK4M/(GS_3JP8S%WLQR\/
M982R$AYH0):05Z&GH=6CA/B((< 4O<(O-+0@8^BJHL<%<G9\%Z4F564W)#RE
MW!J)B@**GY<#SB3> U06X-\82"P\OA'\8DMX47<^/\W7[D4>_P7L.1K\!8"%
MBX^HXZ^+?_P%7)"4R>3UR3R_=C;*ZSGU< O*SD_5>5M46)WO$#,5\J8A;K3F
M:\"G4M8TXEMVH<DQTC:!5@9^#=.S';_6O#QAO8@=<T=%/<5!2[:ME^,E]'8:
M+#D]$]JD.B0ABF!Y1K,R&_>5E>R3SUWI[PF5SF^!W-7Y\T(]]7*;;Q_?_^HF
M^_PN^+FOK:XQ\*$H/\ SM?(-\OM1Z6(K3LB4K/[RVVGV33K==;LFO#[(3=!Z
M8@^M4)YC[<P)IQ:^NJ658ZRY,8D:_AS:YVC2EY^@$B52?$Y5F?742LT&AJC%
M4?\,4J6Q@?L]W;^ ,/K]W+^ EH;SOX"?/O>R'H\=CG\!W]W3GNTN24,;C^L/
M(=LC0/N,L^U?]I="\^C:!I)'*LZ9:P*=(WJU@1SO!C2]#)A'AE?U& HR&-5>
M5:''$Z!59["K%N"B9J3J\<N:\\U1?7R\^PM@F?L+^*+S%\ ]\!5X[_XO?-YD
M_@MXXEJMQT34,R(4R_>8OP<83ZD;^X09@!K<A1]L<VS%D*88!V,X*/9?C\\Z
M2Y)(U%%#<BKX63^HDC"PD6B)@\!^Y'P6;\ /D<O$A%CJ!C=R+%BJ0"__@I7)
MA]M=4>-@K25DVU;;DEZ=BV]>D*E%W[#0LZ@VUA>'W8.C]A \P?G9:,+GS>'I
M.F?MHM_IS1\8.?NZ5QM2_ONVTO^;,"_R[SJE*CO5KB??$_M1'MO%]=G@;57_
M&3Q!D-!94$FW"LZ5(.A52*K!<T&HG\E=>NWPUD&Q*5NM9EK'<&TLSRUK8XLF
MLR'&5Z>G]GU_4O/\+%P?5A9I6CTC6SH4K1])X)O!MKQGYYYO_^D[@SS )]O*
MX!\/_IWP9G/]P;1-4@'1SG*A,6ZNUO_]UZK4ZU!0LP0EWW%MZ=YV*%3<\EGX
M4>=_FN1LN[D$I@F"KXG.<P4&!&A6"NDS&Q^=MB!)U*JY42ERH?=H@U&4DP=M
M%]:7_6^DP!,VG7\ Y(3C8G@A\3JM#BH2AY,17]A0X+["O\6DO^?2G!<S88SF
M8(JM+HC@QEY:/UL#W7;>B#0Y5N/G9(1+9CS$D23FDK!CVG+&@8%3,M5IX*DT
M04]?IDC@\LI>0@HY@*A## <+MK5#A0K.V?:G'F+07A7$WV+(^R_Z30)2Y%"(
M#LGI9,,L^>"-&ZHTD0 $OPCSC8-(U;^C!'W4#>B&(7"!G]LA2FVU2_5AD%AQ
M_U!& <[N1$*O(&^-S>0%*RX])&G%3BFMH;8<2>[%",#O&& N0MU4$<^-H]R#
M)?O'KMK!)'$-9U3GJ M@H\HCU+D[MF7WO>@O!3>7*#1X(Y239BBARP<RM+V/
MA()88N.X^]MM72D3'M*CN)'XT"@QWMZD<('#Q3= ZT$LO-XOW[SW;%@.$5$L
M:E-H.OT!I/\I',Q0G@FRN6 S\K918 3*(&XQ-?P1+ND (P$4#E$RLX]?]E^F
M4!:,#K)[*FO"0@.(9CN/I=[(X&+M539\;Q^T]=N!,9^D@F8MRB#AH^>#!RHK
M#(YYJ1TWX;;+LR/@01]J<W=16@6916T'*";EU(XF%B$7Y<MG&"@6#-=!M9:-
MT%9!F?RHAPO82S 6QY3$!$[;9#1) M-!O5/[R*X-MU7[4P+ ?N*Y8("$NQ\U
M3Q@#'=_%). B#1=PGRQ>*36Y_7N(.1B8+IW[0^!,^2\@!IMZAR;M:@[77 #:
M>8U#,*-25.:ZKR &0,D1BP!&,9\!W='&4<:QF?EAJ)@8*AL8&]B)P$1B$^KK
M?D  RFQ47TO^?<"&,=WW=!%FXF!M ;J7;Q3_#G94PH\RU%O;VXP+9#C7N>@J
M'L/LS_P!,SF[]J]I!["*KX8.!>UB]S') &<H4-QD 43X40)>5P]1+OL0/SX&
M[! &M]=>L06QW+&A#,*#SP)FXM8F+[Y!@DU7"0\3,,W#4QCA^;#)G!FX'")
MTCKBR_I_*ER,"$!(C44P4?";%A- /F&!-8@6R4)TA: N4E9+O)#G1V&(0PL1
M&3],2[>3-+2\ W2:-6V(M2M<0?]T'H_:YX#VY=8]PRS_ H)??:%DP[TG]"V@
M7QG81BWW1\$U#HI-D>VT!E8%X4/V]Z-RZ0 T.6+L!;O*[%M><C,I 'Q-F@PX
ME)GD#$#8AIQ,#HSUOIS3'0#/7F-CV/H":8!S[6"!=B@I"V7<*JXG@?3JSOC:
MJ$$X#L'XW:3I,JX5XR)F(H*Y<G_R0=G3P?Z WY\Y6!M=E$UE'A0%8A>(&J+>
M]>0<FS@*S;[;!S<9>T0<HU3^EJ$X",V1F$JCI"'1V@D5F'GF]\M@$@2S9>-'
M1/QK[X0W^77:B=(G?1!G^>.%-IJ8*\UP2"A#&*"VOX\=1RD8+ =G"&7X,XEI
M*>#VT88Z98:?UE-L=DC2(W?H#QI!Y_Y%6B*_#O6!9W $\$Q,TMX.Y0/LFP2F
M)<\BWT^X1\*.M>X$^]1>P,Y$_VKBN"R'7<;^1>]ONVTW93L&E-2V\6%4*?G5
MMF9)TY&TP6 %0WI^$#!*+'=PR][:_AD/>RB'&(N&<@:.<<D,9/_EVD"%\HSV
M/6Q*2^HYPWFE,,3JR>TX[!"CY9D9:MG\)//"Y&W\%W#ZOWTRWVZL6#1LFG]X
M7A5=XW/>+C X//O^J/Y.6T+YD0.9<!GX>;LGP%7=2/Y(W?G_E[C7J<XM6*.C
MKA2:/7E_B-&!IE.]&<]P4.'V-9U&X;.CX%LTM20/*:*/F:UMA'%$E8F36BAO
M;/$XS0G<N,?(W2WQ'^';OLOE1Q&/,#/AZK>4W9[K5]Z,XY:%\6JZ5EE?F!2X
M*P(#<XRI<.5NFV\4<T5G*GB]$@]=3!=+VW!BQ49MXM^%IN(JH#'3,*+9X3*3
MHI"7$XXR $D97T?-8RG_.#+F<UWE@W":_[S+"ZDVAWG<9G 0C$\M;3\>D@^N
M_N\S!2]1Y^&PAJ"\,_8O0--!D&6EX"\@L_HO )YTP.8-H8&T-C5)=SUXLKQ:
M&7<G[P<5W<6&R5IC[B6%)!#:@A+]OZJ<B#$?Y=VQ,8PZ4EQDIBQ[J2P($76,
MHD&@*,>T 31VHGMD36LD5PR:J/@323&PV&T0DYZ,/-H@PZG_JB,XZ5*0!3BQ
M A\*QUG?UL4]^!&"M?W[$:X65SQ88(NKF_070-"[GY/[A#W.,(;YK##VP7_V
M5(3FMTC;2%\K_2'U)/4NB^KXK@-!7,F_LL MV6TB)F51$OY@+:UN,YD-%50R
MPLYD=\+8<--5/+4#Z$NX/24&8/0U0!.N]5\$'DL"UG=DZ$J7GPA0&<2^O0"]
MV+ >//V3QG>(XND'W16'Z+4)B#HW4 5T4<6("&<;/>_,:,,0XVC.0  P+E;&
M9([^SB.5\]]!UG2P0G>+:[EQ$?X'QYP'H986%[&+;^LE.G4+P@B>M[>U]H_*
M*4CZ$S(S5"S402MCI<U/V6FV%YP,<0P-<Y38W\5]9@82%]X_%YQGQ(*N$G$U
ML?SVP -D$[)-#D,36NSC=S,>8OM3HX7W==*BXW8!<VS:+.>SV@ID<+YM(O1P
M-(SGKMGN6#,#3%#B1&+Y%$/L93M[N$,EOB-E"J5:NAS1H9L.8%:*9D<\1E;^
M1U'QR1]J! /^.7M4)"X-[,4#2A)IL:6#B48!/GS:VF5'&YCJ:UQ(14$YV)'Z
M(-,4%%,\')?LRT+42K1/?T*')Q--0G.JRNS$/"FS+$F%+QNTBEGUZ'_8]R7!
MG%\ECKGX210Q>@A"B914H_D+^-&_Q2Z6D[#/!^>9T.L[7Z#M/*/ZT@O)W8X@
MHCF$O^ 9;XG,G _&)L,.PS *$,G/T")!J2#;C1U>IG6_BW%H/R8=3,)^$*\J
MC,:1>@=Z"&K71#G>E8S%4'["@GHL,M"D_%K. 5IKH[GC7S[*21"LF%KC18")
M.B7FD&BG,A88-X!]B$U?XV12,QB_URI%0H]8>]A><?P[F%+2@_I153&C*9=(
MH%4;0X=Z_&6!XBHHV$MRN\!8\N'BPK%G;@'HA! ,Z=P^@FT>'D6T0G*E-SRN
MK,CPQ>_W\CTI\;OH@$W&,X5W-_"%KJ$](&R_3-!O#R&A?8B9B#>73G1G+H&!
MQA.\-9(ZUEN_HHMW&[6_3YFHF$@SUWLA*[I%D)'J($#,#Y.^'-,:E3G[#:#L
M$*.V_!$J"*87&"\'OIQX:;.[8<<*]&,H^U+6 /X"NC<RXA"HMK@>$6F%,2[
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M]R<SY3I].9:_(_!5" 8WQS0 _)S[X3,2<H!T@97GN+HC;"\OM5PX:7BOCB)
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M*F&Z=5^ISQA<SV@LIU(V20 56Z9)"HXB PJ!2$ L441*Y(_91[/WG>U-]:K
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MPC80;:,<4WT X<3I E0SO-&?V5=\]GJS6>>+K3,H\IO&H=@)+:_X)J=^I*[
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M/>?W?>_[WGO><\Y?=_V&M1=K36;-S/[,WL]^GME["!.$!>#: W4M=0!T"0!
MQ#^ , W< RC(R,C)+E.0DY-34E)<H6*@IKIZE8J5CA[,P,D&X>)DX^#@YK\I
MQ,TKRL?!(2QS7?26A)24%$3HKJ*LI,+-VU*2?TX"HJ2DI+I*Q4)-S2+)P\$C
M^5_>",T +07)!&43"8@7N$0+(J$%$=H!"/$^+X/^L0'_MH$ND9!>)B.GH+QR
ME7A Y37@$HB$Y!(IR>7+I*3$7_V)OP.DM)?I>"14R.@?/B/G=660#(K_0L&G
M6MK":#"(XK_]W"V8\@H3,PLKFX"@D/#U&U+2=V1D[\K=NZ^FKJ&I]>#18T,C
M8Q-3,RMKFQ>V=O8.[AZ>K[V\?7Q#WKP-#0M_%Y&0^#XI.>7#Q]2O6=^R<W+S
M\K^7E5=45E77U-:UMK5W="*[NGN&AD=&Q\8G)J<6EY975M?6-S:WT >'1\<G
MIY@S[!^_0  )Z/_>_D._:(E^72(E)2$E_^,7Z)+7GP-H22_S2)#1J3PD?^9*
MSRL91,&@&O^EM(62[[8!BO&YV^ 5)GZI10'T']?^X=G_G&/!_TN>_7?'_H=?
M4P 5"8CX\$AH 2APBA7^&GCE7_8O^Y?]R_YE_[)_V;_L7_;_(RO48_1.;VN5
M(\46G=L\6HWA#K!_<O00[PVDCX"*W#U=;)Q/F1]UD%)('CQ8--3(%PIZPI6+
MSFKQ]0B5:DP]#H.5M9H$. 4B2&!*WN6==>-1E22N>3,0?LC,5*=F#,^.?(;[
M;X\ 3HS8TN?7LS>+Z3@E9SN-=^^?12F^!L5CE@(5Y<1C&^GB3RIS2J[A#UNX
MH!J"=4TTN'NHIHB;1N/:(Z-[$W1B*^K1?62Z( YT/VO)]<03[Q%2:^32U1<(
M]6H;2+K>0='^V_FKQP@*3-F^_BB^;R.Y4]Z'.]&M7()5EILV4#YV*1/\]&N$
M,/!?LAKQ=QFT B@&.>\07>U:E_K9(OYL(\4TW\"[?03@X5 IGA%^;ZS>I<C!
M=>OYE.S3MY:R"U%YI%5R"5JX#9)1Q\]HE^@*V.7)#J4BJ;0<?C4JD3HMB7$2
M[J?6;II;(E]+>#']"V*V[<,F6ZD*, ='[RB#Z5!0Z:?0)Y^XOM&.9P->7+3H
ML7?+YC[60]EQ6C0*$T+Z9=R*-"#NV%<Z'I7+&61*D.T ]A%QS^@7]'8O0G;0
MYN67VIFH3 *]SS-I<*DG<H#PUXC_U XR6'!V!."-=H=Q'>2$?*KQ=_GI_,O)
MGVXB%[-A++,Q#04E*$@D 5B401TZS#\[9Q*R@Y?(_]H ];V.A3TX6U]FQB59
M..(G$!OAV^.-) 2@6P&!Q:<0 )4'P-$?S7"WZ9KW:9L24U,,TG0$W^O.KVJC
MQZO10Z=\UY#O>T9/(<:K8PH2R5>3>+_QW& ZR53O_6;%I^5]X?Y[0_4B)X$$
M(/X B6^))P ;DX[9%Y\)P JDA ",FR 2!\@K!]48@(=_-U ?IKIS2CQX9RG#
M*%5GF(XWE'&6_\-V4-PMR;O\G@S]%)CM^^BB^C)[@R[^,*Z7]'FFU[C"@#B-
M&L$:1!3^TAA<1SHF/ZOC)*<ZO$.LYBD[:Y=-=\N6"J?O8^C_QTH#)W+_>_FW
MZ_[D!VHO7BDWOX^GZHUU>G:LS<.9C ? X'>9J;&D'#KQ8WD153+-=,_8L]2S
M\DXH"UQEZ6YVB-['HP:I!"99<SI9 N"$5,!2T<P<%S]Z@"H)KU?[6+$K>(+6
M6K.)VA6:C67%V9%L:RJ8+O;F3KHL4=]X@=_QBB^]H'8L$,FS>=JCKD+./=YU
M"J&".SK1)NC1S"9Q+"F60;JUI#>;@*//ZD,6#DM'%BH<YMSF/E["- $O!,"O
M[AQ&'2IS3:HQZ(/^2^:J)(PI6,R@W**W/TV8^>U/<7EWX4U"+2A,Z.I R%@E
MCG/I ]PJL[C(Q4F@7D>D,Y_OTOSU3EUADH!\V#;;BV0KMM L6SMK6157.>3/
MS83;QHZKX,B'#JXX]9%Y ]-;>]3E,K.WEE>G=[=CSC+!!0_'[ANK4Q5*LG $
M*]J/KF=<?CZRB/&ZLJ6JG./E^%#0C8?;JL1I.OQ$>L/CWP?4WX*K<PYGA#+Z
MC'"U\BKR\;HS5"&9._E"WD*7HNLO+I5-BYN)WR<=4Y^P)7^6R;"7%>-(,_4"
M-#>::;L4"U:@; 2@ZVQ)_)QRAAC,8R79> 9BMD@,$(#M1.*.SDR:G@CAS$L1
M?>/2O6":3?HMWT]+[';J6ELF)X:<W4<E:3@K=%@[%U^JB=19AO:P%H_5VU*^
MV),9]_[,YMU^,P"K>VXV5-&JAL^UL5/NIN\K)0"W#9^B;<-N9M@TA4OEIYV7
MSJDCCZ0/+),68;3>D;?MIW1VEQ)_];).Z?WDNHT9^XQL@[!-W[=.;*NVT9"-
M?1EV8* #^+\J+/Z2%'*=E90C1-M2" 76&G$2&"L65QNA[2B[7)WB%KB^]ES_
ME,1%ME]Z]_V_6R^W=!',N\5]LAF!J@*%>0?O-_FD$DS/W\31>%M^]SO)I"F.
M6(73+A?H<4Q;SDR:]KLP5GR%SM/6EMW^1)/QV?/Q?S^3X55_EP<_&_Q$G'1[
M'"O.41JOHK:/]=U$Y)$26P88B$FLYIQ+ZN2;Y]!Z1$/UO+/K/DP0$T!MI$<[
MT?%--,N OB3Q!V=/\[%2H-?);\ _^[\<J_^9P7>7FJ+2Q7Z@E8IR3;MM29E2
M$EI8S?U_5W+D\9<J++@_V<99HY?O\IE3@%%%WV0AJ?KDHQ[&OUY#.' V]KQI
M[U[NZWN:%K6NHW7JQXN]P4M52<MWC5I-HF,**N))[JRFD/!G>1VWK'/52($V
M&!ZJ 7\W$TO),5L4 0@YUC$:NW7*-, 411O'@J+D;.Y#7 %FOS;J##8*8>IZ
M8:%8'<N#(ZF07Y5)O1K<_3>8OZY/,QXG_=.I_DHV67BWFC3*IR:ZAP0IKR3X
M"X..C/OQMS&;".F5Y  F2A>',)=I?N4A3?_'7 S^*M 'A_DXOZ7ML#F\P*@*
M <CQ<@XY,+@,^$>JP3]FXPS1.1\E/QSG%QM_B=F@O!< QZLW%@S/;>G<&=U_
M2+?[Y9Y<)\T ACVP7[;/[E('XZ%Q>W^XI0"73-./\I&]BG-M5GC>4G4<\B>G
M:?AJF<]ZU/,&]T69=Y5@!HR \_&]QC7*J9G?43Y?5./F86F0MX"7E $=P/\)
M-%?&WA$ 87LO9S<FFG[R8B).0]A+:)A$EHAZS_^16_]5.]2+PHN.PB46IV6/
M/IK-.4Y&*+;&/'QL2S+PZ?B(K 81TJB IB;>WJ#GU?//JD.;_'=KW/GN]V2'
MD"DL1UGE\@8JA7R-(#ZBR R&DI>>E'"93%VG.=&K/VOZ^VNB=NY-<W:M*[B&
MQ(&?-XY5%(GC5=D^)^6R$@#-SU9XZ\>O+7D&/84HGQ7:G^KJ7FIQBW''L)U!
MU%#5X?46"OW9FZ?,?>RG9<F@>Q#CYV0(MJ9\W!UT<B2HYN= L9$4>V1K[\W!
MK=?T$0!V+Z(-Y13=]WEAEG?LP%2@5ONQ9$64:35M@J3/PJ< QEKERPP/_\\9
M?!C=V^[RW;O+7J+V_.:'H%M@,B.@%$=&ON"XZ8 9[C06\UKV?^W59XF'V_Z8
M4X8$=@"^,LWSEZ>WJJNY^$9XZ%ILN6-&6:Q971/:$644R-J3DB^.@1AQYSB<
M^#"_9;F65/3QH2DB(6)_XP\_NW1U>MI)KL>\MWLY>(I8ZLON,&K4EG"@R7=!
MCB[R+9GV+S8?QY^D)0L7[5USTQB)S7X&]T1[C-=M>3M,&9EKWRIYQ8#F+Y0$
M'5^AP&D=%>Z_F:?.1+\IW_*M(@ [!;8'[0\Z_CJPXK=V TAM.0Z$+ZW *IC?
MW9],TQZRA.Y]U<P]O(E(\H4&XV_9-=ZHB6G=NC/LR2RKN?JJF^?(>#GC.7F5
MPUXV*K$E-33]I/N;AMW*,Z'JY\5AX\7@Y=2SM'8SSO&W.#6?;[-W7E0F@L8#
MV[[_P 93 _Y93R#ML'?4"ZP>QW(:T\EH:Y[&X56GZ]5\>U4!J/Q&1DPQC,G[
M)NO>RKR_P]K<8JPQ]R66"Q5(C&/PQ5<"L&9& *I++K*5.6%A^%N;OAFAGM3N
MAI7X7Q%#-F_NE_OTWZ:-8W"R](8FNS]1RC]7=7"1IQ92JXC@#GCT^C<?[1Y#
ML=*G\70,7^NIY6TT@YSH;2G]I[_ECVDSF\5B+96Y5HP;FIH)P.6J5*?DJ4W;
MSLL3M5:"_JZG4/04T(K*1:;IJ&/EH==,LL,^J!:-W#2[I7<:M*K1J-=(+KT]
M3M>5[-;KQ)+^D-5N>;[B+I+$2[:_"&Z[I$.#H,9$G&O4/!TRZWGDS3+78%@Z
MS1V"&1^:)Z_\6)D1]EI]L;?7;M?!Y%,"\V4$>B@+E4DCT&27K'YCCN%&SRN5
MD5M$'&HRW/$5+*"I_3*QE;Q,:]%:]K;O]8IU;)Y" .,A<\<\&/'4&X]"<DT[
M[EAT!"%_GX9='+''JHJ,-E[:SG!!^7<F\:U9R+E7^*J?/2, L2Z9X(=UM1%]
M0X[YTR]O=0[)<_60:>'>>K^[^-JIJR"&?+D%N2C^"8VJ6S^!MO76Q%?]SI.;
MRATX( "8#3YT"3G&=G$?HP7WR9W23"OZXE(Q0S--_PGR_'7)LC+$V#[E]IS]
MZVICHWF;=+MDC9" ?='XS[7-W9QRQJ!E6%0J].W>M^&=9W+I7UC;(V*K9&.S
M9.XJ-?MK2B.6D!&KJ)+@U80AU93Q&+$%UU%)RA<X!@Z_>$MZ5'_+/227H)WS
MBF=IE9[<ZGM<?]^ED(G$=']0)DU\DYTXW<>#5,L$WO[9ZSPN_8BCXL,6!)M'
M$YUE1\[6Z_G)ZK*X4IF/===9CE@7\A6#<-O?H6 %KI>-77"9G#/OZ1IE(L.?
M1_@IG96D-O)B'BIP+K-'R\U^++(P\GN.7*.87+B@X%,: 1W/^I3$-HI6!^%4
MN)(]Q*O(JTW;FQP/, *A$C\(@-=850 S)@9&[TW3L[?Z*^55HI-\8L*O!LK3
M&X\SW"U5SI4176=6!.!I%P$X>ED!VC2:9Y$*6B"RV;SIRL+R!^A[5AQ?C>-3
M!A:]5ZSC._W0Z9<.3]Z,I2_?,;N3P7#WO+R\:P(;G 5]ZY9!C0.+QQSG5J4O
M:59,"X#E2_B=%6ZL!^J"E3H;$A]C.!=%BJYG_@CV$VG.M>GZ/"\V[5;*'9O)
M (*U0-@J" #M?$>.PUB6;L/[W5 U_T'-V12A)*$J-\5SXZ_;OK$G2B%Y6P'&
MGT_D39T5&J:]=@PF^FAN1]F2-8K_K,K0&1&J_,"R)Y9M-T/24_<),F(\-L=<
M!V.%WRESNN<>K=K>XF;XPSR$_=.)$%F@DA\F$LV.IR=BSCPFR3]DQ](%5^_S
M\W2' -BX1J=?.$#"TA6),NT*]F3]7&9WWC[::GK]S/R5^Z?=EV/KG6"2C48J
M?"<>&6-]#LM8.TM(Z9L79^G7JW>H;A4GV^22&)46EO9>]=Y=--:[J?HIN8-$
MT7UQOT,<HWOL6 #9<?EQ=LUG&C^ZMG<6V'GGIMQH27@3+6(1P/\F .^,I_'3
M:P2@%YE4_J+_Q/SN_.Y0A8(XZE 9Y7\TGOK7HV_E:JO0C]==J[D)@(2ET[D:
M ?A520!<8.</@C@1;?,1,-3GK7$CZ,3\LP/NP^J+@M^SAZ"HET\\2^Z7$.6<
M;?\9N[0>%DT IB(MQCN;F'46"<#5CES3!X-S#C:)OI\8WKG6QZJZD2_9@10L
MT.7W41>_DLVLA0Q_ZG+&G[2&#7O=A:K$^BY\N\BL?V#SR_=%0JGM7IFFKM)/
MY$&Q2',C;5IGNF"8=LP]!IZ_JNF"/L='V7*MQ)&/-<:$+&H$/RUE:IIXU75G
MH9NO-.Y\KT\%^SR0J**H<'[#^\4&T[ ?YR#W(/>KS%&0DU#)K,,26*A=,7>,
M-[\6;_P]OB]=3WU(N98:C3 9"Q(+T:]Y[/8%/WIG[_8>=*G+\"BBX_N_,,[#
M2='6PV+CH3=714MY:BIF K;6UU4P<1JX*X&*]SK3!5PH,);;YDRPETP[@1UK
M9SY4+>X_R<>':IK(X78A'6S3)D\V*7-:X[3D9QKVCO5#A/B>G_3?W36'L32M
M)#G"3MH(@ 82)F;2XN[E1_WYP^OTU3%2-=F;)H',:-E,L"N:>1?$P*Q''G;4
M4?-.]_+O84;PWC7WV'SR"4-JR,F;!F:*NKEH9Q1]6$+W1U.-/",AZ%\1VU+0
MH$;FLF$Z1<OKGE?'8'/:ZPH.1?AF UGL6GWD4E@0'TJI@>IU@I9@AG>H)M6G
MLKA777IP:PXLK3)$WYZM(>9G=DN^??55Q<+M6DYO',6.QBL'R#7'J@"V@3U/
M/_3UJFJ@YIV,1#?PU%]SVU+^7''[-FNE$^U,!0_3EH#0'C&B_=V:DOS42[-;
MBC;&ZRSZX&DU9DQ\>5V=&C7;&'WR=UN("NF6I)0' U]-D!IU[TNA*,9.Z&U3
M8L&N8 X?TW?V:+BA20!^LG6%_:,XYR3^J;^/;S1-4GIQLTC.EL95+YYJ+%RV
MPB"; T _!YVM(L_%M1LU)UI$'XE:R[("Q:^:+VYO*K/A+V,^?_.>OM,5;9//
MN^=H:L+95JN.YU8*/#=VA=';8;,[WQ5.;KV.,O(S-3)LZ7SEZT^QC"ZI_)(D
M%'PWZZX6@V3&\]O*D!NXYP0@H: (,0V^H.7T/6U&G G%$@#8$%'T7;>\AX[$
M/R@FYLM+Z-%]S^UY$ %828=>(+0)0&8VX.M/9%00&?P Y$#)A !,2$(OV,4\
MFLJ;<"''! "[#3[P76NR Y]!1!$[K!!\='(=;'(>KX(E !>>86>*)(K%\=6D
M LIB,2!9T@M[NTR-\-F @4>FECJ.KHN\B2I\&KR?[^V5?:+%%XP8?\<8M]_"
MY+89F?VB/=-V>U-A7NWSDI*JMKF/0F'!.!#^"K5^HA%-EDOW?/J1G@Q?9M(K
M#L2&$)[4L> BPW-8("<_\\'*AP\6JI1X^H.F[6H\5@JTZ[S-\7*OY:&*:/L"
MR))'?)<A\G:A)8LXRW/&:/Q06RDRI<.7O(/3\1R\.%<@635I&[LSN%QL?::W
MDAV["+N-D5%1$D '?/RV\&']@T_-+ANNGP#$A"A#3.VPDXVHRN+JO.94MUZ7
MDX]\/EX4<5'!)D$X6:&@B(/8:_@!VGMN*&\_;=/E1T'NK]O)L-SK$ .EI%KT
M%-8)VGS-S"SVIDA!1:A.%LE3HZ=-J;$]]9&+ZM%?MQME(_J?3 SXW$2K[CS6
M$>:[VL(9R>$UK<RI6+)+OD0:Q_Z;[Z]4A8L)>%>?4G;:F7&5][WVR*5^:G/'
MZ[9B7_5J*%:>SGM&)%!L28*S;>9Q8BC++\[/_,FFN&YQS4O<.NTA $_&U;YN
MWIEBBK3--MT[5RQ4Y;_IAN3LDT_/W5;FR&B'A3>A A$O"$![P2X!<#I$K"[W
M3);;GHM]VC_9- S@PAD0R\"^45TIOO,<'$_^N6G7TGG_ Y75\^4B-T@%#-<+
M.R&&1D6!R F< ,27/R8 )9"+O K0KI(46L1;H_74;*+L_&FU-9FX3&_7BZN?
M)Y0:DSHP\LOWN83'IEK7-77N, 1KS:WN>WU_PWJ7G;G*I]]A"M-! /@+B*2R
M"H)5DCMSZ+R:]G/BY4Y;Q>G-'[S76]S:@:9W'8!?;'B3'45FG;<"-$>L_<&K
MF\X?\A"O0C[Y:RJUYMD1[TE@HT9M[,C1*_"30O)?/3V*JJ5WL=;&IE]PU*B&
MY _Q6VCM/,LR_ 'L[K*AR\FE>.2X] J,08$2$G2\8561H"5UWBZI;+WZ/B14
MU6^9>WV J&Q"-$=W/&=O4FOKU)CNVEIT;2,7-/2)<+/K;;QS6OCKQ6B%AMO
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MQL?FJ0OI=3'NF:T19.=JGY9K$]>A6$; 8Q#)(<'_D/>;W:7OPLWZ\B"]KQ%
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MK8.8 WX0<2B&F!['#Q663![BU7\_PM<C3K[^&<3X,V=F^(\Y,P@G?!=UCG\
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MX6G %88 LIJ2F #*AI'4Z?;4E^"[P1#!+=EQT6MTAN@9JCA_,GE;KB' \ H
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M3O3RA(C#KLNKON+H(";HX6/1.),_.+/93F$G7(.3^9"CR0M%%8MV1XO.J]9
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MO%*XCR&UHXN-=5)PI-%9!&O5&HM?NF!T[[ :Z,'2@IG\<6XSXB?-TT4(DO>
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M^?*#4IIV<CSJA-S"ND%B=BI):XM,*_0\D_AEG%<"G_4*XS1GIP:,2"59-G#
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MW ?X*YE/0J2KO#8T\\PAATN84XK%F_W2*H5O'[@\,3!Z]MT7POE%H=0%E&0
MBB@4I4TU^E$&<&]]XXS4P47D6,Z>B9@>UNP7G%>X4S_67XP46(!K.VM6YI$8
M%OMC4!9.W-3+]4$G;6V;\&$(Z5J5K':>B-Z*MH-:)Q.L9>GD!B\V_?3S2?[7
M^Y03!B+X_"2\L%KD#5)341%6JTNJ(4'+L+8I#'EC16<9Q>)^+A^'"3C;F=@9
MTZK1;^BL!E3[/[B6?V+D29!1+N ^ECYS\NOY[@R':Y7C^OWU8<E75]15)P'
M SK-ZT,Z%5U11I6;4Z04&9Y96* \W11T89V&'F)MSDM#N+C8['/IV/P!CN(R
M98WAJ2?T$N\  .)N\K78];^.O(&B<5A_E(\[)-D<YVWV1O*,)N-^V3.:IQT8
M139I)J$"!HNDZ&'+BTK"ZOG+<Z]\>T^E'!(]*F<CR::;X-GBJA=Z<89)IN/8
M"J]YXUFT.Y\:3"?SG3NRQ3#7:K9)8G-\]$G.S50FRB^<'"3I-QTPD]*SF@_:
M5XL;C<5/F$;H>>J:IV-GYRPPT>ACBF==91X<)1F#_,Q*JS.7]X2SK^Y6>ON
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MV.@9T)3U-3<"U\TGWW3@LO5'EFFVG1O']C3^!V9_:5QWT)Y"\X&E_64@QKC
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MGJ%)AZ?Q%S<1!W/KA(Z$".PH#WVT#[./<?VEVC>K4;!/94M-?@1O'NS,.S+
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M!R6(*>V][[S ^0V:2.K*>'4_(2-$S]A5[<TYQO-@/!.3*F,'7XQQ1I(\$\@
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MY"=HPJ#'0SYT@RQOA^ZMW-8L'!U7/R/,INGQNS.:WGSY=YGIO\0#B%]QZX3
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MK"2,ML!EX7MDP%Q!.%NI*TD \/AO//VO*H>9^E/NT_]0*XH]\/_Z14<#-9J
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MD;?*1)TD(TA7SBZ*V0 WQA_ZK!J;_KK6U/RA)*9UA&=++_A8U=,9M]_0@86
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ML/<V-#5SMZB=SJ67A3CT& L>R73QCWI5+[1OO=1U* _&G#?N^2^%V[R$X'V
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M72.5)[W2J\ISFNQH*W]7(.2>B*\DJ-0)ALM">I !64%BDA\9"$TU7VQ$7R*
MZ[_F[Z[ )ZR?_+"2_W'SK(R6\%22,[2A^AR)"7-RW&)*%AGP7OUMVE(4&6A(
MQF\> [5;=F#2[4B"9HT,&4AE(CV1._FXFWLDK^8NX2F)--G)O NY.Z,5+"Z;
M:O<2Z/JU:1P)%[*$G]@3LQD.X979AR.TX@[*W)Y?+OG344N 4WQKDO^9,DE/
M0:SGSZ=HCUU6,AK> TP38XJ1<IEWR[%'QS?M$OLG&KH3XEP93C_'1Z=(I((E
MNFMD"%[[^^[-^2W)UU&#MPZ*HE<Q/Z$?8/IKW">Z,_)RFZG)A<(=FS&*XOZ%
M>%**4VD^-"G6EZ/*/+NTMP4,[VO7=WW]Y70)<:GY*_0?DG/$:#>[#72#B@FK
ML]K1MIF&N@0[)S=/X0^D[@MYKWWOZ%X*Q_2QH[BW,9H^1BG)N*R6Q'>?+CU,
MG/"H[COK3>Q4FSY_X@V]2;2Z!,<% 37]!,%=YLZE=(VC#TE#*;H13=/@Q]NR
MG:%85.!U7)</?_[MJ,SQIO$G;Y_GBLMZ-OB#QEG7LO\ZQGT2L<1)_R%+;(=\
MCF,*KM*<&3-89U,]TBIQN7D.AF9]T11S\<Y/L (D617G6E?#@RL,LM\HS1=?
M^]IA-9_NAJ\Q</_X0C?%^^1"_XB<:(+?S$(H%LVD^NF5]C[;RX?FY8%T#!\L
MK 5!G]C#=I>-?8PI9C??<M[L1RIFK^HCXT=]C1[W!C4>.'*M_;"CHZ)RZKQ'
M ^Q*P8-KSE6&27M=+5;W>/388NOY>5."WZS@VQUKB[OOT:.NNE)7OH.LH!L*
MP*'ID4[7/@Q,A+\Z,L5-?L;\/_;>,ZRI;NT67A0)-I F12 H(" "2N\!E28B
M6" 4(2(@34!0I(: 2"\1$%00@M*E!"G2 ]*+]!)Z[S6A!@CAQ&>_Q6>_^]G[
M7-\YY_K^[!_S1Q970C+7?<][C+'N.6;&>FZ\ZGZFE!2RSHG=3C2+-<@I96Q\
M&L)'GT?4H]$(EAJ98%PI,2X^I')^/G319]FOYMXJS0DOIQJGDSH65J[3)J6M
M4L,>TI\#3R+EGAXPTD#&]C*]+^ NBN3Q5N'OX#OS TT$3PKJ'CI,+$(DS/HY
M;<]H<6IF<0!?OUYCIO.EOPVX_L>DLXT+=UG@(0$[9[EOL*Y=-^=$ED_.Z4[6
M0)N@NS+R5L1=F;=%,M?D(C4'75*A(_TUWBH$DPQW[)$T^XFXO*] Z>G8=W1^
M33O+2@=Z-) Z=%B\>DJ*R=+PT?8KX]ARVI]8ZJLO_&H<FGR=L;(+&250-%$#
M5Q*TRE?ZWJ"X[)V0D).]> MO4AWP"7[WA/?65Z( /BGVNGIW:KEJC\D-?@,B
MB!=/F6GLK8@/6'D35N<9_6EFKXLM:)[ 3/%Q^JS=3+WQT3KZ)1"_?'].M?E>
ME^ N0$& =H&IO$5$(Z9"=KQ*6Q_9/<OER)^]43:,8-0Z>/)-D0EW]8<SRS$0
M.BXG?:[-G,GQ/F(IQ>V CAYMMSM)Z9L, #54Q8#(?W7)BC55G_<H,1AG+8Z9
M"V)E=5<R1$;I=G%-A!Y RTVUKDK':%.?=1;G%;^1P]Q<\[Q,EDI)#OU12C?@
M&& HCC!8N5?9+?.''.TS!+KO28_*,%=AJZ:K%/4VF5%0.'DN0;,3]5*#N&66
M@I>%-6+*]4]]?@@D/P9D*2NWIL!^>8K@Y%&=KR;!Q28M$/>*?F(I-N!1%F\?
MS@MY>_N_"=N5].S'\>E(KXSFY^\--E6:NL1C2<6.H0 A3"^_K&?G=-CIYGCA
M,(\S+A=75=%V! 6\L$Y^=V^=YUBKL8=HX\#T@^#6;RWJCO6,F@+AG,Z17I!@
MR&G)8X#C&,A0%2SHC[VQ/^52X-<E>T2QK$1@F1I&USIQV-XO2.1:[WH9U_WF
M<S7%EL]C/5!OB3)_5ZZ(\?R,47[D.8FJ/"9PD"*V'75>T=EI1NQ<;;F'2/I@
M"I]HC3^OM(PTO<ISX, :0T.M3(U_UD.M>V9Y$K4QU)RRQ7-JM5(&)U'O^:GE
M<KY%SYI$W)E:+4,O05EPR$Q7%S6"JE)).F/&M?^.]6J\G41A4J#Z"7V?RIA?
M@"!=6*R.Q-WK?3U5+=WV.6WNS&Q,FX+;4Z668T#1(.U_H\U6#?"NQB?4]M@H
M2R3HA5ZZZBINK4[E)X!'8R$RQ%,H7%C3 (FAW_I;WZQES\;S.Q^: U6[@[F"
M)TG<L=LR(=XR&>YHM??:?=,33,3FE;I;,RE"J^J(#^C$2@T<K$%>JBWA-&+-
M1)$8/?(6#%Z[*-?9>\E7:>$A(6!*1UC;?M^U0BC&<39RW"I:2RE6M7.;"P\3
M)OSCZG]E%4Q>39ROARC*9 6"V*/'HA#2 #3MKZN^'N@F3JRV,Y7@"'=<%B_A
MB.+6,V\.\ 03&/B. #0T_<OOF$"H[[]QYF\M3.@7:"%"]^2:5T/U(&KP%=CN
M4 :UX',@.5+1-K+WP5I!5_<VL(G\?1,F.MM^82.P^JRW*9D.!',\S<A:4E;[
MQ.WT46#XB4/%%U=.8::^R/[ML[\IZ&!F99'T\,M=E4I7,"D1A6-"K2,'7P^J
M-P^V=P[VPTP).C->9/+L9G!PF?"T(DYS9.UY>):+Z@_O;4F*!4;-K=L]MU<W
M%<Y;6T1K+6MMF+5-0BX0E7!*@9>0]TO[K/1$18>'7"96,\<VT5L;CY!$H0GN
M8Z#K]#$@P',,3"\> P$*,Q,'%(C943#1E$K)Z^^A@4%D -ZKSNS2P-K+!+YJ
M5IFK^F?>^I8!27<W5,TN_J8<-$,(Y4N8?RX&)&MT;?_'SWY*"((B57#KG[,U
MJ412SPH^(-X!4>%EP1'/.5B;8&?LKG]9#G-.Z_#9W19O0CV]A_IY:H7XUS(!
M.JG8R=],HF=66?^-&YZJ/BXZ\!AH,CE[H >J)B.;)IQ3[#RB5B-C;7O+@UB.
M_4"\0_B1L6PLTA@TU>@Q,'?'C?59 +. JYX'WS9?N 56T</+G;4A6S"<8 T=
M=6XN?(OL9,M-%)BBCY R4I&_5QB^$[=6_]B'LV16D"KL^_?XS65A>_=XHWEG
M3N?,EJ<" 'TCIAF7%'(,T&X$2+;SY%M_]Q6.ZBJ;^[86;1^'HZ^-D/B15[(G
M?GK-A(V)I58MJ0*$=FA"94@M/ORS)7<KC*UZ]NL*;+?N&+BE 3/ =E8S8C@(
M%?7@<U)*#^[T>!_*$=&BND7U%=_K0]V?@C*5,JE@?]^V:TIF7_(+;U9WW'<J
MP 7%]5&2-]LU1H%G1P.RR_+8S/\D#Z^F?17'$1'<7+U$[4R;X7=NYTYK_;RT
MQ/I3G=?_K;*Y?U2-$N34A/^TAK\C[W@2;SX5*5XKGZ3C;\8_K?MZ7*P$4UK^
M_5#Y:T%S#VM K1S?;'2.AG)-_*P #AR6.V%!L#<0('T<5D"VJS)3K(\+$4:F
MUBYWW.I.(_55\](R:(;09U]OU,@G-GA/P+V<LV"C9F/-5J6E4:E1G?CK<I?+
M(Q2FW,)WY%@LNAS-0=EC%+1@TT%(FN>"'^:DT>)[AF5EGCCAP^9FF[6NIVR=
M6<UMJ$RJP2X:Y#_3"WHR_T-YF57F)QA5FDQ69 NRNL[R/3*AA^KYP.H9(0RF
M<&8*'/'^J*%9ZK?W@?/C*JW.@1H/H@BOA9>. 1JB$8Z<XB\7H7H8_[M]_3?:
M6>J"NQ/ZV3Z=@TN@%HR.@7,^=,/N7^9-'VC$*7#I;/9D^\_='<\ NU9I@I2:
M//$1&E-!X=LM1GQ=CNFGB:_J.D!+)9=]R;"[88*9J#!5)0[]7OV]3XJR-'!X
M6.\8D'&HMQ3<Z%2.W6SH_XDMB3&].[>0I!ZMOOZSB8_TM%R!/G!<O,_R85!=
M2??LC S#/@]BPAW]Y)_3?F!)F9E@##OM?HG6,>7Z^-BWLD3-N=, BVZW2O-.
M^ZOM_\2J!D[!E_LFNYPLNW-]^K,\;IDT5#UD5:34/G=-(JDJDVH!_9>*@3[I
M#.&ANW^CMI<S]XK(M9,CO($QD$NDQR5$FJP67- T=8]BM$WX^FRAA)F*ED 6
M1,EKH<[I)!A$4!YO=>]WFK_L57G.YP51CNM5./W=DQLJ7/#? #3G7F21D>+-
MR0@3[3>.\38G0^"FFJ[@D'LPKG)%%TG'G,C4;.$SY^"TZ#+[-A\>(E<17JVO
M/ \I^4K^$THR<V;O04E6TY7Q5&OEC_.^/ 0C/$2K$G>4'I9CUF"=:=1X42/Q
M=6HS#7.@HB,5X(_-['#?/JO1D 3N<>"8WS,J")4";PUIR^3?:U&NQ9CW85C=
M.^]$Q>G0S%MQ<?>=]*>_5R*P_=6 1(%W_9G BQOX2G\D6>S>-%]S"OB&IV_P
M;S03+>V;4==^>.]$0<GX)E968#3ZKL+3*JI=!&Z[/7.9^V*<.$^D6$%M$^'#
M6T-D,H"H^9H1X$.UC'W/T#FM%=W8QUE<>9<;NMO<BL8*+)D=IB\->*JC3@0$
ME*O:4ZY%2G)2'.E6>P+%_[\[O_Y[_'O\>_Q[_'O\>_Q[4*AY' /A&!%;L[,#
M=V.=,\9''P4/W+ 89 )E\"U@BUT>^'1+MZ%XZURJ%9TJ3S=-!OHJ?0_%TR)L
M/K!7(Z8^GG-N-0LDV0@G]V 4W._OU[N%>&5\DQV[:M*[=4-W284;I:;?NW-!
MQ*!==/NPU#%W8KWE=. #0B2IW^YO8%>XF?@ WPJF=X\[U/2_>6@WK#7WD30T
MM_Z89JK$O)%.PZR?)@"_SF5B^JTW3Y*^0,-5O-;ZT/$H()*B*4ZV0Z$+]*W[
M%SLQ.IC_YI1LXQ9?W*.),VZT= VFK/>R]#O ONL\O&EKAW!.'I<]!M)CKB!X
M;*B&,M%G($6&+4T!I6N)-X^!XH&TH+43G]L%3=8N'PQI-1*&K*A&R6QV9=O
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M4-&#3JX(JK@U= 5.NTS_+?GLW]IHT.)X;".M-_LT;TI3*KRJAS\:>@B-_9;
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M4_ <FWM+VZV9KRCG@W#NG2VG!O2INBDG#LWOSK2K3GJ/;H1>R]2Z^ Y.VZ%
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M*@])M2Z(Q<Q,]ALKNQX]2>(B4B/-*$[V)U#V@[/%\S[B!!B:( TIZLARRU@
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M\$('2[!O;0=864M$&4^[#QNQ[>JS0UHQ0GVB(WI]>>A'YNN7/0P]S_,= \;
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M[SF/S1A.'SYD#4?NH1*BN3J'O':3:RE+&ZE+]R(^_5.0LE[O.S37SVCK_5/
M%/'L5,ST!*N1+?]''A<S-[-LCO#O2IVJZVIPIS1;#I\0<ZZX!%N6W$H+"MY'
MUJ,'J!?M[J#5@V\H=KNK@ULT22,>"]Q/K _(=)1B!L9!!%E<#A$(*5JQ?+T^
M]'[M!G]-[,G&:1">4D/Y8Z>JF=04/8/.%(QY<+GKVPBS[YT4PHRB. F6)[R,
MYLIQFJ0_%^)<<BCO(N[<?$-C)90P[X=RR19.MN+)/O-:(90P00;:RNYAI%HW
MR(%4]@J"?A^%BU@R<SKH_-90O9+_%*-)QLC(I%\8.;&3%&%'[2GP QUD[%/M
M)%V=>T-4).5=G=.S8\!U$#!*Z#OC"\)*K7)4^WJ+Y2SU&.E^&;J54VHD,FDX
M2PYYBJ;-G3RW200QQ@:R,@];,$.J@)E6C"W+1<O@:3_=M&P5:@T1YWO#24KV
M2[JOXQ.6(70B*5%M4I\V32QW:NHH""#*2H%_R;W/_9]H2?^ZO^;F'_V^FX>D
M']&(Q<'LI5/[U7]_!1!N.09LV/H(8-VWR$17/CUXN LY*'9"<1/#K(;AZ<@O
M*52"(JX\ZRGKZ(4MTD.*N21J:]U@;N[KX26[;X"CT[Z(.]C!XLV@6J7K.Y 0
M>3W]5A.)1\W.>S?\R<P"S@*.@#_2U#-\"[#S[2;3D[^6#=>+SH&B,4:9UN%Z
MZW?T&]4 ^#DK!'>EXE!IT<@!"HOR?-+!M$\N5:NH7 ^-<*F4:3'6Y?B\Z1:E
M.K:08R#)8DZ7^/(4VGQ:QTW[^Z$T*M=.^JUE2:S32WR>[@-?E63K7C!KD=A:
M9]#[!J:7N[(52.2ZM1M)UACCB(O\/LZ)=_R837G#I"/]CELX;H:T?SE.E]W]
MB^&PG*)6CKSLE59LSUO59=HQPW<4>U<*R@/5S^2(T\I10T5^[_:!$DSR$$[>
M2KV7K<>DRN%QSY+<!*B4YUZA&G-^;P)20;Y=Z4>N44P7T![2A"L1/R((<QXZ
M<"N!6B<JK0L7NRZQKQ=JTA)OZDDLB/V5K&26BZN> @^NBWBKY6D[2>3Q%Y6\
M5KU$-3041!U9PZ@P7XH,1=%9X'3FJ@90?-&V;I9?0^B,!3C7!$IY,[H6^E:\
MZ? !C:AIAJFVCQ]SG/S96) ,MRD4/6F <,]I/[#Z'V'T$\99/9M*IH!FWQ"\
ML+O8/[U6X8+^^<D9KO._-S(4K[\$H/] DQRS7Z!'>M9#,=>*>K\\GGC\_6A>
M0>$3>;9/[W?1R/R(<R6DI;UA-]#R/Z07ZMRBK*K^70IJP5 N(=UF/#9V2<NM
M_2'/7KI=5"&6^.BO0-BJ9V/M_Y %-)I4P-<6$9O7;*MW=EA)@<)KGH24F^3(
M]M<AK[>9U=O78?9=H*:)<_.EJ&ENS)[<UHG58(FC!EER[(AX6==4C-$2E)ZM
MF9WHKX_$VCSG0WQ8XRTS+>5NDJ)O$'NSY1ZW5CQ&VRC%F*S[;,$&147AITC3
M"%($WYNHV7AY]*#N("C6P^&%N1M[\W@:FT4II$\/-+A7?CXV<TS5U2/#1-?9
MZ5(;<R>;:'@&3^#*X,.]87A<UC.'XM,*7J4G?Y.(Y D",^K?4A[5V:)O'T3&
M:QI$[<=?7+Y P 2A/ ^4QZ>%*VSR'D=9!CYD5%]VM^+E0=;Z*C\A]*8/VIK)
M:\/E6X<[Z+\UCIM6:G/,QK74^DJ8@FI,F6X/0*9X2+V]5]&5Z$(/A&V)T2OK
M]@X9JO!)GQL%RHJ(EINZ!_@P\O+@N82PUMW_B%C#'@-V71*#+X\!>IMXG3K=
M],4#^+N?%1S:]I81H;.<C,F<EG1*V4V_0X^R/QV+J_%/]*74EW^M'GF _X?<
MA.W=IFC_IZ+2S/"AP)_DEAD[&GAA"J*97I=\ZVW(I98!INS3!?G-[Q$.^A]_
M_MT.DE(.$<1-SRV)?_2*28+_DZ!UF96L @45U6@T:-X+VA>GS-DM.<)?6-B3
M,UU"=8%:N!.KI%N&9CQ*0LS*Y2*P!8A%=8Q?,OT)0CMNODX[GYNOVR%Z^#J/
M=C,OFVKIE*F&V@+@U\0[7KDRM5XE$.3](FT\A25DWE" JM+Q5<G<IR,5="I&
M(,<!AS5EM' :VA3W6F<[<H;QU?))-)(+F:'ALP6,>[+UJ"NN'=X..]/%N](9
M6+VI\^OH+MB\_=<\Z!2:& ,'D:J@^_'+F513\0<K4[5\J+.2LF/Z4;F E?E;
M#46._?.82H+]+^+R2WO1)SWU55R92?)+L>5F[[7J?1EV6HA[RUZIN$#=\)G%
MZX=TPAT8YB%C.PAC49CVBJ%C;NI629VB>?>WTU%OW15]$:=VG(;I26I*8J3J
MZMT$Z(<_JP$ 7 CT1E'"P9D3Y^ZF%6KS0=%%PXJCX)H<];DR:C)#_N/\6_T_
MSK\%<[E)U7G__AKPKB,3_^8?Z63$T@<[8$,7_ZW7Y_47H:<6711]V ;C/ZG(
MAPV=?#ZGL697]\/^5WO?%=5DMV[](B6(0%2D=T&1CDJ3%HHT$4%0D!H0D1(!
MJ0DU%.E-0$!1*0("4B)*+Z$W0>D$Z:%+* $)! AP\#OGC/.YS][[YOQC_#=>
MS-N,K/6N,N=\RLHSO]#8U9LRF@E.4C";9249SOJNF7K)IJDM"!Y1=] T!';,
MI>ULA'"=^EC>QW,BT)\D02<73HYS"C4660JP8<Q27[S/WA3Z*SZQ/9VV;X3#
MVT8OQ)E>0Z$\\XSIOW")4 E^MM@.?%[4QK;78X_0GPSI*';@WN%3[UTJ=!?J
MM9)2$6SNX.'+B3$/6[SOQG-W(IDRY_2_-HI*_\9ZC5Q6"8O(9IW"N4/H* :.
M0700BL7_SF@7+&GQ0^FBFQ8I<9]8!AZ+B@2Z)>1W<Y=0@:H9"=)O9_3..'@)
MV[ED/9"TLBKK$XDY6NTY+36308Z<SSF9.LM/)TP!>J</U',,L-:=L\$Z67X[
MN!7=]:F![J7F9)QZN]?^*>JY"O#']Z0S0U.]LS3?PUOA(P,:QJ5",B$$=KU%
M6,5A%G(>VM^ ^T5O:7ZZ_+T[7R:XT/YO/?__7V O>BZ5]"(2B1L1GX=].'P+
M6;0]!BJAAX7F&^T'9[H">+05O)+J+H_Q+HH\*O'>B#%^K0+WS:N-$!,3?8.?
ME7DD@(NB\J_Y;RJ"4MQ$M=6#6Z036_(FU H<GYU]WCR>>'UE57:NC^-0#O,U
MBU!L<=,:M:&!,*][<WACIR1:G7A_CM-9_72.CL,YG.C&^KT T"(D4))ZH60=
M)15K8/9J3">ZNT#G:KO)9+PU80UJX">*AR'DFZ,Y!\@*+"72<(?I2O=(H!5=
M0SQWLX5X\_G+67">AN'4]2_=$=ACP-4?.08)$^Z_0MZ#O@'+^)Y.<4#A$EDN
MF")"CS8E]2#5N?%"^(;P??&=8R!N.YI*MY^U-3%NG&'1*B#39A.E3!RVGH6<
M131?$9%4-%AL;P<B^:7=Y*Y7]K2>E4 ^<ST<ZR.RSQSJZ(Y(B9H9#8JMILL:
M43.M,,54S*7P2'!*!V7LY)-/_/IH>^!9C<C#H+E#TW[#)^(R&=2<TI >8/]1
M?'.]RPQ5[0X*/+V<J&3Y[:ZD\C'0*[,"Z@\ZH6^HS<%FMK!"]US',:.W[MX2
M1I5O1;,<6*[(/W^>N=GMOBZ<3-1[CWC=DJY8EH9KV:^3A@N-#';N& CE.ZOP
MEP"TS$GCDF1KD/,-\Z]QTX25Z1[C3L\=<"N[6?0T #,:^:BCL&7&J/5.M:>#
M+Q!T&6UV##P3;D-NB\"@1#+Q8X!!F?L1!K09KG,T1'3*?UZ;4R;H]L9C[&G'
MT9ZHQ8)QP^?HNX,E17:L88L"H1T?/O(<A04JB?430 .>M73JUTQ'9F\$<NY\
ME#T47K//U<9JO[/J[\Q*#E<%\V Z,);DFQ;E$R/' #[.<<#;X)I+W!<-HZ9V
ME3/!8!NHKI]L^I$+F</=%2^X=&I*OW^Z5LE#^_'36P4M@+=^71_H_J]D\<X&
MAI-M=S*P+>1SU*/#$QH\KX8^$2EO,O:%A+;T(FL\=TDBNLXNI>;>>J[)2,&/
MTU>67;^Z>>V'$A++O#"I$H(W;..,;F<\I2-7&DMY@(W,35&/DV)][!X(JD8)
M$X,VXV\/B#P>),F[<Z[G77SQ<U;^7<@T7,-%^9JB/SA(A&VJK)-)5)5T#- S
M+I!J,/>S_+@WP\HOOI(\H=G+]-=%?XR>?$OW#3M\IB:[K9UWD:.KJ6G;I:\+
M/:_O:HJL(K]I2Q&F@Q6N,C]3$'3(R:(3BK\VJT)RJYR"W&D9I>G!R[18\#6=
M\^YG@!?(K26NJS>15ZF0^'XJ$<;T072;T4?:1N7'P!/(MI_G3_KP8X"/ZO4Q
M +V+7'Z(SB46V\+S25+#:R).CVNJD[J^TYY+]6KMO /,XT^3A)<LV)O05Z+-
M!^>36GR:+TZT]WRUN0)0L?*O98)10O6YA%R2[J6W/3+417?3!&@9PRDX//@&
M4@@EYYNQQ6<5.R-CKMPA5U*ZF[01M4>/T]A$AJ*F'(JE+)3F;EQOJW=S'Y+#
M>V]+DA%DHDCR[XC1-ZM"3((9SFOTB''0]5GYXR=+,7N8]N%Z]UGH!1S^,,K?
M[!XZAA#R#4Y'N(O9+!ELA(#*_6T,@G<MRQ([=&)#RMSI/NG%8VF\@5T!#H\=
M*M]C((S+6^%2MF+?16R1U;60PPU1]WU,H)]?Z-PFH2Y\O3NO_=Y<_X3-]B'L
MA\2I0 "@!S@+OP:($ZEP;6,6]3LI603VLXWJ;[S[T[6X9F+B"S(U&0Z4'"LJ
MQM"E[[N%<G83VOAYXV3V;+= !7L_XVV@RIA68R^9&MO>)&^8JX-<1K6D+<NY
M56^4+9&<\\>(E&_TBZJKY66.G[3HP3UWR"3)Q/_FF"P$4!T#75K11_6V1ZHG
MLLGT<F$1LAER^.J]Y;0WU.&GTE=RG<]*1M?+..Q 6U)?_=CQ4[6YQ"/YMVKJ
M0\4\3 .HUZZ.FR5:+*P\-,"^T,>ZW_.[*V'L;7@=]YEB'^J+WH]3[U1IS<7J
M7"^-#03HM07* 3_;W\. QIU(?"@"=10:>_(SP*5C8!:&F[S$I<C6+F-04K$9
M9L3"$\K!!NSY_MTI]9U)C17Q@Q1,_I![@Z,LWS.*LI.]]_R157ICR- ^V+1@
M4[/%\N*P$K_C;DH ][! I5<,_\<QK>6FA^J=O$]][@V0.(=+2*#<E1&F),U"
MBJ2U%(;@N)8>IZ+,.9"SK"*B0U$E0SO,2/]+8P$K!1<U*OU(%C'6:Y*.:=E_
M@E.03F1UME5+OC:3K^\[P]2+&<6\M.2$W=88W- ]_$!;4/FR!NQ:-I(7KD V
MJ\<PD>,E]Z2+G#MMQ4/P?+Q%J_LVJR3U-%$XJZO03[FR=E07_296(7;<E5+?
MW^UD^LBDML,:'HVEADOI4++"7FM; W"19TC3;KQ>B(@?0Y9H:-;/Q^[H16P8
M+2J^C[ZE<BC)0A3PNZ9"$2RAJ0_#0</2!3]OBH<\4:@-A8T_.'\F/W)O^(4-
MOP^'G1)A_ABX$,#H*&W:]JTRRU0;;NVV:&(5"E>@]W9YX7;O3;J<QZZ2(0?<
MU8+:1CMQ25[U"N_12YQR[WNT*'%0K\]/T#]7Y,?EO'S5/GX:E4>:+(]=5,K>
M^&1T<(L;YR- 6*[B63H-3C7+BK3>6T;GK_70=+M.VX.>@[T4X[DF8J>#ZN[2
MS6]V8.NM$_AMC<P$M7BXJ.6],\'%92Y[9">\@K#&?10LW//+H; @L>;U4!G)
M$^C67DYG#!)0.GVDIDR'*0_="PVVT7Y/J*]XQ02#74VFI/ ] 6+XXL7GW_@2
ME=E8P3<3[MS+<.X83:/PZ\9WWZOH1_/98RK=1)Z*%+/+<U!.Q00FC=J&^KO]
M]5*<#['# M]>CJVM%B58*/FZA9]2#>]&>CH_\Q?VQ09#S1''@)I0Y7FSMJ>G
M&Q]& )# 3+OB7\WE>4=_O6, .60414RWB.\)RH$/_>+G8>-H60>?L.*90EG)
M\3.%WU/O:MJOG=R*XJD\732GV[66)HQ?^"G@\R)6T3SVE3(^5(4N%'!6;]O/
M"8P:8/Z$(.7XO)+B[+JRM!';R0O]9<Z*]V+8B)5F \Z2HLX_=6H,+I<G9S_9
M[5#;Y@-MHLIQWXXND21"VA-$#Z,[G(INUJHU3+S25'_BP?<Y@.LE$#+3$>U4
MCJ)NRM&68(M+0QMJ=*1&<"<$K@/-&:[KPOTESIF?RE,65QZ%4;_XW,5'>9^\
M^C(:TH#OB*H3]..O&BP_(Y@-N=2J\A%\<$V<.R%_72K^ O$MTP!LS=A06?GL
M1N+=]&GQ&Y)D-AU3EZ!,B"\']Z(O?G^IZ4S=M#5DQ>%+(,%&T63VYT>) <>
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ME@^6#P!PN,K:I'<=@41X7$>X,@OQ\@/$%=2U<7$!1\3ZO"&*X\\F0((>RP*
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MY'_8^J,H -@GLELG^VH /GO[HQ[8T3?^'TK?.6F)23\Y@B??%D??/S@B)]_
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M<]]5*/XS!@Y? "@(CYQ_BH/% L"FP,*AP#J<.AHHT6$+EMR1EWA8)_1'&'$
M6-BX>/@$A&>(B+'^WHD%P,;YT4D.P,+%PL'&Q<8CP"?$PSDK=-1)@8-[B5(
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MR\?:1A9F1X@,BZF(-K^VJR+TNJ.:KSO4T%?'".SK#): L,C)$DE[2WJ[N+I
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M!9B)9U!@=#_NR:I&!NX'WBB;JIN>Z$A=%G#*/C_Z9<=4#3 L(]/I*=JK49.
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ME*\IM(OO!MJ,K"?8AV\FYEY?KWFJ-]4'EF,R0E86,PC>G"6Z-]I/?'N&[FI
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M_<I6]?BGJ*3713E>XE'T.DVL%M\L]?%Q]V'QUBU52!V+6RN+=L.!M1:6CH>
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M*.".+GC1-Z #Q"\HM-?>A)@G>,R4UJX7UPJ20M6W84[KF'+,KD2KP-&)4*M
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MUKV6,'*C7RV[JZ*5KNS1"<].N,U?#<2)964--K.<RQVE0J,]AHE4#2O5UOV
MA<L6S[5 ^)8,%RS+IB4-.X0\2U7_4,_WO4<E8C,P&2P<"S%0Q30>)-=8H?^N
MHV\I6VS' V55H1AUA:0\*[I\DN*8+Y9G'N,L.8J/[6!*F_86RC3*1@ADC:O^
M0[*6"8I.X(?S5RH6.!@OH9;S4NC:5MH;30SP@[_-B6,[8?GQ/F>T/KVMKKEZ
M3,(UE8LONKO?@#9Z+"W&MA6Q&!6-_#:,#C_:W::IB]>O(S<\K.E"JC,VT9KJ
MS E;BQSE:",B4*Y:FC%A/2=P"'4<W-R.D7&_=RK$JFS]\?!@J"01C"VTFQ<X
M.$IXF1ASR9F]%5O5=A7&/-XCG'Z4%K4DCVXLLUAA0=$(%MKXFG1$#%0330]]
M-_E;XI=QM*W'CF;F\MK/!7 GJNMFU7AM7471>A9J1\J@^9E&EPWZI)-X1-%H
MY%Z!+%<=4>[H[!^<\,"*8_KE D3#*+^4A,OA8DZ$8BDQA",N>_,VNSNC-KI+
MQ+#"S-?UXX4D\5=]YEB6W,?#J=\/:]@U52M\#X]NU3Z-!]%-?0.D2R(&9,<4
M%!SIC4'#91>IA1H+O%RN2\ ($_CSK_O ?TCM)S8#V%_NK]UQJDO3H&D.51,'
M+V%N]N>/22P\MUFJJ1FU4V&4-W\DOE1ID[([(E@[*XC;M.=YG6$,0EHU1>9"
MO2DA3\Y%EE0IYA)N)X-N^T+JV?<O[?MW^_OY.TG=FVZ;;I-O#R;C IT(;F9=
MD78OO2ARA7:?)P%>^P<CVY^?"F ^GVKP])WL(-TE2KV]KH U(IS@]H5UB,3]
MV?>64%?L&/N"CA %F?>)CTR4=NTC48\$Q^,,8!N/Q-6J6G,W]YPA\8Y9#>X2
MRODLJP:1UQLD_G8FX2_J4 L1&>,YTG:16PL3&IGL'8XFU/<+ !/*7GJ[65SM
MUC0[4:(:_H^+IL7A/ZA='/B2,B+F0G:"4)[3?@\EO?&F:>&,I-*P(J=C5 ";
MR1%HGY;]/4"4::$_^$MFC_GJ'M(S59$+";0$5\<8,'V>L#&>5E\SB=N4IB/S
M(RRWB_GC)FMLM&#\N&^%:43AWZG7+S&VVGPMOG/^M-FI;OBWSA/DZ%+#TG1M
M4"]/6L5[T)'$V9'*?9T92E2>^=V$0Z+1,]F^#31A=M_TH+#E]^DPFS.SI,3-
MHX70+;&=5.RH DJ1_:7>U".-+VN&(?/.)6'>@DQ^J6J F.%E7+5TJB,8I8/O
M)= 6)-_(G0B:(FQDQ_#Z,PR"8?I#F]^/+11$J* ,.C!G7O<Z#]8UXPARLM(W
MTA*#C^+J#U368P[?KS&:=?;G]_2/-Y'60A8MZKYG>!T<&H7!Z?./6]<1>$>N
M<+I?IY+AE-Z5]['3/NO%"]GV, 0L-@P>,S?1I)D9@[!&-?Z>#2'>U8#C:I/E
M:56PM?Z\7C*.-XCSS%+XUKKI\AV4 3+_P^HA[-XZ;G;;-Q[ \*NAM3&L56,
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MET%CQC)Y>.;*Y;H8#_\6F1QI16E6-B:^-79/F=%*145 E7Y_!*/E3+*<_7^
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MCGR[HZKMO:AUVZ+7Y*=&=2BV(;A5P[EBJF6&:21$SZHY\5>?C[CW[^F^V(\
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MFE&*4_N2))CINQC_!(N5[L<_4Z)_9&"4X_57_J,/A3][<=J>_;!->('>*IX
MV9WO(Z=HXK.M78[E%TW0N"1 O;%S39(S/V ;O[>U>8$C?9V/_7<E7\]QD0)(
M5=IF@15J*I2<RB?^B11NY8#K4XTG^U<92^5Z0;:?M]5'9 "R,1ZN]/WV''-4
M%J4&JDJJT M44:RO6 %J_%-#XWV3$_W315..4VPQESR7=9K@_8-]@\5MV:J
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M]*OB!\:R!]F%7C26.>@9).MUN;JB=3.$;>VBH@W%M*,-0U'=\-A&)T*1\RZ
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M+/+C;P\+%%4"RZ-S&XHP;<C&+BPQ'?GI7Z5B9(ALEQ *DD.J1SR,<.PYYAA
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M_J+HN^B18$) N$]RB%^G!@Y(NHZ5M[$RQ"K%!Q+SX893P5U=Y'. :=?5TPW
M^*E$#+0@-+0*VMMBG2_6!;7JOGC0R3L%M&"7B!I<#BZ*!%=?3GAMEC:(4+
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M9,I75VF@QKFP<2S?G#4*M^E."=.8'@,H![7K\OUEA#C.J,.]SONCQ,KWJT\
MQI2O:U;455.]$6P<W=R?Y;2IZPE&[V!434D*A:&2H<*,OD$PCV;*#J,V:&1E
M\O'KS/J-"H,FZ1,ZGH2EOC*W#WF,0G^\AQ;=*G-(-"RLO)SP?\:_QGQCPK2+
M$</-EJ_SOZ."X)Z=?L92/%QO:;=3HB9^=P2,7KJYX5(:BT"+EDGY8>E%YJ0+
MS.*\9"A]; A>"S/39 ZXL8U-/5<3*G]27G1C5A683S VKE2"F%($DP]%G_H'
M>I^UV9<_I&7:RZ-S$99U9]J2#^2->R6PDL'PN5G_CP.3BG^X^P>IT 72T%[;
MV$/\UJUZ-=E*)BBNZF?!*D4B)HU 7OJE9=]/8K.V(2O \T^XW(_-9Y3C@I>U
M)I^3??ZBU,6#&@VL+[4UW.Z+Q2N_)0+$E_G3AFLGP6==/:ZN=I!!#J$[4B/+
M<-MK=H>3L(WYR"MX.X5\RY:7C*EIWMC!;"K=^MOS 9XC]&G\/QQ6(,DSEN]N
M[O1]/5$I&@(%IB9#CZJ#"<)V=I+X#QC7,GV/O7N,)=]8+F.&N'3\(NRJA#A)
M@(<M$EYMRV'?$SLJEBW4L@P> (P[-B3TKYZ_VEG8^G4OS(&M.MUIP :7P-K5
M1:NA(U7$+*>^6D8 G*-3">#URTI&RY@Y&Y?OUZ7@53IKI(D]\EN'ZS9V;'IQ
MT?$WVKW](Z_K1LC B,:0L.T/Q6Q3ES,['!>Z-V;\NG)HMAR_-U?7OJZ1K<N
M;D%[TII$%;6FK?3K7Z(Y)S*IV)EHB$@D\>AHT?2>(MO\OMS5VAS'9OF(PTT5
M\T5WQJ-0.M^+-6?EM"WEPCFQ%?%8@?<LC'*)+_W,J &V;TLU'QCBA6Z89X+D
M*UO%)117,O4ZIAC;%R9+:"D^AAOKQ#O46'KM1X#6KU%DE#A>9;8$F4L9,G]J
M)+;?"/$)=;PTE(HU->M5E1X^>?D1W<-A8Q^X+GY5?ARJKN-RJHDX7BPV/QWG
MH]<O%0GF]H9[-IZ8OP2BO3:E@2Q&+\<."*NX!J2Y:2.LXJR5%J7UF/::GZDT
M+*O#R,^?UW/SO\(3HRL?ZD=AC;CCBLN9J[MP8HBK;^<3C2:H -1I"E6R21I^
M+>$P3WX(@O_\(<"W,1(TS-5["89PZNE/4ET'&MCAUA$1R-/,]B2ZM HM[52B
M+^=5GIHL^_J<<L^2Y,7%*@UJW)KK"1AKC/)T15<.I,0PI'S\BS(L&C)2%",N
M&:C1-2=49,AC2'QMLV>[&9>N[H=(3M>;!6GV2[49V(!+?GY&8]MYJ_R9R6;\
MI&:U6^<(@H=G\67T*"RA#HW]$>.U0TA[\?^+O,^YJ4Y?&G16".?0W[>V[#;S
MBZK^.AX?Q6,L_F)%)[';]5;OSONM&I?)KTJ@V#ABK..L0FR I)SQ7S>'T0F[
M!)W+I38MJA W$3/G+NULH!J(7\&@YMU'P+[=>&CX>/_/KR/LAWB-TI3)Y.Z\
M,O^D.93T?JKTGZAGVG.!'I<'YT^?84<&D'.)%[Y;&46W>0;N='+3C1AEA=4M
MG-361/?4/@>#HPZ6(XS@$]<D)]I:8<VZEXN[+C/=8B&]X251BOUAJ>&;?U&>
M-C OD+#* /G],<&6,+XP+>T?EB^>::XR15T+%:/VMU$P-;^(Y\YS&GL\3]F^
M#RQ3=-(--;L@Z5=+4JY+LF$EU\0Q[79K!S6<;^0KO(93BU=Q!IJ"?EDP-N^-
MA67;)8(1Q& F=+A6?*S2IFY'>NN"J\]JJ@ZE/8U=G+(%MZ*8"->X;7Y7WY_T
MHWK:79&H.\G#, R/9U;?O>X2<5;K;^LA(DLK'A:^E<=@+X\CQ$VW2_,?_GM;
MZWF0X\TJEVL"H&+J</&[N6"8C+[5PM+VID?$/(@F&?$HW]?PZQVYF)1.#_SX
M,E0G0X;/[?<[$KT2<QQGY*+?)KJ+'\P$T@86$GW@3[N)ZM/,=#+3\Z;0 \X@
M[N<@3:K'\==5A5:Q53NS?L:1:.VO0>U$<Y!W[K2@:UM574$Z[WT!T?@?YM:'
MV]&J9BFY1YHC4) $UB\]&2R[UFNOS,9> 7Y$K_Q]6+W&)13J<[AY'=S,/UR[
M75#P96!U*<@M_?2JX^[:Y>+*(RAMV8PC%+MV' (P+0U>ZA8]!R^JN0LUYSM6
M#BS6@2?MQI7Q^:BS:T%^!S7:7\^H/>17%VR^R(WI^2DJO-JHEW)C=G(:L^(J
M&_N2<FSL-?D."2%" JZ 4%:.F0RU-[W0<$"O8%#R:M+8Y7EU:# \G]+LT&QQ
M#CL45,V1T5.4;XE'E\"$8)D=B(,0UZ*GC.-04DQ>\C(H3VJ(,$AE2*\RF4 >
MI%K$=1HORRO<ICX=T;9(.-@E<%IT<X !Q UH4N:+(A8U-KR-,-_SN@<\8)]>
M%_:+-=.O:<13G3P,A!B=6#E'MV"3%;;,06-_(X@9:\_JMZX/#8-+ONI_4?P=
MB05668[>.5Y<BBLVSKX_FR%<(.F8(%F[+7<)'MY<J$R]*#7S^S33G#TG^(S.
MEB50LD*=[0'UAT%$GOL!;*OP$K-D#[V+!0N3#_-_*LU &^E+-@T-R\*!G+N8
M$ZWQR^WZ)CYN>4]$9F%MZ 2-/(TD6!7V5K.J&#EVM(92 U=94345H&#3[F[A
M,:WJL:^RZ"LV,4)<09:>T$T;GM7;^GF[X1^W/#2SVOGPB+*&3"\B04@<JBC#
MNIID8'83*UOJA[\H)MP#,7BG#[C1)?VSF3PI*ILD:FSUZ0XB4,8S^L+,Y4)'
MII?OMN[S5(YQJ,T(TLG"UU8CWWVM55@AO8H3=M)P&3U((VY<!#<1]Q.::JMD
MO[@PF;?HV,SR0HC8N(4RH"PU'8F_RXV(N<IP*USBRQ<8*(RR7)N4!=OLUD-/
M'$F#.G_.5XR_&"0)Q$C?M'C(_-;N1*NCNL])L50O>WQYM/F+*(62/5VD$6IV
MGUMS<\N[_<JQGLV3E*5C>B3:QO7W-3N$CC1+[1.53HF!"@)S+ZZ>I_Z^Z=J^
MK(&18N/M->Y>A^L7D:I\BM7T%C:AH*=%"9FV^QE/UWRM05RXII#]>(8/V.&E
MBRH$^C(@[PC1R^_36%0.&$"9F%5OCN,>O#)?%Z(>;(Y%M!:-1SK8&P61*BSV
M.G1^7GT#*%_-U^?UY\H7K:D.^HNB A#Q_;DO#WJ63(F-J:Q8X6)WSL\%.9LQ
MXZKBQME27SF+$-I=C7Q6KX^&$:]A+&9:E+PO,+.+09CB>;ICX@YUZQX88?@5
MTIHN&']W8*/5X*!/A!DOZX$=2C=&7;ZBED'(:ID ?28/QYF:ON]X=7$0#X2.
M<;U3&^*G'XSL<-:%LG^]QLW,=USP$\6_S\QWE=I1G3K42:!7JK'R)?SL0[#W
M?.W<[0#FJF71/0^_$4:>&>FSO_O2,67Y=<^_!?)DW\X3-JA1V-W\Q?%;N8>$
M08[%L;:4K+,013&E'3:*<ZL<R1BG549>DYQ2!#:E!R4M1C[L?S97J5RL=8[!
M>DINLELJ2B$\#%5-)PM_46[DDJJ 2-KS7[?/Q7W</#,#,":+3#6^&SV;;-I;
MHJQG/9%/\\%/>3'?%QQV# <S.[WJU"B+*ZY?EC_W/TXJ2ASKL6_&D^PU-4I+
MC1,$<H=7_44AE_L%3[ZYN7W^%N(]?W$&+I)>ZGD([^I+1AYZ/=QMVVL/3C=C
M;?BV><$DL:>\/!J/L)L?GZE[_JF8/'&/=9H=,-#L,'5.D&+WCI&,/#9>R9N<
M,=G\[&1_44#-18#9W+CT9R1#OG:?<U<V\D@O!7D3]W%FUAT44AC=*(&/BK;8
M3;%8GGY"\CRO3GMG/EF<+4C\/Q(G9!6'U77SY,@43>_3\(*&VUM_[JT7P7^>
M?SO5Z88N<>R*VI%L2;UV;%FZE=.S,^]$[LA'D4C\DJZW_#"NPRWSWX#/]#3]
MCIBT=@=B2P_D$YB<@8(H1_-F?%_GJ0KX:Q+E!\]#)2O+AYWT2%D/F91!F6HV
M7 E5.TD;7I=U^G]$]Y,DD^R4ZX,X->%=>B4;;8[]8OI[^)\RO-Q%;.O!1C[7
MQHVF^>KW?HST$$YO,<6\R^ Y=#6#+XKMQX6+W=#.'^HZ;*SY4B:A_=,PM;7)
MY9:O1B[EUEL9MAQ>,UWAOYIZN,/6]F%5=;#O!G2WR(C]N^)?>2K/ZKV<49E*
M@U7WX+IWN;=+6%Y_P!/];9/!I%> ?+;^[V/UV4<"@8PI@:^=*F,Z."7\FXR>
M(A@6XG<8ELA^H5O:+XTLC&]$&H[@UL6WY[WF7OR>H/L=1>)ED>F'H:J\P.PW
MK6F=>=#S=;]BVZK#-2ZN@8G4%>"I,M-3^BF7.]E&@-3BC:!I63_TQ( +Q18N
M3HWWP5%<W:)VXZSNB+M(%%J_LA*AU?;@ GU2X^BCI9A@%R-:'+#T)KZJP]YK
M&KIQX^_OVKAY026ZO5Q(0"3\2R>3E]T-;L?L9,VIA^FV4,7NMAN@'C>MG^ @
M=KV/R/F+4I/_97+*6O=$TV'SHXQQTD_EJ3#E#>.%E7?=$ORZJB=T@51>8[0\
MTLJP]D_;@?<G^VK:'EJ_C;KJOZZ]C;CQJ!0B/R8GS<'7>+ON]2 4;7)W(B@>
M9A5+3:"QG"B(:ZU:-T:.FE4YG18#6 TJJF^4G\OVN,Y$>,];P]2J,;DF>^LO
M#_1Y!^B8"'WN,#BALR;=SA*4Z-[\OGC%60D[M.\-T%\?2VFMCNY' 8*-NP.Q
M5G??2S)=E1S.SF+>5$U'9U=%6$Z?I&5)1!X_=8T;4KR(#QI5X*/CY3>N@_*E
MR4;9@7S]^!;2HN(T<J\$F5,G>.0_RA0$]=4*!/7YV&]R4B3(.8$I"D+"C(T4
MN6T-N:&?VQ37EM=O!*KH."I I1PXH-;EE=8)5S"G6IQBO8X8'0,)YQILHF]#
MLA.M& 7E*VJ8&&G.P?_Z9M,G%":3)/5S#>&T*7 8:M>H=-S08]G'\][?SE@'
M%]&II:04?OM*7BFH6R5MV^?4CX>)D>TB@9<M*[M)/-;^>38X7CFWF$EEJK/N
M;'7/VC',ATW/'_,0Q9AM@*^\X@:=QYF%A7/C8.X/;%[-;7FZ:^[HC2Y9\&>,
MNSOTU&WS+>#ZI]RXP@0#;[YFQXF20I(A4EO3;'U ^RNN#P<5J=\-J< OWA .
MA[\/.G5>#]V>#W)?XI"UR2L&3B_GM[WTW[!7U FUZ7R?;D,QF1'BSMWN_Z$+
MT..GX)^;?FDH]BJF)U-1OCKM1)#XZF \9#>**O@7.H[#S+KQ2^EG[07M1;QQ
M$:12N].=\(&?^/S[R5MH8OT0F"@3TE0]+.0 XL7L![>UB^#[+HGNP%.S+: I
MHW7?CCO)BS/F>H[<:QTM.%P7F^,;HUH"(%G2KKN/1SLKC82QIM@S3;2#AK8S
MVDQ,7HPO][4#WK(J?E*(X^%.3720G-CW$";?WH$<C)0Q0RQ9*2WB$QM&)MJQ
ML&@MXM(+M8CU>08%$J@T7-4N?+[-Y_ ?U!:;PTW9OA\'^6C7-FW&QVUF6#(_
MKV2[K73&74_FMPBXE#%RG[60TJSEG_5"O#1%!R:HLU*,<T4S);%)E*Q64M__
M<6R5I?_U(5*%G,L[R$+_[: 7^U*+:-V0<JB7\O!@\Z8\'G=E1E;!N!>AF 3@
MOP2-(PH!?Y!]!&;8X_'LV;9CB?3E4C0*_BF5&];7YFKYH.Q\W7Q0%4&Y:!0[
MEI9> 9(MTY15ODOY1;UU6?\1GHG5O%L6*LD$MR%)XE(J)XSKZI&P'^L-W^]C
MS?X,1PI-<A5OK:8:6P*K6FOQ 97)P=&TZE#T,LZ1E\NRA_6&;W\1HM713<7!
MK]X/1]#B->A51180*=%E 9-Y!'5+Q/L#V9*%!&B^J3E!-MR[$W"W6;5MCDG-
M3A]4#']!#Z@%@6O]R\E$TLL2=351;7S+/Y;#W@G3K[.^#AL:_%"FEDY#\%;Y
M3?1D+H[2H$KH0CUAO-)1E3$T0=06"K-H!6&B')=3ITA32QCH@+VL7/%M6.'#
M%EM\5%3"VZ;#*&PJ;UM^SZV\+W&8),34>\O43>U8C'@R/N:JDN]E;:1X?\.Y
M&+_(1@)8]/7G8\AO9=%@;':V3?D:J*"V_OB)0+#!:D7MM8G]VV*F(:=DC;1V
M'6E00\U5=!Y.U[!ZPZI<NX5S8T!9&S9+73D.41Y@ZD.F:U#VCR&,A9"EQA44
MK*L4KO;4+-=7A!'\]C]=)07B,B)G@PRAUFT(EZYD4]162S#QD>;> $VR*84]
M4JL&TY@#:OI#B6P)2-,(E^.E_QS+<E*-]G(+S;IID@5AS9:S]5P/*EJTM-":
M@-<SA37M,F37+0+XP4XOT<)QH3TWX\==#,IJ&"<*^FS,S*JL:@WTY7&U*2F7
M/W3H5+W<=PFCY6LL3+CUF179EYZ(Y'+LA&AZ3,&">K-V*$Q8)M):6NWXHGI?
M,W$_/(4SS<:]JVX4:'.>4TM+P>$#%#*[EWI1'V[J%HMB3C'6286&#1O5P6M
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MY+KXVA:S7)KCBQO=4.;GP;G4VQ3M76C,]*Q7O)/$K&!\N$_>?Z7A7,WZ//C
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M.BW$*:;TBPQ!E2,NDIO?V5;:/8=^8WY@PK9$2Z=XFW0YWD+=$!\NQ3]$.Y7
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M%[O2#GXY?.]."'>KC4M]S_/"[>W>UB[U>LTQIAD+"_TOL*E/VG/I+/5CT3\
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MBT95(S*_KZO!?3C=<(V:V_A& Z^+N8%>\25^AG&*+D>6^&Z5QFBFAQ"FLSA
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M!DV%"Z5#"&6UQP.Q;VY/.>K)VF_8U']U_2H\KCJ?>?C$D1A:R"!!HZ;F6*'
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M?]FZ;D/B?$PN]^ENO4I^=_\/T'WI\(<GY*3(LZ\<3QC?[S_$GF.H+Z7VYA_
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ML46LP,YGZ_A0<@=IZC[#PP8&VF4],4HU,RW2;\T[7%JD\39<T'@VKC$YRO]
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M'6V?P=2IL\7'C[POQ/\_4-:#$;W#O*:7X"RSZW,TP_@M)/.QWKJ1@I;W]@7
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M&-.:4K-/P(7&XF>CX:/,:?]),ICW=/-7(]]?&)9K$<AU!"^A(O760!%V;>$
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MB9XXIXY0EZ=*!XU#.6Y0,]\^<<+5[P_5!L2[<C-@_SPB+_\LES8/XF3CFM/
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M2_]( TEQ!7)"FF>AM]L/V'\2($%Q9S;HFN,SZ+\MD6-+#75]ZH!IFPWA\KK
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MEV\Y1*S_(T*BVC#OESP[#O_E,P#4K&&S]'/>^!F C %)[1H;B#K5LYA/84J
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M,<0)&6]J\\(W8+%F&H:K%N&PB'=&<P^>DY521*N+QZL F8U0@QDU6%%+\E5
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MR5+[1%[$_O=09?C*S&CSF[4\]K)-'KZ,C,M='BTGXN EH? V:K0R](-N(DC
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M6)JJ?9))D$_$NRV>'$LAI;I]DL>6R+'_J5IGXI]<O2H$4?T]&B%1%1G</.E
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M"KV)^J%-_ AQ?":(0E!HXEE-/X[TP\&JW;>A#?, JN)FGQL_?W8/AX72(XL
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M1RZTD8=NLCU@F0AEY6%.U+?(KC(?RI@!>TNC=ZQHG!K.F26NS>QI2[S" CS
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MQN_E_[E3KD],,=G,7T=W9+V89RP7W50F[>P @!8K7MK)HD3$II-ONW^P^;;
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MVGT(U%T,;&7YPU-8WR8O^X-]X5USD(6)TV7=0G,&06%_,5SS!_OWPZ^96DI
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M:*2@, %6/WD2JH*]N;G\TKO">B!7CF_YZW[HRW(O[Y#Z1*REDWJ>F6:WY3.
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M.9 C5020^I5TNP75#G5@^QH<[P*2FC&I#YDR5L'<&<"EU&LR@T8]PL/GBTQ
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MY[7/)=<*P]PX?J#P?%ZQ3-HT+'!B+H[R.-K7X@4\2,^\^+Q-*\>OCS7PH'\
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MEEW'_) K4&(16[DE:"--HF"+,T"#GZU:CU47HO(ER:Z 9:%^<*Q\P6+T=E$
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MK:DS0AUCB3NP]C-@'=<5CJG0=!]8+!",(E S\8 CIAFI!$\9M2G:*NTP>VG
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M++$39KJ&V_./A9VL=<' R,Z\-E:9<X2/+;\A!HTM=>@VYNFRR])8I>KL^I@
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M5324S7;'O9>DX:?/N3')UK!T2.B;E'G.SC1ID2%T,D^2=]1:2G5IT,%V1#9
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MN4\F^W<DO6(Y1_\)Q/A_!>+\#Q#C_S<@/+_+^/\32/Y_"P3_7X%P_B<*_0_
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MG*T.+29[P.Y@YUH5\=8P(=LQ#EQ#E7TI<+%&]A>Y:L_P ^:I3FX;*<8-?V*
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M)!FVO/#*P'WJ*#:@6TL[-5Z(FHF)@.42"<X5%Y@N4ZN0:6,E!9K0RP.B@0$
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MCP_564S8(IK3B O(+%6K3,C1O-R\Y,S^XC8QO5ABR]*!N=MHK*X904YH6 "
MNS[(^C)++*"\5LW3T>1K&V(F?O8W[[N!]4+H)KUA/\G1Q'Q%IT/N4VI<7;33
MMG:NX(9J_3>F<*EISILV@IEJB,4OZO4QUK[[.>RY'JOQ.>2-@(#>+E-Y55/4
MYFPZY$=Q^C(4>5XCD#P,&S;9*^_YULS1H'BGZ'Y<';H]E$ICLZU'[P+2L5-S
M8:RX77&^X[V_CN YDSZ?9V&&8-\VG*HPQW.K:;Y"_4SNE6J=L\'I!4TWHR=N
M<9"W9%ZL,,_IR^)- RJZ"9_NWK(<Z;'=Z!3,1Q(?R8Q")(C1V)E81@1([8 U
M+O6R%=T8F@P'M.8M<@HW[E$TE3>S?8Q,NFBO/U*8ZU0A;8;KUZ3?X#R_W427
M:Z_^QGF?%H I;+6K>^_L6=%7&)$T)!%)6ND5,^.OWR_;UZNS<E8N))B9QK'K
MMB@W[':DWBUJ<CWUZ/2W*^T^VQFWY:T8^ZK,V4:%[HHF?DCUF9/.*T,HW8..
MPJ.XR],2FDBOD:!0 M-#PTMDZ<&_($Y\E92LX*;J=F/LTUFZVZZ]]=WC[L"]
M(&5#S\$NT)%[W=I-TG7#@OI6N<#>(&-/ +D2RYE\@^X0>$PD/]I'$R&=UO5T
M9+7_N[NM,UR9<U*84,._F(I+JHT19.#-2HPKBPW51=16 T4)WB+(9I^DWL*V
M]EFD&#+C#PN/C\+6C_*?RTI@R!K&I93,;'#UGNZ7/U4F;+U+"($,&%8#UR!7
M]STC!#GU#83G1,SV1.T6M]Z7)P,__-8XEPRZC))5&F<CN,F.\,QGQ4R9IP@@
M ^8$:VS6W6%PPFZ*CG#U-\ +W#ZKT"3ZI"_W,G>3<YXLEXH.2@)Y"W22)#*W
MV!E&PU^K=>'"B,-Y\</)BW]0Y(@PX5[<^NSQB'WBOKV&ZI]9.6.RJT'Y6.-;
MB'8?(\UD4KGGP[T<ZMUY#;BLU>G9LB2T#X4/*5I D0$Z]1;"N_(RK4XTV8-=
M.W:IJC4[!N+<O)M@HH/8LNZ '.J$,*4O,RV3_<T+UTCT0G+3.#@'8*1C*^^9
M+!NT<"*+[TY6P*-FP"/YI>G&6YEQKQNQ"(+$!L&V7'.%VL_UWN'KG@G(Q*>V
MUKIDEC6[;*A([1UF6V-*N>5NK\!;3Z2@-B^UW6^7"*,_Y1Y7NGG^%S_)JPH4
MN>UZY,V31-($;")'!"&QN)*D./+28&EK]:Y(C<BJV%'Y69#U2!W!#  .5AQ%
M5P@C>Z:&^&*'3._WB]U>6]I1PUD&+G3F07TEXTTA'9U)6^6LC'S!08AU[UHY
M$$%5'T/(OHNWMI/6RA>I(([93:BDK49V@?+W/#/!E^<(RF^?97*<#EOU2L$'
MZ[*IVD(I+4!7]]RO$S"+"<6!B4ZT;&H1\)R$F6PI$\L95E^U8/7%Y-H< 2%_
M0W<3'G@C%S6^?*W:?&Z\)/Q]/VKC+)7O[=[H5.!?:JQA]NP5WJ+S:0-RE>SH
M$;O&%X"QDK*\M%K#D-UMK6)5R9:Z?-V0.E%9.% 1I@)3/ME6LH.LCA9'XV_G
M%)&(OBR0A(A,'6\=8@@)C4NIP]8D=>>[UF&&\8J4A[HUMMQ@$A.[=JM^$1U"
MFIIVN"5U!<,4N0F1C!)7PUFSUK*IU%?4<Q2:J,NJVN,[,<KUT9CI]Q'8=)Y_
M:#!/%@PG/3LJ1V38)N3Q!Z3WU.!%:JPWUZE.XTX0^JH+L>STP0:*A-&(8@BR
M,P?Y.7ZJ14W)Z^#@1S1ES,_WF#8M8KOV5Y8@**B$K)T_,Z[8H5?_?=<Z3AH\
M?!RHJEG\AEJ__1$*J77Q5F"&-LSTMY)="<P<K_)DDO,<&^V8I8>!N=,,2'TB
MS/-[25.7RG%*W\90\3+=]NKO6<>^-0_33#* ^2*4&NL3)&*V?:!J'3^8OO8@
MR)]T6Z6:,Z!PL/S 9Y+$ISSV-DOJOC&Z\)<RC8*GGI2\&8Q^$J"[BF/U.91G
M-6T87E^WJ0/OJ1A6N=/^\BQA2/3H&=]<9*W33_NT9&K;DL 3,R75=+23M6>P
MT/!G52_^R#NVVQR.+P]@P>'>77EV1<U!H>BGMXFJ%7#LM?EGE)Y!]OQVMRUX
MA+6Y<5%1X&:%N/%GB%"\N5-UD*;*=<Q[A9=,RYQRC4QXF4EF$[OYAF<74V:'
MRSJX]4D@'MUN5#>'D=$**A3>K"(]H/Q2V)SNM39#ORA8T:<];]E"E"]:!)_(
M8O"L</T 1WG*)*H'$L>(&TK@#$.7V=H39W09BMV5Z."LA4WI1R;G],<1?*E-
M@XB]5.X%KR3"?5 ]:6NY;/P\+?C@"O:D]1G\F!1[0#RQJ@]U+MA2.AJH[G3<
MWBHGB*CCL95I_IZP2&O5J5=YK#>D>;Y&E#Y&D-VYQZKA\J0/49#0E%-1Y'"@
ME^<JT'JQ,@?9\">7WWK8YB6=[8E3/*3U1:4F=MZ<6!1$E(M\HN-IO7DZC2B7
MR^%>\"/(#_/K4_1<@:6Q[9TQ?J:N+OU]>8.77A/^?]D3*8KO3+/QR8@"C@:V
MD@RWJLD&AHER:G#(!;R5L\).Y/"5EQ1ZW8*/&"\J_4MP'EA]+G]*R=WE4O(1
M5ATY_3VXJ L'L>MD!K'SI-9*R;=5>R:$CB6NQ1B:6!9EYY]#!!%/'_^J]J[A
MS\$?Y_O]]E[\Z^_SFK;</>[;*!JL^CXX>8R-IA7$ME_U(5),DO51U&YUVW=P
M:&4''] U[88*(K;L08IIM7") Z?P>4\V@<WG9\)@R473)HL!V2Q_)!G")=<J
MZ$FYWTLQ[W()0?\ 'U]N-D::R,0(A?27#R>\OQ'D3!K'<[91[':$_Y:-_@DE
MU#,N6A@PWLBG8\Q)INY8CDG?O:VTHO+(2DM2\Q^A^UB+GYA%5.=[,Z6T0)1$
MX_=2YPTOFT(2@EQ]E7NWBL2.5BD@EGL=EXTQ_W+E![$I(8G<#WC2SLGQ_[V:
M4&2[**EVMO02&"A6MWWQ')-<Q\YC_?.!8DLD6GSC] GFT.^["(7H9_KHKY@V
M\^\^?C"2^U4FSK&B@R;G?ZJ*KOX!T'3*?^X\4GS^?"%65>&7_NRS3K;B0S.&
MLC)"S.<:X+$:VT,U-/Y%P#@+ZR:H0FP%#T$'$8OA'P ,BP   -!.DJC3E9OL
M<<*0'!4>X+V&"E:#Q(V$1N^(/$2H>5\5JZ V1[;JR2$78->5=J6 -M#A__H[
MCHQ$RK\XHK+_ #2-9,'M>]^L>X[V?MN,>[_=7+Z5!7?^ T3_ T#+16K2<@3[
MP0+@(+WC"/A1NIB7%=69;F^R WC<^[CL6/I]D 3A0,E4CM]+DGDZO*0)(TQZ
MX7"H&('?Z^>Y(*;^9EHY\JD+W<3#?P#KB%?7NL1V#'7'W4$.R_5\#O<2:L\<
M8'N^OC[&>*?'*EWW#LI:D]]EC^QZ/*L" WA5V=4RT+Q%5OM*UM" W=+ON .!
M?:-GYNWD.%/-H%:Y^FU%N<.:3QYA5-$)&&<S0M.Q92TM91,0 .!=(^.MIX[]
MCWA*SJ*@).E9HHSKR6I\ LG3 WZ<=?<(3K;9F-AE&ZU?_(%T7$I:W_E6D9QX
MEBE@I*ZVO_4@6#7T75-2EU7C"^)[,J.7=W0SO"DB-!Q%J+Q=$'*=^_#6'Y4!
M%^L57=:'08[=?)5WUIP["U<L^<US\RS@;BF.L-H0\C(B:V GI%T+QS)KGY"E
M<?4KR#T$-M)HC S'_2[49)+@E9!&_7 #@]&_<)X[<*6JHT^5Z7EGF=W<>M_(
M^_C#^O?Z";9EOC(^B>+X>%TK^8:^PM@;ECY;&2#=+586*_;P70O'>'_:*8ZU
M*K3><35*G;RVS[ #1,\T1X4!:H63.PYS4Z+J9$9CIA):BFA:)9N2=()_IB2D
MH>F"&ZEU]-Z:U"J-RJ^9<IIO<UT6=BYLT?-YJS@!ETF/7=7XYJYU%'QJZ\UP
MJ\+UZZAH^+:1)TS7IF+N4A7J]%0V[>G@=H?-J70R7R?/GB^X/4P^#J4VVF',
MR+7229(9<Z:1RC^+)7&L]L:2N-:V$LW<TC%EFTLEX"B!PEIB"4;N;(M3N<G
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M\\ %%"X,D3#U)I[8M KK@1>+S\&;:=FU2XL36%(TMUN1_;B(T6^P5:41Y3%
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M<$0[/?%>^D%:4R4S>..7[-WCJ54^,>BRCY<>[;\MO%:EBIQ,DE%I)AL:*YL
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MN155B,@1%7;:($J4HA9TUV94D^5AC $F'0W2P_B2:8FB$\,!K J?@A7_X:P
MLDC7OBL9B:L??P&N[KHJ#(^:7S[]!2#BBU7M8\;9!MTDY/CVY3KC5NH<G=C&
MY,%@BN98YN6/0MK:)L!+?:YM!QQ.;>^A8L6!P\04@BO_C@3*L)"$!<<?%S%+
M]EE*R0ZL*;1NIAVA=B)R7."#-LYL?D5,I6 HMU%QD!O3) WWIR-2#_\]":2E
MZW4O!/2GS4<S=E'2F)I+\ID-YI%$R&';Q,7%A(949NLJ(U7?)KGZGPQ/%=X?
MZ>HRH!4#<;*'6\DEV>(T!8;%..N,X57[/$V;MJ3U@7RQN!KXQ7XB9ZW./C"N
MJ K67.N"M)&\UHWM+QAP-)=Z,"*^*6Z\GIR;,>.7O?>JO85D9A+7I'Z$+N?/
MK9 0.G&G4&K7&P<J@FR4?7 1W*L$0F08IS\S;V2SY">>W!CFV,.\-HZ:VY4>
M9<58)+AYDH5SMWP8ZQKS4<<A0/Q[$B*UJ"%*9I*>&&G^@*=1S@6Y@<SI?GN-
MW927 "590=@TE'7]@WNBVG8$%9#LQ 2<U=3K.^X/1=P81!H;\.\OIZ]T.KOH
M/[2]/1819WXF'[\OV7"P6CR]6;9]>!ZUY$H=L>L)UM'@5V3<TKNMD5: 01,5
M,:OH999W-VVW#:*=./="'O3T&3Y 134$Y8YDA!0UZ9@^*YV5N7Y$:V4*O27.
M+APY_U$5L:975<X(=E8XZLQKKI#5W8.=>'');K*ME!0R/P[K&JP4$<F5(5>!
M(;<@AR<L#LI!C!:96<T2[LT2'EMY=?P?)]B?AE]9D9:+3;!T'<K;$0YW<!9G
M?">CX(DN 9$IX:GXXG:%DIQUT2[ND&DRH/4GOJ..NL,J77].J"/]2DKENR0V
M-,-:-$($Z=RQKIGH0[3!VRI\_[0OGS=O%E>/?ZP;E1322:[:.]<9F>6!6-23
M(;J_?NMVM:UO%TT::[K$?_/XQ=]9F3JT/(2!H'N!(C82=764WPUVJ;71R(2!
M8LL/?2R7QF/_HJ94;TX,H?WZ:LZP%7-$#RXDYJO%O4@%TX[3=&<:X\\)-#<J
M+=C2]WA8]F4N,$9D88GX%) F9Y7^1EQ4XX']LDQ7<$FE!=*3'M'(3@Q%A8F_
MIR50];BZM*\8>W?(O=42(%FA;/)D,!@"MP4X+:_G*WGG>6E3?#?U=00@*X(J
MDY1>'0O;P%_5^UL5^R>=?Q!^9A 21%EZ;H= U!ZHT'7/1$K6G!1+)+=[OV^O
M9W)?JU@P5J=.UY 5[%%O(<1%CDXDOTE%Q%E>\KR;.M0KO_08<=L_'DXEP]*[
MMZ.'V^U%RR2=0IZ3#J*UO,E/PF0 V%442=A.FF$7)Y9^#E:>VM8B.NBA^61T
M [BK0H"X'#2,,^W<C-W<B1+G"-$P1'>4:T<M?B>NDP1OO%U5?LL0@0OU;X<V
MH@LV.BJS!G%C!.,SKK/_6?EO,\LT[Y#Z-RW\CBKDM\/#=SSZ64I^GP7B:L/G
MF"$9CS>;8AGO0N$%HQP6;D%>S>%M>.H#D[2P_<T!<5T9#.YV?A=,(4;/L_@>
M !7[48-+$E<_Y'N:]#DKVL0YM:'KK]0S>7CGAM;N/A\3B]X"V7R2"\])SH((
MF^\2^J7U3!*V'#5(YT1.C)VG>CLSEE%=?@)%ULS3_/4M_*V&"EUB7 \66?W;
M!D32H!@: )3E>E<:[VCJP5U9NV4KXIZ'LT?-\C-LATB+4U-J*;I^_^UGF5ML
M>[>=HKE:?H4'(:H"TWV9FSLO#)2.2=()TO5@R"KK8HIWU_PR!9OWR"!;!>EP
M"[--9Z :M6=9OZG<[3&&QIQ/T=RIP;34:A#:#0]D/PR ,?(7\"_Y\AWN=&P!
M>89B;I\_XV&3J9P7KVA=^/@MGC\817W<O%GH>J]Q(UX_@)IB055YL\5IFEAR
M$34TH#[/E]-2NW>N:K_Y-!8>7;)<.8#&-4E0<.9YQ.W)XY ,Y-!,U\T"N^(\
MQ,\ @^3*&8.VW_-@@E"R>"($.-2#;' Y]-_IJ!PY1HV_PP*X 0?C?X&DB;\9
MUB*=<VO2-/7?+2<AR.U7FS[&,#3:I69^(GDQ&#Y%*TB7RH&,OS77@6R^(1%"
M?TM!.=" B^^O]\3F*8LJJ]MPC^:0GJMJTIEOV.^2../#(QHA=&75;MC(@YK@
MBT3.M2MWD/K-@HZL_*G5PGLU&:? #<9&B8;.&7I"F(!;E=OES\Z\:E-9:9YJ
M)OCEUXZ?U%_ 2GSZG^A.D8??3^W>$H\Q6\\&>5>;#0&:CY9YTPF_D!O1,\0,
M3OX?Y+ML-+>1X<]-.9T$@T6M(8I-[*F:6:4&W^ECDCT,DHG@C$8QC#I(;.'(
M7%V8.NC<&BG1D&O8#&P1." 0AZ??.>N)<56CZGK\&9.1\4<#Q9Z_OQ2LJRAH
M0TZJV<%7K+;#@BEU1I=1E/<=ZG:&%#:]S1[;V8(OB8:<&Q_9OK.%ERT>]7L"
M[50^IA5'78QKK6U^DOR0I!Z=LE7 O>.Q>H33KC7J^,+K*KEO(Z,=0%,U_-MB
M+'DVYPL!Z,\OZFV@@-F0>97\<; /O<$D14#B\XX63!XA-U7LU7^BSZ*^_>([
M (%^GW8+;J :+OPXY,:B1AJ&<_Q9N;BRV$]>?TS7VLM4[FKM%_(KFUOQ#-;R
MNQ;/6SN3T(P#0HOZ!\V(4?J+76II>BNCQ3/L=QIPN\6^=)5NARTKDF$)(3*=
M]$?"ZY>XDFYX)\>)CQ];H\]48&I//0.:;.#\!!J$S4G296J4@H)VIQ:EIR.'
MRS/*>'D:JR%$NG5WOV+L4P;SNX35M+5]''KH)<7HR,CHH/R'J&C+97XVUF2]
MX^^'[YB7DM%P$AFL'3/Y98J!73HU\RHH;_ZE.DC4IS?Y&D%H4(B-M9?YS#EH
M-9IC:@ANS5+!F 04 PK5+%>65\8@5Y9KJWT@UC(%H$L" $C;[*6=FO:_"(HL
M"S8*2$%L)#]!Y!=)R.K(0@EI$7#[(H%SHT*7-\)*;5K[^*\C::.H>(D.6$/7
M"2?!?+IO%.94<&(Y-.@&&0IPJO&J\:^I1^F[/^/H?IA$&6N4YN%S8P!HSXV0
M*8C7!W*OFVXO1_3DOX089NX=//O.C>AKQP8>^WC-F'RETU*P?I!EJCPE^R0)
MJGI'U)C,*I^R*9L3@=H<\IX\,1980'ZL*BNP\OKZ(:W<8)2D3%0_X/D="&=(
M'BRD'F^ID2>%;>$NR\"*FY@5P2YWC8Y\"B$$,F?AI#UPK2:D8*\/8+)8-N !
M!QX(Y$@_ .HU,^-_JYRK'MDP75[#2'!E[6>??R1H8HL/(Q*=[<OEZI5WCJ10
M#9(9E% SU<:#DZU70^GEG[XFUAV0,FSJ<0GW41P+6^)<;\I^<='E-@"--3F9
M"[LSJ<S)Y#F"8BVVBRBQVNQ$W]:>\E:..W"FD#U?#*^)2ND6,.$/=,?[ 2JE
MQ,A2/&M^_VP:,3(9XJ0!SG;&<UB<>BPCRQIWH*B\M\J!T'8?E 8,L!;+:VHF
MA,L[+;)B)#$2@?A42%0,:'.#ECR5:LS_!'RZ#E7A]=">&2LRA@V3,NXP& ?9
M,!Y$<P!%]I06P,U9[QS!;_$_X16[]LI;I,$_ 5#7[RV"1/[AHYC8\-/V_WC&
M&X[&WF]M#?X%[!]-?_GM,,@QV+[U6$CS^/-+>T=5*>Q715_!EXM1#<*/LI;_
MW 0SAEYQPM%M+6B9#6W9=A)=>ZW2F7S7^MP?@2"P&2&>>6;%.) :*(0&L5,<
M@K; N^<$TSAH!A=J)H623 ^%LD#D41?%\,W='?Z45EN9JN0^QZFQQG<C6.SA
M\B+!N!RFK#@*/^;9.NG&>-!H[]8@VXF^=XR606@?REJ%1S![9Y^)G&#!^_Y<
MT/U4!%!1P_&7G(VIULDB[Y!FBXJU&X0/(CK/CYMEDI05DAT<9&+V:?!L6=>O
MH^77<<6J?K;BMX4$3OL3GI;)U9;I;"]V^D\-HDF725[:3HJIP2&=35$9I=PR
M3#@A<J\^OELOEZ*-UPA7@F.U:Z'$C7+Q8% $&4TWAV@1QE34K"]4EC3P'^:4
MJ3T2G5^6K'#6I4V7(*E6 ,]PO3!M5P@%UI3OLA#4_16]3>_YLJ7+#XGU]S#)
M!B?:D#+!Z'HF6T),HV5",=C13&W:N19$:GSQ+*E)5C&R:C"%-US;P^OA:P$$
M5\>DS=N\^4!,K?49(B(UK<;DDQ!W*/B5T%7PB397G_"V+7F>DF-6:=,6R<4_
MSR=?X0WG?4I.M%#4NLJ(]7>ZWP<F$ ZJK8WPAPE.5N'^#3B+GM2%PK.(#^,"
M+!-4944-[2\5;5H?I%R>FR9:X2ZI K)/_'$R;"R*$@H@QI#+V>9)G:A59:-V
M(6:P!I*!&#AIM;$$+@"))H(HT+#7;\6 R'U^;VUS*ZO/V>\Y_]1M*2ZWR-T4
M79_97EHW3XRW$!.:.98^_U@T5YP6[.9OFI">40"3A_&6W2O&A>M7G1!1;H"6
M=TQDE(#]?!F;I,6$^E>Y:P;EG%,)1P3#F%E9+3*RQ"E2#$B,T5.O\-^:3A2Y
M!6<H L-@%EX#YSK@+C<ERQ ]G'!!">Q7-?H3"7:44#?#L7JG&0G'9Q6*N&RH
M55&ECF#^$A[0(ZGQXUSBHJ]26/+&3:W!N8%*EW-+BIR]>JJ2UK Z$_OD]\L/
M.LS\MJV$Q?-$OW);'UV 3 <%'3"*7"'%B(/BY)K&> UY)REM'E4K74P*NKBL
MKQT,V99Q2Q;)\&)'D6C\<!,$7K'2$8L]:K\U"J523W /N"6>ZQSW>1#H:/LK
M7#78O:5E@:3H+,0X:VP9^"X3?*@=L7K9LGN]K8-DYM;-/ V1;S$C-MOH3#>J
M-F_FUA]Y;-#/2E=V4Z*TWA%:+Z1Q[L?%2!$P"N)C(/"G)2*IN*##YPLF?5/=
M_WIC0^15!"*!.MZM)][^O8X(D%YMH1O2Y"CVMC73*>>B*FFUNKG':B:1\72)
M-(K-;U)NVHS%;(OCV.7Y8+%EA*Y$7'RZ(>.\(C\PS(?5?HHWU7ZFY2[$B6N>
M/1VWI?GPE<ON?AUWKA0ED\;BU )J'#2<[D,MCR665@;]L2.TV8D1)G S,G4Q
MD+2=AD7(@7P02M-R[.I>:91/GF9MX$DLKZK1VKME K9?8SXGT_>7Y6(3,3J=
MCK1+*94R<)YZH'J(L^11/O_ 3Z*CIT^$>CFI]XA[TY18G:PC^*T86/(-RU!L
M*-$@B@6.(."#6N<R@L@%H>J*02D>EG;Z[]8_K!W5BL6&F5?&7/40O[Q!6S27
MY"!+R:UT(^)&\7Q5 C(R65,[\=5EJ.NZDCZO,7A5]D0G45"!)I/9J7XYE*>S
M@:E2XA U]A-WR=FC=<F=G>>[8Q(!2O7I,H<1"T=JO^#8ZHIZ"Z_M7H8=<<TB
M;\]PX08PURTJ&7X#Y.9T)MU'U7C#]?0]KKMQ*G]2*4FFAM&Q@(F[EM]7WD4M
MA]'YLP3&G;+G!G3WD.>"9J'NY$RQ)?\2742PJY EH;K]<D# 4-F)+*=*2/FG
M8FQ8N ]ZD^7=/O33\P;+2LME-+C/AWOI9T90<@-/*M2+)#NYV! 3.</TS5.7
M458K+P<V\AB=C>EL;-" >8/;[ZU,HS0,[5#=/B%E&X>K309\0,DD\29@D(C!
MEL,@<!9I?(R^RQC#N6J+EO2F$'*SMO5:49ZK[GDS[W.O+ET5R02N'+J1/4C&
M+IDCO]_:F7)8CZ6:'66<J=I6B?%> *8CE$Y,;Y0U4^9 7-&H!P5/-<38,4:O
M[L'EX)Z'K(YOR/#1-LJUH#SLET1ML.(CDHWCF8E7.#Q!49 \6P[?_=!MA?Z*
M/?A$^4N@\\H]T3#;@,M?P./ 0^A?0!T5[PNA!\2)&N]EM^T/_.C78[6)ULLJ
MRZW%GZ_5P8>?=9[__?/.JGUN\!X?_UG"D]"MQ5\ ^8_)_W68+NQ?PG3<BM&4
MWW8+13L6S\N5(1R;.5TZ%[!'\M>KU3(\F0WJ!R\3F>6KQ#$)_A>QVG'6*Q!$
M">=XJL>GC\[FHL$:+DV,:F*0/+]#P@Q]XO;H/>Y)IW-M)L/J*-*@SP4\\N^^
MGJJ]#LI,%A7=QR(M0ENO15.\H]WVN*P>%#K)WJ/54CXPL7SHWH^V*"BZX#MM
M(6"!-G2;5L]?Z8M7=17=J[@!6.9#>FU- FYA<VM%M@3BX&:BX6E2/YRJ8^$-
M*]+PJL;$:69,(XM:%1LX*\/$2ISOS;#;P[1([_R<D=MBQ@Z3$L8D?807(T^#
M?C)GYF1P*A8#/JKM4!8 !2V!$<4L$=LT"3"",0:?7=<RPV<:SZ#?H.9R4G"H
M1.OUA17@*[/9SMY#:UODU!L&E/^<53!""TH6[2LL)E:U%*>J:J5C0V9;3JR:
MC/6H;3@:0[MV,JQ!"N()1<VULP$<1X(_*G[7(0(8[H>Q9ST-Z0P?S[*/!JG7
M@K/>-XPT-.IK,UCQ#UNK]]BH74_JRJMN\:%J6I@<G[K."W-#_5NA'7J<,OSP
MN.\QPZ5_ 6;2_4-*2D!1MVM;A*5^/(Y+I_00'B8,CJYQNZFLP5Y!%R/E/9SA
M5"3SDC1G@\_+4QDD(/>]TJ81%]HNJ#!+ N5EC0+@6+;E4U G I)SH6P@Q,_W
M;\%%-Y"4TM' 82[%FS1=-]?S8':5=5:-@.IUU^D)OH?I$3OZJ8_IU&+-],EL
M-915M,WM!",=I"DOL_D)&K;[3<E)F$V-N5.X^\Z$L5\M9[9DZG*RWQ>_[E]T
M$LPVG9CHZG-,9;KXH4@ZL_GB/DGEZ_6 ]9*ZB[K,;)"R>?.(*M7#GMRV[*>A
M'][(I\4_'Q[3U5[NP(;:$79MR36KPI6YBU!?=ERM4=7@[^,E8^!EH%\[K61M
M2I!YOVO5>&@P9MD4]94IXB3?.B&#KR&%GIE;A3*9F\!J*55;V6<2/SPXS:$<
MI">^G."-;E_U"HZ4F@I@P)+[7((@7H[?]2#)V<.I(Z,T8*SV?#HT4(]]/&>@
M6-IUN$88&T^R_:FIL9?QXIN(E"PML-)'-UK03,P Z]6-RHV2W44F"D],=/0Z
MQ,YY,V"<FM&2<,V8:JDSSILI-P'K^>;-L#NL!XY>+;I$[7+;T%Z=H@$V@72Z
MY=J&.[J, $!Y=Y_U5%=YO/"XXD6-E>OJ;X_%1E]DZN&&GZ,FO0Z3\!PC<A"=
M10UYIXEYZJ#2O><&N;!VZD.%;VUIUY,!A0TQ+"A9$3?5=FGQXUHUX2CJ^IG'
M..[9,(?7JXSVXK/7.*I,5MQ PD1BC("S[HE;S:AH3YMH'--F*5AR*4]X[YNU
MU]N#M;ZFVX94)5]7NE2,<&F8FNSJ4Z?ICT J(V*UKL\PH[4/\)H >P>[])0%
M$;8F7A055OS&B>$:\WM07"7HNT@YV1V?_=QHLN\U2,W>',EC@(SL4F:B_[+8
MFXSY4PP7G8>SD*V;,8O-)\:U?:I\/!4GD[0T0^9Y;O)(5 46"V1^M&-2TY >
M]&@QXKVF HII/]]Y2_Y=ZAO(%X9"(0NIV,2E1!(R*H>.53T'N-V''&.(Y[V#
M[5ETV=(!J5"QTL)V3A)6OPAE2<[\4<P7PE,QO:&'1@P\'@J!AM2P\Q 'B*[L
M:@M*HG+P#2.(DD1;!+!>@]:ZSJCQ)W:,2;V>H!:#18C)"$B#;GO\V7C(ZWT[
M'<]I16WVL&,/6'*],]*WH/?C\(K6=6]=74NUX=>SCA=-;MUZ^W>(Y&AV(\@X
ML U!IM25N'JB3QC -K<H%L%4+/UN_>;C1P)E<K*#MMS%M4G*QP2.89]QX<YU
MTJ_R0 MH^9OT,0TRT@;[!-J= #Y=>0)V1BDMJA(,UO8DK ;T^;$?#,0!/]M&
M04XBPT[(>A#_B-4FI[@=FTV( ?MSLZPHN:K^Z6+FWO&[[[;RJAE,F)3V=GB8
M6VI7B!%A, WSI;%4<L:XH@.BI<N6_Q.MDI]EJ\SK>2L+'TI>7H"2 ._\#PY,
MM?QP$$QV$@^^:9DX-HKDFZHF^>HK^&0O_DF(6>V ^%\5WY%_ ;UO_U7RG7><
M5=3TW\F]R_Y]Y-[_VZ9DK?8IM=SW-B^:1QOJ?+Z-CL.&?.?I+[;5%R\);LO@
M-' ;TYW'D%8WY;"T-MC*^#UI;9G_ZBWZG&LQCUL<7&HW J@5\JWF1/Q\C:D@
M;_I!-?E6R'_]'*CIM'$"O>7-V20=U:]L[K@%*6<)'&!9B/BE"LW@@7L:M&@2
M+SB>@UVJKMLV3"I*S7-_1&[QOJA]2:]*ZY(8^S+U%["<*]W<=(HZ4#>RY1E8
MVOX8)OZ4=QKZ>UAL]8_T'YL_*3=4)7UJ7,2!_+^J[OE&N^D>_QFC17/(>OGM
MAN96XJX,]E_PC?.&%JC_,W[9OPV^^1_XO/\3?.(%YW]=OM@.7J_-<_Y? /=G
MR)?$OX",OX :T4@[FSJI_]2C;/_W_W**_X,%]_^V*1:QPTWB>D]?5+BO, )N
M)9;0GV+\FGY'_O[V8K<OHA28;\CV&_RH>VJ7X"U]E?&G7&)*<R-O7^+PR]EG
MNC70/?*.[IYS9Y^FLM\ C?^W>ZD_YKGG?P%T?P&\?P'Z/J_GM\K?8O51!"P]
M9UILOOEU^*42[Y;HT>8)[RGO67,, @^0;-?^B;BL6_R?_3O_CW_;_HM_T_]'
MXUL\VKW*VWJ01\>-POMV/8W<OG5#/,4W" T6VZITAD(CP\I/IOVJHX#8Q&V&
M#N@3P#Z_SUZ,UC5GH_:K3:4GH0=+J("."%CIKU0+JL2L7 8[BHRFM%R+ICVG
MQQ'>A/ 5LNMA_<NRVXQ,HRX!5 KWO!# 5? 6=676DWNE[W^S_?O^KOX'4$L#
M!!0    ( (P\?51%G4,#</@! *QN @ 1    :6UG,CDV-S<T-S=?-RYJ<&?L
MO =<%-O2+SI(E*"B@$1!@H(RY"$'R5ERSLP,>69@F"$C1I0L68E*SDA. @*2
M1%!R!LD9E"@@\ ;<NO7L?;YW[COG?O=^[T<UT]VKUJKZUUJKJKI[T;\^&CCZ
M!+B@)*<H!\#".H/ECN4. !RM,$RKVR!0"&<;A",#+P<70%!*414'!X AAI::
M!V%_%@'XM&<  ,S?]R8L)[P+\U^,-SCK*%\F>5KG-D)Z*T_JA$_J9H[K,3^L
MDQ*1(](6CE)#HQS1*$P1]YBG[HS2LD0@'$Y:*,)14"@<#?MQ?GR4=D >E\^?
MR&K9NAVWD+)%'<O\J1.*O&T!@VK+ZFO_!/LNH(Y$(*RTH"BTHYJE'1C#)@:H
M Y  !&:S C  M !0  J !CB>B! Z_FS]0XV4 PK^AT7$EFA;!Y0M_$0EIGSV
MI+6TJH'R]]$0.6Y_!OA;CR_^TF,U1Y0M NZ,X5X^Z9<C"OZC$YA.6B)_%C2M
MG57_K$'"I?\LP%%_%E0L'9Q_%FY;HUQ^%F1A#C(_"YAQ_%.U%-C>^H^!^&X@
M0%->2AISP#XYAS P0!!HRUN(3X ?)(^$_X4GY?#7=E)(B+8.'"7'I.F  OQ"
M4@X0AK_C:SH[H$[XZFX.MU#"7UY]9Q.Z0,$H!%+& F7QTRO4K=6=?WC%\?D?
M1^F308!:H?Y.O3;&E?^.KP5V^,Y71X)O&?QD7P C$8YZ-E#,Y&+FRQ9N_6/$
MSAU7:&)LDD*@4 B8 P)N_8<(\8^:8Q-^X9/\X&O:6MO\6D'THP)CVT_VL>=@
MKWRW ;OV$(0)KC,_CB=>=>VD[MR?/9"X^T?TD9P4C^/RRDF9ZO<R]L9)^>P/
M.:P3J>L7O@_SC^G_CH*]=7*N ."TLL+4.&#V>'\(?>>\?![SD\-SLC?$[']P
M0"=[X)^<$YU?3\XQD73TMX0]?US]GZ\[&0N"[R-Z8A?@S*WOOS_JKOP<I^]E
MZN,S;,F?UI\0+AT 0'#FA&<-$ 3P ]P!?  !P,^P^8U^X1W+',O^TP8_Z<\D
M 8"C'8Z=[03.$H&&0YS_(4;!*.X?)A\[]B].!?@'[P-(_?32[V9H_G3"[]UQ
M=K %0YUU'52.PPCK-QS<DSK,R47,#_^DH"CSBVY\:R0"[?@;"P^!M+6V_9DA
M9;6.A=1.>)@RB04:A9"'PJ%("Q04<F*]N^./!$_XO?$QY[A&$6;-\-_0?VPT
MTN&WR\3)X/_.476V_OU2@F?A@-*VL/Z-=PX,Q<A!W5"*S@K:JBH_DA7!#_9O
MC<_:() >D@ZVUC]&ZOSWSBO\8!^/+@1J98$^R59G7:!(U-\TU_W!_KTYD:6U
M-,(!@?QE<$F_"TC)_ZPX-N,V GY\/(M".&(N2<[07P>.T $SD'_A$EN>I+V_
M\(F0Q\GM']@GT<3Z7>[8G24^ _[DDYZ<8GW/0CAD)Z7C"<4_*1^W!U!D_#%@
M+S _S!46ZQ, 4'L+PP\$4 *PC@:.5@#$DA"$)=1,6A5PYF@5<.ZD!(#</98[
M&@8\!! 3$!"<)2 ^>Y:8E(B0B)3\/#'Q>7+*2Y?(+UVB)"4^H3\.?T]8)$1$
M).=(+IP[=X'LW+ES9,>[<V3?14C_%05';P"D!!CC7V!C,0+.D&)ADV(=C6(Z
M2GCT%DL"8R4NU@G],8S8 *PS.+AX^ 1G"8FP_K$2"W,E^%%Y 8"%@X5]!N<,
M+CX> 2XV,2^FDA0;Y^I%;EQ)#8M+C$[W>/#(0E\62#$QDVO66?+R(>]W2N.S
MA&E]GO@"=@91)!4^N"83K@V1K4]&\5_NTIF$KA<];.A&3VW(78](>50<^;9G
M>C.UI+%W9DO7RL4W*JVTJ6]V6T!>S]KU<71Z67/_W XIX,P9C+4X)S;AX^&"
M3DRXRGT1!V.!$^,E7)Y[H63'%M1I=G[F9;:<0-X/D]8B!SOS?6'!.S8 _QJH
MO@MC1/)EB*P./PHZ^=.$?V[!]3]-.!H"$&.?8)(") !;VJ31@<AX7Z!M*YC&
M/C/T-7?C>VBLA-.'W/FVJ^W0 S..3N^(PM=VTO'& O.#,?15GK1K5CTAOEGD
M'C'H+@-@$4Z9ZXH1@)<F!^PF8K*YA)B[;OL6?;]TZV;<#@R SW< -,A/W6W5
M/@(XYFWZQ)W+ZE@T<;Z4;CA$VU:(-&Y #'[)1N>3/R@>M?H TUG=/@P] J0<
M ? "A=&>,3LFSF.C2:H/;W<+%\3:[]SQ*;!&;T_/S*$.HP5XTZ%[Z1D&RL:#
M4-BX"845[QY(3V(8L>$R^FW4)2W,9E.!]!7'3DVL<+R$!$W&1&_LDY5-T]'W
M3CCT)(9KHTC$$*59,;[*EORPZO7K'_M=4^CF]VJKRGI%2#/3XCP,9(EA.MH?
MWRV9^Y8DRY7D$A%EQB 6@THZ7O'27]RY9Q*EK9Q=F2;L?5FO=N3#A]OZ*@Z;
M] 7S%XTWN-I&;%JK&)N+^9O*(<:MB="@ [K 0_CXMW/O(HRD8XWRTI9#)!^N
MI)C9!RS9!CC8CX)SMFA7MC56!XL.0?SML*P\NAE3TUQ1P80@E@>Z5[C8K78&
MY7/:[[>9F0<8K!ZPY*.#[0^"K6L/@0;O.]H7\F!H\[T!=GMJGG.R#D.*F]OZ
M(\EFG=N>!\IBJD< 21&CS[<C7PI\]<[+4CY/G[_%_FQ36'D<CSTPSIK"C_T(
M@(].C.LM#R,+4Q;)0H^<"X<1MW."D=@M!;DC??[;\+&^P^C1Q2)$JDGB]I 2
M2E-?=6]MR_8-?<F%+F;!?HCWOD2[TEJ>"76./)2WKR*G[*.W0TX ]4%(26QF
M6=>=-A.]P:6RW=IBGWYOOG0TR_TC0-X10'>@?@=2)25IDU7ON0WSB2\;/@)D
M+!NULAU]W-)I-[%)SX24FRP,O3.TQVO!WPJL'$7W[E/OV7HG'(PGYZ*RJ5:;
MTY>P!W;Z956;T[HKVAVJ[M@;?NR2GS/<O[*V>#5?MI"^846.9['%TZ9(P#.Y
MI]D3:$]20EK5>X#7-SY?6;9:6'H$J+_*FUFVW&NR_7'9Z[Z!D9A<-(4W78^Q
MA"I<!W@ W#<] GQ.G.^+W][TNM]M)6OZT2CUA;(*/'/?9"UW^,Y]@95S\4<
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M.J53.J53.J53.J7_ !U-R,%L4"A'84Y.N#.'Q?$_#CC "!BGFX4C)S<'%R=
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M'$17[[E>B &['+;-MP'Y$(G+'E/&Z!H?SS5F _?1YN?!5V\ W?-;"!V"ZLX
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M_5##.]YI<8JV__/!\*AM9\H+O^71G#G\FJ]<9(D&W!$C7L8@Y!4%05]OSP=
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MXSJ]'6Q]4G*\YNF)L*%JAA):"_,E)F%^5Z.,#7)CFY^ 7-7[&%'MY#7K!N0
M^P'QFF@C.$7I0U"9Y+/=Q:IGTND/[4,UASABKC#QR$GVM'XD20WN$@>$_\;J
MZE':.<JTN8H"LOO!#<ZFKW%Q>EPK+N4CKK4Q8;WE)PW-*VX4\[C99*MT+U1$
M<1I+!L:R[[[>#Z!C?$L:F6L<PM-@0Z+.\52!#6)#TC^D+OV1/?M/*Q:U=L3)
M5=7(9WH/(5)M6#!5F)GU#\X4022)2F14)";M,>/CX0,FI,5ATJ*J,HV#3YL\
M_&<E7BO;68'MJDE9Q>P:(]9,O/'Z6$7PGI^W:O)5Q; L[:$N).A1^*LOX&B0
ME,52>6GKVTZ6SZ!1X7W4O3Y3*BW#YVLI?$U5:V >?(DJ;O\CW+)OHT:4V,:P
MU51@S'M)=:XB;C9"?X:ASVFS#QJDE"?,'"E!+ZNFL!P:*YDR<1VCOE6)G]6(
M6PLJ2IQ:K J"_%V2Y!]9$&@$1W82VU %*6/G]=^&<G3@A7S/+YZO%FW:-FQ:
M,U \+"DB3??-6+'$9 VO.IE>W4NMS,WU$6^M9&[U*IA)'@33K9*0#.>[==B&
MRB)_I@6M>UX&2U!K_E!!LX:A,,E%M_O=F28H:RC+:OO7E.9RP^'?TFIJR?"R
M)B)@;F^GW#QB_[?\"5_$9Q:H" 0.D.$T(9*RJMNYS25>$\8:6D"D&6.+2:O
M\9"+<0E!<)\UV9>4KWV+SM"<"6S0)3JMS@F_DKHG@-\T'HKWJV^RXLNU)?=9
MBUGHT[ICVU#/.G)"HFVYTC?2VR*=C4%K'9VXD</KT@<_#Q(Y&!%E*-'VQDNI
M"E-7MH0U<WK]SA>8:S4T-N+KFU&LS#Q5BW"0OJ68>8I0D@_"A4K*_?W6/XY'
M0HK?X->X]WQUL%KYRH;OC31H2V')$\@&0V\4\Z)W'E(+O_+VQ<%J1X'&0B#3
MN0A5ZYI"E3,RKJ4W*_>3IY/:3_7F]?JZ5"^C#$W0#V<DDLU&D'X-MJAF+GF?
M7%V2"'^.?_RX"Q-QJQ?M.XO2I/*K;7,12<7>H9F$GS0B!34^?FYTL[49$V4J
M?GU:=%6G0GI^!Y1]0;[-^*@TL=FW9<$2BWW_!=42^J,&ZB9EB^5NXZ<DTP71
M/R*.6"%M/<3&"=\BY*C(.)?HKNR;"K^;U:Z-QDS_RJ$AP1<:9JU\:WM$U93;
M1[MW7V'#(C3K\Y/S3/1#%EUK"U>(>.QE<B7B\Q[LX$&)PDB]U"..K\]V(EJF
MM&$G'N8@CR%,B/#<DR :HY*(_?;6:Z>U;G\JWS;Y%8T[""/Y6YX".5J%_"KG
M7)$5!JYY&\!*,GOP,$:WW7\J)9._L6L@UV;N?'AJG,,C"CF;JK3*J<3R72W[
M/]1<MSI6XZ6WB?0S[MS9^&C^'FKGKEA)$?Y3I!+E?$;VSJ!A YK5^$H#.WK_
M9R($$YT^6$I,?SZ:=?H.1[=,_;JI,PY]B%$E<U;I#$=-9Z'L.J\399K/%BD9
ML3W#Y*BJX9I. RQT^8ERV"VXJLC&0)6H6A"A;[VV"(B<6,ZT5<&5FU-E?(9?
M6@,L&\[T=RS<5JY0M*?JU.;A$.>0_SR)-^NH]@#NRRPR?S$]9WQL71&=^^5=
MWX1R1K<7R7C@*>O)G^_:P45(\2=TIN.Z>^SDE-"41O:\*@14&V4?X^QXA,.J
MOP%#2QU+N;HI=ZUP2>G!2X-'A.(ZNU)[XEMIG\F=42T-G396H:N_A>"CJR?C
M<UN5GK$R%Q"2BLY2N .G O6U^WJ;"W?HE&;"9C/A*<Y8T*74M=*&RR;NO%4_
MH/%DF%.6\GG;X9AWF&N%;X:]@YY! !4+LQ%CE?ZGK'#O)R[AO3T">9^K6B*S
MG^MX3C2I<=B\IE))TN8[Y5&3RM]A*YY5!UJ3"T0N/CWPK(LZC,-;B,5Q#FN2
M("">6U' M4#XIM7EF0G*UQ2!?^6F!F.W!9S/S)W<.X7P<IP>?:1/FQ'"V9(W
MF<P=$TD?$2O@EM%0]&Z=*3S5SBH&C52;,6G4]OYHG4^NBZ:!YQA+6?7UAY4U
MQ1D5$3[-[34T.8 Y#+TL8"O4E/-S,N):UBB'DZQ1F_4Y%Y;Z(A)#.6TV@HL?
M1BH;TPB.M2(9NCLJB^J^VY_V.W .,RXGG#Y[9FY0?")R;(91G9>WE5&Y@'/'
MZX5^9!K'ZX^*/>1?^BT2T1HTGI:!)]G<'BZUMUI@@+!)?A-AWIJA730&]QO&
M$W'8V1TTOVEWSNVVN6]UC5^=%5:;(#MA.0\A*.X +BQI:"G[!^A3%_K9=V>9
MGT$,0=D!NL<*Q:R(R.( 4:(("M+WO:YY.O-<VK+091FK6*HH"3Y=BD3QHHI;
M+34\Y0C2E>W4ZM1Y64KR/==[-7<GUL5OG^+ET5SSZNB:S+:]$'PS7UU3L2 :
M]X5T]N\EFA")AV%/".XT78D,69J/#J.KU)T "8PD8Z _<O#@0SE^:8EMT6G+
M>LW[3P8A_F6_B0P48-@6=^)3_#D?0C,FT(N^J )+W;<'AXJ3@OJB^K24@Q9$
MQ"N&/3?,7C8^RQWEM!1MA;N-VR^ .L?DL1; -7RE Y;=ZMBG,MHUA V%_L4B
MW.S14]9)Y9C:?L>XN(OE_MIQFR0-_-1X6E]'<J=:O&G_B[\L%2F0\&Q#EA-T
MXBK#XY<\<-,H#NVYV].7]?T'SX]V>6\UE>T%FFUVH\63CC3T _*L,V$%%L=H
ML6+;RW:63S+Z^U^YM*5I/P#6BLG-&(IMT O3[BGN1<7- \L.R]*6E;9S9UHU
M: +4XI/@= \;*Z/*OG"5ZF_:4.V/4&X51"TIR%^;]@.^ZF.30S2;J._%%E?H
MN//*AZ$D)N@#$TUR$LW:-&?RM30^>YMXC/BN.:"!=J_%Y1<F&-@[R3K5?/D<
M;+)R(AK6M"XG'=(R'MD*#/69+I_D<<7W%"/LM@WU37MJPB47B9_6BEH)G*LW
M()L%N()#E/!L9PETE-]A;W:E #76R<BL;7L!V'Y$E@J$Z@-><#)["-:?+.TC
M$$:(3B4%OG6@R4[21;R?,?S KS:H=S#FP3I-90#B_)$_(-E,NOP %)^R\+1_
M 'X/YWT 9O5P_DZ RY=[*EC^)KO_S3F;<Y=4LQUB4-0>>:U?%?EKZOX!X(X7
M^?(!^'>_?M_=97P JE=$3DSJV@1S@C:DD8(>'((>#\J3<VD,_^_32GVE#D^8
M0:P)&PN0Y:;X5NL2-_+])8X1YVE_;KR<K_TY;7GHTO:RVYJ0YV9EEL-I;98U
M<$[_4GG,[RZC[0[H9=N;;2LT= QEO%&MYWAZM+%Q4[(YF3ZI6OM"/<=,[?;L
MZ4HA:\O =9C)YI?E%X]WEW.P+DP69>@E%<?;/$K!Y Y8(_2M5JVS-F]6>^(T
M!"D,,I9#<[!^IHFW]I[F'N8>#N"=9LNV)DGFG1;BG1:YV\^K-0G[]&.4%%7:
M[,LHQ2'6G2LT.HH8\I='-.-4#$6-9UE#3DTJCS4N#'5#+T6)YQ7^Z])7QYCS
M[JSS['-PASG_9:U[S#[O#(-6 BZ6"9X.ZO@WTI^LHG %T!ZD#^3-KAB72.LU
M^0G0]NMML\L8/-\/;V?KY<5$S"3V!?3FQG?L&RCS2(\H06(*Q;&'4W.$-]]7
M/@TFJVHK-"EK>AP6+ %A.]#<F'2A+PGGBG%<-P9P<B7MJB\@^<P3M-DPC&&\
M&VDJG^H^+7A_ *+RC/6YYKP#+O>6J)H6+VH\XD@;EQ\@4(/<>I3HRH*CK_8;
M!I(!Q"7XHHPW0LW- X*)@&H&9V^1%H3]HC_GABNO/7_WY3\ %Q^ EAS1FY>@
M('&C#X NBI<!?9<8,37$_VWQ=21L<%[>X)B [C*[G:$V '=:B/]L1]W?^FY_
M95/05XAOV&?Z5IQMH0AL5./CX^@ %SF!)\5/<B[5T]VI/]'9( *[9HN:-W\+
MAW[2+D9*P]0M6SLBN@'O2 [7HV64,:2_/#5GM0D;^S@<NUZ8[,$YS!9C$X5O
MEZ2WC_L*BO58,3#_=STYELBG_<H/ P#P P"]0WZ,JI1LTHCF#JY2B5(]#8GE
MDD3\'BHP 6UZ8_^KE>R_9+RN_,>#1J25POE5')*#\P&@['F3"#3^S1I$<5P>
M]/_SEX=1X;& .@-7UH*=[#4_\PVV#QE,I2CV!N/H"A1/8'9E3XNDY$;&U[EQ
MYS4+.BOU]O6&1#!C TS6%2-9;Q;B7!]X:+!")<B"G^7?,S GI0<FJK)HCE-Q
MEWN=B-(@#5[$E]A8?4QIVYCF8UFW,:OE\!@A["'-!S7<ND0+,R/KDL1'(JMX
M3CW1)<EI<A;YXP&'X])BLT"M;U#<2?%M_.>>C&IFKV7/^PVYC0RVEW#+&G\Y
M-$9DQM,2J!RR7[\ECQJA9\MML>**^HA;XP)_T6M;P]^DKHS/PS2A=S5=T@;N
M,(X+3U9:[9)MNEJ::4[SO_ D*)V7C[M3TC;%Z-Z"82B5]*I#Y[LBWJP<\:^"
M#TC:^7^/I[)Z..<K^KZ07V&56$6'T?%='E:Q,*HAH9 ;B1III\PW\%647[H2
M LEQJ:Y<&1)7M;@:3<%6C#*(TQ<#P=!Q*MZ>Q:,5*HJZ.U[E6!C?:@KOWD!
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MBAK75K/NY*9*HLDY-G!/2A0[YKK79L##[1U%]QN61X]UD48+.6^9*G  -%D
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MMRO$[WMF[(!CJ*5**$-PVZWJCB06[THXN*L=A ]B=6X8G2&MOD&@+IHE>@?
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M_')5$KU(ELT&N+YIKN3<HMXZ;7>$JT.BS/Y?9![3UVVU)!9ABW)EZJ%%M,^
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M2 !S( ;J*%D4 +(3*'<UX_AC66#WLJQ1.<7-I;?J7.T$L_V@M/@?USWF:G8
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MT6&[Z%_ M$I$X+TV5.(YOQ*_EJY!3PO3):IN=S.WQJ>$IFSWIVVVLEA-O!.
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M8Y" D+W0-+L**3T>TNR/NXN(A$DP.LJ<N287N851L,E4IW>K:!%>.9RVF P
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M-.]03,:P:]BR1K25,YRFRF2PO[!T&?0X0O*SO15@(T.HY PZ':7+>QVS?Z!
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MN&WEX27W_A]SXQ=29;')-^-T\$^$<A(*P/7AGF[CE2:34RVW>CN*:[QR!SV
MOAL&& CKE85 D@\!=OWM*Y71E:H/U4>(B1GN:;#4WA9!GEK]'J/WP)Y56M=E
M4K2];DLB74N**;T)^HCI.+[!;_^&JZINT;IO*F[VWC$D8P8<GFH2TW;0THHE
M#Z; :M'&5 45YE.QXF5M4G[X^/Z>@O[KS"+[EEV5U*'L8'A+1M.9:+ &OY#^
MS'6H\T0^&MP?I'50G9F#^2!-OA.>?!R/$$Z[1+)W)7/CF6M!R$VL#9HZ\#?B
M4J\$& %WF5K7ZO/FA;:2HV/-O2&*WTD8V6H;G_>E<>;VS6M+/KYB\\INQ%$R
M#3'ND]6\*>"_'W:)-Y-_LNG4'67#R;9+AQM[[R:62^_ 1*0D"7H>4P3-S9R-
MKNLJ,_\!1!@F<U?= E,=_-"/F,/#4YG+; %\XE7?\QZ:ULY0K,V/KRN3US,S
MID&N=V;@#A)716UFG0W5I"ZQ&; >7S!<*L6$0X><%G<6>5G?N^[U)P*V+K$\
M/Y30W'"P3*M(F<:8-*5#M(\5-O*1IBAPLY*Y\5"][DH[P!>B.\N7;N\N)>YQ
M%=W]V"82'(W,NYV_<@L*,+HUFV:1BL?Q:@0S$E=KN<J].$03K=<T%3X=SKB!
M;FRN;HZ6PM7PPEF[[[1)N,HFFV.2Q=M2!\35#_AYFI.H"#T.E0Y-2&SZ1"UX
M:+K4<).*>4,Z^X8:6V-*93#<%')IM]6*#Y<\4)"($/?=F5NQ5=\1Z4G!1&95
M%C80(I2>GMSL8_0'W1;4_<_SG]S<[PVGAC\VYY81QP N8AN.)GZN>!,@!$D$
MU8?<7!$U)IO;0?!"^-;!KXW L)@C5A\F3/C\-_9,:BRW>@5&0P)F?Y?QOJMF
MAJ3/XAIGSD5B(\V@EJB6?>V1RFL%B!9&FVPS22P;S$7 >T*HI#5^+$LS1S%-
M%YU+0'<?[1,#2Z3&;LSB?J9M]UH0#;2XC5P4(=MH]I*5O=> _(M0">4(CK?R
M%UD'0P%A0B9SZ7W'YAVGO:VDH[ME<34H&5I)DZ/H:^S)<*8!6WSE0R-KC)[K
M47MXUUTA;9:A-VXKV>(/9,L!UTHT>8W&1'%B0EUJ.H:=+%4N*+R\4UW$K7$A
M<.% UHTNA6 F[=0?0C-"<RKD).'\!@],L!B@?]8XQ-Y2R#O/.0C-V<I23!")
M$=-BS-2( -,\I+EKM;S:JOTNI4+;.NM&F$M;29-CNG80:_^9GRSMP"\+K.R0
M%,4_\E:%DY!?SR!]')7C.<Y-_?.3OXK-\+?YF(^7,PNKIQHN531C?(G4W3!K
M0=TDOZNJ"LF<:US-BR\WJIU,"J]4:)H<[I4"Y.I19;L9N?LN</D-+3?E/W<+
MZJU\FUKL+B[I[AOET#NFUS:4VWI7HY@1 BY"!?(WR$2LZ.'G58CIYIDQN@D3
M'_(&9V1U QVF(9ZGF&)3=?)*ASO7_<F,#B?$]=KXVT!_9VESIHJ.Y3+MJMT(
M,0$V;V&;S?.DT@>[9>5SMHDQ,YP=1X+2J1A.%*8)!<2[M&&Z-8K\'<="W<="
M9Z-'O>VM;1.SOB^S0O @1\[X,EM*[+0L2H$F@JY4S-!1MQ4I-93P;/ZJ=@!9
M85W=Q3VH82C1Q8\R$XI#^)C*-!;WIIQLW&Y=5(VI.Y8PU_^[%E+6V=AQ(QD-
M,G9PW^0?&HK#%V:F1;KM2_J+OAHA[<'75,:H])9^V<F"JS1Q%*?FM'[?W'G6
MWC#NE]274_JS3?.X2; /J0YKW="8Q;)_^'[1F3"_Z21+F1 G![HBX)JJ#Y%W
M-EE#($*CMZNW#68/B6.RRN:+3]MM38MJ(RYMQ+&0076PP#;247]\,GO_\Y_Q
M_]NA)FA=IOQ\%2+-[3A4EQM*X?_M8:@OVMY144'ID(:?SCK*A:Y0)5GQ2 $\
M>H .1%_E6^&4! M#).P23C@+13TC-N!OC+[+<&] W)AZ&Q=)R#I;<P\3?<RZ
MP)AITWB@M&[W*6\!;&EE61;#JE.;9S/UG'K[IBY4D.GV'C!9 W1"XK3-:8A0
M]#,\49:CHILVKF48*0&C.NS"7KE_PF8RJ\^/U9.N8 9AF>K$6K%XSBG)"<M\
M\_:\W.AS^(3&($9FF_;";:.%\J?1X(CP-W/W[]8>0XGX7BILZ?82:Q::(16U
M8-_$C^."+#F+P+Y-^49E!&8. DHR%8P5^?95\S1W?740GOFZDF-5(RO*977/
M2/:@65&.7\7W#1& V]K ;^:]RB@67U57J0SVKPE^NO;.-.S3F5WE>B;_+V=[
M &IE;!Q9O+>4NPNYA&4'DDZ'-N<R#HU)"'T>5..DHQA%W+4H! STG&3-JI/Y
MU!,9*3P\E#;./$861GR54BQ;_H)%&LO1#?U+W3K+)&U L*L$1&E=44>V/FX,
M G[3<J-^1?=2Z]M]P8^#VN-@U0<F\:+&I_2RNF#@/N@QQ7'K?-E^02!CF!9$
MI:TQZ8CCA"A:6,9IE&D5IJA\&GDNWI.L$K>V:G.W:/>;*W(TBX@1Q!G\"PCO
M'_O3^P]21:U\G:"[OS_/^K,*-?_HFW*T2)_@CS^@86]MJ1Y"=0-WR/@#7.O8
M_"UMW,TL8;$F<0]_NEC8[=&LM$K+XL65[O:&D2]XQ0MJ]*^31G?!OO')!Q8"
M=ODJIYT;KNW+^K<&)76F&UJ-S41G+D@H4M-S,N!=<97#D=HTJ8GC$'_KL,/$
MY0@AUF[[6#L%Q4H F[EX<SNU''I+2S[1L$&Y&C#=^].IG=X0/E'(8IS9R+ )
ME,(NK%:J@<1C+?FS?F%0!F_1W&8= WQ^3IZ8D1T0W.]3.8K;Q-14^H.EMI7*
M.TMZNM:@=28GJ4#%%P&;Q^897_##FU9F>I8%(NX,LU0/'OX"^LMX7[O3O)P'
M?D->%IL).&,[?*"&9]8E?7P(4KUD=DI;^/+;WXCUN[W/*MI\B5G X):'F\;Q
M*-3"R-?]#4P)QJ@_EOICVA1R*V\ (.)O)R86K ;R=3>R,3CP'VF7$SL-SMG.
MT*X9SVR&9/E1(,]E^#J:8[:PX$C$^G0(:W<=SWH-SR^$NN<G3)]R?9E3W%%0
MS30U +"5564,Y?;P UUYN-LF'TD*%;$FK^6NCP@EHS>!7ZM3V_#-TMH;;B*T
M=I0KUQQ3Y 2"=KRU6/RU^U>V-C]!E7C4.N(XU+,P*LSZUHQYV.>J=8GJ#UP+
M^9);O3IU#XT-%!!14,G06 Y1^ND,RL#HO4B5I-6-<:_231PW]SQPI)"\?[O(
MG6(],U,YBP" EBNLG351(UT!PKX$M=!*=;ZAK'>+D#>TXXO#G!L;L\/2H65B
MQ>,'8>.2RQ3]:,%_UWSL?-\HBO66I.LL82+O(D.&CZV7+WJ4I&;7:46VL-("
M3,THCP5D>J$>N-9XFV+(CB3;H4:IV-/:!Y'_TKM%TGM5KFVKV_KY!55.<F\R
M->6=^?@P<I+6-(TT%=D >PS"3VGQK3[$DJCDI_WCYT)VV-)3\4NWG)"WM#5.
M-DHJ+2M&.<I[J^RD[T_5;0;AC\./"<*7V/T(\217=B<.KJ[ZX4%<'9&+8L^\
M+$8',DI3AJ;=9.B5PB[6;2Q$I$-(1#=/7!-XVUF4@[JEVVO-N:85Z,VM,G?F
MN.P6NC>?2E=C6^]SVRX4P1*S(?3DTC\Q0@J3&6<)+;K679A3.##%K+/'R!@=
MLON/G'>WC]%UKBAPWGX1\ C6(T>VWN?GQGR[N P (<_I=H7-5,+*,X=D?0V\
M>2XK=4E!OYE>0OFV=3D__9%L>$TB>E7H=F%6.5PKE>9%TV\;ZD*0A"-2G,T/
MW;ROS[7@SLTS8INK$*D,'/0N:3^\9XD#"'AKB0NQ9MW-'YF-%W&S1YB%O#=L
MX&3M5B<)]T;AA>.E32$(?M++:\N%B:C/N+<][&7\/P*98*D$D_N$[*JLI,>.
MM-[X*70>W$7=W56WIA'3M,*1$9D!TRZY":K!K%>TK?HK*AX7+AZ%/O6K(ZNY
MUM3J?M2J):FQ$P5?=RF3MTO1/GG^*FAWD=^[!M%R#_X"5_;7.JV,U]-TX:4S
MQOBX%3L'Z%#P2WF_3]ZCK#"OEP92C8W)_!/<LT.X-1W"(C]X*%K>/N6LZ[%B
M]2K.-TY*A(VV&:E/ J*U)\;AB3)O-C<@G5"K_%C=&ZKY;6.NP/T*5*>'LV8M
M.XF?5.[(&&7SZA]T0<OB;8-?$4$,<U)Y7H^H"D^V-/OJTW<,0Z8Q'X)>[U"Y
M>? (U59?UK.\"CRQX-2E"^#F-;!7/;5H"YHR/M#\S]<\^.\)E[:)T>=A=\O'
M3>//#YDD_PTJ//PGO"?3-]#7-;\_F>,1U7_WQU*YTZ6P=;;LZ3?E2) A5@['
MU1#:77KXXQ*RGZRPDZO:)C0!YZU5C57P7%;V^Z:88?,$QTN102,-LLE0796%
M#_JX51]*E)9G>I.J2O,OZP-FMF<-'K[YCE:OW?S)=\,%9MUN3H;99=EO0VY/
MW8PF2AV_&0"\X,/YH'?<NGN_G1^/P-;=>3,$T^,16QW6+#,4(6\^LJ1%7$PI
M[_E'0SE.98)SW_OD_[8Z?GQZLPE_L_=3NRKE9O'5N^#KD94=B[^ T/^YPX_O
M+.H_>A?.6'X)?1^M_^46^NWZ^\)Q=?:Q^.=EPG\\4KR%/B=>RI2^'=3^+[)_
M5E^G6/Q8_WF^<_UQ5O_-C,\_2-H_._0'L'\HUD,5_XDI^O%M!_ZIM^?/\[MO
M K^.19_[9R]OKY2S;T,_+JI\U]^A[[IM^;[R>4>[J-*RX.@OP$3\=Z_TV/R?
M-\W/<7\!!-*WYY]I+$-#?C\\G=D_S7A\B_RPL?\_S6SA_T[ZG[.0_97W(KW/
MWW^>WB].WA?LG+]\VS;:06TY_/A!EV'W8Z]TP+[+]:=_>C](:WP6G_[3X//S
M74A:Q2]+V#?B/]3_/_F_-CGD7_+3X/_;(N'WXO]5>9G_GY77#]A_+_+_CK#_
MJTCK+Z#@[?^7A/M_(%#4A$.30L<?PPBD=/+E(89"%#XG6PO&$LREX\=XSWRE
M5747=UFGM9F"E1NPSA#V^AJ7S])#U'0%_MX6ID.M=W+-G6R*WLHFG ]O#<T#
M7F!YI6(S(K#/VU42A*E:.'PWGM:O:.K.:1%?I_%KX,Q_4@$S*<VU+S?EN RJ
M\*EG?,(_F?RO4[ ^A1<]T@OKT\948,?2GQ^&-</*QK\LC][R1=,1ND*6]P[
M=HT#PD[6-W6^Y"[*.$T0X4723DT<IW$;23@G(PSCVDOBQ6\J[I;,<//)!7;
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M^FO-!E?%\/'M0J7)G%W "S%'KE'K02R]*0 5<IG5MO^CV5F4J:I4";Z2]7V
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MA2)4$-CE9_2G7/G^R0PL=B^)>1,C!3FC.MV7++T12K&Y)-_^L9LKJRAL=X]
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MJ[R3S:+?2V%PYU5@;)G4LB:&)CM4-H+9UL@I+^OVE>- 4='V'Z:_$%-Q=ZI
M6INL2VK61IUYQ9==;;ZL8S.]>KTY'1(D."HIQ2( RBJ]DJ_C(#2B/(CT9K*K
M0@.:)PCS11(GCOQDS/9&_U*X<U&8)!#$U(B^W$0C+TT7:JGG1RK2E3I&8RS0
M3FIAYJ8DDU(^ES/3D#THUPS50%Y$7QS*?3&LSU.=8)WK-0N5/Y/CGD!)351*
M!K+ <Y3G:J<*/AH<-F@E3T'AZ14)2@+CK/'SV]]5&\)+D[?JF5O3ED.ZJAWA
MU(%'"$E8T"V874RP\!9HP[A&&U.*.C3,=J<U]K0X['F1+3=DC-JJ)\F>U^M*
M_@MH2:'SLC4EGMAS"!%@NZ>DYUXMK8@B2%&Q+%RZ*ND?Q58@#-N\O/0 I6Y3
M[O?V+1@!C_/#[C>G3":YE%C<=RCA:#I59I*&:@)9*%ZKY% ^;9$,AJWLPE]+
MKE-&K49C$=O;X#W-&,Z..TR' !SX+/-$,HE9D3RHW?+SBV)FNM0XOSQVBX?'
M7EVQOJYX/'6U]1#7&;:>;''+$3R7G@_QQ<$_0EV(.:*<'!ZAF$'5&!Q5J)<#
M0G8[0FG3]$9KO&7-JA=EDN3N 5R0\I!6N)F@A\DRJ5OB-!PR@.6'7CHH]-KZ
MVAZ5K9,5JN=IYZ+O,1NQSN%*$D3Z])GS6)2DQ/] :Y(J,Y<N_H*E>7A<0(R:
MCD*]L24 XL:[BYD=1>IM[XJ#VLT0-EL1F&%5)Q,%BMV-5_5;9)^4@(8&)VE2
MU$P2&*_DI]Z9*GHI4D(;M)F(BSMCYET./>N  R:7)2V2XXZV0&XO[QI,^\P^
MUC 5&RQ@5TL\/41J8%^G;7Z;PBYAK3CK[NA),41/R(378F:\H+L&H0S%Y&%F
M9(-B,C21?4_>Z"*+^\E4L?A'=W7>X,#;,)=V8+#^_(GL5 AF7LQ:_B7R5"AL
M2J84ZMO(3L=UN]&FJ$]'9Q-Q^7LX:RW-?7_^"E/>L/V-KY4Q#Q"E_)W$^S$>
MQ]\N*E;1!BPF]Y5+L"=ZI -V3.#NINB/YP<,88X(FI]A$?<AB=L'NT<J 1,
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M_=5ES"G?>=.B(CH%2;283NVO253/]<0(^\&)CQ45COTS,->%7,\7-.[-6V@
M:C3;%&2]^>PCY/I/.=*)+6.0,L[=A(HY?EG):= -V\[?>,;MC0?9%@+4:3UO
M0[[ E2(8=!AB9NW##=TU/65K;X<7^^94WG-MC-21?Q'_HOK6RL&\,7?B$FR_
M@[?>T,M.4F7G+@[Q-QQZMX4%%6&F;PU3N7!8, J%<M.WV&I&3[ I-,=.\4!(
MJS9N@ _8&JH1LK6D 6^"6*:^$]^Y P/G;#JYEN=>F)2"%1+ETQE?,1YV3TT9
MX_9#8$++NC"4D@==>:^7([[WV'=RM/E'[SJI:[2X,Z['><%18H%!-UHGNH#:
MSEY2W,HK.F/+P8^&UPO-Z0T3@?<7//$VG&^R-,M1\[_S4!9+%36=Y:XR1K;.
M-[ \9/*R6MKJS2YZO*/<";-E )Z:9@\3W*HW1@CQ1BSD@P]O14;7V,2*=TX2
M'])]LWB.F%,1S:QXV_N@X)-?Q>8T2/"IP%_F<G40D"!FZ]L0[DYR=%@!#[IH
MP^492IZ:/"5I/RRF:LFPKL##.@^=76D?=6$5$/F=G2P'-EHQR+I\*7'!%&2/
MYSZ0OA:H=.;6-?>SNV"*Y6Z\H,RI3]>)%8V3?ZNLF.BV0F><D_QV?=.,=?]M
M8;D#Y_JN7<<;#P&_Y-W&XHF3.W$EC"Q++%U3E&SEG<M/]36AU2^G=QIMY*AU
M*2,PV25R",=U 1/;)G O29+\&"07.6'4JF!JD 5]4X\*'I_N5C'S0C-AXFF3
M(5\V*AN_B)'M'GBGH0/VMQ#Y@?-Z6*LA.?Z?\U.&Y'KQ2&G]'[9NONO#^*CU
M<F4;=ER\Z689.X<=3L-W\(I$3/WGVC!)HYB0_""/\G;RVJ/AUF&7]A%R4CE2
MKEERPF]*"BR\>.T.[//"G[16]7I2FQW\_.A>7AC4@'UQ1%[LO'*Z5#-&>8:Z
M)A/P'N@]2J[UA:O*! 8;18(Q>:4-, -+EWV4@,Q'X%?U&V!<UKKNMLX\U;K]
M3O]"B .D@YAYO8I5HU()D.5)14[VMI(F<H_QP/UA8Q(OL)[WL"%!4D6E)>0?
MR2*5SVD9;YEL_+FJJ?@GOO-^GIL9B6N^I,Z/W7PT]EUN0UOI5/59LF_+*V=.
M5U=ZK.P;XJYIE^VQ-#G$5]LO4_U$DSG[DB,S!.#.3Y!4[&QR9L1*L#:@5A6U
M<>MYR]K2SGJ% V:3S&2.-A9HDL! '3"4ICAM=4Q6#3E23W.L#4MN;_,=0J(1
MW%ZHPZ+=#5=<E.H$,(%\ZOZ*"5>1V38W6^*$'=#&M<I:JS$# ^-)W%RGN3>M
MJK.N3 RL-7T=Y"A)K8E92V^+PTSHMYR<5,Z9J;K3"6(?W,=K(7%P_J)? %P;
M]%M:RCF.$?^*V!K2K#&=_$U-59ED%K>;.\ U8IX*=I]KQXF& <0PJ;>1RRN"
M&^8*052%0I(_T'K;6]MR/U&[U#I-?0+M =-*NB#I NCGQ)X"V,C))K^MGE48
M9E?#%*<+':Y;O$SE\F$-(JTB9K/-C\+4G^SP<Q##-BJPAH3\]KO36P"SI)D:
M57+A1 2@@=B";XU35C?ZSGQ8>J%G+$(7O:5 F22G:&^;NRATT#NEHB&B!B5&
M(H$LL]HN:8#=;T! 1CP!:!W<U5IMW(PN9NJ3B<0N,(8"M(9VIG7UN+5B^#8)
M4*K-?AWI?$3#&:$.XC=<&ID2,I.7Y'O%4FMW,[XYWMYPJ5;7K=R>+?Q24G\#
MN:M3!AECF5L9QN?WS3E*-G$=B^P9F/E$,X'2(A-L,:5(!@, ?Y+9\=CU3\+.
MHM*^V&+>-YHVZRMA:#N;:MB7M2>;V("& 5F!B0,2@ O=+4-*=\8KW4I(CZ,-
MR?D;F)/$-MYJKK:&!4[9X%+8QV^&B00=NY#\K2Z653'[4+P?F#87#6?.$Y^"
MMW4(<!3%<H]G2-D)4XB+HF!E#M2<S)EU'CQ[R:<7E&9Q>B85R8%/V90=R6*/
M%4,-PSB$X?L@K0-]KK"7AO@WO"4?+6:%DTQK6C:@W:)\ZK W;%-!&4WJ4XAY
MFOS\,-OWT%KJL,8Q)F]U_X!#%QLP@9D?5.3SY<F1N[E?3<N9-393XAT/&K(&
MCS70.SOT\[_F-BW!H7M**,)#"DL$/E-$_R$V?BBLHMSI'0V$*:NE(\885IS,
M_4401I"FW*%:$J-/U5ZXR?>;N1G!C8PN-X K+Z5XD:]MRB>Z^8">;8DZHT?*
MFW@RTJ'F9O%8%4A=4AMFWYB7,:KR\O.JQSGVAR47UH8]^6P7&O6FS#3K)IIM
MW'>X=PMI$P1"+;ND&1XU2R3HM>7^+O6TKY"N%,:9;B88<:W))Q-@ZS>Y5@/7
M(_'QPT,4\ZAA[LTN9$#:U'-NX5;47%]K*AJ%]E*"OA<M5[@J3)L?$E%:BZON
MY4&6Y-7<Z;L\=Q*QQ:+@)KR9!U\0[K\1)<(3OZ+7>TI&F[33FY^8\/IMU8.4
M-,W.EHB&PMW\GE4<2DB"934^"CC!EPYL&X<TZ3&%[1%K-PNA;K&*U@EC.8);
M(*-;^.I):VD.^XG:C.&^XHQM@9;O4RL)0S#4.5L#HB+?7Z?+ A)\!HZ>)9=>
M^>=EXQ%E+6[\K/.802LCGH25F'"QM$$%+"=!W:WBK\=>&3M?7-;L2O0%I+OW
MP^A:OQJ](Q__>&PX%;Y_;N)$Y:>@B57BP-2O8'< AKTL2FUDGY/DPXAK4#F$
M\T]](#H>&&8!JGJ9528BA%W@Z<,@[WZ@9FY$-Q%/4[0*>S93GLFA/G66%8TU
M+@.L=7U_AB;V(F!]V@-$H3,3[I8X[./['26I3EV=1Q9!5>+%4L/B>A3C;O%M
M_:69C?][E_BIJQ&@MZ#C3N,I74D[>N(OEV [<,/ OE_A^R_ZAULOW?^\Q$P9
M;LTAL*U'2V\DRTU?(-3E[HI^?(Q_PP6V!R$VNS2;"S>C[?'PK6BK^$>JIS#F
M8 %M#O7OG\W^$8NA) .V-B9(AIZ?!&VP-&>_)M=A<%T LW.F5+;ND8EQ *JD
MQY >Z&1Y!D^2O89!D^X?NX:+R?*=E1OPQ_MW Q67V4FH?C+6N!FJN-@3.?(&
MV;9".&D#(XE-(EIYI *H"9_)?AF_8$(KO*+W:>2([N82K:?)F\?ZC3L@FSHA
MS<H49%W.\1%6L0E)C/1M]5P;=A)/A])T95O!3[SU,-@?L@M>$X4E0Q.F9[BQ
MT[+\VO8H#AA&7=>;MO7>/U\$W 0'&.YYTXO5L%6*"#43-B@>!;Y@5UKY=VV4
MO\F M[<;QQ/)+_J5'O2-DX73I +X3[WEZ>IYHZNC5*M/I>J[>QV6SL/,O*1O
M\!BHHUUX,CH/!._F9T9GHV=9-TD3L#\43FS_P&RL'*9+Y#.DBS92WRA_[<MY
M=*LQ#33RB[;E.[?4CBF(,G:U25,S0]JX8[]+F'XOPUK6422TM2F$8VAW!PE?
M8+&4HB$FC=NU33,/Y\BF?A<!*!C)@BA5)#1[N:J'&.92V[SVS9ER#I!$8<:-
M ,8D\:0M&"0$[A#;V 1_*L>%+D'9P9'KX[2X=WN@<.YP6B]F@=C,1$&B2?O.
M: :4"WW=5(D[MPJ+Q]EF2P&)ELF"MUN.O\@Z^9;QX!M?>Y5-CD<]F9O!N%])
M\;'1YFXT;+^0Q(Z:,IJ3RH@+A(GKMB YKXU ;1,ZUN(D@E>T53TQJ19A<@&R
M%5L+QS! X,&5.97Z7#B7M_8-N#3A35;"N?$ XI9*>F&=LIR:)D!0A\1-%;=6
M'T4%4EQH0',=8K]KIZ_)*=!0V4#X15_+^#./-\:DB^<$6QMIP2(I#9?L&#J-
M8(X>BG)+'S.FFPN?8592E8GHE_/7A(-^[K&5%"\@^E:J4L +=P>FCFO@U5QI
MWX1:3R>0OX0#/[\LN2W;F!SLAZY$7TA73J%\:2]XNB(+V8C1%DZF,5EV%(4Q
M7R5<&7?DZ=3_2J.=-^;&1-+A^36RKKF%V#A,"/-<LK:M>V5\Z?(*:(P0?C/
M(?&#5D;2R'E>BP&Y\/:#"N4GHWC&,,2%:9NP-?EJ>-#:[]Q4X1KSI_.)V0#A
MKV$:ZCG^&XJH<A._YO0<:H$P;K1.H_&TLWSKM7]X/UPYFY4'^]47?-=TQ;0Y
M]KN8!64#1]:CH%F0IZA.U 9ZM(E>YX7Q[P)KS&%[_\$N>RZ16).&3T9EPN7S
M:]Y]/.<.$&,8/-)<]!VAVJ8)V-+RZPR'F&J\?9O(D&&<E\"^KCR)SZN"L]I,
M?]2=.\FWL>87T]:(=WCQ%84HJ5L^W,?JH[%/DA< U;EL6V.?A\><35/URJ%8
M'9F3<2^R=L>FMK9F\^4L'R;'Y&?K(&X5-PJAKB$$R*EX\6.:>2Z&FRF[4F2W
M!^>F)?*^LFQV7,E\20?WSR7RU(@(4'IN"*9G4+!$$0Y/OQ>6(<JAW*_64%/6
M]T%XK]=+"(A(9KNM:PMBM7>D\=BAY3I&VQ9Q>U$C60O,H*-^;':4FB<7D!EY
M+N4=J\?6VR;(VB#K+U:$2%-'T"4O[[HC;*#,8DW=FGR,)B3N$.ZOW 69*I0C
M-X]OLO*N*L 57Z>T>T\Q_Z?GF][GW"D6P1^^ ];2O:X-GF9YNXX,B-)EO=5A
M0>*(.#%_2SYJ"7FJKGT]H5NDYZ""\B6WCY![6MV!"UUT78&>A"I"JHTD[KB
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M#DU<'$@E1#)P^A*'_(Z5P+&KI[O'(33GH  94)RYUL$KQ8$KJ0L#*X:CGZ7
MN,KF'*K^IYT^,PKJ9O;7G#=:JYQJ]3S&W$+0<I/PI;V^(FCGHXXH+#SP:H4R
MW=A&^6FSFJK&"Z?SPM *0X^2=2#F@3>Y.'Y;BDW,*9%+W)I$<9C<^$4-] 2Y
MPBIBB@HN23$I12NG?&'/H4ZHJXEJ 8=1=QNF?*E'YK/8XYEV()+V).>$\YT
M8XC\$$2^T^F<2-(?TS'$=R? []Y)$U?.NBI2Q2P_C^\:\)7VX36V9*3X)8".
MXJF/2BE]@22;F/^XJ,*K* KO^^L]I<J.B''P]]VZ7(Z>\CM]<J/E;PS.-@G
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M!OB:"4[8'2H L%KY4(,;./ZR-NO)V[+7,X%A!2;)T[)&=5)]2)<I$V4;=85
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MP1*$\5@:CNY<D$PNU? S-9V 7K1GVT7,P9CYLKQ-]D'P3?4/ZE]S:5D3D&]
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M H'XZ$@SO\Q.[>EU3[XG^<&W\W49NO0W%8_)QB?B40V;"2CKKQMRTW2+U?(
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MFB!C> -$'*3I=L\MLXASF@R24Z(3VVD4.,N?MSDC5^-BZU#W];?0^:[BA(
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M^B[@$Q_876Y^E(1)JPBRXL#@9>($,S$P>CO-]N<#<I3$64:M>J*LCTY/$+_
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M%)4/A<,YD7$$](^FGBY.=$>STGK88(NX6TZ:Y!,2;YZ!D1MJ,X!Z#TSM]ME
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M\YB)Q$C%QZU36N;G51L#9,DEEE3^XET4(.J]@^6>,+L<6G"?:0-MY3E5I:W
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M$D_U6'I*P7Q'\"C]&&M:3G-CV$BP)JE&V4?B[ML#>NLD#0<[4FQ,#VYZ-*)
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M>^F.?@2B*VX7/XOJN$Y-T[X3GQ6BJ9'<QIW+,$B^7!=_<K]NO;R\O&2)"_"
MM;L2-ISNI,]/>!BZN)D(^*7.QJ6399"U&/$XS2CA?XS2M*@?T-0VQ#;1/70N
MX4)^UP.4XF_O#H,G(MS>7GC6BBVR]P0.2*1.<:3PHJ^029M:P\]JG,%?#,.
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M.%V<XUWJU;'WOA@N;0_[R?^.!X:J6SJ#=>4,=<]9. !M !A@"7 "  &N "C
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MB5PVE&1_IQO-%@KQ</T#"Q4"M;>U_U4KY70NA#0N>>=M'$L/&$0![ *&6L+
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M>V_VPJ:/OM3S"Q>:UV^FOT _9N<3,< I/2RGO8;3KE>%-_%JM;SL@] V7VN
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MRO$')?_I^9S[2TWMO\XO9V>.OY-TA\EYPOYK2?>+G6@.;; [Q -J#9;S!+O
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MVJPAQV)VF;E3=J&<M!ML<(JL5B)<E-%3D*ES5LG(0.\L/:V^JS:KH?(@HG-
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MNCECFBHREW:C%!IIZ7X0'.Y]ZWDVVC4(FCM!._>@M7IV27;A)J-L+D3C^_V
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MO*$)G\@JK]=_7KU0Q'@RPF.,DH!G6B[ &?+IK8MQ/!65MMP)RISE\=<[$J,
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M/?JAD;.^AHACI_)17A/9).S>K?PZ\*:Y%\]M;12I!-DI,^$F?7(')$"*8)+
M9%L9I9Y/U&UN(?UM765WGL= ?5M:VD]16S?MBKA>&M'82OG?TMHYKM'2C:DM
MZ0KJ]\7?>!H33CS+_"5+D6=.V]&YC,\Z':':9GH7+8^N$P,U7G?Y9A;K W0+
M,3'R#Z5[RSVQK4_$S[\'/J[MG>9(EHWUQW<0OC&X,?#Y4U;[%FW(<=/>O&B
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MD-K)><[&4GZAQ&O+N#M\_PQN\LS*43K,>TG%*VX1:=^S3#1#\5@!L+,6HSZ
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M5&2J/4CTAPB73@I$7ZZ$ 1ZT4.&6A5$_'R8/1J,:+ @OM*9U>LW\FIDKG&!
MD'T#I*GCM47!VY&LXA#*MN%K[EQ9*43@YAIO&N#]J'9S]_W4\L@CYS(U0YOY
M4#FG(M;2KMO)=;%J,R=:*G*/$O03#+%FN4,%-]0\3<%M--/*-+>LGETS+ ?@
MKB ?<@<)R.9(VFK9;8ZR?@-HQQ48:L'QZ:JE!DS$\4U3-4(;C@SR:[WGP&GL
M&2<"G@MH3,Z/LQMNL>0>.^8,=/:V]_>^Z"\;[>MJ&/3;V#;8K,F[9768=5X@
MLE'EP9;MEP7"V6O"=$+ PY,)1D=";P@5TD=(.&-NXQ0-1*!4#4W9??=?W3@\
M$.%@O"_5L..MOD5.HQ_@@51H&U^0XUGL[51&I+C)S2NOKB[\V+5?)9SS79:;
M<8W=8(2135;)R$#4^XQ&2"%CJK!BD3R9N9GL*,'J'=%@3T_K.M\O=^5/'^@'
M9)>VO'/#B)M^R5_3H,15-#\ADUD6V(41]7!@_3,R&P7-9ROV?H>T=*7<\ T6
MJKINKL?':^0]I0%B8NZG[NNG8G=?=JIGR.(\SA#WY%4 ?Z:^B:M*L37[,5,=
M9F,$WZ3<G)$C,I"=FB"C6"$14#+EU;F^5>&W?&U*\,AP8M7JW=O;AGJ)<G4'
MQ$#!T@^SM5MTG#BS/8%ZH>*+L81;9.)BG]\9S#IESFY+MB5^+)B8JD/$,-.%
M(B#'UAVF,MI^F7U6<ONP+/%9Y8%W_J$9<,NAK0@0AVRC[:-GB7Y;?J.(9"R_
M<5RQ9T7%H!PMU""&+_+QT7VC-OC;M$;/P/J:V\XS9^/E6J5L*C-*R,NWI^OK
MYBCE*RI4N+I?=F0>MWHCT/1OXIG&A%)5??;8*BUY9 \QJ!G.?F->%ID<=->:
M9//MINIFJGD]Q;T^*\^YVX)A(B$C :)!7SJ-T#A&0.GQ]D\KB16,9\@+ZYZ6
MB@J80JWZ\Y08UHFKM(B-%#LX++<#(UBQ([BRH_G,9NC@&G -NC.Z_GL7_W<-
M%W :"L!;/_T&V*U1ETVYW#?1>_-0_(Q\_9GWQLU'N622473C;4$LN%HT9/1:
M!.KSS\I&'J!29>)>9\N2&Y/R0N9=&'LWY?Q@[OV;939K%ID=#MM8%R^9S[D<
MFHM+4V[3IO^+DK<*B@/HND5)L$!P@EN"!G=G@ @6++@.[FZ#.\'='1(\R  #
M##!($MP)-H,3& @PN#N<?%^=^N_#K;KWG)>NZL?>TGNMU7MW\$ G6\7MS)RA
MHY$JZ ?(6-2GYD\# 9';^!X#?LL/#)%@,&^_22=*.FG!:M_=O86S>GJF ;$4
M[69X,#HQ:MT]YJG[X<3B'E;G55]=YV[S"5;,8/)A]$KBTT<EO&D[P>EN9W':
M"72.-*(LA_1PQCQ+YG JNJA%/E6!V/6E+SC6NBZS-M&]GJ5U&>\3Z"CZ]FD_
M>0<Y3^L7RM2,5Z2'I2=#ZD5&/5S5@>P06-YLK8A$5UB7IKC:W-%F9M<)K]XQ
MKV8$Z;IM'T'9'MT$S\2R<Z81@$7,L!\QF_5]K&]29P#R5YQ3%50U8 WMH.^Q
MW]>PKO/D\,/[?R65HO=CNP+HLC1G:>N;B$Z"-.5XZ2#18M1KE(]YWMPZJZ60
M/(#"KL-:L3H\&>1])NX1KHK]=7=C!)5&LQV3"3"\6?MZ8,3=KT&!\DDA8PEG
M(;8K^ 7I<EX(6;C!B1IRHO)#:J0_QT!RP6V@GP+6&J9 <B4=\"HQ977CTLF=
M?P"Z=>\L.SIY A R^1B"> S^'WTLMFQ5?HV$>-JEAP;/6Y6& XL\MW%K@X2$
MV#)&DMQ)N3E-]G?73.!*35W:C>;;TNYB"8 MU]42D&+)R3N$T+'ZL.FW!HAR
M0=@TQQY2T.E_6F4%S?^<5?%;(_?=86T#( O3#4=#^$[7"F$-:RIEX4+-=>C^
MJ<03 YV*,T4,MC$';2?!)*'D^OE%4&[S%=';!E8XK?!Y.;'(^9:'H0)UOMFW
MC+R2[\ TQG4;P[=Y=FT]2NS)\G<'%?G;SL%5>ZKR^5K3=$K-E7(UL .7:.><
M3$L[=P\/GL! R<./@P/5I<[9_":+-;79 ;B1?W+'O8)Y1K_?UE3"/&FD+->Z
M5AQ!^E=.T"P+,\NEPDQ= 8/\3,M7E62&/Q%&9IQ \YPH9$1[T/=&%TZ?EIY]
M/V/OT?@7&<-(]6H^D@IF[$Z:%[/YS,\JZ/)PP>.8B 6Z(N)9PY&#1EL";:.@
M[#5)VY.0VB:)9'/X]4T 'C<<5M/DMJ016:@Z?Z7UA:?.$>=3%ED'I"6K.FVU
MM-4G]^[DV+(2AE[VB&=U?J3NXB\3$EROU5Q:Z[U(.R:UK[)R9[%F$["U100%
MZIC#$W1'=#2B=90-XV:?[4>87L.>T.[=G]!LI?N+H]-O_R-W-FTY^LK[9RAU
M19W5CS'QLOTNHQ7;+Q=W-2'["VYVNUGBS8Z9&F2"OJ02H7 $]S!;CGP=\C#L
M=OB@0_PFT3?61!J''+51<<=^Z;O813_((IW#IW/P3MDXX\*FWGB@(\J"OLZ%
M?M87N$$,@62#BU_=WI"?(5@U?XK&DH?WO+:&?CRW_Q?STLJ,\1FZ+NNO"D3=
MTF+ X<,[U9R,X%Q5;5TE%>>26/:*);N2@#UH_BX4M$0UX)G$J/DCCJ9#B5^M
M_V)8_S4Q_]!XNO-B24&X^6EHNCP<:K6]Z4[!*')=NMA@82@+TX@:OY@Q;5VJ
MZE]TR38KW0XV.KZKAP(TFE<=FQK?#K9J>1HD9OXS-+YRQGFU(3=THQU7!\BE
M_$J,\)Q=31W^A+;!>0\XW^XQR=RAK]GM@L\(%'VO*'!.:@*YD-T(;TM#ZI+'
M_QA%QX83$&.-N%8L.OL[.WD(4+F<3V?X[]*UVAWVP!^BDRVF0 X2!?.N3FZ>
M(ZQ_G5^2T]:P:[HNCU;R0^7BZ:U9%W0G@#*$="&7IT<MTJJQVCT\@*N=[<]6
M*)\@F<;=^^0%^QIC.G]'\,]5^R61I>]-K^!M.>*$.OI'2>@<"&^Y$+XJN^J1
MQ%'KD.?F<ZGQ^6H6M.D!P!0/S66I\N_$D07Y+K+]\(%]P%#B;AJ7M:M*J3^^
MUJBI:<EE:!S/:O3"A<Y <YPD4;K\<%)"86*_%8DH'DVSQMC\QV+S^E(_Q72!
M/ :Y$IDKJH%D.CX;I,["FS^6Z[I/:)P&+D<:V76+*"QI>1,155VKJ?1,>8GY
M"0K<?7,'JS,CN!W76K=FO&4]@7_]4DYL2EMVW:Q5]J=%J(ZU@L?S= ?Q]]%M
M?*[WS"3/-E^J;>>,S_Y' !\]U$L:"&K.G*B(4T^/'!J9:<3=P#!OL.6)^1@?
MD6I 4#9IVB9;RATOSWKRDC)#=M9'/;,G!KF=X0&+:9'C5=PEC.&=;LO1_X#V
MUW*N;7A^6QO!@<B6FY_'23;DU-ZH+9#JQ&UB'[Z]-B-ZB[>)$J$NG_3Q=*U8
M8YV_H.\9!U;T;/S^4,4QUY)A8,"@HRN#AX-ANQ**^OCW5VIXP=S93K.'QAVY
MC^QX]'BOZJK"YF<];+D1 Q("^;9BO73%SJ_,,3; %@]IA29-E2(N\5O_\HI7
M:^@?YGP-;P7XH+[B!I25[B9W^,?@'I6$P-O=#DJ$@Q.?YS'$'3S85EJ>LS*T
M WW#]K/#&_^+90MYR8J:<$XBJCP1V&S8$HT]#<MW=)OC9$+8,671;_)EUZQV
MR,3H9M"^ZAIVR&%7;"(NO:'T8VH[S(J?6H2.)G(1U]2Z_VIP)7.%2B?M0%!V
M"]:?M2,26Q>,49=T[W/S 8=!$D% 89>\*1/A^>'4.WXN3)T&.MW(RC?/MN&?
M,GQ">UK^X'@RX%</#'X[=6W<<;<T!@_!BRX]LGP$F[0#.CXUD6@3UN36>HDF
M*?;3F$V1NZ43;[&"2D=7QK_X?0F,%[TTR>J($$]D@8X6>(<6]%)F3N7E!V*;
M:LUU>R/P(16"E7(=UY&9L)\K>]PU3)M0H9WJGR5C<:M=C@[9-'_U,;]1KQ7X
MOPQ;[DX-N6G+N4!5@V\A[]0-.Y>7LQMT/RR8: RS:P"VDQ6-(SJ&7-5[ZJ7%
M5P)V,< )W>4BX+ZJTIXM$<P6?F_/3ZO^$W\5G3/,I@:F-JWO#./?MSB]F<)2
M@9OZ7^@ X^W6N_-?;_6XTDQU[:DXPZ,IM#E7IEQX?FA]:0Z>^ADDN5!7G6?T
MIE'&.F$:7N>"*C5[;C@RV*Y=JFIX52.]W.UNX#P\]",]V6Q8P]?UFPO5\^Y7
M*3A"15N'E\S$B*DBB4$-\JT0D(*U+,/8 %4'"'+%1NE]40:5M%=.'F$ZM,CK
M%CKR?;7*&$8\A4A[1C5J+^4G8*G$AU"PK\I<0?31B/H7//#(<^]&NHBD@GIJ
M,Q7ZA^<L+)$F I\T(R1?\E=#+@8[4 .=<\[>/F^P5OPS:]@%R?M$$\8ZEENL
M,W=& QAFGA7<^FBM/C<I(#?5H/O4AB.@#0R!,09E-!])2@S7<SU+-R]CFL+"
M^S.M(8 ZI(V-XD6FN&$5JKT86)37G.M(\Z@S[$L5YLX AX7+>RP'/#MHO@->
M%G-67.0!7#IDGB]+.@Z/-3:YU_7-_Z6N!=\OQ^GA=D8-W4;J%R[8%*A\GF-A
MV8<,#JL8AS6T_JNGD))$';);'NB4!L=[SML!B/%7Q[6IHY;PXU%#%D=*[]*O
M7^Z4S4=LMXYPC/%UA4,5A3^RTHJIU5K:8@T_/OJPY!Z:Y^I%SX#$B5^PYBMV
MM%F>YW[,A2[#XMFKA_9AIN"9\F/^!OOI#5O_?&5/:*N-@7U@' W-IA8-GN8%
M"UZ.CZVNT[#QR.A?27\I OS:!]N#ESA-K(LUE/7O]3Z;R$$7UJQK)R@%BM5I
MOF@8H2LQ3JT@NSMAC7X&GG]%,'A6P(RL!*""(Z-]N4V=;S>F@PP\(K.S67JX
M=@-!E"Y<8'+7P@_"@,8!_)8EB<YWV^ .-DO5V4758/PVJKS")!, 4"%Y5N)B
M<&$J3N=X%UK@I(((Q,N"ED"#;W;.N2RDH^J/@&WMB38\<@9"%7)B<.3\I657
MS+C[H VTQ6COX,W.EDY\%?XO?,G<:$U6<Z"FATF'8;CC<+^@4O?>J( N'HLC
M$7OURIWB1*R4L?X"EWBO>.C[U#>LD6FJMST%=6<J<3'>P\;VY;5J-;V=+B>W
M$08NP01['OE7-:9YL+N=>?B-ZF+64F).?2S(P$?#6=6TB@(R<F!$D<X=OM.F
M0+VEW&#O0'Q8M02<T\]DJJO*TO[@HP6,&T*A8^GJZC[S(2$G:G9@HDRFSR#)
MIWF!\1ERAHZ/U<#^EKD_C7NU*+A/4O=]+HQC2YB^=C9 VU!TQ:DLJ6B<O^!4
MO'4F/3L]-3G>!)_"U+EY??K20)=;;2LM;K^]"&&8\870DMQ%7,KSYW@Y/:Q&
MF5M4OQI]<:3*R4RJ4?N97OI^Z4]Z<>EMUK]"[?]?PC9C#2) B4-M33/) >?@
M=Z&EY&JY[=L1RL0.""@^8Y%H_FK\;;QI&2_SS]F8P,6AEE%@9F^FUH>-?\0T
M:XTF5;CT8;9:&71(%R35N)8C%>UMND87<#)I\I/I<S11.PE$]#=5I>%[C*:E
M$6C3":$E+14M)V,2)<EQE-7N(8)!.H\-_%_\S,+CIS!IAK4:1)1R >F2$8!2
M+7IF_2L>M>LG_NI*-'$>8QKS"X%RYX6TQ*FN>)_TSS]&'U 8-LL15NPQVC9U
M11+/.5>M6.F\MQ>\@.UUN7GP+)AOVLS:[;LO 7WAL^L/[[^D*7*\H&4(1GYK
MZJ;_8[.]=$(H-YM_3]Z+4]>_.SY!G[=XUF7%[0*\\34H*F<-1<5K?C=ZP04E
MD)1XYA$B_3%HWEWKO(H0>4N3WZS"NUL\>.^%/$ZG;Q\$>Q8XU%<$R= \^L7E
MN=301:U"=[.PK^%%&<N"]:<B3BC-$/1)^J!*Y]39-;0V\_CCFOIAY*[C(]O>
M'NVC0R'9/[3Y^*.^>5C+<;MN@A]*=[U.EO@#2)<%BSLLO@U6PQ,7%KP/*:G(
M>;P/+EC2JAZAQ0,W*,B<T9HD/0M>Z]T#\5E>7:$_W!2 OU[;;$51] :-X[X[
M$#<EJATV"^Z/!+ GO;@/8YCP5I27.A*;</L[<P(6-$:>'#N.[D#R;I%GQ<';
M_6RM%2'JVJ"!(!GI@F6=L$K9BL.RE66%+$.8J8&L^62#+4KY'[L8DDDIN)2?
MK'0^I%P1-'DM_:S5O6G,ZOZ>AZ/UE$/\OO+TLOTLYP1_6AU"ATL.OI[@VP2*
M6EM_/"O>R(H<S?Z 8.C=* /+)+D7S^2_>4+#83Q6US9Y0KON\)K_^80F>V,<
MXBGLJ M>>M8DL2\DO9=<X[0JD]KA'C?XA+;,EOL#D#+). 4_7]:#B%HQ7J:/
M8*@\1E'GAZ,EE))'\^Q+L&:F;"N&?LAG#(S0'?NU;>$RO8:N;I_8/%&#:OWJ
MM6+$U9V!4C&)AH.(FRRS(^HG*/XZG.ZV$C>>T3!' ;U)D6+RX"A##ZX TK>"
M&8:STOE^>FI(Z[VZ&F<;^SH!+IEF8?;*P( /GUNH50-6('^Y(^9L'3D'SJEA
M=Y@5/7/K)M@'!*O::0$$A,#]MT*=&;Z4?_@-ND+(LU+3%092_1_DB5DU7P:G
M:(^N3P"/.G[6LME3:&3I;YI=#4.UY)M=&T5:SNO5[/T14N=S\_E2M72DS@WU
M0<$.TM1 -28GX>&LV2UXIE6<0W>V[4!Y7NF":K]AH:[N[R/O%9GZH"[J3BFG
M@[,]</5^ I["D-AHPP_\6B.LYT!KH<V_< !>P-& 2K;"R""Y?S;FJLF4PJA(
MLGZ=1$9&HHY 4N,H<,W<7Q]T^W@ ZC6/GT]1'L'5F%B8O*$-*Z:S02+H!_\!
MZCMD;&MIZZB6E3ERIJU?8WAXVEJC1;;[85*7LUL'_82*\AQ2[":.L4C5]O"+
MR^;;)(/:>V'FFR>TS%K<Y'_^E0PQ:,:75)]?WWE]J/6[1GNHY;PGCZ$4K-:U
MN*ZM+%.:!1NJO%")/7-N?. 6F!9KZCHI\!<<W)[)]?)?2.NS DD)2&1:RT1P
MHKV[C\&R]AS"</.[2W;=OGH(VJ1:K.<F8].3^,?7C 1'*AOY<%0,>904C0UG
MOG'E'.-H7XSJ$,7TDS?TO1 U%IC_U;78JF?]U_EJ5$K" *J](.4_PW9Q^Q R
M#5H1/F.?X1D&35>WV/K4J6K,I^DOJ7)Q/.JQN](LLDF9)Z>E83DU7FBHVE %
M9VT^/XH&Z^K3K(/)UR1KH+ZQG3\EHV>'U;RF)1=&T$;B_ .(&5Q_TO)"/6\M
MM85D,IL*GM#R%_;VKA]\8P5?YO=,V.6%L9QXXM0D6'/W%[_Z(/<O(=CWIQ87
MCQ*>T/#V"I QN3P=CMV 16?PXO;Y1/O _.3]]81[GV+X?<%"2XLR7]Y,QLSA
MS_D_BP*&PAH$>0HU@^F8B+?#I=!AY2WV6B*9(4*W?>A=AYQSP<Z@C7/:RN@7
M][[@'Z;?V"$II^LKCCUG#56AP6PLW,P9"7!,HNXY1.L%>E=UG>V!%H]8?A_M
MQRBAU'7*0[K<E3+?TK'M+5'ZCJCZUCDN9K][A4OD8P50^_%OE4.6$4G3 ?5I
MAV4%P!LDDCMH^6);#"$9X+4\16Y*&J)B*S8EX[TPN OV39_<NPD8MWU""_Q0
M&Z6C46YF,MAMZMC:^,K.T +>@BFNA9! :O]UKXJ/>\ 76:)"$)@J4PLB7%5<
MMHVWZ:MR ,DKG"BV9P4&O3 EL1A9,V*M)BJ,R4;O!R-M7 <L*>%A3<)CK(Z
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MYS<$33E3_1TP'DW=M+'6F 7,\^X$) 0\,5MJ(#/D;:!&/J6\0%T:SE@ZA]F
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MX=3B&H'EI[?.786@7:B,XD66@K*EE9:SW_=$$X6:(#"N7I#/5';2[(*.5;5
MO;\HG*$([5(F,DCG.+Y\Y2R8,5!P;&\<+#)#**.>DO\K,BQ>GM<Z,3JWNHEZ
M&1CIO?D:LC4B,A.DL+4:&C8.N].\;I'5-C@G^2NC-52:L($<>$\PE['OW]B\
M06).0'W(H9N8P<(\0>XU#N-D76\<(_L(095M/7:\C0KF23M@TP41M'@]!,#%
M"W7J^S\YP85_")OTFD*^>NLU5TK?C\43&,["WS3.Y4UJ=+W7AK26;-_[[ICD
MH@BO6__\Z WP)PQJG!P":"070NOMIQ_DOHZ22^NI6YW/^<ZN(]>!:?:P^K1
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MHGNO"S<K+LB(?DW^RR:+L']DET1Z^H*A6^P3&D?L\%J9J_Q!]^]@I(\#8?+
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M%;J_#<4T8#*Y*+E^CN):[ 9""; 1=F,#SVYLK&L:.S2K?U7_O= C*E+-.<@
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M?0O.S^(2U7O"M\*GN!9[QRUS,JE[/%1#KCD.][?RO2G:VO03(WNRQ@\E]=0
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M_=Z,E;X&ZEJV$BY?TQ"9<C9%I>,7JQMH9*/>M!K014OB\7AR27""\KC2WQ]
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MYOW-YB7,Q>MMB1[(&BUBLL"2A,)!1L3F_<MX]'J-)7WK$ GQMK<:/:? +3U
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M:?H-RE^PG]^86.0BE[?H;XO+>%#-R0;M<.S..P#/#^2;EZPXQ-)PZ_9B)]]
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MP9;-+@*T(M:Q(M72SM1@;EU3;5570:4$_:A^0JO*7^O+^7]D@^+< <$$I-C
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M+?M@Z[8R'_MRFIUP66TZ@\Z-<F-S6JPLF*PLMRSC&\[XP957&9N6:ZICFK=
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M]8,^JG<1?H^5TWO>BK;@O35%&T5T-&)HO+M8_"55R T[92Y,5Z<F]6"2+(9
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M8@^VN_Y-:O$A(>M12@CE]"_M K?NZI-^/S'9=^LO%4Q!%Q,T'$^^#.E9/T_
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M$#P+%;NU:4C_=N;S/'7(UV/)JLS1/(.)QUC%PJ1^2.VD+3<I 7XM(:57;(9
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M:8X"\Q(:F8$F2[-DDUG'S$X'#6JZY:+/4RXQV]:%49L=_/D\'9[D'G39 GS
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M.3H2O#OFKW.[]_!GCJK5Q0&_([X:U['^IN18Y'&"::]:1.S@QONSM?BW.Q<
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MEJ4M]YOGOP1N>'10&''_V)N,08@F#+LI8-?M/Y+[&N?(D+' 0][>9%%J_U6
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M9O3UD;^!7U/= BC2\P\">A06\C0[(9WR,KTE&U?YKL2G92G.FWL3"?OV/K<
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MK1?'5^OB7DMI;6QD!0(^B)5?)IMQ\UB3HF?![*KO"=R67,X@%0M% V6V8=D
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MS"G_7\\]_Y\E%WN[8'>#7,E3B1'GHE2_#'W27KO59>C5P,P^"I8555FJU8N
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M>^0TQ$T?A<@)A"]:;,/H,?0&?5Q]4;!.!-M0^8H4)8]@!, .,-!BNN&+B_J
M%@;Y4_YWB./_Q1Q&X6JRD!ZM%H*51*G[J?A6TMJ2O!%Q>*B@/G4L)S<??%B:
M^!1A-X1%((3@A5]<"==KOGOCXJ>"P3XNQ_LGY7_3)K3$E3K=!_G02C/U$B;6
MC^4I3RA;N:O-A@YMW"]&1>^OTS<?+U[Y7T#=X5.]_<]UD:NJNOHL')%/DE^?
M_H-NG_\C%O''\!_;8=+1J=7GY(Z<CH>IU/P*MB8#GVA5W-&SL!9A#6F:X?X"
M5(R)QR?C='LR1 FG:"MJNQ0"/3;KMAL(6-O/[XW;V P"\F #EGW>VU>-/1G/
M.C]ZU^P(V3/M"(E?6_Y#UV(>?P%2]XB+I(1U?DN_(^GR1*PX@M;6]2F,,>DI
MM?-<9ZI72?7OEF\" [JOROW?M=4-E=$_^[Q=?_-ND&O+!IDB[/Q HXM$NH),
M2MM-B\\XJ1),ALF.S^=R>*5E;O8^A%&G#=N^?_K1ZEO#T+OL3/[DN?+NWCN[
MJ=Z\2EZ/1]G$T4BA><>7]SE>U;8<9V!")]81,[F_T+>EXUMAVU_ 2.& <; (
M>M&9\!6%ZL?/)U9'7U6P'[9-7X-@7'96UT0QY[93)!;=YK>;1OW8*7Y$H(M#
MIMT-*[QVFZ&>;B%\+O9H._8?7D,AP1(F/OS)! NHU ?-9IZ*6%1RTCIXDEBL
M%5P<GXR3;5@RAT-+WG^IEI%]"*-[/\41H_5*A:$I\!'V)4L"AAVF_/PDQ**A
MSZ*WNUQOF,%RQ7A.:8;_2IJI?+_? \XX"3N2U?T9$*(.J0H4V6!GD&YP8])^
M+A0I(U5FE?\,(?70E3S/9=_Z,2& &BH:Q]-F54HF/=)*0ZJK^H%46*4EW;R:
MBMJ=,R9>[*WU]X^ S_PS71<H+ M&/V"BJ\^V;>EC9&8C6W0W\B3I9I#3'!NB
M)64G&/TQ<*L7D"'.O9T2']#O74:>8"TJDX)HQD]^GB11)/U^]<W V^N\5E^?
MHV6GZC3Y)OX7D%?@2^9?Q7J)-IC]W'0J=%)!\L.3QR)9?KZOX&KSY4XL4H.L
MC)K&4C"1%[/&;C(C*SYDE@8B<] .GZ=(VTS%,BF4(C,7270X1Y;T1>!D_/&?
M4*Q2ER?"]C)XS;QC*/5%X-<Y[N:&SXWOWE-V1MH/IZ*X1GY,W&K'CO&B5K#U
MU217' H%2^@X)0ZH,16#5QVA-1\I;F9.JLW_OAGLG8*4)#=/$AY)-$=C1)"-
M:EJ'29\T?OOP!Y)A]$/SZ*,K@(!*P\WG./L)1?3H"2XUL.R6Y:YPF8CJ DVX
M-R*1TM&U/'+Y\E >JO<"QY:Z.&IN4O]DZ>99BD"N6*[9[*NRPHGM($73?5%D
M2NF?I0,S$E4&,WF8+(P[*8P)*+SVV<-T\X&;Q#WZ!8W2#N>NWY'=W+A5<A J
MZC#.<F9HV GW-]X(I1^\T"Q5?P ;VQS'11SC8.F51Y^[66*AJ1)3T68#G,3B
M^$ "?PH."Z]^O@>6/13L_*Q,O-X1RNHI$/B#X?_J\\_V=W04DMV)%=J53I2[
M/-;]EC$1@LG,D.<+SSV*P]3P0XB3A,.I^MUEX8S#YBOIGL)/!2@_BLRMDT&F
M_@TA!5JW7QMPR6D$"\#? <E\Z$-]A7THOHC^!02G?*V$NB GQSX%:=GYAO^Q
M=#8,/A4\EW"#RUI<RJN^2SYK_>'#_O6*8:1NY>B" /]W*@\S(B]33Y\U<B!Z
MR44;R"6Y%7M#]@B$3!8V(0P2@/</>_CD2M/^Q^1>&0[4GG"_5Y1[]!>0D"?T
M;7K'W@PUB#9 OEJKQ9JN6@?>F6+8(N?<:/0[,^.^6FFFSZ70N)]$&DXIW_5N
MX_'+6U$P;/+ G0"EMUME9^+*$<P<@&]!UU_']_I:<\:\0.;JQT5TS)JA1RQG
M?NA/'LM%U(@CP5TW+2".WG;D,B\\DS-6@!TLB3J'RYV0$ZKXDNN6D_!\"M%T
MFK6;UAD+#,X9CNRUL<]E8MD6CX-/AK=B9RD]>X_60/JF.G-D($F*./42K2GQ
M<>_S""R7Y)P:;XN.?;I6:#,QH^IE@T3-H'$QF0QKC(#D?MQ=J5)^&[-=LB%X
MS:/<G5$J#R,GG$_C*S9#%5CK_BO3SK!OKS&)B%^MKTB@B90EU4Z809PC7+J4
MMG[%/9_YQ@1\HB]%D!?@"?X5=ZYIS^?N'QS!&LKK?N_T"T:(LM_6$[BJOZ*E
M83=#*=:DQ%K!J_9M7@;SIM]IZCXH'U9=G)NH H/+RX4(<9N7LUHG;#5P'&5&
M&6/R8- WT -,D*W<B-Z':%,;U[(#XBP>I&+SVMF_=ZZHLBKY= D/T!E-^<]C
M(JBQ^S=J73RSM%=F8F=V^HC^_J@N6WL*-H$-;*=EBR@MA*QO)Q-\R-3#YK^3
MO8]I2['[)+ZFY*%4EN=]%=??J*M]A:TY?0+9:#],5,,5C/4D:=I?F%#LNH^"
MC570S@T)%V.U/71UJ7*XC:B2L DGL1+_S2>I;28BHU 59J%\=I+,E$NS2H+Q
MGEV=TY ?HN^BXDKN:/JQ*QOZ(;YHL1;0R>!?PL& EW"HNE<;$S6#E3FR;Q?G
M0S4EAXL56W2"](D"*DL6Z@O7ZGYT T[FIXCY-0=WB?PJ>YR4^:<R.XE/"$3A
M.[&=G3)V^'TBVD_9JFYC0-I6;L(?&35MA,8IC]OKG(:YYL!-%RNMW LKUC;"
MMUIRG/Z&0)?:*U_K#JSAE?H7T%Y-9#:9LX78]G90QTA*Y+N[6E6]J_?RZIW0
MXH /:G5:P,B)(=_L96,2^#.S6^A"#'7(9MECR1"OIG1#/L*8GX._ 2\11KR!
M"WS>X"A:(06T_YFHB6_PIY42UP0[E(9'(EMBQ:<SY0T3Z\.)EI<&+J M[Y">
M:#[(/7OJ-#_0]<<ZM\3;U\2<\.\:9A8:>FW:AC64U#H&].;6,()!E14ZI#E"
M(2KV54)WXG =J9C-;9ZU2EIZHYJJJ#CC$6289(4#!<#[ JT<W]NK@\2-#^<(
MJT>;-?O]<5=U>KX-GA*>'LN&;;N\TD^K@F?Y+?$GAN\B(NX-041S2P0!R&=B
MB=J? G28\2FX0GTI<8!_ 5&) ;=/07+#E9H_LE26S!!8BJ/UNP#)R!3]HL-W
M7 M7I9O7W6J>%HCGK5> %/FAJ;1ATV9BR/0,%KR\A- \-&5IQ87!_GTDSB6.
M<':7@J,4(*[#Y?8VCWWY737PBR9T]!LJ/0WNAXJ*-WNCVIJ6X/MN/GMF#!\6
MS&_.HL))(&M_78+*:GUF>AL7_W1O9LZJ2_C0HTQ@&QR?L_OM1ITT!=//0MV2
MLES ",28,U,T5:\YG'+94<I)GVLWMXR./WSC."M\Y29&.+]5&9]Y&XO6BDVJ
MG-!+=1.16@';0SR6C>,?"]^XFM2;BB2,@QDA2JSC B6"U4C&A/=F%('Z:L&$
MP#KS>:VX#K<N66S%B%?Z V2;_++MDU/1R>0FX8+)6Z MVL;E+S(KED@)))P-
M$(.HN;[,89Y' DU$IC(EV]CG#^=HQV-GP]9I A($;>K,3=/1^.1^N%&CM9PF
MY1!Q-8&O,^4N=5K$J0>4D Z8$7G4&%Y-4U0.$,_4L7Z[GA@M[N' T9V8L!LP
M6);%EV;HSN>X\PH^=IEX90P!4 W7X9E1BL]+%Z#5 %W]Y!FKY ELT@(ME-34
M>8Q]?58_D["#2+A=B3;CA4K( NWYW9(,>_"[3K$6;QXRD733KRER&W4=!#L9
M$;] =7BAR1$4\+3$"QC "7(GB*TC3@R$#].V2A"-3INVW<'4E5W;,@RSMI8Z
M%L*N6E9@+6QW]MLTU0Z>3.&LU ABM7]831R/F1!M7]& FFD2&^/<31LPWI^O
M%>A.6LP+,8IK&E".6Y[S2EY]T'!"/)B&P?@\Q&6$U)XD"=24H8?;NU;+:,3#
MYO+SIOS5!;]6M4WG/8][A?X3K$?/@Q_W)3I'#JBV'*Y  !\ZG:6960>BU(,M
M55?>F-FCJ\!JBEYO=F.0B;UD;_-_9'8S1L^:/'8@0DUE2+7D6JO)?(TDR%]-
M!3ZCDV5FALCG*);<Q>Z L7+#51/#S19. X-!/ P))$J<H88=%B8*4A28;+1A
M%#D6<KD7U++QULEN-FQ'#E &\1:MSY,"+F.25!OHXV2/>\SWR^(',2438^J[
ML-N,[558#\YWL:Q7<R4?$&F:\.4N=-^YJ566WT8CC.$ZV4L=3EM=PJFAF<JF
M[(_%1]6,G:&-\K+,75R!B!"WEGI5\=(DJTD1"2&:^Y<_=];_90L0\TN)-O7Q
MC781?."<@??D9U_9I]0GXKV[&>_?,5<AXK6YZO!BOOHI40S@#Q 0+A ]N?WC
M5N'MM//#ZDJE=FODH>I!\Z@ [Q]U$RSPD)(QKZBU'5YWC/?>1392 \,N'BH=
M;J<XP!=$)J=%'XJ'XR<HIA@,,T ?$<^/=,H9%A?%)I""/:??[9#:/5UA_V&'
MO[O[SA OOX#809%.-6%?OI^9]Y+\Y.-[,;/N&KRCWA3O%#%"Z)MC082S&4$0
M4QA'#A>+(/>](TF"573%C$Q)S"K);>#\,[J#6ME')99S1*.&^NI*L[9FQP]S
MN(TU0M1@)^VAJ )[;FDQAO O01PI7U=DV?/DF']/',EQSGWN<!#!<__SQ=HN
M:!Q3[2C",:MQ[ZZBV!F;G]!&3'SCH<P-DL8:C.W3N,IE#,A.C$-.=22+D J_
M="&:;VR7%,3P4J<E\+H=H@?Y'JI7MHO[YG2)>%).;9)G/+ -+[%6VXV3*L-Y
MF5A86(ZAR*^A3?N!0R:Y4&,R3.@-5<V)/E&0>+%'A]I<GGB X\/&G)7IU)@Q
MI&@:+*0_V?;,DA4D]K9=?1T:Q6^9'BOCM8C$19.W^^H&1]LT(RF&G548E8BF
M,G1E9&JM5^%P'3XOJHY)M,V>KR.H>X<R\7!W=4)79Z8LK??PG6,!V32.A-F)
M[5H:BWL[.LQ\8QVK:JG3!CB]#!#.'FE:LTKPVNZ?R.F=*]I6;NK>^%2U2%+-
M%1B$Y^Y+><IYMPYEYF:O:ZJ;GTJW=+2H4O2<OVVI^$VY2G^W_/3YJ!2,K2=\
M/S SS^%+D0BJES.8RF<CF4/-L2PKWPG3R;CWDI0:K#^IQ7?Q&ZN5&*\L#5])
MK3:KG'M?DR:9D+9@!/&&D!,XZ;XH8_.7]5K^7FOI/$ABKC:2D#R%(]=%0'+T
M-+RT]_* CV6#TE#6/380ZR3L?X3))V 16D3I1=S+$> 7<Z=OS,R,)+&MH;]K
M3&"K[HP,#F=C.U@/1G56.+QP]/^X5LRE_HBJA=U,54<<O\5:Q*O.D3PZ/'P(
M2W5M88E,CT6"7RJ[08,+?=)]>:6X$T[Z>2"?6D?D"DV6<:O]2'DGH(6@\X5I
MH!J$1#.2W\A6I[*=^B+=88'<>X7EBJJ&*%)[J"9^Q1-KZ"JYSZO2P?HYFR1N
MM]-<MF)8II';(-B2>Q"@/(8S1GY++>;O,W%.?9!,ILQH6N#?F^G*D*Q 2YCQ
MW<I7P-="<ZA:MVKR[?CMRE:QG]NM-DEZ[WQ,$<\%O8I_SX.HV:[4<5D7EZ.D
M&V9YM@N$REQ;S$G@UD1;'DDL5[9BF<7/7BW02]):7]:PRY^M@/[A\<14$\$'
MO58;Z7I$R.;./]Q.P+H,SR,F1$Y8TP.D@8XEU?V$J>A?]Y:1')6F;-[2Y=1!
M QEAL3C)I$1F7U]ZQCV*[Z4OX6)$;AU.E77?TTMP8S!+P/[ T*AL6\6JQ%*Y
MG^CHTV0[?9J?SY8#WUO_P/L6.<!^XU[""5DE45?4_3C9+2:6?'%^+=]"5UJJ
M.YYI4^3A:3T";IK-\>SE"91:+F7^EAYVWSDO0"=*(:<X94EC/?/9>OFLE!:E
MFG)KI"DE>Z982+:VR_]7+18SE3NU)P0"3YSJ%%/G]2GFNF5:NWQSI#UOF=*N
MU,4SCCMTS<NEFK:?1NN^ 7K!:H]E+6(J2L$<8?81H^FNI66@D$%>)[I<2H'=
MD N\8W=[\M;[_OSZ].NP$"3\?#*.6*0=>80C?U/&#J/?)<>"TFRZ0>PO+K&E
MV1.MEB"\' A_[DAC 6P_]RLF8GG"BIP?' N9HD>JC&YA*F@J6Y<LB-63;PI-
MD=9\Y])IL25G&-V+'#^@^1'=NF!1N]B0FM/9^Y]EJY1#=2F<6>/DS!I6-5MT
M&>  9%T2AKR&W8C 3K*:T_,&7K!EBM(8E"Z"9U/Q9T/_I;6Q@=L?UJNXM*3T
M6.+FQHI[K9.VW#R"@?IQ8*@&W" P[$ -2JP+#H9JI/P<)),GLOQSLI%A=5S[
MU?@AM9!E'^$])VFD[2E'W%!CK&MS[^KL^N'%[]7K]_W][[G*2I'Y/Z).AN1!
M)O:$7;J^S_$MXRZ'A2Y?_@+B?Q"6LR]G]%O3/C0Y??(\"9O[@VP;V'5N8=]^
M\U+3DR- W(M#ZAB=KW1H&7ZM^O4.M -G,I XQ#<$U@WDHR=27MHT"[KYRJ-4
MDVNS:DDPKQ& ERI'OY4*_D6?LP2M,MW/O Q95I"NO5Z-3]%U$SQ_KJ#W0H@C
M* 12:A':[=@9)2L@P4 A4]$*@"U/CWS>1.,^E2ZBA(SNQES94 YK2$ ,F?\?
MZ\([N#]I'BS&Q%B;JG\!NFW-#CT8$TGJ7$.+%TAT$<(M%G[*D_W%5IZX5C=9
MJ&!N3_5X:2EZ:QX/$.^9>!([GRMSAS:&VT^-G*JEW4C;/MY[#>DM3\5X4Z=B
MY/-Y&GI[!4;&K][4S/:I<(_"5"JK*A-6I-D[BW:GG>LCHE9GO)0=#FC)UC\A
M2MS*5@&B>DVY5N:KW?Y-FH=,7O/YJESV7C36*^J^+9O\@::*TLPQ?;K,^>CM
MYNVHW:DCF>*'N!1MW]/:O,F3JKXT8FB6H=6$<HD*O_X#TX>W-U_1G8"@CZ),
M=*(-^%$L*&Y[#Y7+T ZDOIEC']<UH'T@L-/+X=%;V)GBY^?D,2ZCH4F[Z-8/
MH<WV8QQ0/SITIZ6(8LL#]J7>R3\/# JH5BJWL"7QXS*?I7Z1-,&5O#4N7-ZN
M^QT>2E9(E 1H;BP,+W 0?C,KAG0G&J\+>YWKX""KY\;JIC*7.W6'%QOP;/BI
M38H"R& (X?)GU?!X8<MBYO'UD(WDHUOS/USA6I\G5AF:OGA_/$<X8[JXG\,D
ME44M.M]VUP&;4Y=A,[Q)ADNE"/6%*0@,EV J8RISYIC>]YPZ#9&AL*E0?<OA
M%NAUQ &%^W2+\2E?LK5-5HK'Y7<+21EXV<W3GL4?.&.X]%)OE5<DVC=/ZBUV
M]851PW^&D0\+%1 0S9M0)/KP]C4]UZ_-N\ZW]O[/;N/O5"'?EQ":R!LD]>T-
M?S"=_H 3*H: )8($(U5DB]P;W3=<?!_!\DQ5A\DTZMT+L>,,YHID8I5TX90Q
M_RJZLB-AEXK9\@.J-AO-:BI7/OUF)\M0QS6^Y.'#V79)/\EI6S!&:FSNZ87C
M5=\ZBI];PC90TMXKP_VKAK-WR@[YM_8*<]/;CKM*TE'L*,PKI_D7O'-_%K=>
M=[CY@YY^7#9>H*3"]G]5I\FL\$3S=L8I6APAY#.D"R(P%W8Y,(@#D?LH<,U;
M5B7TTY?;AU(Y'XE6I>$,A)0.PV]Z6K]OE_(IT(0US34:Q^5D6'JO=?H(Z%ZW
M:5SM&K%:C=>S7/U^MX:+O;!&V]&!K1GQR.=8%#!4[9P_YX#</R7UGK-^4EKV
MLG+B49)6/J$T7\QPHFJUXD4'9DY &S)+*GZ?V1-<G,G,-S1X?S%W7I==>9"D
M9A(X*FF,-\!:R)!#YEZR63LJ2YZ_*EWT9HJ:1XP"6O3PH)"2M<^W,U-+A1WG
MB)@<XSTE9ETH;H^-V+?K\*?W:U42>D8XU5Q^?:D=F6IC5@PX<?#0F&Q<EK!L
MPXU':B-.J3$5#7WJN8&3F1=A>E=?V'SOUR0IJ-_TD'[$K'.]%R2KZZLH)&3^
M<%4(7LJIF&I[ID&Y'QZ UCFZ8=]"7"\FQB>K=QW]*8*&NH?!DPVVAXS8P<V/
MKL%U-"ZW5_)3/W#.INMH"=!18Q,#WM2!;L0>4&D,8>;/"(CH2NMX6SC4@Z%L
MAJ6G+<<YQ-'7Y6(L?>XP?2"J%7OHK%_TTS:FDX)]QS_J(B6U,V;,@/:N*WMV
MOT%Z9I;OQ8'NCC/@0%H[(-@FD]:Q(,HA9B[,N[)2RS1R@%(DK8HNDH(<F=AD
M@GM:O7XB/R4L2S8D@:2"8!D'%1<7\+5ATTN^(7&6ZLYTD[&:,ER/+Q6)EL+S
M\4YT/.GBY.;D]B$+5%E_63^ J6K9Y,UXQ;2/!(]#&BD<2/N'9N"#)TM V._P
MU",5\PT[U:"R@0W=D7PS#PKQNCWG<)DCUK(X?,U 1+LIFTL(*XTJB]!4^^T9
M$5<#*2UM+6%<)^W#^_/AEO]?P"<;O?RZWV*@2E<C5 :R1-^7&.3QL).>L ?Z
M%*JN\<R&A!%OEQ&1$901D=PO!UTC<%$$B;R33=SF;>O*AV<35I4E6*=O7=UU
MBG43&K,R) Y5-XC0;LII<[(>-<#1[=-3>DV6I119"[LF6<BD^0!9*N N<!(0
M.%V([)U5145' $_[:'9NH@8M8EY'2,?K'9' +_X\4DTA>7 "8CHYL_E);J1-
M\EDV%O,K$XQ$B8N^=&ZR/:1Q]2$9QGS@SH=^"Q. $_@70!E4V/2+WT'H8M',
M9C61R(NWT2VAGMX?-;BZ+$38SDM+5&<%Z10Q\,P^1?(^5]047ZZY%WU[\O$2
M@?=I#M0F9Q'SNZ(G3TD?'P'LG,$[6T_AG@'Y/!BL\P$N@5TG0><N,$=?JX;Z
MU@HCRY*L_IB++L7I3(I4>EPHX)#$-*^.]OW+M]9D9/@DR\-"FG'1'9&YWW\@
MM 7/@N=[5GNCBW>!0B)6"E8N3_"<Y:4)$A/R91#=5I7>&SVDG!PYTQO3^/6A
MX,Q4$A\]C3G8/%[QL/0FB^3!AA$7V3=A<00Y]>NRL",*RIN 1/$_)LE?%G$M
MC]/J9@>:LID0]XD1J188G0.^YQ*$\9@@ZY6@I7/(::@FC8K<TQ#H2-&;Z/1C
M$?DB+4BE>U'@S,1 O):)#\>%DSXY!;R/;VYNKMT$A *!.70^*J-9:8,HF"SB
M;,@B11%7C,<&M<FGT+JH3B_5I _+@QZ'<&5+22:4ZF;;E7&>!/I( A2A&9Y:
MNNH^;RBZV/3"Z5(.N$T69A"BY3Q4!E:;RUQQ:O][6,>-L=4=/JHU"WF+PS6G
M4XU\&\C+NQ9X0P%4>"G<QU\%;"XN-8X,;W=G#!<CFKK4=E9$-T 3BTBR6N7Y
MQ>F@1^A25F)#W#_M81TUIUMB7[*C<XITVS66&8!X5F7?^36MU16+SV*+%GW;
MTD*NV[=UV[X)[Y./4LS'/$P6;A%7WF3I[#E3E[;R$IJY!V 4N%4I-CJU2_2.
M+]+3;/0JL&-58:4P9@ !/I4*-5>H;"EOJF3!,<0&L&9)LXI<)2O<4!?2H@Y'
MGT840K39'L[#':85W>%WAJ-(OEGCF0!$NE2J\S D!N97;5?ELS#FVYD'U6"Y
M:5*&Y$XR=?4E&4\JR.8A&]X0)%>G%YK9LH3QOCIHHR9)R[XAB<+<SNU/@L2$
MD\P?_I4LQW5-1MPG9P'E"EC\!!#4&WY_B=$GK,Y>>6/\?#I6"8%D\J*M3F)*
M%$H7*A)Y]6<$$8,^L].9HUDI@GATRI;04A5P2(2.(341A;(CP^4]0!M&OKA^
M*J)D!'&1&2"E2*^">W.U_^+J1>9VA@8V<C*?U/A[Z(]>MO!P8NPL%;EC09)K
M:3G=4YZ+RDA :&2^27.)'66<]#F_?3L^U#G'TAOT%Y!5^.OP#Z2H/ Q+F/J1
M+YD?(4/@+N!=L31D\M<<&:STD2OC?X'9LK^>74Y[R%YLW+"X27$[3#&-#RF4
M.1^H0C!=:KY49:6B)<GOQMB'<T(*N3>$U8-B2FR/^[G5+=4E;\X_S5W=G$R3
M)#4EZ+=Q/H<:2CHBJJVD5\J4Z,LEE1 BLABOSRI8HRJW:Q.G7>E?Q \9V(Q[
M;;3+J&7+7-S_!:3?.V]<#QL$NI2?OCX8+*!B)HQ=G]=I.TFATY[;DR:J\PIH
M9U17TSH9*9))5F %3ULF,W9)Q(Z/^YOM6T1WFV:N0]<POU&"9+X5@L2/?-\Z
M?TWL%7Z#UZB#[62H,Q33,MNOH5J.H[>OR62J@+!@]#6,,+@DMED,3V.:Q2ZM
M3)!7G3%IL??W;7CCYEG(?F9H+2-?Q\.OW'!JWJNC>_=QZV<EC%Y68GJ*7UOJ
MGC;_Y^)\HEXNMZ=,8A>42G_ONGWR?WYX/"P(^".Z]4017IV>00"([:T/+!EE
MTZ&DZ^-UMT8?I!N*'<:ID8G <?MC;)6,!<7J8AJG/.+^ZK;J[R1EFFKS]CTP
M+?J;"J/RW!!:0F9?W) KAH^)Y0!K6;J]B7Q$7+:=*:M" 6"F&J%$/__WQ>35
MA;P> 9;MO2Y>KNP1BU\,L.8L=N.+EJOQV&6<OM&M[(\*_,YB#W$A7A7N2ZX&
MRE9)?[OPS6:U;>)QW0B"]>E(J=9@N3W71U%9U3W<:UD*9[@"N1L!6F1#S[8&
M;'E8"9!#>[=ZA-I)'JN'F*P:'@'"9KC8++3BA(GXHE:YIKZN8QX9_<O#0.BH
M%9@2LJ3V617#DQ9IHB=Z) */=QMO.DQWYU#V/',=_"./.5^$9Y8C.ET.][]?
M"B\<BJF ^)<UY#*E=CODQE0W]%24^%_D>R\&\HYY[BK=SWIN&C;G>ZT*C+E^
MM4X6HPR%@7<1OT,2W4OJY"RWDM:6MO T@4+E(9 "S8PH>/;_>R+%+^KNE=A*
MQE5@_G);G2C\#^5#;?JOTI];B9I9%W<]<>0LL19);680\-2]+K&ABOK7)7E%
MVR+INP++%QY^@4(6O(VZ$<'KX-WDM<[[!4<3.?)C/- R;8;X$"-M32A8)$@S
MX/-%8F>C(5C[7NMG5<V2ANVJ=OO<-U8.S=#:;M9X"6.S$M8N7N!$FRK!E Y3
M2(*7<R.'Z,(BI[R=B9T"H87%5T%% F,T-XZZ=D+>A@H3%GXT*']UL=6P@Q8'
M5UP8YW:SR]&HR+#(.K;9<5Y$ZJ8]_UFEVB?BTS4"HCSJA2NZ=1$F=7D!YJ_Z
MV<MT(&2WU@O-):^7,JF^SSPZ\4%P^#AYA1YKB<EJU"CRYE5\()>6J&<7W2':
M .=A"N.IY1@M63T^'9Z(18_R3S@%$?3(CGP1]%*;F8Y=Q%^E=YE177AZ!VJG
MK RQ15M2$B5[HD2VW*@W>US.7GZ] ^Z"**Z."N&N'M_D,EH03\(UC]=["41)
M$W'/K5[4PS:"HA]!/YR Y 9Q0]9Z<1-.0%A+M;5>MJTX%CBLP6:_YE?HV6;N
M';IV5Y ^6%D\9N9P."MF=3]%C;_8N]3+X[2]X)NL;Y'7WHC/(R@ Y/-K?']\
M"^YM)*,M0SX(!]^3P1?N_$KXKHRB?)X,P^=:?())APPZ?TNNMNY&&GS=@=Z'
MO_"2Y+5"89. 609S88[-MM/4X,J!PFBN,H01XHR;O)S"R**8)^5-E3%/R;(Q
M*B6Z#@&3_1IX=1.^\3G<G1/U^35(D06B152!;L=J>+F%?[-_"";MC,00^8SL
MM&*$"IK]#B#SG8NVRQSY:&D&=M]*+&I1)PQO8#2BS'=:LS3EO8POH?_8>8S]
MZVQ0]%RDZ^[6X!U+>&3P^WRF&\U53HOQG_UKC$_&C<=_ 75E6)AT$CXT81-D
MR6*?Y( 9M.R_!BEAD8XH#F9OD=77'[CDUE''?N-\)&Q-:XJP?\ L:M@OLY:I
MKV(=B;W2R8I(UB$)2Q*3AGOY7CZ?)AK=\P5AL%[5K286_"GYX?#G^_O[7\#4
M>,<WKBWA0!0?M3*WOP!5D2V!EZYK(W$ 5EG5L2P+6HS94V]974&>I)^!EJ,M
M<I2X%=!*U1]#U "PR:VP;A#J\Z(S4QP@HXD3)D K/YN_"M\AR>0LNI B-&4M
M2SR/$]/U:PXNT?=PCF)JMT!TY^U/P'/:5G]E4$5?W_M.UL?US3F1KX\O^;V!
MPH^/MR<]A5SD5 <WN([DG(VOY,Y:1>;Y<?_865Y!6 Z%%&)I_32RZ=:"[B26
M+^W4:II$:3S-'Z9)I7Y(*G D<@G=#%^GAHXPC='A$@GL_ZGB%L5'6[GOC5QB
M+\B9$>3>J+6*^%QTMW0?!4(2M)(L:[LWN';/&>P2UF,TN0Y,#RE1+-O#MA$(
MDZWF2EEP W<$\Y/A"/PZ*@#3)OH(^^RY !-]/[1;FNH@5:FBM#"Z.9I=O__<
MNBP.A:P@F+5>UB-+F#;O?@LZ>%3##HEWW[0_CK_Z,C,N9"_:HBME@Z"LTWZ$
MP@>(7$E$B>!2(4J 2QHPNZ]SL/GN6ASZG;-A9 >*Q]LR<K.&"8\# P@;/ E[
M!B$)4Y@/ F\H)Z0U/+RDVE27<SO8< ;*<!+M_2Y1#C/,$A-AZ,CU(W& ]L)6
M\X8CN0IUJ%::SGSIA)6E&7A42TPC JBF6A>DV7E->3/F^S133:A,:3VYO?&R
M^3PM1$HED]\:J>(XDK@UPS(,0P")8L(@6>$;F21@*";%1-C1\\-!F:=679N<
MB0S:^=@ JXI&[E9I*5,R2IJZUAO'_B @>CD(.WVDVG:@)W*[^UIP08GR2J.=
M2T5.J^[P>\T/_:T$>D<V7PO?-Y+.^%FE"2U,RYG!$0.E'S@A\U1W]*]Q^+5O
MW'XK=%VMWZ_;USFZ.:64"ZZ4"DVSOWS'RF[+XFZT(:PHWC.7C7$2EJ:>KLED
MM[5"H615LK2PG+\[@M9HQ(5@',:6T9C*IOP&CI?KPI0QZ(E_'?*0M,1>6WJ5
MATH>ZD0?N%U(^:,X6N<L#02[NJ:(N7*F=IW5?X\?!HR3(.!%SX=J..19:KK\
MH_ZS_D#$ <\J.T0NOG"I98@OLL+55%$%R !VY@G!(*Z;7T5\A@:^J_X[YL9Y
M)<;SV*E<C#0^NL,.M;D@ULW,/?G14.$&=*GI.46Y'K']ZA4W+;1#)[.2]#6[
MP20^I[/+OP QX<+Q5U_Z@==_K Z.10O<'%+U/9</FP_Z./(]5R#CX!7]A<AX
M5U[(R.%*$JZ'C/HU$<^ZZAQK).>IIRM^972%3IE!]-F,,6&-F>:0*Z-_@)3^
M-00\.W"@E1L^7$59]-S9@2[198K%HL9Y_J_^U-UGV2,7H T\CH+O4=@X(-'?
MQPB9# !V/2H $J2-_%<J3F]5!;%GW?)G)3'5%9-5N;F'@7B+ =:&OW>5_B'7
M14?W?QC6P9K4_'^P;'1N?6+S[QAB6-<MS[^ VAAYMP(*6LP'0TV;($;[PB\-
MBZ2_%;&@/K-=NZCG21V@K:N$;\2S+&]C_)WF>6?$"/ZCH!J_T4^W*#T]KT&O
M/3YO/P;LO.H;'9M6'##J'7[G6;!#E/L<CS#E6A",V5B.0M8<KH]"1M:1X:WX
M6&'EF9F2PM.DIB$JMM%;P0IPE H8V@9VM;#BDWQN(K_H>,9X5&LKSHO[.\=X
MP?QC'%.+QC2+?4$E=)S%+=4\S.H3%<6'F*;4EN/,G3&V#!.V'S"EL&*:^-\D
M0I5HG"-2:3G6N,DJ. ;N/JXS;5K-D975T >TJ6IU:=Y=,^O 7J1);9HIL&(D
M5E4C_CQD,75.]JLX;-]>^&@Z-":Y7=8/M3G@%(C&;]O2E[Y2+P"3N?F\B>X&
M/7[:^L-9<JU!Y<7 OX\*FA]TXS?R(2,E2P*A=E&,^ YQ+<^V6J$<-,T9V:*M
M7*_'@*[A<FO0'^PK*.6R>='SHE>_]R?VF(Q9T$_%2FGY?Q N'L;<L(N#.&L:
MT7%:8I!)^L@. ! 2$9$H'\PD$+ FF^:II9*<\J3AI#&L4EF)V,V6:?.XK);Q
M\MJ=4FU*"F+.&CHE+WW^VUV),3<>9RT?9D&]+G'2CEBZBY7*FO.(5WE\8$MM
MEVZH8XU-2:R>0TE-=7LW?46/<__:*O$<DZ:UI:26MQ5*35$+%\>^IH:; HX8
M %9.&)/CZB=U]X^WT@;@2*0F(8*U)3;&//UQ]N"'VTG]YO@L?=;O7N^=GS]J
MVJQ;WJ:K&09R*TFYYO-L"IDOYHE$QGE6RU]NV/'Z;5R;98AZ82A3ZYP+Q6JM
M+NMXH1[5I(K=R>","NBL(T2*2A%F )HJSJ^8,(-U:#@ A6:!1Q5GFUH,#&<7
MF9<;Y5=/#88L>1ZXCS]K_ *D,C8E?S\R]G?;7V^"KAY6#?RNVCGR-;X)#BWH
M[!& Y<A$L1CV:\JV8F!'=1(M1#Q_2TEB^YT=G!8M:Z:Y['JD&4H^JDO-;RJY
MUW1;6RB/G^0$?(A[.S0._0NP\##KF*:Y*;C>%ZZ+K,=[?"5SZ-:[K!$LS;\K
M\3L)Y&COG/6)&=H10Z#;:%=9"]\2T?>ZS+N6RXSK,:07XE1%K'9HQW.!.'-O
M5YR5-[R>GB@E;QHP-W@,T6./]'^8UE]T.L9>*9;^&1Z=Y>)@![O&V+YA6^-L
M7'.BE>"]Z<F]2L)6XV_M^'N5Z'Z3"$K/<7LC@>O03/-9IN31X'I&>R2G56DG
M>U7I5X\E&4M![46"!MCA,M-[C$==\40TS_YKB9<M4^YD!83)IH;IK*2:*?.E
M*K>ZNH%W7O)Q56 UD&^5?_-_2'"#0_[9?T6&?%\)TY"*>7/+,:!D",>@#I/J
MJ^I9'Z?I@H-DC&W//X0VR9FD*9?] ^G$&VS(E.<UR=3^<I:N;/23Y,/Q!SM!
MY]*V!4T/O>MNO2Y=>*Z*VKI44L<(#3GR##!*=477O'!U!=\_4<580YG(W-3B
M,U"6YG@T']8P%3X\[_]J[BJ_HG#8[- *TBT-0X-TIT@--0PPI(0T,J3 T.$@
M2#@T$@)*=PVAE)1T#PP# XAT"RBIZ/[VG/VZN^=]/^S93\]?<)]S[W.>>^^#
MNP^/B4@4P=!\-590>DUSZ&B_TO-JBGR1:C+^MFJ^\N5=Y@W^O1?/2D5H!0 ?
M!Q ,J\ZSW&R_3&#TD&9<NV^>#[-09Z#<XX#YQUXRIDK YK"*'IFOMJW]_&Z#
M1@V',9&MEU\Q1'=?TD(4HCF,/2YJ7PUTB8^FE(7[%-[:<;@]:'ZR'E[.MDO>
M(S<TC7I=4/$O?$2+DVEEI6O?YW2!L"8/BVCA/M3")@9M4!(8(_&SGJDV3I7$
M*@4+4O&%.=$K],9!4AFUE?8)+3B@O6^);VB"-7;!-BFET9G@X=%8X9%SY#80
M9^N-[*WP9:L8H/IBB5]1LB^"S/YRP.9UY]F \U)T[80I/65CMV524DY\PY#X
MEH6?B[U4.-4CC""(L0JFU=SFL#ETEH=HM^^F337:S.9!]M4HCVI.OI]IGWKD
M=H"%,GM*Y8#-EW5\*YH.B%O]WF=O^M7[5QNBI_)^.T5FU/T%;%S6-;49SI,W
MR=8[6L ]4)AM?S1/BH$CW@"9TAUO95"A_''1QVL5KU.+?Y !A0DN!WRQ)Z>M
MB(1<7-K'[UD@SEU$T/8-)[)M$U6P,'%RPWQOB /UL;?A;S@DQ84X<*">!X8R
M6;(TN/3OU.G@4^QY.,K"%X@YGLVO-L6S-,<)>^X1*9@+:V.4$N]DA[-?;^@5
MB\Z2?5)V.YHT@1WV#AM^N<YEH:K[(?<,ZL(T%89#H>N'X*P6RZSI!/*N4"B7
MSK<K:^>?<?8F,']%6MN/\S^[WX"/5L@O79AQBNK%92,7YQ+SYM!SK08]N/7%
M_$C*BT:^Y[EK"U?<E&XTT1?I/>UZZ#-I:6J]17.?IV'W>4452MH.5MK&X)%C
M#?GZ."$7L>0@YM3E<'(+,6Z,D3,+1"/[3:J8,%5@=K\_.O%%6X^-@\2 D4PY
MIMTP,[W?0:).)_ $RCP/;&\JT$G GH(4\(X?I/5GZ=C]DKBH[D%+;J4C+8>G
M/1)"@ER<O-FJ@'[741J4*RE-:O&7Z[^H7+Q?W2/\L%NTWB3"H2_);@CK#3'1
M <(%+>P@L_G[K,=164\R#NV .S)L#U!*8_3FC50--B?<KVK<T]C7-/=_+R/N
M^= C,:A*T%0GO9A_#O>;3P)F?G1Y.<Y80E!RK*X.DH3UQ]46@.33%?\I00IK
MNN[F<"I4^%M*,&N60V(7Q?F* BJ;2\O%HE$*I1A-*M@LX^D?PI^I5K"QH+',
M^;. 9?'5!C0S-+G=@<M(?[U0HX+>MD#:1;0^.8Z7-D.Q J!Q+ CSH:$^<A$?
MO8YZ2;T*9P^K@K,'G]T-<WPM5)LBI=I6,-+A27.D.U4X<_ >N*$:I%WW#P>1
M4J]0"J \*-8?/AY/@O/G0?W&"5YT&S82)AW,[L.?M]<X0P1FN;\/I'3Q]+L3
MR;7I6MZC%W\@N9D[,O+0@RF+G'#J/QE544LI_LK9<#0XO5H>D-'GJ*"J++#5
M=(JG3##;<2*6CAC>(UTOLW$-/RJDBY0**VNP*F\Z)5ZFY5H2< I35!)A$N_A
M&A[Z;@]UXTCDYXFG8-@)Y]B;77J=(*PA,<H:&?YC$X=4VWO\Q^''Y>:D)Z[_
M,MM&"_%2+U8H(H&_I82'TM_*4HX?_?,O(*31G\6T)P ,^0U/+!<V12=$%"T>
MG,0V6NIY[AN4@\%?SS^2N[UF^^*U:R' >-]6/8O:5::M":C5D_<VBGTF@8_"
MK\/;T7CEBAW,GS%*2 56!?/T_;ABIUQV_^XDVK-E2T6.:9T_%I9#T)_(M[<:
M$JD'R=8*0BY%#*R#R,H>DV!EQ@U4/SGY,W(M33#I,8@[?G*2XW\H*!HZKYG'
M(&"MF>:]I.;&--WI0J_U%Q P70^O6U.]+)3'(SQ2=72BT.E\\!=@=TYX^+-0
M@9*-P@':;D>)-&4Q*\M,'VTW>WE6+'D_%9%(6:2ZID8]3/(UQ5]MYE>D9J[5
M%I'ITO#92R6RB.<5XV+ 4[J(!U^?,)S6VK\KSI#S&Z@HE,L"_NH4ZD<M([?%
MC:2]&9= K.YPD]+#RT09C,E51[5FPDD:_3VFLKQA>!>Y,-_K)WE?MHR6=$AD
M,UB,\=3B5VXXPRC GSA\GIT,]Y^':V"FAXD W.@+&^NH5?[*@?A Y>;KVK"5
MOX".4I7/FMEA*LHG&3X\]-M5UM"(%%X,^R=#0=+G8:50,YDZ&&!Q9I]'N,?W
M #4ZA-8W)%W0EVJ(BS;XT%BE7BFU7+SDK=X[K]I9+'%[%\F!,7F,!^(Y8$4R
MT0Z+?#8FS%*NNK6)XZS!6QXS]%<W_IZA^K&N56#Q\\C(C_GFX!.C;!,5Y$2"
M343D]-Q^;855_NI'[)_+<UNGN_6KL8(H\#&KD_@[J2E7+$$R4/_I$:OK9[49
M9Z*+GBCL03FAZM?$ BIKE_OG)!(Y>:Z ,4F"F?:2DAV>B#9:&T-S]QWEJF^2
M@,<Y':'-&O8'B'*0O.:-)9P_+"Z0H+Q^/[1R6^'YU/[H39*K*!=BLI.(JSIQ
M,<(Q?\GX=8B<?T9NVHF_A_/@)OV./59L8JQ0)?.(%Y.R$U9>[IP.4E4^!P,$
MSB-[?4D^-[+B'0%HVD0]K9X=$68X$='/=Z&06H&<F@"&,Z@N/J=*965\NX'7
MVNV-4,U\%+Y:38RI%:V2$,2*F02M3V'WW-O2!Q+Z/>2+T$@7@ OQJ/6>[&U3
M.=VS&_0V!4P@S/8+"$262V&N_8_Z]U)D4SI1LCL(2J0.QF3DR$@Y3)9A)J3/
M!&"U>P0,#$+U#??2'F.G1CI6#&@8R<'^4^\-EIJ#)><4-;XL9$:'"(V\1[P8
M/K_<7?E'L#5\WCY1W>S+"J*BS#JMWCW4"/8& (C/OQJ?J),U$#;BV22U;NG]
M3YG!0+*0P'.)L*0!GKDD2>GM2M-BG1K"%I@\YW&;[%?-MJ>GNK <P+[JFWF0
M:(;ZF)':B,NX(9TAB;YGVP_]GM$YFZ_:C]IYK0\>-;IYRMQ@*!\GX">A)!I0
M3(U AM*&A>4M!F-766U)YTJ**WZ\Z)\-'6D7%*JMU6,#,==R:K[WML:^'/#'
MS=SYIX]/Z?OL;WWJ2F:A%L&9:U7\?'+I*1/U-O&1P2#WT#BJ3@X]*ZW=_1>
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M*5=&'YSEX$7#F7MF+#V".<H6:^+N;$"(P4HY,1,)BG%Y/5P2S/.JT=6@!BD
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M<^ZL^4>^H0\3="G!KY==D_&Y2@R?4D::C#PR\;T)D%MTD_2GF! ^">U(/$I
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MHM7+'4R3FB:Y+>_^;\ "_KOT'U!+ P04    " ",/'U4"F2L9_OW 0 35@(
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M$SJA$SJA$SJA$SJA_V5T,*EZV1&#<942$$"@^4%'-[_YP4BX@!?(54"(7U
M("/OY0H"NT PK'80J!-"EFVEOIF-U<E>ELU$3%M0VU49XNBD[H."&/CH&()]
M7,! >S9Y.6(9+RDON"L<@@&Q>L%A"+24ERS;L7&IP^,CM@ ;Z[$*QD66[?B6
M.ZNIMAZK\M%C &+\(GQ@02$A5G%Q?B%1,7%QH8NLPH)"P@*"AW_B?$*B4F+B
M4L(2K'\0FQSQX:<,RMY!2E]%]0^XPY(LVQ_M\O3TY/<4X4>BH )"0"#PR(RP
M,-^A!A_:&X$!>?$AT.S?C'RWHP)!@U%.Q[^GLQZ5079(=XPL&QLQZT_T#<@>
M_ /'U1T%.T:Q!PM 8! X!(%!'\902."'\2/[]F I!R0*#L+(.<%!4(@ Q!7M
M("/P)_=758P3!@:1^P7WV$-%&.97[G<!S.G(,2D8" &59?/B^^,7'3:YOSQ@
M(2/P3?DOI@7^;OO8MU_<^*;U4XS^W=@=IO]'\'[;^7X)W*&VE/9AS[$'84 J
M( Q$3EA06(COJ$-(&@H)2XE(2(F)\@J*28D(R@C\3?>O=I#V3@[>_Y*5/S7_
M8D,9=1A(R*\V) P%):1$1:1$A?D$1:4$_[#QD^;O;"!1AD@D3.[;*-" P=S1
M&-01EU58E%^$]8(V".R$.'JRAOLG:W_4^?\@(]K:_SPG<+C [VJB,?H0AW]>
M$WWTFZ& /@2-=$>!(8?J[+\W=,D#\]\Q=,GC<*"Q_[6K:&M+:2#0&!#BZ =G
MN4,&OY.3O92(Y"4Q";%+8H(B*H*7E(2$%,45E57$!,6$195%1(7%%(\C_&O5
MOYE508+=C\;V'V;MC\R*_VMF?ZKZ-[/??N$&P7[2<7<_M"VF(BPH"106!8HH
MJ:H<V@8*B2I*B@$%542$Q 0EE26_V_Y-_;]AZ$,0]DY'_4 9!D*CY?Z8'+Y;
M^(OT[PV'H)P\(/:J*"3\N!^Y@E#HX]_:9=F^YX+M+_/)<:^0<OI-(B3^JXC]
MK>KO+-O_.[GX6]7?64;^V^GXA_5_!X/Z!QGYK?3G2?EO*?E[OM2=T(?SA/=O
M5@\#B-L_7#W^M<S^:,3A8)4"@8_G'#3HT)4CUW_B_>-*O^D48D)"$O9@<1"?
MA(2]!)^HL#V(#R@D(L@G; ^1% **@8%@,/B[_7_4,7[!\'2$(/Z8G,7XA(0-
MA86D1$6E1"6^3\X_:?UC(VBD \83A((H0@_3^"_-TK^K]X_M@QT/UVJ(O9S
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M5<^-8^>$&6B8)[ZA;C7V(16_L56AX$#8_X2-_]EY,PEFGPM!9<GAY$&7E2F
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M6_TE&\6:*74DQ8(;#-L;7#MVC<L3NSIL,/,;,V*"GK9BVA(JOI<KJO63QNK
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M51$'\UGP?B7335*A:<L^V4GW.16A<Q>E9W04.O3\FZP"XH&JM+/9NOW%_@<
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M$T2;4U7 3)Z)X B=IRLON)Q\/D=VSNT6S\6JS*I6[]Y["PL12Y_6]R>D=DD
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M)G#E_./G^WW21\)T&]IX+PD:WV6!"9(IU^S2?60I?9+:9L+X5?+C=IB=@5O
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M/K=H3>7_T^@IF5^85L[0"+K-I)42I#6'Y\(./YV-9',C(L8Q'^:)PC!+T,%
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M$%I!\,&)-!EKP2#Z5CH@\NR.R)MQG<.T<SDC^9#_THMMQ^%$7\].KAFGEL'
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M9?,I5'2CL=/3(QEIEE29&<G3PT?)2D>_.FA</;F: K&@?T &_L^9W6\  #<
M.9 0PHB/0.@$O#I^J65S.?%I^]3<=OVP]C0%P?(Y@' 2M_#AO5_A'MY;?SQ'
M"ZTK\TYQ+0D5.\3V7Q(:8X1JY@PM&7<JN1TI^7%6Z3+>R[4D,T/-_I= @*)
MZ+L)(AI_VL3L^N?A%8]&5_<!W\_1U)&T;.+.,0!O7'D:5)YL9L ,-15Z-9H7
MMHPJ^^?J.::PWS;HZ?5T;DW8UVP_)V O?RS=%>S]]%=G'37J[#1!=_&W4K8]
MV\7I6?SK>WPK>PCI$DE>Q_OA\=-<>?[CFR\?]):ITNL?CKV& >%BPI5A]'^
M@"6:-X=YJUI%8\F[ZW<S_+D$(U(DL]-\$9$T(2&W<79A". EN^R#<&Y$(C''
M<L[*<0T?V6_O=Y3B@"8!VLI0/#RMKH\^9;RGOUX/"?I_^_Z3#43A<X$Z\:AI
M;@EGI]M>$#D:EZPY )B=YG5S\U][+R1>,W('2"_=(.6<SQ[!T]/#I:]/WP!F
M*:\NJQN2S#FE'G;!JE4&_4/[9.6I.NY96,.,V?\$R21DI?;#->BO]C^ \L?9
M-+59HMMGK_8H1W["8Q;8BI"EWY.T?.AR16';CVA!S])RMF6FJJJX^;FL)ZFV
MAM QEVY?*PV"R2S'9%W5M7R$+,4=%I?8G 3G<:.HL  X@1JIE[ABXE"]LQ4#
M&@[7)LM0 B_&@^1O$H<LZ;VR'>TAY0&$,(VRYB5LQPBS84B1K*_ W Q'5B6I
MX5B4P?*L[!]#2P1U456_\QOUR!<8&JJGM:^2-W)-&#-L-(5?Y=20I&T<:^54
M">0(;J=_L@_F^"G2G0IEW=RIS?!)Q$Z1_TJ"4-?/V9<Z3?D)NY_;&'U6^P;
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M2?((O_)1!-JWFRJ$T":^C<.^Y\YY7]=S(5RT_)_BX"S)YV7'CH_CKSY3AV(
MU5KO/1YSH:J!AK2)DAU+.A/W_(4'&?K06AB4P\OE*H5L/I:$3#&I!;+<!PZ-
M0Z=PO0-.6-4?D5?OH1_+7#J%=HJ&ZG<L]JQF:L0MIC1)&[>#I C67N:IL3'\
MI"CESNF-5WJ;6B1GG8<N.V,PSDXP-IZZ^?C*SH-"",2LN/ NH#DW*';].<$D
M<>R2&,H=1C)QJOH0IL$_NUG/BZG;[[UO&P<RL"NH-O>M'=RNWV9Y8&73UFUE
M[0AYQ%$3$^ E#B6MN8PU4@;+N5X^$9)O%Q\DIXCYQK4V84HMN+.=!#D47?S[
M^IM#.5^"L <9*8"G?RDA=7F7,F+O&S21BG>I>WY;N_<X,L.L.3[UXB\>Q=.V
M7NG.<)9T90]HMF>B-36V8+K!E6<QZ!BR(WZ'94QV]D5MI6PG]KU\:C8RE+JD
M_[N:WTB Z%VUQ=10GRJ /6LW>'&@/V-<P)\#<B\JS*QO0)C2;AK1I&<+%H8Q
M+Z@.3'NN?*7>-6!J)>;Y@2M#;G,H%2@Q0T!G@]:>VLB/;4%[5T>$MS5$EC3/
MZ>1H.-N>K;;(BQO?$WM[@Z1M(&M7G$?WNY*F<:VEJV-:$[PYE)FLN<J4&CWE
M@ORXILS.L8TZHB1(5T=2??'%X:8^YN2FAVN?=,77@3%%?"7ST;BY^N>;G\U3
ME1DV'Z55.V1SW8CL),6:.Y2*JKOG93)9&)LFX]0P!P-*?K$-C[>Y+3FUEBHP
M/X"86BV<?LBXX#HJ. SAH9IH[:3>X3V Y(/@N:WN-JV\8L0-)IN1AU\Y!,U
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M=+C[.%;4]P_ DCZUM+9_^*M(X)#0BI3H^>EI;[*R3LOR'>(E03C;UR6K:H5
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M4 -^,,LIVHL,DC#\AC7BRY_=ST.]'92ZQ 2_P"28_-?W':U!JSP#\2,JS_$
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MI=:F(Y6%3+PL!6@"^43(BZ.AY5BV )J:+J3'VO@KY2]:'9IK'..-&C);M4^
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MJ?:VTW0R26NQ6XVY&?3;Q<<$U:2/#AF[0K=_;653!/(A\HW?9 M ?@6X]9
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M(8:&*W#Z$\ ^M!Y8:_RRFZ6*3C>>_<6[V@\\-.)K[T4^DU/G\MZI6[%DV+\
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M(8VEP0HO\3;KA*4"K?>E5F@5:O_,5;XW">O&G/UK555_)I24Q//[]0^2-M(
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M<'I='.X^0!>LY3+'K6]'D]+/&27%W<_\*-"O*2:N.L\@?#X0R_1)/N62;*H
MN<"V/"9RJD[7IO:&19T#@QG[?DR%"K OM2J@J$P3+QMD&;NAYX#'PI<@(Y%&
MM:%^]8;R>2F\V*X):SG493< :RQ-I^X/0\??P063$N-"7O+$UNNBKT/*_:1+
MMN*3/#]XQ$:Z!AM%(YFVIM-GT^S(!U,6E\:?#=/V41GQ"UD+J RIIG_$G4>Y
M-,R]$<XY&6>UWS02V*X:9I^ ]$M6E@+XMF4/)0X,UUEK.[CZ'@2? ,&2]U[G
M3P#-1.DI*=B_W/N)_J"+@^-Q_243.XG;W*N+TR6&TI][RM5&FD"J V&68/#^
MBR6*EM]30[.$VSCV26UZC3_FMY".O5)JO)F$GRS7G[/6<#T7,$[\3I?Y&<;1
MO)05B'D,!_*4-\:6^.O+=[PA@Q7^$'B[N>Q.&6*!S3\"G?_9FOHNSV<33Z\0
MF90BJR_5NP?UG?!A"4:('8GI>UV,-!S?W/.C*"].3D[0,C(R&6..OJRN&BM$
M*[R/IL<XOR7*16#NXKF/$078/RF?H_[]/%L^2T-/2%-=P//SYU!H%/HZE L'
MAO2%89M&]UP]9NW%S;G2U%0'BQ^<#*TP%PA"+A U_5030:'<=ILGUZBYZ3DX
MNV(K?"8?>?Y\MKS4,J+;)/<6.+<)\:&[K/:^<"W4;5RYBVQ(F.4JXK6[L_2N
M'.7^P#BLM :8%3)UJ^+"@.2=ZXW;>X5SCB]@#=RYU8T9<]H64YK\+?=S!B;\
M>[23%Q ^3VX@?]'73\OWRWH#E?8<(()QN9<L$^/*RQ3]H2$J,.:@\,]!J<&4
MDG*>TVA\>WDQ7NF/9B$8NU<K_RGD16_S]6S;H_SW$9]8=1\CO<@2M:9OB=*1
M*-&)5QD9V+R6?@C0W?P7B-U:O@P5[*WLEKT5S[R?0S."X?/YO![KER_S7->C
M/TLE1Z]C_96E,+16&?)"[$3G*Y54^7XPB9[#7GY'T<?"_KMPF#0EC!\$I(27
M\(,_V<'$3A&)*QC3Y_LR)I='AMJXO4LIG@$;^0(:#[$3&LM[G&-NT1!_!!I,
M^00PN;E C")VQ@C^!2M5]\L$7KRI)E15?A"\(^Z^)/]AR_N_Q"KZ.'\=X ^O
MN6E(M+*5:KBZ"[ KV%90-NCR.Y\/-5OY<UX9[_$9K$D?]."Q=]\E]BAC%O02
MJO$O$'WC=GIZ6H[_ND3I3_"]=)IVNUKPK@8XO_IR]H'0(+\1&W(OH0@C51]'
M!"\<>%+KOOI[@4-]3I4QW8 3\C;F930N?%7]D8U&Y+658G#SB:F_AZ7;L(<G
M"QJ4CSN$Y1S6 @*UTJR%,;VGO<:"2E&/&G>_=+AU,J$)C,3WI?0QYM61U<_/
MX7^&%_Z=(X/K7C+):::B=+&IV\CZ7_$N??;>"PHG@Q3:%1\?_[E+?K]WI?_
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MR0>OI0MI8$!Z\E?$$' G[)8@B5!7>L:-)UY#N%)\;3;[.+[[_Y#U5D%M.%_
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M%H4&GL) N1*T(PG*HG\M MM0=#<.JH%=JT7,VSC7--;^K]+'?"^%KG12K#I
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M0CW/$$J*Q""^'%<[C8SJG.&5F->OZEA?21NFCN]FW:8N6H;BIVX>%7$PLBV
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M9Z4V5==VQ^I-3&<01. G)J#[32G>)*BQ04<NZ"O 7P_UMT.\V$V2OK*ZY,^
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M3Y=9C"Q61"[_>/LY.:KRV7LYWKS6!\: 'RJ<$D@7L!7M#P\VJ0R 6\[\WWB
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M.-UI9"8Q!3L1_[)1E$^(B%<2DWD$D+[XE#3T!WB->]CT[7?,063_S-8Y4V\
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M<L#VI&*BE&V)I3R :O8<;%^<!_,$BZG92SV?99;D%'T:1C8V7ZL$-&$&UTZ
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M^WU!)H74Y@(O!P7SBA=GI9TWH%1X)#"('\?5PR,;!#YU?UXC]9'[P)/2^RY
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MM9"$Y3;-6[Y^8(,6]75W;LN)F:>U!>)N-/Z($LE'_ R0+^Y]_7W.0Z[FTJ,
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MA3L_$'ER(?IX]#V<0GHX"I1IE^QQ(&Q.1@56#G_*T+"3<X4+0YD#C!6>($E
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MGUT<G^]@]$G'/1F?*(SE30T$SX@4J2*:1NT"H?EBQ&/+RU^KBSO=? (S_=/
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M(P@( T_%&5C3X2[<FD3YHW"9 @?1"Z25YY !3DUQ_6,E[N?GT%!0!_0&Z2:
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MAM*8&^0,9$":9&Q](N4KU]]"&J\EEP.N[/Y?P?QG0QX]P/0U&B?#8?1Q7EP
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M4:R5B\LEO,R!SIV9<V0_K^5@$SG?/-2)-?;96V7&L<7WJ%#)G<57&Q?7,3]
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M%N\N(G 9) ;+_C<>VD< 9("!9"SQZT[A=>#AT>FA[K1T6F#$S]/;T[,JK+2
M3_\I@I[#P.NH(2GI/-3X</?-!0/](Z!%RBTWY8G\7P7UT$/F6OBN 37QEZ'
M0 \4.L_D/C#@ZCZ85_G#,A^Z?HU:ZL$XI#5')B'"Y/H0=1/@G[ &$S(.7LR=
M%E:C6 H9U='PRG/ X_(;,X0LDD\:2_ X\.SQC'.-J2N0Z4L3@!H&>O[22E2]
MJ]PO+&_J66&@6"3(D=H&>"R^2=%PCUA)";Z(1\WSGZQ(93K@:FP(-7I+1\P5
M.F@+'OSX/MX"@U-STY-*WRQ9_]&?:A$,L\)7=RVJI!K5C4&*0@7!_U55I.CY
MD-MNMD>F_B[GP[&RVS\[[IAQ:4+REA+8;<_/E,'R")P&MPC4 [[ PMC$A@)
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M)$#+77?^01]X*!D<S]BWB:\#/#*'/4Q]$7_@44>:SCB9;8\><;?:.1=OMG0
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MYVL:]F)M6AVG[A4ZZUK/44HK[)E]?#=,GSKV=;1?=!LR-96:U,HT:P>=AJ>
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M^.;Q9]^I!7DE(C/2DW)&(*HNLQ>07 0PQX'JKA<8&"Q-!;N$C0T)WO,?;=N
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M32\?Q!VD0FF?M$;:#'YHRA;SK?S=J5K_HVEV\MZ&'/<Y8<=11M)?=*P38=(
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M4K$1=O0<TL=IKSY303VH?>7+6 ('3A7KV608)6&\^F"+FNR6,K-F](I/8XQ
M;I-8JLL3VQ&+RB.NU/:A^M=S^9LR\6;#3CR7@I2"H>S6WE>9XD6KUAN?Z75
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MN9-@_>EH,)#;^\-=2$^A+1E@%:VA>YYU&YBXV%V*E-R,M>5RNKY)W#I(7<S
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MQZF++ V819KK[D3SU^=YCF=[Q)'AD+&9]>O3\,Q^I#5(>"P2A?3X]X(QSS@
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M58(@E,U;V#GF'!7];J:?@&";DYC#;(*>VP^6DLN\K!/V)_75+QI)NP@K.XE
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MS#Z I;0-B@^4]&JNR:5:_==XLH&*M>HOK&3:4B[I^]WK![]U,BGE?S1,U3=
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MJIZ;L8,5E>154A"=S<-%+40OP6&2Y+%=,[7RF3 PTRS2:!B]6K]+>\*R;7Y
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MB'N<JH'G_QL&!!GDE7/HDY0?LL^Z1QR* G_$VXFJ>K;04P*;3N.A#IIY^UM
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M<QY%/'1]1J]MX:$8 X3?9S((2$S3D 22A[@_(!AQ !M629HD\FG8<.BRR-5
MQ4(:>\"&!9#+T%-$)JX7B)BI1$=73V.O/#O+&H3&>K=0*%4!C01E,-/7:/M:
M^=.5K6@_%E3ZBE# =BM1<!HIX@6>'_H\]M/D&N7_CJVL"49?+XJ-!E=@ ;K^
M[1=4L79JHT3 E(Y1N790N/[U19V=C7+4*,QWIQ6^$05YTHGKVY>UPM<MSF%?
M-_\.\[$NQY7Y9%3*G7;?YE@!=IED,"$GL><"OO@1)8D$G3N)0'Y24>)&4?2B
M>U0;BMI]RA1^3C-=.68)>JG&M;?_QR+]O/IP-UVM3_"F[$<%+[L$W)-9\U&?
M"7B%RN!7:YZ8X2UO-#YCD19N>P1R.UXVJ#DO?NN&?0%- 90^]8Y7!=Q_;2?\
MY?72]_S6+7"ZG-?+]CXR L]TZ0VO&K19_-;I1:XWG6?ZV_00U6RH1T$OFKW"
M_M)][E[R>N'BEM^C+U(N94!)['K M84&3(_]"$AWI"(_AIO485_O\0@U<8LQ
MJ+S9VT-XW_F@3\H]6-*'3,)#>O>DTN;"UWZ%<"^/?H62"S_V:$@\D,1!:A @
M]H7P,:9Q&B9*TX2ROE[A/5%Q5ZD,KQDT!IZI_6*/C[*&YW=<Y_U7,19UIC(0
M]0^!FQZDAH4OKF#_\\&:@<>[/_Y[JP.>D*:@ (.&+4,)_$N#\IFD0,P]4#ZI
M\&42IK2OP-,[_(?["^Y]A3#4=U=QA1'(K;&+VJ9.X0H#"5J#I*"">ZGK)IX+
M@JT:KK#77-@-/,;C. ;948+\[\N0L,!+B?2B2"8IB-P^[^L5WH-XO@.QM)QH
MJQJM_@*M*;U90AF[7W[D3@(W *4P$,37')1QS4!Q"!CHYC)17N3QV(MZ>R<W
MH]7G-/N/KKX3J;Z?G>_EO*X78,&\_1#.7]>_6\6XR42N%\T :Y"QUP,<TM<)
M\Q.?I I42\!/31*:1H2"%A^#WA=)+?L*'+L7O%(SL)BI.W539;)IK^)9TMG4
M]6F8^"&1<03:CLL5X6[ "*-HN/4I3T72UVO[G//B$S^;1^:CB_+HM!S7O%!'
M%S#;Y*#05I#>!SV^0#\[/O4L!5<_X%$B5$("JM"'E8#@*D&.Y2Q,F2^".%)I
M7Z]R(,]]@B2M=,!$!!0IU)($+.(D\8$\4(\K&8:>GXC>FK(P!(57\G07]J_/
M=5Z.<(+="@#LQ-YTB6X,V1R5GW6%)N+W9770G.JJ_GUR!?:^%IDQ5S>35<-?
M734[7W!%]FWX\2._S,[&9VOE]^ZBCO40?N])#C"7HG$L$B3@H2")DI2D4G@:
M@(0*I0<86:^\<%_5VEV=:IT"75 LI(1YW(=K]R(B.,IZB: L5HEVA=?7:[^G
M:0U]'65Q'Y%OE1KA6LQIBZ(^@$&R$M1WW4"*2!/*).B!7#'"T:L>QHFKM.^Y
ML=L[41\I+,:9J3&>OP6 C[HY+=4^L/:ZF8'%_+=:7Y$O_UY>\OPN*^MF,GT_
MY-H3*5ZH!,P6GD<$ Q7?BX5/!?5<%?7N5C>=H"^PYI6IXKY$?R-51+G<(T$H
M7")<#3<9T3A4J:\9B_MZDU=4<2N$([4\&)F8X]USGN4<Y'"XP/VZ'F/ Z*;<
M2^!SEC#0R.!&- D"/R))RB(2\M!%@<E+D]Z:I?ND:Z_)@.6&,HJ51W1($Q-Q
M D*-%Y,HC%,W2'R?2G_=M_.]FW<9\.!5;#[Q4X0^H!'<!PY -<:_\H"D.A2!
M"BCH@+V5Y@':RC,]%>X^E-+$H5^SY2WA$.\N1TCAGR4_IUS'<1PPHGP%5\K2
MD B/,J)=7P9,>HKQWE*;]SRK3 #<[Y/IGW^#&?$&)Q_P_A9O=SIHOQB-F]J,
M\%8EO,\MYJ/FF*!C @PK_>^Q+N3DAI7,#:V_:#FNJJPXV11:",I<H$42H(*G
M,7R1$>8SC$YS:1)RID7:6ZOPSZ?E]8#8@#HH%$T3PA7F;' _Q*!W#BHAUTJ&
MD632W7" ^;&(F\WT"L4@ 'B2*\)$*D%2Y2[\Y<; 0"+*4C?B;MA;WM$+7?#.
MU3ZF ;@'9D,:Q$Q[04HBSC'F&"1LH6./<"I=7_E2Z6#MPO7W E3/34:+BH"_
M*AV5QR#MQY)004,TZU/"4^T2&@0Z"&,9I/':G8C?S_+0M'E?EN>NB$9Z--$A
M)JE1%S,"7.![22HT\6+%_%C'(>UQA-*:W9Z/*S+=^VU(W0_2.5:PL&60T8'!
MZ_KS&+@'?\P8R>\#7W<EX)NX89JJ4! WCGT2Q GF?"8>B94/LK^O.4\'\'T(
M0$W!I_Y'UIS:,(;]0H)8@H&<>&Z_9V4M,Y-@ C^L7R_P[Q^)ZZ\JF-H/O8 !
M;&F?@U[@A: 7Q+%+1!J#.!"(.&2]C21XJJBP]1B?%0LUCV1"(A&!7J^Y3YC&
MG#X>Q)0R+V)N;\/:/U<E;+69H#FY 01"J<M(]=<$]@]<E!5O2INB/%J[UV:%
M-A?/37P>18K(%(/6O4@3'D8A\97K^QX5+@U[JT+?RP3[5UWHBN=P?[OJ+"LR
M0"..3H+',<(^D2(=LM"3.L(@/(Z!>9HD;I+ S?*$Q2+Q$[>WBO3]L>[]N"JR
M9EQI&'60IJ J/P[VK9 \1BX/4E!\2.JE,68[ X]2(B5>DDJ=1%'BK5_O62OV
M/<0!<G]Y:$A>,< 4^SIT(\!ZXX '@9J(4 9$AB%S%4A$?G]EZSY<X:)IPUL1
MBJ>!RWS!@0(' 3#86&$)D- EBKJ)YBRA@>IM8J]%\2-^N3MN3DO04Z^XG0SR
MHVH!N)__WZ#(UBHS=_@LO0U"NX)&&)"<8J0[!=6":<% ;8ED3#7#<D9]O<G;
M RD^985NM"Z^/X[BS@4\4<CQ*KV2J:N5E!&)6(1.IH 30>.$Z(AQ/P'4CI3H
MZ[5_T3E N_H,^#&9(['S1@LT!>!KY*XZSVI087XO00%]E@A,A0AI$ '&!@)N
MDBF7)&$, K(?!+&(:4S%VL--OAN,5Q4^Z\=IH%+*B I%0@)%)9I#4A)R%NE0
M,!KP?@4:>6QU.!Q[,@E=1N&^*99F"!GA.H!C\%T.(."RF/<V-O&QDY2>T$?X
M%%4[0"6.=20\X.6N;Z.0$^X#FF@AO40SZOF]M5!M>-#)_5%@+1Z4[S_F6PW_
MNT^733WOG7F@.<)5D1>2R&42R61"&+ -DK H9511&K#>ZBH_<1B4\D#U9P(#
M<V.LD"" M<<L)8FGF!OPQ/=T;[G;+;@U(U\WX-6C>$B3>U[F_-"'7"9+@H0E
M(2>1%'B9J2*<Q8+$?NC&4<3A?WOKN^I%$%1O%,>0AS$+0<KT)0,E0WL")&Y?
M$Y8DH#J&<9#&O0UG[9T];G7J?,1#GYL@PR#"-*44TV$"0#+-(E\PQD3OY+T?
M%LDWZKY[H RX :.IEWI$*@$H&TM*1*05\97O)IQ*I8+^"D ]"RA>D\>,!\R3
MH4>TCTFC*<A;(HDDH52(./6HM_DAW^NO=[H>(XL( \7C4! 6QLI6@F%)&F.A
MZS -8\\-O=XZ,WL0=;-"'L=])B,OY81+CL5D@: ED0_7$>B8"I_[L=?_2J1]
MCK)[U+#-]81<WZOH>4]A9+ ']3"T5\:AU"SP2)1@^ %\(BP*.%&)#$/N^52R
MWI+_E1M2'R[^/DGYT]A/6:H$\0(1V"8R)FY,T-"CH8BYCGHK7#UG-\EZ1.DD
MTJF*I O*#O9C<8'X\P3D!>:I-*(JBCCK;5&EWF??/PT"AZF@.A$IT7%,2>"+
MF CFQB1D7NBF/@W\_I:@OSM6X1F704JE[\<1UK^@"4AC;L2)$* [>3*ATA.4
M\KBWL7N]D=B?SAW:3UUA97Y!S^<!YZ$&UN!QT!5"19B;1"16(/ %2>QJK[>1
M;_UR,*U'WX_=R.=1+(@&,9L$"GBZ2-R T%@#]4]4JOS>UM'IG>7YB?I_!"K0
M88*(A57NI0><VTU\PE*9IAJ4<C=>.^?>#!E')2[S4JZ)3K'C50S_B(!3$L=:
MA2R,TM3MK8.T=WKF$Q5]U*Z. NSWFO@N=H(4A/DP.X^DG\9^$FK>6WJUJ_X<
MVRH,]?NR^J0O=J4LQP5VIOM<E07\*6W^[16WRW34(;8MY96JOXX4'" BAWM7
MU:C^<)J(TB#AC"B%P="12H#3<$ETHCQ/\I#U6,'H(?(]18 )QS[36 4EQ'\"
MST\(2V)0-007*G+]0+K]13Z8067Y&+,39G+UNTN9CY56[ZOR#&]UW!ACP$':
M>= ^Z\IT#?Y]LGR"6[KDV *@S])8<*_NGT\O<JPI#$0SZDHNL/DX.BM#'ZL"
MQ<2-1>1[(@Q9VKO20/<(=?R)VT=(GX>I2M#?24&"3D0(LG0$8B+U0"0,?<W]
MWOH?[I7TW W^H'FML=WQ_MFH*L^MM+$I1F<OI(I%7D#\5$I,38\(![&=1$F@
M!-H1//=YW-(:<]%[@&R!JU-%0T%2*D&( *$0A(C0)31.M!N[E&O96^]Q+Z)4
MOU]JO=E^U?J;'S4X^HE2W-,TX#ZH'UQBO026:B)\[)+LLX3&*HF9U]N0VG7E
M8MZY@&6>RJQXG**/3R'6)C)-?$QT]%(!,!)&)(DXQP+KBC'FTL#O+6GJHQS0
M V[C@L20*@:R7!"B=RQQB?!80&+?UTG*.-=I;Q-<^GBEZU&IA/0CCF&&(5;R
M#%*LMNHI0$'J*A'P1/NRMXGR_:\ZM,*+HA@?ZD4^4< Q28#EO@06R@/&*I4?
M2I;XO37BW562Y"W\6C>9W$-K:S5YEAR.T00HG_*)Q ;50:@\PE@0$Q?^"D0(
M^I3LK0=D4]H:K%#E90RM;)XDRH^P\@*6G1"^)I*R)/$8%]SM+5U<J\&UU:!,
M_6KUN&V/GZC#J:"NC/R$I+&.@"]*X)!" .(&U/-5RM-P_64H?LQ)\=C!Q)K'
MS/4B1M)0"O0S 8L2E!-.8\Z4J=C06S/1S1$-6'H7OEV;J6 L:D-'FW?G\,]U
M\?+*@+424(JI"G0EI6N8[^E4@1[GR1C0QDL#(M)0D3#T$U>XBH6LMUK_D*IP
M:_*9&ZVH,7"BW50'@8]F2("1!  EX5A[6D9<)R%-N?I90M=[HV>$KI]&G,6$
M8D.'0'-*&%6*2-=54:02KM+>I5JONV!>;RZ'>]SGJ0@)J.@N"22VA?2U I(=
M1SR-.1;%ZNOE/#W"]"!7/:1,!3*6) R4)('0,59]$42*T$U2G@0J[JT6^.1:
M_)H(G@Q<'G"06B,?I587Y'L%_R38$M>GGE9A;S6]OI4/Z(&Z)@*@@TFHB2MB
M@54B/9+$W",@A=+4CWQ?]M>3,,B=MP&4E3SO!5 X-%Y5Z#+U0\^C@H &"P#E
MN0I(0\R(Y"X&XP6IJWI;E[\77O/-M-<J(!A)(A@)8Y!^ U^YA#-/@^:CM0A8
MS%34.U%K_26'^EJ;^(F\UGZ8>+X+I"$(0%<"8D!8Y,6$*U]*'G/.@[Z9!I$R
MWO.DKI:9>1!7#A7U9.21""0J$E O(B)A ?%IK+P$=)I$])<K/W*2>C^3X'H@
MVK'$BUPM)=!@/R"!*P3A/J*;#&.6@#:<>KTCR3TN([5*)<I-A>*F34;(.0D2
M-$R(5).0"0_^+TQE?^-X!YZVX,0)4Q%BV4L_\1.LI@>46L2X%J%!X U!F>I=
M-;VG[)#\!%=$ \9#JE+B1SHD\$$01C4'LAA)-XY"+M/>7=%0@[Q_"O43N8E#
M"J*@3@/BF49W*E6$A<#+HT@#&T]!GNZO$;M?,MEZ2D)JH2.FT3(=Q)H$@6F9
M)&,2>PEGFGLJ"'M-7I[6F[Z 8'2Q)=EM"'9EZ(/Z->--82D)&6)E"0:W*#P!
M&!QXH6!NZK.@M\FB?:@LL:;*76'DQE1[A#.LW9ABW: D421*0RH5Q<(1 ]E[
MRB2WP$V"P M(J&+0+AFCA&OX1V$E?Z&H#%1ODTM[U/-O36'J7'(._ AD!N:3
MP(\9<"<9$NGI(/3]-%1N;WG2E3+%5O*;I:G7N^<\RSG@S?NRVJ_K,2_D&@K=
MK>=> B_V4RS,[Z8<6(T;1H0G4A(II0IC3;7O]K8<86]*H-VFI4S97/V/K#FU
M!D? =L1EX(=X;AB?B/8)J6OX8<V L[)*QL#O/$_[ #A&"0B2E'":"- R/"\*
M@".F_2UH\70EZWK2+^EI*J"$'O6!X>M0HU]?<R* ]A /9%RJ0I!X16\C9S8E
M?V*5-8=B$3&*[>N%27<!KLVQ0U\2NFD$VH@KXM[A]Y/EW#Z-.R42"0\XD&#*
M XEYV1Y)/!$05T?2CSF6X.BMP/OTK1]6:7$)W8BJE,<DDA)+JX%TF_ 4-!$1
M>(DOE*!A;TMU/GU8YYK409[&OJ<2$@<JP%8+,1&^C(D.8L:P25\0]S8L\,DC
M-7M W4#Q"+26BO@B0B.8 .H6,D%";&H0NSQ626^+,_<B;.OIQ.$5>.6">WOE
M8.@LF>5!;@VE(LR (YY6$0E2A0E/2A/*0L$2%@:!ZK]][ZFC$WI .*32D9(N
M):E,7+33@F8:IHQ(3P+I5Y)3U5O"?WL"S-$%S#8Y*/1"L<3.^[F>/)@>7*B?
M!E*H."' LS76F -.P*@@.O8BAO7[X[2WL6<WR+F/4NUR734<72%][8.8ZR;
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MW(L]^&]?(:$_/J"UV(DVTQ$44T&!(7"22DDQR4V0A$E.M%8^BS&?,>ZMK7@
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MW5HXYA)_/LWT>;LU>QIGL-X*;B2?."I+4SAB7$I5GL'L$R<=-[;$XSWF U"
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M%6,]_QNB2J%/;$M8X%&-83'V5I%?&BY09P [O.IH*#),PXQN@XWEF(R,HRR
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MC=RT>QNP8<"&WF,#R/E&Z*^<//L&$'):ELJ8]O7)&%A 68': %).<=(:]D<
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MX!3@5'D-&((' R>7S7&0V;EN77^\S<')X3K;Z%!0H=KX*VLFQNN<AX]9L*C
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M62@\,+<D2Z'J;@$MR3!$NFMO#$?6A<>U-0<MO18Y-@T\QT!SI.CM*EKZGF9
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M6F9-ICY3'&QTU2 X+;E2M#9?O0[4!:DFRGF<7RM+'^-&ES"62*3;)^(<(S,
M&94J*U/6&](>7#*+X-_NIG@H8=I)TV\A3?=W49I^3HP*)C&DY1H+DS;?M3B.
MEE$*,WRQ3!?+HJ#OHGV48S:E0>S]!9W0.:>6Y4Q_5M3V@G7KGX<CIM&;_OZ'
M[4,]NES.:6_1=(?;O1MZHJC8WBSK8D*/-_RS1O<TXABIJC^J.?!;T+'@8AKV
M]\+YRGV"44W2;[XDR9O8"R1F>OKVC=$WM(I:5S@TJ/-WI_TXG O) 8KLR'JG
MC=,S[?A_JXT0^H2[3;SH23 I&'LH6IJ:#OL]#4P!\0RY<AEU$"3$BOR&8T;(
M@)+F*1673*-LV?,EZ'.U__ W;._]!U<77;7&UTW<25>MT55K/&A;OE]-9QN$
MN5W. ]YIVL/2TRP![5)QHYM0 'C]48YVC!X-:AVNQY4JQ5X[.[ F=EROIC21
M*S:^2/%;)+V50E!3_>BD:TMK&+Y 5,EZK:9T1XG1HH,VMGB\!6RF6>PHN;S?
M_6I(/[+O%T6OEPWZCS51K))7P&I)>90IP=2C<=7;C9I,%"V>OM6C, \PL33S
M7M.UPY>_/;\\VXWRZ$=?E/,5%5>7&BII^\MONA;RU@6<YLB$KA'CHDO.CX?K
M('.<H,FA3BN:KSZ'J4TJ$E8LDZRPV8BC3H<^]UO4T9F><..V)MQE&!&_(%?:
M>KB?8KVN7417U[>VXWON5:K[C73GKX^U%D8S6RY?SA!L8R\NSZ9]H)+P7BT-
M%.?S+=L ':-;Q^CV\#I9!Y5OH[?J6= B)YLMN7BL)H;K<:.H_Q) [X<0,6L0
MD3/E*+TBVRH:KM)^<3LL@Q(LJF3.P1]((H,) M/<=&&G2X=GM(I[8HKY3..*
MIT0[MO).=FRO['AO$;KJ0DHR+$SV)B@71F^Q-('#GD;4XR8U 61P'K%STEMM
MMVW90J39VYKD&LY]6(4&D<W+"WJX:*ZI30.LK$P4QW]SSYR5 IF-_6N&FK>M
MC6W%,/9!^AKLBM+>:8C:K>QO+Z2]>'=>-F##_<'? L?#D%/^O:N8/'?!INV$
M8R<<MTXX J]3W6(TN/Y4"UTD#;XXHR8.V81P\'IUMUTD(E1@/U7"!3J4*NY:
M%"[$3K(XDF*'KF9T+7HH"]8X(:F*^@:_<L\+79)SF,\U-LC:E&E2<(X9."Q0
M$ST54TT_K4E78Z.A6 VO^]K$=6G^O )N?HLO8S6VRNFX$331K=OT TM;%$XS
MIY*0TQJ+VUPE\I%A(SK;L!-_VR_^7L$93*08:>';B;Y=Y $(;+L\\SJS'& M
M)Z%4F\5J<>I,8['- ;F 9' QL8A*#?0'Z82X%:NC'0W!"BH#F:2%WRV($59R
M.32-ANQKBD7'?E3-:B,[#:#S*JN7)^-64,\8SL),IU4+S<\Q7C1PUW35G\#Q
MY)J2;$.IL2&>@HGMUQA[AK*.3=/NXTKKAG$LN&@F >7S*K 1;';K)E+O3OAV
MPO?AA>^9E5 KQ^O7T[,K'#SRY(JYA6"Y$F/J3)//,%S9POS1EV MP,"[*+;S
M@ '+&<JFR;L#X2+%!$M&N&&<(YF/-"<OUX;NV@U,CN2Q +0-J9+I7WD-H(5F
M*EVXEWTYW!+;PV#T&ROC.!ADM-:ZA$9S,<JA6S[?@ 4UMXEGG2/&JPJ6T+;T
MF5_I=]K85)Y5C+9FH%! :+I6IH3#X&]PJ01C/C/4/G.W&8F\X6N:T((W/F"L
M*?;>^!D\;BR6UQ2D*SYH.I>YWOK-V>ED?B?SMUCF7QH0VY3[[Z:PLM($KFWI
M%PGI.G\KW;5$MU*>+C5] @U_':<KQ1MJ<<I1!M5:Q+$MF^FG?[1P?ZVS=?H=
M=QN*IW(/*$C@&ICEV.,U >$C.%5-]]P8#1A17BQRC5/G7AI9''5H"0^:?@7T
MNFPNY]Q;31&XM*DSE%'0M=.0"Y5-ZR9TDR3-F5G.A[\W71Y2PN9)Q%64<+4I
M(NRAWS=GLK5H6>N3E2LY3(,6P'"BJF4#%K]4ZN.7[4$O*>EC.F/./)!7.%1V
M!CM)WDGR+9;D;_P]7ZEP[C@?8Z46<H"9*<JD;B34$G';E\4:W5CQBF.OJTVE
M!TR2=EXG(N>65J%+38^Q6$ZVS*NL81)R?QD05VZI MAN;;&*QHZ)-ZV 8WR?
MGGTFZ:JXP0=F.&BP4Q5/E:,X!P9E(I-F96W/YU>QN0"WDE+_:LK=RA5&4B]4
MOLA+*8*N6=9S!1UP1S2TLUTN0<=>"BZ^=+UX,-DMPAV+:DKS'#.\(PU>T4^^
M-Q764]E8:$5O[-=;MJHOK&UE-TJ5:4WFS&"R64YWU;9WV-#_S4OW3DD/Z1]Z
M8W1UMSM8 ^ECL*_ GHM)Z,M]AT;.L66) IN ,$Y7E*+P2!J#BWHJP.P%HK5
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M<2+M/[:+B.22.:2 +B4')F&4$DDFT2<O2IOPSOPCRP+DADV6I INPM+[7@!
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M<:3/3S\,Z#Q&+)AZ311F(R:0GDW8ZO9D!,NT^2(I+/YQJ6G@C<7O%??;@NE
MCM5*E3:G"W0OB6#L:11FKO!V30;"[G.7*8'#I,^X=I9CVY'(Y*'^\=6%V(W"
M&/#*>P[Z)CY8!C'<B4/<911:,@K[74:AZQA\R!(:3OE;;[Q@NTC'?72B]<XB
M+Z=MFGEJP,GZC2C</2%D5H63QSUM/[)[;KNODJ;QLLT8Y6U!2!K^=7*=;_6X
M?_J'5GEKQB3; 7KQ>YN[& &JPVWPC(%%ZTT>6LXEKJ2V46KJ=\B)*U0*% ]@
M3>4/LJD*F.&E8 Q9%2^^F6<=<Y,=VOSLQMSL";9;]TV3'*H^5G/&)'+:OK(E
M7?:4C).<RVJ96#,LPKEB?AUCWHCUP>$Z5>#)'"K?YJ7?W2W+%<$^:3MYG+0>
M-WGQD?>'V6]QBR4H9=0H;U%21'Q+(.&16%B[&U+Z)BGSX^V/$SXJB^[1I\R/
M-J3,C]K0_H>-%IMG7<K\WAL!FOK="\\Q2H:#3O7#"(*>8;'7VM5&4U-P#$\;
M)I9UL&ST6%O7W@.\L#DSKBHT[:,K-G(2/72,[JN3ZH]>'7VAO-=A*V>2;-I/
M30=+EV4[.]B$Q;9?>75)KMN0(C>X(9+M5QRXS?/T8\*!3)>_NJ;/C-D_\<IY
M/H\RJ0L?:$:*G%P3[:"% HE,+[C%4A;$FPVC9.;1$'7?;&_71?#^__Z[/]H;
M\OODY_V&\ZYA*R7LR2E\FR?![3H98@JR)S7'CEWIA <\ *_,C9O>+Q\YK6ED
M-KTG'*?<(2DU#2J5A-'NH,R/3AX<!IH,E X&>@4&>O_XZ&BXO[=_LG],9M[!
M 6"@.0LY&KW8"BSHKQ'L'-'Q&G:VV?]O,TT&6QZQN-* .;9R$OU$_ZD3KGQP
MW<JA+=HD T"5LQS]BCZ$&[<5^<G=5K*/1JC*RQ?;5BJ_=C- I-?$TIARBG&
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M;]X2G,!6V752Y!G7D7&NH!2H D-&91NE(GKZQ&]THBM1-5%G"9QQ<K])G15
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MNF.ZP9@CB:,1>\8@/!J2(0$I=;!B4-P :5$E'F(S]*HQWG+K2[=8,TRJLS"
M-H/@?4.LMU@_IAD/M,]KBJ$(,S;66+8/1_WAB1:2AF J%>R>$)/7_ 8VEU*F
M]V">$6L5:9XNH6I:SS0Y:3]IFFOVR0UC8TU;Q_FGO*C'202E@D07#=CJSTV:
M<Y*7V!BQLIB6FU1E4JYN$)J5 ZLZI*,S9"-+$\JO::^Q*,.&8L?K(IAE/=8Y
M:B*V+6?*R@;.D-,OTG&7,C736M>6?MF#ZZ!.!=V+5#<I $DA>X']-[]+T<];
M%=$I)"L=9^!4".QQJ8YO=6KJ46R-G_[!"PXA)(!L<S4?TW^54#%I.SK+LWYD
M4SRI)'>P&3C;XQ$:)N3JTC65LZ;I,6DR485F#_!ZTC5W''+QGOWLP0$/9#."
MMJ+T693BFO%[)R3)TT80F$'YX!!?Y^FU&X+P->+:YLL-*=PD)'=J7I<1"@V8
MFD^S(R153=NK6 ;3E/XMOYP(BV$9J 74:8HR$DQ8-/-8YSAX(E4@4ONO/X7Y
MK$K=@<!X>*+D2_C!XZ1 "$0C"X8Q0"![04+ZR2L'H2<8/4 7 ?0NG-,NDM S
MUR#$](%PK-<_@)YFQD.&PS7]OA>0[YN3^"^2>JYYI) #$+B#2!5@JO(K2'KV
M.SP-@B(+@VZQRD)IX6*$:D)ICB[-*Z%QGD4_@AB+AIY)9[>NJ6'404-SA9(C
M\L7XSX[<QKZ+<P/"L%C4(.=$TH*?)U$3B:E8C(\CP?@(XUB@+>@^6V'"&0"[
M9$"8^)@YW)LU(K+3MV]D\B1:0.-C  1,;E2PZUXD4\0K:EAJI?QUG)(A LN.
M1S<+Q[02RUR;>X]#S>YZ?OW>:^J/'D%"?)>KI[^*C!%BP&,WIW/\S[!(\KH,
MKN2\CY?!Q6]GCV!I=ZE8Z.O;)33BK S&)SD+ZRI_,<X+.N0\%-+HS_=>\.5]
M,D+(P7X^23ZI^(5T* SW>$+U#1'2M:1@GIMR3#,UG!J69_^$]], ;,W7=5(F
M@E'[W-RO+Z*KXF9#Q/[^X&3_&0B^_M<O5;SAHM'1X)FP@-UR$8GED]'P<Q<=
M#O:./G/-L\'^8?-E]$.Q^I%F*\GF6/\\/8&R 8\/Z2*=<F]ND<_(@QMZBI3/
M/9<B.OS"+ XO[VT/7\ ,R*;FPKV3_21;!7J1/6X>J7?\<'"XM^FA-"^;SJ'9
MNE]P$/>^[" >'^Y.89J<S^_YORRY/9G9NLF_Y<;<Z;UU!R&_>9]\Z;9XR%5:
M$0LD\>]!++3,W-8LY0Z88D_Z3Z]5MRFZ3='8%/_UW3:%?HJ8=;<]I]L].[![
MKO(J?-B.U*;S]O<LZ8<VD8&%V-RUMSUQFW;I=@?IS^A567"*Z<FCL"#/E/[P
M67'WK>S275[3[VB7?E?;XK8UZ;3#WVC8.PB>' P'!S\_[=;[1UCO?5KOPY/!
MT=]>[X<R$[N-\6TVQN%)9Z4]^";9;BOMC^NP0(W766>A=19:)YB_EV!^%CPY
M.1J<=!;:C['>M-S#_<&H,]"Z?='8%T=_WT K\AL\X7__M/_3UAAK\R2.4_6(
M]/OV[)CW4@V)ZO;.9'L<2WH.Q+CO$2?MQ/^6K?S^?O#D>#@X[LS 'V.]A[3>
MHY/!?F<'=ANCL3$.CAXT4'>?^V%T>-@S_T>#W %+X$&! +=3VG>+N/V+V*W(
M/:_(]U.JW=+=9>F^F_KK7-WOAB]1IJH2_+=O&[WH+-PM6WGR? [W.C^W6^QM
MU,?=KO@NR8ZN&.7!]\AVFP<OA22C2VQTM2B=6/YNROHH>')$']D99S_&>H_(
M.MM_=@_KW=EGCVMC'#[KBE%V0<%OSX[1&/Z=M?88%I.YZCH3X(>0],/@R;/A
M8-B9?#_(>@=/3@;/.H.OVQ;-;=%5G?SH.=9N$;M%[$H7NJJ3;NFZJI-'Z]EV
MCNV/8M$.GP5/#HX'AYUC^V.L]V@8/#D<W<-Z=Z[MX]H8^WNWN;;T7P!D_PW4
M\:.6&=T50/G[8J]A$$N/Y^,F+(-8"7.)BC7"?$_(I805)2\3X6@2#/J('AHF
MS+3J:$Q!!\8DCKF]O,15]$0AT'BB.<'PK\!2OX" 94DK S;N)));Z,%/!V"R
M+F@J@O\;9F$2_-8+5!6$Z: 7_)_@99)'S&@]VAONO0B&!R=/AD^?GQP^+)-%
MVUS?$[?%Z ?;ML!"6YFYF;7J%^%4B2CO,SO;\S"]"9?EBY^"7WX0/H*O])7^
M#E75_3-Q;+?O<5XKH1)2AL8I]64FTSR#*2HN0.+$3-9"0PB:6":.9=ZE,%L:
M9FM-\C-7JA*Z7<UN/&=>0#P@"T[/SX**^=$&P1\U'I;,P:F4JA#D/S'XKL",
MUUNA#V)BQVB6ERH#MS">/@XQ!GKLO$ZK9 'RM3 "FZ['F.WH^'KXTHB6EUFW
MXK *@ZG*0*6E-!D5GGE#HKL?S<*"GJ0*)BYFEBR/.XL^&C12AJ!Q$58S6K3I
MLB,9>N!C\&U(AHX[)IH=8:+9EKEQAD<RGP9E$?WOG^B'T;.CX^.#X^/_-SP:
M_+F8_@1JT/8_F&I9)H4Y/#A9?'JA1W9P.*)_P JXCR_?9>JI^[)>-?\FB.EB
M!18^RYU.;TSB%-SBS. J)/9&3;Q]>_J*)/\RS4EK1:2[KL6MF*9U5!=YEL10
M#? O#(?ALLS+?"Z\]ZS^R-48UZFFA*0EJR/ET372:$BO#()3S:<',MT>O8'Y
M>$D;*^9 )^V[#,)ZRGR-WLT?DS2%]J,159:+-,/,D8^/GWU>R-WT*#J#;AV
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MUWKTHTKDKPE?RSSN/P\^A*:5G@2Q-/_U:.]:4Q)_ZP67&,*E*6J!L6B;'^D
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M;0'%DF6%LW5:K1O).<%LYY,S5K;X;$F'<4K;$!\J8;,)&?C&5!@$K^E-F6[
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MAL4>\@5HEZD,/\)1#,$CE:MAI9@B6:NB[ 6')DN&A8Z?-B89R_'BI<%/!EN
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MDA/4"6;?H]**;;)] ]"YK/NF[Q2JWXFM7!AM%33[7H"@DVOJJW408M A6NA
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M<QTOWI0D5_)V$;:T,@B%D$":2Q1N2T:MD&0<U'NA-V>8V;BY;8X#]UXWFAS
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MQXO_47*-*K_J%,,?,./Z.#:?RGI=]84R9AS\I S,F ?\]G'-@U4D,$QQ6-P
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MTI&,;!B7]]Q#1 S^$#R1 B"P%A BC>3Z($Y F[*7.G6!NHM /7;DZESARVC
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MNQ)'*"F,N..I\N/]P=K;.SD;R@>3Y8E1>>BJ3CK8'JWHNHO1= *6RE%T:,M
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M,UZ]/)4I?5XL_M%<<G-0=D%#,50KO5H<)I(-I6B)&K_N;18!=UEV'3)V8L1
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MX2.>LE\>0XXZ91OWGN!>0YOKP;0$BT/KLM4(*9=F1-!L;\[ZMA/O"]]SSAB
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MU14I*+XS%J)) ]>+<JO(?M:^LDT8\PF.802;R<;A;+6$E-P$:P59R8E;WGQ
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MLZAB*J4B N%K,F;4E(GP;[)W<HN%BB8W'L.(,_&V";E<#PA18]^\X7!_Q%R
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M&<0=!,K<120\=R6L2NZXPEDOY>@LV] NZ]MJZ6.#-R+<(ENLU^CG1J1CMF'
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MU?/+W_O?J/HFKV,.95^XM:.4FI H7]'WD&0Y5]9%"'$AF)7VVLGG9?S$TU^
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M8F/SR%NE'FR:=UH]7:>YU)I>L'!PXA&KBY)H[ZJJN<?+#[%]G6EG8TI):D(
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MS&!!7/J5V^PPY!>,"#GO5-N3NMC)=4E^JR>:8!Y["9.1!(A&S_7'<-A2 >N
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M5K3 9[Z)CQ("'2K8!R)XWH67V5N,7):*D1*%6N9YN_-F *62><82%@)$# !
M D*_00FP7ZQON9P0(T8]4D9N8O B(\@'':W3W1\N?NWQ'NA1,1GRS&N'C].-
M\97SY6;F1%\36)Q.WPN=H%0CIF8\>DH\H!%%JE&JKV_E\(T>SOT+1KD2*K;G
M;U;'"^Y@G"O$769_:N8H#Q#"TT%P!QXA?"]N+6'?-TS) EH*9BBN-_+I'MP?
M6D?TE"&D#44#V):;<LWZU-@2)-4"%EP[J2CH#;,XX7HENY)C7!?A6&+L[+A.
M,0M>V=JLH4"E[1<%)-R->EH5GJM'1%6(TQ<UH$HN*+@]UDN7/D_6,_6:(QMI
MK"5)JR/!GW$8,X"FXE1U"]?V'28!8CD46)E4'XV)^-:WF TE?AA^><:Q333=
MB20CD61,UZ6#[<0"*WLT39BN=&V'W#!HAG9%NU&+:A*:@N)#8R3$EBK$%>%)
M*=?K]V3.N99UTQZH[GM"X,ATR>$6CM*6,"CLTNB2;DO:7>>_NSJ$SY3=K6XB
M=I3C4WQ='!@<73(::1?8Q T$-=H522GEI^+/V+V)_,#(44'4"$8V8^1N[!?-
M(,]9O)I+M)1I1H^Q.H[P5& L2C%T3*]Q9NY)6D>/FS?)E#-@"AQ?JG5B8<WZ
MI66]K096QJ1F0+^G<251!.D;[G,??QUNCQWVJTN&V&96#\61PA8-SXM-<^A-
M$&];^$\$LGQ=#5Y+;A[8+.#0P7[?E3ADBJO%5<#-P5GR^2%2($%/2Q\8A"F5
MX8)WV#>P+>X:)KUK7;E?0<Q)2"]M^)AMJ@]UA-41]ZG4?-S[TC<?2CP34&8P
M&%_6B.=_:2=C',81>H;YX&*/'9.<T!5[D4**Y/0DIV>>U!(./2,C1FTWAUZS
M%,'UF8==!FZ*1.":UOKYKW77[CM=VX971=%!)*G8EA:U;#^%V3M)QJ?EGI;[
MV2]WSOCDV!7C2X^^KW/)GTHK.ZWLLU_9&/L7%05JE-ITB+%BI QW53/MAVUX
MGO"WI.6?EO\37/X$CPIB;ZI31;0%C!,HF;?5ZV%Y+CH1HO[NQ75N^OH?RV:?
M=D;:&6>],Z@FSC"4^L[5I3\>B"0:CP9A[FP]B>@'G@&I:^^Q77N?IZZ]OT?7
M7C*UR=1^^LEC'QSS[N!>$$S:-I#92L*1BB9[!T[$IIN:X.12I'5^]NM<0:#J
M+FBU+Q- #A-A$.XNK>>TGL]^/1=W15DIQQ^99"'-WV'-N_;@U4F1>%3X34L]
M+?4S7^J'MER;XJ9"DG-#F\-R 9P$$3QU1:UPW #DX1X)Q)C6_-FO^8EI-TO9
M:Y!8T1 6Y\!>BHZ5M RWU8GN;.P6A<!\XVD*? 75YV"PD[7+/=K8-V)([Q'V
MJ89Q))#D3WSQ+[?S$"QJ:(F(>)%=3F*T!095:K)9H%.O-XE2_5>[]#Z2E=2S
M'J"D@+ <+*/U+.&O:-&0 I99(7,R>IS&;:DMK=BYB822P4%*YQ8:(6R<]P2
M='FX/7,X&GT^'<9+5DGR =]TJ/8V:BKY-G[XVJQ)8E ,6I;ODD98T.YK_5CF
M'RDU\SY%0_R(I;RX5/OXNZ/UD)LSUG\&]]JI;:'F?]I ^-A1X#]/K=*8BZ'\
MV;<0@:SG=U!M=_/2V(*GS^VVQ,,VQWLEW!4BQRFZ=G.#)\*+Z2R%C5X1J^ID
M4INA)UXF^"</>C+<2)=&1<A"LW$^OBN.]_4M^FU74T731XL,Y$%A '^X>O:%
MEQVX$@F"1KGN3Q#4GUQ%2I<_,\I%L;DFTE9=&L)E]JII'68N\FBWD;_IF>61
MR$3T%:FMNR.&!P',WQ7MD2CPL:9V0-[1X)X4=5$=.P7<[XUXNS:E"YLI,=/0
M_BQG9PJ\'D3R.^S#Z\N.@>E(#[,@4AN-7V:K;FIL1J;U9<09#?G\0L-Q-*KQ
M0A.F5OR<7Q$\*,0%1)QS+__T OR[2O' @?/""!+)^_K#]Z_]LZ "AA(5T+A1
M/;+=TR;W0H56_79&P ZOA_>$.;C G_OF/<3V2%MD;J*7]5W;JJ-!# !*H:RS
M&LAAD;R)!F"E)?9-C1JTRF' ,@^ZZ^2ZDOA5J1BA^=&6"3B@A@.YX<4*>?+\
M:.!%E1O\\7E$-[!D*F$7$0,.:419]@$B>2#RH>D.&_=NG_+*R 53#G>B*%(5
M*.*2V,Y391-)@9.N4R$+'INT5_&.D3/H@/PY</(.O=^KJ[(Q[ QP,D @3TA<
M6C#,;XF;QS3K&$VQ^<<F$\I"IQSMX%#A+(1)*';XL_$*T=Z7P2_DMGPZ?.QM
MFF%AAB>$>4DX^!_>%XRY/IC,!SDI,&D"__6\+4)?Q^=/N8=COCEXG=$#DG>#
M38,SBH\QNH[U5&:\'KJ.^?C8L*C1)9H(<:C&]&YT@B,=&7W82L_*\>XO*HZ-
M>D=^"ZQOD0Z<.N2$[=/5;5-5LF'8TDJ++>E+R*=HW$)B*1FM"FST:S,3U)HF
MD\1T?$BTV;H]488;PC78S)R<8A*^4*];NPV!^CT%W4@%KZS5;U@Y)CSUSX7$
M(T0=%PB:)F_IWED=0:040:HW"OL\6V'$=9+/O'ZV J,K=[=*/'I7NGL%LZZ+
M@9YL@%FMQD] JL5A(J\E@Z//L28^J_[>D7RQOUV\#DN[J(A9/UQ?-..#:;;V
M#]R(H0\<AYY9+9FWLS%O'\F,'?/3!'(93\QC3GRS\V>"KDFH2VI-V(V-:X65
M&(;5ONQ[P;-6/DO-W$(;HYFLW(M1]QK#6/]'SUS5E?8DOC1ZV9_<5P[[,V5@
MGN"I^]?9IFA.3/13'_L$#VT0B!L\*;-01Y*_3TL:#'A0+S=Y!5BZN](P73,]
ME3:?]YJ.\5D#HF/Q,J@!J4T^/EAD5/B8QV7C^4N-#G(N1Z35$-K<0HP8,\Z;
MB,M,T>GG,5L6/PO^= C>)]MWAD:+#BG/=7K;W!O^KK+W@PGC\#?<^A1MF+.6
MJU"A6,6\=\14C6HNK&F'LW'SPU]>OKBX^BI#'4^W+]>Y%W7!CW/\910/(VYL
M&<KT748B?"9:&U.B"Y4IXO0]J7_'A.$8<]#E9:0A?Z3$IX&B:Y1EZR2-1*93
MZ/>PAY]"I:;>-<15,K/0EXCUN(;'+6/[>&*+Y4(@2M@7UH.)..19ZR4P_L&3
M^WGT'/8S4UC67>\*9%H7'TY>PDPJ<3H%5,.]^NKKV1CW]=0+G;DHQL#H3*KB
M N[%B$P@,94E&$*"(3R(FC0M>19A ,,CXW>'M,Z[A ).Z_F)K&<$3U "NNA#
M5GU&QR2MYK2:SWXULR?&3B^2WF-JRX/!R!%"U^B_!S32)Y9TZH=[;#_<%ZD?
M+O7#)9OZ:[6I$H+.A-V8GM3^>^8_)SEBXA8ZH"PM=5MD1=^W!:,G(OQY$X)J
M@?^4I@4I-1REC7'>&^/@6LS+.Y8VXD7L,>$C%8J 6N8@$4OQ1ZMX5,32 #$2
MN1,4"A-@:,JT\>DASK+Q_DO;)FV;L]XVY*-OP2'O11)^C;XZ:<LR1_')'&9:
MWFEYG_WRULQ)Z[:N;5&K@!P@4B#<)A<G+>:GM)A70PMQ.4)AO;LNFEJ4.UPW
M!R=ZHG<%RBLI:88O^!I$$CL_L4G'O_<-/%07JG\<0TA1$=4ZA/2(\$[_2B(_
MX/K@&8(5WK2-TC8Z^VUDZO"*O@[AK] 4( "/R_N$SR=TK^\D3:L\K?*S7^5@
MR]\C,$2DDD<]VR/#WY6]\^ - DQB7DAW15KO:;V?_7HO]W#5WL/&AY:PTS/
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M+,G6)=EZ"P ISL@0D,B2MM]MW\X6?I<&V+LVP#Y=&F!_BP;8Q= NAO;C3][
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M^*0?QR<]M68GG-*[K-W+Y.VTLA_",C!?\%/?%&TN'0;#]1<+VN$IP_B(5.H
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MRW6!E.$<F',J07Z1'UL/DZ*_7A=HH,*7X8EH:GQKE31;B665WH-/B^M'S-D
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M<=;E3N]B.(4!E16#D4RZD"G$1")-[L>CB6VQ>MMX%Y.\TIR57YB*!=0JON&
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M.JF1U<1HH*K?.WCH5F.\U$:7HD)!'J A-94EAX=)25(LQL)N>S#!9)IC"LQ
M'):B9$)JTG4IY^HVJ/GD=XV4Q$@,B/&AL-I;J9MY@&CJU>4M:I3L^8V_)QPF
M"-;SS<65..=Q7"QE^ D=EH'J AROFC_EV\6[V>% UB(K3'C3M9QKY)X<&;.&
MYUKPPGT/,,YXZQQ+[$EJ0(144:&*L6:1\UX-C(*Q%)*QTM*U?T9?5S!<-VQ+
MHO[%B"8WJ44QEV84%TEM7QR^4K9ZU 7I7Q4NW]2$Z*%Z(>V;^+7@^X23/>1
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MP5="D\6Z(4!(:<C<$U>0X^'O2KD1ZDT@/=H+&.1%MA));THT5NVA:/#EPR*
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MO>G,QHO"E/C$F#$Z86!X*5-@HB;7< 'N\IRX1*I'H@0P:/QI>W(J8,"R[XE
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MD'9_^1@C4@ZYJ7CK2BA7>@0%1#O7=J^+ZW86?L^RWD?S]L)AUXY3+@TKLTN
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M9 "[HJ1&5ECMN>>]R!(X2+8N4J4+:0ZL\J *>*?%=C-\]@VE*&SH^@GRRJE
MM3QQ>Z,!+OCM&"LG<3.=R'[SE+I<F)@X69PSAA&9I)?#X[Y9+9:#5SJL&\?\
M0?4:DS),0]*W+F)N\RE/4\!FG4OQT8F^)5[(_^F+MO!NMHDCO*,T%+V,G)G&
M $=O5\=,DZ(;!PZGG/Y1)2:J*'G-1\TO3W!J&9.L1.Y!^"FUYE#OF3?]=O(V
M*6/'_31/] I;CCS_1]8V"O)53:1+DBE;AVWXQ)VQKP8Z=>FD9+M0QT@FC0#Q
MY A/1U\#V!*;*V^Z(UY ;7(E0[WI4L\WD[*.[-@@UIX##5O+:1%,R),Q7DL6
M@"&,0S^$)1<(E%5NP#X1^$D QJ89&:='NS9L0[(>^RTQ^>@[5^9BR3^Z'5S;
M?_0&RX6R"F((LFF')G2U$Q8E*A_A@0B[]H+UQ>C QS[ZO<N/E\D[9%F3_F0A
MDTL-J8&RN)@F<&[ CGB.E2\H4C[;&,:!KF;MT&,$WK:^I;?;7%ZD\ <=$C@/
ML^8N&WPRV&=F(KUT."_R0!(M;PPL5Z[.9O2.(LQ83$M-263"(@<HX#K&?ETF
M_S*:J0+1 G>UOB'"2,^RX;L1L^&4&(X:(6H>Y"%X!S"X:YP'EP1'L"S\^I1D
M2W+8J&G!5Z3/#[1F; OYU";Q$'*LJ.6PY:IM/?#0!VTEX27/EN=CRSMKS9@M
M@9CU#*&GF8'RF S$+%N&FZ%+<ZWRRLJ9*H_:B?X=]O&'SG?5PHR"G;A?/_,3
MI1DI_ *18SC18L-C<,NAP[JIJ;,P0BJ(-'#E0Y"VRX3.T$(<EE#[++VE'[US
M[)M2&/+JN)C$)?&4N?F/<T*7DK\1=IR4"VG^"\:C,-FB(;A9EIJYZB,)ZH*V
M<FC1\6A+I(V8US685AO4)+%GF2,4T+QLYK*XSW1QD_"LGHP^J'/Y.(>$"7]X
M(*=:;;@*?"PY\@KH#&H\54Q5HP:M,DDJ!F1\#ULQX4\,DD!I@-(,TD:A&DTE
MYY66ACE=Z]<MYBTT ,;*],B=B2H%<96Y'9:90\R*S(J2B*+82B^G*EMT<AU#
M:<C?%\=5KPF@7;F.1$C,%C."=):/;CAM"NKY5&.5:$8>R=NE8TQ8,Q6: X<R
M6H\TC$Q&(19K=VPE_[+V)19VIS#1<&))I)(0X?D$9V*/<(:)=6+Q$)I*H,L)
M57.C%]*U8*/289"1^C(7GNJ+53I3J^2,B'&#."W2C!@@"TT:>L8IE:H-+#T,
M26@]B>LN,15W((X\1)'(]81<=X:=3,(:T5FTR8=F%#!H_F7"*Y4%36EN2@GV
MC51*Z>2GU  <UI2\*-IU*9RMF[CV6L>UV3@("VH?'(3S=@X) Z:B]>$D5;=L
MSB&5?AM*>]ZA&^L4Q%?&0<&#*!O9\1F0HPV9)E1)E+L]%ECEOA[A.Z68.;6$
M[#%1Z*3J#[I'BUDY3[/":(T1@?+, >1IFITR7E.S?""+KEDMT5(JXXJCXS_L
M]]1*7PTV_C!?AM\<,UCCN*[A&IJ9[SV1HL3JR 8OE*"4<,'0N:YF6LV]"$ =
MS8;>C"-L](S69590M)P'JNS>"K^3:42>$]BNQ$J_*@7+#K- QE::!]S&<:<N
MR@07W!>8-7DIZC\(Z 43@7_P&UV$.KCW $;414PLG53KSF(C+JB]"=3>GQ;4
MWH+:^XA->V+-8Y^2*)IN=F#'J4N&$CPG.P8<?'$'!\9[B3ISK&\;D,U$!7Q4
M3)+N7F4<UX^&D)&;U]4^&W5"#;AZI??U1.5ZD07+=HYN"J:P^TKYG>0@Y8(M
MO.FRKG,%4B#O;<V2S&$IXJ\[+!# *LX4FJ,NQE[(N=P!8@/P%Z2OO>(?4G!O
ML!VJW=4-(P[&N SCS<2+G,D.V%W0HIN( \H/% V%&*?'[D%T"P+H@#L@1,V*
MNPI,WD$V;4PC$#Z@@84%$7E2@0%F";?3W;N[31N2TD+$L,)0^.)8-8,8#5XN
MTD 4LNGI;C9H\>762%9 [CA@A_",9_Y50JCYK=0M0E6=@1IF1N)2AU95<JTQ
MA1H-2<;-<Y/%A&%3@FZ3@E,O/]0^B@/H8TE3.;5";WX^?Z_>?.I.'0U7MTO=
M=T0LH(_%B2M)8"'^1@PTH[&H4Q8IQ^UBH%[2,)L[E^4P;PV?&1S^$XDT\W'%
M?=_!.%CMJ&AC_'H;9ZJR[?+H[12=GIH!'U4W*;4F2>B-(F_,>PUK&..&5.@[
M(KZ+:%UM>,Y, SJ#@*@4#C:4$ZWCXY.JZQ.'+1^K/O-=25<F]6<2Q0:L%8T&
M98-X[;CQ2<MM@B;/Y'%/8P&R4,F-H0H1=QHKH"EHY,.>*BZL?V@&ZZH5$DV^
M-RGOF>"+PN9C&BE(C=6.,-PLT9Z$W+3*&/HN;4E;;>IF,(*_PZZZ=KQBXGFO
M_-%B3Y:$:<8BTV?5!JGRX))CW0<-1>YOY?C3CUX+!]@Z(1PEA+_KBG9SY#R>
MD53B! #9AM_PI(J;#_7X45SAB4FI&Y\$4W8A3 L(?[YLIQUQRD<;*>6O<!)
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MM<,4WKB6OWG^YDH;\S/F_E(3+XG/Q<8OB_S!+_+U#B49*>//%#W:XZ_0GU[
M+Y.$D$F#MT8:&T2RL)XUV?JZ=1.E:BJ Y[50@;%6@B!A"#1^ZAZJ0-EF>]_)
MF+7+L;+LN#/;<8(F(3$C@;2W$F!'+7O2&<RM'52+SFX"'HW$WHZ";Y\3L-/T
M*NZQ95<LN^(![XI)).9H7VQ=?1%J;IY'SB1D/76GL'E>SBW\!3!WMQ?S/5.6
MWH)8-$R^RE@;P*X(N%/#A<UJ@[:U83<+TJ,6%9LVP7*#S=P4K%ZRR&.<?Z/M
METNC[=)H^Q$;;3?85#/"V0I[:^A"Y+;8CI;C@.G:)<]?__O5BXLG7_M&Q;AB
M$E,'VIZQ.PL:,_^Y:QP&4M+QL';%@;I. LAWDL40.R4\^'?$8$+,*]((MK3C
MGN.I_*I*7L *($$]U'=+1;FO@;.7B-MQR6&=+O4+%7G-6\][2GQ;R8_]+JO@
M([NBRBZ3=P43H;DJ?"O9P9=:&'F6)]NR7E'O 3*$B"SZXZ>/^=X_U@TLLK_S
M'GIM)2MS6.\9,A3Z:V9R*;]W=*W'H7SX)K4YLE_A]J[94KER*+FHEZ?AX>^Q
MA573!A/;E:7QUL_:G2M9/8W;[?CW$#;531Y3NHGBNAB*;5_D3%.BC&?4-+1R
MKHI(ZY2?LV?ZS]%CQO RX0Y5IE>5@L'ZDAMH(KQW1R6<Y32*D-!1N]RPB6]B
M DQ[H.FVYB(N6\5??8J";+S*:L>L,8:+W?)44^)H+=*2P9$,/5F8=PK4MG,F
M-M*!QQA[2"A[0TT9K6>P)YXH&,R8(N&#M=R2-SZ='#U9/1JQ;653-EHOV;#J
M.\^FKWV97;TT<BQ9A26K,%&79RZ!NHGVW$#QF6U.Z.MX]:\7%PZ;6UFFA,U'
MWBL9'FI_!-M<P6@ZQS7_U.](N"&2BWH.!#@,]P.^2KQ3CQEW"*_AP%@7S;K?
M8SLVF?F.5&WH0V+AE[SVLM<>]%X+&A-$&.(U]3P#Q4"IF154 V_#"BM&:Q*A
MJ2MQ9ZD--K1AACU+E+2J W7W4SPX6J97O2W6[RNA?0MP9>Z6+["%'AZX$/)@
M(I?ESM#P4=S@UW61"[!9I<[0&R$?M41%&U3ZZ0]TDX.KB1 _LW Z<+D89HUT
M3R+E0#G/78WM[^UZ5]?(?U>K=A:FQ]"ZH%!2T5D#MYB*Q50\:%,1*'Y"&H.R
MQZID(:&=)#:POMSM,".#.[GH.J<'*!L69&QI.I)KQLC0)U3J(,$AQ[>U486Q
M4<$T,4$% E@W?5.2[#3L6*-;4EM5.5$4J5RY%-F6???@]]U@^6MY)4 ^FD--
M3"X(9>T;(<47KY4R,L1/B"<.JO@R34U7=+WD9MY7]4WI\BWW"JDTE\T%L7 -
MTVH5555?2R]=Y[(]GGHB;L>> +D1/[LU77ZVD+=LKF5S??S)H[H");8P,W-T
MG?<ZAYE]J[_BN9#FB$:(R.G&^8N-?%TBJJH<2[><HBQ)#4OT0 *.$XJ3*F!Q
M'M'G$*<RA[?FJ)8-O&S@A[R!APR2F%Z?W;J!WW#P$4H'D=C'OJX*\!&U$\1A
M"C\C===LXX19E\[24FL;]#61 J=C4=3 ]1(9?.A(%#X3_BP&S1Q_$H,A9Z$:
MQY8C9V[@6)J/@D@L-93&P6VUO3?*ZT]2; Z?7.B,KE%?TS>048Z?4_,<T^O3
M>50IJYAA("X78,E$PH7&>?QC D]RJ(N%16*Q)@_=FMC4LVD.HQ9*L""9BH^[
MG_$$)>CF$  0LE4S%V.R.+]#"F(%Y8O+_H(-U/1%%UU>/J=J*5H]C/].">UE
MDRV;[$PWF:NP$U\/SL9IG'N O2%BL['V+6^Z9<4O*_Y!KWA3,& BRDU8TG@<
MY$UVXTL'$PM<9(.I;9^VR%X::6R<IPE._)2-^3C=*MB.P/I.^L=.FIS7#*9#
MHG"DEH:Y7+;4LJ4>]I:*PAH6M_,5"L)<(G-1RCTWABE[@A<V;+MZQ)S-#I_5
M 9<HSA,&^'Z@-+%=0K!?\_JFXJ)?"YO@X.F^![ &!4<I%0?60Y98:=F!#WP'
MDII:*UD%/E[6F$ ,9;GL)CORYAH  TX$352NCZY<MX>BP]U!JJWH&[839R0%
M0+R#]!N\1<D H":&7'R 3UA<R677G=.NB\^]9B"\8_JW!$'\S8LK%4^=83P@
M)G4IP2_+?UG^#WKY&Z)C0]B!1X(JS62W=Q&8)+=P'*M>$-,BXY=N9%?Q1Z=B
MLJSQAXG+T^B:7I?,,#2S3A8"U&K6.1%I(CJ3AI<NNWKK,&Y;-N2R(1_TAIR(
MN8(N!_E^7*NRATW?0<A4J/BZ)+]%>5VT"A>W;-D&Y[0-YG#4OR9\^F3?Z2\!
M2:O(V$F8]!W T<LN77;I@]ZE9Y,TO#5G"*,N2"BO/;:XW&>WWL)O<5=^BZ\6
M?HO?@M]BL?V+[?_XD_>'OS1NT[=9:?-B,1'H?(2"+:$'0;B1V1_&ZTA^3JQ(
MX,=M'2J7'G:435O:2Y9]\<#WA1&Q9%<HC6$Y PCI"%[.0@0L$LQT$.VN[]B+
M$:]G.@DW04E]PXVG SUCJONL'8EI%\1<(=K%"TW<+Z>)"R]FR.ZB&4HR@7"_
M(B^1W[(NKV'BKTJPD-AGMZ=>7GV/-@[U"NU!]+1*7O9($#O-')-R*P8\'GRD
MPIQJ4[1..@YO6.F=/T(!;CYQ!VKVO_ 9)=OXSZKNPD$+G^-\+15-A"V*DK>&
MW6XB]D['@?=]N4584#9W\*@4_,OF,3PB'HV-F>8=O.;R&#C=.0O JN0KW!LN
M+^C\(57RHA4!;L6[XW/BAD:L03BBUDH2)(>BIQ^B'WH1B)(_ZC2EBEBWLRLM
M8&O/CT+I JU*Z023C)2#$1:(Y2-\>1@B<1-2FPOR*2@(,$"26@&^O[]@XS)%
M3V_Z2\V:#/+VMA';_]:&5KHP62T<0BQ-G_A'R]Z[:6K\J7O;F>#. 2>J\3+5
ML).\_17=X5BF75XL"@9G"4N<X@(VNQ0S2K0KM+E'@)7\09[E]HZZYQAV[G
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MARA(#3A7B,@)S*H;O<6.1#!]BZ";#-!TD] %L,EB3(G,P4HF /!#^O V$QI
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M+W/F$!HNNB4@\&GUQ!EFS=8EX2<-@^*KN=OL#Z#%NL0DIY_5G$51JUD;Z+]
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M97>4*P0I#+-CXYHRGY-#:M5(NZ*+U=@1C*B5;WW@FCE#:=#;L6]P61-D#13
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MHS"'(^2GZ\V#WE)8&1HJ)(ZRRH!KR%U09=99N5*&E1K"\4&UO>M.Y>1"\RJ
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M5R%\@GA_^7Y6VN-4VE\&H,^V!VHS@**IADLGE3[MA4@8-Y):AH PO8H^?)0
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M.,)^416?1K$BJC@W[;(I%D3$BZ_;<E^TU/5A%-W9Z:/_E=A(!0;-$5'N\AM
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MOD$"UZIFRRS#P>%IU> =Y[^?G#X1?^]=UBRRRK2/WGPHS0Y\]%D?9GTX:'V
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MELM+8G'P0UO@EU1P-MER/0-59S4X>#6@SA^,CWT '=$%X&% QA$:- 2"SV,
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MP#2!K\NQ2<9WI2HZAB%4'Z^2OV6-]8LY&6;%X@T@,;8=Y<C.7Z@<&1X$6*[
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M,IIF1G_!0P^#D= *73Y"AZ,VI,? "1KXK$I@84C*F/@DT'CGA#2=8(;,PR
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M]0GS;&0<=1 0F?BV]L0L'I$(H0WH#CZ4*CO+,W8Q3&6=RZ/?SJQK9"7N#-0
MS.]@L7>.Z ]'6LT)4<4HKTHW3C]+XE[#;.ARE-77J[8F'$45\!E4+)*YQ#='
M+%/5#-X+EHE1T\HO?'>'R]'N09[?6GED=I3,0(<MHK\]@P_#D\.CH_VCH]^'
M!_T_YI-G@4C+]A_T*X#4*Z<O#X^&\V^G^J2&1R?P!P;8[R2:_!3S&9;51Y_/
M\/WR&1ZU%DX6##TW!O..E9N77.0";W/+('TWJ<<Z/,ZE*A/.%T.7NA/6>C<!
MTS]1>;F8R\M]N*2L):K.:FL);-F<ON4P1>_*,(7C@JU]S"9CCRHM*8.ZW96\
MXA'&BMN_B-G\%."!._RS$JA'!V>XC3,!-D=&2?^PF/8>HVYYB1K_*^OQ[=YE
MVGV+"<363!@XEM#M<C%#RAF\TMONYO?:Q 3<8ZVF-MW<MW1M>[ZQJ=M[J_B&
MSKEU2AN7:FN$]C;VB"\T<)(]!1P)5.QQ[*WC%LR9SMX<_Q_C$NQK'Z5V9@9O
M>^SEC(R7DQO9&V<E]GNJ9K) BF<ZM46 O,Z*(_C=EW>_;.;?[0>OS<OR[OYJ
M[W7<LVQA%MK_JEV[3E"6"5!)EZ$X;DJF5DWEEU/LWF.Q*CW'<+VH@VWD&*%.
MXD 'WA*G "RFV,LDS4=5BE)Q0'(6]9&0_5=48)=AV4 6O,42NCA'6=E[31>^
M?0/_Q3(.Q2\D(W)^H=9@:W+9#U@5"866,XJ;"(PM3>5<P=^O>U$JQ3EYAF /
M7V71#WYRGDJ>HTFZB'+07$J)I1T(;$-\;75]S05@D^A:P\(%S!=QR@DQ"7\^
MS3$C!<!B@G?:>>24 P8BBJ@B.P>65A9U*Y#\VP)NQIRNF134! 2>-,/B\0NA
MT-_&!4FZ*H+4)EL7^!\\!<V]<(L8&#R718.!SK#R?4:$@_TW3,&P"C#U8L89
M (WK<U4&C#R!B*L4M QJET?%4\0>4=UH5E24);%'V+-]!Q,>-%%[S-P!;,4>
M_L%4@@D^79B=LY^R+NDA]ZI34&>K>;[)##UU8_:.NZ[8"\=_NNP(U543\&"L
MWIO@@IH4Z='&/;FTB"DI;*BG#5?Q(L-#-Q6)9MN<@,3KZS8O#%>;RZ)3?9)L
MG*0F\X7" #K%RU:P(M*"0$B!&W[%IW.0$QZ*\AJ7B&%K4Z:VLS<AE^Y3](Z3
M:*A6V+J-VRI>1&L^UBV$EE<SOXO0V$HU\W*A@>8J28<W,BU%+TV^RF 03/,9
MUG<23F,TB"5#4P[\\LNKMUH"-$0&FIU@^/44C1W#P%D\/NU-TBJJ@(^C&6=$
M \69B+R _C(UD[,1_)<"!"0<& K+C!&O6N1(?)HA4MX@9B)QRV'3V1,N-0RN
MP3_U<T<2Z\0P\MYK+&];I=;V:(-M]]TXB&N[8U0)J9%BZF4%4ECVXD05U9S@
M3>#217@.:]$UMEH&%MA,E3WA*4J+XBLE]E'E6EV'5O,^T/.Q2Y+EDGI]F@GC
MQ*Q,M:R1%?W@E3(ML_C1JY4FR%58.(X ?4+3 :/>74*IH)$.Y,0YC3S0^8VE
M5*4);-E>7$\^KN.9J<M,][:1F5[%1<_>#(9[Q"RMI;ZD/6MN'"VB%+7@^2*=
M+XH"W@OP*$=H<J3ZXSL@T!FF"FN2OI+3AL&J\DW;8<WD?6_O4Y<@_GDQ ZP"
M0(LN[6H5#T*64*3HJ:H8P_*FW8H1.@V?1BJKKW*&>;?88:/V;]CON<4)I2I$
M%;"]V0)8;F(O8"?JJU_>&T$#YZ>%1)W%_^;75[U8S,2$<B[R;PFHS8 RH<G(
MNE4F PH2RF=W/"G!N*"<\6AANHO8]VFDE;%)1OD,V"0!V%>17Y#_"&.Z('*4
MI-IVK"]WE'AX7:VX>T_-TXO_.]:?Z3]?-^YP<E^;B@BGM;!S44DJ442\:^1$
M,8:CL0U+GX/52]7Y9!*#M9I*&L%I6S" ;E*4.(DS:2M/,B8[-\.W(Z'&R]W)
M^L$'RL&]K(M/IYO==IL?X]DO-8YSNKQ@:PH6M-K.YTX.[9FRP(>J LX'V_>9
ML-3?W0Y^KG_:;2ZQVA_+7=8X/A3AKN7OO)2J$$^5<4;5[3:<0BAN^O7J%[T+
MLX!QOYCGUMT&X=,O;SZ?;4>;"<\ 5^!6=U+$#W/K!B,Q;KIE8E]9'+%ANJ>D
M>F*/@O]$S.&X!N$_QO*"R[%HDKF;;KX9@K6,.?E@M6%X&(,S85 (+B>(Q!QS
M>,(;,M?0S6,$8@317)6Z80I=R;,(**T^-!R=&V':LK0U#=&(V9;L[VQI)*6=
MLO9KL/W1NL6&GHU!S8LZ6=5.8*)".)%R>S2Z#F_0;:ZHU@W="><2,QAU(RO>
M(MZDD.;H6[S,1+#I(/K!E^44S7%%7 F/P6DS3:X_,J%EK'MEZ:7'W)T&A!$W
M_#19N#REQ,R"+=AF?_?Q XL<IW6:>0OWU<W+A*93)<]0(E^[>\O2Y8!WV-F&
M',!HOT13"KE1%:AIUA5R.(X'L)CA4\#IT#DPKM*5/&5<N:RH[\YRPC+FA(*F
M2([<0JYOG757#LZ3)\9J3"\E8#05XY1C'&CDQ-!KKG HBUIE3+HQ%_J=L%FX
M+,VU.!CG"#AW $].353E^6#8/[;?F%P3'(F)9=Y(%,OC/P=T'R;HDY<*NX,M
M7Z$)*Z9RWRBJ9E6J&U\AHO*(GI-!_\@\=RE5P\U+)C T8(#794JSEA6 F#?
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M3T^>GCH!.Z G1^RPQ%LSNFC-E+<6Z=82074Z;W)0>RDYI8Y=$M6:28LHEL'
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MDNWB9#:J"B7=/J<U!^;["-MY".L:K1R5;1ZC 7KT>D.B3OXGO=S^40]%=<9
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M:O>M3MW!;,*L="?;FE0:;>0KSIZYR'3?<FJ-H=-<UL![Z8U&<D+1U7FB9\W
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MZS@\' X].7E.Y4&[]:#M#E?Q0F"KA, @W#OVDYP]I_*@W7[0=H>K>"&P54(
MH+YW_^WLNW1 O@MDER#?'<KX6.1CJ5229[HL*LHS5:6ET(6K/FK5&<'N@=H5
MH'I9?"M9?'BO74BZ=#2/A@(\4#U0MP.HGE??RGEV.+C/E+(N'<VCH0 /5 _4
M[0"JY]6WX-4'X<F)UZNWS[OE,]V^-V7\Q"VY$JFP69NJ"NK)A<ZNG%J#47<N
M[QWNF 3Q,]&>RB%XL7\+YC8,]Q\@M.5GHG6)U#QH.\#%_"%TX!"\*+E-OO2^
M'Z[YM G-@[8#/,P?0@<.P0N26X6-#HXW=$5Z4;*-/DR?H?=]YS1?HV^Y]_QW
M1D!M!%0_PLR/,.O"@79ZA-G@.#P\W.O4L7JEPLN<;06JESE>YG3A0#LM<_;"
MXWT_-?,)<D</5"]RO,CQ(N<!S)S]\'BP8=,*+W/NU7?J)S6WO;2?U+P&A#]?
M8P#ETAS:_?[Q\JSFO?JK&\QJ'ASW#V\XJ_DNAP\?U<.'-YTXO-??N_'$X;W^
MR6TF#@,,KJB07WK-P_8)U(6,BBHI$5YX$R8BES)-9516L.R\R.'5RT6 SU0R
MU=>(B/90WR0 XOJIO)-BCF.#Y=)]2U.2@0 N2AY\C(\AV, "\+]@#AP^B0AJ
M(EOT[?C0;L85KY7(?8-W>#@^L#QKNB;,I;-#-"D0\UH/T8^(OHN!RSP@?$>/
M@WX1O,N 'F0;&CW@)K=KLF]W>,8[)""I2F33<*HW'>]\ 6PR!?8/]\#;/=_M
M#RREHAP \8W<&41*8IX#ZV:P)LF_<_@"A9)03+GT 0>\GXL49\^/1(HLK*;C
M6R/;4Q@;W1WD8LZA=12#$*2K1-2]'E6)L4B* ,X;] SX'E$/3"U  %+ZTD3P
MT.<@WP:Q-4;]9MAQ+>$F*F[(:A 0+FATYGP^S,O>NRQX-2FDG$G4 3_+XCP!
M50/4*\M'4!,W"MY<L/)6G[][E>*[%:IYYTG,"B$^Z!_Y-Y&FP1\Y,(_@')Y4
M%80DP&:&-]/4MX%_7*F'#/:VEGULXN5YGX @B)'V432<B3G*^N"35*#W175"
MSP/H'UX@;$H(_Y3!5*P7^&S&#H_V^T>U(4M?MAC?/]U(4PG!G*5G9[(,TEP9
MF_G(-4CQXN>#H>M1 -8W!RL4A%$*]M^K]LW8Q0'F8)16LXKY7BS'2900XWQ^
M,JA?ZEIVB4>?%F5U*ZS7#U&9(WHP:G1;&[B0Y-U()>(K6M3O/GY M<RX@#!!
M.-X*J ]VPX-=>,3N;J"FHF#ZQC>"]YOE&;O! E$"A0/-[Z(SC2\DLN_V*17
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M.AB;Y14"QBIQ1+1Y(!46!R1J&F3PO(:H"D118(:0%T>>1+I/(K4X2K+S/,5
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M6RQE9Q#N'^]Y$NC@T7QGP\U'"^_-?+-C'D<+MY;:1PR[*H=N =KK)[GX0^C
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M"@.9D.<C3D#?QCQ[FBYG_B*_A:=A3\/W0L-[VT'#'POCTG+HKI%"9TPO0].
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M]QEQ']JY1CEV&Q?-Y@)T:..4X=]D @T.6#,S6]6\5'OF6<'-6 $Z,&Q(BA"
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MA@(.9E4Y3@B'S/\@[5$(!0Q)G! *&'0H0()4A[-6(10P#-,>0@%## 40#+&
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M7(Z27)M7:P-"^V7AJHO/,NP_3>KIN+2KZ]N5(9IA/@\WWCUNVY\K&UEY!#\
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M@PYW:G:L5:?-K\T>T;!W]'XDIU6S5,]Q;'>"EE5RE24N*.&<3%Q[R>JW.FR
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M4N.XEMPZZW077NZ2B]^T5-REETM'C//M!^>?L%LYIID^, (":"/@=A!"!$(
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M8E8;I"E/48I3(PFF5.7VYJX&+HF6 CELE6=$K)$2@4]UAC')M6 W=P5NL^I
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M5W[>V#>JFI23K_4EE?"ZU0@/M]MJ/W/\3S\WX,@H)V*;69=[ERC-LM'J_UZ
M/:#*>";S+V _[(H" _C!?@#[8?OO<E<+7BZH#<V?I2L0RS*#I" <930S A>,
M%*23JHQ-VP\D&^4L!?MAE^R'C52*T(X"3Q0"3_>+^?-TKL9M-Y#[#KZ"\&YD
M=LTSH 7CLE="Z*&).2@;#F>%48HY)'A&$:-4(<T)1FFNG")YIM*\DU[4EP\@
M?-/0;R>Y.LK)*"5=V6KKG/']L]AZS#\ ;034#D*(0 @]U*_QJ,SAAW D-8*%
M]A5%%DYK$#)',B72_X<+++&6-&-=A'">H_X?&++A+ ,S8- >_9H#-X^+U.WJ
M^>/:+^*GA6+&I=+EN)R7KAX%2FD U6.7S*X>%]FTU%ACW 82@7%FHN@>S0);
MVNDBS(I^&9.Q++5_CU-\/31#MV[G/47\=W2*I@71*K5(49Z%@]08TAF6B!1"
M4*6I(5DG1]*^OV#X@XE=5\A'> #I5C=5WS_Q^V?F]5*! *B@E4$K@U;NI586
M.2<$8QTV 1/$;.JULJ,$98[CPE"L)>NDV_=&M#+QZ&6@E'NE/U:A$_^O\B U
M/]X%Q^\>C0;9-!KR*6#$_LZQ1-_:B\.8]L-&R]*$L,Z)2Y0QTU,_WK/0('4R
MG8?N^97_V).<YZVO5=.GI9J'/M+S$U>[P&=-.+39$%:4$S4Q95.GXS\X]<#7
M>[<%W;?ZGDDG\X70SB?,A=*.<<J\^,-;%'>GW_2:8$_.(\@S]=6UB@>IPF.\
MK\;?U5G]ZD7R:_24L4$ 5RMC1:MQ\>GFEL=3C,*C?_S]W7'R\</AQ_<?__B/
M4?+NPV%WU/>4 75#<W)M8FS,YLOJX\N%TO@R+;Y,9ZY2P>JL(Y7XX675=WP^
M]J ;/\XVQ91/&?@*UR8S<^CU?>5.W*0NO[GD_;2N!S!K=XU\7KZ;>'MLNJB]
M1.M1XGX8%_+4)ZWM9B\.=TO4J1_MO/X%A+Q1]?L09^9V[=OX<K?M&E"+^73E
M)8>A>(M]'[]J+D=C=39=S/>+\H>SK[Z7=G[B\6L 77[!A/,-9[7;KYVWYSUU
MK:!IHC3MO5]<S\-_*^NR"3V<[:^^?TLVOGT<YWL2B]\%-&\+%"S'M,=D>N\U
M%//[KDF]LW[/-7@OEW&/9UNE#ST)OF^<G2[6(>0]UI[W\!"&O_S^!7\1RQ[9
M%1+1B"9N&^0?3E7)&X^.O7*L3MS;+/LG[MZUZGIBO[^>B .TTDYH)0I:J9]:
MB3:U1:""^J."@,V S6*;\1&Q&08VZQ.;K:T1">QJZ7AM?6SS39.OB?LQ<Y/:
MU?NPT3EB);5;;>6W;7,!VCU!.R9L@4)@4@/:<9N5YX;6913A2(4-5MU]<K53
ME3EI*C6L^^;&TUFH)(+@2#34-4A0XUD!F]Q/U4-5\B@TXY'J'1WJ',.$YA11
MYS1BU!@DG=!(*%886FB3%>GU;5)$ZA2KPJ!,%0HQ;#@2C*<H95(82R2S0M[L
M,MRRZL'$OK[@U#>M:]_)'JF,C'#&X#1HH&T M>^@QL.:H MW1Q=2IS7)4HHR
MJW/$4E<@5=C":T57%$9IJ](;[=HR9IG+A$72:T3$#,F1QB)%LC!%X5C.<+X%
M72A'F&WUB)Z8)FZ?3UC\2;M[" ILD##^Z"8N[+8-,0%E3\M)6<]#>NJ;@XAR
M9 81=-_=%2& O;1=>XGE*IA$&2J:$PZ%)D@Q0E'*E9;.<"YSU47L8$F^WEPZ
MN$*]75I,1(PXAT[WP$6@:R.9Z*!K8Q("Z-KMZEJAN"DL3E%>^/\PPC#2T@KD
M]:70JBBXOAFG?TIL8A.Z-AUYE0^JMG=4M.8J!SB_;^/G]TUO%-E"C# :O;[F
M;1\ ?RR[;L"@VD:R1QBM&!>(9X)ZX\@2I/.L0(73!<Z#>80[*7PXW\>PM*#J
M3DPH+D<YR>-I" O6$Z3R!P0J:-&>P ]:=+M:U!FG"'49TA@+Q*@JD. I0VE.
M72H-HYDP780EUJ-%"1T)N=620="BL916P ;>SBDC="]-BFIZFEPTCX443F0*
M&J"-$=H>VC7Q\,[P#Q9.>:&DYAIEF27>[,HXTJ[(4$Z$H-PZ31WM-'CQ;F*F
MIRX0>K<G"W<:QQ@PE<4S(9]X+.R 9=-C-0/0@@:/D62&K\&IP(*9@J&,%Q8Q
MJ1426881LU;;5"J;N;S3P,FZ-'BG,90!4UD\$_)6#;ZM3L,047E44[3YB:N2
ME\MBC5^2LEG43VR,!NFF&/MV]M!NV+:5!CA'C'-,J )AP$0&G*-/Q<$NYRV9
ME^_"M';U?&E7@@\7&6\!M#%"VT/%,*A0&G$FQR85B!@G$4L-1\I)AXQACJ?&
MXIQE723#WDV^>6X,K5K:6-J*+3LI1:(1[#V.:=H.C", 6H"V?]""9MNN9I.T
ML$9ZS8:US;QFPP8IRSG2!3.2&(XMZ21)M%;-QB/8ZAO3M.USS>RM^W;!1=\@
M41R[ZEMI7%(XM_32VPK;RHW5W-EDIJKY&81WH]&^ &HLH((QLUUCQMH,,ZT5
MPE)YEYLIAB2G!&%*G%.R<$**Y[CIL[,?]?Z2'M\ZUUHR;STW?FJI\2@P8T>]
MP@CT5AT8.P"H &H_0.VA'HM'-?W'O_V@F#!8!/WS/2%)',<2.CQ1DZ_!^4P*
M55;)-S5>N&1:>/.I*K\UO>*2<:ET.2Z?ZHA"H"?&8##TQ.B5$,!,@/TG/]M_
MP@IG<VT1RYS_3VX-$J3 "+."8$-29LV-LTZ>DC1_?:X5_JC*2=A^\G%R\=D'
M]X@<PX/VDXYHVI5S#JU%XUR<L -U)Q4:""$"(8!5L;7@ ZBC/D8M;LV80Z?K
MS7>ZOG7G)(0!HU%? &HLH(*.A\C!3R('A66",)(AXO^+6"85$CQ72.6$RBQ5
MSBK71>3@PW0RO=J\XM%GD#PL8H#I5AMIQ[2XXM;D3W3\!RF57FH6 !74]>#T
MH2*$9EP*E-I<(T:Y5X6%("B3FD@GI-$4=U&DWX$^W$25/A!#/#42T(&I<PZX
MZ&GM_K4HYV?)J9N?3&U2GF^A"941_SLM_0_?_&^+"K;1QZ9F(5VQ*T+HH6T4
M#]4-/Y21:FYXFG+D,D814X(AP;E%19[FW G#-;7== Y8]=X,^Q'>-(KCSXW>
MN-AYV7%;3BB#&+HE F40.ZG20 @1" 'L"BB#V('5!DVA-VL(Z.G8/E9Z']P\
M&8>@A)J$3J.G_L8G;E(WVS#\QQ#$BT8S/0G4JYQ%]V@6.,M.%WKL>F89Q+)B
M_CU.\8%-\62)QAFI>,J;W!ZGR(K<<,M2E!IE$.,Z13K'!F'A\L)*IU/]K-8)
MYRDF-U_7,2%Y-I)Y%L]1J[<MQ?Z9?[%,6ZC, #,C%OQC61-@9H"9T2\S0W.,
M4X4%HHRPT*&)()E3@U*98L&$PSGEG52RK,_,"*>140%FQC I=<TGET'US+I#
MO^?!JIFK0K#JU'-/?:(JEZ!$J[HT313+EN/%W%G(;T5F6786>@?[LI/5]$0+
M<S-B!#L32F]^8FOF(I1-%\9;F$PAEF&%-"LLPEH2EW.-F=)=A+3>J&I23K[6
M1ZXZ#HKFMZ!E#B;V=:MCKEJ?_D=GC^=J[NJ/Q<&IJ_P*>#T=CU55-U\^MTWQ
M9=N47IBF?Q![LJL@UUJ7*=B@4'@#A@D8)F"8@&$"ALF5[5S6.4V,-S+2@B"6
M9RG2&9?(&I(95G":N;2+(-B&#1-"]QA8)@/GW37'QQX7#X7(V&-$][?FR\XF
MRL.HOKHV+%:'QKJK.-E\:OZ93!?S>JXFUE-'=S$SR,-"'A;P'[X=.2A#K1!$
MZ$Q11(7VAIJB! F.*>)8942GRF%6=!%!6C'S04O,'Q:GVE4?B\;N^GC!QC^S
MWUHNOVR:X9]F,<6(R71$\Z[.A(5$9I\Y"4 %1;O+^(.BW7:J1A(J4X)HFN>(
MY85$0DJ!"B>(E5HZ)SN)B&Q!T9(13O$HR[;:_ 84[5/WI?E_E0>I^?$N.'[W
M:#3(IM&03P$C]G>.A=7:B\.8]LNY'Z[Q _U\XA)EPF8Y-3D+D93)=.Z_%.J0
M_ N4GLB^5FK<G*4; C#S$U>[0'#-5M'FF-VBG*B)*?U%=8C*-@T<]FZ+C6_U
M/9-.Y@NAG4^8"ST>XY1Y\8>WZ#99QC,^=DVP)^>1W9G7G*WB0:KP&.^K\7=U
M5K]ZD?P:/65L$,#5REC1:EQ\NKGE\90JW*-__/W=<?+QP^'']\G'/_YCE+S[
M<-@=]SUE1-WPG%R;'!M#^K+^^'*A-;Y,BR_^3XUIZ&V92&5^>%GY'9\//FC'
MPXO!)T<7W>YB?(O"554S_I!)"5F3YJ<3?R=7U6U;"ODJ:?LS)2]?NZ(TY?R7
M 4SM7:.HE^\FWFJ;+FHOY'J4N!_&A4X?3:6YG\,*9+IMUZ5QW%8/N7RFB5K,
MIRN7.#S6F^?[^%5S.1JKL^EBOE^4/YQ]];VT\Q./2P/4\@LFU$3,:K=?.V^\
M>Y9:O7(3I6GO_>)Z,OQ;69?M<:7[J^_?DA)O'T?)GLC9[P)*MT4%EF/:PYC>
M<PW>8UC<<XW<(^*^9^&]+,L[&8](LWNN$7OYO<]ZX'CD?<]Z&#XTYQW<ISM\
M1!>OU>%PQ/WBVNAX<+JYZ<SN6SI^/.3QX_E).4V^QFJ:1^:"\BC#?GF,F8B=
MA]0#&/[R^Q?\Q=JCVP]LJK<"(A;!;,W:?8AXKSE@EYV<K64Q'M1<KW<"CX7>
MEEBW1NW/EM03SQ$!:0 S#H,9F\I9H,(^+CZP]-;'9W0=?-:[.1P)2QU86X::
M$S7^;UTEO_[A2)768[6=(\3Z(3E@'V"?OL_A6-C'F,7I8JPVNWFH=]("Q@'&
MZ?L<CH1Q/D_G*U/GMOP[L-"66&B[F8W>R6)3R^5FJ1KHC5[K#8C[K7O)-%M&
M-GGT"43\P (&)@,FZ]X[/_5#F .3#9+)((T+)!BU:"(A03#G>KGLP)P#)HME
MMD?"9&#. 9,!DP&3]9_)#M4LM!D *@,JBP=4H+)>S?9(J&RYSQNH#*@L'E"!
MRGHUVR.ALKM:5P"GQ<]IG97?K/L8RRVQ7R1+[#<U5A/C$C5/7COC0H_*)"6C
M)-2N17LPU& 5%@#;,V!OY=AH6IG>T\SW?EPWTB+P(>*]O96OS2D6UF5($*<1
M*[1!,O._<O^Q)#IE><9NM/*EE!A7,$1DIA"SA?7?T1IQ[G(IBA1KF5]OY?O9
MG<ZFE:K.6H.D3>!=ZN%[3]/>=Q_>_K1M+Z6CG+*1I!&<: 1, < "L)';>4^B
MT,V?8@C*<9O*,1P;8PN&4:HT1LQ@AX12!*6I5W)8.T7T.I3CH:JJT(2ZS0T?
MS.=5J1=-O[O/TR.O&2?SJV<!'K\^/^TOO:PT4?ISG4E&DE'0E[VB]757"#Z2
M938@DUM))BZAP&R/ %A0E5M5E813DSJO&QG/O1^9<Z0MMHBJ/&>:6ZNDO*XJ
M-7>&%T(A;2A%+*4I$ISEB+B,$,,SKVK3ZZJR:\=14#%*.SOM!7@A/EX 8'<3
MV&@($[S&'5.%3EF%B?4N'W?> TP-4D8QA+.<R8QE7(MN5.&E5@FMX]B)6TA
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MWG*5C@05VV^[.CS%'\W<_04LA]U36R""K8L + >P'.ZR'#21E.C,HE1J[:V
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M['D[@MIZU.$V=2V[[_2GCMQ PBX6V "*$OO7WW,R$ULME$062125,^$6R2H
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M#:6FDJHXDR0'/4^H"%+"_2PB>2&*0M&4^NFC:?@@7&3AH9!)G-A[? W_8#E
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M&K\5_4=]7]TA@2ZB7M)*UZD8=VFZ&O,9.DKP42FT(P=?6<*1T!YLI=6L=E+
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MLYR8UQI3JW=4NG95 RQFECXQVJU'HGL\-A<[]-YTKLA JP[%1^/@@\LPP/B
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M,\5<&2<93\U(%U#(.HP#'/ZQO>B@PQ>3;;73NG1IP30,,<Y*?G58(C1A">P
MNAGL[%*G$B^QP4<>1WO4.%B"A1JZFP)U7#>5SA9J8.BIL<9UWZ"!X9^R[3.<
MJ\KKS.T[6GT;Z#C=#!8[0G;MBBZ.4[<;PPE[(BXJ.,(&=Z4/9$[A[;76?S&:
ME='#)X"L07CN,03$Z8=7WR_N"/>\Z-WD#V]>:0]Y5;7:K^@R^".@I(7U9[Z8
MP=<K!NO7ZNG.K+Y3@.S?HB_?CRXY^3F?:>=?_Q_/.[0S%04R"P,IB4J*C% :
M*\)4'!$E!8N82"57^;V=J9_T:$]@J=,>;/;@Z<KH:%%>OMY#^NY/T8G7$]4;
MJ/J$F<@OD<\.'/,S[@J:!+^M2H2^LN-.7H%QSLZK88^?8[+Y>+?]S@[WZ55=
M+D>IYGY8CIXD(6WJL!^*W*-T>R_PVYU#-^*5G^PW>T89>7@CB"/F-5>H%?$9
MP^SI[IK%,,1A-QON>7K_++0.*F[F<FA L^7:8 7:U9G9QWV>D[5:"P\MCCJ#
MTZ^KGTN!]90$"Q\7G:VRI?4;/<-(CRTJ*OV8C??6(QZW%H1.GUW-'ZOJ([FH
M/MJ)(,;8L-,(K2U>J[8:P"TW1C_;6T[W\\(VJ)PO*PZFAVYD&,VM[F 5+W&$
MEX&+NZHK=,ULYXH>MH=C%?M^:OB6Q-:2\M(@'=C'2DO-Q0AK0Z%)U>%L]-_;
M\Y[6^L)/M2^,_CM6I8)';5QBO!=.1/F7N9^=MGTSA@P9]7Z7>GR(GET-1U6U
MA\%R^];,=RSIQ7I?;8./P<DZ+[J?FMZ-GQX.Y901K:EOK??1Z7Z@EN*GH-;N
M9F*6):$?YY2DLE!@KA:<9#GGA(N(A8)':9K)+1-7,#\,BIQD:<(1WP*ND2(D
MA>"!$G$<<KF5)=,X!B8^_5K7<[S7!1.FJ1B6J3]JOK*E>!/0@F:+/,COT57\
M)%G1 <ME<T@9AI]0"VY/P;#1+;5SMI'E9OCCO-_\H3!DYG.ZLCQ(\BB@A(9Q
M3B@76 8K8^(G6<8#FN0RXING2X91' 0A)S)+X70%OH33E>8$#EVLTH 6OI2;
MI^L7:Q2<KN1KHSO18'ECL$KV8L5$$ZR8Z-:C%1W;J6HOJG6#2GS>ZV3-R-+$
MH8;#]@U8,])4P/4PVFJ%QW\36<"?.S[,KQNFW[,__G&4^\SG@J0LRPA-X:<L
MC4*2^6%$N8R9RNB6<DV24!4Y*M<4K_%SDO-<$9%G6<$8XTFRI5R_\O@_%D;'
MTQ1X])DQ[3%V1VAP5+9LO"WG\ O/6S!O2IQX[_6XJWFO<D#DOFU'-JUU<*/!
M/^DZ_Z[8S8Z;8,YOM5HCOC'#*MV52?XI;2T]?]-#!B&-"E^0/ (10F.E2!9S
M27)6!"R/5"K%]D2@KS#L=>SZ5!/8;M=?!S*_51NV_(;<\6^U-0*@EW\?9+HG
M,3ATH,* M78(VQ>E3DH:GL14=U?FWN=[I9Z*/NKH'JG_:?0#,>\4> 4KXRJL
MKY#EGS\;YR)1J9",A")#EI09X07H4?!/P\ O!"WD5CV;DHKF//$)&,R"T#QA
M)(N2A(0!D\#%091AY>>(C=]W]!]I3]"EKWKB_[6CO1V,_F7PBY]S5].3]-B8
MO ->' 4/Z[6I1ZBK&[;411CP.78P8X&&YM4A"-=%[QA.6S#0L&:$2\U6YWV(
MT\Z%1 &.44XQ&MNPK#YBE_,YEGZ4YV6K&\,YSK7043E8WZJ\7%]VDM^LZ>9;
M.C I5V$HLQQ.B$@)+?*"Y!GXD$H%C+,4#HV_)??34'&0_: <> $'AC(??O)3
MPH,DS L_ <]33@[,7PV9C?C_Q1!YM\R_R[F([@5+^J3G0DY[E4S-CH%SZBS*
MJ?"?A':&@'W/N,;.,6U.5U?+&UT'M76B"+\AFW^S^F.]:NL;_-S^:(N7L#YT
M^8/W(C X0-M']*OBZAH:V#N'EUIUCUS8>K6K<I@8H2$:1O=J?M2+?!&:16B8
M4#WC8FLY<#>X]8N'ZA5(_3C.TIR3% P/0D.>PJ'A&0'&IU%8^'"*BGL;2_:<
MG/5;:D*@;ZO:&E#RO7U;!%)]6]9-.VB@#W",METU8#=DL=E&Z$=S1(^I2^#[
M[N!V>8,"-V-LC.GBPXV38(_=]E&8AF\14P.K)+==F W_I=-]B!@T3B/IBB%;
MW8"3H%9KM:$_JX\$;WI92M(J^.9T8K.TL/,ZFVKJ/*UV10E3"@TQTC]E7I@?
M+C5VA\&3.E=I\P6]%V&JNZR:L:,+3 +ZUM#('E#3>9]G_:Y#S^YHB*).(S][
MFS!/DU2($-1;7(!-*!))..,^"8(T+6@J?!EL.5%Y1K,\BQE)!"\(584D+$_A
M%E'LITG"X/^3#9O0<A9X3K]TOL [&XR[5Q!R]TN%8:QX&%.P<;$X3P4Y84E8
MD#1GDL&:)8NWBO.BF*F %_ ^3$2$\B @/,\I"5(>A1QL8YF(1WJIG9'5XS)Z
MS<1#.UY43ZVPM?OSPHUTB%#/$1$J=(A0#XL(Y4J-[U3S^;Z BVM$B!$GKC!U
MGCM]YW*SWN[]^MI477 )AH5.)4XJ10W'W%*C:NI.)XSU8GKQ\%6,HX"-L90?
M2ZEN22>4_YH 8VLHGK;DE;SQ9+W6@PU^7^L!.O"HB/YX^OJ5_O?[WL\5"%0K
M=?16EG4_N;MS4WN_V%8XCA%LW__]?PFL5R_)_!P9RWP4?5KA7;J8&3Q]QW.-
M7[V/?'KRW:W-=;#*O^K""SV684\@SM#'S"?OZF/U?E@$[O$[=R6[U<>5 26W
M4^Z6)HYF5ZHC:]V;]62"5X07LE_!Z@@=)#@'Q[ZUKEOOS^VOUL5RUC%'X!L@
M[72S$M:<WGA72]:B77I[G>W6TNPT]8VPG"&:!HUGRZTM[X:=>Z]>!V%DN_/:
MFGFRPI2L]])[\>;E:]UY6O(:C&S8IM7W??O39I6P[66$=:M/5]V7&E%=J:YV
M;D0))B7^I[MR=RU-.WZV.[ U&*C#=_  F^0=UI?>C'NO]#-MQD''?^R.(97'
MIPTH!'MWJ7%G!R:[362LC'08#ZG>R]KP>4?;T4OVM<NC.8N[Z#.-1VUZP_!V
MV%").XHMI,/HIH*5];3><._Z<!KA)F(M%JGCE*[FEHHG,^5R6,*U\NPURGH8
M%M++KM5,"\3B7]M;QSP.AV(%%TQ?$GN0D5SVNK+M&NL&/!#P[52],CV =NPX
M'J=.:/0/_J+W:)H*CI(&_^YZ!GI-H)>V;K;G3.NBSBN386S, ,1U7TV_,Q3S
M^=*Q8=SFT.PW:O&;@)=T<@!TY@7&%U&V5(UK;3U&8\74_GQ>E$RY\(K!J6#(
M UP+A.>?+A5)RGA*$Y)G.$Q+L(SD+ B)'TH69GF<INE6A6[.\Y *$9 \S#FA
M-(6K@U"10(0RIC+)531-E]JJ@2'3\U;MK\K]F@F.87R\J=)1VA&KLCJHC8]:
MK%EA"-+K<R+N=@FW4\"!:&N,[ ,"K:\*,#U:71BF_HE% UK]:PPG*XN_C8(Q
M/Y*%3('_N<2",3^3) N5())%D9\$/!1\:ZQ<'LE,,2QM+U*$FXP9R7Q?DB2C
M4H8\B,+,GYR$WPRU[8'XPGJ!SXTQ/=XST%FQI9WXNJ]GXUDQ&N-!(F-?D"*C
MA1FIRU4 C!;)($_#C'*U514=499D7&:$AC(D-,LHR02-",OC(H\XB&!93!CM
M"V;H?K#]1?=J.0K"11##?S0^-AX<VH[ZL::W#N;6B$*#_?_\!:( SO)I+$C.
M.<4$4TAX01$"(@6FB\,TYEN55-2G7 24DT@QS)KEE#":AT2*3 9)P-(@81,^
M_0QWFHZYOR'1#V,P^,<K+$TS7(#ZN8N%:03F'=7@UG_#O2E7Y]H?[]RJ(>T-
M/#\.2ID"073#^]G1WP2;AWY>Q&D4$15+Q$D-,#D<2Q(68!I+%D1IO(63F@8B
MBWW@ZRP.0>\G8 $P14$Z1S[+XM3/4Y9."\4[FFY6TAZH9#!)CIFM1Z7=7;C!
M5!P5U;K>#!&>#@$?'=JS :U+8'L^"MKI@CIO52$2V[*W<G57>_^T\<WT7*9B
M5*(+YV?)UBMQ@0@#8R=1(Y?A*;,^)1PD#9CP%?6_\,Y]_:\M0=E5![Q9[#LI
M:GJJRDF]M-T%8;JHTL1.\6VT\ZTGP0,53*WE0Q4P^GF2!S07)!6(^RYU!W?B
MD\2/TB!C>5;X;/,0LX!%K. Q"22':T24D"Q2</"S-&$%G& XQH]0P#B4><SS
MH :AJ08\RDK&6[CU1UUWNUVDBQ%?D-4(:U'5.O8-/C7KLQ]E>V.K=J-=5QOF
M;]K/EPSO3H-,JBB_KG[2BJ.[UTT^>U6O9$@E2Q(2@T @-,C!\Z)2D<)/8U4$
M4<'R+54?^TDH"Y:21 B$1$]SDK&"DIC3((NXQ!*LB93X,*+S+X;,[_L-F6C[
M*[#1>G5/PK&^#V\OGL+D3'MS;!I_U,N");JR6O-!M4U*=)N.><<!KRF2SDA;
MF:Q4^_^S]^[-;1Q9GNC_]U-4>*?WVA%,=KX?5&]'R+*]JUFWI;#5/7?^VLBG
MB&T08*, 29Q/?T]6%4"  "4^0*(*S.DQ10*%0M;)D^=WW@>^\#YIO3TO%G^;
M-F-E310W-M[IIN%^.SVU":^V4V4Z3@=Y54]S5]T<N)KMCF9E>G<=>&_6!=\>
MTFIC:H &S<2(M>3PS8*.)NP[GC92IMNQM^_?W="@FK#5]?3%9=I<H]_8?^8P
M%JAGJ-G1I0]R9?6\J&(F+R5H-AY)'GE6:Q+2/AI$'=?2)4HEW^I.@Q5+)@6'
MP R'S\BFWEYK!(**4.&4C7+3)_EN$O-Z'E;C=[SV]FX!<5SL102CP&/(D#PR
M28$&;(U1P&/>D42X AOW)GOIB%/DG"&CA40<=&7 0\P0]M)&,(>3#8]CKZ]U
M9=D"PM^&UI^A31INZ@U A$W_637-S;<Z+BP=XUMB,(>'<MA^*].X!(?W61UR
MLK*CFPEM35'>1I'(K3AY2X'(2ZV\< S+D 0HVS$BSB1%)B0*)K>BR1EO0(-^
MM(1YYB*%_HN7K]<D/+P#[XM/;OXU?IR^.8\7U8^C:=-3U&<?^F:J\U%.?"VY
MS@_OP[MBFF]E.'^%N[Z_>;/KCUZN93JU*23K2UU9R]=)T=^W<-8TF/C?TUFT
M/]P]3SI[U7]]\Z-4&<]VIR5W'OFLSOSTZ_]&Y.N9S:OUY;R[O/.;SJYE[NNJ
M-6Z69HUG.</GBF Y4?%ZS>.<3FCKZ:0Q^<$\G<[:GANWC+QH'=47TS!*5[L7
ME2,#38??MN5NYU&['H&0[&B\Z*+)NV_0K'=]8UP<CV(S]S;?]4:N:'N/R3^S
MM=O&0T#_&T]MR$\:EBD_6]]R/3JA>9C1^@*:J$4W2Z<=>C-97=24N[9=36[9
M$S@/OT0W6XY OF\B[^U'X)94WF4F^7-E\GYE@267=_^YO+=3NR3U%KOMSDF]
MM_/1CK3>%^ M%-(*KQE2$>PL;JU"3H+9)8G2UD@3E=XJ<V<N6>\Y12K/Y>(N
MYGXN3(*!)H-D*D@=Q7:[S68FSOM<&_+AVO7\OAM,7O\RFUZL7[,73R(^'5R&
MV6;B#FXDT?%S(4O*ZI \4IJ$W#C!(4W FB<QI]DH1Z7>SJ?!DEFI'(J$ ><&
MCY'3F".JHL$*[A;8CJ:O!^!",UAW]BI]K,L96X^Y7'8T6VFVRXJV?V5IVTX6
MW)''TH: 5D*XR;B9K 8B=K,"7T0.6=">4ND4\C&GDD@GD(9S@'22U%!L;=1^
MR\V5$U,RDWN1>=ZHB!QQ!!%.A#,X,<-O],_:V>7X1NK)STOJOP'B[X7EU6!9
MON\AWIU##9:9:B^J]D(9QKS1&&FI!.+,,^2,M?"GUY8$QR3;"D1);'FB7*%$
M<E,?R@ S<H"4Z.2CEE(3E9Z\]J)H)0/A, KZ+#4A(B%SS9J5P&'1$Z1 0D="
MC9"$;4EH9T"=CA+1!&HQCQ(DM $A3UEP4H*^S&\D"#X%AQV#QG$'F_XE1-NI
M<-B :INH]L!.JC'/<D<Q';GC4DBY)\7X(<-0R+T"8\.+NZ\YC[KY",O1KITS
M :Y;@"T\;R/QG5_PKHIPYUC[VK2$G1ZG'A'H3CFF+R7QR@O/21*@QD>F$1>@
MT-LD0%=/*5$2;;1.;,&%M(+9IHLTE_DS"?3_7 !EHI',&6-R >FNN/42,.#?
M[&'.V>-O6DOLM3_/48(]5HI0S8>KLP#OK<S-T75J\QJ@G*SG;F>P::LPUBI,
MFGA+2]:P,07R 74<&^G3N3)CO5RCF;\.3[WYXD:]QT&[7W^U4&.C4>Y39+BW
MZ?=/50_B;0S.!X<""8"U$I0XYS%&BFLF(Q%1T"UU[SZNT)=<#X*/M1[D]JJ.
MK]>##,G/L#O=[499Z)U#=;LRW5;-AOM-E)>9CR=T4A1SC5),(..PHV"#Y!%K
M+"9'(T_2ZJT*&"N4$? 9YHW-=> .N<0B,EI+ ^_QI/1!.R%'C(W!U"!E9<XT
M9 %I#4L5RAMN$PDT;2<9WM?[6CHAET[(I1-R#]='6.F$?(!.R"4]Y9Y)HXU#
MY6:FW/0R$S2WX?@$Z++*&UO+A-N<[&XWZO&NM;.-A--W<%-8RW::Z7(DYG4&
MS;OF^V_+FZGC?#Y^$6WP5$P^J621$40ASB)&3EF.-*-&$BH(&'_;8_945"8F
M9&3*>E'^C8#:X9F@EE'X*9^^^=>  U!-'>=FL/-&3SQ@1ECRQ_.7UR/,I\"U
MCQ8I87.LP'M@19>0M4QK4+Z%X5O^1Z- U67*(.)E1#PYC+0#M=T)SK70EGNE
M#M(CC&%V JKVT/CTG@W";N^F?;L[?26_']ZTH6T%T*_:^F4OR[5GZMKSC"8^
MI^:W%&B#"6F4UM;?)A%=;4N&_*QV[3N6^<1+2OG1S"\N<JJUSW[5%67CE^SC
M:;+F<VIPVT-[= .IUQP>-\&SK5YX&0FD,4E.%/%(J< 1Y\PC8[A"@AM-N3#1
M;L]K%S1I+C@#0]KG=#_*FZPG1(30U#&O1:(W(Y3O<\YY#$V*7B-FWC7;4O^\
MW*N]0*,>;N2\.UQKC?I?7\Y&XZ[T OX$W;SM K&,/*X5R/B8D]SMVJBSY2':
MT!)_;EK1K]P:5:>67!<6O8C,(X9)P@EKA"WG>2P609H#^X+>YQB04ANVE;G'
M:-#.)(."SET9.'S&:8!<RQ6FT5/*W69+F(;43])?P9S*H?+XXK(#I&AGX]&-
M(-1*K+=%U^M]"M<C4W HVH'C^3.I[0URW3WNL@&+]IVUF'YWJO[?NHD 3"<=
M?L,]1IL]5T;U]KB#[MAEP)EN-5_Y>CE2OM<MAZZZB.U0ACRR)#5)!UUWW)P7
M^+'[&[ZQ-0M;])Z-/K45/BUXO?[C3:6)..EU,**]>+- =2F0?EH]41N.^%\Q
M9#5G*9#Z_%@YL)0'SRS++V>Q+1NKW&C2,&W#++8+RP)W7C2\-YJO!5+^W4Y6
MY76GU>OK).RUG1Z/K!N-\V3*99MPX(W_ZKH='K^P3BH0$A5'-"F'N+.YNZP@
MR"KO<3"2<ZJVTD056$M82F2Q)6#9@W[BA,]^?V%P$(2S9&_J)]><^&M'\-%=
M9WM_0UZST\&904MYW39 SK(GU;%3->Y0J+?)UA\:"7<K/Z,+, X6V:8">1FM
MSU.&+J>SII@XR_R3=A6M$-[LD[]R?C7%S=]W2_@A \?T(BZ%R%Y*!ZN_+Z%K
M*W/C[?MW^2O>^?FTLRVZ4MG;!'_7"0;4MX]M]DFL%^-Y:V+E*N95 ?:FR%\1
M[F13\&SDDW>RX?CE IS]%)6TR"L/<B$&VLYJM=1%T.U\(F9KB,5]HII+N?#:
M-VDTRSRM-SGV5Q2YKD;;=L3)UD;C#_A:?D"NBLZ5_)/YN"O/W!05=%.5VLA:
MF,6+KH' '?(7MLWYKZSJQ:4#6**IY!HC(2T< N\4,EX$)"TFFAB9.-FR?GJ4
M#G"T[7FV<JK"Z%..;?X%_MUGFAQ/SF#0FG(+Y&S)*A"</!"DG"3.2F'Q=@,X
MDGLZV>21L#GL@;W,%C-#C!OM S$\:'-3</X,SSB_^EN<GT_#VU6HJ_YI5.=6
MD0#X'^#^/X[!#/NNBB ]+W.P<;:(WSTX3O\\0=I^="KZ[J_\M/KWZ0BDVS^
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MB'D#&?.[C1OFJ:-(=\S+'\BX^K[HZNM>_X,&">^4KSV\?1YB!X('[>;PMJ9
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M*.$R,JU,2A09FS#B0G-D%.4H^8158$2XL)6-M7>_PY/!I3DUNJ#EX-%RW8$
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M@@?&</!;FM_C^?&]G;V;-3DDX1^9UGMK)('QX.JCUW+O<E-.-[6SI@UL&,U
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M$H>"8\'JY(BAM ^\9*,EZZ?)S([N>19!7C/.Q9W&.:CTH6ET^'P$PSQ>-\;
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M_1%>F!>",@70"Z _1$4J&226GJ+@+ "ZH0(Y&@B2WC)0GL%AMG'<>.\6[#,
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M'/D'JD2*8(M@AR78 <)>?Y#L\?9KV0P]L5Q+'+8?6^JWV,3IY]CU@;3>3^?
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MNE\MH'\#Y9J=0G_YMS__Z71V-OK+_P]02P,$%     @ C#Q]5(]YQ)D*%
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M[+:4H(:P]O*@5Q!)WW%H!"I%)0+T*)I.;;J\&6<X*LMFWT]\_4&2AS<2Q-%
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MJ[A:4A8RUN>D"FG%''ZGF#V &04G/KT&?_=!]!WSGRE!G_M;7&^U'':(/<,
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M1VA!7%@37UWG_SWBH/'I_U!+ P04    " ",/'U4]YNS?*,N  !.=0, %0
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MGY%7>N!J0=RV.PD\550E=GV1Y0@*Y=J<+0IO(4S\C7-$S"-HM;-6S%8P:6'
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MR)3(%",J1?(F(#&_N'6#WAY?-&N2;3T>0,^' W$Q:_Q@Y27NRM0/@_YR+7Z
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M]WZ"7@MGN#&C'FK\_@*.^N4V2<"6A =NXBB1_PF?6I"VNDP<##022Y:[*+,
ME3?EO6PXO-J^/9AX!05;ZJB,O<4VPTB7+Y9D"<MT'H3;K-9C>"0Q:Z[JRVT2
M,;L!#;C5"NX(I7U6'CLM7QIP[]7HTA=I%JPQ)O4EI:MM> T'9IV^<!B-7C2U
M:_KDA4+_>@N*C%<],>37C_Z!2K_ &9Q6:-,V>U4.H6#M0[A8K2C+05 ^'8QI
MH3H$=VH8,/4(5**U%\'PYP$\#7PL2WNH&ZW!%NT3C>#\"6&NY_XZB *<711
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M?!78%@^Q  22=8U5Z]G;V#WJMA=OC(T@WYZU"F[%H\.[I//-ML_&:'QE?+5
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MS0*[9B5VSK-3)0\3&BOS)V4?ZFX9P_M3)L4X3K.(>?>9%EVS;FFR]B)@YSR
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M/EA=2JMOX8_O/_Q:+:'#K]O#Z"H[V!%L?+'2:O4[>?.0,,91^9V!M/&_="0
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M ]ZU=UV=<5?1!L[V:_I"PX^=C$,-C(?3))QH#Q:A16',]@) AWSL-QL]M>+
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M'95(Q@_Q+4U6<;+&HATL'D@[8PBHD#'JX-KH1F6#'!\F@@@.>#T3XX'K\'U
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M6,#\(TP-;US(_^-4&C55*&D$5(18(:6MC,+V;VD2P^+\"6U0!Y!3PPL[5S'
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M3<9FSRY-/(P.)Z7Z_*M#^<)SN)&PL0PT(1J0S&A1J:\W4"T80.O&RR,_A[*
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M5G:9_=MVQ9!Y-4>GU.I!S_#P,T^H7[L34'8L1(MH*(E(;53\A:R(=)WUB U
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MOS7U+ G5-BDK&IZ+NN:#?['7,1U0G[ 0O%AOQ5Q(U67]5(J+#.;E\GTC$>/
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M$FL^&C\HCV\?E$/NLA%6U9(>]SR[4%?9:O.2B 6)ASU'MB>=W0YSM"U;7/\
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MGJWSLLPRQG6PTG+-NALU@_JO/S1C$I?P/__\']6_B/_ (?+G?P%02P,$%
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M9 &BD>LDA1NL G]-P#(+[N .H$$+M3B7SI3)T=3,!@ ]=[. HY-%SP'N-.P
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MNPH+&C]FR4%"3"^-H9^6-U^?ATGN6\.ZC/3<J(H##KO$1^"CODB<(U.9+V\
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MRMSWS[&'A!B?O#(6'#MA-X.E4>DSD[\$548P?41EMZ^>_5 !(?<.;]44O-G
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M&#3?$4-DKC!E *F4.QNCNN)(T;,*+UDN 2;#X\8\HC/1B&)2DV$Z#&D!$&7
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M6MP#%6[WGD3TQ_ 5M\"]./]^!#^.YG^&4$R=.C?%T7< _2HLRN:?/E"VXM%
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M%-YO\X_2Z#I)$J<5?03]JZF+H%]]>\3F8HJ9J/XW76J2_)2HJE#SKP:3]2<
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M!@0V]OGCMK<!2,%AHK4T9Y\E5<H/B;&X-$!O:]"!=?#&"UQ6S79F:[YB:FU
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MP40^'K\ [_,9/+T!^0>K8*_.+U-IZ)ZREP3\GN%[88</I#-YZ"S(570!HX2
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M8\R&M2U?#YBO9_O,U\]/P/TO6W.QW@A1<-)Y+O#2 _Z6<0.>6D@5D4@@"C!
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MQ:R/H)G=X.I-V[]"Q2G/Z#B@P4R_)]1HCN[K)!A3[F/_V:$;HQFEHKCOJ^&
M#9:-_>O?R^9H\'.8;<#P"M#V#OB5X ^(R9C]Q TN/X/+B UZ@]7WT[>"HYW/
M]?G\CA/&FE>XFT6KG:2](]V/B_COY%@=FVK?H:M[:#+SQ[#LZ?C;B?Y6LN[%
M%RY.[ E[YDL7J_AL8W\;*]I):B>IG:1VDKXQ&._<EPO;.->RLYVD=I+:26HG
MZ2#BW/M"0,X^+HO\G\+9_9?B'?ZDJO;.E_R_)Q\VZ$#.*99IP91/(("ZPW,'
M)N9RSA?6)PCCD_!'4L8G_L^K_!]02P,$%     @ C#Q]5+TMO7H-!0  LC
M  \   !P>7AS+65X,S)?,2YH=&WM6VUOVS80_KY?<4B1(@4L69+MI)$\ Z[C
M8L':N(A=H/M(2Y3%E:(TDHZM_?H=]>(F2]*F6+HXA1#'CL0C>7SN>7@G*1XF
M.N6C7V"84!+A)PPUTYR.II^LGF>[PVYUB ;=VF*XS**BM,Q!Z8+37P\TW6J+
MB8@*[3NV<QC$F="68G]3W\7C7 <ID2LF+)WE?G6",T&MA+)5HGW7=@=5EYBD
MC!?^@J54P07=P&66$M'T7F9:9VD]0#DGX6PE?&E&"0Y&0S-&X].2A)]7,EN+
MR HSGDE?KI;DR!L,.LVO^RJXUN)TS ^>VR1,4TOE)*1^+JFUD22OO-M4[HI,
MIH3?7N/75G PFFX3MF0:*E2-[6C8S?<*QQ#GI7+?@9Q,+Q?G;\\GX\7Y[ (^
M?+R<?QQ?+& Q:U']#ZBZK^&C/;<G-LRGDQ)9MS=P.C">P_AL]F$Q/6NA?B2H
M&X!/G6.8O87%;U.8CR_?C"^F<VOVZ=WT#QA/%J;%<QQO3Y'F-+ZUX]X/U\.Q
M>?G"/7:"9[3HN\E54<CY7VEU+B#,A*"A9IF #=,)Z(3"6(@UX7!)\TQJR&+X
M4&R9@IDPKJV*#IR+T(8C8_KRQ=9SW#"89&E.1%$=1L$KP/'>HD_@.M;O$&>R
M'#AF*L2!"THD4(Q)!&<TI.F22NBY'22OYP)1:,:Q:>?.G(9KR31#YXF(8+H-
M$R)6%'#.E"EE7,>7L8R(II!02='G&^Y52]EYARN D$K-8EQ,OI9J33 \.H,O
M6YIAU4E0[VCH$XFR7*-7UZUK&R-*G+!TE<@E$519LRVG!8S#$CXCR@ZV$^W_
MBZ81NVI841/)$,;OVP/O]6$0,95S4O@QI]OK-#V^FZ9_KI59$9(*MS2DN^EF
M*4VD#DHR6LBA5/E+HJCI>R=U4SRQ89%.C ^]D\/GPN4&*B9*6$K$OFN KX!W
M'9.3@>>>O#[NGWJ]D_Z)-S@T>=!NHGHMG#<=VE?8#D8+9&TM]'C->8$;0IIS
MH[6=_B3]:\TD31$69>BLZOW"[1T1%+H$=W 4O=I)X(M:=TJM=>">]OJ!T?!.
M!0A8_=ZJX2=1@_?<U<!$;/J6%#?K)^AQA&=+=C=2(4RB5G!F9531,<V$<\!N
M5#),<=B0HTQ4I\Y[@HC0G,<!(U8.;5(96JUY*8TLI[*<4C4ZJC.J?8]6]KG
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M:LJBD0;I4;ZBN2K.)X-.^47(0:?X"N5_4$L#!!0    ( (P\?51I5 ?]E!@
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M<8VMG'SWXCFVX<<T%\G[1:V;,CU(=*[KXWHQ%P^.8OKGX<G&=[.')ZNELO+
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M UU!(8C2"I<6[Z\T#@0T%4)Y.FHT!D;-Z!T_ #=0Z]>8WO';#'9HDUO42#!
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M:_F:';6DT5%5MTYZ=(* !,G :O,U8;!E/@)^2WE2Z) R.7@:,P&ZI13E[<[
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MA[E.UR_^]/R'I2WR%_\'4$L! A0#%     @ C#Q]5 BZ["*D:@0 SNH$ !$
M             ( !     &EM9S(Y-C<W-#<W7S N:G!G4$L! A0#%     @
MC#Q]5,5&,2QLJP$ _!$# !$              ( !TVH$ &EM9S(Y-C<W-#<W
M7S$N:G!G4$L! A0#%     @ C#Q]5'BL.[N_#0$ ?(8! !(
M ( !;A8& &EM9S(Y-C<W-#<W7S$P+FIP9U!+ 0(4 Q0    ( (P\?51?>=FS
MYXT"  #T @ 2              "  5TD!P!I;6<R.38W-S0W-U\Q,2YJ<&=0
M2P$"% ,4    " ",/'U4__P2%I%$ 0#]K $ $@              @ %TL@D
M:6UG,CDV-S<T-S=?,3(N:G!G4$L! A0#%     @ C#Q]5 #EF:1% @$ .%0!
M !(              ( !-?<* &EM9S(Y-C<W-#<W7S$S+FIP9U!+ 0(4 Q0
M   ( (P\?52+(MS\;,0   IN 0 2              "  :KY"P!I;6<R.38W
M-S0W-U\Q-"YJ<&=02P$"% ,4    " ",/'U4=@%%!.O8 0!&10( $@
M        @ %&O@P :6UG,CDV-S<T-S=?,34N:G!G4$L! A0#%     @ C#Q]
M5!0!Y)$*30( N;," !(              ( !89<. &EM9S(Y-C<W-#<W7S$V
M+FIP9U!+ 0(4 Q0    ( (P\?52.W_J !4D! -:= 0 2              "
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M-U\R,"YJ<&=02P$"% ,4    " ",/'U4;D$B/XX& 0#J8 $ $@
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M-C<W-#<W7S(U+FIP9U!+ 0(4 Q0    ( (P\?51S&7^AL;,! *P? @ 1
M          "  4($'@!I;6<R.38W-S0W-U\S+FIP9U!+ 0(4 Q0    ( (P\
M?51*:EB=*VX! -HD @ 1              "  2*X'P!I;6<R.38W-S0W-U\T
M+FIP9U!+ 0(4 Q0    ( (P\?52S!RTJD@4" #EK @ 1              "
M 7PF(0!I;6<R.38W-S0W-U\U+FIP9U!+ 0(4 Q0    ( (P\?52E8,+L+R\!
M #B6 0 1              "  3TL(P!I;6<R.38W-S0W-U\V+FIP9U!+ 0(4
M Q0    ( (P\?51%G4,#</@! *QN @ 1              "  9M;) !I;6<R
M.38W-S0W-U\W+FIP9U!+ 0(4 Q0    ( (P\?53(7)^LAEP! &B\ 0 1
M          "  3I4)@!I;6<R.38W-S0W-U\X+FIP9U!+ 0(4 Q0    ( (P\
M?50*9*QG^_<! !-6 @ 1              "  >^P)P!I;6<R.38W-S0W-U\Y
M+FIP9U!+ 0(4 Q0    ( (P\?504;C:QZ88$ "8,,@ 1              "
M 1FI*0!P>7AS+3(P,C$Q,C,Q+FAT;5!+ 0(4 Q0    ( (P\?52/><29"A0
M /'F   1              "  3$P+@!P>7AS+3(P,C$Q,C,Q+GAS9%!+ 0(4
M Q0    ( (P\?53@+ U830T  ).W   5              "  6I$+@!P>7AS
M+3(P,C$Q,C,Q7V-A;"YX;6Q02P$"% ,4    " ",/'U4]YNS?*,N  !.=0,
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M>#(Q7S$N:'1M4$L! A0#%     @ C#Q]5)1OC\;1 @  M0\   \
M     ( !BW O '!Y>',M97@R,U\Q+FAT;5!+ 0(4 Q0    ( (P\?52U0J.[
MRP<  .I+   /              "  8ES+P!P>7AS+65X,S%?,2YH=&U02P$"
M% ,4    " ",/'U4S-6QU94'  !E10  #P              @ &!>R\ <'EX
M<RUE>#,Q7S(N:'1M4$L! A0#%     @ C#Q]5+TMO7H-!0  LC    \
M         ( !0X,O '!Y>',M97@S,E\Q+FAT;5!+ 0(4 Q0    ( (P\?52(
M :T-SP0  $DI   /              "  7V(+P!P>7AS+65X,S)?,BYH=&U0
M2P$"% ,4    " ",/'U4:50'_908   LJ   #@              @ %YC2\
D<'EX<RUE>#1?,2YH=&U02P4&     "< )P"J"0  .:8O

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
